-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 Gz1mhb6bKpidNMNgXZvJSxbqfQmBi6lqr2uKIpAVBZf8Zo4irq9040F59wYu3do+
 GoRh+nh5k/CzuYEevuEPUg==

<SEC-DOCUMENT>0001130319-08-000302.txt : 20080408
<SEC-HEADER>0001130319-08-000302.hdr.sgml : 20080408
<ACCEPTANCE-DATETIME>20080408161512
ACCESSION NUMBER:		0001130319-08-000302
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		23
CONFORMED PERIOD OF REPORT:	20080407
FILED AS OF DATE:		20080408
DATE AS OF CHANGE:		20080408

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ONCOLYTICS BIOTECH INC
		CENTRAL INDEX KEY:			0001129928
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-31062
		FILM NUMBER:		08745526

	BUSINESS ADDRESS:	
		STREET 1:		1167 KENSINGTON CRES NW SUITE 210
		STREET 2:		CALGARY ALBERTA CANADA T2N 1X7
		CITY:			ALBERTA CANADA
		STATE:			A0
		ZIP:			00000
		BUSINESS PHONE:		4036707380

	MAIL ADDRESS:	
		STREET 1:		210 - 1167 KENSINGTON CRES NW
		CITY:			CALGARY
		STATE:			A0
		ZIP:			T2N 1X7
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>o40024e6vk.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
<TITLE>e6vk</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<HR size="4" noshade color="#000000" style="margin-top: -5px">
<HR size="1" noshade color="#000000" style="margin-top: -10px">

<P align="center" style="font-size: 14pt"><B>SECURITIES AND EXCHANGE COMMISSION<BR>
<DIV align="center" style="font-size: 12pt">Washington, D.C.
20549</DIV></B>


<P align="center" style="font-size: 18pt"><B>Form 6-K</B>

<P align="center" style="font-size: 10pt"><B>Report of Foreign Private Issuer</B>

<P align="center" style="font-size: 10pt"><B>Pursuant to Rule&nbsp;13a-16 or 15d-16<BR>
of the Securities Exchange Act of 1934</B>

<P align="center" style="font-size: 10pt">For the month of April 2008

<P align="center" style="font-size: 10pt">Commission File Number 000-31062

<CENTER>
<P align="center" style="font-size: 24pt"><B>Oncolytics Biotech Inc.</B>
<HR size="1" width="45%" noshade>
<DIV align="center" style="font-size: 10pt"><I>(Translation of registrant&#146;s name into
English)</I>
</DIV>
</CENTER>

<CENTER>
<P align="center" style="font-size: 10pt"><B>Suite&nbsp;210, 1167 Kensington Crescent NW<BR>
Calgary, Alberta, Canada T2N 1X7</B>
<HR size="1" width="45%" noshade>
<DIV align="center" style="font-size: 10pt"><I>(Address of principal executive offices)</I>
</DIV>
</CENTER>

<P style="font-size: 10pt">Indicate by check mark whether the registrant files or will file annual reports
under cover Form&nbsp;20-F or Form&nbsp;40-F.

<CENTER>
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="70%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="49%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="49%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">

<TD align="center" valign="top">Form&nbsp;20-F&nbsp;&nbsp;&nbsp;<FONT
face="wingdings">&#254;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Form&nbsp;40-F&nbsp;&nbsp;&nbsp;<FONT
face="wingdings">&#111;</FONT></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</CENTER>

<P style="font-size: 10pt">Indicate by check mark if the registrant is submitting the Form&nbsp;6-K in paper as
permitted by Regulation&nbsp;S-T Rule&nbsp;101(b)(1):&nbsp;&nbsp;&nbsp;<FONT
face="wingdings">&#111;</FONT>

<P style="font-size: 10pt"><B>Note: </B>Regulation&nbsp;S-T Rule&nbsp;101(b)(1) only permits the submission in paper of a
Form&nbsp;6-K if submitted solely to provide an attached annual report to security
holders.

<P style="font-size: 10pt">Indicate by check mark if the registrant is submitting the Form&nbsp;6-K in paper as
permitted by Regulation&nbsp;S-T Rule&nbsp;101(b)(7):&nbsp;&nbsp;&nbsp;<FONT
face="wingdings">&#111;</FONT>

<P style="font-size: 10pt"><B>Note: </B>Regulation&nbsp;S-T Rule&nbsp;101(b)(7) only permits the submission in paper of a
Form&nbsp;6-K if submitted to furnish a report or other document that the registrant
foreign private issuer must furnish and make public under the laws of the
jurisdiction in which the registrant is incorporated, domiciled or legally
organized (the registrant&#146;s &#147;home country&#148;), or under the rules of the home
country exchange on which the registrant&#146;s securities are traded, as long as
the report or other document is not a press release, is not required to be and
has not been distributed to the registrant&#146;s security holders, and, if
discussing a material event, has already been the subject of a Form&nbsp;6-K
submission or other Commission filing on EDGAR.

<P style="font-size: 10pt">Indicate by check mark whether by furnishing the information contained in this
Form, the registrant is also thereby furnishing the information to the
Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of
1934.

<CENTER>
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="70%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="49%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="49%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top">Yes&nbsp;&nbsp;&nbsp;<FONT
face="wingdings">&#111;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">No&nbsp;&nbsp;&nbsp;<FONT
face="wingdings">&#254;</FONT></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</CENTER>

<P style="font-size: 10pt">If &#147;Yes&#148; is marked, indicate below the file number assigned to the registrant
in connection with Rule&nbsp;12g3-2(b):&nbsp;&nbsp;&nbsp;82&nbsp;-&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>

<P>
<HR size="1" noshade color="#000000" style="margin-top: -2px">
<HR size="4" noshade color="#000000" style="margin-top: -10px">

<P style="font-size: 10pt">&nbsp;

</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<P align="center" style="font-size: 10pt"><B>SIGNATURES</B>

<P style="font-size: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.

<P>
<CENTER>
<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR valign="bottom">
    <TD width="50%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="47%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>

<TD colspan="3" align="left" valign="top"><B>Oncolytics
Biotech Inc.</B><BR>
(Registrant)</TD>
</TR>
<TR><TD>&nbsp;</TD></TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR><TD>&nbsp;</TD></TR>
<TR valign="bottom">
    <TD valign="top">Date: April 7, 2008</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Doug Ball
<HR size="1" noshade width="60%">
Doug Ball<BR>
Chief Financial Officer</TD>
</TR>
</TABLE>
</CENTER>

<P align="center" style="font-size: 10pt">&nbsp;

</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>EXHIBIT INDEX</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="96%">&nbsp;</TD>
</TR>
<!-- End Table Head -->

<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">1.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Annual Report</TD>
</TR>
<TR><TD STYLE="FONT-SIZE: 6PT">&nbsp;</TD></TR>

<TR valign="bottom">

<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">2.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Notice of Annual and Special
Meeting of&nbsp;Shareholders</TD>
</TR>
<TR><TD STYLE="FONT-SIZE: 6PT">&nbsp;</TD></TR>

<TR valign="bottom">

<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">3.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Proxy Card</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: Helvetica,Arial,sans-serif">

<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>EXHIBIT 1</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 9pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="20%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #ffffff">
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;
</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><IMG src="o40024o4002401.gif" alt="(IMAGE)">
</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>




<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: Helvetica,Arial,sans-serif">

<DIV align="center">
<TABLE style="font-size: 9pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="20%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #ffffff">
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;
</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>

<TD align="right" style="background: #000000; color: #FFFFFF"><IMG src="o40024o4002402.gif" alt="(IMAGE)">
</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<TABLE width="90%">
<TR><TD style="font-size: 0pt; color: #FFFFFF">Oncolytics Biotech Inc. is focused on the development of
oncolytic viruses as a novel and effective approach to
cancer treatment. Oncolytics&#146; clinical program includes a
variety of Phase I/II and Phase II human trials using
REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>, its proprietary formulation of the human
reovirus, alone and in combination with radiation or
chemotherapy.</TD>
</TR>
</TABLE>


<TABLE width="90%">
<TR><TD style="font-size: 0pt; color: #FFFFFF">Oncolytics trades on the Toronto Stock Exchange (symbol
ONC) and on the NASDAQ (symbol ONCY).
<B>Contents</B></TD>
</TR>
</TABLE>


<TABLE width="90%">
<TR><TD style="font-size: 0PT; color: #FFFFFF">Letter to Shareholders <B>1</B>
Management&#146;s Discussion &#038; Analysis <B>4</B>
Statement of Management&#146;s Responsibilty <B>32</B>
Auditors&#146; Report <B>33</B>
Financial Statements <B>34</B>
Notes to Financial Statements <B>37</B>
Corporate Information <B>IBC</B></TD>
</TR>
</TABLE>


<TABLE width="90%">
<TR><TD style="font-size: 0PT; color: #FFFFFF"><B>Annual and Special Meeting</B>
The Annual and Special Meeting of the Shareholders will be held at The Yale Club of New York City,
50
Vanderbilt Avenue, New York at 9:00 a.m. on Wednesday, May&nbsp;7, 2008.</TD>
</TR>
</TABLE>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>





<DIV style="font-family: Helvetica,Arial,sans-serif">



<P><DIV style="position: relative; float: left; width: 90%">

<DIV align="left" style="margin-top: 116pt; margin-left: 5%; margin-right:5%; font-size: 9pt; font-family: 'Times New Roman',Times,serif"><B>Letter to Shareholders</B>
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:5%; font-size: 9pt"><I>2007 marked a significant expansion of the Company&#146;s clinical trial program for REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> with Phase II studies
and combination drug therapy studies being expanded and initiated. This activity was supported by further advances
in our preclinical development program, manufacturing, and intellectual property.</I>
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:5%; font-size: 9pt"><B>Clinical Program Developments</B>
</DIV>
<DIV align="center"><DIV style="font-size: 3pt; margin-top: 1pt; width: 100%; border-top: 1px solid #000000">&nbsp;</DIV></DIV>


<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:5%; font-size: 9pt">This past year was our most active year to date, with the announcement of results from three separate clinical trials,
the approval of three additional trials in the U.S. and the U.K., and the start of enrolment in four new trials; three
combination REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> and chemotherapy trials in the U.K., and a Phase II sarcoma trial in the U.S.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:5%; font-size: 9pt">In January&nbsp;2007, we announced that the Medicines and Healthcare products Regulatory Agency (MHRA)&nbsp;had
approved two, intravenous, combination trials using REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> in combination with gemcitabine or docetaxel. These
trials are in addition to the intravenous, combination REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>/paclitaxel and carboplatin trial approved late in
2006. These three trials all began enrolling patients in the first half of 2007. The trials have two components; a
small, dose escalation component that will enroll three cohorts of patients and a second component that will
include the enrolment of a further 12 patients at the maximum dosage of REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:5%; font-size: 9pt">The Company received clearance in April&nbsp;2007 to begin a U.S. Phase II trial in patients with various sarcomas (bone
and soft tissue cancers) that have metastasized to the lung. Patient enrolment began in June, and in January&nbsp;2008
the Company announced that it had met the criteria to proceed to full enrolment of 52 patients. According to the
trial protocol, to proceed to full enrolment Oncolytics had to demonstrate that at least one patient in the first 38
patients treated experienced a complete or partial response or stable disease for greater than six months. The third
patient treated in the study was demonstrated to have stable disease by Response Evaluation Criteria in Solid
Tumours (RECIST)&nbsp;for more than six months as measured by CT scan. A PET scan taken at the same time showed that
any residual mass was metabolically inactive. At the time, 12 patients had been treated and five remained on study.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:5%; font-size: 9pt">After conducting extensive preclinical work with the reovirus over the past few years, the U.S. National Cancer
Institute (NCI)&nbsp;moved its REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> program forward in May&nbsp;2007 when it filed a protocol with the U.S. Food &#038;
Drug Administration (FDA)&nbsp;to conduct a Phase II systemic administration trial with REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> for patients with
metastatic melanoma. In January&nbsp;2008, the NCI also filed a protocol for a Phase I/II systemic and intraperitoneal
administration trial with REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> for patients with advanced ovarian, peritoneal or fallopian tube cancers. Under
its clinical trial agreement, the NCI will pay for all costs of these trials, while Oncolytics will provide REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>.
Both of these trials have received clearance from the FDA and are expected to start enrolling patients this year.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:5%; font-size: 9pt">Positive final results from our Phase I U.K. systemic administration trial were presented at the American Society of
Clinical Oncology (ASCO)&nbsp;in June. The results indicate that REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> can be delivered systemically to patients with
advanced and metastatic cancers and causes anti-tumour activity. Positive results from our U.S. Phase I systemic
administration trial were also presented at ASCO. Of the 18 patients treated in the U.S. trial, eight demonstrated stable
</DIV>
</DIV>


<DIV style="position: relative; float: right; width: 10%">
<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><IMG src="o40024o4002416.gif" alt="(GRAPHIC)">
</DIV>
</DIV>
<BR clear="all">

<DIV align="center" STYLE="MARGIN-TOP: -4PT">
<TABLE style="font-size: 7pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom" style="font-size: 1pt">
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="85%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD valign="top">&nbsp;</TD>

<TD align="right" colspan="2" valign="top" bgcolor="#000000"  style="color: #ffffff; font-size: 9pt"><b>1</b></TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="6" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD colspan="2" bgcolor="#000000"  style="color: #ffffff; border-top: 1px solid #ffffff">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD colspan="4" align="right"><DIV style="margin-left:15px; text-indent:-15px">Oncolytics Biotech Inc <B>Letter to Shareholders</B></DIV></TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: Helvetica,Arial,sans-serif">

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">disease, including a patient with progressive breast cancer who experienced a 34% shrinkage in
tumour volume, or a partial response. The trial was originally designed to demonstrate the safety
of a single, one-hour infusion of REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>. During the treatment of the 4th cohort of patients
however, Oncolytics applied for and was granted approval to allow subsequent patients to receive
repeat monthly treatments of REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>. Of the patients eligible for retreatment, three patients
received a range of two to seven one-hour infusions of REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">We were also very pleased to announce positive interim results of our Phase Ia/Ib combination
REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> and radiation trial in September. Of the 11 patients treated in the Ia portion of the
trial, three patients experienced significant partial responses, with stable disease noted in
other, non-treated tumours. Of the 6 patients that had completed treatment in the Ib portion,
three patients experienced tumour regression, as well as stable disease in non-treated tumours.
The treatment was well tolerated, with mostly Grade 1 or 2 toxicities noted including fatigue,
lymphopenia, fever, and neutropenia. A total of 23 patients were treated in the trial, which
concluded enrolment in December&nbsp;2007.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">Oncolytics is also planning to initiate enrolment in another combination trial in the U.K. In
October, the MHRA approved a clinical trial that will examine intravenous administration of
REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> in combination with cyclophosphamide, a chemotherapeutic agent as well as immune
modulator, in patients with advanced cancers. Patients will receive REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> intravenously with
escalating doses of cyclophosphamide. Eligible patients include those who have been diagnosed with
advanced or metastatic solid tumours including pancreatic, lung and ovarian cancers that are
refractory to standard therapy or for which no curative standard therapy exists.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt"><B>Pre-Clinical Program Developments</B>
</DIV>
<DIV align="center"><DIV style="font-size: 3pt; margin-top: 1pt; width: 100%; border-top: 1px solid #000000">&nbsp;</DIV></DIV>


<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">Oncolytics has research collaborations in place with numerous leading institutions in North
America and Europe, and 2007 was an active year for our collaborators. The research that continues
to support our clinical program focused on immune interaction with the reovirus, as well as the
effect of combinations of chemotherapy and/or immune modulation with the reovirus.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt"><B>Intellectual Property Portfolio</B>
</DIV>
<DIV align="center"><DIV style="font-size: 3pt; margin-top: 1pt; width: 100%; border-top: 1px solid #000000">&nbsp;</DIV></DIV>


<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">We continue a sustained effort to expand and broaden our intellectual property portfolio. In 2007,
we secured an additional eight U.S. patents and one Canadian patent, bringing our total to more
than 165 patents issued worldwide, including 25 U.S. patents and six Canadian patents. In January
2008, we secured an additional two Canadian patents.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt"><B>Scaling Up Production</B>
</DIV>
<DIV align="center"><DIV style="font-size: 3pt; margin-top: 1pt; width: 100%; border-top: 1px solid #000000">&nbsp;</DIV></DIV>


<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">Last year, Oncolytics successfully completed initial scale up of our manufacturing process for
REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> to the 40-litre level, and also investigated further increases in scale to the 100-litre
level. The process at the 40-litre scale can deliver 20,000 doses of REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> at the maximum
clinical dose for intravenous use, or 60,000 doses for local use. Testing at the 100-litre level
is ongoing. The enhanced process allows us to keep pace with the rapidly expanding clinical
program, while preparing for commercial demand in future.
</DIV>

<DIV align="center">
<TABLE style="font-size: 7pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="85%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="LEFT" colspan="2" valign="top" bgcolor="#000000"  style="color: #ffffff; font-size: 9pt"><b>2</b></TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD colspan="2" bgcolor="#000000"  style="color: #ffffff; border-top: 1px solid #ffffff">&nbsp;</TD>
    <TD colspan="6" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">Oncolytics Biotech Inc <B>Letter to Shareholders</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>




<DIV style="font-family: Helvetica,Arial,sans-serif">



<P><DIV style="position: relative; float: left; width: 65%">



<DIV align="left" style="margin-top: 125pt; margin-left: 5%; margin-right:10%; font-size: 9pt"><B>Financial Resources</B>
</DIV>
<DIV align="center"><DIV style="font-size: 3pt; margin-top: 1pt; width: 100%; border-top: 1px solid #000000">&nbsp;</DIV></DIV>


<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:5%; font-size: 9pt">The Company completed a public offering in February&nbsp;2007 that added
gross proceeds of $12&nbsp;million to our financial reserves. An
over-allotment option was also fully exercised in March&nbsp;2007,
increasing the gross proceeds to $13.8&nbsp;million. With the successful
completion of the financing, cash reserves are estimated to carry the
Company well into 2009.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt"><B>Looking Ahead</B>
</DIV>
<DIV align="center"><DIV style="font-size: 3pt; margin-top: 1pt; width: 100%; border-top: 1px solid #000000">&nbsp;</DIV></DIV>


<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:5%; font-size: 9pt">Although 2007 was our most productive year to date, 2008 is already
shaping up to surpass the many achievements in 2007 as we move forward
with our Phase II program, and begin to focus our efforts in the
clinical program in key indications. We expect to conclude enrolment in
several of our Phase II trials in 2008. With solid preclinical and Phase
I results, a scalable manufacturing process, a comprehensive
intellectual property portfolio and the financial resources to support
our Phase II program, we look forward to an exciting and productive
2008.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:5%; font-size: 9pt"><I>On behalf of our Board of Directors and staff at Oncolytics, we would like
to thank all shareholders for their continued support.</I>
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt"><IMG src="o40024o4002403.gif" alt="-s- Brad Thompson">
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt">Brad Thompson, PhD<BR>
President &#038; CEO<BR>
<BR>
March&nbsp;5, 2008
</DIV>
</DIV>
<DIV style="position: relative; float: right; width: 33%">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt; margin-right: 20pt"><IMG src="o40024o4002404.gif" alt="(GRAPHIC)">
</DIV>

</DIV>
<BR clear="all">

<DIV align="center" style="margin-top: -4pt">
<TABLE style="font-size: 7pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom" style="font-size: 1pt">
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="85%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="right" colspan="2" valign="top" bgcolor="#000000"  style="color: #ffffff; font-size: 9pt"><b>3</b></TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="6" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD colspan="2" bgcolor="#000000"  style="color: #ffffff; border-top: 1px solid #ffffff">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD colspan="4" align="right"><DIV style="margin-left:15px; text-indent:-15px">Oncolytics Biotech Inc <B>Letter to Shareholders</B></DIV></TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>




<DIV style="font-family: Helvetica,Arial,sans-serif">
<P><DIV style="position: relative; float: left; width: 11%">

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><IMG src="o40024o4002417.gif" alt="(GRAPHIC)">
</DIV>
</DIV>

<DIV style="position: relative; float: right; width: 89%">
<DIV align="left" style="margin-top: 112pt; margin-left: 0%; margin-right:5%; font-size: 9pt; font-family: 'Times New Roman',Times,serif"><B>Management&#146;s Discussion and Analysis</B><BR><B>
of Financial Condition and Results of Operations</B>
</DIV>

<DIV align="left" style="margin-top: 10pt; margin-left: 0%; margin-right:5%; font-size: 9pt">March&nbsp;5, 2008
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 0%; margin-right:5%; font-size: 9pt"><I>The following information should be read in conjunction with our 2007 audited financial statements and notes thereto,
which were prepared in accordance with Canadian generally accepted accounting principles (&#147;GAAP&#148;).</I>
</DIV>

<DIV align="left" style="margin-top: 12pt; margin-left: 0%; margin-right:5%; font-size: 9pt"><B>Forward-Looking Statements</B>
</DIV>

<DIV align="center">
<DIV style="font-size: 3pt; margin-top: 1pt; width: 100%; border-top: 1px solid #000000">&nbsp;</DIV>
</DIV>


<DIV align="left" style="margin-top: 6pt; margin-left: 0%; margin-right:5%; font-size: 9pt">The following discussion contains forward-looking statements, within the meaning of Section&nbsp;21E of the Securities
Exchange Act of 1934, as amended. Forward-looking statements, including our belief as to the potential of REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>
as a cancer therapeutic and our expectations as to the success of our research and development and manufacturing
programs in 2008 and beyond, future financial position, business strategy and plans for future operations, and
statements that are not historical facts, involve known and unknown risks and uncertainties, which could cause our
actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include,
among others, the need for and availability of funds and resources to pursue research and development projects, the
efficacy of REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> as a cancer treatment, the success and timely completion of clinical studies and trials, our
ability to successfully commercialize REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>, uncertainties related to the research, development and manufacturing
of pharmaceuticals, uncertainties related to competition, changes in technology, the regulatory process and general
changes to the economic environment. Investors should consult our quarterly and annual filings with the Canadian
and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking
statements. Forward-looking statements are based on assumptions, projections, estimates and expectations of
management at the time such forward-looking statements are made, and such assumptions, projections, estimates
and/or expectations could change or prove to be incorrect or inaccurate. Investors are cautioned against placing
undue reliance on forward-looking statements. We do not undertake to update these forward-looking statements.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 0%; margin-right:10%; font-size: 9pt"><B>Overview</B>
</DIV>
<DIV align="center"><DIV style="font-size: 3pt; margin-top: 1pt; width: 100%; border-top: 1px solid #000000">&nbsp;</DIV></DIV>


<DIV align="left" style="margin-top: 6pt; margin-left: 0%; margin-right:10%; font-size: 9pt"><B>Oncolytics Biotech Inc. is a Development Stage Company</B>
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 0%; margin-right:10%; font-size: 9pt">Since our inception in April of 1998, Oncolytics Biotech Inc. has been a development stage company and we have
focused our research and development efforts on the development of REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>, our potential cancer therapeutic.
We have not been profitable since our inception and expect to continue to incur substantial losses as we continue
research and development efforts. We do not expect to generate significant revenues until, if and when, our cancer
product becomes commercially viable.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 0%; margin-right:10%; font-size: 9pt"><B>General Risk Factors</B>
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 0%; margin-right:10%; font-size: 9pt">Prospects for biotechnology companies in the research and development stage should generally be regarded as
speculative. It is not possible to predict, based upon studies in animals, or early studies in humans, whether a new
therapeutic will ultimately prove to be safe and effective in humans, or whether necessary and sufficient data can be
developed through the clinical trial process to support a successful product application and approval.
</DIV>



</DIV>
<BR clear="all">


<DIV align="center" style="margin-top: -11Pt">
<TABLE style="font-size: 7pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="77%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" colspan="2" valign="top" bgcolor="#000000" style="color: #ffffff; font-size: 9pt"><b>4</b>&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD colspan="2" bgcolor="#000000" style="border-top: 1px solid #ffffff">&nbsp;</TD>
    <TD colspan="6" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">Oncolytics Biotech Inc <B>MD &#038; A</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>



<DIV style="font-family: Helvetica,Arial,sans-serif">

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt">If a product is approved for sale, product manufacturing at a commercial scale and significant sales to end users
at a commercially reasonable price may not be successful. There can be no assurance that we will generate adequate
funds to continue development, or will ever achieve significant revenues or profitable operations. Many factors
(e.g. competition, patent protection, appropriate regulatory approvals) can influence the revenue and product
profitability potential.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt">In developing a pharmaceutical product, we rely upon our employees, contractors, consultants and collaborators and
other third party relationships, including the ability to obtain appropriate product liability insurance. There can be
no assurance that these reliances and relationships will continue as required.</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt">In addition to developmental and operational considerations, market prices for securities of biotechnology companies
generally are volatile, and may or may not move in a manner consistent with the progress being made by Oncolytics.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt"><B>REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> Development Update For 2007</B>
</DIV>
<DIV align="center"><DIV style="font-size: 3pt; margin-top: 1pt; width: 100%; border-top: 1px solid #000000">&nbsp;</DIV></DIV>


<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt">We have been developing our product REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> as a possible cancer therapy since our inception in 1998. Our goal
each year is to advance REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> through the various steps and stages of development required for potential
pharmaceutical products. In order to achieve this goal, we believe that we have to actively manage the development
of our clinical trial program, our pre-clinical and collaborative programs, our manufacturing process and REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>
supply, and our intellectual property.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt"><B>Clinical Trial Program</B>
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt">We began 2007 with five clinical trials of which three were actively enrolling patients and two had been recently
approved to commence. During the year, we received approval to commence another three clinical trials, commenced
patient enrolment in four trials and completed enrolment in one trial. We exited 2007 with a clinical trial program of
eight active clinical trials of which seven are being conducted by us and one is being sponsored by the U.S. National
Cancer Institute (&#147;NCI&#148;). As well in 2007, we announced positive clinical trial results from two clinical trials.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt"><B>2007 Clinical Trial Results</B>
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt"><B><I>U.K. Phase Ia/Ib Combination REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> and Radiation Clinical Trial</I></B>
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt">We announced positive interim results from our U.K. Phase Ia/Ib combination REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> and radiation clinical trial
for patients with advanced or metastatic cancers in the third quarter of 2007 and completed enrolment in the fourth
quarter. At the time we announced our interim results, 22 patients had been treated with 15 having completed the
study. Five patients had withdrawn from the study, and two patients were still on study.</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt">
A total of 11 patients in the Ia portion of the trial received two intratumoural treatments of REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> at dosages of
1x10<SUP style="font-size: 85%; vertical-align: text-top">8</SUP>, 1x10<SUP style="font-size: 85%; vertical-align: text-top">9</SUP>, or 1x10<SUP style="font-size: 85%; vertical-align: text-top">10</SUP> TCID<SUB style="font-size: 85%; vertical-align: text-bottom">50</SUB> with a constant localized radiation dose of 20 Gy given in five fractions. Of these 11
patients, three patients (one with oesophageal, one with squamous skin carcinoma and one with squamous cell scalp
cancer) experienced significant partial responses.
</DIV>

<DIV align="center" STYLE="MARGIN-TOP: -4PT">
<TABLE style="font-size: 7pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="85%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD valign="top">&nbsp;</TD>

<TD align="right" colspan="2" valign="top" bgcolor="#000000"  style="color: #ffffff; font-size: 9pt"><b>5</b></TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="6" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD colspan="2" bgcolor="#000000"  style="color: #ffffff; border-top: 1px solid #ffffff">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD colspan="4" align="right"><DIV style="margin-left:15px; text-indent:-15px">Oncolytics Biotech Inc <B>MD &#038; A</B></DIV></TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: Helvetica,Arial,sans-serif">

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">One month following treatment, the oesophageal patient experienced a 28.5% reduction in the target
tumour, with stable disease noted in four, non-treated tumours. At two and three months, the
target tumour had shrunk 64%, with stable disease continuing in the four non-treated tumours,
including a 15% volume reduction in non-treated mediastinal disease that was maintained for more
than six months. The squamous skin cancer patient experienced a 50% reduction in the target
tumour, as well as stable disease in two, non-treated tumours at one, two and three months post
treatment. The patient with squamous cell scalp cancer experienced stable disease in the target
tumour for two months which then became a partial response at three months. This patient also
experienced stable disease in one non-treated tumour measured at three months post-treatment.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">Patients in the Ib portion of the trial received either two, four or six intratumoural doses of
REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> at 1x10<SUP style="font-size: 85%; vertical-align: text-top">10</SUP>
TCID<SUB style="font-size: 85%; vertical-align: text-bottom">50</SUB> with a constant localized radiation dose of 36 Gy given in 12 fractions. Of the
six patients who had completed
the study at the time, three patients (one with colorectal, one with melanoma and one with lung
cancer) experienced
tumour regression in the target tumour, as well as stable disease in non-treated tumours.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">The patient with colorectal cancer experienced a partial response with a more than 50% regression
in the target tumour as well as stable disease in four, non-treated tumours measured at one month
following treatment. The patient with melanoma cancer experienced minor regression in the target
tumour as well as stable disease in two, non-treated tumours at one and two months following
treatment. The patient with lung cancer experienced minor regression in the target tumour, as well
as stable disease in three, non-treated tumours at two months following treatment.</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">The treatment has been well tolerated, with mostly Grade 1 or 2 toxicities noted including
fatigue, lymphopenia, fever, and neutropenia. Grade 3 toxicities including cellulitis, dysphasia
and diarrhoea were related to disease progression and not to the combination treatment. Viral
replication was unaffected by cellular irradiation.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">The primary objective of the Phase Ia/Ib trial was to determine the maximum tolerated dose
(&#147;MTD&#148;), dose limiting toxicity (&#147;DLT&#148;), and safety profile of REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> when administered
intratumourally to patients receiving radiation treatment. A secondary objective was to examine
any evidence of anti-tumour activity. Eligible patients include those who have been diagnosed with
late stage advanced or metastatic solid tumours that are refractory (&#147;have not responded&#148;) to
standard therapy or for which no curative standard therapy exists.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt"><B><I>U.S. Phase I Systemic Clinical Trial</I></B>
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">We announced positive results from our U.S. Phase I clinical trial examining the systemic
administration of REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> in patients with advanced cancers. The results indicated that
REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> can be delivered systemically to patients with advanced and metastatic cancers and cause
anti-tumour activity.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">A total of 18 patients were treated in the escalating dosage trial to a maximum daily dose of
3x10<SUP style="font-size: 85%; vertical-align: text-top">10 </SUP>TCID<SUB style="font-size: 85%; vertical-align: text-bottom">50</SUB> in a one-hour infusion. Of the 18 patients treated, eight demonstrated
stable disease or better, as measured by RECIST
(&#147;Response Evaluation Criteria in Solid Tumours&#148; - a measure used by regulatory agencies in
determining efficacy)
including a patient with progressive breast cancer who experienced a 34% shrinkage in tumour
volume.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">The trial was originally designed to demonstrate the safety of a single, one-hour infusion of
REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>. During the treatment of the 4th cohort of patients, we applied for and were granted
approval to allow subsequent patients to receive repeat monthly treatments of REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>. Of the
patients eligible for retreatment, three patients received a range of two to seven one-hour
infusions of REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>. Toxicities possibly related to REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> treatment in this trial were
generally mild (grade 1 or 2) and included chills, fever and fatigue.
</DIV>
 <DIV align="center">
<TABLE style="font-size: 7pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="85%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" colspan="2" valign="top" bgcolor="#000000"  style="color: #ffffff; color: #ffffff; font-size: 9pt"><b>6</b></TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD colspan="2" bgcolor="#000000"  style="color: #ffffff; border-top: 1px solid #ffffff">&nbsp;</TD>
    <TD colspan="6" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">Oncolytics Biotech Inc <B>MD &#038; A</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: Helvetica,Arial,sans-serif">

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt">The primary objective of this trial was to determine the Maximum Tolerated Dose (&#147;MTD&#148;),
Dose-Limiting Toxicity (&#147;DLT&#148;), and safety profile of REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> when administered systemically to
patients. A secondary objective was to examine any evidence of anti-tumour activity. Eligible
patients included those who had been diagnosed with advanced or metastatic solid tumours that are
refractory (&#147;have not responded&#148;) to standard therapy or for which no curative standard therapy
exists.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt"><B>Clinical
Trials - Actively Enrolling</B>
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt">Throughout 2007, we continued to enroll patients in our Phase II and Phase Ib combination
REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>/radiation clinical trials in the U.K. and in our Phase I/II recurrent malignant glioma
clinical trial in the U.S. As well in 2007, we commenced enrolment in the following studies:
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt"><B><I>U.S. Phase II Sarcoma Clinical Trial</I></B>
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt">We received approval to commence and initiated patient enrolment in our U.S. Phase II trial to
evaluate the intravenous administration of REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> in patients with various sarcomas that have
metastasized to the lung. Patients are being enrolled at the Montefiore Medical Center/Albert
Einstein College of Medicine in the Bronx, New York, the University of Michigan Comprehensive
Cancer Center in Ann Arbor, and the Cancer Therapy and Research Center, Institute for Drug
Development in San Antonio, Texas.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt">This trial is a Phase II, open-label, single agent study whose primary objective is to measure
tumour responses and duration of response, and to describe any evidence of antitumour activity of
intravenous, multiple dose REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> in patients with bone and soft tissue sarcomas metastatic to
the lung. REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> is being given intravenously to
patients at a dose of 3x10<SUP style="font-size: 85%; vertical-align: text-top">10</SUP> TCID<SUB style="font-size: 85%; vertical-align: text-bottom">50 </SUB>for five consecutive days. Patients may receive
additional five-day cycles of therapy
every four weeks for a maximum of eight cycles.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt">Up to 52 patients will be enrolled in the study. Eligible patients must have a bone or soft tissue
sarcoma metastatic
to the lung deemed by their physician to be unresponsive to or untreatable by standard therapies.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt"><B><I>U.K. Combination REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> Paclitaxel and Carboplatin Clinical Trial</I></B>
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt">We commenced patient enrolment in our U.K. clinical trial to evaluate the anti-tumour effects of
systemic administration of REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> in combination with paclitaxel and carboplatin in patients
with advanced cancers including head and neck, melanoma, lung and ovarian.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt">This trial has two components. The first is an open-label, dose-escalating, non-randomized study
of REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> given intravenously with paclitaxel and carboplatin every three weeks. Standard
dosages of paclitaxel and carboplatin will be delivered with escalating dosages of REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>
intravenously. A maximum of three cohorts will be enrolled in the REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> dose escalation
portion. The second component of the trial will immediately follow and will include the enrolment
of a further 12 patients at the maximum dosage of REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> in combination with a standard dosage
of paclitaxel and carboplatin.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt">Eligible patients include those who have been diagnosed with advanced or metastatic solid tumours
such as head and neck, melanoma, lung and ovarian cancers that are refractory to standard therapy
or for which no curative standard therapy exists. The primary objective of the trial is to
determine the MTD, DLT, recommended dose and dosing schedule and safety profile of REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> when
administered in combination with paclitaxel and carboplatin. Secondary
</DIV>

<DIV align="center">
<TABLE style="font-size: 7pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="85%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD valign="top">&nbsp;</TD>

<TD align="right" colspan="2" valign="top" bgcolor="#000000"  style="color: #ffffff; color: #ffffff; font-size: 9pt"><b>7</b></TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="6" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD colspan="2" bgcolor="#000000"  style="color: #ffffff; border-top: 1px solid #ffffff">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD colspan="4" align="right"><DIV style="margin-left:15px; text-indent:-15px">Oncolytics Biotech Inc <B>MD &#038; A</B></DIV></TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: Helvetica,Arial,sans-serif">

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">objectives include the evaluation of immune response to the drug combination, the body&#146;s response
to the drug
combination compared to chemotherapy alone and any evidence of anti-tumour activity.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt"><B><I>U.K. Combination REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> Gemcitabine Clinical Trial</I></B>
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">We commenced patient enrolment in our U.K. clinical trial to evaluate the anti-tumour effects of
systemic administration of REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> in combination with gemcitabine (Gemzar<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>) in patients with
advanced cancers including pancreatic, lung and ovarian. The combination of reovirus and
gemcitabine has been shown in preclinical studies to be more effective than gemcitabine or
reovirus alone at killing certain cancer cell lines.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">This trial has two components. The first is an open-label, dose-escalating, non-randomized study
of REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> given intravenously with gemcitabine every three weeks. A standard dosage of
gemcitabine will be delivered with escalating dosages of REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> intravenously. A maximum of
three cohorts will be enrolled in the REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> dose escalation portion. The second component of
the trial will immediately follow and will include the enrolment of a further 12 patients at the
maximum dosage of REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> in combination with a standard dosage of gemcitabine.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">Eligible patients include those who have been diagnosed with advanced or metastatic solid tumours
such as pancreatic, lung and ovarian cancers that are refractory to standard therapy or for which
no curative standard therapy exists. The primary objective of the trial is to determine the MTD,
DLT, recommended dose and dosing schedule and safety profile of REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> when administered in
combination with gemcitabine. Secondary objectives include the evaluation of immune response to
the drug combination, the body&#146;s response to the drug combination compared to chemotherapy alone
and any evidence of anti-tumour activity.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt"><B><I>U.K. Combination REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> Docetaxel Clinical Trial</I></B>
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">We commenced patient enrolment in our U.K. clinical trial to evaluate the anti-tumour effects of
systemic administration of REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> in combination with docetaxel (Taxotere<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>) in patients with
advanced cancers including bladder, prostate, lung and upper gastro-intestinal. In preclinical
studies, the combination of REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> and various taxanes including docetaxel has been shown to be
synergistic against a variety of cancer cell lines.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">The trial has two components. The first is an open-label, dose-escalating, non-randomized study of
REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> given intravenously with docetaxel every three weeks. A standard dosage of docetaxel
will be delivered with escalating dosages of REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> intravenously. A maximum of three cohorts
will be enrolled in the REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> dose escalation portion. The second component of the trial will
immediately follow and will include the enrolment of a further 12 patients at the maximum dosage
of REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> in combination with a standard dosage of docetaxel.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">Eligible patients include those who have been diagnosed with advanced or metastatic solid tumours
such as bladder, prostate, lung or upper gastro-intestinal cancers that are refractory to standard
therapy or for which no curative standard therapy exists. The primary objective of the trial is to
determine the MTD, DLT, recommended dose and dosing schedule and safety profile of REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> when
administered in combination with docetaxel. Secondary objectives include the evaluation of immune
response to the drug combination, the body&#146;s response to the drug combination compared to
chemotherapy alone and any evidence of anti-tumour activity.
</DIV>


<DIV align="center">
<TABLE style="font-size: 7pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="85%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" colspan="2" valign="top" bgcolor="#000000"  style="color: #ffffff; color: #ffffff; font-size: 9pt"><b>8</b></TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD colspan="2" bgcolor="#000000"  style="color: #ffffff; border-top: 1px solid #ffffff">&nbsp;</TD>
    <TD colspan="6" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">Oncolytics Biotech Inc <B>MD &#038; A</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: Helvetica,Arial,sans-serif">

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt"><B>Clinical
Trials - Approved to Commence</B>
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt"><B><I>U.K. REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> in Combination with Cyclophosphamide</I></B>
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt">In 2007, we announced receipt of a letter of approval to commence our clinical trial using
intravenous administration of REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> in combination with cyclophosphamide, a chemotherapeutic
agent as well as immune modulator, in patients with advanced cancers.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt">The trial is an open-label, dose-escalating, non-randomized trial of REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> given intravenously
with escalating doses of cyclophosphamide. A standard dose of REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> is administered
intravenously over five consecutive days, while an intravenous dose of cyclophosphamide is
administered three days before REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> treatment and continues through the course of the
treatment cycle. The total number of patients studied will depend on the number of dose levels
tested, but it is anticipated to be approximately 30 patients.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt">Eligible patients include those who have been diagnosed with advanced or metastatic solid tumours
including pancreatic, lung and ovarian cancers that are refractory to standard therapy or for
which no curative standard therapy exists. The primary objective of the trial includes determining
the Minimum Effective Immunomodulatory Dose of cyclophosphamide to obtain successful immune
modulation. Secondary objectives include the safety profile of the combination and gathering any
evidence of anti-tumour activity.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt"><B><I>U.S. National Cancer Institute Phase II Melanoma Clinical Trial</I></B>
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt">In 2007, the NCI filed a protocol with the U.S. Food and Drug Administration for a Phase II
clinical trial for patients with metastatic melanoma using systemic administration of REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>.
The NCI is sponsoring the trial under our Clinical Trials Agreement that requires us to provide
clinical supplies of REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>. The trial is expected to enroll up to 47 patients with metastatic
melanoma.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt"><B>Pre-Clinical Trial and Collaborative Program</B>
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt">We perform pre-clinical studies and engage in collaborations to help support our clinical trial
programs and expand our intellectual property base. Throughout 2007, we continued with studies
examining the interaction between the immune system and the reovirus, the use of the reovirus as a
co-therapy with existing chemotherapeutics and radiation, and to investigate new uses for the
reovirus in therapy. During 2007, in conjunction with our various collaborators, we reported the
results of a number of research collaborations.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt">We announced that a poster presentation entitled &#147;Reovirus Infection of Human Melanoma Cells
Supports Priming of Anti-Tumour Cytotoxic T Cell Immunity&#148; was presented by Dr.&nbsp;Robin Prestwich of
CR-UK Clinical Centre, Leeds Institute of Molecular Medicine,
University of Leeds, U.K. at the
National Cancer Research Institute Cancer Conference in Birmingham, U.K. In this study, the
investigators infected melanoma cell lines with reovirus. The reovirus-infected cell lines
stimulated the maturation of dendritic cells, which in turn educated cancer-killing T cells to
attack and kill the melanoma cells.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt">Dr.&nbsp;Maureen E. Lane et al. of Cornell University, New York, presented a poster entitled &#147;In Vivo
Synergy between Oncolytic Reovirus and Gemcitabine in Ras-Mutated Human HCT116 Xenografts&#148; at
the American Association for Cancer Research Annual Meeting in Los Angeles, CA. The researchers
found that treatment of human colon cancer cell lines with the combination of REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> and
gemcitabine resulted in both <I>in vitro </I>and <I>in vivo </I>synergy. There
</DIV>

<DIV align="center">
<TABLE style="font-size: 7pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="85%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="right" colspan="2" valign="top" bgcolor="#000000"  style="color: #ffffff; color: #ffffff; font-size: 9pt"><b>9</b></TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="6" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD colspan="2" bgcolor="#000000"  style="color: #ffffff; border-top: 1px solid #ffffff">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD colspan="4" align="right"><DIV style="margin-left:15px; text-indent:-15px">Oncolytics Biotech Inc <B>MD &#038; A</B></DIV></TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>



<DIV style="font-family: Helvetica,Arial,sans-serif">

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">was no additional toxicity associated with the combined treatment. Tumours treated with the
combination were significantly smaller (by area and weight) than tumours in control groups or
tumours treated with either agent alone. The researchers concluded that the synergistic
combination of REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> and gemcitabine is a promising therapeutic regimen for study in clinical
trials.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">An oral presentation entitled &#147;Reovirus as a Potentially Immunogenic as well as Cytotoxic Therapy
for Metastatic Colorectal Cancer&#148; was given by one of our collaborators, Dr.&nbsp;Sheila Fraser of St.
James&#146;s University Hospital in Leeds, U.K. The investigators tested reovirus <I>in vitro </I>against
recently resected colorectal cancer liver metastases. The results showed that a significant
proportion of tumour cell cultures showed susceptibility to death following reovirus infection, and
also demonstrated effective replication of reovirus within these cells. In addition, dendritic
cells that prime the immune system to fight cancer cells were activated by exposure to the
reovirus. The investigators concluded that the data supports the development of reovirus as a novel
therapy for colorectal cancer, with the potential to direct the immune system to target cancer
cells.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">Professor Hardev Pandha of The Royal Surrey Hospital, U.K. presented a poster entitled
&#147;Synergistic Antitumour Activity of Oncolytic Reovirus and Cisplatin in Malignant Melanoma&#148; at the
4th International Conference on Oncolytic Viruses as Cancer Therapeutics in Carefree, Arizona. The
results of the preclinical study showed that the combination of reovirus and cisplatin was
significantly more effective than cisplatin or reovirus alone at killing melanoma cancer cells in
a mouse model. The investigators concluded that the addition of chemotherapeutic agents can
enhance the efficacy of reovirus therapy.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">Finally, Dr.&nbsp;Richard Vile of the Mayo College of Medicine, Rochester, Minnesota delivered an oral
presentation at the 4th International Conference on Oncolytic Viruses as Cancer Therapeutics in
Carefree, Arizona that covered a study of systemic administration of reovirus in combination with
cyclophosphamide, an immune modulator. The work demonstrated that systemic administration of
reovirus in combination with cyclophosphamide enhanced tumour regression in a melanoma animal
model without increasing toxicity. In addition, the investigators were able to demonstrate that
the addition of cyclophosphamide significantly increased the amount of reovirus replicating within
the tumour. The investigators concluded that the addition of cyclophosphamide may lead to improved
efficacy of REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> treatment.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt"><B>Manufacturing and Process Development</B>
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">In 2007, we completed multiple production runs to build up a supply of REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> for our current
clinical trial program. Our process development activity examined the scale up of our
manufacturing process, increasing the batch size from our present cGMP scale of 20-litres to
40-litres and then to 100-litres. Finally, towards the end of 2007, we commenced the technology
transfer of our 40-litre production run to a second toll manufacturer in the U.S.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt"><B>Intellectual Property</B>
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">During 2007, eight U.S. and one Canadian patents were issued. At the end of 2007, we had been
issued over 160 patents including 25 U.S. and six Canadian patents as well as issuances in other
jurisdictions. We also have over 180 patent applications filed in the U.S., Canada and other
jurisdictions.
</DIV>

<DIV align="center">
<TABLE style="font-size: 7pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="85%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" colspan="2" valign="top" bgcolor="#000000"  style="color: #ffffff; color: #ffffff; font-size: 9pt"><b>10</b></TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD colspan="2" bgcolor="#000000"  style="color: #ffffff; border-top: 1px solid #ffffff">&nbsp;</TD>
    <TD colspan="6" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">Oncolytics Biotech Inc <B>MD &#038; A</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: Helvetica,Arial,sans-serif">

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt"><B>Financing Activity</B>
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt">In 2007, we issued 4,600,000 units at a price of $3.00 per unit for net cash proceeds of
$12,063,394. Each unit consisted of one common share and one-half of one common share purchase
warrant. Each whole common share purchase warrant shall entitle the holder thereof to acquire one
common share upon payment of $3.50 expiring on February&nbsp;22, 2010. The net proceeds from this
offering will be used for our clinical trial program, manufacturing activities in support of the
clinical trial program and for general corporate purposes.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt"><B>Financial Impact</B>
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt">We estimated at the beginning of 2007 that our monthly cash usage would be approximately
$1,400,000 for 2007. Our cash usage for the year was $13,569,594 from operating activities and
$944,719 for the purchases of intellectual property and capital assets which is in line with our
estimate. Our net loss for the year was $15,642,191.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt"><B>REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> Development For 2008</B>
</DIV>
<DIV align="center"><DIV style="font-size: 3pt; margin-top: 1pt; width: 100%; border-top: 1px solid #000000">&nbsp;</DIV></DIV>


<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt">We plan to continue to enroll patients in our clinical trials throughout 2008 and expect to
complete enrolment in our chemotherapy co-therapy trials in the U.K. and our sarcoma study in the
U.S. We believe that the results from these trials will allow us to broaden our phase II clinical
trial program. As well, we believe that the NCI will commence enrolment in its Phase II melanoma
clinical trial and commence additional trials with REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt">We expect to complete the technology transfer of our 40-litre manufacturing process to our U.S.
toll manufacturer and produce REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> for our clinical trial program throughout 2008. We
believe we will complete our 100-litre scale up studies and will begin to examine a
lyophilization (freeze drying) process for REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt">We estimate, based on our expected activity for 2008 that our monthly cash usage will increase to
$1,660,000 per
month (see &#147;Liquidity and Capital Resources&#148;).
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt"><B>Recent 2008 Progress</B>
</DIV>
<DIV align="center"><DIV style="font-size: 3pt; margin-top: 1pt; width: 100%; border-top: 1px solid #000000">&nbsp;</DIV></DIV>


<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt"><B>Clinical Trial Program</B>
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt"><B><I>U.S. Phase II Interim Update</I></B>
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt">On January&nbsp;31, 2008, we announced that we met the initial criteria to proceed to full enrolment in
our U.S. Phase II trial to evaluate the intravenous administration of REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> in patients with
various sarcomas that have metastasized to the lung. According to the trial protocol, to proceed
to full enrolment of 52 patients, we had to demonstrate that at least one patient in the first 38
patients treated experienced a complete or partial response, or stable disease for greater than
six months. The third patient treated in the study was demonstrated to have stable disease by
RECIST criteria for more than six months as measured by CT scan. A PET scan taken at the same time
showed that any residual tumour mass examined was metabolically inert.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt">A total of 12 patients had received REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> treatment at that time, with five remaining on
study. The trial is a Phase II, open-label, single agent study whose primary objective is to
measure tumour responses and duration of response, and to describe any evidence of antitumour
activity of intravenous, multiple dose REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> in patients with bone and soft tissue sarcomas
metastatic to the lung. REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> is delivered intravenously to patients at a
dose of
3x10<SUP style="font-size: 85%; vertical-align: text-top">10</sup>
TCID<SUb style="font-size: 85%; vertical-align: text-bottom">50</sub> for five consecutive days. Patients may receive additional
five-day cycles of therapy every four
weeks for a maximum of eight cycles.
</DIV>

<DIV align="center">
<TABLE style="font-size: 7pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="85%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="right" colspan="2" valign="top" bgcolor="#000000"  style="color: #ffffff; color: #ffffff; font-size: 9pt"><b>11</b></TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="6" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD colspan="2" bgcolor="#000000"  style="color: #ffffff; border-top: 1px solid #ffffff">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD colspan="4" align="right"><DIV style="margin-left:15px; text-indent:-15px">Oncolytics Biotech Inc <B>MD &#038; A</B></DIV></TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: Helvetica,Arial,sans-serif">

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">Eligible patients must have a bone or soft tissue sarcoma metastatic to the lung deemed by their
physician to be unresponsive to or untreatable by standard therapies. These include patients with
osteosarcoma, Ewing sarcoma family tumours, malignant fibrous histiocytoma, synovial sarcoma,
fibrosarcoma and leiomyosarcoma.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt"><B><I>U.S. National Cancer Institute Phase I/II Clinical Trial</I></B>
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">On January&nbsp;3, 2008, the U.S. National Cancer Institute (&#147;NCI&#148;) filed a protocol with the U.S. Food
and Drug
Administration for a Phase 1/2 clinical trial for patients with metastatic ovarian, peritoneal or
fallopian tube cancers using concurrent systemic and intraperitoneal administration of REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>.
The NCI is sponsoring the trial under our Clinical Trials Agreement that requires us to provide
clinical supplies of REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>. The trial, which is being carried out at The Ohio State University
Comprehensive Cancer Center, is expected to enroll up to 70 patients with metastatic ovarian,
peritoneal or fallopian tube cancers.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt"><B>Collaborative Program</B>
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">On January&nbsp;7, 2008, we reported that a research group led by Dr.&nbsp;Richard Vile of the Mayo Clinic
College of Medicine in Rochester, Minnesota, published the results of their work testing the
antitumor efficacy and safety of various combinations of reovirus and cyclophosphamide <I>in vivo</I>.
The paper is entitled &#147;Cyclophosphamide Facilitates Antitumor Efficacy against Subcutaneous Tumors
following Intravenous Delivery of Reovirus&#148; and appeared online in the January&nbsp;1, 2008 issue of
<I>Clinical Cancer Research</I>.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">The purpose of the research study was to investigate whether it was possible to use
cyclophosphamide, an immune modulator, to enhance the delivery and replication of the reovirus
when delivered intravenously. After testing various doses and dosing regimens of reovirus and
cyclophosphamide in mice, a metronomic dosing regimen was developed that resulted in increased
survival, high levels of reovirus recovered from regressing tumors, levels of neutralizing
antibodies that were protective, and only very mild toxicities. The data support investigation in
human clinical trials of the use of cyclophosphamide prior to systemic reovirus administration to
modulate, but not ablate, the immune system.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">On February&nbsp;4, 2008, we reported that Dr.&nbsp;Kevin Harrington and his research group at The Institute
of Cancer Research, London, U.K. published the results of their work testing combination treatment
schedules of reovirus and radiation in human and murine tumour cells <I>in vitro </I>and <I>in vivo</I>. The
paper, entitled &#147;Enhanced <I>In vitro </I>and <I>In vivo </I>Cytotoxicity of Combined Reovirus and Radiotherapy&#148;
appeared online in the February&nbsp;1, 2008 issue of <I>Clinical Cancer Research</I>. The effect of different
schedules of reovirus and radiotherapy on viral replication and cytotoxicity was tested <I>in vitro</I>
and the combination was assessed in three tumour models <I>in vivo</I>. The results demonstrated that
combining reovirus and radiotherapy significantly increased cancer cell killing both <I>in vitro </I>and
<I>in vivo</I>, particularly in cell lines with moderate susceptibility to reovirus alone.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt"><B>Accounting Policies</B>
</DIV>
<DIV align="center"><DIV style="font-size: 3pt; margin-top: 1pt; width: 100%; border-top: 1px solid #000000">&nbsp;</DIV></DIV>


<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt"><B>Critical Accounting Policies and Estimates</B>
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">In preparing our financial statements, we are required to make certain estimates, judgments and
assumptions that we believe are reasonable based upon the information available. These estimates
and assumptions affect the reported amounts of assets at the date of the financial statements and
the reported amounts of expenses during the periods presented. Significant estimates are used for,
but not limited to, the treatment of our research and development
</DIV>

<DIV align="center">
<TABLE style="font-size: 7pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="85%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" colspan="2" valign="top" bgcolor="#000000"  style="color: #ffffff; color: #ffffff; font-size: 9pt"><b>12</b></TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD colspan="2" bgcolor="#000000"  style="color: #ffffff; border-top: 1px solid #ffffff">&nbsp;</TD>
    <TD colspan="6" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">Oncolytics Biotech Inc <B>MD &#038; A</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: Helvetica,Arial,sans-serif">

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt">expenditures, the assessment of realizable value of long-lived assets, the amortization period of
intellectual property
and the calculation of stock based compensation.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt">The significant accounting policies which we believe are the most critical to aid in fully
understanding and evaluating
our reported financial results include the following:
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt"><B><I>Research and Development</I></B>
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt">Our research and development costs are expensed as they are incurred. Under Canadian generally
accepted accounting principles, development costs should be capitalized if certain criteria are
met. Companies with products in clinical trials do not necessarily meet these criteria. Our
development costs do not meet the following two criteria: (i)&nbsp;the technical feasibility of the
product or process has been established; and (ii)&nbsp;the future market for the product or process is
clearly defined. With regard to (i), we have completed six Phase I clinical trials and are
presently enrolling or have permission to commence seven additional clinical trial studies for
REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>. We are also planning to add additional trials to our clinical trial program. Until the
appropriate clinical studies have been completed, the technical feasibility of this product will
not be known. With regard to (ii), the future market for the product will not be clearly defined
until the completion of the clinical studies. Clinical studies not only determine the technical
feasibility of the product, but also provide information regarding the proper use of the product
and, therefore, the future market. Once the feasibility is determined a New Drug Application, or
equivalent, is made to the appropriate regulatory body. Regulatory approval is required before the
product can be marketed. For these reasons, our development costs are expensed and not
capitalized.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt"><B><I>Capitalization and Amortization of Patent Costs</I></B>
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt">We treat third party costs incurred (primarily legal and registration costs) in the development of
our Patent portfolio as limited-life intangible assets, and we amortize the costs related to these
assets over the lesser of 17&nbsp;years or their estimated useful life. We also review the valuation of
our Patent costs for impairment when any events that might give rise to impairment are known to
us. If there is an indication of impairment, we would assess the fair value of our Patents and
would record a reduction if the fair value were less than the book value.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt">In capitalizing these costs, we are recognizing the inherent future benefit of our Patents, not
only in protection of our own potential products, but also as a possible asset that could give
rise to revenues in the future through licensing agreements. While Patent life varies in different
jurisdictions it is normally considered to be 20&nbsp;years from date of application. With an
assumption of an average of three years from initial Patent application to Patent issuance, we
have set a maximum of 17&nbsp;years to amortize the costs from the date of issuance. We have then
assessed the nature of the market and the continuing efforts to develop and market new and better
products, as well as the incurrence of costs associated with Patents that have been issued and, as
a result, we have chosen to amortize the costs on a straight-line basis over ten years.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt">As the product to which the Patents relate is in the development stage, with commercial
recognition and revenue potential highly uncertain, should we experience a significant failure in
our clinical trial program or other areas of risk, then the value of the Patents could be in
serious question, giving rise to a possible write-down or write-off of the asset.
</DIV>

<DIV align="center">
<TABLE style="font-size: 7pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="85%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="right" colspan="2" valign="top" bgcolor="#000000"  style="color: #ffffff; color: #ffffff; font-size: 9pt"><b>13</b></TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="6" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD colspan="2" bgcolor="#000000"  style="color: #ffffff; border-top: 1px solid #ffffff">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD colspan="4" align="right"><DIV style="margin-left:15px; text-indent:-15px">Oncolytics Biotech Inc <B>MD &#038; A</B></DIV></TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: Helvetica,Arial,sans-serif">

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">In the event that we are successful in our product development and sales, or other parties
enter into licensing agreements with us, then it is also possible that the Patents may have a
life and value beyond the ten years assumed for the amortization policy.</DIV>
<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">In any event, the revision to any of these policies or estimates outlined above would impact losses
but not impact
cash flows.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt"><B>Changes in Accounting Policy Including Initial Adoption</B>
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt"><B><I>International Financial Reporting Standards</I></B>
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">In 2006, the CICA announced that accounting standards in Canada will converge with International
Financial Standards (&#147;IFRS&#148;). The Company will need to begin reporting under IFRS in the first
quarter of 2011 with comparative data for the prior year. IFRS uses a conceptual framework similar
to GAAP, but there could be significant differences on recognition, measurement and disclosures
that will need to be addressed. The Company is currently assessing the impact of these standards
on its financial statements.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt"><B><I>Capital Disclosures</I></B>
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">The CICA has issued new accounting recommendations for capital disclosures which require
disclosure of both qualitative and quantitative information that enables users of financial
statements to evaluate the Company&#146;s objectives, policies, and processes for managing capital.
These recommendations are effective for the Company beginning January&nbsp;1, 2008.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt"><B><I>Disclosure and Presentation of Financial Instruments</I></B>
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">The CICA has issued new accounting recommendations for disclosure and presentation of financial
instruments which require disclosures of both qualitative and quantitative information that
enables users of financial statements to evaluate the nature and extent of risks arising from
financial instruments to which the Company is exposed. These recommendations are effective for the
Company beginning January&nbsp;1, 2008.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt"><B><I>Goodwill and Intangible Assets</I></B>
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">The CICA has issued new accounting recommendations for the treatment of goodwill and intangible
assets that are intended to reduce the differences between IFRS in the accounting for intangible
assets and results in closer alignment with U.S. GAAP. The objectives of these recommendations are
to reinforce the principle-based approach to the recognition of assets only in accordance with the
definition of an asset and the criteria for asset recognition; and clarify the application of the
concept of matching revenues and expenses such that the current practice of recognizing asset
items that do not meet the definition and recognition criteria is eliminated. The standard also
provides guidance for the recognition of internally developed intangible assets, whether
separately acquired or internally developed. These changes are effective for fiscal years
beginning on or after October&nbsp;1, 2008, with early adoption encouraged. The Company is evaluating
the effects of adopting these recommendations.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt"><B>Fair Presentation</B>
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">We prepare our financial statements in accordance with GAAP. As a result of complying with GAAP, we
believe that
the following should be mentioned in an effort to understand and fairly present our financial
information:
</DIV>

<DIV align="center">
<TABLE style="font-size: 7pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="85%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" colspan="2" valign="top" bgcolor="#000000"  style="color: #ffffff; color: #ffffff; font-size: 9pt"><b>14</b></TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD colspan="2" bgcolor="#000000"  style="color: #ffffff; border-top: 1px solid #ffffff">&nbsp;</TD>
    <TD colspan="6" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">Oncolytics Biotech Inc <B>MD &#038; A</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>





<DIV style="font-family: Helvetica,Arial,sans-serif">

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt"><B><I>Stock Based Compensation</I></B>
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt">As required by the fair value based method for measuring stock based compensation, we use the
Black Scholes Option Pricing Model (&#147;Black Scholes&#148; or the &#147;Model&#148;) to calculate the fair value
of our options. Though there are other models available to calculate the option values (for
example, the binomial model), Black Scholes is currently widely used and accepted by other
publicly traded companies. Therefore, we have concluded that Black Scholes is the appropriate
option pricing model to use for our stock options at this time.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt">Black Scholes uses inputs in its calculation of fair value that requires us to make certain
estimates and assumptions.
For 2007, we used the following weighted average assumptions:
</DIV>
<DIV align="center">
<TABLE style="font-size: 9pt; margin-left: 5%; margin-right: 10%" cellspacing="0" border="0" cellpadding="0" width="65%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="84%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" bgcolor="#000000">&nbsp;</TD>
    <TD nowrap align="right" colspan="1" bgcolor="#000000" style="color: #ffffff"><B>2007</B></TD>
    <TD nowrap align="left" bgcolor="#000000">&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="5" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Risk-free interest rate</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" bgcolor="#000000">&nbsp;</TD>
    <TD align="right" colspan="1" bgcolor="#000000" style="color: #ffffff"><B>3.91%</B></TD>
    <TD nowrap align="left" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="5" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Expected hold period to exercise</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" bgcolor="#000000">&nbsp;</TD>
    <TD colspan="1" nowrap bgcolor="#000000" style="color: #ffffff" align="right"><B>3.5 years</B></TD>
    <TD nowrap align="left" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="5" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Volatility in the price of the our shares</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" bgcolor="#000000">&nbsp;</TD>
    <TD align="right" colspan="1" bgcolor="#000000" style="color: #ffffff"><B>56%</B></TD>
    <TD nowrap align="left" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="5" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Dividend yield</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" bgcolor="#000000">&nbsp;</TD>
    <TD colspan="1" nowrap bgcolor="#000000"  style="color: #ffffff" align="right"><B>Zero</B></TD>
    <TD nowrap align="left" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="5" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="margin-top: 10pt; margin-left: 5%; margin-right:10%; font-size: 9pt">A change in these estimates and assumptions will impact the value calculated by the Model. For
instance, the volatility in the price of our shares is based on the quoted trading price. We
assume that weekly trading prices best reflects our trading price volatility. However, an entity
can choose between daily, weekly, monthly or quarterly trading prices in the volatility
calculation. For example, based upon periods chosen, if we were to use daily trading prices,
volatility would increase 17%, resulting in an option value increase of 20% from that calculated
from the stated volatility. If we were to use monthly trading prices over the same period,
volatility would increase 16%, resulting in an option value increase of 20%. Also, volatility
would change based on the period chosen and the frequency of price points chosen.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt">The Model also uses an expected hold period to exercise in its calculation of fair value. When we
are estimating the expected hold period to exercise we take into consideration past history, the
current trading price and volatility of our common shares and have concluded that 3.5&nbsp;years is an
appropriate estimate. However, our options have a 10&nbsp;year life and given the fluctuations in our
stock price the expected hold period could be different. If the hold period was to increase 1
year, there would have been a 20% increase in our stock based compensation expense.</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt">
Consequently, in complying with GAAP and selecting what we believe are the most appropriate
assumptions under the circumstances, we have recorded non-cash employee stock based compensation
expense for the year of $539,156. However, given the above discussion this expense could have been
increased by 20% and still be in accordance with GAAP.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt"><B><I>Warrant Values</I></B>
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt">Since inception, we have raised cash through the issue of units and the exercise of warrants and
options. Each issued unit consisted of one common share and one half of one common share
purchase warrant with each whole warrant exercisable at a specified price for one additional
common share for up to 36&nbsp;months from the issue date.
</DIV>

<DIV align="center">
<TABLE style="font-size: 7pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="85%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="right" colspan="2" valign="top" bgcolor="#000000"  style="color: #ffffff; color: #ffffff; font-size: 9pt"><b>15</b></TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="6" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD colspan="2" bgcolor="#000000"  style="color: #ffffff; border-top: 1px solid #ffffff">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD colspan="4" align="right"><DIV style="margin-left:15px; text-indent:-15px">Oncolytics Biotech Inc <B>MD &#038; A</B></DIV></TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>


<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: Helvetica,Arial,sans-serif">



<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">GAAP requires that when recording the issued units, a value should be ascribed to each component
of the units based on the component&#146;s fair value. The fair value of our common shares is
established based on trading on stock exchanges in Canada and the U.S. However, as the warrants
do not trade on an exchange, the Black Scholes Option Pricing Model was used to determine the
fair value of the warrants. In the event that the total calculated value of each individual
component is greater than the price paid for the unit, the value of each component is reduced on
a relative basis until the total is equal to the unit&#146;s issue price.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">For reasons discussed above under &#147;Stock Based Compensation&#148;, the Model can produce a wide range of
calculated
</DIV>

<DIV align="left" style="margin-top: 0pt; margin-left: 10%; margin-right:5%; font-size: 9pt">values for our warrants.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt"><B><I>Initial Value of Our Intellectual Property</I></B>
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">In 1999, we were acquired by SYNSORB Biotech Inc. (&#147;SYNSORB&#148;) through the purchase of all of our
share capital for $2,500,000. In connection with this acquisition, the basis of accounting for the
assets and liabilities was changed to reflect SYNSORB&#146;s cost of acquiring these assets and
liabilities. This was achieved through the application of &#147;push down&#148; accounting. At the time, our
major asset was our intellectual property; therefore the $2,500,000 was allocated to this asset
with the corresponding credit to contributed surplus. This accounting treatment, permitted under
GAAP, increased the value of our assets and shareholders&#146; equity. As of December&nbsp;31, 2007, the net
book value of our original intellectual property was $333,333. Consequently, without the
application of push down accounting the value of our intellectual property and shareholders&#146;
equity would be $333,333 lower than presented in the 2007 audited financial statements.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt"><B>Selected Annual Information</B>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 0pt; margin-bottom: -2pt"><DIV style="width: 100%; border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV>
</DIV>

<DIV align="right">
<TABLE style="font-size: 9pt; margin-left 10%; margin-right: 5%" cellspacing="0" border="0" cellpadding="0" width="85%">
<!-- Begin Table Head -->
<TR valign="bottom" style="font-size: 1px">
    <TD width="52%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">$</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" style="background: #000000; color: #FFFFFF" colspan="2"><B>2007</B></TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">2006</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">2005</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="17" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Revenues</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>&#151;</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Interest income</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>1,211,744</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,233,809</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">783,456</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Net loss <SUP style="font-size: 85%; vertical-align: text-top">(2)</SUP></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>15,642,191</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">14,297,524</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">12,781,831</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Basic and diluted loss per share <SUP style="font-size: 85%; vertical-align: text-top">(2), (3)</SUP></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>0.39</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">0.39</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">0.39</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Total assets <SUP style="font-size: 85%; vertical-align: text-top">(1), (3)</SUP></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>30,781,857</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">33,565,692</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">46,294,326</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Total long term financial liabilities <SUP style="font-size: 85%; vertical-align: text-top">(4)</SUP></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>&#151;</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">150,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">150,000</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Cash dividends declared per share <SUP style="font-size: 85%; vertical-align: text-top">(5)</SUP></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>Nil</B></TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="1" align="right">Nil</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="1" align="right">Nil</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left" style="margin-top: 10pt; margin-left: 10%; margin-right:5%; font-size: 7pt">Notes:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 7pt; color: #000000; background: transparent">
    <TD width="10%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="left">(1)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Subsequent to the acquisition of Oncolytics Biotech Inc. by SYNSORB in April&nbsp;1999, we applied
push down accounting. See note 2 to the audited financial statements for 2007.</TD>
    <TD width="5%" style="background: transparent">&nbsp;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 7pt; color: #000000; background: transparent">
    <TD width="10%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="left">(2)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Included in net loss and net loss per share is stock based compensation expense of $539,156
(2006 &#150; $403,500; 2005 &#150; $64,104).</TD>
    <TD width="5%" style="background: transparent">&nbsp;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 7pt; color: #000000; background: transparent">
    <TD width="10%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="left">(3)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>We issued 4,660,000 common shares for cash proceeds of $12,114,394 (2006 &#150; 284,000 common
shares for cash proceeds of $241,400; 2005 &#150; 4,321,252 common shares for cash proceeds of
$18,780,189).</TD>
    <TD width="5%" style="background: transparent">&nbsp;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 7pt; color: #000000; background: transparent">
    <TD width="10%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="left">(4)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The long-term debt recorded represents repayable loans from the Alberta Heritage Foundation.
On January&nbsp;1, 2007, in conjunction with the adoption of the CICA Handbook section 3855 &#147;Financial
Instruments&#148;, this loan was recorded at fair value (see note 3 of the December&nbsp;31, 2007 audited
financial statements).</TD>
    <TD width="5%" style="background: transparent">&nbsp;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 7pt; color: #000000; background: transparent">
    <TD width="10%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="left">(5)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>We have not declared or paid any dividends since incorporation.</TD>
    <TD width="5%" style="background: transparent">&nbsp;</TD>
</TR>

</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 7pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="85%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" colspan="2" valign="top" bgcolor="#000000" style="color: #ffffff; font-size: 9pt"><b>16</b></TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD colspan="2" bgcolor="#000000" style="border-top: 1px solid #ffffff">&nbsp;</TD>
    <TD colspan="6" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">Oncolytics Biotech Inc <B>MD &#038; A</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>




<DIV style="font-family: Helvetica,Arial,sans-serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 7pt">



</TABLE>
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt"><B>Results of Operations</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 0pt"><DIV style="width: 100%; border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV>
</DIV>


<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt">Net loss for the year ended December&nbsp;31, 2007 was $15,642,191 compared to $14,297,524 and
$12,781,831 for 2006
and 2005, respectively.
</DIV>
<DIV align="right">
<TABLE style="font-size: 9pt; margin-left 5%; margin-right: 10%" cellspacing="0" border="0" cellpadding="0" width="85%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="48%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom">
    <TD nowrap align="left"><B>Research and Development Expenses (&#147;R&#038;D&#148;)</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">$</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" style="background: #000000; color: #FFFFFF" colspan="2"><B>2007</B></TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">2006</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">2005</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="17" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Manufacturing and related process development expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>4,325,271</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,508,882</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,706,203</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Clinical trial expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>3,897,235</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,726,331</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,880,059</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Pre-clinical trial expenses and collaborations</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>822,891</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,127,612</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">786,488</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD nowrap><DIV style="margin-left:15px; text-indent:-15px">Quebec scientific research and experimental development refund</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>(56,562</B></TD>
    <TD nowrap style="background: #000000; color: #FFFFFF"><B>)</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(52,344</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Other R&#038;D expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>2,326,253</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,225,208</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,936,227</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Research and development expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>11,315,088</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10,535,689</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9,308,977</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" align="left" style="border-top: 2px solid #000000">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt">
<TD colspan="17"><DIV align="left" style="margin-top: 10pt; margin-left: 0%; margin-right:0%; font-size: 9pt">In 2007, R&#038;D expenses were $11,315,088 compared to $10,535,689 and $9,308,977 in 2006 and 2005,
respectively.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 0%; margin-right:0%; font-size: 9pt"><B>Manufacturing &#038; Related Process Development (&#147;M&#038;P&#148;)</B>
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 0%; margin-right:0%; font-size: 9pt">M&#038;P expenses include product manufacturing expenses and process development. Product manufacturing
expenses include third party direct manufacturing costs, quality control testing, fill and
packaging costs. Process development expenses include costs associated with studies that examine
components of our manufacturing process looking for improvements and costs associated with the
creation and testing of our master and working viral and cell banks.
</DIV>
</TD>
</TR>


<!-- End Table Body -->

<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="52%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">$</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" style="background: #000000; color: #FFFFFF" colspan="2"><B>2007</B></TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">2006</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">2005</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="17" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Product manufacturing expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>3,113,832</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,050,647</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,326,577</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Technology transfer expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>388,673</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">457,975</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Process development expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>822,766</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,000,260</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">379,626</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Manufacturing and related process development expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>4,325,271</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,508,882</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,706,203</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" align="left" style="border-top: 2px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="margin-top: 10pt; margin-left: 5%; margin-right:10%; font-size: 9pt">Our M&#038;P expenses for 2007 were $4,325,271 compared to $4,508,882 and $4,706,203 for 2006 and 2005,
respectively. At the beginning of 2007, we completed the production runs that had commenced at the
end of 2006 and initiated additional production runs to manufacture REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>. These runs provided
us with sufficient product to supply our clinical trial program in 2007. Also, as a result of the
increased viral yields from the process development activity in 2006, we incurred additional vial
filling and packaging costs compared to 2006. We incurred technology transfer costs towards the
end of 2007 related to the transfer of our 40-litre production process to a second cGMP
manufacturer located in the U.S.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt">In 2006, we completed the production runs that were ongoing at the end of 2005, providing us with
sufficient product to complete our U.K. Phase II combination REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>/radiation clinical trial
and our existing Phase I clinical trials. At the same time, our process development activity
helped improve virus yields from our manufacturing process which we subsequently transferred to
our cGMP manufacturer in the U.K.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt">Our process development expenses for 2007 were $822,766 compared to $1,000,260 and $379,626 for
2006 and 2005, respectively. In 2007, our main process development focus was on the scale up of
our production process, which has included scale up studies at 40 and 100 litres. In 2006, our
process development activity included viral yield and scale up studies along with the validation
of our fill process.
</DIV>



<DIV align="center">
<TABLE style="font-size: 7pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="85%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="right" colspan="2" valign="top" bgcolor="#000000" style="color: #ffffff; font-size: 9pt"><b>17</b></TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="6" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD colspan="2" bgcolor="#000000" style="border-top: 1px solid #ffffff">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD colspan="4" align="right"><DIV style="margin-left:15px; text-indent:-15px">Oncolytics Biotech Inc <B>MD &#038; A</B></DIV></TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>





<DIV style="font-family: Helvetica,Arial,sans-serif">

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">We expect that our M&#038;P expenses for 2008 will increase compared to 2007. We expect to finalize the
technology transfer of our 40-litre production run during the first part of 2008. We will then
initiate a number of 40-litre production runs that we expect will be used in our clinical trial
program in 2008 and will also build up a level of stock for future use. We also expect that our
process development activity will include finalizing our 100-litre scale up studies and commencing
the examination of a lyophilization process for REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> in 2008. Once our 100-litre process
development studies are complete we expect to transfer our 100-litre manufacturing process to our
cGMP manufacturers.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt"><B>Clinical Trial Program</B>
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">Clinical trial expenses include those costs associated with our clinical trial program in the
U.S., U.K. and Canada as well as those incurred in the preparation of commencing other clinical
trials. Included in clinical trial expenses are direct patient costs, contract research
organization (&#147;CRO&#148;) expenses, clinical trial site costs and other costs associated with our
clinical trial program.
</DIV>
<DIV align="right">
<TABLE style="font-size: 9pt; margin-left 10%; margin-right: 5%" cellspacing="0" border="0" cellpadding="0" width="85%">
<!-- Begin Table Head -->
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="48%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">$</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" style="background: #000000; color: #FFFFFF" colspan="2"><B>2007</B></TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">2006</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">2005</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="17" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Direct clinical trial expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>3,680,730</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,378,211</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,683,120</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Other clinical trial expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>216,505</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">348,120</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">196,939</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Clinical trial expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>3,897,235</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,726,331</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,880,059</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" align="left" style="border-top: 2px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->


<TR>

<TD colspan="17" align="left" style="border-top: 0px solid #000000">
<DIV align="left" style="margin-top: 10pt; margin-left: 0%; margin-right:0%; font-size: 9pt">In 2007, our direct clinical trial expenses were $3,680,730 compared to $2,378,211 and
$1,683,120, respectively. During 2007, we incurred direct patient costs in our seven ongoing
clinical trials and completed patient enrolment in our Phase Ia/Ib REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>/radiation clinical
trial. As well, we incurred clinical site start up costs for our four co-therapy trials in the
U.K. and our Phase II sarcoma clinical trial in the U.S.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 0%; margin-right:0%; font-size: 9pt">In 2006, we incurred direct patient costs in four ongoing clinical trials along with clinical site
start up costs associated with our U.S. recurrent malignant glioma trial and our chemotherapeutic
co-therapy and radiation combination clinical trials in the U.K.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 0%; margin-right:0%; font-size: 9pt">We expect our clinical trial expenses will continue to increase in 2008 compared to 2007. The
increase in these
expenses is expected to arise from continued enrolment and continued re-treatments in our existing
clinical trials.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 0%; margin-right:0%; font-size: 9pt"><B>Pre-Clinical Trial Expenses and Research Collaborations</B>
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 0%; margin-right:0%; font-size: 9pt">Pre-clinical trial expenses include toxicology studies and are incurred by us in support of
expanding our clinical trial program into other indications, drug combinations and jurisdictions.
Research collaborations are intended to expand our intellectual property related to reovirus and
other viruses and identify potential licensing opportunities arising from our technology base.
</DIV>
</TD>
</TR>

<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="52%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">$</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" style="background: #000000; color: #FFFFFF" colspan="2"><B>2007</B></TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">2006</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">2005</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="17" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Research collaboration expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>785,760</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,064,692</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">652,393</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Pre-clinical trial expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>37,131</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">62,920</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">134,095</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Pre-clinical trial expenses and research collaborations</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>822,891</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,127,612</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">786,488</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" align="left" style="border-top: 2px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="margin-top: 10pt; margin-left: 10%; margin-right:5%; font-size: 9pt">In 2007, our research collaboration expenses were $785,760 compared to $1,064,692 and $652,393 in
2006 and 2005, respectively. In 2007, we completed those collaborations that began in 2006
relating to the interaction of the immune system and the reovirus, the use of the reovirus as a
co-therapy with existing chemotherapeutics and to
</DIV>


<DIV align="center">
<TABLE style="font-size: 7pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="85%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" colspan="2" valign="top" bgcolor="#000000" style="color: #ffffff; font-size: 9pt"><b>18</b></TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD colspan="2" bgcolor="#000000" style="border-top: 1px solid #ffffff">&nbsp;</TD>
    <TD colspan="6" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">Oncolytics Biotech Inc <B>MD &#038; A</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>




<DIV style="font-family: Helvetica,Arial,sans-serif">

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt">investigate new uses of the reovirus as a therapeutic. As well, we only extended certain
collaborations in 2007
reducing the number of collaborations in 2007 compared to 2006.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt">In 2006, we expanded the number of collaborations we entered into in an effort to examine the
interaction of the immune system and the reovirus, the use of the reovirus as a co-therapy with
existing chemotherapeutics, the use of new RAS active viruses as potential therapeutics, and to
investigate new uses of the reovirus as a therapeutic.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt">We expect that pre-clinical trial expenses and research collaborations in 2008 will remain
consistent with 2007. We expect to complete our ongoing collaborative program carried over from
2007 and will continue to be selective in the types of new collaborations we enter into in 2008.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt"><B>Other Research and Development Expenses</B>
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt">Other R&#038;D expenses include compensation expenses for employees (excluding stock based
compensation), consultant
fees, travel and other miscellaneous R&#038;D expenses.
</DIV>
<DIV align="right">
<TABLE style="font-size: 9pt; margin-left 5%; margin-right: 10%" cellspacing="0" border="0" cellpadding="0" width="85%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="48%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">$</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" style="background: #000000; color: #FFFFFF" colspan="2"><B>2007</B></TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">2006</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">2005</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="17" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">R&#038;D consulting fees</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>241,811</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">321,659</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">675,530</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">R&#038;D salaries and benefits</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>1,713,849</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,548,418</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,018,144</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Other R&#038;D expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>370,593</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">355,131</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">242,553</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Other research and development expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>2,326,253</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,225,208</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,936,227</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" align="left" style="border-top: 2px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="margin-top: 10pt; margin-left: 5%; margin-right:10%; font-size: 9pt">In 2007, our R&#038;D consulting fees were $241,811 compared to $321,659 and $675,530 in 2006 and
2005, respectively. In 2007, we incurred consulting activity associated with our ongoing clinical
trials and assistance with our clinical trial regulatory applications which was consistent with
2006.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt">Our R&#038;D salaries and benefits were $1,713,849 compared to $1,548,418 and $1,018,144 in 2006 and
2005, respectively.
</DIV>

<DIV align="left" style="margin-top: 0pt; margin-left: 5%; margin-right:10%; font-size: 9pt">The increase is a result of increases in salary levels along with the hiring of our Vice President
of Intellectual Property.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt">In 2008, we expect that our Other R&#038;D expenses will remain consistent with 2007. We expect that
salaries and benefits will increase in 2008 to reflect increasing compensation levels. Our R&#038;D
consulting fees should remain consistent with 2007 levels. However, we may choose to engage
additional consultants to assist us in the development of protocols and regulatory filings as the
need may arise possibly causing our R&#038;D consulting expenses to increase.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt"><B>Operating Expenses</B>
</DIV>
<DIV align="right">
<TABLE style="font-size: 9pt; margin-left 5%; margin-right: 10%" cellspacing="0" border="0" cellpadding="0" width="85%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="48%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">$</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" style="background: #000000; color: #FFFFFF" colspan="2"><B>2007</B></TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">2006</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">2005</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="17" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Public company related expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>2,739,593</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,494,803</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,156,614</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Office expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>1,248,095</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,135,341</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">926,758</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Operating expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>3,987,688</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,630,144</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,083,372</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" align="left" style="border-top: 2px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="margin-top: 10pt; margin-left: 5%; margin-right:10%; font-size: 9pt">In 2007, we incurred operating expenses of $3,987,688 compared to $3,630,144 and $3,083,372 in 2006
and 2005,
respectively. The reason for the change is as follows:
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt">Public company related expenses include costs associated with investor relations activities,
legal and accounting fees, corporate insurance, and transfer agent and other fees relating to
our U.S. and Canadian stock listings. In 2007, we incurred public company related expenses of
$2,739,593 compared to $2,494,803 and $2,156,614 in 2006 and 2005,
</DIV>


<DIV align="center">
<TABLE style="font-size: 7pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="85%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="right" colspan="2" valign="top" bgcolor="#000000" style="color: #ffffff; font-size: 9pt"><b>19</b></TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="6" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD colspan="2" bgcolor="#000000" style="border-top: 1px solid #ffffff">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD colspan="4" align="right"><DIV style="margin-left:15px; text-indent:-15px">Oncolytics Biotech Inc <B>MD &#038; A</B></DIV></TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>





<DIV style="font-family: Helvetica,Arial,sans-serif">

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">respectively. The increase in public company related expenses has been a result of incurring
additional professional fees associated with the examination and anticipated expansion of our
corporate structure and increased legal fees associated with protecting our portfolio of patents.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">Office expenses include compensation costs (excluding stock based compensation), office rent,
and other office related costs. In 2007, we incurred office expenses of $1,248,095 compared to
$1,135,341 and $926,758 in 2006 and 2005, respectively. Our office expense activity has remained
consistent over the last three years with increases mainly due to increased compensation levels
and a general increase in office costs.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt"><B>Stock Based Compensation</B>
</DIV>
<DIV align="right">
<TABLE style="font-size: 9pt; margin-left 10%; margin-right: 5%" cellspacing="0" border="0" cellpadding="0" width="85%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="48%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">$</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" style="background: #000000; color: #FFFFFF" colspan="2"><B>2007</B></TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">2006</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">2005</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="17" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Stock based compensation</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>539,156</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">403,550</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">64,104</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" align="left" style="border-top: 2px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
<TR style="font-size: 10pt">
<TD colspan="17"><DIV align="left" style="margin-top: 10pt; margin-left: 0%; margin-right:0%; font-size: 9pt">Non-cash stock based compensation recorded for 2007 was $539,156 compared to $403,550 and
$64,104 in 2006 and 2005, respectively. This expense is associated with the granting of stock
options to our employees, directors, and certain consultants and in 2007 there were more
options granted compared to 2006 and 2005.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 0%; margin-right:0%; font-size: 9pt"><B>Foreign Exchange Loss</B>
</DIV>
</TD>
</TR>


<TR style="font-size: 9pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">$</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" style="background: #000000; color: #FFFFFF" colspan="2"><B>2007</B></TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">2006</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">2005</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="17" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Foreign exchange loss</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>8,862</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">35,270</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">253,608</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" align="left" style="border-top: 2px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="margin-top: 10pt; margin-left: 10%; margin-right:5%; font-size: 9pt">We acquire investments in foreign currency to pay for anticipated expenses that are to be
incurred in the U.S. and the U.K. As a result of fluctuations in the Canadian dollar relative to
the U.S. dollar and British pound, we recorded a foreign exchange loss of $8,862 compared to
$35,270 and $253,608 in 2006 and 2005, respectively.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt"><B>Commitments</B>
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">As at December&nbsp;31, 2007, we are committed to payments totaling $960,000 during 2008 for activities
related to clinical trial activity and collaborations. All of these committed payments are
considered to be part of our normal course of business.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt"><B>Summary of Quarterly Results</B>
</DIV>
<DIV align="center" style="font-size: 10pt"><DIV style="width: 100%; border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV></DIV>



<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">The following unaudited quarterly information is presented in thousands of dollars except for per
share amounts:
</DIV>
<DIV align="right">
<TABLE style="font-size: 9pt; margin-left 10%; margin-right: 5%" cellspacing="0" border="0" cellpadding="0" width="85%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="19%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>

<TR style="font-size: 9pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="background: #000000; color: #FFFFFF" colspan="14"><B>2007</B></TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="14" style="border-bottom: 0px solid #000000">2006</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">$</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" style="background: #000000; color: #FFFFFF" colspan="2"><B>Dec.</B></TD>
    <TD style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD nowrap align="right" style="background: #000000; color: #FFFFFF" colspan="2"><B>Sept.</B></TD>
    <TD style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD nowrap align="right" style="background: #000000; color: #FFFFFF" colspan="2"><B>June</B></TD>
    <TD style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD nowrap align="right" style="background: #000000; color: #FFFFFF" colspan="2"><B>March</B></TD>
    <TD style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">Dec.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">Sept.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">June</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">March</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="37" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Revenue</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>&#151;</B></TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>&#151;</B></TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>&#151;</B></TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>&#151;</B></TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="37" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Interest income</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>265</B></TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>319</B></TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>359</B></TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>268</B></TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">286</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">320</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">335</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">292</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="37" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Net loss <SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>4,085</B></TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>3,764</B></TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>3,680</B></TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>4,113</B></TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,890</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,425</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,988</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,995</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="37" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD nowrap><DIV style="margin-left:15px; text-indent:-15px">Basic and diluted loss <BR>per
common share <SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>0.13</B></TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>0.09</B></TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>0.09</B></TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>0.11</B></TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">0.13</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">0.09</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">0.08</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">0.08</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="37" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Total assets <SUP style="font-size: 85%; vertical-align: text-top">(1), (4)</SUP></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>30,782</B></TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>33,897</B></TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>37,670</B></TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>41,775</B></TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">33,566</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">37,980</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">40,828</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">43,660</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="37" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Total cash <SUP style="font-size: 85%; vertical-align: text-top">(2), (4)</SUP></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>25,214</B></TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>28,191</B></TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>31,533</B></TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>35,681</B></TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">27,614</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">31,495</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">34,501</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">37,687</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="37" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD nowrap><DIV style="margin-left:15px; text-indent:-15px">Total long-term debt <SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>&#151;</B></TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>&#151;</B></TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>&#151;</B></TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>&#151;</B></TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">150</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">150</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">150</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">150</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="37" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD NOWRAP><DIV style="margin-left:15px; text-indent:-15px">Cash dividends declared <SUP style="font-size: 85%; vertical-align: text-top">(6)</SUP></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="1" bgcolor="#000000" align="center">&nbsp;</TD>

<TD colspan="1" style="background: #000000; color: #FFFFFF" align="right"><B>Nil</B></TD>
    <TD colspan="1" bgcolor="#000000" align="center">&nbsp;</TD>
    <TD colspan="1" bgcolor="#000000" align="center">&nbsp;</TD>
    <TD colspan="1" bgcolor="#000000" align="center">&nbsp;</TD>
    <TD colspan="1" style="background: #000000; color: #FFFFFF" align="right"><B>Nil</B></TD>
    <TD colspan="1" bgcolor="#000000" align="center">&nbsp;</TD>
    <TD colspan="1" bgcolor="#000000" align="center">&nbsp;</TD>
    <TD colspan="1" bgcolor="#000000" align="center">&nbsp;</TD>
    <TD colspan="1" style="background: #000000; color: #FFFFFF" align="right"><B>Nil</B></TD>
    <TD colspan="1" bgcolor="#000000" align="center">&nbsp;</TD>
    <TD colspan="1" bgcolor="#000000" align="center">&nbsp;</TD>
    <TD colspan="1" bgcolor="#000000" align="center">&nbsp;</TD>
    <TD colspan="1" style="background: #000000; color: #FFFFFF" align="right"><B>Nil</B></TD>
    <TD colspan="1" bgcolor="#000000" align="center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="1" align="right">Nil</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="1" align="right">Nil</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="1" align="right">Nil</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="1" align="right">Nil</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="37" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center">
<TABLE style="font-size: 7pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="85%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" colspan="2" valign="top" bgcolor="#000000" style="color: #ffffff; font-size: 9pt"><b>20</b></TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD colspan="2" bgcolor="#000000" style="border-top: 1px solid #ffffff">&nbsp;</TD>
    <TD colspan="6" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">Oncolytics Biotech Inc <B>MD &#038; A</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>




<DIV style="font-family: Helvetica,Arial,sans-serif">




<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 7pt; color: #000000; background: transparent">
    <TD width="5%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="left">(1)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Subsequent to the acquisition of Oncolytics Biotech Inc. by SYNSORB in April&nbsp;1999, we applied
push down accounting. See note 2 to the audited financial statements for 2007.</TD>
    <TD width="10%" style="background: transparent">&nbsp;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 7pt; color: #000000; background: transparent">
    <TD width="5%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="left">(2)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Included in total cash are cash and cash equivalents plus short-term investments.</TD>
    <TD width="10%" style="background: transparent">&nbsp;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 7pt; color: #000000; background: transparent">
    <TD width="5%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="left">(3)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Included in net loss and loss per common share between December&nbsp;2007 and January&nbsp;2005 are
quarterly stock based compensation expenses of $396,278, $38,909, $82,573, $21,396, $109,670,
$34,671, $222,376, and $36,833, respectively.</TD>
    <TD width="10%" style="background: transparent">&nbsp;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 7pt; color: #000000; background: transparent">
    <TD width="5%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="left">(4)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>We issued 4,600,000 units for net cash proceeds of $12,063,394 during 2007 with each unit
consisting of one common share and one half of one common share purchase warrant. (2006 &#150; 284,000
common shares for cash proceeds of $241,400)</TD>
    <TD width="10%" style="background: transparent">&nbsp;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 7pt; color: #000000; background: transparent">
    <TD width="5%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="left">(5)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The long-term debt recorded represents repayable loans from the Alberta Heritage Foundation.
On January&nbsp;1, 2007, in conjunction with the adoption of the CICA Handbook section 3855 &#147;Financial
Instruments&#148;, this loan was recorded at fair value (see note 3 of the December&nbsp;31, 2007, audited
interim financial statements).</TD>
    <TD width="10%" style="background: transparent">&nbsp;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 7pt; color: #000000; background: transparent">
    <TD width="5%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="left">(6)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>We have not declared or paid any dividends since incorporation.</TD>
    <TD width="10%" style="background: transparent">&nbsp;</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt"><B>Fourth Quarter</B>
</DIV>
<DIV align="center" style="font-size: 10pt"><DIV style="width: 100%; border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV></DIV>



<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt">Statement of loss for the three month period ended December&nbsp;31, 2007 and 2006
</DIV>
<DIV align="right">
<TABLE style="font-size: 9pt; margin-left 5%; margin-right: 10%" cellspacing="0" border="0" cellpadding="0" width="85%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="60%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom">
    <TD nowrap align="left" style="font-size: 6pt">(unaudited)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">$</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" style="background: #000000; color: #FFFFFF" colspan="2"><B>2007</B></TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">2006</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="13" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Expenses</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Research and development expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>2,499,833</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,953,002</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Operating expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>1,189,058</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">840,497</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Stock based compensation</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>396,278</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">109,670</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Foreign exchange loss</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>6,033</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">37,973</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Amortization &#150; intellectual property</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>248,540</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">226,150</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Amortization &#150; property and equipment</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>10,653</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9,258</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="13" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>4,350,395</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5,176,550</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Interest income</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>(264,918</B></TD>
    <TD nowrap style="background: #000000; color: #FFFFFF"><B>)</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(286,445</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="13" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Net loss</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>4,085,477</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,890,105</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="13" align="left" style="border-top: 2px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="margin-top: 10pt; margin-left: 5%; margin-right:10%; font-size: 9pt"><B>Fourth Quarter Review of Operations</B>
</DIV>
<DIV align="center" style="font-size: 10pt"><DIV style="width: 100%; border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV></DIV>



<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt">For the three month period ended December&nbsp;31, 2007, our net loss was $4,085,477 compared to
$4,890,105 for the
three month period ended December&nbsp;31, 2006. The reasons for the decrease are as follows:
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt"><B>Research and Development Expenses (&#147;R&#038;D&#148;)</B>
</DIV>
<DIV align="right">
<TABLE style="font-size: 9pt; margin-left 5%; margin-right: 10%" cellspacing="0" border="0" cellpadding="0" width="85%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="60%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom">
    <TD nowrap align="left" style="font-size: 6pt">(unaudited)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">$</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" style="background: #000000; color: #FFFFFF" colspan="2"><B>2007</B></TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">2006</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="13" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Manufacturing and related process development expenses (&#147;M&#038;P&#148;)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>778,539</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,757,675</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Clinical trial expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>913,547</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">805,864</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Pre-clinical trial expenses and research collaborations</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>91,446</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">436,058</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Other R&#038;D expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>716,301</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">953,405</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="13" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Research and development expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>2,499,833</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,953,002</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="13" align="left" style="border-top: 2px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="margin-top: 10pt; margin-left: 5%; margin-right:10%; font-size: 9pt">Our R&#038;D expenses were $2,499,833 in the fourth quarter of 2007 compared to $3,953,002 in the fourth
quarter of 2006.
</DIV>

 <DIV align="center">
<TABLE style="font-size: 7pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="85%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD valign="top">&nbsp;</TD>

<TD align="right" colspan="2" valign="top" bgcolor="#000000" style="color: #ffffff; font-size: 9pt"><b>21</b></TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="6" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD colspan="2" bgcolor="#000000" style="border-top: 1px solid #ffffff">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD colspan="4" align="right"><DIV style="margin-left:15px; text-indent:-15px">Oncolytics Biotech Inc <B>MD &#038; A</B></DIV></TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>



<DIV style="font-family: Helvetica,Arial,sans-serif">



<DIV align="right">
<TABLE style="font-size: 9pt; margin-left 10%; margin-right: 5%" cellspacing="0" border="0" cellpadding="0" width="85%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="60%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom">
    <TD nowrap align="left"><B>Manufacturing &#038; Related Process
Development (&#147;M&#038;P&#148;)</B>
<font style="font-size: 6pt">(unaudited)</font></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">$</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" style="background: #000000; color: #FFFFFF" colspan="2"><B>2007</B></TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">2006</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="13" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Product manufacturing expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>291,280</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,491,554</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Technology transfer expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>373,715</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Process development expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>113,544</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">266,121</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="13" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Manufacturing and related process development expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>778,539</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,757,675</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="13" align="left" style="border-top: 2px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->

<TR>
<TD colspan="13"><DIV align="left" style="margin-top: 10pt; margin-left: 0%; margin-right:0%; font-size: 9pt">Our M&#038;P expenses were $778,539 in the fourth quarter of 2007 compared to $1,757,675 in the fourth
quarter of 2006. In the fourth quarter of 2007, our M&#038;P activity focused on the transfer of our
40-litre manufacturing process to a second cGMP toll manufacturer in the U.S. Our production
activity in the fourth quarter of 2007, related to the final fill, packaging and testing of the
production runs that were completed earlier in 2007. In the fourth quarter of 2006, we commenced a
number of production runs after having completed the transfer of our manufacturing process with
improved viral yields earlier in 2006.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 0%; margin-right:0%; font-size: 9pt">Our process development costs were $113,544 in the fourth quarter of 2007 compared to $266,121 in
the fourth quarter of 2006. In the fourth quarter of 2007, our process development activity
continued to examine scaling up our manufacturing process to 100-litres. During the fourth
quarter of 2006, we initiated research that examined the scale up of our manufacturing process
after having completed studies that improved our viral yields earlier in 2006.
</DIV>
</TD>
</TR>
<TR>
<TD>&nbsp;</TD>
</TR>



<TR style="font-size: 9pt" valign="bottom">
    <TD nowrap align="left"><B>Clinical Trial Program</B> <font style="font-size: 6pt">(unaudited)</font></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">$</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" style="background: #000000; color: #FFFFFF" colspan="2"><B>2007</B></TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">2006</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="13" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Direct clinical trial expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>882,706</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">595,072</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Other clinical trial expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>30,841</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">210,792</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="13" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Clinical trial expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>913,547</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">805,864</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="13" align="left" style="border-top: 2px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->

<TR>

<TD colspan="13">
<DIV align="left" style="margin-top: 10pt; margin-left: 0%; margin-right:0%; font-size: 9pt">Our clinical trial expenses for the fourth quarter of 2007 were $913,547 compared to $805,864 for
the fourth quarter of 2006. In the fourth quarter of 2007, we were actively enrolling patients in
seven clinical trials. In the fourth quarter of 2006, we were enrolling patients in three clinical
trials and incurred costs associated with new clinical trial applications and clinical trial site
selection.
</DIV>
</TD>
</TR>
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="64%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom">
    <TD nowrap align="left"><B>Pre-Clinical Trial Expenses and
Research Collaborations</B> <font style="font-size: 6pt">(unaudited)</font></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">$</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" style="background: #000000; color: #FFFFFF" colspan="2"><B>2007</B></TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">2006</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="13" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Research collaboration expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>91,446</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">430,493</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Pre-clinical trial expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>&#151;</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5,565</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="13" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Pre-clinical trial expenses and research collaborations</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>91,446</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">436,058</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="13" align="left" style="border-top: 2px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="margin-top: 10pt; margin-left: 10%; margin-right:5%; font-size: 9pt">Our pre-clinical trial expenses and research collaborations were $91,446 in the fourth quarter of
2007 compared to $436,058 in the fourth quarter of 2006. In the fourth quarter of 2007 and 2006,
our research collaboration activity continued to focus on the interaction of the immune system
and the reovirus and the use of the reovirus as a co-therapy with chemotherapeutics and
radiation. The number of collaborations decreased in the fourth quarter of 2007 compared to the
fourth quarter of 2006.
</DIV>


<DIV align="center">
<TABLE style="font-size: 7pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="85%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" colspan="2" valign="top" bgcolor="#000000" style="color: #ffffff; font-size: 9pt"><b>22</b></TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD colspan="2" bgcolor="#000000" style="border-top: 1px solid #ffffff">&nbsp;</TD>
    <TD colspan="6" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">Oncolytics Biotech Inc <B>MD &#038; A</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>




<DIV style="font-family: Helvetica,Arial,sans-serif">
<DIV align="right">
<TABLE style="font-size: 9pt; margin-left 5%; margin-right: 10%" cellspacing="0" border="0" cellpadding="0" width="85%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="60%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom">
    <TD nowrap align="left"><B>Other Research and Development
Expenses</B> <font style="font-size: 6pt">(unaudited)</font></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">$</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" style="background: #000000; color: #FFFFFF" colspan="2"><B>2007</B></TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">2006</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="13" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">R&#038;D consulting fees</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>61,768</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">187,009</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">R&#038;D salaries and benefits</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>604,140</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">641,303</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Quebec scientific research and experimental development refund</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>(40,634</B></TD>
    <TD nowrap style="background: #000000; color: #FFFFFF"><B>)</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Other R&#038;D expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>91,027</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">125,093</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="13" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Other research and development expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>716,301</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">953,405</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="13" align="left" style="border-top: 2px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
<TR>
<TD colspan="13"><DIV align="left" style="margin-top: 10pt; margin-left: 0%; margin-right:0%; font-size: 9pt">Our other research and development expenses were $716,301 in the fourth quarter of 2007 compared
to $953,405 in the fourth quarter of 2006. In the fourth quarter of 2006, we incurred increased
consulting activity associated with our co-therapy trials regulatory applications. We did not
incur this activity in the fourth quarter of 2007. Our R&#038;D salaries in the fourth quarter of 2007
were $604,140 compared to $641,303 in the fourth quarter of 2006. The decrease related to a
reduction in annual cash bonuses paid to officers offset by the addition of our Vice President of
Intellectual Property earlier in 2007.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 0%; margin-right:10%; font-size: 9pt"><B>Operating Expenses</B>
</DIV>
</TD></TR>

<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="64%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom">
    <TD nowrap align="left"><font style="font-size: 6pt">(unaudited)</font></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">$</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" style="background: #000000; color: #FFFFFF" colspan="2"><B>2007</B></TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">2006</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="13" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Public company related expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>783,690</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">487,338</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Office expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>405,368</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">353,159</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="13" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Operating expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>1,189,058</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">840,497</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="13" align="left" style="border-top: 2px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
<TR>
<TD colspan="13">
<DIV align="left" style="margin-top: 10pt; margin-left: 0%; margin-right:0%; font-size: 9pt">Our operating expenses in the fourth quarter of 2007 were $1,189,058 compared to $840,497 in the
fourth quarter of 2006. In the fourth quarter of 2007, we incurred additional professional fees
associated with our examination and anticipated expansion of our corporate structure which did not
occur in the fourth quarter of 2006.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 0%; margin-right:10%; font-size: 9pt"><B>Stock Based Compensation</B>
</DIV>
</TD></TR>
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="64%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom">
    <TD nowrap align="left"><font style="font-size: 6pt">(unaudited)</font></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">$</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" style="background: #000000; color: #FFFFFF" colspan="2"><B>2007</B></TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">2006</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="13" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Stock based compensation</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">396,278</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">109,670</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="13" align="left" style="border-top: 2px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="margin-top: 10pt; margin-left: 5%; margin-right:10%; font-size: 9pt">Our non-cash stock based compensation expense recorded in the fourth quarter of 2007 was $396,278
compared to $109,670 for the fourth quarter of 2006. The stock based compensation expense in the
fourth quarter of 2007 related to the granting of options to directors, officers and employees.
In the fourth quarter of 2006 options were only granted to directors and employees.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt"><B>Financing Activities</B>
</DIV>
<DIV align="center" style="font-size: 10pt"><DIV style="width: 100%; border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV></DIV>



<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt">In 2007, we issued 4,600,000 units at a price of $3.00 per unit for net cash proceeds of
$12,063,394. Each unit consisted of one common share and one-half of one common share purchase
warrant. Each whole common share purchase warrant shall entitle the holder thereof to acquire
one common share upon payment of $3.50 expiring on February&nbsp;22, 2010. The net proceeds from this
offering will be used for our clinical trial program, manufacturing activities in support of the
clinical trial program and for general corporate purposes.
</DIV>


<DIV align="center">
<TABLE style="font-size: 7pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="85%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="right" colspan="2" valign="top" bgcolor="#000000" style="color: #ffffff; font-size: 9pt"><b>23</b></TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="6" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD colspan="2" bgcolor="#000000" style="border-top: 1px solid #ffffff">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD colspan="4" align="right"><DIV style="margin-left:15px; text-indent:-15px">Oncolytics Biotech Inc <B>MD &#038; A</B></DIV></TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: Helvetica,Arial,sans-serif">

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">As well in 2007, we issued 60,000 common shares for cash proceeds of $51,000 relating to the
exercise of stock options.
In 2006 we issued 284,000 common shares for cash proceeds of $241,400 relating to the exercise of
stock options.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt"><B>Liquidity and Capital Resources</B>
</DIV>
<DIV align="center" style="font-size: 10pt"><DIV style="width: 100%; border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV></DIV>



<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt"><B>Liquidity</B>
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">As at December&nbsp;31, 2007, we had cash and cash equivalents (including short-term investments) and
working capital positions of $25,213,829 and $22,732,987, respectively, compared to $27,613,748
and $25,719,870, respectively for 2006. The decrease in 2007 reflects the cash usage from
operating activities and the expenditures on intellectual property and capital assets of
$13,569,594, $852,498, and $92,221, respectively with cash inflows of $12,114,394 from the issue
of common shares and the exercise of stock options. This is in line with our 2007 estimate of cash
usage of less than $1,400,000 per month.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">We desire to maintain adequate cash and short-term investment reserves to support our planned
activities which include our clinical trial program, product manufacturing, administrative costs,
and our intellectual property expansion and protection. In 2008, we are expecting to continue to
enroll patients in our various clinical trials and we also expect to continue with our
collaborative studies pursuing support for our clinical trial program. We will therefore need to
ensure that we have enough REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> to supply our clinical trial and collaborative programs. We
presently estimate the cash usage in 2008 to increase to $1,660,000 per month and we believe our
existing capital resources are adequate to fund our current plans for research and development
activities well into 2009. Factors that will affect our anticipated monthly burn rate include, but
are not limited to, the number of manufacturing runs required to supply our clinical trial program
and the cost of each run, the number of clinical trials ultimately approved, the timing of patient
enrolment in the approved clinical trials, the actual costs incurred to support each clinical
trial, the number of treatments each patient will receive, the timing of the NCI&#146;s R&#038;D activity,
and the level of pre-clinical activity undertaken.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">In the event that we choose to seek additional capital, we will look to fund additional capital
requirements primarily through the issue of additional equity. We recognize the challenges and
uncertainty inherent in the capital markets and the potential difficulties we might face in
raising additional capital. Market prices and market demand for securities in biotechnology
companies are volatile and there are no assurances that we will have the ability to raise funds
when required.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt"><B>Capital Expenditures</B>
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">We spent $852,498 on intellectual property in 2007 compared to $842,610 in 2006. The change in
intellectual property expenditures reflects the timing of filing costs associated with our
expanded patent base. As well, we have benefited from fluctuations in the Canadian dollar as our
patent costs are typically incurred in U.S. currency. At the end of 2007, we had been issued over
160 patents including 25 U.S. and six Canadian patents as well as issuances in other
jurisdictions. We also have over 180 patent applications filed in the U.S., Canada and other
jurisdictions.
</DIV>


<DIV align="center">
<TABLE style="font-size: 7pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="85%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" colspan="2" valign="top" bgcolor="#000000" style="color: #ffffff; font-size: 9pt"><b>24</b></TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD colspan="2" bgcolor="#000000" style="border-top: 1px solid #ffffff">&nbsp;</TD>
    <TD colspan="6" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">Oncolytics Biotech Inc <B>MD &#038; A</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: Helvetica,Arial,sans-serif">

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt"><B>Contractual Obligations</B>
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt">We have the following contractual obligations as at December&nbsp;31, 2007:
</DIV>
<DIV align="right">
<TABLE style="font-size: 9pt; margin-left 5%; margin-right: 10%" cellspacing="0" border="0" cellpadding="0" width="85%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="28%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="background: #000000; color: #FFFFFF; border-bottom: 1px solid #000000" colspan="18"><B>Payments Due by Period</B></TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom">
    <TD nowrap align="left"><B>Contractual Obligations</B></TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD nowrap align="left" colspan="2"><B>$</B></TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD nowrap align="right" style="background: #000000; color: #FFFFFF" colspan="2"><B>Total</B></TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD nowrap align="right" style="background: #000000; color: #FFFFFF" colspan="2"><B>Less than 1 year</B></TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD nowrap align="right" style="background: #000000; color: #FFFFFF" colspan="2"><B>1 &#150; 3 years</B></TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD nowrap align="right" style="background: #000000; color: #FFFFFF" colspan="2"><B>4 &#150; 5 years</B></TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD nowrap align="right" style="background: #000000; color: #FFFFFF" colspan="2"><B>After 5 years</B></TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="25" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Alberta
Heritage Foundation <SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>150,000</B></TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>&#151;</B></TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>&#151;</B></TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>&#151;</B></TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>150,000</B></TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Capital lease obligations</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>Nil</B></TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>&#151;</B></TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>&#151;</B></TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>&#151;</B></TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>&#151;</B></TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Operating leases <SUP style="font-size: 85%; vertical-align: text-top">(2)</SUP></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>305,553</B></TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>178,860</B></TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>126,693</B></TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>&#151;</B></TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>&#151;</B></TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Purchase obligations</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>960,000</B></TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>960,000</B></TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>&#151;</B></TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>&#151;</B></TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>&#151;</B></TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Other long term obligations</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><b>Nil</b></TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>&#151;</B></TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>&#151;</B></TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>&#151;</B></TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>&#151;</B></TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="25" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Total contractual obligations</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>1,415,553</B></TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>1,138,860</B></TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>126,693</B></TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>&#151;</B></TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>150,000</B></TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="25" align="left" style="border-top: 2px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="margin-top: 10pt; margin-left: 5%; margin-right:10%; font-size: 7pt">Notes:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 7pt; color: #000000; background: transparent">
    <TD width="5%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="left">(1)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Our Alberta Heritage Foundation obligation requires repayments upon the realization of sales
(see note 7 of our audited 2007 financial statements).</TD>
    <TD width="10%" style="background: transparent">&nbsp;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 7pt; color: #000000; background: transparent">
    <TD width="5%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="left">(2)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Our operating leases are comprised of our office lease and includes an estimate for our portion
of operating costs.</TD>
    <TD width="10%" style="background: transparent">&nbsp;</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt">We intend to fund our capital expenditure requirements and commitments with existing working
capital.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt"><B>Investing Activities</B>
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt">Under our Investment Policy, we are permitted to invest in short-term instruments with a rating
no less than R-1 (DBRS)&nbsp;with terms less than two years. Our portfolio mainly consists of
Government of Canada treasury bills, bankers&#146; acceptances and discount bond notes. As of December
31, 2007, we had $18,498,733 invested under this policy, currently earning interest at an
effective rate of 4.26%.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt"><B>Off-Balance Sheet Arrangements</B>
</DIV>
<DIV align="center" style="font-size: 10pt"><DIV style="width: 100%; border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV></DIV>



<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt">As at December&nbsp;31, 2007, we have not entered into any off-balance sheet arrangements.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt"><B>Transactions With Related Parties</B>
</DIV>
<DIV align="center" style="font-size: 10pt"><DIV style="width: 100%; border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV></DIV>



<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt">In 2007 and 2006, we did not enter into any related party transactions.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt"><B>Financial Instruments and Other Instruments</B>
</DIV>
<DIV align="center" style="font-size: 10pt"><DIV style="width: 100%; border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV></DIV>



<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt">We do not use financial derivatives or &#147;other financial instruments&#148;.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt"><B>Risk Factors Affecting Future Performance</B>
</DIV>
<DIV align="center" style="font-size: 10pt"><DIV style="width: 100%; border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV></DIV>



<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt"><B><I>All of our potential products, including REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>, are in the research and development stage
and will require further development and testing before they can be marketed commercially.</I></B>
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt">Prospects for companies in the biotechnology industry generally may be regarded as uncertain
given the nature of the industry and, accordingly, investments in biotechnology companies should
be regarded as speculative. We are currently in the research and development stage on one
product, REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>, for human application, the riskiest stage for a company in the biotechnology
industry. It is not possible to predict, based upon studies in animals, or early studies in
humans, whether REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> will prove to be
safe and effective in humans. REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> will require additional research and development,
including extensive clinical testing, before we will be able to obtain the
</DIV>


<DIV align="center">
<TABLE style="font-size: 7pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="85%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="right" colspan="2" valign="top" bgcolor="#000000" style="color: #ffffff; font-size: 9pt"><b>25</b></TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="6" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD colspan="2" bgcolor="#000000" style="border-top: 1px solid #ffffff">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD colspan="4" align="right"><DIV style="margin-left:15px; text-indent:-15px">Oncolytics Biotech Inc <B>MD &#038; A</B></DIV></TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>



<DIV style="font-family: Helvetica,Arial,sans-serif">

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">approval of the United States Food and Drug Administration (the &#147;FDA&#148;) or from similar regulatory
authorities in other countries to market REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> commercially. There can be no assurance that
the research and development programs conducted by us will result in REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> or any other
products becoming commercially viable products, and in the event that any product or products
result from the research and development program, it is unlikely they will be commercially
available for a number of years.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">To achieve profitable operations, Oncolytics Biotech Inc., alone or with others, must successfully
develop, introduce and market our products. To obtain regulatory approvals for products being
developed for human use, and to achieve commercial success, human clinical trials must demonstrate
that the product is safe for human use and that the product shows efficacy. Unsatisfactory results
obtained from a particular study relating to a program may cause us to abandon our commitment to
that program or the product being tested. No assurances can be provided that any current or future
animal or human test, if undertaken, will yield favorable results. If we are unable to establish
that REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> is a safe, effective treatment for cancer, we may be required to abandon further
development of the product and develop a new business strategy.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt"><B><I>There are inherent risks in pharmaceutical research and development.</I></B>
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">Pharmaceutical research and development is highly speculative and involves a high and significant
degree of risk.
The marketability of any product developed by us will be affected by numerous factors beyond our
control, including:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 9pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the discovery of unexpected toxicities or lack of sufficient efficacy of products which make
them unattractive
or unsuitable for human use;</TD>
    <TD width="5%" style="background: transparent">&nbsp;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 9pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>preliminary results as seen in animal and/or limited human testing may not be substantiated in
larger controlled
clinical trials;</TD>
    <TD width="5%" style="background: transparent">&nbsp;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 9pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>manufacturing costs or other factors may make manufacturing of products impractical and
non-competitive;</TD>
    <TD width="5%" style="background: transparent">&nbsp;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 9pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>proprietary rights of third parties or competing products or technologies
may preclude commercialization;</TD>
    <TD width="5%" style="background: transparent">&nbsp;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 9pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>requisite regulatory approvals for the commercial
distribution of products may not be obtained; and</TD>
    <TD width="5%" style="background: transparent">&nbsp;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 9pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>other factors may become apparent during the course of research, up-scaling or manufacturing
which may
result in the discontinuation of research and other critical projects.</TD>
    <TD width="5%" style="background: transparent">&nbsp;</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">Our product under development has never been manufactured on a commercial scale, and there can be
no assurance that such products can be manufactured at a cost or in a quantity to render such
products commercially viable. Production and utilization of our products may require the
development of new manufacturing technologies and expertise. The impact on our business in the
event that new manufacturing technologies and expertise are required to be developed is
uncertain. There can be no assurance that we will successfully meet any of these technological
challenges, or others that may arise in the course of development.
</DIV>


<DIV align="center">
<TABLE style="font-size: 7pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="85%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" colspan="2" valign="top" bgcolor="#000000" style="color: #ffffff; font-size: 9pt"><b>26</b></TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD colspan="2" bgcolor="#000000" style="border-top: 1px solid #ffffff">&nbsp;</TD>
    <TD colspan="6" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">Oncolytics Biotech Inc <B>MD &#038; A</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: Helvetica,Arial,sans-serif">

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt"><B><I>Pharmaceutical products are subject to intense regulatory approval processes.</I></B>
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt">The regulatory process for pharmaceuticals, which includes preclinical studies and clinical trials
of each compound to establish its safety and efficacy, takes many years and requires the
expenditure of substantial resources. Moreover, if regulatory approval of a drug is granted, such
approval may entail limitations on the indicated uses for which it may be marketed. Failure to
comply with applicable regulatory requirements can, among other things, result in suspension of
regulatory approvals, product recalls, seizure of products, operating restrictions and criminal
prosecution. Further, government policy may change, and additional government regulations may be
established that could prevent or delay regulatory approvals for our products. In addition, a
marketed drug and its manufacturer are subject to continual review. Later discovery of previously
unknown problems with the product or manufacturer may result in restrictions on such product or
manufacturer, including withdrawal of the product from the market.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt">The FDA in the United States and other relevant regulatory authorities may deny approval of a new
drug application (&#147;NDA&#148;) or its equivalent in the relevant jurisdiction if required regulatory
criteria are not satisfied, or may require additional testing. Product approvals may be withdrawn
if compliance with regulatory standards is not maintained or if problems occur after the product
reaches the market. The FDA may require further testing and surveillance programs to monitor the
pharmaceutical product that has been commercialized. Non-compliance with applicable requirements
can result in fines and other judicially imposed sanctions, including product withdrawals, product
seizures, injunction actions and criminal prosecutions.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt">In addition to our own pharmaceuticals, we may supply active pharmaceutical ingredients and
advanced pharmaceutical intermediates for use in or with our customers&#146; other drug products. The
final drug products in which the pharmaceutical ingredients and advanced pharmaceutical
intermediates are used, however, are subject to regulation for safety and efficacy by the FDA and
other jurisdictions, as the case may be. Such products must be approved by such agencies before
they can be commercially marketed. The process of obtaining regulatory clearance for marketing is
uncertain, costly and time consuming. We cannot predict how long the necessary regulatory
approvals will take or whether our customers will ever obtain such approval for their products. To
the extent that our customers do not obtain the necessary regulatory approvals for marketing new
products, our product sales could be adversely affected.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt">The FDA and other governmental regulators have increased requirements for drug purity and have
increased environmental burdens upon the pharmaceutical industry. Because pharmaceutical drug
manufacturing is a highly regulated industry, requiring significant documentation and validation
of manufacturing processes and quality control assurance prior to approval of the facility to
manufacture a specific drug, there can be considerable transition time between the initiation of a
contract to manufacture a product and the actual initiation of manufacture of that product. Any
lag time in the initiation of a contract to manufacture product and the actual initiation of
manufacture could cause us to lose profits or incur liabilities.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt">The pharmaceutical regulatory regime in Europe and other countries is, by and large, generally
similar to that of
Canada and the United States. We could face similar risks in these other jurisdictions, as the
risks described above.
</DIV>


<DIV align="center">
<TABLE style="font-size: 7pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="85%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="right" colspan="2" valign="top" bgcolor="#000000" style="color: #ffffff; font-size: 9pt"><b>27</b></TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="6" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD colspan="2" bgcolor="#000000" style="border-top: 1px solid #ffffff">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD colspan="4" align="right"><DIV style="margin-left:15px; text-indent:-15px">Oncolytics Biotech Inc <B>MD &#038; A</B></DIV></TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: Helvetica,Arial,sans-serif">

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt"><B><I>Our operations and products may be subject to other government manufacturing and testing
regulations.</I></B>
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">Securing regulatory approval for the marketing of therapeutics by the FDA in the United States
and similar regulatory agencies in other countries is a long and expensive process, which can
delay or prevent product development and marketing. Approval to market products may be for
limited applications or may not be received at all.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">The products anticipated to be manufactured by us will have to comply with the FDA&#146;s current Good
Manufacturing Practices (&#147;cGMP&#148;) and other FDA and local government guidelines and regulations,
including other international regulatory requirements and guidelines. Additionally, certain of our
customers may require the manufacturing facilities contracted by us to adhere to additional
manufacturing standards, even if not required by the FDA. Compliance with cGMP regulations
requires manufacturers to expend time, money and effort in production, and to maintain precise
records and quality control to ensure that the product meets applicable specifications and other
requirements. The FDA and other regulatory bodies periodically inspect drug-manufacturing
facilities to ensure compliance with applicable cGMP requirements. If the manufacturing facilities
contracted by us fail to comply with the cGMP requirements, the facilities may become subject to
possible FDA or other regulatory action and manufacturing at the facility could consequently be
suspended. We may not be able to contract suitable alternative or back-up manufacturing facilities
on terms acceptable to us or at all.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">The FDA or other regulatory agencies may also require the submission of any lot of a particular
product for inspection. If the lot product fails to meet the FDA requirements, then the FDA could
take any of the following actions: (i)&nbsp;restrict the release of the product; (ii)&nbsp;suspend
manufacturing of the specific lot of the product; (iii)&nbsp;order a recall of the lot of the product;
or (iv)&nbsp;order a seizure of the lot of the product.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">We are subject to regulation by governments in many jurisdictions and, if we do not comply with
healthcare, drug, manufacturing and environmental regulations, among others, our existing and
future operations may be curtailed, and we could be subject to liability.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">In addition to the regulatory approval process, we may be subject to regulations under local,
provincial, state, federal and foreign law, including requirements regarding occupational health,
safety, laboratory practices, environmental protection and hazardous substance control, and may be
subject to other present and future local, provincial, state, federal and foreign regulations.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt"><B><I>Our products may fail or cause harm, subjecting us to product liability claims, which are
uninsured.</I></B>
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">The sale and use of our products entail risk of product liability. We currently do not have any
product liability insurance. There can be no assurance that we will be able to obtain appropriate
levels of product liability insurance prior to any sale of our pharmaceutical products. An
inability to obtain insurance on economically feasible terms or to otherwise protect against
potential product liability claims could inhibit or prevent the commercialization of products
developed by us. The obligation to pay any product liability claim or a recall of a product could
have a material adverse effect on our business, financial condition and future prospects.
</DIV>


<DIV align="center">
<TABLE style="font-size: 7pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="85%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" colspan="2" valign="top" bgcolor="#000000" style="color: #ffffff; font-size: 9pt"><b>28</b></TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD colspan="2" bgcolor="#000000" style="border-top: 1px solid #ffffff">&nbsp;</TD>
    <TD colspan="6" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">Oncolytics Biotech Inc <B>MD &#038; A</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: Helvetica,Arial,sans-serif">

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt"><B><I>Our technologies may become obsolete.</I></B>
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt">The pharmaceutical industry is characterized by rapidly changing markets, technology, emerging
industry standards and frequent introduction of new products. The introduction of new products
embodying new technologies, including new manufacturing processes, and the emergence of new
industry standards may render our products obsolete, less competitive or less marketable. The
process of developing our products is extremely complex and requires significant continuing
development efforts and third party commitments. Our failure to develop new technologies and
products and the obsolescence of existing technologies could adversely affect our business.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt">We may be unable to anticipate changes in our potential customer requirements that could make our
existing technology obsolete. Our success will depend, in part, on our ability to continue to
enhance our existing technologies, develop new technology that addresses the increasing
sophistication and varied needs of the market, and respond to technological advances and emerging
industry standards and practices on a timely and cost-effective basis. The development of our
proprietary technology entails significant technical and business risks. We may not be successful
in using our new technologies or exploiting the respective niche markets effectively or adapting
our businesses to evolving customer or medical requirements or preferences or emerging industry
standards.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt"><B><I>We have no operating revenues and a history of losses.</I></B>
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt">To date, we have not generated sufficient revenues to offset our research and development costs
and accordingly have not generated positive cash flow or made an operating profit. As of December
31, 2007, we had an accumulated deficit of $80.5&nbsp;million and we incurred net losses of $15.6
million, $14.3&nbsp;million, and $12.8&nbsp;million, for the years ended December&nbsp;31, 2007, 2006, and 2005,
respectively. We anticipate that we will continue to incur significant losses during 2008 and in
the foreseeable future. We do not expect to reach profitability at least until after successful
and profitable commercialization of one or more of our products. Even if one or more of our
products are profitably commercialized, the initial losses incurred by us may never be recovered.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt"><B><I>We may need additional financing in the future to fund the research and development of our
products and to meet our ongoing capital requirements.</I></B>
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt">As of December&nbsp;31, 2007, we had cash and cash equivalents (including short-term investments) of
$25.2&nbsp;million and working capital of approximately $22.7&nbsp;million. We anticipate that we may need
additional financing in the future to fund research and development and to meet our ongoing
capital requirements. The amount of future capital requirements will depend on many factors,
including continued scientific progress in our drug discovery and development programs, progress
in our pre-clinical and clinical evaluation of drug candidates, time and expense associated with
filing, prosecuting and enforcing our patent claims and costs associated with obtaining
regulatory approvals. In order to meet such capital requirements, we will consider contract fees,
collaborative research and development arrangements, and additional public or private financings
(including the incurrence of debt and the issuance of additional equity securities) to fund all
or a part of particular programs as well as potential partnering or licensing opportunities.
There can be no assurance that additional funding will be available or, if available, that it
will be available on acceptable terms. If adequate funds are not available on terms favorable to
us, we may have to reduce substantially or eliminate expenditures for research and development,
testing, production and marketing of our proposed product, or obtain funds through arrangements
with corporate partners that require us to relinquish rights
</DIV>


<DIV align="center">
<TABLE style="font-size: 7pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="85%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="right" colspan="2" valign="top" bgcolor="#000000" style="color: #ffffff; font-size: 9pt"><b>29</b></TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="6" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD colspan="2" bgcolor="#000000" style="border-top: 1px solid #ffffff">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD colspan="4" align="right"><DIV style="margin-left:15px; text-indent:-15px">Oncolytics Biotech Inc <B>MD &#038; A</B></DIV></TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: Helvetica,Arial,sans-serif">

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">to certain of our technologies or product. There can be no assurance that we will be able to raise
additional capital
if our current capital resources are exhausted.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt"><B><I>The cost of director and officer liability insurance may continue to increase substantially or
may not be available to us and may affect our ability to retain quality directors and officers.</I></B>
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">We carry liability insurance on behalf of our directors and officers. Given a number of large
director and officer liability insurance claims in the U.S. equity markets, director and officer
liability insurance had until recently become increasingly more expensive with increased
restrictions. Consequently, there is no assurance that we will continue to be offered this
insurance or be able to obtain adequate coverage. The inability to acquire the appropriate
insurance coverage will limit our ability to attract and maintain directors and officers as
required to conduct our business.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt"><B><I>We incur some of our expenses in foreign currencies and therefore are exposed to foreign
currency exchange rate fluctuations.</I></B>
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">We incur some of our manufacturing, clinical, collaborative and consulting expenses in foreign
currencies, primarily the U.S. dollar and the Great British pound (&#147;GBP&#148;). Over the past few
years the Canadian dollar has appreciated relative to the U.S. dollar and the GBP thereby
decreasing the Canadian dollar equivalent. However, if this trend reverses, our Canadian dollar
equivalent costs will increase. Also, as we expand to other foreign jurisdictions there may be an
increase in our foreign exchange exposure.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt"><B><I>We earn interest income on our excess cash reserves and are exposed to changes in interest rates.</I></B>
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">We invest our excess cash reserves in investment vehicles that provide a rate of return with little
risk to principle.
</DIV>

<DIV align="left" style="margin-top: 0pt; margin-left: 10%; margin-right:5%; font-size: 9pt">As interest rates change the amount of interest income we earn will be directly impacted.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt"><B>Other MD &#038; A Requirements</B>
</DIV>
<DIV align="center" style="font-size: 10pt"><DIV style="width: 100%; border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV></DIV>



<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">We have 41,180,748 common shares outstanding at March&nbsp;5, 2008. If all of our warrants (4,220,000)
and options
(3,870,493) were exercised we would have 49,271,241 common shares outstanding.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">Our 2007 Annual Information Form is available on <B>www.sedar.com.</B>
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt"><B>Disclosure Controls and Procedures</B>
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt"><B><I>Evaluation of Disclosure Controls and Procedures:</I></B>
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">Our chief executive and financial officers reviewed and evaluated our disclosure controls and
procedures. Based on that evaluation, they have concluded that our disclosure controls and
procedures are effective in providing them with timely material information relating to the
Company.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt"><B><I>Management&#146;s Annual Report on Internal Control Over Financial Reporting:</I></B>
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">Our management is responsible for establishing and maintaining adequate internal control over
financial reporting, and has designed such internal control over financial reporting to provide
reasonable assurance regarding the reliability of financial reporting and the preparation and fair
presentation of financial statements for external purposes in accordance with Canadian generally
accepted accounting principles (GAAP), including a reconciliation to U.S. GAAP.
</DIV>


<DIV align="center">
<TABLE style="font-size: 7pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="85%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" colspan="2" valign="top" bgcolor="#000000" style="color: #ffffff; font-size: 9pt"><b>30</b></TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD colspan="2" bgcolor="#000000" style="border-top: 1px solid #ffffff">&nbsp;</TD>
    <TD colspan="6" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">Oncolytics Biotech Inc <B>MD &#038; A</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: Helvetica,Arial,sans-serif">

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt">Management, including the Chief Executive Officer and Chief Financial Officer, does not expect
that our internal controls and procedures over financial reporting will prevent all error and all
fraud. A control system can provide only reasonable, not absolute, assurance that the objectives
of the control system are met. Because of the inherent limitations in all control systems, no
evaluation of controls can provide absolute assurance that all control issues and instances of
fraud, if any, within Oncolytics Biotech Inc. have been detected. These inherent limitations
include the realities that judgments in decision-making can be faulty, and that breakdowns can
occur because of simple error or mistake. Additionally, controls can be circumvented by the
individual acts of some persons, by collusion of two or more people, or by management override of
the control. The design of any system of controls also is based in part upon certain assumptions
about the likelihood of future events, and there can be no assurance that any design will succeed
in achieving our stated goals under all potential future conditions. Because of the inherent
limitations in a cost-effective control system, misstatements due to error or fraud may occur and
not be detected. Also, projections of any evaluation of effectiveness to future periods are
subject to the risk that controls may become inadequate because of changes in conditions, or that
the degree of compliance with the policies or procedures may deteriorate.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt">Management has evaluated the design and operation of our internal control over financial
reporting as of December&nbsp;31, 2007, and has concluded that such internal control over financial
reporting is effective as of December&nbsp;31, 2007. There are no material weaknesses that have been
identified by management in this regard. This assessment was based on criteria for effective
internal control over financial reporting described in Internal Control &#150; Integrated Framework
issued by the Committee of Sponsoring Organizations of the Treadway Commission.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt"><B><I>Changes in Internal Controls over Financial Reporting:</I></B>
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt">There were no changes in our internal control over financial reporting that occurred during the
last fiscal year that
have materially affected, or are reasonably likely to materially affect, our internal control over
financial reporting.
</DIV>


<DIV align="center">
<TABLE style="font-size: 7pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="85%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="right" colspan="2" valign="top" bgcolor="#000000" style="color: #ffffff; font-size: 9pt"><b>31</b></TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="6" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD colspan="2" bgcolor="#000000" style="border-top: 1px solid #ffffff">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD colspan="4" align="right"><DIV style="margin-left:15px; text-indent:-15px">Oncolytics Biotech Inc <B>MD &#038; A</B></DIV></TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>


<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: Helvetica,Arial,sans-serif">
<P><DIV style="position: relative; float: left; width: 10%">

<DIV align="left" style="font-size: 9pt; margin-top: 12pt"><IMG src="o40024o4002420.gif" alt="(GRAPHIC)">
</DIV>

</DIV>


<DIV style="position: relative; float: right; width: 90%">

<br><br><br><br><br><br><br><DIV align="left" style="margin-top: 6pt; margin-right: 5%; font-size: 9pt"><FONT face="'Times New Roman',Times,serif"><B>Statement of Management&#146;s Responsibility</B></FONT>
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-right: 5%; font-size: 9pt">Management is responsible for the preparation and presentation of the financial statements,
Management&#146;s Discussion and Analysis (&#147;MD&#038;A&#148;) and all other information in the Annual Report.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-right: 5%; font-size: 9pt">In management&#146;s opinion, the accompanying financial statements have been properly prepared with
reasonable limits of materiality and within the appropriately selected Canadian generally
accepted accounting principles and policies consistently applied and summarized in the financial
statements.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-right: 5%; font-size: 9pt">The MD&#038;A has been prepared in accordance with the requirements of securities regulators as
applicable to Oncolytics
Biotech Inc.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-right: 5%; font-size: 9pt">The financial statements and information in the MD&#038;A generally include estimates that are
necessary when transactions affecting the current accounting period cannot be finalized with
certainty until future periods. Based on careful judgments by management, such estimates have been
properly reflected in the accompanying financial statements and MD&#038;A. The MD&#038;A also includes
information regarding the impact of current transactions and events, sources of liquidity and
capital resources and risks and uncertainty. Actual results in the future may differ materially
from our present assessment of this information because future events and circumstances may not
occur as expected.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-right: 5%; font-size: 9pt">Systems of internal controls, including organizational and procedural controls and internal
controls over financial reporting, assessed as reasonable and appropriate in the circumstances,
are designed and maintained by management to provide reasonable assurance that assets are
safeguarded from loss or unauthorized use and to produce reliable records for financial
purposes.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-right: 5%; font-size: 9pt">We, as the Chief Executive Officer and Chief Financial Officer will certify to our annual
filings with the CSA and the SEC as required in Canada by Multilateral Instrument 52-109
(certification of Disclosure in Issuers&#146; Annual Interim Filings) and in the United States by the
<I>Sarbanes-Oxley Act</I>.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-right: 5%; font-size: 9pt">The external auditors conducted an independent examination of corporate and accounting records in
accordance with generally accepted auditing standards to express their opinion on the financial
statements. Their examination included such tests and procedures as they considered necessary to
provide reasonable assurance that the financial statements are presented fairly. The external
auditors have full and free access to our Board of Directors and its Committees to discuss audit,
financial reporting and related matters.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-right: 5%; font-size: 9pt">The Board of Directors is responsible for ensuring that management fulfills its responsibilities
for financial reporting and internal control. The Board exercises this responsibility through the
Audit Committee of the Board. This Committee meets with management and the external auditors to
satisfy itself that management&#146;s responsibilities are properly discharged and to review the
financial statements and MD&#038;A before they are presented to the Board of Directors for approval.
</DIV>
<DIV align="center">
<TABLE style="font-size: 9pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom" style="font-size: 18pt">
    <TD width="45%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="45%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><IMG src="o40024o4002403.gif" alt="-s- Brad Thompson">
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="margin-left:110px; text-indent:-0px"><IMG src="o40024o4002415.gif" alt="-s- Doug Ball"></DIV></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Brad Thompson, PhD
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="margin-left:110px; text-indent:-0px">Doug Ball, CA</DIV></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Chairman, President and CEO
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="margin-left:110px; text-indent:-0px">Chief Financial Officer</DIV></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

</DIV>
<BR clear="all">


<DIV align="center" style="margin-top: -11pt">
<TABLE style="font-size: 7pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="77%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" colspan="2" valign="top" bgcolor="#000000" style="color: #ffffff; font-size: 9pt"><b>32</b>&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD colspan="2" bgcolor="#000000" style="border-top: 1px solid #ffffff">&nbsp;</TD>
    <TD colspan="6" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">Oncolytics Biotech Inc <B>Management&#146;s Responsibility</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>



<DIV style="font-family: Helvetica,Arial,sans-serif">
<P><DIV style="position: relative; float: left; width: 90%">



<br><br><br><br><br><br><br><DIV align="justify" style="font-size: 9pt; margin-top: 6pt; margin-left: 15%"><FONT face="'Times New Roman',Times,serif"><B>Auditors&#146; Report</B></FONT>
</DIV>


<DIV align="justify" style="font-size: 9pt; margin-top: 50pt; margin-left: 15%"><B><I>To the Shareholders of Oncolytics Biotech Inc.</I></B>
</DIV>


<DIV align="left" style="font-size: 9pt; margin-top: 50pt; margin-left: 15%">We have audited the balance sheets of Oncolytics Biotech Inc. as at December&nbsp;31, 2007 and 2006 and
the statements of loss and comprehensive loss and cash flows for each of the years in the three
year period ended December&nbsp;31, 2007 and for the cumulative period from inception on April&nbsp;2, 1998.
These financial statements are the responsibility of the Company&#146;s management. Our responsibility
is to express an opinion on these financial statements based on our audits.
</DIV>


<DIV align="left" style="font-size: 9pt; margin-top: 6pt; margin-left: 15%">We conducted our audits in accordance with Canadian generally accepted auditing standards. Those
standards require that we plan and perform an audit to obtain reasonable assurance whether the
financial statements are free of material misstatement. An audit includes examining, on a test
basis, evidence supporting the amounts and disclosures in the financial statements. An audit also
includes assessing the accounting principles used and significant estimates made by management, as
well as evaluating the overall financial statement presentation.
</DIV>


<DIV align="left" style="font-size: 9pt; margin-top: 6pt; margin-left: 15%">In our opinion, these financial statements present fairly, in all material respects, the financial
position of the Company at December&nbsp;31, 2007 and 2006 and the results of its operations and its
cash flows for each of the years in the three year period ended December&nbsp;31, 2007 and the
cumulative period from inception on April&nbsp;2, 1998 in accordance with Canadian generally accepted
accounting principles.
</DIV>
<DIV align="justify" style="font-size: 9pt; margin-top: 40pt; margin-left: 15%">&nbsp;</div>
<DIV align="right">
<TABLE style="font-size: 9pt" cellspacing="0" border="0" cellpadding="0" width="85%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="45%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="45%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><IMG src="o40024o4002405.gif" alt="(ERNST &#038; YOUNG LLP)"></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Calgary, Canada
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Ernst &#038; Young LLP</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">February&nbsp;15, 2008
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Chartered Accountants</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

</DIV>
<DIV style="position: relative; float: right; width: 10%">

<DIV align="right" style="font-size: 9pt; margin-top: 12pt"><IMG src="o40024o4002418.gif" alt="(GRAPHIC)">
</DIV>

</DIV>
<BR clear="all">


<DIV align="center" style="margin-top: -11pt">
<TABLE style="font-size: 7pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="79%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="font-size: 7pt">
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="right" colspan="2" valign="top" bgcolor="#000000" style="color: #ffffff; font-size: 9pt">&nbsp;&nbsp;<b>33</b></TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="6" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD colspan="2" bgcolor="#000000" style="border-top: 1px solid #ffffff">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 7pt">
    <TD>&nbsp;</TD>
    <TD colspan="4" align="right"><DIV style="margin-left:15px; text-indent:-15px">Oncolytics Biotech Inc <B>Auditors&#146; Report</B>
</DIV></TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>
<P align="center" style="font-size: 9pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>



<DIV style="font-family: Helvetica,Arial,sans-serif">

<P><DIV style="position: relative; float: left; width: 10%">

<DIV align="left" style="font-size: 1pt; margin-top: 12pt"><IMG src="o40024o4002419.gif" alt="(GRAPHIC)">
</DIV>

</DIV>
<DIV style="position: relative; float: right; width: 90%">
<br><br><br><br><br><DIV style="font-size: 1pt">&nbsp;</DIV>
<DIV align="justify" style="font-size: 9pt; margin-top: 12pt"><FONT face="'Times New Roman',Times,serif"><B>Balance Sheets</B></FONT>
</DIV>

<DIV align="left">
<TABLE style="font-size: 9pt" cellspacing="0" border="0" cellpadding="0" width="95%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="64%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom">
    <TD nowrap align="left">As at December 31,</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">$</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2" bgcolor="#000000" style="color: #ffffff"><B>2007</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">2006</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="13" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Assets</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B><I>Current</I></B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Cash and cash equivalents</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>6,715,096</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,491,511</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Short-term investments <i>&#091;note 16&#093;</i></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>18,498,733</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">24,122,237</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Accounts receivable</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>80,085</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">84,003</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Prepaid expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>260,300</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">638,540</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="13" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>25,554,214</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">28,336,291</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="13" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Property and equipment <i>&#091;note 5&#093;</i></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>201,103</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">149,596</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Intellectual property <i>&#091;note 6&#093;</i></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>5,026,540</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5,079,805</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="13" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>30,781,857</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">33,565,692</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="13" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Liabilities and Shareholders&#146; Equity</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B><I>Current</I></B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Accounts payable and accrued liabilities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>2,821,227</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,616,421</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="13" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Alberta Heritage Foundation loan <i>&#091;notes 3 and 7&#093;</i></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>&#151;</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">150,000</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="13" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B><I>Commitments and contingency </I></B><I>&#091;notes 7, 8 9 and 15&#093;</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B><I>Shareholders&#146; equity</I></B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Share capital <i>&#091;note 10&#093;</i></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Authorized: unlimited</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Issued: 41,180,748 (2006 &#150; 36,520,748)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>92,759,665</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">83,083,271</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Warrants <i>&#091;note 10&#093;</i></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>5,346,260</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,216,740</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Contributed surplus <i>&#091;notes 2, 10, 11 and 12&#093;</i></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>10,376,962</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">8,529,326</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Deficit <i>&#091;note 4&#093;</i></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>(80,522,257</B></TD>
    <TD nowrap bgcolor="#000000" style="color: #ffffff"><B>)</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(65,030,066</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="13" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>27,960,630</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">30,799,271</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="13" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>30,781,857</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">33,565,692</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="13" align="left" style="border-top: 2px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="justify" style="font-size: 7pt; margin-top: 6pt">See accompanying notes
</DIV>

<DIV align="justify" style="font-size: 9pt; margin-top: 6pt">On behalf of the Board:
</DIV>

<DIV align="center">
<TABLE style="font-size: 9pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="45%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="45%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><IMG src="o40024o4002406.gif" alt="(-s- Fred Stewart)">
</div></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="margin-left:174px; text-indent:-0px"><IMG src="o40024o4002407.gif" alt="(-s- Jim Dinning)"></DIV></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Fred Stewart
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="margin-left:174px; text-indent:-0px">Jim Dinning</DIV></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Director
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="margin-left:174px; text-indent:-0px">Director</DIV></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

</DIV>
<BR clear="all">


<DIV align="center" style="margin-top: -9pt">
<TABLE style="font-size: 7pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="77%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" colspan="2" valign="top" bgcolor="#000000" style="color: #ffffff; font-size: 9pt"><b>34</b>&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD colspan="2" bgcolor="#000000" style="border-top: 1px solid #ffffff">&nbsp;</TD>
    <TD colspan="6" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">Oncolytics Biotech Inc <B>Financial Statements</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>
<P align="center" style="font-size: 9pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: Helvetica,Arial,sans-serif">

<DIV align="justify" style="font-size: 9pt; margin-left: 5%; margin-top: 12pt"><FONT face="'Times New Roman',Times,serif"><B>Statements of Loss and Comprehensive Loss</B></FONT>
</DIV>

<DIV align="right">
<TABLE style="font-size: 9pt; margin-left: 5%; margin-right: 10%" cellspacing="0" border="0" cellpadding="0" width="85%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="44%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 6pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">Cumulative</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 6pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">from inception</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 6pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">on April 2, 1998</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 6pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">to December 31,</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom">
    <TD nowrap align="left">For the periods ended December 31</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">$</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2" bgcolor="#000000" style="color: #ffffff"><B>2007</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">2006</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">2005</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">2007</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="21" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Revenue</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Rights revenue</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>&#151;</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">310,000</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="21" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>&#151;</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">310,000</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="21" align="left" style="border-top: 2px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Expenses</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Research and development <i>&#091;note 9&#093;</i></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>11,315,088</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10,535,689</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9,308,977</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">54,536,282</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Operating</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>3,987,688</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,630,144</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,083,372</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">20,758,269</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Stock based compensation <i>&#091;note 11&#093;</i></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>539,156</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">403,550</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">64,104</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,704,805</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Foreign exchange loss</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>8,862</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">35,270</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">253,608</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">657,710</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Amortization &#150; intellectual property</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>962,427</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">874,043</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">786,459</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,999,261</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Amortization &#150; capital assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>40,714</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">52,637</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">69,532</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">448,397</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="21" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff">16,853,935</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">15,531,333</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">13,566,052</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">86,104,724</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="21" align="left" style="border-top: 2px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Loss before the following</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>16,853,935</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">15,531,333</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">13,566,052</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">85,794,724</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Interest income</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>(1,211,744</B></TD>
    <TD nowrap bgcolor="#000000" style="color: #ffffff"><B>)</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(1,233,809</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(783,456</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(6,014,749</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Gain on
sale of BCY LifeSciences Inc.</B> <i>&#091;note 20&#093;</i></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>&#151;</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(765</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(299,403</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Loss on sale of Transition Therapeutics Inc.</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>&#151;</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,156,685</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="21" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Loss before income taxes</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>15,642,191</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">14,297,524</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">12,781,831</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">81,637,257</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Future income tax recovery </B><I>&#091;note 14 and 19&#093;</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>&#151;</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(1,115,000</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="21" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD nowrap><DIV style="margin-left:15px; text-indent:-15px"><B>Net loss and comprehensive loss for the period</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>15,642,191</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">14,297,524</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">12,781,831</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">80,522,257</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Basic and diluted loss per share </B><I>&#091;note 13&#093;</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>(0.39</B></TD>
    <TD nowrap bgcolor="#000000" style="color: #ffffff"><B>)</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(0.39</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(0.39</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="21" align="left" style="border-top: 2px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="justify" style="font-size: 7pt; margin-top: 6pt; margin-left: 5%">See accompanying notes

</DIV>

<DIV align="right">
<TABLE style="font-size: 7pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="85%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="right" colspan="2" valign="top" bgcolor="#000000" style="color: #ffffff; font-size: 9pt"><b>35</b></TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="6" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD colspan="2" bgcolor="#000000" style="border-top: 1px solid #ffffff">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD colspan="4" align="right"><DIV style="margin-left:15px; text-indent:-15px">Oncolytics Biotech Inc <B>Financial Statements</B></DIV></TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 9pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>





<DIV style="font-family: Helvetica,Arial,sans-serif">

<DIV align="justify" style="font-size: 9pt; margin-left: 10%; margin-top: 12pt"><FONT face="'Times New Roman',Times,serif"><B>Statements of Cash Flows</B></FONT>
</DIV>

<DIV align="right">
<TABLE style="font-size: 9pt; margin-left: 10%; margin-right: 5%" cellspacing="0" border="0" cellpadding="0" width="85%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="40%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 6pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">Cumulative</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 6pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">from inception</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 6pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">on April 2, 1998</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 6pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">to December 31,</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom">
    <TD nowrap align="left">For the periods ended December 31</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">$</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2" bgcolor="#000000" style="color: #ffffff"><B>2007</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">2006</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">2005</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">2007</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="21" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Operating Activities</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Net loss and comprehensive loss for the period</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>(15,642,191</B></TD>
    <TD nowrap bgcolor="#000000" style="color: #ffffff"><B>)</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(14,297,524</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(12,781,831</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(80,522,257</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Add (deduct)&nbsp;non-cash items</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Amortization &#150; intellectual property</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>962,427</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">874,043</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">786,459</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,999,261</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Amortization &#150; capital assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>40,714</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">52,637</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">69,532</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">448,397</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Stock based compensation <i>&#091;note 11&#093;</i></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>539,156</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">403,550</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">64,104</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,704,805</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Other non-cash items <i>&#091;note 19&#093;</i></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>&#151;</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">224,508</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,383,537</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD NOWRAP><DIV style="margin-left:15px; text-indent:-15px">Net change in non-cash working capital <i>&#091;note 19&#093;</i></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>530,300</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">811,922</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">584,766</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,435,221</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="21" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Cash used in operating activities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>(13,569,594</B></TD>
    <TD nowrap bgcolor="#000000" style="color: #ffffff"><B>)</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(12,155,372</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(11,052,462</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(66,551,036</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="21" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Investing Activities</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Intellectual property</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>(852,498</B></TD>
    <TD nowrap bgcolor="#000000" style="color: #ffffff"><B>)</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(842,610</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(1,033,035</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(6,351,778</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Capital assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>(92,221</B></TD>
    <TD nowrap bgcolor="#000000" style="color: #ffffff"><B>)</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(35,837</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(61,309</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(715,569</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Purchase of short-term investments</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>(949,496</B></TD>
    <TD nowrap bgcolor="#000000" style="color: #ffffff"><B>)</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(1,035,427</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(22,195,253</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(49,068,963</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Redemption of short-term investments</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>6,573,000</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">13,808,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6,656,746</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">30,151,746</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Investment in BCY LifeSciences Inc.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>&#151;</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">7,965</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">464,602</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Investment in Transition Therapeutics Inc.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>&#151;</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,532,343</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="21" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Cash provided by (used in) investing activities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>4,678,785</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">11,894,126</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(16,624,886</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(22,987,619</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="21" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Financing Activities</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Proceeds from exercise of stock options
and warrants</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>51,000</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">241,400</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,384,787</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">15,259,468</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Proceeds from private placements</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>&#151;</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">15,395,402</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">38,137,385</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Proceeds from public offerings</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>12,063,394</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">42,856,898</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="21" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Cash provided by financing activities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>12,114,394</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">241,400</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">18,780,189</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">96,253,751</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="21" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Net increase (decrease)&nbsp;in cash and cash
equivalents during the period</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>3,223,585</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(19,846</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(8,897,159</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6,715,096</TD>
    <TD>&nbsp;</TD>
</TR>


<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Cash and cash equivalents, beginning of the
period</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>3,491,511</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,511,357</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">12,408,516</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="21" align="left" style="border-top: 2px solid #000000">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Cash and cash equivalents, end of the period</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>6,715,096</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,491,511</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,511,357</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6,715,096</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="21" align="left" style="border-top: 2px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Cash interest received</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>1,392,866</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">940,100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">993,097</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="21" align="left" style="border-top: 2px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="justify" style="font-size: 7pt; margin-top: 6pt; margin-left: 10%">See accompanying notes

</DIV>


<DIV align="center">
<TABLE style="font-size: 7pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="79%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" colspan="2" valign="top" bgcolor="#000000" style="color: #ffffff; font-size: 9pt"><b>36</b></TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD colspan="2" bgcolor="#000000" style="border-top: 1px solid #ffffff">&nbsp;</TD>
    <TD colspan="6" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
<TD><DIV style="margin-left:0px; text-indent:-0px">Oncolytics Biotech Inc <B>Financial Statements</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>
<P align="center" style="font-size: 9pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>




<DIV style="font-family: Helvetica,Arial,sans-serif">
<P><DIV style="position: relative; float: left; width: 90%">


<DIV align="left" style="font-size: 9pt; margin-top: 84pt; margin-left: 5%"><FONT face="'Times New Roman',Times,serif"><B>Notes to Financial Statements</B></FONT>
</DIV>


<DIV align="left" style="font-size: 9pt; margin-top: 6pt; margin-left: 5%"><I>December&nbsp;31 2007 and 2006.</I>
</DIV>


<DIV align="left" style="font-size: 9pt; margin-top: 6pt; margin-left: 5%"><B>1. Incorporation and Nature of Operations</B>
</DIV>
<DIV align="center"><DIV style="font-size: 3pt; margin-top: 1pt; width: 100%; border-top: 1px solid #000000">&nbsp;</DIV></DIV>



<DIV align="left" style="font-size: 9pt; margin-top: 6pt; margin-left: 5%">Oncolytics Biotech Inc. (the &#147;Company&#148; or &#147;Oncolytics&#148;) was incorporated on April&nbsp;2, 1998 under
the Business Corporations Act (Alberta) as 779738 Alberta Ltd. On April&nbsp;8, 1998, the Company
changed its name to Oncolytics Biotech Inc.
</DIV>


<DIV align="left" style="font-size: 9pt; margin-top: 6pt; margin-left: 5%">The Company is a development stage biopharmaceutical company that focuses on the discovery and
development of pharmaceutical products for the treatment of cancers that have not been
successfully treated with conventional therapeutics. The product being developed by the Company
may represent a novel treatment for Ras mediated cancers which can be used as an alternative to
existing cytotoxic or cytostatic therapies, as an adjuvant therapy to conventional chemotherapy,
radiation therapy, or surgical resections, or to treat certain cellular proliferative disorders
for which no current therapy exists.
</DIV>


<DIV align="left" style="font-size: 9pt; margin-top: 6pt; margin-left: 5%"><B>2. Basis of Financial Statement Presentation</B>
</DIV>
<DIV align="center"><DIV style="font-size: 3pt; margin-top: 1pt; width: 100%; border-top: 1px solid #000000">&nbsp;</DIV></DIV>



<DIV align="left" style="font-size: 9pt; margin-top: 6pt; margin-left: 5%">On April&nbsp;21, 1999, SYNSORB Biotech Inc. (&#147;SYNSORB&#148;) purchased all of the shares of the Company.
In connection with the acquisition, the basis of accounting for the assets and liabilities of
Oncolytics was changed to reflect SYNSORB&#146;s cost of acquiring its interest in such assets and
liabilities (i.e. reflecting SYNSORB&#146;s purchase cost in the financial statements of the Company).
The amount by which SYNSORB&#146;s purchase price exceeded the underlying net book value of the
Company&#146;s assets and liabilities at April&nbsp;21, 1999 was $2,500,000. This amount has been credited
to contributed surplus and charged to intellectual property which will be amortized to income
based on the established amortization policies for such assets. Subsequent to April&nbsp;21, 1999,
SYNSORB&#146;s ownership has been diluted through public offerings of the Company&#146;s common shares,
sales of the Company&#146;s shares by SYNSORB and a distribution of SYNSORB&#146;S ownership interest in
the Company to its shareholders (see note 20). As a result, SYNSORB no longer has any ownership
in the Company.
</DIV>


<DIV align="left" style="font-size: 9pt; margin-top: 6pt; margin-left: 5%"><B>3. Summary of Significant Accounting Policies</B>
</DIV>
<DIV align="center"><DIV style="font-size: 3pt; margin-top: 1pt; width: 100%; border-top: 1px solid #000000">&nbsp;</DIV></DIV>



<DIV align="left" style="font-size: 9pt; margin-top: 6pt; margin-left: 5%">The financial statements of the Company have been prepared in accordance with Canadian generally
accepted accounting principles. These policies are, in all material respects, in accordance with
United States generally accepted accounting principles except as disclosed in note 21. The
financial statements have, in management&#146;s opinion, been properly prepared within reasonable
limits of materiality and within the framework of the significant accounting policies summarized
below.
</DIV>


<DIV align="left" style="font-size: 9pt; margin-top: 6pt; margin-left: 5%"><B>Use of estimates</B>
</DIV>


<DIV align="left" style="font-size: 9pt; margin-top: 6pt; margin-left: 5%">Because a precise determination of many assets and liabilities is dependent upon future events,
the preparation of financial statements in conformity with generally accepted accounting
principles requires management to make estimates and assumptions that affect the reported amounts
of assets and liabilities and the disclosure of contingent assets and liabilities at the date of
the financial statements and the reported amounts of expenses during the reporting periods. Actual
results could differ from those estimates and such differences could be significant. Significant
estimates made by management affecting the Company&#146;s financial statements include the assessment
of the net realizable value of long lived assets and the amortization period of intellectual
property.
</DIV>

</DIV>
<DIV style="position: relative; float: right; width: 10%">

<DIV align="right" style="font-size: 9pt; margin-top: 12pt"><IMG src="o40024o4002421.gif" alt="(GRAPHIC)">
</DIV>

</DIV>
<BR clear="all">

<DIV align="center" style="margin-top: -11pt">
<TABLE style="font-size: 7pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="79%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="right" colspan="2" valign="top" bgcolor="#000000" style="color: #ffffff; font-size: 9pt"><b>37</b></TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="6" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD colspan="2" bgcolor="#000000" style="border-top: 1px solid #ffffff">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD colspan="4" align="right"><DIV style="margin-left:15px; text-indent:-15px">Oncolytics Biotech Inc <B>Notes to Financial Statements</B></DIV></TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>
<P align="center" style="font-size: 9pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: Helvetica,Arial,sans-serif">

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt"><B>Capital assets</B>
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">Capital assets are recorded at cost. Amortization is provided on bases and at rates designed to
amortize the cost of the assets over their estimated useful lives. Amortization is recorded using
the declining balance method at the following annual rates:
</DIV>
<DIV align="center">
<TABLE style="font-size: 9pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="40%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="40%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="right" valign="top"><DIV style="margin-left:15px; text-indent:-15px">Office equipment and furniture <BR>
Medical equipment <BR>
Computer equipment <BR>
Leasehold improvements
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">20%<BR>
20%<BR>
30%<BR>
Straight-line over the term of the lease</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt"><B>Intellectual property</B>
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">Costs relating to acquiring and establishing intellectual property (mainly patents) are recorded
at cost, net of recoveries. Amortization of the intellectual property is on a straight-line basis
over the shorter of seventeen years or the estimated useful life (currently estimated to be ten
years) and begins on the earlier of a patent being granted or its utilization. The Company
assesses potential impairment of its intellectual property when any events that might give rise to
impairment are known to the Company by measuring the expected net recovery from products based on
the use of the intellectual property.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt"><B>Foreign currency translation</B>
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">Transactions originating in foreign currencies are translated into Canadian dollars at the
exchange rate in effect at the date of the transaction. Monetary assets and liabilities are
translated at the year-end rate of exchange and non-monetary items are translated at historic
exchange rates. Exchange gains and losses are included in net loss for the period.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt"><B>Research and development costs</B>
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">Research costs are expensed as incurred. Development costs that meet specific criteria related to
technical, market and financial feasibility will be capitalized. To date, all of the development
costs have been expensed.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt"><B>Loss per common share</B>
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">Basic loss per share is determined using the weighted average number of common shares outstanding
during the period.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">The Company uses the treasury stock method to calculate diluted loss per share. Under this method,
diluted loss per share is computed in a manner consistent with basic loss per share except that
the weighted average shares outstanding are increased to include additional shares from the
assumed exercise of options and warrants, if dilutive. The number of additional shares is
calculated by assuming that any outstanding &#147;in the money&#148; options and warrants were exercised at
the later of the beginning of the period or the date of issue and that the proceeds from such
exercises were used to acquire shares of common stock at the average market price during the
reporting period.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt"><B>Stock option plan</B>
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">The Company has one stock option plan (the &#147;Plan&#148;) available to officers, directors, employees,
consultants and suppliers with grants under the Plan approved from time to time by the Board of
Directors. Under the Plan, the exercise price of each option equals the market price of the
Company&#146;s stock on the date of grant in accordance with Toronto Stock Exchange guidelines.
Vesting is provided for at the discretion of the Board and the expiration of options is to be no
greater than ten years from the date of grant.
</DIV>


<DIV align="center">
<TABLE style="font-size: 7pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="79%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" colspan="2" valign="top" bgcolor="#000000" style="color: #ffffff; font-size: 9pt"><b>38</b></TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD colspan="2" bgcolor="#000000" style="border-top: 1px solid #ffffff">&nbsp;</TD>
    <TD colspan="6" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">Oncolytics Biotech Inc <B>Notes to Financial Statements</B></DIV></TD>

    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>
<P align="center" style="font-size: 9pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: Helvetica,Arial,sans-serif">

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt"><B>Stock based compensation</B></DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt"><B><I>Officers, Directors and Employees</I></B>
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt">Effective January&nbsp;1, 2003, the Company prospectively adopted the fair value based method of
accounting for employee awards granted under its stock option plan (see note 11). The Company
calculates the fair value of each stock option grant using the Black Scholes Option Pricing Model
and the fair value is recorded over the option&#146;s vesting period on a straight line basis.
Previously, the intrinsic value method was used. The following tables provide pro forma net loss
and pro forma basic and diluted net loss per share had compensation expense, for awards granted in
2002, been based on the fair value method of accounting for stock based compensation:
</DIV>
<DIV align="right">
<TABLE style="font-size: 9pt; margin-left: 5%; margin-right: 10%" cellspacing="0" border="0" cellpadding="0" width="85%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="52%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">$</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2" bgcolor="#000000" style="color: #ffffff"><B>2007</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">2006</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">2005</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Reported net loss</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>15,642,191</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">14,297,524</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">12,781,831</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Compensation expense</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>&#151;</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">983</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Pro forma net loss</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>15,642,191</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">14,297,524</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">12,782,814</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Reported basic and diluted net loss per share</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>(0.39</B></TD>
    <TD nowrap bgcolor="#000000" style="color: #ffffff"><B>)</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(0.39</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(0.39</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Pro forma basic and diluted net loss per share</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>(0.39</B></TD>
    <TD nowrap bgcolor="#000000" style="color: #ffffff"><B>)</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(0.39</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(0.39</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left" style="margin-top: 10pt; margin-left: 5%; margin-right:10%; font-size: 9pt">As this policy has been applied prospectively, comparative information has not been restated.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt"><B><I>Non-employees</I></B>
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt">Stock based compensation to non-employees is recorded at the fair market value based on the fair
value of the consideration received, or the fair value of the equity instruments granted, or
liabilities incurred, whichever is more reliably measurable, on the earlier of the date at which
a performance commitment is reached, performance is achieved, or the vesting date of the options.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt"><B>Future income taxes</B>
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt">The Company follows the liability method of accounting for income taxes. Under the liability
method, future income taxes are recognized for the difference between financial statement carrying
values and the respective income tax basis of assets and liabilities (temporary differences).
Future income tax assets and liabilities are measured using substantively enacted income tax rates
and laws expected to apply in the years in which temporary differences are expected to be
recovered or settled. The effect on future income tax assets and liabilities of a change in tax
rates is included in income in the period of the change.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt"><B>Adoption of New Accounting Policies</B>
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt"><B><I>Financial Instruments</I></B>
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt">On January&nbsp;1, 2007, the Company adopted, without restatement, CICA Handbook Section&nbsp;3855
&#147;Financial Instruments &#150;Recognition and Measurement&#148; and Section&nbsp;1530 &#147;Other Comprehensive
Income&#148;. Pursuant to the transitional provisions of Section&nbsp;3855, the Company classified its
short-term investments as held-to-maturity fixed income securities and recorded its Alberta
Heritage Foundation interest free loan at fair value. As a result, there were no adjustments made
to short-term investments or other comprehensive income and there was a decrease in the Alberta
Heritage Foundation loan of $150,000 with a corresponding decrease of $150,000 in the Company&#146;s
deficit.
</DIV>


<DIV align="center">
<TABLE style="font-size: 7pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="85%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="right" colspan="2" valign="top" bgcolor="#000000" style="color: #ffffff; font-size: 9pt"><b>39</b></TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="6" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD colspan="2" bgcolor="#000000" style="border-top: 1px solid #ffffff">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD colspan="4" align="right"><DIV style="margin-left:15px; text-indent:-15px">Oncolytics Biotech Inc <B>Notes to Financial Statements</B></DIV></TD>

    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>
<P align="center" style="font-size: 9pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>



<DIV style="font-family: Helvetica,Arial,sans-serif">

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt"><B><I>Financial Assets</I></B>
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">Financial assets are comprised of cash and cash equivalents, accounts receivable (mainly goods and
service tax receivable), and short-term investments.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt"><I>Cash and cash equivalents</I>
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">Cash and cash equivalents consist of cash on hand and interest bearing deposits with the Company&#146;s
bank.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt"><I>Short-term investments</I>
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">The Company determines the appropriate classification of its short-term investments at the time of
purchase and reevaluates such designation as of each balance sheet date. Short-term investments
can be classified as held-for-trading, available-for-sale or held-to-maturity. Currently, the
Company has classified all of its short-term investments as held-to-maturity as it has the
positive intent and ability to hold the securities to maturity. Held-to-maturity securities are
stated at original cost, adjusted for amortization of premiums and accretion of discounts to
maturity computed under the effective interest rate method. Such amortization and interest on
securities classified as held-to-maturity are included in interest income.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt"><B><I>Financial Liabilities</I></B>
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">Financial liabilities are comprised of trade accounts payable and accrued liabilities.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt"><B>Future Accounting Changes</B>
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt"><B><I>International Financial Reporting Standards</I></B>
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">In 2006, the CICA announced that accounting standards in Canada will converge with International
Financial Reporting Standards (&#147;IFRS&#148;). The Company will need to begin reporting under IFRS in the
first quarter of 2011 with comparative data for the prior year. IFRS uses a conceptual framework
similar to GAAP, but there could be significant differences on recognition, measurement and
disclosures that will need to be addressed. The Company is currently assessing the impact of these
standards on its financial statements.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt"><B><I>Capital Disclosures</I></B>
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">The CICA has issued new accounting recommendations for capital disclosures which require
disclosure of both qualitative and quantitative information that enables users of financial
statements to evaluate the Company&#146;s objectives, policies, and processes for managing capital.
These recommendations are effective for the Company beginning January&nbsp;1, 2008.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt"><B><I>Disclosure and Presentation of Financial Instruments</I></B>
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">The CICA has issued new accounting recommendations for disclosure and presentation of financial
instruments which require disclosures of both qualitative and quantitative information that
enables users of financial statements to evaluate the nature and extent of risks arising from
financial instruments to which the Company is exposed. These recommendations are effective for the
Company beginning January&nbsp;1, 2008.
</DIV>


<DIV align="center">
<TABLE style="font-size: 7pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="79%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" colspan="2" valign="top" bgcolor="#000000" style="color: #ffffff; font-size: 9pt"><b>40</b></TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD colspan="2" bgcolor="#000000" style="border-top: 1px solid #ffffff">&nbsp;</TD>
    <TD colspan="6" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">Oncolytics Biotech Inc <B>Notes to Financial Statements</B></DIV></TD>

    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>
<P align="center" style="font-size: 9pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>





<DIV style="font-family: Helvetica,Arial,sans-serif">

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt"><B><I>Goodwill and Intangible Assets</I></B>
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt">The CICA has issued new accounting recommendations for the treatment of goodwill and intangible
assets that are intended to reduce the differences between IFRS in the accounting for intangible
assets and results in closer alignment with U.S. GAAP. The objectives of these recommendations are
to reinforce the principle-based approach to the recognition of assets only in accordance with the
definition of an asset and the criteria for asset recognition; and clarify the application of the
concept of matching revenues and expenses such that the current practice of recognizing asset
items that do not meet the definition and recognition criteria is eliminated. The standard also
provides guidance for the recognition of internally developed intangible assets, whether
separately acquired or internally developed. These changes are effective for fiscal years
beginning on or after October&nbsp;1, 2008, with early adoption encouraged. The Company is evaluating
the effects of adopting these recommendations.
</DIV>

<DIV align="left" style="margin-top: 6pt; border-bottom: 0px solid #000000; margin-left: 5%; margin-right:10%; font-size: 9pt"><B>4. Deficit</B>
</DIV>

<DIV align="left" style="margin-top: 0pt; border-bottom: 1px solid #000000; margin-left: 0%; margin-right:0%; font-size: 1pt">&nbsp;</DIV>

<DIV align="right">
<TABLE style="font-size: 9pt; margin-left: 5%; margin-right: 10%" cellspacing="0" border="0" cellpadding="0" width="85%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="76%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2"><B>$</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2"><B>Amount</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="9" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:28px; text-indent:-15px">Balance, December&nbsp;31, 2005</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">50,732,542</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:28px; text-indent:-15px">Net loss for the year</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">14,297,524</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="9" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:28px; text-indent:-15px">Balance, December&nbsp;31, 2006</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">65,030,066</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:28px; text-indent:-15px">Adjustment &#150; Alberta Heritage Foundation loan <i>&#091;notes 3 and 7&#093;</i></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(150,000</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:28px; text-indent:-15px">Net loss and comprehensive loss for the year</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">15,642,191</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#000000" style="color: #ffffff">
    <TD><DIV style="margin-left:28px; text-indent:-15px"><B>Balance, December&nbsp;31, 2007</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>80,522,257</B></TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="margin-top: 10pt; margin-left: 5%; border-bottom: 0px solid #000000;  margin-right:10%; font-size: 9pt"><B>5. Property and Equipment</B>
</DIV>

<DIV align="left" style="margin-top: 0pt; border-bottom: 1px solid #000000; margin-left: 0%; margin-right:0%; font-size: 1pt">&nbsp;</DIV>


<DIV align="right" style="margin-top: -2pt">
<TABLE style="font-size: 9pt; margin-left: 5%; margin-right: 10%" cellspacing="0" border="0" cellpadding="0" width="85%">
<!-- Begin Table Head -->
<TR style="font-size: 1pt">
    <TD width="52%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="10" nowrap align="center" bgcolor="#000000" style="color: #ffffff"> <B>2007</B></TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff">&nbsp;</td>
</TR>
<TR style="font-size: 9pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">$</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2" bgcolor="#000000" style="color: #ffffff"><B>Cost</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff">&nbsp;</td>
    <TD nowrap align="right" colspan="2" bgcolor="#000000" style="color: #ffffff"><B>Accumulated Amortization</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff">&nbsp;</td>
    <TD nowrap align="right" colspan="2" bgcolor="#000000" style="color: #ffffff"><B>Net Book Value</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="17" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Medical equipment</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>100,816</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000" style="color: #ffffff">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>21,016</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000" style="color: #ffffff">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>79,800</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Office equipment</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>34,965</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000" style="color: #ffffff">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>22,445</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000" style="color: #ffffff">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>12,520</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Office furniture</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>99,730</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000" style="color: #ffffff">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>61,860</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000" style="color: #ffffff">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>37,870</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Computer equipment</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>202,845</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000" style="color: #ffffff">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>131,932</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000" style="color: #ffffff">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>70,913</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Leasehold improvements</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>99,830</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000" style="color: #ffffff">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>99,830</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000" style="color: #ffffff">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>&#151;</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>538,186</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000" style="color: #ffffff">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>337,083</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000" style="color: #ffffff">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>201,103</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" align="left" style="border-top: 2px solid #000000">&nbsp;</TD>
</TR>

<TR style="font-size: 10pt">
    <TD colspan="17" align="left" style="border-top: 0px solid #000000">&nbsp;</TD>
</TR>



<TR style="font-size: 9pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="10" style="border-bottom: 0px solid #000000">2006</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">$</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">Cost</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">Accumulated Amortization</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">Net Book Value</TD>
    <TD>&nbsp;</TD>
</TR>

<TR style="font-size: 1px">
    <TD colspan="16" style="border-bottom: 1px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Medical equipment</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">30,201</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">11,382</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">18,819</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Office equipment</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">32,818</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">19,758</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">13,060</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Office furniture</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">97,160</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">55,999</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">41,161</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Computer equipment</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">185,955</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">109,399</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">76,556</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Leasehold improvements</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">99,830</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">99,830</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" align="left" style="border-top: 2px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">445,964</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">296,368</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">149,596</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" align="left" style="border-top: 2px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<DIV align="center">
<TABLE style="font-size: 7pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR style="font-size: 10pt">
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="85%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="right" colspan="2" valign="top" bgcolor="#000000" style="color: #ffffff; font-size: 9pt"><b>41</b></TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="6" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD colspan="2" bgcolor="#000000" style="border-top: 1px solid #ffffff">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD colspan="4" align="right"><DIV style="margin-left:15px; text-indent:-15px">Oncolytics Biotech Inc <B>Notes to Financial Statements</B></DIV></TD>

    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>
<P align="center" style="font-size: 9pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: Helvetica,Arial,sans-serif">

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt"><B>6. Intellectual Property</B>
</DIV>
<DIV align="center"><DIV style="font-size: 3pt; margin-top: 1pt; width: 100%; border-top: 1px solid #000000">&nbsp;</DIV></DIV>
<DIV align="right" style="margin-top: -6pt">
<TABLE style="font-size: 9pt; margin-left: 10%; margin-right: 5%" cellspacing="0" border="0" cellpadding="0" width="85%">
<!-- Begin Table Head -->
<TR style="font-size: 1pt">
    <TD width="52%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="10" nowrap align="center" bgcolor="#000000" style="color: #ffffff"><B>2007</B></TD>
    <TD bgcolor="#000000" style="color: #ffffff">&nbsp;</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">$</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2" bgcolor="#000000" style="color: #ffffff"><B>Cost</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000" style="color: #ffffff">&nbsp;</TD>
    <TD nowrap align="right" colspan="2" bgcolor="#000000" style="color: #ffffff"><B>Accumulated Amortization</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000" style="color: #ffffff">&nbsp;</TD>
    <TD nowrap align="right" colspan="2" bgcolor="#000000" style="color: #ffffff"><B>Net Book Value</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="17" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Intellectual property</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>10,025,799</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000" style="color: #ffffff">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>4,999,259</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000" style="color: #ffffff">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>5,026,540</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" align="left" style="border-top: 2px solid #000000">&nbsp;</TD>
</TR>

<TR style="font-size: 10px">
    <TD colspan="17" align="left" style="border-top: 0px solid #000000">&nbsp;</TD>
</TR>

<TR style="font-size: 9pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="10" style="border-bottom: 0px solid #000000">2006</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">$</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">Cost</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">Accumulated Amortization</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">Net Book Value</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="17" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Intellectual property</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9,116,637</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,036,832</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5,079,805</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" align="left" style="border-top: 2px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="margin-top: 10pt; margin-left: 10%; margin-right:5%; font-size: 9pt"><B>7. Alberta Heritage Foundation Loan</B>
</DIV>
<DIV align="center"><DIV style="font-size: 3pt; margin-top: 1pt; width: 100%; border-top: 1px solid #000000">&nbsp;</DIV></DIV>


<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">The Company has received a loan of $150,000 from the Alberta Heritage Foundation for Medical
Research. Pursuant to the terms of the agreement, the Company is required to repay this amount in
annual installments from the date of commencement of sales in an amount equal to the lesser of:
(a)&nbsp;5% of the gross sales generated by the Company; or (b) $15,000 per annum until the entire loan
has been paid in full.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt"><B>8. Commitments</B>
</DIV>
<DIV align="center"><DIV style="font-size: 3pt; margin-top: 1pt; width: 100%; border-top: 1px solid #000000">&nbsp;</DIV></DIV>


<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">The Company is committed to payments totaling $960,000 during 2008 for activities related to its
clinical trial program and collaborations.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">The Company is committed to monthly rental payments (excluding the Company&#146;s portion of operating
costs) of $7,453 under the terms of a lease for office premises, which expires on May&nbsp;31, 2011.</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">Under a
clinical trial agreement entered into with the Alberta Cancer Board (&#147;ACB&#148;), the Company
has agreed to repay the amount funded under the agreement together with a royalty, to a combined
maximum amount of $400,000 plus an overhead repayment of $100,000, upon sales of a specified
product. The Company agreed to repay the ACB in annual installments in an amount equal to the
lesser of: (a)&nbsp;5% of gross sales of a specified product; or (b) $100,000 per annum.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt"><B>9. Contingency</B>
</DIV>
<DIV align="center"><DIV style="font-size: 3pt; margin-top: 1pt; width: 100%; border-top: 1px solid #000000">&nbsp;</DIV></DIV>


<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">During 1999, the Company entered into an agreement that assumed certain obligations (the
&#147;Assumption Agreement&#148;) in connection with a Share Purchase Agreement (the &#147;Agreement&#148;) between
SYNSORB and the former shareholders of the Company to make milestone payments and royalty
payments.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">As of December&nbsp;31, 2007, a milestone payment was still outstanding for $1.0&nbsp;million, due within 90
days of the first receipt from an Appropriate Regulatory Authority, for marketing approval to sell
REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> to the public or the approval of a new drug application for REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">This milestone payment, when payable, will be accounted for as research and development expense and
will not be deductible for income tax purposes.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">In addition to the milestone payment, payments may become due and payable in accordance with the
Agreement upon realization of sales of REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>. In 2003, the Company completed amendments and
revisions to the contingent obligations to its five founding shareholders with respect to these
other contingent payments. The amendments and revisions reduced the amount and clarified the
determination of potential obligations of the Company to these
</DIV>


<DIV align="center">
<TABLE style="font-size: 7pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="79%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" colspan="2" valign="top" bgcolor="#000000" style="color: #ffffff; font-size: 9pt"><b>42</b></TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD colspan="2" bgcolor="#000000" style="border-top: 1px solid #ffffff">&nbsp;</TD>
    <TD colspan="6" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">Oncolytics Biotech Inc <B>Notes to Financial Statements</B></DIV></TD>

    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>
<P align="center" style="font-size: 9pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: Helvetica,Arial,sans-serif">

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt">shareholders arising from the Agreement and Assumption Agreement entered into in 1999. Also, on
September&nbsp;23, 2004, the Company reached an agreement that further reduced its contingent payments
to its founding shareholders through the cancellation of a portion of these contingent payments
from one of its non-management founding shareholders. The consideration paid by the Company
consisted of $250,000 cash and 21,459 common shares valued at $150,000 and has been recorded as
research and development expense. The value of the common shares was based on the closing market
price on September&nbsp;23, 2004.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt">As a result of the amendments and the cancellation agreement, if the Company receives royalty
payments or other payments as a result of entering into partnerships or other arrangements for the
development of the reovirus technology, the Company is obligated to pay to the founding
shareholders 11.75% (formerly in 2003 &#150; 14.25% and 2002 &#150; 20%) of the royalty payments and other
payments received. Alternatively, if the Company develops the reovirus treatment to the point
where it may be marketed at a commercial level, the payments referred to in the foregoing sentence
will be amended to a royalty payment of 2.35% (formerly in 2003 &#150; 2.85% and 2002 &#150; 4%) of Net
Sales received by the Company for such products.
</DIV>

<DIV align="justify" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt"><B>10. Share Capital</B>
</DIV>
 <DIV align="center"><DIV style="font-size: 3pt; margin-top: 1pt; width: 100%; border-top: 1px solid #000000">&nbsp;</DIV></DIV>

<DIV align="justify" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt">Authorized: Unlimited number of no par value common shares
</DIV>
<DIV align="right">
<TABLE style="font-size: 9pt; margin-left: 5%; margin-right: 10%" cellspacing="0" border="0" cellpadding="0" width="85%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="52%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 0px solid #000000">Issued:</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 0px solid #000000"><B>Shares</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 0px solid #000000"><B>Warrants</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2"><B>Number</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2"><B>Amount $</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2"><B>Number</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2"><B>Amount $</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="17" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Balance, December&nbsp;31, 1998</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,145,300</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Issued on exercise of stock options</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">76,922</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">77</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,222,222</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">81</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">July&nbsp;29, 1999 share split <SUP style="font-size: 85%; vertical-align: text-top">(a)</SUP></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6,750,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">81</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Issued for cash pursuant to July&nbsp;30, 1999 private placement
(net of share issue costs of $45,000) <SUP style="font-size: 85%; vertical-align: text-top">(b)</SUP></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,500,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">855,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Issued for cash pursuant to August&nbsp;24, 1999 private
placement</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,399,997</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,049,998</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Issued on initial public offering (net of share issue costs
of $317,897) <SUP style="font-size: 85%; vertical-align: text-top">(c)</SUP></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,000,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,082,103</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Issued for cash pursuant to exercise of share purchase
warrants</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">20,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">15,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Balance, December&nbsp;31, 1999</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">13,669,997</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5,002,182</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Issued on exercise of stock options and warrants</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">573,910</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">501,010</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Issued for cash pursuant to July&nbsp;17, 2000 private
placement <SUP style="font-size: 85%; vertical-align: text-top">(d)</SUP></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">244,898</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,998,645</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Issued on public offering (net of share issue costs
of $998,900) <SUP style="font-size: 85%; vertical-align: text-top">(e)</SUP></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,000,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">13,101,100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Balance, December&nbsp;31, 2000</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">17,488,805</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">21,602,937</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Issued on exercise of stock options and warrants</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,702,590</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,210,016</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 7pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR style="font-size: 10pt">
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="85%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD valign="top">&nbsp;</TD>

<TD align="right" colspan="2" valign="top" bgcolor="#000000" style="color: #ffffff; font-size: 9pt"><b>43</b></TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="6" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD colspan="2" bgcolor="#000000" style="border-top: 1px solid #ffffff">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD colspan="4" align="right"><DIV style="margin-left:15px; text-indent:-15px">Oncolytics Biotech Inc <B>Notes to Financial Statements</B></DIV></TD>

    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 9pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>





<DIV style="font-family: Helvetica,Arial,sans-serif">
<DIV align="right">
<TABLE style="font-size: 9pt; margin-left: 9%; margin-right: 9%" cellspacing="0" border="0" cellpadding="0" width="85%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="68%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 0px solid #000000">Issued:</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 0px solid #000000"><B>Shares</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 0px solid #000000"><B>Warrants</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2"><B>Number</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2"><B>Amount $</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2"><B>Number</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2"><B>Amount $</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="17" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Balance, December&nbsp;31, 2001</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">19,191,395</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">23,812,953</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Issued on exercise of stock options</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">40,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">34,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Issued on acquisition of the interest in Transition
Therapeutics Inc.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,913,889</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,689,028</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Issued for cash pursuant to December&nbsp;11, 2002
private placement <SUP style="font-size: 85%; vertical-align: text-top">(f)</SUP></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,000,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,896,714</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">550,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">114,286</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Share issue costs</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(241,123</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Balance, December&nbsp;31, 2002</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">22,145,284</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">30,191,572</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">550,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">114,286</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Issued for cash pursuant to February&nbsp;10, 2003
private placement <SUP style="font-size: 85%; vertical-align: text-top">(g)</SUP></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">140,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">265,540</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">77,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">16,000</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Issued for cash pursuant to June&nbsp;19, 2003 private
placement <SUP style="font-size: 85%; vertical-align: text-top">(h)</SUP></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,120,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5,912,113</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,272,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">543,287</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Issued for cash pursuant to August&nbsp;21, 2003
private placement <SUP style="font-size: 85%; vertical-align: text-top">(i)</SUP></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,363,900</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,801,778</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">813,533</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">349,176</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Issued for cash pursuant to October&nbsp;14, 2003
public offering <SUP style="font-size: 85%; vertical-align: text-top">(j)</SUP></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,200,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5,528,972</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">720,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">617,428</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Exercise of options</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">64,700</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">149,615</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Exercise of warrants</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">174,378</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">593,194</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(174,378</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(41,927</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Share issue costs</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(1,730,195</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Balance, December&nbsp;31, 2003</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">27,208,262</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">44,712,589</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,258,155</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,598,250</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Issued for cash pursuant to April&nbsp;7, 2004 private
placement <SUP style="font-size: 85%; vertical-align: text-top">(k)</SUP></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,077,100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5,924,050</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">646,260</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,028,631</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Issued for cash pursuant to pursuant to
November&nbsp;23, 2004 public offering <SUP style="font-size: 85%; vertical-align: text-top">(l)</SUP></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,504,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">8,693,120</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">864,800</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,521,672</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Issued pursuant to cancellation of contingent
payment <i>&#091;note 9&#093;</i></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">21,459</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">150,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Exercise of warrants</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,907,175</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">8,178,546</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(1,907,175</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(798,096</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Expired warrants</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(6,700</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(2,827</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Exercise of options</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">197,500</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">778,951</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Share issue costs</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(1,796,758</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Balance, December&nbsp;31, 2004</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">31,915,496</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">66,640,498</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,855,340</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,347,630</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Issued for cash pursuant to December&nbsp;29, 2005
private placement <SUP style="font-size: 85%; vertical-align: text-top">(m)</SUP></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,200,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">14,176,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,920,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,908,800</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Exercise of warrants</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">771,252</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,417,271</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(771,252</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(329,984</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Expired warrants</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(1,219,288</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(1,496,514</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Exercise of options</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">350,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">297,500</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Share issue costs</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(1,689,398</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 7pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="80%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" colspan="2" valign="top" bgcolor="#000000" style="color: #ffffff; font-size: 9pt"><b>44</b></TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD colspan="2" bgcolor="#000000" style="border-top: 1px solid #ffffff">&nbsp;</TD>
    <TD colspan="6" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>

</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;Oncolytics Biotech Inc <B>Notes to Financial Statements</B></DIV></TD>

    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>

<P align="center" style="font-size: 9pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: Helvetica,Arial,sans-serif">



<DIV align="right">
<TABLE style="font-size: 9pt; margin-left: 5%; margin-right: 10%" cellspacing="0" border="0" cellpadding="0" width="85%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="52%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 0px solid #000000">Issued:</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 0px solid #000000"><B>Shares</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 0px solid #000000"><B>Warrants</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2"><B>Number</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2"><B>Amount $</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2"><B>Number</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2"><B>Amount $</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="17" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Balance, December&nbsp;31, 2005</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">36,236,748</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">82,841,871</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,784,800</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,429,932</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Exercise of options</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">284,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">241,400</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Expired warrants</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(112,800</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(213,192</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Balance, December&nbsp;31, 2006</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">36,520,748</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">83,083,271</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,672,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,216,740</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD nowrap><DIV style="margin-left:15px; text-indent:-15px">Issued for cash pursuant to February&nbsp;22, 2007
public offering <SUP style="font-size: 85%; vertical-align: text-top">(n)</SUP></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,600,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">11,362,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,300,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,438,000</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Exercise of options</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">60,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">51,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Expired warrants</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(752,000</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(1,308,480</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Share issue costs</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(1,736,606</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" bgcolor="#000000" style="color: #ffffff">
    <TD><DIV style="margin-left:30px; text-indent:-15px"><B>Balance, December&nbsp;31, 2007</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>41,180,748</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>92,759,665</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>4,220,000</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>5,346,260</B></TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 9pt">

<TR valign="top" style="font-size: 7pt; color: #000000; background: transparent">
    <TD width="5%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Pursuant to subsection 167(1)(f) of the Business Corporations Act (Alberta), the Articles
of the Company were amended by subdividing the 2,222,222 issued and outstanding common shares
of the Company into 6,750,000 common shares.</TD>
    <TD width="10%" style="background: transparent">&nbsp;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 7pt; color: #000000; background: transparent">
    <TD width="5%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Pursuant to a private placement, 1,500,000 common share purchase warrants were issued
entitling the holders thereof to acquire one additional share at $0.75 per share until November&nbsp;8,
2001. At December&nbsp;31, 2001, all of the warrants had been exercised.</TD>
    <TD width="10%" style="background: transparent">&nbsp;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 7pt; color: #000000; background: transparent">
    <TD width="5%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="left">(c)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Pursuant to the initial public offering, the agent was issued common share purchase warrants
entitling it to acquire 400,000 common shares at $0.85 per share until May&nbsp;8, 2001. At December
31, 2001, all of the warrants had been exercised.</TD>
    <TD width="10%" style="background: transparent">&nbsp;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 7pt; color: #000000; background: transparent">
    <TD width="5%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="left">(d)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Pursuant to the private placement, 244,898 common shares were issued at an issue price of
$12.25 per share net of issue costs of $1,355.</TD>
    <TD width="10%" style="background: transparent">&nbsp;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 7pt; color: #000000; background: transparent">
    <TD width="5%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="left">(e)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Pursuant to a special warrant offering, the Company sold 3,000,000 special warrants for
$4.70 per warrant for net proceeds of $13,101,100. Each warrant entitled the holder to one
common share upon exercise. At December&nbsp;31, 2001, all of the warrants had been exercised.</TD>
    <TD width="10%" style="background: transparent">&nbsp;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 7pt; color: #000000; background: transparent">
    <TD width="5%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="left">(f)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Pursuant to a private placement, 1,000,000 units were issued at an issue price of $2.00 per
unit net of issue costs of $241,123. Each unit included one common share (ascribed value of
$1.897) and one-half of one common share purchase warrant (ascribed value of $0.103) for a total
of 500,000 warrants. Each whole common share purchase warrant entitles the holder to acquire one
common share in the capital of the Company upon payment of $3.00 per share until June&nbsp;11, 2004. In
addition, the Company issued 50,000 common share purchase warrants on the same terms to the
brokerage firm assisting with the transaction. The ascribed value of these broker warrants was
$11,000 ($0.22 per broker warrant) and has been included in the issue costs. The ascribed values
of the warrants were based on the Black Scholes Option Pricing Model.</TD>
    <TD width="10%" style="background: transparent">&nbsp;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 7pt; color: #000000; background: transparent">
    <TD width="5%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="left">(g)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Pursuant to a private placement, 140,000 units were issued at an issue price of $2.00 per unit
net of issue costs of $37,369. Each unit included one common share (ascribed value of $1.897) and
one-half of one common share purchase warrant (ascribed value of $0.103) for a total of 70,000
warrants. Each whole common share purchase warrant entitles the holder to acquire one common share
in the capital of the Company upon payment of $3.00 per share until August&nbsp;10, 2004. In addition,
the Company issued 7,000 common share purchase warrants on the same terms to the brokerage firm
assisting with the transaction. The ascribed value of these broker warrants was $1,540 ($0.22 per
broker warrant) and has been included in the issue costs. The ascribed values of the warrants were
based on the Black Scholes Option Pricing Model.</TD>
    <TD width="10%" style="background: transparent">&nbsp;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 7pt; color: #000000; background: transparent">
    <TD width="5%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="left">(h)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Pursuant to a private placement, 2,120,000 units were issued at an issue price of $3.00 per
unit net of issue costs of $637,986. Each unit included one common share (ascribed value of
$2.789) and one-half of one common share purchase warrant (ascribed value of $0.211) for a total
of 1,060,000 warrants. Each whole common share purchase warrant entitles the holder to acquire one
common share in
the capital of the Company upon payment of $4.00 per share until December&nbsp;19, 2004. In addition,
the Company issued 212,000 common share purchase warrants on the same terms to the brokerage firms
assisting with the transaction. The ascribed value of these broker warrants was $95,400 ($0.45 per
broker warrant) and has been included in the issue costs. The ascribed values of the warrants were
based on the Black Scholes Option Pricing Model.</TD>
    <TD width="10%" style="background: transparent">&nbsp;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 7pt; color: #000000; background: transparent">
    <TD width="5%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="left">(i)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Pursuant to a private placement, 1,363,900 common shares and 681,943 common share purchase
warrants were issued for gross proceeds of $4,091,738. Each common share and whole common share
purchase warrant have ascribed values of $2.787 and $0.425, respectively. Each common share
purchase warrant entitles the holder to acquire one common share in the capital of the Company
upon payment of $4.00 per share until February&nbsp;21, 2005. Share issue costs related to this private
placement were $367,839. In addition, the Company issued 131,590 common share purchase warrants on
the same terms to the advisors assisting with the transaction. The ascribed value of these
additional warrants was $59,216 ($0.45 per additional warrant) and has been included in the issue
costs. The ascribed values of the warrants were based on the Black Scholes Option Pricing Model.</TD>
    <TD width="10%" style="background: transparent">&nbsp;</TD>
</TR>

</TABLE>
</DIV>


<DIV align="center">
<TABLE style="font-size: 7pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="79%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="right" colspan="2" valign="top" bgcolor="#000000" style="color: #ffffff; font-size: 9pt"><b>45</b></TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="6" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD colspan="2" bgcolor="#000000" style="border-top: 1px solid #ffffff">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD colspan="4" align="right"><DIV style="margin-left:15px; text-indent:-15px">Oncolytics Biotech Inc <B>Notes to Financial Statements</B></DIV></TD>

    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>
<P align="center" style="font-size: 9pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>



<DIV style="font-family: Helvetica,Arial,sans-serif">

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 9pt">

<TR valign="top" style="font-size: 7pt; color: #000000; background: transparent">
    <TD width="10%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="left">(j)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Pursuant to a public offering, 1,200,000 units were issued at an issue price of $5.00 per unit
net of issue costs of $687,001. Each unit included one common share (ascribed value of $4.607) and
one-half of one common share purchase warrant (ascribed value of $0.393) for a total of 600,000
warrants. Each whole common share purchase warrant entitles the holder to acquire one common share
in the capital of the Company upon payment of $6.25 per share until April&nbsp;14, 2005. In addition,
the Company issued 120,000 common share purchase warrants with an exercise price of $5.00 that
expires on April&nbsp;14, 2005 to the brokerage firms assisting with the transaction. The ascribed
value of these broker warrants was $146,400 ($1.19 per broker warrant) and has been included in
the issue costs. The ascribed values of the warrants were based on the Black Scholes Option
Pricing Model.</TD>
    <TD width="5%" style="background: transparent">&nbsp;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 7pt; color: #000000; background: transparent">
    <TD width="10%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="left">(k)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Pursuant to a private placement, the Company sold 1,077,100 units at an average price of $6.25
per unit for gross cash proceeds of $6,731,875. The units were comprised of 1,077,100 common
shares and 538,550 common share purchase warrants and have ascribed values of $5.50 and $1.50,
respectively. Each common share purchase warrant entitles the holder to acquire one common share
in the capital of the Company upon payment of $7.75 per share until October&nbsp;7, 2005. Share issue
costs related to the private placement were $728,918. In addition, the Company issued 107,710
common share purchase warrants to its advisor entitling the holder to acquire one common share of
the capital of the Company upon payment of $7.00 per share until October&nbsp;7, 2005. The ascribed
value of these additional warrants was $220,806 ($2.05 per additional warrant) and has been
included in the share issue costs above. The ascribed values of the warrants were based on the
Black Scholes Option Pricing Model.</TD>
    <TD width="5%" style="background: transparent">&nbsp;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 7pt; color: #000000; background: transparent">
    <TD width="10%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="left">(l)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Pursuant to a public offering, the Company sold 1,504,000 units at an issue price of $6.65 per
unit for gross cash proceeds of $10,001,600. Each unit included one common share (ascribed value
of $5.78) and one-half of one common share purchase warrant (ascribed value of $0.87) for a total
of 752,000 warrants. Each whole common share purchase warrant entitles the holder to acquire one
common share in the capital of the Company upon payment of $8.00 per share until November&nbsp;23,
2007. Share issue costs related to this public offering were $1,063,890. In addition, the Company
issued 112,800 common share purchase warrants with an exercise price of $7.06 that expires on May
23, 2006 to the brokerage firm assisting with the transaction. The ascribed value of these broker
warrants was $213,192 ($1.89 per broker warrant) and has been included in the share issue costs
above. The ascribed values of the warrants were based on the Black Scholes Option Pricing Model.</TD>
    <TD width="5%" style="background: transparent">&nbsp;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 7pt; color: #000000; background: transparent">
    <TD width="10%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="left">(m)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Pursuant to a private placement, 3,200,000 units were issued at an issue price of $5.15 per
unit net of issue costs of $1,689,398. Each unit included one common share (ascribed value of
$4.43) and one-half of one common share purchase warrant (ascribed value of $0.72) for a total of
1,600,000 warrants. Each whole common share purchase warrant entitles the holder to acquire one
common share in the capital of the Company upon payment of $6.15 per share until December&nbsp;29,
2008. In addition, the Company issued 320,000 common share purchase warrants with an exercise
price of $5.65 expiring on December&nbsp;29, 2008. The ascribed value of these broker warrants was
$604,800 ($1.89 per broker warrant) and has been included in the issue costs. The ascribed values
of the warrants were based on the Black Scholes Option Pricing Model.</TD>
    <TD width="5%" style="background: transparent">&nbsp;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 7pt; color: #000000; background: transparent">
    <TD width="10%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="left">(n)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Pursuant to a public offering, 4,600,000 units were issued at an issue price of $3.00 per unit
for gross proceeds of $13,800,000. Each unit included one common share (ascribed value of $2.47)
and one-half of one common share purchase warrant (ascribed value of $0.53) for a total of
2,300,000 warrants. The ascribed value was determined using the relative fair value method. Each
whole common share purchase warrant entitles the holder to acquire one common share in the capital
of the Company upon payment of $3.50 per share until February&nbsp;22, 2010. Share issue costs for this
offering were $1,736,606.</TD>
    <TD width="5%" style="background: transparent">&nbsp;</TD>
</TR>

</TABLE>
</DIV>

<DIV align="justify" style="font-size: 9pt; margin-top: 6pt; margin-left: 10%; margin-right: 5%">The following table summarizes the weighted average assumptions used in the Black Scholes Model
with respect to the valuation of warrants and broker warrants issued in those years:
</DIV>
<DIV align="right">
<TABLE style="font-size: 9pt; margin-left: 10%; margin-right: 5%" cellspacing="0" border="0" cellpadding="0" width="85%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="40%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2" bgcolor="#000000" style="color: #ffffff"><B>2007</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">2006</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">2005</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">2004</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">2003</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">2002</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->

<TR style="font-size: 1px">
    <TD colspan="25" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Risk-free interest rate</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>4.08%</B></TD>
    <TD nowrap bgcolor="#000000"><B>&nbsp;</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">3.82%</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">2.82%</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">3.01%</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">3.41%</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Expected hold period to exercise</DIV></TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>3.00</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1.92</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1.39</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">0.76</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1.00</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Volatility in the price of the Company&#146;s shares</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>63%</B></TD>
    <TD nowrap bgcolor="#000000"><B>&nbsp;</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">66%</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">71%</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">72%</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">57%</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Dividend yield</DIV></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="right" bgcolor="#000000" style="color: #ffffff"><B>Zero</B></TD>
    <TD colspan="1" align="right" bgcolor="#000000" style="color: #ffffff">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">Zero</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">Zero</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">Zero</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">Zero</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="25" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center">
<TABLE style="font-size: 7pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="79%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" colspan="2" valign="top" bgcolor="#000000" style="color: #ffffff; font-size: 9pt"><b>46</b></TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD colspan="2" bgcolor="#000000" style="border-top: 1px solid #ffffff">&nbsp;</TD>
    <TD colspan="6" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">Oncolytics Biotech Inc <B>Notes to Financial Statements</B></DIV></TD>

    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>
<P align="center" style="font-size: 9pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>



<DIV style="font-family: Helvetica,Arial,sans-serif">

<DIV align="justify" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt">The following table summarizes the Company&#146;s outstanding warrants as at December&nbsp;31, 2007:
</DIV>
<DIV align="right">
<TABLE style="font-size: 9pt; margin-left: 5%; margin-right: 10%" cellspacing="0" border="0" cellpadding="0" width="85%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 6pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2"><B>Weighted Average</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 6pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2"><B>Outstanding,</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2"><B>Remaining</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 6pt" valign="bottom">
    <TD nowrap align="right" colspan="2"><B>Exercise</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2"><B>Beginning</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2"><B>Granted</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2"><B>Exercised</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2"><B>Expired</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2"><B>Outstanding,</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2"><B>Contractual</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 6pt" valign="bottom">
    <TD nowrap align="right" colspan="2"><B>Price $</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2"><B>of the Year</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2"><B>During the Year</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2"><B>During the Year</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2"><B>During the Year</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2"><B>End of Year</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2"><B>Life (Years)</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top" align="left" bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>3.50</B></TD>
    <TD valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>&#151;</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>2,300,000</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>&#151;</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>&#151;</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>2,300,000</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>2.15</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top" align="left" bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>5.65</B></TD>
    <TD valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>320,000</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>&#151;</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>&#151;</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>&#151;</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>320,000</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>1.00</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top" align="left" bgcolor="#000000">&nbsp;</TD>
    <TD valign="top" align="right" bgcolor="#000000" style="color: #ffffff"><B>6.15</B></TD>
    <TD valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>1,600,000</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>&#151;</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>&#151;</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>&#151;</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>1,600,000</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>1.00</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top" align="left" bgcolor="#000000">&nbsp;</TD>
    <TD valign="top" align="right" bgcolor="#000000" style="color: #ffffff"><B>8.00</B></TD>
    <TD valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>752,000</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>&#151;</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>&#151;</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>752,000</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>&#151;</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>&#151;</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="27"  ALIGN="LEFT" STYLE="BORDER-TOP: 1PX SOLID #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top" align="left" bgcolor="#000000">&nbsp;</TD>
    <TD valign="top" align="right" bgcolor="#000000">&nbsp;</TD>
    <TD valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>2,672,800</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>2,300,000</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>&#151;</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>752,000</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>4,220,000</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>1.38</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="justify" style="margin-top: 10pt; margin-left: 5%; margin-right:10%; font-size: 9pt"><B>11. Stock Based Compensation</B>
</DIV>
<DIV align="center"><DIV style="font-size: 3pt; margin-top: 1pt; width: 100%; border-top: 1px solid #000000">&nbsp;</DIV></DIV>


<DIV align="justify" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt"><B>Stock Option Plan</B>
</DIV>

<DIV align="justify" style="margin-top: 10pt; margin-left: 5%; margin-right:10%; font-size: 9pt">The Company has issued stock options to acquire common stock through its stock option plan of which
the following are outstanding at December&nbsp;31:
</DIV>
<DIV align="right">
<TABLE style="font-size: 9pt; margin-left: 5%; margin-right: 10%" cellspacing="0" border="0" cellpadding="0" width="85%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="52%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000" bgcolor="#000000">
<div style="color: #ffffff"><B>2007</B></div></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 0px solid #000000">2006</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD nowrap align="right" colspan="2" bgcolor="#000000" style="color: #ffffff"><B>Weighted Average</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">Weighted Average</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2" bgcolor="#000000" style="color: #ffffff"><B>Stock Options</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD nowrap align="right" colspan="2" bgcolor="#000000" style="color: #ffffff"><B>Share Price $</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">Stock Options</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">Share Price $</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="17" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Outstanding at beginning of year</DIV></TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>3,537,950</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>4.88</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,634,550</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4.66</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Granted during year</DIV></TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>532,543</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>2.43</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">187,400</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3.08</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Cancelled during year</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>(140,000</B></TD>
    <TD nowrap bgcolor="#000000" style="color: #ffffff"><B>)</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>2.90</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000" bgcolor="#ffffff">&nbsp;</TD>
    <TD nowrap colspan="1" align="right" style="border-top: 1px solid #000000" bgcolor="#ffffff">&nbsp;</TD>
    <TD nowrap colspan="1" align="right" style="border-top: 1px solid #000000" bgcolor="#ffffff">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Exercised during year</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>(60,000</B></TD>
    <TD nowrap bgcolor="#000000" style="color: #ffffff"><B>)</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>0.85</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(284,000</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">0.85</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD nowrap colspan="1" align="right" style="border-top: 1px solid #000000" bgcolor="#ffffff">&nbsp;</TD>
    <TD nowrap colspan="1" align="right" style="border-top: 1px solid #000000" bgcolor="#ffffff">&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000" bgcolor="#ffffff">&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000" bgcolor="#ffffff">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD nowrap colspan="1" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD nowrap colspan="1" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD nowrap colspan="1" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Outstanding at end of year</DIV></TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>3,870,493</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>4.61</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,537,950</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4.88</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">

    <TD colspan="2" align="left" style="border-top: 2px solid #000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD colspan="5" align="left" style="border-top: 2px solid #000000"> <div style="color: #ffffff">&nbsp;</div></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Options exercisable at end of year</DIV></TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>3,661,943</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>4.69</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,355,450</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4.98</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" align="left" style="border-top: 2px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="justify" style="margin-top: 10pt; margin-left: 5%; margin-right:10%; font-size: 9pt">The following table summarizes information about the stock options outstanding and exercisable at
December&nbsp;31, 2007:
</DIV>
<DIV align="right">
<TABLE style="font-size: 9pt; margin-left: 5%; margin-right: 10%" cellspacing="0" border="0" cellpadding="0" width="85%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 6pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2"><B>Weighted Average</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 6pt" valign="bottom">
    <TD nowrap align="right" colspan="2"><B>Range of</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2"><B>Number</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2"><B>Remaining Contractual</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2"><B>Weighted Average</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2"><B>Number</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2"><B>Weighted Average</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 6pt" valign="bottom">
    <TD nowrap align="right" colspan="2" style="border-bottom: 0PXsolid #000000"><B>Exercise Prices $</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2" style="border-bottom: 0PXsolid #000000"><B>Outstanding</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2" style="border-bottom: 0PXsolid #000000"><B>Life (Years)</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2" style="border-bottom: 0PXsolid #000000"><B>Exercise Price $</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2" style="border-bottom: 0PXsolid #000000"><B>Exercisable</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2" style="border-bottom: 0PXsolid #000000"><B>Exercise Price $</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top" align="left" bgcolor="#000000">&nbsp;</TD>
    <TD valign="top" align="right" bgcolor="#000000" style="color: #ffffff"><B>0.75 &#150; 1.00</B></TD>
    <TD bgcolor="#000000"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>258,550</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>1.8</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>0.85</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>258,550</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>0.85</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top" align="left" bgcolor="#000000">&nbsp;</TD>
    <TD valign="top" align="right" bgcolor="#000000" style="color: #ffffff"><B>1.65 &#150; 2.37</B></TD>
    <TD bgcolor="#000000"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>790,943</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>8.1</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>2.10</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>769,893</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>2.10</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top" align="left" bgcolor="#000000">&nbsp;</TD>
    <TD valign="top" align="right" bgcolor="#000000" style="color: #ffffff"><B>2.70 &#150; 3.33</B></TD>
    <TD bgcolor="#000000"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>800,250</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>6.4</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>3.15</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>625,250</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>3.13</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top" align="left" bgcolor="#000000">&nbsp;</TD>
    <TD valign="top" align="right" bgcolor="#000000" style="color: #ffffff"><B>4.00 &#150; 5.00</B></TD>
    <TD bgcolor="#000000"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>1,208,250</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>6.8</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>4.86</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>1,195,750</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>4.86</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top" align="left" bgcolor="#000000">&nbsp;</TD>
    <TD valign="top" align="right" bgcolor="#000000" style="color: #ffffff"><B>6.77 &#150; 9.76</B></TD>
    <TD bgcolor="#000000"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>684,500</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>4.1</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>8.67</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>684,500</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>8.67</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top" align="left" bgcolor="#000000">&nbsp;</TD>
    <TD valign="top" nowrap align="right" bgcolor="#000000" style="color: #ffffff"><B>12.15 &#150; 13.50</B></TD>
    <TD bgcolor="#000000"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>128,000</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>2.8</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>12.69</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>128,000</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>12.69</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="25"  ALIGN="LEFT" STYLE="BORDER-TOP: 1PX SOLID #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top" align="left" bgcolor="#000000">&nbsp;</TD>
    <TD valign="top" align="right" bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>3,870,493</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>6.1</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>4.62</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>3,661,943</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>4.70</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
</TR>


<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center">
<TABLE style="font-size: 7pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="79%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="right" colspan="2" valign="top" bgcolor="#000000" style="color: #ffffff; font-size: 9pt"><b>47</b></TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="6" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD colspan="2" bgcolor="#000000" style="border-top: 1px solid #ffffff">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD colspan="4" align="right"><DIV style="margin-left:15px; text-indent:-15px">Oncolytics Biotech Inc <B>Notes to Financial Statements</B></DIV></TD>

    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>

<P align="center" style="font-size: 9pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>



<DIV style="font-family: Helvetica,Arial,sans-serif">

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">The outstanding options vest annually or after the completion of certain milestones. The Company
has reserved 3,992,075 common shares for issuance relating to outstanding stock options.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">As the Company is following the fair value based method of accounting for stock option awards,
compensation expense related to options granted to employees and consultants was $539,156 (2006 &#150;
$403,550; 2005 &#150; $43,886) and $nil (2006 &#150; $nil; 2005 &#150; $20,218) respectively with an offsetting
credit to contributed surplus.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">The estimated fair value of stock options issued during the year was determined using the
Black-Scholes model using the following weighted average assumptions and fair value of options:
</DIV>
<DIV align="right">
<TABLE style="font-size: 9pt; margin-left: 10%; margin-right: 5%" cellspacing="0" bordER="0" cellpadding="0" width="85%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="58%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2" bgcolor="#000000" style="color: #ffffff"><B>2007</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">2006</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">2005</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="13" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Risk-free interest rate</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" bgcolor="#000000">&nbsp;</TD>

<TD align="right" bgcolor="#000000" style="color: #ffffff"><B>3.91%</B></TD>
    <TD align="left" bgcolor="#000000" style="color: #ffffff"><B>&nbsp;</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">4.08%</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">3.27%</TD>
    <TD nowrap>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Expected hold period to exercise</DIV></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" nowrap bgcolor="#000000" align="right" style="color: #ffffff"><B>&nbsp;&nbsp;3.5 years</B></TD>
    <TD bgcolor="#000000" align="right" style="color: #ffffff">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" nowrap align="right">&nbsp;&nbsp;3.5 years</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" nowrap align="right">&nbsp;&nbsp;3.5 years</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Volatility in the price of the Company&#146;s shares</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>56%</B></TD>
    <TD align="left" bgcolor="#000000" style="color: #ffffff"><B>&nbsp;</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">63%</TD>
    <TD nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">64%</TD>
    <TD nowrap>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Dividend yield</DIV></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" nowrap bgcolor="#000000" align="right" style="color: #ffffff"><B>Zero</B></TD>
    <TD bgcolor="#000000" align="center" style="color: #ffffff">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" nowrap align="right">Zero</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" nowrap align="right">Zero</TD>
    <TD>&nbsp;</TD>

</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Weighted average fair value of options</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>&nbsp;</B></TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>$0.94</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="right">$1.46</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="right">$1.51</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="13" align="left" style="border-top: 2px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<DIV align="left" style="margin-top: 10pt; margin-left: 10%; margin-right:5%; font-size: 9pt"><B>12. Contributed Surplus</B>
</DIV>

<DIV align="center"><DIV style="font-size: 1pt; margin-top: 0pt; width: 100%; border-top: 1px solid #000000">&nbsp;</DIV></DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">The following table summarizes the change in contributed surplus as at and for the year ended
December&nbsp;31:
</DIV>
<DIV align="right">
<TABLE style="font-size: 9pt; margin-left: 10%; margin-right: 5%" cellspacing="0" bordER="0" cellpadding="0" width="85%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="60%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">$</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2" bgcolor="#000000" style="color: #ffffff"><B>2007</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">2006</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="13" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Balance, beginning of year</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>8,529,326</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">7,912,584</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Stock based compensation</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>539,156</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">403,550</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Expired warrants</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>1,308,480</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">213,192</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Exercise of stock options</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>&#151;</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="13" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Balance end of year</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" bgcolor="#000000" style="color: #ffffff"><B>10,376,962</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">8,529,326</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="13" align="left" style="border-top: 2px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="margin-top: 10pt; margin-left: 10%; margin-right:5%; font-size: 9pt"><B>13. Loss per Common Share</B>
</DIV>
<DIV align="center"><DIV style="font-size: 3pt; margin-top: 1pt; width: 100%; border-top: 1px solid #000000">&nbsp;</DIV></DIV>


<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">Loss per common share is calculated using the weighted average number of common shares
outstanding for the year ended December&nbsp;31, 2007 of 40,428,825 (2006 &#150; 36,346,266; 2005 &#150;
32,804,540). The effect of any potential exercise of the Company&#146;s stock options and warrants
outstanding during the year has been excluded from the calculation of diluted earnings per share,
as it would be anti-dilutive.
</DIV>

<DIV align="left" style="margin-top: 10pt; margin-left: 10%; margin-right:5%; font-size: 9pt"><B>14. Income taxes</B>
</DIV>
<DIV align="center"><DIV style="font-size: 3pt; margin-top: 1pt; width: 100%; border-top: 1px solid #000000">&nbsp;</DIV></DIV>


<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">The recovery of income taxes recorded in the financial statements differs from the amount which
would be obtained by applying the statutory income tax rate to the loss before tax as follows:
</DIV>


 <DIV align="center">
<TABLE style="font-size: 7pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="79%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" colspan="2" valign="top" bgcolor="#000000" style="color: #ffffff; font-size: 9pt"><b>48</b></TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD colspan="2" bgcolor="#000000" style="border-top: 1px solid #ffffff">&nbsp;</TD>
    <TD colspan="6" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">Oncolytics Biotech Inc <B>Notes to Financial Statements</B></DIV></TD>

    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>

<P align="center" style="font-size: 9pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: Helvetica,Arial,sans-serif">

<DIV align="right">
<TABLE style="font-size: 9pt; margin-left 5%; margin-right: 10%" cellspacing="0" border="0" cellpadding="0" width="85%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="48%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">$</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" style="background: #000000; color: #FFFFFF" colspan="2"><B>2007</B></TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">2006</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">2005</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="17" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #ffffff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Loss before income taxes</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>(15,642,191</B></TD>
    <TD nowrap style="background: #000000; color: #FFFFFF"><B>)</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(14,297,524</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(12,781,831</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Statutory Canadian corporate tax rate</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" bgcolor="#000000">&nbsp;</TD>

<TD align="right" style="background: #000000; color: #FFFFFF"><B>32.12%</B></TD>

<TD align="left" style="background: #000000; color: #FFFFFF"><B>&nbsp;</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">29.00%</TD>
    <TD nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">33.60%</TD>
    <TD nowrap>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #ffffff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Anticipated tax recovery</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>(5,024,272</B></TD>
    <TD nowrap style="background: #000000; color: #FFFFFF"><B>)</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(4,146,282</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(4,294,695</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Non-taxable portion of net capital loss (gain)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>&#151;</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(129</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom" style="background: #ffffff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Employee stock based compensation</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>156,355</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">117,030</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">21,539</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Change in tax rate</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>465,321</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,276,597</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">102,309</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #ffffff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Tax return adjustment</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>(314,156</B></TD>
    <TD nowrap style="background: #000000; color: #FFFFFF"><B>)</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(5,414</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">78,995</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Non-deductible expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>9,311</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10,440</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">8,113</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #ffffff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Change in valuation allowance</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>4,707,441</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,747,629</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,083,868</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Future income tax recovery</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>&#151;</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" align="left" style="border-top: 2px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left" style="margin-top: 10pt; margin-left: 5%; margin-right:10%; font-size: 9pt">As at December&nbsp;31, 2007, the Company has non-capital losses for income tax purposes of
approximately $56,112,000 which are available for application against future taxable income and
expire in 2008 ($2,898,000), 2009 ($4,483,000), 2010 ($4,483,000), 2014 ($9,075,000), 2015
($11,550,000), 2026 ($11,103,000) and 2027 ($12,520,000). As of December&nbsp;31, 2007, the Company has
non-refundable federal investment tax credits of approximately $3,054,000 (2006 &#150; $2,170,000)
which are available to reduce future taxes payable. The Company has unclaimed scientific research
and experimental development expenditures available to reduce future year&#146;s taxable income of
approximately $13,504,000 (2006 &#150; $9,325,000) over an indefinite future period. The Company has
not recorded the potential benefits of these tax pools in the financial statements.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt">The components of the Company&#146;s future income tax asset are as follows:
</DIV>
<DIV align="right">
<TABLE style="font-size: 9pt; margin-left 5%; margin-right: 10%" cellspacing="0" border="0" cellpadding="0" width="85%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="60%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">$</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" style="background: #000000; color: #FFFFFF" colspan="2"><B>2007</B></TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">2006</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="13" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #ffffff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Non-capital loss carryforwards</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>16,045,857</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">13,378,880</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Scientific research and development</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>3,376,086</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,704,290</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #ffffff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Investment tax credits</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>2,290,784</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,540,443</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Net capital loss carryforwards</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>249,189</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">244,966</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #ffffff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Undepreciated capital costs in excess
of book value of capital assets and intellectual property</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>727,205</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">553,156</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Share issue costs</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>523,919</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">428,965</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #ffffff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Valuation allowance</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>(23,213,040</B></TD>
    <TD nowrap style="background: #000000; color: #FFFFFF"><B>)</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(18,850,700</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="13" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Future tax asset</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>&#151;</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="13" align="left" style="border-top: 2px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 7pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="85%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="right" colspan="2" valign="top" bgcolor="#000000" style="color: #ffffff; font-size: 9pt"><b>49</b></TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="6" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD colspan="2" bgcolor="#000000" style="border-top: 1px solid #ffffff">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD colspan="4" align="right"><DIV style="margin-left:15px; text-indent:-15px">Oncolytics Biotech Inc <B>Notes to Financial Statements</B></DIV></TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>




<P align="center" style="font-size: 9pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>



<DIV style="font-family: Helvetica,Arial,sans-serif">




<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt"><B>15.
Indemnification of Officers and Directors</B>
</DIV>
<DIV align="center" style="font-size: 9pt"><DIV style="width: 100%; border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV></DIV>



<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">The Company&#146;s corporate by-laws require that, except to the extent expressly prohibited by law,
the Company will indemnify its officers and directors against all costs, charges and expenses,
including an amount paid to settle an action or satisfy a judgment reasonably incurred in respect
of any civil, criminal or administrative action or proceeding as it relates to their services to
the Company. The by-laws provide no limit to the amount of the indemnification. The Company has
purchased directors&#146; and officers&#146; insurance coverage to cover claims made against the directors
and officers during the applicable policy periods. The amounts and types of coverage have varied
from period to period as dictated by market conditions. The Company believes that it has adequate
insurance coverage; however, there is no guarantee that all indemnification payments will be
covered under the Company&#146;s existing insurance policies.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">There is no pending litigation or proceeding involving any officer or director of the Company as to
which indemnification
</DIV>

<DIV align="left" style="margin-top: 0pt; margin-left: 10%; margin-right:5%; font-size: 9pt">is being sought, nor is the Company aware of any threatened litigation that may result in claims
for indemnification.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt"><B>16.
Short-term Investments</B>
</DIV>
<DIV align="center" style="font-size: 9pt"><DIV style="width: 100%; border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV></DIV>



<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">Short-term investments, consisting of Government of Canada treasury bills, bankers&#146; acceptance and
discount bond notes, are liquid investments that are readily convertible to known amounts of cash
and are subject to an insignificant risk of changes in value. The objectives for holding
short-term investments are to invest the Company&#146;s excess cash resources in investment vehicles
that provide a better rate of return compared to the Company&#146;s interest bearing bank account with
limited risk to the principal invested. The Company also intends to match the maturities of these
short-term investments with the cash requirements of the Company&#146;s activities.
</DIV>
<DIV align="right">
<TABLE style="font-size: 9pt; margin-left 10%; margin-right: 5%" cellspacing="0" border="0" cellpadding="0" width="85%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="25%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="8%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="8%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="8%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="8%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="8%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2"><B>Original</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2"><B>Accrued</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2"><B>Carrying</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2"><B>Fair</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="3"><B>Effective</B></TD>
</TR>
<TR style="font-size: 9pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2"><B>Cost</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2"><B>Interest</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2"><B>Value</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2"><B>Value</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="3"><B>Interest Rate</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #000000; color: #ffffff">
    <TD><DIV style="margin-left:0px; text-indent:-0px"><B>December&nbsp;31, 2007<br>
Short-term investments</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>18,230,340</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>268,393</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>18,498,733</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>18,499,173</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right"><B>4.26</B></TD>
    <TD nowrap><B>%</B></TD>
</TR>
<TR valign="bottom" style="line-height: 3pt; padding-top: 0em"><!-- Blank Space -->
    <TD><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 0em; background: #ffffff">
    <TD><DIV style="margin-left:0px; text-indent:-0px">December&nbsp;31, 2006<br>
Short-term investments</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">23,672,719</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">449,518</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">24,122,237</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">24,124,810</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">3.95</TD>
    <TD nowrap>%</TD>
</TR>
<TR style="font-size: 1px; background: #ffffff">
    <TD colspan="21" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="margin-top: 10pt; margin-left: 10%; margin-right:5%; font-size: 9pt">Fair value is determined by using published market prices provided by the Company&#146;s investment
advisor.
</DIV>

<DIV align="left" style="margin-top: 12pt; margin-left: 10%; margin-right:5%; font-size: 9pt"><B>17.
Financial Instruments</B>
</DIV>
<DIV align="center" style="font-size: 9pt"><DIV style="width: 100%; border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV></DIV>



<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">Financial instruments of the Company consist of cash and cash equivalents, short-term
investments, accounts receivable, accounts payable and accrued liabilities. As at December&nbsp;31,
2007, there are no significant differences between the carrying values of these amounts and
their estimated market values.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt"><B>Credit risk</B>
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">The Company is exposed to credit risk on its short-term investments in the event of non-performance
by counterparties, but does not anticipate such non-performance. The Company mitigates its exposure
to credit risk by restricting its portfolio to investment grade securities with short term
maturities and by monitoring the credit risk and credit standing of counterparties.
</DIV>



<DIV align="center">
<TABLE style="font-size: 7pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="85%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" colspan="2" valign="top" bgcolor="#000000" style="color: #ffffff; font-size: 9pt"><b>50</b></TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD colspan="2" bgcolor="#000000" style="border-top: 1px solid #ffffff">&nbsp;</TD>
    <TD colspan="6" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">Oncolytics Biotech Inc <B>Notes to Financial Statements</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>
<P align="center" style="font-size: 9pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: Helvetica,Arial,sans-serif">

<DIV style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt"><B>Interest rate risk</B></DIV>

<DIV style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt">The Company has exposure to interest income risk through its short-term investments in fixed-income
securities that
are sensitive to interest rate fluctuations.</DIV>

<DIV style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt"><B>Foreign exchange risk</B></DIV>

<DIV style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt">The Company purchases goods and services denominated primarily in Canadian, U.S. and U.K.
currencies. To manage its
foreign exchange risk, the Company, from time to time, acquires short-term investments denominated
in these securities.</DIV>

<DIV style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt"><B>18. Economic Dependence</B></DIV>
<DIV align="center" style="font-size: 9pt"><DIV style="width: 100%; border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV></DIV>

<DIV style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt">The Company contracts the production and currently receives its supply of REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> for use in its
clinical trial program from one toll manufacturer based in the U.K. The Company is in the process
of transferring its technology to another toll manufacturer in the U.S., but has not produced
clinical grade REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> from this second toll manufacturer. As a result, any significant
disruption of the services provided by the Company&#146;s toll manufacturer in the U.K. has the
potential to delay the progress of the Company&#146;s clinical trial program.</DIV>

<DIV style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt"><B>19. Additional Cash Flow Disclosure</B></DIV>
<DIV align="center" style="font-size: 9pt"><DIV style="width: 100%; border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV></DIV>


<DIV align="right">
<TABLE style="font-size: 9pt; margin-left 5%; margin-right: 10%" cellspacing="0" border="0" cellpadding="0" width="85%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="36%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 6pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">Cumulative</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 6pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">from inception</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 6pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">on April 2, 1998</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 6pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">to December 31,</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom">
    <TD nowrap><B>Net Change in Non-Cash Working Capital</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">$</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" style="background: #000000; color: #FFFFFF" colspan="2"><B>2007</B></TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">2006</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">2005</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">2007</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="21" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #ffffff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Change in:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Accounts receivable</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>3,918</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap>&nbsp;</TD>
    <TD align="right">(36,613</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">377</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap>&nbsp;</TD>
    <TD align="right">(80,085</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom" style="background: #ffffff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Prepaid expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>378,240</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap>&nbsp;</TD>
    <TD align="right">(98,172</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap>&nbsp;</TD>
    <TD align="right">(290,003</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap>&nbsp;</TD>
    <TD align="right">(260,300</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Accounts payable and accrued liabilities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>204,806</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">923,940</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">743,223</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,821,227</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="21" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #ffffff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Change in non-cash working capital</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>586,964</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">789,155</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">453,597</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,480,842</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Net change associated with investing activities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>(56,664</B></TD>
    <TD align="left" style="background: #000000; color: #FFFFFF"><B>)</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">22,767</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">131,169</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap>&nbsp;</TD>
    <TD align="right">(45,621</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="21" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #ffffff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Net change associated with operating activities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>530,300</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">811,922</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">584,766</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,435,221</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="21" style="border-top: 2px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE></DIV>


<DIV align="center">
<TABLE style="font-size: 7pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="85%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="right" colspan="2" valign="top" bgcolor="#000000" style="color: #ffffff; font-size: 9pt"><b>51</b></TD>
    <TD valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="6" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD colspan="2" bgcolor="#000000" style="border-top: 1px solid #ffffff">&nbsp;</TD>
    <TD valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD colspan="4" align="right"><DIV style="margin-left:15px; text-indent:-15px">Oncolytics Biotech Inc <B>Notes to Financial Statements</B></DIV></TD>
    <TD valign="top">&nbsp;</TD>
    <TD valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>

<!-- End Table Body -->
</TABLE></DIV>

<P align="center" style="font-size: 9pt"><!-- Folio -->&nbsp;<!-- /Folio --></DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: Helvetica,Arial,sans-serif">

<DIV align="right">
<TABLE style="font-size: 9pt; margin-left 10%; margin-right: 5%" cellspacing="0" border="0" cellpadding="0" width="85%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="35%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 6pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">Cumulative</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 6pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">from inception</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 6pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">on April 2, 1998</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 6pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">to December 31,</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom">
    <TD nowrap align="left"><B>Other Non-Cash Items</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2"><B>$</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" style="background: #000000; color: #FFFFFF" colspan="2"><B>2007</B></TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">2006</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">2005</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">2007</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="21" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #ffffff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Foreign exchange loss</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>&#151;</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">159,204</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">425,186</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Donation of medical equipment</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>&#151;</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">66,069</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">66,069</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #ffffff">
    <TD nowrap><DIV style="margin-left:15px; text-indent:-15px">Loss on sale of Transition Therapeutics Inc.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>&#151;</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,156,685</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD nowrap><DIV style="margin-left:15px; text-indent:-15px">Gain on sale of BCY LifeSciences Inc. <I>&#091;note 20&#093;</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>&#151;</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(765</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(299,403</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom" style="background: #ffffff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Cancellation of contingent payment obligation
settled in common shares <I>&#091;note 9&#093;</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>&#151;</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">150,000</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Future income tax recovery</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>&#151;</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(1,115,000</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="21" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #ffffff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>&#151;</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">224,508</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,383,537</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="21" align="left" style="border-top: 2px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left" style="margin-top: 10pt; margin-left: 10%; margin-right:5%; font-size: 9pt"><B>20. BCY LifeSciences Inc.</B>
</DIV>
<DIV align="center" style="font-size: 9pt"><DIV style="width: 100%; border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV></DIV>



<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">On May&nbsp;7, 2002, the shareholders of SYNSORB and the Company approved an arrangement whereby the
Company would release from escrow 4,000,000 common shares held by SYNSORB. As consideration,
SYNSORB provided the Company with 1,500,000 common shares of BCY LifeSciences Inc. (&#147;BCY&#148;) along
with the rights to receive an additional 400,000 common shares of BCY upon the attainment of
certain milestones by BCY at no cash cost to the Company. The Company received 200,000 of these
400,000 common shares on November&nbsp;27, 2002. These 1,700,000 common shares in BCY were recorded as
an investment at $170,000 based on the quoted market price of the BCY common shares at that time
with an offsetting credit recorded to contributed surplus. On April&nbsp;23, 2002, the Company acquired
694,445 common shares of BCY, a public company, for $0.18 per share, and warrants exercisable
until April&nbsp;23, 2004 to purchase up to 694,445 common shares in BCY at an exercise price of $0.27
per share for total consideration of $127,123 (including costs of $2,123). After these
transactions, the Company held a total of 2,394,445 BCY shares which were all subsequently sold
for net cash proceeds of $591,725 recording a gain on sale of investment of $299,403.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt"><B>21. Reconciliation of Canadian GAAP to U.S. GAAP</B>
</DIV>
<DIV align="center" style="font-size: 9pt"><DIV style="width: 100%; border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV></DIV>



<DIV align="left" style="margin-top: 6pt; margin-left: 10%; margin-right:5%; font-size: 9pt">The financial statements of the Company are prepared in accordance with Canadian GAAP which, in
most respects, conforms to U.S. GAAP. Significant differences between Canadian and U.S. GAAP are as follows:
</DIV>



<DIV align="center">
<TABLE style="font-size: 7pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="85%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" colspan="2" valign="top" bgcolor="#000000" style="color: #ffffff; font-size: 9pt"><b>52</b></TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD colspan="2" bgcolor="#000000" style="border-top: 1px solid #ffffff">&nbsp;</TD>
    <TD colspan="6" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">Oncolytics Biotech Inc <B>Notes to Financial Statements</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>
<P align="center" style="font-size: 9pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: Helvetica,Arial,sans-serif">

<DIV align="right">
<TABLE style="font-size: 9pt; margin-left 5%; margin-right: 10%" cellspacing="0" border="0" cellpadding="0" width="85%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="28%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 6pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">Cumulative</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 6pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">from inception</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 6pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">on April 2, 1998</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 6pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">to December 31,</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom">
    <TD nowrap style="border-bottom: 0px solid #000000">Year Ended December 31</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 0px solid #000000">Note</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2" style="border-bottom: 0px solid #000000">$</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" style="background: #000000; color: #FFFFFF" colspan="2"><B>2007</B></TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2" style="border-bottom: 0px solid #000000">2006</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2" style="border-bottom: 0px solid #000000">2005</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2" style="border-bottom: 0px solid #000000">2007</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="23" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #ffffff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Net loss &#150; Canadian GAAP</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(2)</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>15,642,191</B></TD>
    <TD valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="right" valign="top">14,297,524</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="right" valign="top">12,781,831</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="right" valign="top">80,522,257</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Amortization of intellectual property</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(1)</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>(361,500</B></TD>
    <TD style="background: #000000; color: #FFFFFF"><B>)</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD align="right" valign="top">(361,500</TD>
    <TD nowrap valign="top">)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD align="right" valign="top">(361,500</TD>
    <TD nowrap valign="top">)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD align="right" valign="top">(3,072,750</TD>
    <TD nowrap valign="top">)</TD>
</TR>
<TR valign="bottom" style="background: #ffffff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Future income tax recovery</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(1)</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>&#151;</B></TD>
    <TD valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&#151;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&#151;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="right" valign="top">1,115,000</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Net and comprehensive loss &#150; U.S.&nbsp;GAAP</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>15,280,691</B></TD>
    <TD valign="bottom" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">13,936,024</TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">12,420,331</TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">78,564,507</TD>
    <TD valign="bottom">&nbsp;</TD>
</TR>

<TR valign="bottom" style="background: #ffffff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Basic and diluted loss per common share &#150; U.S. GAAP</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>(0.38</B></TD>
    <TD style="background: #000000; color: #FFFFFF"><B>)</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD align="right" valign="bottom">(0.38</TD>
    <TD align="right" valign="bottom">)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD align="right" valign="bottom">(0.38</TD>
    <TD align="right" valign="bottom">)</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="right" valign="bottom">&#151;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" style="border-top: 2px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV style="margin-top: 10pt; margin-left: 5%; margin-right:10%; font-size: 9pt">There are no differences between Canadian GAAP and U.S. GAAP in amounts reported as cash flows from
(used in) operating, financing and investing activities.
</DIV>

<DIV style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt">Balance sheet items in accordance with U.S. GAAP are as follows:
</DIV>
<DIV align="right">
<TABLE style="font-size: 9pt; margin-left 5%; margin-right: 10%" cellspacing="0" border="0" cellpadding="0" width="85%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="26%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="background: #000000; color: #FFFFFF" colspan="6"><B>December 31, 2007</B></TD>
    <TD nowrap align="center" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 0px solid #000000">December 31, 2006</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Note</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" style="background: #000000; color: #FFFFFF" colspan="2"><B>Canadian GAAP</B></TD>
    <TD align="center" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="center" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD nowrap align="right" style="background: #000000; color: #FFFFFF" colspan="2"><B>U.S. GAAP</B></TD>
    <TD align="center" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">Canadian GAAP</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">U.S. GAAP</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="19" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #ffffff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Intellectual property</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(1)</TD>
    <TD>&nbsp;</TD>
    <TD align="center" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>5,026,540</B></TD>
    <TD align="center" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="center" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="center" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>4,484,290</B></TD>
    <TD align="center" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="right" valign="top">5,079,805</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="right" valign="top">4,176,055</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Future income taxes</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(1)</TD>
    <TD>&nbsp;</TD>
    <TD align="center" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>&#151;</B></TD>
    <TD align="center" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="center" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="center" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>&#151;</B></TD>
    <TD align="center" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&#151;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&#151;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #ffffff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Contributed surplus</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(1)</TD>
    <TD>&nbsp;</TD>
    <TD align="center" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>10,376,962</B></TD>
    <TD align="center" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="center" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="center" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>7,876,962</B></TD>
    <TD align="center" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="right" valign="top">8,529,326</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="right" valign="top">6,029,326</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Deficit</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(1)</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" valign="bottom" style="background: #000000; color: #FFFFFF"><B>80,522,257</B></TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" valign="bottom" style="background: #000000; color: #FFFFFF"><B>78,564,507</B></TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="right" valign="bottom">65,030,066</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="right" valign="bottom">63,433,816</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="19" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 9pt">

<TR valign="top" style="font-size: 9pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap><B>1.</B></TD>
    <TD width="1%"><B>&nbsp;</B></TD>
    <TD><B>&#147;Push-Down&#148; Accounting and In Process Research and Development</B></TD>
    <TD width="10%" style="background: transparent">&nbsp;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 9pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap>&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Intellectual property of $2,500,000 recorded as a consequence of SYNSORB&#146;s acquisition of the
Company&#146;s shares comprises intangible assets related to research and development activities.
Under U.S. GAAP, this would not be capitalized on acquisition.</TD>
    <TD width="10%" style="background: transparent">&nbsp;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 9pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap>&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>As a result of removing the $2,500,000 from intellectual property in 1999 for U.S. GAAP
purposes, the amortization of the intellectual property, the future income tax recovery,
future income tax liability and contributed surplus amounts recorded for Canadian GAAP
purposes have been reversed.</TD>
    <TD width="10%" style="background: transparent">&nbsp;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 9pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap><B>2.</B></TD>
    <TD width="1%"><B>&nbsp;</B></TD>
    <TD><B>Presentation of Stock Based Compensation Expense</B></TD>
    <TD width="10%" style="background: transparent">&nbsp;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 9pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap>&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Under U.S. GAAP, stock based compensation expense is to be presented within the appropriate
category of expenses on the statements of loss. As a result, stock based compensation on the
statement of loss would be reduced by $539,156 in 2007 (2006 &#150; $403,550; 2005 &#150; $64,104) and
research and development and operating expenses would increase by $375,156 and $164,000,
respectively (2006 &#150; $131,890 and $271,660, respectively; 2005 &#150; $59,974 and $4,130,
respectively). Cumulative from inception stock based compensation would be</TD>
    <TD width="10%" style="background: transparent">&nbsp;</TD>
</TR>

</TABLE>
</DIV>

 <DIV align="center">
<TABLE style="font-size: 7pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="85%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="right" colspan="2" valign="top" bgcolor="#000000" style="color: #ffffff; font-size: 9pt"><b>53</b></TD>
    <TD valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="6" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD colspan="2" bgcolor="#000000" style="border-top: 1px solid #ffffff">&nbsp;</TD>
    <TD valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD colspan="4" align="right"><DIV style="margin-left:15px; text-indent:-15px">Oncolytics Biotech Inc <B>Notes to Financial Statements</B></DIV></TD>
    <TD valign="top">&nbsp;</TD>
    <TD valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>

<P align="center" style="font-size: 9pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: Helvetica,Arial,sans-serif">

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 9pt">

<TR valign="top" style="font-size: 9pt; color: #000000; background: transparent">
    <TD width="13%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap>&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>reduced by $4,704,805 and cumulative from inception research and development and operating expenses
would increase by $2,671,085 and $2,033,720, respectively. There is no impact on the Company&#146;s net loss.</TD>
    <TD width="5%" style="background: transparent">&nbsp;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 9pt; color: #000000; background: transparent">
    <TD width="13%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap><B>&nbsp;</B></TD>
    <TD width="1%"><B>&nbsp;</B></TD>
    <TD><B>Stock Based Employee Compensation</B></TD>
    <TD width="5%" style="background: transparent">&nbsp;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 9pt; color: #000000; background: transparent">
    <TD width="13%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap>&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>On January&nbsp;1, 2003, the Company prospectively adopted the fair value based method for its
employee options (see note 3). Consequently there were no differences between Canadian GAAP and
U.S. GAAP with respect to options granted subsequent to this date.</TD>
    <TD width="5%" style="background: transparent">&nbsp;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 9pt; color: #000000; background: transparent">
    <TD width="13%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap>&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In 2002, the Company applied the intrinsic value method for employee stock options and the fair
value method for non-employee options granted after January&nbsp;1, 2002. Prior to January&nbsp;1, 2002,
for U.S. GAAP, the Company applied the intrinsic value method prescribed by Accounting Principles
Board Opinion No.&nbsp;25, &#147;Accounting for Stock Issued to Employees&#148; and related interpretations in
accounting for its employee stock option plans. As well, the Company provided pro forma
disclosure as required by FAS 123 for those options granted prior to January&nbsp;1, 2002.</TD>
    <TD width="5%" style="background: transparent">&nbsp;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 9pt; color: #000000; background: transparent">
    <TD width="13%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap>&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The following additional pro-forma disclosure would be provided under U.S. GAAP with respect to
the fair value of employee options granted prior to January&nbsp;1, 2002. The fair value for these
options granted was estimated at the date of grant using a Black-Scholes Option Pricing Model
with the following weighted-average assumptions:</TD>
    <TD width="5%" style="background: transparent">&nbsp;</TD>
</TR>

</TABLE>
</DIV>
<DIV align="right">
<TABLE style="font-size: 9pt; margin-left 10%; margin-right: 15%" cellspacing="0" border="0" cellpadding="0" width="65%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="81%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" style="background: #000000; color: #FFFFFF" colspan="2"><B>2001</B></TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="5" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #ffffff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Risk-free interest rate</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap bgcolor="#000000">&nbsp;</TD>

<TD align="right" style="background: #000000; color: #FFFFFF"><B>5.0%</B></TD>
    <TD nowrap bgcolor="#000000"><B>&nbsp;</B></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Dividend yield</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap bgcolor="#000000">&nbsp;</TD>

<TD align="right" style="background: #000000; color: #FFFFFF"><B>0%</B></TD>
    <TD nowrap bgcolor="#000000"><B>&nbsp;</B></TD>
</TR>
<TR valign="bottom" style="background: #ffffff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Volatility factors of expected market price</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap bgcolor="#000000">&nbsp;</TD>

<TD align="right" style="background: #000000; color: #FFFFFF"><B>87%</B></TD>
    <TD nowrap bgcolor="#000000"><B>&nbsp;</B></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Weighted average expected life of the options</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" style="background: #000000; color: #FFFFFF" colspan="2"><B>2 years</B></TD>
    <TD nowrap align="right" style="background: #000000; color: #FFFFFF" colspan="1">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="5" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 9pt">

<TR valign="top" style="font-size: 9pt; color: #000000; background: transparent">
    <TD width="13%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap>&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Pro forma disclosures of loss and loss per common share are presented below as if the Company had
adopted the cost recognition requirements under FAS 123 from inception.</TD>
    <TD width="5%" style="background: transparent">&nbsp;</TD>
</TR>

</TABLE>
</DIV>
<DIV align="right">
<TABLE style="font-size: 8pt; margin-left 10%; margin-right: 5%" cellspacing="0" border="0" cellpadding="0" width="80%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="32%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="32%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">$</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" style="background: #000000; color: #FFFFFF" colspan="2"><B>2007</B></TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">2006</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2">2005</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="19" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #ffffff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Net Loss</DIV></TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Pro forma &#150; Canadian GAAP</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD nowrap align="right" style="background: #000000; color: #FFFFFF"><B>15,642,191</B></TD>
    <TD nowrap align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="right" valign="top">14,297,524</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="right" valign="top">12,782,814</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD valign="top">As reported &#150; U.S. GAAP</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD nowrap align="right" style="background: #000000; color: #FFFFFF"><B>15,280,691</B></TD>
    <TD valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="right" valign="top">13,936,024</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="right" valign="top">12,420,331</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #ffffff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Pro forma &#150; U.S. GAAP</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD nowrap align="right" style="background: #000000; color: #FFFFFF"><B>15,280,691</B></TD>
    <TD valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="right" valign="top">12,936,024</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="right" valign="top">12,421,314</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="19" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Basic and diluted net loss per<BR>
common share</DIV></TD>
    <TD>&nbsp;</TD>

<TD valign="top" nowrap><DIV style="margin-left:0px; text-indent:-0px">Pro forma &#150; Canadian GAAP <BR>
($/share)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD nowrap align="right" style="background: #000000; color: #FFFFFF"><B>(0.39</B></TD>
    <TD nowrap style="background: #000000; color: #FFFFFF"><B>)</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">(0.39</TD>
    <TD nowrap valign="bottom">)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">(0.39</TD>
    <TD nowrap valign="bottom">)</TD>
</TR>
<TR valign="bottom" style="background: #ffffff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD valign="top">As reported &#150; U.S. GAAP</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD nowrap align="right" style="background: #000000; color: #FFFFFF"><B>(0.38</B></TD>
    <TD nowrap style="background: #000000; color: #FFFFFF"><B>)</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD align="right" valign="top">(0.38</TD>
    <TD nowrap valign="top">)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD align="right" valign="top">(0.38</TD>
    <TD nowrap valign="top">)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Pro forma &#150; U.S. GAAP ($/share)</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD nowrap align="right" style="background: #000000; color: #FFFFFF"><B>(0.38</B></TD>
    <TD nowrap style="background: #000000; color: #FFFFFF"><B>)</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD align="right" valign="top">(0.38</TD>
    <TD nowrap valign="top">)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD align="right" valign="top">(0.38</TD>
    <TD nowrap valign="top">)</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="19" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<DIV align="center">
<TABLE style="font-size: 7pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="85%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" colspan="2" valign="top" bgcolor="#000000" style="color: #ffffff; font-size: 9pt"><b>54</b></TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD colspan="2" bgcolor="#000000" style="border-top: 1px solid #ffffff">&nbsp;</TD>
    <TD colspan="6" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:30pt; text-indent:-0px">Oncolytics Biotech Inc <B>Notes to Financial Statements</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>
<P align="center" style="font-size: 9pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: Helvetica,Arial,sans-serif">

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt"><B>Additional Stock Based Payment Disclosure</B>
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt">As at December&nbsp;31, 2007, the aggregate intrinsic value of the stock options outstanding and the
stock options exercisable were $222,018 and $222,018, respectively. The total intrinsic value of
the options exercised in 2007 was $90,000 (2006 &#150;$618,960; 2005 &#150; $1,223,400).
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt">A summary of the Company&#146;s non-vested options as at December&nbsp;31, 2007 and changes during the year
ended December&nbsp;31, 2007 is as follows:
</DIV>
<DIV align="right">
<TABLE style="font-size: 9pt; margin-left 5%; margin-right: 10%" cellspacing="0" border="0" cellpadding="0" width="85%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="65%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD nowrap align="center" style="background: #000000; color: #FFFFFF" colspan="6"><B>2007</B></TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD nowrap align="center" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD nowrap align="center" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD nowrap align="center" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD nowrap align="center" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD nowrap align="right" style="background: #000000; color: #FFFFFF" colspan="2"><B>Weighted Average</B></TD>
    <TD nowrap align="center" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD nowrap align="center" style="background: #000000; color: #FFFFFF" colspan="2"><B>Stock Options</B></TD>
    <TD nowrap align="center" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD nowrap align="center" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD nowrap align="center" style="background: #000000; color: #FFFFFF" colspan="2"><B>Grant Date Fair Value $</B></TD>
    <TD nowrap align="center" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="9" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #ffffff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Non-vested at beginning of year</DIV></TD>
    <TD nowrap align="center" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>182,500</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD nowrap align="center" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>1.38</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Granted during year</DIV></TD>
    <TD nowrap align="center" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>76,050</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD nowrap align="center" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>0.94</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #ffffff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Vested during year</DIV></TD>
    <TD nowrap align="center" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD nowrap align="left" bgcolor="#000000">&nbsp;</TD>

<TD align="right" style="background: #000000; color: #FFFFFF"><B>(50,000)</B></TD>
    <TD nowrap bgcolor="#000000"><B>&nbsp;</B></TD>
    <TD nowrap align="center" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>1.51</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Forfeited during year</DIV></TD>
    <TD nowrap align="center" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>&#151;</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD nowrap align="center" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>&#151;</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="5" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD nowrap align="center" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #ffffff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Non-vested at end of year</DIV></TD>
    <TD nowrap align="center" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>208,550</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD nowrap align="center" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD bgcolor="#000000">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF"><B>1.19</B></TD>
    <TD bgcolor="#000000">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="9" align="left" style="border-top: 2px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="margin-top: 10pt; margin-left: 5%; margin-right:10%; font-size: 9pt">As at December&nbsp;31, 2007, there was $93,929 of total unrecognized compensation costs related to
non-vested stock options granted under the Company&#146;s stock option plan. This cost is expected to be
recognized over a weighted average period of 1.48&nbsp;years. The total fair value of shares vested
during the years ended December&nbsp;31, 2007, 2006, and 2005 was $75,500, $129,276, and $59,630,
respectively.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt">The Company issues shares from treasury to satisfy any exercises of stock options.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt"><B>Adoption of New Accounting Standard</B>
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt">The Financial Accounting Standards Board (&#147;FASB&#148;) issued FASB Interpretation (&#147;FIN&#148;) No.&nbsp;48
&#147;Accounting for Uncertainty in Income Taxes &#150; an interpretation of FASB Statement 109&#148;. FIN 48
establishes a single model to address accounting for uncertain tax positions and clarifies the
accounting for income taxes by prescribing a minimum recognition threshold a tax position is
required to meet before being recognized in the financial statements. FIN 48 also provides
guidance on de-recognition, measurement classification, interest and penalties, accounting in
interim periods, disclosure and transition.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt">On January&nbsp;1, 2007, the Company adopted the provisions of FIN 48. The Company made no adjustments
to retained earnings related to adoption, there have been no material changes in the amount of
unrecognized tax benefits since adoption, and the Company anticipates no significant changes in
the next 12&nbsp;months.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-left: 5%; margin-right:10%; font-size: 9pt">The tax years 2001 &#150; 2006 remain open for audit examination by the Canadian taxing jurisdictions to
which the Company is subject to.
</DIV>


<DIV align="center">
<TABLE style="font-size: 7pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="85%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="right" colspan="2" valign="top" bgcolor="#000000" style="color: #ffffff; font-size: 9pt"><b>55</b></TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="6" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD colspan="2" bgcolor="#000000" style="border-top: 1px solid #ffffff">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD colspan="4" align="right"><DIV style="margin-left:15px; text-indent:-15px">Oncolytics Biotech Inc <B>Notes to Financial Statements</B></DIV></TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>

<P align="center" style="font-size: 9pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: Helvetica,Arial,sans-serif">



<P><DIV style="position: relative; float: left; width: 5%">
</DIV>
<DIV style="position: relative; float: left; margin-left: 1%; width: 20%">

<DIV align="Center" style="font-size: 9pt; margin-top: 6pt"><IMG src="o40024o4002404.gif" alt="(GRAPHIC)">

</DIV>
</DIV>
<DIV style="position: relative; float: right; width: 65%">




<DIV align="left" style="margin-top: 100pt; margin-right: 5%; font-size: 9pt"><B>Future Accounting Changes</B>
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-right: 5%; font-size: 9pt">SFAS No.&nbsp;157, <I>Fair Value Measurements</I>, defines fair value, establishes a
framework for measuring fair value and expands disclosures about fair
value measurements. The statement applies also to other accounting
pronouncements which require or permit fair value measurements. The
standard is effective for fiscal years beginning after November&nbsp;15, 2007.
The Company is evaluating the effects of adopting this standard.
</DIV>

<DIV align="left" style="margin-top: 6pt; margin-right: 5%; font-size: 9pt">SFAS No.&nbsp;159, <I>The Fair Value Option for Financial Assets and Financial
Liabilities</I>, including an amendment to SFAS No.&nbsp;115, permits entities to
choose to measure many financial instruments and certain other items at
fair value. Most of the provisions of this Statement apply only to
entities that elect the fair value option. However, the amendment to SFAS
No.&nbsp;115, <I>Accounting for Certain Investments in Debt and Equity Securities</I>,
applies to all entities with available for sale and held-for-trading
securities. SFAS No.&nbsp;159 is effective as of the beginning of an entity&#146;s
fiscal year that begins after November&nbsp;15, 2007. The adoption of this
standard is not expected to have a material impact on the Company&#146;s
financial statements.
</DIV>
</DIV>


<DIV align="center">
<TABLE style="font-size: 7pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" colspan="2" valign="top" bgcolor="#000000" style="color: #ffffff; font-size: 9pt"><b>56</b></TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD colspan="2" bgcolor="#000000" style="border-top: 1px solid #ffffff">&nbsp;</TD>
    <TD colspan="6" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 2pt"><!-- Blank Space -->
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">Oncolytics Biotech Inc <B>Notes to Financial Statements</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD align="left" valign="top" bgcolor="#000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>
<P align="center" style="font-size: 9pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: Helvetica,Arial,sans-serif; background: #000000; color: #FFFFFF">

<DIV align="center">
<TABLE style="font-size: 9pt;  background: #000000; color: #FFFFFF" cellspacing="0" border="0" cellpadding="0" width="80%">
<TR style="font-size: 60pt">
<TD>&nbsp;</TD>
</TR>



<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="45%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="50%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #000000">
    <TD valign="top"><B>Corporate Information</B></TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #000000"><!-- Blank Space -->
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #000000">
    <TD valign="top"><B>Directors</B></TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><B>Management Team</B></TD>
</TR>
<TR valign="bottom" style="background: #000000"><!-- Blank Space -->
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #000000">
    <TD valign="top">Brad Thompson, PhD</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Brad Thompson, PhD</TD>
</TR>
<TR valign="bottom" style="background: #000000">
    <TD valign="top">Chairman, President &#038; CEO,</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Chairman, President &#038; CEO</TD>
</TR>
<TR valign="bottom" style="background: #000000">
    <TD valign="top">Oncolytics Biotech Inc.</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #000000">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Doug Ball, CA</TD>
</TR>
<TR valign="bottom" style="background: #000000">
    <TD valign="top">Ger van Amersfoort</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Chief Financial Officer</TD>
</TR>
<TR valign="bottom" style="background: #000000">
    <TD valign="top">Biotech Consultant</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #000000">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Matt Coffey, PhD</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">Doug Ball, CA</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Chief Scientific Officer</TD>
</TR>
<TR valign="bottom" style="background: #000000">
    <TD valign="top">CFO, Oncolytics Biotech Inc.</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Karl Mettinger, MD, PhD</TD>
</TR>
<TR valign="bottom" style="background: #000000">
    <TD valign="top">William A. Cochrane, OC, MD</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Chief Medical Officer</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">Biotech Consultant</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #000000">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">George Gill, MD</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">Jim Dinning</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Senior Vice President,</TD>
</TR>
<TR valign="bottom" style="background: #000000">
    <TD valign="top">Chairman, Western Financial Group</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Clinical &#038; Regulatory Affairs</TD>
</TR>
<TR valign="bottom" style="background: #000000"><!-- Blank Space -->
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">Ed Levy, PhD</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Mary Ann Dillahunty, JD, MBA</TD>
</TR>
<TR valign="bottom" style="background: #000000">
    <TD valign="top" nowrap>Adjunct Professor, University of British Columbia</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Vice President, Intellectual Property</TD>
</TR>
<TR valign="bottom" style="background: #000000">
<!-- Blank Space -->
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">J. Mark Lievonen, CA</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><B>Auditor</B></TD>
</TR>
<TR valign="bottom" style="background: #000000">
    <TD valign="top">President, Sanofi Pasteur Limited</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Ernst &#038; Young LLP, 1000 Ernst &#038; Young Tower</TD>
</TR>
<TR valign="bottom" style="background: #000000">
    <TD valign="top">Bob Schultz, FCA</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">440 &#150; 2 Avenue SW, Calgary, AB T2P 5E9</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">Corporate Director</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #000000">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><B>Transfer Agent</B></TD>
</TR>
<TR valign="bottom">
    <TD valign="top">Fred A. Stewart, QC</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Computershare Trust Company of Canada, Calgary, AB.</TD>
</TR>
<TR valign="bottom" style="background: #000000">
    <TD valign="top">President, Fred Stewart and Associates Inc.</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">For change of address, lost stock certificates and other<BR>
related inquiries contact:</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">1.800.564.6253 or www.computershare.com</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #000000">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><B>Legal Counsel</B></TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Bennett Jones Barristers &#038; Solicitors, 4500 Bankers</TD>
</TR>
<TR valign="bottom" style="background: #000000">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Hall East, 855 &#150; 2 Street SW, Calgary, AB T2P 4K7</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top"><B>Shareholder Information</B></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #000000">
    <TD colspan="3" valign="top">For public company filings, please go to www.sedar.com or contact the Company at: Oncolytics
Biotech Inc.,<BR>210 &#150; 1167 Kensington Crescent NW, Calgary, Alberta, Canada T2N 1X7 P:
403.670.7377 F: 403.283.0858<BR><B>www.oncolyticsbiotech.com</B></TD>
</TR>
<TR style="font-size: 50pt">
<TD>&nbsp;</TD>
</TR>


<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 9pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: Helvetica,Arial,sans-serif">

<DIV align="center">
<TABLE style="font-size: 9pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="20%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #ffffff">
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;
</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>

<TD align="right" style="background: #000000; color: #FFFFFF"><IMG src="o40024o4002408.gif" alt="(IMAGE)">
</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
    <TD align="right" style="background: #000000; color: #FFFFFF">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 9pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>EXHIBIT 2</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><IMG src="o40024o4002400.gif" alt="(ONCOLYTICS LOGO)"></DIV>


<DIV align="Center" style="font-size: 12pt; margin-top: 50pt"><B>NOTICE
OF ANNUAL AND SPECIAL MEETING <BR> OF SHAREHOLDERS TO BE HELD ON
May&nbsp;7, 2008</B></DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 24pt"><B>- AND -</B></DIV>

<DIV align="Center" style="font-size: 12pt; margin-top: 24pt"><B>MANAGEMENT PROXY CIRCULAR</B></DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 50pt"><B>March&nbsp;20, 2008</B></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio --></DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 11pt; margin-top: 18pt"><B>TABLE OF CONTENTS</B></DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="2" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="90%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 0px solid #000000"><B>PAGE</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
<TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Notice of Meeting</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>i</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Solicitation of Proxies</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>1</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Appointment of Proxyholders and Revocation of Proxies</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Signing of Proxy</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Voting of Proxies and Exercise of Discretion by Proxyholders</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Voting Shares and Principal Holders of Common Shares</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>2</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Voting of Common Shares &#150; General</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Advice to Beneficial Holders of Common Shares</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Principal Holders of Common Shares</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Compensation of Executive Officers</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>4</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Summary Compensation Table</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Stock Options</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Employment Contracts</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Termination of Employment or Change of Control</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Compensation of Directors</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Composition of the Compensation Committee</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Report on Executive Compensation</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Performance Graphs</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">7</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Indebtedness of Directors and Senior Officers</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">8</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Interest of Insiders in Material Transactions</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">8</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Equity Compensation Plan Information</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>8</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Statement of Corporate Governance Practices</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>9</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Receipt of Financial Statements</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>14</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Election of Directors</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>14</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Appointment of Auditors</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>17</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Amendment of Stock Option Plan</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>17</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">General Amendment Provision</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">17</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Black Out Periods</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">18</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Eligible Participants</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">18</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">General</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">18</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Interest of Certain Persons in Matters to be Acted Upon</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>19</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Other Matters to be Acted Upon</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>19</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Effective Date</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>19</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Additional Information</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>19</B></TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE></DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio --></DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><IMG src="o40024o4002400.gif" alt="(ONCOLYTICS LOGO)"></DIV>

<DIV align="Center" style="font-size: 11pt; margin-top: 18pt"><B>NOTICE OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS<BR>
May&nbsp;7, 2008</B></DIV>

<DIV style="font-size: 10PT; margin-top: 12pt"><B>TO THE SHAREHOLDERS OF ONCOLYTICS BIOTECH INC.</B></DIV>


<DIV  align="justify" style="font-size: 10PT; margin-top: 6pt">NOTICE IS HEREBY GIVEN that the annual meeting (the &#147;Meeting&#148;) of shareholders of Oncolytics
Biotech Inc. (the &#147;Corporation&#148;) will be held at the Yale Club, 50 Vanderbilt Avenue, New York, New
York at 9 a.m. (EDT). The purpose of the meeting is to consider, and to take action with respect
to, the following matters:</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10PT">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap>1.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the receipt of the audited financial statements of the Corporation for the year ended
December&nbsp;31, 2007, together with the auditors&#146; report thereon;</TD>
</TR>

<TR>
    <TD style="font-size: 10pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap>2.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the election of directors of the Corporation for the ensuing year;</TD>
</TR>

<TR>
    <TD style="font-size: 10pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap>3.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the appointment of auditors for the Corporation for the ensuing year and the authorization of
the directors to fix their remuneration;</TD>
</TR>

<TR>
    <TD style="font-size: 10pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap>4.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the approval of amendments to the Corporation&#146;s stock option plan; and</TD>
</TR>

<TR>
    <TD style="font-size: 10pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap>5.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the transaction of such other business as may properly be brought before the Meeting or any
adjournment or adjournments thereof.</TD>
</TR>

</TABLE></DIV>

<DIV style="font-size: 10PT; margin-top: 10pt">Shareholders are referred to the accompanying Management Proxy Circular dated March&nbsp;20, 2008 (the
&#147;Information Circular&#148;) for more detailed information with respect to the matters to be considered
at the Meeting.</DIV>

<DIV align="justify" style="font-size: 10PT; margin-top: 10pt">A shareholder may attend the Meeting in person or may be represented thereat by proxy. Shareholders
who are unable to attend the Meeting in person are requested to date, sign and return the
accompanying Instrument of Proxy, or other appropriate form of proxy, in accordance with the
instructions set forth in the Information Circular. <B>An Instrument of Proxy will not be valid unless
it is deposited at the offices of Computershare Trust Company of Canada, Proxy Department, 100
University Avenue, 9</B><SUP style="font-size: 85%; vertical-align: text-top"><B>th</B></SUP><B> Floor, Toronto, Ontario M5J 2Y1, (fax number: 905-771-4414) by
4:30 p.m. (Toronto time) two days (excluding Saturdays and holidays) before the Meeting, or any
adjournment thereof. A person appointed as proxyholder need not be a shareholder of the
Corporation.</B></DIV>

<DIV align="justify" style="font-size: 10PT; margin-top: 10pt">Only persons registered as holders of common shares on the records of the Corporation as of the
close of business on March&nbsp;20, 2008 are entitled to receive notice of the Meeting.</DIV>

<DIV style="font-size: 10PT; margin-top: 12pt">DATED as of the 20th day of March, 2008.</DIV>


<DIV style="font-size: 10PT; margin-top: 10pt; margin-left: 50%">BY ORDER OF THE BOARD OF DIRECTORS</DIV>

<DIV style="font-size: 10PT; margin-top: 10pt; margin-left: 50%">(signed) <I>Dr.&nbsp;Bradley G. Thompson</I><BR>
President and Chief Executive Officer</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio --></DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><IMG src="o40024o4002400.gif" alt="(ONCOLYTICS LOGO)"></DIV>

<DIV align="center" style="font-size: 12PT; margin-top: 18pt"><B>Annual and Special Meeting of Shareholders<BR>
to be held on May&nbsp;7, 2008</B></DIV>

<DIV align="Center" style="font-size: 12PT; margin-top: 18pt"><B>MANAGEMENT PROXY CIRCULAR</B></DIV>

<DIV align="Center" style="font-size: 10PT; margin-top: 18pt"><B>SOLICITATION OF PROXIES</B></DIV>


<DIV align="justify" style="font-size: 10PT; margin-top: 10pt"><B>This Management Proxy Circular (the &#147;Information Circular&#148;) is furnished in connection with the
solicitation by the management of Oncolytics Biotech Inc. (&#147;Oncolytics&#148; or the &#147;Corporation&#148;) of
proxies to be used at the annual and special meeting (the &#147;Meeting&#148;) of the shareholders (the
&#147;Shareholders&#148;) of the Corporation, which is to be held at the time and place and for the purposes
set forth in the accompanying Notice of Meeting and in this Information Circular. </B>Solicitation of
proxies will be primarily by mail, but may also be undertaken by way of telephone, facsimile or
oral communication by the directors, officers and regular employees of the Corporation, at no
additional compensation. Costs associated with the solicitation of proxies will be borne by the
Corporation.</DIV>

<DIV align="justify" style="font-size: 10PT; margin-top: 12pt"><B>Appointment of Proxyholders and Revocation of Proxies</B></DIV>


<DIV align="justify" style="font-size: 10PT; margin-top: 10pt">Bradley G. Thompson and Douglas A. Ball (the management designees named in the accompanying
Instrument of Proxy) are both officers of the Corporation. <B>A Shareholder has the right to appoint
a person (who need not be a Shareholder) other than Bradley G. Thompson or Douglas A. Ball, to
represent the Shareholder at the Meeting. </B>To exercise this right, a Shareholder should insert the
name of the other person in the blank space provided on the Instrument of Proxy or complete another
appropriate form of proxy. A form of proxy will not be valid unless it is deposited at the offices
of Computershare Trust Company of Canada, Proxy Department, 100 University Avenue, 9<SUP style="font-size: 85%; vertical-align: text-top">th</SUP>
Floor, Toronto, Ontario, M5J 2Y1, (fax number: 905-771-4414) by 4:30 p.m. (Toronto time) two days
(excluding Saturdays and holidays) before the Meeting, or any adjournment thereof.</DIV>

<DIV align="justify" style="font-size: 10PT; margin-top: 10pt">A Shareholder who has given a form of proxy may revoke it, in any manner permitted by law
including, by instrument in writing executed by the Shareholder or by his or her duly authorized
attorney or, if the Shareholder is a corporation, executed by a duly authorized officer or attorney
of the corporation and deposited either at the registered office of the Corporation, being Bennett
Jones LLP, 4500 Bankers Hall East, 855 - 2nd Street S.W., Calgary, Alberta T2P 4K7, at any time up
to and including the last business day preceding the day of the Meeting, or any adjournment thereof
at which the form of proxy is to be used, or with the Chairman of such Meeting on the day of the
Meeting or any adjournment thereof. In addition, a form of proxy may be revoked by the Shareholder
personally attending at the Meeting and voting his or her shares.</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 12pt"><B>Signing of Proxy</B></DIV>


<DIV align="justify" style="font-size: 10PT; margin-top: 10pt">The Instrument of Proxy must be signed by the Shareholder or the Shareholder&#146;s duly appointed
attorney authorized in writing or, if the Shareholder is a corporation, by a duly authorized
officer. An Instrument of Proxy signed by a person acting as attorney or in some other
representative capacity (including a representative of a corporate Shareholder) should indicate
that person&#146;s capacity (following his or her</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio --></DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt"><!-- Folio -->- 2 -<!-- /Folio --></DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 12pt">signature) and should be accompanied by the appropriate instrument evidencing qualification and
authority to act (unless such instrument has previously been filed with the Corporation).</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 12pt"><B>Voting of Proxies and Exercise of Discretion by Proxyholders</B></DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">All common shares of the Corporation (&#147;Common Shares&#148;) represented at the Meeting by properly
executed proxies will be voted on any ballot that may be called for and, where a choice with
respect to any matter to be acted upon has been specified in the Instrument of Proxy, the Common
Shares represented by the proxy will be voted in accordance with such instructions. The management
designees named in the accompanying Instrument of Proxy will vote or withhold from voting the
Common Shares in respect of which they are appointed in accordance with the direction of the
Shareholder appointing them on any ballot that may be called for at the Meeting. <B>In the absence of
such direction, the Common Shares will be voted FOR: (i)&nbsp;the election of directors set forth in
this Information Circular; (ii)&nbsp;the reappointment of Oncolytics&#146; current auditors, at such
remuneration as may be determined by the board of directors of the Corporation; and (iii)&nbsp;the
approval, by way of ordinary resolution, of an amendment to the Corporation&#146;s stock option plan,
all as more particularly described in this Information Circular. The accompanying Instrument of
Proxy also confers discretionary authority upon the persons named therein with respect to
amendments of, or variations to, the matters identified in the Notice of Annual and Special Meeting
and with respect to other matters that may properly be brought before the Meeting. </B>At the time of
printing this Information Circular, the management of the Corporation knows of no such amendment,
variation or other matter to come before the Meeting other than the matters referred to in the
Notice of Annual and Special Meeting.</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>VOTING SHARES AND PRINCIPAL HOLDERS OF COMMON SHARES</B></DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 12pt"><B>Voting of Common Shares &#150; General</B></DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">The record date for the purpose of determining holders of Common Shares is March&nbsp;20, 2008.
Shareholders of record on that date are entitled to receive notice of and attend the Meeting and
vote thereat on the basis of one vote for each Common Share held, except to the extent that: (i)&nbsp;a
registered Shareholder has transferred the ownership of any Common Shares, subsequent to March&nbsp;20,
2008; and (ii)&nbsp;the transferee of those Common Shares produces properly endorsed share certificates,
or otherwise establishes that he or she owns the Common Shares and demands, not later than ten days
before the Meeting, that his or her name be included on the Shareholder list before the Meeting in
which case the transferee shall be entitled to vote his or her Common Shares at the Meeting. The
transfer books will not be closed.</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">As at the date hereof, there were 41,180,748 Common Shares issued and outstanding.</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 12pt"><B>Advice to Beneficial Holders of Common Shares</B></DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>The information set forth in this section is of significant importance to many Shareholders as a
substantial number of Shareholders do not hold their Common Shares in their own name.</B>
Shareholders who do not hold their Common Shares in their own name (referred to in this Information
Circular as &#147;Beneficial Shareholders&#148;) should note that only proxies deposited by Shareholders
whose names appear on the records of the Corporation as the registered holders of Common Shares can
be recognized and acted upon at the Meeting. If the Common Shares are listed in an account
statement provided to a Shareholder by a broker, then in almost all cases those shares will not be
registered in the Shareholder&#146;s name on the records of the Corporation. Such shares will more
likely be registered under the names of the Shareholder&#146;s broker or an agent of that broker. In
Canada, the vast majority of such shares are registered under the name of CDS &#038; Co. (the
registration name for The Canadian Depository for Securities, which acts as nominee for many
Canadian brokerage firms). Common Shares held by brokers or their agents or nominees can only be
voted (for or against resolutions) upon the instructions of the Beneficial Shareholder.</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio --></DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt"><!-- Folio -->- 3 -<!-- /Folio --></DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">Without specific instructions, brokers and their agents and nominees are prohibited from voting
shares for the broker&#146;s clients. <B>Therefore, Beneficial Shareholders should ensure that instructions
respecting the voting of their Common Shares are communicated to the appropriate person.</B></DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">Applicable regulatory policy requires intermediaries/brokers to seek voting instructions from
Beneficial Shareholders in advance of Shareholders&#146; meetings. Every intermediary/broker has its
own mailing procedures and provides its own return instructions to clients, which should be
carefully followed by Beneficial Shareholders in order to ensure that their Common Shares are voted
at the Meeting. The purpose of the form of proxy supplied to a Beneficial Shareholder by its broker
(or the agent of the broker) is limited to instructing the registered Shareholder (the broker or
agent of the broker) how to vote on behalf of the Beneficial Shareholder. The majority of brokers
now delegate responsibility for obtaining instructions from clients to Broadridge. Broadridge
typically mails a special proxy form to the Beneficial Shareholders and asks Beneficial
Shareholders to return the proxy forms to Broadridge. Alternatively, Beneficial Shareholders can
either call their toll-free telephone to vote their Common Shares or access Broadridge&#146;s dedicated
voting website at <u>www.proxyvotecanada.com</u> to deliver their voting instructions. Broadridge then
tabulates the results of all instructions received and provides appropriate instructions respecting
the voting of Common Shares to be represented at the Meeting. <B>A Beneficial Shareholder receiving a
proxy form from Broadridge cannot use that proxy to vote shares directly at the Meeting &#150; the proxy
must be returned to Broadridge well in advance of the Meeting in order to have the Common Shares
voted.</B></DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">Although a Beneficial Shareholder may not be recognized directly at the Meeting for the purposes of
voting Common Shares registered in the name of his or her broker (or agent of the broker), a
Beneficial Shareholder may attend at the Meeting as proxyholder for the registered Shareholder and
vote the Common Shares in that capacity. Beneficial Shareholders who wish to attend at the Meeting
and indirectly vote their Common Shares as proxyholder for the registered Shareholder should enter
their own names in the blank space on the Instrument of Proxy provided to them and return the same
to their broker (or the broker&#146;s agent) in accordance with the instructions provided by such broker
(or agent), well in advance of the Meeting.</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 12pt"><B>Principal Holders of Common Shares</B></DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">To the best of the knowledge of the directors and executive officers of the Corporation, as at the
date hereof, no persons or companies beneficially own, directly or indirectly, or exercise control
or direction over, shares that carry more than 10% of the voting rights attached to the issued
Common Shares other than as set forth below:</DIV>


<DIV align="justify">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
<TD width="8%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B>Number of Oncolytics</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B>Percentage of Oncolytics</B></TD>
<TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Name and Address</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Common Shares Owned</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Common Shares</B></TD>
<TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD align="center" valign="top"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="justify" valign="top">The Bank of New York Mellon</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="justify" valign="top">Corporation, New York,
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">6,512,978<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">15.81%</TD>
<TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="justify" valign="top">New York</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE></DIV>


<DIV align="justify" style="font-size: 8pt; margin-top: 6pt"><B>Notes:</B></DIV>


<DIV style="margin-top: 3pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 8pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="justify">(1)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>As reported by The Bank of New York Mellon Corporation on February&nbsp;14, 2008 in its Schedule
13G filing with the United States Securities and Exchange Commission</TD>
</TR>

</TABLE></DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio --></DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt"><!-- Folio -->- 4 -<!-- /Folio --></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>COMPENSATION OF EXECUTIVE OFFICERS</B></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Summary Compensation Table</B></DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">The following table sets forth information concerning the total compensation paid, during each of
the last three financial years (as applicable), to the Chief Executive Officer and Chief Financial
Officer of the Corporation and the other executive officers of the Corporation who received total
remuneration, determined on the basis of base salary and bonuses, in excess of $150,000 during the
financial year ended December&nbsp;31, 2007 (the &#147;Named Executive Officers&#148;).</DIV>
<DIV align="left">
<TABLE style="font-size: 8pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="28%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
<TD width="8%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Long Term</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">&nbsp;</TD>
<TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="11" style="border-bottom: 1px solid #000000"><B>Annual Compensation</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>Compensation</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">&nbsp;</TD>
<TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Other Annual</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 0px solid #000000"><B>Securities Under</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 0px solid #000000"><B>All Other</B></TD>
<TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center"><B>Name and Principal</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Salary</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Bonus</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 0px solid #000000"><B>Compensation</B><SUP style="font-size: 85%; vertical-align: text-top"><B>(1)</B></SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Options Granted</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Compensation</B></TD>
<TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Position</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>Year</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>($)</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>($)</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>($)</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>(#)</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>($)</B></TD>
<TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
<TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Dr.&nbsp;Bradley G. Thompson</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2007</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">364,681</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">72,206</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">19,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">149,160</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">15,881</TD>
    <TD>&nbsp;</TD>
<TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD nowrap><DIV style="margin-left:15px; text-indent:-15px">President
and Chief Executive Officer</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2006</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">349,982</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">168,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">18,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="center">Nil</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">20,999</TD>
    <TD>&nbsp;</TD>
<TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2005</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">324,965</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">107,667</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">16,500</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="center">Nil</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">19,498</TD>
    <TD>&nbsp;</TD>
<TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 12pt"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
<TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Douglas A. Ball</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2007</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">246,240</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">53,917</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">19,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center">33,333</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">12,374</TD>
    <TD>&nbsp;</TD>
<TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Chief Financial Officer</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2006</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">228,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">84,500</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">18,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="center">Nil</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">13,680</TD>
    <TD>&nbsp;</TD>
<TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2005</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">206,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">53,333</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">16,500</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="center">Nil</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">12,360</TD>
    <TD>&nbsp;</TD>
<TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 12pt"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
<TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Dr.&nbsp;Matthew Coffey</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2007</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">246,240</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">53,917</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">19,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center">33,333</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">10,574</TD>
    <TD>&nbsp;</TD>
<TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Chief Scientific Officer</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2006</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">228,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">84,500</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">18,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="center">Nil</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">13,680</TD>
    <TD>&nbsp;</TD>
<TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2005</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">206,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">53,333</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">16,500</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="center">Nil</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">12,360</TD>
    <TD>&nbsp;</TD>
<TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 12pt"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
<TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Dr.&nbsp;Karl Mettinger <SUP style="font-size: 85%; vertical-align: text-top">(2)</SUP></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2007</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">309,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">53,356</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="center">Nil</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center">33,333</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">34,880</TD>
    <TD>&nbsp;</TD>
<TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Chief Medical Officer</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2006</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">300,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">72,614</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="center">Nil</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="center">Nil</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">31,175</TD>
    <TD>&nbsp;</TD>
<TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2005</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">112,500</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="center">Nil</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="center">Nil</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">200,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">8,660</TD>
    <TD>&nbsp;</TD>
<TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 12pt"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
<TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Mary Ann Dillahunty <SUP style="font-size: 85%; vertical-align: text-top">(2)</SUP></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2007</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">150,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">26,678</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="center">Nil</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center">116,667</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">14,516</TD>
    <TD>&nbsp;</TD>
<TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Vice-President, Intellectual
Property</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
<TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE></DIV>


<DIV align="left" style="font-size: 8pt; margin-top: 12pt"><B>Notes:</B></DIV>


<DIV style="margin-top: 3pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 6pt">

<TR valign="top" style="font-size: 8pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(1)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Perquisites and other personal benefits received in the respective periods did not exceed the
lesser of $50,000 and 10% of the total annual salary and bonuses for any of the named
executive officers. The dollar amounts set forth under this column relate to RRSP
contributions made by the Corporation on behalf of the Named Executive Officer.</TD>
</TR>

<TR>
    <TD style="font-size: 3pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 8pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(2)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>US employees paid in US dollars, all amounts for each US Employee are indicated in US
dollars. Dr.&nbsp;Mettinger joined the Corporation in
September&nbsp;2005 and Ms.&nbsp;Dillahunty joined the Corporation on February&nbsp;1, 2007.</TD>
</TR>

</TABLE></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">There are no long term incentive, benefit or actuarial plans in place. The Corporation does not
currently have a stock appreciation rights plan.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Stock Options</B></DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Option Grants During the Year Ended December&nbsp;31, 2007</I></B></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Stock options granted to the Named Executive Officers during the financial year ended December&nbsp;31,
2007 were as follows:</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio --></DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt"><!-- Folio -->- 5 -<!-- /Folio --></DIV>

<DIV align="left">
<TABLE style="font-size: 8pt" cellspacing="0" border="0" cellpadding="0" width="92%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="45%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Closing</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Common Shares</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>% of Total</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Market Price</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Under Options</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Options Granted</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Exercise</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>on Date of</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>Granted</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>in Fiscal Year</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>Price</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>Grant</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>Expiry Date</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="font-size: 4pt"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD nowrap><DIV style="margin-left:15px; text-indent:-15px">Dr.&nbsp;Bradley G. Thompson</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">149,160</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="center">28%</TD>
    <TD nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2.22</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2.22</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="center">December 12, 2017</TD>
</TR>
<TR valign="bottom" style="font-size: 10pt"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Douglas A. Ball</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center">33,333</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="center">6%</TD>
    <TD nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2.22</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2.22</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="center">December 12, 2017</TD>
</TR>
<TR valign="bottom" style="font-size: 10pt"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Dr.&nbsp;Matthew Coffey</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center">33,333</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="center">6%</TD>
    <TD nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2.22</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2.22</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="center">December 12, 2017</TD>
</TR>
<TR valign="bottom" style="font-size: 10pt"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Dr.&nbsp;Karl Mettinger</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">33,333</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="center">6%</TD>
    <TD nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2.22</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2.22</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="center">December 12, 2017</TD>
</TR>
<TR valign="bottom" style="font-size: 10pt"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Mary Ann Dillahunty</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="center">19%</TD>
    <TD nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3.28</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3.28</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="center">February 1, 2017</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">16,667</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="center">3%</TD>
    <TD nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2.22</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2.22</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="center">December 12, 2017</TD>
</TR>
<!-- End Table Body -->
</TABLE></DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B><I>Aggregated Option Exercises During the Year Ended December&nbsp;31, 2007 and Financial Year-End Option
Values</I></B></DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">The following table sets forth certain information respecting the numbers and accrued value of
unexercised stock options as at December&nbsp;31, 2007 and options exercised by the Named Executive
Officers during the financial year ended December&nbsp;31, 2007:</DIV>
<DIV align="left">
<TABLE style="font-size: 8pt" cellspacing="0" border="0" cellpadding="0" width="92%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="32%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7"><B>Value of Unexercised</B></TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Securities</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Aggregate</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7"><B>Unexercised Options at</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7"><B>in-the-Money Options at</B></TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Acquired on</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Value</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7"><B>December 31, 2007</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7"><B>December 31, 2007</B></TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Exercise</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Realized</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7" style="border-bottom: 1px solid #000000"><B>(#)</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7" style="border-bottom: 1px solid #000000"><B>($)</B><SUP style="font-size: 85%; vertical-align: text-top"><B>(2)</B></SUP></TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>(#)</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>($)</B><SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>Exercisable</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>Unexercisable</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>Exercisable</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>Unexercisable</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="font-size: 2pt"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD nowrap><DIV style="margin-left:15px; text-indent:-15px">Dr.&nbsp;Bradley G. Thompson</DIV></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="center">Nil</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="center">Nil</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">786,160</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center">-</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center">-</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center">-</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 6pt"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Douglas A. Ball</DIV></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="center">Nil</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="center">Nil</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">674,833</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center">-</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&nbsp;</TD>
    <TD align="center">$4,250</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center">-</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 6pt"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Dr.&nbsp;Matthew Coffey</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center">60,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&nbsp;</TD>
    <TD align="right">$90,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">650,883</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center">-</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&nbsp;</TD>
    <TD align="center">$190,018</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center">-</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 6pt"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Dr.&nbsp;Karl Mettinger</DIV></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="center">Nil</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="center">Nil</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center">133,333</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center">100,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center">-</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center">-</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 6pt"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Mary Ann Dillahunty</DIV></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="center">Nil</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="center">Nil</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center">41,667</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center">75,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center">-</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center">-</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE></DIV>


<DIV align="left" style="font-size: 8pt; margin-top: 6pt"><B>Notes:</B></DIV>


<DIV style="margin-top: 3pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 8pt">

<TR valign="top" style="font-size: 8pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(1)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV align="justify">The aggregate value realized represents the dollar value equal to the difference between the
exercise price of the options exercised and the market value of the Common Shares on the
Toronto Stock Exchange on the date the options were exercised, multiplied by the number of
options exercised.</DIV></TD>
</TR>

<TR>
    <TD style="font-size: 3pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 8pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(2)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV align="justify">The value of the unexercised &#147;in-the-money&#148; options has been determined by subtracting the
exercise price of the options from the closing Common Share price of $1.70 on December&nbsp;31,
2007, as reported by the Toronto Stock Exchange, and multiplying by the number of Common
Shares that may be acquired upon the exercise of the options.</DIV></TD>
</TR>

</TABLE></DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 12pt"><B>Employment Contracts</B></DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">The Corporation has entered into employment agreements with each of the Named Executive Officers
(each an &#147;Employment Agreement&#148;). Pursuant to the terms of the Employment Agreements, Dr.&nbsp;Thompson
is entitled to an annual salary of $444,996 for the calendar year 2008, Mr.&nbsp;Ball is entitled to an
annual salary of $257,567 for the calendar year 2008, Dr.&nbsp;Coffey is entitled to an annual salary of
$326,224 for the calendar year 2008, Dr.&nbsp;Mettinger is entitled to an annual salary of $318,270 USD
for the calendar year 2008 and Ms.&nbsp;Dillahunty is entitled to $231,750 USD for the calendar year
2008. Further, each Named Executive Officer is entitled to additional benefits and
performance-based bonuses. The Employment Agreements provide that each Named Executive Officer is
subject to certain confidentiality and non-competition restrictions during and following the course
of their respective employment with the Corporation. Each Employment Agreement shall continue
until terminated by either party in accordance with the notice provisions thereof.</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio --></DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt"><!-- Folio -->- 6 -<!-- /Folio --></DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 12pt"><B>Termination of Employment or Change of Control</B></DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">If the Employment Agreements of Dr.&nbsp;Thompson, Mr.&nbsp;Ball or Dr.&nbsp;Coffey are terminated by the
Corporation other than for cause, then all unexercised and unvested stock options then held by each
shall forthwith vest and become exercisable. Mr.&nbsp;Ball and Dr.&nbsp;Coffey shall be entitled to 12&nbsp;months
pay in lieu of notice; and Dr.&nbsp;Thompson shall be entitled to 18&nbsp;months pay in lieu of notice. If
the Employment Agreements of Dr.&nbsp;Mettinger and Ms.&nbsp;Dillahunty are terminated by the Corporation
other than for cause, then all unexercised and unvested stock options then held by each are
governed by the terms of the Stock Option Plan. Dr.&nbsp;Mettinger shall be entitled to not more than 9
months pay in lieu of notice and Ms.&nbsp;Dillahunty shall be entitled to not more than 12&nbsp;months pay
lieu of notice. Further, if there is a change of control of the Corporation and Dr.&nbsp;Thompson, Mr.
Ball, Dr.&nbsp;Coffey, Dr.&nbsp;Mettinger or Ms.&nbsp;Dillahunty are terminated without cause within one year
following such change of control, then Dr.&nbsp;Thompson shall be entitled to 36&nbsp;months pay in lieu of
notice, Mr.&nbsp;Ball and Dr.&nbsp;Coffey shall be entitled to 24&nbsp;months pay in lieu of notice, and Dr.
Mettinger and Ms.&nbsp;Dillahunty shall be entitled to not more than 24&nbsp;months pay in lieu of notice.</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 12pt"><B>Compensation of Directors</B></DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">Each director who is not a salaried employee of the Corporation was entitled to a fee of $1,500 per
board meeting attended and $750 per committee meeting attended ($1,500 in respect of audit
committee meetings attended). The Corporation also grants to directors, from time to time, stock
options in accordance with the Plan and the reimbursement of any reasonable expenses incurred by
them while acting in their directors&#146; capacity. In the aggregate, a total of $98,250 in director&#146;s
fees was paid to the board of directors of the Corporation (the &#147;Board&#148; or &#147;Board of Directors&#148;)
during the fiscal year ended December&nbsp;31, 2007. During the fiscal year ended December&nbsp;31, 2007,
there were 122,500 options granted to the directors.</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">Following a review by the Compensation Committee and an independent compensation consultant, the
independent directors&#146; compensation will be increased to $1,750 per board and committee meeting
attended for 2008. An annual retainer fee of $15,000 will be paid for service during 2008 and the
lead director will receive an additional annual $10,000 retainer. The Chair of the Audit Committee
will receive an additional annual retainer of $6,000.</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 12pt"><B>Composition of the Compensation Committee</B></DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">The Corporation has formed a Compensation Committee consisting of three outside directors Mr.
Stewart, Mr. van Amersfoort and Dr.&nbsp;Cochrane, none of whom are nor have been employees or officers
of the Corporation or any of its affiliates. Mr.&nbsp;Stewart is presently the Chair of the Compensation
Committee.</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 12pt"><B>Report on Executive Compensation</B></DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">In arriving at its compensation decisions, the Compensation Committee considers the long-term
interests of the Corporation as well as its current stage of development. Based on these factors,
compensation is focused on performance-based factors. The Compensation Committee undertakes market
comparisons and provides advice to the Board of Directors on developing appropriate compensation
arrangements, based on information from other corporations, published data and reports from
external consultants. The Compensation Committee also makes specific recommendations to the board
of directors of Oncolytics with respect to compensation paid to the Corporation&#146;s executive and
senior officers.</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">The objectives of the Corporation&#146;s compensation arrangements are: (i)&nbsp;to attract and retain key
personnel; (ii)&nbsp;to encourage commitment to the Corporation and its goals; (iii)&nbsp;to align executive
interests with those of its shareholders; (iv)&nbsp;to reward executives for performance in relation to
predetermined and quantifiable goals; and (v)&nbsp;to identify and focus executives on key business
factors that affect shareholder value.</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio --></DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">- 7 -</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">Submitted by the Compensation Committee:</DIV>

<DIV align="left" style="font-size: 10pt; margin-left: 3%; margin-top: 6pt">Fred Stewart (Chair)<BR>
Bill Cochrane<BR> Ger van
Amersfoort</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Performance Graphs</B></DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">The following graph and table compare the change in the cumulative total shareholder return on the
Common Shares over the period from December&nbsp;31, 2002 to December&nbsp;31, 2007 (assuming a $100
investment was made on December&nbsp;31, 2002 at the opening price of the Common Shares on that date)
with the cumulative total return of the S&#038;P/TSX Composite Index and S&#038;P/TSX Capped Health Care
Index over the same period, assuming reinvestment of dividends.</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>CUMULATIVE TOTAL RETURN ON $100 INVESTMENT</B></DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><IMG src="o40024o4002409.gif" alt="(PERFORMANCE GRAPH)"></DIV>

<DIV align="center" style="margin-top: 18pt">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
<TD width="1%">&nbsp;</TD>
<TD width="32%">&nbsp;</TD>
<TD width="2%">&nbsp;</TD><!-- VRule -->
<TD width="2%">&nbsp;</TD>
<TD width="3%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="3%">&nbsp;</TD>
<TD width="2%">&nbsp;</TD><!-- VRule -->
<TD width="2%">&nbsp;</TD>
<TD width="3%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="3%">&nbsp;</TD>
<TD width="2%">&nbsp;</TD><!-- VRule -->
<TD width="2%">&nbsp;</TD>
<TD width="3%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="3%">&nbsp;</TD>
<TD width="2%">&nbsp;</TD><!-- VRule -->
<TD width="2%">&nbsp;</TD>
<TD width="3%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="3%">&nbsp;</TD>
<TD width="2%">&nbsp;</TD><!-- VRule -->
<TD width="2%">&nbsp;</TD>
<TD width="3%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="3%">&nbsp;</TD>
<TD width="2%">&nbsp;</TD><!-- VRule -->
<TD width="2%">&nbsp;</TD>
<TD width="3%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="3%">&nbsp;</TD>

<TD width="1%">&nbsp;</TD>
</TR><TR style="font-size: 1px" valign="bottom">
<TD nowrap align="left" colspan="33" style="border-bottom: 3px double #000000">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">    <TD width="1%" style="border-left: 3px double #000000">&nbsp;</TD>

<TD>&nbsp;</TD>
<TD style="border-right: 1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD nowrap align="center" colspan="3">Dec. 31,</TD>
<TD style="border-right: 1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD nowrap align="center" colspan="3">Dec. 31,</TD>
<TD style="border-right: 1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD nowrap align="center" colspan="3">Dec. 31,</TD>
<TD style="border-right: 1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD nowrap align="center" colspan="3">Dec. 31,</TD>
<TD style="border-right: 1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD nowrap align="center" colspan="3">Dec. 31,</TD>
<TD style="border-right: 1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD nowrap align="center" colspan="3">Dec. 31,</TD>
<TD width="1%" style="border-right: 3px double #000000">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">    <TD width="1%" style="border-left: 3px double #000000">&nbsp;</TD>

<TD>&nbsp;</TD>
<TD style="border-right: 1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD nowrap align="center" colspan="3">2002</TD>
<TD style="border-right: 1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD nowrap align="center" colspan="3">2003</TD>
<TD style="border-right: 1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD nowrap align="center" colspan="3">2004</TD>
<TD style="border-right: 1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD nowrap align="center" colspan="3">2005</TD>
<TD style="border-right: 1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD nowrap align="center" colspan="3">2006</TD>
<TD style="border-right: 1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD nowrap align="center" colspan="3">2007</TD>
<TD width="1%" style="border-right: 3px double #000000">&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
<TD width="1%" style="border-left: 3px double #000000; border-top: 1px solid #000000">&nbsp;</TD>
<TD style="border-top: 1px solid #000000"><DIV style="margin-left:15px; text-indent:-15px"><font face="wingdings">&#117;</font>&nbsp;&nbsp;&nbsp;S&#038;P/TSX Composite Index</DIV></TD>
<TD style="border-right: 1px solid #000000; border-top: 1px solid #000000">&nbsp;</TD>
<TD style="border-top: 1px solid #000000">&nbsp;</TD>
<TD align="right" style="border-top: 1px solid #000000">$</TD>
<TD align="right" style="border-top: 1px solid #000000">100</TD>
<TD style="border-top: 1px solid #000000">&nbsp;</TD>
<TD style="border-right: 1px solid #000000; border-top: 1px solid #000000">&nbsp;</TD>
<TD style="border-top: 1px solid #000000">&nbsp;</TD>
<TD align="right" style="border-top: 1px solid #000000">$</TD>
<TD align="right" style="border-top: 1px solid #000000">126.72</TD>
<TD style="border-top: 1px solid #000000">&nbsp;</TD>
<TD style="border-right: 1px solid #000000; border-top: 1px solid #000000">&nbsp;</TD>
<TD style="border-top: 1px solid #000000">&nbsp;</TD>
<TD align="right" style="border-top: 1px solid #000000">$</TD>
<TD align="right" style="border-top: 1px solid #000000">145.07</TD>
<TD style="border-top: 1px solid #000000">&nbsp;</TD>
<TD style="border-right: 1px solid #000000; border-top: 1px solid #000000">&nbsp;</TD>
<TD style="border-top: 1px solid #000000">&nbsp;</TD>
<TD align="right" style="border-top: 1px solid #000000">$</TD>
<TD align="right" style="border-top: 1px solid #000000">180.08</TD>
<TD style="border-top: 1px solid #000000">&nbsp;</TD>
<TD style="border-right: 1px solid #000000; border-top: 1px solid #000000">&nbsp;</TD>
<TD style="border-top: 1px solid #000000">&nbsp;</TD>
<TD align="right" style="border-top: 1px solid #000000">$</TD>
<TD align="right" style="border-top: 1px solid #000000">211.16</TD>
<TD style="border-top: 1px solid #000000">&nbsp;</TD>
<TD style="border-right: 1px solid #000000; border-top: 1px solid #000000">&nbsp;</TD>
<TD style="border-top: 1px solid #000000">&nbsp;</TD>
<TD align="right" style="border-top: 1px solid #000000">$</TD>
<TD align="right" style="border-top: 1px solid #000000">231.92</TD>
<TD style="border-top: 1px solid #000000">&nbsp;</TD>
<TD width="1%" style="border-right: 3px double #000000; border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD width="1%" style="border-left: 3px double #000000; border-top: 1px solid #000000">&nbsp;</TD>
<TD style="border-top: 1px solid #000000"><DIV style="margin-left:15px; text-indent:-15px"><font face="Symbol">&#042;</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;S&#038;P/TSX Capped Health Care Index</DIV></TD>
<TD style="border-right: 1px solid #000000; border-top: 1px solid #000000">&nbsp;</TD>
<TD style="border-top: 1px solid #000000">&nbsp;</TD>
<TD align="right" style="border-top: 1px solid #000000">$</TD>
<TD align="right" style="border-top: 1px solid #000000">100</TD>
<TD style="border-top: 1px solid #000000">&nbsp;</TD>
<TD style="border-right: 1px solid #000000; border-top: 1px solid #000000">&nbsp;</TD>
<TD style="border-top: 1px solid #000000">&nbsp;</TD>
<TD align="right" style="border-top: 1px solid #000000">$</TD>
<TD align="right" style="border-top: 1px solid #000000">115.24</TD>
<TD style="border-top: 1px solid #000000">&nbsp;</TD>
<TD style="border-right: 1px solid #000000; border-top: 1px solid #000000">&nbsp;</TD>
<TD style="border-top: 1px solid #000000">&nbsp;</TD>
<TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
<TD align="center" style="border-top: 1px solid #000000">$95.25</TD>
<TD style="border-top: 1px solid #000000">&nbsp;</TD>
<TD style="border-right: 1px solid #000000; border-top: 1px solid #000000">&nbsp;</TD>
<TD style="border-top: 1px solid #000000">&nbsp;</TD>
<TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
<TD align="center" style="border-top: 1px solid #000000">$92.11</TD>
<TD style="border-top: 1px solid #000000">&nbsp;</TD>
<TD style="border-right: 1px solid #000000; border-top: 1px solid #000000">&nbsp;</TD>
<TD style="border-top: 1px solid #000000">&nbsp;</TD>
<TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
<TD align="center" style="border-top: 1px solid #000000">$94.40</TD>
<TD style="border-top: 1px solid #000000">&nbsp;</TD>
<TD style="border-right: 1px solid #000000; border-top: 1px solid #000000">&nbsp;</TD>
<TD style="border-top: 1px solid #000000">&nbsp;</TD>
<TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
<TD align="center" style="border-top: 1px solid #000000">$73.19</TD>
<TD style="border-top: 1px solid #000000">&nbsp;</TD>
<TD width="1%" style="border-right: 3px double #000000; border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD width="1%" style="border-left: 3px double #000000; border-top: 1px solid #000000">&nbsp;</TD>
<TD style="border-top: 1px solid #000000"><DIV style="margin-left:15px; text-indent:-15px"><font face="wingdings">&#108;</font>&nbsp;&nbsp;&nbsp;&nbsp;Oncolytics</DIV></TD>
<TD style="border-right: 1px solid #000000; border-top: 1px solid #000000">&nbsp;</TD>
<TD style="border-top: 1px solid #000000">&nbsp;</TD>
<TD align="right" style="border-top: 1px solid #000000">$</TD>
<TD align="right" style="border-top: 1px solid #000000">100</TD>
<TD style="border-top: 1px solid #000000">&nbsp;</TD>
<TD style="border-right: 1px solid #000000; border-top: 1px solid #000000">&nbsp;</TD>
<TD style="border-top: 1px solid #000000">&nbsp;</TD>
<TD align="right" style="border-top: 1px solid #000000">$</TD>
<TD align="right" style="border-top: 1px solid #000000">231.25</TD>
<TD style="border-top: 1px solid #000000">&nbsp;</TD>
<TD style="border-right: 1px solid #000000; border-top: 1px solid #000000">&nbsp;</TD>
<TD style="border-top: 1px solid #000000">&nbsp;</TD>
<TD align="right" style="border-top: 1px solid #000000">$</TD>
<TD align="right" style="border-top: 1px solid #000000">289.06</TD>
<TD style="border-top: 1px solid #000000">&nbsp;</TD>
<TD style="border-right: 1px solid #000000; border-top: 1px solid #000000">&nbsp;</TD>
<TD style="border-top: 1px solid #000000">&nbsp;</TD>
<TD align="right" style="border-top: 1px solid #000000">$</TD>
<TD align="right" style="border-top: 1px solid #000000">272.92</TD>
<TD style="border-top: 1px solid #000000">&nbsp;</TD>
<TD style="border-right: 1px solid #000000; border-top: 1px solid #000000">&nbsp;</TD>
<TD style="border-top: 1px solid #000000">&nbsp;</TD>
<TD align="right" style="border-top: 1px solid #000000">$</TD>
<TD align="right" style="border-top: 1px solid #000000">124.48</TD>
<TD style="border-top: 1px solid #000000">&nbsp;</TD>
<TD style="border-right: 1px solid #000000; border-top: 1px solid #000000">&nbsp;</TD>
<TD style="border-top: 1px solid #000000">&nbsp;</TD>
<TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
<TD align="center" style="border-top: 1px solid #000000">$88.54</TD>
<TD style="border-top: 1px solid #000000">&nbsp;</TD>
<TD width="1%" style="border-right: 3px double #000000; border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR style="font-size: 1px" valign="bottom">
<TD nowrap align="left" colspan="33" style="border-top: 3px double #000000">&nbsp;</TD>
</TR>

<!-- End Table Body -->
</TABLE></DIV></DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<P align="center" style="font-size: 10pt"><!-- Folio -->- 8 -<!-- /Folio -->

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Indebtedness of Directors and Senior Officers</B>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">No director, officer or proposed nominee for election as a director of the Corporation or any
associate of any such persons is, or has been, indebted to the Corporation.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Interest of Insiders in Material Transactions</B>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">There are no material interests, direct or indirect, of directors, senior officers, any shareholder
who beneficially owns, directly or indirectly, more than 10% of the outstanding Common Shares or
any known associate or affiliates of such persons, in any transaction within the last financial
year or in any proposed transaction which has materially affected or would materially affect the
Corporation.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>EQUITY COMPENSATION PLAN INFORMATION</B>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">Under the Plan the Board of Directors or the Compensation Committee may from time to time designate
directors, officers, employees of, or providers of services to, the Corporation to whom options to
purchase Common Shares of the Corporation may be granted and the number of Common Shares to be
optioned to each. The Plan provides for a fixed maximum of 4,052,075 Common Shares reserved for
issuance pursuant to the Plan, which represents approximately 9.8% of the issued and outstanding
Common Shares. Of this fixed maximum, 60,000 Options have been exercised and are not available for
future grants, leaving 3,992,075 Common Shares currently reserved for issuance pursuant to the
Plan, which represents approximately 9.76% of the issued and outstanding Common Shares. There are
Options outstanding to acquire 3,870,493
Common Shares, which represents approximately 9.4% of the issued and outstanding Common Shares. At
the Meeting, a resolution will be proposed to amend the Plan. See &#147;Amendment to Stock Option Plan&#148;.
The number of Common Shares available that may be acquired under an Option granted to a Participant
(as defined in the Plan) shall be determined by the Board as at the time the Option is granted,
provided that: (i)&nbsp;the aggregate number of Common Shares reserved for issuance under this Plan,
together with all other security based compensation arrangements of the Corporation, to insiders
shall not exceed 10% of the issued and outstanding Common Shares (calculated on a non-diluted
basis); (ii)&nbsp;the aggregate number of Common Shares issued pursuant to this Plan, together with all
other security based compensation arrangements of the Corporation, within a one year period shall
not exceed 10% of the issued and outstanding Common Shares (calculated on a non-diluted basis); and
(iii)&nbsp;the aggregate number of Common Shares reserved for issuance to any one Participant under this
Plan, together with all other security based compensation arrangements of the Corporation, shall
not exceed five percent of the total number of issued and outstanding Common Shares (calculated on
a non-diluted basis).
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">Options may be exercised at a price (the &#147;Exercise Price&#148;) which shall be fixed by the Board at the
time the Option is granted. No Option shall be granted with an Exercise Price at a discount to the
market, which shall be the closing price of the Common Shares on the stock exchange upon which the
Common Shares are listed on the first day preceding the date of grant on which at least one board
lot of Common Shares traded on such exchange.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">Options are generally granted for a term expiring on the tenth anniversary of the date of grant and
typically either vest immediately or as to one-third on each of the first, second and third
anniversaries following the date of grant. Options are not transferable or assignable except to
the person or persons to whom the Participant&#146;s rights pass by the Participant&#146;s will or applicable
law following the death or permanent disability of a Participant.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">Subject to any written agreement between the Corporation and a Participant providing otherwise, if
any Participant who is a director, officer, employee or consultant of the Corporation shall cease
to be a director, officer, employee or consultant of the Corporation for any reason other than
death or permanent disability, his Option will terminate immediately as to the then unvested
portion thereof, and at 5:00 p.m. (Calgary
</DIV>
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<P align="center" style="font-size: 10pt"><!-- Folio -->- 9 -<!-- /Folio -->

<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">time) on the earlier of the date of expiration of the Option Period (as defined in the Plan) and
the ninetieth (90<SUP style="font-size: 85%; vertical-align: text-top">th</SUP>) day after the date such Participant ceases to be a director,
officer, employee or consultant of the Corporation as to the then vested portion of the Option. In
the event of a sale by the Corporation of all or substantially all of its assets or in the event of
a change of control of the Corporation then Participants shall be entitled to exercise in full or
in part any unexercised Options previously granted to such Participant pursuant to the Plan,
whether vested or not, either during the term of the Option or within ninety (90)&nbsp;days after the
date of termination of the employment of the Participant with the Corporation or the cessation or
termination of the Participant as a director, officer, employee or consultant of the Corporation,
whichever first occurs. Currently, the Plan contains a general amendment provision and, in
accordance with the requirements of the TSX, no amendments to the Plan are permitted without
Shareholder approval.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">Notwithstanding the foregoing, the Board may, at its sole discretion, extend the period during
which any Options may be exercised, in the case of Options held by non-management Directors, by not
more than one (1)&nbsp;year, and in the case of Options held by other persons, by not more than three
(3)&nbsp;years, but in no case longer than the normal expiry of the options.
</DIV>
<DIV align="center">
<TABLE style="font-size: 8pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="23%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="20%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="20%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="20%">&nbsp;</TD>
<TD width="8%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B>Number of Common Shares</B></TD>
<TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B>Number of Common Shares to</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B>Remaining Available for Future</B></TD>
<TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B>be Issued Upon Exercise of</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B>Weighted-Average Exercise</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B>Issuance Under Equity</B></TD>
<TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Plan Category</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Outstanding Options</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Price of Outstanding Options</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Compensation Plans</B></TD>
<TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:0px; text-indent:-0px"><B>Equity compensation plans</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><div style="font-size: 10pt">3,870,493</div></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><div style="font-size: 10pt">$4.61</div></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><div style="font-size: 10pt">121,582</div></TD>
<TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:0px; text-indent:-0px"><B>approved by securityholders</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:0px; text-indent:-0px"><B>Equity compensation plans not
approved by securityholders</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">-</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">-</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">-</TD>
<TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="1" align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="1" align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="1" align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:0px; text-indent:-0px"><B>Total</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><div style="font-size: 10pt">3,870,493</div></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><div style="font-size: 10pt">$4.61</div></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><div style="font-size: 10pt">121,582</div></TD>
<TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>STATEMENT OF CORPORATE GOVERNANCE PRACTICES</B>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">The Board of Directors is responsible for overseeing the management of the business and affairs of
the Corporation. The Board of Directors is responsible for establishing the Corporation&#146;s policy
direction and fundamental objectives. The Board of Directors delegates to management the
responsibility and authority to direct the Corporation&#146;s day-to-day operations, subject to
compliance with Board-approved budgets and strategic plans. Certain matters, including the
acquisition or development of new lines of business, divestments and long-term financing, among
other things, must be approved in advance by the Board of Directors.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">The Board of Directors discharges its responsibilities through preparation for and attendance at
regularly scheduled meetings, and through its committees. The Board of Directors reviews and
provides advice with respect to key strategic initiatives and projects, and reviews and assesses
processes relating to long range planning and budgeting. The Corporate Governance and Nominating
Committee assists the Board in matters pertaining to corporate values, beliefs and standards of
ethical conduct, as well as other corporate governance issues and the Audit Committee assists the
Board in matters pertaining to management information and internal control systems. The Board of
Directors also monitors financial reports, the conduct and results of the annual independent audit,
finance and accounting policies and other financial matters. In addition, the Audit Committee
reviews and recommends to the Board for approval the Corporation&#146;s interim financial statements,
and also reviews and recommends the year end audited financial statements for approval by the
Board. The Board of Directors also has a Compensation Committee, which is responsible for
attracting, retaining and fairly compensating employees of the Corporation. This Committee is also
responsible for succession planning. Subject to limited exceptions, these committees generally do
not have decision-making
</DIV>
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<P align="center" style="font-size: 10pt"><!-- Folio -->- 10 -<!-- /Folio -->

<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">authority. Rather, they convey their findings and make recommendations on matters falling within
their respective mandates to the full Board of Directors.</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">The Board of Directors supports the principle that its membership should represent a diversity of
backgrounds, experience and skills. The Board, through the Corporate Governance and Nominating
Committee, reviews on an annual basis the appropriate characteristics of Board members in the
context of the current composition of the Board and the objectives and needs of the Corporation.</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">The following represents a tabular review of the corporate governance guidelines as outlined in
National Instrument 58-101 &#150; Disclosure of Corporate Governance Practices, and the Corporation&#146;s
alignment with each of them.</DIV>

<DIV align="center">
<TABLE style="font-size: 8pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
<TD width="1%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="39%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="2%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="49%">&nbsp;</TD>
<TD width="8%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
<TD nowrap colspan="3" style="border-bottom: 1px solid #000000"><DIV align="justify"><B>Corporate Governance Guidelines</B></DIV></TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD nowrap style="border-bottom: 1px solid #000000"><B>Commentary</B></TD>
<TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">1.</DIV></TD>
<TD>&nbsp;</TD>
<TD valign="top"><B>Board of Directors</B></TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">(a)</DIV></TD>
<TD>&nbsp;</TD>
<TD valign="top"><DIV align="justify">Disclose the identity of directors who are independent.</DIV></TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top"><DIV align="justify">As at December&nbsp;31, 2007, the
Corporation had nine board
members. The seven independent
directors of the Corporation are
Dr.&nbsp;W. Cochrane, Mr.&nbsp;G. van
Amersfoort, Mr.&nbsp;J. Dinning, Mr.
M. Lievonen, Dr.&nbsp;E. Levy, Mr.&nbsp;R.
Schultz, and Mr.&nbsp;F. Stewart.</DIV></TD>
<TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">(b)</DIV></TD>
<TD>&nbsp;</TD>
<TD valign="top"><DIV align="justify">Disclose the identity of directors
who are not independent, and describe
the basis for that determination.</DIV>
</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top"><DIV align="justify">The two directors of the
Corporation who are not
independent are Dr.&nbsp;B. Thompson
the Chairman and Chief Executive
Officer of the Corporation and
Mr.&nbsp;D. Ball the Chief Financial
Officer of the Corporation.</DIV></TD>
<TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">(c)</DIV></TD>
<TD>&nbsp;</TD>
<TD valign="top"><DIV align="justify">Disclose whether or not a majority
of directors are independent. If a
majority of directors are not
independent, describe what the board of
directors does to facilitate its
exercise of independent judgment in
carrying out its responsibilities.</DIV>
</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top"><DIV align="justify">A majority of the directors of
the Corporation are independent.</DIV></TD>
<TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">(d)</DIV></TD>
<TD>&nbsp;</TD>
<TD valign="top"><DIV align="justify">If a director is presently a
director of any other issuer that is a
reporting issuer (or the equivalent) in
a jurisdiction or a foreign
jurisdiction, identify both the
director and the other issuer.</DIV>
</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top"><DIV align="justify">Directors who are presently
directors of other reporting
issuers and those issuers:<BR><BR>
Mr.&nbsp;Dinning: Western Financial
Group, Liquor Stores Income Fund,
Parkland Income Fund and Russel
Metals Inc.<BR>
Dr.&nbsp;Cochrane: Resverlogix
Corporation and Sernova
Corporation Mr. van Amersfoort: Paladin Labs Inc.</DIV></TD>
<TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">(e)</DIV></TD>
<TD>&nbsp;</TD>
<TD valign="top"><DIV align="justify">Disclose whether or not the
independent directors hold regularly
scheduled meetings at which
non-independent directors and members
of management are not in attendance.
If the independent directors hold such
meetings, disclose the number of
meetings held since the beginning of
the issuer&#146;s most recently completed
financial year. If the independent
directors do not hold such meetings,
describe what the board does to
facilitate open and candid discussion
among its independent directors.</DIV>
</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top"><DIV align="justify">Independent directors hold an in
camera session without the
presence of any director who is
not independent and without the
presence of any management
members, at each scheduled Board
meeting. During the most recently
completed financial year the
independent Board members have
held four such meetings.</DIV></TD>
<TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE></DIV></DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<P align="center" style="font-size: 10pt"><!-- Folio -->- 11 -<!-- /Folio -->
<DIV align="center">
<TABLE style="font-size: 8pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
<TD width="1%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="39%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="2%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="49%">&nbsp;</TD>
<TD width="8%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
<TD nowrap align="left" colspan="3" style="border-bottom: 1px solid #000000"><B>Corporate Governance Guidelines</B></TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Commentary</B></TD>
<TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">(f)</DIV></TD>
<TD>&nbsp;</TD>
<TD valign="top"><DIV align="justify">Disclose whether or not the chair
of the board is an independent
director. If the board has a chair or
lead director who is an independent
director, disclose the identity of the
independent chair or lead director, and
describe his or her role and
responsibilities. If the board has
neither a chair that is independent nor
a lead director that is independent,
describe what the board does to provide
leadership for its independent
directors.</DIV><BR><BR>
</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top"><DIV align="justify">The Board has appointed a chair
who is not independent, and has
appointed Mr.&nbsp;Schultz, who is an
independent and unrelated
director, as Lead Director.<BR><BR>
The principal responsibility of
the Lead Director is to ensure
the independence of the Board in
the discharge of its
responsibilities. In this regard,
the Lead Director, individually
or with the support of the
committees, consults with the
Chairman/President and Chief
Executive Officer on selection of
committee members and committee
chairs, Board meeting and
planning meeting agendas, the
format and adequacy of
information provided to directors
and the effectiveness of Board
meetings. The Lead Director also
consults directly with other
directors on issues of Board
independence or dissent,
conflicts of interest of the
Chairman/President and Chief
Executive Officer, or personal
liability matters.</DIV></TD>
<TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">(g)
</DIV></TD>
<TD>&nbsp;</TD>
<TD valign="top"><DIV align="justify">Disclose the attendance record of
each director for all board meetings
held since the beginning of the
issuer&#146;s most recently completed
financial year.</DIV>
</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top"><DIV align="justify">There were five regularly
scheduled Board meetings and two
special meetings in 2007. All
Board members (Dr.&nbsp;Thompson, Mr.
Ball, Mr.&nbsp;Schultz, Mr.&nbsp;Stewart,
Dr.&nbsp;Cochrane, Mr.&nbsp;Levy, Mr. van
Amersfoort, Jim Dinning and Mr.
Lievonen) attended all 7
meetings.</DIV></TD>
<TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">2.
</DIV></TD>
<TD>&nbsp;</TD>
<TD valign="top"><B>Board Mandate</B>
</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top"><DIV align="justify">Attached as Schedule &#147;A&#148; hereto.</DIV></TD>
<TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD><DIV align="justify">Disclose the text of the board&#146;s
written mandate. If the board does not
have a written mandate, describe how
the board delineates its role and
responsibilities.</DIV></TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">3.
</DIV></TD>
<TD>&nbsp;</TD>
<TD valign="top"><B>Position Descriptions</B></TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">(a)
</DIV></TD>
<TD>&nbsp;</TD>
<TD valign="top"><DIV align="justify">Disclose whether or not the board
has developed written position
descriptions for the chair and the
chair of each board committee. If the
board has not developed written
position descriptions for the chair
and/or the chair of each board
committee, briefly describe how the
board delineates the role and
responsibilities of each such position.</DIV>
</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top"><DIV align="justify">The Board has developed position
descriptions for the chair and
the chair of each Board committee
which delineate the role and
responsibilities of these
positions.</DIV></TD>
<TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD valign="top">(b)</TD>
<TD>&nbsp;</TD>
<TD valign="top"><DIV align="justify">Disclose whether or not the board
and CEO have developed a written
position description for the CEO. If
the board and CEO have not developed
such a position description, briefly
describe how the board delineates the
role and responsibilities of the CEO.</DIV>
</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top"><DIV align="justify">The Board and the Chief Executive
Officer have developed a written
position description for the CEO
which delineates the role and
responsibilities of this
position.</DIV></TD>
<TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">4.
</DIV></TD>
<TD>&nbsp;</TD>
<TD valign="top"><DIV align="justify"><B>Orientation and Continuing Education</B></DIV></TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">(a)
</DIV></TD>
<TD>&nbsp;</TD>
<TD valign="top"><DIV align="justify">Briefly describe what measures the
board takes to orient new directors regarding:
<br><br>
<DIV style="margin-left:21px; text-indent:-21px">(i)
&nbsp;the
role
of the
board,
its committees
and its
directors,
and</DIV><br>
<DIV style="margin-left:21px; text-indent:-21px">(ii) the nature and
operation of the
issuer&#146;s business.</DIV></DIV>
</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top"><DIV align="justify">The Board provides new directors
with the Board and committee
mandates and reviews these with
the new board members. The Board
and management review the nature
and operations of the
Corporation, initially upon
appointment and continually
through scheduled Board meetings
and other sessions as required.</DIV></TD>
<TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<P align="center" style="font-size: 10pt"><!-- Folio -->- 12 -<!-- /Folio -->
<DIV align="center">
<TABLE style="font-size: 8pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
<TD width="1%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="39%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="2%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="49%">&nbsp;</TD>
<TD width="8%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
<TD nowrap align="left" colspan="3" style="border-bottom: 1px solid #000000"><B>Corporate Governance Guidelines</B></TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Commentary</B></TD>
<TD></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD></TD>
</TR>
<TR valign="bottom">
<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">(b)
</DIV></TD>
<TD>&nbsp;</TD>
<TD valign="top"><DIV align="justify">Briefly describe what measures, if
any, the board takes to provide
continuing education for its directors.
If the board does not provide
continuing education, describe how the
board ensures that its directors
maintain the skill and knowledge
necessary to meet their obligations as
directors.</DIV>
</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top"><DIV align="justify">The Board provides continuing
education for its Board members
on issues relevant to the
Corporation through Board
interaction at Board meetings and
ongoing communications between
scheduled meetings as required or
requested.</DIV></TD>
<TD></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD></TD>
</TR>
<TR valign="bottom">
<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">5.
</DIV></TD>
<TD>&nbsp;</TD>
<TD valign="top"><DIV align="justify"><B>Ethical Business Conduct</B></DIV></TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD></TD>
</TR>
<TR valign="bottom">
<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">(a)
</DIV></TD>
<TD>&nbsp;</TD>
<TD valign="top"><DIV align="justify">Disclose whether or not the board
has adopted a written code for the
directors, officers and employees. If
the board has adopted a written code:</DIV></TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD></TD>
</TR>
<TR valign="bottom">
<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
<TD>&nbsp;</TD>
<TD valign="top"><DIV align="justify"><DIV style="margin-left:21px; text-indent:-21px">(i)&nbsp;&nbsp;disclose how a person or company
may obtain a copy of the code;</DIV></DIV>
</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top"><DIV align="justify">The Board has adopted a written
code of conduct for the
directors, officers and employees
of the Corporation. A copy of
this code of conduct is available
on the Corporation&#146;s website
<u>www.oncolyticsbiotech.com</u>.</DIV></TD>
<TD></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD></TD>
</TR>
<TR valign="bottom">
<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
<TD>&nbsp;</TD>
<TD valign="top"><DIV align="justify"><DIV style="margin-left:21px; text-indent:-21px"> (ii)&nbsp; describe how the board
monitors compliance with its code, or if the
board does not monitor compliance,
explain whether and how the board
satisfies itself regarding compliance
with its code; and</DIV></DIV>
</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top"><DIV align="justify">The Board satisfies itself
regarding compliance with this
code through its review of the
activities of the Corporation,
discussions by the audit
committee with the external
auditors of the Corporation
without management present, and
enquiries of management.</DIV></TD>
<TD></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD></TD>
</TR>
<TR valign="bottom">
<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
<TD>&nbsp;</TD>
<TD valign="top"><DIV align="justify"><DIV style="margin-left:21px; text-indent:-21px"> (iii) provide a cross-reference to
any material change
report filed since the beginning of the
issuer&#146;s most recently completed
financial year that pertains to any
conduct of a director or executive
officer that constitutes a departure
from the code.</DIV></DIV>
</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top"><DIV align="justify">To the best of our knowledge
there has been no conduct by any
director or executive officer
that constitutes a departure from
the code and no material change
reports have been filed
pertaining to any such conduct.</DIV></TD>
<TD></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD></TD>
</TR>
<TR valign="bottom">
<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">(b)
</DIV></TD>
<TD>&nbsp;</TD>
<TD valign="top"><DIV align="justify">Describe any steps the board takes
to ensure directors exercise
independent judgement in considering
transactions and agreements in respect
of which a director or executive
officer has a material interest.</DIV>
</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top"><DIV align="justify">The Board encourages and supports
the exercise of independent
judgment by directors in
considering transactions and
agreements in respect of which a
director or executive officer has
a material interest. The Board
requires that any director or
officer with a material interest
in a transaction or agreement
under discussion disclose and
declare their interest. The Board
then conducts all discussions
with respect to the transaction
or agreement without the
interested director or officer
present for the determination and
precludes any interested director
from voting thereon.</DIV></TD>
<TD></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD></TD>
</TR>
<TR valign="bottom">
<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">(c)
</DIV></TD>
<TD>&nbsp;</TD>
<TD valign="top"><DIV align="justify">Describe any other steps the board
takes to encourage and promote a
culture of ethical business conduct.</DIV>
</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top"><DIV align="justify">The Board encourages and promotes
a culture of ethical business
conduct through its actions and
its support and interaction with
management and employees of the
Corporation.</DIv></TD>
<TD></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD></TD>
</TR>
<TR valign="bottom">
<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">6.
</DIV></TD>
<TD>&nbsp;</TD>
<TD valign="top"><DIV align="justify"><B>Nomination of Directors</B></DIV></TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD></TD>
</TR>
<TR valign="bottom">
<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">(a)
</DIV></TD>
<TD>&nbsp;</TD>
<TD valign="top"><DIV align="justify">Describe the process by which the
board identifies new candidates for
board nomination.</DIV>
</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top"><DIV align="justify">Directors provide potential
candidates to the Corporate
Governance and Nominating
Committee of the Board. The
committee reviews the
recommendations and the
qualifications of the candidates
and contacts the individuals who
are of interest to the Board.</DIV></TD>
<TD></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD></TD>
</TR>
<TR valign="bottom">
<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">(b)
</DIV></TD>
<TD>&nbsp;</TD>
<TD valign="top"><DIV align="justify">Disclose whether or not the board
has a nominating committee composed
entirely of independent directors. If
the board does not have a nominating
committee composed entirely of
independent directors, describe what
steps the board takes to encourage an
objective nomination process.</DIV>
</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top"><DIV align="justify">The Corporate Governance and
Nominating Committee is comprised
entirely of independent
directors.</DIV></TD>
<TD></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<P align="center" style="font-size: 10pt"><!-- Folio -->- 13 -<!-- /Folio -->
<DIV align="center">
<TABLE style="font-size: 8pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
<TD width="1%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="39%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="2%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="49%">&nbsp;</TD>
<TD width="8%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
<TD nowrap align="left" colspan="3" style="border-bottom: 1px solid #000000"><B>Corporate Governance Guidelines</B></TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Commentary</B></TD>
<TD></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD></TD>
</TR>
<TR valign="bottom">
<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">(c)
</DIV></TD>
<TD>&nbsp;</TD>
<TD valign="top"><DIV align="justify">If the board has a nominating
committee, describe the
responsibilities, powers and operation
of the nominating committee.</DIV>
</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top"><DIV align="justify">The Corporate Governance and
Nominating Committee, in its
capacity as the nominating
committee has the responsibility
to present the annual slate of
directors to the Board for the
board&#146;s approval. Once approved
by the Board, the proposed
selection will be presented to
the shareholders for their
approval at the next scheduled
annual meeting. During the year,
this committee has the
responsibility of locating and
recommending additional directors
to fill vacancies or supplement
the Board as required.</DIV></TD>
<TD></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD></TD>
</TR>
<TR valign="bottom">
<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">7.
</DIV></TD>
<TD>&nbsp;</TD>
<TD valign="top"><B>Compensation</B></TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD></TD>
</TR>
<TR valign="bottom">
<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">(a)
</DIV></TD>
<TD>&nbsp;</TD>
<TD valign="top"><DIV align="justify">Describe the process by which the
board determines the compensation for
the issuer&#146;s directors and officers.</DIV>
</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top"><DIV align="justify">The Board has established a
Compensation Committee comprised
entirely of independent
directors. The Compensation
Committee reviews and reports to
the Board on director and officer
compensation issues. In
determining the compensation for
the directors, the committee
assesses the directors&#146; roles and
responsibilities and an analysis
of the competitive position of
the Corporation&#146;s director
compensation program including
the ability to draw directors
with the background and
experience required to provide an
effective Board. In determining
the compensation for officers,
similar principles are applied
and an independent compensation
consultant is engaged to provide
additional relevant information
to the Compensation Committee.</DIV></TD>
<TD></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD></TD>
</TR>
<TR valign="bottom">
<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">(b)
</DIV></TD>
<TD>&nbsp;</TD>
<TD valign="top"><DIV align="justify">Disclose whether or not the board
has a compensation committee composed
entirely of independent directors. If
the board does not have a compensation
committee composed entirely of
independent directors, describe what
steps the board takes to ensure an
objective process for determining such
compensation.</DIV>
</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top"><DIV align="justify">The Board has a Compensation
Committee comprised entirely of
independent directors.</DIV></TD>
<TD></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD></TD>
</TR>
<TR valign="bottom">
<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">(c)
</DIV></TD>
<TD>&nbsp;</TD>
<TD valign="top"><DIV align="justify">If the board has a
compensation committee, describe the
responsibilities, powers and operation
of the compensation committee.</DIV>
</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top"><DIV align="justify">The responsibilities, powers and
operation of the committee are as
outlined above.</DIV></TD>
<TD></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD></TD>
</TR>
<TR valign="bottom">
<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">(d)
</DIV></TD>
<TD>&nbsp;</TD>
<TD valign="top"><DIV align="justify">If a compensation consultant or
advisor has, at any time since the
beginning of the issuer&#146;s most recently
completed financial year, been retained
to assist in determining compensation
for any of the issuer&#146;s directors and
officers, disclose the identity of the
consultant or advisor and briefly
summarize the mandate for which they
have been retained. If the consultant
or advisor has been retained to perform
any other work for the issuer, state
that fact and briefly describe the
nature of the work.</DIV>
</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top"><DIV align="justify">The compensation consultant
retained by the Corporation was
Lane Caputo Compensation Inc. Its
mandate was to assist the Board
in the review of compensation for
the selected executive positions
of the Corporation and for the
independent directors of the
Board.</DIV></TD>
<TD></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD></TD>
</TR>
<TR valign="bottom">
<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">8.
</DIV></TD>
<TD>&nbsp;</TD>
<TD valign="top"><DIV align="justify"><B>Other Board Committees</B></DIV></TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD></TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top" align="left"><DIV align="justify">If the board has standing committees
other than the audit, compensation and
nominating committees, identify the
committees and describe their function.</DIV></TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top"><DIV align="justify">The Board has established
committees each of which is
comprised entirely of independent
directors. These committees are
the Audit Committee, the
Compensation Committee and the
Corporate Governance and
Nominating Committee. Mandates
for the Board and the Committees
of the Board can be found on the
Company website under Investor
Relations/Corporate Governance.
<u>http://www.oncolyticsbiotech.com/corpGovernance.html</u></DIV></TD>
<TD></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<P align="center" style="font-size: 10pt"><!-- Folio -->- 14 -<!-- /Folio -->
<DIV align="center">
<TABLE style="font-size: 8pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
<TD width="1%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="39%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="2%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="49%">&nbsp;</TD>
<TD width="8%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
<TD nowrap align="left" colspan="3" style="border-bottom: 1px solid #000000"><B>Corporate Governance Guidelines</B></TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Commentary</B></TD>
<TD></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD></TD>
</TR>
<TR valign="bottom">
<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">9.
</DIV></TD>
<TD>&nbsp;</TD>
<TD valign="top"><B>Assessments</B></TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD></TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top"><DIV align="justify">Disclose whether or not the board, its
committees and individual directors are
regularly assessed with respect to
effectiveness and contribution. If
assessments are regularly conducted,
describe the process used for the
assessments. If assessments are not
regularly conducted, describe how the
board satisfies itself that the board,
its committees, and its individual
directors are performing effectively.</DIV></TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD valign="top"><DIV align="justify">The Board, through its Corporate
Governance and Nominating
Committee assesses, at least
annually, the effectiveness and
contribution of each member of
the Board. The assessment is
conducted through dialogue with
Board members and is part of the
information used in setting the
slate of directors to be proposed
to the shareholders at the next
annual meeting.</DIV></TD>
<TD></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>RECEIPT OF FINANCIAL STATEMENTS</B>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">The audited financial statements for the financial year ended December&nbsp;31, 2007 of the Corporation
have been forwarded to Shareholders. No formal action will be taken at the Meeting to approve the
financial statements. If any Shareholder has questions respecting the December&nbsp;31, 2007 financial
statements, the questions may be brought forward at the Meeting.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>ELECTION OF DIRECTORS</B>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">The term of office for each director of the Corporation is from the date of the Shareholders&#146;
meeting at which he or she is elected until the next annual meeting of the Shareholders or until
his or her successor is elected or appointed. At the Meeting, a board of nine directors are to be
elected. <B>It is the intention of the persons named in the enclosed Instrument of Proxy, if not
expressly directed to the contrary in such Instrument of Proxy, to vote such proxies FOR the
ordinary resolution to elect the nominees specified below as directors of the Corporation. </B>If,
prior to the Meeting, any vacancies occur in the slate of proposed nominees herein submitted, the
persons named in the enclosed Instrument of Proxy intend to vote FOR the election of any substitute
nominee or nominees recommended by management of the Corporation and FOR the remaining proposed
nominees.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">The following table states the names and municipalities of residence of all persons proposed to be
nominated for election as directors, the position or office now held by them, their principal
occupation or employment history, the date on which they became directors of the Corporation and
the number of Common Shares owned by them or over which they exercise control or direction as at
February&nbsp;19, 2008:
</DIV>
<DIV align="center">
<TABLE style="font-size: 8pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
<TD width="20%">&nbsp;</TD>
<TD width="5%">&nbsp;</TD>
<TD width="27%">&nbsp;</TD>
<TD width="5%">&nbsp;</TD>
<TD width="7%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="7%">&nbsp;</TD>
<TD width="5%">&nbsp;</TD>
<TD width="7%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="7%">&nbsp;</TD>
<TD width="8%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD nowrap align="center" colspan="3"><B>Number of</B></TD>
<TD>&nbsp;</TD>
<TD nowrap align="center" colspan="3">&nbsp;</TD>
<TD></TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
<TD nowrap align="center"><B>Name, Present Office</B></TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD nowrap align="center" colspan="3"><B>Shares</B></TD>
<TD>&nbsp;</TD>
<TD nowrap align="center" colspan="3">&nbsp;</TD>
<TD></TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
<TD nowrap align="center"><B>Held, Municipality of</B></TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD nowrap align="center" colspan="3"><B>Beneficially</B></TD>
<TD>&nbsp;</TD>
<TD nowrap align="center" colspan="3">&nbsp;</TD>
<TD></TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
<TD nowrap align="center"><B>Residence and Date</B></TD>
<TD>&nbsp;</TD>
<TD nowrap align="center"><B>History of</B></TD>
<TD>&nbsp;</TD>
<TD nowrap align="center" colspan="3"><B>Owned and</B></TD>
<TD>&nbsp;</TD>
<TD nowrap align="center" colspan="3"><B>Number of</B></TD>
<TD></TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
<TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Appointed a Director</B></TD>
<TD>&nbsp;</TD>
<TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Principal Occupations</B></TD>
<TD>&nbsp;</TD>
<TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>Controlled</B><SUP style="font-size: 85%; vertical-align: text-top"><B>(4)</B></SUP></TD>
<TD>&nbsp;</TD>
<TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>Options Held</B></TD>
<TD></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD nowrap align="right" valign="top">&nbsp;</TD>
<TD align="right" valign="top">&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD nowrap align="right" valign="top">&nbsp;</TD>
<TD align="right" valign="top">&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD></TD>
</TR>
<TR valign="bottom">
<TD valign="top" align="justify"><DIV style="margin-left:0px; text-indent:-0px">Bradley G. Thompson, Ph.D.<BR>
<I>Calgary, Alberta </I><BR>
Director since April&nbsp;21, 1999</DIV>
</TD>
<TD>&nbsp;</TD>
<TD valign="top"><DIV align="justify">Executive Chairman
of the Board,
President and Chief
Executive Officer of
Oncolytics since
April&nbsp;1999.</DIV>
</TD>
<TD>&nbsp;</TD>
<TD nowrap align="right" valign="top">&nbsp;</TD>
<TD align="right" valign="top">652,900</TD>
<TD nowrap valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD nowrap align="right" valign="top">&nbsp;</TD>
<TD align="right" valign="top">786,160</TD>
<TD nowrap valign="top">&nbsp;</TD>
<TD></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD nowrap align="right" valign="top">&nbsp;</TD>
<TD align="right" valign="top">&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD nowrap align="right" valign="top">&nbsp;</TD>
<TD align="right" valign="top">&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD></TD>
</TR>
<TR valign="bottom">
<TD valign="top"><DIV align="justify">Douglas A. Ball, C.A. <BR>
<I>Calgary, Alberta </I><BR>
Director since April&nbsp;21, 1999
</DIV></TD>
<TD>&nbsp;</TD>
<TD valign="top"><DIV align="justify">Chief Financial
Officer of the
Corporation since
May&nbsp;2000. Prior
thereto, the Vice
President, Finance
and Chief Financial
Officer of SYNSORB
since June&nbsp;1997.
Prior to this, he
was the Vice
President, Finance
and Administration
and Chief Financial
Officer of ECL Group
of Companies Ltd.
Mr.&nbsp;Ball held</DIV>
</TD>
<TD>&nbsp;</TD>
<TD nowrap align="right" valign="top">&nbsp;</TD>
<TD align="right" valign="top">3,000</TD>
<TD nowrap valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD nowrap align="right" valign="top">&nbsp;</TD>
<TD align="right" valign="top">674,833</TD>
<TD nowrap valign="top">&nbsp;</TD>
<TD></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<P align="center" style="font-size: 10pt"><!-- Folio -->- 15 -<!-- /Folio -->
<DIV align="center">
<TABLE style="font-size: 8pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
<TD width="21%">&nbsp;</TD>
<TD width="5%">&nbsp;</TD>
<TD width="26%">&nbsp;</TD>
<TD width="5%">&nbsp;</TD>
<TD width="7%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="7%">&nbsp;</TD>
<TD width="5%">&nbsp;</TD>
<TD width="7%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="7%">&nbsp;</TD>
<TD width="8%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD nowrap align="center" colspan="3"><B>Number of</B></TD>
<TD>&nbsp;</TD>
<TD nowrap align="center" colspan="3">&nbsp;</TD>
<TD></TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
<TD nowrap align="center"><B>Name, Present Office</B></TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD nowrap align="center" colspan="3"><B>Shares</B></TD>
<TD>&nbsp;</TD>
<TD nowrap align="center" colspan="3">&nbsp;</TD>
<TD></TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
<TD nowrap align="center"><B>Held, Municipality of</B></TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD nowrap align="center" colspan="3"><B>Beneficially</B></TD>
<TD>&nbsp;</TD>
<TD nowrap align="center" colspan="3">&nbsp;</TD>
<TD></TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
<TD nowrap align="center"><B>Residence and Date</B></TD>
<TD>&nbsp;</TD>
<TD nowrap align="center"><B>History of</B></TD>
<TD>&nbsp;</TD>
<TD nowrap align="center" colspan="3"><B>Owned and</B></TD>
<TD>&nbsp;</TD>
<TD nowrap align="center" colspan="3"><B>Number of</B></TD>
<TD></TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
<TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Appointed a Director</B></TD>
<TD>&nbsp;</TD>
<TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Principal Occupations</B></TD>
<TD>&nbsp;</TD>
<TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>Controlled</B><SUP style="font-size: 85%; vertical-align: text-top"><B>(4)</B></SUP></TD>
<TD>&nbsp;</TD>
<TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>Options Held</B></TD>
<TD></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD nowrap align="right" valign="top">&nbsp;</TD>
<TD align="right" valign="top">&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD nowrap align="right" valign="top">&nbsp;</TD>
<TD align="right" valign="top">&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD></TD>
</TR>
<TR valign="bottom">
<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
<TD>&nbsp;</TD>
<TD valign="top"><DIV align="justify">this position from
December&nbsp;1995 until
May&nbsp;1997. Prior to
ECL, he was
Controller and then
Vice President and
Controller of
Canadian Airlines
International Ltd.
from June&nbsp;1993 until
August&nbsp;1995.</DIV></TD>
<TD>&nbsp;</TD>
<TD nowrap align="right" valign="top">&nbsp;</TD>
<TD align="right" valign="top">&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD nowrap align="right" valign="top">&nbsp;</TD>
<TD align="right" valign="top">&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD nowrap align="right" valign="top">&nbsp;</TD>
<TD align="right" valign="top">&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD nowrap align="right" valign="top">&nbsp;</TD>
<TD align="right" valign="top">&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD></TD>
</TR>
<TR valign="bottom">
<TD valign="top"><DIV align="justify">Ger van Amersfoort<SUP style="font-size: 85%; vertical-align: text-top">(2)&nbsp; </SUP><BR>
<I>Oakville, Ont</I><BR>Director since June&nbsp;15,
2006
</DIV></TD>
<TD>&nbsp;</TD>
<TD valign="top"><DIV align="justify">President and Chief
Executive Officer of
Novartis Canada, a
pharmaceutical
company with in
excess of $1&nbsp;billion
in annual sales and
a workforce of
1,500, until his
retirement in 2001.
Before joining
Novartis, he was
President and Chief
Executive Officer of
the U.K. SmithKline
Beecham operations
from
1997 until managing
the merger with
Novartis in 1999.
From 1990 to 1997,
Mr. van Amersfoort
headed up SmithKline
Beecham operations
in Canada as
President and Chief
Executive Officer.
Prior to that, he
held managing
director positions
with Beecham and The
Boots Company, and
sales positions with
Bristol Myers in
Holland. He is a
recipient of the
Paul Harris Medal
and the
Commemorative Medal
of the Queen for
outstanding services
to the community. He
has served on the
Board of the
Pharmaceutical
Manufacturers
Association of
Canada (now Rx and
D) for more than
nine years, serving
as chairman in 1996
and is a director of
Paladin Labs Inc.</DIV>
</TD>
<TD>&nbsp;</TD>
<TD nowrap align="right" valign="top">&nbsp;</TD>
<TD align="right" valign="top">5,000</TD>
<TD nowrap valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD nowrap align="right" valign="top">&nbsp;</TD>
<TD align="right" valign="top">77,500</TD>
<TD nowrap valign="top">&nbsp;</TD>
<TD></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD nowrap align="right" valign="top">&nbsp;</TD>
<TD align="right" valign="top">&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD nowrap align="right" valign="top">&nbsp;</TD>
<TD align="right" valign="top">&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD></TD>
</TR>
<TR valign="bottom">
<TD valign="top" nowrap><DIV align="justify">William A. Cochrane, OC,
M.D. <SUP style="font-size: 85%; vertical-align: text-top">(2)&nbsp;(3)</SUP> <BR>
<I>Calgary, Alberta </I><BR>
Director since October&nbsp;31, 2002
</DIV></TD>
<TD>&nbsp;</TD>
<TD valign="top"><DIV align="justify">President of W.A.
Cochrane &#038;
Associates, Inc. (a
consulting company)
since 1989 and
Chairman of
Resverlogix Corp. (a
public
biopharmaceutical
company), and is a
director of Sernova
Corp., and a former
chairman of
University
Technologies
International Inc.
(UTI)&nbsp;at the
University of
Calgary Dr.&nbsp;Cochrane
is an Officer of the
Order of Canada and
a 2002 recipient of
the Queens Golden
Jubilee Medal. Dr.
Cochrane also served
as the Deputy
Minister of Health
Services for the
Province of Alberta
from 1973 to 1974
and President of the
University of
Calgary from 1974 to
1978.</DIV>
</TD>
<TD>&nbsp;</TD>
<TD nowrap align="right" valign="top">&nbsp;</TD>
<TD align="right" valign="top">6,000</TD>
<TD nowrap valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD nowrap align="right" valign="top">&nbsp;</TD>
<TD align="right" valign="top">116,000</TD>
<TD nowrap valign="top">&nbsp;</TD>
<TD></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD nowrap align="right" valign="top">&nbsp;</TD>
<TD align="right" valign="top">&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD nowrap align="right" valign="top">&nbsp;</TD>
<TD align="right" valign="top">&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD></TD>
</TR>
<TR valign="bottom">
<TD valign="top" nowrap><DIV align="justify">Jim Dinning
<SUP style="font-size: 85%; vertical-align: text-top">(1)</sup><BR>
<I>Calgary, Alberta</I><BR>Director since March 24, 2004</DIV></TD>
<TD>&nbsp;</TD>
<TD valign="top"><DIV align="justify">Chair of Western
Financial Group
since September
2004. Mr.&nbsp;Dinning
was Executive Vice
President of
TransAlta
Corporation (power
generation and
wholesale marketing
company) from 1997
to 2004 and served
as Member of the
Legislative Assembly
of the Province of
Alberta from 1986 to
1997. Mr.
Dinning is the Chair
of Export
Development Canada
and Director of
Russel Metals, as
well as other public
and private
companies.</DIV>
</TD>
<TD>&nbsp;</TD>
<TD nowrap align="right" valign="top">&nbsp;</TD>
<TD align="right" valign="top">20,000</TD>
<TD nowrap valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD nowrap align="right" valign="top">&nbsp;</TD>
<TD align="right" valign="top">105,000</TD>
<TD nowrap valign="top">&nbsp;</TD>
<TD></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<P align="center" style="font-size: 10pt"><!-- Folio -->- 16 -<!-- /Folio -->
<DIV align="center">
<TABLE style="font-size: 8pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
<TD width="20%">&nbsp;</TD>
<TD width="5%">&nbsp;</TD>
<TD width="27%">&nbsp;</TD>
<TD width="5%">&nbsp;</TD>
<TD width="7%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="7%">&nbsp;</TD>
<TD width="5%">&nbsp;</TD>
<TD width="7%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="7%">&nbsp;</TD>
<TD width="8%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD nowrap align="center" colspan="3"><B>Number of</B></TD>
<TD>&nbsp;</TD>
<TD nowrap align="center" colspan="3">&nbsp;</TD>
<TD></TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
<TD nowrap align="center"><B>Name, Present Office</B></TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD nowrap align="center" colspan="3"><B>Shares</B></TD>
<TD>&nbsp;</TD>
<TD nowrap align="center" colspan="3">&nbsp;</TD>
<TD></TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
<TD nowrap align="center"><B>Held, Municipality of</B></TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD nowrap align="center" colspan="3"><B>Beneficially</B></TD>
<TD>&nbsp;</TD>
<TD nowrap align="center" colspan="3">&nbsp;</TD>
<TD></TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
<TD nowrap align="center"><B>Residence and Date</B></TD>
<TD>&nbsp;</TD>
<TD nowrap align="center"><B>History of</B></TD>
<TD>&nbsp;</TD>
<TD nowrap align="center" colspan="3"><B>Owned and</B></TD>
<TD>&nbsp;</TD>
<TD nowrap align="center" colspan="3"><B>Number of</B></TD>
<TD></TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
<TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Appointed a Director</B></TD>
<TD>&nbsp;</TD>
<TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Principal Occupations</B></TD>
<TD>&nbsp;</TD>
<TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>Controlled</B><SUP style="font-size: 85%; vertical-align: text-top"><B>(4)</B></SUP></TD>
<TD>&nbsp;</TD>
<TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>Options Held</B></TD>
<TD></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD nowrap align="right" valign="top">&nbsp;</TD>
<TD align="right" valign="top">&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD nowrap align="right" valign="top">&nbsp;</TD>
<TD align="right" valign="top">&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD></TD>
</TR>
<TR valign="bottom">
<TD valign="top"><DIV align="justify">Ed Levy<SUP style="font-size: 85%; vertical-align: text-top">(3) </SUP><BR>
<I>Lund, BC </I><BR>
Director since May&nbsp;17, 2006
</DIV></TD>
<TD>&nbsp;</TD>
<TD valign="top"><DIV align="justify">Adjunct professor at
the W. Maurice Young
Centre for Applied
Ethics at the
University of
British Columbia
since retiring from
QLT Inc. in late
2002. From 1988 to
2002, Dr.&nbsp;Levy was
with Vancouver-based
biotechnology
company QLT Inc.,
most recently as
Senior Vice
President from 1998.
In these roles, he
was primarily
responsible for
negotiating and
managing QLT&#146;s
strategic alliances,
led strategic
planning and oversaw
the company&#146;s
intellectual
property. Dr.&nbsp;Levy
served on the board
of BIOTECanada from
1999-2002, and he
has served on the
boards of several
technology companies
and not-for-profits.
Dr.&nbsp;Levy holds a PhD
in the History and
Philosophy of
Science from Indiana
University and
taught philosophy of
science at UBC from
1967-1988.</DIV>
</TD>
<TD>&nbsp;</TD>
<TD nowrap align="right" valign="top">&nbsp;</TD>
<TD align="right" valign="top">5,100</TD>
<TD nowrap valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD nowrap align="right" valign="top">&nbsp;</TD>
<TD align="right" valign="top">77,500</TD>
<TD nowrap valign="top">&nbsp;</TD>
<TD></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD nowrap align="right" valign="top">&nbsp;</TD>
<TD align="right" valign="top">&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD nowrap align="right" valign="top">&nbsp;</TD>
<TD align="right" valign="top">&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD></TD>
</TR>
<TR valign="bottom">
<TD valign="top"><DIV align="justify">J. Mark Lievonen C.A. <SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP><BR>
<I>Markham, Ontario </I><BR>
Director since April&nbsp;5, 2004
</DIV></TD>
<TD>&nbsp;</TD>
<TD valign="top"><DIV align="justify">President of Sanofi
Pasteur Limited, a
vaccine
development,
manufacturing and
marketing company,
since October&nbsp;1998
and holding various
positions with
Sanofi Pasteur
Limited and its
predecessors since
1983. Mr.&nbsp;Lievonen
serves on a number
of industry and
community boards and
councils including
BIOTECanada, the
Ontario Genomics
Institute, the
Ontario Institute
for Cancer Research,
and York University.</DIV>
</TD>
<TD>&nbsp;</TD>
<TD nowrap align="right" valign="top">&nbsp;</TD>
<TD align="right" valign="top">3,000</TD>
<TD nowrap valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD nowrap align="right" valign="top">&nbsp;</TD>
<TD align="right" valign="top">105,000</TD>
<TD nowrap valign="top">&nbsp;</TD>
<TD></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD nowrap align="right" valign="top">&nbsp;</TD>
<TD align="right" valign="top">&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD nowrap align="right" valign="top">&nbsp;</TD>
<TD align="right" valign="top">&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD></TD>
</TR>
<TR valign="bottom">
<TD valign="top" nowrap><DIV align="justify">Robert B. Schultz,
F.C.A.
<SUP style="font-size: 85%; vertical-align: text-top">(1) </SUP><BR>
<I>Toronto, Ontario </I><BR>
Director since June&nbsp;30, 2000
</DIV></TD>
<TD>&nbsp;</TD>
<TD valign="top"><DIV align="justify">Former Chairman and
Director of
Rockwater Capital
Corporation,
formerly McCarvill
Corporation (a
financial services
company) from 2001
to 2007. Chairman
and Chief Executive
Officer of Merrill
Lynch Canada from
August&nbsp;1998 until
his retirement on
May
1, 2000. Prior to
this appointment,
Mr.&nbsp;Schultz was
Chief Executive
Officer at Midland
Walwyn since 1990.
Since joining the
investment industry
in 1971, Mr.&nbsp;Schultz
has held a variety
of senior positions,
and has participated
on various
industry-related
boards and
committees including
Director and
Chairman of the
Investment Dealers
Association of
Canada.</DIV>
</TD>
<TD>&nbsp;</TD>
<TD nowrap align="right" valign="top">&nbsp;</TD>
<TD align="right" valign="top">10,000</TD>
<TD nowrap valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD nowrap align="right" valign="top">&nbsp;</TD>
<TD align="right" valign="top">200,500</TD>
<TD nowrap valign="top">&nbsp;</TD>
<TD></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
<TD>&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD nowrap align="right" valign="top">&nbsp;</TD>
<TD align="right" valign="top">&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD nowrap align="right" valign="top">&nbsp;</TD>
<TD align="right" valign="top">&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD></TD>
</TR>
<TR valign="bottom">
<TD valign="top" nowrap><DIV align="justify">Fred A. Stewart, LL.B., Q.C.
<SUP style="font-size: 85%; vertical-align: text-top">(1)(2)</SUP><BR>
<I>Calgary, Alberta</I><BR>
Director since August&nbsp;27, 1999
</DIV></TD>
<TD>&nbsp;</TD>
<TD valign="top"><DIV align="justify">President of Fred
Stewart &#038; Associates
Inc. (a government
and corporate
relations consulting
company) since March
1996. Prior to
that, Mr.&nbsp;Stewart
was an associate
with Milner Fenerty,
Barristers and
Solicitors from June
1993 to March&nbsp;1996.
Mr.&nbsp;Stewart served
as Member of the
Legislative Assembly
of the Province of
Alberta, and as
Minister of
Technology, Research
and
Telecommunications
from 1986 to 1993.</DIV>
</TD>
<TD>&nbsp;</TD>
<TD nowrap align="right" valign="top">&nbsp;</TD>
<TD align="right" valign="top">24,000</TD>
<TD nowrap valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD nowrap align="right" valign="top">&nbsp;</TD>
<TD align="right" valign="top">167,500</TD>
<TD nowrap valign="top">&nbsp;</TD>
<TD></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<P align="center" style="font-size: 10pt"><!-- Folio -->- 17 -<!-- /Folio -->

<DIV align="left" style="font-size: 8pt; margin-top: 12pt"><B>Notes:</B></DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 6pt">
<TR valign="top" style="font-size: 8pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(1)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>These persons are members of the Audit Committee. Mr.&nbsp;Stewart is the Chair of the Audit
Committee.</TD>
</TR>

<TR>
    <TD style="font-size: 3pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 8pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(2)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>These persons are members of the Compensation Committee. Mr.&nbsp;Stewart is the Chair of the
Compensation Committee.</TD>
</TR>

<TR>
    <TD style="font-size: 3pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 8pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(3)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>These persons are members of the Corporate Governance and Nominating Committee. Mr.&nbsp;Lievonen
is the Chair of the Corporate Governance and Nominating Committee.</TD>
</TR>

<TR>
    <TD style="font-size: 3pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 8pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(4)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The information as to the number of Common Shares beneficially owned, not being within the
knowledge of the Corporation, has been furnished by the respective nominees.</TD>
</TR>

</TABLE></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>APPOINTMENT OF AUDITORS</B></DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">The Corporation has requested that Ernst &#038; Young LLP, Chartered Accountants of Calgary, Alberta act
as independent auditors for the Corporation subject to Shareholder approval. <B>Unless otherwise
directed, it is management&#146;s intention to vote the proxies in favour of an ordinary resolution to
appoint the firm of Ernst &#038; Young LLP, Chartered Accountants, as auditors of the Corporation to
hold office until the close of the next annual meeting of Shareholders or until the firm of Ernst &#038;
Young LLP, Chartered Accountants is removed from office or resigns as provided by law or by the
Corporation&#146;s by-laws, and to authorize the directors of the Corporation to fix the remuneration of
Ernst &#038; Young LLP, Chartered Accountants, as auditors of the Corporation. </B>Ernst &#038; Young LLP,
Chartered Accountants, have been the auditors of the Corporation, since August&nbsp;27, 1999.</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>AMENDMENT OF STOCK OPTION PLAN</B></DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">The Board has determined that several amendments to the Plan are necessary. Subject to Shareholder
approval, the Board has approved the following amendments to the Plan: (i)&nbsp;an updated general
amendment provision; (ii)&nbsp;a mechanism for extending options that expire during a black-out period;
and (iii)&nbsp;an expansion of the eligibility provisions of the Plan.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>General Amendment Provision</B></DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">On June&nbsp;6, 2006, the TSX announced that, effective June&nbsp;30, 2007, TSX-listed issuers having
&#147;general amendment&#148; provisions as part of their securities-based compensation plans will no longer
be permitted to make amendments to such plans without shareholder approval, including amendments
that are considered routine or of a &#147;housekeeping&#148; nature. Before the TSX changed its rules,
shareholder approval was required for a plan or option amendment if the TSX considered the
amendment to be material. The objective of the new rules is to allow shareholders to determine the
types of plan or option amendments that require shareholder approval before a company can make
them.</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">In its June&nbsp;6, 2006 notice (the &#147;TSX Notice&#148;), the TSX advised issuers: (i)&nbsp;to incorporate detailed
amending provisions into their securities-based compensation plans (to clarify when shareholder
approval for amendments to such plans and outstanding awards will not be required); and (ii)&nbsp;to
have those amending provisions approved by shareholders at an early opportunity.</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">The proposed amendment procedures approved by the Board would permit the Board to amend the Plan or
an Option at any time and from time to time, for any reason except for those changes for which the
Plan would specifically require Shareholder approval. Under the proposed amendment procedures, the
Plan would require Shareholder approval for the following changes to the Plan or Options granted
under it:</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV align="justify">increases the number of shares reserved for issuance under the Plan;</DIV></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV align="justify">reduces the exercise price of an Option, except for the purpose of maintaining Option value in
connection with a conversion, change, reclassification, redivision, redesignation, subdivision or
consolidation of shares or a reorganization, amalgamation, consolidation, merger, takeover bid or
similar transaction involving the Corporation (for this purpose, cancellation or termination of an
Option prior to its expiry date for the purpose of reissuing</DIV></TD>
</TR>

</TABLE></DIV></DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<P align="center" style="font-size: 10pt"><!-- Folio -->- 18 -<!-- /Folio -->


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 6%">Options to the same option-holder with a lower exercise price will be considered an
amendment to reduce the exercise price of an Option);
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(c)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV align="justify">extends the term of an Option beyond the maximum expiry date set out in the Plan (except where
an expiry date would have fallen within a blackout period established under the Corporation&#146;s
Trading Policy);</DIV></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(d)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV align="justify">extends eligibility to participate in the Plan to persons other than officers, directors, and
employees of the Corporation or its subsidiaries and consultants to the Corporation or its
subsidiaries;</DIV></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(e)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV align="justify">permits Options to be transferred, other than for normal estate settlement purposes or to an
RRSP or similar plan; or</DIV></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(f)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV align="justify">permits awards other than Options to be made under the Plan.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Black Out Periods</B>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">In the TSX Notice, the TSX also noted that many listed issuers establish, from time to time,
self-imposed black-out periods, which have the effect of restricting certain option-holders from
exercising their Options. The TSX recognizes that the establishment of such black-out periods
represents good corporate governance and fosters compliance with applicable securities laws, by
restricting affected individuals from trading in securities of a publicly listed entity at times
when they may be in possession of material, undisclosed information concerning that entity.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">However, the TSX has also noted that, due to certain restrictions that otherwise prevent extensions
of the time during which an option-holder may exercise Options, an option-holder may be unfairly
penalized by not being able to exercise Options during the period that a self-imposed black-out
remains in effect. The TSX has indicated that it is not TSX&#146;s intention to penalize option-holders
as a result of positive corporate behaviour on the part of issuers and, as a result, the TSX has
confirmed that issuers may amend their stock-option plans to provide a conditional extension to the
expiration date for Options that expire during, or immediately after, a black-out period.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">In light of the foregoing, the Board has approved an amendment to the Plan to provide that Options
issued under the Plan will expire on the later of: (i)&nbsp;the expiry date of the affected Options; or
(ii)&nbsp;if the expiry date occurs during a black-out period established under the Corporation&#146;s
Trading Policy, or within five (5)&nbsp;business days thereafter, the date that is ten (10)&nbsp;business
days following the end of such black-out period.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Eligible Participants</B>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">Currently, the Corporation does not have any active subsidiaries and the Plan does not allow the
Board to issue Options to directors, officers or employees of a subsidiary of the Corporation. In
order to provide the Corporation with flexibility to restructure its business and continue to
provide flexibility to the Board to grant Options following any restructuring or expansion of the
Corporation, the Board has approved an amendment to the Plan to allow for the issuance of Options
to directors, officers and employees of any subsidiary of the Corporation as well as any
consultants retained by any subsidiary of the Corporation.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>General</B>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">At the Meeting, Shareholders will be asked to approve the following resolution:
</DIV>

<DIV align="justify" style="margin-top: 6pt; margin-left: 15%; margin-right:15%; font-size: 10pt">BE IT RESOLVED, as an ordinary resolution of the shareholders of Oncolytics
Biotech Inc. (the &#147;Corporation&#148;), that the amendments to the
</DIV>
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<P align="center" style="font-size: 10pt"><!-- Folio -->- 19 -<!-- /Folio -->

<DIV align="justify" style="margin-top: 6pt; margin-left: 15%; margin-right:15%; font-size: 10pt">stock option plan of the Corporation to modify the general amendment
provision, provide for the extension of options that expire during a blackout
period and expand the definition of eligible participants, as approved by the
Board of Directors on March&nbsp;5, 2008 and described in the management proxy
circular of the Corporation, dated March&nbsp;20, 2008, be and the same are hereby
approved, ratified and confirmed, without amendment</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">The foregoing resolution must be approved by a simple majority of votes cast by Shareholders who
vote in person or by proxy at the Meeting with respect to this resolution.</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>INTEREST OF CERTAIN PERSONS IN MATTERS TO BE ACTED UPON</B></DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">Except as described elsewhere herein, none of the directors or senior officers of the Corporation
nor any of their known associates, has any substantial interest, direct or indirect, by way of
beneficial ownership of securities or otherwise, in any matter to be acted upon at the Meeting.</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>OTHER MATTERS TO BE ACTED UPON</B></DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">Management knows of no matters to come before the Meeting other than the matters referred to in the
Notice of Meeting. However, if any other matters properly come before the Meeting, the accompanying
proxy will be voted on such matters in the best judgment of the person or persons voting the proxy.</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>EFFECTIVE DATE</B></DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">Except as otherwise specified herein, the information set forth in this Information Circular is
provided as of March&nbsp;20, 2008.</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>ADDITIONAL INFORMATION</B></DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Additional information relating to the Corporation is available through the Internet on the
Canadian System for Electronic Document Analysis and Retrieval (SEDAR)&nbsp;which can be accessed at
<U>www.sedar.com</U>. Financial information of the Corporation is provided in the comparative financial
statements and management&#146;s discussion and analysis of the Corporation for the most recently
completed financial year. Copies of the financial statements and management discussion and
analysis of the Corporation may be obtained from the Chief
Financial Officer of the Corporation at Suite&nbsp;210, 1167 Kensington Crescent N.W., Calgary,
Alberta T2N 1X7 or by facsimile at (403)&nbsp;283-0858.</DIV> </DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<P align="center" style="font-size: 10pt"><!-- Folio -->- 20 -<!-- /Folio -->

<DIV align="center" style="font-size: 12pt; margin-top: 6pt"><B>Schedule&nbsp;A</B></DIV>

<DIV align="Center" style="font-size: 12pt; margin-top: 6pt"><B>ONCOLYTICS BIOTECH INC.</B></DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U><B>MANDATE OF THE BOARD OF DIRECTORS</B></U></DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Policy Statement</B></TD>
</TR>

</TABLE></DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">The Board of Directors (the &#147;Board&#148;) of Oncolytics Biotech Inc. (the &#147;Corporation&#148;) has the
responsibility to oversee the conduct of the business of the Corporation and to oversee the
activities of management who are responsible for the day-to-day conduct of the business of the
Corporation.</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">2.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Composition and Operation</B></TD>
</TR>

</TABLE></DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">The Board is to be constituted of a majority of individuals who qualify as unrelated directors. An
unrelated director is one who meets the requirements of NASDAQ Rule&nbsp;4200 and National Instrument
58-101 who is independent of management and is free from any interest and any business or other
relationship which could or could reasonably be perceived to materially interfere with the
director&#146;s ability to act with a view to the best interests of the Corporation other than interests
and relationships arising from shareholdings. In determining whether a director is independent of
management, the Board shall make reference to the then current legislation, rules, policies and
instruments of applicable regulatory authorities.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Chairman:</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 0pt">The members of the Board shall elect a Chair from among the members of the Board and the Chair
shall preside at all meetings of the Board. The Chair of the Board shall be responsible for
leadership of the Board, including preparing or approving the agenda, presiding over the meetings,
and making board assignments.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Lead Director:</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 0pt">The independent members of the Board shall elect a Lead Director from among the independent members
in the event the Chair of the Board is not independent. The Lead Director&#146;s role is to ensure the
independence of the Board in the discharge of its responsibilities. In this regard, the Lead
Director, individually or with the support of the committees and the Chairman/President and Chief
Executive Officer, shall facilitate the selection of committee members and chairs, shall prepare or
approve board meeting and planning meeting agendas, shall assess the format and adequacy of
information provided to directors and the effectiveness of board meetings. The Lead Director shall
also consult directly with other directors on issues of board independence or dissent, conflicts of
interest of the Chairman/President and Chief Executive Officer, or personal liability matters.</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">The Board operates by delegating certain of its authorities to management and by reserving certain
powers to itself. The Board retains the responsibility of managing its own affairs including
selecting its Chairman, nominating candidates for election to the board, constituting
committees of the full Board and determining compensation for the directors. Subject to the
Articles and By-Laws of the Corporation and the <I>Business Corporations Act </I>(Alberta), the Board may
constitute, seek the advice of and delegate powers, duties and responsibilities to committees of
the Board. The Board may establish ongoing committees of the Board with specific mandates and
obligations to report to the entire Board, as well as establish <I>ad hoc </I>committees to deal with
particular issues that might arise from time to time. The Board has presently established the
following committees: the Audit Committee, the Corporate Governance and Nominating Committee and
the Compensation Committee.</DIV> </DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<P align="center" style="font-size: 10pt"><!-- Folio -->- 21 -<!-- /Folio -->

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Responsibilities</B></TD>
</TR>

</TABLE>
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">The Board&#146;s fundamental objectives are to enhance and preserve long-term shareholder value, to
ensure the Corporation meets its obligations on an ongoing basis and that the Corporation operates
in a reliable and safe manner. In performing its functions, the Board should also consider the
legitimate interests its other stakeholders such as employees, customers and communities may have
in the Corporation. In broad terms, the stewardship of the Corporation involves the Board in
strategic planning, risk management and mitigation, senior management determination, communication
planning and internal control integrity.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 0pt">The Board is essentially accountable to shareholders. In pursuing its objectives, the Board
recognizes that the Corporation affects and is affected by many stakeholders. The Board will take
these relationships into consideration in discharging its responsibilities, but these relationships
do not change the nature of the Board&#146;s accountability.
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Specific Duties</B></TD>
</TR>

</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>LEGAL REQUIREMENTS</B>
</DIV>


<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Board has the oversight responsibility for meeting the Corporation&#146;s legal
requirements and for properly preparing, approving and maintaining the Corporation&#146;s documents
and records.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Board has the statutory responsibility to:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="10%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(i)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>manage the business and affairs of the Corporation;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="10%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(ii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>act honestly and in good faith with a view to the best interests of the
Corporation;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="10%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(iii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>exercise the care, diligence and skill that responsible, prudent people would
exercise in comparable circumstances; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="10%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(iv)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>act in accordance with its obligations contained in the <I>Business Corporations Act</I>
(Alberta) and the regulations thereto, the Articles and By-Laws of the Corporation, and
other relevant legislation and regulations.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(c)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Board has the statutory responsibility for considering the following matters as a full
Board which in law may not be delegated to management or to a committee of the Board:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="10%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(i)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>any submission to the shareholders of a question or matter requiring the approval
of the shareholders;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="10%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(ii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the filling of a vacancy among the Directors;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="10%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(iii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the issuance of securities; </TD>
</TR>
<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="10%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(iv)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the declaration of dividends;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="10%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(v)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the purchase, redemption or any other form of acquisition of shares issued by the
Corporation;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="10%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(vi)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the payment of a commission to any person in consideration of his/her purchasing
or agreeing to purchase shares of the Corporation from the</TD>
</TR>



</TABLE>
</DIV></DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<P align="center" style="font-size: 10pt"><!-- Folio -->- 22 -<!-- /Folio -->

<DIV style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="10%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Corporation or from any other person, or procuring or agreeing to procure
purchasers for any such shares;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="10%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(vii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the approval of management proxy circulars;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="10%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(viii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the approval of the audited annual financial statements;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="10%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(ix)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the adoption, amendment or repeal of by-laws; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="10%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(x)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>review and approve all securities offering documents (including documents
incorporated therein by reference) of the Corporation.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>INDEPENDENCE</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(d)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Board shall have the responsibility to:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="10%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(i)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV align="justify">implement appropriate structures and procedures to permit the Board to function
independently of management;</DIV></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="10%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(ii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV align="justify">schedule meetings of the independent board members separately from management and
management directors as part of each regularly scheduled board meeting;</DIV></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="10%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(iii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV align="justify">implement a system which enables an individual director to engage an outside
advisor at the expense of the Corporation in appropriate circumstances; and</DIV></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="10%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(iv)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV align="justify">provide an orientation and education program for newly appointed members of the
Board.</DIV></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="10%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(v)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV align="justify">In order to allow the Board to function independently of management during the
period of time that the Chairman of the Board is also the Chief Executive Officer of
the Corporation, the position of Lead Director shall be instituted. In this regard,
the Lead Director, individually or with the support of the Corporate Governance and
Nominating Committee, will consult with the Chairman/CEO on selection of the committee
members and chairs, board meeting and planning meeting agendas, the format and
adequacy of information provided to directors and the effectiveness of meetings of the
Board. The Lead Director will also consult directly with other directors on issues of
board independence or dissent, conflicts of interest of the Chairman/CEO, or personal
liability matters. The Lead Director will also participate
with the members of the Compensation Committee evaluating the performance of the CEO.</DIV></TD>
</TR>


</TABLE>
</DIV></DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<P align="center" style="font-size: 10pt"><!-- Folio -->- 23 -<!-- /Folio -->

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>STRATEGY DETERMINATION</B></DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(e)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Board shall:</TD>
</TR>

</TABLE></DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="10%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(i)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV align="justify">adopt and annually review a strategic planning process and approve the corporate
strategic plan, which takes into account, among other things, the opportunities and
risks of the business; and</DIV></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="10%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(ii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV align="justify">annually review operating and financial performance results relative to
established strategy, budgets and objectives.</DIV></TD>
</TR>

</TABLE></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>MANAGING RISK</B></DIV>


<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(f)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV align="justify">The Board has the responsibility to understand the principal risks of the business in
which the Corporation is engaged, to achieve a proper balance between risks incurred and the
potential return to shareholders, and to confirm that there are systems in place which
effectively monitor and manage those risks with a view to the long-term viability of the
Corporation.</DIV></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(g)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV align="justify">The Board shall review the amount and terms of any insurance to be obtained or maintained
by the Corporation with respect to risks inherent in its operations and potential liabilities
incurred by the directors or officers in the discharge of their duties and responsibilities.</DIV></TD>
</TR>

</TABLE></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>APPOINTMENT, TRAINING AND MONITORING OF SENIOR MANAGEMENT</B></DIV>


<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(h)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Board shall:</TD>
</TR>

</TABLE></DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="10%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(i)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV align="justify">appoint the Chief Executive Officer (&#147;CEO&#148;), the Chief Financial Officer and
senior officers, approve (upon recommendations from the Compensation Committee)
their compensation, and monitor the CEO&#146;s performance against a set of mutually
agreed corporate objectives directed at maximizing shareholder value;</DIV></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="10%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(ii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV align="justify">ensure that a process is established that adequately provides for succession
planning including the appointment, training and monitoring of senior management;</DIV></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="10%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(iii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV align="justify">establish limits of authority delegated to management through the annual
business plan; and</DIV></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="10%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(iv)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV align="justify">implement and monitor an appropriate Code of Ethics for all directors, officers
and employees of the Corporation.</DIV></TD>
</TR>

</TABLE></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>REPORTING AND COMMUNICATION</B></DIV>


<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(i)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV align="justify">The Board has the responsibility to:</DIV></TD>
</TR>

</TABLE></DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="10%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(i)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV align="justify">verify that the Corporation has in place policies and programs to enable the
Corporation to communicate effectively with its shareholders, other stakeholders and
the public generally;</DIV></TD>
</TR>



</TABLE></DIV></DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<P align="center" style="font-size: 10pt"><!-- Folio -->- 24 -<!-- /Folio -->

<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="10%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(ii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV align="justify">verify that the financial performance of the Corporation is
adequately reported to shareholders, other security holders and regulators
on a timely and regular basis;</DIV></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="10%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(iii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV align="justify">verify that the financial results are reported fairly and in
accordance with generally accepted accounting standards;</DIV></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="10%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(iv)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV align="justify">verify the timely reporting of any other developments that have a
significant and material impact on the value of the Corporation; and</DIV></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="10%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(v)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV align="justify">report annually to shareholders on its stewardship of the affairs of
the Corporation for the preceding year.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>MONITORING AND ACTING</B>
</DIV>


<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(j)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV align="justify">The Board has the responsibility to:</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="10%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(i)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV align="justify">review and approve the Corporation&#146;s financial statements and oversee
the Corporation&#146;s compliance with applicable audit, accounting and
reporting requirements;</DIV></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="10%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(ii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV align="justify">verify that the Corporation operates at all times within applicable
laws and regulations to the highest ethical and moral standards;</DIV></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="10%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(iii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV align="justify">approve and monitor compliance with significant policies and
procedures by which the Corporation is operated;</DIV></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="10%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(iv)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV align="justify">monitor the Corporation&#146;s progress towards its goals and objectives
and to revise and alter its direction through management in response to
changing circumstances;</DIV></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="10%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(v)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV align="justify">take such action as it determines appropriate when performance falls
short of its goals and objectives or when other special circumstances
warrant; and</DIV></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="10%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(vi)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV align="justify">verify that the Corporation has implemented adequate internal control
and information systems which ensure the effective discharge of its
responsibilities.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">5.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Other Activities</B></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV align="justify">The Board shall prepare and distribute the schedule of Board meetings for each
upcoming year.</DIV></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV align="justify">The Board may perform any other activities consistent with this Mandate, the
By-Laws of the Corporation and any other governing laws as the Board determines
necessary or appropriate.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Date of Mandate</B></TD>
</TR>

</TABLE>
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">This Mandate was initially approved by the Board on September&nbsp;3, 1999. Subsequent to that date, the
Board has amended and restated this Mandate on each of December&nbsp;13, 2002, April&nbsp;23, 2003 and March
5, 2004. This Mandate is effective from and after December&nbsp;13, 2005.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio --><!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: Helvetica,Arial,sans-serif">

<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>EXHIBIT 3</B>
</DIV>

<DIV align="left">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="96%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%"></TD>
    <TD width="5%"></TD>
    <TD width="47%"></TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="left"><IMG src="o40024o4002410.gif" alt="(ONCOLYTICS LOGO)"></TD>
    <TD>&nbsp;</TD>
    <TD align="right"><IMG src="o40024o4002411.gif" alt="(COMPUTERSHARE LOGO)"></TD>
</TR>
<!-- End Table Body -->
</TABLE></DIV>


<DIV align="right" style="font-size: 10pt; margin-top: 12pt; margin-right: 4%">9th Floor, 100 University Avenue<BR>
Toronto, Ontario M5J 2Y1<BR>
www.computershare.com</DIV>


<DIV align="left" style="font-size: 9pt; margin-top: 30pt; margin-left: 50%"><B>Security Class</B></DIV>

<DIV align="left" style="font-size: 9pt; margin-top: 6pt; margin-left: 50%"><B>Holder Account Number</B></DIV>

<DIV align="right" style="font-size: 6pt; margin-top: 50pt">-&nbsp;-&nbsp;-&nbsp;-<BR>
&nbsp;Fold&nbsp;</DIV>


<DIV align="left" style="font-size: 12pt; margin-top: 12pt"><B>Form
of Proxy &#150; Annual and Special Meeting to be held on May&nbsp;7, 2008</B></DIV>


<DIV align="left" style="font-size: 12pt; margin-top: 12pt"><B>This Form of Proxy is solicited by and on behalf of Management.</B></DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Notes to proxy</B></DIV>


<DIV style="margin-top: 1pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 8pt; color: #000000; background: transparent">
    <TD width="2%" nowrap align="left">1.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV align="left"><B>Every holder has the right to appoint some other person or company of their choice, who need
not be a holder, to attend and act on their behalf at the meeting. If you wish to appoint a
person or company other than the persons whose names are printed herein, please insert the
name of your chosen proxyholder in the space provided (see reverse).</B></DIV>
</TD>
    <TD width="4%" style="background: transparent">&nbsp;</TD>
</TR>

<TR>
    <TD style="font-size: 3pt">&nbsp;</TD>
</TR>
<TR valign="top" style="font-size: 8pt; color: #000000; background: transparent">
    <TD width="2%" nowrap align="left">2.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV align="left">If the securities are registered in the name of more than one owner (for example, joint
ownership, trustees, executors, etc.), then all those registered should sign this proxy. If
you are voting on behalf of a corporation or another individual you may be required to provide
documentation evidencing your power to sign this proxy with signing capacity stated.</DIV>
</TD>
    <TD width="4%" style="background: transparent">&nbsp;</TD>
</TR>

<TR>
    <TD style="font-size: 3pt">&nbsp;</TD>
</TR>
<TR valign="top" style="font-size: 8pt; color: #000000; background: transparent">
    <TD width="2%" nowrap align="left">3.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV align="left">This proxy should be signed in the exact manner as the name appears on the proxy.</DIV>
</TD>
    <TD width="4%" style="background: transparent">&nbsp;</TD>
</TR>

<TR>
    <TD style="font-size: 3pt">&nbsp;</TD>
</TR>
<TR valign="top" style="font-size: 8pt; color: #000000; background: transparent">
    <TD width="2%" nowrap align="left">4.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV align="left">If this proxy is not dated, it will be deemed to bear the date on which it is mailed by
Management to the holder.</DIV>
</TD>
    <TD width="4%" style="background: transparent">&nbsp;</TD>
</TR>

<TR>
    <TD style="font-size: 3pt">&nbsp;</TD>
</TR>
<TR valign="top" style="font-size: 8pt; color: #000000; background: transparent">
    <TD width="2%" nowrap align="left">5.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV align="left"><B>The securities represented by this proxy will be voted as directed by the holder,
however, if such a direction is not made in respect of any matter, this proxy will be voted as</B>
<B>recommended by Management.</B></DIV>
</TD>
    <TD width="4%" style="background: transparent">&nbsp;</TD>
</TR>

<TR>
    <TD style="font-size: 3pt">&nbsp;</TD>
</TR>
<TR valign="top" style="font-size: 8pt; color: #000000; background: transparent">
    <TD width="2%" nowrap align="left">6.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV align="left">The securities represented by this proxy will be voted or withheld from voting, in accordance
with the instructions of the holder, on any ballot that may be called for and, if the holder
has specified a choice with respect to any matter to be acted on, the securities will be voted
accordingly.</DIV>
</TD>
    <TD width="4%" style="background: transparent">&nbsp;</TD>
</TR>

<TR>
    <TD style="font-size: 3pt">&nbsp;</TD>
</TR>
<TR valign="top" style="font-size: 8pt; color: #000000; background: transparent">
    <TD width="2%" nowrap align="left">7.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV align="left">This proxy confers discretionary authority in respect of amendments to matters identified in
the Notice of Meeting or other matters that may properly come before the meeting.</DIV>
</TD>
    <TD width="4%" style="background: transparent">&nbsp;</TD>
</TR>

<TR>
    <TD style="font-size: 3pt">&nbsp;</TD>
</TR>
<TR valign="top" style="font-size: 8pt; color: #000000; background: transparent">
    <TD width="2%" nowrap align="left">8.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV align="left">This proxy should be read in conjunction with the accompanying documentation provided by
Management.</DIV>
</TD>
    <TD width="4%" style="background: transparent">&nbsp;</TD>
</TR>

</TABLE></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Proxies submitted must be received by 4:30 pm, Eastern Time, on Monday, May&nbsp;5, 2008.</B></DIV>

 <DIV align="right" style="font-size: 6pt; margin-top: 12pt">-&nbsp;-&nbsp;-&nbsp;-<BR>
Fold&nbsp;</DIV>




<DIV align="left" style="font-size: 12pt; margin-top: 12pt"><B>VOTE USING THE TELEPHONE OR INTERNET 24 HOURS A DAY 7 DAYS A WEEK!</B></DIV>


<DIV align="left">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="96%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">

<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><IMG src="o40024o4002412.gif" alt="(TELEPHONE LOGO)"></DIV></TD>
    <TD>&nbsp;</TD>

<TD align="left" valign="top"><IMG src="o40024o4002413.gif" alt="(INTERNET LOGO)">
</TD>
    <TD>&nbsp;</TD>

<TD align="left" valign="top"><IMG src="o40024o4002414.gif" alt="(ELECTRONICAL LOGO)"></TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><DIV style="margin-left:21px; text-indent:-21px"><B><B>&#149;</B></B>&nbsp;&nbsp;&nbsp;&nbsp;Call the number listed BELOW
from a touch tone telephone.<br>
<B>1-866-732-VOTE (8683)&nbsp;Toll Free</B></DIV></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="margin-left:21px; text-indent:-21px"><B><B>&#149;</B></B>&nbsp;&nbsp;&nbsp;&nbsp;Go to the
following web site:<br>
www.investorvote.com</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="margin-left:21px; text-indent:-21px"><B>&#149;</B>&nbsp;&nbsp;&nbsp;&nbsp;You can enroll to
receive future
securityholder
communications
electronically, by
visiting<br>
www.computershare.com - click &#147;Enroll
for e-delivery&#148;
under the
Shareholder
Services menu.</DIV></TD>
</TR>
<!-- End Table Body -->
</TABLE></DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 30pt"><B>If you vote by telephone or the Internet, DO NOT mail back this proxy.</B></DIV>

<DIV align="left" style="font-size: 8pt; margin-top: 12pt"><B>Voting by mail </B>may be the only method for securities held in the name of a corporation or
securities being voted on behalf of another individual.</DIV>

<DIV align="left" style="font-size: 8pt; margin-top: 6pt"><B>Voting by mail or by Internet </B>are the only methods by which a holder may appoint a person as
proxyholder other than the Management nominees named on the reverse of this proxy. Instead of
mailing this proxy, you may choose one of the two voting methods outlined above to vote this proxy.</DIV>

<DIV align="left" style="font-size: 8pt; margin-top: 12pt"><B>To vote by telephone or the Internet, you will need to provide your CONTROL NUMBER, HOLDER ACCOUNT
NUMBER and ACCESS NUMBER listed below.</B></DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="29%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="39%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="22%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>CONTROL NUMBER</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>HOLDER ACCOUNT NUMBER</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>ACCESS NUMBER</B></TD>
</TR>
<!-- End Table Body -->
</TABLE></DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio --></DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: Helvetica,Arial,sans-serif">

<DIV>
<TABLE style="font-size: 25pt" cellspacing="0" border="0" cellpadding="0" width="96%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%"></TD>
    <TD width="5%"></TD>
    <TD width="47%"></TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&#043;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&#043;</TD>
</TR>
<!-- End Table Body -->
</TABLE></DIV>

<DIV>
<TABLE style="font-size: 8pt" cellspacing="0" border="0" cellpadding="0" width="96%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="45%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="20%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="font-size: 10pt">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Appointment of Proxyholder</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>I/We, being holder(s) of Oncolytics Biotech Inc. hereby appoint:</B>
<br>Bradley G. Thompson, or failing him, Douglas A. Ball</DIV></TD>
    <TD>&nbsp;</TD>
    <TD><B>OR</B></TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><B>Enter the name of
the person you are
appointing if this
person is someone
other than the
foregoing.</B></TD>
    <TD>&nbsp;</TD>
    <TD valign="top" style="font-size: 18pt"><DIV style="border: 1px solid #000000">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE></DIV>

<DIV align="left" style="margin-top: 12pt; margin-right: 4%; font-size: 8pt">as my/our proxyholder with full power of substitution and to vote in accordance with the following
direction (or if no directions have been given, as the proxyholder sees fit) and all other matters
that may properly come before the Annual and Special Meeting of <B>Oncolytics Biotech Inc. </B>to be held
at the Yale Club, 50 Vanderbilt Ave., New York, NY on May&nbsp;7, 2008 at 9:00 am and at any adjournment
thereof.</DIV>

<DIV style="font-size: 8pt; margin-top: 12pt"><B>VOTING RECOMMENDATIONS ARE INDICATED BY <font style="color:white; background:#111111">HIGHLIGHTED TEXT</font> OVER THE BOXES.</B></DIV>


<DIV style="font-size: 10pt; margin-top: 18pt"><B>1. Election of Directors</B></DIV>


<DIV style="margin-top: 12pt; margin-right: 4%; font-size: 8pt">The nominees proposed by Management are: Bradley G. Thompson, Douglas A. Ball, William A. Cochrane,
Jim Dinning, Ed Levy,<BR>
 J. Mark Lievonen, Robert B. Schultz, Fred A. Stewart and Ger van Amersfoort.</DIV>

<DIV align="right" style="font-size: 6pt; margin-top: 12pt">-&nbsp;-&nbsp;-&nbsp;-<BR>
&nbsp;&nbsp;Fold&nbsp;</DIV>

<DIV>
<TABLE style="font-size: 8pt" cellspacing="0" border="0" cellpadding="0" width="96%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="84%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap><font style="color:white; background:000000"><B>For</B></font></TD>
    <TD>&nbsp;</TD>
    <TD nowrap><B>Withhold</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Vote FOR or WITHHOLD for all nominees proposed by Management</DIV></TD>
    <TD>&nbsp;</TD>
    <TD valign="top" style="font-size: 20pt"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD valign="top" style="font-size: 20pt"><FONT face="Wingdings">&#111;</FONT></TD>
</TR>
<!-- End Table Body -->
</TABLE></DIV>


<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<DIV style="width: 96%; border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV></DIV>
<DIV style="margin-top: 6pt">
<TABLE style="font-size: 8pt" cellspacing="0" border="0" cellpadding="0" width="96%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="84%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap><font style="color:white; background:000000"><B>For</B></font></TD>
    <TD>&nbsp;</TD>
    <TD nowrap><B>Withhold</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top" style="font-size: 10pt"><DIV style="margin-left:0px; text-indent:-0px"><B>2. Appointment of Auditors</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Appointment of Ernst &#038; Young LLP, Chartered Accountants,
as Auditors of the Corporation for the ensuing year and
authorizing the Directors to fix their remuneration.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD valign="top" style="font-size: 20pt"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD valign="top" style="font-size: 20pt"><FONT face="Wingdings">&#111;</FONT></TD>
</TR>
<!-- End Table Body -->
</TABLE></DIV>


<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<DIV style="width: 96%; border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV></DIV>

<DIV style="margin-top: 18pt">
<TABLE style="font-size: 8pt" cellspacing="0" border="0" cellpadding="0" width="96%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="84%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap style="font-size: 10pt"><B>3. Stock Option Plan</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap><font style="color:white; background:000000"><B>For</B></font></TD>
    <TD>&nbsp;</TD>
    <TD nowrap><B>Against</B>&nbsp;&nbsp;&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV align="left">BE IT RESOLVED, as an ordinary resolution of the
shareholders of Oncolytics Biotech Inc. (the
&#147;Corporation&#148;), that the amendments to the stock option
plan of the Corporation to modify the general amendment
provision, provide for the extension of options that
expire during a blackout period and expand the definition
of eligible participants, as approved by the Board of
Directors on March&nbsp;5, 2008 and described in the
management proxy circular of the Corporation, dated March
20, 2008, be and the same are hereby approved, ratified
and confirmed, without amendment.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD valign="top" style="font-size: 20pt"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD valign="top" style="font-size: 20pt"><FONT face="Wingdings">&#111;</FONT>&nbsp;&nbsp;&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE></DIV>


<DIV align="right" style="font-size: 6pt; margin-top: 12pt">-&nbsp;-&nbsp;-&nbsp;-<BR>
&nbsp;&nbsp;Fold&nbsp;</DIV>

<DIV style="margin-top: 24pt">
<TABLE style="font-size: 8pt" cellspacing="0" border="0" cellpadding="0" width="96%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="63%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="17%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top" style="font-size: 10pt" nowrap><DIV style="margin-left:0px; text-indent:-0px"><B>Authorized Signature(s) - This section must be completed</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><B>Signature(s)</B></TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><B>Date</B></TD>
</TR>
<TR valign="bottom">
    <TD valign="top" style="font-size: 10pt"><B>for your instructions to be executed.</B></TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 5pt"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">I/We authorize you to act in accordance with my/our
instructions set out above. I/We hereby revoke any
proxy previously given with respect to the Meeting.
<B>If no voting instructions are indicated above, this
Proxy will be voted as recommended by Management.</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="border: 1px solid #000000; font-size: 18pt">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD valign="top" style="font-size: 18pt"><u>MM/DD/YY</u></TD>
</TR>
<!-- End Table Body -->
</TABLE></DIV>


<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<DIV style="width: 96%; border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV></DIV>

<DIV style="margin-top: 50pt">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="96%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="10%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="50%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="bottom" style="font-size:18pt"><DIV style="margin-left:0px; text-indent:-0px"><FONT face="Wingdings">&#110;</font></DIV></TD>
    <TD>&nbsp;</TD>
    <TD valign="bottom">0 3 7 7 9 2</TD>
    <TD>&nbsp;</TD>
    <TD valign="bottom" align="center">A R 0</TD>
    <TD>&nbsp;</TD>
    <TD valign="bottom" nowrap align="right">O N C Q</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom" style="font-size:30pt">&#043;</TD>
</TR>
<!-- End Table Body -->
</TABLE></DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio --></DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>o40024o4002401.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 o40024o4002401.gif
M1TE&.#EAB`(\`^8``#T]/75U=4%!0924E"DI*7%Q<9>7E^[N[B0D))*2DIB8
MF$5%1>SL[/#P\(^/C]#0T)J:FM+2TIR<G.3DY(Z.CNKJZNCHZ,[.SN;FYFUM
M;<K*RIZ>GJ:FIM34U$E)2:"@H.'AX8N+B]_?WZ2DI,S,S,C(R-W=W?___\;&
MQJ*BHDU-3=O;VXJ*BO+R\M;6UL/#PVEI:5%14:BHJ#0T-,+"PMG9V8B(B-C8
MV#$Q,65E9:JJJBXN+L#`P#`P,&%A838V-E5555U=78:&AJRLK%E9682$A(*"
M@JZNKH"`@#@X.+"PL'U]?;Z^OGQ\?/3T]#HZ.K*RLBPL++2TM'EY>;R\O+BX
MN/GY^7=W=[:VMKJZNO;V]CPY.DQ)25E75U-34S`M+3\_/R<F)D='1RPI*D]/
M3S4R,AX>'CDV-CLX.4-#0R\L+#<T-3,P,<?'QY&/CW-S<YV=G:NKJ[FYN8.!
M@3X[.S8S-$M+2R$A(3HW."HG*#(O,"XK+$(_0%935%)/4",?("'Y!```````
M+`````"(`CP#``?_@'^"@X2%AH>(B8J+C(V.CY"1DI.4E9:7F)F:FYR=GI^@
MH:*CI*6FIZBIJJNLK:ZOL+&RL[2UMK>XN;J[O+V^O\#!PL/$Q<;'R,G*R\S-
MSL_0T=+3U-76U]C9VMO<W=[?X.'BX^3EYN?HZ>KK[.WN[_#Q\O/T]?;W^/GZ
M^_S]_O\``PH<2+"@P8,($RI<R+"APX<0(TJ<2+&BQ8L8,VK<R+&CQX\@0XH<
M2;*DR9,H4ZI<R;*ERY<P8\J<2;.FS9LX<^K<R;.GSY]`@PH=2K2HT:-(DRI=
MRK2ITZ=0HTJ=2K6JU:M8LVK=RK6KUZ]@PXH=2[:LV;-HTZI=R[:MV[=P_^/*
MG4NWKMV[>//JW<NWK]^_@`,+'DRXL.'#B!,K7LRXL>/'D"-+GDRYLN7+F#-K
MWLRY<\<N)T*+'DVZM.G3J%.K7LVZM>O7L&/+GDV[MNW;N'/KWKV[*A<-P(,+
M!TYBN/'CR),K5UY\N?/DS9]+GTZ]NO7KV+-KW\Z]NW?N)8)?>'#A0G$2%R*X
MJ+&BO0D3*UQTZ!#A@8;S$TY41;!C1X_^/>#P7W\[S+`##@0>B,."#"[XGX,*
M"N@?@0LFF""$%E+8WPP]1$%@@`AJ.&%_#/8P8()1>&A@A1YF^"&`)(8((X`G
M^@=AC1;BZ&*+._"HXX!1Z.CBBSQFF.*..Q[9(_^/15J8XI-01HFBDD-&00"4
M4U))(`%7*AGEEQZFR.652_;8)9A?=AE&EU>.Z>:3;IX)YIA1QNGFFD$"L,`"
M:20QPQ-I`)%#!@4$<,45`1001!!`>"#`#S\4"(=^5/'WH8DU(E@CIB"6J."#
M$EI888*88CBDICG*Z!^.G0HI:HBNCCC@J!FR:NJ0G`;X7Y,NQCKBD+7VIR6P
M!/**I+#$#BOLDUDJ6RR:6"*[`Y?,/HOFDG0N"6V+5IX9IYAV4@LNG="&:RZU
M?P(`A@<J+/"$`"H0D4,!;P30!!)+3/&&#T&TNP```,P@``>43H7`B:%JJ.JK
MGMXX8*:J=GIKK3(^7/'_PC%6G".%`@8HZJZ78DJQK0GC2BJP7O[:*['!5IDL
MRT;"G*264B:[;;'65GOSN&%:V?.V<(J;XIIR`@WTN7'VD(08,33=+@#P$D%H
M`%1/<>\4!?C0Z`)BK.M!#'$4+)6E-N;J<<<FYL@I@!U?2*.#)ZY=Z]H:IQHB
MAB)G"&O&NGX8ZL-IFZPVJRK+O&S,ER)^LN$L^\CXXU,F2,#AD&O[K)'*&@VG
MA]Z"&R:=7&)+KN90"NUYT`B$\60/`-@1PZ(^D+&`!T`$D0/55QBQ1!-++!%`
M!C[$H(('Q*N@`MAB1V6IQ`TV/S'%M!XX:X.LYLVW]'W/?;>GP'(8K,<T<LK@
M_^(L9TJB](\3+BW;T3,9I)"`&\YCR9`;V[B3O!IK?_[5YDRZMT5[$^DV5ZZB
ME6Y,")C<#Y[@`1]D8%`PZ-?7;%>`*5BM"/C*%]:TI@([J(`,,:@=%)('%?XP
M+U<XX!#WYF8B!BDI5,W#40IG8"".2:AC]'-;A-"6J?\$KDSLLYZ-HE<^(=Y-
MB*>*(;#$%SWU5>Y83GJBS7#6(_GUSUG\&]:7A&7`-)')3`(<8+B"9KHZ(7`'
MK8N!`PM`J`P$(81!\$$%D<"[)=`Q45?(6A>:!@0@$"&.4B#A4P[FO!K1,$+P
M<QZL,*1$4AD10CC4T8)FL+U"4NA!/QKBK3JU,KW=:O][JV)<W"C'/+C%+WN]
MPE'_HKB^+S9.9_KCEH=`5D7%&6ERML3<D08XI=$-<$YC/%T!PQ`&!,S@=8.B
M6@#>``,?^&!0;]@='7N'-1CDP)I!(((VM1G'("A!D$XA)/<"=TB\F3*%"'(0
M#BG)/5/.B$8D`M$.?8A#!G$(1*U:80I#.<3P_5"32!SEIU#(-ALYTE=+-%NN
MRH;*N4$1951\:$2KU"20=:AR^I/9+['4+=-I:Z/?.E?0.LJEU"'@!X+*P*&H
M]L!!S5$(2,`7O@H006WVL0N+ZJ8SO[D?6DF,1"NZ83UQB#ZAYE-`#<I84J7G
M*52:BI+RE"?U8J0@]K'-8HK_C&'?/#;+%NKSD\^3X@JEF",LOO.A'L)8+:V%
MOY8]T7W[VR@9NRC7S4V+@$(S%S'#H`(8%*H)O)M",W-PA2D4P0A%$,)AD3"%
M!P(A!B#TPA^OF0-GYB"050D#)?TVOJI"<GHR&I4I13;#G^X0;99<E<421$.D
M^E.U9:MJ/UNER:RR\T8(:M$);4BJ$B&Q<F,E:ZEJJ:HFV4]RLH4<#I2E5OE9
M<:/8VJ48@^DS*ZFNNGD-%S%QL,9E3F%W&?!K3&T@!".0UPA("$`S8V`'=OG1
M!S"(('PO"\ZF(`"U](255S<UU5')\T`O.JU2*PG5V`:(AINET&;-]R+1+A*I
M68TP_PSI2=S;)JRSJU(D^7[KR1S*3&Y4Y6>6+$<YM;%2H\=]ZW-]]M%K?719
MFC/72*\T@Q\LMUMP(B:7B!:%'Y"A4%=H0J&^>Z@EV*`(+%`L"VR@NP+D0()?
MP^DS82"O!V*AODPQ(5(WJ\[F^7.1X&M5F(':H-9J-:B13*%7'=S"O)GM;3!T
MK7]-6T,BPG.UK_W4A9XG-WS^DZP<*URJ_@QH$\<6P+,LW^4@6C^YE@E,,$;3
MM\CH(0"DP0-@"!".2;HFU0%`:E:S6A.^:P3T%B$$-F#!DE%=!*Q5ME$JJ%T<
MG3EE&&"V4N*#:H2'&#C3EK*VU&MMI^X)55!-TGO]E.U43_\X/1^:V:#L@V&(
M/P9@@_JYV7M.6.":ZN5"[UG0O0UK@&$F0_+E-DB,HU+::O:XNCZ:W5L\H)UT
M3``<P(L,7O#`$V9`TG`)(*7?78(1REN$Q`HAU:H.P9(/ZVH?$"&$1*#UH@9%
MJ"OW-+^[;N%M'V3AM%%ORT,]\)H;66;?5MO!N+4D))^MJU)52,P*_>]5)WGA
MB/FVS8IT>7.)%:NT^8J3WBZ<*J>$4"2M.UJ%CE9U=[D^Z<9[KF,J)@%F``!V
M2?;)*@##M,[UA"`0J@!(0&RJ$1X""IB=`B%(.Y.-T/"<2GQ1,,@`H:J`Y:5H
M5E/IS"I06WO(4G*\G'GW,MQ*1$/_C!\;D2>OI(28C<XX>ZR4%>KR@&G>VP\E
M.+F0#Y&9VVGG\(T,BC_'L**K;3U?66E$*2KZ.[L:])EQ$4HG2O21RO@S3O/X
M!V+P@!?F%0"L$8$,/QA3?Z).@+X.^<@V("\+*."`!#B@^0E`.]H5*V1GSCJG
M?W1@O0)`]_T`V[:08N2Q(5QF?J,3P4EMO.@/O'$;-FQ49L9SY/6>^:2:-GQJ
MKBH^A?K@SBYUG&S36M1V56=E,EK"8`GU,DCB80^S880&,\Z"7'?%+$B7.,>U
M12UV0%&``%$@``L@`*]3`$;0?!0@6#G@`:?W!`"P=6'P`W)T!4A@`PIG=B&0
M`#9H@P/`_WPDF'Q%(&25-5^T-F5?EP&W9C#?)V'H<UKD9T\&(G/Y='FJ!7E,
MU%_JI&N+-U19U0-6F'%C=6!_@W=(!2I8Y7_O=V'(]E_H%#=UPW.=5("MESA+
M1#YDE6+2(B45>&*Z!$O0HEE]%5XP\`8VH``2L`$&$%-7X`,!`RAI@`,[Y@$P
M,`6(Q0(YR`(A`'TVR'QEQWP4L'!"%E]REP.4%5]Q5P"DV'V5PFLCUVW9,T[4
M@T\V@F"W=5O9)F%9N$-FUG[U5W*Y"(:'YH6NJ$D$N%6-=&VU4D/@DX;Q)(>"
MLS'>]H#IPXQ21(<SDS\2U2P:F"9AD`0^<`5"L&0RF``#8``0X/\`B14`.0`&
M./`#`-,#5](#1%``O!.#-%B#-QA]99=V9<>)I%@H-/5U;.17_VAQI^A4Z&=/
M$`9:G#5X*'=L`AAA[+2+D#1XL+AR-.<\?&=A&A95<^:%7[A/2;B*2S5MOT(_
M)!<Q,7=0;S8A%05B+N(PSAA03J1B'\96MK1*NO0LM'<D0-`$16`#:)>)FV@#
M33!P3@8`/;!`/V`E.```/F!!4V`#]DB"-S@`#E"#"K=\G(@HAT(H]5)8-#6*
M!2`'=:<4]V60BH1^OJB%#>.+'T=)WG.%%MEE51A_S!-_M65ANN999[EY#)E.
M;WF&8!B7Y"<D$9E:IV5XH-5FT?9.&@;_;-#H2..FC./V2/XD1)L2*[P2.$5"
M,V'2+"6&/]P20%QB!U/``D90=N1U6."5`523`S$`B_O&.C&0`V\`B<MG=C;X
M?,]W=F57E:IV9(PE:E-@*(B2*`_D5T0XEDE1EA5ID1S2=R#"3GM7(FV9AG!)
MBTKD<^I'E\UC80=2;&:#G8T9A2\GGO8$.*YX<[^8G5,U3PS5<B"I52,',PL#
M/T_4-NF#F2CC/F\(1G(R;S.0`ZEV:@X`4W3$1L[43$$@`'H"``S$)RH0!##0
M>_+H`#JHFQ;ZD_BX9.5%1V'7!/8R:LL47M<T=\J)%,S9>!IW>,CH'P\Y0X5W
M0N?WD$=HEDH$_Z/=B9&Q6)V*5TB[EG_:B4XUBH2[M4)^QIZ<EW)JJ)`Y!U"1
M&8=N!5RJ%S\;$X%-AU$VXT4(%`4JT`2I)@1IUSN,U4RTU@6-X@5`8#R+4F6]
MMP0]F786VIN[F7:J]IN*A5YV1$=.J4QL)'<9\`:F:#"IU7@(]IVA$HMN&9AJ
MQH3GY*/J]Z@I]`/%9I;1N824)UH3F7Z^-3YI*&PSA%IRJ2`;EWGY!3$AMU_P
MV5FZMJ3JZ3P`U6<<9I]0>BI3ZH8JN43+E2&X!&YS^)_WE0.J9H,&0`&'Q7;A
MQ5(YT$>S-E_S\EUAUXU+YIN5.*=UNG"+94>]`UC%:4%OX(]30`4G>O\4S"E#
MS6-C75:0A6>>9^F092:IH`)XS4F+E6J>#%-^.NH]4K5@C11NAMF6&+<A\_DI
MW2:2W9F*1`1F_`I/!?531W)N=N,K$J);JK<^,%90UFAZ/6,M!%!,`%``-M!\
M`S``"G=DH^:F2Y`U:!I'<0>*&4!JAX5PE(B/9V=V'*I8B\4[B*4[H78H>?1U
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M;B9B7"G&M\5"5QLK`!Y+`2$;L@G``L4J!-17+TX&7P506';4DT=V<)`;N73J
MC7=JN0/7H1]J08FRCT,&KCUEE@4IM9*Z<>F4>7SIOT@;M07,=ZP+59M7P#F'
M?O?*N^F7P.@*80`+E^T'J0I<EP?)5+B[JK\62C(GO`*KD`O585,XL!F&,-"F
ML.!S4'XSL2V\:"Z3_VYL\BT[0`9-4(.#FP"#*[[L6UX:E+_V8KF/2[YC![/P
MFV0V6[F.NUAAIZ?%236D^+.@2Q3&Q*B^RT[_.TE9Z[I\R<5=[+I3"W(.B9=;
MN"#AAV#L]ZFGNTZJBY:ZPKS2J815R\&P.Z-SV:_JJK;[FBKUVE3)R,+5]DY:
MZ$.+F3X[]Z0H,JL92"UD$@5)0`134(,*,+B#&P+NFYKH%5-BFEB)A7#)EWSD
M^[[52E[D2[X%I\KT:P2C-@53_`9O$&1`V[\,&<?H>HN%>D\<66.X?+6Z;*^_
M;'^^',9C/+4%DJX(YJZJA9U3Z+M,>YTYFHJOFX5+&W/"K)Z<M%MWF\)?5?]N
MV%-Z^!IM,CS#RYA+^QDT!8(#29!"*I`#7IH`$*``X+N),9O*-A!VH5RM"3>R
M-@NS_%RGHWQDCDO*B56RL*Q,;<H#5SP4A"3&N%S,N=Q:21`A$8VTO7R1`7S1
M$!R&,,K&W_F_.LJ0;0S!#GS+DWK+K(O2#WFT#7Q/>0RCPVLBNF:7DQ=AK`IL
M\&.UM:A_%S-@<3/.M45+Y;/(#86'G00F2I,$8#`#CE@`2R")\ZP`-]B;]JQJ
M2+Q\NXEVWCC*I1R_`YU\OUFG2(S*Y)M!(KI,L_RY/16C'%VZ94RU-&2N+.V6
MDOK1$*VZ6JS+QJS7I35#D)*I'/W+%>R\I061:.G_EPEVG<+6-]+<QB[*?XHJ
MGC`<:'IV(Y<BGVN+GEXU(\.66RKVPE!J/Z+=,_]!=0*0!@)`!`$@<"$P`!`0
MVP;@?)J8B3)[=KK)U:1<UC';U:,LT&0=Q`='7AJTN;TW:OQ;*1!\UXAZBV4\
M?GC=W,XMT1<YV!']T;,[T7GMUUO,W1DLM<A;?KHHI`/5EP/5Q1JGKXKWQB$I
M,?HJAGJ&,*8BA=$V,<QS/?UY/CP7*BF"5%"3>WSTB(GE``90X)<\`,Z7H5N-
MV\]WB;J-RF*]VZ<<T-Y8K9B+OU5C04U0RU2A6<M\UWN\W;=HKMX=Q\.&M.5$
MW2A^T3B:W=(MM2)MW6)L_TIQ+-XY!S<3J99[6<V3O6R2+:],Q,LGKE_IN7B\
ME9#M"7/\]7^BEU`YA$0R<EP"DE90LP!-XP7+"G:I-@#T'(Z#B^"6F.`86H\T
M*+]B';/Q^YMD9\HRF&11G-;?E=!9T-!"<7<BKH4_H(6$C6#M'-W1?=V"K=<[
M$'YU+6'='<=K+.,V_M+7#=>)[675O>(.S)V%U&LC=])$I.<Y]T/PZ8KR+9YC
M2&%PQD,HR9+F['I1CFY$UR-+209`0&M^99Q&AG8.X.4*T.4X^+TWN)NY+;FD
MO.9I1P$#/=P;FFJHEIKEI;.B9K*PG-Q3X>$:W9"2_N<LSMR^;.W5K><F#HL;
M??^1FN[H\1>IW&[2X\[B,E[CI1OCLJC`L]LPT(Q;`CB\<IG&K7CC8/A?9Z,I
MVLEQY%?"Y1E)93-)O5M%?V.Q%#)+BZRP0[*K40``LUDH5',OI88$W7BA"A#;
M\TR5M:[K8I[;<6JG9W[L6)W5E$BS$&[0E9LO`E=J3!93'/[LW5[C*B[I-&_2
MY^GMHFK=XS?N?T[&KZCS<5WCD!+8Y[[C.'U^SMEQ[[[2_@6I6-C'&MFD\W=#
M_+[-2ZC30XJPF9U(/R+#9*(G7H<$E*AJS/?;97>#%X_Q"!ZR7_Z]X-OQ]JQ\
MD`NFFHS/P1ZG)U_6JORF"9>:SBX5+8CNRYP$,;_GPWS_B\F\M+#H)XU.[C/@
M)Y$:P-$M^=0^D8RNUQ2LZ+?;-B57D>F=[DM_D?^.QGWLHP4VY'F'>&GFXT@J
MS8)WA<9V:!F60R9'454D`$'`1@&P?/5H@\'.?-^+\;'-]@5._&Z?F[L)W&!M
MITAL=KHYLKLMUK_??!G*:B\/^!M=^.)N^2L.[@R\S.F(M$E`^(0_\[?X!'[2
M[7I^E))_T87/[=A.0^,?V(0WUT1?]+?KJ08YTR$-"#@S,SB"@X>%B8D].STS
M/S,[AH2*ASV&BIF:.)>$C)*5D86@G)*7.*2).SN4BJN(C9BGA8Z?EXR"J(NK
MBY^-/;.VJ\,[45$$QC]!!6]3_T84#@D&!@/5(2P.T0/3$!`*W=7AT]79T0GG
M"0X4+.PV(>\L[D)"(?-"-A30V>OQ-D+M^!Q4@[:.0@@;19B<^,.PH<.'$"-*
MG$BQHL6+&#-JW,BQH\>&82`=&OD(T4B1)U$60DFRY"!)+0<]H:32),E$CT06
MFODC"<L?(H,>`CHT2<N5/SWERN624DRGJH#J*G0TU$A%G5I=S44,D29$LS*Q
M:M5K4Z8>45(MW8J3TR"JG&9!;<MIURI<Q'RI4JLJ[2]C?@EYR!``"0MT!A08
M2)<`FC@%<"1T\Q:NVK@!"<*=4Y?OG6=W#E@80<A"2!'0CAV\L\':!HMW%-`U
M9G>-1?\1(S06?MS-N[?OW\"#:PP#%IA+3">?$GK[:"5)E9.>&^W!LF5UHCE1
M`MV.?>C/[RQ7"NJY]>I-IC=S+O<:O6I5L^U?QB<+MY/9L&7AV\U$_ZLN8+'T
MYX@FP/0"#%YWH1++*'RA`HPQJT`XX`\^!#!%"-6<,PTULFWSC022=:.`8I5M
MB)EFZ>S3&3LLY&.:/_[,\YICLQE$&FSJU/;:-0<5D9MP0`8IY)!$]D:<=39%
M5]US0SVUI).$7.==2D8-0AYUD'!W75)6-NG5#^,]65)[<,UGTU%>H=G?)N;-
MD)53_6EEEH`+ZE?7G64>6&!;OU0B%BMG\:))(ZPL:.@HF_S_\HM]/P"0!!DY
M!""$`1!@)LUEF4WS#1QPB#BB8AM2,^(Y*);#V37_`'1:$?:P&H(YL[6SXXHP
MFI:J$#\6J>NNO/8*'`*3W*E<4](EX=,AQK:G74S;+;=EEMT=!0D.53HIU'/3
MDFG(M"X%Q6V79<;$B"=>GJ<F3E[)E29][`FK%)MXEM(@@>_JQXAQNMP4UIZN
M)$@++>/.<JB#<16LBT\]`?"$`!Z0X0,,-B0PXHF)F5AQ8A)LX`VHGWY*J0*9
M:59.BC;>P]HUJ[)ZFQ'8Y+/90??,NMIM2S1AA,JY^JKSSCSW_`>P5#G5W=!3
M;G=L2LQ9V^S149IWM);+31(MD\0B_SGL>LI)]9296P?-I-==HPLG>^=9E>A2
MJJ!M'W[PV9=@)'ZA[?4FCL`B2"?WCB(P,8+R<B\OD"2Q@``,DZ&"%T3XD,$5
M(7R\S62>=@S9!Q)\H]@WD'M#367HF&-0//?,@ZK*1:SLSFN<Q0-ZBZH)8002
ML,.^!!)&\*";S[CGKKMO")QTK)C8/N)3?$1M66[@5UNIY=3)-R\(T\U3#7ST
M))U"==C\K8M)F6!WJ=5;W%NUIIUU?1])GW'&^TF_=`]SRH$,TO*V@M0F(0`9
M9!`!`PPY^)!#!LZ0!HDVM8$"<HI3$H##!^`P(@B`"'(@JER&9-.Y;-0F1C)"
M2,IN<YH=>?_&,P:)36AN$[LE3.$*4VB"0G;'PA:ZL")'\LZ3EE0\Z!7->XCH
MCE&T`[SEC8E@31K/]:CGNVLQZVK,`Q^Z@H:=Z<7I+5*1"UVZ5QY+R*U\<7G?
M%=N&-DN`PCY^8IM_L%*@O`GJ7PH:Q@Q\`HQ&`6`!,<@!,P)0@#HZPP;;H`;&
M/C""$:3@`X`,Y`<TIH`0.7`#!V3@YF13CGRL@S6F*=UI(JE!#KJ&1;#)Q\@<
MX+K7R2X`H)P"%6[WPE*:4G<Q9(Y1A(@4JPW"6,'S5K;4TR7M5$LZ4"N>3:;5
M1!RZ,CL_>5I,A)@=ZWP'?&.;DO*B%ZRDA0][R0R?6[!6KT'QJRW__-H3&&FA
ME#>1A2@#4I`62P$P0_!M!@JS$@``D(8X3F$*2Y@=$O`Q``AL;E,IX``'^LA/
M/W)J`PFT)V3^:$#-<2@=COQ,Z$IG!"/8XQX,O9EK6A/";"!4-46@G>R6<(50
MCO*4(`WISGJ7Q*88*UI$V5:3M):<;7U+>"*QX1IW2,MR[=)*3\-$$H%RTJ#<
MTCS06A82KQ<F)#$1>&)34]W`-:Y@10>-VY,?3,XRB%N<T:E+T>92R8(+=K&K
M/O?1$S&>]X1CV<\.0,B!$6;G4&Q(K%.%_$`*^L@!&7!@KOH$)"+AH#%N\%6O
M`-4C.@RB#A9%<AX-E6@\;M90V(7N'@8)_X$^..,Z)-2L"9@](2@_*M+.>E9(
MO0M>2ZHTM!GRU$W<85:SA%<EA"DOM:GUA';"5-K7$B()937F\E`Z1"HV"R=@
MJEJ4C#8UE?Z2BLG+WO?FI$2ZD(TM:Z.*<1[1U9&`XA7F&Q_=#L2WO`CB"4\`
M"@`\$`0YLLH=L:D&!`:Y7GW6508ZD`%=.0#($1!2CP0L($!)I)E7?:Z2I&/5
M0TG(5I7]`X21+4T1:I;"FEWAP5?@[&<G3.'=$$=J"!,*#H+KVC7"]+70VC!*
MN<1:G/XNEX&#FN\ZS*3BR7*9M@4FTWIB%14K4;@YA'%ZVJ1CY";G3&Y:ZEJ2
MNF.XC`07/\@*5O_J9*ZCJ&N)!/H75[N;%U_\0`!@$(`*R@M`>KPJ4PK8P%WA
M,`(=Z"`.0T!S'/:95T1JSF/Y7:`],_.RU*WL9@(V&0=I%L\F($&2KH$'0!!B
MPG<:&I0!R`(I*\SH1L/PE]V*,;1*PM/`_2YIZD'.:G.",)]D6#V>SG"6,LPT
M$1=%*L2,+4]/O&GES3A+.\:I$=?%XS;%=EA@DQHE.B$FKB4W:*50\E3!!I/T
MO`G8X`L+I@UQ+U]$:"P*2D+#@/"P#!1@"0$1B(<^((,_RF`(0SB"$HX`[KOV
MD7(?8B#'#FE`"0Z@D2N*I"3/RYH[K[4)\:1=Z=QQ07^PZMY-,/04`O#_AC?(
M8=&.3KC"_Q`2'ZJ6.3T)ZN]V>%(E>4LZ1>N)L5@,RYER9^,Q!0\P1P[3W?9T
MIR55[6[!]%-K68+2G_[QC6>YX]*&A\CKX1J\Y@;L8SL5F=1<R[FX&Z"RIA2=
M7L@!#-X`RB70(S8A^T8*NLT!<HL;"DHXL[E'0+G)C&A#W]@`(".CN10U)L$8
M9.A")=G8?"?V'H+V=T,9'/!#@_+@"\^[PAN^:IDV9\,IJ?3(P2G$CD>\6T8Q
M^O(4'].9R%I+K'[ERF<`7E'O]O$IC[C1'@$`&0H>F-1RDC"M1$R2=PW'P?/U
MU9[*%N4^%[C13%)T;ADOJ0Z#K%E.PP)VKX(<_SC#=45XE3;R6,@1V'4(2@BW
M$K".9GWV,05NOIQEPCYVS;T[&JK1D=P;*N`_LYV$L=/W)2%)X+K77;-O*$`5
M$*[W]G>6[TZ<Z4\[3)Z<@)<\+*V_\'`JXY"#W*>D126D!7*8UT2?9V,VABVY
M9'@4)TO;$7K#$G';LF$LYG(01VLU141C,TW#M`AFLD2$,!9/=!Y)1AU@X2]_
M`R$B"`8JT`5!$`0^\##S]"HM8BG3MREE)@-*(`5'<'4\F'7.-T@(9$]@UPV<
M8GV6L@[PH$&>E%AJURHD]#KY1F_S4#H;U6=V5T=8P'[NUX6F%!*?5D/>LG'%
MQ%K+<U)KM'G"HW@3]_]BK@9>X(53X=4M0*%XP`2`+K9R;NAQ,F=Z%/@=T"-X
M/(1$L':'-'2(@ZB!BN@>[H$<R=1ZS\,<=4,^G'`,/4``/@$`,:`X`Q<`5X`$
M7W8BCU%/!61\/0@%6+=\4H`%4@`%0V!7^S1((4(BB;$Q"L`Y"-4.56B%L%,Z
M)D-^D31W;+6+#%5"F#4[=4=P=;1^7MB,(44<EW9R1W-RQ`5;JQ9RWM,3C&=$
ME79:&G=RKT2`=.@]N#6'=TB-JW5K9;AYMW9XQ@1I94A$Z@B/R#)#U+2(0W1Z
MCNAC8J,2`_)D\C(,$-(H]Y,#5[`$I\$CVE8BB:$8ZY5/<7!UJ`@%JU@%5>#_
MBCH0BP4%#GFT#9:R&>6P&K9R,T(`.VT%&ZV!$`@Q=_I6A7CF29:%6;(S<'64
M`1D@!5SHC#J).]`XAD0Q<9;W`T8W$F;U<=<1E+5D-)[&$Z2&';@U@&!"+0ZH
M>8^'CF=X=!]VC>CH=SH6@=,SB*KG)2^5AD<4EH\()<G5@4-5-O?!-\;@"`*P
M`#Y0`*-1!-@P?*&B*9@3=OGT;3VH!*IHD57`@W$@7_J%0!*@1R?2&`BE29_S
M4+13DFUE*I=D&Z;!DB3921'5=K/#8`%@DS;)C#LYFKO3D\L4+9475'A(ED")
M$CV5@4_Y-&,8E)HG:IWV8B[E8E8)>;=9AZ^VC4[9_RS7.&K0HVL*>!R!EX\/
MYW<OU6K/%8&Q!BZ1=I9HN1S;)#]AT0CVLPQ-(`0$D5[W)#F8XT`))'8C\%XZ
M,`10@`59(`=R0)@9R74`!0&1L4B,N0TDTQEIMP0.A03>V3DK4AH-Y3H%-@\M
M:6\FZ9DUJ7XY29H.NBLDY5K76!0_=7B>IG'?V(V3)FNL%6IH"'G0<E(B&I2V
MF8$:YW&\V9H8FJ$`:$/N>)5FN&G4R*$F@7)'Z7G.67HDQT188Y;9M368MGIE
M(R<#,@-9!@8L"`-+\`X6-8H58SD04$`.-!D*)%=^Q`$1"055@`6L>`0<H'6R
M&*4&E2&<DR,L$B,9-1KND/\AG-$9]="+:^5]Q9A8W&<:,?E.=%1'`2":#]JG
MO@)_H::'JBFB'O=_&[>5L5E6]T=Y964L<[AQC_H(C7JH@EBB*A9QA]I3:"A_
M?:>I+6J-1L%J/I6'-61Y,39XL.6B+6=Z-L6(T4(\S@F=7Q)_3<,]584EC?($
MU`:#,#`%(D0!E7&#>C2E$L!>D*-`\\4!X*9\X[9F\$5?B#2+D-,QF*$:+-(/
MM^&=T5`Q&4)8%&"@&O5G]L`:<9IG&U5W5U!'3*=H?MJNO!(&3T-_ULB;Y&&5
MF<J;C:HP0YF:3RE_A"J4MEF'X?6-H0IB9YBIO=FHG=J;AJB;9*EJHJJ:4_EQ
M39G_JNF(8_.(C\Z4FX4X5*GVE31!+E3U!.,%@];V!@BI2<-7(I:#,0"E0!H#
M0?E45VA&;C(0!X7I7G;%=8,$4)+!5]$J(M5Z0?,@$*2R#1E#A`/`#@9AA9W9
M08;%09#99^BJKE>P0NZ:M4/"=SA$@638H9T&2]2HJ0@;5)*GC0ISH;A%L8%J
ME$(YL(>J'M\(A[D5F_T*L"QJJ)T&8F2X:F>+C3+Q::]I8FCXE,4SJ6)8?QTK
MJ&+RC5["HU%%CZ/5-+#$0TF!'[O6"&L$``)`!'5T!348K*+K(0U$GP;$7A\"
M(C.K`X!);A&I`UPW7X(D2.TF&222#O!P#P,`LT08=ALP_PT)<!JMD5'QY'22
MI1HVX)^@<YDTDUGO5``9T`RVH[74"R1@.*FG"6LG>F(C6GF)QQ,SD:FY!;#`
MY+W:Z&GZBK`]E9KAJ+>0RFEO2ZD:9W2IN;!F58XP!X`@EIS[MZ*5MF'A&ZJ*
M6H?<D5M9J1/*LAV->CPD<33C*ZA>*4./URZ^=!5)D"])%C0+TP4`A$<W2!G$
MMSF/\T\`%7TE/$AS]6VO^*6PN$_Y))]_-4@]*V?C@+NOX@\.$&8%)$'IQE<0
MD`"[Z`]&@%FND@^KTP^0)#O.BT(=U0336[U0[!O$4:KE6)M:26H>2K:2ZJ__
M=W\4"X>;B[",-Z-I:+^'"K>0*O^_ZANVG7HMQ*F&0FER:NR_PAFJ;'Q_`VM+
MX)B40R._RE2/?QQXM&I;QMF.P[(#5V8'*K``*B``C<+(/G`%1H`A8#<`+9N7
M#21V^B49(,)7?#575^I>^B0#.TM7\JE?/?M/E$$-V&?$%+!>MMN0Y1E(<&``
MMC&@?8:03W<-Y(>F5GA"FH5H-I,S45S,'0&OQ)7&Z-MW*QJ;_@MRX0N'79RV
M(%>.`]NH1E>.[JN48CRI:^NHRARVVKQJ;+BIE+I&BKJI`%NV]^JI9XBBF)J)
MODF`5"FWK3:<']?`A6A:*:=;$.>`K6H>'M`%B?,P0>`!,1`$,'`%[I`9'E-/
M</5UM?C_R7?ULD:HR7SD?*(\ROLT7SS;LU+Z0!-##G0&K!TI#E6:T1HS`"'@
M246`;[/C*H(F;Y[$GX6&IQ8R!?Y)S,;<TQB1!_2;Q\WL*,J<S6-L:6L;7HZ:
MS3Y!LMZ,MOR:J'3KS=YLN$M-U?,+J5>,6XYB-.4<:IP'M]*LH?(;%(JJU!J:
MS\W<6@!`P$#E8F4\-9HWUX&88J?*JF8K6LHTR"^1!$2@T!D``W7T@O_3!"$0
M,B)2B[/X*1DC5W5E7QF#F`64T:.<9FQV5Z`<A+0<&7MY&=?7K:VL;6'&3_JT
M`2##`B;9A.+J02'`=C&);YEU?OCV9R_0H#Y]VPZ!S!EZOU<]_]57G1V5FS!O
MJY7>.]78+,U)0,WK1*G&$@0.(`,70`(7<`%2X`!!0+"&&\?:.-9O:]P*RVG@
MK#QC/+C;3<[U6[]E&SCCW8UES3076G((N,=W^&,;RJHP5Y8YMTPRQ8'+05YS
M60`Z;0138$<LHVT-F3F>L@'/]U[0"M*(M`%X55?@5LJD?5>QJ%>2`78B_)$D
MLX380"D?\%Z&R=(V\)*]**XR<@U2B&_O1+7`G$*SC01/C-LT+A$AP=0?6MSU
M:]X4BZF3:M363+?B^P1@T-34C-Q)X`4<@`$GT.1._N0M(`,Q8.15/<>^O<;*
M;#3KQ$/,[<57S;WV^Y/K79ME>XZT&?^B$AJQFR8E^RO(Z5@E/)I:HDHN;[$#
M`N`#00!`QJL.K'&7'4DID1%!$:W@=!5?+CR[F7V>#-[1(BY?.[M`9)>7EK(/
M@M8/MH(A$H"E.?L!((,0M".%WH=GOLA03=!1%H*,IHY",(YO6%OCKI[;!,O=
MVRWK]>J]G9;-Y[O4CKI.M@ZI3NW=3[D`,@#E%R`#D@'=+?#D4K``OBW-BG?6
MWFW<VCRBRXW%NX[&LVYI9NQ:V?W,66RO)]J^Q/FU.Z2'%2S(QWF:`6C/@/Q;
M;-%[&<`R_P`-"!4R%X,Y!Q0B(!+B;!8'\657<I4"`M]/_;31-PMN&:F1L[CA
MC;F$*3FNP"K_9CMKVBR]5I>5;_QIDC'CZ0/'=,?8!'3$=*IN:!+VZJ^.S+X.
MASQ%LE@>OUU,MWB+W`GCU"N?QB2K,.NTW$^0`<E^`BT@!3Z`Y.`5!#+0\RUP
M!4*NXU0-7NF[ZT2M\K&NL-FMOJ.&XWV'WA1G[8CKSB<%]=-HJ"N/YB!Z>8;X
M?U-"6\QLSXR;<X@,`QG0!/I`*AOR0/3I#2+BLY'Q5YE-RBT,R@/O1Z!<X:1\
M9CWXB@1UA)_"X6:JB\)[,L`:9F,F0110XKEL698O3R2940'74?"467E:`#G=
MB>QJ\B8?!LC]]$J-Y'8+J3E/OUQ]WK;.\@H#U;K^ZTZ=!$7@Y#+`_^R\+NW2
M!@=.[@#8K.M5[/34O-1M/<[D//M+*<[6[/S-'%Y>'MQ#7N7B:&*5*HU+.9ML
M3*_C?J]((YQXBZIMZ"VT)0""+02,T9`-1'::[$"!/B)`JU]B]]AW%4@"+T@%
MSV:##PA#1TI'0W$I'W`0$@H*$`8#"0Z3%!0A-D)"145&F38L%`X#"ALI<`J0
M"2PVG$U+2TBOKZZO1K%+4P%7`5--OE-O!0%ON@'#!50G?\O,S<[/T-'2T]35
MUM?8V=K;W-W,84_A24D`23_CY^%/`.SBX^8SY^,`3_+B3^;VX^OTX?WNZ_:I
M8U?DQ`D,/M2MX\>NW3L?&`SJP%<O2<!W^_\<#BQ'3B"Z'^GHV1,I3V`[?.DP
M6GPR`YVX'_%*KC2',9Y%="U1?E293Q[(=S!E`@5)]";,ED!GQ%/*5"E(IS][
M$HW9,V;3ID]4^+AB(\&`41LV*()`%L*&#V+AA%TD00*<MV='<.`P(BP<MV<_
MH(4`)\4(OR/DRH@S1-"1PT-TC/@`P9&!1I$<5+(48I40(YL\L0A1*8&"MZ@B
M4;!LQ)>O64VFJ*:U)'4QU5-V%1!F+-AL9,J\Z=[-N[?OW\"S@7-7+AU%=_O>
MJ>OI\N8,E#&7S[/8D)Y'ANR$&%SA@9U'<O]0_G@B9H5!(2OQW52NL*(_Y,GC
MAPL)!D!4D^I51IW_?T\]59[IY8?1<N.QE!-&125ATT="$>6@3T$!>%53/SU5
MDH,QR0,5A0J2!\,41H0P`%]G^97"!HO`\0$B:)52RHEZZ?677J<X(D%>+3J2
M%V`<Z#"($D`6$H<,>Y%EP)$#2!:*9)*M8L.30GP2BB4..*+`5PE8P@(+FB#A
MY2RJ[7(%;+^\ELLQMQ6009K)!.?FFW#&*2=OP_478$/*6;=2._14IUY`/BT4
M5'@+)<=/?0#XT,()*XCASW?M+1=.>08E]&>DUKUTTTOO'0?3I@P-5.!Z,P&U
M9ZGB"06@146]Y-1\.16HJ52J3E454^<D>*%2.!SE%(,I%>4@/%;-@`,._SF1
MD8$-D3RF5BD<R,`!6C'JQ2)=<P46&&,V/F*`6:7HM58C$*P86(^#0*%N(3IP
M$)8$C1UI0):<4>)``EE6$D)E-NR[KV>/)%G)EI@88;`18,96S)BP72'FF0&D
MF0$,MV5016YS9JSQQAS[5F='XP787D/M42==@":G?&FD`)UTP0DM`#&00N6(
M`P`8[ZWDP:(K9(IS=7[2+-`/?98LLC_]`/!</9+^.:"`.ZDZ%(3FS+>>>CX)
ME-^P]5PXSG,/4OA3JD]E>-2#"$+X$U1''0M`%RKD((175MXHUUQTX2CCN=IN
MNP&\)#*BHXIGO8L**7'U.(02ZDJ!&%TUXCN)`_^;53+Y5Y-/<HD#]7HEL+\V
M&%R$$%_"MEHN8[I6VVS&Y!),Q!FLJ:;%&'=L^^VXYUXGT0HFG9]"=T8ZDW?4
M$:K1G22#Q$]!)Q3Q#Z'%$S\@`%.<UP^B0)\TD-8UTTPRR\HCE1YU\:UZ']3Z
M/%VU>AQMG>O8J[)TX:P(&DN5@$H!*W:N+6FH$JXPP<$.9A"#)E!,1(]QRP<$
MPP$3A<5<=\N6MDY$+K@HHBU_^X!;WG**QY!E`W/1P>(:!Z0AT.415XI,93@3
MBDA$!E_XLH3`](6)3&PI$P@K72YZ`8LE,"P7%5L3+Q!V)M;!K@`7RYT2E\C$
M-^6!9-EC&?#2DZF-'"?_4UB<1_;\!+2(7(`<&\$3>$)E,G\\X"#8.PG01N:1
M<A@O//WH2$?X,3/CI$TAGZ*(U@""#C"NCS]ZR@=-2G7'02K(.3@9EB`%%)5A
M/>B1X1#?UYBBH%XM``:K*`(%R"4!O$DP$2HZUURDU3=$_(U$=VD,O!2!HA1M
M@%QD^8`,9*"#.!R!A$?0P8D8,2])2.9)E?.EY[Z2I!#0RS*;P,R31H>$*>!"
M-<\TC6J,$;&*":,)G6!!$8#(BS-=(0NU:Z(XQTE.:N2A/AEYE'$6,C.0;4J0
MQ2$'.L$#%#IND8X6\8%!,F"R*+*C/B,#Z!/```.#3`%IX2$?132"CZ0E1T\E
M_ZM(S;S3LCBB)%3'<6<<:=(T!9T#BW82V=#&IZ%`^0,F.C&5(*=6*UWU,:7V
M4PH8M#(%!WAPE1^(%MY,^<"[26LN"Y31BA(A%K*@XI0W<@19X&4E4@RF,+>4
M@A24,`09+.:5,[0$E(2P&<XD`!+$',V6N,2)37#B25Z*#2YT08O4N*X`Q$C3
M;)J`A,UHLS6\:$TOFL"$<);SKX`59QC*^(]TCI&=A/('HM0Q'CQI+XQ1;(\.
M#O+&[($!9QL!J'<B(@7L((V."&T/]O"SQT?A\Z,<>>P]?->>/+K#.`GM%#OW
MV,=%IC15RDE.R%HUE%4I)X^#C`I2@F*_'RP@"##(P/\40J"`%"#B+B#T9(L>
MR"/G:E!%UKKJ!FMD%\"]!7"->`P(:RD(*$@!"U-M5UVNE"\M0:D(H/AJP$2S
MI1!T:0F=,"O"<'&%9^9"FK"3G>R$H1IE:H*(=&T-+'C@U\`Z^,$<^]AA0[O&
M@(`6G_S(2)_62%@_%>\)YI$!GR!;'<PB]'LRH&S0_*E:``@`4?B1XO52IMHR
M/@J,VX,M<F2+T2EF9"?Y$)0\XJD?F4`-:U)3'W-6*EQC]0``9$#N;*;``@AD
M2RP@O%M=U'*7!;+H;^02UXPT6#A5BF656(:7O`P`!\$0AG%8P`(4JCJM^6*)
M,JQ@@4W=PH@L<2X4E\@$9R[_T4RWTC4UN]"%;&:WIM@%(#6I0=C!;%$+6VR"
MP1#.M*8S-ECB;+A/`A``T`2*G?:I<:(#)?6.;_:]EQCD"NVXK&4;@MD5VP<`
M&3`(T(!P@0OHH"&B+L(%-@`T\$Q!![WN]0:F\#T``"$!-$@V#QS@!2V*(]H)
M^3#1>BT%1^ED"KW.`#VBG>QR]UIFX^#U!6+P1W)D0`+EEL%!2>8#&9B;`T98
M@$Q"]E+Q^%:W0-Y/A?+G@2!D(*^:5$!0PR(7O^1-+?!*`5W^@J+'Q`BH?FD1
MX,J"EZ4RXBM'DH##:WE+]"HA#M,2%Y<7`0FQ@L(`?_NXO52!"5#8%PFJ<V9I
MC-$$_V/(5:Z]4$TL.&$++QUL$T^B08,WS?2F=^.)4`P:0[2X153;4P`+^;3V
M*%H?[#$DUR?P`JM1>Y)0OYC6BPW5`@P"`U&+&NPGJ$)UX'"""UPX`Q%I`0WN
M<H$6R."S=&>4#"0@`_.<X._MV2=V?J8=1BT@(,R30I_(W7>8)9L&RRGH"3*`
MG"!8`&9[AT/?I:#%P*^@+?:&61`J=)WB"`T?_<L5@<#82'F`P0MV6``9@.`#
M&"Q!"$T00@O;?-6<TL64XEI@\:V[(A-)/%OB:LM8MJN6QX#560N,UN(8!P52
M9DL'/TV!`B31.074)6":XQQ9DPDQN"*!%?_5!*2O@,V>M__N%TLH0OZ-`$TD
M<'6L6X("2^=T!%B`TP!UFL5%K%5U-]-0SZ-962=U?-)U6P1V?!)U[&!V:=1J
M[+1/%`AVBX(%#4%W=D<RU7,"6"`&-H8T"6`014`SC8=XZL!VC45KX=!X*[``
M21!Y8/0\+W,!')@$FL=Y#0%V4O!XP+,@!B%W#44.^Y84JM(?C41(?@0A2A$$
M4^`#1-![`0`+!F,#%#`B$K<8>O%3TX(C@&$M+0(7=Z,#X)=RXH)4*W<XUZ<`
M-_)\MP0%C`-^M>2&[')"Q20*7[$BC5%,8(@)!6,+3?`P(,(*OO!^^N=_48()
MN$`+.-=#7D)7FU`YF=,&`VB`H!C_BN#@8HMU:B?F3PEH'6H4*JU&:Z*V@>P`
M=FF4BF!@=F?W/*<&``91`"YV,V!7``8A@@"P`75W@1'1,U87*L=H/$IW`H[2
M#C286?Z`@\R#!0L5(&<$A*HUA`P1$1AP'`B%3E)@$!<`!QG@`W($$/:D1_8@
M9,V16X0$$F#0!<HU,7`5`)G`56!H`"D@+<H700U4(H`Q(S,2%F<1+80Q)&>H
M<DOU%O%B?2#G"*'$`7EH7H0A)+=T!-+R2N0W(I!0+G=A`!209YQP8,UT)DU0
M!/UB7]!D!*P@!"Q4":&C"9O@)4A`:?ZW&?<R3`.@`9\8BD#I=*,8:A>(6/^T
M@0!%#B^V_PXPUH.LN'49^(I0%&H66(N(@CVV:';$PY2W>#.[V(L"\(N-5P5@
M0(P7D(`&06R.M48&\0#%]@00H'C0N'GL%('KP#P&(7D3130+D8VM^`1@QWDS
M6'?@N!PD`P,,9A`P\P+H`5'TXV_%\Q'K4!*NYSXJD`$YH"8PD%<V1SF;1)'3
M`GT#&18#&1@.9YJC1$L*>8:&TY"-$%ZA,0`>9!8YE8=*(`50%0<^,F=U-@#Z
M`G,;()O090#VU0D&<Y.7<06TL03,90`.4))2\B0KM"2C`268X9(&PU4A((C$
M]!4^&93@"910!UF?56I]<I5=5XK`QH"LECVV>)5@!P086&*SV/^5M=@0'B"7
ML;A/`&`#P4B,#W"?ZQ",V7,GY#A&U$&,=.D/_+F*0--XF!=:2/.#/0:8BC>8
M)5AU2%,?&2`$,O!YAV=%A4*%5`@2<>1BA?D#.+``.0`#F;DFKB`$@H@O!B!+
MA4%*C!$7,2(79,BCT!="0[*1-X(C=M$8X65]1W(XL30",C!">EA5A3`$ZF)"
M&S`O]])<IO"1:#$:G/`E-UD$S=1-1I``9S$`_:*3F,,E,0DZGH"=7$4!/-F=
MWQF>=$J`4+=BM7:?&)A&_!!JYLF`L.AB61EJ8&!0[`ELKUB+9V>516@0W7%9
M8`",FW<S_@DSQ0ALXW@"/G">27-V%Z/_J0B5!'FG1@U*:FQY`G`@HB3S@WA"
M1X&I$"EV`O-F:[16-#M#F)UR-(Q$A;C(2.O@`YB9`5XB?/TB"AX$0H8A+2?R
M+7B!",[G<'@S2ZI9&*QID*ED5&L6D4;%%Q-I2XQ#"(4!51J9I9*1`'``5(V!
M(@F`"<EDDYBA?[FP!!1@%A"PKI8`IVFJDIWS2YE05O"%K_+RFD<RIW5:L)J&
M@,W&G@P!BT2Y1NWY3X":E8I:B^;Q:_3Y3R^FJ(2J@40I:Y-E`5$I`)(J;K58
MJ9?*:A[P,BBX!+.C`PE`B@#@`>;1`D*PJ4``;C`C;GR2EK'3LS)SJJFZH1?(
MJHGUJNH@!LTH_P53T+-A01T>0`-2D`#G.#'-*`0Y(V,^!H[0@Q'(PJ(%``--
M8#E6ZA7?XA=-FAC^*`$127QY`9"S1!CAFAAD&(>I%)L1^9I&RJW&UZ2V"21Z
M6`CN\@CXTES4*A8I(`%<4AHJ273O2D1(X`!ND21CM9UWYB1Z!@F48U8U!Z>S
M^9JH8``$:["B&U@(BU'?HZCS>3-N=YZ0RI0W<UFBAAVB)JBV"+,",`0G8`&0
MJKJS&VII\&(<FY6""@:?)W>T.[)'V7C:N)0$T8R*B0%8T!W_(`2&IY@M@`7R
M2:J*N;TV<"@`91`.0&**^@+%J#(62I?/4P3.:Q`6(`4QX(N5M[TG0/\#.NL0
MD9EUPG,3":4?-$$$R26L]\*=7_4M;M8N>5.O9-MF)Y(X@A&NMA2E*<=3=G$*
MD2`)HV!4GYM`!XF0%6E>Z)5+ZP4)I$"1&KD8IL`E-UDP[7J=L,!<$,"OVND5
M"6!?^IH`C>$`K#`ZJS`)H\!GV.J=/SFZ0HP[=UJKK+:H6EF?9_>G)5:[3?R[
M;A>\HB:I!2"Q5FF51-FPHR:RA@H&"Z"!P]NP8GR+1!.SY[A&C'I9P,J+U2%J
M%J'%]%"+#$&4>8*+[ODS.#-A3*EJ9KRI`&5B^/"_7A!&[D&>%T4SO#-[[D0T
M/C`%PE`$DP!#7R&1<O&&=8$BF`-S!9E]V`+_M[H9KHI!+=U5%JD@FQZ4I$IZ
M(WJA?7DH55+%FXO!"&;!`5)Z<E8%`0-@7YYP&4A0D]<9"RSP%2.9POMR+R.)
M,,(W(@.@3?"U"L;D%4-Z9@&3`"40Q$-\S1M3Q*.FNNR0!AFHQ(N:BA!+BH@R
MNZK[NQH+QS?S>0]@Q8,:Q>:,L0#P,KJ;SADKL80:LI<%'K/F8@OP,[W+GDB)
M=<6V)X=Z3]'S6:IE3P5J$FM$=IYUR-LS,IE"$S,@`#Y`3?!5+V'X+6K!R;'<
M9U\!`2/0+C+B21S@R6[HAE8EP8H0&O@RR4HEFU:2I+1IMB+$.%+UP<K:(B,0
M!^=U!"C'&#/,KF;U_Z_Z0CK,.<,A\`K],AJ541KYAZ^Y7$,K]%4];*V\%`F>
MB,U>O41/%*CE['97V<1(&:@PZ[WG7!]0W+%:6:E-(`#H#+P"\,]FU];O&6I-
M8!`L(-=X_<[Y#`!__03Q;,3Y?,6%G8%;7&*T>M#TP+RYF+I)LV$1S<1<%+LG
M\4?OP9<YLUL6008^4``^$`2\4%>5`!9=QJ/3A<LCDE/*^GRT-!<J+:T[9:V%
M&-,@%[`93$QV:"ZL#"3?NIK9DM)`XH]7HB7]RE6B$%[K:@LLQ"5ZEB69U'-(
M("*2.SI/S;DV\BQGQE[4;,U?'=[!\42SB[H/B['I&95ZZHH3^XK`:UGOV?_6
MOWN4=6T",*,":?#%P@O%^OW.*L`S8E#7<UT?<LVQL!O8LB9K1PE%C(JHBLW-
MJJNQZ/W-1@RI2MR+&*YU0#/?&@J5:!V5GX8<W?-0H.51XR$`6N&B9!`WFPF&
MHM`7I%F0A2,!%J=E$82V?)L802I=16HD8)7;,HTDQ&0`$I!]M"0(5/4XGB2M
ML]1`,@=HP+0D,)0EE['1G#.CE8%SJM$5Q:09<`HPB#/!=Y%"#M#5XGWF&I,'
M2-R5%3ZH.NC%;$[@@RJHO%N+?^V[7]QU'O#/^L0H*K``WAS8:0`&4)P&AF[H
MH:8"AI<#_>V[EWD;&FCA1)`#M<JHH3T;P`:I8=G_LP5`!,(+!!5#X1HH.Y2.
MX6;7!:5N!P4`NU%YB@VA`@5@!S"KND2@LQX@;B<&!L`:.T9<89<2#P*R6N4@
M`#&@`E%V<!E`!#$0!)D9MEX!`<^G4]EU?FJA4]$:+5%J&(9053^U+6@ARXTQ
M7_(RY$(N"3"W(CT"?H.P[72&TMH"9G9++S,J.?SR"5NRD[*9RT(0`#!P!2%"
M?@!(N1X=S3''5*E0S6B>\'*BYN@YL2!^SL)+J`J^L8-JX7*]`(V>E?F]\82>
MYY6Z`K).NW2M\8AN!X;7UR./\<`8%A;P`G.=@1_P`(ANBR;_`BRP!"^``5UP
MX/41%G&W`3D`SV!P`1@@_Q8OVW5FEP,6@`5-\!4/;G8;$*```(S=O`X<_N`-
M`8Q$F,4"0(S<D6OH"0#E\0":L`'2BTZ570_T\!R931TJ4.PQ$`-`(&53T$QK
ML@0!8`3!3.3&IV42]X9A$4)OB#<B5`B,(PB)84(2]&7@#I$@UYW$%$,OOLIQ
MH)N(D>-#,K?=!4N+\#>0P*RX3`&D$WPQV9U98@3\G@%-``J2L2^3L=P2:9#2
M;*218>8*?_O`P?!-#-CO[,7>'.'VG/$AF]\C;XO$C^A/@/&AAKN,X@/&+VI?
M+-^&G@.&5P44K_R1>@(/T'=RD.<6'O7YS;M<7,4"T`4G,`!17!TGP,;ZW'<7
M\/\`0=^[H?8"+3"\3Q]J'Z#]#V`>L`L(8&`"A(2"8`")8!DG!0)/B0"#'RM8
M+0,GD9)@&R=V`HB1H9H`3Z9//VEI"PN/2:])`"HY&1D!,$`^!5-%%`XL%#9&
M%`,&!A\<'",?(QPI<4-Q,LH<,C+2R<DCUS)#WG$ZV2/C*>7E&Q(*$`H&"@H#
M\/$)\`GU#A3$$AO(T$=*4%#^03F";=F&#7`D2%C7#LZ&%!\<KH,`(8$0)$V:
M%`$VST`\!T8"U.)%+`$^7_4&J$OX$([+A`P]UM-PXH_-FSASZMS)LZ?/GT"#
M"AU*M*C1HTAOYB$D*5$A0FE`M2HTB"HH0:`D/=TJP"G_J*V(L&Z-"B9J(4PG
M3GQ0(<`LF*EF!:CXD/;$D*T+Q"Q(5.#$P1<MB#`MM.$!TT&#5*Q8T20#C<!,
MM0YJU!5`UZH/,#C\($@KJ"8ML&0<H`BQY0\/$#&R7'60Y<%7P?3-4`I2J,(`
M$J0E!:`+A@<L"FSP4'I4[2=)3*E8'F,!\N1/P,PJ$"#`FUH9D#@PYL`&$AO%
MU#%;-D)'M($ZPEF3H:,@.0XZ9!P94HW:A_OF[D=TYZ[=NWCTT./`/2$0HX`^
M',1Q!!12`-3@$?%-P\%]!R$D@3$'[@/1!Q`,8)(-0A2!!!)%V!!",3)1$`(2
M`5S1!(G%F(12>!`<Y-(&$,"T_PX[!B3@0`(T)27DD$06:>212!:5AVM?0375
M4YX]U4I56;&FRFN%*,*5(66I4@A97Q:R1`MIM3!$#D\L$)>:.<1!Y@DM+!$7
M(:P4$D,!>!;`%E=$^&#9DU7E4$`M3X52B)Y8VB8`+1G@2>56>?KI&2("="&I
M![2QUA0DA5:E0@8>&-K5$T#D4(H/F3:E"*H%P/":<:9`]T.:,/@`!!!Z$<?I
M`D`$D8,/0?@*PQ1"J!2,$"<JL$$SXS"C@S_HK=<>>Q)FDR`X$HZ0`@<'?9#"
M,A\@U*$Q\'A$3SWH>OAC"#:P\.,`$&QSA#]*>!-.,]E`9.-"_-7H[0@7.A!"
M"$((`?]BB<`(:,,22U1GA!'(>G3/NP=*``>%$U'$GSL##`AD34F&+/+())<\
M9!Y>X:6*6V!),N>636;IU)15F:7FRU&V18@*5=1U`@8O4/C!"Q;X7`41*P_F
M951B-.DE7HG4R:58.:=,"*>5O9;RDSI#N8EI4U=96=:Q:=F:4Z$<PMLHE;FF
MB";/F?+##Q[`$`01K`SK`W&6J>!%L$#\#4,!31`3`@LV4&"`!-M8"]\1#0YA
MS3?83.Z--?<RJ^\^^AVT$`3F>HBNCS[>\Q&[+`S\HP$;)&C>$.$H@Z\RWZ+#
M;SL4>5O..X<C'N+#)?HB<!%78!>`$`^7Y+%*-7(>+N@;;RS_^@!!FFS]]=AG
M?^22`G`]""M2E\5U5EW3.?Y3JTS5VF#J1STE7D\14<6;/OO<PM%1K:**U%)V
MEOZ<C\+2R\1B""Q%)F=<^A-71%7`KWD-,>23&6^F)BJMH$U5O.%4*$[Q"KD]
M@0@Y"*&O0C`"`Q2`#![PP'+ZY`,?T((ZWP%&"!)0(VU4`QI#^(?DJC$O>[%G
M/M^PQCBT<1\%Z(="_&('@.QQ#W0YH!@=(YB)?*&2926#6N/((CF:`0<(I",>
M_K+1.X+1+N0]S&`L0%P1II"!7\'@"D9``K%"T$3F:6@9GXO)CC@V#^J!3'N`
M#*0@!_F',>0/9O"[C%6XLC^J[*4M_ZP`DUG2H,`"OBP-@UA9^EI1@*$]X),/
M")HCVJ))\+7B3VI"Y/?^ITB8?<TI3^L4EZABF:BDC!17T=*K=':V+&&M@)'!
M9,Q$T4"W)4)1Q^Q@$F;0P33$(`-&:$(`*``')<0A`3GH0@R(T(4<3"$`>0K`
M%#1B@R?62%OH0$8.E:"$(T@H#@.)0S_FHR#8R6"(X-I'.L/5187$!$4"H@#I
MX*$.`]SC).;4$#.<,3LM?BM<Z<"0/L3%,0KXK@B_PRB(Y#B%`OSJ#5,(20&6
M($-SUJ@<]TEB1'E$KGA4CY`PC:E,B[242UXE3`LHRRPI"$G^`>!)+S-E(4SY
MLNY]:9.:7/\%5/XWR?V![RLWBZ12LX3(JAYB@6^)S`'75Y6?FB)FZ(-949FB
M04VPCZ=AD9EI,GB*MB('#![P01-Z%((/]`,"N,A%$&"PA":,DT1QA!B\%FH0
M;W4C&K'K1CR'0*]H1&,:Y="6T#AD(Y?LR!@R&5U*4F(`+W9(70*MHN[&T;KX
MR`Y?X(+HOF!2435BM`@0N\@4.CJH(&1@MDVX0@"68*(9PNL@&XH(0R(:NB66
MX(\S3:YRE\N3I4AMJE]Y6D[K1"FM=B^54/G2H[HFU.Z)!;M'1=_-G+HTHFK2
M?)!T$OCTDK2JJBR[#USE`KFBM:ZV%RSX'6MU]?>DU^3T,*J,DB;_D@.`5VC-
M`Y::`@7V`8?RT(<",.@"$1K5A(=5.`0R&9!XM#B"@Z`67S)@IS?H!:'V9..(
MX:J0%S_W111A-D9/!!"\U,&0CE'L`]*ZIS_<Z3AM,:M9Z=A8ARQZ$8C!5D0B
MR0`,?C7A*X1T"1!+70(\(@'\=(Y?H)/Q1QQP7.9Z^<O*7<I;HBH55GH7O&-I
MG_B&FE6=3>6I_"-J=OE'2DUZ0$U/O:Y4)]F*.O%ODZS02_><FM]41G)+^M,?
M5/,<ET1XP'R8Q!(!O:*(*1D0OX6`1)JN*[8%7AINKUA`%X(0@T\M`5E5-NVS
M.*``&Q3`5X0KPG;@<<X12,1?S$B!%[?U_YX$!63$C%5/MB:[K\_QI[CT".U'
M5-(.@DJ,BIWE@(C],02`6--:#6W&![Z(V<X:X'!"6,)WBM#7;[8QA"$49P`J
MW"X3J40!+F%&Y[I8T'*]V"1<1BZ8]\UO[(V!:X8F;U.A:]VADK+.>8F*G[';
MYT@>NN$Y%8,=6K&*.Z?RSHH6JI<,#3Z%WUG/IG3XGJ5V:5L:%=(X._E-TQ=!
M)G6*@._=KEDB4;Z?TFFL7=M$U$H1B07$M0EOT,6)O/@!\\RG&C+XP``65F%D
M#:AC"5``>^@SKL[:J,?-D`]C=8@-&RH#/RGHHL;Z\V+1D0[?/E+V`()Q(JA/
M#P)#D,(_I$#W*O_0'0OMC!TUE"$NC]#X0AU3D8@RTC#L+#D',("!.)L`98/1
M<0!5U@]**[20>/`('C_RQ4O[S?G.AVPI(+\Y4R']/O.)02]XSNE;5B:UJ)KR
MSK!/9:X4+@94"MKUJ`?O5#O.\NZ=/N2Z'^IXZ1S607Q\S+%DW_F27]6DK4(,
M:[+I>PGA@30TK7PP"\LH8O4$.XQ:.P9+@$,>P@'&SD="</"00`UJ`QL4X?T.
MV`"T1I#E8E"D==5RQCZV<8W'8IL<5W99+24/3C0@PC,/3A0,J2-0`Z4L<0<0
M#@(%59`%=G<$$T)8%$)OW68N!!)-&2%->%(K/I!XU.%D&N%X4Z8AD67_$!1E
M>2TU,0G099XW@S0X)(;4/1X`?9`D<$CU/JST4WAV75W22#VX7C[G<^P5>[Z'
M%2'G5*GW7&]F<3<C:$9UA+PW2=?%>G"1/T^326UA<4DU)W$QAH@FAAW'"AAW
M7Z3D@^EU%8]T:51Q")T!-ST7`SX0`%%'0^.W#5M'$'&@#("G$FMG(NU"`1`@
M`P,Q!-L6.L8@`=MB#=CF.-/@4),G+O\D8YJ5=KZ`#P-"(+Z#1L*C$A<#3PZ"
M!550!51`!17(`9O!@L)U;!ZB?H=#;@PS!6]06R"D9(JW>$9@(D]D1+.3#"G@
M.?_A;!P86C)8@\JXC$'Q;ZS$>\`G5-_S5*OG_R0GMS\*]UQ+U32GEWO0QW)P
M)H79F!<^9W&Y)V?1^'O1V'$]]69<:'(@=X7$=VA*-3[8B$B-=&A=TTA9V$HV
M]U_P=4"BP'.F,!5W@@3B]RW@PH?LU$[?,"&L!5I/M#CR,2$(`8NB^(CU,40]
M=A_-DH'HH`[%F!*BXS%I-S#XT#MI!")&H%&%:'_[(!\,@HI,P`-4(`=54"\7
M*'D0D4=?E'9IQ`*_TS"#X@,QL$TA5`!O($Y05D[VMRW9,`TI5G_VEF'VT`;Z
MQHQ:N96%Q(YZIH6Y\I59Z'//ES\.MU1^!FCK&&@Y"&@IU&>P9XYZD2MK&6BG
MET+6AWHZZ&?G:#Y>J?\S9&$S%,=4V+5)7"%HXJ,F!,1\5=AG;39=(2=\`*!P
MK_$T7O(VFT!@'@`$:>`!!9``589TDWA#C+5.$')/$9%$Q]99*)80<*!$OP65
M\)$MUK(A#V$0771K2H2`?>1$]:`B*A*4:10BL#4B"$-'4[89Y:<$6"`'3$`#
M3'"3>#>)"TD.%'&=H@-N[U<P1K`$;V`W*K``=I`+C8(GO&`B\P`!"^4X&%.,
MY7(NI9.,7#F?R_AOT#AR"0=\I^=[J0=5`O!H[=AG3R$&U:=Q;'F.Y8B&U:>.
M;(F71AAR!/J6U\6@.?B?4EB7D>EZ#8=>"-=Z3]4TF629/45]3P(7:'9P8:7_
MF)1THK1D3(E`-T3@!0@V!0T&'^P$(=;2#?WG3N"29:P3=D)F,1>3$!+@8NIP
MFWSXAQR&8L-(;Q314J1#127Y(R8Q,(@3E.TW>!E!(D+@+LP#!RF@`TH@!5E`
M!37)!%F`!0-Q3Z25:_N01!U2#X@36-UY!=_9!8^6!BK0*XJ')U<0/!D9C,S2
M@@"";/4@G_29J)YGGTTX?'E!EZ:$>ACW5/48H*W`7H1`H)'Y?`0ZE[[WE@E*
MCN"30IIZH.LEJ:8::*H*JJFGENN5@Y%*<5(UJ_S#7DD3A(.V@^R(<59QJ;OG
M)#8CHA0'%A4$"8J@`K4G:@50#"DP!%@@=W%`#@KI_PS?HFL%-0]P((S7Z0Y>
MQ&`*\6*XHR&S>5H?*32L]:0?(3Q46CK"<SB'TWZ(PY)+,%LFB`1"0`PJ@0R0
MDP5,T*_1607Q1`W#R#F>$Q,),##N-Z^SY5'`X@43)YXQT$UY`D=%D"R1-QZT
MHR_K(&/FPIL.@)6*&K*>EP>`QEYGB(:=:7VQNHZKD)A$U6>ENK*::HZ^IZD1
M*I<*>H1ZV:"3JJ`8)Z%(*%0B][+E6*!@:)9O!HUM"`JH^G#1V'O?(P9@X*F#
M1H[999FLT&;%]!:/%@E/4&H`\`,"\$S$\`%#4`5J.@2IA1#;1F-+I`#PH0Q$
MRJV;L1`152[NH`_((`Y:Y/\\#G$C%@,ZQTBEG7@2*6FE!M-^[H<$\UH=)EBQ
M\Z``SP`%SLD#/!"=<B!WL",[87<CKY@BOB-'X-0JOW(WVF0''D`&Y-DH`<"X
M-A!U.=(MS!(NS_,.&`*;ZG(/*)"5(MN[RT6R,@M\CX9Z_`EHG,JI"!JSH7J7
M%RJTD9I"L'IZG6EQL%I];@:]WIB$T!>ITOMZI-J-K9J79RB.:P)G7XB@==(T
M&?J7\>BT3/-("U=G7I(V7V4'OJ)-*F`'*@`#*I`FO5(`(;`!B&BF60`%?)<Q
MN%L/G24!]9%B+I%'K]D.&.)WF)6M^-2W%((.WCIV'-B)!#(P!9*2%X51R(,1
MUB'_3K-E!+XEN=+&KY8KG?&4?QPR45W4(^T*6XT[**4;+$0`!$=)!D0``[6`
M)R_"`@/@$'I['U\G=I6'M[;;(9V(J+X[Q3,U!I@J!LAJA=JKCC=+JJ<JCR=;
MM+#:H*^'AG59<;`GJ9!:?1Y@!W/Y>RHT<=';C73,JIVJCK1W7QCZ<>UXCJKP
M<04*?,_WJN@+<5%#)\*GAETUMCF`+*Y6`.\7`E?@`V_P,"$@`?)1!31``U0`
M!?>$(R*Y,1C2+%XG634<#Q,L(,RSM]KB#/I19;83NWFD,:"%DA:51B`,;HI;
MP@R36R;X(N64GH8E!2\L!VJJD]MB=%()41U[L.0V3E>`_R<Y$`2!$P0^0`1W
M8\T9H%LML@O@@6O_,KN"RS&H_!\]0J523,7J/$B,FA=CK+P+$)YJHI<Y2,]H
M:`?X_+#<&Z%GR,^CBKVO.L9J@KUT?)=8K`*LZLX)&J$W2\=6JV=U/*EJ.<@,
MFH7"5*K@6,^=:5X.Q\=^V80X^(7IY7!J2"=B$`,P8`20-P"\I0\N$1Y&)*;,
M^<)2$`[#J`_=FL&MHPP1@G34N@&VB[L<>[$HA@XU(G;J8&PLI7X"12"*^]3M
M5S#%.:\9@5N,UPL>8@`7PPQ'P*\4*'<XFLR,=4\:V[$4("*-"TYVT\.J&RPN
M-#CKAA'S:@0.T#SZM'_"M;'DTO]'Y6QC,<B[ZQS8V6/%[ES/.3NJX6FRN=*I
MY6BR#UK8"7W',TN]]?R6*G1GS%N]")I"^:O9"LV@[JS&H4TG@4RJ`FV7.9M[
M3HBS_9F?&.J]A7Q[O_<)Y&BK!D<6O`($1'`%4<<,[K`!?X@,^!('8\H@92H'
M2A`[WD*[C9-%2!<-TI`MPVC.C.AL]D<1?\M/=LLCHLP?N1NY:\<"&E4P!9.E
ML/4P\RIN?D5X0A!C1\H,<2`%59"YB2@AUB!/%X@CQR@,&7$=M<!DS>%]UBPH
M2SD%XB9N&/:F1ZVW%U)VQ:7`?.0+NRO8%!Y(8X#97ORH,:N_03O9S:NAWDC9
M)ON]!(K_SQ@.>VZ<*_6<V67L<ZA;O=^+XBN>X3`NA2J`QJ#]Q17GQNN8X:Z7
M0ET!H:"JA8.,H2F+V>&[<FJROTA`'0N&#"86=J6%0POB('2WIMF@ME'Y+]7P
M.M+PAU]'7%KFQ/YQG4+Z$K0,4`25$.\0N56F`#XBE,@CU<7Y?MW)>`\CUTB@
MPE/&K?]2;?)]HV">'H3.+5EF@.Q";B)1*T30Z$00`QZ0!`L0`]8\."#55WU5
M!#3T/+!<(4(]YO:6NQ->X:1^/82-A'>IH*C'X3F(NFP)H>K8QN_\>UALCM#+
MV<N!T-!KQO\<EZ!:XBI^ZSE8V2JT',(^[+Y>X[(>M$\+V><H_]GK^'L@=[.%
MF7"0Q-BOW8Z7V12\0@0V,`*#A2/[H`/TER,I,"_6)A")Z`VR@XBP8]/J"1_>
MD$,00A]\MX'3`R"P>;LT1A'IL+%09'D'P1#PMBS3[:X&,]4CPK@5%DWCU)+M
M,I'&H)[-\"SS(A_G!Q_I`8FVZR'L@CP-4RM!X`6Y@KIID`0>\#>(IY13@!$O
M@F'-XQ"2%9+%Y>!M#D6D,^JEOO,CT\ZA3>MOR>K+#MM=+.PA[L6F#;TO_N(I
MA+IN+.NWKK_+8>*NSO163^SZ>^R<K1<FCH0(C="HR]"_A\9BG.'4'NVGNK.J
M^JBP+GO1^)\"L+U'2REB``2V<`5PQ_]W%;-'Y\18##(0#0E$4LG3?S@-,F]T
M/70YS/)96C8Z`,77+M99'2+4*7$@!'\@#E$.<#`Q:B1N."QN"=]730<,3]01
M$/!0/S8"(C8-A&X-&U`Z`@/RN=5&U)S%EI8$E!Y"C=+R:/VZ6ETAS@/*C(A9
MT;.;Z*+S/)_\1W+A23^73:_KE@VJ4;_K\:ST3(_9"%WB22_KR)K]G:I"$?KU
M;:SK*D`&^<OTC-WJ*'3]31_VG5WUG3W^VY^#T"^>/-Z9NI[JJ,WLL0X(8@N"
M@X*$8H@>'H0+C8X+BXV,D&(>CXX"F5U-#@82<4<<'Q0**1\?`P,2!A`Z<4I8
M6%!*M+1'0S+_([HI(QRZ'W`I'$.S2D>WN1\C'Q`&!JD#"0X.TA0.T`D)T-`*
MW0K.T:G9VML&WM]P'QL&%"$A+$)%0C9%2$8V[S9&2$5%^!0)GE$8`$$='#@0
M)"C@``7*$1D<(OH:,8`"O'CUFEPI`"-(#!4@/0#`D20)&"(9,N3($`").R'W
M'"B0L*$FS9H(NSD#9PX"A&^>(&!+T.;$GZ-(DRI=RK2ITZ=0HTJ=2K6JU:M8
MLR(=HZAK(J\>[*BP!&G15T6-QG;M:L=.U[&#/(!TNU:NV[&(*H55*]=N6$5M
MQ:H@$](M);=B^*Y5'/)O745ZW_Y-K$(0V$1Y(:^5I-=RW$B%,AN:_P39$&1'
MDQX)4-$E@X,-$4?D@E!DP(9EX1)`D$$,BY2&LV[%T<$AA?$/O$QM@#."F!1C
M0XX0'W$PYTYQU*91RQ:-'#=OU[%3*Z?SF0*?!AQ8"V'#!@L6-H2\OXB$G[5I
MVA(`-&?.&X1A#LE@R@C*)<!"$4;LT\045P3`41!`A+1`$C^($0,1.13P1@%3
M(,%"1?$(08$G&YP"1TW+_73.,SWY],U/V#A0E%8TUFCCC3CFJ*-57&T6F6-A
M6;:6'96HT,AC2`*F2&%UJ6#'`HK9%9A8B24Y5UUT/0GE6V.U!9*3=7TE%ADQ
M_"B9!X0A`E<E9RTYY")APGD:):+%Q0A:G_^!AAHBC\A%Q!0&C*"##,"P@X1,
M*6R@'S6[#1&=$H\*)P-$IRAWW"D<'/&;0ZXD\Y-//^WTC#CC<,<=-**RZ$PV
MZ@%4#CBH?A..`^^%0$$[[\"4H!$BNA-"JZ[B!PUL.MPB"@0I#A!"$4LTL>"&
M;P000`8^!$&&!P(``$`:0/C@0PXP%'#%%%.PH,``#KC7R8G(J5/B!@JMZ!^H
M+HXJ#0I&[:COOOSVZV^-/:Y5Y))?XK78DW]!<NW`2%XI%YB6]*79D((4C!9@
M;M'EUUV$A7575S'$@.9=@>T%IV!MR:FD6&YU7-K+J&G)%IAE`6D)GWFQ61:?
M-:=&29Z$I.&!%S#_A,`!<7"$0X$-TT@@@7K:P'%T1!#)$$=T0W2JRP@;%"01
M!U8K\=M#E):HD(O?@+?-4.*DDBJIK&KGW=JCGCL`.+C>VHZN]OBCMWKNN<JJ
M-;:EH$/6QS:CGPU+,"AM`9!K6$`.$0HP`TD>^`##YM\&T`02"72-[C4*E)B<
M.B:>D_:GH%J'';[_QB[[[+3KR!64"]@A<F1B<;F8REA^F3%=+GL,V,"(:?P6
MRH@)##%@3@KFYF)C?4GP\`\C5K-9EI"L\8^<;99G5]LGR=;-GQV)%IMB"%U:
M9HYX``,I<<1A`'LL3`-00*-K4Q#JJ!O&,9`Q$7=1;5"O>`YQBF,<G-Q$_P)H
M"U4YW(:NNXFJ.ZS2CZVDX9U3C6J"N++5>YBUCR*P8'_3"(%\H%:1=@P$61^(
MS=F4!9,F.`AR-X1<1R(T$AS\(',<@@%*BF"K@DB`&S<YQ6V681/PG`<.3ON4
M0BBH'MC5[HI8S*(6CS(&PLSE><:K4E_,M"0O0J\P&3,>RTS6NR6)C"T?DU+&
M"M8E,ZK@(W:!F!B\U*4Y>DECC?G+']D$)PG%17M@(=*1E&>^+#VF+.I[3"7*
M)[`]Q@`&;Q"".NZ!A"88H5RWFL;=;F,*9ISG-IF:!2X@\K5E\`)L0U!"@'2Q
M`6&XZT0H@D,WZH4J"X;C@M%0SZ]:U<&XE6IMP?],H7N$$`\C^&.#ZH%'>]QQ
M*VIJ@S_@($>ZBK"@*;PA)3BD5H14X`4!^-`.7<A!AV"0@R40!%E=<\83)8#+
M=IU"'3=IG2[/4Z]G2$-&^=JB0`=*T!OE`8Y[8:3$R"0\-U8/8H&)7F.<)+PO
MCJ5C9>&CQ"C*48OICC`?2<Q'&OHPAO)1+<]K8\K&9"2Z%"E*>-GCG#::1N,1
M[$UA,DP8/:;0*(4E!D`(PI\4X`"7+.$-&_&F$0ABD%Y0YUP)4(`R-`6%54YJ
M&4I$CFQ`88R)U%(42JR)$G\2Q?*HZI=KJX:M[A,0?U;C;^,9BGXLPDQGUH-7
M+`@!NM@C'_A8!!]YW8[_-H"E3",X"PE+N,(;HC4%&'SD0C%8@`#$@)(I,'-#
M+)#`<;H&*IK4$W6G*Q$P#@+!%@&E.],H04`+RMK6NK8I8QB+R%BVQB91M)`:
MHZW#\N@P.M+QIGOYHEAR)Y<8G+0Q@OF2%_$8W#N&#"0C383T^J)2ZWG`N`:;
M;O.,Q+M"4O0N?&D,PWH'B<ILR32]]<MC5`"$:\7@"D68PA*$@(3%<D1#G(CA
MB8XX@'/92@(C.$)#I",#'2PP(EH%V]6,94M>W!-%R.&LTR`8JK/Z4J[9:(=V
M8H2K6EFC5.3`GSZ60.)F(0$?Z()/K6P5#[[BPU;HNE6&V6.$^<XC!)TD5P:$
M_QJ$:AF)#!FHL0D12P$)5*IK4*QG<J`HC%V@"`('09N]C)D`U;[VREAN[1CX
M&%$PH6POS(6>%[T8$C)<2W</\^YOLS>8D9+YCM4CDG7K&#(RDRD&9T[N2.ML
ML;F8]"U>N!9O!T,&DA%,3(Q,65?(Y!@CL86,2E(?E)2'2+F0H1)W`0(0B.`1
M'TRA`$M%`@RZ$(0W-(%#0GA-0>"P-+W^:@`?<`XNXC`1L!6G1(*:E"].02!U
M0%D=B4J'+EN$'A8!Y8/DJ,8U3.4=]:0XL-M!ES9I3&+$3L%9\JCF>EI%WV8Z
M\Q\A^.>BU!,/?!BHVC;,0`%4$@2AJA,^+[X&!!Q\S_]3(B<V8-5%1,3JP".*
M6Y@?KO)JLTSP@L\N8`^3:/5"5M(N?>FYOI5>QY3KVX*Y)61\MBATE7LM/U/<
MN2&YXYB>ZR4RE_3-#Q7+&W':1O5:7$D\A;GQG*2FF)*%MS)?Y//4,D?B?B0`
M,%"!M]1-!&RQ5W<%:!8%8J@#!W0HL*08!J0,K&M7[+H7K.1:*4LI6@="D77T
M`D]XPA%,PG6'[`*IYC"C'>-HP@2Q.?Y<>_3G*W>P($$C7H(1\AI*4:8BFGD-
M=PCN08\%I5O=2OTK"W2#:W?5Y-=./5HNMH;/)D(1.]54L:T<8&6#>_[S_(HM
M7>"<7.O1D:4%0WG!1-;1BOO_ULQD(DS+G`14.-]V:!`'"9F?FW`RJ7S,%2^]
MF2O#\S,FW-"*;K3&>Z>7WJ&49L4M=,+!=*VR[-;2#_=]%'8```%L205)`,#0
M*D$&+P0!!E,80$0@8`,/134:4A74$61)B^@8*R*N&%1QL,H+IX95'3,!03EQ
M'CKA-A^43.IQ#09P*JBE/X%U*M30#O#Q=OO0..1R8B*B-^[0'NW'#\VB=VLE
M2O*T@-OA;!2`(/+0#YT4`%=@#U.`#TPS$S7A?P^F#&!38%F#5?@$95/T#>.0
M>>W!=YPW<*!7A$:(%7O@12JW9JYG>WLA>TU8:%Z`9TW89I@&<HJP7(^E:'<$
M>U18_W%FUESD!`1N1H7'E7KAM7HD%W$F1S!5.%W(924VA4>U)8:#<4=!)0`$
M``!`L`-/(!<`0"$>H!*:XP/D5``L4!-ZES\&D`*X5!.94@59(`NTX!!Q8#4#
M=`PZH(.O!%9:]0$RN%]I`RL7=C<.L'F$HP`,F!]_%3C1=HJWPDQW56.-,RY+
MT`_OL1XJ5%?UT01ZURNN,A,J8FP5E"Z!IP\Y-@7N<`W1X`G)T0NQT0OW=C2.
M0FO``&$4YD_9`2QU=Q^==X3@&(Y2L66Z)WN]IX:M!X5@`G*Z-U+.E7MDX@7*
MY8[D-%*EYUR6ICNL=V<.=UW&E7&"`01>,(5\I@BYEWKNR/]2!9E<9A1<QV>.
M9_ARO7./X`4Q5Q)FO8=Q*I`2/Q`%Y1<%,R``'O`#.S`#*.$M/D"07C`%[1``
MO2(!`L)O'Q`'4E"3P`$%FV*3\Z<$Q.$NRO!*E/<!3O.(S3",%"0."^A"<15,
MR7:*'-@>?2=,?,5,=T=B#')MM[B![!$?O&AB0O`KUL`*3T0O/@$-IYA7\(`@
M-K0$X28KK%!+G1@;RF`ZLC$IE+*#72,KU`"6&J@W;/6-XAB8@KD5'`>&_XA'
M=+1G>#12$:*/#X=Q&LE0A!8#!/EFS[6&8UAG_GB9A':'GHF&9*B1('>/KF=F
MO*<[@=90I'E&]L@\A$9F@G%GTN?_90WUF71DFF00!%>@`@2P`P*P`R4I`&E@
M!]D2`T+E`4```.PE`#X0`$:PE0,`C;=6(KP12S@I!57P`DQ`!5E0!37Y&[BP
M=5LSGF'E-"E"@-Y0#ARD01^&6J9"5_-Q0GH3G_#F'DA`+@UBBR:D8NW1#PBR
M#]_6"?V!(LL116ZE'[62EE/`@D5`.FE#3PFF;URS''2Y-1.1*+LD$+_"E]IV
M']H!F(,9HN"X!U\(>[#7CN57:%WXF/PX9H)F>^\8,E.HAE_H6QE'&(0AD!I)
MD(_5HY")<A\1FGAV9U189R?ZFC^*D"YJ9[*7,IV)4O0X?*]'<M*G74]ZFYN6
M`T0``#M`_P#>5Q([H`(8LFE"EP,"``-/<$=B``0P8`,TE``C<(G'0A.]D$!4
M0`,E<`$:@`(\P)W=^1Q#,!'C"91A]62@HC;(5H*;-P[:,1YGV8T2N&+O<!&)
MM:#1<@6W&(1]Q4RZXDSYTU^>]9,%"B/<F*`PT2#ED@IIPT_!L`L1UEFF8QS]
MYVO7$4T6X9<N%'"I180BVJN>1Z**B7$X.A@S"ETFFG%WY(_ON'O/)9E:2(7Q
M>)#`9YHQJJ.0B8<R2H:Z=T=3.$[0I9@S*IEP5GZAJ:+T&*,/]WJI)WMA.'TF
MEYC655Q#VF9X5J]>H*5@$`51\`--$`0>$)(%0`0BLP`QX`-=$/\R/1"('H`A
M><4L2+`0A/(IMR$#`H8%-$`"'?``#T`"?+J=<@"HK"2HPK!K!`H,/@%!Z7DW
MJLB,";AYVYA!?P>I=4=-D7H@]QD`EWJ+\P`/&Q@?"=(/(2"6Z6"#7-,,XO`.
MOI*@]<`@5Q"TYN`VYZ%96!5/_76R<'E/I@04_X2T?(>KA/-/,^*K8OMYP/JM
M18JCU]J.D/D1PU>9;4:OSL6/&;FV4ZB2Q$JW[85G1,"C7D"&T4JD&#>0(+6V
MO+=Q#!5[[GBDL:>X%"6NR^J%H@E=NF-Q;PA=RGI=\G@AB2$&,]"E.*`"0V`$
M8A`%/>`#":`",Q`6;.H#C9`&,0`&!)O_`[1B6$U;"A"@&\(02UB0!4R``B2@
ML0]P`6WP`CS@G<%Q!)<X'5]S+$)I9`.H(MU`=AV4@-0;5ZPRJ;EXBFL72N]!
M#_U08POJ.7CE*Q3X;:YB9/U7'+KT=Q8Q@2<T']R$GRX956Z9$.\"15!U35&[
M@RB+0=K1M8V*'R`F<&-;P`6G!D/ZHT::I-%:<MH:(6X&N"'37C%JI!*LMD!P
ML(&[MEVXMPN\MK+9MYKFM_;*HU`ZA>579^7*P1Q,:,H:K(0KFI'9<-\:<MM*
M!D"`)I?Y$>:W`#AP.3\P`T_`'HK@AP70!.8D%\W98SD`$N%'!$U[#^3"DA7A
M`'$J-I+(!#2`_P(:<`%>K`'#2P-94)-54,8@N[Q,!"_YU`T*<1W))@Y*2;W,
M%DU/F3_+J`T6(4P3*`_TU2!-8$))6P](,`]?*6^BQ6OKP!WI,@_3U`X^VS@L
M^,<.($&LD!#XFTWD0(`4)BLQ9@WW$96F,AX'J`&\:L"F/%!C$+GT*INVQ[86
M[*/M)<'U*J2FJ6F$RZ.S3)#82G*4R:W72IGU6J]CV*TQ+*P%,Z,ZVJW66LQ?
M2(\PS,R4J:V!ML!H"U+#2DZKC'%$H&E)@`-A`)PS``0+\`0`0`#A#`27@YQ!
MT,2#8)P^`&J?5"T!\&EYM7?-(05,P`-:C`(ET,4:0`)@3+S=R;L\H/_/50`I
MNB:7CDA:9%D>VX#'?JD_[1DW9^D>[Z"](70?OD(/,-@L]V`K=H<1:`D0!:$<
M!7HNV9$/'G8K\.!,]]DA0A!5_<%/+G)V##C3/JA!+KN-^B,L!K@-I'S*0LU:
M)%JL,@K,`_FC()7!HDF&MFRO0.6.0+7"18IG3ZV2M!S5V?I<E2G+"HQQ7:!I
M<:NV0WI=@YO!Y8?+0"6P0$6D+5JDE=FM<#;![46082VD$%=G*"R9^CBXYJ><
MD44`3]"YE>$%@ZV<9`"<=N`11+"WF9,!_*"E1&`'1+`@!2`B\@4!<5`%/$`#
M//`";:`!HCW:*$"\5'#:GUT"*,`$#H$+$D'_(-3!T&4E=G?3'4+(0;J:'6JU
M5FK7OK\R8S-[(/(`;AM(E;\]`">"$(\'-[CR8FSEE"/&#XNW$RNBC<LV'M=$
M*KT=@8+5J-SQ-M$`HD,]WE>$P$3*H];:M[>,UT#5K5[0!>K-7L&<K12<U!CW
MU/>-UYHFP2#5V,L\P6H-5+HC%D2@>R-,UY2YS:'YU".\U]D:CP/)MVT6X0Q'
MAD&`!#X0`_#=;A.LU4>=POQXH\-'F9#P!$"5!`(0`X,=`QDP!63P!"(9`U%`
M``N0$BF1`SZ@$AD``]=%AJZQH'NW!"P0:U`@!R^``OP\VJ3]`I[-!/G,Q1I0
MO)QB:SI8H*((O<<6_PT6<=R#U1VZJG9)&WB+^D^XF@]!Z,FYPJEZE0I0IDL'
MD:BMHF(#4:LJ_6'HB1X(N(W[,SBY2DW>+6X<E"JC7,KD7>C^8MXRFIK`O,MX
MZ`4J%^%/S5XDK-Z!.Y#_3>E)3>&5;NFAJ>DA<]?LK6F87BU^2P0XW%[+G,+.
M)<("28;OK:.F2>D+SM:43M=,;9P90`$9H'<P@.%&X`/:FN@C;*W?:F<A0P1H
M^@1@(!?<]S`%4`0P``E$`"51@`,"<'X%D.$PD`$C[`'K#`-%D`#38FI(T(CU
MHP0\`.4DL.XDH*>J7=HO$._\/+Q,X)T$!A&)HD3*C1!83BJV:D&#Q:C9X?^7
MV!N$8QY*7NNU;N</4&E!-)&-`]RH-O!"&V`W__0>F:PZYX*K$EUWN<CQUBO`
MM8U,!AC4AG[RLO,%PP[,4:W,=#O+MJS>.`R9F\;R!S[5,;_@Y-JWD)[SK9[S
ME,GIHL[J`MFW%!``=Q0$89T!-C`%.^;!U6*<$#+LPX[5F^;J:^OJ^"W"8=VW
M39`!YB<#'8$$DE6P>ROJ0IKVY6JV%X($(J$"*9X&.2YT2)`!`M`#QHD#.[!]
M3Q!4*G%)_GI)1ZRS(3`%09`!31"#@C($G-T&7OSXP:L!)=`&)5#YDW_DI<T$
M8^S:!6004`8O_9YL'.1+))@??!Y"=B?F&NW)?R/_@6"9M!RX>57;1`=:*L(R
M$PBAC4I)-P\-+`1/\+S]VVQW3+'"R4!-Z"B?_#<"K%/-ZDF=P9R.U$Y-]='<
M\S8?N&A/!*#^\VN]X-,/X$-/]`J.WYKF`TMP!$&'^#YP!>B"$(D_+1\@'T<P
M`E,@PO[MWU2_X$%_X'T+"%U`0%TQ1(-`,!D970L>!2H>1$\X*C`^/D0Q9%Y>
M0%XQH3&>FV1`FZ=!0&0`"S"&1#DY.)("`CA`03LSO#\J0$1$*D$J:3Y+1BP#
M`Q0)0AE-12$)$"D<1W(\;1</#Q'>#R0:*"@E&N<O/#0H-%152D,R'",<\Q\;
M$/D0"@H&"@,&EB7P%Q#@_[(!"1((3.B@(86'+"BPB$@A1`@6(2I:I.#PX46.
M%35:S#B`G[Y]!`4B3-!0H0()*!$ZT#BPX$&6#!O.%/F0IDX'(1S@E)GPX$$#
M!9$J':#AQ)^G4*-*G4JUJM6K6+-JW<JUJ]>O8,-"W4,F5*=1B(!U`86(U*`8
M:0=Y^@3W[5E0GCJQ%507+E]!;Q'QA1OJ4Z>X@P[!#1;#QP`./@S]4L#B2H$,
M`2"\6/(!#I0-`Z;DR)`CR*$@I@$CECMW+F#%@X(4B`$@C8<9"\"H(+,#!VH/
M/H(4.FQ8KUZZ/APTF0+#"W`CIKH`$$#@2;$%,TC_2-+*#A`5,6#,%J`B0(@B
M+/^J;5!`H8D0&Q0&P!DA0PH3&AJ\N;CAHD.$"^.T<8X&)=!PWPLO&(C%$3K,
M4\\(]YP$4T`.".2`/_^49)1"*^UT44;P3332AST]Y-"(%DTD4E`#G<0/4OT@
M%!]+0BUC``0!)<122"6]6%1+.7F848D<Z3C42CH:I>112AG0E%A01BGEE%16
M::57>XABEEFKI567:X.H5IA<;2T6S"&N$6$:(8!YHEI<H*"%V&*J=$$$$@&@
MMDP09`CP1!!&!.%#:40(P8(/14BP00P>`)$`!Z&I8AIJ9W9AIZ5$O"G8(;%T
M@5H0.?Q``'?;[0#`$SL($(1UF*QIV&J<RC)%#`L(0`;_#`$48-T"NXRZV`Q`
M"+`+&%X$U]@5@<8BQ`!".##"$4-P8,`231B1P`8<Z'!$%>JT\4`'*YA@@@O?
MB*/!!0!J0(,Z-"#X`A-21$L/A!O`<9*]_\1'(8;+Q+@241J)*!%0$V$TXD\[
MB<2"#0P+62&&_/2SU`!`R?3P4@C7J,`^..)4HY$>FFCBD4L6M6231D6L``E.
M8?4%'')P<>7,--=L\\U593F*FVEUPM@I7O!%R"=#>Y&I8G5MNE:7@MB96*9A
MMG6(G5/#"IBG,031A!*EQ9#!$JIXL8,/0CP7P'<+!)!#$2-XD`88,,!`:6.Y
M?$KIF6H&T[2EGN80@!!KGQW#_PX$X)#$#&#@]H.I0<P@2W"4=DE(#@]EL,,.
M0,@2@MI/?,?+#DDT%H0`"SPA0!(+^!#`<D@,E``22PRPW@9*8*'$$2DX8`02
M`XPP!!125,'$?21$4(.X_3T`8#?*7]!&@DPD2`,-51PA#P?WV'L2Q"4A-0`$
M<&3X(E$)A.114`ZP`)0-AH;TH44=*6S#1$)RU..+`=E$,4+_%D1C^?'96+U0
MXC&%<&A')9I)C19B0`XQR2A-LHG*GH05.;C!#1/`F08WR,$.9N4+IT@,7(03
M#$)DZC5IR1LP7)66(,PE+98*X2'4@@BHN:E248L+U5:H%C3Y(`0R"($/,@`#
M61"A4?\^L$$(/!`$).1`!2K`!`P^(`0BP"`)`O`"=7HP@R=L)SR9"`(,\L8I
M-3V-"%=PP!NN8`LB)`$'``@#`7K0@Q\`0`4"F($``("#N.4@.)C`6R8.882*
M("$7BPM"`)8``3)$(@,^N%P4_C0:(A9`&!DH@@$V4#X%I``"&9%`MF2@!"E(
M`0I*X``$(I*"(T!!#O?IU@4Z8((5?"-=W(C`-]3%!![X,D%R@$(<[+$>E-UH
M?#!2U,8,4"&&&)`C0!G2BD84,($UY"(%,Y004)21%MF+7R?SWDUNHI--;F`#
M$N`'3LI7(8&83T5&,LB2YGG`"/)K8Q"X0,NN\H4_Y""#'@S_J$`'.C,0NFEI
M1YM:IEBX*1O""AAG"A.::B@<B.I-H@IM4PE-"+4RVHEL(2!B$#P0@QR<0@R)
M*``,,A<`&)!!$Y]2@2/NZ(,%_.`.!)A!%!!0"5`)*C@Y4`0D@_.8E@X@!WLD
M``)V8,<D(""G3WBC+01P-AP8:Z.9`H^D<C"`(OQQ`4C=@0H*\)`H```,P-#I
M#IXPFF%D@`49(,(;0O"!.'S21@J``P=DP%<9;,N40QC!,C80A]H="`7Y<<$*
M_/.``.6G>25($`]ZF2`JR"&5*8##A""H#XF9)'P;\]<ZX8<P;HZ$2`[!2,%8
MH$UIPJ\F!H#)^%82%(!$3)S>*]\T_UZ"3@,@L"5(T:V)?F(R_<T39;#%+8PV
MID^M<*$!.2"H=*=+7:Y\`84--:$@(JK=Q!!--4[#6PD]-:G(44V\'.5H1]>K
MPH2"*@`^``[8[#",((@A:^2)A!@/P8A3R%0,8@!.$``0!:;R@@#=^4$4Q$"$
M$;`/`DL@HNP*4"N=$H!P.+"#!\``NK/B0(_3\4`2"``$'X2I"XXLG0!(FJD"
M%(```BB`$1:P@$)!H`N+`\`A9D``,5RA,GE,PBJ(L+J]ZH"9$K%!`O!)CR%P
MJPH<V$`*SJDM)5"A78C]E@NZ00)VO"`_MVS#]-;%`P0Q(0M*@)!L?8O7C<&$
M8_KX`([D2?\C@F4,FP8[+<(J,K^%,4R)\$$M0)`"/M\V4X$WBB#_"A+-^(`/
M1R`ITJ"%"R22&5=)BAZT/?L1L>9BY;DRJZZH1SWJ+\R0"'.)P0XOY32TZ.V&
M:^);,+P@'$QQJJ)VHM3=[*;>[49NA234=1E],`4//$$(.HAO$CS0!0'`8`FV
M"#"C!""+4)"A5F*P*1CVN(,>;'@'D_Q!YV:P"Q@8^U2ULD,.8C`#'&`8`'5<
MP*FBP!T!_$"/*T[#+0"0-:,-0J9/:(48_)0$+P``!E,P`L)!8](C`B$#0@A"
M&J:@@`1<809AV,6?%LF!85ZA"<Q`3P#IHP0YB!D*.AA"@X8P!&S_^)(&;2@>
MN0B$@G0D=LLH>'DZ7I!S*<3A'KT]B)L_BP\)R#9#.:+1D()"I-7V9"-"\8B(
M_OSG$,!')P]1B#_VD0"2R,CKPTU(D1!HOY=`@!G.7(A#*HUIFTRLS?_PAZ:W
MGH\7*<#35S'Y!4G-][X'U-2O,4T)-PILP7,W:,!0+Z7\K0F]B1>'P3!Q",]X
M4361UU-EM)L',A!@+(0``$FX-^G$XP$`B,$+*C":"SU0EEJ1CH^@Q\$30D$X
M`DRR`&F0O0\`L(L>/*$'?%P`ZGZP1R#P0E4+P,&*:75OXH.^%>`1A8;=MH"!
M>_%R6<S!$H2`A1<8P0Y&^",_AA#A*1M`_PH+"`,`9J"")MC`"`J@1Q$"8`0#
M](0%"8##!X9`A02]P'9*H`10`#RPM`Y?]BVWI`%M4',/L`(.2`('L@[K0@58
M$`?#]`%O)C$W@B\2`%J$IC)UMEH9@74283`4@1'-`!0E."(%,W8JJ$"#1C'8
MQ!'P$USTXT[25"*V]0]&`C*_Y4#\8R.)-EM,XB]S)R'@`P=X9Q5O<$%NX'=0
M&(4UHP;`1D8X!`R>D#>O,35+<UZ/MVIJ<C=XDWBJ(%Z&9X8116P_!%3KY@-V
MT`0A0`QV8&_DT2C3)P`Q,`4%0%*[(5-[%%5/4'J[8"NW0``Y%0.H4@GNUAM=
MU`7NM@`Q0'S;,?\#:0")3_`$:0`>I7.)"Z`"8%!C8,!ZJ^`!NY%M'F!]ID,$
M7T,!2H`"`Z`".2`!F,!71R`$/E``'"`%4Q`&"-`#,8`$!6`#2"$#(X`$F#`%
M(1!<2+$!4B"`*'`!-"`'56!*`R@\/,=S8-8-%]!E-%`"QK,"#[`NTR-9\,)7
M'#!EBG).,-&!)F%T^`(!1^=;YN,1T%0_YT."V,2"(U@B3)>#UR0P(\$A,U$3
M7\>/W=1./9@D%B,4)I,A0H@C1+A<&@@Q^%1W&Z.$^R2%&KF1&F1J>),:GW)J
M6/5X%25>OA8,9YA0>+-=851X5BAL9TAL;V`#:E(`/A`)?N,#>(A'I'/_7XF7
M1T,D4W;@!62@8;7R`XMS;\.RB82S`S,5B")F8'M$8!Z`'2N&`S#&;J<38!IV
M.G!#!A[P1Z"@`IGB2#&@878@!@%'.I"T!+>3``40`!]P5#G0?2/``C"@`%7`
M`C\@1PL`.U,P`#(0#QSP!I(@!-=2=TOV`;G(#07"!-)X2E60!3R``FVP@.>B
M`21``LZS#1'0`1UP`2@P/&/F2U7`<O)P#Q\P`E,&!Z[9CM@B9PK0&?OP#PK4
M$0R9,/4X7`EC6ANQ(O08G"0R@Q:R9/OP=7@V/S0H%`R9D$"(:4)(:!BB%!&3
M#T=7D1!P3@,$/ANPA!SYG>!))=?EA0L5DA85_X:&]RFY=H:Q<1KE65[I24*9
MX)+H&9(FEC=$M`B:H"JJD`8PH`)VT#F;D!MB8"G!`01BD`%```"D"$4>4)5B
M`'H'1@`_0(J7F`0[$`9=Q!W`H0)1Q1VHDQL!5V,]@`-IL"I[]`/W)09@X$6#
M4`!-4`!"\`K>M0K3EP1/,`,_``-=\&-#)#M9D``9H``EH`0LD"O`LP!+U0,N
ME@'P-XT<4`5O4&)%X`!%QV84,`(\T%B7^2YR@`52@`55T'_G0`XE0`[G\#PO
ML`V--9I4X$MPBF;P<(X;P)C9TQG\T($?D`(?L*<1XCVZ.78T4H_E(W8DJ!'3
M9((1@8*[.1,H:'41`?\01>$C79<B?A81&Y$3/0A<ES9W6S>=6X=/1G<2\&AT
MVGE.^O<!WAF>K-JJ7>&19822852>CQ=Y@G>KAI=K9@B?=O,IF0`Y@I*>8>@I
MF`<#%*!2)A4$H6`:1412_#E&C3(,*[4(06`'%0J6IUB552DL41`%/0!C>*1\
M'`8Z24`L(W6)I#@#I[A^`/`#8`!'`A!?I`,&`%8KEP@$!0`'-@`-/Y4#,Q0#
M,K5^.8H#C5$`IL$,,L`"J\`"11!732`#)9```E!@/F`$;X`K$$!*1Z`$&4"6
M4\`"-]*:\2<%7V8NCTD%65`%DZD-)7"98K8.)"!FW=)EP\,$5$`%PT,%IW3_
M!`PR`G"P`?22`CX+CZZI?R-PM/C@/UE'(\6I(RW13LTY$R.H@M"DJ"(R)%AG
M6F5W=@8Q$^US$89R6J3%G+FY0#82A.*$3Q_H#^E4JF_6@=R9JMFCG:OJJG9[
MMU,!JRB)DI-R-+@*;/-)1B'9JV)(N*TB*,%0&I##M[TJN$UP!3Y01#GP!CGP
MH%-``76R`*?P1/'*%D&P!(=4>J$S?;5"8V*`E1_&"U49>J?3&]N&&NUJ'63P
M`X[@)WQD.+8019F@`A%:*U4)`\LR!96817^#&G11.CT0>J8".12P`4O``05`
M!A_+HT&@`$IP'BJ`8`-@`Z+Q0QQ0.P:@"DW@`$)`_P%P,`3#-`18<+,\\%@7
M4""3Q;XU1P[D,#W;X#SKL@TO,*83>+-90(WP,`)&)[3U@$ZNJ0]UVJ?XT"$?
MTQ!-ZYR;^H([P9PC,1'*:3ZIQ:@3?"T?P&A\=H)A2TW0Q!#+T!+S=%RA59UO
MI@\=>$[<F<!`E\`/D)%X6\,U;&J$*VQ[R[>,6U[UF<.6DL,_A1J0H[C!\9%V
MHR9Z6`1Z&``!8$ECM``48`-]8AM`L`!VT*Z=>)-!L`%/)%,_``0/Z@%[1&,J
M`&^'DP8X6CK3X6Y=)`:F,542"HFE$WK$5XD_E"<\VG@9$`13L*]>T*)WT@1+
M\$<EY#8S<#@PI@E(D`(4$/]8&5``4#``1$!L"5#)NK`#&6`#2\`"?\0",C"-
M@>(#9Q<`+"!*<3"8T((%/$`"VBBS-ONF6$:_+X<"RE,@TV,[5$`.\1O+6!`M
M^)"=\V(O<&N=1;O`(W,36H<D)J,0E<80A/JT%2PPB'H^&,&063>;'V";U91G
M*`(20(*0"BF$3*(4\`AGCT:J+5PO,`QT??H!,\P%?#//]$S/-GS/?(?#29S$
M83BL/QRLO`J3/ER?@%0:0QRLD'.XD#,%$&`#[@&\.4`&D?M$L!<#:6`J^@8>
M2"E382DW#IH&HH)%V>8(G9C%,]`#:W5OK<`H'J!AAN`!/X`#P,=%`'#%:FQ'
MNP'_`ZP%`1R@`%?`,`.`!'*C"CY@-`7P!G`1-T=,*XM8.#&P`5EP!+N,EQ+@
M`&,TDRP0"1P6`Q`0==22`%!PCG'%&4)`5O;"F-GB2CR`+AKP+CF;!2DK!^M0
MOS8KC4S0<[=3#[N,`C?;?Z.)<BAA`/JG*'+VPL&<#W!@:,V@$IIVPLW)P.O4
M3`Q1P38@M2SXJ"S"3O$7(3+R=#.(9Q$QD/&$)&=;VM4)6BQLJBM<=_`H9_K7
MS@JL3W#@LK1=V[6-S[A=75]@-T=,Q+V*"<#ZV\$MQ,2-T`:=T(?[4ZWB&`K0
M!+=(R'TL;[$``V(P8K1B*H]D4J?`*`8P&P\:"<+2"@'W_Z".`+`QO58+T*V^
M<(I_PAQ>,(<@6CID?)1DH`I3X"P/D`60NP2T,P4R-0C!P:,P('P+T`5RDRFW
MT6V7,P55H`,%8``?\&P0T`D%,!I5I`E@D`,Q(002,)@R8`.12Q]",`4&,`+V
M)TH\*P6M+)HV&\LXR[X\QPY,8#L\FTK9*;0RT->D)`5OF@5Q`%HFD0_T<$Y`
MET[C4T`F,W?0R9!JUPSCO"/3S*CZF(,L(3OS@`_C\Q,2D8/#M2'/"4'4J3)N
M1K1%JSW6B=AR)@%\^LY$WITTG-MP+H6[[:N^_</`G=PYC.?$?>>"\D>^>N=A
M-"C`:@0R\`%7L`0)L`3#T%+``?\+7K``U<I40_D&443=,Q``4\`G#YJ6Z3U[
M-K5']`H>$YMQ`_L#=N`IY?U':0!ZFANA`+MB`#`HVE<$2Z`VD:"*ER%&?Q1&
M3$12"Y`&*]0%'MJM.T`$=7K4&S#@$/?$8U0$"8`:CH0$QXD10Z`$4*924Q`'
M=VD#$'(>CQ*`NXP.D]7BT;.`[-`N/$`%@84]..(]\3<$0+N:(P`%4;T>^Z!,
M`[!_V%,/M$D0[-1`9GL48,Y`0>*<0A+E%!&<"40-OL,!B:TDT#PRFNI`)"-/
M$&.1=J=_9%ZT1J?:\,C.1WL/+=RG=1OG)D]J<^[;!SW<RKWG>I[<:@+H,B_S
M1+SKHV'_O?:7`$4P&P9@!/#EB4^@.K2"1\OAQ-(A`&E`!JL37T7I"&F04Z0H
M;UVT8@"J8&$0!>ZFH99`"3.P"3D*?(T07U49#`50ZP508G+C7V$)`9@15.O6
M<&3LAV)@"D"0Q0*0`4,P`)B`!#)@`+DPXO[:!81,;&*D9.E3!`.0`OQW*`4`
M/@/P$0S;+'`PF$QPF7-=<V-V@&V=(%&-/:#Q/1(@CTL6`@H@91_@2E$V#S_K
ML_%'C(Q)C+5YG,M<VO%D7$41)#KAG(CZFQ6A(@D4/Q52^MACFT61([R9^U_>
M=IM&JOR@\1U8YF5.F^FXI_12IW3[YB>?_=6E!T(,K,O].`>M__+`3<3+C=R`
M#OZ"C@F[#DCC#[SK4:5+<,3MHY-V\%8WN6(+`+FCX0-V!`@"70%P0"HJ`&!B
M"SU)"X=V`#@X`BHQ=C@[FC@$!&D%:9TQ0`))/P!I:4!7EC`%!0%+4SXY&3Y!
M04!`N4T%.4(91$$"'HD^Q3,`N$0>01(Z,#T+0DH)5[T!,#$>1`4P1DM&4T84
M-@D2'U`C1@%7*0H)%$4V!AL2`W`C1U0O+SQM&BX\T$`0A88'`WDP@<)AQ`8(
M!@8,B.B``@6)$"1PT"&#@XR/*?)Q^"!A@\D/.HYP,*``C@0%+"%`4#!1`<UX
M#A),C#@@0<6<"7PZ&#HTJ,^@%$(H9?_!(D3%$!0J6K1(=*H#B1--\AQ@DR+5
MHD6#8AV+U0!+F!+-VE2044)&.'!,;H`K]V3=#RD^Z-7K4(*$!R?^"!Y,N+#A
MPX@3*U[,N+'CQY`C2YY,>;`>'YAOX0IR2W-FS+A`?QY-NC3I'#E,=T;M(X,1
M)$M@!"F08<D5(!2:$/%A@$.**9QC+/!@!\R"'%Z>X(BQP4<1,AX6"'B2!,",
M'CBZ`"&C(LF.'@+LJ!`P@\`.'#.B[%`1!`#V\:J$/<$=!$:3-TV:3,E0/\=N
M'T`0H0L,.00P``Q$9+!`(@O$D$-WQP%(1@@*^/`&$4N$T$0&,+PQ!8$J#!=#
M$$T(<45ML!G_\,$(.B1@`Q)"*"!/$4NP`,$'<!@P@@Q2\.#C/P)U0$)`%PA$
M`D`O<."234))])0!<(W@D0Q2=@0!'!QDF5<*6<HPQ`@*;)#"0S--]!):\2@5
MU5A"(3555$$!Y294%#!%9U-J?B45G!&)!4%9-O6D)U!7D6763F:=A1977-ET
MI01T[37727M5^L$&*^I5%QP0`%;9IZ"&*NJHI)8:V66J?98::)QEMFJJG=&2
M6A"LI<K:JSX4X`"-1A`Q2@8V]&I$#"KXX)L#P0B71!)/")`+(C,T\0$04S#S
MR((`2+*#`(^$6!X.W0H0113H11'&#T'8\0,!,QP2PS=IB%%`:T48_]&$#27R
M!R`1.7011`P!;.!-$ZT9H<(,W"X`H`<,>^%%%R$L$<,M0K"`A#8%7%%+#$^H
M$"`2%%PQA0U%%'$53/'8$!4X1ACAP)4S<1!'%310D043*)0`$$$71!"!!B^@
M0(,4'(PUU$1QOKSB$4,T!,>**=Q8Y0A\;23#0RN2*=,&([S4DP-*J:F31$F#
M'3:<..F4`%10/475V40E_17941F@TZ%?HWU43X8>FNA9,D5DP$M^0>I27)52
M:FGBF<IU*00;=!"8J917;OGEF(.*ZFFRKHH:KJKZ\!^LLA*(&>B@??XJ#$*,
MT$0V/BP`1`#YJ4!$-U,X(`,%/H08H@=D+/]`X`(_B(&$#P(4$`09,<0@!@#+
M[L#N#]P6)ST`S,?`R7GC1O%$%Q[L@+``8F0P1!,>^""$$0/L5R\,`*!+QFY!
M^%I`$3EP!@,,0$2G`G'#`8(/NG`[]G2(!05@01$,<(6)^0(Y:9".%XJP-@<8
MH"D6&8!%;*`R"E1,)_:8"`1D<(0L\$`*56""0K!0!10$*0(OJ$(5&K(!LOD$
M3G*2`(NJ<(0/1$0!?E&`;T80DHRL:`0Y4@!>X!`HKHT`(D^QTYK8=,,W$:4J
M.3%;%I^2$XL8Y8M7I,H-MR*4H>BM4&D1'$O4"+BU;`UR=;F+IC"U.$GAY5)S
MX10$."`%$$PN<X#_#*0@!SFJR^1O-+6BA2)EY:K/;,95B82D:#YWNEKE@$"?
M@T4"<D`*0]1F"A=2'\ELH(`,;,-V'C,$#*80@S3DX`VDR$`.FF>(!22A!]\Y
M!0"(0;PPX,`#E@"`>M`CO1[$P`L]D(0`8&"##Q3A7_,`#K!LD(,=."(&1`@`
M<&;#@7FI8!Q!"%$,!%`)%1"("##P@1WLX)P4"&$)0"A"`-29@P)@DSA/((,Y
MN"(!,T8E!.MCP50T,A)X)&"$^V""$I0@!RFH1`;\Z$`'-####\B$)E\+@4#7
M-K8/;$0*2D@!3@8PDQ2,228R@<M-2,JIED")`P]9&U-LT#8*C&T`8*&3_U)^
M\K6?^*1M_K1B5`@U%;AY46U1L:+:^G:6ORD*4BAE"^3T8M([*JZ.BYN+7S(B
M1"K08`)_)*18QTK6LNIA5J;!12+7RII6988SD;1D)55'UTMB,C6OH(4=@#<%
M(0CA0^&PD!!RT*`G>"$(8(#>OV`@RS<,(`,9``X9R."%$'E'/=_!01(2"X#O
MB.$08L#E##)!+CL,XSI)$$("O)$#'&2@":@1J"\6X`4P>"$#7<A!$V8SA?R-
MXI)$V*MU*H$$6<XS?[`PPBNF`(<3"0.6X110!NI6)HT.97U&F(=-]X@CNY$T
M#D.`@A+BH(,X^/"@'^'!T'PH58C@-"EM2P`0/_]`)0Y@@6@#:(H%29H"AYB$
MB6DQDSVXJL,-*,`!3+%3W,9VE#TE56]-BH>>K!@6H5#E34H%6Q6/1I8TLJ4K
M:[')5DN24DR9=`1$I!H=JTI5D^;%4G)!QP8X0(,'O`"L9<VQCG=<.39X+E6M
MJFOG/+<JMU9RR'6MZ_[NVE<?C,(+`)`-+#S4BU5R0)9!2`(W2I$,#WS(!Q_`
MPA4H4%EB"?<)DL#.#LCU@QG\(`H$2,(A5/"$'LQ@M#.PIA>T]QT8%*&WA"W`
MA_K:BPR0P<D+J%]J%L`O>W:!#%,(`1"&(X`TC`@&9.!/$"`@!.7%Q@A[M`6`
M9@D$,:3A#380`@6`^$/_NX6@"$A`@A%4-H`97[0F'XF#KGVC`!8(X2H4$!-$
MIDHUFH#-*A#@4AQ4P@$EZ``"`&5!H?:H`R+.18-<84F,+TH2#89-OUO,"=F(
M`A4)5UC<9:R*5<!H1G5CV(PAN&%1TNA41\TDQ&SAU.!(\K3^HCA+1,0+$5U\
M8A2CV,5SA$A<>!"!GAT@K#R.N,0GOAA#+O+(/MC?(9-LR;M2LC^8P20M/(YD
MC:.&L?,*0A?R.04.%`$&`0@`*8(@!!K`$T'2X)`==@"`!`'K"#;P00"Z``8P
M`),(_V/$#$R!GA_T@`"8%8`7&-9F`7"B$S\@A29V``O^J(`,JPR`H+.!VP7,
M_\`#C#V&<2Z9`6\FP0M$\,)D/4!.&`B@"1P(01KL(':\'X^3V.30;FRP!`N>
M!2@4F+400*8`"ND@:C#AR8J&0`4LQ&$$^=6NJIVBMC!A](8[H>\1C@"%(W2D
MAB&@-5<X,(2FI>`E\S931N8"$=CG*;XX-:/:@,*"#C[EBS:4MU3"$E1X:Q3#
M165!&9-6$WQGY*(H=0M;W(*IDQ@\2[[I;T/\_6_L&YQJET+'I:K@`A=$8`4-
M@/AAN*!K.E#\_?`7I(\MR?'ZWRKD!#*YDO.?FI/;E368E'^RQ`SB\00YD&P4
M4``50P9IX`-R4`,90'<><&<!$`3/`P0A4`#A$!O+$_\$TC$<'B`&7/8#XW1G
M3W<>/1`%`-`\9``&:C8N!)!,29`>*L@90&`'L!$$2_`BTP4#Q/$#3Q`#'.(%
MXC$Q&?`&.0`]EN`%Y$-GW>`#,G`@"-,%'F($EP0.D-5V`2!0A:<3@3(`3@$C
M'`0!5Z$$2%1#$X$5&Q!>4C`$'^!M2<%!`M5N/D$6:S%CI%<%6#!>'[`V4]0;
MX&5178$54N54,V%A%A%O'79%8&1%'98WR"=&D9B(8<,V`K5N7R0X:*$H*!5]
M<%$X<L%]WO=]5--?*P)P'N5]DH(.4(`0/6,"Z<<8$^`&;C`!\7>+N&@J\_<Y
M2[9DJI-.&?<J)Z=QQ.AQ2D;_5P'HB[YX29@17&AW$0,P#SJ@(0%P!#=P!,T8
M`_%C2P"@`M,U`#:03K)!*X9F'6AF=,60+5RV=$G`"<O1/W2&'I/0='"&`^:R
M`PRC,`E"4B_"`0%T9X>5#<+@(+KP()40(0%B"08R`BQ`/$9G!T!0($L@!"6S
M>%LH!+0S%GND`"4#CJIE-QOP;%"4-/*E?1M@-XF8:C9@)T[A13RA-@9P(S*@
M!%`@7E]B`-;%%<GF>C-1;Q>%)MGF8%Y$%@TF)VUB%'$3?'&2%)?X-I%8B6JR
M4U?$5#'1%F[1B599?9@B)=CG$0TQBJ((<%)R<(U#$SJ``B]``R5@`A;0`NI7
M&'0P_SDGX'ZY6)=V*1F[>$F4-%?,&(S(:'*]:'_Y%X##6(P:9S\=^`H+A`0V
M(`$%@`0?P`0CX`T<@P-/L"T_L`-V,`4LT"M=D(7[,AQID"UID#UB``9H1@P>
MD`:W1``+`#YTEPEK-DP$$`9KU@G*($L%D`52L`2<40#=Z!XSX`4$0G=$P#P>
M,#'"83LV`!Q$L`!@L`%44`6ME01D@`D$0"T@(P0K601-X$&J-FL3<2DA``Y1
MH3(ZT6U?XR8G@S)<!#8KF6"7&&]BD89`A(=#T!%/A&#QID3Z``7OT%0Q$1<2
M8!8C)2@8U$5H-&Y'29)(>6Z5&$48IE]OLA25F!0VE8GU%O\3>007+05$'FIB
M5=.54\*5`-<0)MJ59$DU;B$#3$`%3*`!(H`!$Q"+BM$%<MD%=[FC/*H8NV@Z
M(Z=_=,4A=X5D1&J,PVA7A/E_2JJ;A"4&7I`:,.``A&<#&Q`R.L`#YX,@LGD>
M3Y!G7D`;!$,+D)4+>S4*PA$=KSD*W#)G(?($Y)(M#=)9F@!G/9""G:`>40`$
M#D!?*4`!PP`&NQ`#=QH&RF!//2<@Q.`?T3&E$;@`3[``2D`#&P`&.Y!H`O`#
M.!`$D893/6$R2>$`G=8$`Z!#`X`$^M%711`5;)$33H$50WDH/_6J8(A!&C6'
MH=HH<2$3(Q`'(R$3&B1MI2HS4"#_!3X4DR\1DW1T#]ZVE'427^+&)E=18>D6
MK3UE%4*9?"V9?'@2E=!8%FH!$Y[8B?8@8HA352F*?3+`$22:KNJJHO\U`B\P
M$#<P`0S``!7@EHOQ!2?P!?SZ!3T:L`+[!V6PI(7)=LFXC+RHL+TH2WH9F/_7
MB[X8612`!,R0"P&@!!Q@#C(0#P8`!1!@A=J8#-91/P!``.RQ(>E43\DB@L.Q
M`#!+F@L000!`6X8@`)WE9C4+'<($!E'P=.1B'FN&`#E`>*2*+P(`!#:`+/$3
M!MEY"PE"(%[0C..1`PY`(-:!!%(P`L=@!P\B!D_@`0%@!(H8>0AV$0&0`11$
M$Z]&D=E%_Y&J5C9IR&%'^1.'`F\V51$:=!4E07N0PT0P@6!-(5^0PR4/0:`P
MH0!<PJ(:]!5JHF$9:A1I"(F,>$,)@#<]@8@61E.)*)].,7SJ!A1IN$8]Z2A;
M]18>>I4E(7#N^JY=\A$?\96QVZXPY5$;0`/F%P$@4`$'T+M:\):%T09R(`=M
M,+#&NZ/S!['*>*02NS\91Z1V!5E+=J0GQ[S-JW&VH(`A,`7>`#\;$`=&P`);
M6P3?JP1%@!D3"`#BX8W)84P>H%L4($O%=0O-<PD+(`;$@K./X`4P&P./EJDJ
M6`DB>`BEF9FV&3_=@P#LP0(RL`0)I`Q4L%L>H*<.8@N1Y1_8-/]U'O`*8D`$
MI3`$<,!8]<0,_Q,$RC<VD><3$)``,;<$.I%JJUH1+M($2"!MP$>40R467GAO
M*'EN5_$65XE13D(4-?%\YSI@(N$0!I"M7G05-Y6Y.ARZ43RY#PJZ3`F5"094
MQ)>4?G-O(=86,F$X'AHI_D:BKPN[9XS&'L&N*@I3,#4$+K`"$5"O%G``+=`"
M5@"\A?$&;W"\?ER7!:ND";L_UBNQ@IR,T3N8A\Q8UUL+]70-;R!+`I`!5``!
M2*`$'^!7/!(;GZ6-0```P.,!WK$#^&L#(Q`"M,"]Z;0+]4-`]0,$,3`_'E@)
MHV`'WN$(=C!.'N`%0%!;=Q:V=O`$FFK_J&+7/L$PM4)@6N$3!0BP@LA%,/DS
M#*!</U$0(CE``>,A!LD0!$X\`)AW%7B3$Q]@,3"27RMI`_:9>&1KK65!-[&'
M$7&1%TML0V1#4BBE;XQ":V*A%F&<BF.".#@"#U)Q-E^Q%?4,Q4M)GX:2-U?D
M3UF,)RPIE499AVF1N-#G1C]Y)71!1ZQKQE/R$1S1$3HPTB3=$3)`7K0[8RE`
M`R!@`C4``A-0`0UPQWG\QS;MQV7`O(LLO7=UO3Y-R!R"L(-)R--;U)"%'P'@
M!3^P`!M0!4-0!7)0!$(`.2P0!$0*3`7`2^GQ'79`!`,@!RS0=KI`/\*P#`$B
M(+C0!=-A![R\_PUY!CTXVS'$$AUI`#S.0W=1,`-3K0`$PKW","]`8$TJ*$`6
MX@VRA`AAZP%`T#'STXYK1CU3H`1./2;?:J`V-0#@@`1!L<X7H1;!NJ`[(:U)
M*1$ML;CP@#27VQ,Q.1,D9A9_HA29>(<2D`(Z0$-TX5Y9!%_HR5./V"=?=%0!
M-K?82FZWNA1-L9)LPWFB"Z[A"D0SD=%8:3B*DZXF#;LC35X<4=+7+=)LW)63
M]P`B8`(P#0(,,--XK,<WG=ZX6+#7FX4_W;S2FX7RW;!'ZM[*6-2,=05(\`;.
M$P!4(`?S.@0)\"49&`[\\P.FA3!M=@I)('0T`P'[02QG?3NW,]:^@O^F:=!E
MS6,'`G`>F6`*P.,N>W4(`*0)&>``L`0$&>`QM?`(V2(^7HL:$O!."$($,S"S
M:IH&.-!F._`$7<T""B`%-0D'0\D6/H&3M!-OJ7?9.HD6-H6YF'L4&BI"6;,5
M!GHT5QD7M'<3E_N%:+$U4F)19Y%[18&ARMUA-P5&:?[$X^93ZO9M176A<2*Y
M:_0W6!G=8SQ[>61]70F[ZPK2K3<$HQ?2?CZ[;$PE7,(!+[`"+0W3%M``3N`$
MYZW>E+ZC[-W>1"K?/$W?'*+I]6V]FH[ID`5KL$`!,D`#*+`"E`H%;0`'37`%
MJD4LU',P/[`LD0H``4`!5;`!".)D*B`>8ZW_'0)2OY?0/*50L^1D2_*XU%_W
M==`A!L0!0.6A4<12O\7B@P("`%^J`J_``D.P`:@L&PMPG<#4/],A/@#C[5A2
M!7$@(]^JVN`X#JF'06GQMQ!Q-TY%1FK#8#\T5<P:VO7IW%&U*#?R.(E"4@/V
M$"^9K;`->D2)%5\4\6Q^K7!2H1$MYQP&\8T2DY%WYYU8.'Y1%R41EA^]KM>M
M:ZTW>KHVTK`+7AU!HGDQ`D-P?A,``C!=WI'>`+];Z3R?BSG]TYGNZ:$>WT)?
M]*%.U$M&9=$X!09P!'+0`2Y``D.@!"@@!0GP3A3`2<SPOLE09\G@')=2`,=9
M6<3AIK]>A-Q1UK#L_P'&41V)99DA>#O$LF?_$^+$D@GQ)"`"8G9!\`9%$`(!
M4-<"$`-C1SL!D`)V%Z8VT$H<<V<[W@6YPT=4<`%_NK1`X=JO[6LT!<X<*GV;
MF"A=(:MI6)\HC#*7>^_XWBAE4M$WXAM+4L21Y]OFAD55)%\'?]`(C=!A,<0#
M_6#P)9_(C:V7&ZY5&:[1?;IZ[CAX4<9];O+E%>A#L&Q'L%`I'_TH'_W9[:NR
MBP)0;P(3@`$5P`"]>P`,X`3HW?/H7U8YW>GV3=_3F^F,Y=YMM^GO;_1`O>D%
M0`X)\`$E!`@:)ATO2C0<`PI%,6E$4T1V`AXXDCUB,!`4!@$^1`L>H#%D'O]B
M"V*@J`)=/C!>*AZ?"Y]B8`)D09TQ*J*B9"J[C#-@!3`P4S`Q3T`%2"P)060"
M`CD!%`4%2Q`93P`^.1Y`0`L`/S@_/D$9#@-42A+-%"$."08*"A(*"0XA%`D)
M`XGN28"@H)Z!@PCM&1BP$*`_@`#G_9OH;^%$APOK*8``!X)'.!\V*`1HD.$`
M??%8\'/`DN5)??\0&O@'T1_-E_XHL)SH(%Z(GQ1\AF#!P@;1HT!7QM3HT6/!
MC02;?I0@H>.&#Q]28!W!H6M7&3*^ZAA+=HC9(4>.*%%B-BW9.'#CH!T2-JP4
M%RY$F)C`X$`%!@PJ6&AQ@DN7PX@3*S[\I['CQY#_(TN>3+FRY<N8,VO>S+FS
M9\AE,F2`(;JT:=/%1I,NG?JT:M>L5XMNK1K&E253!A3A0*)#A`@/>$`9,(**
M`0\Q,O@0`"#*CAT`5`1)P42*D"M7;#3IXL'.*5*F0,DRE69<*0\JQ-R*80>6
MF!BK?`#Q0B0&$"+U[P=1\40,A1P^!(",!SEDT`0$+'@`P`PSI%.:`AD$D089
M;\!`1`8QP/+$#P"($T,04PR$6U`D,F2`1P.TU-"))Q(DDT(():!333;U%-0\
M+?4CD3\2K0.1`55EI,`&^"@`T9$G]<2/3C?JL^--""'I$(U.MN0DB20"E9(-
M_/SD)5`T:62/5/:4"0%5_QY)L,$((X2$50HI<.656&"1-99<9Z6EEA)'M!67
M7''H8)8.875%`W`K[-777P<P8,$!)\#1QJ245FKII)]EJNFFG';JZ:>2A18;
M;*(54!MIIL[F&C&HDHH::J09T\0`(5Q110<=7-`!$R,,(($4*`B1!#@S``#`
M#C@4"X,2#VAP1``9)!"'`Q+*(D`:I*"R0!H"@+$`&`"`4<HI0'R3+2\%!!`$
M+KCD`"`ZD"Q`Q@8^9'#-+F\@X0`+1@3Q!`$X7*$`,SD<`8$NM_A0@`^F=#M#
M&BJ0(1\,1131A!!)\@,05">==!!!<-3CHHDP'M2Q0RW-4Q-+/N&X(\L)%)0(
M5?\?7P6'/4?:Q*.-+/>#TT-(UM-Q00VEN'/*/>?H$Y8J89FECP>5"56:+D)5
MU4!78;45FW."Q16@<8TU!)]HZ;E6GW/E.2A888T@!0D/M-&!HGXM"D(%)X"J
M]]Y\]^WWWJ+:ZVJIH[VV:FG7F/;&X*DE7EH``1@AP1(?:/#`Y33H!@<*%[31
MA`=>^`#&##]$,4,277#@`@DDC%#@"'$T$8,LI'R'RNT>2-(=,$!$Z!TX1"PC
M!%%&3)%!#C``N.["R:7S1@%$P!``"RE0%4`:/>`P!0OU9@!0`5T$46`.`FPK
M@`H_D%$NM%<@(800..KTT$CTF$00/B.33+3))J&4LL[_-F)!DT@RDWGX[$0#
MB1I'C.00G3G02CIK8-`TLJ*&^$,>/2.1C9:4I2\-A4DINY%,9$(F,S6E*AM(
MX57@Q+4Y>450<#E+6_B4%AJ>S2PTK*&>CA`H#L3!<AK0@`OH]A<+@&`%%LC;
MWY;(Q"8ZL6]U2)7C[#5%Q%WCBE0L7!9-=479.`Z+B"L5;J:PB2)@X04HT$`5
M*!```[Q``VWX``P6$``B@`$,3\`!#@#@``U$@`D#B%`,)#""#,PG!C&@#WR(
M\`O\D(85!JA/`::`/!L480J)@T&]C'"SHE"R&&^80A.6D($`F$J4;Y@>$B00
M@@1(H`C7N!`2()>/$$SA#<C+_T$,```).WRC"380PA*:4`0A%!.$#S'9_$R4
M"#*-4"93JE((E[8/I6P,1054&<Z.)#,:]0^`.Y+2CQ(1-08V\&A!\9)0?D(4
MH_QD>$-9"<]V$I`Q2<5%+8)`"N&`PJRD8$UL:B$'P#)000T!4#K8H=ELN):&
MGDTM?5K+0>-`A1M$P'(F$`$()O"7"4P`!#7`@!*?2-*2FO2DD0G-%TMU13"V
M]*6F255,85!%PL74E"P80!.Z(H0-5$$*:;%!#FS`!!300`I(^(81@%`^`<Q@
M`4NH`@G:`($@R,(+&3`2$>B#B^,I9Q?W,1`GA,`*"@AA"E/XAUE)62`D^$H!
M%+`8Y/^:P(*>(&$*(1!"!HJP!"08)0$I>(F7`C"%?1E!1@&P@0WPLQ\Q%`!Y
M2X"!$8;23B$THY4X,<E+R+F1J1&D9/S+V?]V=J.3@"E,!7'`06Q"3H\!!`)%
M.Q+_',A:C9S,)":+4I)<MDX/?JDH7`J!8E6RI'E"26I2<TI34HB5K,$I*P&5
M$]MDH`,\S3"'#LTN%+;KT.U"X89#@`+G+N#'1&G4`@P`@7I=`(*1HO2]\(TO
MJ%0JQ9?:][XRQ:)LK*A%F\K4"$T`L`.D,`#J#8$)'+!!$(Q`A0=0H0IP$&H,
M*#"[3PB``G)X`0F@8(0<V"$&!7``$V3@`U\@!PA=V.J'NG#_GQR\(0A$J%<(
M+`*!#T!`-Z1I@@,V$+(!<$E&\DA1$Y"0@!!D(!X`$8(!JJD4(U`@*@7A5[_"
M$0,B+`YCK2PR.Y%2/P(634QJZLAG]Q?;!F:P1BRS$@1K$@*&U/8E#8&MEX54
MM`B29)QW%B=*F)22HO@V*<(=7E&(@B4,RN]'%$Q(F*D"!SAD[4U<DY-7ZA1#
M&8[MNS7,;G>]JQ8H2.'3GUX+%'B@@1>40(@BT.@$+&`!$=S@!@\0@7OE2^M:
MV]HR480I%>_+TI;V.K\NE>*NO[@$%BRAC0Z`0`)&8#`A!$`(62`$!XH\A12/
M8*OH@0$6L(`"'@1R"AD"D<$"`(0T_]C!"UX(`A#L$P0OV(<T.8AQ#I:P`0Y$
M]P,4$(T1!@"2C)PH(D46@@UZ4H1U'&0>1+F)0VK<IC4)P9;*"0*T8$"4I\BH
MFO%066[W)[5Z[/.S"2GSE;#T0);QHTHZT\F2WZP/C&Q,@;85IXEFHO#^B59)
M7?JM3XBKI4`3Y>'[2&==>?8/J]WS3#8#24B8&R>N%&K2U#6H0M-R7>]:?;N@
MOKJG/PV%*M#@`D9]XPHP\-%53R!7#T!!>V_-]K:W/=?X'79,KVC*ESX/O[S&
M8@&:$(`FA)@#+%F"`XQ@S!"\(`(ED($#<F"$=!5`"5/P@2\IB@(FA"`'Q'@%
MMMQ71R#`6/\7C)T/$+R!CG5)?`-ID<$(#,`"=?F@"%G#!TBJAX\4S1F:<(:(
MD8;T`3$SA`)+N`8FGXTQ9>Y9@$67V0C-Q...0$4AW5PM-3.N$Z392'XTX9$\
MM'Q`*36$:-`GFLP1G5G1,BF>PBT"E^*Q\Z91X"B*5>SP^(PEB31SS$WAO9J:
MZZ8W=<V%;%,V4[=05P=J4J!U2B`%6`!J6,`#%_``)<`#G`,"CK("'"4"&G`!
M)/`":^=V'OB!*$5?5_0&=U<`)(AW>C>"=S=W+L525)181?`&];8PF.0]'X`%
M;<`#O5(`*M`$V%$`4F`-.:``)"`%"B`$0>!W8N`%,%!NP+,+[8+_#OI!#9P@
M>KCP!@,@`T>@`W!``9$G,=337&="%422/\\46C-73MMT9RR`!``F2D:04S)#
M6B>G66*2$/K4>QL`6Z"U(BFB02U17#F"--DG3>RG,N+T?6JX/^/G;S\#3ED"
M7,8T?UY"%$G13O$W7!AT??T0$YY%)E>Q?VYR%6TB:2[T%3(0!YFV0]I5@%FG
M=0Q8!3Q``A%P`30@!Q/8``V0:A:P`I9#`VTP`;,&@L18C'P31?92=R68+LI(
M@I!S#9`3C0&PC*D4C;KV:^DR!480.5#``KW#`D6`!`K``4QP!"$P3#X0`W$8
M`D@@!_B&5P/0!9@$`P,`#71%!)*P+0L0_P/HT`6C``!I``04@P3*H0O)4000
M,`12(`,#$%E$('$#T'2]QT#0!UNYI5N(]DR=-1)&(C](,$D8,X='@XC)-Q)1
M8S,B,7-(0A,9]P\X(HAIMF<\D4Y"86=IJ(A,H7SCMY(V47TC]V=(05D\QT[O
MXT[$57T99W\(Q&@#T12.=A5,]P&F2%"H6!?7I6D-M74&N)5<N6U80`4T\``K
ML#I9D`6'-P$-<``B$`$FX`)^A`(/D$3&.)=T^2EG`"TM=7=7D)<CN)>.ER[/
MDTK7D$K+^%+3F$5^IXW#-``Z4`!!@#')1@%&(`=%0`$^H`(+8`>1,P!",`0)
M4`0)(`5-&`+U,O\`<4441```UJ([NZ`"Y;./.3`%L'29=K!@!O`!83$`!.D#
M/G`%+"`!*6!OO=<0/L(0W20E,&$1QIE"1F)!B6![!88$H)E`/_,D`8%[R]E[
M%KF1%F03PM6)0&9</$-9Z[!!0_%CB$A`98*38Z*3<V8D%$%S$70EOV5,<3A<
MF.A.*5&40VEH6581SS>&5,%HS-5H4BF5`_5T"<HV`X46HO9=6+EU7KF`#.B5
M57"A52`'5/`"%U`#1T0"8$D#-;!J()`K->`"O]$&&B",==FB+MH9:U!WT/B,
MS'AWTFB--YJ7TVA?T2A*5V!*&?`\/QI,'Z``T2,/]E8`%"`!1G`%73#_#E`E
M`T7Z#E,@`QNP'[@!!THP`DOB!=P"!MQB!YZW,*Y9F_7BF.1R9''"`1M@`P7P
MH]-SFUW!8\.9(CM!#[H%0#Z3)/200C>F6@RDG+`U#X$:J*:960K$D?ID%21Q
M#R#G)!2Q9X&X$C<B%):(?6`R)3^RD0343&+"B.<TDKME:!20B4-A3$5`>$<Q
M/,%D%$W#`OPY:"UY$21Q=%<S$(ZF-5JQ0B/`H$ZG`UUA4`[Z4)T&H6GA:1CZ
M4Z^(K%G`!#Q``VGT`#4@`KY(!7)``RNP`C5PHFSY46#G1\,8&5P`%W3PHN8Z
ME[E&@M6XH^D"I^HJC>OZC-'X/)!#K\Z82DL`_V`R2@S/9@3[$@1^]6E-X`.S
ML@0Y``2NF09&<`1KL@D9L`$L@(]!,`1MH`0;T`13@`09D@9B\`H2(SY!D$@*
M$R&LP$@`*P'"*0'`MXX&L"9=\0$#(7ZLQ9-H=A.>")^`VC'?1R52PA(+D9ZA
M!17\M&3WUTUWVHF3"A1*DTZ457A*TA/%.4&QM7%HN)+6IV8ZL1+G&4SJ%W^3
M6)2*I7Y#"5Q'05SVEV<B,Z!5T6BYJA5-=XI05R=YLB=GHP3?!:%VBZP8RI6?
M5@54\*QO]``=D"@UH`%4(`554`(W,$0K(`('8`$74`)M\`(N$*Z0,0%NX`83
M<*Z<"X+I>J/U&@#8,?\%T@BGI6NZH<NNR?BCS<!7-)H!EG4%?/4&73$"265E
MQ:,"=N":`%``4,`5-I!8')`#7N`!1L`$(R8$V7B9I;"[X8-Y](I6`C(]VX@$
M$-`V6`$!\^`13<<F(=&4:[@R3U)S=V81R?1EB+83+3$E#K!-T3<T^6<T)X*S
M2$-_3"8/3E.)15$Q=14488*1FB5;_---Y&N(];<O[\</*E$4QH2?J%HQA->J
M`A2)P*5.2ED2#,$1C=9/O-I"5!FWU"5#->1=:W&`>X)U"IBL$YJL<L`$:&0Y
M'7`#)M"6&L`$VU4%;>`"'V4"Z04W%_`"LF89=*!$)U"NG7O$M[8&)RBZTDC_
MNM%X!6@5Q:"+'4P\KRV5L>$88"QA`[AQ!:$DASZ&LDFU+I^@`L@C'VGP`T!@
M%G!PJ!]0`"BFD"*A5\AC+]`P>L^VQ?VK6/2P$6HR4%RC>KGJLFX2G".@%7)F
M(GN&?0JW%!EQ6\R$G",73M=T)C?&(L;I$3,1-"GR$T\+9#")<UTR7/%GML^Y
M?+>%>\IDG&5&)3S"?OAK%$'A9Q4,7);T/N^S!$6`%/*S+Y5EP:C562?"8_ND
M)G"RIO_7%6$S%M0%49E6@%!PPHB[;<E:S1C:PM$:`1TPK33,`S^E%C=@`:LF
M`E2@`23`!"4@4I;1!43<!4C\SK0614_,Q%`,.5",_QU4#+JE:X+[>@U#5DQ<
M8D``!J<&H`,%)DP5DCQ,E00`"2"Z$)`AT1-"8`\8$@1A$1)%T'=S93RV,7#D
M="4Q8XKVALQN>\S_!%V%\D_@EP_J6W,S"\D[B3(]$ZGS8\D<!ZJN]1+FR4%.
M4VB5&$Q@>Y2JQ8>M/"51`TT547ZN#+5%<7Z#]A.EK+\,C*H"QW.EY1,"QT':
MQ!0G])0P"P<!=8K3-5W5U180)6H+N'4/*J'4+`=N;<T7^K>6\QN#"P(F4`,/
MP`19(`>>5@,-T`(3H`%9H`/U=@%X8QE?<`)?D-A?`,^._5XQVJ,82UA3\*-0
M',6DRXRH.Z_U6H*$%0"ZC/]\_F`#?H4$;U`\2Q`/-F`$=X4A8@``2:#&ZA9N
M'\!7#L`E!JL"&=`F!"%<L"IEK4H!B9!".%$/'"!#;<,5;:(U6D.*M0LG/-9Q
MD#IGDKP4.XE.Z8EH&VE"!0%.2RL4/JU.LPQ_0"UP\;=]!D$0'?/2>.9-H9I]
M\_1^$]QGMJR)6T:V\H>?IHP26G)HY90F!+I"(2%I"CK6;%/6F9:W"GB`6^==
MGX8%+/S6&2H'U\P$7_<`$>`"-;`"ZK4")>!I%GX!:%D!&-@&S-8;D'(9;>#6
M;?#8+FY29U#9EXW9&!O%-2Z]EXW/IANO-DJZ?B7<&W$SPM4$!5(`A.=7EW0%
M%A+_`Z\]`V)P'_.!!'!@*@,`8`,+`R%@8S(B!*I*(A=Q#SS&/_J44'H"K,K-
M?\WMW"-`S!OL%`5TL]B9?3'MRO`MM6)"-3B;)1WD0>$=3_1WGKA<RE##/STA
M33:YDC>W$ST-WEM;RD')3IGX<V#KJDAIO_]K-6S+7/Y$X,`J%G;"S*F8X&S-
MX-MV@`]>S6Y-X560!=::ZEDPBQ$@P]DJ`A-@`B50!45U`1:0EN+\`%@@!V*Y
M`BE^&23XXL;^1&=PXY6-5DV@[#?>[,J>S_H<O4M@`\(-!\%YT3XV&I,DXUY\
M/*4W"BJ`'_S(IJ`-`48F!#G``FUB`"%0,:L=AS_;,38-_R,H*X`\Y!7_I$*/
MM@'!:6][:'3J#310$>?_"]/C!$$UQS]"(S(V39Q?PB26R.=,RTY+4K:G&NA!
MAB379Y[5E]TUH5DHIR1,:]7G*;:#AO%;"[:X'.C]N32HY?!KFZNZNJ#59?/+
M3"@R,*P*WI7*JH`0[M9[G>H7RNJN+H$14`,9I>$B@`$BT`&7TP&.>P`M@`&$
M,`2"NRL/8+G'WO4FA0=(,-FBA-FB!.TU#NV8K>.57:]8=!L#-R0^=!:$;0"-
M)R#H(#VF`B#NXB[ZH3[ZT`0)P`'*6TQ#TL:WS>5&X&3P&1/X8!!^C)NK.`1F
MON8<P1%2R29KJITFA"*RA3-10O^^$R1^+\%^R:1[-\9,7-V=[V?M*L$2?Y9S
MKZ_RE?5P-)TC%#]:[.V<*M,3&/_H7NOR]@U<Q?3`[U,Q`+TDZ'=`3N'';#O(
MSHV*P`H7U(4GTS47#\K@5K>5UTP%W-_]K6[TK$X%1?4`&34(0S3#>O$`&_6X
M(-`L*GI16<`"2L#U7E__340'(6#E9F_V2P`(2X*#2TU34X:'AU=7`0%3139%
M2$4)$ALC,D=*0SHZ,B,;!A1+04`^,(@%,#".4P4^/D%V=@4L"1\R4Q0R2@X0
M$@,#"11%1;<*!@8*S!#*$`,*$!L<0TK7G)T<'Q\;&W`;'R,<Y"/F&Q#,S^G*
M[0/+R>[_"<+T"?,&[_#)PPX4+"P4$CAP8&^>-';YF#$;T"]$"!8V0@@<V(^"
MPXL4,CYTJ)%C1HL>682@0-'>0(\4'?!+:4]8.V7#3%9T"/&?#1O_;$H2PE,(
MSIP/;_+$*<083V-&(UH4.="@0@E0P7D+]R%%BG'DR,G@("/.D*]@PPXYL@D*
M%BQ2I$"IHA8*%"E5SLJAPH1*EBI9J.BERX1'7QZ`7UP``6*%B1LW'JP`X4+#
M"A$B(ER@H2&"!@X0$AC0<>*/Y\^@0XL>3;JTZ=.H4ZM>S;JUZ]>P/],)860)
MDD)-".E&<EN0H2:_#5TYM,1&`F8)(.0:XO5:''-7X:2SD:%`_XX<!1XU$D+!
M1I,`JWP4$!+"0*XB$!PHL"&*)$B5!M(I5*=`0GUQ.I1`N7;D4[FK')B3U599
M?2#=/@J]I,Q!,`ES3SLM)21-@L1@)-`\PAP$@7SJ*$,,2!YE5%!#'[GGCT@=
M;=110!\*1-)$%@444X3T..A2C0Y2=*)#-^'4(T0]'A."#3[EE!.110[Y3U`]
MXD12/P1AJ-`T&T@`!S?<;'`55@3*H`,Y.I!UQ%?8C!G'$6ZE=59:;,)5Q9MR
MR)%%%G'*N9=>3.0)&&`TD"`""":8(((++M1P@P@3@/!"!!%T4,,#3#@0PRDY
M2-!9;)AFJNFFG';J*6M;%&&$,4A,L?^$$4B@>MNJ1=T&W*N'--'(<)5L$.96
M,HSUU9@<H#.A,Z1<D<@213Q$#VU-4$*02QL(X<`'"@P`[$::+9/.ALUL"(<$
M*7"%IA1*C$E@5@/B^HD,6XV0`CKXY-/N,@M.2,^R-SZXSH;MNFA10>U*N^&_
M['A8HD89+3L02`0W--)'%XU$HKX517PACNTD^&Z_PPSSY$9,-GD3D$2)]+&1
M2$8B$D`R@4@OQ?]*T(TW5:7`S99<H>ME'#A;$RZ98I*E1)MH21'TFT1742><
M<^*)9YY_`4;"8R#\Z8)AD%W`@Q07F.""$D($(88`*J@PPP"7?FKVV6BGK3:F
M:!AAA!"]C9K_&VY&'!+`%:?:AFIMACCRB!$4*"`#%&,RYXDGV\`1[3L;)K"3
M#:F&((R5WPQC0#`)04#!AB'LX^`]"EW9S8:44].<6^'&@>[AGJQ^[EBJE\.N
M2PO"N"R\-M*#>S3K2)!.3!]%B2$\5:;C^^(*?,AP""5=&+$_$I6X\$<H%GRP
M]4V]0WLR]6%[4#RZXT/03$O29"10(_]X<H]#1;0P?)KQ<]Q\[68+%98S0V?.
M.#8?/A9_A1.3?M[R%J&=94U8>%,"B28G.L4I+WWABU]X0`,:`$8#AR*,"`1E
M`09T0`-M0$$-+""'`GA!`#$``!D\0`"R<:$+,(RA#&<(P[79\(8X_\RA:<YP
M"+ZEJF[)F@(,JI,#(N3@;@&@1'8$,1Q%(,$&!I`!7*1PA'2-H!O@<,:"G*&\
MAR@`$U>D!K20D[QH;"@.#&%',Z(5GPVE8"L?L`\PKM05K^BJ$^BR(U@*%P<=
MP(X<Z[(/QC0V$I\XS%X70UZV@.&,'#VI((R3#H?8T1)]C<0A4)I'RDX2$!T-
MS$C8:Q[HY`,PJ/@.&-^0`,8\Y(`EZ00G#SG?DD8&))$\I">&S)[E\-$A*FV+
M0Q.2ALOPMR6L<.5<A\N5?LBRQ[(44&AL>1.;%FBT!^IE3GGABP3[0H,7O*!/
MBT'4!";`@`8<``1MX`$53%"%''@@`SZ8P?\,R+```%@*#FW(IS[WR<]\ZO"?
M``WHI\X`GN%<(0,9@$$.A@B#(/@@!T$(`GA\T`4?9"`(1LP.<-X6N!3$X2U5
M4`(HT)$A;X#C0`L91CH^4(UM=*M751+D,L`1#'5P*&-?))>!&"<!0&I)'#;K
M4L[&PDSF""@4\EG)P48R`)HXM5K;BT<R&&DE[BE5DP^21L4\!S&.2>20#N#(
M^)HBDXH0+$8'TZ5+UL@@;/V2D8V<45@A@LNA#$66(H,E4"[YHQ=%:*O-^.E4
MWDJZJN"O*L;$51^]Y`FO].PK9[I&FJ`I3:$5$`L/3-J=^)(G"5+0FR@H@0M`
M,`$,6,`"!S`G!C3_,`(E=*`-#LC!%!(0A`*\`08"2,(&RB;0WOKVMY[:@@V6
M<%L?``$(#ETH1*^#BB98!Z,.)4(0,A"`)A2!`N9YH\Y""@K%,60`X:#*@?)E
M`#B\,0[D"N.!2.>-XRTR6IJ!0":VLJ[TM'&\T5*.S+@Q#AU$=A,]VT8W.N0@
M$)FH(__PZSN:88![4.EX^?)K2^#E(9C@PR366U%8QX>P1_9C(LHK4?8*,KQX
M:4B-S""L.@I\$DF,:A*G$I5/VG>RH)`'2`U;DHPRA@]XS-$;XU!7EDH'#,/B
MK[];\0KK#G<F/S;S9VI)2YHJ&V6CX66S>V':T@##S1>0X`&CG<!I&=`"_P94
MH`,<2``/7E`$K^56#&^8`@L\D`0(\!:X>,ZSGD]#!P?8X!5%/*YT<^`#(V8@
MSD68PAN*V`6'3A<)+*C/?/^WGR%LA5V:N=*6/H`0AJB$&D']CX%,*17%Z>,E
M[^!6@.+88/A<F"+,6[#+,E&6MES#TMO8`!L_%];W362IYG.8]FXDC2S^CL6_
M?I`P'.`A7B^L80YC'JQ-Q&$2>S*3.'+7.J9*ROEP+ZZ>UH@-]@8W5[VM)S^*
M)5W3?9%_J"0?"_;Q)<+QT@#M%QQ9@MG^KLB_K?B1R3C#616?#.4"3CDN;3*:
M72"(93SMJ8*?1<$%(C!:#%0@M0RPP`ID$((J//_``&#8`0&>`(`GS&`!*13`
M!^Z\YY:[',]T(,82K'-<A\(@/`$`'`4&(`3G$MJA&8`BJ(D*P'/EVAGWP4H*
M!+GLC)@G5XM%E[WS?4IXK))Q\L&'/Z!D5O,%1+_5^)DT]W,$].HZ=\!F7K+3
M7A-A"X1W`%OQB#A,$5[GJ"`@@K9[TEJP@IGD<YJ4&(VTO6U_,<-WJ,9=A2XR
M;K@-PE5(*$H1BO23)J&[>C&*AK?A:J7\I5=FX5"7D,&X[\0&7(]D<K+/PN66
M9U(V:&JJ@EWD5!<L]^6;W?QF:#4`YA5,X.).:``&0$"%%!R!!B&(`0Y^,$\`
M[``'.(@"#E3.\I=;__K_.>RS`Y#P7%1<9X@!.$XZX)``N`4`_$8`KR:PP1_5
MC2N,UQ*'.3B]CU__0A.057)6X(^@'M?#8-`6%"B#=PAC`*$7!TJ`66PA+B/`
M=!\6$PH3$#&R>`,S/ABB.][#51(F8<F&(2F#>0C3%%#R)-9S@3S&$"(B/Q0#
M6!:C((.4`"P@!#'($VY#"'/#&Y,G@^J&2T)Q5T^B$AIR2NB`2IZ'%=`A#@$"
M'?O%7P)R,V'Q6$IP)JL7+@.4%D6#<&TB!79"%UEF%WQ20:#U`B7P92Z`*`S`
M`!C7`2@@!QIP`5*00BGW`U'`?%$@3RK``=6'?7JXAY\2<R$@!%>P4%=0`-61
M_W,4<"6]$BW=T01OL`0R(@&#(V65=B9#P`'[-17Z!G^_<X&6D"NY`A;N!T?Q
M(`__)SUMIV/O]CGO(2TNPP',A#.)J#W4EA(E41$"@1(#,6P*TCT+X2(DIC&T
M6(O!,Q-B91%I12)^]XO9MFPJ00PK$S[]0F&#E",G`21%(3=S,PBC\F(R:'DY
MF(/H)A'P<`G;\@WX%E/[54S[8Q5&J"Y7417DLCJHMRN<T#/V6(4'%'L*=$`)
MI$U]P3045$$T@`(HX&4/T`%3(P(=U``-4`$/$`=8T`$?)`,>@`-!```SL`,S
M@`,J$`-!X`$+L')\.)(DV2D`T&!_V$.G$CB84`X&DO]%">`0R8$)0S!9^W$-
M6G@$VV!*UR(Z*+4X,%$?W?)1:L$)_@$M-2(3,/*#:64/R9B4*+@RRT`YHP,\
MP5-6PJ.4)"(\VC8?_Y(,*;%WU\,2(S*,*X)))&A6(E82%*,](D@O@P>-J)9M
M+F)C-#@JKF(JML$;HU(D="5Y1\&7;V,#.U<?IW0ME_`R_+5?^[=OY?(?B26/
M?@1@1+5Z]DA`(*5`;L)`>O$F6=!9>\(G8=@&&E`9'7`#)C!.'50!&J<$'/`"
M(O`"1Q!/=;@#._`#./`&"O`$8@`&3X"')1F<PND:?*`X!R,M;*1J_*8NX<4]
M7T1K9$%``X0F,A!'"8)UV&+_=9IG1I?``5#&"0%R=DD9C",V>"9(E^]F+<D`
M24KE,#)"8O!I?U<)C>^55%=I$ABQ+/%Y;5TG;:%$GFIU(^+#EM185LLX(VOG
M#T0B8VX#8X8@"+RA-Z,B%,;P-D81H4]$F-$`!V\E3.%P)4'FCN3RF!S0.J``
M($%U,XX%0/_#?M@@-+$7)U=H-'EQ%PIG%]P$A@293[R'D#4@*&)V6@=@`E0`
M!=TD>QD@`,^W`U'`I&!`'4FP`.(Q`GDXG%9ZI7_`!^MB1AM"%<>$*R/UCO1F
M#E#W45@P0)4X`M#@+M[F#AWRIEW:"^$R4HL#E;E3#S'1+U"U@BW!5>T&$(\4
MGX(Z_W=,>8%;!5?7J3"GF&#Z.:@9AE;4YE=DR9ZZXY90@B.W.#V3:FVT."1$
M@BJB@HV$P!N]D1N3%ZJ1YS9"H"I/!!#2@HGE:(Z(E80"4BZ,%6KVUF^MXU_6
MX#.%@PTW*5EP@18*1R=72`5RD!8R6J-,()`#B0*DJ0$D$`$F0#5_(F8.Z152
M\``2@`5'$#91T`,S$`91\`1(\`$%X`$P,``^0#98^J[PR@=7Y#NGU(J?."[I
M-3->HA6:0#C]P6F\A'1M6C&D@SP-$@WH8!\0F(K+>+#Z@*DNPI4UTF#=D6Z9
M!XP75HIDU0]XRJ;SY@W_LDLQR7A_Z3[I^6K4:#U#<DF'-/^H-+(@&1L3'3M6
MR-@P%7@BZ=,JJ8($P,&S@Y"-Q%((,K:@;E.TO5$<.[=@<W1*YJ4_(UJK6>%?
MYY(N_,JK8>%8F\!^DMAZ9E%-<B![LS>C=5(G$,0G!!E:8]@!AE&M)D`8IU4#
M!C`":_$"3(`%,)"131H&8:"1&.4!#A``3[``4E"E\%JX>L@'6&*.,'-,=H0S
M_K%JF`!Z($H.<117\3&$P#2*$@*S/68`J0AB$^:P`2.726E_9/5_8=4D:!FH
M]8!A=6E6!`HOPL2A'*I*SG,B-E%+:D<0#<*)MM,0-)N5$)MM[H"@!%B70&$D
M.>8^=T57J'(JJE(;NJ$WJPJA/[3_-T6;&ZD"$+Q[8I2S/UQ1,^70F)G`JX];
MM?-(C]&9%CC))FZ10)C%!#3ZM6*+34GS%[E'D&,X-8$2**0U`2+P`%7@G2E`
M`P>I!`4``-*'`P0`DC,@`&00`DO0!4;``2!`N)[Q!F[@!F]@N!X,7(A;%8NK
M%6$B)I#E'T*F./21G<V@2E1%2AEX$%9B=18V`'MG$H:Z$-:2=0>*N@<&NTN!
M)+!DC,J(J?R)P_?`.%/2,HNS>-#6E`<[O"GS(JU[(7'9PZ@;EH2I;G]95[CT
MC>`8JM;K-CMKO;:!%*)2H0U:M-++&^1!$O%VN?)7M=HPHE%K1U.;Q^G[/\[4
M>EG8M0H'_R<SBC2;U67>5)H74`,BL`*&\1@;5`.3`04;`&E8\`)"4&@YD`$Q
ML)%VD`1,&@,*A5Y'X`(8_`<:W`9P\,&J+%!:FF_E:T?\`19&-W]LU+D6-B7;
MHA!<FH&'BG2EJR)4K+3JR;D]C)4=QL4Q.'E#?`L]#!/V-SS#$RV\Z&W[(#Y,
M"<>ZPSTOF,2_QB*:='?[23L'RW5\5[%_:#+)_&)JC!37*"JI,@D1:AM[>2J]
M<;31*\^4X!-L;,\H$\?3`"#AFRME9ZN-!8I+UC_IZTSZT;ZN!TTR.LA%LX5+
MTTT$^0)MV`&+7`.-O`(NT`$7T`8TP`$#,00O,`!VL``9P`%+X/\!#RP&!$``
M"(`#3^`!0*`#/'`!I>P9$\`%J]S3.H2XH=<M`OU8NA([X<G#V;;$4!$/X@<P
M/!Q,SKRP,>)W+N$,`=-CX),Q_+!C3?>GUN@3'Z-V4;Q@U_FRTO@]P#"*#7*P
ME?2`;)I2'?MJ37FG\-ETZ3F>T_,BK=031M$3T5N#/R28K@(<B*"]\VS&A8`(
M/AO8;P,1\,PWIBH2\Y#6]4%OQ^0)8X%,7](53':U_M$5E6G"?<RUI)V9#^VU
M8^M`<T$7?M&LT%H")<![/]J_U9H8=$L#4J``*0`%+P`%.:`"1%``KP`#1)!H
M,S"'&0"2/O"W,I#373`!/AW=-Q3"+^7_)969?\PA==L@L&K]$L6F15H4'SQ)
M'U-%8*#;$+9$Q8@TUAV+P^-I$>YC$SQQ,MQ+U@[;IN*L#_0C#Y2:;?I).VOE
M:2SAPW`,U\;;C'&)=WH'$HY]JB_VO#:8+*\R-[GQ&TM`'*JRE_%<"+;1LWUY
MEZFRJD5PX3HXV=<2>EPAA<SD;U6D3)TP5'SDA`)TDZLG90-$V@9$37`RMF2;
M37H2&-%Z`6!&V]7:`0]0`C\#!082!U7`!"P`!`5@`P/0!`G0!"&@!$:`D2J0
MP'8`!"J``P:0TW$P!])=YFG3ROQCQR9J,ZN&=+;L@AK"5MI2NRUC/)HK/^0C
M5DJYC.8)>.<)_S&6E)8&@6);!%?>$Q_D36",X[EP6<2M6[K#<$F,6I:K:.#P
M^6Y_#B-<+("?:K2DBAO`<>'"H@B%3>&C2L8;7NI`J\[P3`DG,PGN$U_:@H0"
MS7YX!#N[\N*A#5GV:`UDMWJEC3J7-4T+Q./+REFA:=%"3G&&H=$U0"B00@55
M<`3QX8IZ(1%'``="``-+(`0&4`1`@$+*1P`_D`1@,`-ACAI?<`)T8.;N_BEH
M[I*8F%ZRPT5*3,UQ3H[R426T:U(<JBT=XLQ=E]XD",>9SHE8_#ES"6]5_0UL
MU`PTE47?XVWN,K'I,&%*);&F.P^P=DMO'"7$F,00"TEO5[K$6$M\#?_A93R]
M2^`*L?(J/\N7:9R]L<((A:W8C-WJQS!7Y8.=6G),.E,FH$@6JH/91%<X.D.9
M`#:%PLJU^I&%5H@77RLG#X07`/E9+T":#T!QSBZ1C'(!*,`#<L`#'$`!W7($
MT@X%/'`$ZC$`'!`'L;4``@`&T=<#.*"1.."NI_$%9/[N?K\I?$`5,B-3S%`E
MH^;P0&DMB6F._2X=[46O4H&)DO]+4!%7(1:`[[.Q@TJ\Q9LA^G6)(GP@[L7=
MG.><:UVG#2NS=HJ@9\4P-?$X.'$][W&RZ#FQK:NH'W,4&=ZS'"[/H#X%353J
M&L[&X,@3H9X(H<[AVQC8/`MI=,<\4TD5(^#_9)*%.D(/63:S*UD[)O;(]&4!
MK#=IDV^10&HR%U^;37>2)V!(FD*^]0A)*!T0`0\P<1<`!3)@0<R@D\]A@",`
M"$-,64,H+TQ"7AYB8#\].#L"3PHG?Y:7F)F:FYR=GI^@H:*CI*6FIZB7?!NL
M<!`&`[$&!@H&K[6S"KJZ$'!PK,"L'Q_!$K\;O\/*P<@2QJP*L=(.%!0AUR'6
MV-D4#@G4W0[BWK*TLM'G<",<[!SK[L`2$`H0$K00\[RO`[/]`PD``WI+\&]:
MM8`("0)TP(*%#1;8'`H18J/B1"$LM(60"+$@K%@('8!,^`W<1AM"BJ@T@J1)
MDRDP83990M/ERY@Q_UTN0:(R!,.)%1NB1%)SRI*71'<68;G$R-*C1;S-DC:@
MWH84(];%.:($BI2O7Z&(A:+D2!P9:&7$&7*$:UFV;>-R)5NVJY*[8O%Z!2L%
M2Q4I>_W*H5*%"9/"AIG0>(%"PX,($3I([A#A@67'))0(&4%"R@8I2B!P@&`C
M@8TI+)K`R'!E"@P['CQ(FC'CAX`>$BJEVLV[M^_?P(.36H5LWD=IT5[1@F5K
M7B]6\N`H&X;L*G5@TXG)PS=/7JUH!*5]JU9M8T.'#R&6)Q\N8+E^!'-!^/!.
MQKNLQ#9\<(YO%RU=5/&ST#CD#330/]TD-(XXVYPG5$4V%#%1$1%*F)Y$-O^$
M4%`M_RP83C?M#4"@-2P(@8013+EDU%$SJ:@B3*W-A,2)%$&4`"P$4N/04RVZ
M-.-.+`6I$E%">$//+L^ET`X'6QTA%A901HD%8&_%8>40<.4EUQ%8#J$$E6R5
MU=9=>NWUE5]3GEF%'%6L*8<<62BV6&,D6!8999;EZ1@-HI7`A`Y2R`%'5":R
MD$$000Q`@004$`&$'6DL($`2MOWP`PX0Z";<IIQVZNFGNZWR@2NZ'+=<J?/P
MP]USRJ3@*G6^T(>??BD(T\IW'TTU(#7BL$<B12A11)%Y$%T3CCCAX?+/C4A*
M0%\[66$UZE4;U".!?_SX(XT!'FKS88(EE30BB>K_A?`0A"56)&%*$:)8Q(,U
M#@3+>#IFZ)"QW5XS81$_%E5333=-89/`0@Y+CBW8,J0N44@(/*.,--%8H1%"
M4,`L/L;\LDY:.K#E59MMOED%%G3)%:9=9&XY%UE8<L6E6UV9^=7(?4WIYIHC
MMTG%8B^TH0$)%SP6665Y6H9"%3)X*<,1/.A0Q!17O-'4$C!X$4`&',`0`QE`
M;"U&&@(`@(,/#KR@*:AHIZWVVK[Q(2VI_>122SZ[T(,Q'!+H=]4(*1`S3*W3
M]6VK=[HF5!ZQ#0:KTI#"0OA0-LB&EVTM`#7WS+,<H`5MWWW##2`_Y5"UX#4-
MD7?-N.PUB`T%)3K(`H4E_UXD!(HH6N2XQ0J!8TU*$U*<C;'DONY44C85S^(2
M.1VEU(DJV6`Q/PJXXHP"";!^$>TN&8'\3BP:D6&%&4+?RS'TH:7#6ESUE<7Z
M65"1!<UD;8DRF5"\+!>9+=_5%EEB2?$76#0#X)K>][_!\*!G&KB``O,$F3P%
M[09'&,$1=#""(5!!"2$P0@CH00$;&"$'/BA``080!!5X@`A5\T`,@K"`!<!!
M`R`X&]MF2,,:UI`/F>/`J/+!'?_431]VXT[>I@.,>O@B;QM`HCV.@Z##/2A8
MLNL=[5#$$\<%!7+Q04ZN[B&,#RA)!CH(8\?.PH[]_,=45`F)21ST.Y]8PW01
M.?\/-\Z%$0@!"XHI6<J,5'(1">&N5QLQ%TM.1!2G2"@CI&L([XCRDM;DQ";(
MPXG`=G(B%`G!)^2HFXA89Y$))84F-6%>AD*`D6[0`HFR8H<8G?0DD*V)"FR:
M$EW()*8M0:%+5KI2E^#2%;[4;&:N="6;@DF%G?D,:`\(&@.+U@$-?.4#'#B"
M%%*`/(LQR@9(@($/@$`$(@0!"$#P`AD\L(`8>+,+"^@:!T[`A2ZX\YWPC*<[
M;4C/>MHS%#AT!S%<L:I<#."'=@-B<S#6'WT0U&[B098#2(>23J;$78MCRA0M
M:<7'=4-5W]G'J8PHC,S)(',Z^*@[:G4+\(0N=[Q:J'G_'F>>-FX#&^A"S_<D
MM+A+1DAV%&,*\W2:$=.=QT0O4<H@WU4LH2R%*9)\Y$P$!I,`!&"2$ZT(Z<*#
M(])MY*&#G%%+FD`QU]V(B_K9&!B[Y*2^!+,*[YN2+&GY%OD-82VX3`M<Q@0:
ML_X%"EAXDU^R\"8X#3-D<<H"#4IP3&4FLVB1>0`*L!`'#@RA"D,PD<4ZN),,
M^(`('O!"$)H0@!CX(`,%@,%J"O`&(BA"!R>`0QM6R]K6NG:U]XRM;._)AZSP
M;8?6V@Y_C*./,V;+'__Y+7.8.)X/2>1ZLZ/145<RT2C*-$,':8XNX/"=[QC#
M65[T:%KTB3?C+(>)!AB0KUS'_\:6.LAV-ZV10PSIE#OB]*C:XU[W8FH1?MF$
M)RUI"D8B@DWMW21@/7)83*[PU)AH=8_GL1BR%-6>#@[I1RC:"4M+=S'LC$`M
MNYP+E'`FS+N.:2Q<TB661/S6,,)U?D\"IO_2ZI<V\15.5!C$FIAPP#:40`,)
M-.P#2)!`R;R`"CK8P`B4(`/3.,0TG`U``7(0A!AXP0=&"$`.8%`$!;`@`$TX
MS10*X`$HR'"V8`XSF&L[JV:LZLS>Y86V`I1&R671("^5"!^=PA()#7**!\[C
M1.38$,C]1Q?7.M(ID9'*);4C!=3-%4B6%1YQ(8MU<92J0WK*W_<"BZ8K65=]
M'_PC&?\5CR<4TO-#`7:3IE`HD=ALV$M<U`2BR"1@4"LP@67$DQJY<2".A@7K
M^*55*KZ+&]4XF`&>L3&XADDL.8MQ,=_W/M!\6"PA/E\NSX<E:I-U93$#3(MS
M1L!MNR_&/&!",6G,L\9HH`1UN@`)>,SCR/`@@AP@"R>=DAJ93,&R.<C`EH.@
MS0!4K"%&F$(`?""`#7Q9S`A/.`V)`YU?\//,=9-;J4;"GEZ]L3UNI@:QA/+0
M(2TEHI6D'2B9!Q1@0_JB_0@B;_7S"ZSPS>5\&\%^1M*A;WD#'*,;)>F&52(W
MD@@EF%X<<U>B%*$?M7A!;<DD@30[FAR5D0(G+50Q<ER:7`'_E#J9VE.1=X46
M0>W565]"$=QXC=PM1,'F,A&0W`5=@-`<>M)A!QC1UTO_Z8RO(8.ELV%6I9#*
MU4HA[5A<:#D6KT"A38)A'YM$%F-RT\`P-(B\Y,]-)PV@P&<+1($.E"0%&@S!
M8D58PNR>VNJKM;H)2PY"!C+0!&]8PP@%`,("Q+!.A=O^]FL#`$`-NBK_R,T<
M(.$DNK(1%(AXB+]0Y./L^&5)H4=Q1DX1.[M`]"W<02]Z272.WO:6'V#X`@(U
MQQU`RF,C\JOWDA&ID457"O39T7F*-$'13*A8R4\6Q2@"-XJ/&J9_KP?@#2)4
M`(Z$!.F17/A'2+2F=%\G??8%?7IT_Q0\@4G/LRP'TB'FDA0(=CKB\V?TL`'M
M8#['MF*O)&[NTSY9@`5B0DLC%E+M4&USQTMVP4K](T#+5H-\16Z,@0(TP`.2
MUX,O4`(ED(/FI@%,,`2B(0>'P"U09`2KMF5+,``%X`,YD`,%X``?4!I&`(#:
MU$U`,`0'AWM@&(:\00?B`3JQ(&BS``=G.!7BL1#F8D40844[EQ%6M"\6PEP3
MX13IX3B\!A27I!Z]@FLEH2JW0@]Y,P_'X'#Y(""<9'SAL5"39A(8@2+G=1'%
M!VQ`1S%"-U$82$D'YFI'(3!.-6!0TW4P4F"QIF2K!UI*)GIZ%GI+M1-)YVHZ
M@1$ZTD=!HO]T2\`"(C$OO2(Y@(1-H*1!U)`MSE(M^4!H];$6V:8SAL$#T"AN
M<<($<D`E>*$$0\""()5A;W4R^F-X](-X,%9,Y`@GT,B#C/$"ZF@(D0>--*"#
MY&9N3'`$!K`!BO$"$+`$#U$CLS-)5U`$5Q`$4OB$T>!?6Y8#71`$3(8%7RB&
M#OF0H4`'"%&&9BAQ:R80NG,2>UA?#04AZ[(O6<6)[74A]354*1%("6(@XQ`?
M>G,WR.![56$<MU`]#751L7"+H\01>W8>%25'I,,O$44[G19VH#1RJH83!!9K
M.1%K`=B4!;"*`3@%O38D,>&)\%=(/H$C+(!G+#%_O/B(X"`Z)!+_>I,T=ID4
M/;B%#W@C9'+'C'LQ@NX8C>R#>(!A>&_U4>;3,2W#)5X2/RM#)=*T;>-(CNZ3
M&#S3CB\@>3Q0CG'"`S>6!8TE052``ASP!DVP+M<0(:`$-3G031FP!/\8`D\I
M6JLG0@%0!"C0D!"YFJQY"1*Y$&8WD;.`#]DR$MVB#4]47WD4(<P3E$C01]"G
M/;6V7U?U<75VDJLS'L!V(+WP"D:4:`&%"_ZD*"5"(0WV*Q82+-K)DW!(7MKS
M=%H5?RFR5$NWF9+D5`2&GND)@$[I5*KXE"+T!C"QF3,Q<NZ"5#-1!!=5"PZ0
M7$!22*,D$M_@'C5W5?XE8<_3@=!AB.0C_W=ZV4M[]8P\N(/AQE?M$TMM4C_9
M:#YH<6T>TU9Z029J$C(P1F/BEA@\&(V.MX.P]"8TQH-RH`..A06&404)X'3#
M0DI+\'^AM61`D`,[<05"D`"JX4U3"$(^``->V)I,VJ2NB9'TLB!G*)T?41+!
MY@!2]7-UR)M-!U_T1T41PUX7450IL5.:^%+5(%7`$UUR@P_,42I,Q&#M0E1%
M94?-IXF+0U[HP9T3$YY8UR,N(A.4=!-7X$C_YYY*]@8`6)I-F0&K49I*!I];
MQUDK(I5`PE5"22/&8@X=U!*$)'K)V8O+(2(:!W305R3B@UU)1`\:\T69<V(?
M`R<ONA@]>*+BMO]X5:"A9Q$'?D=6*3AX)5-6).,_@@ENBZD8X988XS:ACQ>/
MZCA-]*$#N8HT#E!K<2B,40<#G1D$3YD#`2`2HHE_;Z!-/N`#1Z":3IJNMD<'
M%G<LD2,.YT!<P=8-DT8L=>A>$95IVC-1(F<$K?-$>;0N[75'/=E2;K=HL_`-
M;P<0,/5Q]+4C[!5_\==0<0@4SU5?26%OKR:+@@HU1W%U4_`&ZNE4(NN>BBJR
M`>BH3YD!XUH`5].4I.>RD52?E=04FN@]SE.;"X5-]>D]B>03-^*F<K-KA62+
M\:$`J"1S^"!DSR)27K(__C,8X/:..[B#ZT.8:<679Y$TV2AX+T-XA1?_MF,1
MM6_2>(UWCB8ZM;2*MHR1!1%403IS!/UY?BLQ!0Y0!#`0`#,2LDGJ#1NPE4LP
MKAG@324D`^BJKH@;9A)I<8R[4-7PE8S&()+F/!<+%!YIA[2CKS;+KWH8L,(2
ML-ZS7/1V$K)#7F4'+BF5NI!6G>QE=,S%2+]9M'2D.-F)BZ&($Z4&:[B;?__'
MBD[EE*1ULNRI9)'ZE(L*6J4)LC`BE0*C$I04NETEJN$E(A[$.^CQAS;@`'$S
M;`J@,`]52D<+`?HA*Q]@#%[4M.RP%7=A5HTG)^S8@\EJ&.^3%W<I;>:C2VY!
M%WLQ%O0S,]-(@A*:HL\HH8;1HE0`!6$T!(<7_WE#8``68J!,B`0&0`%1&$*G
MD0-78``<(`&&HJU4*%HY(`8",`*'F[@F?$^O>9L@HG$]17U7=4=RUD<?^7'+
MY8#&N;F&5%-!9X=ZM!*5I&FT"RPP?')MY"W:4(!TQA-"N7;VIT>@MB.TNRZ;
M>+M)]4BEB!,NZ[(\:IHD&Y^*&KPB!%HPL+*K"%H!V!J.%"-&(2$.6")==;0<
M`HG::1&*)!+G<"T)4)RE)*I(FTHR)QU_HUU9$B55<+;EEIB'>8[A=E?8J#EJ
M86)P-29V,8/\V[]^09CMBX[-^GCGB'=]061)<W@'1`433&>*Q#`6@P09`$)O
M8`-+9@-9H0!O0(7E^O^H04!.'U#")[S+-42&NV+$'41U/FD>EOLZ'1>4]*='
M7SI1II;#1H='F]AK0\5K4NRP4+2'PVQ>BK2/28Q5R@.F&#A4!'B]F\B)']M(
M2+F4`5"H345:\.FHOMO%3:FH9@R?VIJW,>&>+T%Z2=EJ`@L[LW-)_[0+BF(L
M-V4O$.$0%+`LMO`1#N:S<#Q$6:%/M-*TYS/)(-.8[KB..GA`B#RAA^%L,BI2
MQC97]".V;%5WW);)<T*AB!QYGHS`2^,5>24'4)``2Z&=*7&90O`22^:M$Q$"
M$I`""3`%4Q9:/J!Z.0`$9+``N<S+4`UF9!BY&F<L"OV&?18LG4O#0IE<7=G_
M%`>V/,$Y(\M7SIDV='A&2/4WL);HA\UCNFF:(75$,24):LQU9P`S-:)',9<F
MNF&M(HY4BNPL<&\PV#`RO"*T&J(%O/,<6F9<Q@$0,4_QFSV-?Z1'2!0QPQB1
M`+\`?@M%$8U((@P5`FZ7L-3KAQ00#1VH#.X0+5VT#M(V%V;5/B_*K)>WCHD9
M;BF:JV_A=QVZ@MY(>/KC)?U[>-,JH>](6(:0F,O-`WP%)EY"0&[[`2&`!+RH
MD;.C95<S6KOX#09@!/!\!:$%`Z[1-2I@N%&=WB@\$N)2/6V$I3QWO9;+?/"%
M7^'9(I3D=,$987D(NN_'7NS%2#;[B6S-+A$RI]T)_[!MC<QI/:@NDE\W.T7V
M16H#EIX"YY[IZ;(G*XKQF;*CZ<7LZ91CS*@B9*F:6$DFLK?S:4AY.,W9BS#_
M8,P_RY-4-X$#RIO6F2VLDETB-0+CZRK;*-MP*7GJN%J&@`)(WM'1*`<H&&UR
MM4O7)LEBXJN$!QB%/*OFIMR7QXZ$43)=L6Q2``<X;0.TD'8=M\]AS!H5XSP9
M-)];5@!&G0$J``1*H,OJ?>>;,M48:7$-LI-U&'3P)78_<B+*0SR767^_R2^\
M<\PZU9N9&C']$J9&-R'N%T5!@8N\TWZOVVL"OE5@)YY_/3!5C*@G^[N-VN$I
MB[QA#+QEO'J/6L8N"S68JO\4;LR$!/.Y)L(4%H)K#+(4&.&'ZL)'O-@A`.<C
MI3&;712M'R5S?U-L)S/;4\O1EH<"0+A:EJ>8)\B7)9;`(X8^]T,7(X866Y$7
M=<6^Z/@SZ(YC&M`&B4D8C+QB7++!U:`H-^7#39&4;RZ?1O!/NP-]2*!DGU6N
M=8[G!,\VOKPKD+AQ&**1NDE3$9N+PS,UX8SH*L%5F>CO.M&;8VV4&4]%F1N4
M-&6Y0(>'%L([5_FIRL,B&@L3]4<3^==4Z[S%&EZ\I$7SK9[F\/SJ:4[&KTZ:
MC&JHEWE%#QTQ!.M^QTG:1AP"H>?,F,82X$L-X%DQ";#:?H,Y^3$,$YTT^;MB
M:LO_&-9N8^I^8R@0EU0@!5_;[=.F]2<=/[QZ/FI15H;72E108S]3)\ET`81%
M`V7_%64A!7$"!2.@AK"@"R5"`0]X%`%G%*KV$OMN``E-.U$W9=I*!79>\):?
M"K[<(2/R4HZS4@ON?CX<G,Y[F9;::D89GCF558P$,6K=B=SC(Q/ENGR]?$)L
MUB7OI:I/X4VEQC$RE#"/J#1/O,#[Q?#9J*+UZK!>SSCOZJZ^&J.H[]G;*V[\
MS<J'589$=MO`?+^I.)DKS.NU1]X3'^*+':[B*EV$%6VIP#1-VX[G]4"(8]0.
MA"4P]N%63'S?%5HK1GK)=_@#"'%Q.C(R0TI0B8I04G)4_SPH&I(D%Q>2;2A,
M5552B5)55%10$D5"(0D*#B$L+$5&2$M-4TM33;!-2[%%`P8L1C9(K[(%&06U
M-"=_RLO,S<[/T-'2T]35UM?8V=K;W,MT`PG@#N,A#@.J(>FL-C;K0J7L0D9%
M]/1&]Z_X34U&L?O_MI`(Q(<O6!%82Q#:NE<DUI)^N/8E1+)P7JE7]83(L_BN
MGCV&&NEU?`6KEJPI4ZX$4+E2UI645UZB3!F@ILT`!7(6>,-3I\^>Q8AER)`C
M!XRA&6`<15J,J5.F1VL2*W!EES@6[T[BPE>J8RD6#A*,HT#!@:][-E;9$#*P
ME$>21EA1X*4`@@0)&S[HW:LWQ?^'$1PXR(@SY(B4PUBR4&'"A`<-&B]0M"E1
M0A)DR250O.!!)4N635(0'1DR2(=I'4>.*%D]^M`1PD-D"(ZC>K5M)5*P@*(Q
MF3(F&CPV8_DD9304.4/@#(B5UIRI$"%?30D@*U=U4S82&$CG0&21)@&0R)O"
M)%FW\^C3JU_/OCVV;^'$C@U!MCZ%=.Q8Q-,8O1[!>P/UDPM%">4RH$!(V/,0
M7`@BF!!)L4R!$"T%-FC1?P*YPM5''KGU%D7\$.C/22@%0-,;)MYD4P$UO<$B
M3CHUY=.,3RFE%%(WTO@4CD<I55-2&01@A#GGA&`#1`<:H5$[J^@'%B\&B&.D
M$&FI]<[_/%1JR!6381F@`!P;P"%F7GKE-<((*0#&`6&J,5*%'(HQYMAEDY'0
M1F24^?88$U3(`0464`PAZ"`RG*:#(((F6M@1A!0B&VJWV788%%4P\1APG''"
MB6Y0**':$`9,D=,48-7'PBI7"@2>0_D4`=8I"=C@92ML26C$&U,8@8Q[O/;J
MZZ_`I@>?6/:M0E]]ZJS%WUINO7)E/@`*Y%"!]TS48(*N!(0@2=?>8MT^TGIK
M(;03+N%*@QLQY!\]P=P2T#\FH41B`"[BNN)..DG%HD\RZIC44<3<.%2/`,^(
M;XI"_4L4##Z]5,0I`PQ`02L#M95?60[<5\X`"B@0)3DLD&5D_U?O4+DAE>F4
MI1T$><$A`01@;B!S"H'5/%AM2B2V&`^,`4<#9I*\P)L&);3Q&P^9LD:(:8XZ
M*E@A.A0VJ&R!R2:#:JEAC8@G52C6&6BK48I%84JD(,105-F`K,AKW8/+$M2!
M1!8KIX101%A.&O$23B]185ZP@`<N^.#K?2-ERAH7VZ1^2Z[%CK*N:+@MB/XL
M^,^U"W:+D+0`253@@-\>V*Z#TIZ[+8"B!]-/M`7N,Q-*,<G$DKXZ\80B3K0;
M["]40?%NL$VXELB3PCAF\$9"IHR3<5GW^=(5.[!&G`!9YG0L?<89H[KDDAY1
M>2H%X1@`\P<;2!`SF34_7>@AC'P2)__2P4$VF20H/(9"9B_DSW.?H8T6!]2F
MJ1K5JB8H'03F3&J:3:*RAC-$;,TVJI&#GV+#@2+`P`<P,)$1RA$6L:#J(-6I
M15STDQ8;P`,8=U/``-C1$/"X*`-9^!OA9DC#&MJ0#@F0C^).E8X>THUQCUN7
MNABTN<L12%NJ>LA!&F2@`77.'])*R-L\5S$'&2A:X;)BZ@HR(M>]KB8OF9W!
M;'>OGNB.7V@KP%*:TKN@^*0FTS$11682,.)1A1\A4X7*B*66QZ4E'!PS@%C"
MT3$OB6-Z5O+CX][!)/#Q@F5^<1F9TC2"IA5"$&WZ1-<8TYB?7>9^&M#,"R93
M/\AT1@Z`8@W_:0R5OO0-QH!HV@M@''4H067-EFT*FQ(*`P4J5&$((_@`"V`0
MA`Q*""PY!(=:SC4+(S3A85B9QRL>9(1<,<\&37@)>*12'AMZ\YO@[!4.=8@L
M5IB3AR1T7!#]DR&N"(@BG!-(,ZWE+6X)`Q?>:F+EK#4+6DBDBE;$'"S>>:VM
ME$M>,XD)[&PB1ACEQ$6ZH]?OT)@3M*4Q1B]:"8QL(HNWP2)A-LI)`.C!P7$`
M4CX92R?$%'"7*$6L+C`%Q_2<Q`KL".&<WS.'^.#P`0ZDP"X;H*0`"5,HPFQ-
M"I_)`I^H<)G(H``S=QJE9B!#@TU4(1$0'`(K.8#`,PD&EGX)TP;4_P1`V`P*
M-JDAS6APDQLH<``"+%!C#JB2*Q8`TBSQ@!:SA)``Z`#HG]^9@A!FY443[6-7
MX4RL8A=K#3J$!6,]5$>RSKDDK&0D718QB+7XR8\#'8B*TC+)M-YFH'],I+01
MLE`^3SNZT\8B0>Y2540Z2J+8Q02,^[HHC5CTPGW]!$40%<I4*)K1FZ!(H2AY
M$!*ND#"DX"JG.0R?`J;W6"?1)QQV@8#'HN0EZ^4PI7ZDDB)Y"#XOY25-'P#3
M!](DP%I*C6R4XA,G+149H=TO3_1[*@TL104L#*=]GK)E;`K12C6=*04RTXN!
M.6"H..QR:42]Y!``U8D4),`(`4!*>%`6#O]RY-4@3"K'?4P("X,4819^H0`S
MZ=6$M&A`AHR-L8P5Z]CE&<N'YVR'._:3)6QIJ"'FRER#P$4BCX*V)*+U7!-!
MBUHE^_,A'MVL<D67BWX$@!:UB!#L9@+'A?J612<R8XL>BI.>V`NB;@SN</>E
MT=O1:R4R`=<TF<L4JCQ,91'+LSC"@@Y'[E2[*LRS`08MT^RELW&.`U\R@=H7
M\O5EEJ9!:]96TXCY=M*I+ZB,)#3=AE#NEPD2Y$0CKCKI(Q1*-K/D*E?+)*9'
M>S6`AE#4H$Y#&]1`8038!(](EV"*/7J0+0BZ*7WF\T%X;,0!PM3R%5"$!!9L
MX`8PGK&TITTXQXK_[%B+@YZ1=*PL96FD'T5H6X8.DKEI'M$6H=NGNVB+97VJ
M&T2NBW?G3`LZCPKC(:.UQ>LB4B*9=/FVO)V*1(MA7#C.[B8R(89&@9>OE61T
M)RU:R>NR;`OP((5%2P!+!_4LT^AZG&-VD<!VP<%QZ447K\NZ&)3$)[.6I\`O
M0IV-I#/)"*7.]S&1(5J>*H.)R;R`3TG5U&="TRE/'4H&7D5U+%NN7O(%DV96
M>\VB;DD:02!B`]]I"2Z$_5WJ3>DKQ^I@]M1ASE5DB$`VD1`P$A`'$D2;VG"/
M.Z]P2+T<-J^$S1%O3:DDCX2<2YKSR(40RGV+?LY"*[.M=Y9KH1(GO]NT_]KL
M9Q=%2[ER`<1`)4%W2MSU1>.Z2"5KIEU/_KU-F90(S&^FJU2DXL:'\@3.-ZD%
MET5ZA2:8`I`1"PLO).8`049LT"[UDB")E.=DDEQZC$.T.9*I@`_@I4PO_XM7
M&3QS1!!GDXQ9C'WIE[_\A7*4/Y>@8C@!)]`P`JN$(=2IST0^,[6_?,$<JV!X
MF8C4_&F7I%F3`810<7S88"QVEQ]K85T8,Q;,<VU-(@\VL"`F80O\1QU34`5O
M)W<46('<8&T'F&W+DBPWY3C_D0_?!BZOY4R>$V]8-A.=DUS*-G$IF&5S-$4H
MZ`^B55JR8"+R$B%O,P7DUD7P@E`H\2(L\A(BM?\30&$B0;AETX%<VJ02MV-;
M#+5L$@5QPP5<8"1&!-=,V3$]!1@?VK%=P*=GN(=[8!A=4))2ZX!,7F(78`(F
MZ-5^+S=+@W((N*$(5M4U.],SD7$G3Y4_/U,_^Y,%<E"'=8@%GE(;I#%`-1-,
MS@<!D?0R<$`S"I0:1P4HIB8H')``[%(+]9!'TG,?J@`]ZZ`V'D0?R&1W:J$?
MKC!XLX`$]-$$/B&!%AB+LJ@-=,=G*142)T1V\?!WW*(ZF-="430B-R@O\Y82
M^T9;$Y>,)6)8)TB,\O8MQ^A%`,$Y)!*-7*8B<<2$9H0B#0=GMQ5G)V&#RU8[
M8#8=P<6-(H4[8X8O+.+_@'^43-_%A=(#?"Z5>Q]7<C+U>^?0/'0C74"58"\7
M)F!B,^M#&Y1V&*.V";JQ,\$1"3J'"2@P)Y;F2X=A5:$&!4>0"%-#8*L6D"T'
M`3`3)G^Q)H)`&W^BD!B)&J#"%O>`$N*1%F61>Z:"'TVB-O;AB1XW=LEW)0X`
M!1`@*L,#B[,XE$0)#8[%'3;F3.*E8^@D#^+21)E'.@J1C+C@C``11UCIC,H(
M$[<%1]689;E@E2AHE28X6UO9@V%D(BX"//1"1C%"<#9($Q)76+"34>#A;V\V
M'6_T9E'H$[G2:QMG<KIW2/0XAM*#CX=9?(96#MWUCV2B%S'34PS6*#?C";KA
M_PB!.!R@T!CY$PDDH`$0J3\\,U]90&$6F4J&`04JV2B!T7[D@Q<;`))KF!?4
M)RB(H!NI%!IQ``>JP`I`]@O'$A_+(Q=&0G8IHSR#E),3HV.D*!XLX$\.8`09
M(`436)36:8%TL&VZV&W<]CUV@R!4&0Q.=&6JLHP2MWC1N$T+=US$J(P,%7MQ
M1%H)@8+5J&53=!)+4'M?Z8.R-QTUJ&NX8SQD)"I!0@S!4UA:=R(FPA*C<HWO
MJ5'IN)9M*5+/I#8;-TA[Q@O)5)AZ1FBXQZ$<%UT:@PH@&9*/N1>4!'5-XV!<
MXPA\4@7^E05(TX>9]GU"0P,EL!G`P2>H-!RZ@9*"TO\IH^$_1Z>(Y0,'VB4S
M+@,S>`$8MC8I&+DH<<`!J3`]'>$]&!,?]:$V3:(QYJ1HYM!!?&19[!`Q-I`B
ML6`6.2&4U]FFLK@%WV$+T+0?>50631)84S`4=&84+"$A2!`>018`!>.-M?=D
M^U![/P*7]**7_J:,*H%<"V5ZR76#+_B5YQF7T]&?+F&,[AD[V;B.YPAF$:(B
MIF=;(O4ZL].57;F7^G(%"4(EQ`<E'4<L@TF/A528PO>%AJ28S',JJ.`EZ@48
M:.(7ZY5TCL(FE-(ICK`)7[,8?2@9I;2'D;$G@K@8?0*CG7`;A=$__R,;8260
M=I%>,@.;"<8!AA$:GH)T:*+_'*I0,O30#G@V#ARC0H@469)%'R:'2*%867WU
M#A1!`0;@`."!!(CEI@9+@6=0@VJ'4XXD,4U23:(2`QY`!#X0!#E@@SXF$&R1
M%$:1`T%`%6^`>)A7"RMQ<4'1EG!VJET)1O)2J6&I35J!A%ZT4)P:1KAPGOTY
M$Q&2EBJRCK7#43L+1@A'$^.8(DX(>TB;43&QEB+4:[OW>]IE`-2#/8!DJUYH
MJ_3HH1UG%N0UKRQ#FS)P7FC25543-:J1&X=1?J#0&9TT5?KE27ORHNZS&(P!
MHYP0*+51=+FA!`/$%TIZ%W71<BU72>R#53(``3K41X[CJ[5J%]-U'Y#50_4A
M=A.S_W?UD""G8D+?L02Q*0NN\@+5>;"BNUAE8#PP(B'A=EV[QS:T$`!!X`$"
M````(`8P\`8Y4!7\D1/2Z0/%H!0?6Q/M5F+.)"%P@Q0^X`-%@3:W(Z$!]P:2
M^I7VB8-468V02ATJ(7O7^Y4S&T<+RG`RDG81P;,HBW#JZ&8LH:IL^7J<JD2B
MR'$QI3Q4^WO=-6@=4[^W6I@GI3QR(:\@*0'2=T`&ED"#84O6YU\_RJQRXACU
M!1RA,"><09&7&0JA(&J=<@B=8)E5H`0&M&I,)YO:Q:2".Y*T\1HC\+CPZT-<
M,DAI"`'GT&$=%EEB.A_[80_!<%,4H+DL,``04`0U`18\$/^ZHQO$WU0&.Y$!
MQUL`KWHJ.C4`]&$D?UH`/M`%`-`#3P`&,``N5(($.;``03)7#&.$.R%[_$`2
MV8)A0@$#0``$1)`#'(M!SJ5&$!4\D<J])O$2THN]D7>]F5J#KU=Q>BRI$W=;
MLM>SV#A%801<QQ5QB@QQW?N-W"MFM8`@KJ*Z'^HQ@HEG4%)(,%6B@(:_NT>K
M=8==3>I*5#-]-R.)[:-)_H7`G?0SH:0)FY`%.YHIFE2'$D2)J4$<C*`;H4$(
M'`"9+_/!81)R,#,F"<9^+-Q7>90]"%B`.@R2@G1R$:,QZ4"&-F997H$$:5%3
M+*``(Y``0E`+)D0!H%L-8B+$Z!S_.&<P"U=0#*J2/&(A2"8$#`#R!CX``#B@
M`@+P!K`E!`&@`DG@`UA6#%!&$=0A>)+#:[A@L4U1%,5DQ%X`!,B;`\=[O`!C
MM(]J>CB[H%@FCJ@*ON'(LOV6LY)*(>)(+SRK4.XFEQO%$F1T$Q"'7%U&R%D&
M#WDDAMUER3JD>U&B0B7Z,L]'/DMJR9E\/8,)<E^20.ES8&1%-F'3"9I4D9O$
M,PK\`OV%&&O+&')0D6F;K8<A=;AQMX@A!4-P0#PE)F("5'>!UFJ(UF`B`84V
MM0:(.-13%]`<HG8WN?(ADVMA$""AS/KA`''P`3=<"@DP"VT`Q,K0`0V0SH[]
M*V@0>-31_W?A9J?1B1+`.`4P0`1/@`-```/8E"`9D`8+L*!7F$1RYA$)(H-)
M80QZ60QO``,4'01I#`1=<+Q&$80+)ZEQN6R9NF6X<+VI.@4\L3>\;3`G.SLH
M(<=(J+.JXPI8]JBO=W"/_!/&D$UQIH+4<BK"ALE0&[5[1B3`US']ZS+/ER9A
M!9+;=:N_5Q<OHP!B^X9>=6!_42AF:QN*D!NK',MTRTFEJ9";P!A#EPC^U0B=
MD)&[9'^+L#6OP54(5CYW83YA4A=L;3Y+JEV=&)/?I3R02ST#\#)?V*%%@IQD
M^#$CTQ6ND!WZP3$:&@*JLD$<X`**G0-R,`$Y\-@XWAYTT`I-D/\!N9(A-"4$
M;Q`D2W!!`0,$^<P?*2+;LM</LA<,^!0YOS`,_-`$#%,`Q;0BQ`UFQ)`#7J`"
M7:`"01!<"R>7S=T2'FV#2&MZ$HHB7U3$2D'1:--X5W`CM8MEI+45X<9WUN&@
MO3W3KY>7"86Z'X$E(3.UQD<7ZATER6F_2:J&$![?>U$^F6R_%&[,YR6X8S6L
MLQ1KDGA44-TU@0@GGA$*+ZJV:YN9AP&(75,<<?A`M9%6`;07V=6_$U[,2&KA
MX+U[)G4]*K/"G=RAMGH.@1FKQ,XX\.`J6#$`ZY4`=A6GLV"N*Z#8<3`'@I#C
MV)X>?+!"?_H0-;%!WG9!>:H"*I"\1.#_!4@`#@$`!!G`+A8$`P\A'I$S4!V1
M<4O@(BE1`#%PL5UPA2@!E[?C`T0`!`LP5XS\T6K.9?T)1Q$'$T@+/$.1(E+!
MQFP<!,54CK*`(AE`!$&0*ZL3+MY34Q*14-FML`B/J<GU"Y9U0B&3DQM*WN!M
M?/8K<L.<%V+5%S!7)N7-R1[LOPDFU#'S<NSE*`3\U`B)5)WQ&6\2B(HQZM9*
MZJ"A&X`X''P+-7(88++N-(Y&S&L=FQ9NWD,=?/68X0X`WWN!I.(@[-Q%[&#(
M<>!5,D%D`U^R'>7@3#5!`84P[=0P`1W0`1.0[8#/#0``SE>**]J,32<6!&LL
M!CCP!&N<%.E._P%(,!3ZL5S5U&*1,Q+A9EGF(@^EH-E=D$$89"][HY=`H6$I
M0>8BK=R_O8RB\B('IR)J)-M?S`]3X.5`L!*UFP,JX`$?VX[Z[@4^CEE?<6V9
MK1555G@XN&Z&)Z?"5IQ=*A8FU]Z<K-/M7;\O,ZZ0J5Z41-_I]=,_/9LX7R:/
M*51,8[:2B+:?@`7+*FI6M<J/0%7^G<$_BIIF)6N#0"B"X>#D#PAP$'`2<!L0
MA7"*BA(*"@:0!@.3DPD4%`X&'R,?$`H#":$)E`.0E`D.%)*EI)44+$(L-K,V
ML#840D9&LT9-`05%!D,U)W_&Q\A_7,5?)US)T-'2T]35UM?8V=K;W/_=VG04
MM[8!4U-%2&\V,$$Q"U$$3SX%\T5"10%(LDU%MK!%]?9T";$A!`F2@;)Z^0#B
M8TH3&!D"-%GRID"`*P5R9,A08,JO*1G*>9P7X.*5*R-+HB1WI:3'7Q9_O9E9
MLN2\##ER^`@B;PD2GPM]$(%1TL./HP06B'F"PT.,'$@<S&+!(@2F5"&*&#&X
MI$D3)$;^R=*JJ\B2)44(:@6[-:R0MU,O574`BI(!1X@..7ID5P&$OX,V?!C\
MX9"$#2E&*%Z<8K!>"9`-"29,>7#B$9<Y<-"A0X:,.$..'($"18H4+%6D5$E-
MVG05*JGE,'F!HDT)%#1H\,AB&HL4*$J.#)'_H2-.9\V</<O0K'DQYL(2$!4Z
M)#T1(4^/(I&R1-?O)P>I*(AJM1T5J%'D486H*FM6"((VD$P,^],C6`,/BE'K
M\L;8G"[>!"C@@`06:."!T@"0``L4A&`/.0$8@5,37:C@`0`X[#!###YH%$`1
M(80P0"VPO&6/5B86A`197N425@8^Q.`!$1%E`(-0,!3`T2\0%?#&%"A-85&0
MY(C44@!OU(32DDA>D:2.$2594TTS0;E1!C^:TT0.'BP01A($I`&&"CD&48`/
M*I"90Q`9'!0B)I>`YX]91OB4%E7OP360/22VMQY\+&@E:(A5H5?*7=@-XHEV
MI?AE'1R;6%;8!I2F_\`<8Y02,MUD*30FV626+<9<<L0-$1III56!16E2**'$
M:K(Q004/M+6AP04DE/#""SRLUAL41RS'@6><:>89<\QUVJEC@O@5&&!_+1(=
M=H>N,@EXHZ@7IRB&EN?M>.<-$-XEY*X7Z#D&&:2++QNLH!^"\,8K[[ST(DC'
M>P3]=.441*39I0IB`!##4+Z\440"=XT82WMO467/6^>8LT2=(F6PP`)V^"#/
M1D$(,(,''7E$4447!;`CA%2B3#*2+GDD)4DDI=RR2S]>T40!.2YA3P%D>!!%
M&`C<T<,3&CX!@``9^%).1$+`"=XE#JJH+E7L]8F0+'B&B`K6?Y:()UV2(/^*
MR%]X66O`((+`<9EBE3DFV-K/+:+(9,\UMD%DE'*JF+''ZF#J$$J4UAJPKBJ!
MA1Q4,,$#K25HX#@)#Y#`Q!%2,.&;$J$=H0,'(QB;'+*<)%99IHQ`-JT"E$*P
M@2"(\-5H=I)P!][LV69;"7FGA%()>.>%DHH#NCM`Z,1;^<2"`T@$X(`2[M;K
M_//01T_O%B0VP3$1V"\@````/)%$#`4($4(FL%`P@"/BDDBB/?X,5(0O2Q3Y
M!DX\D;$`FSE>$80'7C!D$SE(F()/0)(ECXPD)E)"TI-")I,K=61*+)N91*8@
MG_BM*0"UL,$NU@2$'_PL#'>X`P($8#(V$6$&,R#_PB-"`;4\Z4(7MWB%N:@V
MD#Z%:#VIP!K59#&0\=D%48SX2W3$-8FSI6X#G6N.I-KV@;79+6^4:N)S'+,I
MPB0F,<,:UF<X$QI7H8HT1_#BX1(WJQ>T@02Y0@$3E&"$&`!A"*T:CG*.Q1QA
M<:YN'Y#`$Z&XNFD)<1%W\\2B(D'(V`%O=KRKB[5PE[M*<,MW3P,>"U-A`T&]
MI4%;H0`'AA"!=TGODZ`,I2B3@8:M3&$=1-#>T1;P!#`D`0Q$0(*(BHB>NZSB
M%56A!4%2U(0K_`0C.`&"%\00@R?8`1_D@,'%%K"#!<`@!P%8`I":8(261`1"
M!>CE/"HR)"3%[`W`M-$\_RPRS@2>A"4H.4O\,F`4%2CODNFRV`YP\(,%="$`
MSWQ#$!;0`S,08`H&4`^A=FDBJS1HAE2A1=9"I+[V)!0^XEF%(!,1G<-`P!*C
M\$NFD'@IYS3&,HUQ(A,[]1S2<4J*F$DB<H;0F<R)IG"%:TVL9H,"%#CN!54P
M0`Z2\(X,`*LSG?D,2^]XJ8\V\1">.@SI_!@M3U`'.\YRW5YRQZT?%I*0C'RD
M*,+#+?%(!:+"(\@`4K`!!6C`DZ-,JUK7>J`S``D&0!``T6;P!`%H3P4+\$$P
M>O>T44!B=F_B82X@%K\IV,`7/JC0$XB0@Q@(@$T98%,:""#"'VA,!5V1B4<P
M4O^2F43D2-STT<ML@C.=!$$C,?%F3<K1,B'YR$8Z`8`*ZE&+>AAV"=LL4A=@
ML(0K^"`)`###`F;7H(?ND%"$<F@_;LA0A1(DE[6P"MCV$ICK'$8!J.B.ZB:E
MTH[:[3(HG6)E+F.WR(175'54CM],)9PNQA15LJ$!"DIP@0=<``5*<``0<!"%
M'0```G$$#6?B$`=A[8USDY*,4E>7M^M`"UJ-<!9@8'<71S#J%*Q8!:(H7,CR
M8*N1OBMN#^4TD`3<;1(D0"M;5\SB%E-C#6<R2G\1`(`N>.">8*'+`"X:"G/-
M,J"6&-\K<K&BMZ`CFA209A<6D`8`!,$+2?#`*8/0003_F`$!/0C"2KJ"DIGX
M8D=52E)%..+`SC908T$@PFG)Z:/5;K8<^Q!2#KH`!&J*[(:!.LA4DN<#`8`!
M!L],0AC"8(8=%&%$#MBA#MF#I_9,);I_XM,_3K2G>C`(>(U"Q*<:<6$%S(TP
MW2WJ8)+(F&5]0!$@[=P(^FB(43O'.5HT%H%=&IS1D`8+B6M#?1_P@!5T@`DR
M6((*,D17,$``"YB#0H&'4&#O3HK!K/Y4@Z=ENN@H@*D3AD14S^:)UWW"VY&P
M<(6QVKLX.5)WCGS%+,QWT/%!P`!@.RL7ND#O>MO[WO1VL;[W_;PQB.%".[@#
M`3";`".(*&%U^5UV4:$[7-3C_R<^^4D3/)*!)80@`1X)@AUFT(,T[&`'3\@!
M#'K&TQD`@2A!^LI+;@*#!8H928#."9DALI$YJ\"-0.!)-RN2)`&J))J5/`L,
M9D"`*"P@`#Y0GBW.481Y]&(>@/;2E>]@!C.DH0`#P(2CC5N5@>IR*H)]2UG*
M(B@;6*66@9F,@R4L'69M`EF@0^]B*H/JT44K;YMXM:CFF!R7BD8*67@!?2_0
M`1.`0`0NZ``(JN"`(#QA!C\X&@"2D(80K.H(H-'<'8U*=VE'D5D57800'YQM
MO"QJ+QS6-G:TC?JI4O7#=3EWB"]Q-O(,1@(CZ,`)X-"&WOO^]\#O/;^'3_P#
MA>$'./\H.O@2,,3SO9L%"*L6ZS.Q()Q91"0^F0B,IH`)`PQEZ$FPZPR:B8`=
M]*">9DI>`:Z0(P%B!)C/]%%NY9^3G=`\)S?R0!+JRI"3[UQ*`@0D#L$/-K`$
M,/`$E(4`",!3`)`#%E<05Z`+%3=Q#A%`.=`_.2``5?<#ZX$O[J%<S44+*9(B
M_U`G$<<683$^8',7D`)2"?9ISX88H99><'='G$`9G\<L@/$I>9<9Z$4LG-$9
M<1!&6,`$&A`!'5`#*^`"-]`!#Z`!';`"#Q```A!^`)`&<A5Y,R`&&T`%4!`:
M0R5>;3,W?$08@O`HK-,(I)<H$]9ZA-1ZWF%A484^WK(=LL?_0IA@8IV01V3#
M`>_&`;I7?((XB/TF`&G@`TCP;G#P"=^6``6X!*@0#L>3=1`S<1_A$%X1<3`A
M!`D``1F0!"J@$TER,P(@3#,0!OZ'!/H#`U.P`)%'(Q(!3F_@`SGB33>!,\_4
M(37"6WWV2@#@`4`0$JR5)$32%?-1"S8#`U%PBF80!B(':.&3"]+D$!TQ'QX!
MC4)P!2H`!F$`B>WF=>;R=6IQ(D9@#](D'Q-Q%F!A:9B&%V^S-YRP.J<V"$U$
M7A]0@WRC'!UU@Y91*82Q.IK"@VQC*38X*IOC-X9#`QK@`B(@`C5@`D[X`!$0
M`9%S`1%@``NP?W:U/4?Q!#_P!$#`_P'(]C=#T!QL`VW3!D5FF!=R8VW81C82
MAA?65F&FEQUS>!<S26Z@8`J[<Q55942"@7N-<%3W"(@J1HA(F90!0@?B\VYG
M`V\&\"<V<Q9F,3%QIA$$U'.]=19V9C(>D`$.``<V0&-PY0-?T0NX500V0@X%
ML!7S,`4^<(H[``8^L",VPG._8#+SDP%$T`58\EHVDP,J```S@`,+$`,&(Q\2
ML5KJY!8LH`!-\`-B``-&$``Q,'EB(!%$@2]3\".1A20KTA5:04U;8@8>,!"4
MI&A\4B+U4()M88+JZ!44N"+\@&G.AT1Z%T7Q*(,%B8_$02K'PC:A4AF[>6VI
M`P']&"J;(?\#F#$L0P`%5/`"&D`"&H`"A.<"$\EKO`8"3O@"']`%```&`N!G
MW),$^_<$C]<%(CD:Q\$Y9+4Z=K,)=^-Y`-E@<K,(B'(8+0E5#V9ZA`0M<GAZ
M<E@7M01)#4(N">!ID,(!AP!$[JDLG:24$CJAW/!?L2,)&O05-T,4ZP0#OL0"
M#]$A:])R/Q)-12!`*F<C(:``4P``8;`#52@&.($D6D(01N`1U-0+)PH&4=`#
M22!R-9*7.5(`.8=/.9(S0*`"$:%,*D`$._`#*M`1ZKB5#N$370$6++`$0#`#
M"(`#8G<0-[,5-S,^67&E/%%Q%#0Q`20D,+`#".`%37`+'1AV8D?_CELA<9B8
MB7GZ%6\Q/G[E%WD'.I0!-T25CWQ'*B;)CZ)37I0B`3@)*>_X@W8D`TI`!?)U
M*Q)I7[M67QUP`S70A"9``OIU-.,)!MZ#GJCJD2871D>012<IC\]6"#%H4J1S
MGXLX82QY.FNX*+N*>E`%AXZ*%W`0.[AD/BW8'!LP"7^Q`<O!"9T3B!0:K=(J
M#7P@`Z@`;U+Q$29S$1$A34M``4A@(X"&$W69`2VA%4$`!F!@!^*9`>$`!`@P
M`T$``#VP`\3D(Q>2`^)P6/.@IDU@!T47<J@5$C;1(4!`!#L133[2!!X0I5CX
M`S,@`+R53<1C/0M0<2]D$/60@3^``$FA_V>B&1(3UT;A<Z-(8`,S"B3P(02]
M14U,"EM6$6DF(A!WJDX3%R1P5@Y6N@N7YE>(4)1Q=X,$>2GIY1D$1F!!2$<D
M]5&B@QEZI!<:)0B(89)8)%18P`,V10*XXC@6J9WUA81*Z`(NH`$EH`"7&9ZJ
MM$I-UCU)<!0SP`*_82J*8511U$?T:)^>9ZM!1#:Y"F&D]PB["I-X87HL":"_
M(SSF`P$^"`>A``&K]@'-*CKY,:V46[E\``=&8`D!A!+E"''E<++)@Q,W(A1F
M4C(VHT_`F`,X8`9`D#PQ@'P%D`*=":0'&`8$``0/%Q\_@I9%<`5,%HI$40!$
M("/T-)Y&L0`1&/^N*)$#P@L&&;(#^@I-)7@6$?(3)9@6%#`%04``&1(&\CH%
M$L(F:HI;3Q$H<>H64\"\$*,+=E*`.,.73Y`6(F@/;#%Q72$27B$2Y6`S+\0/
M9U<*>3&T1)M2>V-'GA.$?V,<<S204S2WG--J.B`%L`$%JL($-,`$<@`<8:0:
MM'$;MJ*U7JNU7^L"AU<##X`;KY$`*C">6.AGXDF>;`MY,Z`"&Q`LS#DZ460(
MA`!(A%"K?511>,,Z]^E'I6-M<TBX;8C$::.&JV>;I;##B>&H=Q%%=U0IE!*A
ME9O%%(H&:0$>%G$7F#"-E72C&1`#7E"7""NZ$C$1Z""84;"Z20`A6#+_`#)`
M`0'06!'[`T"#`!X``_&1#Q/W#P%T)F\`:*SH`X^W`V%PB/<C<N`;`$3P$'PY
M3`"`L.#+BO0Q<6=)=K(``T007'<0!G9`([+D`"Q;F5P1%BQ`FV41K@60#[MD
M)R.[$060!&^0:!!S#K(Y$;WT$CE;,F^P#W`A79/@:6_'.?A8P'2D1<61P`5&
M'`8&-\ZZ')LC`Z82!U4@G1J`!5F0.!=,!530S5CK..1<SEXKD1'@`BO@J1W@
M."B0.!!`!"S,/?0\GO;</4?QD47PA7$P`I#">59$5F28-Z&7-YZ0"`#I8)&A
M",NZPT\EN(,;D\[".@\=2!`@+@GZ;A*6.BS8_T3WN&J4X@AP,+E:7-))B0=Z
M9EB=T`0\$00NG5GKH`)>@+!!T'(Z0@XFJ`)9U@-A\`2OC$$!0`%2$`+)(P:%
M"01/($+QN@-D4(H!(`3FH`L"!",WTI8%0'1D20[U8*Y+X&1"T$M`D`17E@81
M`B019XP^H0LKPB`PD`0X($)`4XI$("$%L![WD*8WTG045!]+H#'A`Q]U@@0Z
M(@0E$:X9(#XL4+-<*9NL522]5!,6H3,#D8>W691SM,P&R7>@@;3ZF$7-@47#
M4AQAU$6L$D95(%\6S`.YP0063`.V\CAH5,[3>0$C3,(K(`(/T`&T30-R``<Y
M8`?:0YZ1EP9,9L]@,/]Y$#L#`2`%F&>#3.0VSY8"<X,WS_:"#(V&HS<(U`89
MJX,=UM:&JD,==U-MD,&K@B`VI2=%R.JH1716)OW>@X@'E_#4`R`$@KD`9"#3
M\L!!5`8$_CT4M+P/#Q$$2;`A.!`#C_Q.@M$$V?B141!72DT`MNNQSM26'A$#
MCA<&?2Q-;T`$=Z`"00!`#D$.[*05IP1E8$``(!-`$)>)Z>(5_-!&BNRF(41U
M"/`#4\`"(?$/4P`$;I0&1`#5!8`+/Q$"[$0$.D,5`J&]#A',@AT`%R?(Z7*_
M#J&_$R$2>8D6M5G,@6'9035'=82TH/$WF&=@H78LUAQ&I8$%R!8XP$$:64#_
M`[NBVG*.`KORVHXS>+1-SB"<VS>P`H8G`A-P`2)P`6W`!!_`#D&PPJ<*`/^V
M3.2)GA"+`S[%;)_-1"HY*:>VMSQX:@LVGWPT-]H=+2TY+=W]8-S=T**W*9JB
MT6U81)7"`87Q;K53`D<)W[B^8G0P`$B'3\/K`=LC`"JP$VE"!BZ]$#'0!2YM
M)DW``C```'905P`0!1D0,5PY`,83`&`0!#M0=$!CN^,7-"!C,[^0(1[[!!Y:
M34L@!AKQ!B*W?K]`!&\0%M*T?@6@9?;;XND(<;M0!`N@@"%D93=.`#M`!`$@
M"P50"WT]600`!A?K`[$0'^";$=D4"W#1!#ZP!!*O_\FJ'"@9V\LN/N69A=-B
M\:>',6J&"N9&RVQ@*!S"X9[JS3<Z<`15D`6KH2J^0AI*$`>X)E^J;><=7,XB
MO&OV%=LC?-N'=]LW(`6(AP(R4`!B8`<Q8`<N3-S+]&_;XSV35Y@Y(!R1^]QE
MV!B'`<3+"D5E[\/U*1B&$!W2)F%*I2F)D-V/(D2(\505]A?6XFDG;VVQYP"V
MGNN`[V)ZL#\W=W/#I*X+``#+E"9`D`,847\(V^P!T+8PX#-A0`8%H<F7,'%@
MZA3=_L;OT$PQ0'1!D`M-,.\^$`4($`4Q(!$%`.)=(`\^T`-10`8")'$34Q`!
M.('41#SH.'$Y4DU(H`)!$_^OH_^BE&4''9,#5N&[=N`%J*6O'=^BKVP0'P+8
M0B`/`Z%^M[ANA"(?*Y)![B/(%/0/6F$#)A^HS'&T7UY'Z^7RQ2'K1\51IB('
MBR,K<G#SJJ$X$@P(/#PO*"@T-&T:&A>,#XZ-#Q&.#Q>3'1$=)B`8%B(F(E4V
M)3)(.4`""QZJJ@NMJ:Q/`+%/23]$<5`R'".\'QLI*1^^&\(?<,3#&\?#R<K-
MRA(0T=,;T<L;V-40VQ#'T-S;<'#;T=P*$,1PYQ`*[>T&`^<*<.7N!@X)`PDE
M)W_^_P#_O''SAPN<@`@3*ES(L*'#AQ`C2IQ(L>+$,D22`/"@PH,``&!2=4S5
MQ8?_#R`PIF2``2-(@2)+%MR)@N,.`@`A6"`Q,F4)!`=-IB`)`<-##@\S!`3(
M(<8#@I,[KNA<LB0`F3!A%N0H$``(#A@%@@2`(>#'@@!7EB!!TD5%SRE->#8)
M8`3)DB9WITRI&T-%@21`A`!`@.!'A@)7<M@D0.#.C@P4C``)XL'+FS<%;`BA
M(,3&%")+I@1P4,2&C2)"FK`XC(0%BR)ZD000DV%*#AAH>RYQ,("%D!`40B0P
M;<1&3B&E$Q@X!^<#+PX<9,@X0OW($!W0H\O0$:>[#NF[E&'[$$>*($-RF-"@
M0B6+G"I4>*A/I`%%FQ**-."OY*B#BT@=!/@("1&XX(()_RL86(,($XAP0P1=
M!4"$"D!XI(H8*JC02E,>B-'*1P(\(:*(1.@P1!R[\)(",LD4(P$UV<3X3(S9
MT`/'BM)H(P$QV-`CC3?CL*.``=*\&&,Y[/PXCCWVP*/`--NX,R0^!B301C\,
MN7%"%UVT8=&78(8IYIADEKE0'3X(@$,,1,202@Q`Q$"&"D$$<9L/=&9P6VVN
M$6'&'6$@L`,.`;#05FT#0,""$4T@!\!7*@#P@PH!^$"`7TU,AED&/N1`!`X`
M^'`%$J(UD<$/"`2Q1!IPVE5<`3A$`<,25^"EUQM(-)%K:'#9E8$'=IBQ@V8J
MA!'%'3@0`8!-9B`01AJ["8>$J/]BS!!%#&'=%EJGMQ6P5VE&%%&;$`DDL`0,
M&926`1%!)-$#``($T5(01;#0*`7X.,""<<&]9H-RYQ#SW'8G=F?P=])QA_`N
M*8KW@1(H:-#&"R_P4`43+S#!1'OQ%:(!"1*74`()E'P\R0/^N8#))9)$@HF!
M*]3@0@TKK"#""B;$$4,:%[;"<RH>M@)LAPND\5$:`"2==`;4Z?+<"./UR"(T
M$A3CRX["8"/!,5N+TUR/+U)3SC7E[*@-.,R)0XZ/W"PIY)#+L6/`W-V8`_?<
M"3@`CP98+N3&!&UT:>;@A!=N^.$0H>D!`1[X$`01.60@>0&U3>A##&``X;B\
MX=H`A$W_@,Z00P(9[+"#``4XEQJM,,P0@P,^).5%#&;5>D4&J`M1`%B[YX!6
M`04@\<:R=P@@Q$I!O*&K$$O\0$`!3;P!UUNNXE57$W-]CH`99D21!+LX(&!3
M&`3X\`2@7<`$@P%&_`#$#N(C0(`9/T0QPV-Z%>`##)UVNBD,;[C"6()WA3?`
M8"L^2,(,4!(#`CS!#@L(`@L@D+=]N69?0F!!/,CA'.C(H#O221AWXA!"\$!'
M1<:(`Q4408,LQ*<$5)#""Q[0!D$P@0<?(P%^%/$`19#,$2M;F7]8%H&7)<@%
M':C9#6R&()5E(!8+L$,,(.@S#Q1M`1RR(A@$\!$PS`(D-H#"_Q&DPXL1!*,8
M4GN&U:I!HVA4PVM?ZQ&1C!0DK"GC1]@`1]F\1@XH/4D"<'O'`)9SMW.\2$AS
M2V2YVL&WAKC!#1V(@Y<01\E*6O*2$E$#`,)@!@#`R26BX8I0<D`&"'HA"!!4
M`0R08(.8`"H)67'`%'YPAR=TH0DIH$"<8O`1'/1@`4((`A@R8(0"8&L)1FA)
M%X2@.R)D``G0XTE/BA"$'CC&`S'(@9VF,`#-I"$'1JC*7;@2`*'4)39!N0(,
M=G"'=H(.!SM85J!B$`1!H82:29A"<*8`/\+89`<QR``9F@"32JV+0CX039T>
M5X`EY"!R5YC"%7S@`2"H(`D73<(3`O]%@!\T80,)"$%G\+4O"@PR;!_(CHFD
M,X0AE#"$V4F1&3?``2D0*`(D8$(5L)"%+,"'$"^@`2%*X(@<DN"'E>@`@(08
MH``5T4`NN`&"EB@"$*Q`JB#PQ!"\H)%6C,1#J&`%*P0`AB1L,6DBZJH"E$!"
M79Q1&&=D8XMFI`QO;``=71,'&C=@R/$@"6PU0A(W\@K'NJWC'<M)Y-T(&:5`
M"C(>"KA`WQ3RR"Z<8)*8S*QF-WNX,.R``&'X@1V(@)OI72$Q>B*"#XA@AQ"!
M(0@]69Q-$/`$N`@@#'<89@*:D(3QA<&7XDO:#IZP`';EP'&@.N`2D$/0``2`
M*@%H5!$`L`/_,'BD`*JU34L00`2]E#-R`0C"#-(5SKF`90H^((QZ$2"`GJB`
MG:`C#`"(T(0=F($`V/+!9QO#&`0L0%PH$4U%89`&.Y`A"([;7Q!BX(,,G/(P
ME/%`&DP"/`/:(0E1H&T&WI!!UPC'`;PA$C92H%*7FN@Z)8SI":'&`3EHX`$N
MJ(\A?"H?0K0!!83P8<L8T0BG*C5E445B$5^&1!?4#&=5M0`(%K1D)F0@"1I-
M&BI0L0`N9G$!M/"BTD#R`Q'%@`-'^,XNK$9FNGJ-1LB`V@?,-IZLV;6->(Q1
MD,"A)#BR[4F-'9*4$CFWPSIV2`,8I`$DZTB"R`&SG$VTHA<MD3#,_Z`'/]A(
M#@BZ%I7`0+5U(L(">H!;F\0``(S!K:R"$`4SX!8(\1!`L]SI7R`\(0KD(^L.
MHI!APH1AT@V-RQ)@\URNY.H**D"=7WP0WH["SRU5*8`7#K,```0OG%>`4SGU
MN]XGE),"<"B`*@C@K'@*`0:F1@`,*."!*'0!"'9`%PS(583.V<"8.;`#1ZQH
M!\WAR0O&W5VDB'`*(.CE,+<#P@)<%X/&-0$X@8Z;`@168EV84,4CB`X'4A`'
M+*"@`Q<@61NJ@&,7(F)D%U!$QDT&XY-%(&9-3;F0G1KD#M#L!@?RA`4F8(()
M)"@$8D&O"KP@AC2$I,H\Z]!'-&HT+GX$K?])R($27`J=%4T-KE";&HO*#-<-
MC*`9:ZR:,:8ACC>V<1UZM#,?F5,//2.2SX1$K#T"K8]&,H1+?Z##&QA-][K;
M_1]CR)!J61*`#`0!"%N9PNY\,"=4D>\'SD-`AKFM@@0$H3$(2,(21E"`QMSA
M3V;`00Y8("$@5.@DW'86`02PA`$4(2A%D$HIXDV$<`JORS_H^Q3`8!/[^:X)
M$27"6!Z:EP+880=G\8%,0(N#-,#`"&EX0@[>0)4N<)L`=KB"`.2'@!@HH`#G
MC@$,BE`$!X3`.$8P@A#"Q6\OJ"(&#'YH!OJ"+LG9*:!D`:AS!3AXR`5!!7;(
M@0U,ND%R6#T[,H#_8@^7(MN1'5"``B@38QI0,32@`33`!/2A"/O!8P*B5$.&
M"9$050$"<_^!,C5P`S6@"30C,SAC,QA0`0=0`2+`!!M0!0]0`VTP!`GP:5R$
M14&7!@J4!*@`!EL$!FCU!#^P!%#`=#)P=53W`7'E"WKU`>@@=<V!A$ZW1N*P
M(W/6-G(E'F`7-H?4-34R)'5S#.Z09X5T#GVV6&RW#Y-U=VJXAFNH!Y*S)QVA
M.9HC%$50`!J2!+;F0`(0!03`AXX6`&\`!K@U`ZGC`&"P7I[E`TT``]AB`TB`
M;P6P:>)#``'&&76Q?RPP!>T"!KH"`#.0!%)46C6!+#Y0`&\0`+F2`0&@_P*!
M!TU(,5_HTFR`AQHLD`/<1CZ,L5]1(`"01QB[^`2T$P;HUQ)5IB8;X8/V`P!)
ML`!>T&!^=Q)!<%JJV'<,)GP+@"WA)QL;=A=]MSLVD'!A6#41IPO<$8#8X4&[
M0&)%*`-9$`D:4`,=\`)5(!^(<&,1TP8D``F6H%0N4T0=`'-7)3-150,?^`D(
M@C-990(*"0(F$%43P``8``(W\`(G=PE58(=2E@9-@47-AG@`4'1DM65)@`,A
M``4D=$)O=819XPQKME<]LD8\D@U4&';^1S9,.%A>PW5(`DA]=4<0D':$I%C;
M0#=RPW9LQP]LF)1*27=Z$%V<LF`\LS_D5`H#9_]KY+,#6!$%^[5N8B`HR2(!
M*9`!N0AK!!`$2$`&V],%OI$#"A0+SB(`/@`&:7`%XS<K^P(\8O`#>")ZG@0$
MP`,_=\",Q^4#R/0&Q2(&>+$$,3`#2=$%`&`*!;`O"N!X,P`H]T48W`90>"@^
M[>0LGHD5'74LC.$1*B!\Z@4$7H`2G9)I@5=.2]$*71`$DE,:WX<<FU&;0M`:
M(1:&S>%!VT%")XF.'(`=,@`%,_0`A>`"-(`%&/,`.F0?]W@!0C1D354@+`-C
M!_*!((AD-B,",Z.0FO`)"8D@F@`"#'D#[O@!1X%%6X1%5M1L,Q!I('ET(B(I
M,P`!898=9J229"8CSH'_=?VI-=G@"VUS#./P(G8%`6NFA3GY(WH4#>>@A-'0
M9V4HE#^Y#H.T#4;I=DO9H1YJ26O`2M]V2BH@!F308%Q1`#FP28%"/L9":UJ)
M7Q20`:"V`RH0`A]@`*NH`NCG!0,%`WQH/^MV!0O`7T^@`EVP.#=1)W`Y(;2P
M`+-VBS.1?YK63J/W2]L4!&(`:QY0!*1"!(."?C%0*Z8Q.3,@/N13:^1S7+VX
M7O)3:WW(7P3P*(-R/_:C??Q3F@^E;L\D&J9`!D"@BD@`#PE7)?D04K28#XDE
M8NJH`R,44PGC<$-`!<Z)`OF(G!CC,1>P'R.S"-8)9#-S1"I3(#%S,S<@52*0
M_ZH':2`&*0(A.`$1:54B,',W(PE8$``\5XSPD@H?TI8?PD5*DU;P$@=CM&(I
MN49PM9+88(3`X`M(6&;BD0)7%UC78(4[H@!**'9<5UC*,`]F\S9S`UD6V@[2
M("4;FH8?FJ[J.B9X$"Y%L!3KXGDLL3^WH0(_T`.*!UIQ:CI@@`1"L(?#%0#B
M$!KHYP-=<!AOD`HP@(>VT`6PU%$JL"[]A9EQVE^T!EK.XFA$4``;Y2QD\(9<
M`0,`$`5IL+'VT@0Q("A=<'RL%``#]UN!XEN!@@!K@@.W"%HM>G@ST%\SVX<_
M$)^-HTT+1EP"0$^=<D#/=06#%SE+P`()@%>--4@#0/\!-L`")E6&`1-QT6$B
MV*&U,#4"1X"`C7`!AO`"BA`Q(=<&)P,@2)0R4F4"\#BJ!P*>WPD"$Y!5-O-R
M3'0S"S(!%A"1$Z""-5,#&F`#&\F#\((*/>=%&D%E7.2#20-EB!<$2W>29M2L
M<`4,FBNM;18U`A,,TOI6F)NL/&(V<,17Q+`C7(@,-L)U,ND-6Q,VY!HE:=<D
MR[$UV*``A6H`'+JNOON[%%$'IUAAMD$$D.,%4O1W.<!+&_$$;TI\2#``!2``
M.S!A\=`$7F`$E-$2&=`$%]5@-CL^BT%:1'`^LT8^-'MX20`_+BIJV+(`?X(`
M,V`G\[I^\<DIV708ZVN6_N+_=^-CE5B!%9@Y6QD;P`&LC!DVL_ZD7K]%&2,Y
M>G:@`JI54=T+B`3%3!1@`,U!#Q+*#@.@+_@R2&&8(UZ[M;J@'=%Q!%GPCPKR
M`#Q`!0C8!HE0`F9+(-@)50;B'R%8,S!V"9E`,X-;GN;I"0E"GI[`D(.["7=K
M<^:I`3I`%@+PB;)@-%@4(EV4!K\*N<JH43]@`-9AN;V0#=):1F44#&U&=:%;
M#&6\5\V`H'F$A'?%9LC`1G74(V_&-FBC=K0+6=T@#!"PNWS#!5PRR(1<R(,,
MO(BLKF7@7,JK)Q:%.1I!!A5E1:KU7OH:!D$P`$9@/HP372'@!4TP`'TA!B[!
ML4"@_RSZ>LEA``!89@=/4"&<U`/:I$`:`D\$,`->,`-&000"G'GRYGD"(`9B
M`!B7@P.:]UX^T&[M%@1WD`3ZFH<&W,R\.%LS"YJ,X8<"O,"XB)513``]@`/Q
M65RF0&QV@1H4D`_S\*QS+#?>)QPBK$<,A\(2=T(I10,&@@DU$`$+*('2&0$7
M,#$P]B"24"!013,*^:DN9P+;*9Y9556I>JH*J:J>\`D./:L@T`%5P`(F48P_
MH!%/0,4A^0145C2/JS10U@-$@`4F*69E+,9D3,;'6F9I+`PM32-N=F9R90PU
M@F8YV74T@L=T)B2-A;6ZJP_*`0^\>P)P(,-,W=1.S=2)'/_5'9H'`?4X\Z("
MM)"#`L`1@VD*(RL_.S`:EC)K^!L$:1`$"\!1/[!@6E%E2IJ5&?O-J,!13P`:
M4]`%L&8_?&C,"^2\MG8'`!`$`"`LJ#(3_`,#!^8!8:`"S84$U"1ZV6S``5P6
M!LS`C''-?(BQZ@5:.]`#]A/,J@`&B"<`$EP;]2($O*&H`E-&6J.[(14"(/;.
M;0.Z'D1"$;>?#W,!#RT)*L-#^NR.]Z$!Z.ER;0M53+0"F:#0VUDSXGFW#9V0
M;]N=!BG$594S2_`X_"8`K?4$6R327)2#6.P*1J?%4"8`'R`%87;"^KFY+]T+
MSG&YFNNL2(C;[SVM<N8<=X73X3#_QSY]#0;JQLW`-@Q:NC])U'@#CDC=NU*]
MX%$=!1Z`8$O@=YCSB2'R`QRA6B:A30N@@ZQB/GP8C9V]`S\@!H!)/@&%&0$@
M!&`::MO,UP(W`]UU!4%`5CB;IO9#(:'7HCCP`_`S`T\@XJ7H`?/BX[C"?:B(
M!/@::@R,%3,1FZ\6P#A[V0:,E3T+6O$)`*P(/,M+5AS18.UF'/F@#_%@=<$0
MQG<UM<"1-P`SNT\HK=EA=5;#`TFT1)-P`0%",B#C,HZ0G45T56^;JEEU(%GU
MYPPR`88^Q.9)T0%95>9I<Q/@`IXP`3?``D!`!D)C16`5"UO$12+-D>'M1<GW
MN*_L`%0`_P5BQ'0R1=_SK>KSC9(TO<;0P9(\G9-L%B2GRR+32@]W]22_D#6&
MQ9-PK@UZ1B1\QG98F]0,GNQ130"@HDIOX`/(ZT6Q8%9&VS^#&3NTUMD?N[,V
M.UP]$'J15YHJ2@8T\>-]"*,^"P8Q(`9^Z5`S8+,$8#KRWB9@@+&X"%H9YDGC
MA3UOD`&G0(AV80HYH!)GJN09ZRRZS`(AX%P98`><!II1>NX9M@-VX`6DC:3$
MED%>&A8Q$)O+5QPA'*[Q(`&XS;D>'!QIKJA]5B3BB$(11PPZ\``E>`D@R`@%
M0@E'A3).)3-/%2`K8)Y#C"`.3=%`W^B&?NBI>F2`GNA,?P-'(/]0"\"XC6MT
M(,&#1S?25H^X7.0%+,`!2J!32K!TY[AB*A+?^MG>90P,9?3>SMJL:%97.`WW
MMPZ3NNX-':P.>!8P2DB[/UG@:'?L"J[L@O^A=]"'.*`5)N$%B1OU0K.R_/-0
M.=`%\$0^@3T#:9`&NNA.X[,#\:EXCC:2F6TL\<Z8MWRG4^0\\2[O.-`%=@!J
MH9;Z4?`#KW4NMN)W=E(KC/@#H(*OIB/E6KEX$:L/ST4!WLOBL[:^J*",L+@5
MT;49W211>N([IHC:B8)G@=8-9#[&*2`!\!!2%!#"NVM(.>+V!LH!/'`@.)/#
M,S/0*@-$;IO/_TB0,\/HB6XS16^WAX[__T?OW$(/""*"((0@$R(:,E,Q`F!/
M``!/20"-`@*/`@N1EID+:8V08`(!4!HT-%194D-'0S(<L+$C(QPC*1^TL[J[
MMRF[(Q\IMQ_$MQO'Q!_'Q[=P"A+(R\O$&W!PU=#2V!`2$`H0WA)P$N3>"M\*
MS@8&W^;GYP8:)W_T]?;W^/GZ^_S]_O\``PH<2+"@P7IW$"2<D<:+"A4+GJ2!
M)!%`D@4Y<OB`D3$&`0)AD@B(0L!#D!Y)=B1$P!)DF)<(HH2)@F#F#I)1>NS`
ML2,,`@(Q">S0B7/G#"\>9A`@"9,`#B!7EBPQLN1-!A5`I@1HDN%'%!P]7A+H
M@0-DE*\\=ZC(_Y"#B`JP,W8L=?GQR=`D,W[\F"F&2(8F(2C8*``C0X$`4XH8
ML4$A!#AN"A(8D)`,EZT/$`9H3N"@L^8!Z]@]CK:A&P0.&D28J+%BA8L5-R)$
M</&@0PW9ME?4N,&ZAHD;MD44$F1BA0E#A"8HGX!A^01#RT&8&"1(>"$I,#Q8
M_#')8I))G#Y9`@/)4Z<%ECRH,"GEP@44JZA4D:)DR)`XKV+5@@7,E[!D*=1R
MF2^V$$@,+<PDLT%ERUBS(#+*2*.@.-5<<XR#XX`#AS<:;FA:.]UL`,$ZW'3S
M3FCR'*3BBBRVZ.*+,`X44TT]"+`>>I'T<%84/P#@@48YP.`#$$\DM/]#$"K]
M1!(.-;'4DD\LA?$12#7-)51.4PKUT5D[R/75#PN\M11)8R9!Q!5-3('$%%>1
M\8,74Q101%=/]!!E#V0L`!(.4>STQ%HQR/32H%7^M&6?`B2Q)0YB``'#$BS8
M@$0`B#5AQ*4V9$H!:-X8P&DP"_ZWH0*>>KI9`IJ)]M@U'UP#`1Q'/*":"=.I
MUEIL#UP0P0H=/'`#K;#YIIH+KT$'@@BZ65<(<Q@TZYP%T#YW+`@K"(*!(2*4
M4`42B2:AUQ/@?D>)*)90(L"XF0B0Q@+LBA%##!E\\,`+'$Q!!!E",($%?4?H
M@)]^`O["@3"__')@P;;0DL*""@83(80/,TS_S3'B/&R-.08\]AB%(K8##H6D
MO@K..Z`ID&*,**>L\LHLKQC4#DD\!,D/,^CD4Q0>`!%$$#[X$(0'=MV1A!T"
MA+'2#`"0Y&254#(MUJ$]U$QFGS?MV.52(JT[PUETJ54`$D@TT40!0`!0<Q!3
M3`4#``O0]-,,1*0A4Y<_``$$>H,.ZI*44XH511),2LE0##X$$#;88:>-A!%"
M-,["`*2:FC'#PY36*6B??<9.QA8^Z`P'5*PP`:V$N,8;K1VDWH%K$=Q@JW$B
ML$:K<-*V)H)RTTX`[>[*86!!L\T]IZSN(&A@0``^V.'M=]]Q%PH8Y)G++GJ<
MD,NN`!X08<0(5Q"A_PD`8#J`!110**'#$#KD!W#`_-V",#"6%;QPA)757R'#
MVN3/:H,9AD,..9T;U3M`Q*$-<4@!)3M9RQ;(P`8Z\$52RDDDNA04H-Q!2DD`
M0L]\H((HS.!/.8C+66XFEQTH)$I4,M3>II23'GEP3$,A"M6BQBZ+\.DC8GE"
M$`HPA29,I0`>P,$/S@0#&``!##B(RT]XPK<QX2`&"YC!2\B4);WEK6\DV4$:
M8N`%(L"`4D@H0A&64"DD""%3+'#`9E+UC`4!0QPC*U6J2O4.;DB#'#)``2%<
M1YP;$(LUIB.6;FXE+-7(CG:%.(ZQ#(&!"NSN=[ZS@'.D!9T)N"`.,%@7)?_,
MQAU)3()<Z2+/><S%"75A!09OB($*R/.#)]`,3!"H`A6.H(16Q"%]Z].%+-X'
MO_<M#&+VRU_]AADA8]PO0]9P$/XTIC%Q&'`<'T+1/!Y(S6I:\YKT,)27IF:T
M"[(D"F+X&0!P@(,P_"`'`0"`DZ#4M'7BL$I[>YI0;GB318&E:CM)`Y'(<C67
MP`T&/+S"%&"P`!P`P`=ON$(:/H*`&8@A"52CRU)V\",]X3!+((DGWV0RI2[9
MR`,Q@$$3BA`"!["@*F_8BA!"$`(6L(`"#H!IR5X5(!$]1G(X596&3`,'.=3@
M.<<1A&YVXP(_KLZ/-[A5!UQPNV,=$CG&4@ZT?`?_/*D^,GC.,40-2G"$)MQM
M`6(00QIH]@A26N)ZZU+7]<R:"0]XP2%$`U=>P("7FJ5A"E`X0OGL@S[U[7(_
M_-&%,/P3OUD,`WZ$#28NZ#=895A&01*+6#7P!R&;9L.`Y>C0Q]Q!@FEB\[.@
M#6V+?B*EA,P-#')9"0X\X+.>L`0`&0A"D99&VRC!LR9BD>>6R$+%&2;QGD*,
M01#TDD0J$N`'/BA`2M^P!"25A(?V\DD/A"N7K>&V:@L(0@R4<M$M;:F)&!WA
M4L"D`B($0`B=H0`+C#"%*T0EC3&U`4DW]8UL^$("'@O-.C3'#H]M8`3/8(()
M)&F=6;6F!L1*J@B22M1?_QFK.*]A3NZ>(U7F.#)XD:R`AB5Y+>3<0`H&R,X"
MH+<`#X@A44\X%]M`L4E2C@L2:567&#Q@XD^01Q*2F(&.R?D$4D`A#D?HU[_X
M$UB`\5)^Q?C%,`!T,&H(UHU+GFRH?KF,691&&]W(!C//P0UG0,!RWNBL:,=,
MYC+WXR<M`0J/`&!"DOR`#$$0T@SNX!05Q,!.[:RM.X$"$WBR<"<_N*%0>J"C
MG:2E!P?U@2MWH!2<H`0`0=A*G`0P@[5<H0!7`$(8=@#6N/1(+E)*"Q&Z`&J,
MXE!**GSG3`C=)X?N$`F/<X`-&@>V)<#:`0F@@!",L*DO_Q=^'1L@J3`'FG5P
M>?]DIT$!<Z2E'.+0ZC>O,?!L_&@<0B"K!ATP0;.F50@+.!):&FX.`Q@`[@U;
M@-S48H(!"J`"2.0EQ>2*-P"@-V].A,(2GX#Q]*Z7B30XHJQDI=F.9X`$*M#'
M?*[@@%^%L;Z&\_)@!1JLQ`]F#,$N&;).YD`V@$F,9)KF&!P:F<?J^R$%ZN,-
M;O@#%^!@YI:[O&5T?DF2!``$%3QA!M`3[@:!$(-(E%,A=PCZ2O2L-WB"=TMR
M(><VN4:U+`I`2.-,5-1(TH.]>*$`T!5N!J;`IAP\P8,0)8#4I+3IFSRA"WL!
MBI5VJV-3XS`GY&QE%S(0@"7`M*61&N/BBA"I3-E@`%__)D8M0(5?_89FV(<?
MN0X>\+M"6+M:!BXDA'U%.]\=P@41J$$EI=J<<WO[D=[^MH:_/8$'4"$.!C`"
MUHV`!##,(`G@$D4HY@W*3^3[/!/I=[KJ/1Y)6"0OVZ'9.`'``BE((<A]S8\,
ME-_PYNLG%_'KA9(/!"#!4L-^`%I8,BU4TV7\[U7.&+G'-C8R,?/##2?H0A?:
M\/+VN]]%=ZCG#TP<@RZXB2$J"`(1?$`$(NRL3E"2$$.G9ZD60>&U(W,S%&MG
M)8PV`PM0`#F0!D\``W:@8US":"+5!&^@:`!`!EBW75JB31]!9TN!`!2U`&2G
M)%FR`^!B-J<V45TB%Q*!$6_`_UP4<(,L)2EI(T8\F$;ID`SPPP&8D5/&5BI%
M^`UP,`0/4`'182Q)U1K/AAPNH"M)-1V$@`$,(`*I4TF?5P'DYGD5T!R^PX2?
MQP`'P(0KH`$Z@!D#\`$O\``&0`1YT4J8``EV"`GV!DK4$PG\=B[@$3TX!@G>
M\BTZ%F@"H`!9D%?V<4OKLWP.-PNY)`NX8""Z$`S`X$8'$C!+=G'%\#`<8S'\
MHS''1BIU1'[@8'[[X`83T`;K]WZN^(HR$H,_T!>$0P2.L`!`T']#4EYZ$G0$
M&"5Y$Q/UY%U9TB=-UR5EL2/>]24XEP-O$`0SX`,9((UI$#,7<04P0`0"`!([
MD`--,/]<?&."0*,7/C$314$7?L-")"$`WG-<7P>#=),&K)4#6S=?(6`#[+45
M1;!K9Q0""?`JDS@QRH!`<V1XQ`8:<``%`W8`DD1APC-(M7(L*_``$?`;L+,L
M#/`;M[,<X,8`HO=(HV=5$Y"&3"`%^*$$/+`K2X4"(0`$(#5JC#!O=T@)XI&'
MYK%[%-$=-P8N/#F(DZ!C0$D&,C`?M91\L>"("F=DD'B4@,4+AF58Q3!8%O<^
MC@4@VF")^2,-=G0AI;$Y.L5,%^!9^N`&;M`!<<!^L)B6:ID/")`6/=)6JV0C
M0.`%7>`69*`H9N"+!,@W>1-1"W@H1D%H5X*`?_9!8I!<,8#_`PM01.Q6(V`0
M`P&0`430`PF!`VRA*!\1@W8!:DRS%'E#=N;(%!4$%#O@%892$U$@C^65`P4P
M4C;`4BQ0!%S7!&%4!#`E&=`0#!<W*@:`*G,4.<1F`&Y("-[&;!-`;J232+%#
MD<4Q.U"E.X(P5<_BD>?F2%YX``<P;L=I`3>``EF@!'$P!%)``L3B`DO%*Q=`
M!5B@`3Q`!3)@!':P":24!C7)">Q"G^?2@N(2"2WH28-85I*@%WI!!B-0!550
M'W%P2\NWH"/@+X]H9`'SE!'G'P%2"Q6:,`CC6+]TB<A`(--0.2#7.:!2BJ)X
M#A(0EOU`EEUP`FBYEBZJEB9X$S&S_P!)X`%$@XM$T$4QX`%[48X#2%M'MVDZ
M,2;A-11)1#,]<"4QR#7SI&-/4#C#Y8#LX@'("`2L&0,O@0-!D`%/P$)/@`,)
M(10P(19\DF9/LVE,48X9!5Y9]`/K`6<9$!6+`5.-P0*[9FLAD"JO0CF5@3&^
M63+`Z2D*P`$E<"VZ<RVV0IS<YE3`D6TFX`)66$D:IAP;QI'E-FZCAYT>.3H7
M0`/C4P4\<`$U@"SFN52]HBNCFCHT(`44X`/UABXWB9^E1&^1\!V>)).>U)/@
MXY\T@P-$P`%$V0KWH:`R@!_+ITNO(##[02`6JC!)%G$'$U@%XU@C4`V704P,
M0@X@YS'9P/]E%[,JR82BYY=R<M"B+WJNKB@4-P$F/J)*.>,%0-`%=K``N/6+
M[B1/74)%3],G43,#Y#07%S@F3!<U.P`&6+<`.Q$U?#(4A%,`/G`V4]`%&>5=
M3M,D4X);[W06,4HFY;BO&95$/H*+,#`%EV($+/"G`V!28N0`),<@RS`BF:,Y
MYZ`9!*D#$0`"5;4<TQ&IMX,L2'4#244M@]!MOT.IT:([NX.IU7F=%6`"%]`&
M+U`"&E`;$78`(N`"K"$=YFF>-W`L+J`!(Y`#;XDN]=D(:04NZ.%*SM-**N8\
M_NE*L,<\>/$#02">2G"W]Y$^KY!PC>A\S[<+4?FLN_!7L&`,D$7_.<;0.=X'
M1Y%C;,RD,<IT#.*Z#^KW!W3P!NB:N>\WF%("`#%`!G8@!@_!<S&0!JAF6WNI
M-TAG7']&3ENS=/S*)5,3@SC@`U,P7`V(C!0%4%>0`>P8`&F0:L!XIGR)L53B
MF0*[0J:&0=/C`U-A:T:0I_UE`+)F!$7`LM"P<=+@#`/`&2B;>+UILY]7M,="
M.J1S"%I;D;:B>:+C>,"C80S0`.:V.UZXJ:)7`<4SM:^Q*[0C21VP*SNK&[WR
M``]@GG%`!-X""N6R27J8G^7B+:^'8XX`/I,`M\S#DSD&E#X0!ZJ@B,3*B$G)
ME'XKK8/W'Q"G,!4:H?#CLI5E.=N'#0]2_WB.BVS@EUD?,[F:F\,O2F=6LR>-
M,KH[Z@4(&XR_>$6KRW3X9*1E<2@[`A8Y,;LWH19QH@*EZ:])1%&'\09&D'\%
MH!3UQ$YJ*E$=^X)T,4*ZY3==8@?QV@5O8*>V)@04P`Z%)VM%8`/86QK_DPW=
MX"G>&[,TBRHZL`*AUY#*41S*20CE>9X01BV2!!T<UI'P.WKP2YV1U!PK4`(%
MC&`K@!P0ME3"41RM<:H:\+]3T$IX^*HM!DJ1P#8WIA>PA\$W5\%Q"Z#A,G"6
M*055,#[U,:SWL:!(Z5<CO$L2-[@,9Z$3%TS;RU.F42+N(&PWU49@MC$XK,/4
M#(LDF)D9E02JI/\S7B!<3T!V*92Z\M1T7*(374)H.N*9A)E$@XET.P%;`8`D
M`N>O28!0!;!U,8"-5",7ZP2::48E9UI%X7ATQ:B8'M`%MGLI9I2G!X1`?=Q&
MVEL-E],9*-N]-$L%(-"0R6$(C7P`AHHLU"(;D.<:'8`L#9F=S"%)7GB_DHRI
M8;C2&+`")$"1D,K)H6R>!U:J#U`"*&`*<``TE.`!W[-[L]H=3R`*Y.&3VR%7
M/=*"=HC!@ZAC*`$#2B`'4I!7PFH?RZ<#N!3"P6QD!"(P#&=8*0RMDJ6]`E1?
M)4JBS.1,VS?-U1S7[<?#,9BO4>"Y^N=_02``%=O/)\27<Z&"$T46Y.3_NL-(
MI)FI='(Q:$8!`#"P)E;\6PM`=W&V!#E@!.G$4:=&O#/1L<%(T"[QSP88!CA`
M!N]2.$9`FW6L1HY+D%X)&1_C*@,@4Q;MQQ"``A:`G<V6T<=Y`(>P;"#@`B!P
M`;*"2#=0&\BA'%]8;N4FR<WM2)IJ`2(0`91G"*[!&KDR&Q1Y&Q'0!DQ``VT@
M!390NM@#$;&G>]>C`@+021:1P87(/*]$AWB(GS?6/$"I8W4[/N132T/6<+X,
M"^JSE$:&"P(BK;F`H0DS>*&B#'"@#.!P(2'G#B/R#"%G`![73-KZ`&(IUQS>
M<M=,F(@F7/JW,V"P$H1"=!<U-1FE8S%TSD.J_XY_1M@WT:\X\!U!L`0%(`9)
ME!<S$`,UZ`,Y<+M+\(WEU#=&C,U7-*9NI[P3.R7LF`$9P'J(,:>0(QK`*;/<
MRKV=@6L5;0`C8`(,D-$M@&Z\W83E:P(D4-+3TLDF@#L3,+^2'.<M/6YG2)V2
M9`*[PLF]0=T$["NP`1^@:@`Y,&(T%KKG,AYMY0&?X`&4]LH\&=\"*G#?4E:O
M'+>1WJNN&P0<D`7[4CZMD#X):JR^_-\IW'P"3@L1"N#L(X3#-`[*H*UY'.LB
MIR$2[7%Y_"#RLN$=ONNB%7,1Q'1BIP)`GHT`,'1]QA()$<8&N-@Y86AVW4\'
MB'11HQ.OAQ="1`:&X?\%<1=H'I`!2'!I!1`$8Z,"_UQ%*ZC9`KWD$M4W'Z&8
M0/`&AU%WB'&]D`.H^X4JH=',,+OE"8"R%/`!$=`"R@TM+6`!R$$[T=$K$="S
MQ^)'$<:18=C<XS;Q'EF_%)^=V#E5A%`<K`&TL)$Z$8"J$8`"078$0A"?Y*$>
MZ`$];35CZV%O->Y*V^&OA2B@->_4YA)\D1[9/.$#.F"@5UV4?)5\H^Z(I?[5
M*JSJNL3J418BK=+@__/"VZ`A#%XAD8N)N<X%ZK?U7-_U6\_K8+\R:8:`:;8`
MPD4$Q=XD]@K8.#%17V'.4R,HT=Y1.B%$O1IH:8"8?,+B7F`I:1(`6.%U?K;_
MO*NVV!BE6\M[^%."`P+`0W^!XTWP.'P,.</6O0/4*=.;:VI4VZ@"!TL8YB)@
M>1[YG(=`'`4,A;<#&]%V+,?)A+H3R71.\1:?J0?0`DY0M-.!8,`1`4M55#5P
M&ZFC`5(`!T8PZ'A(8Y5`GW;P$'9`8]_C<[#72F!1:$($WW/HU`!JJP%ZW_==
MM[D<]*W@RURMM[]\E,#L?`(CH0E>(!'B]-;`X`]^(?L3_QV23`H2(`NCX7#0
M!OP/"&V"@X2$?X>(B8J+C(V.CY"1DI.4E9:7F(L(FV%A!`1A")T$."H`,YZI
MFZNKG:.C!%&Q.SLXM#N@L:"NGCNR4<#`/3/$,TG$_S])*E,923@XQ$1(2U/,
M`D`P`)M1.V'`G^#@.Z*XF^&PN;*>X*&[W!XP.3`!4TU""08)`PG\"0X)"B`(
MA&!`@4$(`QPH].=@P+X$0U94F#"QQD0+#"QHG(#!`H@5)ER0>"#"A`D1(%'6
M$,&Q@H4)$S16P,`@(X,#-7/>=%GA9H,6/0_`7%'#9`T7$9*Z$%'2Q0H-`W)X
M$$`US0*K"P0``"!`10P54Q=,3<(50`]H/V;8`K;#V(^T/YXD(0M@`8`G>//*
M?5LLF;.V1'10P0)%B0XE0^+(T!%'AXS'CSE(YB!C,F7(EB6/&)&9P^;/(U)L
M3O%!](<-<"`HD+"AM6LX$O\$PCD-`8YMVQLDL,Z]X<-GTJ)'/#B1J;CQX\B3
M*U^NG)4H5<]G](CB_,Z=5=:O/\_UJ=<S7.MBR0I'X%8P;CO.%H.&3$"!``O.
M)HL18`D](`MR%`!`0%3_3]^P4YXGZKRRBH#D=8<`.-S,H$(07<Q3P!0L.!""
M/@[U8T!KL1EDP(<)4?`/!?I08``3$S!0P40@@(`!3!9@(.-+3('@P@,7N-#B
M!")T`$*-+6*P8D<KJG@`3CHEJ6)0!\RTH@D@F6224QU46=0**UP0@AT"B*&"
M'2JH(`959'*U`%AB+*"F5@)<]0PQM]SB5C%))`-&67KE-==;?*9%S#,J;,!$
M%5+_2*'$$4<DEIAC'.@P!&0R<!;999U5VIEOFY4VVFD;R.;::[#IUMIMMZ$&
M1Z<?G`9::*D.Q]RKL,8JZZRQ.L=)***($H4GVMEJ72OAQ>(-+>=TAVLXOIR'
MGGIJ#5,,&#YD(``M,_R`C0H+3!%`!@'`@,IS"P+(3B_G\(*.L;JP$VYY./3P
M@P=$Y)!!!F\8$0(%#N7+SP`!#:2``0\Y(**%++"0@`8K>C3!CQQU]!),+YHD
M`@DYK@#"E"75P-'"&/&44P5'XM23DC4%Q4"+/[I@P@1'N5###29$@.4-*XAP
M@0T>B!5FF#E?U6968`C@P=!IDDG5*<7$F5ZUZR73)IYY_^*U)Y_%J*66!P-0
M00447!\ZQ->*R1#'$(Y-:FEF9E>ZF6>AD9;J:;&92BJ'J>V&VZ@<]I;JJFZ[
M2NO?@`<N^*S8]=H*.9_TVHESO)#WRWCH!"M>@`"RU<-9S[#WIPHY`.'G#%[B
MDL.V&>1`G2OBH=N.+[N8F^`NNKR22GDSM/7#`D'(4\`2!G\(HC\.%230OPQ1
M$()"(81@``HJPN@1"!2Y]/#"%]>@00DB7-RCCAC4X"),%)4,<LDAJWA33C@=
M.7(%/YIP@PLQ,6422#.Q7$,'0N0LA@=@DC%5&CTKVE86((8TI4$`:;C35JKU
MENEPXTUI>=-=P&`7K>AE+G.1"_\&/Z<6:.Q``$:H`A8*51A$?0ULC'%,V=!6
M&<E`JH63B=1G-",9TNCM-+`QE6XD<"K4=`H"'-I-;DXUF][P+3A^&YP2E\C$
M)C+"5H4S1P^Z`45@K2L<ZNA.[";WC0!1#D#4LMJ?;)$$#^0@#</X`0"(\`,"
M^.`-0"`"$<)P!]2-!W8`FL[B;B6Y<:4"=>*PA724H9\I&,$!'S((\?Y1$`\M
M,GD#HP`$$%8_FCS,`@T0"D=>$C,-=.`")SG)"CI0LQHY;'PZ"=D!&M``\RT)
M9*RTP@$T\J.2N*]%)L!ES:"'D@M`X$L>V!G/U%3`-&6%*FHZ8%44N!4$+N`)
MOJ"%YM#_LI4G@.$)6@%`!C'(3;^(L6K&F((4Y##"$B;JA%^KS`M=J)C).`J&
M;*.49S+3ME1]BHBQ@0`/YT8;@;`F-A(XC:;B"9HD.O&@"$WHJZJ(@%\=B*'`
MZN/KLLC%U*TC/`3"G+-L08LHE((,3W@3$51``&E\20!WX(ZQM@/&`BE(HJUK
MW2MH=XPD+``(&9B"$/"52-6`*)$&&0#`%$(!$B4@!,(9THMHLE20320F%A#!
M`U"0E)6)X'T/*"7TPE<3)-UDE:P,:Y-61-:;.,$*#7!)+:%42A,\H'I.04D'
M/@`$,,0@F#$@@QV":0<"%O"8"C3:5@``AL(FD"M:J5UZT&(,_[G<!2\6U-,&
MW[)!<";M"6\8@ARJ<*ASHI-1,2P;I"BC`]"R$#-L`XUG;/B:?.YSAZ[9H6[T
MV1LCTO,S!E6H;G?+VT@PU*$-/5P5_[C%_]PQ0<&PJ!;1A9Y:$&.*W"A/F-J%
M`[+L8`%-R,&90D&@<JW#/PAZG7=EV@X"].`)0R."#V`P!21<2*@&`")!"N([
M$.W#>"PHJ@..8((F=01B&=G(4YMR@1)TX'T76P%2EH(!$0@)(U]%4E!863Z<
M6"!DF3R`%K0P2PRL-9?9$\%20G*#&BCX"$00RP(H>,#]Y:Q+?_79G00P8QH;
M3;`'?$*?D#&7K5SS"<;82A*B)C6_</\P:3@@PHFH((7">.UKC`D;I!@E6A7"
MTX4QU$QP-,,J>Z+&M;89B-ULD\\;BF:>J=U,;GO+YC;OUE?7^54GXIPK<#%N
M%+L:Q143)+GC2O2!..`++F2Q@S28XG)66T`7?*`"'R0AI=%E77^Z6QY<H$N\
M,O5N)Z)01B#(*Z?W")X!>(B0?`G5(/QP``N$(`06A.`(*:)(DS:BHAA![V(Q
M0\$+LEHS%_BZ`[FT&`@P`N$CE<P"(_MJ5VN-D9!Q^$6US)Y1W)>]CZS@?6U8
M`GKO,L`TA4E-!"3FFH)&IG$3%K'(9),"\:)-NOR8+$,V!@:?\%@C(Z-J;4D/
M&(J`A<%`P5#_)S3A8J;\F-*"-FVHQ;)J,U6:5*5`AZ[UIVZ(2&;6G.;,:.8R
M!R)`'#=[_.,'A3-V)MV?Y_#"5A@U^9]5RJ`O5DX8?:E=,*[K@1DTR.9Q"J:E
M[PC(EI-7O-QUA<O+DP0Q>"$(&8!!O4)PZD8"S-3Q58`_0N!J&X0`"B*8R(J,
M/9&:O.1[*)FJ!FY0X@AX$DNB;(F10@9A9?M$E2+;24^H)X(:>&\B3)G`25`2
MDAL9P!0"(,LQG:D_K/PL*X1%H#(56.,T6"6;U:2W!MG-[6/H>+)[J=8Q+"N=
MS.T@"0'(`A9&J(3.)DHQ!H]#8R`SMA9>F;26@2%HW/:V#Y!*-?*M_TUN=!.0
MU/30-Y/A#`TEPW&0&__X@8-H0ZF3%BWBRESG@KZQ\,SREV.QN6Q!1EINP1[Q
M;#]9'R0"R5GQW77MD:5^[#F?:9>&W,G+D*%^^CY,;>JBAL`&0@C!$##)$V1;
M&-DL$FQN13$/<",WH@$J`R5,L74XD6$V<204IFRJU`)+HB(A9DLG\1$KX6$H
M03-)$0=`T$PL5EA5,299D4S)I!7D1F,95!98<4!WPF[T)@!RL1=#1F]3@WEU
M8C5[8EG/<!8[\`,%``4\H`3E]&1CDQA)"!DI]$).&'N644]PTQNKL4.J45L6
MEQN*Y"D8UQG"QP%KAGQB.(;&$475$08?E/\$"V)RG`!T>P0+C4-1UW=<W'`>
MG^!<.T@+MS,MOO`=M(,#'N`#,Y!^=N8-D-,XFA8LDK,@'K4`ZP4#,-`$2(`$
M%6)4&-(/^_`/5,<"5@<%(#!+TL,36O=U35$#9A<!-W`!#Z`!#]`!,H-+,-%5
MK-0"2)(^Y?-5R;83&W$Q";9W?4<S"V,"=O=)-#`%8)!`:X)-5=$F;6)X/D-C
MA45N[*9`5U$7/D9C/O9N?H$7<7$*?E$G<5$G(94,.U8U'`4-..`#,L`$5"!"
MIF="C9&$0T!:J^>$KP=/7=8:]C00LE$;7@8W^B0JMC4I::-F'><(;P`'?Y"0
M9-B0#HD(A@-%=[#_`QX``"D57(L3+(>X"RSU1]^`49*S#I331;7@3>SQ`]%$
M"U-$#`(0!$2P<]XP?=U1A^.2"[(3?7M&(!\$!$$`B>\1`/9@`R22(425:OA5
M(7(P`:VD$<0V),C&@2!Q,:V()0\0`13C`J2$,OZW2BU`81`884C22LGV5#`!
M):&$)5&22UL%)5BE`7&0`W=1)G61@@>D)B_6C%1!;@<T6(%%@W9!6#$8@S:H
M%VE1)^!(CH4)9'W"07["'L.``S$P`%7`!*2'*$?@-?&83@77&"J4&`AW96UC
M0Z11<0+Q9;4%&Z&BCZ%Q&::5908)"6[0!G\0FP]9FV.H?-IA:`2@'1>E_Y'+
MM3CI,!XT65SC=4=VV"#DJ!8-Y%'.Y2Y)<"U)\)%`MWXV"9+39XCDT18J$$<P
M,"\94``%<`5&4"%$:3SW0@&<*`1&(`>K-$M,V74,,`&T:&*N:#$NH`$FAB4=
M,!(WD)714P$9YI48!G<_$3+2@S)KA99HMQ0+XV$EAA0/4`(2X`/-=(V.1V,^
M(VZ.)V-FHH)L<HT`(`:55X,ZQF,9Q(V+B4'$L"=38XX[V$%_0@`"T`15(`=-
M5GJE!X^E98\%YYGPE'!IYC:H`42P0:0\9'L[]'O"%QF5(7QK8QG%]PBT29NV
M6:4@AW*L<!UF,`,Q\`/7`8>P\$7/-PK$@AXQ5?]1U\<@6+0T?X(YT20,4>`N
M05``=S4=F%9IDN8ZD>,ZXA6$\!($/I`#@OJ=!=`$19!?YLF)-E!U0E`$$-`3
MF"0RR(9L725566*?JQA*+=,!K<@23=F5`@J!M*A*2?)U+2(_U^8R4:)@(+8P
M1Q$!#T`"5(`$-$AOUT@F+/8S!_1X-Y8&/69CW#9C=V&8?G*#+3BLVO>-.SAD
M1N8G;U%=1\8>@=8$4#`83>9D)K0H!D=P!<>D3)AQO\$IN%&D`=D:NC<;*;!E
MF4$:3NJD'W`!!]D(4RJ;5EJO;88K=49^=10&5E%R;6A':AI1Y7$YQ`)3Z1(+
M>B0N+;=8/]A1Z>$+4P3_#4!`IS)WL,42IZRC"I<&"GQDL0Q275Y`!$'`DY]&
M#TC0:HK:J$8@!/@G!`/@`FQ'5CWA$A98E1>``C!QGQ%0$@H&;`K&$D02%%U)
MH$Z08>5S82)#/0E&=B6&=C2#=BO`(RL`JSA"`Q0`4M.HEQM:ET"3E\YD3(79
M3-TX6,CZ)DG`C(Y539M'6=MT#,F@>7Q!CM!Z;]+1%L_P`S#``9MUK3D*-JJG
M>@;'&.JTHP-'&4/PI%QF0SWT9;@W<:Y1&EW8I)[1&BD0&2,0*:T2KXPPK_;:
MN;RE?)R``$D0!-K`"C%U7.0'"MCG1W=*DW;(1=+40:SS'6KA#%WP!D'0+BYW
M_UP=E47/=RL<"UZI,R`951=#8P>+5@#?:4A%P&I%8`1&,(DV@`1%,``1X`1D
M%2,8@!/;BVQ9XFO]5FUC!P(1`&P=D#T6DSV4>@"@:K1PQY4M0(M?13T\\C(=
MX&M.,3\M0A0T(V(X<K,;(!6.E9?'"&X^HTP(]#-<815I4#LS(!>U,UCT=B>'
M218TIF/)((-NRTV3537..A=,\ZQ\\2<EZ0,?D`7D]&]0<)F6.02G=T+UJ'J5
M$;@_R@$7%QH^-"JDLK@-=V:RMQFM01DCD!L8UP&:NPA=T`!NT`%NX+E.G%"@
MRPD]``1IX*^N8`X\U[$*RV<:*9+*DEQ<%*>,96EMH?\6.P``/Y`&/D`$`(`+
MEE8N&'L+T#5I8[I<=3AS/0!&@6:K-]63W7D%2X`$T#L-D_B\1C``#Z`^,@LR
MLS1+UG,!&L`#5?!6'I8C(<$C.F(2T%-L!?H3H_J^[<EUX`,]?>=K)9:!M\:_
M'O@`.*($4X`M`TPF%UH5CJ>7=JG`=1MH$42VY]9C)%I30&:VS<HGW.3!)OHY
M<&&.T%`>,6``FT4H.6J9+(Q.,=Q./AJ%JY6NIE%;KC&:<*#-FM*%7&9$.!P;
M'S`91AP)7>`&.?#$[NQ$4>P?(=H-)W<@YZ=RKP.2@"22K7L>*OE<OY`,Z3%D
M2;#&ME`>Y+%IU<51LP`>G]#_A@,K32AYA[I[ASU0P`?D%>OU'DT0R),XB490
M!$7P`1$@GQ28)&/E$2]``S30;SZ"`0]:`E%K`585M;(&5F$5O^WKOL;F=?&S
M2PI&=BD!)+:4JIP*JQI``3$0-.QV8]BH>`B\)F)@%6(`36*\HM:T;D*F1F@\
MPF31)V@\-<2LHLG*-`RD?>!TMX($0NPX0H:"HXGB68M2<&63&%[XI*LY`KZA
MS:+A-K^1`AQP9FO3-A(@&::"&N<<&E'ZSHS-9O%,(!Y`S^?WI2@'2.C''4%W
MI\C54:K;AQ--``_L+@1@4T$@!C/0QA[K463Q!!'K7.7P?-024NYB%GCVS\H8
M3-BR_P!V$"WT((G0RVJ-ZK(@,#Z*G+TQ80(=P(XR0`/`B)6<:C'@HW?#)FN>
MG$E:4+2>O--@=20*$VW7!A)1N;\F078HX[\W0@,I``06=*M&XWCN;<`=:A>#
MYBZ4Q14*1!>;M[;@:*LU!8Z;MZ(J"A>'B0S:)+=FG3GM0@M)4`!90`594"@0
M'M>>58^+0;AI,T]7!MB@`7R!G:ZLHN&8TF6>,1NU]S9AV-@HWD1TAAV;D!VW
M@@!@D&>NP)OX2GYC>B[B18=#5SE:A![2T5R70P#OX@,>\`1BT%%"![%6LP-Y
ML14XD&G5)19I\%A/[@D(0`O8I&(>(`8Q<%=$,`]7T`22J/^R(FT$"6`"%Y9*
M7473%0`2-"`%6)`C;S4!#W`#)+"S+<(B%L.`/\%*3O#G\0OH$8AA\5G>3%%M
M[=,^)4%VV?-?R.U6;2`%2V!!3IU-57&"/F--;0(&-D<[#YP5<E%8-UAD4B-D
M9PMD+XK6'DPUB':8<+&8//8Y$8L#.:`$5+"WI6=.1^`HCD(V\FB/:A-\E@$'
MEYO8&+<J?_V%3<K7)Y[BSCXXOM+B7YHX5FXNBE/C+\ZGK3N'F*;CY@4G*OD#
M4X0[P1P&T]%0!(`7IYT5::'E"]!&>P3:71$#0$`&;5RPMR``]!X#(HI>\5)(
M];`$(1V]SZL`,,L`1OM*+M$`D"[_`U2PLZP\`23@:Q<P\</&/@SS=F#5`M?M
M!('>OJ3Z=10!,3!QJFJ92YB<OQTHC/?[`%4P!318%HEW-(B5@GF9>%/>Z4'8
M8V]!MA=4HB"<F,GY)F:=K"/<%U2SF+"^'@F^`X'!!$U6!4=PHT@X-JIW0L!^
M-AEGP^?LX:F59I[1PS,$KLW^[&9/*]'>4-,.(.<W9U9T9V"JV18+QMU>.6?1
MVGI8.PL``],""LD2!C,P-&)!!C%`6`L0`UU@!YP.#IMPQET!J$0PY3^``X0V
M#"I`!%X`!&)`%EX!`Q.R!&(N\-`;T@D0`4="@:0*/0W@$1I`!1`@!1%P`;#*
M%&_U`B^@_R,IHC"4&E;9O6$='[\\W20EK[[J`Q.VE.AZEZHKX!$T4Q0U0`5-
M\$QDP4SDUDR'9S1:"P;YW?/)X/-Z`O2;!PV7=V1F'1>O?M8,%+=*3S5,/T5M
M$0,<T-),=H2EAT+R2#:NEW"3@KB3`0@?'QP?*2,<'".*BX<?&R,ID2D?BXB(
M$2=_FIN<G9Z?H*&BHZ2EIJ>HJ:JKK)P(K[!W=PBRLPAA!*^VKV&PO+Z\8<($
M!,/$Q\C)RLO'4<@[.SC2.#M1/=))060[/<[.!#L`,5XJ*EYB'AXJ=@)).,X[
MQ#-D/CE!/D`J1`LSQ6$X`KIDL.=!0(QZ!98L0:)0H1$A0@Q<J/_0H$&+!@<R
M-F!0H<($$!WD**BRHLV-%2!`K%CQ@$8-$1,F>)S`H.:!BBV<6''2P(D6+4Z<
M7,Q(E,$!!A9`8##:LT&%E"!$B%@IE:J)&R94UECA@DJ"*SF(M$L"`("`)P#`
M""BK=H%;`0+2I(&[MBR`)TF2S$@"]RX8`$F>"-8[8Z_@PCA^*%9<>''APH$;
M_WB\V'%EQC-^))E<N,<U:=!B2.#!0PH6*5"@*(%R9$@<'4-BQYDM`Y&,V[9O
MUTYTR!(B0R,>03J48@.E18Y2(!KQ`0[P2(HP<>E"O;KUZ]1;:=_.O;OW[^!E
M^1(/+-:N\>=A">MU"Q<R9^Z1Q?_&C$#_%/K/9E##T0,:MQUB$)$$?-[L(``9
M*JA3CAUV+&`78#AD]L,"/A0`0SU!!.&%!TGD$L8/7F0PD(8J5-B$$45`9(01
M)T(TP`4,5(3141QIP1$(6+V@@Q(1\'!!2A9@L$($&CR0%0@3),5`"T=99)%/
M%P$5E%`R'G6`!5A6<-,!&&`09$I23;65"6169<)4*YC0@0P%Y'"A#V(()L`,
M`.0#QIUWRK6`&`L(H!88:0`F6%EX:48HH3,(AA=B>Q&665Z<439#-)9A)N%C
MDDFHV&:68CH-#AXX(`</65"A!&I8'*&JJK+IH`-NNN6&FV^60)*(((4L,@DE
MMRIRG"/.,8)(_P<GP-'&L<@FJ^RQX#7K[+/01EL*>;JDAUYYM%C;'GO&?`-?
M?<2L%]][^!'##6+]W:=N$C$`8-]]T3P10Q<>+)".6PL\`<8":2Q@1[UN!9&!
MA3`$T*8*8/1@[@(Y%)"!#UT`040&1MC``@L6%V'$%$(8$0(/%!554P4Q8G"2
M"%1P4((+&J`@0E85F/"`!B[48,)+'4VPY4TMY*234%KTW#//&'$T4PLV0A73
M1V1&E1*9,:T4U0H=K)`"Q!GZX,4"9-5)P0=$B!'76V[U6U=:@MI5Z`]HW:7H
MVYL]1EA>@^DGJ32-01HIII1=!BG?CWWZS@(LD%K%:5)(H<2JK;4VV_^KNLVJ
M0QR[T;I<(I(P,@EP@OCJJR.*1&+;#9E(:_KIJ*<>K2[F85NMZZS[LEXPXWZK
MC#'B+G.?,M!$F&XUZAHH!O`[S)"&"D'D``09=HBA5EEP'>^#UC'$T/`4!12P
M<09!\!-%.$"X*>+T&5QA<0@8"U&$QAXS0=--,QYE`5)2F?""$G+4\``)::8T
MP0T7,)()5E`#$&0$`_![TD^T8`4K_$1H,ZK(43QB@0-4X$LV`].9RA23EWWD
M:2YP@0AXD`,[`"$(1"!"]404@RL8`0AI`=1;^B67N=@E+P\"C%ZZAA>T5"9N
M;'L"9.@FQ`@!3C*..>)>-G49)0HN0@#Y&!7_LG`XQ3$N#D=00JMDX*I7<4`&
MCXM<(FC%B-Y`@A*[V@!P:K,!.!QG$KTAENKF2,<ZVC$4K\L6[*A5'CYN*QC;
M6D9\<+<><"6C&M$@'C2<T0,!^&!`!)C!`HA0#^JHT`-I20*@X!*##+S)!S`H
M`!*:,`4*A,`(!0@")A?@!1^4+P">+%@3UF<#&W0,14@HG$QX-I0)/F4"*-.!
M!K@2@0N0Z2D#%.!)E)(1"\BH9S[Y20-W<I$J980C#%!*D)AVIJFA1`0O0=++
MI)*2--5`!P6(`1@\0(83(H$)&VB"!X0(`$/)<"X"6(!:UC*8KJF-,&CK85X&
MJA\<H&51A1',#XP(_SC&))%1<GM493+5F():U(@+^!@5JY":Q;%*"5J,C:O"
MR($N0@XWBK!-&6L%1T=L0(VAVY5RSG@<3-SQICC-*;1@5YXPB*<6MS#/+(3A
MNG$9TI"%;`8X=H`+>`%/J8T$0A*@P9<82(P(*%1!G^!BK[6$#P8BRD``FF#+
M)5"``JB$05B2)U8D(`%[!9AEBM9'UQ1182E$<=($+2"5#DSQ!3<000!/(A,1
MG,0%:5J!""Z8D0KDI&=/THDTI]3+FB`E)MN$"E2F0B:IC9.<&&C:$8)@AZVE
M`PA+D`(<5%!/O$T&!YI,"UW^]+9!_5,_^CJH9@9:1#H]03,%#0QA/(,IO_]-
M1C.12N)$*9H93SUQ`1Q@0A82IQJ0=K0U(H7-:RIW&QV0D:6;N]SG7@H<Y@C"
M$)@[XP9LJM/VNO>]I^`I,'J1'J+&HCU%38:XC`&NV=WB/>]JQO>J\9X/>6%2
M/P#``L@0@R#```9`B($`^-0O.QQDK%.8@A%80($!&`"M1;`!$MY0@`"8N`!O
M6(+Z&!*`*2S$K49`@OI8\(()1'`C1FDF"%P0@2P$L`,BZ$`$.O`2J2"V:2`X
M4]$PTA,I+7":.^D)DZ[)`,Q.``,?U.S+5I+!^I5)!#A:`0V"<"<%!X$%-!"!
M#,0P@_X$KLV)81M;8@BWP!!J,Q$*8MP&*MS)W(7_,?TIGMV(V]#=!F9OF8DS
M-C@3Y^(N-'"?(H`=!E""+&`!"ZFIKD?C$!O'N6I67*15;4*G*_'2%*:*,,XA
M4OK%Y<@1OK".=:SEZXM<N&X7LL`%>^:K7]H==;^UTYU_PA6?&/!#7T``0BM+
MK+QUI(,,`IO"^I!@@P%`8``*D(`!0F`#![``"1NVP?J$$`(*L*`(H[R"B\%-
M2PK(H0(8<,(!IFP4HP6V1RB(0`1`4(,0=N!D$U"L"TR`91/8F)<'"(K0<@)E
MGEA$"U2^X$S`Y+\D)[:;8>IFDJ7"@7P](0<OVO'5&'T-2$-F4&US&]P&,YG-
MH&4S?`[,HM!2T?T\AKB1_\KS;M?FQ#PS*KF`$]RD/#`")LBA"E5`#4B7SJI6
M32X.MO&N)2K'`?16W=0TU9RN!D'U5\OZZV"_(ZW5<VMKV5=VN;-U(.N35&*_
M:W?V><8[CB&,*"#@"78HB[U4<)`W3"$`08B!'<B`51B<R&(4<`"V#9#M#0S`
M`0:X=@*PK8#*&V``"?"V$:XPUB8L8:YQT)E0Y$V4">[X`FW00`34=`/$NJ!J
M+E#*1SKPP5U:)"<)7W@#M'""$S3P`!UX@,YL8L&<=1#,4!D@5<!4/Q%8X",K
M^$`0VI$##71`"R"(@PTR((`>3*H:CYI4R?$2F+^L+>:.LJVB=AM$\G.&;0LU
MXO\T&E5</C\4,G9C:*<J>D3^)-(+T24'<H!I3)=%BQ,;KL%I0U`;LU(K#G@Y
MO&%>N2(LH>,(@^`;7A=V&KB!TB)?Y,$>N[!KM#94:;<M_&54;9<,WQ-W;Z=4
MY4(`9"$`%F9A7I`#&9!A:I5"-C@%&,,"(>``Z.,`E0<!"F`#GW=69Y4`!K"$
MC*<``T`!0O!W&<9N.H!`\S84.583%@!`/&!]:=(!57,##^!O*5%P2T,R\),3
MNZ=P0&$%)F``:@4%54`"!K=7,G%93A,5&==-5Q9:FA45.D`$T,8!*-$!&-``
M)C`"8D`-T+!W9#`P^&`'3P`-C:(8Y`=S<2,A76-_D'+_B8`6#4\T?VVV`TRD
M1`[U9D-T7.^':.CR&3L0`T/`!$B'&JJA*JO1.`CH&I!C.9;#:LLQ":JV:BGE
M*Q(`![TQ1NS%@<JXC-XQ=K]`"V3GC&CG'B;H'OSE#TWE#^3"=@C`@L9`)P<"
M!.I`!`7@8FV2`S9X!2IF2HEG;C80`@F0>:A48K,D!#)&`?&(>=ZF/DO`>7[7
M!#)@8TXR(_/3$0Q@`AK``TR`6(8U9#)S`6(86#%195@R/PDT-`_D)%8P`I,8
M!1[``R!0`4'!)4A",AY!3LT7)D@2$Q67%!/@`@40/AL@ABU!>Q=P!$#07#^0
M`0;@>$YH2T6P!#E`!G'"-H>V_QAQ$R$PMS:786A[TSO.A3<%Y90/I7-V\VA(
MQ(K]!T6@D0-*,$555(L@M2JY^!JS\5U3ASF^05,36`E;IQR^D8S,.)=TB0IC
MYU\A*(W32`S5.#OR88THR()P%V!Q!Q_=2``XX"#Z``2N9`04@`0B$DHAY@"9
M1YD#$`+D!H1&J%8/=H,H8C$<Y@`48`,QIA!-$`!^)P,@T!02=!1+<5D:(`<T
M@`(!QQ)844P\M@)+LTW8E$`X<847`5E+@`-A$`4X(`-#@Q$79`$7]$%[J'&;
M!0+/!P)5U@$V,`5R\`(:<`0<4`4HP`$&D`4BH`.`YR`+$`1"@(]0"!%N%0`4
M``'<(_^._-0IF_);3:23KU5S#%50TK!;?5.*?`-T/A=^GJ(I1^1F.Q``<L`$
M5#"`U<4:9(F`K_%IN^&+M7*,F'->T.&6PP@<EB"7=1FB(NH)=TE4YW%VTIA4
MW"(NM-,+^_5KQ6`?!):".Y`$"\"8#1,`1I``++(019!XUG9Y"7!*X+8B(Y8#
M/I`U!9">W`::';,0"O%64\`!".0D3,*<\-81.*($-*`!$U$#`!0!(O``8GH#
MTHE9+X.&/:%P"P=-0S,%U/`]01`C.,816/(1SBD5#\`#NIEDW90SS^<"+S"3
M_W,!*'`!+R`#CM<&.U8#+W`$.L`#4,`<QE$Q[XEI*T&F#Y#_J"$``V*0!GOS
M-X6"GXSQ*8@AE9!FE8SB*)#Q?B:G1*;H7-Q@4$+`H%1`71TUEJ[A&MV%&U8G
M:A6*'+FRH18:@94`HJ``!W`PHLP:=CW54R8Z7]H".VG''G0';"_:7[,3!HD$
M'X2$F";D)B56!)F'/A#Q@XN7`(]I(>A88A>2(?>PI*:4(A<3E!E&2J2D`#J3
M0!9T95@Z`1V`:?G6`0S`%20PAA'P`$[S?%:F)14Q)1`[)0^D!1(P58T8`2,Y
M,M.))/YS)B+&L8IUA@%G`E30`3I1$S>@`53P`31P&@J+`E0P!&#F!!C0`4=0
M`Q\@!%0`D4/R$5AV92_S`$?``O:0_W?N(#=ZTT2FRI]\(Y7(M:I[<Y]V`ZM'
MU"E"EP8#P`2D@CBYBEV\RD45RHN',&JW<EYE5`EIN1PIA:R?T`$-T*QP.VNQ
M@RVS4U_3:H+JH:(GB*UIIU_9"@[\\0TJVHT[L`#6(U974`0L0)GN"(^8EWDV
M$``YT`7S@B$9@J0"(P080TOV>*]+,`5-,`(F0!'5U%C,:103\`!4H`-2$`$K
M,0$UT`$7$$`#QV_2N10ZDR3SMJ81&Q0_H1-6\`!`L$@XX`,:8`5V^(=(<C,!
M(`3+BQ+&MP(H,`0V@`$-A%@UT`991`*!]0`=P`0C0`,/<`$84`,C,(`;H`1@
MEK*U&UHWT/\`%M`T-Y`"4Z!NL&0/<9:T$R6*U/`90K=<K3I13:F55*N5GW(-
M1'`$5(!TLZAT5Q0KHN8;<&DKYE5>*34)$:RVA\"VG9`#<C`!.1"W(MQ>K4.W
MT5HM/J67+]IV?-NW?VD,T("8DW&MM1,A'N!*;Z"CBSL`3XB/EU=N(5`$!>`#
MX]`%@@@`YD!),"!MM@01]L@03>!Y2"`#*W"(P8D1S^<E*)LJL@E.B$6F+(,5
M*0%D6$*1,G%[O2L4/B--$Y`![W`N`2`"$P1,'(M\4>$"$C``SC=`T@EO(E`%
M11``3&`%)S`!&J`!-T`%4,`!*(!E7H@"5<`#8X@2$0`%-8"GX[3_%=XKODGV
M$1;P`$)L!(=``060+T#4E$P[BNKR/9]17([V0ZN8%Z>ZE4ZK'U;K&?PQ`P50
M*EEP=+CJ45\[1JTVS%&'.1.,MH@@"%^$4I!@P0]0.J(0!W,P&R-<S3=5"WY4
MC=#H@=AL=M#:PG\+;._B&5/U`VL!#Q["7]4@`$2P@YG)P_$X>=[F@RPP!:HD
M,6(``#@``.T4!-H#FD`9E*3TN1Q`<"(I(QQ1>@=0`SPP!%A0`KKIO2MP`2%T
M`9><9"]Q)5A6>CY#61"TIEKP`$O@!6#P'YD!`R"3%%)Q99@,$UE``3!Q)"OI
M`AO@`QS00`Q`IB10`B\@!1LPAC(S<$<2_V0/\,EBZD$?40,1H#\J:TQBNDVI
MH@`<``<*P&TL<HXDTB>]%6@$)F#G$G1(JY11F\I-*XI5>ZJXW`-@P`+25054
MI!I08$4+N,R\P8N]N)9K6:PR-:S/3`H`2WO6'-AT)%^#M,WWU4=`Y8S@_+?J
M$2Z`2XH>T`5>(``_,)@QFDC%0P0DIH[OS,,\O(\0<05!P'?T`CT>``2&]Z/Q
M#(7K8YHC\#X[$R,9<645$`$C(`6J=P,6H&\N$)%$$@'(]!18QIPRPKN^"Q2W
MAQ,7$`1TT@\R#`T"``4D>8=)X305D`5&0,<3H"8TH)U'H*_QA@$/H-15<`12
MP`-"U@8*&Y(5$/][(/``JEL"K/<`*`#?A?@"/!`!)3`!5H!E(@`!5:`$4V`#
M0R`%65`")7`L,Z,!;=#=<1`"`0!#_?L]45!(@N;*3IM@K.I<KGRJJ-I044D-
M"[`!-.#62==1E+,;8&O7>7W79'2,$GA>EP#-H,`%F?`%)\`%@KWCIT/8=&?8
MLD/8M+;8??L*2^4-A1$..8`]4K5(ZF(NW_<#0<`02$"OEOG9(6#52!``,`"O
MK`4`:>`!01``[ZB$ET<!Z.9B4S``AZ@1-))P&R$3$X`%2B#1%O!Z-:#4\`W?
M)L!7JYDDL#UZ/B&QR`U9N[<!*O`$8O`#_1%)E%(`\P,3=^HTP,0!4P#_%2N@
M`6HT0%5P`0VP`A:$$@>P`CKP;R[0`"I100<@J`_@6#3;,UJRW2)`)#/S`K/Y
M`BAP`QWP>@J`!$,P``N@`CGP!B$@`TS0I8=<`H>,`BC0!DS``470Y%WM'Q>N
MGPD5(46TGV<-404,UH5AO$EW.+7(79%#=;V(H1#8XK?R4FVD1E^4@9_0!6^@
M"7/0!3Q^[]""S73[X]J"HO,E@OU.Y"<(#OIQ+G&S`(8W!3Z0!MVP#(O$,#E,
M;67NV?`<`J-$2K#D23&0#@V6`4B@>$N8>=^&\2'0ZD/3`@F->['.!'%`,^4D
MI@-T`?\F9*"%%!:T)4XF)6PZ-+F7`9,8`U,5_P6%89R)J0%6@A24_A1#@`0K
M4`$B0`)*P`%9\)(DL"4^L1-.,`%0H"4K\'LM`+03<`$BP$`Z03)KVA%B&G`4
MC0)00`5'P*<WP`$U4`4Y@(D`(`;6,QH:@.LH0`/=S0/EG0##*Z.LK.VOQ5!Z
MP0TEU^W<#JO)17(]\`,<P`,#F'0@Y44<0#EV'3GHCM>ZP6JC]@$2T$80X.X<
MT-?XGOIBY^/^T**_$/`ENE\\!0Y$+_1X`5L`(.\GD@$Y:8U*%4F$=X/4)@3O
MF(0ASP)+T'D9]KE!P)BA-.#61H0.<$M3,$I58!2511$V[Q$T,`3H#62O9U@B
M-(8U<R9)$B1:PA30%/]-0</^.O&P&.`#C`X`,V`-4T4-FD&E/UM['P$(+DHR
M#R8B&API"D@43`PK+596)U8,'1=.DE9:+4XU<BM6&"`-6DY.#9L3#*<M#0]4
M2@\K5'$T)`\E+UEP10L_24D_,S,_/T!"2B4T3"A,-%)R2@H9/V$$.U$[Q,0X
MQ=PSWL8X.#L],\+<.SC#P]S>W.[$[L;U[]XX!314<EE84$IT<!@H0^`(@@0+
MRAC($"'"$1`)ZDC!800$"!LV8/QP,,*)/R!#BAQ)LJ3)DRA3JES)LJ7+ES!C
MRA2)H*;-FS6O$0@3)B?/FCL1W,'IDZA1GDA_WN1)H.F.>CAZ)`$`P)B`'$O_
M;%R!X6$&@2@[FS9%$.6'!S(^8"PQ8@1)$18A*`P8X$!(@0)3KDQI@F0)#!\9
MIJP-,4"!!`,A0A0QTF2*#!`'&D@^0+G"`0:6+6@X0J-#A`B>18"X8*+&"M`B
M7(BV8`%#!0:1&[3HY$0+)U.S7<U.Y0+(#',[LB59M^W'E`G(02B?@&$"B`@D
M5DP0\6##D@$A<L`P`$5#JDVO18@P<8"2EA,'5E2I<$*+E=KN6[@_,.D]AB,C
M:+11PJ&#A0@:=/``!\I,(4!5QH03#@X+%%$%#3Q0L0L350RQ009>?15%%.20
M\\T[Q?P0%3K`R!/<.?)X"`XX\L0##CP+R/`"$U0`_W3$0AS@V%!%',21HXX-
MZ0CDCS(<-,(&'VP`AP0'%=3!1S-%*>645%9IY94O&8633DHA551-0RW5DY9B
M)C6F36%H$U82"P!`SA,')C&#'06PL$00'OP0!9=?$9#3#`*00400!32QQ!1(
ML,""#10T&@(2`5P1@&!"&''H6D;8D(`"%V%G0Q%%)`,"`ZY0=D!F#*0ZP054
MT`#:`Q&L`((('71PPP,N7-`!"+).4$$%%KPFF6RYG5*;$[M=Y@0K5:11SH;9
M/-%##U'T@(,/(C@GGG(@F&"((:PQH0`%"BA0@!"?3B")%B#<8`%E*[`GR0E.
M\/I>??-.<L*^^UH!`@\=U/]PP0=0-,#`>-J:L`(/&<@9HHCE>!.$`EE00:,<
M4D`Q!`5=\:2-.?"T6(ZUYGR3#C$]!`=/5"IV`\^'+'8#S@X%9,&$'#8.F2-#
M!^G0Y(X.[=R0#@95!%&2'_P8QY-8-NWTTU!'3:669S(5U%)?AHGFF61V;1,V
M.V##9@S.XC`5`&!X`(,0%`3@@QA/X+`A6&,AD&8Q"P"15F-3&$'!IW`EAL04
M4P2PE@WHNF4#7`-<I$`"#K`0*A,5-("*P;!99AEF+CSSP`TWU%#(K!&X8)H+
M+JQ@P@3!4H89J;KE1MLIG$A&J@4,Q`$`M<%ID\2SU6:0;;<FS'J#"Z5EBUP5
M#C#_RD)?(:0020LB5,&!"?0>$`DE[X'@*P/S\LL]OU:T4$$A&#PP!!0,Q.IM
M:>]SX$6(P0"3LK4_("$',Q%*,<0'00#`$Z)`%I6]#$0)6A`[6C2#E'4#9."P
MEHM6!"*7">`#3)""!H<PD(C\Z"%%`IH(@18'GWDP!1^@"$-DP#2IN?"%,(SA
ME;SFDZ9P32DT_%(.M_0Q0(DA!BKXW50$H+8B4$`(2R@`G@1@##GYR6YA",X.
M%A`#'^3@#7Q90@@D9P1T5>I0@D&"$4+%`B$(@04)&(`!..6``91Q"!.@S&3D
M:*H&5``$3,`""51SF@<H9P4=0)VW4K>Z7\%&CK.A'2?D_S,[VAC,,AW(P0($
M,`-HG0-:,T""!6;U+86I;EL3(,$0E&``"%!!!W!0@`NT<(#4C*`(&F`%"%[S
M*^=,8`5'H((%^E6!";2'/O-RQ0,*$2$=T`!Y*W#!#;ZU*B&@PVQ)>(([1G8,
M"DBA?T,8`0R>D(8G-.5CYW#1`8MQ,@6%(V7P0.>+QOFP==XC`UFH`D`X.,*#
MB%`&^`121/+)3Z-!1(5-PJ='N-"%@AKTH`@MJ`P7RM"&-LTH81J3U:J&PQQ6
M=(=`V=`,P"``%0"!"`)XP@+L4$5&;!$)&<B!%8-`!@'L0*)I.H<']!8$M2RA
M"6<LPA*08$:V](5OF7)`"!:71O\U)B"--M"!"`YI*E,QH`$'V&0'I$"%XBD,
M?>(!Y`U6P%7Q^*IUDIF=L8S5"5/4I@6IBLP-I@"#!.0`#-G8!EBB,(,K.,=;
MXUEFMU2'G!H<+T`34`($H!`LY*S@!9SA@0NJ\)E`\G4%**2"$]`#!1E<AE23
M``$*0%""!UP`!2:XP.=J4*ME;FL%6>@*.5/4`[`EH0!*X`<44E"`J2S`F^#L
MT#TZQ(Y@=".<Y)#@@M`A#)%1\+C>.`<8X$"#>2ZDGQW\69#RV1![YI-H^*RN
M/2LB@R'HP"-P:(-XQTO>\HK7H>A-KWI98E$S07$G7//:17>(#6^(E*0^\($*
M8A`$P"S_02XA$,(4K`B#'!`A3T]\+PZ>0(8<Y(!038@P6T!%X9XVX0H8SDH(
M',#AHZIQ``D(P09(,<?(-!6MS:$!9\9C@N-A``.B,8'IE"D:$+CFQ=HKJUEI
MAPKYF!6JI@)6%E@``1\(8&XX^,HZ,N""O8I@!3=0CFCZ>IKEK,!'3'A`#;[E
M@@Z(AP<#J!5G27"#J89``1Q@#P.@,``Y5/54*U!"`EI%G0Y,P#.H*ZTAN.6"
M)B2('BZ3(@ZZD``E'`$..2B&`!8@MQ/Q5H&/=D<TI_GH;Y2(TBT[[@.W@0,8
M5"%C-Q):=4<(W0ZN,`[>S>Z.MBN#.,C`(^N-M:QG[9+VFDDG__"UB=:.$E^B
M]!H!!.@!G!8-!""HM`LY*,`;_#87!QBA`,96(J,3K&```"$#!8!!I`+0A"Z6
M40B@LH$-EO`&O`A&W`XP@`&."CD')&`#-WCJ4R_35.V="@0DT`$6+B#()EL@
M8:`+F'-`$"P<TVY=R#J6;!1.2]QAY@9I7((8LA'L/N'`"#%6'92Y)8+03>!6
MLZ(."CJP`A1<()DN*!T(:A"'$&#A`:GYS&(Q`@<=M.`$+A@!'%B@!!1@X4AH
M9H()VM`M7-2J5JD3358Y0,D$4CIE4DQ"!B2@@!AX@TT`B.LZ>-LR$4T+10U<
MF6X3%++=LA.YY%CNIX^@`QUM5]335?^UT58XA%3K[&?9A36M]\YWOF,T*6*Q
MX7QYG9,M):7P=B/`#-*P``_8P0M!<+"VN1V"4DJ``I`B,!!<^LVP!)N;0(@\
M##+P!L.QQ8QP:=2X"X#M*;Q%+NJ>BP(0,P0+(`NJ3*5W"RX3`12T`0LE6(%X
M4-><&FP+-#4@N/<P8X&%C[458\T-D)T*+!<48`8BA3JT@N.`X@W<!'Z$#:^R
MQ=60*P\7J%-FZ)0C!0ZD7,:S*-X#\,,^+="@(EA@`A1&D#0JC&X6MR)SZ:=7
MW'(!B59<]O`.(#,M'F!D3P$G;8).P84/'@(,P]%##11.*O,AY;`.ZZ0B":AI
MY>`#&G0$J3;_=V^W(T"B,SHP!*[&3QX4)&W'`7K7=S9X@P[U=T@1>+F&43H$
M1;^&#6!`!BI@!V+@4=IA.(+!`FLT`C:P%P&0`3Y`!`OP&]B79-@`*`M`!OSE
M8`&0*>#V%BP@%\T#*=CV7VD4>PH`8@/P&.6S>\("5=/7/B.G`7N4.@^@`7[T
M;\9'*S>0+<"B.:S`8[&#++*S>VF%>ZG"`"[@`#^P`U,1'!8'!#2P+:W18J/"
M&@;S9(;P9,(G`C2P95UV"3`'`O\P`8(4`0J#`3?``P8P`AHP`4/`!+)`!3RP
M/E*``GIH`AA@`J4#*UM5`Z8C'N]C`A+P!/-0/^ND,G[B@3\`@6*P_SLH4S(L
MDXP=N`T*$A7!,0_#8"T'-"*:%H[DD`0C4`6&5G<RD#1NUR0ID`(QN$(K=`0^
MHC,)H1`X4H,XF(_Z&#4Z:#5B,7@XL6M`*!0#"28Y`8DJ0`0QX`%I,%-7A%-M
M80-J9``V$`"34@#:`01@`"@>X";;D#8)"1AWL01%(&Z6(FYQ00%%<`4%8#AL
M,Q>QMVX.L`$KP$JE`AM`-AM1Y8DW@`NZ<@,H\`+2473%4WZ_\BNG$AF98!NV
MT0JRPTJ6,2RG@I,7P`+E0``J\`-*!C=7(!U/QCK%`QFD<@(-@!PB8!JJ0UHD
MX#W>PAI@R0-8<`"]]RW&AU@L$``L,`1R$/\!L)`%)%`%3&`ZFR0"%E!FI'AT
MCK4"-;"8-W`!!2!-]<!`#:1XY[`.QO`$8+``8I`&OP-UUJ).Q"`,'>B-&>@-
M`E1.9A>.XC@<4Y`QYR@00@,1LOF.09,CV#4D.E,0!-%"^]B;OEDENM8U9@)?
M@D=#=[!K7K(U`1EL`O!19.`!'L!?@9$HE<("A=$\%EDX%AD$T>@!7O`+V$<&
M'Y4!DW(I.V4$A9,I*%D$`5`HB]-&$PEB!K`!&J`]IF`JI6(Y3G``=]63GZ4!
MIJ&'R21\&L`MA?0KN*,]EK,)\($;KB`93L`:)G8JKX$9'<`!8(`#8<"0V3`#
M39`!*/!O'8<<WO?_'I-Q5\JD.L]A9[,R2_S9.55P!!4@`B^0?'K%9@/0!`50
M!!'``R``!52@&I_3`;K0`3(F(+C`E["2.ES5I":`!6(0#'*20#-SC>T```+`
M>`<B-],27%O'C;_A@>'@C`+41`Y3#"6S(I0FCM9"!AP@!4>@!-[5=D)2$>Y8
MFPO1).BHFRK((PSQ@D/@`E#RFX1:J%E"0[?F)[AV-;:6G%!$%(I'10OI`5VP
M-S80%XI"`;%W1."&!$T``UX0G42@`I0D4FF!;=QV81E`GH33!"49%W5Q4T6P
M844U%Q^&`L12*I%1*KO!`!/@BWFHAZ$C,)XU"]UR`.V2+:DB+(9X+(D$_WVV
ML7NMXSJLP7PN0`5I$!P_$`/9``!5Q0#-AQS_-BM?A1RWE#JF\S[\MG*K0W`6
MT#DT4`+!LBL6L#HB<`2%80--8``5$"`ZD`4KT!QW!@4OH"W'`RO#Q)>VLIB+
MF3H7``,D$B(KPG7B\`-8FJ5I$%+#U4`0]`X;P@[G)`[I\(QRTJ76`IDC.PR9
M!C,=\@-+$*-0((]TVD]&\D&CUEUR2EWPJ&K9Q4^\::A`&[0ET:B)*G@`Z6N.
M.E\[(%)BL`"-5U,%@`27"CEI:*M;I%--$``&-H70"08JX`,!X!9+H!?*QGIW
M<059@48&X$:+0P%IN+8@E@`&\`('<'NXIZ"4`?^'S=$!&J`!;:`!JI,K758"
M1NH]_%D\[V(J9R568^4>E/!(3(49AF0)#\"M80,`'B``"<`M3<HM4J9T?H68
MG]A[R:>BJU.O&A`!2E`\X]$M'5`%'S![(6`$<1`Z@JLPL^0"G\,:@(0\`>@9
M`MAEI>,"'/`+O34/'UBQT20`S.NT:;"1*].Q*`,6V%B-WR`.')L-)VL,`C2Q
M,L.RO]$#*O"F\U1"1(-=0<-/>=IJ=3>S"?&^'#"##8&/0EN_04NTB>=Y\'6T
M6]*#C[H4.-"\'B`&T9EL/`5[A@$!<,MA+&`ID/(71!#!7I`#.#6&2#1@HS=Z
M!7`%36"=I;1N<R&WY0+_`;.W1B^P>WA+1[IW`#`66AIP`7]+<KGR<3!GKACP
M;QB0>XN;<)M05NL"N?5&H4]U`2*0:-BP`$@``6OY/J@C*UNV5U`62"GW`(5+
M'<:JHMZC'"FG!"OP`+\J`A?P<QN0`)*S!%#`!,SQ'*IC`O]F`AK08A=0`C=0
M+PC;6'D&&LKDF)$IF6H:34\``).T`!FKL6(W3KVS=:2ILL3@:.O0`S^`(@ET
M=B_2R#\@!)\FIRX8!YJLR;FILRUH=ZK6=A31LR44)#]KOZA,J`%YG'8C)CZQ
MJ/O[O_+%J*VL:XH7#)K9>%44&%-K&)S"ALVC&(,3`'\1>3X0!!E@1&5D*5NA
M_QTM23A(D&Z&L0'ELK:<`@&'42X\8&_3%\2N,RLN@`LEH"N`RV^H6`/307`"
MBP&R\50^EG"UH0F:H`4&XSKUEGM$[(@[D`,<P"M0$);,@3#F5V:@D4Q'Q[IO
M/!ZFP3JC,`MY:`&RL@(7H`,?H,`V,#A+D(M:<%?"9QD'X'TD``4Z4`(8(#I*
MBL?">W01P`)3:H&*3$&7^<<<Q;P"P%%)0`#5N++9H`U=NHQB"FDPHT`4I"(=
MB`,YX)I'8((S.[/\Y&JGMLE`L[[7Y6H!Q4*#FLI8W9NK/!0W!%.P["7\BR;^
M6S7`]H`T[9T3'``VX&ZE-'M4*U1#Y:E3D&W:H<%9H?]3-U4X=T$X>R$$:L0I
M2B(!%W$1$K`D`Q"7]I9[06P!X_$9HJ4!J`.@R]28O0(L+X:4817/IL"4[K$N
M#TIO:>4ZKW$9%:`:2B``1A`!)!J8X'HJSJ%QRB&,B#F\Q=.8I$-RWH,<4;8"
M4,`14L`$&J%&*IFU30`%)9`>K-%[J3)^#8`!)1<!J0$K?-E8GP$:U3T"3U!<
M4AJ.W(LV-#W3S!LQ%`@SU/(Q(/,R(T.QND74*_O2UZ@",A"G)NB"Y\O)1-)J
M.()/Z$N;]5@0\DNGIUP27-`&65W@ZD4F%/6H_FBTLBQ?M[8U=W,VF-M?&:!A
M(NS6'!8"D#.[C;$$[9D!,'#_%WR1%SLE1A/6%T9TS1*0$1D!!RXN`85]!*,R
M;QY=;YLC`J7SPL.$*Z4#9:+CQ=_3&C6NG[;!H$W)E*A`1X*85N!*2[]Z`2/@
M`$U6/"[0!B\`+-/Q;RIZKET&*S50.J:!XRXP';`R9:-0/%.5`"H68AO01D*@
MH]B&`I]C50_P`KRB,"[0QG.NNY\AW=5=W</$`]U4#PC(0$WDW<P+!HC^O-G8
M,M$D-]MW(B'",E!G#E\'=>@-LF5W#\&Q`".0,76WR9KL@@MQOCI00NJ[$'<*
MO_>-Z@OQ@@%.$EUPU09>ZS&$X#6DX%_]$Q<5!ES=U?^(-=B`(E@J!A`VJVVT
M1B3,_X84X``*H!B%D[6(,@58A$06R5.72@&)`3@#4-@?\.TM#@<M+@%Q()9-
M)94F!ANL^``D<`&I6RNQLF6E$RNK0*%(J3V*%*W.%\_[F>[+6J&2"QO@"GZX
M<I9)UXJ[TBMW99929GP6@'1-5@BB\<1I['&Y\%E90)$BI@!&\`8.QF2HLU<*
MDQI=%;@!@SK2[>=XW.>PX@4I>YGM$)G!0!4T3Q4S/=/E,%S9K0X:LH$^+46,
MC`\NP\<3F#)@L`%8(*>NKM_8)>JB+B10'_7X?>JMUG:Q/A*S;NM:?^N&)];!
MOC4\Z'F_AN!!<7A`L0U/4,`DJ>'J9GEP:ZM_TQ>M.BEML?\$-V4H9^1N'I8`
MS6X`*_[M*;0!*T[-!@!'_#DLNBJ'+?!O[0/#*(`\"B,@CF4"=N:KE,$:P>+1
MM,&4B50LGWU(BTC:M%2W#/!BW7(\Q*,<'<`#3V8K`</&E>'.K>09)^]EXF'P
MHA'.`>N+_M(&*`"3Y=($04`$!:"'8[X<_Y9T$8#.M)*PHSC%L"(@%R!:M1($
MV?W'51$/4FJF:*/H-._]?]Q-V@!H91HV<Z,-V*N-('/>[N0R,)V!4J0"0R`%
MAC;?I*[40Z#43#^#^`T('((<,C*#A(6"AB,R0SHR$2=_DY25DUV2EIJ;G)V>
MGZ"AHJ.DI::GIPBJJZP(802P!*W_8:^QL+5AK;JS!+2LLJH[,P)$,&](12$#
M!@/+"LS-S2Q%2$T!!049!5=32TW=0A0.R\X&"0,*<!L?[!\;<!(;&S(B#!5.
M#`<'#0WZ_`<,+%0P4>*%A@@F:M1P\8#$@Q40)UB8@*%"A0D2_35HX<2)EH\<
M.SIIT4\?@WP`!5:P=_(`QP,83(B0"`*$1(D6VC`A(8?$B@XK;&*<4&'BC0</
M.KB(\"`AQ!4F9()P<0,$!A`MBEZ04(2%`0I""@098,*%4A,@1%QU(:)&E8`K
M:IAX$,%LA`@=.M#5^^!"T@<QD@C^D>2)X,.#!3\!``8,``"+'T-^+&!&E!DS
M?OR8`2")_V5847;LZ)%Y,PX<.U"GQEQ:\^89IW&PGHWY=`_11)1(47+DR)#?
M<73\;O3[D8Y'B63$,30HT2$.QPDI"L[A029/F%!IW\Z]N_?OX$'M8E4+EJI<
MKFBI[X7@UOCWM("IDC\CC9@8,`HL$:+LF8'_SPQP3@(V&.'-%0%DD$$`W'BS
M1!$4"&C`,PI`0"$<[K0C#QP02`"!"?ULI,^(_/Q3%`@/:$!"!"*8<(,(*RS5
ME(L3@&`"3A@QT(]('FG1D8\=D30B0">=9%%+2$X@TPHBS&2C!1/5]-,+<IB@
M%U10H9763TA1U5=4)D#4XHTQVG1##6E1L8$"RH0@Q!5-O+`"4O\UY"4E"!:(
M$$$+%KB`%EUVX:477G0A%0$/"QCFV0]/-*HH8HTRYAADD4T&P`(`S$":9C,\
M\0-J482V6FFPQ7:;;+1Q6BIMK*%J&PXY5($%;[X%%P=PR@$71W"%&"*##AR,
MT!QSA^BP7+$RC&`=*)BXX08=X44K[;345BN*+G>0%PMZW*KG;7OLO;=+>;&L
M0H``9!"10P9O3!$..@K$&R\S#E!`08%+>&--`$@8V$TRRYS#3(7/0-".AO)4
M>,$!%32`$I$,D%02`QA$H`$--)`)40=XU0#C3!@)!&4%+C'PT4=6`/F1$R&V
M(+$^1PYID@4VVH15`Q+=<]($*US%`PW_2H)YIDPPFL5Q5!%<`')4$*&E4%H/
MU"2"%$:\$4("(311P`851$`%#6:AF9:2#V#00ELQWF6TC'O]1=<1`H!!&&2N
M:09I9(U!5IADC:8A`*:GL>:9IJ.-AAEAKV'6@VRCF>HJJ[2=9MII,&21!12]
M#1'<;X[\NBOGCTCW:[#"(G)(K\XIDNRRG]#AK!M?6"O[[+377LIXZ]V2K2OD
MD8O[';OO3IXK!("ZPRTSD!%$#NN^T801%$`@/3P5?F4#"R'80$T3110A1!%&
M=,]?"!$J@(Z%Y2BPP0@I(&PP"ONT,.))(0G)@!,6F(`Q"G[*E1<*+%K(3.R!
M@2*A9",\`I(3_U+6D1`-J0(8L`!`]N&PBX@@+1<,V4HN,I0:B<`@((@1EM`"
MH[P\)"X+Z<"8:@(FM#`M`A.X@0ED$``C<"`!16@"#%"@A0@PH7\VF<D%7T"%
M`YPI1BYP08S:AI2]$&H`G6%4HQ"3A+E)!@P"H)2G&/48O/W-,Z29#0YN0RHR
M)LXVC=.,JV(3F\P<KE2RB0T2Y%`%)4"!-\`YSN=\H[EC<8!7JF-.Z$90NN2@
M;@0?8)WM%LG(1CIR$[C[%GQ\-R[A\6YXKY!-$L``FQX(H`M!\$$.\G,%)(1@
M0O&`@_D<P`(AL*"5W;N>$&Q`2^R1+QK-F)"\I&>P]LEC`Q;Z`!,.H/^%`SA!
M(ST24@6D%`$4H*`#5@)*!TAP@1LHI09$*5)1\J$C!?)()!(KR<0L$$$*ZB-*
M4;E@38;"@`G`$`,3@!$(+L"#&O3%1C4("@@T8!6YK,":>($1"8GF/STI;0(=
M&($#D/"!!`C!>1.P0@5$`"4G73`H+KK*`ZI`!:K<@"E,:>)>;N`"#@#!,%I\
MU!0KU1A'%::*E.(;%F<@C%)MYC:;(ES@/B4:P^'@!YTQS&94!9O(L1$'2:``
M$^0@A3OR47-YY!7J4'<ZTPFB=,]1!"(5^<BN>O6KT8ID+N+3"_2L(CYHE>0E
MNX5)`@@#`&(00!87`(10-F\*$!J`!-BAR@3_4(`%M!2"8*]W/>R)(QKRTB4$
M-B`!=<B#';]<!QQX0#(A[:-'Q[2`/8Z"$;\`94Y-N8$&E$(3DJTD(!+DQP*_
M^4TAB<@D12FG9O6!P3&ILT4S,4O#*A`7$'2@"@P)K0PITH&)=$`N#+D`0L34
MI!HQR9HO>$`\E?`,%J1``128`@=.8`7Y.2$F+/S)3`Y`S@XPX0)*X1A3_-)$
MD$HA"'0KC*/F&ZDKQG0P4I2OH[)8JML(!@<$B`*J;B.:VHAF<;093&84'+A6
M'14``\@"%II*JZ=JKA%235WJ"#'(K`ZB=%N]#EA'3.(2AV*29"WK+%Z15O7H
M@JUG)5YHGK"`&'A!_P5DB`$11%F`*2"!!0XPP#H^``=S."`$@/4>86T0@A",
M(WV\G%X*',N.%+R#L>^0@H[^D8\6@"0@&&`81BRBI84@I44KB,"+1'#:B@0D
M?CX*B4=&\J.1D,1E$".@:8L23Z*E129,:U(')F!,!KQ0"BZRYG&M`J7\H5<$
M>E%NF*"207(B]`$TB("-I"`!#LQ#`=I[@!5.H`4K'(`J4G,1""`H$:?\)"^1
M;B]>:)"!!0@@"5VDKZ,`D$7)W!<S+SW,8A:3AB<0>`?_A05I5#,:!-=&<I89
ME6Q<LZI6]>#:LEF`#'C05*=F#G0RX..NB&550O:*D(=`]U6%%6(3N_O=\/]&
ML;?F?59;E%4^]3Z/+^83*E$E@:XJ4`$0@`!*8TS!"#:(4"HA\)\!U,L&_7HE
M]APPCO_HLK%P4.5BK_Q8=T@@!?$8@@DLVTYB:B$K((C?1/@<)20^P$\,4>>1
M9BM!EXVD`3XZ&3C]P9$6L&1$$B12GS%(S@LN*9U!9\!%20#<XW9`ALT-LV]5
M")6D-$DJ&!'*RR_@`A#0(%GNV,``D!``$7"W!::&.D0\9NDF,2E,2<P+2/?2
M@0N$P`./V9NO]RZI+.JZBHC#=:0:]3?+"%@S/8A"@(\G*@(O;HS29J.T6<73
M9<]@`2.0`U.=RKDC((<XN@K=<[!*.@\;(@6$9`?_5^'-^M8W<EQFG;<DO;6M
M;?W"WF6EQ6C<.@,PU-@#=AAX77O<A/$E(!T>BI>`[K4$)-#R>A0XAS,ZA'$.
M8;SCD'6'.FXP$IEMI(+W:T">;`:"=B;D+@VYH*9A-($&0#`?#7,91TXN?W"6
M9$@/.R?#H!3/)F4P:"QD$Q*4#R?0?SQ!%R!P`T\Q$Q(40R\23W1Q=?\W$RM0
M32CP`%G``59F(3@4``'@`J36`B?0`#"23Q"Q:C420OFD$&9!%W?!%$OA`G'0
M!6"`:WK'=WOG=_.%7\*&4HN!10!P&XAS/*^P`Z\0*CT51CCE8)!W8`TF1@@F
M&V(@`U1`!136&]_&.5J(_QP>1GKJ1DA?^`&IET@GP`5=<(9HF(9J>(:NUX9N
M>`K``SQG%7NRMV_<4GNA8E;@$F"X%P910$8`8`<X%G`J$`/#YV/0EP`&P$OS
MD@"L9`1&(%BVY&325R'5-SW8EWV=!C_\8`_&1'_Z\&5C9B,W`141T`8:\`!Z
ML@(6L6KN-P$ZXA)VMC)!TG/W!S$4U`\!T4Y9)X$@4`-JID1H$3/YH`5!<P%0
M\`!5<75:DG4W($,AI%Q75Q,VTQ91HQ<8,@(60@%+$`!OH``'0&HI,U$NDB56
MP3/Q%!<0L11^\8*P=@$!L`!@L!@W.!DZ&!GWV"AU\U(KY6NWQBB>$05C%07$
M`_\+/15'TT93/96$C7-4FA)&4J@#5%`%4$!A2H!'6JB%Y#9Z8`B&Z\8^A-0^
MJ;<!%W`"<-`&*)F2*KF2*/F&+OF2GO!B>BA[*W8>M^!68P0,!-`#20!@HA$?
MHH%4"^`!`6<'.M8%=D`&=94#->1*$:)8RE<OV&,#_&$OM20.BE@AC+AQ';<A
M!L`!'8`/_$`2#>0R]\=G2H(F\#1^<X(F+%(C1`$0[Z=:/W(R"G1R`-$/)*,/
M9@ET\42-35(SO>5!(F,1Y_2+-4`"1T`7'A.8-F(E262">N$G8%(3!5032@$"
M$2`/$#`.85$`%!!1)W`"?*(D3U&-S21#+90T[1A2')/_`'ZS:WNW&%FT-T^`
M18*A10H6;"^E10*0!@IV/."2'@9Y8(^'*D7%*@C)1E%X&A"6!9O'&Q?Y5,*Q
M*[OB85D5DNC&;BF`>F#8/BFP>C`YGN1Y+;VS8GJH+0.I>&Z%:SB0"U'P`P+P
M`XHG&KQW&D_@`3$0`_H92CY`!#%0B$20`4C`'Q6G2_]Q9$C69"P@#G]E2Q47
M+U'66!P'3!(0#QH@(B4REN$T(A!D,PO1=<L4)DVA)T(A$`84/R)AEZTE,_+C
M#Q"3@AZ$%A@P@=1X%4*1(P=@(VT@!4=S08'Y$W613VC!$!$@%S0:%1A1@1K@
M`DJP#$=F`TM0``Y@`AXQFCL:_T)B`FAS0@))I$1+=`'LI38=,`1$D`9:Q#?U
MY6N1(C>Z61B;P8/Z%2F)XD8[H'@":9/-=FT$]H2$@1AOQ(1!&1M30$=7B(5#
MX!O",57I]AS,P3[>.0B1&BQBR`&14)Z8FJDQ>9Z]DYYGQ9ZB<J<[\$6,MQ@T
M]5.)5U/R*08!5V-$$`1!0`1D$'P^4`"1Z`#G,"_-X%<.2G%-1@$+BI7+,"$3
MZE@;PB$C`#]6T``WQZ$O*B(3@5!H<1!I(25ADTX8`$\KP7/?9)=`(C%F>98H
M80_16JTGFJ-#48U-PB?D5P)5\'3Z)!4?!:80H6C".(PM0A$,40,:8"$<(@1&
M@%=(`?\"6L!=?UF9S[B.))47=M%$[;@4&A``<154%+MWN#:/N$:QBO$H?]JQ
M]=4HMF8:QR8+Q?-L8\2GAM,:FN$IK($X104JL;$#/B`%67"HF7,$RQ$'5755
MJ(>='0EB'9D"B'"IFEJT1HN>G8H[]AD:H($#6/0$-,4HMH%KL)$$<F5KAI$&
M-68,!>`#,:"4/I`![B(@0>9P]@*LT2=]1P:L$R<P`%*L&W*A\*`!)K<1-A>N
M&]H`?^:E'[,"_5="'K-.$M$28\E:*WIR)6*+(<)-)P%/%*$D0I&MY`=/+8)!
M0D&-,H$"[SII',,DZHAF=<*P:4%2-[HE((`"*<`#)<`,0@#_`TM0`WYA!1(5
M%;45-+A5%G72@NQE*'>Q`2H@5XJ2:SBX=U*T8%64&("WL;OF>U![&J)ZIYT"
MM=8F&]BV1FTT;:\1LZD1&S,;G5C(1\;!J%=5J:?C'"'Y8>SS`8@`"2)FM.X[
MGD@K+KF0+6YUIZ$"&C,@>)O1&'#*&<`)<&+`23M`8T"0`]@0!%T0H#$0!#`@
M!`-@+P*B/;1$<4]FMK^*J[GTMM.3<>H`#Q8B!<3THBIZ<R[1#RZC)$=3K3_Q
M=E:BI&.VK134(RSJ$2DC?Y;U6N?$?S@"3Y8Y9C0C-?ZGK@G1)#0@!909`0Y!
MKRN81"2%%#6RKR)@3?VS`B_P`2;`_P17H"8&/%HHT`(8\!1^9JXX*A,+R[LN
M^`!4D`,>@"G!VT4X2)N\YE*,XAKX93>&(9N7L@":8CQ!>4;'R9S.6SBIX6S:
MVVQC]`0%,)%0@#G?VQO+82S622SL@YVC)QW!TIV63+3ON\DO*2[C4K_(>;^Q
M$!K&>[&=`1OY28AB@"F8(0#ZR913D`$(3'!A"SU-1G%3RB^WO*N.:"\8G,$%
M`P_O<*&,M5=48`$-1"*V.#,1PP`)F$]_UA9=5Q:T2U%00B2%6VHI@S(*Y%KR
M8Y@L$1#I.LZ62Q06A%M`+$\LU"0HH`0*^&KY9#1UP3']`[L8\3%7D4]HE@54
M``(O,``\H/\`19`#":`$6)`T_I?08W(C'O1/?.&"L(8"2+``6-O&PSL9CN$8
M\L4HP%9%AR-4>,QK?F-@!PF%CP='#6:]8K20@XP#0?`!$]E4C9PYOZ*1E$PZ
MZI:=S3$('="^G/S3K.?)K)`M1]@IN,F>O0`:H1%&7713^0D$_!EP8L`87K`\
M,#`%5\`\/A"K5_UC#&H#`3!*4T!+N"0@O`S,N\3!O+2(67``LNM:SEH25R%!
M%W$CZA05<A%";`&7$`3#]>>MM"C",+I-+'$1U$A^&"03-T$TC/T47YHE3:(!
M<0`59E'9'),7"Z&`8W,!5E&CYYB"4_$""`$%+"`#"<`!``L!J:C_BF$"I&`"
M%>VDUP_M@GA!`A3PNP)`7Q<]FWIC&)V"&9!Q.`#)&2FU7S^P.$[(1DR(TL*=
M.('*;`<F#`$`!7)@A8O<R'FDD;WR"%CUL^5;>L9"+"`(U.3=>D+=J9?!&(G"
MGBD&&@7VIU4D`(8(!.KB`T#@!;7Z!MQ@#3"0`3#PGU=M!$WF)MU8``'0!+><
M`-(WK`J>2Q)J(>ISH=)3(550`2#AS69I63D3K4H"I(*F%,-%,^140+%H<X"M
M0+=HMQ-$)'FBV!$T%$%,,P(57DPBS4GTVB+P`'%P051AI%^J@/H<F"K$P^FZ
M)2Y``JF8`F]0!`H@!4,P`G`P:%R::E!Q_P,H,*(`14V\6W=PX`6VYAAKJJ:5
MXFL9>YN;L44OE;]VHU_"]AA^8SS+MI#(B1IM5&VU$3DL_8<X$`!20`5,)06[
M\;W"X0C:'=[D!I(YG57*X4=@Z=/E_>A?I0J6)#QA<`<SV0.\1I1ZG*=[:`L%
M]H,>0-^ONB#_#0/%)P1(L`18?04(`@/KT@0VX`#:XR]-$'&'-:S,P`QN*R\4
M$F7/(`43@+@'='/ARC`5$25$X;>_B!8@CA&.BR<"4<*JI7-U9C]X]C#C:FF"
M>Q5`FG4V0FEC$A1*DD1/@26_"`59EQ!K0Z0D!16CJQ;4.!%!H1>P&P%5L`$!
MX`-*(`=#4`@U0/].2BKC_S0G);`D?+&[>.$"*!`$?],9#@_F+A7'>E/F^'CF
M*WN\R1MX_8A%"Y`$]MM3_;;4BC.HR+DJ9P0;HHJ$`C8%5,`$$SEAWI:1_<X!
M,Z_H&O@!WLENR;*^Q4$LF@SI0.]5,AECM$"0=T``22`&!9P#0>`!/V"$?HC4
M18@#RO.J/@`#,!!*[:(-SM=D`)OJ!2H$^I(,K`0^2.!CD=B@BJA+YK.KN#XO
M#\XA$'`$()#,%!2NQ0XEW'X3-?$T4\&``0'MI^42<G8R#,2L\M-E[K>71R+.
M6==!ZZ2NS,4T"K@42L'$"G$C-4`#_!>B7VJ")$6DK0W:4&(3?E*""N#_`$N0
M`W!P!(5`!22!`7YA3'U6%AMS?B+E1"3@`+^)*861VQDK4[=6*8,7&18/D"X;
M>(31CX]A:S2%A,?6.)TTJ'_LA*-2*GD^`XG,!%D@*]V&D3;-Z-GID82`5;\R
MZ(5P'.P;].S?57-8+@@@AV&0&KD-`"IP]=H``UX`G/4)"%$$80@(43-`.3`P
M&1D%&3DY!4M(1BP4#@XA+$(V+`D.144L(104(39%2%-(G2$.`P8&"@JR`[>Q
MLK2T$+T0!B,K5EI:#`<-+4XM#<PMRPT,&!83)BL3%B+4$2L@$]83W=T5#0?E
MS$Y6P\1:3NWM+0<,S`<5#/`5%OD8$_S=T^#A_T!4&PA"A`@3)D2LZ/"@@XL.
M'6JLJ-'M`I5K(%QHW'A#XHH5-U:X6&&P(`@0TK*!,X'A@8X1(:9\B),BV`DM
M!PX>L'*`VD>$'QD^&#J480<.,00H!?#D"0`P`))`!4`5@("G3)\D2=*TZXP?
M7+?^^#H6;)(?8+5R;0H@S0(`.Z)$Z8$#1X\=.^K:O8N7;E^^>'?0O3M7;]T>
M27)4>4&E"A8I4"(?.3*D<F49F#-SV,R9PX@1G5]RUA&G<AP.,H;HX!#AQ)_7
ML&/+GDV[MNW;N'/KWLV[M^_?P(/'+A2&@"`"A1`4GP%`!1`808+X4!2@0(X@
M0!;@.$[`^`\/06!,:?]R94H1(U/27VDR"I,#4YM>Q7+O(,&K$$)6&?%$(<$`
M7@HD,(LLMOSG2R^SZ#`!.U98@,$!RCC###+.M,#`!!445-($&-00@4(G32#"
M/B`T,`XYSAR3CA/K$*-,.<?`&&,\^_!C(TH5@',04$"1=))!!D4PDD8BB5#0
M-1$H09$('3WD0@TW=(30#04A9)`)()`DXI41D$!#%5(8(,0`#GQ0@A,G\%3!
M`0[ZM&,U-0P5P9QS,B1%4E9EY9134&GEU%-;:?5#4UN=-=83S`DZPZ)C<846
MH6$E894`3^`05V!Q18&I8'SIM>@,>_U@:0]D?3K#5@*HT`05+V3Q6&10*$'_
MF65QZ("9#K9F)D-GFV&&&@>GR:"#9:L)F\(&#[@FW++,-NOLL]!&ZULAQ@E"
MG'$[-#==)-?EX(AUUR4%ZJD`D%%``$@LT<EY-GB2BBN8A%`*!:34YQ\HN)#)
MB2I%U&>O`;_\9\`MLRAPH"ZUR`#",!,:<TR%#6A!(3W[W"!"!PB9X,U)6*)$
M#S_U,+!F.Q&W:$6$Y)B33#SE5.`R/S7R8T$+/('#S8\K)'2ED0().5%(&V*P
MP@4<B""1T1I!F31"(QF9<4A8EG20''!(!H$#-@BAP4XGG%#.A?M$\``(%72P
M0@0=B(TVV@^X\`(,2H'1)U5_.L5555%1]0/=DDJZ_V@/3Z`E.%IB?66H6DV!
MX50:,P`VV*9XU05J7I(;+NJGD@[.'*4+0,`#%5F`"1EEI<T:QZZXIK[K9Z!Q
MIJNPI`UQQ.F>L=Z:M+CGKOONO#NK7'>#)&?<#`+X`,-TC#120!,!9`!##D0D
M)88'SF4@A!";G&)#*>^API\#+(0O;P+^X0)*?0.`XGTG[\%","VV(&QP+_`K
MP`$(:3K1#(45+@./,0R81D844HTC(<0"W:!'/M8T#P@IHT5:.)F$9,0,D=4#
M'_CH!@:D80$&>!`#5?))SJR4$`PQ@T/8\%&(&"""-L3!&SD#B4@@LHT>Z<QH
M-=B11DSP`!D8X`-#6)T0EO^@A(AUS0KUJ,8$:J"!&G3L!G22TU`T@@2J""`-
M6:$;W:8R%:90I5!_\EM9R$*X1R5A46(9%-Z>`(:W;$<PD#.,Y"P%*APP"BV,
M*I2A)"6`).`E"%A@0F,@HX1"3H8RN(I#K7#EJ]JUKE>OB]T0.'"LFJ#F=KW+
MI"8WR4EHW2$,Q0%E(>Y@"!P`P`.*4,2WWA"`*3SB>$0@0A!4.04CS.L6H"`?
M^>A%"NWUD@+Y,A_ZTG<*>=$G%@0;F/QFX0N`*6`#(DC',AZ6C'=4Z&LBXX<)
MF@8BC=U@'UC*40</\`QGN`."$KRFC.+AL@KLXQ\H["`".782&;X)2QUL@19H
M=H+_%IA@&]E`8`>4\,*/?,0%(?G91&*8LX(X$2$A8H(L4+,!#GP@`4C@`0.T
MT+46?-,"U>@`#[9!@@?P\`(/J!.4,`:!!;Q%*5VI"ENXJ,6N!.J+`##<J00U
M*,.=Q:?DPMND_*BIP-#%5(VCRQPQA0.PF(5P:*3*#*)@QR50@0IR>%6L"FF:
MTJB&D9QA76=NQ4AAU<JB&T@!!W#5`65U\JUPC:M<_W`'X!%">#WXP0)BD`@?
M^)41RWO>=8`0`R*\H0G[,87[\I4`4ZBO%)QX!?KZDPOS"0P4F-`E^6ZA@'PM
M<W[TDT`'2!8C9"`C0M=<1@#!48,GX0Q#';"`"U"RP37)_T-E[8!@!%$[30\>
MPT06R%$WHM$-F?6#&@IQ0=2`D@T,N`R!%CC&A?J1I0C(X`@B&)(+T*81B*0M
M(B#!$D2MM((V;*"S'Y#`,PW`@BI,@)]>ZX>1+D`#&BB`"0[1B)R^&X$J$*$M
M"[A*3.D6QKK9K6]LR1L:$Q6X08W%<I9+RQ.N$A6ES*`XE+,C4@53N<:9:E![
MW$H/\GJJ&>!E!FE(`1-"]QA9Q4IVDSF=ZL+ZF;&21I&HT4R-4:.#ML[UQT`.
M<K1`28@PD)(`.Q``&:(#!"(TF0C).UZ3@Q`]#_B@`$60SW\4((&`I2\3[PE?
M^!2;2UP,+'T$2Y\ND4F@,[^/?O^U,)@L(`"'!UCAM$X@9V[7X3\8!;`;(.D`
ME;)T$N7&+!_2Q>TZW)%;B*US30K4QS5(A"'J5DDA.[.2D3"R$I0LD2+@B,`'
MLE"-*-T@OR:(4D-\]"81(30C5=!!15.`K^V]-QE=<X)P5X`"*D"A"`JXP';K
MQ-V14"$#`;XBA>4FMS_IB2UJN9M-#=54M@1JCV,$"Z/VM#<^-BY3D9/CY"+W
MJ;)HA5$?OEL2ZK*#&>1`"CR0`YA@9<A9!9%VG7EDCJ][8UMY)@4?^,"^?2SD
M@AO\X+@A<B@)@(,GJ(`(?NU"]+Q`A$@$P0MV4`'%?4"$AV<`"3:@;"S@9PM=
MOH>7W-O_;#*#Z>9<*)-`R9Q?E^D'@0U`(`5VMD+_(&9.TGHP@`X2P9PT$H'C
M^B,>&#)&RO"\:$8_HX&/MI&-.&A<@`@D(5CW2$-%Q.H>&4FY(KB``DIPD(6*
M!"%0:H,&S*8AJ6&)&MM%`1,VL(%99$($%6C'3:+;@`Z\``5#8X)"4"KHASC$
M!"BX0AJ4LO@L4@6+,NV*5I@B*<D3"H]FN>,,>%KN,Q+.*7M+W+HSQ1UL*34P
M&OY!N\,RQLZWD52!F4$1F,"#*CB&D/6N#%AY-5;,'"%VJQE!P`.>XS@0'.'(
M3W[!%7XI24TO!EWPPI1SX(.+>V`!*N`K=AX.@P`L(>3#+%@M_\RWRWEAPLPM
M3R:!:M'F-O/"%_,;_P<>L$]E3$@9[MAY/#PHP`@(NP8,<1(@\`\8D$W1]5O-
ML&<N4DTLLTXPDB-2QR$P,X#_@#/B=1`UX$1NQPT%-%P-@`$WH%\)\"'5$&@(
M%0$W8`(O$`'5P#,"&"(`(1(HH':?<00?P`,N@`%HT@`6X`0N,`14(#8K$%QJ
M\R0B<8(VH`*+MWARXT56)`!387F1$B@QY7F"8X6$8R@/IFV#`P![XT5@8&)R
MD2G=450CUBF?DA=X9&)V%#B&(P8+T&Z5LP`R\`*"E%60L563<1G"TDB]`DG\
MIDBK\P$UT3J5<7S*EXB*R$F?!$I(EO\7H#)A=@`$5&8\!8`=,:`"=L!7G.@!
M,1`$&?`&MF0O(T<_Z9=+[R$@9A9,Z@<_6^9^!B,!719GM+`!$G`F.&%:*-(`
MZ,`PQZ`_#E,!1M,&#Z`0:*,0UY`0+.-!$^(_+**`J-6`,)(RJR5I^6!UP45=
M&4-`9?>"(X2,]U<!$J$1*!`"&-@1#Z`!8D,"5))0.>2"`J@CU%`"3M0!%84"
M'!`9$8`.![`//("#$=`&%&$"WH50/],!'P`$;N%24+$4%`:%4;@6=B,XDM<W
M$79M3G6%FM>%DA(5$_8#/3"&(\9A=Z$7);DH=J%A=M%N9,05*B``IV='./`&
M3$`#=YB'>CC_&8GD;Y"T;]<EB+M2.[_"`8?H5HMXE$B).X8P",4Q/&WAB:#H
M+8\`/9EH!YZH`GOE'-*1`;9T+P`#`;2`?@.3"2HW,&O&BLOD<NYW(.\'!Q+`
M!`<@,?(P(<U03?:'#$#'`%G":Q9#D-Q@)`@T`?3P<_/`BXR66Z3E@,:09Q1S
M#?-47"$B:5=G$-S04`(1#MMH)&O200IQA%60``H1)4S$&.KH`@K16C5T$)C6
M#=L$`@_0!MV``E5`!300!R,@`5(P`=#@3A=@-`VA,=L%$1+16C4@!3FP`&FP
M>!3V%,NF.'@#%I0'1I*'>5YH%JR7A7CT4UNH1V>1!)1B8I>2DJ!R_P@H>1A]
ML9)'94=I814Q\`0LB9X",``\8).V=WN%=)^D,RQ!^2O#(DE[N#J@D1FV@DE)
M6:`&NBQ+>5<$D`16!@G&(PD%\$H^X`5B`(6>2(G1$1T!@#W_<C`%@DOE4S`@
MRHJYL`OMAS"]((OJ]4SJI00[\3]T22%.ES(Y@G<:8P)K=Q`8(R(8,H`!!&G-
M2`P]QR+LT%LNTS+1Y3(UDHT1Z)@O.)E.LUP[4Q`WDPWTM!%0H``F`"4IZ)HE
M8'@CE&HY4Q*621(F<`%48@)9(`-2H`$T,`0*P`(T(#+YD$,+$1+5)6AA^@(%
MX%(NY9%"Y7A-T4?<*9UGT12+4IT_M4<[M?^&$69&8'05((D7<J$I=E$8G[(7
MXZ94%.D4`B`&79`$I`(J/;"@/6`N+&``<2`'\B8%N!<KI*,:/ED:BE09>Y@K
MKI,9B'B@O-JKN)&@"$``/Q`#'U<$5U``SR-8%A<#`08&*F`\U><MZ,("9#EG
M8!EG+1<_,$>BZ%<_U[H+,@<'X@H'O0`'0U`!)W"7"(AG**,_]>!<P@@":)-#
M!,D2^N`PTZAGASFC,N);\1!=U_A<X#!I$:B:/&.P5R)>8&<0&G`$*]@Q'(,V
M'&`##1$ELP4"$)%0(Q1#3Y0S5%(.5\($54`!*'``$7`$'*!1;')J1WAX1R@1
M5M(!3>"G;Q&HSF;_L]$&*5G(1HI3*%?8G66TG8*3J((2%HH#GH(PAG%QADIE
M*N)Y*F6!%F`PB9-#JGD1!92'8D%0!$>`55@0*[!JJXN4&;)C&67[5;W"DZQA
ME+[:MF[[&@G:'3.@`C#0!*N0`;-$9;+$<9I(*>#!<4$P"46`/6AFK227K2=J
M6>7C6>#ZK;0P<W0VK@##`1.`,M-4EWOV=#V1=#:#,91))8$I#_!@#N503<D0
M0=6$(OOW6ZH57/C@N@B4#2]C=4:R(S;#:K6;$-U@$#K``A]0!6S',_X'`0%0
MFB$()1DX)QRK7&9*7\J50P*H@AQP"RA5!5U6`CP8#SFC=0*!4"GH-'&@_P+7
M9Q6>ND;EFV!^@CC=>3B!LQ4[M;YE<4:E,K^>=WE](U6!(1?80E6`T6X/AE2F
MLD<"4$<R"7NDXBA;H0(A(`54@'NR4K:ULBNIL8>T@JMKA6\XQ[9ON\$'NI2/
M.`-65@!3<`4P0(EVL(E\Y074TT<+``1-E@--(#ZPX!^&RWXLE[AJMG)GI@L'
MHJ(2L`'D"@$J2@L<L`+]E"+3:)B+1D$@5*,'$8(=`!`BXJ,41`ZGQ0Y$^@['
M(#'U4+K`&$"15B/^<`VTRS$:<W4_8J4E(1`U(#L;H`$9$0'AL`(:X``9P`0/
M<6K>!1)`DS.SA24=(`</X`WOJ#$7,`0?$`KY./\"`\`$]F`,&)!JIEE/1_,3
M(*`!,`"'S<H43=A%D6=Y%2EAAAHICCH6ZKF%#V:%>J1%8JBT1L6T+$G`GO)A
MH.(HE<.T4)N&B9$"8'*?LK*'$2Q)9LN3MW)6QW(!&LS!RGR42PF)`!`#$!HN
M9`"%V:<"FHB58"``GN@#`1`"(.H?<G:XB+NMP31,`E.B*0H'=+?.07P@(Q`!
MPZ`_3]>,^F1_\N`P`WMUVV0V*K%IU\!`/6=.)W-.^D,A(N,P4&=;,3.P#@)"
M3ZHA$!W1)E%<$Q`!ZI@1``@G*_``(X`$*7!JS*LT"*5UE2D1(?$0+`$.%D`#
M'S``4Q``1D`!(_!"%R+_#]Y``BCP)`B%4.)5T0[@%DPX%4H!A3+5D9#R1=,6
M1HWB;%&K.9IW*O([M-9)8.N6M)3#5!J6J8"1U;>\*`+POW?1M/_[-RKPNWIH
MMEVE2&JM2,1L5JOQ`<B2S,L\U\F'`'4!%@*0"-X""41`!C'@`1X@?7Q%6!D'
M?=UG`ZMH(-B:V"=Z9F<)"P1RK2DJ`>K\`6XIBT!\(+V``E9P$_ISES&:?^0`
MR1Q2)0:5$-P@,_A0@,90(1!D31&29S_G9R[#?_3P7`L]#08!$/!(IFF\(4G7
MCP7A`@V1@0>%!1O@`!<@G&VS$#K-O#S3$6=C,3RST5#0TJO0!%,@`1'`)B/C
M_YHDT)NI!B?B50,&D!W+R9Q!':A?))&AO!:C3$;8&6%`U2A0^WEZ@K38@M4R
M*9.HI]4:1CD]I6&X'#B5<F(_H`(C0$CVQM8RX."ILWMD]6\;@,QT?>&*F`=4
MD<W/T0C4Y\*R1`1>T`78P63A<2X@=R\C]Y4X_'+M9UGKMPN^\,,V!P=P;8M@
M:8ORTP;HX-G)L',\9YA?@Q&F24`9XP\8Y-U*APP1M(`0,R'2:$&O6UL>Y$XR
M(\9K'-&Y^PT94T(PHTTB,9!00L>SDP#X!8!M$`%.5$_4W9D@,(,7NTT34)LR
M,`(!8JP%L`&""<G;Q%U0/$("(0(?\-<>4!40&3=#3?\IA))@@)J1CQ(5:N2&
M><53:>1@`"PJ6I@6A?(4($D897@I?C%B_IW5F6J>F'-&*GEBY_85F9H#L2(%
M0^!5JH$9I6$K$>Z3?5@[,K"K&-[K0C8&+G5%B>`(>@MQBN!7T$-ESQ$`B(4]
M(1KCC0V+;7;#C2O$E`W7-0?7;@F6<`8'!@"7Z2!!U@3DR$!.NRE/"[&E$3$2
MU."C/S=.YH`.+L);HXNO,=+%^"`SP25`/BI<6BXU:6S&P!TB5.H0$.&]-HD%
MM1(1V:6:K`51$Q!O=EB,,/,`%I`%J[$!`Q`"HB`!)M`3Y"2.&3@2IY:"$,L$
M/N!2:3!33TC4[*TGA:I'B-/_%*D,OT_EAJ4LW]RY-WVTDI6J*9HRDJCG*9=C
MM:).RUI]5)D#U2`)!FQ*4+9J.J81X;D".[NW&03JZUH/9,">;)^H")4X'8[0
M"(L0"3!P!47@"=SC<LBDEN(G/^SG9K`8KI5-KAL`US,GX[0`[O%<(>,>HS/B
M(!V$L2.1-@"($IKY@`A]#O&,6E#N6RF#32+S3M/0)AQR0;Q]L`<;$%6BNS<2
M#A[R`"%HT>Q(!1J@!%2@`"3P)&C'@@6$)0>PT3CH::Z9)2BK\2Q@!+^K`?D>
M\MW%#0!HIJ%F!(`M8.@[U"\?G6DT\PVF1P]&Z8MZJ$T]M"7F4^N[>#X/.9!S
M5"/&_X;?%FX`/"Y)U?UGU&ZDTE1PX*I0<$@4//6O\^"+Y&\/+@/)LO7V_V-C
M`-B`#035!P@^03XY,#`9!1D9.6\!2T5"+"$4#I0#EP8*!I@&G9D0F@H*$*2:
MFY<#F:.D$!)P&[`?$A`;'QN@K*(060=6ODY.+0TM+<#`#<@-!P?*%1,3%A,U
M'3<B*RO6#!,8%<PM!Q;,R"U:Y<#$Q,L5%0S,3@?K\=$@&`P5],_;[?`B(B8B
M$_J!&`AB6T`1!`="FS?!1(<('4Q<>_#`!90.1TI`X+'B@;\5+QZL*`C"0H-P
M%D``?,;DB!(.&P:P,#*E1(T+*2<P4+;"A(8'(*XA''F#0_\0#P(6)`$`!H"`
MI@*B`IA*=6J2)$^>_,AZ=<8/K$^2;`T[H^R,L&/%SKBZ]8=7LUZ3X$A2]L=7
MNV(7+)C18T>4'8`#"][1`X?AP'\)%^[1U[!AKS]P>.U;&(=;'#LL[U@P!$H5
M*$J.'!D21X>,(:1-RU@M0T><TCIBDXXC(\*)/[ASZ][-N[?OW\"#"Q].O+CQ
MX\B3*\^M9E"0((8$#3JD"%&!`HYL4*`PR8&#!*E2F3I%7E2H5>8UA?_$JM6K
M#7#@0'B_818H55`JG/"E)9BR`\6@@\PR!!Z@#30.=8#-@B`P8$$WPQBX$S$-
M.&%%?_T):`^$PWPS03<.*F3/!`7_/3/0`5HT<$\_""%4$`;Y$&0B0C&2Y`)$
M+B@H40=2U##$!4=(88(+(%1`C8L6)+G.0!=$,$$$&@P1@@$2*$`!$E,4X8()
M7)((H(H35+3"#3W]`P(6,*@@Q@("3`4&&%$U!>=350$0%E5V?567778^8=6>
M85VE%F1VP0676I:)Y59<:8B1Q`X$1-%7%`0,-@,./5P*6%^"269899A*MFAD
MF3VF%5\S['`%$U*`%AIJL,+FVA`<R%!K'*2A%L=H0QSAPFW+!2OLL,06:^RQ
MQNF10P8P%-)L$$`00<@AC4RQQ".24`)>`N!M(HHGIXB7WKBZ=&+**!*DZ\I[
M]M$WBR@;_Q@`Q01:\)>A,.1H@2^%_]F3Y#,=5:12/QBDQ`XS!GJ##C#W"F//
M,@,B?+`S^43SS#Q%VA/B0"PF9&*)"GV(<8D'B5`#F2M$P(2/&FB00LH`'3%"
M!"^:.,$*$W0@`@,N*`'!)N"%\$8&0P",<TG?6,#`-2Z0^8\(;301@QA23175
MU71.E155=_8I*%Y@+P4`77$I6NA=>1JJ=EU7C?V5`&(`L$,8840ZF%^<3EIJ
M68Q=RBEAGYHEV:6.U97J#P!\0$45K88FVN.R]MI:;*_UFBMJO@*+[.:<=^[Y
MY\$JRVRS/@`10[2$+/O&%8\(88,-DGQW"7CB_>P))M]Z,I[NG?^`LLHK']@"
MGWVKY*))`D<<<,()_06#3C$7[BN,,O;`:($(-TQS00<@<[,.`_MX8PPQYP@#
M3SOX-@!^PN!'\V!.SSA#,@8'D)C0_3-^#./]*DU#YC0NJ$$-(D""&AQ!`R#8
M@`9,T``3R.`"`#,!B;AD`H58P`5'@(`-C(`$(T"@"6]`P01NX`(7Q,\"'<G1
MD'K2CP<4P0,+L),,WX2UK-E);#(,R];<]C6O<(5L:%M47/(DQ$(9RBUG*TL2
MD@*&'T0!`0BH%&;\0JDH6+%39<%4IJ88&,<,[C%9S-0.O"*9&$@A"W)HG.,>
M!RO4Z&`(;YR-Y7`%JPYH#G1XS*,>]TC_K"^DSA`Y$$0A$-$L1$S!"*Z+1`A"
M\)UM)<``I;A=[G2GGE2`"Y+MJ44*4@`+XNFB%*;0007JQ1_I(:,<^")0.QQ4
ML)N10&<!'$@%DO0@`@VH0L8H7S#@,8$#.$$9Z6B'TM9!RW7$"`,%N4>1GN$B
M_&',1?G8'\?*5,)KW*`#)83("J"@@1I`@0I*8X`(2HC,#]W#3+VT0!8<P((K
M9,"#56!D!05X`X4\I&DCJ0$+1;`!(+#)34ZQT]7D%*<Z^4DL8LG*5\!B%S]I
M12U?^2$0B6B60AGF*I)1B]E^P,0GX(``=4N,7^P6&%`QAHJEPE1),;46OGP1
M,(9Y@E<*\`(J_U!!"D=PU>-X!2L9',$TNQK-:.@(1SL*!PYMD`,7^,C4ICJ5
M<\HJI"(,@8@`!(!9B&A"$2`!.TE,@G8#4`\ES35)5(@+$_,1A02"1PLXS,(5
M]O%=6!/`@0GPYQ?C,!\RWF&^%K1#?11+600<<H,*0B,>W7#"^H;AA.8UUC_J
MXT:$&)`T"W`#'@4C)HD,,C`+6FQ&(2-(QYXA36M4$'L1V-*.4GN!!]P@#@MD
M0EV?08(4.`DA2?('--1W`06$P`:'Q()+4H`%9YC,3!AH@P9*6$T*1B``,5Q*
M4YA24(!JS4]<\UI6N++0MK4)*PT%0-K6HJB'1H8MES$+5NB"%ZT`P/\#:?@!
M8)Y(`+LMIHN?XM1?/%494`'.4%.L3%T<\`(Y5`$+K8(":'[:1ET-00FX$DT;
M:R6#F=W1-VV(@QL:\-0.>_C#Q6$#5:^3B*IJM0E8O0(BN9HM;8EG$^`Z5UE1
M82ZRZJ*3'VA%>WSWK5%PP`+[:<&%'#N]<?Q2&%I8QC!960/7FB`"_BC)AM;G
M5P"AP['^V<=.P%<A>+B/EA?[[/XD0J-9\@^:S$22!57261"8H`8Y<L$U5M"T
M$KAV"`OL``1H!@(55I""A;W8"C@P@@%`X`,<^(`,JL"#"7AH(!C@QHT*2T$*
M=J``8Z.N#:=;I[&M]RH_W&Y"[Z1$)`IJO0O_-=RHTGN7++YE+4A$W`+$T,0?
M]*!N).TO8PI7N"QJT;]@%%S>#&,7(;R`"5G`@H+7V&#2N`16$H:C#CA`[1$\
MX,*]:8,;<L!A$'O[V]ZN@R(",`6K6M5:1FC"%=YPG2D@8:NN8\%VO'.);X7'
MDC:^G5DIJ8GYN'6MGNRQ*0;P8U]8@7G.&U]>BS$@RH*#&S!R@4@ZTI`&.>A@
MS*!L+IM'H?,-2!@54.R#9IFD5GZ,L]$H&,3/7")I<JP@*0%(.2=H37SV9`59
M>("/2``0&<C!'Q*I`:"Q"9"2/``*&QC!"W`%!1E(000G.``RL?D]$)")197F
M01#:INGI<GJ'GA;4_P_'@A:%TF4IZA6[$H$(%SU9]-45->)2DN)1PT2*I"7=
MU&."[1B8<LJ+@PNCWLL2`![P8'%2:)5HE*"$9KMDIT.UE:U&P(%K"Z<-RWL#
MN#?/>::NH=U+:`*YF["$#B+A]!WDX+OC30D'X+L3^^:WOFFL"EVX50$2J,\M
MTG-)`PS!EUI@GA4"1'SG4>@=R7A?;I\<D0YT@$3#K*4JR6>.<_0+84GNAH28
M\2"-(=-CD9;?0F"4#_N]R&(JJ:#X[;<0-Y/9!!2AF0B.H*`AD*`@&OB`1/9?
M`X",R02M9`$1(`44(`<YQ7BUX0L-4!(!L0X'<%R51D$&$#=]XB<TU";9=?]#
M8(%=7[-=:,%02Q%K:<%2Y'47/11LA`(9AC-W,606(V5%5A0I?[%?*K4I_66#
M,.5K`)9W/1`$4L`#3$`%67!@KO(JT+9XS#9MM4)HE8=MO*%M':!YG3>%5,@Y
M:W!N1I!NU[($1K!5'/2%+-8=LF-)L1=CMD,>M9<["A`?\:$N[S(N5#(`1R`"
M%V)POS0^%,(OR=`,Q71!+K`]?;8"W><@X!,^PU`.S:,O#B,.R_`-X#-+X<,`
MUE-^Y5=R!;,3]T")WT<R)`(0!])9'^-^)G`!'!`'V!`F7*($*%`0-3``U^!^
M-`**,'(!/"`!+W`!.C`"5-`&3G`"+0!_*3$0/&'_6O^P?P\``QB(%=F%@6[2
M)A*5%@JE-7D"7HE"1#A`%GN"7FA#-FNS-E_A%%%Q*9H"@W<#.)]2*HA!&)DQ
M;"AH%W^3&4\@!(=7!8RC1CL%1[W"1ODH>=1&;;9Q>6[0!0WP!558D`89+&<P
M!>X&;T(@!$60A:Y3!*77A:^3+8W$";U78Y-T2>2RAFSH5L;#>PH0!R!@!;W(
M'\&@<,\3,:JT(?30`0]``ER"#2#R,'^55[ET#`4B(`522[]$,1<C/R4':>T#
M(N1'B0*Q60'!#1SC#[&X`@+T`!T@7!<`?T)A`E7P`@(!`2+19B6!`?T0$"3`
M:#9`!2L@`52P/0`B`A'`_V=*4S]")W3%.!)PH`)W@EUO8EU6<5VBYH%<)U-L
ML5%$M%"181F$22A&U(U'](T"D`9I``"$`QCU=46#P1B%49E7E!@BY45F(5.=
M0@!IP`$T0`5R@&`)QGA&"'E("$>KP0&;9'G!\09=\`=O0)`'>9NX*1QGT`1-
M\&X0:0,.F85&$'I<Z#JP\U5@E9%C]7JPEX:E\)'P83S@0G!T>"',HXC%8'TK
M^1_J\(@!T1$_T1,PMPSKXP[DDTOHD##*,`PL27([43\@DS^1QGY!^5D&47XR
M\@P&DA!A67(UT&<DT`9"!P(:4`4H`&4_>%P2@`)<DI0ED1(]X0)2,`!Q$`('
M]/\`!Q`!7=DB)E!+#3&3#>H/;>`#`L`G5E,U!J6!52%J;<-=@8D61/10D#E&
MJ<8VJR:.W1B83K$`34$X?5%?0(IW@<$7@R&D*_4I@^,6>H,9.%``/\@$]&B:
M"K93J,EX4RH:2DAHUN:$N=FE7DH<:+!5-O!;10`[P;D$Y38%O6D$%8F<&,E[
M,09C&9D>K8![ZE(?N'`?H2`#($!*%W(,Q<!Q_#(]!>(]'QJ34DDD)"<A^U`A
M@8IEW]"(5<:=!O(@AQ6,H;@-,+(_FU4!\[D2"V%^T+!9E'42FS4P)C(2_2!G
M`($"%)`"]P<%3!"6'%`%9L)F)#$0-X`"'$`32P`!-P#_#"-4)*+E)1=4C!2T
M`AU@`RK@-G[R%"C::8&RH@?%4'Y2-DO!7G@A7EE1&&"C:J:67CG*7D]`=W3A
M191"-P@04O/U%WQ!F92RCC"%I#68*5GD%R7U!%,@!TQ@8%(@I8Y3I8S7*KE2
M8?W(`?_XI0J[L,&!!O$6`BS0545P>FAZ!>46>I!@D=VRG!@Y5C8629_$"E52
M/`HP5Q+0`09GDM.3+_YAGGI(($IS/3?P`"AP`3=7#P;"#NBSLHU%9`:R,-I`
M3`<#/B9'#T?)B?;C/@ZR#0!13#.W/^&@#/7B!-$@04UY#0(D<3<P`6T`!1'P
MGW+``PAA`CP`!4YI==5P/2)P_P$HH`0C$`(!4`!+<`&]*'6\I*PK<0`W(9?7
MX!`IT`5*`19.\01PDI?7Q9<>Z(%6H8V@=BJ0P:*6\6H9A:,JJ)B56ZZ/*0!U
M)QD]0"D@!:0P2)GEB*^;DG>#IZ16U`-2!`84P`0\,(3UN&R/8Z6=H02K,1K\
MR`%&Q;"\V[NXL040>YPL$&_`.9RD=TA+\+!N2DD#X'IF17L"UY$[=BX0D`H2
M,``;8`+[@5<=DIV#*B"46HC2<`%,\`(042+:=S"XA"]X"`\(@SZ1IDH&$FGB
M])7F!VG_$DWT0+5-:UFD%7XPX@SUL#[UP@`DT0\2`95.PSA$HL`F\$TJL0)4
M<`3_R?\E<J82'8`"3-!XJP%'2H!3#Q`][-!GLL0SA>4/_;<"1P`$'B!VV%45
M5;-#'!A19O=I9I-0XB4J8`%JAAF89(,H%=5VAE-1Y=HFFMMK*A6#,AB#HCL8
M(O4W[QAXF#$IB2$``W!L6?"OIXF$C/=XLC$$MD)M,K"[OEO&7[H%+!"Q706<
M:=R07^B;706Q(3``W/*\">"\=/R\JJ`*]\%C.\9C`Z<`*&!P4RNIX-LA>U@@
MZU,!*Z`!*$`#%4$SA)@PMI2=Y?,?X[">\-`-2GMQ_ANJ,6(0M#2?%>!7"V$Q
M#_)]VY!REO4]_'``H@5TV-`"$T`#""%G_P`%<N!^*"`!?V;_#:V*!1^<`M.V
M`4.0=`8P!13``%9@`1*4#[^4$C.I3RL0!P6@%XFR->7*%&\R73(<*#2L0]5Z
MPX+"-I^V%;`VC3*%F$)T*!EE:M*5!D\A%WMW*:$K4J-[SZ:KCH/A19#2N5&`
M*4#``25``T,H!4JP8(\G5#Q5&F%<*V1LQA)]FUOP.L!IT<;9D/#FA6VZ2-P"
M5JA0Q\]K23T&2L6S8^\""F$U`"A@(;^0#HY:9'F%R`2BOA-P`330!DU20CNS
M2A60#(U8+RNY$_JRGN_P/>N06<8DE/:YROB9))25?15C6>27)`I1U3L!(RV0
MJR31B<@:%%PB!U3@E"X`!P'1?S+'_ZLCH``V0'DZ$`%0\#/II@$-D#)"@0&^
MP`#%2&D:D`$>(%.B\L)MXG7.B+@;R'6+NU%F$Q<2I17M3%%Q`1F!]VIYLET[
M6JXRU3>>(KKXS,\G-;J@/7AXLU(PH`19@'BRV\7--ANJL1JVP05=$-NR/=NT
M'=L3?=M-M04:#0D-V=LVX``A`)%<Y3JM!])D>,<C'59J:#RYT-SID0HO4"'5
MMS#&MX=Z^!_.\#XBP`0H0!'=Y(GJ\-,"$JC.LYX!(B'?$`_M,W+X.4OE9W+1
MI"0C$F8E%TVD+,#K``P7$HQA><`?06<*(L&SBL`<T#3_61).,&@0D``4H``C
M@`(OH`,*X/\`7/A[IB4",5E!("!TP(P1?STH6]%I5M,G6B,VA]VX.C1J,-I>
MB0OB:P-&1C1>V:B,3K%$D!DJ@_.C,G@W-%B#-5B.G"L8[R@83V`$*""$C+-L
MJCT;E:,KL;$:=H14;3#E5%[E5MX&N)WE>N2PP9EZ$,D"P.V0%1FQW?'1QDW'
MS@O2YF$N(?DM)CUP`\`#+DT^SU,^,MUP&4=R[%`!-:#3`8H"*W")Y$E9SV/)
M>H5*U\>H_@)FY<<.]HFKA\4-K2S?_A)-%_.>YJ03R,!,(2H0`C$D%"0"5<`$
M'',#(Y`]`/@^-/`!(\`"2/`!-,`#B<;6`0`#57`/L401V(#"_I#_P10`44CT
MPGJI0Q5H%2SJ0V/S@=K87BA^-MQ81'A!N6IS-MOU`W"RSI@1T%E$-Y/IQ*4R
MY*'-XZ.+`V(P!#95FJ<)&F#L1G$$*],F`[^BY?*^>6'ZD&C:FV4J"</+>MPA
MAF.(YA_=O-R"Q\I-O:"D8[Y38]["`T(FU.7-6-6]A[>$6<Z`,Q/@`B3P`K?X
M?-`@OX5^R!*O2N&@2B1'B2+SZ/10<O\B3$J2LY_E66(6#7L^0845%-:`JB!P
M`=E3`Q.`!2(T$"LP`#IG`JMD`4=``0-@!"QP;#*0`@J0`,!5`%*I3S=O=0($
M9W1&`T:Q4<@.PU31%%R!70\U=J>VXH.9_Q8;"-F+.<26R]@!9>*ITACB."G=
MGHZ'T:[[7(Z?'=HYH`1!&+L+ACFL&2M/K@,1/>^(_U1<_I!(0'KY+@D7+6^5
MX%6+%-)W;.9ISF]JF"Y_G#OU9@!2$'(FB9W)L#!Z93X%`I\6H`$T0"0BH`$V
M40T:XR#4@\@+8]1)0SV%J,B9&!#O/0\84S"6&`W"=.D4LS\T4B,O(OP#$V7)
MZG[/4%AE(@4OX&;]L`&#Y6AZ.X`.``=8\``TL%8+'@DV0`,7?UIC2\W*:@(W
M(`=3(`!G%S9;TQ1I`!4DSA1>\VF!\J(M#@A)24]/@H4`/S\XB4D_,X^0,S@[
MD3.)EI&,3P"<@_\"`#BA/3@].Z:G45$$!*D[43NEIZ>QL*ZPM*BIK[([20%9
M/%184E!*QD='0W$R,CI#RC)QSQTG?];7V-G:V]S=WM_@X>+CY.7FY^C7:$5"
M1>Q"1D;L-C9"0B$V+"$4(?L4%`D&)!A(<*"#@`,,&%#`L"%#"'`D0)A(48%"
MA0,&0)E@14M')PT:M!A)LH63%@T.'$"I4B4##"!`N-!0HP&##@]N@!`QH64%
M"R=7.M%B$F5(D4X.,&`04JG+"E`M6)B`80*("5:O5L#ZDZI4#&"E_K2P=8*%
MER)`5(V)U2K6F#'/6DT+PH2)NB96B!!A0L2*#BM6Y%7"(Z^)"4,B@*C_X,0"
M$RI0I)`PR^/#!C@.D"R1<L`"VPE;([@0_/>!B"Q!DLP8-4.0H4V?/G$"0&@V
M;4*$!-W.[9J1ZT&%!B5!]*,'(T>50EE"OAS3HT0_#.T>+FD&+%$]LIM2U<K5
M+EV[>&GGE:N[J5A/;%!YC*78L61Q=#1[1O^9BVKI\NO?S[^____DX/%.$?FT
MXTX1\=R3CS\.'%0001EEY$!"$2KDT$025=001A3&`8(6'G74P@$BE5124RP]
M15=@5$UP@UU8G9724D.9!*(3)Z4T4DAD'=624A:$%:14;<7555L82#4D60=@
M]9*2._&455M%QB1"!2TP@!<*$=1@5V!]F5`#_TY@UC`$#7Q=A<(((DPE`DY0
M1-`D"4-\\($$+#0QQ`0,3,!76E"Y`)A='6#1A@8P/.%<:Z\!\,DFG!0"Z2:X
M%9+(;KPA%YUKE.8&P",[0,?<(\HUAT,DC6BZ*:2TS?#$#SM,T@.IH4SB77BM
M@&?>+).$APIYIA!PB@<*T$!%%<2\]TP<TCQSA!+)''$?@-16:^VUV.Z'AQ'V
MV,,."S84@40\!.I#@8,1'A3ANAD9(%"["S&D$`0-3>00AP/$(<)(6IR@!4@F
MGKCC2C-NM5,-@ETUE9]Q2?6C20#G>%11G2EE$P,^*4D653`%&2-46YTUE<AD
M5<#`DD?"51=/554)@O\%*UF0U@I5=%"#7RL@7,.++D1@ETQ'/!`36"8HH)@(
M,_'P`I85O*"##AP84`0%%F@Q@5VC737!"C<$UK4,!3B0VJF^-?HH`&#0IIND
ME3KR`Z;1$7)<=+/A]K8DH8KZ7"7)+9(J)(+\L$G:M3T1JW*UDK+=*J^4LNMU
MMMY2WN+`>H=#%#/$P`$362"KK#)#*.&L,<9,F^WIJ*>NNG_K"$&/M]X>Z#H+
M`$4XD$`0LGM1A?'66Z^]O0_$P0TM@`CBCB6&A*-11_G865U_Z656DG,MQL!/
M)")UTK\AC43B228[\5,%3RTIE=98M5Q5D`I3:1;,!XS?U548'-ER^EH_X`+_
M2%95==A>AIF)!L"TES?)(`(QPHH,7!"3#C#A",3KC`9DP($-#``)53C)UKAV
ME[_4!00=N`$3EA`I3?U&.FFK6Z56N*E!$`<XHHH.="I%&^BLAE&9<-NHJL.<
M2S!";;=Q5!(H(8G$9<=QC$/%K$I!BEKQ0A=/])4MMF.*4P4!"X^I0A6*\2QD
M=-%9[KD!?E9'QC*:\8Q_0,/LZ,$">]2C';/;1T`N0L=WL4MW%WD(12`@@3[2
M:R'N,L`&..*1?R$O>2)I2O.:HA2\_&D%+V,86<YR/8Q]#T<B40DB@]*DEV'L
M9$%*DI)^4A6HN,4K8*'*6,#RLOA]94I%<E^++&""_RJ`0'Q7`4%@"G@5I.WD
M!B2(`%UN((,.4`4OTD(:#7BP`IA9H`4T@$!"9)`%$&0):36HP0,BP(,2T'(%
M+J`"$!1!-A.>$&TJI*'<WI8;Z`SG$Z\AA"4`T`CIJ`82F\+G)9H#";(EH9S+
MV93@#"&`?T9N5J$PA762Z(I54.*@N/`.L*3XG5,0P#H9P&)[(I,L:`WA6<8H
M!A3$B,:2FO2D_MD"/>J1CWR`"X[F4A<==X<0?*UKIGK<XT0":9$/=*`%';E1
MBA"Y2.<ULB]IZ:!:TJ?*I3!E1`W`48U.8A22A*0"=S'9R9"DL?A999+I4Y+Z
MM(8!GD0E*^A3F?LLD#40B/]$2W6Y@9<^\T&]R$`.A]'E\'(I@AHLX043<`$)
M!.,"$VR3`RR80@(>4+\^!<8%#]!?!TBP&,$N00`))1O@1#4<VMA&G:]BIZ5^
MV(GA6&J>]:S-/2TA"!XV@H?\!!Q`C].;N*F&%@BUU4)9@0IA)52*E9,H>1JW
MG1X(*U1&X!RRI$`,]X#4/9&IP1A12MWJ6I<;*GV=2_O11G8P*'?KNEU"W#5'
MC.S.0A1Q5T8L,EZC;<\*RTN))I%'$I`8U44\B0D#(;F6J4#%DBNQT4F<8,F4
M1'5@,;F>4DXI2K'`A"TM(U(J,0#*)"UFDA"&I2Q!PZ>6X'(O>.EE6F9F`0[8
MTD__-?C`#=($P@2,H`,TN,!H'E""#Q"&!0IX@5VJPI>=]4PT-WC`!3H``158
M8A2S&A5G*?59W,"-4_1,E6H$6DX7EC`ZK7F5:S5EG>8XXE2S%9S@P/#:N,$J
M<44LA7;`$ZLV;P>XYY%%=]A,W%OM`@Q"T"*R(@,%D9+.&,R5[G4'3>CJ;@&.
M*UU0&X5@+@95Z%WJ':_N-C1>GD9:0@-00`E&8@7X>J]$A]2D(ILRE;RH+"U4
M`D'\3&8R4$-,OMD#=52W\LFS>D5C93&KQV9YO8Z!52K7@\M;WJ+6%E%8)29I
M@)]X.3/#2,4$3#"-558P@AIPI0(UT``'%*;+*FR`!1M`_P$-KN<"OHS&!!TP
M`08,ZR4-Q.$!`UC`J201PWVZLS:W^<VD$M$ITZ;JM*UAK7"&\]I:T9,U7Y9A
M=?"9B2(^1U$S0,246U6K\1Q.<<&J\Q0;R@KSP#FX;U;%#,`P`"9@`0M;[#-S
M5][G/I,4'&V(>1<*3?.:\T>-[NC6[-IH`W_\HT$(N2.\;MJ[F5KHTA!0"`HZ
MTND!%U760R4PA:T"HYWD,M6K;K54AV)?^2XRV6;!V/BN5[)03MTS,&D1GTK6
M%HTE22FK;/NRT=<6GEBR`@_V2UY!+)BM58$*-Y"93&0``HR%!`,K^$"Y=W(!
M#DB@"4(XP@JLUJ6=W<4$)7B`S?^R204#.*`('EC-O`7*V=0&,5*&")QPY!9Q
M3%FJ$?@NK:(6(8G1<GE1#"<5)A;AB'M^ZH=/,.(M1O%;[MQJ%<+21<<]_@HV
M@US.DUB``N2@<N:VO/K,7<%TNW&".73A"S8/O_C)H49X(&%<WP+7/AIT+@<%
M_=+PLHB%'$)_>=EN`!"X@"$-^6E&QCI[+D%A(^(65H<^#;9VEE0\4L4\S,-(
M*%$R9%<R8[%K9J$62S4]9O$^_?,^1`(D:O<6>[%A;@$R<\=+,2$:=:$!;0!)
M(`8"C0<:+I$7T68"%E`#3)!T0A``4T`#$Q`!QF16;Z(!&N`"1,@#16``2[`$
MLZ)/,?3_'&[#9)'2*<'!&X&#*8;00IJ@-J^UA:P%6WRS-Y6@0\XA<8)#&\2G
M.*PA?!V'?!VW`PZU*^#!.(\#<HTS`Q[P`4P@!W)0!<.P<GZ(!=H7#MTW<^-7
MB(:X#>5G!$F(?B[E(`WB?N]W1_$R?WE$+P\A?^&%`D[0:<>#24SA?S]"(B2B
M52K!%2!P,^H3%4&"/2A1%"R12(<T(UF"`1<C/Z_$,2UR=5^Q,&H184(R,EN!
M:F;1)&J75O13/Y[Q)WZQ$SS``X75@Y*!%WT!`BB0`E+B)T.X'G>1!0JP`1]P
M$#+`!!C`0`\661?`)1UP`2\0`CDP`@60`/^$'*\54&'(*KDQ_SBL0D_W&&7`
MD66IAQLN%%KY9%"DH@A?"(:XEPCE)"ET$WQ.%"NT\I!KR%NE\(91I`IR^'$3
M544[X`-4\)'"@')Z=G(G%XC@<`(=T`:'N)(K>6CBLHCRP&CG8CL/(A#JTBZ/
MUE[MI2'R=SL)H`0'$"(?T8#($VN,M!0M@&%!8FKI4S]1\1-,,6"&!(!%Z1*?
MM!2JJ#[KXS%$\AE<$2.><6U<%4M*LE5LX95:\S([81BF5@,E,%@^@P(T81=T
M`0(\<`1V<3,3H`$@\`)'(`(3]`$C,`(&H$4/L!2>$1,DH(XTX0(OD``QD`8#
M``,AT$_EU$-Z\S9@@&^Q1T/T]#:<`O][[!20C7)/O^%P8-9P".EP3M@:J'<)
MG%`<F24*561<L,!;Q@<LM,!\<R@+"74KI_`$(?`85"`'QZ)G>ZA%)K!]W'`"
MA,B2T"E^ZV`$YR</.9</M9,`C_B(!4$A`<%>="1_"\&3ZC401P`"3-=TL5B4
MS?,4"Y8^%1""3`4:(`,5!/-J2`%51>E4\`,R1,*!2@*?LI0DZC-)_XF,,;*5
M77F6=$<D2:47=($5(Q99*/``>D&7>X$LZ38TFA<!&W`$(P`!&S`"*4`Z*Y"4
M?!%D%Z`!%^"#*+`!0>`(/A`#/F`)RJ$W3FAO48AZG:()`=E..F1E:L-DJ2)F
M@K,W\Z::.Y3_0Y;03H&3&X=S<6J&-\'"6THD7.6A*UI*'K^)I5%@!T,0##Q`
MG"!)!5D@!R;Y#2<0!VY`!]'YIC2W+=1)("O%`G9*.P[0?MR)$`ZP$+PSGO)B
MB0I`GK@3!Q-@/)S8@-UC%$8)=S!#H._3%VJ7)/_E5`=`50P8%+)620KV)!+(
M:J#*:EO58$/B%E]Q/R*S5O?CE4@B2LO&8B-V&(]Z`T.6%X+!%S1S`6DI`@]P
M&#1``0,0$2,`!1<`+77A@ZJVE]L4`6T@`1F@`M`1*JU%CSFT3XP"D&5(A:9'
MA3(D'9C2";&U>^04":&PI);I98+S*JI'"!=G1`FUFU8:9QFI?,NG_Z7V>AVQ
M8!ZA4`!R\`+-R`0`RP1C^AC+&0YN<+!N"J<*:UURRBUWREUVN@\^=Y.8YBX*
M(!`&4!&`6G_LE0`4P`$BX!&;V'1&N:BCUA2@U"1;114A:#"4NA0NT0!$P1**
M6A0A<3TFXX$2N(M:Y14],3)N-Q7T(TLFLU9X1W<?^(%6`A?*F$MK>6[GEJ)2
MP$#TPP`=5`4#L`$3P0$7L`)#0`6"H@%R(`)6T``M&@$7,`1(X`,+T$_/L868
MV80/IUHGM`FP!QRAJ8\K9#>8<`E$5"L+MW#SEJ1(6J[,(1SN-!Q5!+@5%RM,
MY(9)%`O(IROS2KGUN@NT.6>N```2H`$T(/]NS4@#-`"P5%"P"WNZA[@.\Q"Q
M^)`@"_(/YR)>E\93@RI_]3<O[^(`0_`A014BR/9T+9$B&/-V9O$3<`%)6P$5
M3OE))$(4)#(B"F:RHT@^.INS(8.S40$6&!`_J:0PP$B!7'$]M^9?O$AWPD9L
M+8BK?#&-=I&7+H`P=-D!DE>7)O`B2L`"`O$!'!`'AB4'F5<#+Q`'<G`!-(8"
M'0`%0@`#'B!Q6E:D"K<(A:"D0AH<FA`<B`"0>+LVA1,<\\AP@_NV7TBX@=L:
MQO$(%$Q/`1<%:E9QU@$LK""'(1=RN#*YJ<!0YY&YW[%$7H`%*(`")8`"1S``
M0K`01@`%S(FZ2%S_:-L2.R[UDN42`MN)+KQ3:1R[(8$4(1!`2)W6::)(5$75
M$@U`/F"A)6(GJ8$Q%3@K%@5F(B?[O"-Q=ZJH56J,F./+:FNGO&Y')=0+2EV9
M:FH52D*[E@#T)5\"27DQ)N<F&':A`7_Y%B90;CPP``ZP#Q_``EE0%A;03#BA
M`2_0!@]``DPP`$L`!*%EMP,5.-;:P7Q#*6E33Z]Q0@,G-YVUCY(RK8.@9+27
M'&[KMI=`>T_JH\(Q"]D!9E,4.:H0!F&0D9=KKS2\<>=Q1+CP"J3P`P-``E@@
M`P.0`V`@``NPF7!PQ$D<SM5U!DB0:&^$(*O;#_W0?@111^)I$?)BQ1)B_P`)
M``</,!1"J04I`1)4!6OM&8"=T2)C`2-I,3*4FK,$\SVMR'].<90C@YBLMKR(
M2:HEL[TD.$G:VQ;46Q;$9HQ4PA.!G+YTL2(=%!A#"`)=T[XO``56MXPP1@,I
ML`$9D`,!(`7VV8/3^`#^JH)*4`0^X`'>>@B_84.KR4]QHS:7@GIW>\I3V&_`
M87N]H4_.,;B`RS>IC`/_]@A/2D]M1@L8)QYNB``(,+F0:Z\US(8?%PNC,#G9
M$0,!$`0J4%"Z-P/?+,YV/6A+C)W@@L[VH`\2NWX&D0"5^,Z3.%,4<K$E`%];
MK)Y1=6",^B.,-!4'0#T9&"5#,SYGX10!)E_)UO_%(T(^!0-L]3G:9!&!HS2!
M@0P:X!N^!H-6])/:5,$`/G,U!91?+0@7-0`]>U%8V#1B`HO2.,,7&J`$$M$$
MD+<$-=`"6W$#HU$#)-`&!.RY'U``'E`X!<6M1(U[#9>NO/%9CO!Z,12:]X8<
MKS?7?T-O!LF:4JW5\:A#6.TV]$0*1R0>$>4*8DW6E8N1--P=&.<K#ZFO>$.;
M>-,#!@#.=WW@980'2$`@_1`NY,+@/]</0'<[O2,O%6[ANY,0"<`#G+;85F!5
MCHVR)'(]%^-?[U,_/<8R8?%V\?.[WN,]HJ843&&5_)DDG-HG%&;:8E&?O#@]
M1ZLUF1V63.)*3.6]?2+_H7JQ$W-1VY"T$[T*/7EA,Y<G!7S9OFUB`A<`!7`@
M`Q+P`0H@!'*!;AK0PT*H`8NI`4Q@`#Z0!IX%!J(%R[<'ACY4.$\-I+FQ'+S'
M;P[,A(-`*ZV9<&(HPI6PYWW[MHH".?(MS!%%`,F<WV;M?'(&X+^9PZ2"9(YK
M"@7.!5VPZ9S>Z9Z^Z0@>ZO]!S@R.#PABG:_+#U`L4Y;X1W]TNS/E`!#P`HK]
M+URG(U7UV#"K2<K[8`E:6`ST,>,#V28[5-`;BJ0-@3Z!=Z!Q,@<]V@GD24*>
MLZ,ZC"DAM%SYE#L!3KW4(DUK`NC8%[P=&#GS%W+POAVPED++!`I@)R%JTX'1
M_P$R\P!E7N;TC@44D`-D``:MK-1/7:0'&5!/D#;<W<#YUH6MP6^]5W`"QPA%
MM$_SEF1S_8674&;0H5E8=NAG:''`,@F.KBM9BBN0?AV2X#A49)G.7.!P$',L
MW_(NS_*B'O/[H49L%`)V"@_N$+$'`70-DFD67KOS=R\VQ00-D)Y;K)]5=90(
M+7;)BSX'$!@?Q(%8:7@*[74,^".6M./V"7=.A95!'G:H7185H!7O\Y1'@HLB
M&'9AB98<IG=6EQ,(LXQ8\<@F+07U&T(1T$PR0P5PL`$;(`$#8`(^0TLX$=UM
M4`)"N*)M<`0.$`!$L``"X-3_[L`^!.C</?FS\3>H'/]0J%QO4D8)];0:"$4)
MCD!\)<S+O:<J0Q10<6,=&U_?&VEGCXXKN5`Y@SM%K[`HN+\#!2[SOI\Z6Z!^
M#6+SB08NM/-SN8-3MCNHEH@O"<`!5;.)B-IU5-F>5._U9,$60HMJ+Q,570_:
M7!>\7M?03G'C-V[V6J6*`;I60$N@$GCD4_%@!4@_3QF6&P83T_A!>>$"*0T(
M("`B*X4N-#PW*!T/)"L6%AU2(PH.#A\F&B:,&AIMG24EG207%S1'+#`>:0)@
M`$^N24^SKS.V,S^WMS^\2:^R2<&S3[DX,TFYQ[A/P<FZN[S&ML72N$DX/3/8
MNMN\T[D_P;C)P0!).SWIZ3O_[.U1[?`[45$$!//T]?GV]_SW\?/L;.'`%D]:
M.V,]=A@X\:>APX<0(TJ<2+&BQ8L8,VK<R+&CQX\.Z5`(03($"Q8V;)QD$6*D
M@P0#8LHT0).F@ILX(4"X25.FA`Y:M#C18D5HBP9(D;8X>J#I@08'&#AEP,#"
M!!`3LF*=(`*$51$6J%*MX%2I$Z9/H4*M0+:IV*J0++!ERX"MU0EVX\;%P!=#
M5KU9`X<]4"&KW\""!/W=JU6Q80R#1)B07*C0C1LF!%%>X:*&'`T/+G30<`$#
M@QH\9'PPH.!("1$H2&@HT:9-"10O4'0B7:H$CR%"5"P8+@#`JR?':^GBQ7RY
M+./,_\(A3V)+7/5ES9P]V_Z,NJP?`ZN)'XCK6_-IWP',(!"O_;OV\O#UN[</
MWOQ_[0021,<N&[9T`[&S$$@$%FC@@0@FJ"!'=`S@``4KF<02!10DD``%,?64
M(4XWZ;13AQ\:X),&#10UE(D-+*7B64ZU^!9;5SFFF`EX<3584Q:DJ&(#9ZF5
M5`N$2?76D&+1-===$^BU5U^&A5585X9)A>1?D#7IUF&)#;)55I)M5D,-*TPF
MF0EDKG`#9RXHX0(*-$C!1`2/H*#$$11L0$,'89*VVVRDR:8!*:5<0`(/1^3@
MP0(J>%`<<M#-0MTMS`3S:'4_P/)++^:$8YTWXVBJ37DX:/^WG3<[<!-J+CT8
M`QYYR'S372U/](``?/;1R@X]_+@#$#SUO2=//*D.E!`\P6H3WK`#+JCLLLPV
MZVR!#0YP(84C4>"`3!;*-$!-K.4$@00>ZJ2`AMORD.()6K0PU%DJ+H4482U&
M5=>1AB466)6%85"!5(3]V&Y23:D+\+[RSLM65!4LZ1<D?>G5%Y/Z5@`9"!C(
M194%?FVE6,5Q$19C8I(Y-AF9A(19")DFF+E"#2[@N4(;'$1010H</!#!#15<
M0`4/3)3@P@H@K/``"K;M6<J?%X1F<P2V26#H*F*P(L"BLA!3772<8O?<+Y):
M$TXOSO1"7:A/:),U-\>,K4TVRWW_"LW7Z(4M3MGLV?JKK?/UHRL^[=G33K#[
MK;-#@+>$2E"RSR:N^.*,(]C@N`-0^!),,-FDP$XS&2#!!QOH)$'G<(`^KH@&
M?*#!`2T0Y80312'EA([O-@555'+1-2576&&LKPAX03*75$KYJ%14J)_%`)!N
MB4687!9#4I>3"0NIF%5>\?XPPQ-4O&\#A2$FR+YW08)[8S*"0&/**8<I0E>$
ML)QR!%E$(((<0T#!@0Y'<*``$R0\T,8#';A!#5+6!AIH`#=5X(%N/%&T3@1*
M4%6000%BX`$QJ$`,QFE%HZJ##.9$ISJ-&D8NLI.=9XBM59WRU#3,QIUJN&TY
MX-'.>2`%_P`<_&H=J1K6/]Z1#ESES5=VDT<]`.(?;<C#%D`LG$`4PI#&.?&)
M4(QB0P#P+0@XZ%K:VE:'P%63#L$!#A*00.C""$8)0`X"!GC!ZM:HNA_!KD6S
M:TK"LG>5)$W)?(*@D5WH(KO9+>4`JWL*ZH32`'XECRK+8PM??)<PN4RECAQ+
MDO4LEC#M):P"0*+>O2RP%;D$AGQ9&L157("9RHB)$"Y(I=!&H($5#`$+,HB#
M%2E@!"EHP`4/6$$$.A$:W;B@!$R@@@8B\(`#%JV!#T@F#[(0`A6PP@.KF%IQ
MC&,=8D@G.](!@"L^B!Y),8=3W_PF,[AC1&-98P:#0YMYP+FJYO^`IP>50J(]
M4M4?6A&1GOOX(1!I51]TD,>&@P/H002B'P4T48H(3:A"#\2'+Z)16AKJH@(^
M!X?+?2N,G]N`1C<`QBI";@!#8,"Z5A<4M;C+77!T$2=CE#&-=66.^E)>6?P(
MI+-4`"JI*R0B$?:[2R;2=U)IY+ZZYSM]Y6Y?=<E>7BKPNJN8QBK,:XM?*G:5
M]5DU,BG#JB$ZT('.M$R`>.)!"1X`!R7$Q$)U`D$-@K9+T/A)3[A!`3&-*8H&
M$I-I+Y!!#NP@@`6(X5"L``,8%I6+2)%04EO#Y@D[&,ZP]<)JYBP<0E0U3A2^
M<)WC&(@[;3B#)QA#B(/#FS\`M(-\\D/_'_K8E7W>`R!IV#!8!8GL#`RZT-K:
M]K86H:($2#<`GO0V)Z'KG!@URKD/C(!SH=,)''1B@`1L8`5L#,I1S'(4E/;1
M1=U3ZB9X%R,1,"![CB3>NX+W%*8("755F8K!ABJ7=S%LJ`3S&'BM@H$#0)4J
M&4O2PD3*O:A\TBX98]['K+H^,I6@!AV(0/J^5(@:1*`#)KA!!":@I])]BW,#
MP((([`L")MC@`P$4!6WDH`0%+K`VHG!@TI*F`294P09!F-H"H$F<&1<'&;ZP
MVF,==<)A8.VPWB3H-\?!0EU<@QL)Z90NTFD-%\[0ALPH56G9XRMUW&JT/?#A
M?%";6OZXHS___V$;.IELPW<8@SRVH"UNU\SFVE(1)^1BS;8N_`'.$1>YQM7H
M"#IW.04DX"8D:D!05M<"0^KH7V4A#%FJ0J.[K*`#O&.`EI)$%J2B;KKODDIU
M@?2N^`JI=@F3(ZA]!U47U=$JE<P*[0S#7K*D#D?3,XQ@O%>F0D0&:!V0:U=7
MQM6?">(");B!FZ2P`8MR;G\'("8(I#`%&T#!$S2HPA`X(`?<?"(4H/A$*9(9
M&AI@@0-3\```TC#C0PTG#:[(%*-F$8Y&;0T`THEWI2KK6.>8D*`X0*&J+GN,
M'X@9AF3[%)I?L:K2AL%OJQ6BWMAQ\%LA/+3OH<_!A]B>,_]M/S-(A_]^<("X
M-GO\XXP#P.BRJ*V);J#.*$?YR3^0@CJG(`4;$./E)*`!*Y!4NH:&'<#<PE./
MF:!BH6P,)^M+L$SS*X[D%:2EW7(C?AW,*02KBZAA)#Z,1:F2M9,CI>&RL+]X
M+X]>,5\J!1&FE*6R!C=HV8/3#IJN<")RUSIY`D(@!`/(P7\.'H(24'`;)LB@
M"C203?\XD6+:].F!&JB"'!+0!0$@QZ_0%`-QJ"8,9JS;Q]K\,8Z;\2APB,H;
MJ?*:,_2-#33O(N/<\88WMJ&+5PPNRP?GH;``HMIX#%$^_OB5K^03^]B.F<S#
MLKB`#DJ1-]1F#B!/OO(9)"*2SP0"*W?YRU'_/H*7C^"X,&?N_E+$(YNCI;R8
MCM>+I#*!R6!,3%C!(P@D%I:CZ]1%:4D1O&C'Q[<<4NI306I;*@G@3X)WCDI5
M20US&(+!`"UU54E2?FA7,DF32L2$=K@$0+JD8!/P`+]Q!5,0`@E@/RT!`4S@
M`M9S`:"A`8B``KTQ&P`4`2208K/!=WX"*&W`!+]A`S'P!`L@`.0&37VU`%)C
M>=1T><-@'.;0;_&V0AX$'JZB'RMD+*6B1)*%9JPW*D.V;[;`#&PS9:QU97>3
M</B0#[E">_WAA0\'9L<`9L?2'[;0#@-`?!/A!AV0`R?`!<LWAW0H$=$B+3"Q
M+37Q+2?W<M;7<B=W_WTCP`$<P#F[]2U5(%('(!16@#Q)H7/Q@C#S0GY`8Q63
M$297`31XP4=Q1!6=YFK!8P%,QT?;XW1%,A>59C%!0E\`^$D8@S&=5"7BDX!;
MH4@34U5;8CYD`B83@`AHPC*7<0.,$`&X!((B4`6I4``FD04.0@-)XP@8(`(U
M,#0O4`)MH@$OD(W5V(*?,!NWP8)(`VQ9<`0?L`1`T`I3DP9_)6/#(83;%$*T
M\`I@X!V/M4*M\AWD<3;X]D]9`S?&XEK2H(_@(`Y#%@V&@ROV43=C&!\.QV7S
MX#=F%B`#868Z%'KG\`Z_)SB&DQ`=UX9M\`4G0`=U.))UV"#-)RT9`GW59_]<
M@BB(UC>('+"2&O4M1P`"Q;-&3'%H[O*(A21'I!@C7%$FC@$66<$`<90\@H1(
M:O$4BS86P$,\4R&*!V`:\Z)H\[("=K0E="1K6D%IOV.`&U,[F@0R+E5@A6`!
M:/(S(M`RI(1@`/0"R30!;>``05``&6`$'!`"4A`!$9`;*[`^Q71`"$0%-)`;
MW<B"WXAMI%`"LO$`P*0#@]A,TH2#.QAY-ZA-@P4=[V8<V\18C\)8_N@US_!/
M;.-"Y)1ZR7`VX=`V/U!#TM`#%!<@[^&%JS6;J94K_I1Q_D21#`DX\Q`>]80.
MJ((#:E81;G`"#8!\)+F<RF>2(I(`UV(`T/<!A,C_`3)0G=A9G2ZI<B/0`:[#
M+IBFD[$S%3Y9,75Q&&42`:(D,5UY:9V8%@B3E/+)<Y$XBJ>8%Z+8`ET1%DVB
M7_YW:DC%+W$A4E9P`!]#,F&2?II1"%TQ0*GTH'S9")W1`0YJ0#)@`T`P!4&0
M`!"@!(&)`@]`"(%Y`6V`&TS`!#1@>$>S&X:W&Z2@)\7T`E!P!%00!S&&@X.5
M@^8V'#P(`%,CA$`:I(UU0I[W-JHI602U<:=)9$N('DHD':$G3[(7'P]9>Z"E
M>[>W*Q7I3^W@A;M29L#)'QJ'3L3)AA+A!FW`G&J:?`#`+3%A<BPWB#)PG=@I
MB'7:<I]3,\5C%+/C+],5_XF+%A:^8QAB8@(N$&'Z51B&9%Y*"15/61BO$U_O
M*8F"!`DX(JA.>0!K)6!49W7D8T<#JCH%8R\BT%5DHJ!YI#X@\*``E'8!Y`+$
MB!LM@P)#H`,4T`0YL`0L(`520*(OT`EH)X)\4IBW41N_NB=\$@HOBC2'UPE,
M``54``4!L```(`;LZ%>2-QR2AX[2E&Y`.EB&Q:0P)"I**)H`:9KDY$)4Z*33
M8$V>%7K^%ILXP#<,>67T<!"EM4_UFA#TE#?Y45H!989-B`X=>:9INJ8(RV8B
M1SH=$H@P.:=S2H@M6:<?$$:F(Q5#L9,\"3!'*4=CD1==$321,0&%$!B>J"Y,
M0?\7FN:H4`$"'2"*0@(\LX-(.Q54^[=H;D$63@*JKP@8=?071H(Z=Z%^0$D(
M9&D^)\,99H)@"78#-*`$0\`R<<`$&I`"(R`!#F`#4V`$4P`!S_8`L-I5$=`;
MV_@"!N0"?U),<<6B#O2"PBHHI?`"<D`%6,`"1""$ZGB#,[8`8"!YK&`</#I-
M0"I-EB<.9Z8JVG%F)M0<8E8-,D2NAXNX0_:/QU`V\(I.]W2EFIM[_%%[/01$
MGTLKV9"OZ)`0%K<?!1L17?`&"=NZM]6F#*M<QF6=$*L#$7M]=UIGRT4%F)0Z
M0I$6_W*4/>FHJ`@)J#H(?XE'?R&S`^-(W"=(Y0>S!]/_J(YZ7O+R=#(UB<\C
M"'RA7X/:)%,%:G:A%2';&.L3&5UA`E^ROJET`7Q)C!>@!"%@!$-P`TI``R:(
M`A\0.39``5.@!/V33'P)JZ'A"71EMOWC)[0Q5F/;)\B:8B_:!@K$`Q\@!$$0
M#&"PM^<&`!6T"FG@HY/9K8/UH\!0#/YV*@)API.;N/>6I*-2>C!D6=!@N&B6
M9:JE6A2G*UEFK_KJ'A6G<3^0KU&P#L)R<<7IND@,<B(W+A8E1K,+L;%DN]EY
M?3!7;!)0!2!`4BP"O#O2L?QB,*06LIEA/C=0ODDB2'#$/?I27E#A!!80&E"9
M4O,9E0-:%6WQ/(L&E-?C2??2_S!+0CT4(R.3@;Z"`"9H=QF=\6`/`!77)P-0
MX*%4\`$4H`$\4&Q&8`-%@`0/`)=\LC3$]%8HP`.*1P+9:$"\!*O(NANZL8*`
M@HTO(`5QD`)3X'@^RJ-IP`IIX`&)<ID9A(.W',*O`&\KO!WY)L-+"BI0B*[F
M@5F(BV/4\)IZ@Y`*=UJ[YY`]?$3\.J;*H'LX)#BEF[I)',ZVQ0?B,G.A\\00
M.P1Q(,40*[$M9P!2``)FL91*T<7Y]\7TXA<AJQGNDW[U59^*=C"/>`"Y%@&F
M45ZR4VAH'"^7=$D[=;T[NR7AR\>NZ*F;>$<NM3(DDT<.QFW$V`%9?`(M``4&
MP`0KD/\%Q+8M.I`"?F8#0D`!+P#2)@`HW'8TM4')6)`%*(`;ORH:P@ALU\:B
MML&"SSBVIP`!(0`$C)+!4O/!ZGA!8C#"(4R94R-8`H!-27AF_[9"X8&DH.(J
MCELJY&JN`9E9X1%F0F0/%%>E0Q2;4X9:/%P0K96/Q9"O.,2E_`'.XKS7"$7.
ME[-<T*=GM*L#0W`$ZJP#<;#.,C`$,C"(-%,#*;(NLA,PX2=^3">*4S+(06FH
M-,(7=SS9W--^*XLZ$U`%&C`!QQ,O\E>?JQU4@U&]S[-(^=4D%@U)_B<76,(^
M5F6H((@RA1P!3-!5#U"8&&`%5F`"5,`$#Z`$!K`!U[<!-A'_=TRP?A;@`DFC
M@GK2"<::C43SJS20!3S0C0T$C@LD"H`BK*\\`C:0`63P"U+35[,0>8>R"JXP
MF>]=U;40*G$#D(M+S`#2I*&)"X@K6V9]>N-D>K:09:CUD%S6>^@T<;2Y'M>,
M$`%5'KD`L("#UX-SQ'S=X7VM$QO%<C0SIXD=!T=@V$.0XK5*NQRP`3JPR#R2
M+CO'QAW;(D<B/NDWQF178!.PT#9>2#B+T`QP`3Q@`F3Q?FD,T$Q))$6"XT`7
M&.P'R$#Y25JB&2%;8"A3:UW!:S4@!:;]`B30`4D"`J&A!!"`!+VE@99@`R,@
M!2E`!<<S`:-13#20HB*(;0?T)P5$_Y@H(`?XRW>T,=1X7J)MT#_(*H(\P`%G
M?J.<V5>L\`2Y[+?U36ZV',)@@&Y6`Y#L=LRGQ]]N<Z3E42H(?L(%20W/H.`+
MCGM?:@Q1`.&WAP.]9RM=786K\@SL4&;#Y^&ZWM?11YV$&$N%K<XHGN)QH,XR
MH`,Q*0,:X"Y!0=E]-..`6CNTAA6#G$>H+7^&A",X\M!006$F8$@[U:?0CG]U
MT>2HJ$C_J2](LL\:HQF%6NV[K3Z4,1FX1*$7<`,78"?O^P#C>`0;P`(2,`!V
MF0-!4`0W\``<L`(M0.:.B1NF+!MX?D#=-@36MM.Z8=.UT8VIO"<D(!M2(`,.
MD`%`X*/:1/^94?T$%;3!@)OR]RUC@=5Y+$2N8RTJPI)O8PT-H@<.=.UY-G2Z
M1F3-N7>Y#P[7:GU[_H1/HAZ0X"&<R3"O$+?A<=@%4C_U5%_U4K_K6&\@?.#<
M$WN=.J`$<U+LQ9[BA,W8.D"=),!4J;/%KK.Q2FY?FZB\O#,(FHT7::&RB'13
M!B@O2L<5VU.]XPF\L:.]J+U4YTZ`78GC/_NS]I(8@WR^J'0F*\.@YL,$64`"
M\D,#ROX"0X"-,H@%'Y``!D`!&9`#1!`$0P`"<C`"%2`"8&X";9#<F*_`+-@S
M:KL;_U-*$1#H)0J.&]^"<A`'<E`$5R!N@Y5NESD<T*0H&40<Y&;_WSPH-9/R
M*:L'UF<MD:>.PNL:D*"I>I>%`\9ANI2;"UU(`&$P<=(<+/`T`^>?6K%7#V$0
MD<."0\L<I0`U+`BY$'"0\?P/"&V"@X1_AH>(B8J+C(V.CY"1DI.4E9:7B0`2
M'Q\C*1QQ<4>C2D=#0W&GIG$Z,API3!4-+5I.#;<'N2VXN+D'O`P,!Q83PBLK
M("(U(!,@-283%0?"#0<5%M,6P<+!N<+6%=+?W+\MOK_5U0S5%=_:&!;Q\O$3
M$\3US1/P]188^"``F34#:&*%B((B5A2,T&&%BQL12A!C(.6(A@<W+FB0@V7`
M!BPR.&V00$$(C!@>FI@P\6$(B`<:7*R@_T'E!8D+)#1H*-&F1`D4/%X(TJF!
M!@T7($S`1#$(10D-)'+JO(!3JH8V<E(9(2(&`!@!7@4L``O`@UFS`IX`$,"6
M[8(%:<2*'3OVR8R[=W'@O?MC!@Z]?__VV$O8+V"^>ODJ_L'8;X\=>W\\28(C
M2A3(>0$3"$-@,P'+FR]?[O&7<90PJ$,3V+$C2N?.K&/+CMQ7<.P>CUM?'G`"
MD^_?P(,+'TY<.)\-&SYQD)&JU*A1IZ(SES&"@QP03EHXT5+MW*U=N;KKZJZM
M004,T@**<"&BF0D0V,)/.S\,P[1OWG[5PW^@A;GQXG7'CCH,A%-!/?#$XP\]
M]B`8$#,`Z8///_\")9/,2B;4\%`-*]1P`PHN='!4!R`P@<(#**)0A1`&.&#`
M!BR$X`F,5^3@A0<.H$"##`^$&($+*+R@TT]$%3ED&TS)P804(RQ%@T^#/&6D
MD53A1(,4']C@@P=JM347`#^(89:8"X"Q%EL``!#7`F*X-98`;28Q0VV&X54;
M#GWAE9AA>PJFUP]X_C5#$GG:R1@.K,WIUZ`S]&#9#J0!II=KKWWF6ABB02KH
M##MTQAFEN8%&P%^0LA;IIK7)-EJHK!G06W&PQBKKK+3"RH<GR[&B`RE*.!?=
M$#IP$.P'1X!P2W;@^?)=LMXE6TP##%AP(`@N(,4A/MJ$QTZ!PU@`+3K_OE0@
MDS2YQ+..+__)-\TT]GE#+CX)\G,>/`M*2-![`PF4[P0KE%"M00ZYH"$)5/#P
M5+4\#-'&31J8(,(+"13@`!P0C"2!`@,D@$0&/G010P!&A*`!`\V00$,;4Y'`
MTU,W5:G13U)P0,,%3/`4Y%51#NF33BCKA.(#%[Q`A0P#%`"$F6#$]=5;20@P
MI@=BE"E6&FFR!088;Z61QEA1IU5:9GH1NFEAN.T56-E^]358H8DQ5EL/C>&0
M1)HX6'I98J16^AJEK%UF:J.7[IV;;COT5>H.@B+>E^&6\8W;;3@H\&JME%=N
M^>6R\B%L'#*8TOD1O?IJ"K`RE*[$#=748DYW_]3XERQ^LUAC#3;7#`-"!#?P
MFWM\!4H#+;GF]2>,?]VYT(8(Y]PG7@O?W+*--<7D<LTU$\8#D+37T"/M-`")
M(()ZWW?_/3$/\)M0M2Y,$,$($LA!Q0,1@/#"$"A<%$$\-<B1@@&<C,!^`B$(
M01,*X`,@$*$`!1B`"2IP`PW43`-5T4#]5C:EJ_`@*#8+T@M^TA2G$`5)4P%:
ME5#`A"-\H`E!2-/<S"06#P@@"0LXRUO<%!>RL$4,6L/ATEY8*#HE04YZ@11A
M%)<GTB!N47(;5&#T`K<Y]=!LA.H4:*(P&#[IC3.M68T461/$O>U@`6L97!0F
M=3A3K2TQE-I,&"`U./^]2`YS<(RC'.?("`$L9PB@"QT4]OBKTG%@.:!P02Z<
M@"S_K&L6KA//.<P1K7:<QP+?FP!20-"!W#&`>=B3!GH:B0YL$))Y#&!&\L)C
M#N(%Z!;0VF0P].&/?%@/!/OH![R(P8SPY>L@R?`>OI)RD!7<($24A`(-4*01
M*&2!!!WXT0WZ80(72.%%G=C``!S``A8@`08%]`$,IH"""HC@`CQ@`C%5]I2?
M2`F"'XP2RDKP@A<PQ4@^R>`+JG*3GUV@!'(8`@H7,)FKQ04`*@"C!^QPEC9]
M)0UVF&%;PC(6#]"%GX(Z%-XR,R="+8I.>8IH9.JDJ"0\83!BJZCA[/:H(S+_
MSE.OT8W@(%.WRW3&`V"8@:6$B*C'1,$Q0EQ4$A"@QLY0$0>/8PT$)D?'HAKU
MJ,41@`Y2D<=>[1$*O1J%*_[X`1T\P'?9\46!UN$ZXLWG>>I`3SO\`8UF+(,9
MTK!%/!Q9GFXT``/V\9V"@->+62#R%\KZSKJ^*LM98@`^!T!0*_WAO0>!SV$8
M<MCW$N*A$-V@`RY`D0MH(`$FC"``</"7"T@PP1)4@1,0^(`#D&`#&R!A"068
M0@!@``,X7"`"&E%""30"DW/ZI'XP(0I/="*5-@CI`<_H@`1[<MMVNI-EXY1@
M%8X`AP#X`(P'%0`8Q&"'M9P%+6ZQPUS@8K4T`4"A_W&14U[`9C:\X<DQ3ARO
MV13U)\:$M#%\`91K&M>XUC3Q,9[QJ:A,A2B_Z`UQ?HN-W\;X`](\1E!_"@,"
M.#-3W`SNC4B-L(0G+(DTX!%T3\TP5$?QQQ%\@`,/(*4BV]&?KK*N'?A9)?;J
MT9X)B*`#T1M/]@[D.[?J0AH56$$QW(K*'N_B7-I"9?+,TTH$:2]:$IK00<('
MOEXF]AB/94@R4<2!(SR`!"NXP!`N@`(.M"$B5!A!'*2`G!%L8`0R2`$2`B`$
M"B#A"A*X\@<HH($.O+8F$7A`"7*+SIW81,\XT=F0D(F,9#S`M\>]+0H6[<&6
M2>4%58""#):0`2"`10!QB?^+!S1]W3<A=+LUE&[5E+90())73TL$#&D451C"
MY,F]XFWU#SI%4E&-T<"GT6\:1X.H(/*-`)SJ6^`V@R?^^FE.M-;B;4(%80H[
M^]D47H!SE*#A/9:"<U3]P`NDY1];#+F07NW&.;9ACWBT^'O`)?%>"W0/K9:C
M`=I@1C/+!61TH-(<LLBK>(+1`$*>IQ[,H$<KI?57@1#C(`-9[$$RI)"5:.@!
M]8M`GA\@!P5`(0(HB$`+@+8"%%'A"&W@`0FJX``%P$$!G'!``990!`0N@08@
MN$&8JT65+-`@F7TFP97O.<^K7)DH0:+!HB_0`0\]0"@:<4H\>4M/J%#E*E2`
MPA#_%$!`JK4%C$Y+PW71\I6$0A?3<.'NU;ST%@``<:(<-9OBQ%;%/3$*3Q:=
MP1,*+-'([.!3CZ+4%/V2ZT>]!HM]&PQ0!0PX3W%&P:NAHJ80A3BX]^`SB',4
M&V/3;&A;_O)RE+84I*#A:9_"PQ[6`._&K2SP.&^46V4W7`_T/62,3ZON"$:V
M[E/*<%P/EN+.J[*\45>MAD.K"\H>/2($\`H9-I=+3@J*3/#8$#W@2;F-@`9X
M<)$.+.0&1V^8"5X`A8]OX`,F5X`#II"!*1AA"A\P@14.=`0>Y:0-0RC?BP/-
M6ZE812=#_UD6I-#S17=P2O;',E11`C01,R&0`5Y0-9@6_VHMY%!C\15B(091
M\T\+V!9C=W5>\R>+LFI\PFJ*<D2NIC8@J">%X5$_D%)]`WEZIRJ>L8*R$1N5
M`7FM@1JI\5^I`H+%1FLOR$6/47F8]X-`."L+``6;EV%1!3I+968C``458$CD
M<A^EMV_)$PPH%@[W``*%Q@_>P`W=P`";I%7,4PU_E7KBU@OVEE6PMPW3\SPT
ME@WR8(57""'>4P_OH4O><Q"197TK,''PPULZ(7TH`ED25Q!ZEA0<D``;4!(2
M<'(VL`0!D`,!$`(TP`!:$!Y#P`0=`#],``$WT$SW1!0,XX<[H1,\(`<H$`I,
M4##MQ&B#\$$J<R(0I!%,EW0TD/\%1S``39`#8,10<+$U,>2`TA6!9L%=-A06
M7M(6<3%WJ#9&G%(8B9%3BG%JBZ)>Z@4HM49?>_,H^&5X`;:#VYB"V6@9J-%$
MC'<JLR9@B$,XD>*#0=B.[O@;0X@%6%"$H4,*I>-A4B`"6A!NVP`[_[%5XY9Z
M5N@/`($,8L6%[B(,!P*0X3$.$[!7$&E*/:9(6K56TO,-X<!N\T`]Q2>'+*9+
M#I,4QR`PSG<!(K1!)@D_#V!G@?@O#P$"#$`#%#``$``!9F8`2/`&K.4#KI4,
M%]`"%3`$,E$M5/`!KT5,%0051D(#)10"'\`$[K0P$L040W$D[>1T]">*;4`%
M6#`".1G_`][E%I@6-1+X%E+S%@YHEF2A@,CH)F!1*`[F=G;B&'#S:M.87H21
M:O$E1=>X:S+(&IO!4["A*G[C*'^I&]A(`$]@%XS'1#DH&X-'.#O@*I#`!:%`
M!^^8F9II"`L@!54@CYQ7CZ#C"B.@!"908@2"8M1@5]*C;NJ0D='"(`4)'PKY
M>_-!8M*R5;@`E(.D#0RY2+MP5SPVA7A%#;G`2O-0?,I)D`%1$(J5%!HB<51!
M3'T(03]BDIF($_#C(]"``1?P`1+``7!@9@E@!!F0`SY`!$+``B7@``G0#%1P
M(1CW`CV2G5*Q6U%Q?SYA%%0`%;[U$ZSH?Q^$E5-1)%;!!')P_P2FI8O>!09V
M8'518Y9ELA;@]19MLIA>@3281D-@@1>#01J%4E%R\J&L1B=Z28)\XC:S]AE]
MN3<S)1H,EE]V8RGXY3=`-5\JN$;/V"?GZ(V-V0.4^0@3X`9N,`&;>:3MN`#R
M")I050JA$P<CH`,7,`TCMF/#$YRC!"YKR`__\#WND)'7L$D+B2Z[X`3&.4JL
M&63:P3SMH$C;L@W0H@T/R2#TT&(#YV)W*`(WT(DB^7#PDV=[AB*QB!%YEF>"
M"%G1*7$K0`4*8``)8`-"``$AL#$^0`9$D`,9@`4P$`!$IP%_90+3:9)Y%A6B
M6'^<)4'E]!0](213R6@\PXI3\A0IJ?^4-!!I&U`$;Z`":O$$;K$F$?H68,"K
M#K6A6[-0WJ469W(F8)<6*<J!Z:4X=UE>>:E1B-$7]'6MV*J",A@X,9J-+_@8
M-O6"GS$83X`9KU89.RA@N!&DC4`'KW("F(FD\FIY"U`%]CJ/G+=AH[`K'6"<
MO9,]Z\`+9IBETT,,M-0,[?$\8MI7K00[`=(ZR9*F>%4.>)5O6]@[W&"%X0!O
ML3E6+98/Q==+C]4!#?%+L)5GZ(0"0S!;TM<&F0@T-P<_B)H1):`$,@`!&6,#
M`9`!'M%R,(">/A``1Q`$,B`")8`!#2!)2)EG53**!HI_PS4E.B(4$;`>H\AH
M`FHD+8.4-)'_3P90!+HH:E\1K`!`)@^8-&_R76\"=DIC)@#0)9=FEFDP=X\1
MK8Z!)X"":D[D=GA#)WM!&=@Z8+JFK9E"``APN(?9*=_:>*HB&UYQ7HCR0^C:
M.#95F$!*5(O0!>_:!?/:N<Y6K_>Z>9M7"J@P!!VP.JEI+I<TD13Y5;-S(.BA
M'AB@AH&E#<1`+_6`8OU1L3]6#EYE5V?J;E0:+KZIAK#4#_1RL-0S+0_B'@[1
M<2OI(TBI<P\@`1OP,X(0(B_``2S`!#_B(37`J`DP!2PP`)`Z!3];`%4P`DVP
M!-<$`P5@`P:`#26`;]D)%4R;E4N7$[NU:%)"@"]``\;D`A8`JJ_Z_TZZ%4\N
M8Y(7@"0TH02).`4Q<#40F!9-,XS!>(P;6G;$*&K'.C=IL#3AQ;=WL6KPU6HH
MC&J;D@2.$KB!JZV`V3<UR$8?&IFEDA=;I'A1P$^'PD4Y#!OU-7B\\0A?<`)?
M4,1?X+E*'&$+(`=R<*_XJ@2J,#*^0V(:JZ9"!I'/PV['6UA6R@UBI0_2@CV<
M=&_LH&_@$;$"BPO\\88*:;!CO$GR@"VX5$L%^1!2)G&<M3(FZ0(1T)_21W-)
M`064!@58"%LBP`,0D`)7``,)4`0YR5I&H`%*`$`4,`4V4`0!L$`8@`(3X`3B
M(GU1`5N!)B6"4#]#,B03A*I5D(AQP#."D/]H`E@D"T-_]-<&3``%&R!`1,!"
M8_NV3Z!U;9+!O:IU9;(UT84F<X<G5_,$2V,F=C&-<HF7?1)?K+8I@5%1,Y"8
M4R1L+KRM7H0VL[8J5?08"]8:I6)V<X?.+9A%RJ8J0_P(6"$';;#$]FQ4"Y`%
M3QRZFW<$.@!SY-*%_4!BK)O%L#<?!^MB:/55_6@!Q[N&&5EBTP!*Z)(.%HT.
M6`HNLX?0Z#$,]@"'1=:1O%0A)G`E$F>?&L$#-,!T,;$"&Y``+$`%$?`"$]``
M51`"5%!T#^$")E#`<F``0O#2;U8`&6`#4J`#<)``!B`!`S``'%!*-&`!H)QE
M2$("L(5..[,3/1'_JX(0`31`=0,P!#R@(SL1)!.TU3F!RAY$%#AADD61!8>X
M!#FPEFFA0FH+%KSJMFTA)G-!=AZ,H5Z1)F.Q%F!R*H,2HGG!@7_R0_'U)Y(R
M*'+2.-FXK;;FS2]:4@:&;-UX%Y""13)X7IRR&I5":]TH8/'L"%_P!F^0Q/?<
MVG&4S_O\F:%Y!#`WO%LU8T$VL,F#8O<P(5J8#6-Z'NV!'O?PA(3TF^.Q2!-Y
ML;VSVS,V<&$JTDGQ'L0'$!<@`390!9M%JN@43K1U/Q7``0.@!$Q0934P`1#!
M$'Y,`FUP`35``Q\@`QO``1MP?@$0`$60`"F0`@-0!-/D`!W0'Q8@`2L`_V_K
M<661M1Y9>7\%*B4\D`44\`9PT%M"MVBR7"0JS12-)JO$!!1*\`$A,`4>H,Y@
ME`1F\@.$32C*K"9J"1:#O194@ZS>I8"$/>(%9E(A"E39S"D_\$/B]4,9M5&5
M(2J5(AJ2G7>!:RK&QMG@6$7;[%*0AP-JP<(SFGB4;=J8Z]I:SL3Z;*^R+<6>
M[-P:&;#+C7H8"[O_L$D_!@\&4@%)D2`&DA^]$!\577H9;6-GN@ULKK$%2R$"
M45CJ(4E'``%%H`!;[=87$7*T%2&1)06=HP'GTZE*H`-R@!%4P`%0J0/@)P1-
M,`5-4`1"X)X4DP)*H`':<0`7$``1<`MN?IT:0/\M;0V`45%;*J,!+R`%3-"J
M?F9<4:FJ]>-_KZBJ[1UH(5<%<6"^/C`9/T"V9C(#*3X#6,-":DDU9W*!<S<W
MP`S";YLT-607()K">7%3AD(H%A6BC).8?2D:)*52JZ(IX>[.=X-L>K,:,`0`
M=>-%DEE??7/:6][O1P6Z<N"9G"<%H@>%TD-POE/F`9F1N6FP^7"0QRDO]6`0
MV:,.RJ,NAT3F(B:QL<-[H)1)!H(]8SSQ^M(]$((,<C``2!`"!`\T+H],Q'0!
M"O$")M`!5(#K*ZE,$4`"#10!''(!-X<"2O`*YFL$2[`$38`$2&`$#I#?UZ$%
MW#$"%'":M&`%('`@3R?_BU`[BK'.,U<QE5>AX:L8H$Q1`J?Z?N[D]5:!R[IL
M`$V0%CT.S)/Q!&(0K$WCMFF2-&A"P1`(S8OY0\B*]VP)`"B:PJ"M*'="C7SG
MPB^L@DD>[QR(F.VL%X9[>+`Q)X@R7S#8*8`W4Y.9Y?X>^G`D!E10^E60!9_Y
M`B"`>MGST?;6NK`G\OQ@<.;"/:SDYH4U/:W++>A@G&EJ5P;]"P$M#-KC#W!U
MN\:/O.P1(4MV#:V7`AM0!>W],X'($#]C?2]0M"(`%<W'(0S1!C*A8R[6`4PP
M!%(L6D(`R5-0``&`0`@T`%B@CU9@`AP0YK/``#^1$4!C)#T#"&T:%X0:AB6(
M_R4HBRAMBC0OBHV-B(8H@R0H+X(E@B0:)!<:3%(<(P-``$D_JJRJ0&0`/TD"
M`F```&`":6D+8+^ZM0!/Q$])Q+BX3[FZOP)),S@ST]31U4FKQ]8XTMS5.`11
MXN/DY>;F.^([/=XXX^EA800[W`3V!/+AW#T[_?;]\!#\2S=NP(D_"!,J7,BP
MH<.'$"-*G$BQHL6+&#-J3"B&"14J5:1(X7'C0(,#*!FHK&`!0P63#6*BG$ES
M)@.7%2:`F&`!A(6?/U5:X#F!IP@1.S%88##S9`4&%5["9#JSQ4F35FFJ1+GT
M@$JJ*3$4%5MTYP0,&,R"`$&B"I8#$V[HE"-'PX-!#_\>$+K@HL:-#AUNB"!D
MP81>$DP*18B`XD(5.1%N@*B2X(,4+%`&%$&RI``,&#Z"P*#P``0#+59<2+$@
MM8*(!Z'RWC6DH01M%"5(?*IMFW:G18XT77+4!K>AXKE%+3I.&Y0H)E6.R!B1
M`0RT)S]FX/J1HP`T'SF.X0JVP$.N6NB'%<,F'E<29>/3R*KV[=JJ[-+J3_OQ
M`]RY_P":$TX/T^Q@3Q3^#(2#@?;(\TXZ_8AS(#[QA!%%#^08M-&&'';HX8<@
MAGB1&%1D$1(6)*5DDE=1,3`44S%=]9577ZW$DE(L3<"24$^UA)9K(DR`U%DZ
MUC344RO&Q$`#2Z(D4P-9T=C_(E1"'5!!E#?A&-501>G4)0@/&%"$$"#4$,$*
M-R#V25X1'':!F1VX`-@-$;C@0@E9T$"#`CI(04,$/&#A@A()R#`$!V*.@!D4
M8C81``PYY!!$$-WIX((%J-T@0PM:``6"(22T>4@BH-0&2B<:+-=<&R]LHL@+
ME]BFR'&,U+9(;[2"<A<364BAA`PLJ/#$#*L02TP7`RR0!`LPJ/+$+>C)!P!Z
MPA1CS"K67IMM+M#0%TU^_'TC3;CYX3"+?P&20U`XY[`;A3W2O!M.A`?N,$,/
M]SB(C[P#O9O./?7*:Q`7711L\,$(%RSBP@PW[/###)%814A4=+"BDP?\=&,%
M)VTE_V5*+495`5ICL23R4$"=]9,()B!%EDLF-7G65U=A7/-5,MF$TI10=<5:
M2ZRA1?*7:ZTE10`9"/&`"P^T>1<ALC5=9PUVNK!8!TYK0(4,1S";@P0B:/""
M!1?HP($22G#PP1!5<+`!!4LT\08,0?A@-Z53Q&&!%4Z0,,0$#>@$P@IY87U!
M*+3IYML#@O#FB&^0:`)K;YUPTL;EETM.R:C.E<`$KU`,`0<,8,PP;#3O"2!#
M#@)`X(,MR0B0S##P";#,??R]UPI[RZC7#';C3N--=OA]&_Q^Q$,CKX3N,H^@
M.@`>*.\Z[ZHK_8+Y#-3@/?02Q+ST41@$!^;DEU\^Q.BGK__^^A`M4"(43%@\
MTXXN_@2SC#6"U?-2(P^UD\90$4M:Q,*2HGW))4PQ651T)J,8>>4`49+14YRR
MOZ!0J7\C(UG13+""_TV`"@J```WD-(@+Y`5J4LM+U>1T-:>1@`,.,,795F"%
M"IB@3!HX@BDDL`$.#`$"-A""$(P`@2%,85)$J-O76F`%+;0A"RX(4E%6T($4
MGI`0NSF.7FI3'`T4!S>2X\$DO-@JX/1F-[\A3B,2IQP:4$$)<4B!$3Q`K&B`
M(0@>^`$2A"``#OC@6;,+9.^(`09C\(=XA\S.#&9AK=@)X%["&]<JCE>?<.UG
M!LO+I+J6YST!-4\=!K(0@^;E#H'_W&,<IRQ')_DU#@,<A'VPC*4L9XF0!62!
M"DRX`9*8A$&@+:5F-/(8B[84P)R```,S8D"7D.(3P1%I)STJ2O\<B)*L+,F!
M4`(FB^;7,YX\Y2O]2\L*@H2!%=RP2T6Y"]:J^`#`/*`W)K1+!ZC&IG6ZH(,3
M"!,+(*`$&MQ`"R=H@`AXH(0CI&`$*9``'$9PBB($8`DCJ<((<@"$2?F@`"0X
M@15J@(*\^&0F((C38MJT%U&4X`&-N8NL6/4"#2SF`34@'"+:"*O'@<HWB"C.
M)MCX"3=*08<#^.,D51`"'TQK"0-``1">=8M`>B`#4'T#5`N0@RYX`';L420U
MV',,9!32_QCWDF0T+$D-;]`G.YD$WSLX&;U/(BB4",H'@F:P`U,"+!QWG4>$
M4"F]?KB2EH`-K&!!1*(L1"`G5PJFQB9`HYK4:"9!L5(`O73-%K0`+E,TH."&
MQ#\0N`!P,+IF4V(4(\O6#"PKVLI*D`F5J(P%!#=PP4[6XDV=K,`O$<":;+#X
MN-BT$S"&:%H[V\F4!TA`"`5`@EYNJP$I4,`&!H!`"N#`PP\,0(A-$((+J/"!
M#0B!4CEH@@P.<(()5$$&%^@`8[6`&BM@H'`1**DHFFN`-E01B[:ZP`HP8((:
M5-$%)G"!%QNWJDU\<1&M^J)M0M$('GA$#C(PP!64%0T52&`*JO^``14N`(3W
M_&)V`LA!$5@00@,H8``H3H`-D.`H'U@U#??9#U?%4XMAT:-<W0IK?MC!#7!A
M4GIJ9>OS_E.O?_V+>7*U5UVS!S`$.-E!T&,E*'&@@%<.]LI8SO)#2*0!';TD
M)J[M"DRT\A)A#O,I.6*-DUK@!"TXP443,&?+XARDHYQ%+'SI$55(&Z4^FQ9)
M%HA9C=1\62L%[2R#6X%.I%BT,LG&G;"YJ2%,N#05SC,O+'7!E2SP@NX*R@1Q
M&$(*#$`!%K`@!";N[@<2T`304$JA'(#"&Q_0T@A`$`0R&$`;@E0!)YS@UQIM
M@`E,JIM/2$$""M!`.>-[N#9<P',OZ(#_!N[97Y7:JCF'.#""866<4%R@#0ZF
M`F8^8(,8&`,'=H!"`FRW`"AHP`M=188M5%``"CC``0.```1,G`!2CY@%%!`"
M$ECP!O!(R@[/,.0/>C<,NM+#6P3ZEKVL48WFS>M?>O7'6]^Z2E1N?$`8GT<W
M`&8@!%CH75#&Q[]2KM<H_%7+,(_YE1>@`=8TB2LCXXF3:M:B8(+S9"V9``,L
MBY4VNUF9'+13@!]P%+684T?"Y/-5(A@CJJ"V9QC8F9)Z8A:>I.680QF2?V4C
M.1I<(HNY*1Q@.F#"W.9)`QT8R@%,P`0-!.D!$"A"$Z8P!2%0P``#,/&^A5#P
M+I"!"#D(@`2H_Q!;$T0`3^HUP0:6@(*U,,`*OW9"2P(\7]KPP&T;>(`53-`<
ME7+`!BQ834\ZSZK&D6K;C"BC39M-`P?+H0HZ2$`!%O!(,1SA`V+`!03:H`+U
M$.,8"_#!%!Q`@1"P(`$04(`0!I"`(DP!]<\M@@W&5.HA3N$*/HC!`DZG.V/P
MHQMEG08[U!^\*(2AD]Y+I82&G*ZULHL=1;[7O-#A?BB?/)7[%SY6)G,$6(#K
MXP<@4$T=XR(YPC'`Q!)=82-;`A1*H69NMF;M=0">M0*WE1<UP$Q-9P*!MD`[
M5UI3AS-5=S$L0H$JD75>`10[DQ,:U'5TDA<:8':A\`D7X$)2,U)7P_\R-+!K
M$#0!PV87@P`%#L`"4V`$;Q```W!B"K`!$.``4P`I/@`$7I`!!L`#*^`$+0`"
M*/`1';`"$0`'4\!T(%`!J-$I46,JB<`#!L4!*"!@:V0))3`$)C8Q-%`">V@)
M.Z5@7H1@C&!&V-8&>O("5"`'1S``2&`>2;``'"`%1&`[2_`"*F`[Q<`?"P`#
M1L!\S_5W0'1O(6`#U.=\IL8"FS%$010"2'`%5P`#1!!\R0`&^-%CPG.+M3@-
M\F)7[C(AS9,@];=)(O</"X(]>A6`(3=_4K9_!*`A!OB,T-@P?5!-9^822\%F
M$O0S@=9:X`0479%-1!<3`&4%+6`!-V`F)F3_`D(B`FBB:#SQ6*05$U9Q$M1T
M,TS"%168$U`7%0+D=2`P)"SC$R=Q%"8`&$ZC%_@57"YP`S=P&&UR3QYH3C=@
M0A=P`U(0`MHW!0&PA$@`?=$572S0!#EP41K)`1<`35H`%^-T0RO@`A(``TSW
MCIQ2`<SF199P"2\`!7)P4J"216+C$6[4"#HE>SG%;91S8*Z"*[;Q16W`!%@P
M!!\0`D&`"ZWS`@&P`````SP0`PEW?$^0!D%@`R$0`@E``?8&DD\872K&`O=F
M!"NV1P!G`QKI*`7@`V20!DUU"S]P8]]"5HND?OR25_,G?QH7(/02@-###?2P
M`W*UC'CU/0"((.'P_W+16)F6N2'3:!,MTA)?AB43B&9:\C,\$6A$-V8QX01-
MU`(V%&`14`/J.`&@(`+(I"-B!A/S:%FX&8^7!2,IH2-.P"3*A"-CX2,M\8\M
M8P(M8W,'(!9T0E*4=CBQD5MM4B<GE!<\0`/2UA@=]!-#(`0AD(1&0`%'@`)*
M\`$2``&!MP094#<PH(6P(8(FT5]2=&>C(P*!-C\"]C2@\`F/8U-<1#F]88@M
MQ90YQ5)?5$:((!PO$(2F8@G8%H90,`()D`&J```&\`(&X`4+D`,TD`H+9PP"
M(`8J<`6HB)':]YW[!@%PH`!E.9;V=F\L(`2FAI%(,"8VL`0!4`!U.7[30O^+
M%!=QWD)74L9_`+)7S_.+U7,.ZS`-`/!C\="+*'=Q!I*D`3B9`WB96)JE$9&9
M*[@2>U9H*Z$Q"G0R$#A!5H&-6]$`J*D%+<``@^.:KKD"M?&/7O9`)8B;7HBG
M*"A9B@4E*>&-WJ0Q8<<R''1#6<=>%@!IT&E":Z);E4:1&@`L%&`$33`$4-!1
M(H":%L`H"F!B"M5/4/`!"L"BS&*%7D`!+:D!`OEF2&$!,C$!">`#C&596E`!
M+B`*>G$7G_`)E]"@V48J-RF(KJ<)D,!MK=(<L*(GG+!2V'8!*%`*K*8L*K`!
M;9,!*I`#&A`$][$,0"`$4[`$%%``-E!J^%8$"8#_8@,0<'YW;TDXBJAG`S>Z
M!$90!-K'8DS(E>.A"NT0268EI)JD2O:G+AT7C!(B#3O0I._R9.PBF$<Z#]5S
MF,ZHI1([L0HQC:UE,BKQ)`O8,Y^Y)5NB%%AA%4WTFU#"*:EI)>S8,KFJ:!?P
MCO9(CZ95LJ:%,:VE=<'D%4J10%SR3/_(@8;Z$A7`@5&S%U?T6Q$`=U;#=L<V
M!7*3>%#`CGNC!2[P>_O60T-P!%6@!'"0``X0`D=TA5[@`5)P`/?T$E9`CL=T
M`&WF!!@P`$'0`:?A!`>P`O,%-=AVE&?DDPE*1L`A.0O*;=LV8*FB4YP@E/XY
M"&U0!7AH!*E`!'RB!$5`_P0%T`8Y,`R,%`090`$^D`$LL`1#E%V>BV_41P'G
M2GT.,&)C>8I%,(KS*G#T>@5!$`/!USO08%8XL'["PU?_,;#E,"'T5W_K,$KA
M4"%YA0]%]@\/^U;->*44V[R7V0<<B[$0-(\O*#(BDX]BFK-0X@2_N9L-X&;<
MZV:%QE]4@P(<1#7V&6A/0KU848(8(R52<1(JPQ1>NK-EL1/L>`/CA$PV5)VA
M(ALC%35L1P5MH!>RV08;@)&N"`7#-0&=\GDCL`%P8"A0<`1#(`,08&I&``,!
M8`-X%`,I4#\J<0(M(!9#9W0,D`!OZZHM,!@YZ!R.@"J^$<.TTJO!41LMU0D(
MNO\<L;<)"88;"E8<F#.(MA&&1Z``&RP`'K`$&Z`$$%``"4`%,("5\?8$*G!5
M!7`%&5``8P*7#E"ZHVH`7&MOSF>6SR4$F[$$-2H$CC*2L2L[TU*[ZK=(Q>(.
MSN-Q2;I)O?N8G>162EJ\>`4P3PH0B&D@P1NQ#S$^<L`%SMO(5Q8#9"$R%Y,5
M-X(6/R.#_.@21;$DEL6]W,LDV\NF,.L59-A.!=FJ4*&F)4B/G]P4U;1`W*BS
M2!)FRSD6]WL4="(8MG60LD$"@@`U[L2H+Q`*)J!,&I`%Q^4`3"`'*-"01"@'
M$BR%',`#$5`%<3`"<0`!2#`%!3``BF@`0``$`Q#)W]O_`"[QO:CI!!4P`%.0
M6Q;@PL;1>=CF&XG#*HB08(F0'($(>X`[B"A@=F7DSP0V*YE0!0E\!62P``5@
M`#+``2&@`TK@`[P7`T3@`4F@"RHP&D8P!6\PDDQK!`EP8@:`;`90TMYIEN?:
MM>,:`IX[KSBZQ9X1`QY@!\$G`#_`#W1<QWF\+@O;NP1+#O+W(``A+TD&(7?%
M<0,QU`!!F0_1!G'@!@W@R%(-6'[0)3\!0?38,?UC/_:C<S)X)-/+9JT<(TUT
M,W`A)WQA0LB4$C+;UB4;CQ?#L7\*%CEQ)#DG.,AY6RL`!7!P`2)@-=-Y)K-Q
M.7:!UI#@4EC#-$5!`UG@8!I@_QA#\`(BZ`0KH+@Z,`1[>+0\`#]4L`&/D@$=
MQ0,RD`%DP`(T4'-S^T^JR41K.P$08`0E`&`@<+2V84*50`);-"NF8E*WP0CY
M?`B,<#D!'=P!2JR,<(C.9E+Z7`)0H`!+D`-BX`,.@%`*\`)'``,4O00.@`0+
M@`.J$`-O4`!3,)(98`-[QP+4EV^=.@`.@'K.%W@MZ@`*T'Q&L-%,JY&>$;M8
M:0MR?$C1D,=`'=3^\M._JTH`P=.@E,=`1@#XDG$1LM3,RQ!MX`8Y$-53?>&P
M%`,`=$WRN()"EV8H$TT(M+W;R[V7=::[::<-8$PL<T^H99MB?9N%9A,SGJ8K
M_C-0X?]UFOQUA,I!9$@%U+QV38,UG)=V(G5/B_%L49,3Q<$$#T!%\=0!"?@I
MURG8+H`"$2`"'=#<(AD$1Q`!')`"4T`&`>``5)`C&'"VEC6RZJP`(6`"08L!
M3'-"J;)@\Z64M'$YLC(JKQ?<7E3$AEM3J6*LK<)M`VU3GC,"1?`&,1`#37">
M$)`)6"`%0_`Y<#`$,6`L'K"Y[>FY+%8$^-9O\!VC%)"6S)>$^'9O0F`#]<T9
M.1H`W1$$ES@M38H\_PVE#;O'O"NP![Z[!QYR0(9D`*/'H+0#3.T0;?!K;X#A
MS*X^,8`D[TMT`;04-Y$R2B$TR"2/>:JG)]&F0B<C&%,!T%3_$RKRUJ1%$T\Q
MXQ<#G`RXR2TB.#WKLX-SCGIAD`"\1>D54RT)V+F:%S<@MQ,0&([7)G&"G&IZ
M`4?P`@$O!1^!!5MC`!^0`D+@`T@@EQ(?`SI*`2,@!4+2`&>;IZ+,T,J4@(&S
M&+SA'(>0YPY:`OBL&XJ@PX[0*IUP.$TS8/<\.<`AH$DI"@9V*[7!`SI``0'@
M`T\EP2,@V!U`!0Y@!)(B!DF@`F!@+@L0!$N@`*?;!!WYQ2@&`0F`:B7=?*<6
M>.Q-QJ0;HT:P!%?@&2-YA7"LK^;2'X%I<7)/?Y]DI!M7I+T>I<-.U+SXX+R.
MR,CN!AVP[,U>^`X3`R^^<R]H<\KD_R(O(S1BIJ8B6ZM>&",YH:;LCC%J1NXP
M#K,UPV;J+A-(HEK[TTU'03@:<`/G&UMV<HY5A-M,HX-GPD'WQ29SGA@B<";L
M:#5-0VT8P&8HD(16N]E\K1DI(!T)D`#;C&(^0#<^T`07T!,M<`)N)HY>Z,U.
M`1>RX47%AC@SS!R!R!N54#FI\L]4<`2\[X:$*PD(%CF,<!=F=RN5`(<28`09
M$`,Y`/%08$X=``A,"3EV`DDX*BP923,S21Y+"45+2T44$!`#$`DA+"P412PA
M-B$4IJ8."0DL-D)(1DL%,$%$1#$+`+F,,S@[.P3`!%'#Q,51P%&_P\+%.#W)
MOK[&T\0[P_^_P=?6P&'"S-K6T%$#)W_FY^CF;6Y=#5_I\/'R\_3U]O?X^?K[
M_/WZ?0<:'!A(<""#"@@K,+!@H0*&"1-`3,#`4.'`%@<26IB@Q4D+@1,LM/#(
M`(3(!A\+#FS`$F6+EP)="F0@DP%-C!4:'F1P8.?&C2!$F%C104,;%R)N/'@0
MH4.-%3<B+&7Z@`2)!RY6#'4AU06/$3PT,)&BX<:%K!VD/G`JPB3%%RQ@P'@C
MY`@*+",<V$AQ9$`1#@:0L'#P)H</&%!:(&1@!:43)U:L.*%`I8$%H25*+"6!
MX@()#1JL?@8-ND0;#1=`?T:!`G5F#2A>T)`!!\X#V#1:&Y4-FL;_B]\O6+/^
M;3HWZ\PE7O"`(F-`$Q\Y!HS`8F("B@$%"#U)DN2']R0`'('WT81(D"40%*2'
M8"#5``.J.%$(H6K`@`1ZBPAAH=]&DRD9^$"$"@+D`H``/V"S#3+44,/,-^#T
M(*$T#1H3CC7=5+-@,!Q">,TXY=3S1A=_O/&./RBFJ.**++;H8CQ]P*123C3F
MQ$!(#T4D$446#>2$"!&`@$$%!W3T44XH=53!!$321%!+4+[T$4L!R1C03#T%
MM)!%/&6T$45!U>""F!V4V0%13)GI0@=,<56"9VNY<`-7$43`U5@D<'6F5&Q>
MU<&<-]3P5`1`2I&`$$8$(`%S'`S@@`0R_W!PR1`;*)"`#4A,P0(#3E0`0D].
M:&'%":2V8$05!XC000DT:+#4!2^0!MIFLK;1AE4:E)!K9K:6,!P4'\`Q`A/"
ME<9K&[X&)UP;PB6+@G$H(/<L%G$H4,05.1B1`@UM9=%$$#%XD,$3.#2R0[D_
MS/##@89ED`$%"E!@`PL&H"+*O*30YT`J#E`@RF`#"!$"HE/(`@09"SQQ(!A)
M1!%&&!52L^`R$7]8L<71,"@-,@1TPR$QV41A0(@OEFSRR2BG_")`*1744$4V
M*60!!AB`(!%$,SM$9`LK\``"0J)6R9,6#6BA&$\Y*]0"3RQA=,!C4PI4I=,%
M89E33Q4QE.-E)O\`.F=:?Z8)]M@N7'#!`V?_R=52-8`@)E,D-*76;4LYM385
M:$=T019'7)IK%1RDH,D(,E2J`P=#Q`'!"$-H\!@&(F#4@JBDGH!!$52T8,(#
M+S"Q5`2<Z>H9:JG)*JNNLK*6Z[,Z?"`%#[8R:[I1S8+&+'#,LD:#;RC$7@(/
M1XP0;Q$%_"5'5C0(`8,/8C2AP@^[\+++#T]X$$3!1,`PA1`4W*?))Z<,T/U[
M\=U'R@`A.""*$04O#T0:!@+P!(,,1LPQQ1?GKV$T&7L,<8<1(X?*!DC``AHP
M90"A$D&V5!&%*"0D.HI(3B#G`@P<8`(:D$-UBM08)P@$,J%J@$UNQ"/_+5U)
M:E9:B0)7TK*>C+!F$+&91"0"E3*Y8$UUNJ':;E"F.K%I*:W!RM<ZD)4;W@`%
M5#C+"D2P`J[`B2E\XH$.W!8!V*#F"%)801L`\P$)*&`$'.``'#X``1E4X0-#
M>$!`#M""FK'$"BT8U0E`,``7'*`J/*""#TF`.M+@RH^CF1ULDJ,!V5"!"9F)
MS>WZ:)38G28VP!&.[G@7.PW0``H<R$0(KM`$#LCA!A.H@A%B``8``,$.!^(.
M([RC+NX(@`Q!\((/BC"`#;S'``;@7@),89]>PL<&K3!"",2W"O49H0E+>`,,
M8E`@^24,!Q^S7_WT%[%P[,\7$\)&A^I'(6,(__"`X`RG.,<)(YI(K2<ZRPE#
M7F:2"(+@1IN[P$*J$@&(2(DQ'XF,T6:R3@LXJ24M:\F37I*EBWC0)@7UE$1F
M1C,0F,`$./S34&IP`QZN@*)B\F&9ED(L.ZFI`T.!C11>D,0ZV0EM*&U*5F!E
M@17P1@08;`T5)*")#4#@`V%,P0@\P0$92($!3N.9"*"V`@N0:@40"`G:#ODG
ML[BJD:=1C>ARA9I`@J9W*"#!;[`:G*O2`%F.C%VTGO552`)G=[VKY`NJH`09
M0"`$4YC"!XYG`2H8H``#\D`I!?"$5B;A":QT1!H6X($<4,`!$`"8^M`G!!L<
M5A44,(!?2.'8]JR"%?]%,$(1`@`#(GA`?G8(0BYFL(V*A0QDIZ6F-:'!OQWT
M8$/`0$"&-$2-;Y+SMKC-;<EBT"6#Y(1)!]$:DV*X(X8`J4XAN4!3/C60"9B@
M(Z)J`!P)HI`15DD@47.)E%:(4!/NI"<YRA%$1'##IDATHE%!"Q&EXM&F?$Z'
M:TJ+"2+P@L^X0`-U>A55XB0G(TZ@`4G!0*>&(@,=V%0"(]C`!CX`1@@@80D&
MD,(&*M``FBD&`U;0`@-<P"DK=,``)@#!"C2`!2:X8"AF*\I6D4."T]Q&-Z$)
M9&QND"O90+(U;?A-[ECC2-WX"C=G16N/:9`%MGX@`;#X`!8>``(>R(`"LJ#_
M!1"F3*`%P&\[W6G$#%[YAA`80`$*V(!D!\`"[LFK%*E0`/KFDP!+K0(5_LI4
M!@:$BP6`!P!)4(8T/11-:B:C&-UL+0$00&A">XRVT["M;A?-Z$;;@[<%64@#
M&0J1D`1E(CD1"G[/9`(4L$DBU0'!#;30D<>XT+H*S*X*H73.@HZP2PG12`R[
M-K:TG'AS3%!B$]-T-O..+8=E4VX-J""'&K#IA_I5RYK&]-`0/ZW2(7&!'(XP
M!.$%"Q.8H,!_FA""-\C@`2)PX0-NX(2#2$8+*%#"IQJP`B9H8`4BWO16=7,!
M6X7&BKGR3.^H(`,J%(5VM_,-[FYW&H*79JS!D<U6_[>*+-G(00I2<*LJ=.!N
M%[Q`!P980@9D`8,,!&#.M(B!"@"0+EXTH@=B\,$2%,"!O`BA7R&(>2H@BY]Y
M42`!\+G48SDA!"$T(0,Y(((8<@&&`CW!FAWC\S2E::%C%(,9JVWM-L)@Z(=Y
M[!OU(P`YN-"%KGO]ZV#ONJ/'3G8"\O8E(]0(S=8>D0FT)2%,O.^<4!`!*MP0
M(2^80$J65"2&B-`B*)$:E%;MPI44M"!<8LA!'MC$"/3:I!>X`0-$4!6MQ%>Y
MH#O;>V]`E!NN@+T1R`(/S$*5U)SF;&F+P!)K\``><"`!HP]Q1,J&@C@4+A.J
M8$'[`B`@'W29"N&V``V.H/^!HIW`"0>(C05$U=)/8:`H98L5(4M353^2I@24
M4H(<C,*KX?!NQ;'1E:_,JBSA1-+&YB<I%K!PA,!Q@`:M/U,5-F"#`@0`K^3A
M``QRD`./!ST(*F!GC8`#'G`%FK`*1>!8\Z$O-E`$EK!+I7!8#D!FG2`*#N`*
M12!G08!*X*$PO'`,2><A?@9U?L9:_+,,5"=;WH`,T?!TY``'816#,5AV-%B#
M+L);,Q%K,P,1:V<S(@!3![`1Y45$+L!D)-!$(H`!;5`!+7`"6E`!-3`!7B*%
M!15X;+1=3>,T*%%X*L%&01@2+S,SF[,61*$6$?`41=@63)06[(4VFJ=22I$G
M=4/_47/2%*@Q%7QTAV8C8E$A!7"@%V^0`BX``FQ8%<16.`H@60Z`!(;A`QD0
M!$&0`P5@?Q1``Q/P`$Q``Z)B!3VQ%@<P*A4@`DP(`DMA<;#3.;GQ`J+S&:N!
M1,&3`J?!!,QB&I(4'+?#5>+W&KER.^7G?924',]";$-`1HQ#!2^`%24@!W#0
M!/8''3Y0`&]0&`7`B!EP!3!0`#Y`!@*P``M0`!SP!A.(/J00'R$0"@EP'ZJP
M+ZJ@9OMQ6/[""J0`(#Y`((:P'0@R:'W6(/GX9_RH6B?8@AWS,%A'`"T(,HIF
M@PB9D"@#$(IW$)5&$6L'0TN$`26Q.1%P`R!P`707$1;P_TXBU&$G@$X'E1"]
M%7A2,B4GV4)KM!@(52,;`1&?-Q505(IL6`.J0H2@-Q4YQ$,=P%1I<T/P912]
M5B:]]@#-AD$#4!A3X`-`L`0H@(06<``F<`$C\![]8@/6F`%SD1W]YRX98`-)
MP62C0FH-X(FC(I4CH11<,2LH(`=5H"Q110*C\P!RH&:62%]1-1QZZ2N^L4BR
M\AD!UXO/P@.[$RM:Q1H\(`=0H`,C\`%0P`15\%079P-34!BSH#T<%R`PP%E-
M(!<P8`1PH`!P8&=>$`##Y`"C4`J.!5FM(`3]X2@S9Q_]`H$A@`0!D`->8&?<
M`0`,`X)+-PW[*`WAP(*`AC\F"/\.L$60OGE:6D<R"OF<T+DB?;`E!P%#/_&2
M':DC&7%1:Q)OM]%.1:(8)I!A+Y%AG-@EZ,E&IN88&-$`'L1J(F00,=,0ZM21
M3<1Y.H121<@4%;66RF5K:]-#3F%L33&4^_DJH*%Y<EF$+X`%)1!J$5$%]0<#
M2`!T$+`6;5,#0\$#[;$)\_%Q&?`&4\!9&Z>5T>$V;;`"4*,81Q%'5L`3<%2$
M*P`K&Z"*/'"C./9CS-(&3"`#8/8`$U!%QQ$;-,`#+Y!COE&DN9%CP:$K@(E5
MZ4=6N2-^L,$$5%`%4*`$5``;<H!(L<%O`Q`@0+=QE?F,'9<!S+A__6>:1B`&
M.\`+"T#_!%>`+_L1<T50@8@2"H=5"@)S<PZ0<Q2`*,PX(`4R`ZGT"]W@/U>W
M35#76A+3310C=2:((1P3#!E3#`<9G9JZJ?<PG=6U@\/5$#HB$8M!B&=8'1UP
M`9171%)H`36@`2'!`*+R$CWR)(.G756R$M_%A8LW)&X7=W92AW5"`O!W`R%F
M`AUP%7(I-VR8%F<S)A&E0VDADYX1-XZ'7VB#`O#"9"8@`B206`XPC7_Q`)]7
M'0^``F&A!"P'!^48``%@!+8YB06@E=#Q`1?%$9/#B2(@!360K])U`@S`GVV0
M`D+`!*#S&[O3*@_P)K<Q`@:0'FU0EN,'&\K!!%;*`T1*F-ZG_RRKHQSEIW`W
MRG"F`1L\P`19(`50(`>Q8DG$H@$\@+)"D`/+\XB3N'^0^)D!$HG+4P`VD`,Q
ML)D`,@6:M1_[X0GH.!^7``%L9A^XY(XP!PL%XP,>@"!_!09IT`-6%Y`ALTV3
M"JG5(#%.]X_8]`R,*@RE10R9RJEJN[;G,)WHM(.B6FE!T:T3<"/&-FXK,`&"
M@@%1P40F@`%=TQ9S\C0\022"YYY1\R21=D(*Q#3?=1G&-JWM)14H8)0K4$-U
M8C90)+E2\9-LXFMSXX::FQI7D167^"87,'HHD`(L,`0\D`)9@*%`\AL/T`81
M9DDR(`$AH`!#D&M#D"CS"G2'D0"NDO\03C`!+I4`)4!J'1$9$Z"J$0`%0T`%
M5Y&@+RL%I[$:/4I&!G`$([95M%.QQ%9D(3MOD@1)O*,[A%F8P'&D`0>96)`%
MLG@!)9")OU,%BJD(<N$#T"$7`>(#2VD'*G`87:`"2Q"HE?`):,8)FL4*J'ES
M]B%F_R$$]\&GIWESP32BLR`&@.5*`-`+69>/7ELAP+!:@-:"T8`#(%RVQ@DB
M;/O",`P0`^$0/[$D.O*#$/%`\;4F;0%J17@46J$J)F!)P8=05#(2C^$1`M6%
M5S+#O85.-_)Y)L6&\'6YY55Z*+6Y,[D6_]F&5Z%?://%=:(!88,4]#LK+J`$
M<2`':]$42P3_4S0&4BY@C.?Z'HBC!&]I*%<0O/MWC9TP!!'A!!;@`B.P!%2P
MB:&B!2(&`H['!"JKBG()!2-P!!=`+%V5!1]@'\<3&ZJC&N0*)#R@!$S0OCY6
M2`S'R;*1B>V;L+681W)`!50`.X4$F5``!57``UD0%UHY"]#(64$0(%/6?Z<T
M!0$CM`[H90K@"HAB!#:`'_TB"CW7"7\:<XXR`)8R@?-1!,ADC4"P`-2S+KF0
M(`7)@M94D*9%D`]BMB?(6CW0"\N```"$6LT)P_2LMC+L);]%$1VYR!3!`#7S
MN7028A5@`B2@!'91N2)P-I7K3ST"G]JEDA?!75#LD$!B)C;41&RX_T1$,:TR
M:5)RHU\G9M!<'"MH@U^E<P$V=#;3^\4HS2:1AP$TT`%!<5$D<`-"$15G&(JA
MX17#Q`&S*<HR(`3SZK]$G0`/`%0'4`,;0`$IL(FB\H2JLA165`55<!12P`%4
MP"H\4`(D0`5'P!X<\`(7\%6PH:`N8&D/D`5?59BM81I,JBRRD;!)JJ0).WZR
MD4=44&2(A"R7I`-Q<,M,H`2/:*(Y<)LF2@N0*""A%7-+8`1&L!^HZ9KGF#X.
M8"D]UU@0?!^HL$M(^\!7V02WF0,CUQU5FP3/P%J]D$U2YZ@-`C%.]ZC\\UJ_
M`,^I!8)A,#+UG-O1*</J]%L\Z(,F$80,,/^5:\$Y&F!'!U"$E"(%6?"?<KD"
MU66KK':2K69X7>@0%`%19J)1Y04:3E%1=XL5G.O1GW,!_(8$!:``9"$'):!B
MHDO&9V&D;_EN"\M>+N">Y-5Y('`$//``-<!>-ETV3"$%%#`%-@`+5Y``54`%
M<#")[K)_AU'8@&P!#5`#/DH!GP@9DH&\FE<F-2`'<?!NI4$#J",%$,`!CZD;
M414<;<'54OBJA*EP/$:R<HVPZ1O7[.N^%6NQD`EQ/""7)>#5/F6Q/#``0>"9
MCCB)/A`$/A`#9``$M.`!9(`$?K$$VR,PK"`P..<O`V`#2X#9\=$*JXD?L+E+
MY^@`Q+-QMSETZJ+_,(9@#2DL=3B0#+W`VO)<VR<<#>U<YPZSC]R0MKH=Z&,'
M$/X<$K]U,S93,S8Q$55T0[%Q%A8PQ*ZW.'%P`=41&N_TQ`Z-A2NT0-TE0K/G
M0SAD)VOBAJ0.E&`SZA[MT97\`2R`!#9P!.<J!5GUN0BZ)BMP'-ZMN:J'Z+;6
MD:ZN`_EU%2OP`'C3`4K@%YX`"Q3`WU(PH@]N&#M+`U'9`"8`!0.`!#PP.8_!
M`,6^L#10!5S,!&$A2;?"!"G``3Q@-IZ\%B_@NJU'`R#0`"[PUN9.BS;>OLI2
MX\"!L6U``Q:;UUB*QZ[Q`M.F!*+'`UA``43`O_P+C4#0\$Z^`#'0!1[@_P%3
M('.9T@1(@`2--2^OC@1-P/$)2-F3\-@L4,'B,TSX80HA?W^/F##?$<Y\7N?\
M,^>N):E/Q[5/U[4HK$U+%PRX+>A$7W8,B3,[*$,VTQ`-P"28"%(\2L9=HWY2
M0-5#@`(F4)'^Q#2,NT(.7=T(51(8;5)K`=`_E$-EPD-3+)-E[]$NU1Y*T-]1
MH5SX%;J;<19$U`'/8I25?-QK8U(B<".-'@&=`6^BEF,10."B``'[\@%Q/W]A
M:J+\VP14`%RN&@>UE`),,#E&,Z,?[IA(9!I'@`5B8=),RM5ZJ+FP$<NS\0$B
MT``1@.^YHXJBPY>L+..%F>,DKAQ%:K)8``5'H/\$634<3!"_5`#P51#:-[N_
MM&`'"V`'X9(&,/`)-E`8U>CQY1@"37`%_M(*GF!FGI`*?FH?$-@OJ`E,F24$
M&A<$W<P(=[8=.`_GJRW_(TP_W@`R\R^<OI"HBPH(!%$$80,G?XB)BHN,C8Z/
MD)&2DY25EI>8F9J),183$QB?HB`@$R`'#14,%EDT)BM44A$N*S<1&A<U(A,K
MI`RK!P<5J`W%Q`W!Q"W&R,D,%1;1("X1U=81'1H=-RX=WAVS-=0/Y`\1Y!<7
MX.G8+C<\'#RU$>GF#Q<:Y.`=+K@NX@](=*A1X\6L!S0ND(M0PT(#"R`>Q&HC
MHL($$1>4?-B@P\84."/_-FP8(B5+%1D<"F0(D"%'B`@@HEG`T,$`!7,C3#BQ
MTF!%C0DHI%"I0@47"A1M:.#2@$(#B7L:G)*82J(-BA<\J&RPP63"O1(TF!Q]
M08/&BZ-F7Y#E@99M6;)ER_+00'8MDRI0A@SA<:'$6"98Y#"A007+E"`Y$@>9
M0B1#$#("%BP0`(!(@2D!KA1HL@2)#2%%*`@1,F!``M`)!A@P[<!!@M04'(1P
M'8+%;!9%6-B@D*#(E`(PNG@`,"/)$P!@DNP@0&#'CBC0G4N/[ARZ]4&"KC.W
M_CR*]!T]PG\/$P9!&.;HH1,P).E-F_<Y-LF?3[^^_?OX8WS"@(&4B%*D?.)$
M_RI>'2$/"#Q44<,V((BP@@FEH&*!"18$TXPQR1S3PH;+9!C,,\%8(((+W7SS
MC0L/2'%!-_^4Z,T]YY0C8T`*8;."3^*`0V,U]PC$#S_<H(C/!=:X(,(#X&C`
MA`:SS+1"!"0,(0$4-YABP@-R0%"$8TO`H0$6*%"A1!585#&$#$($T$0&33QP
MD2A`);!!#5J@,($5+:S0@0DF,%6"4#24P!03@UW5E%/X6(5H5%>%)<-N+T2%
MCP96J?66I7'Q4!:A-&B*5EQ*P<4#H5GD)0,64S$5EA1'0$&H!@KXD$,0/A!!
M!&(^9-!%&F`(((`*&4PQ11.8&5&$;Y\9(81N+"QK6O^S(42+V[(45#N;$"$D
M8(`""61+@0U%+%%`#D2H\,,/3QSW1!(S#')===5YUYUVZ-6[W;O?Y5M=>6%8
M=^]ZAT1"QQPG=/$%?@@GK/#"#$\20RBC!$C**<(P\$`;1U3A0@47O-!-*2;L
M\@P#(/CT2P,,6-A,AL6T[,S(OP0S@0GCF`CDD_^80R(_W=Q3CST_UWCSDT3.
M6(U"#P3)3PU#XM+!`TSQ,!4Y&F2!PBS\D/,"%2@\X,(K#RBA``4AC!L`B5A(
M(044:RNA`TI(Y`"#'#-/<,,N%C`1@APM:'$``RU$Y'4-#V0!`0=8\*#6XF==
MU494)3Q>@J!/E=`X#U`X,(7_#%#?H(%91X4^UJB#\:"IZ76-Q7C'-#2:E11#
M<!!'/B2@T"D62BB1.!5#A!#$[[;"$$0`C($!```J!`&#L%,L,46WG.5F6VNB
M"6&##4LL85L(-ACKV@`4L&!:;`JDD(`#-F3;/6:UVI&<<0`(`,8/U\D;W?W8
M^:N>O=FYJ^___$+/>=3#'DET(6`-2Z`"%\A`2_2A`A`;A2E*X82ZX0,*=NJ)
M-B@T`8M,8!4FJ`$&5,&`"W7(0P=8!C)2=@`+_&(8J3A2C9!$(A8]Z$GFX!G/
MSG$+.71-1SPR!S9NP(T8+00=Z%!(S;IQ%")QXT5%NX&>[I$T6_Q)"2BHT45*
M`(=C_X4@`%XHP@6HP`$6;``O1WB;#&2@&SFLX`(T(0%,)@`%"'1`"Q;84`->
M02(0U``*,E!<H-*A`;^$K@V&/-3D2E"[UKV`";T+0`I<,!=&(45UG=)4)C/I
MJ4_%I2ED:0-<`!,[#FB#+F61@Q*@D+$V4.$(12`"$"Q3K@R\P0=+@($'TK"`
M(&3@"IF9@F^(M01G60\WX0M!;KSE`/`9(%NR28T#R*8`VS3K6^!JPKB(,)P?
M)`$`WQ1`$O3''?NI!SO9X9]VY/4_Z?2`$.2)9_\*&(D#-O">^,RG`CL!,0"5
M0F0M.-*54("%"*AB`O^8P`$Z^+>9[8*$P>"0"C.4,I>QL/]"?\.`"&QQ#9[M
M#$CMZ$8-:M$S)$6`D?;`QM-R^",@5D-'3R$'"=AQHP[$E!SN$`<U(@"ADHGC
M'$^K0K7RT8LWTJ`*!K!!`HS@`Q\48`G=DD`LE'"$4D+A`J_XR0.:8@H.C"`F
M#%`H"&ZPH`CH23`HB%Q4K-*H%U#N*)&;W'N:8BB"ZF`(5HM4%DW*5DQM\BUI
M89Q<%(?(I,CEE2/X@$$N<)6L8*&J2B"4F99PJP#X8`%$2(RNC),&,03A"IB1
M&_$*<(4F>*8S+#`"$J9@+!NP()GHZ]ZR9B.MUVK+`=CBC0-8$%HBQ"`-3Y@!
MN@"PKBB$85[L_(YW[K4_YG*GG?G_&L1Y[#4(>D+"GOK,KG:WFPD_?&)B(`C9
M?TI8`<^9H`-'-8$'(=+"";AP9A!*6<Q2R*&5S;<!'?K%"RMPWB"&U$37,`<)
MF-0B;_C7B#-R*8"Q<8Z;1H4AU"!!"9"60Y':J(;E(!06X"`$!4`-0FW`0APV
M,(#=".$*O\M!!C(PI2I4508CT,$-_-B!\#*A*!:X@0(VL()G:$`$X+C!2NER
ME,<5TE!P,4M4*)76R%EEP&:)7)/O4@4:@&`5*[#=XD#U24.]I5&=4@M2+&<7
M*'#@`U7X2M1X4-4A0"$+5)`#!X+@A2X`005VB($/NA`#`:SK"2JXC$H*8(0`
M9.8RGA$"_Q*6`,PF6*\(H/'6:ZOUFO--4PBN"=]KHF6#%6<`!CD`@@#.99SC
M)`$']=,7='I0/W3V[[G0I8ZKZQ4%ZSX"N]S-M:YWC8B'P>DB(1M&6&^``A!T
M@%`@J$!,6J`*GVA`O"(;643K^R$088@8*;/;2F/T4IM5PQT17A&)NHU@=@Q)
M9U!B:8PH[&"OS8/)DL+&2,>=PVHPX0.\2<$`%,"##OS'!%3@EFW`UX0FD.M6
M.8!=">00!PXH(0(B@M(!1"`%'=CI!47XP`-:H`$I['0>4!/E(:WR.%$V;L),
M:?)<*Q6Z%UA%!ON&0LCZT:G`+LYV;Q$EJ%!GJ4,9B@=R@-T(H/]`M0LDY2YZ
M*4DLJA"`&*@@!D3H`AF`IP(/_```BRG`&UJ2RPP`QPA&8`$+EF"$)A3!"!08
M`/I"4QH#M*8TMHE-M:99FVFB3PA+>(-F"@"$!<S/FTE(`F50#>OI-,>YM$XU
M=*/K:G3:VA%T<`.O)T_Y?'HW&M]M$,4ND@X,1"!0R7;A@$JF@2.L0`0/_5M%
M6X9?^\)0]:A8J`@6!$0%Q\@;M!`!'_GQBFN<0R$SE:E"@`0.;@=Q1@%!DHY$
M?JB%$!$;]^C&"ER`A0$4H0D4F-W7POL`*"1`[A(PP/5A,$M?*L&K*9C2"BP2
M`<6U8`(T&,*S#<.!C9N`!RX(K^Z?-BC_(Q=RR5=Q%J(D.6M%%@%X%F<1%F+S
M+1OP.%AA%H"U98K35FF1%52@*4PP@9^T*CK``5`0`3<`%8]4!:M4$G=!!1"P
M9[8"!#&@8L+C`3/P!#'P!D$`!([1!8FA8JHE!&4'=MT#=]'23+&Q&[*Q3.FC
M&B%@/4$H&[I1<$T@/*+V`\(%3L?3+J^F7.4D"(FG>(LG'<QA'O;R>)4WAF1H
M>1C@"0'B(!/0`A`Q"Q-0`_3P`"!PAA4P("9``F#R'PS%>JQ'#']C(<*@"B'B
M1T!E?`N!>_O@#C>"(OEG"AS%(_5``K&01;-`4CM#14:D4D;T(SYS`0,V0PM!
M)-9`$"+0!G$P_P`0@`4/\`HF(&0!UV%J]P$I\$P9``1=<"L0D!?X5R$,8`(1
MP`0/8`4@H`%58!!2P`(\$!,'8`(=9`I3A`]<LV11,6`!B!0DYQ248H`M!U='
M8!HA<$9-81668SIL$8`YYV690BCD.%BMLRI#,`)*4`)"1BE),119(`5$(0=F
MT@2_8P=5!P0^$`0Q0`;!]01RTQ+E`@0P\`8J=@4.Z3S%Y!E(T`3I\UJO%0+6
M@I&MX0`&D`#$8@.MP0()H!L4@`1%@`0LD0,QL`!)<"[I<CP_L!S,P7CVHX7H
M@5R%IVJ&5QX(4"]B6(9`&90+TPFFH(>ZUT'3H`$XXQ-S]`E:T``N0/\H).)"
MTZ9'+N,,R5`!P]!0Y^4SV^9[WE!$N#=NO:![.V4-/O,49M8&[C9])D)%,M)2
MO\>)ZO"5Y;`BY8"/*[("6#(`@<13M0`UML,$.F`;$A`2"9`!*K"87H`$(S`$
M-]`"+20"CR0%&F`%$^!*5C,"`^`"#\%L*/,)OH@.;"$ITBB`B`0Y2\9RHH,4
M+R`#'\`!'"`6F-)8&8A)8G9)HZ(I6$$%@W$IIM,IL0`%.B`%5Q,0U/B`:5,%
M58"/&R`\"V`'DZ$"72`\`+`#.$`$4X`$;[`9M@@#G[82;Z!-`<"#1B`LD)8;
MH+$]&"EVF78]X>,`U10^(ED$W4,L",F2@/?_DJ?V'#19'38YDZU&'?]C/\Y!
M"#V)'C\IE`S:H/+A71.#>B$S0OV0#V61#QW@7D[9`!%@$,\V7\?0ARQ4;;\@
M#?1F#D]R$/5F8/I08;IG"T(D1)#H.$[#E,6'#K]7#MYP`4JA(S\28/8@1"BR
M)[@`$RMP!+##!$_Q4N6``G)F`P.P`1RP`09P!?^8`Y>1`";P$`O"`U+@,3<@
MB1/V``I@`"[@7I+);*;@`E.1#I0#%8)"%R5W%E/A%X5EC2LG5Y72.FEECIJB
M<ZC35JY#*(\T&(Q#*(V5!5AP)E@484QF*<U)%/@H!380!'PV'`(0`T&@`L$U
M`UYP!>("GL.A`C``_VK-HRS'DEBKM02A03;9,BVZ-7>O\5JEL6AHYP#JR8/:
M]$LL$`0X`$[P$US=,1VR]FK>,:#>T0,%RFK'^AQAB$`.&JW2B@F7=Q$.PHP'
M8&Q40`,/\`)00`5Z:`H68`4,L`M,\H>`F#*2&:+5)@P7@4-G.0O4,$,E@C58
M@Z*UX*.S<&%0DE9>PR/AL%+H4$CLA@(QA0_1]R(/!B-EE7LF<J0ID`^0HS-\
MV0&O&7X;D`)PL%0PX`,P,&A+$`%'0E>1:0$N("9F]0`L``'*9P)Z-`%/PUCO
M`3D&RQ0TPEA'48"-TP9&EYI7\3E/(682R#A8L9M$ZSA8$8!9H4F:%!94D/\%
M3``!MG$$;=`G1*9E]R@4L<`$,E``M>(%50<&F`4$.!`#+5BJ.6`N,P``'H"E
MX*E:+'%:BH8]9S<;W2*2W:(L)G8]+&"2U\.#N7%WQ!(`RP,#,R!<WG0\Q.&?
MRDJL,QDOLY:3JM9JVP$PTWJYF"L)WF4E_U81$5$%/!`C*]!"*2-Z3E`!U;"5
MQ7!"*:0R*'0`&$`SY%8D+L40^:I2.E,#,%HC1J=D"L%82P*"M!`D0G:(MY`/
MM^!R0..)",$#,C)N\LH0"X(D@@DU2!(6&F`DID`0)H`"'``!Y9-8295W*K%B
M+J$:&Z`B!V`%%5`#3HN8#:@I(X!?(``EGMBG`V;_.=@HC7,E*#E+CTXV9FTP
M8$SP`@$QF*`B6.3H.G+1*1EH%N_1.$FF.)$R!+RA(@B%L[:3%?K8-DP@!Q_@
M&)NZ2V"0/#-`!HF1*X[A`1Y`!+(2GMS95`O9&9T1`$B@6M<S&Y]Q/:Z5JWV+
M+=,4&[(1`L8R+"T1!,&%`]Z4+ND2D\GE+\U!K%YHD\DUN93+'(;`!5VPQ5S<
MQ5Z\Q9D;QF3H7:CW'PWR02YP%F9U(Q@`NZN0;`V@!16`-UJIE2.Z(:Z+KIZ`
M0S0DHPQF#>!`$+K[#WPR$-.;EB@P&-U:90)(0T3T(#2C(T(D1R)P"]Y`%\C[
M`(+BB4C#%)&")+N7O`^<_T4R.Q`K<(:D8`),P`$2``$CD`)4JALHV1*S\K&E
M90-Q,`$GD"=E44='H``R$!8HL`0/T``P&Q5D,5,#5D@OH`07N#A'5BENM4B(
M%(`3-E-845B/Q*<(N'..!%@9N)N>PA1'!BHY2U52P`,EX&R>[,`F@1=5!@5R
M0`$!";8J(`!I0`0+\`3GZ049,`!Q0RL="YY8VA(P0#QO\`:L6DQV1RV?<7;&
MLM!%@#Y&X%K1(BVB`2[G.049T&<M>2[G8CPS@`/=T3\".AV&EQZ+AZP*>@)P
M\!XP'=,R#=-B7-.3IQ\WDLH5@0&,Y6]/(P(8D&W4L'G2!J+3YKHQPU\Q*[P\
M!/_(W?8-E>@@^V!@`,;)*<(!2A$5^I!_?J1\/)(/4A2"V$`"9D$.AS*O3D$.
M@L(CNC!%?G$!9/5(1<J()'(D+_#*&Z``&R$!`Y!:XD*XOY,KAC8%#G"95@!P
M%Z@![Z@$?`$"&T`"#/!&<$57:O4`/,`"'R`'NVE)15L6<>H729N\E%*:URAA
M#"P7-W<4O"F<4*L6$2R!OGDF98)_((`/.-<I]Z@$<?"M<I`%2L`8OG5G`-!G
M`#`%5CIU'F`<'N!T9\L\35#1?9M-D+8$Z0,NS6*?=6?1"9##U?(MJ<$"N.I:
M-H`$5T!^"R"%AXLNZL)JS"6@-?DO*MU.`RJ3EFO3]BW_K7YPQN%5`\DV`7YA
M`D:'53%1`2X0)@\`#:H@B*Z+7\+0NOHE(CXA9(`\U4\-5$`RO!0.ED&$R4LV
MID,$@O10#_1`5&$JBKB0#D4C1##]%."@RE*01+RGR:TS-?_@(/R]`CHP`!L!
M!QLA<(7V2P40V#``6@%@!//+`%@U#!?``56@E&M8KAW``7G5.E'A*27P2@5\
MF]U<M`8H5V71-1%@<D7F2*5Y26_!<PV<YF1!!0DX%@X<9S=V!$/'G!>@)R;G
M%SQ@$E"0.V^6(!(@/&9K!V(`!AX`!FPR'$]`&=&YW%Z@8@&P=2QA!*QJ`YEA
M6EYD+*F5/M%2+2Q@`!`P`!+`_P$\&"T*H':@,7=O\+$P<,_>A`/"]4W&@P-:
MR(7_"2_?$1[,BC_'6AX)`*WW_>M`F=^IS`](.6`K0!B]X%X\S19P5"&">%]8
MZ2$3(D>^J(DJ96#7'I9/Q%([\WOJT`;M<`NI*8W#1PW@8#E%PP]=<WH6#A5/
MD0XO4`4\A*,=@`&?(]K\1V'Z`"%68FQ,<`0H\0%P(`%E>AJ8\1L!Z51&,`"*
ME@4'0`(\D$(54'I2T&-]DZT\X``%$`)1R@1LJ2IS83E%QBB@HXU1YG+)?`Y,
M%CJ@+69@`6:YV3@'N#ABP7R<M+3Q'F-5(`<_YCE<'A9!ASM(^K10,``%`+;^
MV%D>`/\#1D`$8L!+R9,#`2E+'[MB!0`<PG+UAH8$WK*>1NA:X+V1$``'2!`L
M0O`M8@?>S?(;6Q<#??<#/8`#KEYJ[+(#`W2379CW6+@_A>#KP/[WE"?LKT#L
M)-,Y1Y6]2/D`3%`"]>[L^C6BR(!?ZRHS>N(/FEAAW59#87F)X9`CF0C7,2N.
MY'[MU)L/2<18(FNQHBA37M,!<@`%6.")#58/E:S6)6`/2_)@?-(@I^<"2%,%
M(R";'P"^!2\$@SLNLG+0$&``7P4"9M%"&$`".J`$(L``3A`,+K`!%)"V79``
M5)`T>L*\B"0H26$7NWE)E^07G=(UB1)*HO391W$+$$C!HD/_M,)<9$7+F[Y)
M&&<""%5R/#4F&B\\-"\T/$Q54DI#2E545$-&02IB"P)V9`5&,$`J"VE$061`
M740Y,#Y$"A0!!1D9!5=7339"0D9(NR$A+"S!PL4A#@E%-KM"-BP.+#8A0E,!
M.3Y!:3\S.S,_24]/`#]1403H!#OK[.WK4>[Q[>;FZ&$))W_Z^_S]_O\``PH<
M2+"@P8,($RI<R'"?'Q`@5HBH<</"`1`/-'1H\P@%"`83:6@`4<$"`P8'3!Y8
MR;*%E18'&%0`4:-#AP@/+D2X^2#"3A<^;;H8>M.%39\N3)BHX7/GT14K(F@H
MH0$%"@TD-&AX0/1FA`LN:O3LD//"_X6,;<X^6`LV(I42-R+PN'K!YLV;6SNX
M6.&B"H\L&DV(\-G3YPH36>!L2+%!@8$!`QP(*6+D388<F`LL&0`A#@VS(%I8
M`$%B@Y()#%J@C'"$!PLA$)C0>&""+TX-;4C00,%#BE\><JC02(LUZU04B*B\
MP-H&D55%*-I0.?+"@HD.%U`P8L+CA7?HWGDH?Q$=D6SR3+)4JA('2I4J%TR0
M0/Z=AGTI.F0,D5(I"X0"1)"R`"<9-)&!#T"4(H8'0.3@A1T^Y!"$#P$4L<04
M!4ZQ!!)&.&`$+[Q,8\.'S$`CS0`&<`!'`16^YDPO15!`@34%3.@!.3A\DT0X
M`)"S0SKJR/\S#SP]]+!.D46Z0\\YZ`R03T-01BGEE%16:25"*H@@P@TF&#7!
M`1/L)1<62D`AP@0@7&>"216@M)*;+#700@L-@+G4#62MI6=/1#EEEUY>\13!
M"FGR5-B@*V"GE58DJ,6543B1,%8-0]V`IQR`28H33F0U=P$)0/'``1-KU0""
M"&MAAV>>Y-550PU:U=2!4BZ@(`4<$*3P@0(#4.!`"'#04(4-!<!P!05'+$-!
M"`E(`8(6#30P00D&0#%!"R6U`$)5`T@@@VPHY%05"I*6I4%VYNUVU:*+:K=(
M(B5H1Y]W5$@Q`AQQM&G!`^2A`$4*X")GU2)7M1$O(HF0]X(C5%3_(8D44M"P
MP@,EJ+N(?50H$8<DZLFAA`TY$.&!!P+,$$03K\1PXS@J$-%%$##`X`41,!0+
M@RU(;,C,$DL44<04+%#61!$AV$#!!@,D``>O%!20`Q)%.),S+PX,8`3/,$A(
MQ`(_X)#CCN,`D`0.0=+S#CQ#[N"UUT:FO20]3EXI]]QTUVVWE"I(=%0'(!Q0
MP00=O%`%%$H<40)$($R`09MMOBG322C)"9,(1`&UYUI!_2G4#4`Y%50-(G1Y
MU)XV950"58VJU8&E.%5\U@MZW5##Q&]II=8%BQZA`PD1@'`#<FNYH"539N%>
MUU8Z[256&S=,$!>E-'#@&`0;C``9,13P_R`"%2,PED4)#]@PQ=5(#%"#:`TP
M\(`"63AAQ45H2J3`%%/$(84,/%Q@\%J.G&N65O$Z3ANL8A6#:66`B+"/Q?ZB
M@P]`A@(7`%P)R$,")NA@$>1I@P9YHPB1M($1"?/.PI@@!TD0C@H/N('^)OB=
M1)10/UAH6!4D4``@C$P`.%A`UA`D!G$```PJF)D/7!&#5L0L0@&P1H5\X8LE
MA"!J'!)""%!$@0'`P08WFT(NC$`9)`CC,1^BWQMHD8,NE`P'._C!$]0(!C`\
M80?G,!L<T78VM!4)C>\XVQS?%K>[^?&/@`QDE50PNU2M8`)M,@$3?%.F(7"@
M!")8'$H>%Q.9-/_N`'6J``9$X)7"Z*DI?AK*3RS5N;T5PC8]40M.Q(6ZU`4/
M*A&PA`:D0A6NS$Y+J=R*5!Z`@B,PH0UKJ<(+AN("SN%)?[AK1`D^U0;<#(HL
M9UE!35P`@@@,`0(R>@S2@L&")2BA`T>0`9E$\H(E%(!%%U*`$EPP`0M0@0)M
M@$D[3X(F)D"!.FW@057(LQ8%O&$`<L`=NZBRSV6R<ER(>%=YJL`!""@@&@K@
M`0EXD#!%,$$VNVF.(OIE,07:IU\OR,(1&@D%CT0`.?9!*0VH<,^1^D8.6'!`
M#E2&PQGDX#*96(`'%J`",J@@!C'XJ0>"<-.;%<`:4VB"$`90A)HA00C_3=B0
M$*!A``JP@`)"0((M`K`$(QCA-45`T1,U="%K&"@'H_#`#'#0M1_T2`!K)(`<
MS;%'.A()CW2=8UWA]B1!^O6O@`WL'PA)EJ%@@)X:<$0)X["!%)'$3924B4JB
MU8`*3,1R.3G4ICSGN=@9Y0%>J12><&*61J7R4U@Y"PE,VQ.H\`L%$2!>\#A'
MELU*10-22`$*9`<52A1&+QE!7B.NPD\-S"8NPE,*5#`P@1<,(!@=,EH"7O.&
M(%"`!D<8P1&@H$\Y3($6,:M%`.)P6"@,P`78ZMM,7/``&E!E.%5IYEE,$`$E
M8"%U\;V*5185KPB08(`J'=C"I'`$#D1&"!QX_X'^4,H$*O`@7A_53G=`.![O
M((<[WM$*$Y10.$E(3"H*K$_#6@H%F&8!"IB(P0)F8%,@$)44-]+$$V(0(!?#
MK%CG#$#-C#"T`!#UJ$NPP3*(,:(B("$`36C"L:#H#&;9``E(&(:1EQ#5-T!M
M`PD00`_6.@,>`4``2=CCC]`FQW:T[4A#@@=?!<OF-KMYD*,E%`-(,H$+A#2<
M<!C`!S10@4O*9"45B`DB_1814>K)M#M9I5V(24Q2;HH$P#T*8<QRZ)RD[E-G
MT4L$9`=*S$8`4B[0`!2&@"<77*`*V7U!1H`B$JDLARP:Z4"C;!<!$Z0IMD!1
M7JYO@(44!"T$40X:RO]>`8,`4.`#&QC">RHA@29P,0`9N)D,J(D%#F#`"0Q0
M7`U6.$L:*($)X8K7,HTR%:WPJP0&B]=53J<5%!C4=`1L@ST#6@4(<(`*&$V$
M1QO140O30#;<H6AW%I:(=?>F3!J3@@9,'9V!)>(O9"H3%K+0X`WX(`9I8"L,
M/-`%!`E`##_<:0QLV+(@F#P#&&J"4X]ZY"E$;<K+&-&'H'RU)LPH`Q4*@56%
M01EI4"!G1K#&$JH(@S"K#1P]ZM$3HA`&.,I5KT**!UW?UJ2^OOGJ6,\Z0%1`
M6Q-H\@(6J`!32!"'%"@-[`P(.^18$A/FKJ30P+6T__:4N3^!MBB*YIPG1U?_
MO+[WG4\2,0JC2_=;GUS``.7#3IK.-80A7.`P<BG!;;EBYV;.Q[U<X:3QBF)K
M$^")!@-@`1*2FL2@Y8`,,)O%&VR@@#AX;*0?B$8"JOJA$$!A!8-SWP&82[E-
MW6"B(NE)<Z8REQ=4+%SE'A<`!]ANXPO,@!353B5>()Q*Z-L^W&EX<[JS?7`W
MXJ(7Q3>\J@(<*1!.!G%@PN_Y^T'NK!024)AX^(TPBK7F0`4>B($/O*`)'BV`
M#`(@`&00(4%0`&]P!4?U75HT1DE$&4+0,\S@,[Q0-$\5#-/`3<CP*U;%#"-B
M`UW5!+>0`4FP5CG"8DCG(W(E5W&41U'G="I8#^G0_T=:-X,T^&8J0$R()!_M
M5!LB(`4;P`$:D&V4%!-U$A.)XS>4DRB?Q!::U12:1CJ=LUKQ\@!,\4FD]7>L
M]4E[D2B!`BBI<A8[L0)'X$2]8P(/0`+H!EHW0!-YH6D:D`7D1!ZI]86KTP&%
M,!%D00+O](`!D$174`0J!P0N]PNOT1E2,`0Z8';$4#50U00T("U#P`16@&T8
M4(6.8FD9H3\MI!UQ\`O$Y6[[=1R+,$"*`%H"I14)Q1O>AV$B=!6,L%$?91^)
M(&\"QPA90%$B85P7E07F)P,Z(`4[<3#ODC`L=03;-7$.)@,!L``XD`0!H`)/
MD`9!(#)V\%8>H`(!N`!``/\#$]*'`8"`.4`_4P`U2P!5/>,S0C89PS`,%)``
M5L,,4[4L590`0N`KR.`S2W`%0S13/[`#/>`U.K)&8```3E</;U-74A=':O8.
M,EB##OF0@72#7))V2S$!85(;6*`#%X`!%K`X@?8F=6(!*W`#)2$6/'$NH,44
MB=8G3E%,I-0!4($=GP(Q7'$Y9?$IIC5WG?99GP0H/*$I'>`\<H`"I5,(2]$3
MIS)->F<[[!5KFG*%-Y`HMA81I?,Q&$)4Q68#`8`$OS@$*=!0#@`'4$`%<<`!
M#M0+,V>`#]`"(K`!)?`2,M&46Y$3`[1,S4&65;`;-"`#YI0##B!.[J9!AX!N
ML4;_!1P@`QIQBH&)0?6Q&]=W4?4Q<+BH",*14`OS+N^5")4@!^&D`R5@AA/T
MB@]7+XCX,._!!`H`!#,@`%<`C0(0`R87!"0#`&E`,FD`FP&@"CZ0`04(-49P
M!3FPE4D451;2!$\E9$6##-*0`$PT#/'HCD3&+%*4,U<0,S``C3-@)#^`=&$#
M`#WP-BNX)$^7D'D%1PT)D>B9GE?B!U!A`?*4)M4D`AIP7XA4$FK'$G]#.8*!
M)ZFB0AD!6EQ!%G:!%'9X&%'Q:983*FO(7C:)DV!X%EMA%%#!7F>A2D91AV!8
M3((Q.T#ADT%Q*MC!.[<5`>U$.9W#)=>Q:5!A`O&S2QJP_P%%D`-VX`'E$P)*
M<&^S(@*"8Y@?0"I#L"L)\$1(H&1/@P%6<`$;X`+O(R><A!ON%E\O`$R!<P2`
M\0(24%W88`0)-A6G<WSIH1-2H``2\`)?,17V]&`BQ`@7,T(%=S$>]::R>)EJ
M^HI5@3'O06!#0`,,JE'?1P59D`55H`0Z8$)5@`504`!)T`6MV2/:6``^M5-P
M!0`QD`$Q0`8_!`2U0`LX1P22&B$9@`M(QB'#8`3/P($?4@32$"+168]5$P(]
M,WI(<$XA`P1BL`X`N2/A,)#=@`Y,HF;I4&;L<)#G8`!6IY[&>JP,X0>V=@!:
M`";PN1=1>EA]!CEKYS<8T"7$5/];'8`5P7-W=T<8G%,([,5>=D&%2W$J#(HY
M<H<YD0*&@[(4J]03GI1HF38[EJ*$EZBB$W`=/7$#_RD1$S$[B2,12:D4A5`H
MWO9O15!=.I4]6,`#1Z!P$>$P5*`#/Z@=L1<,@%@L&<`#[L,](%`G3N`$$S`Q
M`?0I*(`%-'`35@$^-``'P9``'S`7_^5N77H(53`"')`"<"`!*_L5_L(!@$$?
M_[9OC1!";KIOL<@;:RH;!H,P_7&('``%C_<`&A5P#?8(@BH#1R`'-%!B`V!R
M4T`&G#`@)A<#"Y($`E`*E6JI`M`@T89S33`%1(5R!?!4?^@STO!4,&(AW<0+
M5>0`S.#_`)*1J@F0CEQD#='F(%R#1RS&5E\&`-W`)+P*),!:1U-'`,2*K)S;
MN0?!=>[I!!4@&(ISE!;9)G#B9]<J*#=A%E\AKP):6(0Q*(*'%*ER%UNX2O%*
M=YQR")]V$P9J*+M[.5XH=Y^&.3E:LMEJ&!8)$9YG`22[%)3R*GN16*C6&E*`
M!`CB`PE`*O'R&%6P+7)`.(3S`1^0!1P@&;V`(3YP!<^B!06VKR;@!"TP,8>0
MBR50L:1B9_J$`I$00UA`I<;7I5U*?=8#`>8K`3Q@%#00!Q\P`E6@4A0U0I$)
M0AN50(I`49"93R(44OK&IQ<UOG$@`R^P/._20G+P"#K``?O1_S!8$`<4<"";
MD`8"X`%B@`H+$`,`H%/2&`/\)P!!P(!)U00L,`6N\%U<=+?.Q@L]0R)9U4W,
M`@$&D&3U"+C`$"*]D`M7$&U$H&+9N64ZHD8],C8PV*N\2D?!2@_J@`Z;Z[EN
M_,;]H`)]@TF#<4C9EC@E$6@GX3@G`0(=JKM-`2GLNI*68X?D"A2J]&F"889L
M43PHJ:XY$:6K(SM:@EF-+*]@F">5-FG(@Z"'`#N`)TV'02F1!`(WX748<"HH
MH`!/I`!^P0%3$`--D*<1S`/W-"HH4`DW"@7^80"&28%]&#(!0`.B>Y@T(0=A
MMQ<4LT]4@`4R4`7EL@@,%0DCL`$Z</\$?K$NBX(%$F``C64`WG(N*&"6)\0(
M?NI@`C=PL7A1CMD=UT=Q"`0=O)'+5?!!B0!^4E"6<M`3S^%1&.4Q&Q.Q@S,$
M%'`%,?`$8'";-Y(&0)`*`5C#18`@.<`@IW`9+%(C/949EI%D4^-5/8,,B&<#
M!E!5HS<T'?@KO.!R(W(A&V(9KP`$:3`V1?(-7?9E8/8CZ1`&!XE':9Q7YW">
M<!S4R!H#D7,`&2$")L%<8?<F;_*1UUH337%W@O*Z4CV@OQ4H05$IU$O5EX.&
M;;`3ZKJ%TD01HW/)M>6$7O$3ED,"<M@!N*0>:-TYB?:[LU(!5M``?GP$1;,,
M>;D!V#`J+(7_:@-P!"A@`O>\L\J6`B.0!1L@#>9T($20`0-`$QP0ONX403")
M)X.!&QK0'6KQ;[CA7*`PEAG\2VV`OHWQ`1*P&#(0+KQ!.!C%40USBT<+BT;K
MSCPP0/C6SPJ3B\V40.'WPC(@!7"!.Q+605;A"%*`!;Z1!<S=*P%0J6*`?PL`
M`$$T,IOP!#H5!#$@`&GP,N<4,P60#058"SB'@%OY@'-+-`Y``52&JI/A5<$0
M#=,@#3WGV%%U!1A"1"4STR:8!$J7!-])`&$0!I;[CWME-O4`U$+=X.C9!Y0%
M`KD==API29B$NHQCRI`,UJA5+JKS)Z"4*IPU.X>!R)\BKWI":8*,_SG%-)*C
M0QAEH:Y@#5I`<2YQ<1L5HT\IY`+2H6HP'ESGLA.>1["G<@%4D+$LL`$D\`$V
MX`-=X`"+X`@CP`)'$`$'4!/W(P,R$`G[`0&O\5VNX`.:D0)0L`$O@!I,P`%Z
M(3P08;5."DRX(P=,D!T<H&,P,`!4@`*XTQ,O,`()X``*L`$?@#]W9]SV<0A9
M,`)0P!W!H6_GX:91CHM8NQM9@6XH-5Q3D4_BL1Y0P+7[>^F4R>C,S6&^,=`C
M@`1$,`HC1S)/T,5`(#)?9@K5K0(F-T0!,`!8-(UC5"QC](>CZE6\`.SCLPOH
M*+A0`R,?HC,/"&7EJ&/3V-V/RV(Z`N!B0_\V!FZY_HC39TQU#.[@WDZ#?7``
M3F#4"I=V(&`!Z/Z1=VR1_,J$B;:$L*MH=O$J16$4G/,5:QX7F',[`]4;R^$H
MFK99E&9IJY4ZK%4\<DXQ$]2F9H$=RB&OD8*2G,(7[$H65:``0<H,$I``X5@`
M79`#4/`"+VP`1J``Z,4`+@"HEA`)6^[E13`+M5!L&F(`"<`#B[,"(]`&1J$4
M&9$55I$__$(%8"$%XH,$6ZH6Y!8]`[`82J`!TM05G:T(]Y,`0Y#;W='/Z0R+
M&OQO%Y67PT$?O)'.Y(("Z>&G?YJ1.H`%P1CVZ"$;C0`%ATFH[$$!"+(*EAIC
MT<:-2:!&"X`*8B#_@)LPJ3,%5$"6`9:Q1:,G5;U@G%.@<_(H9!H21202`A]R
M-="%!%L,V3'`#0#Y#>/P!-0^`]M>GFG6JU'0[=^>^E<'X2F1!7&@`1-06>EN
M$7^#)D<)AIE5KCU)>,A;[Q4?KT>A6A4ZEVL!/AKP,4V`!<"T*IH\%O%:6K9#
M:9T$6E+!;S0@!^!3%R<E4&>A=SVO)^4F>"7``>[X9$40EARPVB(3V5,@(U,P
M`"2ZK\+RI_C!81^`54T`\P8X/@8`"`5,%0<'52@1$34U+@\D)2@T5"01&B0U
M)DP<<3P7;2\H&FT:HCP<"BE2%Q>)#Q</#RA9/!HR1THHGSRC)2^^OC1,_SPT
M/#Q,PCQ45$R@)"@O)9+#3#1M)!K$/%)R3%1*'%@:$6TT-,\TT*+!1QR;4%50
M<@H90$1='@(Q"P+T`OL`/YYT6?!D@0<5"Q:D41'C((PW!7P$R9&A"1(D0D(8
M,2)DR10C15BPH!!"R,<B0I"(Q&@CA,@015HB@=BD0(X"1,#,Z+%CQXP9/Y(\
M&3H41Q0"!*(H[<FTI]*G3PV<^$.UJM6K6+-JW<JUJ]>O8,.*'4NVK-FJ?9RT
MJ"'E2`0+%2K`;7"`@0@3$T!TV.NJ0X0'K5[!`ISH[^`(?%T]<-$!%F*^A?=&
M$`SXE88'6(:,,("HPXV]?@<?GDR*5(E5KT#O7?_1"!:V%XA=:2C1.,(*$R)N
M(+Y0HDT;%"A8/9`#:H."!`,X4'G!8\2`#TM\'`PP8("1*3PF-+"@01D\&3ID
M2'!@HTF`\U.:-`DQ@(B&"@U:V#;A`K$+W9^ND?@,>(4&'J&@8$QPI+1Q`0\2
M<,#$*Q>(<MD#_S&!"`^_%`/@;[\`(TPV&_*011;,H"#A;R)2$8PPOF531174
M5#'$-M>\$(PQN\C(A!Q2*#'$$$I((045(TR1`Q$Q`&'0`C\L$,,3`,1@!U``
M^).&`!Y,Z0$90,1`!`PY^.`#106$B41-'@70Q!4VV##%$D4TL01&9TXAA!`<
MV<""#2#-F:81%W&9`1'_"^BT`PXX_/`#4$(!`$`2/^Q`0!A.+<445%`-,-59
MF&:JZ::<=NJI6#%8P(`&MZP05UP,,)!7![EU4%]]K/S5BFB.%7887R20\$!H
M@($FZV3.T&#:"VV`H`$30S`1`0FOW/!98K3ZU6!I&J#FF*NL.09A</6%-MD#
M*TQ@@JOT;2OC935T$$<5-(RPP0<:B#"!"S1(8$,""H0`0Q`C1"-#`0F88$4%
M%Q"#!3OM0)``"S.]<5X34X@7A*DMJ(I!#;#4L`)^&J`@!PT7!`O)"Z4QP6X<
M0U#!0S10,&%)@Y"<UF`DYH#B"W`8HI/AC!P.D\PRH%SP@C`"$M=-B#Y3P:)W
M_R:3;".%-U)(A1Q9P#/$+=M`84`&70!!1AH)V;&`%QX0`4"AAP)0)0!B)$0&
M$41D\,85!<!0P!5O?+1FF`%,,441;PIQ!1(V"&'#18`OP4))B]M01$PL`#X%
M$D9<$4#=/@#A`0`SX-##3S@@.I2BC28%U:24/F7IIZRW[OKKL&L:PP0B3!W!
M`83$50@(=S'VEV2N6!N;MM=^^UBOAA$6V6'1O'!-;P]4X-]EKKIPF^_&2Q9:
MR+DRB%JUKJ&P&"RMT;H*8(LUMFNUCY3@`@C+NOP`#W)T8,$$*UQ0Q0<&5.>`
M`SD80'!H,(`00$%4'6B#-G30#@Y\H("`4T]Z=,`#!_\880(':,$!XB,"U4`H
M&2:CA8U41H,2:.!F/(#".^B7!1.><!3,>AXPBE&.8?Q"0!3*D(6*T8UE\)`:
MH<`&<3PD(B`RIX956(8DEL.,FS&'1B`T&12N=@052F$(0LB!YCP0`P$((`E`
M\($^5/#%)R0!#/OP0)8\$`0?O&%?3;!!F2Z7@<M-#B46*9P1*."XC8P$<"&A
M0`(2X``%#$`(CT,D$HJ`MS!QB0R;(]0./O>3GP0E"8LRBND(L(/446IUL0NE
M*$=)RD[U@0$K:,,-,%"7"DQ@`@PXP`0842O/\.<:+[M5(O@2"<(`AC'7\M6W
M!D.*7)'B`IZ!D`D[L#$3?,;_5H69U;1,V"!8-$@XO4"$"UY1/EJY@EF_,D$G
M'+,"O72@+8@!`>]$(`+]<8`"+`C`$C90!!A<@0H=&`(%BB`%$)B`!-IHX`CX
M]P'-&$`!$-`!"$I@@!%4@`'Q.8`53'";QB1P"'+`AK!J!`$94.%!LGD&<&XV
M4A10<UJ?J"&%@&-24LB(9N5`QC&FE@4?$L,<)GT!%2)!#668XZ8R2B(WF(`%
M&H*B%SS<83+:<H2K*0$*4H`#!6#@`;&1+HP)Z>(,%+4`%7B@JPL0`T/$V(6*
MO"$#&<A!#B9BG@P48$U%<``%A$`>CJ`$"8HS'$A&DH`04,X&<[6(W_H&@PP$
MX6L"_WC"#W#@DTH&A$F*G4$GC]+)I$R6DZJ[5"DWR]G.>O8/?3@`"%8@JD+(
MQ0(8\.=]JC<9Q!S/F]&4C$GK\ZM=PH)7O`&?)2!AB=@<TQ*[N@$(7$#<U1:/
MF+QUQK5J,`X`E6!X@PF9\D3SEU"88'A[<8$)3,`!&=CF+NHT`0V&H(,$"*%N
M-AA`34;@@EI<YP@F>``-H"`#&7`@!2-@0@<.I,0:M``*+'`H1"MF!7%M#)CB
MBX`O9K.**O"`$HKHP&PZE@M=^)!:(B41C6QF4A*=HQS$,!%SE+$AE1KQIR;J
M1LV(X8ME"(,*4G"P22,Q#'1T@X<P'D(<=,`C'\E@!&\00_\9TR!6,=H!'S/`
M9)2JJ@\GJ4`B.8!!WS(``[ME8`H!<&L!FE`$(S@@;Q@I0@#PJAY$+HYQD3."
M#?X7@O^=!PE43FN6M-J#T(4.*$-)`J,.M8,PF"YUDXT"*#]+Z$(;>E-`:`$&
M8%F(0K2@`2!@!+96(&'*6$]]HXF,7V(3F,4`TY?38E:#KC&*!SFC!-W;E78]
M0UQ>`8][N0*G9U8@`A<`E`HF#%[P0G896XGF!56XP*>OA9<+F.J5(,"?!K)P
M!!DHP0!-R`$2VHR$`,"!!D<PP)J8P8,CA,>!1\"@!GH48Q$<0&LI>&A=)N`$
M"XC@-I1>`2Q($(Q12$)8+YQ-+DK_\YO?'(-8JXA&"2#A&Y@2(T`60L=-@X%B
M%]?81CK+Q;VC=@YAZ%2)1/T1@60$8@OUL`I*"/E3L2`%%5(@"'90FQ>\H*08
MN%P%`#!C08CD@8*(H6Q:>L@5A!``,!FA`&[U6QX+$&:_%6%-']DC!*PC!(:!
M)`2%HX`1]E7E+&?@2T'P@&07V]@D[UG/29#L4:(0:+('>M"'3KO:UZZ5/LCE
MH:F"*`,B71_","96N@ZU+V.;+HO*RE6.X/1?="4;7#*KF+@$;@08\RI,J^8O
M#':%"^Z"&W5B+!+5NJ9LCAE=R@S!`$I@WV5683T06``WN'NW";J30@XT]0A\
M*@)REA``_P-(0`'5A@,6F*"C.+2#"@T0`0V4<`0L/$"60T@`%IQ0%PNLH`$5
MJ#5N=A,R<CAO:"L-1:G;<)I&/.@9';M,QT"!PYH9@QDC*\<)L\$<:@RMAQO*
M18;DKS(>R/@9QY"$'.JOM"J\(.`S)"/%H`Q5DP4^<H!84`4RL`1!D!!MDR42
MT1`)L2A@T$4Q-S8'H21=<F6`$@1R,P5O=063\R9J=CA7T`1-=SAV8@`)4`0#
MX#A+L!%MPF4V@'M2-@!%`'0]1P1B(%D^^!-Z9BA@QR@X\&>2\A0$@'9LMX1,
M6&A^,`&B0@AU@0$K<#R442N=9DV[(BNU=%N05QFC`%VNL0J/L/]OS*)KF=<K
MP*-+R5,:X$(?+H`)[]8:V%!,UE0:N@)2JW`#4B`!4E`"%"(.O:(Q*Q`NM/,J
M!?,"65!?WS``<V5[^_0F:9("6?`!(V!?4"`L'=`"()`%+_(`VB$"(7`%-,!\
M#&`!$8`!%1!?:AA=QP2([C<*O^&&C2!JP!$C^L92'(<.&P8<M!`*`M@A[@="
MYV<.GY`A.H4.^V>,/O,AR$`#4N!^#;)2)A0)(^9#['`+4*`$5'`$1:!%5+(`
M;;1E5^`!'B`&I*,HF+0`9"``G--50``$0:`/73`1:`6"2]`1-"&"BW01(4`2
MD4,GCE,$>/4X!)F/"D`!]$!T<98#;0/_$(Q59VB#9V!G*)ID=I%R%$K8A!S9
MD:+D!ZJH;JY$'][B%[HQ&H[`"J_P&*T035@X;KD2#,'A3<2B;P`2>7=(&)*1
M/*I6=]_C`DDD'"30:M^R7RJS+(<!(2#E""9B:Z5Q(`KR,AV`">'5+8W1,2M"
M!3(P``KP`<CQ`<=1!&^4`5P9`%?@$1^P"A.@!1;`'&\A%S=@`$OP`!5SB@]@
M`@<P+HKQ``/W#"Y$,PD'"M2"AQ1F&KK2(,>8"Q^&?N7`4M5W(L9`0@G'!"#"
M4@QW(^504SBE<$J###R`!2KS?P43?SHE!Z;Y(5D0!W"0`K;`C4<@)$$`!%T`
M-P4@!!3P!OX@_V0`D`9``!`"H`)D]$5B0`1!X`5:$@->T@4ZB%<,0Q%=MDA\
M`IV+\S@J<3B4`SA-MP17`#D1X59?LB]B8`=I```]X3EWABA!^`.<TTE-42F:
MY9'P&9^L$P,/)1>C%8>4UA_R)AIG2$RLH#Z<MFFQ86S=L5_!T1BH<3[H,RW'
M%!IGZ"HW4'>.D1JN<I6`X0Q#(`.JP!I5&%W+(@K1M1B3$3*:5T(0`@T\H`A*
M<`C"=ALBX$^11@DDJD!,``4?(`$?D`+&L0%PH`!&8%CR.!%U\U8I@`4@L(H\
MT`$/=3]8@$@@L!VN!"[11Q^KH%$"2*,J90Q)!`J_X4*SX1NS6`*.,/]^Z,!2
MOE@SOM`\S`*+/Z1PO'@,QW"F#`="T+"855!3PY"5PJ)@<"H,E*DRE`ER#<0C
M5<`!!5"/6D)&:6`'7:`".Q$Z39(#8/`#O[D`,?<#8"`&8J!67H)U?Y(!=%-8
M01``/U='6#8%(O$XA6,19(8$?A.#M+<$;V(>@P-T,"`=^J`3&'F>7X=)B\58
MJ*,4&RF?Q%JL9!$#J8(!K>):A!&AU32BX`-YK/9WCP&AZM,(M6$"D08L9SA-
M)M4+_R<MJ8&?ST0KD">:%1H@6$`#BR%O),`K@IB2J;$MRJ`!&%.EG_D;#U`#
MO3!P@(@(->!/5\E]:RH%AH0*[@(!<+`!!H#_!/LB$5_B`UL2``EP`>Z&`DJP
M`J=XBALP!2E@6G8Q>MHZ7(#!?1TC(?=V,Y]`!>_`I98@"F"*,V(J0SKS<$?$
M<?@G/BY50[]0#DY$8CY##"\V"^1'(UF`!1\S--M@(@]`#L9((K"H#`>S(U94
M7F[E!79`)>,I``TX*#_ACH22!.[H14(!!FRD15M2974#@GXB-P'@`_;T5H[S
M-T;`)FN"$3$81PZP2$VW$1##9855`!/1!6WS13SAM98D.F&79(Q%*4GXGL8:
MN9+;%?3I;A%:7+L43;XS;RNY2YO6*XSW3+Z"/#>0GYK'H*3`4J-`ALJ378H!
MH),A"910'PJT8["A_UU\J0&81AG@(QA*0`$;@`(=$`JN@`))1`*_,8TI%`>9
M:!N1II2$=T(CD``&``'O`@<2\"X#@`1=$F41NR4%P`&C%0$H``4BX$JB,@0!
M(`.X\U#&8@)0H+$'L$WDBVH;$BQ94#,69XP8-G#]%@J\U@ME*G\25RW(^'\*
M]PPYI#.[6`X^%'*W4(S&*`W]=S-)U`UBZD0<=@Y+A34J]`U7D`,"@*G!R1")
M=2A/8$F)DL)>]YOUX`.7(P3W."9XQ3=](T^QIYV&LP1<1@$#(`$&L`'QU":+
MM"<00WL5L01J101?A0^$PA.5=&=ZIE@!T3F.@A1(,:R3N\5;_(2UYBJ2MO]+
MM!6A>YEIT>2Y%>H(]]&2SO*YI'"'B5=J@RD8U:,;"FIK2M-K:7Q.4+`8XK-O
MP7.&A!>'$;!ZV,L$N5LM&M4;(,(<XB,)!YI,3SEO5'![$"`!<+"P'_`!&Y``
M</8E:2411`##%S`!"E8%_70_<-&Q4'!:L]0!(#`%YML`S@0"Z+,!#I`%L(`"
MRS$T.T5A+M0;9BJSD#!2Y3!PFQD*R'L.GV"-.@1B(/9OC:E`)!8,LX`.D.`S
MF.D+=YH%<H`"+C`R'+>+-$0%6!!R5O2[&1`#B_433Z`"+&<'8##/B8M)7Y0$
M8",`9`"WYR$W1``$>9,!(1``;\`G7F9><M0$B\/_948`!P[``@XP``XPBD%@
M-_E(D)+3$5CF`S8AL6W4@YU#*"(=.D)H*(=R*$>!Q5K,Q2Q=K'Z0+HE@/3ZY
M*PAZ/BN)A:.A/=H"&8BA,9.Q7R8$>9F'>+$&/N@#H>F2E%`P`C3P%YBP`O=*
M7,SUKM>4"`HZ&*;G3Q$@IA&0#&)ZE1U3#HMG&X81`3?`7!1&AJ)0J!MPO=;;
MUIR\MS9!!$,"-T$0!`8@;\,G`0^@3KP#`@[0!')0GQ,PE1H`!`4@!ZQAUERJ
M`P90!9:@0$+KL[-8AHK)I1TVS&8J+%IS!#AEILPA(P*XP""F(3T+<E4T-:`I
M+)^`#(I88U6`(_XW;P4W_U(]Y&(P!E4K@@4R0`%+@"07*`9D8`<W)YZ+(A2,
MDF0SL``^,`5MXP-`"MU45@#G466!BP0.D!(@01)\$@((PA&1\R:6<V5UP@+:
MK9U\4S=11@1I``9AQQ1U5F>69-(FO1.3M=(MG=\>J0*_4SV8UI\-(G@WW9)G
M[!B;FQH1.GA5JBN&5VJPUKG)PRM_$8<TH!QUMUVL45S>%"VR`2X8H$'Y64X]
MT@&X@3$35@/(-ERNM1="(SZ"@0)2L`'6N\F<S,G9"P%R#0/_3)QW'00A``]'
M\`%R4&O,TA@?8`0HL$&I4H4:$,(0H#&PW`%Y*`S7P,O48&,5=HL=TY=!-'[:
M-_]2P``AS.!AELF+H,`SHCUAS.$;XJ`!O.UZ"9B_^@;-^P<@)K/:NBLT7%Y#
M/50U.7($4N#-^\,"/A!V8NL/0"#<1(!8G%,0`*`0`N`%0#"I`A"/L9DE\MBI
M-^$WB\0"%\TG>"(X3:!F+&`$<420!6`$(1"#=%*0LSH%(5QE8D001<@4YDG2
M[KRXRMT3^*W?OKZ$*K`K&<XKNN8:UF35T^5-.PEXYY/&TY*@$W9"QW35+$GB
MK5&E-Z`!^V<)E+`QGEO6UF0ME>$(),X`)U`!NV1ZCJ&M50@:A2BAG0LAHO87
M)2`%'+`!F+S)[Y("-:X`#K`$<QVDQ`G=1:``,J`!M/S_'^#<!@]D*JY4V"[0
M`#Q0`"&0+N$B[Q/&EVWP<2I##L!H#B8$M4Y4#<?X"\&LP//GLQ5B(5/3U.G"
MH`&K%S$N`T@K8B328@D(-54`FLQ0O#H4F7)@#`:H8SV"M%:;!NW\Z&+D<DZ2
M!J,S)?/\!%Q+!"$-`!Y-FU?@)3EP!:9.$P'01T?GZ0&PP]66ZJYJ'C;P,'VC
M'C&(91'!J630$"G<`Y(BD9TS`Y$5.F8D6;W^ZWY_:,&N7;(R;.'>NY7Q.SQ)
M7<E#[7_!/=">:\ADKH(A;/11"282&I:00*.0/N#4DH=!7(OW3!/^HA5@3C%?
MNJ9R`%1H*^?#DH,G"@VB,2^@_P/9F^_X_B[Z;@`4T`17UP5>,,IM1!$_W@$8
M!#_HT`$O\`'BNV[.]WP5,!Z.\1FS48W8("#;&/19<(PGM%(JFS.;22$WU3R_
ML7#DY[,<S(LPI@09I5J5D&P'8`'AC)6[]]G/8,X.-C150S4\``L"#`@O+SQ,
M5%ER5%522D-#1U!2<E(2&4`Q8DD_,V!/`@(+'AZ>`F*BG@`^1@M/`&`Q/D$9
M!3!O,#`%4S"R,%-32`4Y5U,!&0$!!<57`4U(4T532QEO-D9(34(A1KBY&3DP
M0$%>`)H[!%$[.S@X,^M),^\_3YHS"B=_]_CY^OO\_?[_``,*'$BPH,&#"!/B
M4]$A@O^+"`\B2+QP(>*#"R0>:-0(L6%$B!M==$"A`2,)%!4U5HS@D:)+#24T
MD"`1P25%B1<?=.B@40>%(Q<TM-FH`23+G!PA5KRPDZF+C0]<F#`!`H,(%U@[
MN%AA8L)5GC0W:A495$-)B3<ZO)`B8P0<"!M2;(#[8</<`11R^?"1(P,,OAD@
M1*C10<0!$!<016#B@`.#`P<F3#!AH0$#(3Z@*-7P@F0))C(O\!BAX\4#&B5>
MT!"$`@5KF1I:JZ9!6W46)K-9M^:QNG5M0:IY\.C\HA`4&B!`:&`R`4.%"3=F
MHI`R!$OKZZZIR,'-0SL5*CRPEG!-FQ"3\XFD0#FB1`DD.5G_9!@)$D[>#$T>
M@*@@$T.%)R\+I`%`)PO$(,`,3WB00Q,+-N$#+4U$.$L`0>0P"PPYO(%$!ADL
M<<P;2Q313`#*"+&$,$(,`,$5380031-+%!!`7WMU<<H,.YRS0P\]J'-?$D!F
M\LX,$MBCT)%()JGDDDPV69`*.!V%TTI&0<7112R)A&4$K8WW0$8[J631ER0$
M%10)JY5`@EEEKE015A,Q(44;)MQPP0II-031E"F-:11%%PFWE`L3@/"41F.M
M0-@-$K&D9YB#E+141$Q(8,`&<!A@``1P2`!'71`HH(`!0EQ1`#(%F)J!#Q2`
M8,%#(DC6`0\1@"`%!U!4<``#DYD`_]D&78BQ`48/</9"&]^E]$(<4+PPGEFN
M7:=:&R7$)%0;;?!&$@K"!==9"6VH!AP*V`ZR&@U,#*<:MSHD,,0-)50QP0$5
MM'#`"A#)@84.2J@K2`G=T88N%4Q4044$)CS@FW"$9/%=%5A@`044[4$"<0(9
M!`&$`&DL$"``'JA@R0(``*!"$@L(\(0*HB0A`!FW-&&#,3D8,PP%(13!0@93
M"&'$$C"R8$,"IRX!=!$F]E(`"R+VLH0-5V2`A!$L`HT$,3X0$43(8LS0`SI@
MIP//#V3/,P,$1CJI]MILM^WVD0PU%.:79S5Z%%0NC16F6;`QT09+(*ED$M^Q
MF75!&R3$]/^E2R#=`$*A5W4D0@TNW"!2X!<9GCE&,JUY45!4C!`'#S*IU&A6
M#F&%)^4-!:63:"BM($).*'#@@`(?0.#```IXNL$';X6:P!0R%K,$$E'[,,!C
M(-0@@@4@1&6!"4Q``,4$#=";7/8;^.#!%#QTL$*Q9F6AA`;%(AN)LT*-1RZT
MKAUK5K7EED<#"C2H2RYPP&$;?_Z\H4$;\D<#*DAA`TQ`014Z4($&M*`%%HA*
M&ZJ@A"-D05K<8H+`"$$P%)#`!"NX`+>&@RZ'&<)A6%!"'&0P!"A4@0D;6$(7
MR$"$##1!11Y(0PRZ``10>```/?!`#`!`BE"\H@D%,)$0;5B$!!3_P0@L:`(,
M!``$G@G-"`Z`P``"@(0E4(`%2$`""RA0A"L4H0@A.B,+3-1%80@#&4'0FAV`
MT`4/>"T*>$2'.M11-K(-"6UO"Z0@!TG()MF!<R7YB%;F-C<K1>5R1+&6!CI0
ME(NT:4V$6Q-)7B*1-ETI`BN0W5164#DM,0ISCKK2FMK`IF(5*S%QJ`(/2M`G
MB>BM(U.IP0KT=!'Q18`V=0L*"F00@A#`82X)V)1=.@6!9@Y@9F^`D1"$,(55
M=2$!%F#`<R;0@@D0B@$FD((#7M!`[6&O`360PAM4T`02:`DB68#"!2"B`8*]
M8`@<P(U04!"35;[&+*PLTP@[TYO>Q`\X_[T)5VT$9D`J\).5W7D!!AR8/?2A
M(`N$\)<@-IB_0KQ`*(5Q`?X"V#!$%*(*4%@AO[!0!0XL86M`@$$`II"#'R0A
M%&00Q2I*QHDD@`$4/@`',@P$@!@0048Q6$`7AN@R&"!A:+L;7H5\`2,8V0!H
M1KN&B:IAA)S9<!BT\`L,NI"#',0@$^C0$8_$!H],:*(>A8RK7.=*UX5\#E`W
MD1NB>+*1U-7$(GT*B4[N2A%,%G8I\\P(F0`5$O&Y@#"?(Q\*(IN3H^!5DT61
M"DM(\*D7I,11-4'?1MX$$6<%5"<:2*D2TH6;%X3N`R$00@(DP"D%T&4#M#7`
MJ"@`M*0U@7AE]?^!`D#PO`JLH`)=.4`+-"`$%CP`!`Q@`/2PUP(GU*``"R""
M%$IP)93RDP39VN6M"`8M:O&M-823S;&BM:YP$91_!,2@:X:#@G1QRS=4X(`&
M&AC=I]CFA!K$G\`TB"X2TO(&-^!,1O.7!2G<IL'J801[E$"%!/B`95H#PA-P
MP",$]?`)[\!!)I(@!I(M0`QD\$*)6Z$?(ABH$VE(@E%S(`1BR`A#`GB%-P)P
MQJL6H0E7L$8UFH$T(_BB",9`,C+>X(4N>$$``,"1CL[1HSW.P*U)*%)=M\SE
M+C-)!9]T9%)&BSX3U*`FH4UDHZY$IM$6%C:,"TTE/P>XL5A.+*&=)TC_@A(!
MSZ6$(FI*RP->L,L42*$A6V&4)3&I$59VX"2=R4A%-!`'(2!A!%6@`6SDL`$1
M"<$&"DA!73@P`MP:P`$42,``6``TXBEC%O2!@1&4T`$&S&X%(%`N`ZI``040
MJH$6F``#M&"O(:AX`4N(`_HJ0D$JQ,9,T**->_DF"&K)AI7X.VBUQ],9\JQF
M$)U9MB`F+:W[M<$U6!!5',!#@PB8A6!RV,YWG,TM\#",-^LE5`>R]9UTW2\X
M!:.8A*50A3B\`0AV",(J?N`C'/V@9$^(.)`\!B0`4%P3/A5`?@3T@Y1Q#*9[
M\4$U@1#3OD0(C#9`@J6-Y@QKI+P(-G`&"Z;0_X0R<HA"6TM#&D!<#AV!K4=#
M>@=<O4STHAO]'RIXR&*MA)/7@6ZR%W'!50CK$C%A9-*27I/KD**3RKFR`Y#-
MR4YLJ24K_3F1*E$SY32@*28\X`9<(0MC33)/LV@$DT49GPP4<`0YZ$`*'U08
M%!Q@A*$-8`,C$/4'1L#X$"`A`:)RO(=.U81NQ#$#1D@`<P"HJP-@@"U'J`H#
M&F`!"T#&,B^80HGM$(`L<(0)')`#9[)UGO]U29CGMC9Y5..WV"R,@._%'Q.&
M0.$.$+<&L`&7;/!]/RP,``E%V-T`Z!L3`S88"K=15P#1):[)CJ\$M#D/;[A=
MPD6XISV/&$`./":/3_^`H61)V!&/RD8@,"0!9./843L6<+*'>_P',2!6-2<$
M,,<-`7`\U`!S)G(%;S!3T,`"U>`+7Q0A33!3,R4++@8*`A`%.!`V/[<.?Y0V
M1S>")-AE#%$35R=F&Y$6BA,1'<`HH6$3>)5(5S<X;2):&2%H"M-N8Y=V\\01
MCT)/I1,!X5)UD24^5`$%QD0"-6`"81)82+$4DB(F+G`!+44#+D`#&Q`"58!\
M&B`'"<`"J@8!BS<"'Y`"I:8`-L`"$B`!&S``)O(&'((,094#8A0"#J`>4"`#
M#(0!$0`%I)$<!T!ZG4<O$3`$1-`Q!2`'\U2%4``:+T`"KD5@M.$:H`$3XP'_
M+MVV+GR#+0HU".HB,%*0`@,0`@:``AB@32*0,)HD",PG!T,``3YC`VMH&O45
M8!IP*TK040DT".DB'`)4*R%T;MV!&\MW'EAP!,37'DI`'2&0`V0@`/'P0QZ0
M`5T0!`\"`^/P(RGC#@"0!/(P(/?Q"??W"2K@!2H@(S74<D:`1-YP!9]F#4L@
M!,Q@!#\&#?9H!`-@`/,X#$M`/`VX*F^P-5#F`9KP-1ZH1SXR="78D`Y92%R@
M$:*E@K8$%DSQ@A&A`:C1)G]V$;24.<O&-Q4A:8)0+"]0!4=0!5%Q9E,X6H*C
M$OTTDFW`.7WR:\35C.*#/F.75Y2%6'^E$9:3!2F`_P4N\`(Z(`-2P!)",02J
M=DQNR'@?0&IO&`(J$A<0X")RV`UOD`->D`&H-DUP,`(<P`$H$"L=P`$V,`+-
MX4`64`&/07K[=@6@T`4.P(B/53B1Z%H\,%\?E3BP\3[8`C!'(`,\(`(A-#_8
M,6#GP0'%1`%I>0.[8@'CHU[$@3\M!0$48`3V6`1,\&CB1T(-13#`Z!NU%Q,N
M``)<,@@=%!P9)0=*(`,<$`=*(#%[R`(%H'`@`P9BD`$L,%,&,`#?^`X[T`DL
MPWYI8`=D```<E@D"H`)@H`)$H`+>X`,'R$5Y(2->]`$*H`Q&8&DN$D;0@`U4
M"0<Y0`0P<`5+((?*,(<^,/]#_;$`7I.0>+1'.,"0#WF?^*DV7,`2?<)8'R%F
MJ;0F92(X@343A%,Z)R$IG+-*YD,%-'$#5[$2/'$6Q<)='4`19P%V(G$Y2@%*
M%N`$#``"?Z.#__E7Z,-*@)41":HE-'`$DT4%>X@;W-4&0V``$E`7:,AX:`@\
M"K`[<#$7#G`BLV`AMUD`Q<0"(9!J$,`!)(`!$W`!"6`#2D`5#-`"C_.6KW(!
M'!"-.88$3#!IXT$#(L0;)\$#U"),J?%1,3$=&Y!,UU,!H24M!&5`#E:*(2`T
M+$`#GH<8EDA@H)@(1_"&GE8$7<@9+Q1OZ5(%\"&:^.:*97$#%E`#X9)1YU8;
MXH?_DF,Y!'$P!"BI`+FP`.5(!#96"S%P'_-0,BR3!LGYG##P0S\%G=&I`C`0
M`T%P/`T8!`%`33(R34)0`'8@G<XP4_8X(DC@`#8@!$&@`K%@9`&@#;B@"UZ`
MC2H`GQV81VE%`%5&#R*8G]S:K0D!)1[!=%.B@BKA27=U5R6!288E%,NF9XDC
MB4-X`V:V$W!")8?C="P!=W@BKY;#5V!G`A@``C?@2$W'$;1!!0+D.<M!,!%0
M`2*02/N&"!R@``,P`HX@`RKR`8LG`["IL1(P*@.PCYX"`4YT#'[!(37S:;3(
M`F)H`&_*`ZB&'!.@*\GAEI[W6#00`"1C,K/&)KRA4`+$_P-R<#\R02ZLE"TH
M,`0#@&H.L`$FT`*4Y#[GYAOQA%()4$PV("(R,#DN@":"T&PD`058D`A[9VE/
M]`$3$`$EX%#:4AX0`Q[;`6XO0$D:('5PRAGQY8O?P0/QM$*P&0=2<`02,)`"
ML`.:D%U*Y0.8P&$@:'\'Z0G\EP/3Z@'\5R'E^2!]8;+8:(?823S)Z@4P\%L%
M,#4A<B(\]@MS"`T.>(#`D`%$D`-!<`E"TH$)"73VZ:VXF[L``68_^&=E`A&>
M(V:(-7=XY68#:C@S44LBA!*1@CY[LA/A*I$\L(M(L68K87<9$25HMB=EMSB!
M(@CG(5HE`!\7,"\8L!7CLQQ2H/]%%)!J^YBQ:,BQ9A@JFC(`JF9;%&N;'((A
MMC`%W4F`/P-%*3`!6O`"=4$"-X`]3G``P99-T3,2$*`"X>@!`S!`!$1"YJ%I
MY<5/,0&+"9!,9!0"-'"W4ULMY,$$68"28<@T792GV*9ILT,%Q<(#<``'L_0"
M4&``3]2="3QH/-&$&EDP6.`P!A,P/"!"=0L"3I":`D.:*-P=*>2WQ+<O4Y"L
MJ]`.(",.\M=P5^8R:>`!)?8)3P`&GA`#532KV6"YV$@?'5*!?>$%M&HA/'9&
M0X9$O>`-<WB`QZ,SMM#'T1H#:?!P28`#YT!EZ-`CMZN[BKS(?Z`"KC.#:"<3
MF%-U4-C_DQ]AA'97HE^2=M1!2UCA2),"$6=ZH'!V`>&K6!*:)0\A-R10!4BY
M7BCH@J<AIE)!2K+3`4S@FBE``7CAOKLC`3LZEFE8OQ_,._1+`;/`(=GH"P!L
M#5,S`!%P`%0`!PH`2O-B+Y(Q`=`C$2\@!SF@,DG@`T.@`3R0:>CB;42+`E2@
M!')@,/%T!'%P!!^`%SG#`56H?*P4&PA5SASP3.VX!"R@;/?3&A0Q632A`2S5
M!CS!`SK<14Q0`1=`!0V!:U](<.U,<"94"#$QDR)PO@!3&^0R7]^1PBKD"$=P
MTE(P`*L"`W8@`.Y@N!SC#@>9(X?\`Y]`13E&N6+0<3$`NV*`_XT^X'AOD"K(
M\UL4,JNT>IX9("(V$*1+=BH=\@9OX`OM:&3<\!<P@(TSE#+*B4?F$#8]D,B,
M/-;="F96`A-0,:ZO-*`V,1,""BBBO&RA10*W-"7T-!1:\;S0RV:;XY)DXCF&
M)18[T0:?+`<?T)DE@)9'@#B*PA)3X6XQ`4)/$0%FJ1I5,`0IH`,*D$RC<J.,
M)\PI\)L&4,P)L#L46]K$XQ=X[`M3HYD1@@04P`,U(`%-D``K(!D,L,!.:B@6
M45\)8"`+0`&`@CAKZUI5D,)4<)*,&0`#(`?:@BUQ@!<.@`TH\&C5`A/1XFV$
MH`1P*`02L!W=,E_#H28F(`)4$#4C4/\L3+#++&``(G`#1P!W#J'.4'"4%=2,
M6("H:>I.%O"P3<R:'?4=]3V6_.(>:)DQGW#%`D#&@PQ_#/<U[(`#/Z`"75`R
M'D`&)`,&N,K2"L*_J_*/58R-7I`#5:0,5V,#CFD$QU!SJ5(,T``-1S,,SSH+
MYOD-HA!E-)V08DW6//Z09ATX?P8X41B#=S6@9O<"AX`^A.,4K?.?=P<FE+02
M'[%G2^X29:*N99$YV8LHLTD#*\1="D,%>S<$/*`1I*1T-%`%G/-(J2@"CV86
M)_V&"E##<)`"I`:;I8872XN'5QL"Q>P`OZ`+IT)S1J.9/R,,2W`$),`!Q-<<
M&'``3M`";AG_J4L1+E7PS6*0`Q"0/YE67Z=!?%E0$5(P`BS@`%7`;=;6+JE&
M#31@`N`EI_S#,,51!55`$@(3?N#A&A>``0_PFF1>&S!*Z[PA!<6R+>I[TBS$
M'N_!&DSQ.&I;;4)A+KQH0$=)?%*@'G#P"S'P!,GY`V"`("0S8N[P-7C4`S-`
M`#,0!3,@QE$&8PG2QR1BA\+0"RS@J3*5*L)*#4C$,]T9`&_0CL+P6R%R-31W
M"[?P!NWI'ZS0`U\=-E&PXST>\2/(!4:>%//4.K!1K@1:6`:J$=.!?9[U2G#=
M$F/BUS/ADCBA=5>G.241&XI3.C:1$QKP`4HP`@I@+>#W`4BCYF=>_U@MN@%E
MCB4U4"B<0=D7``<ARSMMB'AC*<SS7.KM^\&-N3N.)PL.&$9A]#-3\&I-,`)&
M"0'R4GH'H`5.4`%5(0+`&^T4$`,Y!`.Q^0$J20+*H015H`$@4`$CH4'4@BR\
M004?<+5,8P,'DXGN,U*C25(.)6#?1@@#K0&-/1SE3.L$8V\24S`!]AF#(#$5
MI.S8IT\(,P$=D!JK`5"@2`@0<^T3TXS8=P0.D`%)Q0HH]HTN?7_?Z`[P@"/@
M:.[O("2:0$14%$=`X`UT*"/82`NU0#R_E?Q3<ZQY8:O;X+\L]PRHDBJP:R,>
MHYP("3918`#;*O'>?W047_$<D19+OA$5O_\FP#$<RT$:9>YN6SX1$Z%G8H(W
M\I^O=!-8AK,G%Q"35PX(%R07$0\/$7(.%`X0(THO;5!+`S0N-34/&AH=-R0O
M-(8:#Q>')7%P)28H&Q`&`Q"L<",<'".V'P,L(8L)"8J*+$A(`6]-4TU&R4)&
M30$%4P4)-Q=Q&SP8!]E:6A@=*R81%Q>:;4<9"VE`&453*>(=;50O#S<K)#2:
M*&TH+RA,1Q(&4+!1Q,`+#2A0E-!08A^/ASSX,>'Q@@D3?C0>]J.1L5\)?0QY
M8($"!8L4*%FH5#$`08J<*E1X,*F2Q2(5+$J.*(&B1$J6B/0FW"C!L6A&*DA5
M'ADRY(A3)4JJ0-G_("2'#P\"`*0!`,!#$C!`%G@0H\(KCA\_GLSH,>/)CQD_
MDCS!@2,-$2!`?!3(`<-'#A4%`JCH`N-*@<!7C$T)8$3($A9+IDQ9DN&QD0)7
MC"`QLJ1(`,I[`S0)$@.,'3$+?M"-LF-'E"@&3OR93;NV[=NX<^O>S;NW[]_`
M@PL?3KPX;16C'G3H4*A##1>9-(PS9$@0J4P)$?;3(0%*&PV#7KRX<*,#(4,=
M#$4H-(H]=>K7DUL7=UW<*$'220QZ[^*&(1D.O"(#2OW0,HYY'[U`@@LK0*=!
M#1J\T)!T52C`F0T<*,'!``-(L(&'*=@2X@<0#.!`""P$B*(N-B"QA!%3_Q0S
MF1!((!,9,3!,D04&/,@0P@L,-)"-$UI,\(`+(J27R4(H#$#$6![X!<$+5*"@
MR0,H9#21/I_P\P(6'XR0@`TL"/$!"1JTT4]"XA75)@\T),0F"C)1]!`3_;31
MQD(:T*`2%E5(T902/(SYP5,D56&2%('FI%-/6&0QW@,BB'!!G#1\(E-2*I%T
M1!R@ZB0%%ARPD(-50`B01A("+#`#&#DL($8:8VWUA``"J/85&&OAP*H`8I!!
M5A#$I@J$%QEDX-=A`<"@`@Q--)$!8TU<,04%,!)31`CL3)'8BY$9LP0,ISY)
M1@P+X)K$#*V]%L4`LADG[[STUFOOO?@&AYQR+O\LUY]YXH@B'7WW76`E"9GP
ML$^52Y+0@290X4/*>H6L%Y]RZ\$G2CCJ53>QQJ0,(@X-4LPS2`<F?%G"`UF,
M``$'*#PPWC0/?W?0*"_`.0UZ$3`Q@@.2-:&`#"-PJ``<<'R@=`I*M^*``P8D
M0`$++-B0#!*3M>CM9(I5Z\P;1D1P@`@C2!""V$X<T$`++4RP0J4=0$="&X=4
M(=@"1$P!1`&$VBD'%5`,D867^NRI`14Z#/%!"$9`(!U#XGUB5*:95B2GG#18
ME#F<>0Z,IIK]?$(E#XKN!-41`Y[^%%2#*H&%PB5T`((+D&?)!!5,_'T[%5DH
M(</O@\HQA`,!Y'`L`,#_V@%&NK1Z`$!:R+.ZP+I)`)"N&#$0$8,*"SSAP0)B
MX?6#]3X$`0,009SJ`QDP'%9`!E/4^%@(6"^Q&4%-!!:`#5Q+5H!?&2""#X#@
M`>ZI!0?M>E>\\L7`!CKP@1"4%Q?$$0'F+*<0`>-!<JCC'OV,`RG@&<=^QE&"
M"W!@`U"04'7>,QU1,.<^[S$$FD9X@;A=260$ZP`/.$`%0]Q`!!.HP00FH($C
M.$(#*W@8<PYR$`TH@0D:X$%)J*`!)H#"$QQP0`*L500.M6(`+-G`!S8@Q@W`
M00$&X``-+J"A#3B`'?9S$?XP$YG$.,-]!A`2"39@@!%8X`!::(`6V%:!"3"`
M_P$B6$$XI/.`/?H`,!_@"Q9*P`.$#(X&1X!"E4"2#_$P(0L<4(`2#*:)R$G.
M392#DU$2PA%-\<-*(2-$.!"&GX_L@R,V,0D4EJ*#.#!%)XBJ`E!J((((1$A+
M%J$)1.2`NM\E#BI*4$`(_D<$7'%E!C.8G@K`L*[Q+4`%UGS+$[I"!"_$(`,%
M$$`/>H`6%<1@!@0`0`QB,$`@=($O&?!"#@HPC`*\X1@V$,(4&B,_%C1F"<^H
MD6@6XPQHG"H'7K`#^-;5&M?`*X(8S:A&-XHO+@R"8AF389HJAD'K5"=-"FFD
MYR(PPPBT4D\B\]A^2LA"ZGB..F@BA-P0)A_I<,*"'?\0`0@.8($5/.`B-*A@
M!_ZA`1><QZGRN``/CD"%"SBUJ6W0`01L`#4(&&$`"3!`U,`(`3C``@X?,D`5
M1(!(&E1!!R/PS&2N9H0KY,A%D7%?!F"P@4!2(6H2F$`+!FF%0!:2`2VP@`A&
MH9\(N.`%0LB+M-Z`CY7124(-R51"^%2"A4Q$/`H!R2LCAY&$4"1T:]+.0^*4
M,PEI0A2$$,0A5&HEAF0I2YJB@A24$(=>0D4&.C!=%1+R@"02194628E%<K>4
M6G"@*9G\0`*:!81;6:]5TQ,G-FD%A!ALI7I9L4M8NM"%&83A!^CHK@?R\K__
M2<9^4T!G$_IYF,T4`6PV"$#__(J`A")X)C!+"$"-GF&,'`3!!\KB'E;8Q1K8
M+)"C$(ZPA"<\P4.\T#XJ79EZ,%@(_>A'$_L91`@7HIR0>5"FI`C8><9!GX"=
M^+4?FPZ&EQ.W&]@X/1%8;!OP89[FY,PY+N"PDC2Q`@L,T;$/.((OAL`$)3SM
M%:[@4"X"0($-@(H##V!`!42@`2FX3`(&",9`A1&`##0A7#$Z3++B8(46.%D(
M%)C`-IS@!`9@P`)K:T$#0,!2\"`Y!40@`QFZ0(0AY&P<F8L):0G'IX3HJ92A
MA01HL\3:B%C)2QO)")R\I(F&P++3@T#31Q;R$8R@*4T9D8/OG@M=ID!A(FUP
M@5-W__R)VVWJ3E*0@@Q2P.HC8&%X2,A`%]*`*Q78(2L`F`$.<+4`B:(#`'*Q
MI@"(``,/C`4`/?`5&8QG/G0N(<`%Z$P3WG`%^.[3,$6P`>.2(9DK"(%;"-7?
M8JY`[L.0J\SE<]Y7=H"#UUQTP@`/N,`9B!RE%B*$XB"!8T%JB""#V,6"*&&*
MQW$16<;0I"6]`(EG&4)-?.SAC(7M(5Q@`D4ZYP;&G(D+)I">&SA5.34(Z<-J
M6!YO-%($!["S<E:@!`AD@79R$-0'@!&"L.H-!D7XM0*J``(+1``*@AH`%C0P
MA!+U=QC%:,85B*'F*Y#`"A5(@;>DT`(B60'L&&#`V;7@!/\3C`,%"@\R%0(0
M`VM[X`,D>XA*8J)9CJQ6(9U^=(2X5.F)J.0E6:B"'.3PDXQL#DZGK6T))$<"
M?2AD'Y?SM)J2.K#!TZ!W3@F]4[(0IQ^Z8/)^QY.?7B('+%#!B!SHK:^EX``;
M%(`(8D!O`>4"!@$D(5T"*`L0[H(:Y('A5F3@RC4!H`+MD<$+U%;S%$X5`!;P
MTS-70"<ZC4`!!9QY6_)]41'VJE\CB"9:T"A"`<A5OBYX00!`R($ZP_#O@=O_
M_OCWC0IH'`Y!G+J&6!(!2=0Q^"%BX!$=%]`EAY,"61!#&[1A3C4.*L0>\^%Q
M!P=B'S8P,%<#Z<$@'7`/*$`T#U+_'M;A<-(1#BOC<OTA`B;@#89$1'0C*(X5
M"151*LOP;D#3%V\0`F%T!"5$!270.U;$6U`P`C#R3TO0#'>4+`5``8!4`\13
M!!'@!&RS#796`0U@!2=P`!WP$300=RT(!V$A%D+S`?+@5JX7=$GQ67(B'IAW
M6WV".SR0!3)`"P/R$R>!%!,!)Q/A=Y6S)I+S'8Z&:9.V#Y]`2J?V'1$2*#HA
M%3*@!+B#1,64)9!7%+PS$[TS"W4H*@H@!/_C`V(@`$^P/&D`!L2V`,A3%F1`
M0-:3!#_0>Z,(%S@``-@3!`%0/#!`!/ND+`5P8/\$/](B&K?87U2#!,$@+7MU
M?6_`&&!S_PS6,E\(12Y!@#[5)`8)$`1T47_YMXW<B'_[@G'R@0(<(`<,TB"S
M91\P]@"3)QVX<PC\\#@A!!_UL1SC\!VT)$,!\UH(@T$.J!Y/54,(P01E,@"D
MHS`SI`_G`7>'4#%QLP(@<$@@H"0EX#,R,`01(2;<`B/?=D<)-0`;0!D#<"E0
MH`,?(`,?``=4I0"+$6#6<D?M4P!QT`)6P$9PU08RF38-H&46P`!:,#8NP%HK
MTR\WP`3.DBY)$`1&(`.$T`9T^(A#@`5R`!%5DC.9\AT-L0^D4$4?P`)#H`'&
M1"=(T29'`1$Y<UJ.EQ&#"`F@0VEO8D6#IR?B(0KW0`,OT2A'H/]X5654D[<1
M$+%:,H$%<0`\4`<%,L`"4^`#Z1(72>`%T$<$WP1\RB<`:R%.'D`$`(`#RM86
M`G`N75`677$^>N$#1"!`D^$^4U`$XW9FD;$9TV(5_-1?+V(8S^`_SD`NR/A(
M,1`$H?@$.Z``#]:-P!F<$#9!UX$"NE8%A_`"(P`'&L0<CN5B&T0*#2%#1V),
M#\<G+;:0U?$1&0AB#[@>%S0=]Z$?I:`PF^!R+P`3#L`9+'`$4N!KD[<R-5!R
M%Z0<(_=#&-`")Z"%;L-EC#(/3)`"-D`0989.=T0,[F8`#M`7!K`!=6@`"L`!
MAZ(AQF`8')DL;R`$('!V;4`T'+`"6F#_!4ZP-A5@`=A@9QAP`_(`2_2`<G`0
M!!(%`$*@<A,0`4,@!'J1`,-%25E`>@KR6HYV@(?#`0D``26P`BBG<:Q4.7VI
M.:W$.;;#.:BW)G6R*<*4)F6)6VDBE2.I`[L$!540:Q&0(&`9$S:!%%703$,`
M*4I@`$B0B^>R/</7!3'@!2I0%L<'`+`X3C.`/&^Q%CN@;,CC`63@>P(0!-1F
M&`2$8%/0%].8(\ERBT7``F*5`*:Y!$+@&)N1A#&RC$&3H6^0`8@:!%T`/N#D
MF\*9JJJ*41XE'2Z``CIP!/A`,B5#8\GA8;)T`R7'@4A&'PB!`NFAB`,S,4J2
M"9US""($0\HZ_PJ>TVGVR2<=8"1TZ64;8$4\0$900`\F4'+]8D&.A0D78`(3
M8`'ZZ006L!Q88FE9<@0$@9H%BDYOL(R!<2T0T!<Y$``)``?=-P)#$%PPHE?)
MPH0;0"0',`(()0<ARG:!I&5I=P`@``(KP'>B,'(=0`,L@"X>8`.PA')>!@$?
MP&0<H2A6M"<-(7&'$$5#(!`*,`0N,#O&FBFJ=):[HVF;PY=QPDJ;1B<381',
M1`5HXB?RL&E4(@<700)50`L?\%Q90`B_:CM[^$DID::]Y!10AP5B<@6/A`YD
M\3UI<*>I\01/4#U<$;:MH1J8V1H(-`/!5W?(XQ<!4*IE04]ZD0%V$/\$Z+1/
M1;`,9X8U=B!9MY@!;V`_`:8LYW8,.9`!.="HYG,58%"G$/";JQJYDBM!@^</
M3$`*&2$*_8(E]:$>LO8V)D""7FF=(=-A*[20S,%B$5(",94Q!A@?!(,?X/$=
M%90)54`#%4`[6;`!1]`&3^<(/OL-("`"O`H=G!!D#2FN%5`!?`8.^>`S4,`#
M<748D<$7AZMF!AH".A!L`I9&4?,R:VH#%@H#>W4J9G8!(<H`(;!7)#!8;&<%
M0I(-!^`V$R`"F3-<RA&MZ1$'.5!W/K`!"N%95)"T5*!I5"`'XG$!>S)"<P,%
MN(`B`S`$*\"\7ZD/?L<YF;.S<NBDI!,3&M'_$92F:54@`U6@'YF3:#=+!5'!
M`Y[@91Q`-$,0,RAU2YK%`WH(F!6Y%)GT5A2`!#E`!"IP*\YC/0LPC<47%W'!
M+OP6!6Q!%_S6`_P&MFH1%T\@!KP2?#F`!%AK/#!PBT804#<"`S#2/H<+`WTA
M&7_;%X#[(DUPKUVL+/FT/<'W`9`[N79\Q[TA!A&!,/H19`I!"N8Q"AT(GG'C
M`OKAD$%64@<X#AZG,246"GLB6XT$,@<8"O%!)QS!2(9@"GCW`%50I"Q<"'#R
M`)<``C7G+S5PRLYA`B`P`1!+<C%G,"\@!7V$!1OP!C!@MYYHON3+A%/@`$R#
M!.J6`!\0-27)`57`_P)E]C[DPA=&P`,30&<D@`0^,`4XUP!T)B05P#8.^PT6
M\``DPP3=.@&G1P4A<!79<P5]1'I,T`AW0A%N,@3(7$F$H`0;H`"^,!!#(`(D
M:@*&7#FM5!2;(H=\QP,OP02NQX8846M,0)A8H(Y`JTH2\B55<+E5I"&TH`-9
MD!X(88@R@5N?\'K`-;4P(07T\P;[I`)JVSW!X@&])P9P\170AIG*5E%0S&\(
MQ&]HD14XL%[T-'P!=&!$D`%"\!F7L8M!XXGO@QGW&C_]I!>2T3C'X$^X;,:Y
M^21TC,=:O=6Z46%QHZPM%@&S'#,X!A^'X)"\RLB"4%O783$UU5,\Y6&GYO^=
MEEP=^R!RF:`F@,.Z0U`%C.2Z$>!RSADW]<D)#PL")?>PBK2Y%\`$TM6@&2(#
M&_`,M=`$/@!`9@RX-N"@"DH!10I6$)`".B`'DVV][<,"(_``%9"?!Z`$_4L!
MB(7-+:`V@)0V(#"?3H<"C.<-2/*J_H`$Z+(\7L!7T:LPH/01+]P/M(Q.,B`>
M2A`04U,U10`!%X"%#;"3?$:F8HE,?I@Y/7J)G$.5H:,4'(`%"BPZ`TT#02@%
M4)2`68`Z+PP%7BF!J80["D$E6&!$(Q!<C6@AS0(#T[,\FZD"Q-:9"^`%<K$N
MV88#4+Q.%;4#;,'$$(X6L[@`,;`7ZC!\AWNXZ?/_/AE@C)*!-<=@C(BK7\TP
MK_V4H<?0S`=V*EZ[`77,U3)NQ_NR'P87'0A3`N5]'NB*'C6P`HI4'6@R"FV0
M<(#,'OW7?R<5URTVU[%E8>R!)B0%8A9!'D:U8DA60?TB:]T:9-IZ"3]N`L1+
MR!'0!G&@`"C4%)ES!/SU,@I@8)>-3\_0?2E@(F!D(@DP`'`P!'$@+?XT!3+@
MD*V,`<L+`8XY`MF09]G`DSTI`I90HR4`.$U%<BSG6%)`MP)@BD%``6ID"*,R
M`2;PD0-`"PI@`TJ0)7$@92<24),J!4.UVA!9P5YB%'YY%$CQ$Q8!$9]U%%A0
MA^;-EK5FWSSPGP;#3$P1_YC(V4B7E3.:PR:DDP)BY`@G`0?L0"[<4Q8_X`$Q
M4&QAP3W0EA9N01<UC;9HH1KKQ$Y;X4X!E`36U@7J8*^'ZPS4(IH"9AC)0D^S
MV03I%@(%*F"-FBSED]*T,@(Q/N,&KZI<X&>%[.4(J'"9D*[@<8(U9AX(QU,:
MMS$7]PY##F,$TS%8"EN!O;GH00CI44,=L'AH/5LX9!\]1AW'2W(LN`*IC*0,
MLN7PD'B*HP32477J=Z\&4#RB&7^B88P.@`MA!584L`A@%&8T$@`*4%LK1U0F
M8`/;PP39W``YN;QTYI.R4^9-]@(5Y)#:6@)4[P'$Y@%=8`0O$&0DL`(,``)4
MD/\`5R,$&]`00Q`"0J`((3"@`64$"B`V!U`!B<YEH'5*N+0I1\&S&:R'J[5<
MI#("6$`""5(1O),2''$24%0":<H3<?`!.H`/")%*K=0E$\%;')`"C]CK_'XJ
MI#&:WX,.LK)M4Q#<UB,&;H%-#-X:?4HKR@8&:#&HN7BG,9`7*H!.Z;,L/WR+
MPP>ISP"X[O,,-((U'@YNT-#,0-QL'%#P![_]W>A1!T$1YWAJ//4`;4`"4,!#
M=',D_=)_"^%_*G8D,5<P&GA#-T1+%),)4O`*#?C5LP4(#QV#$8,N+FT1(C<N
M@A$/%QHD$1H/)"0F'8*"*R8B)B8KGS6,'2N#%Y0\0Q__4#1,<4-P#AD^0DA3
M304Y&0530B$#&PX)-C8L(39"-D935U,%`Y5M+QT3%0PH&6!!+DY.#0P-%M@-
M+14@+A&AD3P7@S<B$1,F&@8%&2H`'@LY/"LW5H!@<*/-D"LPWCB`\N+%$`HV
M'%!@@8R%$",VI$PX4*'"!`8,'J!`\8('$QHF3:(P69(*$QXH8?*@0H6&S9<\
MI*3@4.7"R)(PJV"IXE**E"HH-&11,D0'AQ$CJFA`$?.EAA(E7U*I<H2#5PXZ
MCB@QL.2-#QAH?>CZD0;`DS1`<JA0L4"``#`S?NC%P1<'``!)%OR8\83P$S$J
M"A"Q0R2(CR!><@")`<1'AB`P_S!GR`$CPY4<`3+`$/(F1XX"2Y`T"5#`UY76
MK',$,=U8MHP3?W+KWLV[M^_?P(,+'TZ\N/'CR),K7Z[;CD\-3%!HDD0B$HD'
MV%-EH4+B*@D7-1I)*J'A0O<+Z"L]0I]>?8=(YJ];NEY=@X8V2HJ\&5!"W?M4
MV'7@0@?KV1?!"HT\4`DD5U5RP0,O:*"))1I$<$,-"*X@B@GA/4*3?0PR045)
M4GQ``1+-9-",`QQ\P"($#D"@@PY8#+!:$RPD<`L2*$XQQ1(#1HB)!18P`$47
M`@3`@!-6.(&-!0T<("4ZZF@X(`\5,I*))`]L($,*/BS`3Q!*/.#"#2!,4$(5
M'[!@A/\$1YRDP0M02<&!`R$D(T0116S@P@&BK+#1"N1E)6(6*;U@TTPG/6`3
M2C0Q(2D5/.3T@0Q4E!<)2B508=1)51B%)0]8Q#&"#$/(($-2*YG$Q`N%MD$#
M34H\A:I32BC0S!5(!%$96@"T)8`79'@`@!@+_.6!`$G@\`-?,_CU1`]VY36#
M`&)X$`0^M14``Q!!Q)`9#+*AQ4L!CN%S12\.-+%9`$TX4T```4#36FNU]"*;
MKRG@QMR_``<L\,`$%VSPP0@GK/#"##?L\,,01RSQQ!17;/'%&&>L\<8<=^SQ
MQR"'+/+())=L\LDHIZSRRBRW[/++,,<L\\PTUVSSS3CGK//_SCSW[///0`<M
M]-!$%VWTT4@GK?323#?M]--01RWUU%17;?756&>M]=9<=^WUUV"'+?;89)=M
M]MEHIZWVVFRW[?;;<,<M]]QTUVWWW7CGK??>?/?M]]^`!R[XX(07;OCAB">N
M^.*,-^XX<UVX00=R=+C1Q<%ON"$P'%P$S'EN.;2A^>.DEWY<&ZBGWCEP='1P
M^7%?Q#'ZOSETT(;M?W#A+\"?'_<&ZKM]_D4#='QA^O'(_X9;%VW\T<;E7$RN
M&QU=&/\\%ZOKAOUNU.OFQNQ=2/_'%Z\+E\,$TON[O/C4BY_;]KF1SWKYN;NO
MV_.^,3]]]LGW;[K^X^L`'$27&SG(_R$.S4.=&SJ@N3<TP'8-F,/XVB`'.'1@
M<M_[PQLFL$`)UFZ!$]A@`[@`AQ.\83<=.&%N7G<"V37@<G-@8`=RH,$'MB&"
M?_B@-;C@P"YP80*#F(`<<M.&.)00#KS!7VYZ^(<.-*!Y<3A@\_Q'Q<<!T`U(
M_`)N<C!$.IRP#2<,'1$;V+PY3%%V?\C@"_]`!]S(@89=&.(&<SC$W9R`?KDY
MP>3@H+DN7`Z`!/S='][XAS@2\7)N:%X;<]<!(O+/>?3#G_ZZT,@FXK&*F#0<
M(">@N@S>[X]3E&3SY#"Z1*;1#;K3S1WC(,$Y(/$/(XR#"G73`!KRQE^>-"/N
M(%E(*+;RE?_X\R1NZ#"!+WRAF$F,)"C3^$34S3*3T"0<`.$0A]V\H9J?[.4A
MM6G$W'3S>VTT7CA;)SKC_0$.<&B`.75SP/>]$I<-E,,7Q,A+_9'3#>8,YNAP
MV0$Y7!)_GQ-E#B<0S8(>+@X3N!P=(ABY\37`<CD@9C412@>)_H&B76C`&S88
M/=31@8)QK&8,W1#1W"RTCMR;`!RZ8,9"FO"C9?1G&Q)J48J.M*1=F$`U/?J&
M.\(2#G/`8TYEE]"AIC&A38Q#%][P2(,Z56]^E!X=YD#2^%&U>GXL9/7(]\?J
ML=$-<Y@<5XV7.5O^;H!ZS,T,?Y.#[W6.>ES@:F[F$-;PR=6/7SC_:QOT2+VN
M?H$+=FT#'.2@4^[Y$:]]S5WXQI>Y-ZSSJ9"-;![-V8'.'7-A)Z!L4W>#1="A
M5+*@#>UQ8NC,0:9P8:0%HW!@2L''BO:UL(VM;&=+V]K:]K:XS:UN=\O;WOKV
MM\`-KG"'2]SB&O>XR$VN<I?+W.8Z][G0C:YTITO=ZEKWNMC-KG:WR]WN>O>[
MX`VO>,=+WO*:][SH3:]ZU\O>]KKWO?"-KWSG2]_ZVO>^^,VO?O?+W_[Z][\`
M#K"`!TS@`AOXP`A.L((7S.`&._C!$(ZPA"=,X0I;^,(8SK"&-\SA#GOXPR`.
ML8A'3.(2F_C$*$ZQBE?,XA:[^,4PCK&,;&=,XQK;^,8XSK&.=\SC'OOXQT`.
MLI"'3.0B&_G(2$ZRDI?,Y"8[^<E0CK*4ITSE*EOYREC.LI:WS.4N>_G+8`ZS
MF,=,YC*;^<QH3K.:U\SF-KOYS7".LYSG3.<ZV_G.>,ZSGO?,YS[[.;R!```[
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>o40024o4002402.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 o40024o4002402.gif
M1TE&.#EAN`*$`^8``()Z==73RRLD)?3T\G-K:(N'A\W*PNKIY:JCFYJ5E&):
M6+*LI.SLZ'QT<,K%O<;!N7AP;%Q54_W]_6UF8QT7&4Q%1%!+2]#-Q9*-C;ZY
ML#LT-(5]=R$;')&(@;:QJ.;EX*&:D9V5CHF`>L*]M(V%?C`I*M[<U>#>UY6-
MAIF1BN'@VKJUK:^IH:2=E=K8T?'Q[\"ZLD$Z.L2^MJ>AF=G7T>CGXN7DW[RV
MKJ*=G+*NK-C5SN+AVZFEHZ^KJ6=?7N3BW=W;U+FUM+BRJLG&Q<3"P=O9TL&^
MO,S*R;6RL+VYN-[;VHJ">Z:AH-31S_GY^,?"NIJ2BY61D"0>'\&\LUA14*.<
ME,7`MXR#?:VGGI**@X^&@)>/B+VWK\C$NX1_?I2+A(=_>+2OIKFTJ^[NZT4^
M/IZ:F#4N+J:?E\S(P)N4C7]W<KBRKMK8UC<P,)"+B,?"OO;V])^7C]+0R"<A
M(:.;D^_O[,&[LXB#@O?W]IZ8D)N3C,O'OU5.3:2<E$E!0140$"'Y!```````
M+`````"X`H0#``?_@!9_@X2%AH>(B8J+C(V.CY"1DI.4E9:7F)F:FYR=GI^@
MH:*CI*6>@J:IJJNLK:ZOL+&RL[2UMJ.HM[J[O+V^O\#!PL/$A+G%R,G*R\S-
MSL_0B,?1U-76U]C9VL[3V][?X.'BX^2'W>7HZ>KK[.VIY^[Q\O/T]>CP]OGZ
M^_S]N_C^`@H<2+"@)(`&$RI<R'`>PH80(TJ<&.TAQ8L8,VJ<97&CQX\@0U[J
M*+*DR9,B2:)<R;+E0I4N8\J<20\FS9LX<WZSJ;.GSY_*>`(=2K1H+:%&DRI=
M*@HITZ=0HT9R*K6J5:M4KVK=:C0KUZ]@<7H-2[8LRK%FTZK5B':MV[<,_]O"
MG4O7G]RZ>//*NZNWKU]R?/\*'HPM,.'#B)D93LRX,;#%CB-+I@5YLN7+JBIC
MWLSY5.?/H'MI#DVZ]*+1IE.K1JVZ=6C6KF-OABV[MF3:MG,GQJV[MV#>OH/G
M!2Z\.%SBQI.G1:Z\.5CFSJ-?A2Z].E3JUK,GQ:Z].U#NWL/G!"^^O$SRYM.O
M1*^^?4KW\.>RCT__XOSZ^"'>S\\_X?[^``KT7X`$[C-@@0C6E.""11W(X(/I
M.`CAA.)(2.&%VUB(X8;6:,CAA\]X".*(09%HXD8BGJCB+RFNZ*(N+;XH(T<S
MUEA0C#;FF)F./!K8XX_UX`CDD)L(2>21EAB)Y/^24T5$P9-04L!!E%16:>65
M6&:IY99<=NGEEV!VR:1#3H9IYIEH5OE'FFRRN2:78^Y5YI4<3!EEG74^F6>;
M?/;IYY]PQNF.DK+<::>>A]*Y)Z",-OKG(%>^&:F@\1`:BY1I)DKGIHY6J6FG
MH&9):3N6PH+HIURB>B>64ZH:ZJNP1CDJ.Z6^<BJ>G%+I:JNL8AKKK\`^.>LZ
MM;KBJY9XXJJGHISR^JNKP0(ZK#K%MG(LLEXNBFVTW((Z;81.)JOLLHBFJFVW
MZ$;[[3WABIOHNUG:.6ZZ]/ZZ;CG5LB*ENX9"Z^FYNLY;[\!GW@O8G*>N&F:>
MR<;K+Y\-$^RGP>/DNTK_P*WRBNNN_9*[K[OG,JPPQ`_GRJVD4%)<8;A0*INQ
MO"##W#+`MT9\J+,>MTGSER6_RH'*X5BLRKXU7QLSPS$KRN^QG_9LKL1@)BN%
M`$"#(W0J'XM+[IZH-JSUQS,OW;(4FCJ]Y<Y=HNUHG7,(($`)9K010]4[S?DU
MT5F_JW7$5GK--]%W"[SPMKV"RK44<YBA@1]\\%$!'W1[<[4I(G-`=MXW9WZT
MV"+_V[+#>']^)KSQAFKYDX@+T$8%"O@P@0(*1)YA1"X?+3KFM6_N:^Y@=]PY
MF_*.;++9:<^!Y]0:\#'!!`00`('LVDQ>"NY9WUHSWR&['#;7F__=)[R"&WTV
M__%SD,V!ZF10,0$$#:BQ`?392$\*YF$7K3O@2&_L._VV>YJSR?[KVJ*X=KL"
MIFH."&P#XQ0``?=M0`3P*TR[M&<Y?FUL7MV[8/V2!K:]Y0]3W"N=H3"V/9F1
M#F?,HH`42B`W"U!!`01PGPA$0(((7D-^H\@;X*1@OKW13X52**&X>@@S7!'1
M;R#KG0Y%:+WZ%6UF@"O7M1#%0_/-(09\4,#R"-```(A@"5?H@`T[-,&8!?%X
M^:O3$2]H1B1F\&46'*#W^H:](O).=&K3U1Q*`#<S*$Y][.LB&,"P!"UHX0MC
MK`8.1?&Q(_(P:?>K("1?UL'N@;"('63:SI((Q=YY</]W>434%1]'!2I$``(`
M`(,(P$`"$BR!!%KH``H228U%AD*';SQ>$'&WQCCFTH.8[%<<A;BLP&7P?[M:
M80PBL#X(</&!5VAE*[60!5BF@)85*>,OT[C-;MJ.@QCSV_4(:,S[?4D`9B"#
M#R#0P%1>`8R&C&4'.O"%#F0!"MB$ABU!T<B7/?*;QY22^?[I33BF46GBS)T;
MN6?.+@G``EK<P!(&6<A"VG.>7T"!1C6ZA7R&2)MHM%P5>_A/Q!&QEP5-(C`9
MJCND;8]Z;#0G)J70AC:889D-(.0[E\#3#L!RGK%$00JVL%%$>K09^_P$$'7Y
M2+*-U%U55&-(H4I2_L'L<I;_'"?NMHF_K<X12CR$&QGX\,(8#E*57YSF%[(P
MSRQ\80M02(%&,WI4I-+NI`3=W$"E*K611G6J"4VI+[FJQB6"#*MTVJ,+88A*
MG8(QFB2X0C2SP-:W<A0%&7UK715#NR'F]6A[-:-?4?I&TG;/M"GU*LZ\)@4S
ME'4)]8QE%N+92LE2,Z-;D.M&44!4/6QV&4GUA"35V%3B/I6O:QSH:)W*5R/R
M$K4J'6<NJ]=27R7.CR5`7`DTH$4UV#:6:^V`(6$9U-S&E:@<W<(60O#;$D%$
MI,QUJG+A.]KADC2OQYW2/U4HV/ZFEIM3$D`,8E`!"UA``^FD`BI%`-YY\A:S
M\[3G_UOS$(<0$%6]&$Y!'-J;C.!V0J12O:^(ETM<XRIWC0(](XC]N\W/*O23
M4N3`XB+0.A]$@*P*:,`#E^!6MQ:5LD)=;PNJ$(>AIN#(ZM7#ACE<#`]S`K[T
M-:Z)^ZI+$_L5M%)NKC>A&U#/$K%^`B"#!5S7O@8T#Y42G>QN,4O9%*0!"G%H
M00M`H(<40.'.=T[#DID\#"=O`H@(Q"^)J5SB%9?TK_1U,9=_Z>*0DC:_7^,`
M%M?7Q0>"`0"0M2<)LK!1]6+V"RD(@1Y`T((SM"`/(4AUJBO,7C[W^:Y1E:^5
M^QI:21XZU@15](D=J>73/O6D(68J5.]6`C[X(*>KO$(LK_^@6_72<Z.<SFVH
M00`"4YL:!''(=K9!$((]N_HQG5WN0,L'9<N16]#B1O2P>3W<*$-7W<,N]*)Y
MI0$+3&`#A*0F93,JU#2D@-\H<&NHCUSG.,Q@SB%X<[?UL`4]A(`.WQ:&GS51
MWW1?68WDIF^@Q7W:(6:YW!F$M]0,C66J(LX/IZ2A+)&,7CO+%<.\'6INX^!P
M$$#AP@T/P<WA"H*(!V/BF3"I?&-=/J)SG*D6'_31FYKKTHH\Q"<^[-$>2@``
M\/2M>L9VG<T;5S<G?-791B\*#`EJ/9P7LT+U.;@A8M*-^[7H375[TN=>7^/5
M-]$DK?)A&SU56<>:DV*%`!BS0%3_#=/A\!7N>AH2'@=J@X`.=-X"O]?*Z11L
MG:BS-:K:10/K7_/PW'%?+@+A7D7C11F^13\WTN^N=]`^O9=,E[(G6<<'`)!`
MEG<.@9RQ+6J':_OQ%([#XMV:T2/CUM,/1H$]-^\+H&,"[QLG/=U+7_K4(]#*
MTR^NQ:$^WT3O7=X5+-<<VC`!,$!`!%_(:)RKT((*OUS)(*@"J5E=9#WP%KWI
MOS_:]S]+YO/"^9>`>J,W>I\G7ZG'<6U'-M8'>N4C=Q;7@%-V7-V'=[>F99"F
M)R4P5A``!AB66R`P`WW0?N?E9G%`!U5`!RT`!0IG>6G@:>EW?+N5?_WG?S`2
M$4)'@(@C_WV?-X`$&&CF]E<YZ'8-B(,YF&X<T(!&6%RG)VY%IW=*J%]F8`$T
M1@!+D&T6M@745H(69F=0T&T55F<<!6>C!@5O150PZ&F21UDT^`^THX,%:'U!
M&(0]Z(9-6(1N6(#5!W?29V@7)X%#=W$@=ES[8@991&9+``61AX785F1#)53=
M)FHIP&D9!05TT'A;J%N=UH@:)5YK6(/O57VB-X?2!X=")X%WR(1$:(04F(1S
MMV)QPT(QX`<PY#Q6AP(@X&^C1FW^E@9FIV2K%@(Q9V<AD(4,!W/I98:454.=
M:`L`:`E'.(1S-X`C18JDQX.C>("EN(/3>(K9MXJX5D$E$`%40/]@9<5.[J,%
M#R=JPPAY+:@':;!XO$<'(6!D-2=G<^9OR!=S;*9IR\B,-AAH#CA:/#B-VEB*
MUBB0V)B*T)ATTKA]5Y:-(T6(L!,!/N`#7*0&`-``(J`',V!SOF>%1Y9UC8=M
MMWADNC<#"'!PW(9DG29Y/K5L_7@4;5B0;S>0`EF0"WB'UCB'`K"#W!B0#OEK
MY^:#<\`X+D0%9#9#@]0!(,`""(!PE@>2Z]AX59`&=-`'V=8",S`#9\![=\9P
M115A\T0"$!23-,)V0V@\`)DZ!RF'1&B3.-F6"BF$/"@`!VB7$%F$GK=T6%2(
M,:1CD@5+'(D%3\EM:]5[\"=J%08"(5C_!7V`D@AP!G&P<\8W5^(53Y1GEF?9
M$.9FET@(D)X9?0CD-@,IC:+8D#B8BI[IDP.(EW&(BF^W?1Q0`A40`:>42F1I
M=5I@9RV`!839`G0`!>1U3ZHVC"19!9")`+^YBSNG4;/U3H9$?)JGF:_0C)5P
M/FDYFCTY-:8Y>J29FFV3G3MIAW#)G>+IEGK)C02IBAI@2C[@16#$4[>G86>0
MD@B'`DM`0RC@<'<6!U5P@J6FG"S@FPA`!T;6@5^@!?E92#V6?M09"]9)"4$8
MFG;IF11:EZYYFJT9FF[9-AQ:1:OYEN/9=C99GH-&!K`S`?`)1B20?EL0!_79
ME?_6`3WEGV^6_XOQ-P-8L)4(H)PS0'-GEU$=L%.W)Z1J^*#523O?N:'?Z39+
M&IX[Z9U.JIU1BII%MYH=VI;4YX#0*(!/)0`H5XX`L`$;0`)H)Y(,EZ`B<$_L
M-X]Y,&3_69];R96%J7-#17E:$)B'-%OT-)U(N@H1.@ER.*4>6J%.:J&%BJ&C
MF:A/.C6A*:6!]J$Y"9Y0ZIIZN8V7RD-MX$(Q0`84J6-@H`7J-6TK*5<^97C<
MUGAGP)5:V:/V"8+8)G-LI@6P!$NSU:+S]*>N$*B2,*&'.J6_:J'!.JP56JB$
MRJB_ZIT>6HTB^J@!&8@3BD!PLSH*$`$5L#C&I@;Z.9+REVITIE$I$/]_O"=G
M]>FJKMJ1?;"(<85VX46KY'5[AJ2KK<"KD>"KP$J:Q%H"ADJL^^JD^AJ>2QJP
M31JP58J7Y_.:0"E@`S9@%5!6!*!%RZ,&A:1A\K=[I-9^>D8'!P=YC=>JYRIG
M1,9MJ0:&&25/D159DJ5L6B"OK$"OD."HQGJH4NHV_RJL,<NOQ@JE&YJH/*NS
M,JNS;\E'_YIZ]4:1UBJ%!"`"5[`!`,`^-)0%NL=M<W8&OTEM(:B2O/>8RFF?
MCO>(W>9O:S5VXO5.*!M-^<FR@&J#^IJLRPJS`CNP%`JW]\JVD.JHJ7.L32J7
MG^<';:`!;;"=;6,&*%>MI91R66!^&GE[*-#_>%VXE2S``ELY9"`X`T26!_$7
MH#LJ?Y5X9-EF=E``86Q%JY!%I$N+MCO"=G-KJ-K)KZR[K,N*KZS[L\**MU%*
M?;,9`600`R7`.&8@K0I4`0R+E+8'!NU32&D@?\BKHPN`!::&DEMI@JO*E6=@
M:AR;;?[6A<+W:>)%ECPE6:N4;Z5KNJ;@LH_@J/V:K[&[NOOZNJR[MLDZN\=:
MNP4H:1;@!V1`!A"P!1.@`7VT.'[@!PT;`03`M&K@7;;8?G10KBRP`$])M3N*
M`%I+F*P*>8LX5'"6<)]+66/[3C.T8S,46>\COJ5`OHZP0K&+KWP$OS,;K.ZK
MNCG[-N<+ORYLLPHX_XT:8)$3H`9IP`)GH`!DH`&Y2Y&P4V-<!`8=L`6+Q[DS
M\+@#"IQ8X)0\2J#VJ6V0>(F:&'#U!%GYB59@)$LK*\*D0,*-X+;#>K.$2K.I
MV\+!.II#>Z@U>[-F+)?E@TX6H`8)F@+*V0(^P+#&!@&NTT`-P#ZQ]'A`F@8@
M\)0GB();*Z"$B<CRZ(YOEEMHZ)(7A;+Y.4,S]$KJE05@',81X9U"R\*A/*PI
M?,+$&L<>JL9J_+-(.#6]N[OJLP26]X$(``4$P`=8I$6!#`$;(&&R9(LC"8R(
MN(Y:^<2-+,$@>'@ZYXXW5U2;/$VT>LE?U+T_)4N=C`LV2+.EK,UO([2K?/_"
M+?S-_KJVQNJ^XHRW=(S+?+"!'9`"&@O!/TH"!&";S`--(M`!:8"54"!ATH8"
MQOEX"2S%/7H&?=`'%.QO+I>&;*7!AK132X!OF1R89-G+U]P4GYS"HXS&WORK
MYSS.YKROH[S-;KRV-<NV>#E^..5,8/`%W08"!#ID4'"X@W0%&*D&[$,"+;"\
M>8`"D45-0M4'[#=G'2MGSBM_CD=STD94ETE>[HK)WPL&^#91!*QC%1T*8LP(
MW=S-(>W1H9S1VHS1&"W*;CS.:$RW/YN#`K;.K51YC3<#"^"4!)T"6O!%>=H^
M:I!34+``"S`#]I>GX!6N_BG4C1>"J\I[C\B+,E?_3]L;30T]2*NT2F0ZIDP+
M`#;=0%4-"E>]"'NDU23=U=X<SM]LSAFMKY]-FJ0MTJRLLU-3`G.@3@#@S\5)
M!\KIFQ(,C#XVUU!]!5F`QU6YKI<I2THVP8]GT-16G,+7@;,:64H;60OZT),-
M`-!]UX'L/&IPV9^0V8JP1Z7\V=P]VJK\U9T-VF#]-FVSW>*\<3?5MP20!=FV
ME6<@?WU0KECPU@A0E9@G2PE*3[N-C[-*3;G5;:7VWKSWCGI0X`YG?Y0783P5
MT5O\3M%=P`4\W6?6`-;M&1"AW1O-V5V=U3`\TGQD!J+MU=M,VEI]RM_Y>0A6
M`C%``+NIHTXIU,/8JEV9_Z9YNKC_YE;XW8%L94^'E'6E5HE?Z+EX)GEK);I;
M?%:O!-6K!-T-T.1-[DS+LT45W@G8G0@8KN'=[=GA#=;B'=;<3.)>/;"L_7D@
MCCC<U<LS$`8>`+EO=F10`)9?`%FP9'"3F5%`ULQ*'4^RM%XAR&H)9W9'UH@O
MR%:N!-6._;UDRK0;X.1/3@`34)&M,^6<4.6(@.%;GN6GG>FEW<T@OM&>_=5D
M;:%F7F!^H`$:@$5F(&`5,`$B$`)8X`$WX`$(P&T!!V%CB5'NW'[S*';.>5&7
MF7G&^74$+JOZ%W"$OK1G]=S/_>3LU#R/WCH3(.E%<M&=_N&GK=4@KN%87MK=
MS?_A7#[>,DN(53<!@-0`9.7H&Y`"5,L%([`"6""/[`I>U*1AI%:Q1&:JFS9;
MH1M/N]G2JK9U<Q6V115;))#HE%W`8TK93LY.$!#E%6F1TJX)E'X(EK[MU<[I
MFH[I6?[EW8[&Y4V;#:`%^`D!7U!G88N%"+#`7#`%0H`%W&9VA?=P=_9XM&R/
M*_D%FY;?XQ5/!"=J=Z9;Z;=O$$:KH@O=,Z3PC,[LS1[E44X`$9\)$V\(Z.3-
MV.5'V&7M%T_:U?[96Y_Q7;_=7TU[$Y`%AMR1#O=P1/W$8:#F:S[K,9YPCEEA
MA]>J/+JY6S!;+#I>MMJGQ7Y_0;_0&)7%&W`%H-8!E[;_R\SN/%#./(XNY4\_
M$A&!3E^O\=V=]=F^Z93/X;ZK`0W0`6J`7KIW!NF7`BT@H$S,Q)$IM3L*G!:\
MJK/]FQ5V]V/Y12FKLOP>89Q63;%%6Z*:AO.D845&TW>]],Z^/`W/^%7W^)`/
M$9(OM)-/^=`_WIA^^=KLJ0J`QW4N=B[:FPO\N&_]TM@FV^\=!^K5FSW:R)1[
MBU_`HJ[DU*\D3=!<I(H-_ZYDIN'E8Z$6!U\`U1D)"`03!!""$`T-@Q"'8'^.
MCY"1DI.4E9:7F)F:FYR=GI^@H:*CI*6FIZ86J*NLK9`"9F8EL;.R);>SM[2X
MO+BVN;R_P+VX`K!^`%=?"%@@_R):<2$HREDH+2P+'BS8+%@(,WUQXG0@<7I;
M>@@+"RP(WW1Y(6E;'5I:)")@(OLB5_[_)+1TR)*E'@D25Y8H!'.EPT$M7[X(
MW`(%Q1(``-04:K`(@AHU'`DU`-#(E<F3*%.J7,FRI<N5JE[*3`E+%JV;-HG%
MVK4+F+!?.X7=$C#4#!D?'<[T"4$G1`,P*=)`>7;%&A868;!@6>`-P9DJXO3H
M"9L"1+9V,Q"T2),BRY>";[4L$:&PKMTK`0<6O'=OKH@-2T@$[H#BR\$.;R]N
M^-@`Y$>0ASRJV;!AIN7+F#-KWLR95,S.H#?5##HLE\V=M8+]).:KIZX21$MH
ML-``1/^+.%D0$@!`(L47P"*LN>O:SMV,*B!";-D2IUR<*EC"<&TQ`\3RPH4'
M&@2XKZZ_@/8Z.$1X9=\&$>0A'CR<10M>$1D!;,@8DA!&^:'SZ]_/O[__2)_]
MQU]J/JD6%$ZGH?9::POJXMHM%JB1`A9;@*$&0V`L`4862VR0T!=0I`!%""&`
M@$!Q,[103@@IE$A'%2U$M\`9S<41XA8HX!A1>_;8LUY`Z8GG8WGZ@&'D$M^Y
MU\]#XM5S!1CR@;%!`P00<L@&4E8FX)9<=NGEEYP$".9FJ1UX4RT'HAE+&VLZ
M:(N9!B;8!A\^`%#%1XOL=J2'*$#!UELHM#B#5EZI"`(=YJ3_8=L96V%110A0
MB!,B"CE>]U9<5_AXT&`](I0/94:BEU!"^2`96(_N98G(JHL`P$\#8\8JZZRT
M:B9FK3*-QJ9I9IK!9J]!M;'@@;\22VP,9/@!`0F'3."#`@KX0$!5YH1@(PIR
M=0`%`MH4JF)S>8Q%!Z/>T)%&&F%-FL(6ZT:THX\*:8%>/?<D5"26^P3T))91
M9OB//U!"UA$A%U(&`:X()ZSPPI_<RG!*:KKIZT[%]EKQ+,*6("RP%`<;0PQM
MQ.##!!.H00`55/`!+0$DZ-'G%J7JD\49ZWQS!CDUCF5;6C/0,9:-4`0=Z');
MN!M18>T%--AZ<V7XESZ!X2-E?!AE_ZC0>QH54J4@!#1`V6(/ARWVV+4Z3#8K
ML+#91L6_8ERQ36^_F2!/QL*-K`5^Q*#`!`U$H,%L?%@P`03!B:/1>6"08.("
M[B!`!QTMW'8N"$J5HX>?YJ20@ECLZD@0TF\).>2F?_6C$%WV2`DE1E@&5AY>
M2YA<)<F*3":?EF?GKOONG9G-.RD"Q+VVKVMGG.;P</]:?-NU%*OV\QJ40($&
M;&I`AMQF:,!'!!!$GD:5=.F#@FU::77&H&>`H#X=U9%(HCB2:C[/%Y1>NN->
M`A$D6*@;RH67O?/YB--(]1<\;8UV@U.#?##RNP8Z\($G\1T$/1$\8BU/`\1;
M$_*>I\$U:?]0>1Z<6!O^]K$84(`#)?A#\`3``2G$@`\5L$`%-%`!".@A!5?2
M`J5RE((X9,,#TF''#-)"*"S,(`1Z2(.+FJ('$J6`4CH*G8^TXZ._?$TNZ/%4
M`1%QGO`9"0#U*03)1G:(CS!P@FA,HQHS(<$U8F(T%*->\8CW/.4-[VW(FU@&
M[3A"ZBF`#"K4P`G;,(<65B!P%0!9&RR0$1]X#1KFR%$:9A`&#RP@B.L`XCJX
MXC,1-4=]Y9`*T3Q'$-'9(R$:HHRHYN*ZOR!"@:R;6D8&)@@?C(Q@CW&C+G>9
MQC;R<A)H6MZOY/C!Y>WQ;Q@481[E*$P2DH$/4E`A!TXH&UG$H`+_(9M#]-J@
M`(^01`\I`L$3A:..2MKA"5.XP0J$`$06+"4-370.HBZW+J(AC2!)\U21Y+,D
MJ;T'C(]1(&7N`Q)$U!):TI(,2'[)T(:>S9<.=83&UL9,8=[QHA2E8_'^QC:*
M<O2C,8R!(S3@AQ)P0``5(`,&9Y/-$LPA!A:`P)18!KDXT&]\)UJ`&!P0@``8
M0`89$,,-I),B1-4H#O.\D>;J5\KM7$U#L:0+*Q$RGZK.ASZWPPA'2(90D61$
M#1$-JUC+-E9+3'2$%DUK,S>X46+&`IF^0N;'J#<'"E"@!"2@@@`H4`$?Q.::
MMY`""V'Z$0(H0$+2T$(/KQ$&+LA@#W+0_X$<N@#4&[#C&RJR%BA!0$^*/-%=
M^$,(DN0"I5!U1S`*N>J%X!-+68+DH&0<24;*2MO:"@BB$3TK1R](/612U*,7
M[:T<AQM7CUIO#G6U:PF@H(`VG)``?*``+"P0@1CX86U2:$,$9DHR#X%!"R"(
MC@>$<(,'7$`.%[B``[HP!2%<4CHLZ!D(8`2"/G2V74;KU*A2J0^IT@6`]!G)
M0#&$I<4(C`"V)-A];,O@!H,&MPZ5S4>'JX$8]-;")$3FA(7;V[CN5L-DL/`T
M[<H!,B"7`E+@PUYEDZSLT9`/)(O`(2?039-U8`8LR``7,M`%!Z`AO0:@;%#%
MP`4[C"`#7#E."_\>A\1Z'LU=XQ%M/EI+&;N8AVKWR;)",+((@PY"MK-UL)C'
M+!,(-]3%?>PCARML83(4#V1SW7#(TMQ6$FK3I(7DP`C-P`$.Q"":)4AI(J^I
M`,,B2P/<*[0:)@"&%BS@!B.001?V8(!*[\$*4["#.C-@!30\0`CM:(%2HL&6
MSBT'M-N9,DFDVKJZ7%F@6:Y:*K,LL,DH$%9DSK6N(TAF%VN8A!@F:0,.>4@+
M\"'.&L8P6GWKT1C<PL]2D`)L!$"%"914-GL5`!^H$(%G4J$",VP#&6K8@+T5
MX@OA#8,,GN#C2E>Z"U:0P9%A\`0#."`#88COS:)Q0W;ML!IP<=)?Y-/_$(0X
M#6JKPX@"S<A/NGS*2`%LS`(7NNN*6[P49F:H&2P<;&=6F+H6L,`78@IN,JB4
MS25$]F[57%T43MO"-;2`QC0@!;O.8=Q4>*$%0N:'".Q-(\;F6P="$"-.4SJ]
M<I`#&KKPA"=8@=WKE<$-W*N6%=V(ATQMCS_\L@0MY(8$5NN.+#-BX-9F:3$$
MS:I6+\[VMG<BX[_<^%Q37D(+*(`/@8:`MDT*4S^H5-F_WO#?W"P`CNM-`'[P
M`PNI1V(I6,\"UW2VX!"QNNU!``!+*`L6/``#`R3]\_;NPJ31X``KF-X.7/``
M%L[P+4A5)(K9N1IX\F+P?J!R(?&Y:JSO\[7%_XQ$2F;$M=N'3WQ)P)V7OD9Y
MB,==`=A(#S9DD,(<L)GXDY<PP\&.@0A\T.T13H"&1/G#'&8Q!S[X@9HE@'-U
MTR\2BJ"`!(.X4!::H^XN&"``-'"!#@)P`32P&PVD-P4C\``R@'JJ1U\D,@\[
M%!%@=Q")\P7T@A!#`E6VHW"[UWL9`G%?PWN447P>Z(''MTLA8W(?0P94$')X
M8P9V)04M)'T4D#T"($-^-W=Q9F%^@#(60!3:]2P"H`%]%DC7QH(N)(,1```G
MJ`!@)P)GP`)G``6)L"PFP@)"``./%0!`<`)`(%D&@`;H=0%[0(`P,`56\``P
M$`8SH$0L`GLX(B^;HO]##@$1'7![`P=+7V,AC<%P4J6!"F=&7_.!?NAV(:A+
M(5-W)1,!MF0&`O`')#8'QB!=V05#%>`'D5A"(79-M`$`$_`''/`L&^`#SD8&
MTB-^)NAFLH!2!*`1`!`"7Z`1\90-C*,'&G%C+.`!*Y`!,-`%<F`"*I"%<E!I
M%Q``2;<'0`4#IC<%'G`<8%$T!:$7$?&&)-`!3\07':`AX7,[4%)5(@`2'$AV
M5J1PJW([N/.'XJAK@>A&UG-W9```/E`!?%8"TN<()W12L!$#>B9#)N=WRU>)
M8``!$S!N>T4G5Z`!P8-W%*!",D1=ZU@!#9`%:6`/;2$"'0`Y9W`BEH0%(0#_
M`%K0![.8`?+V!+EH`I)%>ES84W+PA3"0`5,@;V*`!2H"!44S'OGS%N#Q!9_5
M%Z32(=988+NG=CI)4(W1>^,8E+E6CFM$!@2P!1!@834'CXV(8C7G?#Z(>"A'
M5[+Q,1.0@V0P`8C(!^I85R7@!RHX!]PCD&8P0S"6`@B0!QT`'QOB22W`+:`6
M!X$2!R=R`Z:'BT7@`OSG`$_0!;_8BZ4'`W:0`2/P!%RP`.*4'?X0D_2#3U^`
M(\O8%[*$):[%.KEW+WM84!)W.T+9F0Y&E&K4@^!F5XY0<\BU5_)X5\;`0GI6
MB1;FCKH0/-$3`<.F`%D``<F2?M!2`@2`0R9T0@)@_XAHF0=Z\GLDD`8QP@56
MX`&BQGK,(`8R\'0&H`-Z:6^FAP8Z(%E[,`)4.`*B=P,L$`<OZ1[/Z!81<1T$
M$1?KL2^\=V5?M4`8L0]3\QAWR'"4Z9GX65N@F4;2)0#(Y8X<8`9S(&WT.'XQ
M4$C2QT*W0&>(>`L#BF*+Y`,0P`5YX`?/8@%;0`=:0`4```58$`$V5T,0T&AI
MX"SQ*1\H$`)8D`$$:%G;L`Y"8`?QAHLTP'^A]P`T8`)%8`!3P)&GIWHW,S^.
M61CT`YDW%3JII%JN\BD*-U"4F7`!!8YU6!+Y6:41M9]H](+2$PO2-4U#(5A_
MXU+9)9#-IS$@DSVHP8BSX?\#5S!4D2@"5.`'""`$'6"(8=`!!4D!M[0%DZ0'
M.3<!&X`M]X`"0R0#`?``8N`!0!0&4[AN7?!CG]=_#X!_-'`!5G`#=C"80>4H
M5>`R*`!/1.,N@;(N1#H>JW-583<?JJ,ZG[*!%CA0'&BELMI06#I!)\6(MT`!
M,9"(LB%8TN:@+D1#/F`!*F5R'!4+`B!8<T(%="`"W80">F"(3]`":A`!:8`%
MB4@!1GE8ZF`6B:0&5Z`';M$_"/``E094*Q`&C,H%(^``ZX4&[F8`>_`$YY5T
M#W`#MB@#0-45XI0"B"(B15.DUK(ND](>UV@D4-,TK6-:20HJ`410CW%&LSJQ
M;E3_JQ#$0D2!H`(J6(KWGVU@#'H6`<Y*`,2:+"&&0>Y82#>G,AH``5D``CZ`
M#"@0`1&@!G8`!G8E`-Q'!0V@#EIA`1IPBH^9!H`B!`!H;V0H!F+`3ES`;GM`
M>NOFA5,P!?:'!C"`KS=PDF+`%8Y3$7DP#RQ2#932(O#$(JFS:OC"#Z'2+VJK
M@:RU@8P!2Q0[MVIDL0\DH..7K#4G6(5'K"B;"Q7P$=A4`F0``1$P@Q_;9]-D
M!G[7`'$H`GJC!HDT`7&@CC57LU?I`W3)`@U`!D4(`4M`E^RS`$7FE[TH`UJ[
M`H79EWPY!>9E`%9`C&@P`AX`:1EP`TH+7V>@'&F`,T6#_P(#$2CTE`5GMQ!2
M9;RFD@]M:UI5,X>.T8%T&[T/9+<.-$UW-J`M9`RT>8.0]T(J0P!@*0464"7?
MYG<8E&=_0+@*T*P+4*TMT`$QP&B'JP%_T+*$4`$1@`!B@`#=YBH^L`%TZ9RD
MZP!`-@*H)P0^^@!-%[LPX`!*%V]3P`Y34'IV0&3K%)Z%`07J(Y>/N4,\])"J
M=#I10T"90B1M>SI/.I]\&([2V\*Y0[T--$V_FK(ATTU9,`-;(*'RDE)^ET@T
M:Q0P9+XU5Y!2H`8>``+8H`!:``8P-`$`@$V%1`#RL@$E`R,B<$@I8%A+@",E
MPB@[-5D]>@-<(%1"H)Q\>;7LM/\",L`X"!`',Z"O:?P$=A`&+=`>T(@C7ULI
M41012VPD^$`7LX=*@B&?;6LZ>:A:'W%5+KS(+TQFXY<:L!")@*H'5\`'B-:)
M)=3#XN9\U7>@=J6K<=`!%@"G?K`!>,,'?+`!?.!F&G`%!8$1S#`#"D`;=P(!
M:8`"#2`":4&Z\`I47+`"8J"Z`RAO1W:,2R:>;Y$%5=`.?1`CP-P"+YD=6T`C
M(K)4$'@Z='$>5X,JJ-07I5(>I8(D^Q5`<2NQC'S.#`/#OY-^J-$&?14MAQ1B
MU9,(S[+*?E!ALZ"#'],&T68!)%"M/G`&ECP(U14!2Z`R,1`!]["/7]`'&9`%
MVU8T'W'_!0`PHE`P`PO0KO`6;UQ`A?9W`4_`G:IG(U]`#90!O%?`+B'`%9OC
MDC;U!7%P!O'T61"X#YER#P:WS7V!)/S@</)I9:H&2[`$`.A<U`NCSKPC;6;`
M!^)&!=%"8YZ+-\6Z/0I`!000B;/@>+LJ;2G%N&>P!<XV`6=`8[:T<]H34]+B
MQ%ZS!2`P`WTS`5!@(8<0-2G@:%;0!9&V!^KEKJ8+;UR``"!0$0AA<%C2$%M0
M!>=S,RVP+M9"*7D`!54P`U`@MA+A=3SB$/R5*:2#L/E@6CT-JV!$$E9EU*2-
M*TB].Z\Y`?@[,LXB8ZN<+(=6U8.C`50P;8S+SV5Y/?,1.#4+_P'4I0`1P`>R
M8#U\LS(0H"TM$#N[H05Y$J@AD`47K;J$Z9?`Z(OHU71B()?Z`P;B82$;D`51
M81LU8AW-L;O02CD(X!OP1*1'4Q!0A1%=9P_4"'%1TM/R:563,3706]K\/2:G
MK3N!4P(R=%B#4PB':W*)]$Q;0``1\'T0X(.W@"S9$S(:T`!4D"RGF)1^`-QX
M%SQ&V0".="4.N`$RA8F+$!S8$@<LP`5<@,!/-VF5MG]/@+HL``4X_3H:\EW^
MZ@[)L05(Y./SE1R]FR++D1PH\#DW9!C9:$;H(9FSQK:FE25?5&!]V-]6[B7_
MG3L3@`5_Y!$-(#@0$%TNMFTT!`8QV_]7%B`+&],&U;=S,4`%CZ$`JOQ"U>5L
MP4,X`,`AE($/&O$4\A<T)7W#+&",+*!.^<8%][>C69$'E*(D4/,UO8'1+*`'
M@G$T<9`'XP2MJM@02T40>@`"P$O._/0_K)1P^)+C"`LJG:V!+'SEKLX?67XV
M'&X&U=979MY\/?AM];P!AVL&"N!WLL`!<V`&5XDR*G5+LPRG*?5'?Z<L)/"8
M'0`EL<,1(R$"+_O<)```'?"6'J`6S5`82+QN"P`%];`7.%DU>%$BCK8`>I`1
MSP#>-H*>[I$I'DR3SWT%$;MJ=J&PK>5P4M(T"$O?^/'J!`_K9(8R5$#;/L`'
MBP#<UF,4;P[_<]5%4FK@;+#!N'&:\%5"LX;8`7D00^-688C7-=10+R)`)58"
MD72`(_50U]_P#:%,&>[QZ5M0#4CU?N>^`5H0*49$EPB``F"4."1`J+<AEPEA
M#QV<(]60`F!'AU'>'?)IC:7##_L3\/I-I06?];U#9BH#M)[[+,\B8QHP?M25
M3#$$0RJ&5FNC318&`@WP4@WNA.#V,?8H+>!J&/]0T512%W%PRSBM!7I`!UB!
M!7&`[W>H[SI$#P2$$"A`!S[;S"E@A]^%;NX4(E@D&(11I`/Q!3A95?W%V?,M
MV@76'26<ZAJH#UJ?^IP1ZV3S4B!3U5P)XEG`CH7TYCE'/3)$!81$_T+(6@%4
M`!5D<%?X.P'5!@'/$BVG2``R@Q@=H$`BT0$`0/,I4,)XL05;(=,6`D9<-%"F
M,BKA41;EY`V1?R&!4=='%!?N`1&A4P_B@0\+U#KS#LZ=G>-U^%]2)I]GM]^J
MO_\S`0@6?X.$A8:'B(F*BXR-CH^0A%)F&C%^:EL-$WDE&G,4&A81&GXQ9&T5
M,0)M,3X6&B4Q:EA:`G,E)0*M$+P-!`1J!!!@8%H=6QW"&PU+5V`@6U]:(DM@
M`!M:>B%?5P``8&H-#0!JWALB5R3I6E=?:2T(+"PS(%KD)%\H53-Y*%D=6HQE
M0?'EWY4KQI9X`R"B(4(MZAI*7"("#+6*#?^74*QHL:*Y#1LBB1Q)LJ3)DRA3
MJES)LJ7+ES!;"HI)LR9*"@)\`$#!8D*;-F0T"*#PIT0$"W-BQ/!$AHR9-CXZ
M^#$CQ8^'!WS^_/P48P*8:F`:E"NG`$('/2D@$/`A3LV2+%E$?!-!0L2&8ATZ
M.",'IMO8!N?N+A&X92`(!&>@H.BP0<V&+'G.A$&`0LM`@"C0+EYR]V!C;P>;
MD0AX16+?C<THA@8+$B2Q#0MMRIY-N[;MV[ASZU8T<[=OF`+"$5@R(4:;"1`T
M</A#P<^K"GS\M*$2PTP)!0WXE)@#88$:7!4\S>$S@5J'+`HW7"%`I0&)#F#4
M$D`^KG1@$JBG40/_`_(M"6)\O88-"EN@0!!:7W2@D&/X;!%''M&@D`(*[^D!
M0@@HI.?1-=]\19%HI36T034C8G0%0!%Q1`Q_"P'PVXLPQBCCC#36V%N-."Y"
M%`45J!'"!&I48,$3!,1`P9%D5$"%'SY0P0H9)4#%AW5DG"%"!!$HH,%3&D`P
MXHEPB6#9!!%,H$5CXU2CQ@0$=&C100>I0PPUI0$$5UTK7E'-%5FD4.`7"1XD
MUSGX7+8%%'&$4-@6(2@*7VLL,D1G.OA==!$QG$GT7J4:F>9-.2#E*.JHI)9J
M*HTWGIHC!T?RX0,)"EC@!Q]%DG%D43%88($KN6YGAE.3^."#=1P(H,!;_U?$
MH=%H`6U`X7S4B*6&F!")(Z8ZE)*@+44=:3'861CJJ1I^A>;C#S[@8%2NA"#0
M`8(>6VSAYZ/D7-,:G:,YDYI&W'Z%CIX0<221B"UZH^K!"">L\,*,I,KPBP)(
M00$?631`1I8Q*!F#%!)+088%M`J[%`>XM(%+":Q2($4;5R"P``)0?'6BMW1!
M`"0)XWRE13Y?V#5SG`$%Q"]%>I'09QPIL*.MGF"04-@7*4Q($']+6P:1@2"T
M`$(*`WWQ'T/6F$.-:$OORR]'2VB[-'^NK6B-&N60H\;#=-=M]]VZ.8SW;0(,
M90$$0045`Q\5E&!&Q!3$H$`$:60Q@08^D"Q`E/_;23S'KBE\P<("*?1'VG\3
M3`!;`W191F`6=;T'$;-!BT:1M\9(2.%#(9)@(($1LM.!@?^@.%`*(62^:=BM
MN89O0.A`-'2G:7>@MD=WN0U;W"ON;?WUV&?_B-[:UY0+CP`LI8$G%E`Q@0*'
MSU&!`O0IH$4L5/`A`"QSL#J'#UEP@44&+(1U#ET%(0$`Q-$`8KQG(-'(0D#R
M<AX%CH9<$!%40":D%V/H93#J^$*!%"B0%%SH7'#1X'D`HJ?BF2-/U!):VM3Q
MH=6DXX5VN0;;8",WN$FK>SC,H0X?QKT=MN0I<Y""`BH0`2J000!^*,L5+-"&
M^45`#0I@'QTF5P$H04G_"JQ"102T``4/H(``!214%@`%'V^@XX#Y@`M`+(BB
MP>CI@?UJ!IS(MD(1K+$#9-0""J``A3%JZSRMJPALV&81YC4C(-HBS8>VU1#^
M%%*0'ZG7`&T(M[GY\)*8S"2,>JC)DXS/<`"`3@2@9(&R;,`/GS!6$<O#AS:8
M(0)"LD`N.+8E#9#G"S;[AF!BQPUJC*:!@!)(@AA8%PP.346.M(A@JB$1Y6FA
M0`#1X&+TLHY*1>HNUZ"3'`<3-&;A1R-ZX@A(9`@;&M)P(6*1I(LZR<YVNM,E
MG'QG)$BQ%`CX@0H**`5;L@``!0C@#P+H@+!\<(;':4!)%6ABY<9G`2*JA72.
M_Z0+012TCO,`*I@69:#SJ*&?.66D(1^1V=E\^1YH[FY"-)-C.`5DEW.`DVQ!
MRTO02".]<]IT>AP*!X<Z),^>^O2GBX@G4!>11%<<90(^8)\/T($""(2G2XLC
M'02H`+(I&:X-&H#*0(4!&+>E#77-D.EH"C+&?ZB1@=[R#"%-&*F^-/""_#D1
M02`"R&]BZX6&'!'9\(.0]S3P'^S@ES7&N9";+L0Q]2(D&(;*V,:Z4ZB.-01V
MV$2`,H6N'"G8R0;48@$P$H"?PFAH!9(B)"%!``"]@$!7.W(BNPKD/(7I&EGM
M!%AFNDU$G?%&7XR1#]TUQ#*H0\@(U<&Z"&ZDD!H!Y/]#%IC(-@K,'`4[+-RN
M`1A[W>5_D<VN=G$(V>TB!TC]7();U$`A>^F)`(@\TP0:X(=*M($/$1B'&@8K
M-[&(Z2!62R1O4Z`'`UVT(,Y[(-/:-J<9VD<PZ]#(-):[K`5"9*:*_-`*L57<
MU:EMI2OZ5"6CJP8(C`6ZY6#;=D=,XKMU5[M``HP(&I`.]'3`+2AB1[*0-@,4
M;*"RT%%`>P"@QP/7BYL+Y.!?">3?V2(2/_2U;O18Y-*-F*89(V)6G(K;.YD:
M=QVD*=U,C[DA#2>Y10!J"]S&&>)0E?C,:#[8B;,[@;19S8(*%!.*`"E"YS&&
M`.P+W3B891<F<S.19!TC[N+_51!_K#%H5RBGHN\5PT**BR+]D8O.(!S30`.6
MA:+IIO($JY'7U+`!JCTLAPDHK=;8BQAI3K6J<[3FR!)@A!Q,)'$A#!?4Z3<L
MOO!!FXSQ'Q6=(Z9XO*.$_&1HM,XTT2.*W@D;&1@/X7:&#7E@<X,<Z`<O3;_6
M%E=%\!0I<I#:V^+0L#A46\GH@40BJTZWNG_3:L=.0*SZK8N8''B,:!R:-","
M`'+>DA!(.Y)9#7SP22=4:S5F.8;J4;8,!00.AK`F;BX%F@5C.D8`=U-M:N.7
MMBL"EK==H\/CD!;(XQ8.<D]WR731R+I7SG+:M+NQ9D(DG`YBD=%0Q&F*@5TW
MEP"0_VOPFAM(9NT"S_/'WX'P=&WT=&`(:UU1+[PQCLE(6GE[:(OVKIM]/=LC
M!19##7>8J](B8-P&Z.$-9]/-!VFYVM<.SY7'W%M.'EHX$7*G%)(F+XP<S`H;
MC.6$\,E<>K'C1+U58`!=4[>1JN0XGMU7;'WKWF_5=")+8Y$5"=(U(%&\F%.K
M6@(>5LR@*N0O.\#VTIN^)"]G[*NGX1IP!DRXQG4S"3/>J?W0!4Z`G#AZ>`ZH
M+)2&YPH\</&2B7E=TC`<;>'X<@$BQR,/'<+X1;1II%<OQ"(_[&KA!=A!E7EI
M+61L[P'4Z<=/_H:MG`!(%J0O`^;FU6&9^0F&9&>8B1">!?]:'<"-X`/EW[93
M=_M3I"8M#8$Z$(9M(P1(JJ$\6)8B`G)=U4=)BM=AO)!]TV5&UB`6Z30M8751
MY=>!'C@(J3=4Z!5W"\@OUT9",@8TW-)Z$>%F%==[O>=^6D=8D#(]8^=U)==Y
MY4`7M>8\>*5?:(4GVZ0GZ=`I)F0O`Q2`E71]R&=RE:1,-61&+68N'UB%XQ>"
M0/59^C$8@$5"+90.*+@M"<8\$#13?P4H_D5X-&AJ+6*#)W=\34AN#N<\RH,1
M<R)'%R8H$^8,Z,`93=<BUR=RE$1`'C9N)D=._K="`V$@5MB(;(>%/_5JE=(.
M`.9`&T$II&$9%&5S:*,Z$,9`@C;_47@B-]=U@R!F=DMH0VWQ#>H`'S-$@QUQ
M-CS7?NQ`#'I"#DSW>:`7@:K%"R6GA$A83F>T,[CCB,;(<I#H4^CU0OEG-??%
M=Y@X7!IQ;D2S8'#Q8,)$(9`$*HA8@63&C9\A79/4-!T'21]A;B*%0=YT7-.3
M3@4S;F(G%NT(:H1(B*$6C@Q1?PFB05MPC/Z8;LG84Q-`7/4W5QMU2)LV>GFA
M0-.X</YR0%7V5G(177?192=D3L<'8NIQ#9T&A3)D%Q>Q/+0H?9X&;F+7A/7X
M*=[FBX$(CSDCC'^'0/GPCS299@$I3^BUD'`Q>,6D.J[%6WGDAW-!%^9A?Q9'
M`C8(9IW"_V2#5$[=%F*ZU6N"5'D5B1!`-E/X!Q!K-&#GI(KVJ'GA-DFD-EV)
M1Y;AQ%&]%R\$4I-L26(W^4YF\DW+(E,`(W#8:%$B9(3?X`Q*PX]H&'Q?(VIO
M8DT.""E/Z1C#9YATT5QF!8.]AR)P9(XUY)6J"&Y_88B`X1HH<I9L]&"U9B#R
M`@5M.9K9]9;NU&8Q1):^!%@.)A`$<5'!YS;_$7Y%-E>"<DXGU!'*=%W_TQ%=
M^73WXGJU]E^W`YH%D8EU(3>?)E]+B(-M@29B5R(597!0$R%DY0\:!`5ZD`9I
M0)K>R5BFV4X^X)10-V8\!W"]4W'&B2(>A1^6D0]6YX,"A(1*UO^`EE=[_[=D
MEI<O[QF1Q7D[":)"B4:/+EEVJ;B<\IB$(6:"0(E'&I0&\/(GYB(A>L!'HOF=
M&-I3X<E./K"#A[F#7/@/OX0[`8H?@H$O#3087N-X1QA2_!%U&"%8%MED#68,
M0%EP+QAH/KB"$JA]PM`+P/B+Z30ZCN$Z:S2A\A("('`AQ!8OH:D-C9*A4OI8
M*^<#A51@;LB1?-4,TL1!@>6;8U.$<@8G?8:;PS=#R/4O:DI#7X%Q:&5UBV@@
M&K5SQP=JO_`+E#6!3NB5J_@V(_):KPDHAZ(-2[JD(8`6*:"=(0"A<="H4_JH
MFK2AG62EG.$AN!DV<S*B`;J9@G4.'0'_DJM1#?7"FRN"CJT'3NZI((/5I@]D
MA@:G47=$7)`&-Q-XI[:JITL8@'+X&G2!1[>CE@22`G%0J$N:*-N9!B&0*%"P
MJ"$`J<[J0Y*J25;J:\MVE0&1HPJR/`+C9(5W;LO`?4MVIO>I-H@D:1Q'KHCF
M35AY82M(B'<:.J'S"Q.HJWK:BXMG4;<S(?*BK\B:K(WZK\-:K(V:!E```L]Z
ML-Q5I<P&B^;Q5O@:0&Y#E;K52+H943AEF*\8L3(3;R$RF'))AI26-H\&=:`F
M'WC*)O&JI_:HIS^:)OSXJWN4!HF:K'I@(85*!W30`CK;`GW@+LA*!P@;M-@3
MK9G49I!&8,,H_TS_E2`:TDA@)BB/9+&D2&`:.Z[QAEN+&2(2@6"/IG=C<X'B
M(`QB"Z_S05GR:HCU*J_ET`Y.FJ]1HP<!RYTXB[,Z>P8S<+=GH+-Q8"%"V[=X
M0[289+3;FFD+&:S09#7@D(K/R4V7Z+2O\895NSS"18?L%VW*\XKGF)BXN)+9
M]Z[P:K;R6J\LBQR.08GR\JO("K?M`@)Q4`6NZ[HM<`9VF[<M0`>-V@)^F[MT
M`[B7-)[7-3;`YZL%<CLT$V;Q""H<]7J;5E,#,S"R^$*P-WM$"&D*D5,'ZFU\
M:J>V:JN4E:=WJKUCRR:G-2*[\Y]0D`;#>@99,P/NTBY5,*PM,`,(@/^W+5`%
M6:.[^*LPO.M#5KIUN.<U_UD9YHA8'7(.+U0VU=1QB^1D$W'`1[8T`(%,=H%8
M&-AY8YF#%FRGXFNRW.M9H;N]MZIB>/0/^<`HPUH%L8L8[J*S[D('9X``,(RW
M5>#"^5O#JK*_.V2T?45W>>$/!0>9HCH7L+%"`L&:+&1SI>I+VJI-Q[,ZW-*\
M]1*/)>NC:0O"5MS!\FJKX^:YPL`0.Q--6V`A.7L&?0##KTN_=@O#,3P#,SP#
M-OS&I(+#.C20%#=,/>A-R;-_L;A\1)<:&<$T`()V<_3'B[1S"(=YX0!RO<C!
M6%RV9'O%)SL?V]MY\F$SNA9B1K.3RQJ[\HO_`%B``)R<PIVLQC%<!64,QZB,
M(W*<0Z\&BF3DB45SE@=!0C(C<4&#IF?44K9X'J&:$4.#<<Z0>.+V4+7JR([L
M`Y_[R/&*Q?&*LJ'K"V>;?;JU,_D`/"#PPI[,`I]\MZ!\!I],RFH\`VF<RN0L
M(ZN,0Y]U5D$X5LT'R`T6=&?$-#BH'J\H:Y@V<^`'0X0U76T!OMS[N<B<S)][
MISXJT(_\HVK!)H"!?.6P!!>U!6F0-=F\.2P0SFL,PUB0T1F-T5A0SA[-;N?G
M8,",>TQ#*:416.@PD4W7S[W@&"7Y(0'&5W`"S!%1IVA[L@8-K\(RT%F,T&)A
M,P)=ME:\;T?;%PB$_RCQBP6;LP`+H,T;'<-)+0\:/=$?7=6Y<<[=@UZ8)HOC
M(EX1UV<7D9$`N,@M7:<.MS1GZ<L94=,V.,6.G-,ZS=.A9I+E`,W)?,7RP0R:
MMC-PV[KRBP4+$`:"W=1,7='RF\8:_<T:;=6,71M8K3TCZ%&65Q&AH1X=]W\:
M!FZ4C*M)J%I]F'Z).4CAY(!?]\\YC<S"(LDLN0%Z'$,:S-.2?+:_X!;$B(8%
MNZ0OK-0+X`&\W=L>T-3?C-'R`-R>W-&-?=PU\=C9,P'.D(L+H9OCM&38"X`5
MC('T6,F_6*3IX$C>X(N@YM)=1W;:!]<&?:NG!8:@N1@76-"1G+($J@9CY?^D
MAT('W)S-82`$8B`&*[`"0N`!8;``GYS1P\W43>W4R'W@,*'<V--F93EVYF98
M*IG(U\>24URO)0L`&U%.PO&CPC!FB5>KY!TZ`0VZO#`7>I2&:**G9(NR"@V/
MY!NLVAD'\?O7F^,!^"T$^]W?_^W42BT//BX/,(S@0LX2"GX].O&-(D>?@,C0
M$E[A\$BK)NNC8%0\HY/0R('=$3[>(2[B`2VVO_"<%95HBL?(0EUVNM7#AZ*D
M56"W=ZO;]RT&0H#?8N#?A>WCB9W803[D>GX216X]'=J5USN9<3BO%4YNI%;,
MSMSB95?09JO0Y18,\['3*Y[,`[7349Y.*](,@S7_.E><Y$9=G4H:OZ0,V+Q]
MXW&NXS\.W,$-SK_!`;$B$@JP"'?P3XQ@!@U%%'^@!K@>"19`ZX5P.;(4"61`
M!8I``%&PZR=Q"B8Q!\3N"+W^",Q^&Q,0!5*P:GV^-T>.H)VWY"4[Q84>S=K+
MXBR.S`A=S'BZTUQE0T`MZ4@E[@`]4,O<LF>W+)TA`AM.T.,0/<QT-2:<LS3.
M`O?M`2MP`_UMX[]=X#Z^QK([RK_!`U&0`SX0"4QP"'Y`ZT:@`8V``3W`!$0P
M"$B`[(,0`8Q0`!AO"#&`!$=0`9&@`)9T"%+``R6P$A#0;GQ`%!I0`(]`\H^@
M`1C@$K&^"#W@ZZEV[7C3_Z&6R82G)5UN7>X]7<7NON)XNKW"$D4*0.Z*]]8X
M_=;-'._P.KZ#Q2G1IA#0_+T+:@RSO#N,`@(H/`,]'MAQ?@-<P-\>D-\[/MR&
M+<X+K\:^T08X,`A!P!Q%,0>$8`:#7^U_,/&X3A1N8"2WPAR$SQQ"_P<8@/%(
M4.V)__@4D`.X'C&$@#)_0/*>7P@6@//,(04Q/PAF`/*#L.NI7PAD<.R.7PB/
MOQQ_0/NG7Q2L/_.&<`NK7Q2&O_HX4.TW+P6^_OB%0`%FH//(W_N`KQ7+P?.K
M?_I$,131+S&W;_PX\4^9#_+(/_TXH/IG1O1W@QU/KNYAB4ZBR\'="\("'=#P
MCO]4.SU0490E5<_A5K[^."V^M(K0D0P(:@!+)%=@8$M:2XM@&VH$D`00`!LB
M)!TH*%E97YDI(2`M,P@L"PMA0F(W&3`9&2LW7&*F+*4L"&>YN:,("'^_P,'"
MP\3%QG\*:K]#?Q!,#4044CD`&'],$SQ^UW\T9G]!$T1E$!$?<QI(``TQ.5[?
MP!@5Z7]\1W\:/`0Y?P4T!10:J.DQX4^.`@DH(&Q@1)B%`OB,`.A1X0\.`#RD
M#.,!X0_'CL#*#`&@H0>!)%($)`%PAYN4,A2,J/'1#X(1/C$!&+$0#,(=+RV]
M)(`6+,(1-_,D(HDQ1U\2#L"D)%$S1$,))@204&!#X4__$S,X)N0PH\$:%1YJ
M>/PAP`.`U@HYU!P!D&1""199_U"AEL0,@'\:?Y4@J!7#$2_'$BM>S+BQX\>)
M>4*>3+FRY<H*(#30K*:SFLT-&@`8/1J"Z=.F(Q&8`(FUZ]838D_P0=N'`MJQ
M;=]6<#L"%2H1>+.&=%KV\$BQ)0TB`0`U<@*4EEP1(0*,B$5+-E!JL)IU@PV)
MLJ#8DNG+EQ0H4L2A<P8!%E,+A*Q8`0.&G1$CN,`2$B:,*?^XZ-(>%@1>=ID/
M($7C`Q5_8#!'`03\(D`"?Y@1!3=11*B$0AK\<L0<;K3Q"P%N#&/8$#C\TL,?
M=Y#13PQ_K.C1+TBT<>$O!70H_R,P#_TQAUD^:%"&,19TE,0P95FD@$<1$,`'
M,$S\\1('271%@5H:)&!!`\U(]@L_!G7Y!TS!D*D!1`M&05,/#/X2`4TY-E`1
M!FVP>54,B%%!0))$N#A$#%30Y`499\:(3`%R-MA&D6+N^$L#/`%@P4L&5FKI
MI9!YB>FFG':*S&D"K1/:J()X!H%JJ!K7W7#&U5;;;:[R%D%PO"E`JZT^R+9J
M<I&8EIQH2W2@Q3JH$O#=(")L`!X))!P"0&?<Q0;!!F!HT<D6Z)F'0AJ?@-">
M>__)=X,=4]@A@PP9W""&&$)XX*X'"P0XPRZ]8.$I8U0@]@<1?RS8X!QL_M(C
M!2M&*?]%#VU8DZ.'`'?U"P0\"!`,!AT6P."*9<S1S,6_[(`!!A!0`5(_.CH$
MT8]Z^>`%1,4PRH=)P?#)$P8$4`REE$,JP$,$;33Q<6UB`H/$+PU!P!.9(755
MZ((]Y/`QC`\SF",&3'QLAAEED$2%$1_SD20-&K,9Z,:%KJA``51;S:C1AD[<
MH6V4WBOWW(]I2O?=>!/3)'$"?3:J0'^G9MS@K0[NJFZTU:KXK`H`Y]NLD"N0
M&^&]GBJ)&H>0H(4(`*S6JQJ.5"="!UEH<87IVEFN&0":7PM%"EN8IUX:='A;
M+PMAN"N&*U/@-P6ZL*B;"KQ8(###\;FTX%[>Q$PCY8K^.OC_TQ\4-/5'#"U%
M><T&+M[1X1\?NK$-!5U5H.\O-I?!TXH`/%E&"6'^@014%+0Q=%<+._I'CR@'
M&H-:4/&!QG@TLJ$!(TD9`D<%5D.]&0D)&"LZ$O7(@)@[:"H'7>$'VY#V"S.A
M260E<M@O^!"A,F@`00T<4XI*H!;J)0P<3VI""<86!;)`Q&P%\`&7NK*V]0F#
M`'"*0=R81\2[V:V(2/14!%07&FB%1C-/3,VN5&6X5KUI-K72C>(6MSC(12`V
MDIL-KU+S1-%<X72F`X/J(.`901!"6%K@!',V(PDS9@$36X!"&KCEB1"$H'95
M($4M<B>$561@!$_`SPA:P85&WN`&__YA0?%:<(89M(`.O4@B,+S0`R-L(P(\
MN8/&B,`$C$4!"1+K`9<4T(1?4"$)0PO"''I6-0BLP0A0^\4=GN```PY)`$:(
M`H7`P00_1(`(/$!,#Y!@!`H`0$1#`D8%'-"$",RA)1:(P#5X,(0YL.%)TIQ`
M3'"@O5^TH24<"":%I*`#)D2)"3Q``@]*8`0>0.0D08C0!7A@!)H`0P$Y8,*2
M)E`1-XAP+4A`01L`\`=0RH\)0X#'+YK``R(P:!S-_,,$&/J'!/1@#16@`!$B
M$`,CX"!"5%`"#E:TT#'5@Z%$Z"0%*E`0@AJ$"5Y*)]7^P($2:?*GF#HB4(=:
MF25"XF]1U/^,<Z9(N-GDZJF)VV*M&+=%+T+.<<&I(FM2HU3E:$$+'>C`=-2`
M&FAUQA+,PD0'EM`<TP@$#)?00GI"$(<X0&$+V()"'%I0A3.\QQ3N6@$7,F"N
M)\A@"C`8@15&0"X[<,$#_BG>&2@YKU$,]:##$"%FJ1?-%`9CLY8"+6-$^]EC
M'%2S<Q,M:8&AVF,$:K6>70QLB4I;Q@BUMKA5C)Z&PQG0G&JI3<U-KIP*55O5
M"CA5O=549\4'*O`FJK5Q:G*X2L<&@(%T7^A`LD9#5C9^9AV(..-74;>928C@
MJYW88QQ`$`<]Y%4/WAK%`DKA+B$,]I!6D($5#*M?_)PK`^VZQ?'_^J`\X_DB
MMXU)0!ERB>`&.[@8%;CM@R?<*0E3&,%4.(Y;NTL<RW7G<-$E;JQH-2LJ\(&J
MD0L.5DL<1DFLYE3"S=51?6N:#7P!"BA(UF<<(8AG/4LT8+@"LTBP!#"4MP&C
M`^L6_$A7]G*K6Y1%`'P\D(I89*!W^K6"EK4\A4,".`R3I"PO#GSA,IOYS&A.
M\Z4LK.:?9GBZ:X2-X6R3.#I'%59<!([C9$556WG1N-+BJN7$*(FN=K@!P5*$
MD=GH8[_U#0!P)8&R'C&!28`5CU"``AWXVMY,@X*2O2A%[L0@6,)F^0FH3K4,
M8("NR%JRDL?K!9G;3.M:V_K6#F8SKO/&_P?9^*!8A(N55)<;'!(_3L\I+K%O
M?E-BYSZUT)SQU59'->C5->(0&^#.)$!%5F.!KCI/W.H&,)&"UZ5`#U6X9!J@
MH`<]K`?46*"O*K@`@]\]`-5=<("^]WWO*:P@7K(.>"9W3?""&_S@045X$GL=
M7>2`<<3%)O%N^.Q%$S>WN<QF]E4?AW'&87$"HH'T.B"P5;>6EV^4Z/&S.JQ4
MZBJ+6,110R*^$`+8J:>N-?_$IRD9[U+(9["_LT(7\NV`/1A]#P[@;[H\0"`"
M"7S6"H^ZU*>.<%U3?<W$G?/$[VS<85<<E,WU#<:9[6<3+_LWO^%#;P(%`1%,
MQQ&>4XU;E0JL1O^\_+>AHBYJ\`[I2V0!K]C2P[K/[<>]5I)`IZ"R&%IAAP<(
M709=V`.^A_Z$Q=Z@76&0)!8F*XKC7?WSH`^]F:TN^LI8`+J(L\VMM&C5KU<<
M[6D/.^-:#_NT%]NY!-C`%;+3;51Q1A"A`<#I.D#D;#-ZY'AW#F>H18)KH6<\
MY4X#"-C+GE'48@$>6!=]!BN#$3S``6C(+R\=,/0'3.'RKD9>YV=0^O:[__U%
M)#W\&\,'U%<UN<7V\^L99_:K.E?_4N5_&A<<OZ8&;I<LVM8KH5()V@%IUK)6
M8#`:U-)6H+)WG4$)YX4ML),)V)(&<4!@FQ9K@U1(L5`?BO4`78`&#C#_`C+@
M``:0=%U@!3#`!4*P`%@P`WUE/"VP@RTP?S[X@T!H&?(7A,90?UPW;,L5@"@F
M=H^S;,T%@(DC7&47>\Y5:9"F'=:A'4<F$,M"`IRC>U]P1XIV")\!18!S9((0
M9'(5`CCV!7F4`M)'8&(&+J<@!*Y@:@^`@D57>4^0;Y5G!>FR`AYP"[@P+[E`
M!XA(A(JXB(PH,(TX&1;P7%*E14J(?\K69WX&*ZF'&]UA*[%'@,9B'=8A9(WP
M8TVT+"C0+.&!`F%H.@CX&;`8BX\V<QX(!9V@5SL':Z,0;W582*Y@+N?2!;PT
M=$FG93)@!^P"+[50/,8S+[4#`FH6`_!3#&TP_XV)H0$#9&84X"*.817&,`<$
M$%(3H$V*40'66$04P&"/R#Q#N([[0V=)Z'7YET6JUWK&1H"2""NZPAJJAW:W
M`7(&N`B[IPC4`@9^`SK!L@5P!%:;("QO=X9_<X&C42WG05<X5FYTE6YCYAZE
ML`"D!@NFIF7CIV](]P0/<(P`QA^G`&;NT0L[6%=J5@9M$C._X`9<HAAEX$]F
M-@?#U!@8H)/#4`;2X@4WV3S3.`1%642%,@QS(#'NZ"GMN(ZG-U5XIERJ)RN*
MHQN8&''T^%RV(5W[6(]5R$;@<48#6634H1W4$D?E43KC50A+D):FB%36M0C6
M@I%L2'@@0`=5L)&\6/\*L3!8YB*216<`!H`&2*=O74:#_.$NF1=ODC4#TQ>3
M,_D+%-!94<>3C_&3QB`C#G(,C#)42RD,_O*4%6::M@6/7==U6I0K]/@J^,AZ
M>):5("9&LM$XH(@YV"$=B;";TJ$YXL&*6C!DN^>;U"$JI.)&<@5][-9N>@`*
MFU9)[M%TIV`*L6!EOS-^1*=O?L@%-R"(]:62M,",.PA4"8`!/*`Q+.`&=?$'
M&,$$4M`&.)``+2&3L_('"P4!%]`B.%`17D!.@?$'2:`Q.<D#+N).5#!,0P(!
M]-E05,,3":`EP>`#";`4#9(`E:D`%;H-P#`!41`%#2$%."!,%#!,&U`"$7#_
M2A:@F:RE8"D2`TS@!D;P#5%0!DT`E!`0!3Q@!F1``W=``$.P!1-@`5&``]ID
M`3R``U3`!$%P!Q4`4@0`(Z>'-5D3#!:0`#G`(!]:I6I0HT."`5'@!B)*HAJ@
MHUQB!BQ0!GN2!'<PHZR5`SRP`2R2`#L:#&;0`VI:HLFD41_3$!91!M9PGCRP
MC670`^<8A%'YB%-)&UNY=4^5=6"DB;&2.,;VFKM!7,:5*]95"-3!FXH@9,PR
MG$(VG%^P"'#9J68I9(Z`5."1"'W$ANS69&(V`SU'7_WQ2(.56+R$=(Z7AWWH
M`%.@"F+P+NWB+O,U7\7C>9H4`Q"A`!&R(G,`$_?P_PL)\`U:(9-FP`^V<9F_
ML"!7,@P)0!,T0`%LXZ?:LR([LB($PP$M-`R,8D##P*P3NB0.D@`%$01\``#;
M,#0K<C`L*@Q#DR0+T@9?JI,4\`9_0`8WA#X:TT+\2D`=1`44U%%FD``2`Z_`
M,"$-(C':JDUE(``%<"'V"D-"HRB_D"7]4IG^(@4(2P8W@CXB$@QCT"_T.@=Z
M\@MXLA;6!":,F*B-&(GYR'IO(HE0A47#=3BO>81]]BI4N560=@B+0!T#60AR
MI#EPB1V@RBQQZ7;,8@A^`VE7T`%N"'A;T&[DL073!VK3>7VY0V795X+Z-71"
MAP:&I5@SF`'Z4:SA^9@$<O\\5?!3MX$/UF`P95`!+/,'?DHG,OD'%T"P4L"M
M*6NXPR`%3$!"8J(]YZH7/;`-*O`Q%+(!'UL44<`$'0$!.'".1)H`AYNR_[(3
M#4(`)8`#Y_0'G8L!"?"OU(,!_H`/'[0R#:*3/6.[+>&9&G,!'S,D/!N:BRL'
MUL,U&*`5!W2>%/*9/4`!_E(`#]$1KDLS)4"?1R)!O,NZP.`ODDL!%Q`,X-M3
M=S``K.L@7B`9"A`$&&"D*/.SJ+D84SF;7(2;_UB;1GMGN`'`682$LX(@:2BU
M<4DMA`"U7W5&6INJ0]:U`BE6<HDY81N<*9#!&HPMH-!7EF1]_^&VD&5?5[9?
M+JC_@@YPDK^#MWB[`OZ1?2L@!IE7"X2(`#VH21;`4'S`)81[IU"B,4S``8L[
M`5X0)9"[(%A##&6``UW!-IBK(I;)!B40!,)0`N!K**$Y!S00#"LRFNT[!TQ`
M$SS`($;`!/!#Q;^`NX'+#TMC8M:@)JPE!R)$O/(C0FB\/R"QN`W``S3Q/L,P
M!&V@L9^IK5I:`@70$6'L$0G*L1XQ0&T\H0PR&!6"F>E)K33!`%\,1+_@!R];
MOSU[OXIAA$&;9\XFA</E5'CVE5`%8D>(E;\V"6JX>T3VF]JEAL-IM6@T7F\)
MJJ>#ECHV<QS(9"&P;E``"J$P"J+P5ZB0C.UBAZR6:OF6_X=<)@.RP"XQ#%GK
M0CP]YW0WK$E&$`&&ZA)#<AA1(`5\$!8I<@<8<,8^900$<'H,4A?E7!0RXL0J
M0@`)<"1>,`%RK`9AT0`_`@"KFP,14#44`#(I`D$*4`:8&3WHD`0*D%$3P`Q_
MH`8)H!D4,`1>0@8$H00"\,A!``%-P%$=1+I+0L?9L%%_L#)>H`!FD`1[LKA_
M<`!0X0=!X`/6`$%WD``-8;L$,"0^D`,^,#2'C`\0W4RCX07,$`$?\<@\@@,-
M(`5(B0,,!LZ5QA9>,`8"X-#`-`$ET@1`P10Y_<F@?`Q&R+24N+0QQLI8I(DB
MAK1=^5QU5`F:<\MH661KJ<MA=?]I>_V6=5V<R=((!BBVZ>&!=85S'AB=QP/"
MO:AXA9180I?"B&187'8#NB,&>2L$-4C#!$+#.`A4%#`IOP`5//4+9."49I!+
M9-`5^BH8'4(^U%,!3AD,@>$PI#U34J`Q'.`'#L.C$J*.NUT]/L*-K,7;`4H]
M5O(+4D#<?S#;&O`];?`])ZL!M8W<4@(CQUTAWW/;P%`"''H]TQC=/.4PLRT`
MO"T,9,`!&D,G%=$O/F`!5N(PRPT,?B``@4$6EFG=P1`#,1L#L]W=W*@!`B`Q
ML.TP<W#>X)W?]EO61?@JPO9GN-$J#A[`1,O*3"NI,L89TB%>FR!IV*;`EP!'
MI+,)=X3_77!4"--1BA)(`L&Y!8==5],7XQY,JZ+6'VZ;"O3&@E;@>(BE6".0
M+L.*"O/Q2)J=>1QY?>YB2;06`6[0K@S./&Z0C3X`3D^.8#[;LVW]X*QYRB+F
ME6BMB?WKX%DI&Z8!.L0IML.9+,H"XJ3S56(KMG<DAF!%9`>HXI401W@%!:'`
M@\^(B*(0:HFGMU56;XCD`%:@'RN0`:LF"Y!%93$L'S*L>?"1>!Z@Y+1&VE6>
MZ8MXY9L>;&'^7+S2Y?J[&ZWIX)BJCY<C$!M>UYLPG-FA+%P[XIN@+1K8BJ$:
M5G1>'1/LAL;,@RW`7B"0;NU!PX%>@V$P;_7V.S)@V?45F+/0_[::?0IB0)W&
MVA_^8>F:GNW:/E2<KHBG9^I'JRO0MAH7/N%7F45@2463<(&5X,!Q9!ZNKNMA
MA5W:PH'%G'-;4#J8()SCQ0ENB)%Q0%>'[4?'?.2BYIA"'IBN<'GOHCOH1^GN
M(DDV2.P=:8-8T`)QL.T:O_%$U.U$.)4L)ERNL55^0^ZHC.'E[BJZ0D=U1`F'
MH.M"1CJ:X,!Q>05A:!ZT3AYNF&EQP$<H0'R8,.N=`'UI,,ROPV0!'P<:.9V\
M6)WQ,1\?Z>S%BN./!5CO`F:[.%^:!YF]0`<AP/%@'_90N?$5X)H+$@-?1$<D
M=SD\]F'I?CAO_:AU5(:<@0AQN>%70/_B/_]5M!R&K/CO&YA':=!N?G17K#@>
M0Y\)S!GPKZ,'GQ#PE$0OB/<?HW;-FMWPF+WP\P%9E#Y?WQ)P3K<+._CU8E_Z
MIB^$&Q^?&A`#?F`5,4!"CI:&$1@MJG(:#E=R#I?JL.AC:.7FPN+O\#Z0YB'S
M>95I-H=S`N_XL3/T@*?\SQGPZ\8M,,X>-KR+[V'CE]_PT>Z1,+!?,6@'&1#D
M`68\G\^7L/;KP5X[I'_Z[-_^BN'Q05@"%O#<3%$"9$`&2U0JE5`=&P`($`2#
M!!,$#6IJ#1`0#8X$$(J.C)2+C`T``!M+6EH=65]?H"BB7QU7)%DHJU\H4"`A
M>GHI6REI(;C_<7$AM%NK6[50L2E0MVFRL7$@('1G,RTS"%A8"V%A'M@>80O8
M0C="8ADR3WL&#E8R&6(>0AXL""W0"&=T+<YG(+KY>B%__O\``PH<2+"@P8,(
M$RI<R+"APX<0(TJ<2+&BQ8L6+6#<R+$C0`YM2K2)$</'!),F-P``(T(E`$J"
M#B4"(,D1(D0T`;14H\E2(YY@2'3X%(H5*:$=4H7:@BM%B#C%0D#9H@?8TV6\
M?&V!0DS/L6/`@*5PFF99''O0HDUCL:!:&!98V*X0PP6&'2L.'!BX<.')BBDK
MMK&`6R5.81#TZ-"I4@76TZG]/$J>3+FRY<N8,VN^K'&S9\UF%/BA_Q*#`P4?
M'9:(6)))D:!(K6DF<J2(YTR5M!4!H!VT0U$4P%JAR'*%DZJQ*`S3V:4LUE2N
M>G2%2--+;)I=LWK9FL[K;#P0+1"(C[M@<%OS8;QQN9L7C0,9"":$?BO^68ME
M(*K,P(^?NJVQGP58T1P&$4C0'`(0E.`?!@94@D$42+%9@PH6M*!'%#[$@1\"
M=MA09QZ&.%$)<Y@1`Q\0^*$`%6U0\$<))"RQ1"(UT:9);35%,ALB-$JRHTY*
MM1)6+5MD`490Q\T2`G[*Y".54\)(EP845%(9G9.SK!)E+&71`=X98,X0%Q;2
M#&8F6QZL9T47#ES@0!A;5.#B'%LL,,T,9__4UQ@S^1S#53``"LC!0A<VY")!
M$,A1P*$)60"!0(/^$<,1!?6@!D%,^#-&I`"-$4%!/E"AV024%B1%&05E*MD1
M,0C$*$),\,"AB+0.!&*MN"H4P00G*5"!!C[X$`,%@TX@`A@;^-AC3K/9QF.-
M-M%&VR8D"#=D*UF0P)(67]0BU5-Q+-:'E]R!P(^455+99`A:U1+=+M?E<]8,
MS^0YS5IE5B.$$#)T@48`+EBQ``'#4D`!'Q[82:8T\.1CUBQ#CA5H@#TL=,!#
MCA(T00)_-'#'0AD'5+$_&0)DQ*L`J5KRBP:%.J%!IZ8Z6<D0W'K0R+GF;'/.
M/`L4@0*#B.9'#!3_`KO!T3[RR.Q-.,T&T].,J+')%=P"]^<6HG3B&W"V4,>,
M8E6TT-@NBX$+K\1C/275*EQ?I0\N]8!YSPSOE)GF%%T8X((*0!2AP@506#!'
MA'-(,4<#<8V'0&.Q.,>5Q&%-[)D"--P1@R`%:!!%&63\L3$3`B@P@.43W($#
M`%[PX.(=45R*211,4,!$$'>@_$<2HOYAQ!]E0,"$#R_B4(9&#411NZ,4/-HQ
MY98?$CP.%L101@((!G1'&1]G2D`4?U3@!08YE,`'Z!1L_J@;97CQA\O_^.%%
M%!R7T``/&C2`010N^H"#&Q!0T$`!%7!#`K@W!S>X@0<-R`$?`'*'!ORA_X$)
MX-BIRN"#F*6(=U)H`Q,2$(0_:`X'G<-``C[U#SXDH`>M\@<%/O:'*!1P@-UK
M``Y\4`9B%:`,%9A#$)BP"!?Q00,`L1_^(%`Y3O4L1#L[XA$C$`$?$,`D)RF-
M`![TH@:X9!$^:@V-;+)%1A#B-8.(!+4ZP+5BR"(%P^$:+6SAE<6$S1Y@\M)W
MG'2+K'"%2K00$C#>Q:0FV2,:8+K7`C*`!CGH``A`.($+=*`#%8"@`E*(I`#F
MP`&07"$,TL#"?D!`G>S@42MC`4:'1E:`2^&`6!5S41D4\(>+_:$``*#`#_Z`
M@3;LZ@\]X``&"O"'(;0A9`(Y0F=V)TP*7.`/"?\PPXLJ@*H>*"!C2?`'$G#Y
MCXHE\T4)D)!`R,`]9:JJ8AKH8`)8200-`(UE+F*#%-CGCQCPX`\`\`,'V/`B
M5$%``12(9@$<.(8*_$&54J#`.Y-I!E0!I&)EN%03Y@``?YHA9F40U1'F4(8$
ML>`/IRQ!#\S`O8"X*`)N``@;!,`!2@%4`/3DG>PB0`$5)$\C`!!5%)3ICQ+8
MDY4X4R(2=<K3/_"A5X:`@`^8Z(.:)4@!).!))I+%11Y%ZVF$,(0A(&'%U:3"
M%6FXCBX>IQ4S\N-K]?@CO<X@-B]AYREIP\54?L&/6SC)2PZ+AUP1P(T;H,$%
MB"R"#@(0`!U<H`MR6`#_&:0P11)%4@H<T(`>Q"`F33HI#FBC!7"`0:51^B-S
MO;S#'7+P!S(4X`C`<V4!'M6$5VK`#7FX0Q#(@`'@E1.8`1G",/\PT3^4%F<)
M`-X$,)"Q*+2A`@[$6<5PQH<>Y`X@``#1-SV(`5JZ5G,7\H$;:C`'=GJ0EU0@
M``50I0#@Q<`-?.#>:%OI#P5\=G"HPD#A#%I-WDE4A_^`Z'NG^8=,#4&S.:``
M$@I@Q!(4``?-_8<:!+%`'YPW9BIMPA;NT(02U.Q%T\QI=R75W)SV-$!)O'"M
M^!"L"E`A`A`(*J\F0`4.",`'#0"#;G9S"9_`A!"%*,2(J:H&,"Q!*"AX5Y/B
M_\`/.RI#%X9I`=CD&HT9*$9>C:..,(8!2F%0YRGQZ@,^0D`'!(2!"P^X@!SX
M8D@=R$$.?"T"$"X0`C+,@423+%PD*:G8,)")3_F(F![6&A;+FO8/'?S'-%M+
MWE>2UK3)_0>?7ZL\@P$$!Q/X0QLJ5MO2YOD/_/N#&KR0,3)H5IG"Q3-`*,#;
M@#2`A/7U!SB;.VC-`?$/"FCN1*VK`5YV=[M_H,*CO!<#'/B9O!I(+WIIN5Z1
MN9>V<T#"H>0+;/IFZM'M?.<_>)#8`"_;UAH@=:]5.H04_N'!?R!"!3KJ#UEW
M3WT6UO!F,BSN$$4`$J)1`*^H.H'N#LN<$]#)!B8!U?^HCOC>,X:-"$B@A2QL
M`<[DDM*2S,H,M/PQ3'@RJW3:>@ODL(UMV[D*?JH<A@SD#0U[^?*7^0*P(@2`
M!@$0`=$$0'))"L!PE4PL'5@0#;/P`FU#\@4*.A0$DF!VGV3X5!+:8`0"_$$)
M0QMO:3.G`23$8`*<?FZMR2``(G#L'R5(`AF,P,I&TW("?JB`&8)@!B*0!`,)
M8H.JF."'SE6LM1:H0/0*8#,-2)V5+'C0J)V;;0U0@7,_PX$?:F!+`C0HG&3@
M00E@+84@""`!K4H"`"YPJ8MIH`=M($*+=(W@]D84V!"X`QGX0($>%+``5#A`
M&^[P,SF\D@!^B(``(A#X@VK_(`'L]0<&0JH!',1`\@BN(0%0Z,`)-(!X06!E
M?`V/>&J6^S/D/KZ`^$`('RC@IUY<-P0B8`$^^,$/$-C-(A8!B9C(&-\GF>I/
M-N&)+T!!,?5@7)^4D?YEB)5>]<'3?:2#BW/I8HWAH@/\V;(`>$2#!2M@!^.`
M!EJV95SV90%@`B<`!`%@`".0`:I'<A)8`B5`<H53212@`/W7`KC@.'CT"V@D
M2@)"!A/0!BWB#[OR($<G!:UR=";X(/YT@I>C$1J0('[@(MW%`=$3$&9``*=V
M@]WS3R9!(!I``%3D`PL4`08E`"4H*4*H`"4R`0NT31/0@M[U!XGE03;H(A;0
MA%1`_P5,1P$3T#G^D&M85X9E"`%D2`$E8%Y_T!D_U08)`D0:X"*G]@^MH@$$
M`H0I&&O^%"IA*(4II&Z#MRL44@(3(`#65E,+0@4*((<>A(:=Y8/_U&[^$`1&
MY$%JV$[*YQG)UXF>$0$-$$8DYGN3``DRQ@<*(``6D"P#%A/X%BQ0)(OJ=@DZ
M<6/',7#-(&3RH@QR506+463B@0#T<A_-H#:XD`_Z)V1A@P49X`!=\`U<,`5V
MP`5S<0/L@7%H4`Y:QA<7$&9BY@(&T`7AD`4U*(%S@"`5F&:()04E(`UGP"["
M\#AC4275`8H!4@($8`1D6"NMAA!>,`':AH\,P2M/1Y`[A?^0'E(!WN<#'J8C
MHT@`"J``GT8`U)<)$3D(]R:+P7(2P=)=MK@:W)("T1$VP!@V]%!P<A,/T1!_
M9/6+=!`O("!E8G(FF.0!4_``U9@!/)D!(_`$>H$&!&@`1+D7%[`7?04$*J`"
M!N!7>\`%",`'A75RZDB!%7B!D10'+(`/Q$`6:Y0NV:&0F^$#=U@K9X80`@``
M5"26!R$_ML.6FO&)<#D9%1!O@O!IMO037E27)R%4\>8:J`A^&ZD`/T-5&W!5
MWO(E]]`"?4!D]-*2TS`/<+4,P)@/T$`-^N(.Y4$-0C`",F`'`F@%3]`%;()Q
MW.B-1VD`A:0#-.`"'W`"'V``3#G_!5!0`21!(NEHE12((&I625M`C%6`"UN`
M'?5H)?XQE\B9G,JYG``AE\QY$1SV"%WH?!/0")0`?1XYD02`&X\@?6`T",%2
M"6#0;Z[`'&\T5O$0-H\Y'G!A9%RQ)`6'!1YP`RNP+V)P#1F@#=J0`:(I`P_0
M!7NP!VURE-^H90'0C40)9D6P`P=0`SMP`CJ``B8@`U<@E2)A!KI)@6:`H8<5
M211``N*Q'"#@%!TX)7A$DGKPG"JZHBS:4\[9HA%15([@`]7E>Z;XBA\VHX3I
M`W[`!SX1D5>`D;OA&HU@$V"P-4X1+L[06/"0GLTPC&2")^_)#PC@`3XY!3=P
M`^L@!G1A_P<KP`5/L(U=,`X.0(!@UF6K&0!;1H!]Y7$T8`(?4`.P.0,^@`(*
M0`8:8)5F((<:NJ&[V9L<T``+L!_*<`RR,&?V.%DPNJB,VJCCYJ@;40'.9Q(K
M\F&\\@C3YP-2<T\H%@$]BJ%DH")-]!*8<".(P)WCV0I)V@SPYY(L28Q"ME6^
MD`(@L``R,`4C,`)"``.`49]"@#>B:9H!JIIF"F8NX'%]Q5=?QD@N<`)%0`-*
MN90ZH``FT@9^6@+7VJ<4F&;I&$D=H$GWP4F'BJCV&`J0>J[HFJX2\:+J"B$&
MHXY-]'S4QP<60)A\\#-#M2M(2`5\\%`E8`$EP`%FH`$:``%:</\%KD@3F*`4
M6Z$+K.H,\2=_9:5P3($`A/0$&<`%,C`"+``#>S`",&`7>E&FVQB49]I7-$`#
MC+17?<6L>M6L>+4#)E`$18`"9X:M(:&A>HJAZ\B;W5H">/(,=!`+XYHN]]BN
M2)NT2ON&2RL1XD."0E4!?!`#9E`!W95U9$`%4F@!310!%=`&><JGVB0`!JMB
M2J4).+8%9:&DZUDO+SF9L/!O0F``6R8#[)`!=N`!(^``#^"?#O!E0EF4<D"W
M:MJR>\5(?,6:-&L"0&`"/Z`">_,#)V``"F`X.LNSV*JA%NBSW:H!6RFTM%"T
M]D@5*=JTIGNZ+<JNJ/M/%&`&$/`KW:7_`;\D``,;`QI@`18P$K9IM7X`MFV0
M72<QM1(R!V1`D<DB`L7!;RC@%.@GC$(K-LJ(%?PPMZS9MWO0#C>0DWL`E"1[
MIEP6`$"@LF#&FBX`<GNELHK;N"KP`S90`PIH`@$``&JFCE.)K1A*4NF8CMPJ
M!1:P`&`2MRAZJ%,22I6UN@9\P&RINJ>+(@VP!..Y$AM`,&2PH1NJ`600/;^E
MBK9I!C\D!58[D4@HNQ/\KVIP8T+1+2D09.$Q#V)3!2D)'E*6#QE@`$7@'@[`
MGVB`9?YB``'JC0CH91K'2"J[2"NK`XM4!";`N.7;N`I8`PS``"=@!1!P!@N`
M`M-7@;JYH52Y_ZV;&TD$X+_W,:4"[!S$(((B\I81@<8,H<;_Y!%LC,!P#!$*
M;+I^4*]48)LE@*=M8&(DIP$5P$13&P.$N2*>"H;N"#0GX8CM1@75UP!)47ZU
M8!AD58QD%3825Q@+`%@!4`07,`6?^9-/$,H.L`='N66&I*9>QK(?5P3'RLJ+
MNX`FH`([H`*,^P,RRZ`O<``!,`4``P16T%!35%C82E+NN(Z3%$D<(`5:H$F*
ML0M$.ZZRD%5F_!D`,%H2HBH.808%4`"@IHK_4P!SL,W`LQ#1!A#A3'JQ-LX.
M86#@/`';S"A4H,Z2D0D!00`*/`=*L!`$`$MSN,WJLT(X0$4^1P&7\O\'H<$!
M=\`#K%3-C](_;T@@)<!$:QD0"Q7'!#''3?NN*H0@->@/+*@!]%H!9'#!*#$!
M%C"P9/"0"LL(\R8(OK<$5),%_I;"^K&DX2%D<!6,-_"-5@!F-X!E!#B:>4&W
M+#N^B=M7AI1(?(-(C)M(SJJ`2TG+DNL"CON:R'H!"$`%]SM%/'MR)F;,W8I8
M`I`'>#(V4R*Z7C$ET^P923`'?&!KV&PH/K`!G)(`$=+6J!8%F7@0Y?P/&@`Z
M"!3/$,$!4<!*4H#7_R#8&,$'+/0/)!<0V,80_8@003`',3!-3E0XV48%<]!@
M%%!:M/4I1*``T+,A##($$G($CY(Y_*L&2/C_EF2H;!;]#QAMP`'%`0A"NVI'
MM6IWKQP6O"1A`2@6"@>;+5K0$HMPF"?L;U`0+H]Y!F_DP@C0#![P!&Y2E/]I
M!>5@#JGYC8N$OH<TLRS;-R<`RR?PH$EL`L>*WK'<H+9<`P?P`ZQL!1.@`5O-
MU14HUEQL@<A,!N\`W;I`'5F555121Q+3(?0530@$0G^P/;ST!^^C$0;F<P#A
M;36E/G]`7Q;PX/_@X/Y``%Y0!D#D!P/D;!Z$*@3@!E3@!=_C#]?S*`)@0"[2
M`&X`:I?5&?25V"S>7&:@$;^2/*SC`]=4/!\C!:53!C3U!P*`!$.@/@96`1C0
M*EZ06]>F$520!LJ#_X*=TP`D%P5@=P>/TD2SMSH)<`>%0E^8/<[SY`^(]MG^
M8`9)4`&V9EP`003^P`1-T`:9(RH`%FL"P0?-Y0-L@`&AF@`8#L>UO;K$`A(?
MQ@=M0%@EX,=US&'.Q\C163580]S:H@A'"@I"$BZ*F9[Q0%9Y$`9[80!J:@4C
MX![^<@%FFJRMN;)4[:PNH*9%<`*Q3+,G\`,?\*"XWKB[+KF.>P`'8`,,\`'J
M;0(L$`-3I+]363@WN]^]20!AD"?\H55`!F3L4@L=D@0:0,]#X,<<`T11'@-%
MKE$8E>2QEN40<&H:SN%H&.6V50+?]0><Y0,F_GB3P@=4D`0<<$W*U$$X`/^%
M?W!+T000;"=-`='O_][C#:T11T`!1&#2ZJ-,`?T'*L!0AXYJ#WX$_B38RF0#
M'/!@%4,AI78'&F`:H58`TT0$?N`#ZI,$KY($^'XI/I`#!?!#G$5+M0/:R)0$
M<W@`;G`H=EY?!+!+!(N(/F""`S$R3O\'VH3HL^T0`4LR(F$!!*MN3B0U(J`%
M5$$,:X4"QYT)X^GIO]`,<6,?<A4""#`"-/"LG)RK1&F:5O`OJNQE;X_$.^!Q
M0,":M!S+L;P#[/N@3*T")["4"NB:<5H#2[D"(3`!^;UF5CE))+??)1=0&D#%
MQM@?V9[MN'`,':+:N9,I,=,&7A`$@H/ZGM,#+"__?-V6Y0?Y[@%A^JI?\AA`
M`9S5UV5(!`2@3(*-61M^`:<!>2T4!04P!.J>\!F^\,"3.1E#\KB$];SD6>5$
M36[X#]>O*H+M!P7P`7/P8#@``5%/=^44`2ATY[?6`Q:0`'(7$$G`!T/@#YDM
ML&L@>U[@YOZP:/_@/WD&"$1_?TQ_2%$:?U1\?%2#CX\]@Y)_!7<"D)F:FYR=
MGI^@H:*C%J.FIZBIJJN0%*X"<R4"%!P"9!41$!!J8")765MZ:7%Q*2DH62(`
M`&`D7\\HT2$A<2W6+70@<2%00D`F.G(!.GM=%Q?B%V@.<D4Z.N,T-#I`*B?T
M)RXN12?U/SL_`OZP9P((_Y`3.U380[C#Q`\Y""+$B-&F1`DI<V`)N"AEHT4!
M($'.F<-A#@`/6!"<J0*BY3!B,&.&2,.JYB`DD`I)*4/!B``(I2BHB>)C@JM,
M5"`,4N/C$<X_%@JT\@GTCZ0Y&"CD^*,!`R0-91Y1:5I`0PRO//_,X=$UQE%(
M!4H90DI6@P6E527UL*"AP%H*9:W^42#U$>%!A13YL!#VR)RJ4(-`PM"42"(!
M"4H5*J!T;Y0V@B'A]-+41],_%&I,BD"AR:,Y82$-H?!'$*$_$6PD`D6)TI\8
M0:38'$Z\^">YQI,K7\Z)UIPV%B)0B5%BCH8V8R$T`'!%RQ(M6Z;IT;9ERQ=E
MS/]$D.CP)1J*+2F&96LY,PV"!_6`A+L`#]VY``%<$$`_<M#@CD$FJ-!0/2HD
M:,\/']A@@T`)]?/-#A-6J-`',$Q`G1EMF%&"&;!DE%%'%LDBTHIF3,`"%BDA
MT))+,<D$!10T,2?*4XC]L1,'25#`!!]S@,A#"424$`,'CU!`0`&8$$';'V88
MH0$%$Y2!R2!`"LF'8%A9-8<;"7P5FV*5V`6``$1(0<8<7E3`1Q045`")`&48
M58*5D(R5)AD8S#&D8'OU50)/.9`AV&&/6)!`";<I1H`;)7Q0P@2.++G5(W=X
M8882%$DQP02W<695=&7X\$,F.$DAB`]J:)!($#Z4T`3_!Q2P(6M)L?E@1@R"
MM'&$&9$>L%LK94)""1(<*$D!#EOJ*.VTG2!'[;78>C)'#&;(&MTN!$Q0@0:W
M6#"!=LUDH8466:001QHSA8#"%R1LL$%ZW770P7OE42/>3"FP<($)X-!#@QQR
MP".'.N\4480+[^C##T`_]*/"/P%-".$''->0X0D%`43Q#R;L($<(%I`X!T8@
MR3+2BBFJ&%()%>0Q@P="L,""2BW$T1),,^D1PL_;A)`M)XXTBIJ=/A1000PF
MW0$I&9PQ.4@)NE10P6E_^*"+%+I\^4C33T.%FA]<%1!#TH-(8>?5Q)(A'`!J
M6"!`!7>0.A@&>@_"Q]>Y0##E_Q\C_B'W'PW<478I?`C@YA\$Q)E(*24H"DD#
M:E`@5^$--!!!=6Z8&WHK=$=`;@$-#%(*&8DT;C@9:8DUR`0<F*&+4A1`<,D@
MMY=0YR`56`+IN4W)98%PF?"1.B1R1>`&&1%@H,#1U.MH;?78Z\A!1S'X$8$"
M$`"P!`$^*-"(:00`L%X67W1`PGLI4`/"-.TO`<"]WVFA;Q;N;0$O%"A(P1?H
MD($B[``(1=!/$0X6@"(LC#_NH($^#'(0BNV@'R<0B`T^4(,(<8QC!_C`/Q"B
M$'M(Z`![0`$?+K(R*;@P(R%I64=:MJ(B`0`&#NB"'58@A)14X0PS^MDTAJ:-
M>!DM>__,2182E\C$1VC`!WS@T1(M,+@F6M$XU[NB%DU!`2G01DD1V`X$(A`!
MTYQ+.^K+`GO<EX(;I>%G>OB"%JZPA"6(8`E7(`&[VC.O+=PH&%](PQY.`#*"
MG6"!X0B`"0!$`P0:T@00,X$-.DBR"F:,@P<X0`TVN<D0_J-D`_D'!R]`@!)L
MSX4N+$D,9R:%C\Q,5E1X0@`<@(4OL.`&+%@``A!@C?EH@QA%U$/\CKC%FDRO
MF,B<%@7ND(`8)/.9T#Q.-*>9B2E1H`0:^!L$PL5-`FAG%R108P?659YAXF@+
M*'"?NK0@`E_H;U_HA$)YT,D"&I"L0M\P01$`%``@N$""]C#_R`D:5`\.?D`%
M!^$8AC2924URL@:>O""&*&F')?AJ>QPXY0M'`D-7JBA%`M!`!;#0`@)H`!86
MF($87H2%&9P!&_/QV3:(,41JVO2F.,VI3I.3Q9T6\SDB58`""-``")B1J+L`
M`QWQJ(5GN"L-_$+!'+5`@O7HZQD=@(\Q`)B'+ES,(2"#6!$()L%&CM4=&209
MP2A$LA]`U&,?:&@F(2K722IH@S^8@@).*HM3DB0C()W9S&#XG!@LAD12*$EB
MR;"%%81A9PB8`0BJD`V9#HTEQ/"I9C?+V<Y.LZ>>7>)SS$`&'Q"`%PTH7U'4
ML(S[V0L,^@I@'*#0GBUDH:KKTF,'__@W+SY2]0P!"$A""*I/!";0807YIPDZ
M>,!Z4!(@*HAK0]_*R;G&M8,'^$<1#+`%;FT$)!E]&0UCZ,KO;J1;UZD.KE*)
MJQ*DP`,+@-$96$#9(`*3#O@-K7[WR]_^\M2_3+RF2,,'!C`T8`)F5,,=B[J!
M9KQ'#T*S;33:]TZJLBL+O(7",3Q``XY1"(/^S*<_':8#AXBP'QT6(80"0M=,
M,L"A#64``ZBK`CDL``(5J$Y&1"3>[Q)V9CHV[XC,8(83822QN,*5!D(07Q:<
M80:]))K/\$L'`%OYREC&,FBSO!Q7T,(,8VD`&`!0U&UZ<SL;Z-P2@`$%8D!X
M"[O%L+HPO/\N_>TQG7H800<U]H\=-`22!`'9//B1,10O5\4<A.B+#R!C&8]!
MQIJ$]`X"$`8P^,`/?M#`]GY<(O)JQ,>Q*&\L8*'84R:9`V1`P4I3\E*8:@,$
M5*XREV=-ZUK;=,NV'HXK:D$&H2IX&6J`P*BVJ9WM:(%?(,A#&U.PSMU>>+?C
M9,^QLY`!#DK(SR5L$,A4L$%P&$B2'&2`"6@0@`VV>`R,;K2+%ZWN`]`@`S-`
M`0!$D`<PD,$Y)^+H*LGK,O."I)4B025[UULG!*!$)2^M0B][F=]<._SA$*<>
MKB.>BE>T04[@NU>:$>Q-76`.#%]P5S%PI`<XYU:WXUS7;==3A0O_V*`.,PZ(
M"/5IR(OEXQW^^(<-QJ`"%YP@A.EFP!AJ\&)%-YKH+_Z``;@P@S2H]!T!6,#Q
M0**R%7G:ZAXQ$<M*M-&,LM<5$5B`!R`[`\KB5^$M:`G%U\[VMK-BXFX71;-^
M98&A;H?,Y!NVF/6(`CVXV1@I0&<'ZHAR_65AS23``@U</)`-9C?G"QD'(4<&
MPA/8X`!#IZNC&\V`%\!<QC4H@@,6,`.#.X`>$`,"#9YP!ABL8`%;:-P+/>)O
MVO^[1!P=B<`3*_",<H`/6!A[2Y^,#86#X`QGB+ORE\]\U36_X@+HEO<ZSHPQ
M%_5<8#!\?/YU#'UYISL59A>[Q.""&OQ`_Y,G_GD-$C0AD(TC(?[X(*,MSVB&
MKOOS8_#\HT^P]`4(800&8'GZH0/N@#!%0#(!(`-AX`/[]A$.*#-<YT(!MWL4
MZ$41``./M4N1U0(*UVJ:90%<PPHEL`9*=`H<T#>;X`718@I2T`,XL`D^@#R=
M\$1,E!4UT081P!R>`@EW`'?,YX//5TT6H0$*,`%GM@16I0S>M`3]`WAM)%4D
M<`5Y9&?>MS\K<'Z99&T)`4K0]3`$\PT#13&7!VGU]V*--@:/%G1C8`-R@`9[
M8`#B4#('\`(%80(#M4CD1@,F<`$L,'7[MF\C(0N\MU$MU$(5Z'4$$`:/%2,<
M>`8(4`55H%EVH?\)7H`*!6`&560*89()!"`V/F`UIX`I5508@?()C()$!&`3
M=\$<E@$)/G`L0:@)0!B+5R,KRB-LX;-'7W`%&Z`=2Q!RT8!.QH`,WJ%4%J9'
M^D,"6R`#01="'S!0[3<0A_1/A%00`V5^.U!_1%<'GR=T9\ANF:0#:)`P#N-6
M-M`0_30A=@@$"%,@&7`\,R02XF41+;01AEB!^.A"M-!%!)!+NI02I0=E+;!$
M4N`'!)"*%%!:(`$`IT$%%:`&3*(U"N`K5.(%TT,%;^`#1=(`!!"1%4`%N\$V
M<Q`$!$!%IR4<?M`&M4(&`,`'8=0LH`$U8?(3#0`209``?.`'IU$!.SC_(EY3
M32?)`3@0%X_@!T/@*Q@0`PT@%[`"*8:!`>%".,3B![3@!\+F!P``*1$0)VH1
M`Q.0.9"0DDWA37.`&@?Y!QS@3'\@)SD8`QH@.'9B%K@!`,2B"7[@!8ZPBH/1
MDV^I%']PETXY"%CB!8G0!AIP8(-`!0W0!,=B!@R8D#PI@[$XB[2(37XP5,0&
M!NS3/B0`!KRP+X'W'BB@8<A``DN@5%$8A18&!7L`0@;U03.V`S4P4/>`#RKP
M,`,58Z#GC8[V:#)6!VD(>BX@(/2@`C70$/.@AX3T,#I@`#FT!TO@.%D'0X*%
M$=2Y,AJ52@*7>ZCD>]=$`$*P`&&P`#M#?`.)_T12\`'.\R5R4``4P`,QP`-*
MH0(),`%W8!4\0`9WH!0Y4`(XX`=\\`8*0`&,@`,`\`=-@`,6D`2HX1J#,`=(
M,`%48SXO>`>)P@=)X`=*,`&TXB=E$2:]I@8)(`"'4`%D$"1D@`0:H`1S0`4T
M,`$]H):#4``4*I1W<"QD,`0*(``8L!=&,)=4L"F#H`!-0`5RL#6.$"A2H`,5
M0`1>L`%1\`=WD*-4P@;1DX.<DB@-,%1A$003@#GOB1H^^@<3T`0Q&!:<H0$]
M4`%HHPD$0`8T0`:KJ`"(P*!4<`06$*/Q&0--,#@"T``5(!D*0`2!&E)!P`<?
MT)A)0`44<``%H`;+0_^+E!F+)=`&,3!41G@_>\0^[J,O[%%;`60>)-!.=U15
M4CA'<1``+_`"')2-<54';L4`=0`R[&@0`P$$Z?@#._<"0<=N0N>;G2=T!P"<
M!W`"<0@A^E2`.@`Q_Q0`3P`##\`%#=`&L2`B)?)1T2<`BM5"OJ=1OF>=)J)U
MWDD+!'`#C[4`NN12R;=$DE`"4<H#:@&O?R`9CO$'JD$)=Z&FBBD5B0$56N`5
M-$`;1Z`!5)"*CU"*E"`95;&*DL`9'JH!FVB0DD`9@X`HCI`JJP@9DS`("GL]
ME("P5B$=0P`)AU$&8Y&D<T`!8:&D83$'@TH!8>(GCU`504`%5!`D(_L'!T#_
M"!10/H*A`5&Z$Y4``1J`!*"Q"10PJ%2PBCE`&UJ2L7F*EW@*"2HI&0^+`]/3
MBH]@L@B:-K3H?%\;"B7@DD9H&N`49\C@/N"W6U_`6X/78';4'75T!6(05PPP
M`.CV`3,V29MT4"K0G%PX;CK`;2+$:$C7C;UYAFB8?WN+0"3T#?L$('+@`B8@
M!S?@`1D`!A5P7A4QCR,B"WVU44CVK=T*KA$XNKA""V$G!/`%([O$1)*`&;=A
M!B\XKW]0KPP0&G=!!GN1,I$2!1%@`0!+&TT3!2M8BIO"H`O;&4/[L&$"``0@
M`!-[&CR1!*40!1,`M9"0O'^@L1O[!R![J!9@+25[_[+@F[(KNS)E8`:)P@0P
MZQ4RRSNE8+T64`%2P*!_D+ME5+N2T!4^@J9*T0918+"9T+Y+JQ3X&P4E`+5!
MX`7C6Y9^@PCP^K`\D(-:6[&.X!I]$;:3&H0"`()F5(0`P"XI=W+[TSYKI`5C
M!@9XU!UTQ`*KN@.^^0)]NUSF!U$!,IL7,V(99)QR)70O(*O`N;B<!YPO,``,
MX&&WR0\$V$BX&@`0(P-TD`83<*U$1D,CDEXGXJU>1@L8]:W@.A*F-JX9Y0/^
MIX@LQ40X\3>1\J-^4"9'4!U;@:^"@[_"D1B20*=_$+"34+L'6Y8YP"22L+R"
MX;"I6`8:(`5>P0,4P+[@2_^]@)$Z1B"G>&$M@2P8WAL:('L'7R*9Y2M4A#`+
MZ;L3!?L'31NS(5@53``:PL$`L2`)%'"3&^N_'`"O92`XJ`&O$0"*M6S*$5`!
M2N$&SK054*L&;D`XD.`%]V:U==&+%*`#,OH'7*O!A2&I81L*C=P(1>@U&V"J
M4FB:X<0^:O0,]+($#4:J>;0$86"WV9A)09Q)=C50"4-(EM=S"15NB\9HGP=S
M=?`"8P"<CM;/1SP`'E,0_@0/XY`@DZ8#7+`!?!`#0-9OW5(1'P%#7IRZ7N:M
MJ*1UVCEPWLD!/N`!KP<C,\!$.I``"4`;>L,'">`7MYL`.#`\@W!QBH`#"9`(
M$)#_`-!#&:EXG[SC%23+)!J0`!B0"!4`&C1-*@XIE&6@!HJ2`+^<`-I!.$/9
M-8/@!1B0@S1]U%]!U$9]M(\@HM_#)*3"`5&0`&H`"3&0@Z\H*`D``(G0%`J`
M*SZ@LFZ@!J8T/>0""5R-)PF0BA60`&X`P5Z@EJ0B`,=T!ZDR`4!;!FZ!OX_@
M!6XP`;N,`QI)U%^RU:#1`&7@!H/CGW>P`12PUQ&`"6X0!5/JBHFP`7\@`%AJ
MS=?\":Y0`GZ`"Z8Q;QL@`KD=MU]0'FV+PJ>9'D@H`LL(>@,!FW)50@$"!"I6
M,@W!,;SI8OFWN/_<ST.,>:OZ8K"*4-\P8@E=$$5P!A$@_R(6063E-2(4;:V`
M==%=/,;AI1'WV'O=FF0*4`7A&5^P"PKU6A,DH09M&MO2$KP`7DP=_'Q>1EHN
MF0MJL`%2B$<LS![N02^C:L[WLPPDL`=!;`,,<([5-5<'8`(?L(>4>XY?*)O0
MC6Z<-]W\[,_Z!W/3_4%`<$'&E4`$"(8RD&-#%B(Q\U'F#8&S@-$9G4JNP#(<
M?62[UZVT(`41P`(CS425^`D)`(JK0`9$X,<#?N6S5N#-E]&T77<3,,+1-GCJ
MH8LH<`4B,&;SYIETH*J1UD%ZVXW'>4`78`7U8`.J!Q"6UTG__)N/5@<#T,^=
M%\0N_N=H.)MAE5T!<4@_,&,$\_\`FXO>Z;7C/`ZZ059JJ)'1&97D-=2=1S[?
MJ4L&52`&88#EI%[JSZ3E6S[DV&&$L*4_[4-'X<29Q=A@]@(`,Z#A(50#=>`Q
M<TC#>GM`!B`@&91/"@W=PPJ<W"C0`[#L?_ZK=SL`3N`$N^ZW%](@"Q*&0.``
MG],&AADB/4[>_182XM51OM/>OI=[14Z!GH[14J`&HV[J\![O4R3OJ+%C:\/-
MX%>:SK9&4HCFS```52"L'41T#`5S&V0#-&``!J"'V95Z$))NGN?/CC;0JYK=
M8[#L$2\!$C!T-A!H`%&'"S16(Z``E3ID*0+N@?6'?T@2I^9UZ4Z!V.GI78PE
M]%[S-C__+:B^?!0@`&W@!U10A&JP!"D7#5:U/MZA#&K`6DN`!3N@W2U6=)J4
M$+/D``G$W?3@9^?7YP,@\8Q&\17OFW[NYWB0M]DV4"J@A[=9$#JP`43V,BE"
MT9*^2N7E:;K7G=LS@?%MY%Z'Y/LHF3?_]X#_=O0.LQ?GDK"2+R2,6[K%3AL`
MJ0VP`1EPN/Z,?P<P222S70X0``:"#K::$)@'<T>,[+*Z]16_JELO8T',JQGR
M#1RS5@F2K`&``&2P$0#G$2*"\G-?T2;2,BY3B/%=]_BX[IGN98%?_,9_"CFO
M?(2/<4;(X'/TS7J$6U<`!HV_"RQ0Q/^<28\F7`UQ`<%^,#J0__D.8IS3;?I&
M;/JF3_K+[N(R=FT71$@(E(TD\T]R,`4,^%TR(^DQXVFS!PAS`@(E@W-S4HF'
MB8R)'!R-CH^3E!04'!1_FIN<G9Z?H*&BHZ2EIJ>HJ:JKK*VNK["QLK.R%K2W
MN+F=4AH55%03!`0`&V!@)%I:2R)+RQMJ#1M6#`,,#`?6!S4'8SL[)N`!`3IR
M<A?B-"H[*C4,8R\O`R_O\`/R\"]U8W7YUQ\[)TZH&#@0G(D?/TX4<1'@PI(V
M@PH=*A2QA,6+@S(:$G0HH@".&1%)>70(TDA&D!Z-I,02DZZ7,&/*G$FSILV;
M-6WAW#E3BAD_5")$4*!@`H0-5Y(NV?_`=`,`-6H`C(!WP,:8:W7<O5@'!,B'
M$Q<`TM!Q08X.'3]V<'LW`,X]?/'JR>-WK0;"M#M^&#1QPL:/&B:*%"$WA4`)
M01HI7L2(4:/&.84L"E*$:-+(RB8MJZ2T,N4CGJ!#BQY-NK1I6#I/JT8E0`,9
M"Q$L!"VJ1H0(,$^A/FT``4L=>_->:(7'((")`$!,Z'#PS01#.0%<_'5'+RZ<
M>/+>XJNC[8<Z%8&+!`P(Q,:)`T!<D+VP@`S'CA0)+;:8D3XBQ!\].I)D,M%'
ME2M)$F!+*ZT6"@=^;$*!#YF44L$<K?@@!2=^F)%*#!!&T.`G$N)202RI&2CB
MB+.$2.*)?US_4@(9?I!!AE!%0=```$]!(&,#.(;P0QWZ7#5&#5=QIT,`!EQ@
M0Q$-V="5#B?0D,X'!V`3UQC9M94/7._444,-'WAW@@E`%`%$0'R-Z55Z1++G
MATCX>11?8A>I-(A_AV`FYT=T5A:@@)EM1@F*FVB`P292X#!A*!I$H$D#&K2"
M@X4$:%(&%:D4T*@;AVY"A0":/(I+&1NF(H`"FO0`Z*FHDF)BJJI9`ED)9I#Q
M2P3!R&BC,#9"T,(!`W`7)0-9C3'&!^7(@<4>'WQP`9@Z`(&6"2H@9$U<]E0+
M'#[V\%.'7Q^8MY`+@GUY$'A\*5?.$XP*($6;\SE&'WV6<(`(!2"5_Z32(I&@
M1&!+GDTB&@=46/B'BYJHRP<'%32J0105E/!'"6W\(04%,9"A20Q\3-Q`&1!I
MD(D4&:<XAQDF<GK)'X,HG(0&')010<.="`!1"50X_(<9?$2A00F-#FP+!2Z;
MT9HF.',@,AD?=H*T)BQ;K*`%#I>!L,U+WSR'+7[8K`$?F43`1*,]S$$%A'\D
M7#`9L-:<H@!D1,SI'V2S*K=-J\Y-VB7K0A9#!7Q$X`,!MP8#.`%9`($'7<'V
M<X`<>Q@@!@PN=#LD#2?L`(3E-MAP@%S6NG4M/_",H4VTR086I@LN@(,0>6$&
M`%T>#<\A;V(>P1E9"9C$^\B<=4(BTDKS[O^Y+[\LB89$%$G\44`.05#*`Q,]
M&!&%'']H\$$".YBA!AQ_3!`$$TUPT`8/9?0@0!)'%*#`$8T&@<$%`L20!`]$
M)-UI]Q#\P80/!\SAA0IET$`9DI``%6RH!#G(00R"$(4CI(@(45""!M2@A#\0
M@`=(F$`;CM`#+_!O#FT@`@9R\`<+$*$,0^B9)B*0`QZXX0]&X$&D-I&`,AS!
M#.5+`!+^0`4>=/`/2L`!$7*@PS_(+P%,X$`/FA"%/WR/"4SX0P_*0`0S2,$(
M.2##\1QH`3;@0()!,-H=$F2W,L*D;F8$#;T((1^,^<TH@,L5`6;@`K:X`W17
M^8`+,L`%+'3A!!__`((<!/F#`_R``6F)4AW@@`>WX,$);GE!).'2CV0EA#SB
MB98-UO&-,9F`!JX+`!H`0(C[.*9VM;O('"RA.RG@21%]`E!)UM49SA"O3Z'Q
M@QHT00'J4>`$?P#5'`8%*D']P0T-^,,!>.@#Y36*`GX@H0(*H`E+>2&9=P#`
M',K`3$XD@`(%P(``!G6$59(PF(HJ)R<,2+0@4$`!S;24%'E)A00X4Q/E3(##
M$F`&#5#3!Y3:Q#F#$,QF;F(.4914)J)HOCFLX0_EI$(SH\B$"574F'\X9P]*
MP`2QW<&)@7+G/"/@A@E,8)YI3.DMT*C2F[S*#&UH0PG\`$\?U$J.6&``_SQX
MQ".='N`#@'F`!U9@`!<`1AQH\`Z4E(0-G0X`#VV!)!RF.LEJS0,A_P!(Y=:A
MCF^<H"O3L<%8=/`$%O@A;Z>TW6'D(P!6DN0C=<K;GG[''^+5LE\`"HT/#.I0
M33``:/0B)@6,60`O*+.;EHH!$R*PPVE64X#-]`$&YF!/B7+"!Q6X`P;<8(MR
M4N"<DX)HW/[0!+@A@0#N)`"EY&DJ`N!@`O:4IVA9D(D").R?`=7$.7,`M-S^
M(0*#4JC^8&BCDT9THC#4!`;:@%%32;$"2;#1ATPUAQ[X0*2FTL`WY4"!A+;T
MNZY@*7AG`JO#Q(IO-A4&KB"@!A`<X#=9`IT[#O^@@Q%@(0,JH($!%L<0`P"A
M!MQ)"[#@`0=(/I*J3@"./BKY%QLDJP8J$$B7*O<!%;@@.7H!B+,N((8(S&XR
M[EJ,8U:9(I+<ATWZPHPK'W&)2ERBQ;?T%V@RNPD;7&((P0QLCHV)`U(MT[*6
MND,,_L"#/SC6F6KX:!0(0-EN;L(,:U```(Z0"<^"EE+JW$1I@:$_"M#J#Q@`
M&T0M$MN>E3/,?\#!'/SY!X!R`@F9V&%H-R$`Y^9XN$C(U'&'6P:'\6"PP75N
M#Z2`XTV8BLM,R(2I(&#8Z.:/#^.--"K$*^F7]/,CL9)H,$RZ7A3\0#OSB-)5
M:"`&.L#@`F<9"`TNT`7_.4QG2]S`SE,+[`0\V!JJV'J!-KH%)7M499,_`+9>
MD@.$M#1+D`N8P&'JU";$T*>4K[)3?_`EDI344MK#B_%G0E.&!-AS`CA(0*,`
M0`$IY(_<$YABHD'J!T@;A@Q,<$.1I4!$"ACF#PDH0!3*O<MV=^(-'(B!8?4W
M(2):```)JB@GBCR''!3@413@`1)M04T(X.`.1:Y`#YI8T1+PH`#)+$&D^$!&
M350`!U$@%<([X84RX$``Y/Z#86/`@@3LLJ+^-FP;<."&2%&@!PF0`C659T&)
M)XB:U7VXA920`/.5\`(P;4*H*DWU3E"ZZK>(00QXYHN_J5<8O,G##_*1X*O8
M_^-'_Y!!"IYP`320SED.T($WH@3@?-B#D;5FY".AJIVL1.F]]X"P=\!T`KT4
M/CD1%D\&`!`!/F`(,:X,R2#,H)B,R-41[Z%K9T;2XL[`V#)WO2761R\B.V>B
MR*1/O2:NKOI7:"`&O?C;C=1K(S`T@0%.")W9!X`>(%P@#&&XP!.D4P,;F*`L
MJ_L1-7J%G0+;&I*0E*0\KF*-W\!!&]LPCT`('Y"TF&`'2%*!&`A0`0M4P#UX
M:H,%0ORF_U!FKK^K#-XFYB=MV]]HK<\_:'"P"1PDX:3ZAW6L%X"JH`&NH0#L
M12,`P!O"@`(&,`;7L1TZ!1@_T`5Q(`-%$'?KP``N8/\``?`E13!VW'`=;?%\
M$I!@;L%(V#$/UP`L6A(0?N$E*F`#7%($7;(.7P($76`!KH$T$"%3/J`'Z\<8
MC;$(S+8?&Q$)+.89*/%YNE,)_,((!#B%5%B%N#"`5D@*2`,,,@(-N3(!*``$
M_.`Y.Y4570(#'H`&)V``<G`0!V`Y@_15._`!O;)(;8%WC^0$>HAK^Z`X?V<7
MX.`7X@(MW5)XF7,"TN$!`0,Q%:,&"```&O!*KM08(4$9<`4\29@9ED!+DR`[
MN1-C+?9Y,I:%I%B*I@@*6'B*GL`'\)0KM\(;&T`#/")K<^$7)L`%8K`'X'<!
M3_(#3.("Y/$C]V!K3Z6'>GC_@BB(#U?!)5'B8!$VAQJ6'.,Q$'YQ.1G0-F9`
M>3$``6+`!_/"$FDEB9%G)_@"()C@.[(3+YSWA/?W)ZKXCO!(A:D8C[_%:;17
M>P^P?&X!.MPQ)B/`A@$Q)(0(!#3`%YND`L$A#XPT`,9X@B=H:]?!#Z*#?3>8
M%PA!+I4387P1;.`1``H@!191`0`@!@$``;D3BINX+G`55XP05^=8;:!W$HS@
M5B<)A>U(CSB9DP*HDZ6`@!.07H#3`!UP`?SP.:%V`JYC!>F1'H,1)E^A`D6@
M.3_P`51"+8T4#TX@`5KI!**C+7YG#994>-VBD85W211682=0!1H@!620!F^@
M`D^0_P45<)(HB3=LHGF-<"_X<A)ZXGDHZ6*:03R6P).$69AI-(_QZ`-J,`$U
M92,`(`/QX#G,IVLV$``/@&K.@1SJT16`40-%4'Q0PA90=6O%*`$GD`0F(`?[
MI5/ZT%15,1#>IU5]T24#,8=V(08-XP=GX`+<(`1J8`;Q$B_9*``UN9<RN7E[
MV1^<>(Y+R&)_V1^W-)B&.9W4"2B("8\^P!L_:5-J``-6PH?8\%-R,`4RX$GC
MX'N@!`0J$)ZB`RQM\9X'!DD2@`4E0`$E0`*1<W;8("QVX1<J\!5?,8<.-G<.
M]@$K8`$Q0`!R8`-=<`$?8`(ST%:7P`?1$!40\),5(#30:?\9K;0(`)*7SDF3
M-7F.=25ZU7FB*'H:U_F.M$(`VSD!`1"9`Y`E[F`-`7`#5B!WQR$F%W`!XJ$-
M#+`EUL`6]C":C?14`T``#>(#U'(-V%`#7$4>FY07?J$6/^4.%\`'`#`%7<`"
M('`#'H`"0O`#*!`!:RD`%=``5P`&T2`,/D`,?$`&0G,2+`&BM;2.(3H)(GI_
M+9:B?OJG/+&BJ@@,F^8#4T"+3@I@8U`$0[4'T7)\.F`"!O"CV+=)^U"">%<M
M"SD`#&()9M`$,SH/HM,E`ZH.0"`&!RD0FK-K0#`%86!(.B`#!B`$(7`%#O"&
MLXH%#N`!<9`&*2`C&[``*\`D?('_!C.P`18`$1/S>24ZHGOZK'BC;8`ZK=0:
M$X)ZBGQ@4G^S`$3:*]G@#B8@!@C0!0'P%T5P#N<:81^0J.U0+7G82,X'?4FT
MB3B`:SQB25,IB#DP`<6G#ENR5`$0!D50:U"*!@C``E:0`1\H!`@0`"HP`#O`
M`FB`!5?P`(.!%C\P!H5T`!VX!A!`!62P,X(`(##&>2'Z8L'IA,-32]7:LBY;
M"X":K1,```[P`9(T5<(!)%D!!$(0!AX@!V)R'`VAGI:SL=PQ+<8(K[>6=Q(P
M!@GBJ3RP4X8TE3M`@^8A!`U`@U^R#16&`$A1!TYP``YPBUBP`#1P`.>P!T(P
M`HZJ`X[#_P7EZHM%`"W'1P,5]A<T``%_@P)J("&;UQ*L%+B""V/,^J'N^+*(
MF[BG<*VF"`P$L`(9^SE7H6L?\`0MD`%AH0/J@1P?:`/@L:Z_(BPO8(QY!Y%/
MA0<OP`-D$+@Q4`;"XKD[`*50\@TZ``#^^1=0<@$04`$T$+9%$@`C@`!8X&H7
MD!X>^`/C\`-N%RW;8&$T(`<.,`([@!9;@@#1T`(=,`$@&P.4]Q]U*9T*@K*B
MF!DEJKCF>[ZH&+,$P`).%:JS.`\UL``+\``!T"7(<19`8``9^Y_A"6#N>FOP
M:@_1MP&NQ$OG"`#8<`+;\%,!>@(0H`Y3J0*J.0(`L`"_`01$PO\%+(``3Q``
M>V`D=`AA)P"]#A``@U$DT)&_(U`.5+D-83`%+0`!"'`#LFH`3_``5J#!9T`"
M/N`'$LI*X4NX-:DOQ8.^1HR^C%N*$;`'UA<Z+X"ZPK(#0C`#8?(#S@(FT`$=
M8UD7.O7$SP>O4Z6I3G`$?L`!P`G$\J(#+W!(5Q&#-2`'/C"5QX$`4%"9WOD!
M^F`"68$`"M$.*N`.-<"&#``'1<DC!Z`"^=L0#K#(Y8EJ=*`&"^`#,Q4!$(`"
M+"`&78`&B^P`7>``0M`!/F`AF1"X4,B.G\B<1YS*BIO$I+@$FT."5W(E'P`#
M"^``ZKD0"H$D-`!6#M9479R'>JAW>TC_56?05F=,RF7`#6!)I1^P!PVPH$40
M!G2P`)EL`U*EE7A0`S?`E6,`54Z`B`>`'%F9>_?`#URB`CV*!A[``E@P#AB8
M!6T0((*@`!S\`$]`GEQP`T(``ATBN,P)A<LJHJH\T"[+REF8`]E1'<*1%0[`
M`D^`O^K9+,X1J0$!)4`B+`I)NGB7=Y'4`6TU,2GB5A-``US2)5-I%PX@`Y0C
M!UN@#!'0`%:P7UOY`C:@`PRPE;FGFH1,)7M8:V`+22H0!N/J``L@`ZIY`2-P
M!BTP`43,`25@`4L@!B.0`1F@SRRPU&3CSRP1K9V7.P3]U=-JT%88!)%$#SPB
M.G)P`T5E%G1K_\)G(7=SUX*_<7>W-E6UIAT[,`$G66*L%`-#\)I`M3HA6&%8
MX!0H0`4VL@!9F<TVRP`T,``..0!%<-/CC(Q:>=D2``1JK0,@L``#8'P1AAP&
MX`-UNHD6$`*/<P,K(`0L0`=4X!*DO-4HNQG@"]:V79UB785)L%-=#"P,H`(P
M(`,Z,!@.6],T4`2@Y`)YL:[9T,TWBX=Z]Q9C<`$6`-N;V-=O((BV*!@#47P(
M8`Q:X`,V(@,GN`.RJH<'@`>8_0-9B=GN_9`[<`&`@05<,`8TX"4*H0(M0)RT
MS4IFH`49``,W(`;L#`'$R4NF?,KC>]L,3IVY385&,*._,0\S.LL_"_\.0_(5
MJ%,$S?&?=U0/P+R'>Y>I/@4`E&<T0)PB$<#A`A%A82)A![`'"+`%&^"E).#9
M<&`##W`%9Y#>.AND#I8!"U`#6@D'[(VZ[3VC#U`#71`&QW)A%R80TSL!T;J.
M\1(!"&`'7+``9W`%RX;@):O@_#%U#5[F]/C@4Q@$V@$'ZWH!""`#&JG<_P""
M8!)A[;`-=$VZ*#CB<\%[D0P%%3`ATDD!%>!V7Z(0E=-]"6%\17``>5`%<E`'
M"'%\BRP'#4L..F`>,Z`%"S"Z%Y`%\OT"6LFS`0`#/V`%'Q`=+C`6&^D==L`R
M@,M*`C`!"]!'&V!%AQ'2L:T[HDCF@()_H`#_[+`@[+.0*;_>"KZ.[*E0VYU`
M[`X.J&H.'+ZF`@S;AH&QGMT")@0)2*#;#E3U?,9X=W>=#UDQ#REPV'MM"170
M!>I`.7TQE86W`^*PGG+``C=PSQ@>MPL`!OY%).5@&WK0!1+P`UL0`BA@RQD0
M`DO``HY:;&9Q%L8!$!4&!#ZP2O\<N"D2`U!`!Q`@.X2`XKO^O>7F[#?A!VO0
M4:C@79\`!_;S"G8V"Y\U"A'@;0F0/[<@`#CP!@9%"B^_"3[@;0#X"98U"X:"
M"K+E"05@\RB*Y@2XVU@Y#T2"!3)@',[")7^!B,U2TNU9@DMKC"FXCV=]M"C`
M@X*.X`J`%@%:KC_E_P(S^"6>.R9@(0>[S-TVP`)Q0*Y(,K=/@`4I0`>ZA@4M
M``5B@`4@$`=G,`7GJ@//.P[J`2YE>0)YP#*U)+Z6,.L*("?UJ=5/.,HO%AH4
M0%!F@'JFH/*:<`<],V2D,%D\/PNFGR+G)`J?S^REX&:A@`01TRBM+PH]+RGU
M*0I#'PLB62DJU`E)[Z=,'X!)4)3"H0.MY@#'[0(]2H/?-[V4JLPW.^)*>]<S
M6I7[\",I4/G^G`8MS@`[(!TMV`T!`1#M+@<JH/CET.A"D`&?%!C0L@,/H`=T
ML!Q.+@,P``AA9QXP`30[*CH!<@%%+D!%)B<J)Q<3')B84ID4G9YS%!Q2)?]F
MH*&>GIH<J!1_KJ^PL;*SM+5_%G>N1G]4$U$)KA!E$'\1&!@<?TQ_&*T$5$1Y
MSPFK&&4^?UX)&J]M0UL39%0X9@G7?Q0)"3I_4G?;?[[$L%Y15'\5$VXXL&;1
M!!22-&!BYH\"#`5D(7%5(4H4`7\(-*!BYE>,/W<FE&E`(0>/#7_X1$$&"PD?
M5Q:B18B'(=<M'!CF]/A3`MNK,G,8DHG'08"Y"E3N%.!'`0..!O@@8.`!\4Z9
M*!?KV7R%(YF&,C$)!/L#84,/`F56%O@UP=6=*&4+S+/%MJW;MW#CRK5E8:[=
MNWCSYDWR8L"`%S\<R;D00-$4.1\^*-IAPL0/!@?_&-2I\P*.D\N8X?C%XV0`
MY0&:ZXP!G*;3G!*M*`@H<>'#B1,U?ICX\*+.91L[3@"1I*)1C<8,&"2V(L.&
M`1V\==P`,$%+&`==NG!QP$).$15%;/0>;$B'BR*[30!1,:-$)DZL4HDZ76)3
M^DZB5J'2J]?'/"(4?.0J(\4/OPH=&834,DG4=80&!7#SQQ%S3%!6#!5@@`XL
M,?T1PPX"=/)'#O$H\$<2?_#`QQQ#;#CA*W<@]4,)5+#`3$&O)(C.BE00P,$R
M$\6RT(<61J$,-DRLME`/:OSQ07[W4-`$!PH@]8H&-230BHP"\/"'&BL%<0L'
M,_4`HRMEX+`-B258&04W_S&T6%1!4ORAI0:[E*%`!<`D4(("V.SXBHM_/)0,
MB'\LE$11=U!08@$>@NA#64A(H19]D$8JZ5QU36KII9B^D@0>>-11PPY%R&&`
M`W*<L(@..J@`!!`'3'+`&,'UY9<3>,#!&:V:V3K&`7Z]`"MD.@21(04:K%+"
M%0C4\(%CRJI00VAC?+`#$"Z8H((*<JCP`1`_4*8"%T)8P4!A/SC[A!9+$*!`
M=30L<,,)XNDPP@7BT1#`!7(P4AAXNT%"P";HO1<*!W.L)H``\IVB7L*A9/I6
MDZX0\8</]\2$PTI_^)$0!U8N8P$UN\BXX!Q5N<(!$AY2F!."KA!PQRX)0#23
M"O\CC2$%#FKD],H0%^&@`!78B.R*C`%:``$?1F#0@Q<ZML./FW^4T0J'?^S2
M0UTT()FQ&W]P\(8L$"PD(YX6NN&'CZ[T8,0]L)2!FBM\*)'33*X`_8>,^M'P
MAP828N"#%W7%9`X&1WQ9M2L*X%#"W3&P/-.C3=S-#4XQ7\G'HPYGKKE<E6[N
M^>>U;#K``34$8(`!7?![@0%HE&H#K+.-40<#E<%A:ZVUVI[9"\']!6MD8P!Q
M@0:M')R?"@=\$)L-L>WPPP<_(()J)"?\8/H)N<6F[!07C""<"N6>$`8*)*@!
MP04ZT,"%#C^<<``0#IQ0QPXTH*J#OH84443Z+H!@WGG_`$0%)@IVL!*T9Q4)
M.X\`03<+#0"#1Q1CQAR8D+(82&@.95"&*W(0@:`IB$%,T%DPG.2*"K&,`$#J
MT^)F0H/%O<(/6GJ%$?P0(BK836B20P>'C.8'ER@$'71;B-1,%*@_7.T/68M@
M#(`Q!ZK%X@@YC(!6_.`%/V0P;0I81MM$R(0>>&@-K[BA!BQ0I)GPC1D^R%%,
MW*"@6,3P#P(@0@4<V("=/(X8D9-1#R@0A39DHP*88Z`@/=>Y01HR<YNJ@[16
MAX8N`.$$W\%6]0Y`21L<8#)C&$!G+',K6CE!`A+H#*Q>0,K:_,H1%DA-"280
M@!_8X'[7000B'),^(*`*"#NP_\$>#("]1RI/EW(`@0[@-2TQ0.$+2S"?%710
M`R`T0@4V^,$C:A"J$S"@"(6QGPMH4+]**"`3`%/@P`98`H,94`H#@P]ZT)&,
M0[HB"6TPQL0J-@<JY*`$*S&"%""`#1XDXPX]@`@`(K`3!KFL!!5H@SB8%B,_
M-"XA#5"`!J!HGPHH@0)CN=,M2O#&/S0``P(X@A3$"(N!DJ%HQ!B"0@U7Q#^L
M00!4`$#46L&$&)!A&4?,F@(@0#PEM(&?L*@C'T`T4`LTD0-F^P,1S!`!F60#
M8V!2@`5BP`<)&2$=5(A!FCQ(A0;$(&MG])L&B$``)2`4!P*`:MI<0882F.0/
M;-#B'?__$#D,$*`-8(R`%Z2`!`H0P`NM<*=@)57(P1I6+TD8``.P<X$+=`%?
MV)Q$`%Q3`P8HBP&>J0RN:H693U[F+Y/QU608,)H7G(`&`)F##YBP!SO`2UF[
M*5=N7*`(%[@@``$83R6JIZH=)(]:^2*F#A:@!Q2``0(34,,-QC`&&[A`6Y+!
MW@FXL``Y7%-?J*I?-@/P!2D`#&#I'*<4"'@P@Z5'G"=R9PD`H!6:0"0&K:B`
M%W:B@3NDS`)E$4`,I>"%LO"A%7^+@0`F`('`NF(.7O`!![C!`35,@(81\8$?
MVD0%+UQ$`1:.14PALIJ]M=,5_"T+#>=0$#-XP4:QJ(`K2M#_7[::K`&7R%A.
MDJ0&@)A!#2E[10R\`($V20$`'B+#'2K5!B]$@`(0+B09?.`#"_BA%3%`9P,(
M4,[%%8LK/B##)BX2@\65(`8RP@7;4(0F`)SD%G2CH08*<A*@>`%&"@"`'RG@
MU</:^2Z%O;.>WQ*$&IQ`!\<Q@!QT<`']J>`"K(H,\.K@%\MXEE.=[8SO3%G*
MX`2G!CK`0AMXX*PB<,&2L'+-M<KU'1KL#U76HNT/:&"='=2@F:`Z`QU8X`$0
M=$`+5VB`#W:ZW%^B80<,L`$-9F<"*P3`!+A=1#85H8@`"*$$<]!$.!$H;?(*
M@(#H5%@`T[MGMQ!`(MT.M[A=(8"!__:U%B2#18-ZH-9QNSLO>7[WN)%@@L$8
MP'3V>H0C+J`"VD&&,IFTE2<YVUG/^$5VHR2EI2%S@3QL85LG*((,]O`"Z!V@
M?=$S`0WJW0A4)\($S@W`"9CW@7[K@`4SX$(6P$""*VQ`77R`P+&Y=0('T$!5
M1:B!#6Q@'?LU&U6X5<1@R!!M47@7@)HH&`'G4#`#FD*=G."VO&/QMZE;7;`'
MN8@M4/P*"(SYZF!O2[S#;F<>!."QC<"F#B!A6VC*CI*2(:6CG6"[W#GZ+Y[Y
M%:Q&R^CO/?*5N#S!",;SO&61O`;)2QYM(^&":.I&!;ET!*;E\(,1M$`-)$@!
M&";@Y`D,,_]ZV5&!":ZSJM-R\W[:+4RR<6L"'VQBV@#T+M.O/=YK,QTUZO2N
M>\C.^][[_O=D'SOP#0F%TPU3/(-Y9'9BM:L#U$;NGMR,P#5#RLF(IK2CM$SR
MG%<N&WS@=308`0T>$`#;`MO2O'.F=>I-"9QCSQ'1^P`<;!``%*CA"LFD`AFT
M4!A<@N^:IV4%+P`JA.8=Z=-LN'4ZC>!ZXS5MKS<'LC=[UT9[M0=U1V=@PY>!
M&KB!'.@PPM>!FZ,':+!VSX5L<B`>L^$LEO4!F/4"N!-I=&<[O>(K"!<<S$49
MOE)RSG)Q/Z!SD($&!A`&M)4JE.`\-F`"MW5L]08OH_<#0!!-N.3_9Z2S!R&P
M!"*P`1%%!3)`6^6G6]!D+WB@'?7V'=NU>HP@!Q,6>^&D>TS7AN/5AJMA"M*6
M,"!8AW9XAW@("Q^8AY:2`B)'3(90+=P2&Z05&97A@C"(*YK1*[-#6I]!2KMB
M`R/W&(KD?)#A&A_@`'9@`^`Q>H^$"/8B!X)(>3_@A+I1+KQQ<S^0`1!``%>H
M+BC``$]P`?63@M$4`+(C'LYD@%QXAD%W`Z5@=$;W71'8AL8X>^<T3NO$A\S8
MC,XX=7OXC'IQ!A&G?EV@<47@6S9X@W6`!YI$*YP1C@-0*Z0$6I!!.[T2+8CP
M/,\#=]"3&#J'!E8`28_4&"JP>-L$'OO3_SZ(,`GPLANTE1AA\&UI`&,*,`1P
M@#Z4\'W\^``GL"V-96K8A%OY$G3W<@44J'L:^88'PW1OV(`<*0#9IDX:(HTF
M>9(H*4C1F))RP0+V$BKX\AH@)QF-6(Z8P2DX27=^,8,#T'PW^`+)TS[7LH[:
M<@`!X%NN@6PC<#\FP!@@ESX,H(O;-$S@@3V,02W8$@!^A@#LE0(.U@`,X`0U
MP%S/(TN0IRPN@``98&JWE2]N.6@N$`9:QH8:"8=+!X%'1Y>C,"S45I(L^9>`
M&9AX)ICTP0*$%B_'YFI]5P>O`AHW>2OA*(/IR#O!<7V>(GKA0PGVV!L'``=U
M4"TZP`7.I(_(`_\]O0$)BR`'I7>6GV("W4,#8[`'4+`%2T`'(@`!.0!*</`"
M-L`M)3<>D?%J!K`J!S@8;LE-74`%(AF!Q;ATMN>1PRA[4M"1J;![A'F=V)F=
MMZ"==L$#+C!HNC%9/Q`9I,4[F@5I<W<9NPD:H+5WS\=<!Y`;C?%JV-,8$6<#
MI%0N/R`'7)!OD0`^-B`<-""(MT4)V*,\L'4OX\$%(:`'6Y`&_,0&H-09\"*3
M1?`!//@:NF%J0I=LA$8`%.B1;%A>'<F<YT&7IY$,H9!MW-FB+BJ-*_FBKF!V
MC76$0.!G-J!8SL=HD*:>D.F-I12D./@KEL4;0``]KP%Y/2@9EE$#V,+_!>"I
MH;D4'.F32R:@`[GQ&M#C/*KI`&BP`"#@H%_`7@IP!*'DC;CAB<`F:BXP+09(
MD<QF`EJ@`7CIAA\I@7@9@=*&HM<V,.AD6.O57E_F"A"F5_`E(7(A`"1D%XAJ
M"V=V91;21AA6%S'@`Q'0)J[096&48;%``0P%%UQ#"Z$*"W\#(VP#7S317W-0
M*25`!H`EHW@8HS+*`T`H!SN@`QCZ`9EDB)KUC;BBGG]1&S@XCM5G6:_6/J\A
MB7]8E)3I&;DA!PN`:/T(>3O@&KM!"??3?JZVI0$@;'N0!<4UII8*``R@FP.8
MI),$+]NR*MM4D<LV`A80HF[HD7"XG"*ZIW4Z_WNZMPJ&!4\1X",^$#E&-#%O
M1@PM%A<L(Q<;4"ET8PMRX$&N,`16PA465A88$`41T`1:QP.(.@%WP%$N]`I(
MH&)QT;"R8+)W,P%F,"A_L`/T%!!FH'\V<!%$H``Q@#:P6H>R^J(]T$W#!!F7
MQ)B?T4F9<1EX4$J3L9.[Z2L'X'UB&#T[@`@,J3R4=$ECT$P!$*W(,0F0!TDZ
M$`GB@5M)6G*N%AB-H')9(`+'%0%@T`2@)`'1(GI-68H[T%CV"4FBXHLN8``3
M4$[Y>HS%*))V^GHH"H&K<8&#50&AJB@H,[!(\&$#"PN*"Q`48`$1X`80P3="
M$0OZH&85``"OZ@K^$/\6&Z(/BZ,Q[<8#32``5((#_L0,.88!Q/!1<(0#,<2R
M$-,-#V0!;E`!6@4W&B!?$>"Q4T,`!;`X<P```-`**`LH`'`/2"`'4A`3@/0*
M?-`#%?`T0:!U.=N!.^NB++`_IS6><"<:N9*(MK.(?Q%WLN,[I!,]KH24/;@\
MRE,N&'I)+W!H"U`8CB%;&N<"_KB+X[$#8]`^RB(J.F!<(@``K3@!%S``;_L;
M!CHMLL$(W]$8]T(8%4D#"*`!MM><@'NG('ETX/2&MU=T&&A(.Q4Q^:$`.D`!
M,P%%L%`R820`:_,'+T``R14H)=``"?$*$<(!^.$';!`#00!57`(!BT,#5+#_
M`04P!T9P,A#Q"DS@!5Z`-W%V#QJ@!"DCNWMC)@3`%#QR"S@;#TER!`CE`\!@
M10J0`V;`!E243QVT#&NC'Y'["A(S,671`PF@%'.PPJ^0`SW@0EZPJ-VK@=_;
MHCV[<45I@Y0A<(E8*XT&I,&J<*2C+*6H/,*1R8D1/NZC2,]3"0NP=JKR"/=8
MCZI26Y.0':Z4/$5P`@:``AZ``&#P#"E``V@`!W"KI.`3&!6J=K356!296P9`
M!7X[G28,N`6SD7FJAL9X,'3H3H",'Q03!1`0P[%0`!`&8A,P!-@0.0AR(WOS
MPZX0!04!.&$U%5'#-F;D-WY#NE3L)AC`#3R01@\D_P!E`")>'`-6T@0$D`!:
ML0MD#`MN<!$4<`1LHR5,$`%VLPQV0S<YX#6NP`!W'+&NX`-:L4=!$`5_O*@6
M,+%_0`8/=,@;F,C<V0.C!QN6-#OMFXB=I;Z?$=.4A'B0T3RO5@.>XGA"&;_(
M6G,+L"K"DUOA(0D#BDV(D0CL<Z6[4016@``GD`8MD`4QIP)=<+7OU\MD&[63
M,'JLIGJH@@8-<$X0.-;S>HSM4:?[>AYD/9VG,2PI+$A^@*B*<@])8"4\$+)W
ML\U&I`%1\,WC?#/C#`MV<B46D,YMP\Y[@P$3T``:`*FNL`P^H`3<X,T^4"*O
MX"5>+!1FX,T3P`8?`F!K\?\'!>T*?@4,\]4$%-#0O(`-$"T%`GT`%3W&7G`2
M,P$!;#`'(@T+9\16(TW2&6C2VLD#TO*0AKB3X_B8-UF.1[MPS/4I".I*T*.?
MP6F@[-A^I5@]%X`%8#N@JU(8]6,=NW$!#/"0SO(!L?0!8F``/S`#+)`"!,`'
M58``,0E-U](O12F)SH0O%BD'5=`&)0K"R7PP#UC"A+L)?PO-#>-.`4$35A)!
M7C`3$R!3E9(`F.H*0^+7++,0"D#.$:8,4F#8-Z$`S)O8&A`$%``*L+`,%/`"
M&A`#5X0$K4H!4H`?&!#62D`&!.8**K!C_>1'K_`,(#:P%N0CJFTW?<7/1B(`
M;;#_#'QR$Q?QN`,K!7B0$T>@&MRPVQ0;$67AV\`'W-G)`C=]CJ/1:)$&F94,
MB;(C&C6->,J"I".G+%EZ+5R+A``L>I7``H@PD0>H;]?A2LP43=7Z?4CJ2`;P
M!6D[`Q!``D)P/_#"CI*`A*0#"=A$&,H6`%,0`8=[C&6MZ6\8'R2\K\Q,0/PJ
M6'Z0`!P=J7^@6JX``&707D[4,@7`!RN!%'-P$E0`T.J<#21P#S#%"]S[!VV0
M`#*%#;VN``G@!A5N$!<]!WZ09&F"`SA0%U2``6]F$"[T8!3@%$S`!`9F!ADT
MO0E0*2.[-Q=&[ESQ"XL3`VYP!\D0`04PQ>W@!N%^T:XP_P&M4.I1@+QCE@07
MT8I<WN7_+@LYH"R(5]R;4>:<L;2RTI.4$1Q-:P(%SY#/HW,5JIF.\6>/8"V]
M)`3?=Z6H\AW],A[05`0]F$N?$CT&N`=B@&,@X`%8L`7>(WK0)(GZZ$CW"'1O
M601VT+?0ELQU6=8F_'K"N(8;67OM\=;CY@9;GH?)OB%*)@`H.TA+%/"_3?4E
M`8^5.8YUA_#4=[38U]S*\XZD$TUAWSZ\\8^O84L9WQBXX3T,($VVI3^20"VK
M@AW>]SS>YQH!D`@7L`5J8`%0(`18$`>X>``Z@)^_`1[?"<#.-,SV(P(>;!Z:
M;I=W.M8B23"@OJ?K(7L&`[GN1O\!32Z-'%#&/G#$@U4`36_UP:?Z&\2".-@7
MZ8G<GD$9HK&^BI88\#BUUQT>E/!(E*`_I[8_+H!I,*`L7LL__1()];ASWJ<L
M>3^>4P`"63`!>C`#4``#[$D#!]`91]@8C#'I%"D'-'`!"]`&2C?YE`^2]+KY
M2*<*;(B,J<_Z\C__F>+EV-D#.#VLNN-)F`$(`X*"+W5U+X@,!S6,'XYC-3\[
M.R<J*D!%)Y(JDD`Z+D`F)IP_!T!B.YTN+D6M0">B)[*D.YR6/RY[&6%5#5<;
M"`<2$G!CD#5`0#^9)S1R<@$ZT3H&%7-S`E+7U]K;VP)S4N+C4ASD'.CIZ.3=
MV'-_\/'_\O/T]?;W^/GZ^_S]_O\``PH<2+"@P8,($R*TH+"APX?R<ARH,Z;.
M`#QP!CAQ`F<CQT)C7@QX,8;!"P8E#WRP\:$&@SI.ZGSXH:(6K%&4?M2PP>K$
M*Q6:6EY`<**("A.NBN@H0@E(35E0=]A@MB(%E@5Y2/A0H\+)L#H,6!X($(#!
M#DS2`LBY<$%.$0@"XH;SUDWN-7#:QH5;)VZ=WW1ZLV&#2+BPX<.($RM>S%@Q
MP\:0#R,Y=$BC$SP;,5\>B0@110:@#RAB=*"T(DD_?MPT(6O4!Y&$IE;:X>@)
ME@^L@;!J10-4,M9`H09'<Z8#B!8M0C00L<>K!(H'1CE+AHNL__4`K-*8B0O.
M6W<I=MWIY4:AW#AS?\T%UB8@LOOW\./+GT_?X./Z^/L%$2D2CF:/&V4$1V>>
MG;1(::4QHDA+-5A"@U&PA/+!1!35,>`'D]CP@PX>M&`"*R[0T%L1-.B@`PTF
M4%<+<"J(@<(5*<2!@AXB0''"`,/@<<),/P0PQ0@+.*`4-&29*$<5,7`'3G=,
M=B/.-D]RPT%YZIFGCGKK?/-.?EQVZ>678(8ISWUB?IE$9Q=YA%E'&'%D2($G
MU<`@(S_8P,!.+-7T"B4[B$+;G9&X5`=-&A:!!0)(E=B;B":Z8,(F&/Z0XC((
M;-%!'R1<H84:>R#BE1,,="*#&"*(D/^6=286\0`?<97`I'?AD*,E-W,`UE=?
M5]H:JQ1E]NKKK\`&^P^9PLYW)B+^J=G1@"_`,6!()(V1X$P3'B#62G4^)4LH
M3J56RP\?P(+B)2H4H<<**NB0XBJ8T&#`!>H>=8)4ETREPP4CA(!"!V``\`9'
MPR`R@!P/Z""'!Q]"\XDT0'0Q@9+>8+/DKD[F=0Y??IUWY7GB%.OQQR"'+!^Q
M(D.6Q`#.XO$?1AD9,@A)AJ@D\X&+T'E`+:]`E4Q0-\EB`TEPU,`*$%E,<501
M(988P`YHZ%!)2RW15H-*/P#QKAPBL+!`&!=TY80Q`6!QP;MR7D`6#;HMY8,9
M);3-W3:NXB7_:ZQ0UFJK.AKG^F1[)??M]]^``T1RX(>=S.9_EPG,WQB"A/9!
M6.`VDF"=E?1L25"XJ7:"#0,:DDR)`%R0(A`!//``&G(`E38SJN5IP@=J?2`'
M%F$($<<,!F0TQ@<R8`?O,B[(<6(1H6SA=MO?A,<-.U'&RM>NZ.6*]SB$5V_]
M]2(/CKU#1JC,LG\J<V9,(1/%V=(B8AVXTR9`63**:K2AIHE.*]F0HC1@R-$N
M$`Y,(4=ON2G"*(#"&@R=P`6B.P`76#`%&9Q!"R@P@;0.X#03*2-X.D@&\590
M@;:5P!T@C!A>]J*>Y4F!2NP`C/1LQ:OMN?"%,,2/]F)H$"-<QEDX_\P(@0Y!
MDM`@:!&/`]1,4@$4&P#%)I3PR0!-,(*F>6L9`;@`!+K@@J+8X`1+>1!4<I.*
M5R@C5)N3@Q`Z$``3L``*6)A(G]#6DP.B#2@_>``5!."VB$G,CA;#E3E,6`Z^
MY$UZU*.A(`=)2,+,L)``Z5YFOL<9_@@B)3^D5DGDM`E*O$Y2J8$*+/KT`P,8
MQPZ/X@06K:``+B1-@R[(8&N\^`$#&,`$.E`!U6B`A2UHP01R:`$*<E>'Z'"+
M-1_"1-6*``"V=>>.R8,27C@`/2S5BGE]7"$+$4G-:EJ3'X>\ICX4Z9&,H*R'
M(L'#`$`3&D88T254HTFV;*$)2N1)E$"0`?\"6B`'&Y3QBD!@001`X`FDG0@(
M#P(F4S"1@0"4:Q(86@`4-M"`%E3A"S+HS*`"0(.;A`(6DD"`!CS(I%?A<2Y[
MH1C%I$>!Z)D4'=?0IDI76LULLK0>-L2(RIPU$HHPKA"%0,D$52*GTLQ$0_2B
MR2QJT3Z6?$!:[2M1*(PR@B]H042]2>5N,B&*90@P1*^;D!P0\(4)^&`").!"
M+P\0$QTXP``^2<8K)#$""[@J>6^+RY/&,]<JE0-*+(PFWJ;7PI?Z]:_7<RE@
MX1%3_PBHICP$2VA0`IJ>,F)]J7E*9*MJQ".N)#0`S2`!59`!.H`!#20:@>C&
MA0G:M$0.H""J"J;_L(`SH```$U"`#_8`B3NIP&P5[(EJ+D``MX%'8F^CVZ[X
MR#SG1>^/*^SC8)?+W.PU%Q_=PR%G*B,(BISD?(JPUM08@*U:2&5>WGI:9>?E
MB/(>+12P/`$+;@`"(2"-HB;800T.F`H7C&`/(Y##CG!1`RR<`00=6`($")"&
M"2'"7L1K!7#ZI(:-9N.W2CIF.R@&S2?=385ZE.9S-\SA,@EVL$:@J6=0`IL!
M\)"[HB'-^7II`TIPPHB22`6/<L(2.MG`!IYXT+TN`(0;B&$!=*"H)4BGB1<?
M@&!R`-<'AM2"./"+`#-8``T4(1)89G`9K*G%`?*@`;9Q8TG!%0\?[6H>_[T"
M$DOIN5*'U\QF&;8Y'B'6W6>:58A>2HL1DV30XPK1(/*F!D-2J<$DZN0(E^PD
M$BX(`(3N%8`,>``&:4#MYYZ@`R4?("134W+8SK@%,#3`!RHP`!!:P@`XG`5U
M59O$O.00`=].++B"H;#&V+&7DO8Q+W:59CK>S.M>,^;#@#V9B5\"FXP<@'R.
M\"F#:'.1.NR$%(ZHL9QNK*'4W%A.CM"-6BMA@"=XP`X(@($H&,`6%=A@IS31
MGPI&@``2:.'=$%#`!F;RJ-=@Y`4`5?"\=``!ML4-N&"VHS>.V[QL^#'#NE:S
MKQ?.\(<`^Z]G`@ML",2``?SPL8T02V-38VT>U?^)VF)Y+,?E!0L!&DR,,-A#
M%HBG`Q0L().;J,0/0",'.H@```T```$LP(5PT8`E%9E7,'-6A`UH`,QV@=B$
M)SS<6TL)8PE/1TG5T?"J6[T@#_=K$$I#"$+D=*>C:42UIK8(J51;)X\%.=0B
M*PD3/,@3%*4!15=@!QUHX0(#^$`LP76"LJN@)6/XP0Q($.\)9&$+/J@T%L6B
M`KEO&RA8(,,'DRD7N2Q=5BFLV$FC/G6%7_WSH-='UE\:!)1TO8?D%$W8*1FY
MJ<D)VT"=MK5OO'8XJN832&F4`6BP@`R<H`HR*$T`/#!J!EEBNU/0PH`AP()Y
M@J`E/EG)`1R`'05;P@7_$"A!E"(<9@E7>&[H0>Z5.M]YJH?^_.@?4Z_/-(@!
MB>;B"*H6QVV@^OKQ2$,J^1:U(N$(&=M/T6C3"B<P!470>SMP`70`+JG$">&2
M(G^22VFP!7E0!;?3<\5P%!/"`+WQ>!_B`^'0?2$D:]]W*[=V'E02=;F2?BIX
M?J/'4G%V$B-1$:IW)PQ"?X&B9],6;7^V".P#+AHR(3L`&JIQ"1OX(5@`!$(P
M!8Z0!TZ!7CM"(B:P$P=P`5B0!1X0!C-P!BUP`1O1($7P&B\@"E75+1=@`04'
M0L=D<"2H%^=P,5629BJD:RLXAU?7@BN5!,XB42%A#(UE5#H!+F&Q9S18:#/A
M_U@?4!.EP1)*)FA-80(!``-HE4]`X`$9H!-8L`>:=`+SY13O9P!1)@0+@`4S
MD`$O(`'S%2HU<!*9."\JT`+:!U*P1A??YSP<8QZV-B48YH8K1(>\R'!VJ%+"
MUD.,4PROYU-H!XB*4'&`(G8M06A2"`D:H@D:DALF,@-8@#8?X!094(D?\`!"
M8`M2(R><8`HC<$8V@``+@`8G4%8Z,!/'%AUB>!0J$`86(!AU@89W03=SQ89^
M=&9[]8\:UHL"^6:_J$TG\R8E<0@'P`G;)7TJ46BB`1:O1TFL9U2*0%29I`BC
M<`%=8`!]L@?^HP.@R!I#H0E^MA.PH`(P$`=Y<`47(/\##-`%E78449B*![`:
MH7`4!&`&=X5,L_)@>81YT[,QZ'&+*&A^`YF4'%:0UQ0$/#1!0D@_.S$ATW9M
MH4%["E)MYO0XC=-=Y@8_H5!%.R`#`+``0``#"S`).E`%X&5$\G6(]X(`!#`!
M$&`%S2(I=R(I>+8A\B(O6'!T>]1]QR1<M#9KN(:+%H.8`"F'2MF8S<64UA0$
M%7$2QL!3W.6#KH=MCD`1M,<@0(0@LH0(F&%QWU(Y8OB2I.,`L#`%'G!%)W`&
MLE`+-+`#!_`#<K`+('`%#4``(+`#G:.*`?`(SM`:EC`"?*!]@7D7$`,E%=9,
M3L)7)W24XT<!CEF=@P69U53_>A5Q5&8A?]-&=@_9$H@P=N<C,U-C`S4`%C"!
M!^FT12Z@`BX0)`>4#!F0EJP!`N%5!/9S`:R%``A`!_[)`G2P!Q+P-;M3!!$9
M"[B@&B)@!G;#'LH99L95F'ITF%C2%T9YE!1`G=;9H2R%G=2DG<9`=H\3GC:8
MF:71+-E%&C937LD6D3/'`'^797_R$_-R`G:0EJG1FT1%?_($`E^``O]U`RGP
M!1"@!B*Q5BJ`(X-R%'TB!P"0)%,'H0`WF&O(AA4:384YE"25@A[ZI=<$HHBT
M=:91,V-W<=>F>GRX7:I7,U-#E2FZ)K;U=U,#1Q%"(@ZP`EFV`$[#&L=&`S.0
M!1L@_P)Q@`9/H`=+T``0<`%CD`PV@`8_=X@N!@0(P)-X$X*#62NR5C=EMC'-
M5'X;BHL)!Z:D2DUB6DBEER#HF8S2,B$>AUVB41*,98Q4"2WD9!+CE!H[(R\V
M,30FD`%"\&<L$`#*8&@RD`<=0``DD*,@H`4;0`!4(%]N=P(74$5(H0PZ\`0-
M4"OE!QZ61UPB.`[@`'5DABMF=H)Z%:KH4*KL.DBG2DBIBFV/E8AULH,)XA*3
M9!++B"WE^7XN<2=]4CGM$Q2@,`IV``.1\`,(8`#M*)%8(`(;``$>P%XIL`0B
M0)>.2"Z5\!NCX``(4`%ZDX\B&S'E.H(EJZ5Q.'Y>VJXLZ_]"[SI(6[<2:^=Z
MK@J>/^0X$]$@YH2>UE)>K\==J9`3FH038F@"*W`#DJ("-W`!-E`'>``$#^`!
M>I`!2@`$*``%7Z`&$+`!0,!)ML"Q!H4&#2``>36R`O>@;1@EQ55F:RB=N]:R
M<!M8O88$JDI))5JB&#>#[W<@AXB>.:ADA)*>ZD1?/B%`/H%5J;``"#,O:'`#
MY\8``5".5@`N>Y`&>I`%$#`!83``1D5_-J!4CO@&)P`!=F-7RBF+`U<E>Y&8
M!T=A4Y)A4U=^TA.WM$LX+RM(\6I:YW-GV35)98H@-'ACUN9Z/+@2%W$SIU!&
M1U,U;J=?/O%M-J@">5!/)>(`,O#_`7"@`PB`!71P!1/@`0-0`\3SGB^0C<J0
M"2B0`A"@I7UQNLQ)*Q;&3&Q[:\^30K+KMK6;OWYSNS04LSSU>G9B+:U:"J*1
M4WOKD!`Y,S5@`'+`GK(4'9(""R<0``Q,DT6Q``_@MS;@`4G6,"RP`R:V`U@@
M(VIP!6,`!Y(2"K9919>@O2`K#E/J=.$Q'A-*0B.80E-R@M*DKIZGOS[L,?P;
M0W2;(`LBLS03?ZNZHD9<Q-BF$B8P!2>`!S]EN$^S#$NF%K2A7@:0B"J``!=P
M@",P:A-!`R%P!5^``'(P$EC43U,0`)*B`V$0`^6@P[?"3#-,5S@<E&Q;0G:3
MH7J3P^2W_ZX_/,C"$L0PA`0HT6+$*S/<)78_"QHNRA+55F.+($L?8"$+N4:I
M\'&<!"3Y=P9[(%1`H`8YT#!E)`U=P`4D0`!'>,FX\2&X90"6,`4*<$(\G"MX
MA,=UM4?,PT+7@`Y^+'511\C$_"N&_$*(?)F+G%TU0T[H9`S44HBI4&/E21''
M.UGU6D2TN0<.,`DF@#NI<)/<>T#E(D\=8`=8\`#S=8A>1!,4!009<*@E<,N`
M%#$4V@[0-#W,"<S,)*HJZ\](6<P"_27'[$)#?(/;19DUHWI3LZ:-P`BW,">.
M8'HO\&R6P`FI,`I3*`25EAIH?&EP`#LA4*P!,`-:0``((`-.8/]/N@$4:W$B
M)K(`(;`$,0#0&V,>6M*<\'LQVT<W_)RN?A&[ZC!U`UW47E+0VW/0Z'D^-IML
MY2218F<MK0=$^&<(DAJ;&:V?0+`'/$9$-M`"4V815P0#.H">3Q`"6>!5*?`"
M^A,N,EH$:$"L)A`&A#<!.1QUOV4Q<T&AKDMFNW*_"3?'HFK4A.UFO$:W%$EJ
M8:%L*L;,K6?5#YD:CLR#$@P+<!P`.R('>IJ2EI`"`=`@K>0"*S`"-7`!6P`%
M4"`""#`#R#!MSC`"74`6-Q`!$'"DT8G7XK%'^=C+QZ7;0HEF](R"A3W<(S.W
MC96#Q0@HQPT:?ELM5[F5_)=BJA%?D47_/%;C`AF@+J/@A0A@4#10`SI0`UW`
MIS,0!V<0!PB0`6(5OD=A5@RK`U:POA;@`SY@9@@'&"!%*\,E:Z;;=$ZG#245
MW%(7NQQ*W`8.&4B-/<E<C(_UHN\'>'=2&CJ!(`U.E2IF1*Y!:)JXD%$42U6%
M2QP=;:ET`H.'`BAP.RNI`PS@$_/5%F1A!QM0TU)0`F9P4F9VTVJ;84OW/`+W
M1]$IX/P\V`<^Y(N1X->3S#\T+:3AIBCQO^29P"^J@Y/@8H0VC67D$[;0!0Z`
ME;:P`%J0!5\`RFC0`IY@!5W0+#1P`33P!%I@`34NJC@L36TX4C?<#G*CH;JV
MH42^YXAAY-:#_^0)$NAA1VI03<3I!)'4S''><M&7<]'$@Q07G7(U@='Q1`)9
M@`)?L``FX`!"`"\WX,5*X$JS,P%^D#<W?N/X36'$A=-SL\^W'.#2J>=\/NL0
MX>?5D\QW4D[_.AH3PCA0>:^L5R<8!U2;7`F6D"'AHD%*!!0+\(4W<T53H`=@
MH`8D``8KH!K(`#O<+`,7@`8(L`$6$%*GWJ7X+5=DIKHVK-_["(=^3,_J2NOP
MWA"V3CBX7G]L>J\%'(@ME@H9=SZV"40_94"5A4EIY;Q[HEZ:D"(IT@4W$`)J
M8`$*D`<F,$X2\@-[8`5HL`<@0``:P$SND&NHCLLBM>IK*"6'2;]#??_7&PK8
M@ASO+H]UO59ZJ9>P#%UHC*4A#8EQY:4(1=!GDN`(X!4<FC.$55-1E[``JJ,)
M!_`$")`")$`"*``!<E`'1W$!#K`'>Q``>R`',A`'$7#'<9Y<OIWCNMB/Z6&"
MBGEK0CV[+]_V`C'O@2/S#RY]*&'S%<%=&8AL--O0D>`G@-L^1^$,+F";E2`*
M7?N(\AC.17`#J$T'69"`C9<B#_`$#N``;'$!&;`$?O!!(Y3/P`S8>0T]>J$W
M**\.M2:[K[Z+;K_Z_@#W@).J*9:9*/&O#KWDM>FS;+H3,N98MG>`*=)XU@(+
M+K`#'0E+2&/)4Y"^4/!4RG`)470!6+\'[V+_`!X@`@K@8-C@^<F5X\M#0FC6
MAG_LSZ%*?D#.^N:_#Z[_-XA-O*.Q""^!$F"!Q`U""O0'&M)B5'D;+I)5%*``
M""<_/R=`12I"`08!%Q<'!RYB(1U+*#LZ)SH777M[#@9H!HU/"QMD9B4"<ZM2
MK5)S4ARR'!2SLZ^PKZVPMJVWOK*UM[2V%,(<4L;*M,<<?\_0T=+3U-76U]C9
MVMO<W=[?X.'BX^3EYN?HYQ;I[.WNT4@U-8_S!PQC!S_U8R\,-1\`_ZD85&-,
M'08'`'ZPH?"1#14[5!0R8:((D!,["`$Q`43'#!<&Y,@P<4!%F!8=.K`(4&0/
MFD\&NGQR$*K1!2LL_R:4*(%*U1Q5NGHALX7L)ZM8L3CPZI64&-&G0ITRF^KL
MG=6K6+-JW<JUJ]>MZ[Z*S1IOGKQY#.H<V/'A49TQ\C[\^%"#88U[`UXD'"27
MH0V!&$]0W$AQ8D<@0!Y@D3/CS`4@/W0L6(&`B\03`5RBV2R*LTT=3X1$T,`S
MU:JC28$U18I:M:Q71)M"?6J,V+':Q\;JWLV[M^_?P,N%#4Z<&Y(#\O[*LY=P
M^8L!C_JJL,$`X8?J?@$.LO'#QHD3$BE>_FZ"A@D7%^0`8<'"`P($&1:HWV-`
M!Q"V<@S8V?-@RB=/-:6GR!,M3-`&*F:H(H!/J:W68"ZY-.C+:J_%(HR%4/\E
M4TLSM<U2W(<@ABCBB"1*,UR)(I95@S[SC('0(\B-@4<=*]I5'4#^)&0#=S:P
M]4%&W1%F@F`#%;(1$$)PH4,<-X1`!PH;`#"%'`'H$$``5#ZPAQPP""%#(PYT
MP8EG`72101X5()C*@KF\AHPKOYPVAU"NN3G4F[/<UB&&MC4C!8J`!BKHH(1Z
M<V*AO\5CCSSWO/A(=6,,`)=UU]ESD`W,23=(1BY,5$@1+FQ4A`X<F6"`EFE@
MH04E#2Q@@@HJ!,`%&G)X8H`!(TSQ1".>.."`2R$Q8D48/B3(4T\++DA+A!+J
M@I2#LT75##,<%C,MHMAFJ^VVOAW*K5A(M$5/6O[_+%?0<Y+Z,Q<^;=%5W8H2
MQ1N1'*,&8`BHB.F@PP\TN$##'C!DD<(6(>@A@@'^V)"!&E@4@<8>77#!@A`/
MT/2K)_2)(L<F4VA1P4YFH+*3::RY8O+)<%9X9[2S54M4A\1\*_/,--<,CK<V
M9Y5#NVU5AUR+"/$#!XT,J9O0#LAQ]Z-%X$D$A`HTZ$!#ORY8*<</#,BAPPI5
MG`'&%AV@D`44(3D`!!9JS/!$%PL@@(45+VT&TZ_!4HE&!@A`L.:QR*ZB%+.`
MM_FFR5&Q3-N&MP7C8<Z,-^[XMC@_WDZX<=$#HT'X,&=NS_\,,A"F-E0TD`GV
MZ6M?$7+(D0D:0'P`RA<3_P#0P0(=0-``"Q>`=P$,H)@IPV:;Z7O!KR]]<@$:
M%]RZQYD*_`2RFB2W9K)1J@%3N+4OYQD,XMHC(_GWX(=?7.3BEZ,BC'+M@.F*
M,%JWG3U\R3677-\A5H08^EI4A$55%A&`"S^X0`A\$`$(;.`):D#`$U(G#TWL
MX0E/X,+Q9(*\XKU$)O390_(,`+`PZ*$";!)`:4;F$U;("1:K$$#UGL*G[%%K
M6DF!&5'*1\,:VO`JY+OA-X[S,^0LQ%TQ&L/\JG.C?^QH$-WY`:PX,I<`D"Y?
M.BA"U!1Q`1W8``%4X(,"`'`&$E!)!ETX@0T"L)FU>6`$,K#"$SI!$T_(Q%>W
MNO]5>J8P@SB@:4TB?)YI?E)"$YXF9;%AF3`&*</N/46'B$RD(K>1PT5F@X<^
M5(BX@@:'O+S`"4Y@P%Q^X$3$L.4'$1$,1O8'!!H8PDH7N-(A:,`%,5S!`E10
M0`KB`+$P'4(1G1C!`[@P@K7!)!06Y&`<D_<2#[#@!@U(Q=[TB$<VG9!Z+&SA
MM#@TR#Q-:X:.S*8V$=G(;5+C./5847?:4@\&P$$"`R`B=^92*A5HYR%/^XX.
M7*"U45E):BM(G0S.L`4U\&$"6?"`%0SP!%&80!$&^)45C$>36STL3%H2A1QI
MM4$[+$`,'8C!'$B81S4M:"?./(TJ\&0X%VYO0]:$BC#_O,G2EDJNFRY]!A(0
M\J)__.PN!S`(`^A"B$T-P@2#`,\.*.("%U1DGE6Z4@NT$`8@($!66(#"%1H`
M`0)L(0-5M%+4CK<V-'3A2R&10Q<>0,%A)H^8H>#@"(1@A3@82`HB%)DRUY1"
MNO)Q37"Z9BUD(Y6I%+)E%(BI8`?++9C&5%$O"@A:<EK3<>ZH+ACY49%.8%0@
M5"UU19`'"*``@CCH@`5;0(`!4M`!`J@!`A*40RA21R75NL0!4Q"#)Z;0A81J
M30X-C6,M=?L$&2R@!0I081Y!*@"1*2A9S5Q07DNZLF7P51DP@RYAITM=01G6
MI>'2G$(62Q?T`60Z"ZD(8D[P_P'PN`!+5[+/&)PP`!2<00=A$(,>.J"'&>@!
M#`!(FPY44(1@-2(_#GB"%6X@4%^)B5ZJ%5/&O&HQF"1O#PL(00/(4-=F'BNY
MPW6F]0SI%#U!MZ3+J*Z(1PRBZ[:T+-')3G=[*$XEPDHBI!+E=XHP`CN0\0E%
M<`(<@,`%.R!`!"E`01S20((.7"$+34T(EC:HO#")Z0D.L(*98/")"Q+OH6+:
M#+`X"(,6J*%8*?RH*D9&7!$F*UE\G!-S[712/:E4%B2.LYQY8V*6(L%%R,G(
M613RTU!"A!!#N@ADGG8>U-W@`D(P0!$(@08/@*`!8-!"5:NZ`C'0X0,OL,'Q
M3B4#4/\PV%9HL(('IJ!+*;>Q>+X*$TT>U@E:/<$#*8!`!8R21P7)54$<-;.9
MU1S([34E<7Z]IE-\4P(U8,`+9)BSLEM:9V_F`"'SV)$D^Z+$'>Q`J$HLPJM^
M<!_^U7:>&=@"W/+3'BPLH0-:H((%8D``&\C@!B\X02K1`$;DW8IN#IBW&&H+
M,5H-Z(VM;G4<1>$`+LP@"S[0``?.S*8+X]JX'R6AFC'$:UHDPS:*.RDR9+A2
MWE3@`TPH0`]ZL`TO"&`;$_#!LE>>K69O$YQ&-,M"D.C.C;Q8GJ<#`DL8H(*+
M*CIY3T"`'F#`@C-,8@D-6+<&5O"!+5Q`!5WX'PQNX(#\)!3_@P^P`QQ])8.K
MQ:J,8W+HEAUJ`!A@00P0(,-Q=SVRGCB/S,@EH52JJ3CH+N-PQ8#S;N;P@@D\
M(P9W^(,4U."&"/S!#VEO@!LT</@#%$#E?"A``XP!`3Y4``-4^(,9Y$`$"/S!
M`A@H@,M93OJOC#Z;.:@+0/(\/[G\(Y2"N5=%'$9%.:B`"U6G@0/HH(8EB$`/
M`/A"'%(`!A^<@@]"6`$+2B?6+Z7:8IHIWA-6D($SP"#49#7UQ5B=5CG*X0DL
M``$!-(#"B,.B-*AP7MQ!NC<!Y%VE*'VA->G>"M[X0`*!A08'V'`'!<AA`AH0
M!$/@`UY@`W^@`2I``!4P`4;@!UYP_P0<4`9-X`83@`?!901!0`43H`0Q``!(
M4'H@&"*GYT@]<!GNU!?3!@1[$"H5X0+\`P-VL`@'A0#V)@<F,`4$,`$HL`7S
MA0):``800`45T`85X`,0H`./$``R,`)QM$;Y-E%0QC8S<'40M#90EFIBXBL"
M%Q)<=@8`8`$EP$>XME$A0URF@4=P5UPJY&86TB&$A!L?=DB[00`2(`U>T`3/
MX`-)\`=E4`#/@']_0`.,EP0%$$L2@'@_\`Q'X(<]4`9_0`!U0`!DD'\A6(G`
M,8*+A`3K=$2@A$3CY`).4TI`8`,PD`8CD&^:X`$:)`<[,`9%X`%0@`(A$`)Q
MT`$B```$H/\`9$`&%A`!4/`!*G`!#[`K#F5E#65@`C8"3^8`#R`#5_A\8=)5
M-M$(N,("*,`')?`*9[8F(6-<:;B-<'=Q5"%_&O="TV0,'B<!,?`,`D`&"3`$
MSZ``\%@&GO<'@"B(?S`$4>`#_"@`$)`#BLB(CO@'5)``-'`$EIB0W:)L.[,=
MGO-BL`)*0W4>3X0Z3Z`#72`$(Z`%B_$__9)*UH@"*:`%:@``$``!"J!N%@`!
MN2,K6+4QJ*9JRI-05R@W7;!&5P(Q67B3SH@\9Y4Z#R`$"#`!,1"&SK-1"]*-
M9IAK859F>/<R;DA(L]$;1M`$&D`!/E`&?C`&?*`!1N`%%,`$&_#_!QP@`7_2
M!!$P!W=(!ARP#AL0!,;0!%[P!SP0!%+`!TQP@`>@D'RI&YBH2#T@/P\Y'DW#
M$::D"7*0:')``QD``@&@!55P)1G0`C=P=C,`!7KP:#ZP`0TP`1"``!O@`Y$I
M"C?0!4S6"9T@$YZF9?^Q6D50"+C55='X`!63'JFC5D+``@#`!S$P9G-%AF48
M<=]85Q_%"U(Y?U&Y/5/9&U'P`1)@`VKPB`?P`A_(!U-#`7=``WKP!P7@!/#8
M`PSP`D00B#30`#YPG1'P"%2@!!*@!`30E_#I%7^92#TP%[`">]]!'IK0=3I`
M)0N0`EU'`PR@:%@B!A0C`S)P!2C0`5L0_P=+H``$D(L^<`,V8`!Y\`"IXP!A
MD$H2M4&UU`G$U`52YHRI5`A>%1-1Z$N;81,U\0`PL`!QX`/8N%$[@91\DWZU
M)IQHMHUSL`Q_58YTATWQ.:2E-Y^(U)`0"2N,D`GG=0&=MJ)HL"M.)$5`X%7\
MQ05A<`.RN(,;,`%4$*$=D&,'\`1?D&]RX`$4:@*JE5"^LJ+"]`G\25`L(`,0
MXTNI!@K``DPT08U/4)E+0)3GMVMQ!7%DEEQB>&9S\H9!"H?7I"%$^J@L9Z0Z
ME`-*]!T9H0*D0RJHPX6[<@$:E$I5$D4JT)^0\`4=``8-$(NXF)(^T`*7-`9P
MX`!8@%1Q(`27,/\\#T0?#Z,\H6`%8F`'4%`%&3`"#S2,`49!<I-6#S9P:``#
M'J`'#4`%);2-MS9<RN03:Q=W[H<X;CB./]IQD!JN<2:I-Y0#,C8Z4G0E5)(>
M!!56J;0QH!HJ+G`7'B`"=&!'*```"L`'L'0&&K0`<.`?%*$#6)`!59(?GMJF
M<?02!/4`+$`'B7:%-PE!8](KR@H*`V<`,N`>H:E1N`8RA6JMM08+#*>M&O)A
MYRALX"JN+$M=Y&I#/5`JY)&N5"(*_Q4LZ-5:4F-*`<!?M*,%`'`%'=``$5`!
M&E`!$0`"7W8"!C`0.[`QK&436@A,M](%#-M0-QE@5I!&SR<F5KNPQG/_5F@@
M!AZ0!I5GE+4V0C7*4;FF0BFT"K^IG'TUM]9"B2U[MX+ULC44LQRQ$5*C+UBR
M)5.P)8U``^H*N`%0/VCP`&'P!4NP!/R8!0#@`U3`BQ80!U0`!J.B%B8PC=2(
MJQP$/,7S`&P*"E`F957"0=&(K,"SBE!K`!FP`EA``CX0`W!5G,5E7#3ZL=?J
MMLZDH^/89G7W?GA;O#&EMS3$`Z:TF%9C$R$Q`UL0=;AE)4_@@U0R-0&``+#3
M`"+0F?RJ!F<``1,P`1;`!YTY:'#@B@B5'NRKA=`8"FL$"EPG!!E``P>@`P$V
MC*K):G*4L7L@`V+PGVH@K6'6"G'5?F+&?C5J_Q2Y8&8@%4/"VV'$:[P4O$W(
M6SX\$`!3=#S[@3R+V5NBIEI%L`,@X`-?<`CTL@-<T`(^0``B0`"4RP=9D`%?
M``97``%+``$&,`"CFA=`L*:?^VG02!^_,A,LT`$;P`)M^@1DI;#,VGW]NU9Q
ML`$*@+9`0:,8)IP8!B''E0IM&(<2G'%54<%DK$@7+#XSP`AQ%#%?DCP!4`,(
M0``D@`8W$``,L$NCTA$&8`(U$`8DH`4A\&4*X`,`$`=0L`0;0`(`P`)Y(6\#
M4`=?)R#Y\3"AT&J<$;I=8`=7H``D(`.K2[$8@Z=N9)K.FZ%3,+L`*%*Z0*-A
MAEQE:*C/5+(GZS)26?]_97S+.G3&X9,%:+4EL.L)<B`/%X"E".`!.K`#AAL`
M`]9U`>`!6!!^(0``$Z``GKD$7["@(9`')C```[`&6,`/-:"F&W,>3.9I&5M&
M-Q`'+,"F(CJ,5J!&`">BG!!P])$\73`"'E`%`""M!OP3!JQ"<(6&91:&;+(+
M)X1<*A2\=`<SN-S0-:3+X),%9G4EQW,!I-.SX`<#5?.1+D`3^G(W:(`%58`"
M0#@!$4H`$'`%:J`'%P`'.G8%7&!.[*4"#*#&$J6ZG"!1&<-&72M@`2:Q.5T3
M-\EJU/@28J`J#6`&*'04&T6R(03+:&9"VMC*">UAR:EW#IW5WP/1WU,&[)O_
M7E:3N&)@`#]04//TFOUET4BDID*`!3.``J>5@SZ@`(.L`"@P`J^Z!0(Z`)ED
M!:.J6ZG6"38;N@^UNA#S``N5A<^W92)ZR3:[.Q&V!13F+*=AN\@@0JU,5U/]
M1V]+U2/%J(5DRUH]VHW#U9(#`NNZ)?;$$CI`UIIF`%:P!YJ@S#H@,1?07UG0
M`1X@!"U`53',!WY0`2*`-.=4!$_P`G603J;2"%A"4!CDV(4=<+0YFQ?3M3D-
M,;I*/+:9`6'@UA-@!F["1Q#0!G-`ODXM9DA9T-,3(2+%)LPEVJ0=WS1CVH^#
M`^A515$S-5%D)08@!M5WDE`@!V%`)5D@9'1P!2"P_P!UU)D*4`$.[N!\T`(Z
MX`024`0WP%[1A@84C3'`@Z?%HY-;UEO&VJ8??MB?<).UU60290=<X`%G\`5\
MT*-)`0L*``%S``41@*W)@@L:!B<G,SAAUJ-V=TWR7>0S0]^.,P.I(S6EE%1:
M<U8+<`5IX)EA4`?[L@-=X`&_%0<@,`-?``"=&3L6X.#!K0!!(`%.\+_D]`$T
MH#58`J]QI%HK.CP&)B89\``CD"LR0%;R?$&IR<2F)A,YG3Q68`>4$0<$D-#(
MD`H:$`<E``(6\+MON\IML@L;A@NX$(97G2=&WNF0HVR.<;UM?K#S9%0TL`5@
M0)DZ,`82<``F(`-<``)I</_-<>"@.?@%'K`"#>`'N^@'!$`#$O`"M^("]C`&
M'^`_]UW1E9QO&'.G9S4\5AM@:62L:17=B*V%-NL`=B`&+!`"2Q`#&Z<!Q2(%
M*8<%L]9'(N0',5`!O*[N"3(G2/$+)Z-<*34,GG[OB(+DC5,%`C(J&D,E.H!I
M.I`":C`!,'`!_?(`9Z`&"CHP/+@!XAL!*R`$(+`%=!T!#?`&3O`">',U##``
M$A#LY]'<!$=O"+``]$2-`68`)U`#I*(U-,!!%:.PJC:Q-D\W8`(#K>3E5``+
M%!`#66`!<V`&Q>P'MTMK?C`!:O`%6D`"-NS;!%0!,4`:K"#O#`S&6(WO6H\B
M^L[_.#A`)4[NJ4^`!D4P!F,@!W%P!C?P`;^5!DC'O2DQ,!V@`&-.!E_3`D*P
M`/?<!2H`!P>P`+S,$"`?\ANOIF(B"GN``%FP``SPPTT60<*H;=S&TSL]F^],
ML153SP0%`SH?86_%`3%`!\$E!57``F0`5^I7`GRP`9'6`2E``B0@`BJM!FK0
M`"@]`7R@;D4)T+&00M0BI%L?_"+2]3ES!NF%7B9PSVA@`_SP`6B`"7*``F%.
MR&'3`;,>A!:@`3&0]`MP`<!(4"NP$0LP`0#DG"$?.O0$HE:[`G0`!6(P1E8+
M+`ZP!1"``DX$8,QXBC$I8.\,"%U65@]=#@:(72-3*T)8_QL5<U)F,PT"4A`S
M,9*24G-^/FI@:@`=7Z4`!*)@#6H-#0`-$`0$$7XQ)5*>`G,<%+_`?\+#Q,7&
MQ\C)RLO,S<[/T-'2T]35UM?8V=K;VA;<W^#AQ#PZ`1=H`44F`3H?+T!/4PXR
M4"@-!#X^$20='5M9#118H*(@0HH`-A@X&:##@`X5`1!$H+'#'1P)0.3(,7`(
MC0,'8EH@>'#!`)H]*/=D.!-FBH<N71X\L0+3XT<'79X\>6#EHR%#:((Z>/#`
MCJ,./@0(*)$B1`PI$:IL\L2!5PP"&ZZ(``!F"XD-(L`L847JW@0"#<"DFC`A
M`ID2'#Q)`O9+'#0*=HU1,"/,C/\`:#&2X1I&(7#>PX@3*U[,.)JWQI`5SY"C
M0TX`.4#.T>`HY\>)'W'03O#1``L+.EM09"$QH4*%@EB``*GQH@:0'PQ^?/BP
M(D+".F->C+E\;@_'+B<+G7.PIPM*F!>>9,#I8,I.FS"S,Q_ZQ$'WD\V1,^]R
M8T&*!AKFE.@@ADJ)"@C\Z)K3ZQ-:-00@J-F`X@J*+1TL`0!7(FP``00`J`$!
M6P1,P`<?%;3!RUS!1$;,`7@9(Z$P&CAC&#)S$#%$$Y@\YDP9&1I3!A7#:%"`
MA3#&*&,R4<V(F(DVYD@-#Y9MU,(7(J@Q0Q@CZ/""$S4@L(06JD&Q@@QT9*'%
M%010P8?_'Q7D<<(>.]0Q0!T_J/!!<`=@0<48<.`!!P,Z[+&1`<:%AP9'>]C$
MW!YWZN2`%7A>@*<,5NBDDR$XS23#`S=YYYQQ:#PA1`@;6""%!B@(H48,%GA@
M`0=Q25%!/ALH\(HH$"Q)PA6NB%#@!K'`HF!^!S9(@`4E3"B%+RG"B.$Q*PK#
MA#,]*,,$`7_@!0&.S*"(3*\<OJCCL]#:Q<0`!T0+#K+69FL,C^S<H`4^?!`@
MQ`XF..$$#6?DH44*<0SI00A@@`$!'Q:0H8$?!M@6G!-P?'#`D4Z,@84%/YC[
M3DD7;.3`G!XA@F>=)WW4:*$YP313%X?N)),A@F*\,$PX$>KP_PT@+.%#"3&`
M,4,>$?BP`!62Q!4#%51<Q=8$LT``UA)@=4!"@@F*HB``"^9<90QF<'))KA;N
M^D<,9>``@087\.`#!$W<(8`?"3`QP1](N*'`,&K0<(<49.!0AAK$3$!$"<)`
M4(8;2?S!00(X)/`'!E&XT48"91!;QAU1E/%'&WG?\4>O`/#`PXL;N,&"4CST
M($4""6"K[>;:5E!`M9QCHWGHUN)P`0T'7)#"!CY,P$4Z.@SP@1WL?M$""PL@
M<$8:LNAS101FD)$!`PP<<%$=-7AI,!9\J##``"I<4)+#X"T<<4I[/A&3#.(Y
MYY$@.^%$"/@P(<K33X:@I+U),LP`!O\!&IA!0!QT-+`$"'S8ZHD99O"A#\XX
M`X"J2*":4X%A*P+<@"N*EI^V6*`"N)B#4J0P(Z?A`"\Y6!R+_O`K#@H#"7\X
M@A^*$2P.4C`(Q2#`#RKP!PBPZ(+#R&`!H@"V$=J``F68@P<3P!<DX)!%2OB#
MBSB`@S_PH0%_&(+=>$"Z)F[N<TZLQNBBF",<!.``*I#!%%J0!RNP0`8G.,`)
MA/"?-(3A"3H0`PA8T(()*&`"3X`!`LA`!A:8X`=C8$`=ZL``.)@+#PRHGQQ,
ML`,=?,0X=$*$31YFDNS,I"<V4>2>]C2"F6BO$#X1E$[.-R?F&.`<9%0#K120
MAC-\`0$HJ(#_`,A0L[B\9P/X@""#.J`%`M)2"PK:#PEXUH"MO&HT"E``%?R@
M@1*HIX(9,@(&,`!"9G60",MDXA%T2(P2@G!QU!Q&"6I`AF,MC@(<P,`=CO"'
M`D#@#TTH`P:24`)E_<H(PL!`&U8TAPRZJ`)#P$`"B%7"#93A+U0,J(R@*%!H
M3+&@,)K!#E(G@]>IH`A[N$`17O`#-(R`"P;02$9UT(4J^,`"$SC!$T+`AQA`
M@`YZ-(%"GF<N.-2A$B<04T:D5Y(Z?7*1GL2.]CS2G9#-!$^(4I10Q;?)02`J
M*$C]V"-\T(88B"`$7Y`!"U*PA!8L``4$R,4<VL`'!?BO`6Q1PRYO_[D!6(A@
M"04:4"V)UB"V^*`@5]J0C)S&@VPZ4Q@YX,`PIDE"O.*EA,+(4!(BX$T4M>4/
M,CQG$DSD3@[JD`D<6!$%R!F#`@B@@\(`;`GJAM#.+H:@GEW&04/+F"K48``_
MH(P)$A8`&A3!!@.@01@>\`.,98`+-TC#%[9``#XL`0)?\`$9%."#&3S@``=P
M@@3\.("%("`%8&+`"];AIT,@@D[7PY[V(/:][:SO`@$P0/H&M3V=#")0G4P4
MGCR0@@G8BP!0O4`Y+E`%,/#!/4OAP!QB$`&U+&@#&UC"$DB@A0V`@00D&`57
MEG`%`.^':&X52`4LT*&YNJ$`%>!##B;@AO\_`$!J?^C!!/R@`!9,0'%\)082
M"!`#'^S3<,,(0@(*<`$*%)8"%B@#`)1``7/^P0)$F$`&&\L''$R@B'?`0`F"
M```D9#`'^F%1L.:``0`XB[18_@8&)"`!<F;Y&*/]\F%0`(0B`.$$12C"95Q@
M`A4P``\!0%53PK""&:!`#5E``!02-`%66."!/FA'#?`@@0'`H;D#F`$6A'.`
M&H#W`H:X+E)YNIV'X>D0E_[(",*``#G4U">$P,D(`,63G71!>D&%27-6T`(`
M1*#%*6B!#C(S`Q]L(BX5H((`P"D`*KA"`1!H@!96TX$$;8`$O6P`@+ER0)ZY
M(C\$4`"6R#`C^LS_`2\E($.&-O$'M`DCVWBA8#'V*XPV5)@830VL,/3Z-$D4
M*T.>P@N[V6V&#VG[#]H6-QG:L&YA".!#8@YX-?3K;H$/(\P&!T<>3*`#&E1&
M(SHPLPW$)(<M!%,!5UC`#,[3`2Q("01:&)`/J%`!+#B!`;2!`\`6@@($C&$'
M`?"(1H`RIT_"J9/>LQYU0-8%.\Q@"R%H#GDWEI-`&;5\/*&)Q6*2`19\8581
MN`(63``$,4B[#7#A%#@YY4HJ:*`"$,A"%I9T!0`P^("D"/`52!"D49$%`B,?
M8<+G3O>ZDQ;A=L<&.0)@#O#2P`6R*4>9N0#@":`@#%B`5P=`D`8P@,"4_PE6
M4+EV4`,&-%>Y$G@!&%C`@,W(@+7IFU/"X/1)3][I.=DASQFVD(<51(<Z=B)*
MQ68R`J7S9&/B6\%5(1!,,"R@S$*(@`7,H(!;`8/KGAA(Z[BB;`$M83^DX,H5
MXL6J9=OC52//N_:WS_UHX;W[TN@!WTO"]R+H0`<P8$$17'L!!]P@"^?8.`J^
MP*XT@$`/"%A`'!90!#Q0ZU\#H"9<=@`;8`5UT"9<4!DTX!S797,0(TDV<1+I
MLP<PL``O(0@YX4DF(73.\4@]%1-6`"@_X2BH=`4-$`$;P`(!8`)"X'520`5^
M$1=<YPOZI0%40`8M!@9:L(,DL!_QPG;\@`*K<O\/#69@^.$#X)>$2KB$>?%]
M3,@,Y*`#K"5?KH4(#.``([`''P`$:'`!(P`%6K`%6Q`'<9`'5=`!:M`"9]`%
M*H<F)]!'$G`"A%8#'7!'!O`$8@`$`0`$#E`2-P$>Q@%I?7@3QW%J%2,(WK$'
M(N@=VK-):/``(R`(M<<3,G`H,=$=7+``+5!LP(8%`?`#-]``,1`_UM8IG&)\
MZE$"%J"#/",@\>(*9G=L2Z(&I"!6SM8*2/2$NKB+O-@,3MB+QH`#GN9I`>`"
M1<!F>X@\)T`;!_`#+*`'*9`%*)`"U`@"<;`!$P`%(;``@%0#<'```Y!Y1H('
M)Z`%"!$`3\`%LE$$!A#_7J&F2(B$$D$A!]UA`".@$7B2$SLA*.8C`]JCCPLC
M/I58B;77B#J1`6'``G&P!*I0!>F0`5O@0'Y`!L2T%)>@"[C"`<2G!DSR!5]P
M*FG!*CJS!#Z3("+PD0)B8```C"S9DKOXBR[Y!S,@/9?!=SK@`B?09BIU`#9P
M``R@`IN&`"&``D0I=K#4.JT3!G+P`B]@`P9@>74@`7@@!S,`6PP@!WN@`C^0
M,!Q5$S7WE1[1A8K``E@@28)2>R%8"(.`$M[1$YG$$R,P:H!B25:0`1[@`<]%
M`EL@!@Y``PZ0!Q`0`1%`!1;P1GY@`3&`"Q@)#`)@`0T0!R`0"ZP2"P6B%O'R
M_PH'%A8^"`8QV9F>F7<PZ9)YT`49Y1#FMQDWT`)J``(7<`*?41DRL``@\`6K
M(0(.8@%NX0=4X`,B``,3)P9<4`?F4@=R\``UP"\U\`&R@PYR8`6-PCW=(3UP
M4B=8*`1]@`5<8`?4(7N$D'0SD6JWUYU$<5Y68`=3P)UVD`%"@`!QH`<S<"A`
MX`)B@`*C$0&Y)@(/8@'Z,!`XF`L:^8IJH4!HA2JM\(,%,D"T"``;\)D,:G=W
M0`,0&J$2.J$2*G<"%YHM:3J680`XJ0)`D`=J`$Q04!DN,&L4&`>TJ18*,&$D
MEV&".0%A8`)P0FAX4`<N$`!C()6XX00G(`=%4%TPL/\",L$<8+D'"-`!*F@`
M=L`1>X(H'UA)&9@HXA4/I&9>&0`#F/0`,C`"C@`"*-`"'F`'Y[<'E5`0%J";
M9BIAPN159!`!$U`%`D$`7"%`"OH*5Z`%"#0@.JB@!]:@?IIP$5``@CJHA%JH
MA,H7!H>A+,D$%P`HL_$#CJ8&@[FB!/`$+O`#/V`#/R`$.AAR:N`#]Y4/5#"8
MA$D'F:$#?K00X16.`Z`0<%:,#K``,#$%W(.(:)"!7!"-!K`#T?$](6@'&$,(
M<SDH.J>/WRD(Y'D3@F"79'D##R`&?$(>?8"?#])5H'I?HZH/&09L8.`'G"(`
MK^$*M%@6XYH?`E1V^_&GZKK_KE2DJ,#(!"Z`!6G@$"J@`R#0`5>@```P`P8`
M!!&G`T_P)%60`B"@(!,@"F\E3!!B`4)P`C:`!T="+2O`AE)):`QP`4#P``CP
M!0X0`'L@$_)@'!K!!?.7!3(0/5/P$UHJ!AZ0`3P!`Z,6*"#C4S1A*%-`JS*A
M/84R`BO@`6'`!:1Y6X&R`E@P*P_"2L*')7PP8C&0:V3`%KE&"U>C'[$0"_&R
M%1NP!5^@;/S`KE[[M=GBKKW8`ZF540^@`U@@`B.!`&AP`F>F`QD0``X``AYP
M`4*P!4N0`AY0'0`03(,Y82DP`A-UG#8@!UF`!7C`+\JE`G*P`W+$!6]B`#*`
M`'S9_QT/P&HI0`(LT!#`VI960*MBL`!"P`7^.`BI9UZ$\`0R8`?FF3&!$C(/
MD`%B(`1BD`%868EVT`AAH`8T\T#W%0$0$@$:<"\1T`9D,`JTH"H#Q@KY48M@
MH!4=8)NEL@1@6[W6*R-BRXOD0%/EP`(C\'?I<`([L`,N<`$J<`*'A`4`0`=Q
M<`8+,`5;H`^#:0%=10!+(`=]9`.AF`;-A0>)RP`G4!D.,!UV\`0!(`8IH)TR
ML#"3VP\9T'XR$!0(`P0V0`,>L``$>529-`A:]*N5>%ZUQS%UN0)BL`)`NP>.
M8AIAN@`?)7R%*4P9AH-^\&H:L!^T@!8,)@NP:&"LT"H_R/^9UQO$0IP8V;N+
MIL-W+L``8R`''GJ3-T`#)D`#?*<"J\51;20"]U`:'A`JI$HOA3D#_U('7:`%
M#7``$F`N3G``)D`9G@8$",`%$&4'-/%Y(T`'>3`#-[!S3X`&#&<`*O`")]!S
MAN(]S1$HXSD%=B`3Y0D#J2M[HS8%LBL$'C`"TC,""`"F,`"_?G!?]"N8$&(O
M31L#`N`#\G(6K=`J(M"#`$`"LP`+!_9\;#/$LCS+W%#$NG@&"4,#D'H`4EP$
M!P`$8-`"Z(`(-]H%;5(_!\(6*0`#>5`05O)G]%L%R/4"#O`%$V`':/P"T4./
MGP<$M^4`<H`&@>*%U@@#GG8(";/_!RR043*PE$4`B8-@D$5'%$2A1=U1EUC*
MP7PR!3!P6T*0D&*`"`Y`M%BP`NJY`8>))2U#!A40/RB#"XYIL#C3O`FR(&RA
M'RHY"[%,RQS=T=)@RT_(`R/0L7Q'&0'PAC]@`%*,!DQL`R>P@7$`"Z>@!3.@
M>[R3GQ,&!3;@#C7P!%]P!7$0`$[@OWIX`7G0`G8P`@:P`BW!!2R=$P]0)R*;
M,.V7`78@!FD@`R_@)\8Z*`Q#GEI*$U8P`ID\GOZ8R>G)U%BP``+M`#!`9S?`
MI1`P81E&+Q5@+R70!GYQ%64E?*;\"@O2"D.3H*GBT89]V*(5Q%AP"'(`$^:@
M`P<P!H6[_P!LC4?LR`)LIP43<,E5H&A,C0`DL)LMPP([S0"[L0`;``,J@`5^
M-`8/401<<%LK`"<#^0#BA1*>UH4F(5XRD8D&5AFW:C%C/0)F7=N(/-:5.`4C
M<*4RH(B+D`$WX`$L@`!*[1,(&096[0`$L,EW?25WC75*T3\)^T;0IB`C659G
ME<H&MJ"(W=[N_6-!/`,U:;=[\!"%&P!<$`=A0`,JX)1.5R45L`47H)U$^\\(
M0`=P9P%Y4`0?8`,U($8ML`4ZX`0F<&AK',5H(`8LX`$PL*PA/`6(-">V71(\
MI1)8U0*LQ1W=:5XWV\$P``.K.]*KV\%=``.LRP5J30<>\$D?^__6&V[5J>0:
MM_!G*TH?>:V?9V'*#:(@@IT?89$S1//>4F[8(,V$93",`4":[-`FZMF%+K`#
M)\`"`](`-3,=,Y`%84#9[&EG/K`%+G"IE,'+(;`"`_`"AW8`13!()F`%5D6K
MEZ:/_A@RM[HP<*(]#855(O!)[>><1;6EK(O(B`SC@6(H,@`#ALX3=@`#&IX&
M6/#4#\`%B(<%0B`#81`I.(B8GT*_2!,\+9,/R7P6T)<@KY#%*CGEMD[+5;Z$
M,Z`#)_`!)K!^#2<''@`&G58$#V4`=ZN@TA8!!+`5+)"0,X``(``"-\!P'DH3
M'X`&6["4P%$#)W"C*[AIP(H<$AAJW:7_K#WULBT`!;+J'8AP&8_$P94>LR*(
M23";`?ZH/>4)W1Z@!W1@P""K>PB`!?Y,`A.I`,/[(#Z@`>%=`?6YFVYT->9]
M#[1PRJ3`BYSB#$PC#1N?%P"%#!U_Z^T:Q$R@`R:`9I5ACRO`6RH(Q5T@!G8&
M8+U%!O7+`AK.`C,`!5S@ZY<ZT,=E!UI@`,BU?I1!`^"EI3WUB/0<PH1"*#@1
M%)6NI88`W6)P16P2LX0P"#A[B5A8"'$)L]TA")7>LW0``E5_"%8``QZ`!0,/
MG"P@O'C]=620-)Z@`6]%,\#4.@<R"_F`%K&RDC+2`-1&`8#?&!D2!.=T#`6P
M3WKE!AE4#7-0_P//(``)P`,?3PP0</G(`#K(@`&)/\3$0G>YKH1,H!$EO0!H
M^)$A8``.6P0LH!9JT&!N=`O=9`<62`=TD`'-F%%7B``94`-ZT`!=L,0R<'YF
M%EZRESX^@:R$D!P?$?:%4*M17057\`4&\`-RNZ6I6XEAK=Q)A\^?F[)[D)9U
MN9YIL`!M<H<R4![Y1_4;H`&):2\4.8JZ4`&U,)@C-ZHX\PHW#`@0&TMJ!!M_
MB(F*BXR-CH^)1V5_&TJ0EYB0-8A)%(Y!%!`\?QPEF9!MIW\X'!H%C!07$)@'
MD`(<JKFZN[R]O65&OL+#NQ;$Q\C)O4QR.D`F)V$D!%LR+B<G0%U9#?]:&U\H
M#1,Q9&03"VET87(,##0W.B\!84\F'6`78PQR-C4?)W(,[!GQ1.`%`P*[6'G0
MY8$5!V@</%EH1<:3!Q<S@!`!8(F'/5UD=!DQI<M(*U-&6*DXPLZ(!US$9(`Q
M9<J#*3`J9A`R`\2"`$`,2,P0)LR"%6(\L)C@QX^&-GZH6-!PRXP",A4JF(G*
M1\&$KQ,(0""@IH$@-<IZT2A#P4B//WZBX-#PAP"!!+/\)&`2XT\%'&[N_(G@
MQ@T%"EX*,)G`A*X"#*_FJ"G00X."`7?\"/ACH<PK14@0$9E30$'=!!/^E"A3
MAHP"4V@%)(AB1D.9*!S4H"WA)@%='SZB"%;_Y,4"!"J,"D!X6_?N+`L)YOZI
M->L/%3/0O<QQ0Y=`E-1IPXM/Z^<%W?'HBZ5?SU[7##09#-``<N%+B`S.3.@P
M,`7+&1(`=)`"-S%H$`,5+2P@QP`O?!#`$QZHX$0`7&3@P!<(U%'#`#6T\P-`
M<EQ@$1H7H+'''A(Q9-(3#B#TQ$1/*(21#$)LH44<*W3AP`,/."###5-<](`,
M+TU4D0P/C+`3%S55Y-(4&:P0Q@P+7*##02-QP<4"80A1U!86Q%!""6UH@%4)
M'$C!QU=44!$#'W!&H,"<"A1"@`\$`%!=>X_8,($/7K`E!04Q8/!'&<:\A4L%
M"?S!1AN%4C#*G7\$_Y.$`GYXP0$3?S2`'!L4-.#%=(J\Y0EHHE&@@:$&_.$)
M#B6H6@!=;P'@AZM1"'`JIT%4(,`%?RCW1Q"+"/`"#HT<H0&QAR;ZAQ1_^.`&
MJ1CTA8,`ID:+W"BG\NGMM\.J@<%PX'YK3+GHLL=#``_P(X<0""#@@`X!!$#O
M!0\(`8`:*(2PA1IDE*"!!1,T<,$+-9S@P`(9`+$#&C(XX```81Q0QPL#U'&`
M"D5<X+&.#EP@\8DF2>S`'@8\@:)$$C?$XA-*!BD112GI:,<45KQXD4XTP<!%
M3@[!8(<5(X@A!`L(+&!```@IM-(*"]R0E`<-D!%#&P((@-4M4E3P9P01F/]1
M@@416.!#6&'=\Q59Z2IRP!Q*M%$&!Z%BT"A;?W`JA1=NE"$%L:Z0,00&3$S[
M5@]3%<"'$1CT,.I;"KQ22R)>1)$*JG\,\<>J?^10`+3,!4LK7#WTI0`/M^;]
MQP"(R&'&K'^$C@@/?"0AQ2B)S/$"!$08@S>G`MQ1AJ&UD!%%['\D!JT/R/4`
M`;1M1Y^,!4IL.JWTZYV+_?;#L`"$"_4"T0(7%^R!1C,NT!"`'#=\H04**:2P
M`:9=S7F#"RGO<4$=/UP01A<!L`($%*2"`#CA!>XH48_,UP7SH0PA((D1BB+&
MD)7MJ$=/0`.,9+`2BN0,2EP8`0=7(D*<R,`.=LC_0`8X"`,19N`&(\C#!D30
M,#F@84@HV9('O,2%%O#!#P4:4PEB((`2^($/4M'`H`3@![#Y0!P1@$`A)C`6
M[#6A+G_`0`F"8($YW,T3G(*5%.8&+%=HX'B).%SB_$`NY$6.5(IH`Q+F@"H.
M$&%SAMI<#OZPAD3`CCE2Z$%JQE@!U3'`$SH0P!\5(05.Q2`)DTC$!#:@`1]P
MZG=YFP/G)L<&,GQ&`TV8`_,088$]<N^4NO`!#6B`0#.@,CS:>Z4L,<$#.3!-
M!B)CFAT,4(0?).P$)A#"%SJ0ACAL`0P0``X5(D`%"'PA"U"0@0TDP(``3($+
M=``!`!:`RSP@D#YR\!%$_Q#R`#1$I$4F61'(2E8R%AG`"C`P0$3L0"2;\,@*
M,UEA19QD!Y^UT`$*,8D,.$A/.6!!!%G@`A!.L(<GG)`+-_!`48[B`3!4P"EB
MFP,9S&"&LEE``5,Q4P68284)6*`"5#B;77P@/0I<$1$8T(`1"/863/:@!``8
MQ1`VP(-I$<%`HT.<*S+7AHVZ\14J:,/E?,6#S22B=T9`RZHHP(<2A(8'%2"#
M!M0P#AT0R@P8@$#``,`'U>5@`LL2'?(4H2P-'"&/B&B,JYS``9L*H#=_4,%F
MHL`#Y%2@!&P0`/,HH)70S/*PD.C!9Q!+C%@R]K%_X`&^1M2%B"Q-!R>P@0U^
M8/]0$'P!"GK8PA+$H8"R^>&C9Q/!!20P`!UD0`QG8`$*PB`#(```"`?0QAZL
MT(40`=0`2(/!1$32!8?B["$`+:Y(Y.F`BD0$20!=23U'`(,1\D@&.(%!!KB`
MI`QVH4DD>0(+9A"&#%Q`!1H<J';%8!0/K$`(6)A`!:ZF@3FT06P0B(`Y(A`#
M,V2U`DADGE?^5##PM(VPB8C!''#:Q#^0`1$/-H,7VE!(!Y>@43@E`!UOY8<Y
MM.(/$B8`+FXE`+IDZCP6N(-CY70Y#IANPL\2QRT*X0<IM$$-+(V!%UCJ8$10
MT1,:&/$B<`H!47:KK(C@@]8@O#D`E*"0%@``*8S@"0O_>($N)=B,#P!P.<A"
M%J1>%H9CPSQ+'%Q`#D6XT@VZ<%D:G(`&.PA`"Y80ARRD8`L=V$`RY\0'K-2/
M`&F`PPO`IP+Q_<\$\MA!%[B@D!:E2']G.,-,<+8S&6@W8BAJB!7JQ<&&=)>W
M.[(""@=*SY:HI"4XDP$7Z/D0F*E02QGPSP*$T(4X#\EI-U@``EC0)1B$0+\:
MT(`9BE@"'RA@P0*0@@`XJH&1&MLK4M03C\FL"!P78-K4+A=P&I7M;GN[%V/^
M-O9"8*5P'N0@<@"""C[@2R"P(`X(2`,44*`%,#0`.#[@0U9\`(%[?V$,+8(#
M'@S:A1_400).^`$"P.`3#X3,_P$OA$%()BZ1$:+P1>F\B"T#ZJ,7K21&1B(:
M/2VM$I8$;2$621(,?+8"&2P@#E@0PPCT$Y*5O%"B6,""!UZ[!?X*C-AGRS*9
M_%".&/B!3E*)`'#F).X2>,'`XN93BG$1]:I;?1'AOGJY0$`OC)RO"-?XP0Y,
M<.8`L*`%+=`#"I[IC3^!-"L1($`X#/"#%<A!'SIHP0,VE#$#:,$'6$'!'FA@
M`J8=Y&01P1FJ73(2C,2(NB$SWTN:VR.)%"0D)YP"!U4D)!FLD$<*02'1@"2&
M%LS``S=PLX]L\H0IB&$!2&,!4L(`,+$5L9+R;<.8B$Z.&%C@I&91@`_`9AJM
M&__XR/]/_C"RKOSU,"'-GI^"'%P`A'H%@`;.<,$"^A4"]VGA"@VX`@`BP`<+
MI)0`),C"`M"@`P9H2`Y?,,`8ZC!_B(=`#6F8@@-<`#YY,K?U3/):PA4RYH0&
M0O$$6B(#!C`2*2<2=K``"W`"/U`$[_0`4H,D(C0C.:$CQE4D,"`36$!>8?``
M)Y`R(_`21'(#_H$`'B`&I7<58C,F7C%?,4AAP68!Y1`!7Z-2S=>#/OB#R<=\
M0)@63+`^")%N-.`Q.T`#O>0"&4`'X!`"67`%8+`!*"`'7)!,$P!O95$6"#``
M#,(`.D`""Z(A+W`".H``&]`!7+`"#A!.0A$B'G-X1*)I((/_,CLR4%S`6Q?Q
M(A;8`EOP!4TP`#^P!R*!!57`:#&R$*`G,4E"3XNX`EN2-"QP/W+@:40S!78P
M)6>P`%KB`1M0`<*&)A7@`QCE87,0`^1`!5EE?K_'!V<SA+(XB[3(6$)8B\/P
M'EUP`4#A`N4#!!^@`_R7`7IP!1U@9WD&!FH``C3@`2P8!A>P`G>")PW0!3I0
M`V-@`!MP`DXP!OWP`0>P!]Z0`0M@!PWQABL``'G@`$QC(B;3$`\D,1`3$C#$
M$`XP`B]7;VH0!D!0$0(%0SBQB$3BAXPX4!^TB2RP`#J'9OA2<BE!CC.``$(@
M!&*```HPBAP@`&VR4<1F!JH8`UI1_P$6`"==@6VX>)(HF9+I<8LJJ0MY$!'M
M4GU@!P1%8`(U(`<M0`(-H`8```#BEU\$T`4LT`='X0!8,'QRHG1J$`!UL`)+
M<``-4@=U\`$=,T$-=2*\*`=+``4C4"+GA'@-I#\"D5Q3`!)),@5"``+U!@!G
M4'%=X#.:=X(T$Y<B1!$BQ$$`%08YMVM64'A$$S$G%%$L,)@[Q`5IP`=B0@%C
M<U$:($3U528&<D3,=#;%UY*6>9F8X`.LL9F<V9F=V65!B)G$P`,_\`,Z<)I`
MP3$!L`,7<`8`4##]-A9E@U(D``(AL``>``,+L`%G`S9F\P`,4'I@>``,H`(B
M$S(/6!`"L?\'`0`00A$`]Z@S.F(`#!$Q<IA<5F``-\`"VZ4'>2`$=N`0*#03
MV)4S%S<1&2!J))$!7?!J,F`B,*"7.><!]J(R,8)"=O!Z6)"08M"&!"!L%"``
M%H`=_24`R%8;'MD4'R4GR"&:#OJ@?Z`&1#"A%%JA%EJA?=%\+`FACL`#:(@&
MZQ,`)O`,]3(#>A(6_$8`$:`!]3,!:@`%13%>7P``:R@.$(`%)]""$@`'!_`!
M0*`#<M`,%Z!_9P9!.V,%+*"`""&/"Y@S*V,^(^,`6H)/*Y")&4`00T-RBZ@2
MV'6E&=!/3+("&6`3$=&&'J"0"/`$3',RJZ=YN3:88;`",#`#?*#_`0%J`0*C
M5<,V!T4T;&:`%2,U)R;)H81:J+.XH8::",QP`83G`BI@`\`4`!>0!@0P`<L4
M1</G`X0`!F```"E@%#.@!R+0;WJB``!@<&?0!0>4,$P3I.5#(AID!6(`-%QP
M!:;Z!&(0,1!A,H[F@J=9(D*A7/NDB4,R)#=3$]G5$J+W)/0DIG;@717"7EB@
M#D%:<9J(,UP0@DDC!#=P`UI0`:6@`%E##L&6-60RK@H@D@I`!969J.[ZKLB'
MJ.[*`P9P`=3G,"=0!+9T`2C@`V$B)V.Q!$\@!QEP=E\0!WL0!B&@!4L``6C#
M!VI`?REP`0<T!@5D@![S`">R@&$0!PZ7_P%?(!46``;R$B,[LB,78`)/``5Y
M8`!R8#XG))XG%!($D9YRV1+:14\W(VH5\J4/<*5#`U`NP05>$I'L%TZ!"5$W
M,"4S@`6X^7H3(`4QX`-94U1A4@)2P*>I2`8#&@/D%P'P&K9B6W7RFJ@]X`+0
MX#`[<`(!8`<)ZREB`P984%XW$``UX#\P@``I8!$RM"_)!#8+X`3P]P,8,P`,
M$!0Y<S*R*@<T@`9N*`<I,`$*D"<+`%`7!!(P(%$(``5I8`!`N@=<$B06D1)$
M,P*K)D(E=S.H-D(K`266AA(C$!%?N@(KX(P(8`?@XR-$LQ,W,(E-*P0>P`59
M,#`^4`(+-C"CN/]@1J14"X92#3JVT!N]D%6VALH"14"317`"CHLT#X``^D4&
M#9"=,A`'6C`%-/"`+(`%"/`%X[4!9C$!$5`!&R`A#]`!-J`#!S``*A`B!-$B
M\$4BK6<`,-")2A$&^@=0$Z$C-P`%6I`">A`'5J`#H`L%DL8C*3$10C,D.)L2
M1'*71%(A&0$SINL2P_6E*MB)9X8&3C(DKZ67+2"1[X4%#1"_MD<F&]688U(@
MPF893">]/OS#J$2]A3H#-G``D)H!&Y`G'F`%6W!T=*!J4V"[1[(`()"0&S`#
M,^"^!*``?08!!O`"0@`%'\!F=9`-0G$!3Y!K6+"+%X`2>XD"4)`T&:#_G!ZS
M?<^4!;.%$!Z0`EC`K14RD6#ZK!QD:6/*$M@E$K0;(\(E0C?3<B<H-$1Q!@A@
MC=2IGC<+7[O&)2P``#[0!@MV7\L61$5$?D;WIV\"Q*B<RNDBQ(2*!&!H`W+@
MFOTFIU\0`R30GV'@`5<``GL`!';@`"T0`O&2!V&0!](6OR.U!0&P:S[J`4!`
MD^I6@FSVGF=6(?Q!`G%WNP[U$#>0`B2``EN0#BS@,=05!A+7P4I"D3TS-$DR
MR/UT@AR4$@"%,UG*00/1$C$!+P@``U<2>@2%$QX@49[H)0SL`SL\)IIT7WNZ
M%5A#=.VJRA`=T>+!RAS*`SI0!`[0!^+7`!VP_Q17$0%K'&MJD`4&4,8&L&M)
M$R]IH`9_"R=XH@5?$`8,,`98,`5I%JDM,P7UN@<>P&9?,'PW&C*,RCXHL`3]
M@@5/X`)I%A`GA(`I$`?<):>DEIXP<A-"LQ+Y61(F$B-ZF`$:VWJO)00KP`(H
M#)VBQD(TP05A$"]<$@8L0`<$4""JF&5_>B99J]!/<1X2O==\W5BJO"XZX`$D
MH(QYT@!Y8M`3L`5;D`)2Y``,T#_!JY<1&0+25EHZ6#`-@`4S;0`K4'AO%B(G
M`@,/4"+6@`9?L`%Y\)Z[Z+(B@P4"@@5H\,PA*@?4Q07QM@`O\A*8E[HHI%UC
M"B4K\*S%=1%,8@=[N/^`VT612UL%6+`'&(U"=:G!0G`&+>"T$+@`56,U9F!?
M`@!2`2,%RE:@`@":?5W>YIT)%`VA9R`$!C`#6B`"6J`.,$`'60``-ZP`(G!O
M"_`!#&`"_>F,+7`&(6!O;C=@(F`!:_`">&`#S7F:_,<N&-%;^Z$?*Y0R_001
M)_($>@`%'E"D"($E<[P'-[!"+6$1FN;.)X@3./-"*[`S*B*F/O/+(S$%4@-1
MZ;L"0O$S-8$D0[(E6(R;+=@!5*!56-,&4O`44C`FX"UT173>3O[DCI#>#YH'
M+6`%"(`"+*`#$\@%6]`-G%P!2A,&$W!;3K`#>Y`!'G`&=-`'(3!:DHMO&Z#_
M!Q4@!_G;#@XB!RK@`ON!73=`(@/)(CNR7?%R`RM!#P*QI#M]$R)Q3P)Y,SE!
M$B`$42&T72&D,@\@VKT+`]Q*)#3Q0EHB)3\S$"Z10L7M@F>:<[B)W40N1`*@
MPW/@81R`;*8`Y;0.Y5+NH%4@!C3@`%,`!,5Y`1Z0!UIP#QV@`%N0G?*S``QP
MM_&937V0!C^)-@UP`Y2J`@.`!Q@CAFD6`'O`!3LG!KPNJQ!E,P21D*LF!MD)
M4&)Y$$0C74330AU4:C?A$B3AVS.A73F!!ET@<_<N!!)7XKSK$L&=GCFCP8X>
M$TJ1<T[K`5LPY!PU;*WP5V(#W@LF-MC3!A.`9&TC_P`YP"F)`*ZNDCKIX@85
M5BQM,NO*X`6Z0@")0`'70@8BCYD6$/,G!82W+IHMD`5"<(TJ(($!L``FNL6$
MP`<0X`(PD`(-(`1+2(XM0`>A10<)V0)50`=HL`-Q\`46(VA.<+AD%Q#TL`?Z
M]YY/D`(%@9H+Z#+[I!+Z4S[821(C$%#RU'@HT4]?VH92,S3PM+/?U07X*:>7
M[A)6(`05DKEB$"1.0S1M^,ZZB0`1R6L(4.QCDC7VI1E8DR9%I'O2HP%$0`4$
M$"M2EAR-5?*-8-_=\@<_,`L8H#G@0@'30@%$4/J)H``Y$`%'H/'(X`-I$DF(
MH`8<,$KZ=9D]8`1LP&U$(/_\NJ^A?TV?I:D"!Z`#,N`?()#Q/N"^/I`'5K``
M.(8`6(@`D08%,[!N,I#+7%`'-O!,'W`Q##``8S"BZ8,_+_NL!C"Z*%*DXY1I
M5C#B#U"OQ642%@P(=B,C4UUH3X-/B#`R7"-6&6(W&78R,G935D]671D9(Y,/
M#Y!=7#=<=D)A*PX&75-3(YB-7%QA+%A8"QYA,VHQ)7-M&F8Q,1IM<U)2<QH:
M?]#1TM/4U=;7T!%ET51&/@(Q7@1_?D,^9G\1`.@1X2435-`^:B7I;0!D%`EN
M"M,^#1PXY%##1YJ1;428_-$``0(%<GZ\/+LWX:$9`!$L++Q34(`?"'S\J'E(
MYD[_A3]M8A`@0('*$1]^VOP)IS&:`@Q_"GCY4\%+C#\4(/B00J9-@YH53/[A
M0&:>E#\*Z/GQ\4=*CP;]IO[Q084#C@(1\OTI40^;V;-HTZI5^Y1*$Z`[^;Q=
M2[>NW;,U[^K=R[<O-B1`:HRI<<+$$RXLJF`Y`V$"!!(-?'QIT2$JEAN+6Z0(
MPT"%!UU[X*A(T8+!BS$V&`PP8>*$C@`7+NR!92###1D/NNS9XZ#5!=BQ1W4Q
M(.>"@R<R1CQPT$6&IR=[K,BP8N4!#"Y61F"GY2E3\TPRFJ.Z<6.YE17:A5"Z
M$<9#EPMH+%F:XHF+F#"JPBQH+^:,`@TEM&%&2F0<4X(`_\RT499?=U&@1`(/
M\9&$`E),0$89?)`QA`("5%"`'T'\D00.:C1!Q1#I`$!%#B(B84$-%$110$'1
M1'&'`CQP<-5)T>0010P-X+#53?T8$04?/:13`1+CZ.!#&2,A(0`29.G`!P->
M8!"!C@(D,8<%;$1`1`1\'$$A-$'$0)5-3,1P!!EFY&`&$7\T0``$`DPP!!5)
M4#"E`$;,P<$'$_#00`4X6!`#&7U*H8(%1U!!Q@<4<.75'18H!4$\#';J*38^
M((%3-`4@\>FI?>6%ZJJL\M6#"3;L\!H0#SSA00LSG/'%!@U\@8*=!#0`@`=T
MZ`%"%3<X$,``0(1QA@$'O.```?\SX#%`9RJL)L>VP%U@P+>=?.(`;WL8@(8!
M`12WQP-[=/&$`VBX^T07V<5"7WC4'=<<)3+``,,4=GB""0S423<%;ADX)X8=
M[L(0B7I<P."!&#*@<<$#ELS[R'5<9,`""`CL)P0+!%1@AADEQ,"'#P2<?.`R
M`K2JU@1RS$'!-D!%D`!52?Y1A@+=Z&B!!@7\D60/$9QHM$8T5,II-`<\1(,`
M!3P3C4!\$%&"J>1@`('1T/3,1QE51_$'%5Q%044!$TBQS1%SH.U#`51$$8$&
M.&'@`P4L1I/$3](H8,00)WG1`!4]J`0`-&C_H88%FT+%,U0?\E!6&12X_<<$
M;OS1-%?_?T"@D08*\?"0S*C?5<8%.'/`@Q(+IB[[-*K.;OOL/7SP`Q!RZ.""
M*Q[8`D46(6A!PO``^&!!!!LHX(,/$\S@P`E.J""#'`<PP,`($,!P[1@JN#"`
M"@$8$!MSN?7F`"$CR'#PN^2>"R\:Y\9F;G,RH/]`PLTIUXH!D'"$'>S@L$I,
MH1:%>,`(/'&#3@AA!(JH%0Q64(L,"$$(7'@/)!+6"%4(P0-"P$(*]!`'%G@`
M`3`IT*(B0(`)S.%``A``&6)V.VM`@"4X8T$%)C"Y/S`A(QKIP="*EJ0@\,$"
M062:TZ8!!VC(H015DX8`$O`'(;&(20KX6L^2E``J3*``%<`)_]HB@`$D(NAM
M<8,>IBS0C+SMK6_0D((7%&(3#,0@"3D1G07:8H08-*X!?/""1B(P`;`IH&@:
M*`-5,*<Y`A3M<_$0'32:8`8ZUO"2U2B!!!Z"A!X\!9.SJQTH1\D@'IQ`!2:0
M0P"&8X`1".$,6D!!"+;0@>%AQ0^+J@`5E@<!!.S@!P:0@0U>P(`?@*`!`8##
M`6I0A`L<0`4G"$"Z(.BP)]C&$M2)A!@2Q@DT\*8+S`'GM^*5G2[4J@M=L$.M
MCK/`<Z5S@``3A'0(2$%W96"#-Q""#!1!""Y\<`4P8,\*'N`*?TG'??7A@@=F
M0(<^L"`,+5"`'\@`H!B60`,VHP`'9/](0U":@0-_<`,?*""D/YB*AV"K$U6>
M(D2B@8TC55F:YRB@@`A,8P@QH,!;HA@-#5`Q;!2P`4T;D-(D\:!.!="I&?16
M@J-2('-H1%L,ML$!"N#M#WJC0(BB\1`X0@4G8XK`'6+Z$`P0P(L^$P`?B.H%
M,A@RJ7^8`Q4Q-X?2]:-I-?T#`6IR!YV0$I1'<<,/@"*!`D"@'W]ME2@3RUBZ
M\`":.BC7'HICA1:0P%=ZV$(6])`%"$3`#Q:H@&C]$`$?B*$&.F`$,0^P@R\`
MX`=C&,,!7K,'((SA!*J$#AJP@QSZ2+`6X6F%-WN#3G$:8%V6,*=PIA"=Z5"'
MH-')CB#<5QW_*\!@@=A9P0?%8!\[<,(YD0B#&`;A@15D8#CF=!<Z1U$+,;``
M`0]=`!9(H``RD`5E`@!00#B@#)".,@8XZ,'B0AH%"S2@``2@"A]PH``*N"$!
M.R%`&P1@TT)R(`H)4(->93)6`3`A"I_\@QFB@`%V=%3$B-T<!2:0@#MM#AJ%
M]('>QD$&<7S-!SB(0@DJ]0<`<$`#;B5`CN<@@'[4-R=EJ`D&$E#(:,2@'QK8
M"0!PX`8*Z`P#4J`"$A+PM3]XP0WC>'$,PI*`,LB$*A5P`P[&^H>QE@`'5*AD
M%)YJ!+<VUG8%2`(/GL&!,OAYP'?^U&(#36AK\*`(.H"/N6!S@Q3$_Q(%*4@!
M"CA+@`A4@`]4J(`?0`N&';A@!`MPP`%&K0+CU6#4'Z`!$*XP@P/80`<FN(`<
MQ-`!+$S6NN"MU;O0H#YTAG,/PQV%>;Y;"`,XX+FX<6YRYD.=!0[0#M94!7?-
MBQMZC0`&DIB.$,3@@0S(P17(.:AT%KB"!>Q'/S,0G:"DP(&4D26&-O-OH>>-
MECUZ-K&-8Y49*'!4>OO[WV89-,`)S0,Y\-I\P+9#%62)@B]L`0J3[D"E15L!
M,EB<#T*P01>PT`<=_.`#']#!!K(@&`:8(-%\4``:3!``(.1O!5=HP7"><(,I
MK&`*HGB`Q=KEKEJ)`IS%?8)Y+J&%&410??_[G(YSL].^:Q/08.7&`@97<!MT
M7F>!'!2#$!:P@G3QFCK(L4T%1V;",(0A#1"(P3*D4(*3N6S=`X][C8;0L[_Z
M@4>K\L*&Y,[W?PN\[W^=`6]DO2TNM`#2(0A!"J``A8>3X+`6*)"FR4`%$,A7
MYB>(C0ZLT`$]O*`.=:@!;`B"A1.X8`?%D4._QO6`&_@K%OGCS7&+J[[CY$9>
MTG'`!3RPS^*B<X$P4(0GIO.(<SEG.>5;:`MV(83E.."`,+C@=3.`'RXX0`=R
M`*?/R<T%[2[@H9)@P1<BH(P7NEL#,3!##`'/_O:[__U\_SO\;Y<'*YA/FAF(
MPQ:VL'@]I"`.L[3_!4M```I0`<8P47Z0<@"P`"90!RZ`,2[@`2E@!Z"G.P'P
M`B>@!GGP&M%T7-X4'UUP`V(@!BO@7>`D=/&B".Z2'?NT"2/P"N#T73"@3BI8
M78\0"PM47A=P<M]V`2IP`$`P!9=!@F!'+U.03UPP'1Y07C!@/J,P'P&U;1\D
M7RRP"UR0!Q-P(%4U!S$@(`."(/,7AF(XAF2H6&4(2JOS&S00`!E`!UL@2R&`
M`K*4!A`G`A-@:7<G6A9`!0#P!">0/4#P!&(0``MP!0;``'5@`Q^@`G7@!`AP
M!:]!6\,Q+C*P!^^%'?^B"4(G"M#A+NZS3P?5"`J$+ZU4A#BW"?U2'<ZA_PI[
M4`,V8#&(6`._4QM8,`*]$4%VL`(KL$\7!%"]XP#)$3`9H%U:]WU8\%#BM0`0
MH&D:L%_MUG9M(!-G.(W46(W6&`WR=XV>,@.RI@,R<`8CE`5:P'^3%H<-MP$^
MD#14H``*P`=\$`*Q(@>IH0+M4P18L`5-\`(OL(@?,`![$%I=H"ZX805<<'^]
M,`6\=@B:,`K547OHHPD.$##L53#4-2\1M$^$,`J/(`:;(0<0I#T#<`#I,@4+
M,`-A0!TT>$#)01X4=`%`<`'2\7KYI'6\@`M5V!XH8`%^@%%$)@`!X@SHH(U"
M.91$.7#96)1[P0+FTP5Q<`4H``5+``9?,)7^]_\%62!Q$9"5$]!"1[0&RF0"
M/W``F<=,0I`'%_@"8FD:*Z`H9W`!.J`#K9`!"_`>%S`%2Q@>WJ1>MV@)#MD<
M5E`)GXA.P30(U:9T[E,)XV8%97D#`6,#=0`'XX-](;0`ZC20@Z`<ML&8#J`"
M1;`^E)`!_C2"-U!N"-`"5;@",S`!.UD!/@``:H`,BQ([2#F;M.DI3?$\N)F;
MNIF;<U"-1UF;CC4N6```8-!X5T`"<O@%DH8"60`&$Z``$^`8!"A:'@`'#%`#
M'U`'G#D`-`".0/!YQ70``_`#,Z!++*`#-"!K)/D$WV(%-S`",X`%X4$NW[('
M*#A<Y[()CJ!K&*->C_#_",N!/\[1,>,U&Z\@!'+P`I!I`]X"FM2F')=`0)=@
M7NA$`RK@``\@"(P@@@P4!HN!`%*'!273!JQ)`'P00V:`#,"YHBRJ.A+PHC`:
MHS(:H[_)?C7:HF:Q!0C@6A``!ON'`OPG:1VP!,;3`-')0S[0CJ"%`"X`6T#P
M`SM0!W@@!!"0`C]0!VCY`6.`!W!@`'!"`-ZF2J!FB\:&GJI@![V1&\/5&[OQ
M31&4<U:`H=61H1F0H97@B9.H"+#0GW;``BUP`;KS`P&P!W8P@MO$6U8P!3,X
M`C>W'`:@`MGG+Z`YC+603_*5"V8'!500C16@`5+P5!H5E#@ZJJ1:JM9PHZ8Z
M_PTI@`````$;0`);D'@A`(`=H`8;4*0)YCP^D"$JTP`M@%M/$`!8R@`LL`4L
M8`-C,``U@*4O,``R8%\:0`!VH$HRP`*L\"[M<QP$PPG@MFLJ:&WS@C&:6`C5
M]0!3L`H&4`1%8&S@=!QRVALR,`/"D@)I@`#,D1U+*`:4.1T'XSZ.@'-[X`)`
M@`;7,0F]=VWL\7U5:&X;0%$EP`%2@"#L=CJI6K$6"YRH>K%Y``(```!$&@(M
M``)Q``(AL`0-H`4IL"L$6%KM2`:LZ9J[@`5AD)TV4)I"4`.F<0!CT*RSU0!D
M40%B(`<T8`#X`8P.8%X*I`D`DY>&L"Z<,"^ZL1M=\/\O`4,OEL`%9X`"5\`%
M_<@`T>0MZ-0O"G0#9R`"P=(`';`<[<,)8J`'+)`!U^%=,^A=&;`'-(!;"A10
M_/,$`^0![W6,,CL#/C!A_(4R!2*;%YNXBNN;BYL6;TBD6;`%(PN`<9`"&R"5
MLD0""48F*3=F:M"J2T`'+5`%.F`#*M`""XBS>'``H$=,0(`%$^8'4&`%.W@!
M%ED;&8`<3>@*2^E.[K("6.``O.,*P*@(U'$)7/"(&Z`&6W`!=3``(6>?E[`)
M"K0`:?!X:@`!'5`<H``#YJ0*D]`Q[J,=_*,#.T`#>T`(`Y6TJ!!"+=`"(6-N
M6>`#%8`@!V(!S]FX^KN_8IC_L18KAY&;`B'0!U4``G0H@%>`69V5I.Y(OU&A
M!L(B`E```@'P`45P!6K`M0>`!S^`B*[K`#Y`%M$Z'+(Q'0;@7?&2/V!K3N0B
M!B%P!4O`!9WA+1'$3UNW`FEPN0T``2VP3#N`,7&K=/[DACOLJL0A`Q3D`034
MBQUS7?-4/SM@`W(@'>\I78U@!Y]!P+EP0B(0`1\U!V:0E4_#OV1<QG'GOQ6K
M!BC0`0(,`J.K?W)(`E?0`?N7!6I04U1`!4F310T`P3VJ!4\P`'(@`E_@`!V,
M!Z<66P?@`G*0!3$@`,W0`#)P7`HTM0?C,,/!:VSJGEL@`F#`PS8`3&B0&Z.P
M"?JZ_P!?\+EV0@+H*0?0Y@!B()]=X*'N=08;L!)J``,U\'SFZK3V,0GJ\0CO
M42XJ8'(`E`&90)"V@6T+@`!G`+_R)0(6\+"9@PQ68\;8G,V$AL:I.@%$VL8M
M0`<A\`5:T`$D(,=9\`4=(`)`0P5'Q`>.L<,K$2Q8@`=R,*L^.`!P\`*GQ@"O
M9@!"0``2&P'*41Z?``N/0+N'<;QR&0=90`(B\+D/``3@ADZ;``MVF0(`(,\$
ML`#1\2ZOH7MRT,P!.=(`L!(=('I6$``Z<`!RX$_;Q@NC.0GS@@8N8')H<)GA
M"K?;YJ$S,`,AXP$@T`[V-;&]J<U(G=2CQ,VF2@"Q-++'$O\'**`%QG,%5P`&
M6I`%1`H/1V0!*3?/+;256U`#"T``4-"DS[N/-G`"11``!`L",4!D6-">#G!=
MAP&:SH$%ZSP#VM4^-Y`%(M"J*>`MP,9KBM!;SH&Z#1$"0K`)\T)=!F"A=O`8
M3R`'6"`"#8$&.K``O7.AGP&XNS""N8M.\J@"7;!`FF`)V*50+/#3\8D+&\`'
M)A-#$*O4MGW;LL/4I4H`7V`L=""Z<?`%2T`"&P``)``&&[`$(G`%!.C.$0"=
MT3G/T","-(``'1`&/["L<``'8^"UZ7+,WV`&)``#QW8!+5B%-V``-Z#880""
M#G`#7R`"&_`8+$=<17C:E<`%)1G_!LV!")^)<U;@:6&0!6F`IK;ROAF`!A[P
M;<;V`"<$U"`J,A"D>V`9`,6+"+)`"=?FOF=PC&$0!WOE,OR%VR1>XH)FVQ"@
MG%50P"V0!UF0W!NPW,N;W"?-CM"SE8[1&$FJ``W@``N0`D^0&B^`!TZ@.[)2
M',/1`<"@`230`B&0`0:`??AQ`3^@`WV*IFCP"3(P7\M+`")@X?#2+A>-F-BD
M3]_13_NI++_C,!YD'P"S`-S5,<@1,!Y@C`M[<^\!!#;0F<IAT0.:3U.XL.W!
MSH]\(-)HXHB>Z'6AVZ0*`4\ILB%@P!W0L0#@R1W;Y;D:W2MQ0\]36AY``X78
MTLU*Y"9P_WHT4!SP<0,3H"!D4%K<2(GEXBWAT1RY(0-"``(=``;96P6N$%S,
M<0D`G@D1J0B7(%V$T$VW:`O&N!]B8-5G\'TK`$(7E`%^>XSFIL1NN0,G\'RQ
MD!T!I8L>B@`(`-3RY0$@'A(8=6**ON[L7@V,/JJ.'@=0L'B11@(;W0#([9H-
MX0.<_CQ@S4/.$P(JL`>^T(`#8"UX``1%<')#2S\&,`-^H'XQX`<=0!]"5]>>
M``.Y(1W@9.Y;`,$B(`3T,QT,.4`98UT6*0H`@U#JQ`GE`HSDH:_HG;4@D`NM
MO>RX`*)5R`)BL`=NJ0(7XUP1,PDK4(QG4`5T`%]"@`";HFD',O]P;L4!>)<6
M%7#4T/!4[<ZB%&N-[XZC!!"D)+L%$&UY:;`$&[V5*['#21J=N5E3","Z+!!+
M8^`$!S\`3J"(8IE*%B,'TV(&(K$\8<`P(Q`&7!"?RF%_LV>78:#1+"`'3Y""
M&",+3]L<3IS0!!0+"3,OW_(MWF(^QQ4=`$.32Y\+XIX+6%#Z)C0%#B`';&T`
M0D>^]A$Q%G0&;JSS"V"VBD(6B74'9G,-"E$!9L,'@',61B`-&&`$"6`$ZIX6
M(Y'U?'<'=3`&A40!1%`'2G#-U-CU+4H`BT>.61`'3P"$?:H'R;.5-T2`"I!@
M2%I3$9`#XQ,'6D`'7'KPUI(]UMF!OZ'_`T)@@%P!"!`7#W)[=A==,G8R3T\.
MB4\/0E,P,F@.F%V15C*=5B-33R-6#P]/GS`CI59=>WMH<K$7LP8.EZQ6BU89
M*PL(,RT(++]8"PLW>W(F%Y]3=BM<'G8C&4)8(7DS6`@>4``1%@)S?^3EYN?H
MZ>KKYCPYY`+PY!HE3']S'!1E!%+D?OU_I`@00(%,007F,$#XPP0A!S\4_N0C
M$^\/!8@6*6B8HZ1$1'8@0XH<2;*DR9,H4ZID5X&"@B;D^#!TL[*FS9$6;NK<
MR;/DA"P$`'Q!$,)#C1<['+1(D84$!`@3"$#PH8"`CPD3J$:(8,<)$"UJ1`S`
M@\<)'`8,7IC]_Q'`@8$``2Y,T$"72I@I%QQ,X0*#U0,9K!SL>6``<!<#!DYI
M^FLEDBE&:+I,>=!8Q@@8?;L\T.P(,2T#%]`T0LRYEH,G4U:PF,$:@>MB(QP4
MD?/$,K4,&;CD]A"F19PSKCV<`>/#0HEQ/4^6P%&FQ)\R$>V1(1+D"(4>/6*P
M&5+@#X8R2F)(R=&C@A$F&-`I_'.$S!PC"7C\(7#>B,4@"9)P4)#`B)H7.420
MW(`$%FC@@>7,X440Y%!0@A$$("@A.SE-:.&%YDRP1`05$(!`'"V@48,<'GB0
MP@)HT)$&&%`IX(-5"L2XU00V2+`'`0K(8)833M1A@UH2.*$",P[(0?^##C/X
MT48)&B"PP`@CW+""$!F,8D<&E731Q2./:"G#7Z#`4,T"+'@@AAA""+'"%%-<
MQF8&H;BU1Q=63/&((PXPUL@C?\EA`!H&:#)"+PAL4R@+&73APC*)L`G#`URL
ML(('0K``0A^LA<'"%1-8H$%%&)Z#0U8+0<<00QR<^D</WOGP1SU_:&#/`?U<
M@-PY&!"A!!5_>!$#!4S,8<%"$/"!081ES"7?'S1\%.JST$9;$PT#+/1'!4HP
M$(.T$E;([;<W*3`5'Q$0L$$*2VPA1&'!@3!#&$MDA94/6FTE@A-XB+'!!CJ8
M!0<>+]3``(\OM#5%%P'H`(0!/M!30@43G.'_B&IA8%&F$':T25D&3VB9R"-?
M"A&"'@MP<<,49UX&PY49+"(F*:H`YL@>IYC26".ER#!%8JUT@<8>!CP@Q@)A
M>(`%%AZLL,<)1:`Q"BB*<"'U#2STT0)K+"RP!0%45.`<MQ^4488*^D3W!Q'D
MV+-JJW]$D-X?]AW@#P[6)@2!&A,\%T4!!0B[$%4]\%K`'1ITQZRSX":N.+<Q
MX&%.`4@L/J"WDE<>$A_TQOCB%QOP0<`*FH801PAI"%&%5?36&^,"$KS`Q0P@
MR('O`'`$?,`+8QP0@&$7!%"$#B@8=QP`+>SA0A<S;*`%"!@_@1LC,N3)IV=/
MS``&`@&X$!IF4^22_QMN+8]BQ<HM-[;9`U-`OX@=,-S`A6B4-5;D'NT+L8#%
MQL#@`@UHD"(#9KG1#0S"@(`6G($%2)M!`R)`#VZU(0GDT($?3&4/)D1D6:S"
M@*L$(!\-E.$/<BO'.W`%`0K48`X`D`DYAO4'-53@6,]IF.&:9;D:VC`Y&O@#
M'P80$.>4@54WM`GE@AA$/VPE`BZJR@8:4($(3``,*%A""N+P"S5010%'W(H/
M:N"$&H1@`B%0B[]><(`QU($!'RC"#0#S%H4]X`HQ*($9L."``.P@``AX"A2X
M4"</M$PP:'C`+.2`B`5\@01?N,`)`B"'/.TB%:#(S0U@T+WQC2`1J8!9EO^H
M,05>$*V1,.#+"*(W!37)8`4(`(&[%O"$`"2F$:'$S0K$P(5*!8,%+-#4%PA0
M@6U)BRKDN(-5<I``)%RD!TPPYA^B\`<+!($F7H@"#]KPAS=8I`P),)PYK/B'
M.WAA#CU@3C.)$!^)H"<*%#"#M>+C*B*Z\YTB(0(<;.`J,K#!"4?((3Q1,L1]
M2BX&?*!"%GT`@=,Y<0,A."046A`&$<1(`52P@`7(!8*R-&$"9&!!6<@"ASJ,
M80`,4($*;#`%,_6N""J0@Q`4H`$S3&`26X+!&8J"I>]9X307,(`LQ!"'*P!`
M#2D(``-^((?(6.9_?>GDU+#$!3N8[`8WP%+Z1E#_F_3!8`46HTW&^&*'+MC!
M`ZPT`!<^U`(Z+("0G+D,8#+@/@\4\&@(*!H*OD$&?Q*(A7;-JU[W:J!^\E5:
M9`@HN00JKA2`X&Y+^$('KA`'$'B`!%BD0D0MH(`9G&``+V!!!&)P!-HYX04#
M&`-9Q@`$$WS``*"[``V`\`,#C*`#9&A#&R"&`@\XH%!2DP$7-",##W1@"PO0
M:092<`4P+)$$`7@!'`[P@0#TKQ/=PXU3U\0^:JP`JE']4FUREIL6L(`VF!'#
MRA[%A;O(H0MB\$T($+`''5Q"$6ZZZ11N@(4S!,-B0CCL!"KP5YU8($+]#;"`
M!TPA`DM+#1R:*+FJTH$S_W!.!%G0@@B^$`(6M``<5.`#&+NP@Z/4``4Q\(,*
M,#N``9S1+`<H;0TNP`46&``(*/63#"!`#P&T00%T0-0>-.6"!9!`"#*=@`):
M\`0QI($$8%"#&AJ@AAN,X2QC8(`.##`G*]3)45P807792DLQ=4\1I0BE!_+`
M@@O4IC:8R?(`5W")#*P&!&?@PBSV\(G_M:P4DT(`"O0@C`6<H0$34*&!!TWH
M0ALZ'7X]=($FH`8J^.'12/1!`[1`7"TL%@Q@N`(4TH"WJ]P@828X``,N`($V
M^*`.)`8I`_!P%B#HX`1RL,)=$F:#(F1/"!$HP4#(,`$ZP$4&<GB!`QH``3``
M`/\`+'``%D@@`N,VX-D0^`(-7G#&,P*A$9S@A#.PM#(K2&T%55H9^^Q@93&Q
M(`W!I1,UW'>#40HA##(H#)DLA0`8A.836FX3(_[B@194(04S\(4(`JWH@AO\
MX'9--,)W4@$`3,#1`'V1&L"P!1)LX-C&W8`:($``J\2N%46(\@URK0568[;:
MH&4`$`)@`AKL(0-6T$$`?@`$(.R@"Q!0D@!*4((&Z,`%11"8',XP`2=V@(]Q
MF/C%E4SL!JS`C"]@P`!JP*<OBUL1<((&)9TA)CC9(6-VP`(4PG"!.5'#9%22
MP=#>-P5#Y2$.6.B8RKKJ`)WM10@S^-`9BH$"`@AHX8#_#[S@HZ7PP:O$`@T@
MP!:V<"X`@"$/59B!%1F]!*APG"HH4($I=&`#M*0@!F9(0I!"RX`ZF)Z,)@C`
M"6C@@LBX@.4TT&D7M(``X0E@`HP\P0=V8(40<'P+8;"#`6ZP!=:(X*?/)@`4
M&%"#$Z@@+6WI`B7;US+,K$P,*]!2*D+)U6F,``M;$`-B`ED*,81!#*<\_YS$
M@(4\&!`!(T"#G1-UB4B*`79[[\.''&[X_OO___X%@#<!`/]V!7F``%QP/_:S
M``]'!1#0`%>D``T0`C1P`<!F`C6P`R=0:F3P`Q(`!R568J"%60?P`S9``RH0
M`$]P)"I@`D!S`2```["E:V2P_P"]HP(T,`(@,@-"X`$P@`;]8P!V<`,IH`8;
MP'$0P`4?H`,F@!8Z<!JX(27<=AEG,@FWX7V4I`A"H`=Z8`47$`MT8@6\<0-6
M<`,+(`1N`0-^!AS<(`I2PQ<R(!E1Q7XM$`S",`,HL`$"N(=\>`X<,`>`&(B"
M.(B"B#@&5GA]"!)7,!4^0`=VX#1&$P<+D`)0X0-\,%@$``,JX`)AH`,J<`(N
M0$@38&IJ`0=P\%D?96+*!3#-9P([\`$V-R07H`,+`!@08`8[IP9[$``TX"?5
M<'X>P`7_HPI`$P)2\10$\`6SP5H!X%6=($E2=250A24WX'WQ)89B%P<R8`(F
MH`.)8/\'YK=&">@!A]%;]W,_6,`(3D5)Y+:.E8(%>==G6]``B5B/`%@&$I"/
M^KB/_+B/B,A7_VB/Z```'=<"0A!SEA$&C84`6P`%'0!H/D`%/K``#F!OS&>!
M-Q`&5-`&;D`P_S(&'U`#(GB*`W``LY@[/U`#)P@7'7,!8:``9E`",:`&8M`[
MN]!)E7`P@@$T=F!%Q-9Q8#"+EZ!N["-=Z?,`5T(-:V4RH:`(1I,"(5`I#W``
M-0`$#E`G&7!^6!(&"V`'I\$;Q3`,7#`G&?",;>(,[\@"P%$,"'`%`OF6@M<&
M$C67=%F7=0D0A!:0<$D./M`!CEA'"R,#A<(-=7@&<=`!"$#_D`<(`R=0!S4@
M`]N0`CX0`6L0)&E!1FD1@KB3.V$@!#N@`C\096SQA6_1!5@@/!$0=V*%&\X`
M)7N0%X*1`2!`!UA`!WJ`-^QE@8!Q)_HF,P\`"E_7=;IQ&4*`+@VP`?$6<FAT
M7NYV)C`P-$(0A^^&0-09/5\2)=^&&[[@9TY")EFPE^`9GH<HGB"A`%DP`S*0
M,-KS?0M0(L$P`RG0`%&$`K\0!D)E`W8`'"B`16_@!""%.\J5:FA4>G-2@CMP
M`'6@.XIT`=H3`&!`#WYP!9?T*&=)58>A)7K!,EP@!@B0!0"`!871"9'122VC
M,4_@93(`/@\@25C@4QTW`Q\P,*:H_P*&D&944EY^A`:_:`S&L%N-0`F1DC2]
M8"AA&08A0)Y(FJ3^I)=["0"NL0`P``0ZZ@%94R*%T@):0`",E@5Q4`6TB0DS
MH`<>\`45P`?W1&TF5F)UH!8#\`'/%U([\`-Q6@,UT%P7L`,Z\`,F^`0*T`9F
M0`5VX"=%E0E`\PB1(2A7(GQ6``8N-CY5`@I2<R5\U`4M4WU?QQAA=P5JH*4`
M<`(,`()PL`.B``TW(`2Z\6Y<8`!6@";M*09@M0=0&$#00"@'E#584#%*FJNZ
M6D-,"I<-T`)YL`4C<`(R@$NX9*6^@0(/V``&&`(@D`(H,#K!M0%4,`$[@"]F
MD:`,@*`@./^@8U`#/U`$*&4#'U!K-D"5H,F$7%`!=-$`7'`:W9,(5B`:FL`(
MW@,#C2!VJC`^3@4GX),;7Y(QEMH]7R<<2Z2E$X`%)E`$>#``WN@]U7`RO0!O
M5I`F6=.#M5@+_Q,IU^6J+!`'U)DU"["K)%NRW-*K;ZD`6@`%(&H`]$8F)3(#
M55`%6P`!%_<%<1`'4(`")+`$(E`%(Y`5&W``3A`DW_J9GDH69U22&6@"K/4!
M>FH"=>"?II<]._`%$`H"?Z$8;#(^M1&&D$IN(/L$NY4!#H`EH]2O^79E*?H\
MHQ0&G)9X6'$%J%&NYY4!#R`EII0!)=)5GM2>G;DN5WD9U2`IH,/_9_%H#":[
MN(P[(2@KD!9``G&@&5B0!EH0`L70@\```F#Q!6^W!7J0`BD``,2V`1T0%6"@
M%GB08D`P4D#P49^E7&C!7.4*M4!@)&,!6F8T``[`4G\:`M``)74R"IIA952%
M/ETP5AT#<U9F"DWI/AF3"BD*AY6`&5H#`%`Q+S,PEH#R!.S#%[3D5"7",:=4
M(I+R;C2#&9P0*=B77[]P2UC0N/([OSWQN/88`4O``CHP`O>S!70@*0B$`&?`
MN1N``B`0`B@@NBF09(DWF1&@!C;0(T`0DF[*<D7P`1ZUK28F:LRE`K-QIQI\
M%CM0!&)``#$9`Y25`GE")UMRHF(22<V;_V9<@#Y6Q@O7]8;B)B;DECX;.@-?
M``8(>Q67E!B(`(YF,DF=-"5BL`@E0BDK``-4HC(Z0VZU,:18$'FN0;]:O,4I
M8;_U"`%8D`$T4'=%5G?;<#2P\P5:L`5I`*V+AP+'1VQ85"X/T$4JL`.O6`1O
M$0`JD#M29V*S:P.N%B@ZL*T'4((G4*<>P$`[9P8$@*$>,[SM(P9K9`?.,THK
M\#^<@!LK(R6+P$G<UQ?LHV=@@!6D4AM<<#!U@B9<I671$`8<4S2\$0;/Z0&7
ME!M75:EIXAIT<#4(P,7`',P@X<6)V`#!Y5RSD,D(4`6^\`MT$`)0D`);@`)O
MC&382P`68`8=LO\`3OL#S@>+7]BZ8Z!<46=&=6H"L8`&7"D'-:`"952"X^P`
M&U`!9/#`*Y`Q>0$FG6`R7X?+C>%]E#%?9:DS+<,(4949FF`%,_"0!-!L!)`"
M!@#%#_`*>Z$;[`-`/>B5-\`;QA`&H/,^*2IN,7,#'S*;,\`"PIS2*KU"B_M2
M+A"N7=`")(`%O>`+K%$%(%`%:?`%6?`%BK4$&M<`(N`#,4``"T`#Y<I\,7H`
MBP0$GOHO/%*2=ZP#594:7=`[-5`'>*H"-7``-'`%5``&:>`!!C`%0ZEET\`(
ME$H*U14*IS`*VZ<(W,<^;-()O,4"G$,')H(`#G`!X!@*ORDUE:H;&TK_)5>9
MD4?#`J!3BYK!R:S@O0M`!R#P&R.[TI;-Q<3<AUG@`J8'!`A```V``-:@EE<C
MV7V`P%G0`5K`;$D&`'0@`A;0`J`)M6CT`1@\!KZCIP.0K1FH`@MC/\&H)NT%
MM7[RA1^`VR$P`R725(\-&)01/[J@"(!AR9R@R:(L7>[#R3#';4(@7@L`!C/P
M`&@P0.3V">`6G$M<2Y2""1DP-$<3!IJ"?ISP=:Q`#=;0!VE`19)CB"7!WZER
MV0#^+)G-AWGP?";Y1020!0)<TC@]V=`:8:LM`A='`C.P!`I@!V/0U#O0NK;]
M`1@(SY_U`Y]X`B;@`B,P`[1Y`V_Q`5/'2'5:_Q8,L`>CL*$]\Q?/.`ILHAN*
M,#Z_V;R44%/8!UV26I;LX]Q"@``BP`*;D9%\A)3@)C50K&6NN@!3L`>S5#'%
M<#]AT.2-@#//:6%G0`<S\"U)D``)4-1WD!(1L"SE(`4?9`[QD0-M(`5?<P[Z
MM!(Q&>#/$@%$D`1U10YSH#:'-N![R`1%<`)`D`&1!P)7H`4M4)NBD[,A,,U:
ML`0]:UP`D`47Q@<CP``;;G,GH*<_0)6BUM6F!ZZ?^(DP,#HKH'J)3$8A66+Z
MZ)\F&0U^HFZYH)6%>V?2X!BB@%WI@QN;@)-6967C4P57(`:N`,4K8+R$#0T>
M4-%4*@:4ZM[%`(\+T/_LW7,*_YR1=3B;WW(`_'T3;FX.=\!,*U0WYB#H*J%!
M>AXJ+N0%1U`.0_#F@[ZX/+`_.@`#MM`"(G`%K@'-(1#I6Y`%5_#O2V!L:A`'
M7V!$&<!<*GD`<WK<=4J5`D-&&DCB.B"&\#:+I87.<E!&68T'^_@"<D"1L.D6
M&_\$KG`)FW$!8@`%4!!7DX1]2TP*,%"\G#`"4B,&-]4%-[#3\>8`0W@#C+$R
M[`MD&%,IT;D+1B/`+0`"6$#ME&!WWE:JOV!?X1X1%%`%,G%L2K`0`/`&(W0'
M&-`$.=$&;[`&&@`""+$!%_`.Y5X./D`$'^$!;Q`"%'`'0R`?/J`$(<`''/3_
M!G7%9"J@!D'`3"70`T:00Z1+`UZ@`4W0D\^1!&;P[A.B`//>3`-P^8I&Z`+(
M!!.\L#OP`"W0TZF$`B$`E6V,`E?@LQ='NI,6`0(``9<UNWJJ@0?:SC\`M6:4
M.R.<>@&P!Z7Z``%06E/F"#=8`W"PCT[@`L"V*.B,&$4R&WX2%PSXH7"52UT&
M&"G:;H]2&[3$K]!L;V2995^"DZ%$2U%HOO(%#'TPFY+(\J9`)RGJJJZ1Q=QR
M`-@$"'\6$'\])85_%'\`%7]K%%)E?SP4%',:!8F+%9%_GIX31PJ"A)H8;7],
MGF4<%#U_&&8E/']-<SB5KV4:D[`^?Q!>G\/$Q<;'_\C)RLO,S<[/T-',-'"_
MM0I1=]+;W-V"WN#AXN!E134'##8/,R%Z9U`H6R@I6RD=8!L;:@W[`&HQ<Q#4
M8,#@@PT30`+0V'%@AQP7)SZ\8'#@@XH3"(%<L"+C0H`38VKH""#GP8@'%QB\
ML/%"@LL7>VX4.?"#!IHN-#[(,:!#1Q<Z*&:P$!)&"`L$+!9D>.+@P1,9&3)T
ML3)B!9<I44-4D6%`QA,8-S+`F")CRHH,-\1<S;!BA8<55#,LP')FQIDX9^R@
ML<+13M05<SUDP#*.VP%%I!"E^D,@2A`+BRE(,O()$S`WCSL1F]-$P2!/`#`0
MX:7J#Q$,&&AAF-/IR)P+J/\EE5&D"L,O"@G<("[,N[?OW^/F3&#PQX<2*DEZ
M<`#.W!GDYM"C,RNCHL:'&BH<A,@2(L62*]U17.F@90D8?PT@-``PH82`-1\J
MUCA11,<%&C]^[`B@XH=*BA_DMT,-1>QAA1U=F#`@`RKT1$,`:,!P@0Y`M.22
M!`,4$<`Y`8QPPQ[VR5%$$7(L<,4&"(AQ`Q=8@("4&",<^(`57"`X@AUAR7`C
M'0AP-<4(4<&P`@Q<C#`%%UQD4"-87'C`!55-8H$`%E(BP,5>3SQAQ1-DK;"%
M"$))E\QAGGSV2BH4$`$,9*I(]D<2E15``2T06*`9,5%X\9D`+/Q1`&F>(#',
M:JW_S2'H)[,M9MLG$Y0BYJ.01OI,&Q)0X`,--$QDAJ1B/L?II[ZA8$-(']#@
M`!8ST)%%`QN`H`<*&VA!@GD`0&#K!DM4P$$%*AS0D`DZ9&G`1T"<H(-U=;PP
MP!@$4<2`'#)X(!,0#NCP0PT'G6!LM!X`@0<<3EPH@1,OG"`7`@L$H"X0P#I`
M1PMG9<#"70B\%54&=L``@Q4/Z)OD6!F`T$)'1JY(I`Q/(HQDDGZ)(<923W"Q
M`%(+5.S!`E8X@,8%%\AQDQTA*`!!GZ#^069B9S)!P1$^(/%+FY(DH(87?F!"
M01(*N/Q'$&1\HD8"`!S11AM!$.#'$#X$P4<A/BC@`Q,3_S0`"VN2N`9!&1,0
M\$>BJA#`1`,1J!%%!"67;39S)Q!A0P+#])#)V;]Y"O?<SZCA0D$JT-#%%!X@
MT`(`8(2P!0E@E"?"%;6B>$,+?'#0P`LU_&#"1D:M(,>$<JC`P`YU#/""K[ZJ
M5$<1//UP008>`0&$#0P&(`,6:;"@PQ@#A"ON"PXLT`<+#_'W@PMH9"##'F@\
ML4(8,P@EA%A<J(4O643"(,,#8O@]Q04PV&&5&&6%Q45;S$>%I&`.6"$&%A4O
MD!067.QA@!PD=04#`A-,0#*H<PRCR')_+#<'&118#O_X1P8!>$(1`HA!`/\@
MBV&4P`^?:`,O!`!`14C!#PBL@/\B$+,<*7CB@9X8H"<T8,"AT>V$*(0&!?R`
MBF%HX!`I%(?<8DC#3T2`!4#`CGVZ(+PG("`+6\A"%N8!`!&4YPLW<,$3XN"'
M.0`@<C2X@`,RT#<$2.4)70!"'1@P@"Z&;@S)@D-!3N`Z,>Q!#CJ0@PG&H),;
M8($>5CA`[9Q@NW%=8`8(L`.[/J("X#&%8WMAT0S0)P0Q>$`M?H'!C=`BO!$(
MH0\=$=X*H`*D[W'A!C>``5HN>8,PJ,4D-V"!*.>B/A@8H&-R2.54PK`!!<R@
MAK",I2QG2<OFS+"6<ZL`!&!P@/E<0`Q/*`(0#+"%#:0!!%O(0P,Z@`4'.(`%
M=F"!#V+_$(,.V"!81=(>`D#@`3E$Y0(O@`,>G"#&`XSA!74X`$(^<`('<$$&
M:$#C'I[@*QBPH`I?R(`6N_B"<5YH#%C8@@=TL(,?-$@'!C#`5&#@@:0LH"@K
M4M)9F)1)(\E`7WZ3P10O,(7HZ4M%-Q@26,("`Z.$87AVZ!OZ\!B&/71,7:ET
M0!=NH`<%0`&7.,VI3G=*RUOR]%,5(`$:!N`KDJ@@;WM8@@\FT`$ZB*$++C`!
M&LZ0!2Q`(0)D4$`7#B"'@UFA;RT0@@&X(`0[V*`.XH3#1)+%@!IT@0L!V($.
MSM@3'3R@H4@1P@CD<(XQT$Y9=93`"5BPA!#(80`_((D48SJ"_Z2$X2T+XX(F
M+WG)LT!%20A`@!7VD`$T5':R*T*2)L6@2+&$02E6P`K%'.L!&0POE5)T``RP
MP-2?VO:VN,TM<WRJ6^D`(`,N(.H'=*`@`EE!#1&8P!=8X`#]R`$!*=`""-10
M@1*H(21R(,L3[("%%K0`"QXX[0IL,$XG>`Z,Z61``+(X'S2>("$S554'PI"Y
M&@RD60/`PX7(&0`4-.`,"(EG??JC`P<0)0S9_)&1F(250FI2DW-Y0':;A*,D
M665)0H(1%26V@!5P:0JCQ$(A65"4*W',`'L1@AK`T-L6N_C%,!X&;V/L&PC(
M0`<`<L$%3%`#`X2A5E?8P@).\`(YL/^@`PA`P1D:H``_9$%S<K!"%QX0AA:`
M(`[?19<,6**L%Z#S!7XEZ@G0(3G[RG4%<4!!%@"PA3V<8`<?(`@ZSFD[.@[@
M`0#80!XHI&.2/,B=]5K2"&YT`]=*%DE*6EC%X&F'(W$!P=\#G_@>1E;`+,`#
M6?HJ^A[J%B$(@0M=<`!)'""#&W1@`C1.M:I7+<L9LSH<$0#!$S[`Q@#<0`XG
M,``(OK"`*I``!"H``NQ`$(8T_,T'5#@#CN4P%2[,JP5QH,-=PH#C,'O.<\H2
M[A;SX]<?&.`,2P#!#+X``C7^P%<VB#,ZPND2.K[`#F!0@QTH8H(`<&PG;G12
MONS`[WM);P3_V?M11ROV`!X>B(HW.!+X$CX%1!*)!>A#T!/$P-I"1MH.3SBE
M`29^!D>]^N,@#WFG1,X;"TR@!2JHPP?VP((NV*<%*TH!";)@DC.DX`S0C0,$
MFK:`'5^@"RF=V!G>=080"$$%?GV!$_`P`#A<NP[8(DA!*:("*T`!`(.<@0QH
MX()T[^`$-N@E.CHW+CS@X0-<V,`*N,C5"R3T"1DH:T2E%S'AN3:U=N#7`[A5
MO@Q090J%A(IH;V`'J$1/+NB[`56,XEA//LP#0NA"%_:PAP=,`0M2([GF-_\,
M`N3@\Z`/O>A#SPL7NYKSS@F;`1BB8_OHF-F`Z8,!5@`"+:1`*%N8_P`5(%#H
MO1Q(#%6.`Y:K0.P3$*1S2\]V6W\PYI#4@%DJR,`7KH"`,[`@F.>N@0G\T\MS
MJ"1<2\?#"T;`A0.\((IHO`"7,ADO)#6ZAWSQ"\"GP+<P\'`%C7Y`W+'R/"6=
MQ`Y)8DCH(P8R)3&;-A1"X`$**`-25GG-DP:H%X$22`P14``6>($8F($8N"FF
M-X'<4`$6H``MD`%%L`-1A`8!H"$!8`!]<U?R@$=VD`40$`$-\`1H@`9`<CXM
MH`<ID`9XA`498`/>IU]T1$YC<%1Q-@9S1A,7(`29)00/X`!=]W4F8'YM%2`_
MH'3A9UX'``(Z,!%?=P#!\@0W`A;98S#Y(O\6FM1H80%X0M!P0J!(0#(6'E!X
MFA05`.<]520$P_,`0J`^#Z6'^O9.4_$`]^.!B)B((7=ZBE@,%?"($>`#*T!&
M/S<A(S$"?8`""_`Z(S!68M``$\`''=`%S&8'.BAS2R!=2!$`-:$YY=5%YF4#
MY\8L!U`'8V`#QK('CL0%I]03)!$`$D$J-L`ZY>5N+T`""*"$2L@`2O044Y`O
M-^)^^:)(%Z4DGB86TP.`V7-)`,@P?B$^UX@6$!<&(R!3?PAQ+(!_<1<&89`O
M,M`%.K(`C3B/]!ACC%B/?_"(?A`#9.`#8&`'!N``&,$1"Y`&=-!:.Q8`VN$#
M?D`%+6<`8K``,_#_*N61!7J`/C`010YP`4A'3OE%1U!W#M?!`%!G+`$I/2DX
M5UU@`"[P`08ABS\0'UWD=./T`@N@!A?@?!\0`-^H)'^Q(F6E)0R(%<!7%%(Q
M%1[B/!D0(Y<4/0`H!D+0%E'"`D_R5F'``H,D!"MR`PTU!5GR!'LGC_@XEF2Y
M4_=8CQ9`!C%@!AI`!GQP?7+P`3LP`F&``%"`/#U'`PBA!1-`!@3`%%:P`*Z2
M`M/W!3RR`J2(!@]P:09@4"[P`T[79111B^>D3O9Q@R("!#XQ+$"@`B9P`A?1
M'S6@5LI27C6@!5\P$'5P`@:RE,_H%.*3/0PXFQD`E42AE6+!;PYS`U%I_YMD
ME0']0E8AY6E40CXR8!1(<3%E159>X0!D^%5E&9W2V6K3Z8AIV09L60%J0`<7
M4`0JT`40%P)U*0034BI+``$Q(`(*)08M$`(AD`9;H`5Q@"XX<0$C@`4\L@<N
M,'M3L`?J!@=*:'[H]`$F\"!N%P`N0"*B!@0[H"'L4BQ"B$ZT4X0?$`(38`4L
M`03SE'=4`2*I]23\)SUEH2^,)`96,2,9MCP<=EJ"$5(.`QAX%08P\``X,C&7
MQFE(X@#$HW\P$`;5^:-`>C9G28^ZU`!&TY94H`9=<`$[\`0VFH!/T)D'8`?^
M104@$"%8H`=8!A17D`=6-!*Y@P(H@$-%(`-^`_\"X'0=O:02GW,"7%=@:*0Z
MOP@$/Z`#:*`#)^`"Q*5N<D1.`"H'$*`&8K`#!C!_1C)H"(.'KL5OTT,59L@6
M:F$%V:-(5H`&7=$D1Y%9+*`B$@EQF>4!T6BC%Y,43A*0>T!J?!.DJKJJD#*D
M\Q@!````#5`!;>"6$X``(O($$&>#8B`'<*8",W`%!$``+!"8:78&+?`%J-D"
M,(`&>W!)>2"F+'`"/]`%5O4%,#`&3J"$UB%')W!1#A`6PV@1]5&>)P`_"/&8
MW<=%3L>F+#`!(H`&96&'&4!_?J<O?O%.#*@E`+<"E412`",64I90!O``:0%\
MZ+(`='!E@\0"AU24IY7_J>!U`<Y:/N;#JAB;L7&SJCYP#Q!`!60`@GR@!E9P
M.0\`(K\45S9@`'2P`8VRJ2T`#W20`F#P!7%@?S#`#@@0`EH09+-F9"B@!0;`
M`!*`!UM44`-0!WNP`#+UA9%S$/:F`Q51!`J"$3%94,GB.1]0!WCP`W2P!>K'
M4!%U(VHA63CBKWAGAX1')(6&%E*I2%V`1<Z:)4XQ:.-3?2"0`BD@,"]R6E72
M<QX3MT]P`QI;N(;K#:[:B#X`BA.@`!7@!X^H`%7@$0%@'P_E`D>5`=&E``U@
M2,BD!U^P!!U0!;R(!E,@<V*:#PV@!Q(V,4)0!`P`!W)9`P7E946`@BE!5#$Y
M_SEH9%\J2*<-Z@)`P$7IM`/@,@!SV04K0&*/52/]%A:,RA%@L93Y\HQM`21J
M&Y5N%[>4YTS.^947L`?Y`E8I$`)0``90H#Y4L@#I%X5[<[CP&[_-D+B*R`?U
MHP`1P`>/ZP>#@`6XRYY<P"X7T`($T``6T`$2DV9:(`)@$`<\L0="T`(>:RL$
MH`9SH22N500TH!'.B08#<78?87P#T%8ZM!#6H0-68`#:LG'XT3DJ]P/?`A,C
M@#T=MKR;>A;:B!:%)WAV<",C\!0&DSU<<CPK$(4<X14K*47N<TJ45SQYYP%]
M0`)JH`5;\%V>)@<TP&Q3(0/RV\5>3`STFXA^D#41\/^(^UL!$0`!U*8#*X`%
M7.%-'>`#/F`!>1`&+2("1H<4*[P`>A"K:E`_/@``=C`#+;``GP8$^('"%6,"
M$L$`Q.4?GV-?!_!>/V`#-!`Q.O`!)*+"`Z$L6Y1?<H`"4V`%5]EA28$DF%0D
MM7D5Y!<643'*,M!HL4P6S:,B>5=P>4=JSC1Y"O4$\Q2W`<D%+;`$!```\KD`
M-W`?]N9,7/S%SBR_88R(%L`/6$4&?G#-(@L`*(:L"_!4(Z`%GA$!Z#)N6:`#
M-/`D!I4!"/`%$%#`]4,%?``!4.`=*;``F/(#0,!L+54#GW-4_!R2YF0#G:D"
MIS,"GQE7)B"$YD01M4,#R97_6NC(CF(14E:A+YF46B9Z2?A"HF.QC2'%FWG7
M47<GM^YCJ6]7/#?1HR!@I!!06`O0!1K";'M7-AA@0`I0>OHC#GZ`&@#P!T:P
M&]"`!/DS#$S00B.4`#@`04"=T]ZPU,_\"250`%Z0/Y8BQU1@CZNZ>S.HEOP+
MN19`!1,0!WT`!NO1(\=5`69``!(6!E?0+5T@!H^I`USP!1T@.._9`A/`O_Y8
M1'2`IP:POG3``AE``_VQ`Z*##E(7536!18Q\$9@KBSN@`N35!#Y@!A:``.>(
M+D_R/9A4FROP,`''@-F3E&<Q:-K#V<M#:)^=VF31J,Z$197Z%$(P;FJ@'H%S
M`\!R_P&E9@5E<P!1L#5730QGL@QUD@P0H`"5\`=&'0W+[0FC,0QCT`8<L"G#
M/0Q48`W<0`$Y\-3&@`-WD`-!T#\]T`--`"<P%LT>:+\^$`$6P`<Q\(@6$`$*
MD#4$L-X*0``X-TTE```/D3T<DW`_H')R$%WF:YAA``7(QKFUT@$S,07PD`;=
ML0%?0&W\O"Q1-P:1[9([<++;ISK%(CG%4@,2T`$Q(`!F$`$I("7HPP7;E7`(
M\S#^QH!447!60$5BT,-$4EDA=7`FBF!BD6AT]Q3O^!3+.WUD73@SH"['29YE
MTP0Y(!E7S0=>$`."@#0EP`'JH0AD```<V#\X4`!D8P9J,/\*P_"QGL`'9*,!
M,0`!J,8!$^`%J!`#;0``UN`'<*X!OS`'Q7P(S_T)3@!#9H`T?B``!.`%`D`!
M;I``O]`&7D`V`N`'$,`'?J`&BJ`!=[`T;1`#PTH!5,`R)JX&2\/=9]X$P\`#
MF?=BZ#V!\1T!^<L'&@""5*``LB[K\,P'"J`&6:``;5`"/0<#3'$#%>,`S]<0
M+(`"=+T%H(L"`!`!L8[K6A``4PH"=$!\_@4!*7`!'V!G-,$`2EA0V+$Q!87(
M>JHZ)F`"7E8%$>`>)4`%*=`"#DM:TVAXSQ@5F)0]A;=W27)1TN,7:0%YY`=\
M"6A9WQ.5?@>69,$OT;(%Y$$")+#_`5N0S'Z($DU^WV5`!1%P!U*`!%)0`DF@
M`9)A!GX0!:Y0`C"4"`4P`6;``410`EY`YIX``3F``7Q0`N$]`4G0!DE@`?]C
M!J\P`0E0`CT@!52``V:@`',`)P+0EJ_0YZ!P!*@F!1TO`"6@YCC`&&H@W4S`
M`050`0)@!&:@`C2H``*``QR0`#'@!Z/1`S?=\13`!FHNZEO3!%KC"0)0!P9T
MWJN*YDZCO[5:`7Q0ZQ80^%_M`Q!``A,@0;I-10W5`EIW`'"@?0;&LRB@!T,$
M``J`YE&S!`9P`!>`E5?V!4:J!1=0`^,TPO%!$`%B`I>C`[B8$&@D3)+M!`?0
M!2A`!B7`_Y83@`+HHJ+0*SS/>(<]W%'2XV@'L@*$)ZD*Z`%@H9SV(@-0:16%
M-P6A1G]UBP7B<06S`B938*<TVN1O@@-4D``&!.J*P0:H01D],/>?4-Q\(#6S
M4.;([0FOH`"94/%_T``D$-[(-C5(``@6?X,]?Q0`2TE_1!J#CAQ,7G^%?QP`
M=X54/G]\1A@]7E)E?T=SFA%!&#D3&AA_&#X4.8-1"0*.N+FZN[R]OK_`P<+#
MQ+P^.'*./8K%S<[/O8+0T]35UKI\$3X*"A4:9&06$1$6%E1\X@H;5PIF?#I=
M8@A8,WH@=@<O.RXZ#S-;7[YD^2*"P+@)$S9<&&-"2(LX(;XT(/\`(,./%R\8
M'*C!@,$/&S]TH*&A8P<0('+DT`!R8L<!)P=H/`%3H8V9"@V@(%BP`@:,#!FX
MC+C!!8:=##"L6!G!Q8X=+CUA<!$C-(.0%1Y\B@DC1DA1.V(\>+AAY\$4!PZL
M=$EKY4:5#@#`?+F21PB:+G9N7)O6Y(\7-E02E/BCAL^D0<P<%;B#"X(@/FK^
ME&#2F(JR/PH*_"E#A0"!/Y1]6,8PQXBTPVHB'&:D2XJ3PW\*",JTR0(`1Z)(
MF?(188*C5J]BS1I4P<C>X\B3'Q<@@8*A%PV42X=V>KKUZ\4J*!`=@8H""V2R
M1>##1\&X[5\`\(D!@880!`_U5%E@8,#_@`]R@`3`LD6+"!$`$.##!!`0,$$#
M6.@@1Q@/I;"$@02T<``<=7RPPP\''+!##3_(80`0:!@0@`I`Z."""21^@`<#
M0!0A!Q1\:/!-!1.`P(45,OB405Y<<#%%CG;\%-1/-ZRP(Q<>K,!4!F+8(8-5
M5QVUP@U74=74`P^,@,8>2\$01A\;`)"%3C=<$(`#,&`'3%]S#.!=`5+TP,$?
M0930!A-4E%`!!Q7$@`0N",4PQQ`E`*":(Q!81@AFFG%VAP4Q$/&':*_,04`9
M9LSV2@P*&!=$!8X(``$9#40!FADQX)!I$'_81H8`2;1!AAFYE:+)'$&8X4<)
MP,%"P1!FF)'G_Y]J%FNL-3T4$,00@_C@Q"W'1CM(==)6.YT%#32@`!]43#">
M.>AX9YX"$T"A!A46?-&%D0BDD$48(USPP@`L'@"$!UFHT8`6'5P!00,00(`0
M`$\X@,49$06(T!8[#%!'#1_84,,!'WP`A)GPR!#`#QR>\,,.)3DQP`$_5"R&
M!6:4H+(%"#QAQP@P+\E%!B,`)=60,WL@A$]7C2!5DE")(<8-,LBPE1@K3"E$
MDS*L($,73SQQ@U4AB+#$%S-X8.8%,EB+BV&MWA*!%VT,0H4:&E!`41L4^*"&
M%+A8\ID&`"CJB!G0_N'''P(T\JH4`/@`:@FWQ.`<'P`TLO<<`/@!JO\&7LSA
M"!]>;/*'&7?P(8`7?(#Z1P,32&&&%P1P0`$9G%`@P&!M>#$!!1S$\$<,@U$!
M0!M4>(&ZU[SWWBKI<\YNM^_644O\\<U$````$)S7';CB^+"-`A"DX(,?5(#P
MA`MRL#"#&"<8L-`+)(]!PQ1Y!*C&$BRDH*_`-<HAPP(S0*&%&@).$((*Y$>,
MX<,FD,,%BN"`J.6'`1\P08L"L`,GP&$`&+F/'F(D`"G$X`PS*UK1B@(5J<PL
M:4@1R@J$$)0I9>!)5RD248;&E`4(;05A"0-9BN*SH80A#"S0`QA$H`<$&$`%
M-$`#\H9(Q"(:\8A(O(;QDIA$!<0%=-OXUCG_RH.0;8"!!`KPPP2P((</7$`(
M5BC"#RZPD`=BY`0.6$`*)@*!&2`@#_Z:``%&H`,6((`.6P!#@19V`0;80`4_
M^,$87O`!'9!1!U&;@A7DL)$3E$@.-G`"1O`@R3JH``41B($9-)`%#R#%)S`@
MR@J*0I2I6.F$08$*"*TP!2--H4=8D:%5J#2TK?3(9Z$D(1>$$(899`$`'8A#
M!H!P`!,P\9C(3*8REWF=)3+S>'($V`2B:($*6%,3`]H&"AH0@0H`@`LTJ($.
MXE4#$Y!Q#$YPPHK0F($S@`X"6ZA"&.*P`82$H8XS:,$6F&<@'T#@#$7X`,=J
M,,@/T,!#"MH#+PW`_R(=!$!\*J+8(/'@L!-@(0)^B$$,&L`"H-P`!ET1`U(R
M`$.DW>`&4Y@"48X2%BX\P"H9F$()Q5(DJ@C!`U#Q$0QJAB4QP,`#=J2#'JZ0
MA1`L``TGT,$SE\K4ICIUF<Y\:K4*-)%MH,N:UBS/=B*@@"PXQ@]Y>((.[+4'
M&MC`!#0(``/4Z00&Z,`*:/"`OAJP`0RRH`,"ZH`,$,#7-(`!BM)KP`(X=``&
MO&`,(=D26O>P`"X>(``7,``:+O"!"@5R0G!XH`U"$(%9*8`.0%G!%%J:@8_R
M<FI`D:G04BF6+@SE!D(CY=*\LLN;BD4,4P!+3+F`A@>(809Q@,(74)`"%O\\
M(0`!D*IRE\O<YA;/N5X+V#2W54T_D,%QWND.'PB0A^M-X`$BJD%2?Z""(B#W
M)1)PP@[VD!46;&`#!!`!#!X@A!!`0'H`T$,+SJ"'+"P!L!,`@%EK0%"/Z$!\
M+G@H"27VT`OHH`@4LY<);(!.)Z2W!BQ8CQ_`@%,/CK*TN\R*3&<&6YP>I4=F
MF=I49A:4J0F!A%V)996BM(<+=.$]:>`7UC)@`!I`]\=`#K*0<1'5(2<'`DL0
M`0JV0`(U=",&X1@'.OA`@B]HH`U04`$C:Z""$Y2S"'O80P,E4(,T/J0%<80"
M%QCDU0%!(`MQ`$$*M+`$/0Y(CEV`V`'&,(8/%('_'SH((`P,\((Z!``-.O`8
MR4CV`0)C))UP>`$(_."'"&R!"T3Q66EW-$(C.>661RE2CW8$@QP19:0T>W$L
M=28T%X]E"EAJY0)"T`$M@"`,!CB!D7?-ZUXGL\B^KH8(%G"#$3QE!0A``034
MH`4H$*!S/D#`!DI`!AC\<0PF^4$=3+`#`W0!")(,``QFD():XT^P+(A#'.!2
M(``T.P500$$'E@`_Z2'`!":8F(8>_.`QH@$(=6"`"38VL3H$/.`=&4,=*&GA
M(F0R!C[`@E(>\*23`F678I!!6WIDE*#$U-@C>,!1@$)2&+02AB_V0!B6AC3;
MTNPI2\,"%*[0@19,`0C!_\ZYSJ5#!NGY_.=`![KD@`SLG3NC#&@H6-&>X*6'
M+``!7^AFC28@``MT<<\JV-@!5&`#[@F0"UA`@/VN$"`"I$$,9X@#'5`@@H"1
MH`-+CG<'-E`@Z4U`"W)@H`TH5@0:%$$%-7"!"QA`(?(6-N'V.>P8)G98.$B@
M#@"(@08J0`)%&ALLHBWU5*Q0VA6$P4BG'($53"Z#E(*X1PN`5VFWLO+5#\WD
M4O(\U)<`!2SLP>BXS_TSU$"$WOO^]\#_O>R(KOMKE`$M!GC:$\2`A2I4H3]:
M:``5OK"%"I3`!PX(`#']6-@=%.$"3V#!%]ZN!RV`P3\%ZD!$4M""$&AA`TO8
M0O\6LH""^G]A`U7U@6?NN?<,J<`$&.(1.V!8?=81#!!P-8`1Y',A'D-0-K`'
M#8`W`E`!51!*2-%J(D4D4X,5G/91>>%Y'@!K7?`D,G4#?%5"-T525P%#*P`U
M#I!T,O!2"Q`'6Z`'9U!\.)B#.N@+1;>#O5`%8?8$GF0'O'0&OP0&^D(`,T`"
MX-!&^>0`8[`1XG4!7,`"('`_$```&P`&64`"`J,&5T!S(``"*$!__;$$9LAV
M>W1G6]!%`H5`'M,1$\,`49B`=!B%%U$'B.5W0`"`8[0`5#<'HM,`N/5*4V-Q
M0R$40Q,E-0,4'D`'(0`"8I!H<C`",I4!"\`"+;=RL#3_2C!`0C+@``;@`'9@
M!78P!;U4;CZXBJR8>SW8BK@P`S3@`@<E0'80!EL`,&H0."*0!A,0`WP``1V`
M`&"P`2"P$R,P@D)@A4W6`/H2%_]%`-DB`E!0!2U@/P/1`2*0!5M0?U<`,/U$
M`!WP`$6@9S9P`BY06`>@AXNW9QRQ$8+42&D5`"Z@'R)7!15001Q@!F#0)#U1
M,T\2)%1Q<43Q41F0;%<@`F`P`XQD`PZP:;RD,T#E0E/!2S<E4J(G`S!C!5CB
M$%D`BR`9DD/VBB')!$!$1F0D`QZ0BUFH!0#P!02`+N0BC&HP`=L!`22P``LP
MAB#0`?A#`/\"`&IP;MO8C<$U_W^UI@7UAP+C!P#@*$=GH`,E8W!U\`,N8(=\
M5@=[!Q)[]@%=YE`"Y``7(`<*\B0><`45(`52,`=DH`4+P`6EYR0D]R,O!4M=
M@0#:6&=JT`$.T&TE.!6I%Y@L4"1)@D,L,!8<]R2AM!5GL`4B^9B0N5PD"9(\
M4`2CN`<.\``W,$\"0P`;0`)8("!D4$5RA!#3M%U(V`#+XQD&,@%SI9H#D04=
M``+EUP'SII1+YE]S52#B^`0_P`")]S&&50>%19P(I'"6I`-I%5GB$P`T,'"6
MF`%AL`$:P`$<(`6D@@494$"66(4+<!9MX1490&Y+<`5)%A=<!#.FI')AL``>
ML%JF)O\$F:B30$-2L!0&=/"1D;F?_`E5_;D+3,`U.Y4CHX4`5P"47"@"%1`!
M9B`P"D`%WM$!;I0H^L>:"/$O$``&0GE%7Z`%2@F)6D`"=%9E]:>-&Y"$%]H"
MVF8?8[!W?)81'?$!)Y`A(8%<`2!`S4F/.N``4S`4&<`"#:`!:BDZ$,`"&AER
M/P(#2O(3,R,$_B&B6G`%)WH%7&``3.=17?&>2.)),G`4O#1J/V(55B($6)`&
M_WFF:$I$DPF+3,`]KG4#"_`$/XH%++`$6R@@X!$@YC$>!``""[`%K0F4=2>.
M'?`%VEBH*$`"]9<&4#!OYDESA=HO=-=/<J0''W"`Y,,18T#_APQ03AX2$G(`
M@"5B2!@C!WL@`U"Q(QJY`$&ZEE*@`8)%,SZA`SI`4CA5>F'`H?-GI_IR!A^`
M!KDD%AZP`%>1B3*T4U;1HUUJ!2[C%#>@<BV0IM(ZK=:RIJW(`P?6!58@!*!%
M-/2U3R@``!.0*:"C#=O@FMPHK@2"A/?E`R])?XJ:!G%`?QV@![0&!DFV!%H@
M$.87,)XQ31.P!26SCA!C6`:H`N!W`2>`;[_9=0IBHSP::E3A%##``@30!FHY
M!S&P`=_I)!RI4D)@D&)0J`'Q!<7(/%DP!LD78KR4>A'I/3.`!6(!%`ZP!R)2
M0`[0!4"!!=3:LS[;3-0:H%WP`%VP_P!0T`(R(`=",%3I06EF@!#D$`'+]HSX
MXT]+,&\$0"Y@V`%9(`);$`+]10)%%0=?L`1"*0+[F@51J@9[9"#_M"$*=P`4
M!J,_<"8RP!+_=Q("=*-D1(HJ]IY"X!2C%09!*H@6M`4X53#&]D))$P8B.G_^
M=:($H`5H9`=),Q4WU'I!$0;-!Q$(<)@BTG=@&5EZ\;.F>[K68*VLR`28^20W
M9`478`4@0`*>\1V2!P9@P!O;10(DP$_1)`(^:9-`25=)]@50D`(!T0'P1A#O
MM:^YN00H"I1JH`>AVF@<HG`0,T;Q0IP+VR("1$8"Q'D[`P,NZQ.[!*<0("A2
M(`!^(`)B@/\69M$CL'0&(MHO=@J.*%")M35"[IF"3,*>")`&*!`"4#`#@]EC
MRHE<%X"Z#-S`Q:"ZJ^A#X"<6,+`'3]`"_]4;XZ`!V)(MWN(V``(_GO$OTZ1_
M-GD@\$=_V9@"R&N>B@H0(2JE;.L9V:(%#A!.7OF;G5I,(C>C+\`A/V`"AF2S
M:-`TMPJG;TEB*X4%#8"Q@E@!6X`6+H,44Q!*+$!K\R8"0^D9(3!Z(W05JJ:D
M5**3[BD&+-`"C.I^':"=,N!@9.G`<!S'O`#!/C@#D64%60$S"_"--OD=Y$`@
M3KE'!`*._20]VV$@#^I/N-L!C`H0+%R&`]&-7*NVO!HP85(1Q%3_`S;P`1FR
MCB[P!!>P$3_\`TFEP,!JK)M[0S<COZ>(!3Y0`FHI`!&P`%@"%!HW`BOPIQYZ
MGO]2!:5U4C!4D;HT%6+1>D!%!W&V!6G0`GD0!P@``PZ@5+U#`=Q@+-A#!<Z1
M"Q%0!HTP#1S`&')L+;A#!0(@`!`Z?'^@`1/@.4%&QSO(`Y#U!'#5!0@0!X!%
M+@W@7YH@J+PYE-)5PEQU7^:A?X<:`E6@!PB-O%JP!2G0'U56:UD@P\X8)BV0
M:X?7$8?E`A>0AQ1S`B3Q`$^0?"Q`!P@0N%BQF:$T2K`56E7PRM?9!FJ`!2RF
M01Z0`CMTLJIY!J)7)53R2CTQ6B'[Q6.!_Q5V!!]N=`8"G`*?ZSL7P`WNG`N:
MT0M^D`,$D,VXP`.&\`Q,`#=J$\[6P@<U8`00)P%!\`*N8`%.P`-$,!CM3*T]
M`%D")`<KH)1I4!#Z=T4H$`>B02ZM"0$;`"#BNAT/.@$]!`+BZIE5%F<A0(,"
MT0%0`!#_X:%:H+;X-]%[*03$M(X4DQ$[L`-U,#(D0@,T<`$LL``C<,4A<`9?
M;!1#@R1@3"5(@@(5((CLJP8L@)E/80=8H*%V>K8(,`(:F32`BVDA2]PC%`:L
MUA4X=$=GP%<(0P)+D`>]4P+#,0A\$CRO^@?KB\X:8`:#H)9LXP=EPP%(,`?.
M(0!D8-6#@`&-,/\GLZ+=/6#>%.`'V2P%L"P%L3,[P4,&@\$!35"=@C@()3!\
M<*,!>>/5RG$$$#`I$C`'&"`!?\`#++!K3YV#/&`"&JT@,[`!56`6"*`&2MT"
MB@H!W&`>W@'(S+,MVT(`,.`"!F`'XC<@2Q`'9T`'8QA<]1<'*&"VB+#+9+>+
MN*LO^;L1&D%A=%@'\]*IZ&@`88$`!?$O)%`%FC@53/*)(K5"+'@%,>"J=#,"
MIXH4TM8`)(!_`"`$(\AB$:ER27.*18(5[UE3MO5T"X`PQPL%`=([?!#5?-,#
MJ#`'&G`$C$$$`%``DI`##9``JM$#96`!T\0#%<`'<@`!;>`'43`!$X[_"^S]
M!Q#`!!-@!-2LX`*0`PI`!+-B!&X@`#K0`#T0!010"+V1!->S`QLPFG^R`5&@
M!@GP"@E``)*"X-*AX`P.`4<0'4T0'496X3C8`PH2JE,@MEP0`%V`!2$P`V<P
M9R``!0CQH%Q%+LMS/=P"`1\2NQZ`QM(8`GPU`S<NP"C0DR>*"+6FD$*I!AKJ
ME((5,<#Y`A2UJ=BK0!H]%E60M5<%`2U`0IUW0Z^M2KE,==9I01L0LALH;63W
M3T(H4J.D,\CM0H'[B2OW8AP44T_QK/+9`BU0#UNPX+Q#!7J>*)BQ"<-!"3T@
M`!-.`6P`&Q00`0FP"910!@]J!,&SWHU`*:0!_QJ$(0D1$`44L`:#0`-M8QF4
MP0EEH!FE,`B4<0#.00,"4`"-0`F^GAS`[@,2P`0T8"HZ8/(C2:TLH"`:S2#&
ME6`((&="^04I8%^\8<C;(4<^8`%\,`$>$``'MDM80`=_505\U?9QX"[TMV[O
MA;9J2P(`DBWQ+C!;X`(J<*D'8!]Z.`!C$#XZ4"(CJ&P/QRM+X$)4C`5TR@*'
M^9Y#@3Y^,`?7*05\T`(BA32.2W8`X`%/L#16OG+N69@IQP(K]WE`418C^($>
M@`!N)'\HT#MD@-6#\"A_T!FPX?)MD.M_``>P@0-.B?.#P`(84``%H-Z9#O22
M0QD8L.`Q4`:RD/1++__T;G`':@#U0T<9$$X*;8#UL+'UR-'U#1X!$@`()4,8
M?X6&AXB)BHN,C8Z/BA:0DY25EI>8C6<!-')[81YB*PYR"`T$,0I+$!TD/E0*
M!`06$:\0*&!79S(C'F%86"T@2R%Q='%0*"DH62AZ'6!+'2A?6B(B8!L;``!J
M$!`-"SLV!S5U+P/H)Q<..CLG`1<S`!,6&F9S9&!87%,9"PA`A`"!)<R*$3!N
MB$$EA0('`3[29%C!A0Z`!G'Z61$2)H,87PL6A.(BQ(.O,$(43H$Q0L83!UR`
MA62!!<&,8)ER*OK1AD*;"!#^>/'SIT>A''\$\*#0A(.&,D6/_IG@(^H?-0K_
M_DA!A$'#GU=_,,SYP^1/!1Q_"D"@@/0/#0I@R_+XTZ#`GR,""I4]HH$IA0)>
MC>H<3+BPX<,Y2["),L>'!`)!7DBY\\('`0Z(,Q>6I+FS9\1E+N@(\&0!"X4?
M-T"@TL9'@PEJ.A#@$V&"`@M^*DP8D0$*&#!QJ"'`0@=*P&(A4*#HL(59,RU+
M2#3;<F5)M"7;ND$@`$'+A0\OQKPX5Z>&'`,!BKP[SZ*!CPIFS$B9$P.%@2<9
M/+"@`Z(/@HXR/-#2#!#(QP$')?"!Q0AAD`#&%D\\``,,'BS`Q0TEF:2AAJ"(
MX>&%7'!AQ0IYJ`$`'::QL$!!87Q&R5-E>.6%&P04_S)!(4%$@8-7?"10`&8W
MTE4``57Q@8,"%+B1@!>'J%%&&1R0X94"0!9"``9J6%G('7](.=57&%CV%0XW
MWFA&%!B8\4<$>07IXIMPQEE8!$^20<:3!:CYQQU),)&7G(`>PEF@A`):A@XN
MR#&"&"R(8L49W%'AQP24=M<`'Q90P4<%,?BAA0XSJ"&+&B)`D8$,89S!`@LM
M]*$'-5ED\44''631@19:3&?-==NHX2MW#0BA`AX#%/O"`2>,!D01)\!S`0L0
M*.!'&R5((44,+*#QA!UBF(8%"Z!H)$,&-U1!10D'2J%!!QZT$`("7#R0P13<
MAG&#1T*(D>&&%:YPZA0APO_0!0LI`$`"`B(!PX('-Q2*B6`.1RSQQ!17;/$E
M@UZL\25YR.%`2VBL(`87=J3AV@1`*5!;I!7X$8,&&E2`P@)@V#9!!PO`L!'"
M,*PP`P)IZ/$%"5O$D0*MLGZQ!11#;_";"$MTT\#4IY#PP!@#X.'$"S4`<4(1
M0)APP@]HW(`%!!'`)\`<)0#PQ`AVK)!O2`N@)$0&/6?`Q0H@1#"'%!S,40$$
M8'@PA17CVI$!1RLD),J^'N0K]PTK/""#'3)TP7<:*9P1TA3!A,'%"!LSPF3I
MJ*>N^NJL+Y)QZZWG(42^3US`+0QB-&#!;!%L\(K*/D3`Q[0E=*J`&A,0T(`'
M=CC_L(<0>I!`4!AYI&`]K<6`D`8*6P0=1W+8B*`%"=AAMT$#WT`0@@G%.C'`
M!RHLJP.S.W0!`@FV*1`#VQ"PL(<#,A#9"N16H1MP(0,>0:#>LD`&P`6N!%3`
MPAZ>8(4'`$P,H$C)%$RR`LIUB&0WL(,51/@$-"P`!"!`P*I.DP',.<`.L(NA
M#&=(PQIFYG4VU%@5[-6%>,1$##,@`!4T(`5]`,`'*E-`RY1H!@V\K`(^B,,*
MY%`[.8@A#E?X@AY8@(`M6$]I=*@"'5J@A^Z%@`XA^`+4EJ"%6UWA"MGPABR6
M!QYBU<`$7@."UWX0``]T`(E"C`$5\K"`$<!-;W++D!!(_Y)(DD5(!&WXF[4T
M@`(1/L`*".Q6*$;PA-D-4&XA$0/>8/``!US@`IX(PXIDL@`KH$$&5N!"#F=)
MRUK:LG4XO&7$>H#*"Q3A61V(@VPLT(:8=0``"O`!$OE`!@AD@0J<B@$!PH`&
M5#H`""Z0`0)04`R:H!`$W3N#.%O`M*71(0U?N,+X9!4KZW#C%,G;@!U>X(0Q
M%`$]S0*""FP`A`>TP#W,K$`$P$"'`;9P;[/3$!?"X"$A4`0&H)M`M3@@!3,$
M"W$([%D81$<YWNR-0QO-@!5&\``T/.`!>^`-0&R"``/(H0N\T:5,9TK3FM[0
MIA'C@0YT@!X'I"`+(5B"#\@0@_]4I.`*ME%F!,A`!:1:H`(-"(-H3E"#(M#`
M`1F8`11^MH"?N>M64$C#0%+@12B`X%6QRE5S4"""#?@*?<DC@`A.@(<=>,R7
M)P#"#CYP`@?,8`DB0&(67%.%E%S(0_JJT,@,HB]1&'`%9SA7NL@`!2[`P`YP
M4T@HIK#(R\*`"R?QA;_NM8=Q1>X7<=C"K820+#E<`*>PC:UL99O+V7J&!460
M`QIT<(,.0`$+:5!#;J@@`CJ@`)E(C(#+-,4''X"`DP%000UVH(,'V`$!*6C!
M<%IPAM1F`0QM1`$44J`'Z^D!"LWYPG14^TY?02"N!-C#"VA@@&H6`6P_4$%N
M/1""%&S_H`4L4```JN`!+GCHDQSQP``=VE@%PX!<2_##WQ!$@!E8]L&A&-D#
M1J*WQ7%H=A-9%4<`@H+Q@0$C[P""#FS+XA93+'!SB+&,9TQC&5,@MK5U\6%X
MX#$'."`,8.@``K0P5`$`8'8@^&/P+/`R)Y+A"P800P>P\`0NQ.,!!C@A`A!P
MAN&<50_JG,86O!B"$$`!O<MA)W2ZX2MO4(I2,K`!:;I@`!JX``@_^(`)+B"&
M%BSC"5BH#0G2T($6.)1<&>K@#4Y2DM&=JCT&4I</6*"X$"DD`R.X&T)-DM`%
M&-`.88@#"(P&@BR8R*T$6`(0/I!?';OZU6\J@P1F3>M:V[K6_SF^9:YAG9,9
MU-<`!F`!`/*`@`Y$H`UF0,`%#!"&-!!``=#40`F:R`<6.&";([!"![S!@B>T
M:\NJ6D`+1#WF%'QO"U_X`O=2$#187>$:WD@?`:CB@PD$X`0J6'8`7(!O&]C`
M!/:[R!4RD(9CEZ`-5/C"#4!A$H7,;G:)C=P(IC""&\Q``>BR5@DF,`.Y799;
M&,3;#19MD-G=P+0(*',UKC`U[<!&#A^(.:]G3O.::V;7-J<$#G2@XA%\%P0H
MT)\%^#"%+CS@#%E`&Z9B,.V8M9*+>^`""B```$_+8`8#42%`N#OJ*IQAW"A8
MPA7$6^;F=*"MYY.%+"B%1`@T*WX&8/_6#P[P@1T`P:<H:T`+-C`!*E"!`"!0
M\&D=NH*3++C`(90!2<00`BK,P2'7@@`"./@`?2U@9"(KB2@.8H4P(*`/R\B"
M"```@;?.NP%[P/<'<L[ZUKN^$3A_/2-8D%\'T`$,(=!#S5`6`90L8`LD((#P
M*B#M-B@@"VB8`K@,<`$$0($%#^C"M;.@!0![JR9G^-D,R'BK-,2!<UO(0M2D
M=HIY4T4!L7C"#\BA@C$<X`!U^,$.]ER%!D0@`@#X0@BV`((S=$AR&+(O^0):
M'61(B!8&6E`!#G0M$P`O3V``/:,O&6(W!C0%,@`059`'(%`P4Q-O5$$`*U`$
M*K!ZLE>")DC_<[%W@H>`!`=@`@N0`M+P!0`P"QHP`=V2!B+P7@JP*16`<*V$
M!EV`2@$0`)=C2A<@`V?0`4N0!RI"$\,!#%@P`V<`3MPT;LFA!2<&!MC@5N^%
M1-`V`2P`?P,`!TY`+#9``V`C#^FF3%NP,'7#<%B@:1_!<)(C,IBE0/X"9`WD
M$!2&`#!P`5UP-Y0C!@XP!1BR458@!P$`1/X'`KZB'=M!%5L@`RKP`RIXB9@X
M6RF(B3GP`7*0!VF`;E?P7C"S`4+0`DM`)*\0335X`S"@+7*@`W+@6@9`"CKP
M!"V@7G&P0C4!A5'X==\7!U60>QW`<A`@/M"!/,D5`50``!<P!F3H_P3U5`.C
MP7,Z(`3_,0%\H'>G%0J>MP`=]!$B@1+ZTD)3`#!"`#"6A04`L#\<0`$"0`8$
M@`!HL`<4-S)BL`</(#>J-`47H`(.P`(SL`#!Y30>2!40``(T8(F9V)`.J4N;
M>(E(<`)<X'7+,8,*T`9^0'VB8AO"XP?WT`83@`5_6!SQ\H"*.(0.@`5Z4%[?
MLBJ^&(4S((7'D$:M(`*GL`&X@I.4@GX3H`53P``O@`YC4`,!@!X!$(LT8`4`
MX0,:P`=9H"(<5"$J(A)V\'`"A$`7,A&B(`8`LP`;0`;OJ"Y^X%RU`T"+4Q(4
M,7)<\`0JH`-VL"H%TU9R1&\^``&L]9!ZN?^7-121*I@#%]!!6+`%H0(!/I`*
MIX!^QR1$1$4&%@`&=K!3*-``),`",&``\1,`U=0%784"PP&3OCB3""`,+<D]
MU*`%)@)8I/>!].@U'R`>`V`#R^9:IY24F;8`#:`!/I`"HZE*^K("JB02)",&
M!B0&,,`X'01:)N$10`0&8OD0=M*,0A``1N<O!_19(S,%!F"/"C$,;H4^YD<5
M$]``7<"7YGF>JN.7)X@#,L`"::`%Z'1,5!`#AOD*5'`RFT(&$Q`'(N5:*>`-
M,W`#.J!?!B`#BGA=?;`J(0&%--$"/P,"Z%5NRW$%VX"3I^`#5V``.P4$-7``
M#``'=4`:3[`'24G_"FBP?6?0`(/S@FK0`@R%&F$`+AZ`+QXA0`^58(07.5AP
M!60P!V9@)XZ)ET!@._<2(@YU-YB42"W05N`Y;\I4;SY`!^@YI51*,>II@F7@
M`&*@!1M0;-R@*6B37/?Y'F3@!PT@!G:P`+"4`LK30EU0!#]P`7O`4PN``@51
M!2T@$RHTF@A`!WJP?UZT/=!Q/FH`5ZAG9R8P=^0!D&)002YU`0&P!\GQ!:+R
M!3*`!7&P`/NR42)A$@9A!Y\V$1=R-WJS-[XW`R)`?';B!T%J!P&`50>44!SV
M43!X$6M';\GT7U6ZJ[PJ)U=:@C@`0&>@!R#P!1&@`&2@``U`#SM("\KE_T1J
M$!)G$(<D``%G\`2D)`<NL`=R4`1/H%6$Z6=+\%O`\'G==49DY45#,WKH\UXC
M:0-C4P,?P`!U,`8_H`-:*@0R@`;`9@!6`'1:\`4[U"W@6'BGM5$BLU%=^4D?
M,4#<PFG^@D$L(`),9B>=X@<00&4(<9QJZ7#YX@$RV*3GUP#<I#>]>K(H>U-5
M6@7:LBJS,BTU:*UJX`/#XP<NHP%DX`,;,"LH<`97D`(PX!)H,(MQYP)V@`4;
MN``90`?O504`(9.C=E;HUDY@4*AKUP`&<`#R9P,?\'XJX`*ORB@P8$K\V@4M
ML`5Z4`4SL$(%IC@3B'B^&3D,&SE"<)PAP4$8XO\!"$``=E(!0,H'(G`OB&1R
M"#4W6M"NYE=O<2`AUI6RCONXF?"KLI>E,J!\@*4_NAD!2_`:$?!43Y4;?!`+
MI?=N(:!*76"/>^`".Q``9H,`0@!L=M`"!#`S#CJ357!>Z#4K<'01[LIQ>#:"
M-I!G\(I'%\!9HR-]([2@DXD"QJ"I>^-8*>%P*#$2=O!9_&BD(9$2'A$B9^`#
M3]6W$9`%'?1@HQHYSRL&6$`"(HM$/N!K0`@#D!N_\NL(DOMZ93`"\0("$U!4
MN8%^]V<9?4<%N$$&H:M,T$8%#;@`(RHR16`#.H`[+K4#8-L%*)`''I`'*-!_
M5KA6Z;0$A1H;GB,'-&#_`A]0`R9L`_,G-J^Z478`A*>BI2`06`2079>':)Z$
M(8M&$9I'$8CT$1^[4?:R2)3S!>^1&RWC7%Z9$'IS8`E[>]OAI%Z(!09P.`XP
MOU9\Q850OZZ7`CGC`&#@!S_J!Z';N??9#;;QN9G"!VHL4%'E`4'8!5R@1X$X
M!46@NB9@`"L`!5=07EMP1FBT?^FF1MWP!4+`KT)(5>8P!B?@6OJDF:`F!%BV
MKW*`A!M``&I`:&?`:<1Y0(77+2FQ+Q0Q0`O%`D>JE@HF`T+``EH`3;E!5.%P
M-_XB`]8[0"^XFN>G,A'0`HR$!EC<R_&KQ:W77,KC!Q,E!6W09#'@F+@1`_$1
M_Q_(5@+3%@.[HSQRQ`WS9LEJX`5>\!H[>']4<*RXS(Q^ARE\0`!><`?HXRL;
M<`?LO,VC8JOF]PW4W'=2(E#)]&9O%I[XC,_Z7&^4HL_)8QM,-VTE,`<:H``!
M?:OXW+FL6E0PXT0(76\UXLL4C;+`7-$8G=$:?8(7O=$>_=$@K6,='=(D7=(F
M;4LC?=(JO=(LC3HIW=(P'=,R'2<O/=,V?=,X';DYO=,\W=.?4=,^'=1"'=-`
M/=1&?=0A7=1(O=1,[<M*W=10'=6.^]127=56C9Y4?=5:O=68F-5<_=5@S7I>
M'=9D7=8B;=9HG=;F.=9JW=9N34ML_=9R/=>X1-=V??_7KA;7>+W7?!TH>MW7
M@!W8-R?8A%W8,O37AIW8BDV_B]W8CATQB/W8DFW8D3W9E@W8E7W9FGW7F;W9
MGOW6G?W9HHW6H3W:I@W6I7W:JGW5J;W:K@W5K?W:LGW4L3W;MNW3M7W;NHW3
MN;W;ODW4OQW<F"W<Q(W7O5W<R.W1QYW<S%W1R]W<T'W%SQW=U`VYTUW=V'VR
MUYW=W$VEV]W=X,V7WSU#ZI(9)9`$4($)`#`$67$(%#!T;8`)21`%B4`&1E`6
MAB``TG8():`!F#$)<\`&>A+>43W>,H0#$A#?B$$%1)`31Q`4AM`&;'`$0X`'
M7F$)&`#AB%``1W`(;O`";'#_""5<`8_@!WG!%EM!X`7>JQ1P!$1@%TG1%S%`
MXG_0W^\=`X5P#S'^WWYP+H7`X(@P!YAR8^KB%!E#P$V@X7]@!&CQ!VX@`$U$
M`7R`XSE.!7_R!X*D`0;])TPU%FG1X8=`!`=`!H7@!6-`"$DQ1(:@`5:>%$=`
M`-+F%09-`3%C"$(.DE>NXKS=J^:L``Q)!6.0`V5``U"Q`1+0`PDP!G;!!#3P
M!U3`!E61`#R@!DV`XT!N"!1P`&K@!D;P!W[P`WTR!$.0%&R`!!^NY#SP`Q)5
M"&HP`#T0!2J0)060`P#0!$2!!#U0`"?`!S]`"$-`ZP=`XAR."$20`$A0"!]0
M!H1`_P4/G@0-D!:T;NL^H`0Y@`$$(`%27@-K@`-R$`1_8`%*X`5,\`-5H><Y
M;>"PDP1J0`5P0.4T<",1@.US(`$W@@&C'@&-7A15H0!>,22.WN!-4@@U4`A$
MP"4:(`%FL-Z%0`-*3@$\,`"'7@@'0`5KT@04\`*/UP!E,`%*P.I_0`2$``$X
MG@-<,NQAS@<)[@=$``&$$`1($@-O@?$4H/$?3_%_@.UW$105(`%2D`!!(@'_
M;>XWC>ZL4P%*4``%8`1H3@->80'R+@']WN$*D.\]4!46@`1E\.#_C@B2G@=P
M0/`4/^\:P`,0S@9*7@A2K@)9<0!Y$0,_8`82\"1ET``)T/\6!$\(/H#U1__E
MQ#X'35``9<`'+/\'38#U99``<"_WSTX$-H_S1R`)!S\'!#`$5-``8"[T0\^K
M0P``A4`&`^\632\!?R#V:3'J?C`&\*@$54'Y?Y`#-W+IG1_B)3``8#_Z$E`"
MG$X!9N`$2IX$G'\7$?`'!S`6=V`4'\`':*\`!U`"A@#R?S``5<$&3&+RS3\'
M"J`"'3[X/>`&:/\'Q]_]1-#>C@_Y0"\%36#M-X;YF5^EU^[M?P`!$I`$?#``
M2>#PC^$%<<\!-,``)`X(34TZ1$=_"4UOA11!#!5_D%)U/$EL:C$,0R48$A@:
M+SIR@A20?T,,94I-D`=)2`<:?Q/_`S@Y#7]E`SEO%0Q*)49L24--)31U?*5J
M#&E_*@DE34HQ&F-!.#RRM+:'36L0$FD5=6\<91(`?A(\$!:E[_#Q\O/T]?;W
M^/GZ^_S]_O\``PH<2+"@P8,&W2%<R)`AASES(#V<0P'B'RES.#R4\@<B*0I^
M*#R$1$9`Q8X4WTFI4)%#Q8@8.5*HP`$CO!(5S)0Z0(8,*4AS+.B$9,8"18M_
M8@@8Z;'4QC\N47ZL$*-4T*%_*BR=(^7EQ8P*RE!IH*1`P[-HTZI=R[:MV[=P
M`RJ,2[>NW7LQQOBYVP])@1(:FMSB2[BPX<.($RO>-W>QX\?]$A`I`SE>FR!-
MC@"HS+FS_^?/H!4W#DVZM.G3J%.K7LUY-.O7L&/+GDV[=F?7MG/KWLV[MV_>
MN'\+'TZ\N/'C:X,C7\Z\N?/GOY5#GTZ]NO7KB*5CW\Z]N_?OC,&+'T^^_';M
MYM.K7\]^-?KV\./+G\_W/?W[^//KE[N_O___`-9C7X`$%F@@>`,>J.""#"Z7
M8(,01B@A;0].:.&%&'Y6888<=NCA71M^*.*()"X48HDHIJ@B/B<Z1P8$,%J@
M@0+X5%!"0%20P8\7\$2``0$_W3,'$A&]HP8\&L3R!XWX4(#$C?W$@,,&\O@`
M)3T<J.'&(P1PI`^/\X`)20PMEA#%'UW^<>0[8M+3)CR4E9)F/O\5P`A!#!#L
M50^3)>@YIG01N*'CFY`0&H\&.&!0BA030*)`D/88!8D/\Y`I#Q48T.A%H_]P
M`&&+S<U(@P)%08!/$H/]TPX_/;RC`1$Q%.#E/11$`>D?3,!S1P)_"`"'/004
M&86G_3!!!3QN0%*`DO1$L4$%FV%09#ZMSE,M)%10"A`'IDJ+*SS7TA,N/*N4
MXNT\6L`3PP1'*""`6/8,$5$!3&*KK3P1(-$&$A2,"XF_\;B!U1\:2+#7$=/:
M`\$M9@0Q3[;Q`"-``E+XD$P4S-)S!`TTD,)'$Q<,;""HSA$!B07M)/.'&0H0
M6TH).%3;!@545$4!3A%`$DL).E7@[A__JY9"<P2D^"'%SW]$8$$.[TQ@*E$E
M1#!4#`H4248$4L3PR!P1'/OM.VZT"L$0D+2A`)0QY#Q'#PJ0H8$[$/FA,LL:
M7'DRT7,0H0:S%1!A`0<%D*%`57_XX74I0[B,@=FQ4,!'SG^T@=,?5'C=0PE(
M6Z!0M9A#0*D`/Y=`<U9$"WUC51BY_8>WN;[30]H?Y0BN%!%`R8?*Y5*-0\)F
MZQB#WP*\,P?3N$0001N05%!Z*53(:D169U.N[>WP#.%GJU+H5$)$/6@>C^$7
ML:VCSCQD@S#I%%"@DP;I!P\)!2:7H2/X*TMA`<09`^!U4`*8T<0$&AB?!EQ6
MBM9!PF%D,."!_TC6')/]P0)(H`(/R%2&"AR!@#CP00X\Y88H4.%Y9AB"CZ@@
M!<H4``)SL!C3@C:F"!"`5T,H`!5T\`<W^$`!21#>$+P0$1\0@0I#B`$5[N`'
M)"Q)AC[P0QT>R`<O$.!KI4@``2J0``QP0`-1($,0*.`%+T2@!\-+8@Q^X+@@
M*&""4@B"!9A0KS]XX88\$``1O,`L"_R0`@5P@P6>AX$&^.!,I8C`_R"!`2]8
M((<^@P"/F."&&&"`#SZXPQ^20``%M"H)/E#D'ZJ5`PLDP$I,\,,1VC"!)"@@
M`C+$"@=X]8,*3*`"%6@5Z^"1A`D0``=_,((%HM"8'C2`"DR[`Q4(</^F56B`
M!WPP0L(48($>M,$//TS8\"!1!B;P0059LEB<2H$$(_"!`Q/@@\,@)DQBOL,&
M[MOD`TVUJ@M$H`RI.@0`+!G&\1&L``G0`,+4H$U<_*$)5##>.PC@AEPE8)ZM
M2D`%LT7%=^03*#V`0!N:0`!]5L4(]GQ?$@Z:%%[]@7@*8B!S'(@RH#6SHGY[
M!QO:(,,_+$N=<U!4MDKH4E/-Q(@LA$0)J-`J(L3B`.H,JM!ZT`0*:$!1;FB`
M_#2`!`XP(4A`C1P!S*+`/^#`#%7$@`"\H`!$Q4`';K,!!\[5L9*V8Y@F?0?Q
M'-8]<"DK%JWZ0)(&@*0=KHY[0/$!K\I`BB#_)"F'U>H!!0P`"0:H4P/)RE8A
MCSD!B"G`#;<J@P;2T`!;J7.6KOM7&W`PHV25HEJYRD&2UO!/H"7C7*4@0QG<
MX:]IXN)8"!.M!DC;M!S^82;/@YAL:0N)&J2S569E;:\46`-2L$$`J+UG#*(0
MV]$>0@`%N$,!$D:!%^REN'\X[DO'D@1(2;84)_R#3_\``"HI(1Y2P$&M(J``
M17V402)=#DG9><@"^,`'Z32#'#"`#9?"M2,R]0%-3T@&'D1@A8V9P!V:*=Z?
M!A5@;HC`45WJ!1Y,X+X4>-Y.:@B!"5`5'DP[0@665<C[SN$'%_8!!<A*@>`J
M@%(Y)5X.^C6::KVT_U5XN.^]WK$*;[5*#0E0P%Y)T83[)B.P4J`M`_J5%;-D
M2Z'W-0/$DM8#/ZU.#3%UKRPC4M7`5@`)]R7<OR"1JS?<]UBK6/!=7:<`7@K5
M*L2#%\*,<%_(E<("9M%`#R*00XB9V0>'^X,<KK?.M+9*`-DHA1,@<00S)%<#
M9@D"&^9`9Q_DK``-V(1[WT&#B"SZ#XW>;AF,^`YA@M=4XZ5`#LBPF7E8P`N;
MA01(%\B>^9IT`I0)B3*TQ0`SW!C`TN/`C'T)@`I06A8J(S,'OMS@/P"5"7/0
M@&TAX8<V2.%U&L@5$BQ`@,W$H@`64)^SU?G8/R2Z%`YTJ>84%0MV)&5U9O^(
M2%GI:X8<4&';[V!"O)G65K6*Y-=!H%3&L-:&'/K8%&_#)5\W&0OD!?8/2C`#
MHO[`@HODZ@X3\,.,-2`%B)DD5N\XXQ^BL*96N>%&50W"'"KPU"98.YU!S143
M8D`!Y-&0#PV@0!*NE-Y#)&/&THPS;.=008+!`\^R:)DA^-"HF=?\'0U0+Y`J
M[H<"4*`,R2`"'N-)!&._8<VE@#3E)$#T1\3"`@XK`*$Z+5ZO^U=Z?/#LF(`K
MA?!B-"()B,+,XGE;"B3@$4'@EB07%%_D`#)M2:N*&YH`QE+<`4J\G,"-)"F%
M)_K!'66X``34T(8A]``#%(B!$<3\03=($AKOC4'_$Y"P:<H10Y(:8$,3M-R$
M;,CQ"$]<X1K4[D8%>E06>TD`#?C5KR;PJ@)-<-A3$1^!JOP1`H$N>!(><0<Q
M$U(.9)#\'R3)`20TH=60B$)FN,0122K`"!C(AAI(H0%B/''PDJ2"*R+2`".8
MX0Y-<(.I&K#Z9[HC`D<P!`,C`*;B`^,3?\J$`;^'"T,P!+$0`0UH98.W&69`
M!!=P)$S@`7^`!$>``1G%!$EP!SDS`8.T*(.G!GM1!E(@`$G0!(-7"NOR!R5P
M!#W@!BOH315X@?"``;.'"VN084<0869`5('W#@VS!L@S)SK%*4FP@BW(?9M!
M!8\`#TS`$4>(/-IW>34$_REWH`."-0$YXP--<"85<`%_P`<O"!5'X((GTP0Y
M,"NTMB(%,6&(<2-J,(5R^!P<(`!G`@%PR"&%IR)1@QAXE`"&DH?(<0=:52*!
MB(B.^(@1THB0.(F4&""26(F8F(GT<8F:V(F>:!Z<^(FB.(KG08JF>(KZ$8JH
MN(JL*!RJV(JP&(L4HAYM4"0L<0]/-`]\,!<E8!810$#P(`#(PQ`M1FVW0@\:
M8(OS$$"K(04-ASQDD#"E`$#\\(OZ`!)E(XVR"!^ON!L0P"0O<(SQ`##*\C21
MDPW>\BCQ``!591`%$POG@P\+HX8/LV/RP`<9%3EO$`3#^#X)8`"-@P,7$&AI
M4?\"V8`#9W($^?@O#Y)<]F`&'R!K=E8/,9`#%FEE+Y,$HP<5./`&.L$!/'`$
M[N!4<@!^VV@;W:@;Q_0'JM4KMY@^&N`^)4`&U2(`/B&#-4=@I"`%GB(M%,`$
M)?"'/%`MQ$(LT2@1<T`XP7,2+/F'.H,$N'0^,RD14/$^0F,R\]0KA,,10D0I
M?Z@!-E,&2KA)'&"05LD#+4,#'```R>`P[R``-`$/'!`#/&E]P:@GZ1,#_7A`
M?Q`$E/$!Z:,50$&3(YF4[V-L.C44);!<$6$&A%.4\5`!;&`T%]`H,\$1Q"*.
M/>"4V[>'1A0$?#`'JQ`XD_0'#4`C3`!S)SD;*:D;/\#_`0WP34YD1!B`!`2P
M4GY@8>?E!U$P`14W!#B`9T8P`7(@`!/`--)2@;]DA$S@!8]`:H(5!3X0!!+V
M!@`0G%=7:&5P?JX!:4"),!,```0`>I3!!A8`20/5`$9$`&4``=E0`$Q``-FR
MDJD%`7D$##@PD;3%;SD$F),$080D9EQ42N_`9[?9`#VPD'_@`QC@`[GB`SU0
M2@G#+U$`#;S"!%_4!@*`!!.@!#)BG=AI8#E0`KBF!F49H0AC`6IP0H@&":0V
M4`!0H9N')B08`W%40W9IH_402W]0`XP6`Z26`'#)!#0ICJOY&JV9&VK$!,12
M`FEG*MWC!O\5!28A6#V0#.&%_Z&JMF8+YU`$@'1WP#X\0`%CJ@%E,`>\DBW9
MB3(EP%<^<BC@Y@4((UA,1C&&Z`4P1P%U0"E-$#Q-8`80D`Q4,`%$`@\U)TOV
MJ'*J=Q$Z(0'_<F_*,AHE,&T$HR@=`VCRL%8T0RDO50I1X$H)$`$3$`-W0`$1
M``'ZMTE&D:8^@#(4<%\8L":-!79DP"L.(W;P<$)E\`8@%SZ#VBBS!@D\8(_O
M()GL4RY^0SR>X"0?P'='&AM):AL34&$K8V'/$U[=<Z;JQ`(84`!6UU;AA0./
M@IP1T:6EP`9,4`8,P`%MT)M\,%'>6C6LNJ;0%T,%,)$Z8Q8MF#?>NAEN4%%1
M`$CO</\$L>"?7;<J/#4N$?!)B*HN8GEN?[!DDU0!;ND)I8!H!$`V86>IKTJ0
M+DI-<P`QG0H)$X`#9-``3*`!\N>M%E`&E-(]:"H]"N`7I*D&/"`%:B8M#@H!
MO%)L$("'YN(#```!FS!R`&`$5,`!1_"3<JD#1NH'@M5;C,94D""D9;`7&!"M
MS^H66EL;0:`HC95A-:6JQ68*:D(C'`&N1R('[(.<P5,&!-0&#H1)XE4MW?45
M\YH-F:1SD8`YKF(6/N`$<\`$R,,15)!V:3BUN?0(3<`M[I`M$Q!/8UIOJT.L
M5D4I$4`I2/"+%\!%SQER-/(\',`C$W:IQT(`=@.4&R@];Y?_6BI`,RK0*TPC
M$M-J"JLJ/6V0*^G#$3?T8ILD``(8`Y11`DR`2Q9@92Y+"D1'IA^5,SFP*?!`
M`)Q".0G3`^ED!,9&-E%0%49T.4#3,H>XM:?1M;2Q9P1C!#D0>)XS<B5Q`4F0
M!$M!!.G+OH=@!$:0++6RH#G@!Q/P!N>F`)RB2?8Y*4/P!A,@!3Q2`<<2!$+0
M`Y)$`&_P!@H``;E(%$_3!,[H#;PR!V>"J>"B$S&0!%>ZH#JBP.;6-#G``[DB
M2B\J"V_@7CA@1'GS!G!S!$90P3(HOT&PF!_``69P)#\HA:#6&!K@OXUBPA`P
M,(.U,K9U!_:[%VN0!&:$P%EQ+%%@_[^DJI$4$<%!X`<-<`UNF024(9)@HS)2
MD"P]P`3Q^4!_"B<NH[&?Q3&MTGZ\*H,70&=)<01KX#`QT,/BBZ0GV7H3(IX<
M(+#Z`+'Q0`9K\L?.0;Z,/!WM:EG\L`$XD&R/7(J7G,F:K!J.O,F>_,G_T,F@
M/,JD+""E?,JH#"*IO,JLS!:BW,JP_,BO',NT_*RS7,NX+(NWG,N\O(J[W,O`
M/(J_',S$K(G#7,S(/(G'G,S,G(?+W,S0C"+/',W4_"'37,W8C"'7G,W<'(G=
M_,V,O,W@/,X$(L[D?,[]8<[HO,[WH<[L_,[<",_R+(KN/,_V/![U?,_ZW!WY
MO,_^;!W]_/_/`OT<`3W0!HT<!7W0"CT<";W0#@T<#QW1$]+0$EW1T&K1&!V'
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MVJ[-S;`=V]@\V[1-S;9]V]"<V[K-S+S=V\C\V\!-S,(]W,!<W,;-R\B=W+B\
MW,Q-R\[]W+`<W=+-RM1=W:E\W=A]RMJ]W:3<W=X-RN`=WIX\WN2MR>9]WI><
+WNH=SNUMV8$``#L_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>o40024o4002416.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 o40024o4002416.gif
M1TE&.#EA+0#'`\0``,?'QY"/C____UE75YZ=G3T[.TM)271S<ZRKJ_'Q\=75
MU2\M+;FYN>/CXX*!@6=E92(?(```````````````````````````````````
M`````````````````````````"'Y!```````+``````M`,<#``7_("2.9&F>
M:*JN;.N^<"S/=&W?>*[O?.__P*!P2"P:C\BD<LEL.I_0J'1*K5JOV*QVR^UZ
MO^"P>$PNF\_HM'K-;KO?\+A\3J_;[_B\?L_O^_^`@8*#A(6&AXB)BHN,C8Z/
MD)$H!0$%2@,"`Y>9FYI)F)Y(H)V;`J8&1Y0!JY*MD*NPL;*SJP<V`+BYNKN\
M``2NP,'"PT"QED<"#;@+2`(!2P((`ZC-I@!)SM#/2LFXU$;&Q.*!`^7FY^CI
MTS:F[>[O\-;C\_3UXP7GWT0![K]&^`H4##AV!-<2@TH0)E&(A.$1`O[L29P(
M(9[%>-=JJ-NH3A_%CR!#[N'7#L&1`0$:_S0($,J(0Y<9%\9L.+-@39@B<P;K
MQ;-7Q!FT@M*RI;.HT:-G='D<(@``JV;;L#DEBDS9SR+9N$6M9JHED7/,D(K5
M(K0L+*HS>JK-=76LV[=PE1Q8]6!A`@#1:$(@($`O@P8-325`2P2``@()PL)<
MD*"M$(/\"!(Y8&N!M+B8GY@U2SC&VK6.,XL>3;JTZ=.H4ZM>S;KU"7SFE@8A
M:2KT#X`")1=YN?MF[X.^"P<?`M&U<3`7D[<;WH*C\]C'HTN_8T"VD`5XFRK>
M)Z!ZUB(!180WTE0$7F09SQL9/[X(/^];ARQ08$K!]B+5I^M'\5FM[1:;E=79
M?@06:."!"":HX/^"##;8R`(.`(!`74<PD$``")B$S']!-.#,?404@%<"U@DQ
M0`*`*<$/$H<%D("&1AR````.@.C@:0$*->`+_?7$X8U`!DD&2Q!0HIL0V8Q"
MWC-*8B6-`YR0YXY72#(9)5964AE$DE?NHXF10J;VW',EMJ"<<LR%J>::6^27
MQ`*FV"C$`WA1>$2&"L!HQ&"((?%`-'AI"01BJPCPXPX-,"!>BB$"0%2$1[(I
MJ0AG)I?F"F,Z5^:DG'9:RHNB".``E#O^,,IW7T7#0'<G"4"?`Z$.P%L0H&!2
MJ@^C`,`H$I%Z*E://!V:0HY!W>KKL<C^8(`NH2(0@+$]--FJLX("@8G_`H[&
M2LHG[B"QP#G)ND7L4+<`RXNPX::KK@M$@KDD!-(RE24R3W;)U)3(S/MNO%7"
M:Z\0[5:R[E'CS@*M"N:>._#"#,<P``,,5&NJ`!#_&X2%(B2@Z)[I)8">>7UQ
M;)['1F`,@<:M5BRQ#P]`;&?#(67*T:8K5'K1I3#GO"X^2ZRH8LA)^!PTT$@(
M73311_"3"Q('L*4S@S9;A',*,F]$\]-8^TK287+^P`]*J`[A<P,*)!VR>NZ=
MC33`(9-M-MCQL>TJNEFWEO`N=)M0L"P'U^TWF\LN/>VSVG)+;:C8]JT#OZFN
M/'$[WH+[-SU[QZ+X"7?KDO?DG"^HB@.]6NNJ@H>AXYH)G''3FHD!`EQ^`R;6
M=&VZ`Q?&ZF+IT9X.ZC\".Y!ZYZY4?E:YF?L"_/&20BCART18B*&>1!BZA(<!
MR'[;B%='BV+/:PO1XNXQSE@C\L-4W1$[4<,S-?GLM^_^^_#'+__\]-=O__WX
9YZ___OSW[___``R@``=(P`(:\(`Q"`$`.S\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>o40024o4002403.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 o40024o4002403.gif
M1TE&.#EA9``[`.8``'UU=&QD8XN$@OS\_%M34IN4DJNEHJ.=FI2-BTM$1/;U
M]%-+2SLS-$,\/&1<6^#=VN;CX7-L:MS8UC(K+=C4TJ:@G?#N[=[:V.CFX^SJ
MZ+>PK>3AWL&\N_'P[O3R\=',R2DB)<W(QMK7U!L5&<G%PI>0CL7`O8B!?^KH
MYN[LZA41%?/Q\(%Z>?OZ^KJTL;BSL-71SK&KJ?KY^(9^?85\>O7T\QX8&R$;
M'L[*R)&)AK*LJGIR</CX]_CW]M;2T/KZ^;ZYMA,.$BTF*+RVLOGX]]/.RZ"8
MEK6OK"0=(*ZGI,"ZN)V7E7!H9B8@(\.^O!@3%\O&P[RWM(!X=VE@7XZ'A3TV
M-\C#P;ZYN#4N+[.MJC<P,LS'Q48^/\2_O>_MZ]#+R7AO;59.3EY65DA`02\H
M*H)\>W!H:&YG9V=?74`X.?[^_OS[^_S\^_[^_?W]_<"ZM\;!O[>QL,S'P\2_
MN]//S8=_?8-[>%]85[.NK+NVM*BAG["IITY&1IB2D%%(2?___R'Y!```````
M+`````!D`#L```?_@'^"@X2%AH>(B8J+C']J+@@HC9.4E9:7@QD3*DMNF)^@
MH8QM)T%!)6JBJJ!Z1:FA%D*F+ZNUEAM-`42A*09--BHDML.,:E-!5`.?:A!C
M3R,C$QG$U(@69"I*GT1*?"HV84],:]6V;C*>A2Y!(R*6:BM08$]!G$9!>^6B
M:C4A)P0,<G0@U(%+$"00O'QHH6B``@@&F&![%H2+EW`4]('R4$>(#2U3&HSH
M0^B%BB!39/09D:#$@1@;.JSX8.2$%#YD;`1Y,H;*"R$JG$!`0F:%QDMJ*!`8
M02"&!34/FC`9Y,&,*1=_))SAH\7&DQL3L#1Y8F,"@S`L#FQ1H`:/BC$]_TBH
M`/#J*"4K?)"<\/(*0Y,I@^"`"&)C@R`B&20<F"&E,8L21R@\Z$!.D(4I3[#V
M"9+$+B4U(K1H>9%.D-\=@M0`,$5`QB<]([CL$C/B@>=&:F`(69"QT`<;"`2)
M&/QD"R@Q-H;\4<`@38_;BY*"F-"[T!005@11,45&P:<+2/B0>X`$05WHAMIL
MP:+E0AM#-80$J/&G8+T<I2NI08/$@*,3-U2'GB$X<$$&'.>E]L8(_OVAP4D@
M&(;)!TTX8)0,S=$WH"$/-("=-620,<T:"]2S0X*3#("&#4`(XL,()6QH2`9^
M3*#-(6T8H<(>J>!`SP1T?%+$$P&0XP8`3^`@(_]!?MB@07Z$.&$#%]ZI48<I
M+$`YB0=\C`"#(!#<P$`*2PI2PPXWE,`&(A<)`8%P9`1!ACN7#&"`"E*D<X4*
M>J`(70\(C&#'+H?(((4-)Z3B1BG(:-E(ATW0:6@3&)2I1@$WA.'=(6XD\<0=
M#/V!00)!I#$04BOED(H:2CPAAI^WB=`$%Y(<HD86X9&IG0HC</!)5%KH*H,9
M(Q11I@AF!8F($TTP,(T@/1@4@:.,R'"'#0W^`<,$8R@C8P=\W!"'HVKH4$4:
M%-0%15ET7C+'$V9X,`@5-V2Q9`=2/%$`H86X00(#"810UPIAP`CK(N""D"Z8
M55`I8P\GJ,`$OX2T4(#_#7?8-@@;`@1QQ[/O5*`"`M[^,8,*`BQ9@0T,;%J(
M`O/0X$4A73SQA#"8X(!$&BZO,485$LAXP01:+%R(#PO8T(?+8#(01`(:6E+#
M&2/(4=<!3U!!K48*.$!&'@G*D$450AA0V2`]G&$*V)@L8<,4)<OPL\;HL7'"
M$PW@/(@""(#0P+B%J!&#3DV`7(D$#6#1[B,C:#V@&EO8`((0O@K2!@0!V!"`
MX8-(T(0I$1R<B!MG/+$$(2ND$>'C)B`AA!]"A""(#"6`T$06)1.R014C-'%#
MI9?\%H"\J8D<W(`2I#'"#C9$\)P)7(R0L9\H)/`$#4TLL'4B'6B!A)*#5`^"
M_P4#\G"&#3.DD<8%@APPP0A,O&F(!0$\<4()2)APR0H!J&!`?B48P0FV1PTU
M1`%C.WA"$E[AAA#P9P%66-,@9""`&SB@`PNH`M,:,0`=/"$!NC)3`\A`M]M@
M8#H(L`$:-KB&%S#`!CG8U`!HP)04P.`)$;B$"*H`@G8)P@`C2!EZB%"_$G`!
M!.P[!/U&X``4N,$(3^"#;>PP`ME50@8$>$(%"D&$-%2AA'91PYUVX(`;'.%@
M:XB"%L:PL@0$#05D:`#Q)K&&.BSO!X4XPLC.YIDO:($,2T""+J)C!!N,0`LB
M2(4>3D%`==A`#!(:1`JXT`0P'J4J3\@!$AJ0Q$48X/\&03B`(-;@`!O(;Q(0
MP`(6(CF(.*!,@K<IP1,(T(`G`$%T@@B!$$;P07+@@"FP9(0'ZC>'!'D@#$C@
MW%%V5P4PJ.`$>%Q$""8`@@((`03RZH,*.C.)%D0L3X8XP#,;:8LV.&`$57B"
M'XRBB#98`0L@B`$$0$"&&J0@#&F8(R-R<(,%1&T0(F@``_1IEP\0Y09"4%8B
MVF`"+8"@`FLP@0JFX(9/)FH2%-!"&GQ@"#64P7ZX'(8;%O`$+=Q@BXIP@Q->
MJ('EV)$./QB#$#J)L#0TH:6&P,`$N'"JV^"AI"H(@.C8D(0;@&`(:G##`=XV
M@`O<``"3^`$!5'"`W*6&!B/_0\\*QF`*/[!R1@[@R0=2`82/H$`-R*$%(]90
M@KELT!%1N`$G-?*<O5TI"$)`$"(&``,_C``-&U"#&D@@A`GHX`\>$((#R+>(
M->R!)<K\`PHF8(,7A/03'M`#&`9A0%D$P0A6'40-#E"%)AC!`X+%`0.:<(`6
M".X)>FB$#VQJ-$+\P`XJ`$-=B:$&"02``.#[PPH:P!J""F(`'RC8&$B0BC4X
MP2-]^H,,TF`#`2'B!Q%X0A]0I`8K?.24MH"'`820`(7^061!F`!C">&&#9P/
M!`<@G@(`<(,FN.`5*7CD;B&P6\[JX0F:FAW(=J@"#5PV-3VP@`4N@(,W*`$&
M0Z@`_P*`\(8AT``+*A!#K02A@"H$X096*T0-P#"6"&`@%0/0@#/"<(&ZX&";
MCLC`$L:PX<XU00L<58`&'$"#041A!$$``0$`,`,!%.`$)YB!DI4L!3$0@`!A
MP((-#/D$%:B@RJ:P,J\64`*F\>T9G2"$#&*P@!N((08\^$,/H,`\(12`<U<(
M0@4X4`8LC,$)6DI"$*I0!@",P0%XF*.,67"'*MP`&,^8\I01BH4J//G19P!`
M&01`Z1AP@`,'J$`<OK#!M@#9`<`3Q`58\)$#3`,J`*"L&.#`1T'`8`2%U<()
M'N`G"B1`"WXX@Q$ZP%T%/,`)<>B#$9)PZ4MWH0@B>(`'EEV];!D<>!`;T$(0
M&A#J/SQ`#"K@PP;6L`$7,,$C87A!:`7!!B/T(02\5H0,/!#,,OW!"B.X`4W_
HT+$*H6$,-U`!$G:P$'?K8PUT^$*"-A`!)-BL`6"(`P;(Z6]0!`(`.S\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>o40024o4002404.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 o40024o4002404.gif
M1TE&.#EAP@"J`^9_`*.CHT5%1<[.SM'1T:2DI"XN+IV=G?GY^9Z>GNSL[*>G
MIW%Q<30T-(J*BN[N[K2TM#<W-ZBHJ(B(B#@X.*RLK#HZ.K*RLJJJJO'Q\:ZN
MKK"PL&UM;8:&AO+R\C$Q,4E)23P\//3T](2$A&EI:2PL+#X^/DU-38*"@F%A
M84!`0&5E98"`@/W]_7Y^?O;V]E%147M[>WIZ>D)"0EE965U=755552DI*7AX
M>'1T='9V=B0D)#(R,L3$Q,7%Q<+"PL/#P\'!P<#`P)*2DI65E;^_O\C(R,;&
MQL?'QY24E(^/CY.3DY&1D;Z^OKV]O<G)R9"0D):6ELK*RKR\O(Z.CKN[NY>7
ME^#@X-_?WYB8F-W=W=[>WHV-C<O+R]S<W+JZNN'AX>+BXIJ:FHR,C-O;V^/C
MXYF9F;FYN9N;FZ&AH=K:VJ"@H+BXN-G9V>3DY,S,S,W-S=C8V+>WM^7EY=;6
MUK:VMM?7U]75U>;FYM34U-+2TN?GY^GIZ=/3T^KJZC,S,____R'Y!`$``'\`
M+`````#"`*H#``?_@'^"@X2%AH>(B8J+C(V.CY"1DI.4E9:7F)F:FYR=GI^@
MH:*CI*6FIZBIJJN8#2BOL+&RL[2UMK>XN;J[O+VZ-+[!M!HH!<;'R,G*QR3-
MS07/QB0V)-#.U\S7VM?4T-3;SLGATN'3U>#HVN+IZNO--O#LX/#T].#6\<U#
MQ<O]_?'9R,G+)L^<MX+;"")$Z*Z@,F[V%DZK%Q'A/G\8DP$DQ]'</8'RNGF4
M6`WDLY$D2RH<V/!=OI3U)%[,2%,:/&O&1'Y+:#*=SI0JN9W;F;(ENX?:*L)\
MZ2R?P)DF:R([B:VGRF71K)5SV92GUJWI5F8M:K7DSX4'OTXDFM`C5+52_SG"
MM8HQZU=\`%&.5<=2[5YTZ\1&.UMR'%^1:)E]>QL7:=VK&>WZ'-INI5^>@"\#
M-?R1<SG$FYLAX=<8*^3`4B6'S=FN,#:?;)O&ELBT:EK/40V&GCBZ=#^[CE-?
M%5I8+$ZXL&<KI5U[W.UHGD^"+@IO=%#?7FL:;&G3AM_+1FT+K)UO]F;!MG<7
MA/<6>.3L-+<W[([WZ%2T7(4>3&S<@V;GZEE$VG'W_79:8Y!1!5USJZ$'DVL!
M/N,?2^]$F,X0*O@G5X&F^?;8?Q*%!U0W(!8U(4(,6D@"AAYHF)6+WG7HH3$3
M"O3?-V4!QTZ+/.*H3(PEDE3`B2&E:"%C,\J(G?]X/S(8'CWQZ14::D$NQQR$
MVB"9Y);<^9.B.P2QA51%2#'$89!FYLB.EENZ1^663E5FXWURJK71E/ZHN-I$
MZ+"9I)MGM@D=D\[112=7:MI7IIZ=I>@GE\#!6&=<?]GGDIC(^&BA@8HF.AF6
MUV`(S9#):$@JER#E:11![QF(ZESQ<<J?27?F!8ZH-)9ZC*F"%AKH=T2V^FJ>
M3+IZ9G15`9;01@I!,:"NN0XK;'^C2MLKH&\>YP&RXU!4*)\%.7LJM.-:JV1/
MI`:5X('F1A6E.'26E5-,DL69CKB\[JION^<^E&Y`O_+K[K31CF3:@9])9Q,Z
MX@H<UX0D*CD-I9/">BC_N[DJ&.UW%E^,[$OF7=-PB[MN*Q6/))=&LGQ(N0A?
M>)P>C.W%&P<I:[(.>36RJ2G7[##&UO!:L;$$SJP=J3Z^-W1F#-W+3\]0Y^OP
M8T(72RS`U;:9[G!N?K0HS@-=^#3/&O+X,,H8]9RQ@2BW+?75;[XM7+D>).TQ
MT*P^IN`V6J;LMLR0R>VA<V5GC2#6'TY-L5<I]>WV#FK7)'C)VA7:XL38(6ZN
MT8-[G5+#I>;;=NAFJSRYYCQB+GF_V2*(=^>,DP0Z,I'3&/GHIE>>C=FO4]YZ
MP!2WFQF:(C]K^S(>[+"#;[4?_ZZ-RHN.-NV1<TY@\)M[/OQ74&1X>C_?H]J[
M_\K[^CKCT*49S;D\+(:OC/M:PX[M\EJ!#[\V\,.M_\!EM:\X^?\K`/VN1[T9
MY>]/D/&6NOCF/0"6:UC-:]<`#5=`#QTP<<$YA@+1TSV_30]\HX(?[DKV-\5!
MCB811"'-TL<NZWD-7\F#'-DH2#*WG<Z#%T15C?)U'>;USFH&I*"#G-$^&PZI
M1M2SX?<*QSS:.7%U/NMA8RZ7$9>-;W4(*XC_2B9#$BKQ@]B#8LUR.+6WN2R`
M:-JB[4[HQ2^F<%RFLMX8GW@R5>G0C-+8W(8\10(8RE!#RRN)\@;IQK2%L'0/
MH^,#D^@WV_&N)"-T)!B/B$=R21)^,=)1@W;613@.,O]Z;D395798NDA6,6TU
MG!X3D3=)0_KLE?M29&28429_<%)M+=J!'W:YRU!.DF>DHZ+D6FFV$2)R6(&T
M8$#(6"KS':,*8SMF+C_Y1U\RP`]LC.4E(<G,4QGSC<H\VA%?V<W?&0.:SBME
M\GRIQ&MVTHP?!.?)XBG/<`X3F/5D83_0.<XCTB^7[+R=*EG)HT[&[YON,V7;
MJI'/M154B(+:9S$>-\&`&I&2&'4C&TGPS2DVU)LSM&,5>87/<I:F"MZ;)B%1
M1DV+6O2=.+QH/S%V.HP-\)A3&68PPQ<U(/93&2AE*36'NE*7^K*3NZRF$GW'
M4.1=4G(W_>C[RBG5GR8CJ`7_)2I1C<I.I(*R;09UWI#\X%1*MG)7T2,A*U&)
M4^9-KG81Q*I*E9>,EGYQIQKU8!NQ*;U=,:"L2S6K?SS`5[7B-7)\;2A"_8'3
MN*8TAH.LZR>Y"M`A*36L9CUA6*5&-G5FM;$QE)YH)6E84[XJ?WU4@5;_.5=0
M7C*ON:QK3`?KA\$.%%Z63>PEO[K3WB+CGZZ=:F"MREB3@2FG]^G>:FFDRZ'.
MMI"$M6U!4V;0Z`H6ELRM[6S_*%R!*A&XF'WJ6I&[R`S2,KFJU6IF[6H,NRYU
MG8+M9'5K*]C.EDJ7KS7M=1GY..:&=[]3M1\(Z[(.Y6JUL`)D;P%XN4N\MG&=
MG:6M_W1Y9U;:X=>?,O7M@UGJW^;IE[BE%"Y_*=B,#H)UE]<$I%)57-0,8]2R
M)_PL?$MHU:RN4:;?G6!]_^9B5[[OO[X3JVE,7,,=,(`!+<YQDD?G82-#SKWU
MO"A`I6S#M.8WH!INKW=%.=Y82JW$C\WM7Y/GAS&3F<'8G.Q=X7OCYD+VJSW>
M<=D@C-!46EG.[)1L9'_KX;,V,;5J7JDNM:O+:S(8RCRFKW^U2UA$FW::N)LR
M:#T;XQ5C^;>?E"T\$2G/2J+TT*!<J:'A_&9+LY2O7Z5OH]4\7$?2=:I*W1T]
M5<UHH[)URF-495LK"*V@EAD"[GQRHPL`;"1?EM2D)C/D$O_K`22WUM2VQC"D
M^0O6Z:)MQCC>M-]>W<8@R\@N&O(U`XJ=9MH6X,BC_F2Y"]I@?ZZVN3)\=R%'
M#.DS:Y351L1V)*T[[^3]5<CDJMY-(/II7AXYS?_V]\&'NFZ5KO'=@EXM986:
MRUY^T='73J4QW6S1#7/3D="*ZPB"O?!!MPC822WUNE?Z<(F76JL3KSBA+:[D
M9//X<<4L<ZWGO6$G5O:)NGQ;P=$=;`\`N]DI5SDHU]URF)]9WA,O-`-D?N\E
M<]BR8*VFSEVZX91Q].?[BF[D4*H\%!.]V5.'L]/3;=:DACK4O'P[OEU:=F-/
M]K48O[:3`QV]K7=5QRO6\)S?!H7_$23VR!!(/*+?3?0QTQ?-5'^ZW,L^>6BS
MF]![WJW+BUGH*O?2R:7.<5V/P=JHPG37!2A\N=&M^+DS_NQN-OC4[7UF,5-S
MY7/W/%D5'K6L.IU'3*<>(4&/:'>7D+!K=/5L^U'XA:/;[1`G:N,)FV(R'SGR
M)I?\('&?9+L.6LQ8I^CO6^1.J165^'._<MD2GCQWG]Z[6!BYH4M^>U!K=?I^
MISX$L`_]UG*?U)!'>Y%%6#OW<JYG<PV'?DG6<S3"?G_$<GB&,O%'<J.&9FD&
M=Q;8>(46;^.V?Y"550E86`J8=9$7>KZ7=4O&1??';!P70[46@66S<_[%71E%
M(V76(@9@_W@RU'@\J%L*QX-$)WU'5G]Q-UF@)T#`MF!J)W<H6';`!W5DQC.,
MEW0"2(4)EH)CM6_!!6&!9'3C5@$$H(.0`X1$UW!E1H;HYEYEQV`::(3.)D#.
MMF[E=VZ%U81!UR(7>&!G*(6K184"V&+%UX#5!DBE-&C_Y@>)!P(RH`#RATUH
M6(:&"(1H=GM_](@M17P6MVY)EW3OQFAY>&!#.%C1=UG]!UG0EVPV.(-L%#D[
M``$3``&0`P$@4`(54`(1T(AG^(CSAX:OYTYM"'.@1W,-]X&F:'].B(=0Z(1C
M!7$>-&@A.(1S-W7WQ6C!17H3``(3@$W7.`$E(`.W>'"YV'AF9_]H9SB&T#B)
M;-1X*'>':WB!_K9L?U2$X%=QWF=RI#=9^1>%'79FQK@\+P>"GYA5TLA%9%5?
MN^('%8"-A.6*$Y`"`7`!N,AZB0>.4H=DUW=N*8:1D.@?=3=NVI5FX5AN9?9D
MGS1]UN=^@99T[86/*=:1#\>1/9AIU!=OI^A<M-=J_="*(``"X_:*%?`!+Y`!
M$8EXQ9:&OP:+H:A;ZDB14I=4YPB)R]:2)1F$=>=[?+=]T#A\J"9USDB-,3DA
M"WE]VK=5-QEGRH"(V%@!:ED"-8`"#Y!>X3B10"B7$%!;>8AF16ELY:AS(`F5
M1@9L0T6&%C=H3C>.-FF*99B)CKB1-AC_BF-IDX29?HQE@Q!0`B60`A_0EBA`
M!QE2D1UXAHGWBBC7@5/WBVN8AIZ)9`D6DG6WCE/)>N!H?79'>3N86,X%8Q7I
M@RDFCNX8=/Y4D]YG@069D]NG:@P``A]@`B\P`RBP`2.P!JH%FD%(=!7PBD0W
MFHG7>C3Y?..H>`L6CA1(;FSH=L46/48&C@;G=KI5G`\HG%HGF+P4A2Z8GDCG
MGGMG9-Y&?=?DD<D#`0'P`C2@`B.P`#B``TT@?W)Y<`N)G1-0`;J86*"9ET19
MFC%YGFAX>$5WAN!IFE@YF^>)<!LY;I*H/(^(B%,GH4GG;$;V31!0G;6(C0U:
M`A]``QMP`RVP_P(QL`(^@*"P^&L3L&#9Z6^NN)2_5G0E*J(6"I4/.D@EIY])
MRH-$I:%L2(%!J)\5:HE')Z%H8YZ*9F%&=ID!\`%BFIPF,`,X$`,B,`4-(`(2
M8`0\*J03T&S9.9&+R7JUQ0`3\'Q/JH&?2:<?2J(7FHL=J:%H1X91>J&`6H8_
M*(Z)"H1(5ZCH%E\TB!.%*@.9B0(J\`H">@,-T*E"(`1BD`1.P*.%-J=YVHJA
MF:=$EXW-IJJ&)IYSBI03:9UW2J62")JR68Z0"J4,AZA/6I>RR:A[>G:JR8,5
MYWB#10[>87376*8C<*8Y@`,Y@*9;L`1/(`15D`1"P`7R-Y<)BGBNFO^&<CJ7
M^UF&(IJ8SX=V*$>HAKF&A5:GM]IWXZB!-XAFYQB)"V>EQLI7%DA]J(:'_V(#
M.Q"C']"<.2H"(G`"(L`!$B`&0H`$2%`%2#`$W*J+D%BD1KFA^[F.&JN7$CEU
M19J+=CF>\9::OJJ+<AJ85,F:4O>M'MI2-Y@Q.T`--^$!%8"9-3`"-X"P(M"I
M#;`%4S`%3Z`$0P`%57"T%0N?O`28I/E\%DN.AMJ42(IX1Y:G_CJ.Y=:1%@NB
M9`AL+4J.\^JQ>CJLJ`ES,<M1!=`-&N**_XD""W`"#?`$6]``4Y`$2R`$2O"P
M4(`%6'"T5<`%*G"4O+FT&YN7+ONQW2FA]-?_IQN;I[\6K,YGJ[S:L=>)B.'J
MJUJ;F$5HM@.I(0>W8)B)`F@J`73[J4)PMT@`!5!0M%50!F7`MUC@!H';M%W[
ML1*IN'@*BRU[N,'VEUY;N'1J?45I=EP+A)F+ABF[M>I&M>DVBM3'D;4%`3(@
M`R70D":@`C!`MTNPO7?[J4J0NJIKM$?KNF7@!CQ:;'49JZ8ZI+Z;G;>[B]<Y
MI]"'L=A)FK7EN_8[A&%+E#V*KHK[E^.F2Z/)G?;*O->W=7N86X!TORWZD\R)
M`@&Z`1Q`M]5:!4.0M]X[L>+KMV?0P6\P`G2)B`ZJO@PY`0VZ?QW(D"F,NVD6
MJ\7YM`='E$6ZHHNJ_XY%Z:=XRIM$V9_EVGJ4FX8*.I.Y)4.AB9DO\`+-N0$+
M8*,G$*I/$+00&\406[10\+I\6P8(D,4"`,+#VZ*B&:LF',9U291BC+O<&:OH
M"<-0JG/$M\;@2:<&?(Z[-,;_:[)K[$ZXJ5E'EI`R<+W.>:8KT+-)H`1+0+2G
M*\513,7D&P9GD,4(L,4I[+O5&<:4[+X)FIVBZ:VW.Z=J'*AE5IVNZ*":6Z>)
M)YT]:'!F?+R"^:[Q1DHM*@,O\*PXT+-\6P6J.P2M:\%#L,M#D,A&R\@&$,R.
M#,FAF;MX2LF57,I#NLGN&[_H.Z>@;+'J"X[H:\)>^\6<7*X=B+]@+)<#*_^K
M3/G#XGJ#S9:0UGRG#?J?*H`#G"H$85`&NHS+\$S%MSS%ORS,COS(7)RJ7HO)
M99S#0TK"EHQRG-S-S?RJL!F_KVBB5/MDSGRX6-MXT8QDRGS0YDJ:1S=NY/=7
M$("9)B"F)A``+1JF9;H`+9"F$&NTJVNTKMNWM]S+N[RW!H``:H`&:A#,!K#%
MIFK-ZIO)QRR://W3$^F*U6S&H2F>JKK,$NG3L(FQM,NH)==X/AVATRR8=7EN
M^[>B_JF<,T`#P$`#`9`")E`#-#`"(A"J2;#+K0L%$8L%96``9^#2:NW69=#(
M:$```*`&'7P&'[S3V.S/_OS%SU?&?VG"*=RU)8S_QBYKG42-QD[MLA8-OS9L
MP]D\H;VTM-B$304``LLY`R/PV<XY`V--HS'0`(7\!!/;NEBPMV40!G!=RT:+
MTUFL!@"`US<=S%N<S,E<M3Q=QEU<PF=XPOWLK;L=V3E<9G]=OQ.ZJG1IQI1;
MU9;==T?7=Q_`G".0`TI\`SC@G`*Z`#$`MW9KP5@0!F$PWAT,URW=NFI0TP!0
MVPJ@``2`!L.\`;I=R=<TR:]8QH*=JM;9D]5,W$'MW[7+@\K]U(G9S&A<?K":
MX&2XD%'(`"E0`S.@`@0*`VPJ`1S0`C?PW2?``=JZ!.+=P:Z-TV?PSJ];!NS=
MW@H0`1%@V^L]`"/0H%]L_]^\G=PDC,S]?,-@7+4,_LP#G9=S;-3S9[C?6LS4
MW-P,_K&==]DF``P+``,PT.':NP42(`%UB]J];,MN_<XX3>+O?`9HT-[N'0$7
M`-]B#N/;V('VW=@(;MBKFLR1S=\54,P"3<)D+)=^X--YZ;@K?-!T[.9]?N-(
M3L"?-P$3O@`K0+I5'K>]G`1B\`1#@+=#X-:PR[==?ND&T-X$L.D*<`$44.:;
M3@!Y$..@S-\S+M`\'=BI;NI`+<9JB:JJ_M=WKN-$+N.H7II)G>K\6^?/W-0`
M6P`!H,39^P1/7+</&^G8>@:NR\C*3KYOW>5G(,RT7=L$T.D40`$1`-^;/NJ)
MG?_88HS,.,[K?MW;/*V6?:Z6Z)[@1YW-;0[GT%R:<[[3/F[GATW-&0FR,Y`#
MB/[H4Z#!JGNT6-#(,^W(F([I-!WFU-[IV6[F[0WCW?[MH(S,:KGJXH[J8?R%
M?QWN",[F;L[/._ZDIP[-_<WK9*RG)1?*GIT#(E#(4S`$S][LC#SB-`T`!2_;
M^:SIG`X`:+#SPQSCX&[-,F[KB3?Q/Z_8*JR.0<WF%9_C2K_"JW[1UV3J<NG;
M[.Z^EDO`*<R-`8"I+=``$>OR,]W>"&``)A[M"-#>^#SVLFW3ZWW78M[>MRW;
M.IV=Z*Z6_(V-B%?W1&_8F-R3$U_0(\_8)0SNEVR=%!__V$;NB@`,Z_:=Y^ZN
MXZR:PQ0YU!70Y%'.`6*@!&X]TW>]Z6@`U_@L]K.M!OD\[6]OTUD,U\S>R/H,
MS74OYU^L]R!0ZO[<DT'?H'.>ZDEOPO@-YP(.KAG_]-]ZE/_\TQ2_Z^A<GLMS
M<!,0RS%@MZC=VF&``&%>[0J@\Z4O]FW_]CC?WO*M]G"]NM-_\`Y/]W6OW^6N
M]Y.,^(//^^M?R>3^\[L/^6"<])"]Z^,.[FI.J_8+"!X%!1,!'P$;(F)"4UAG
M!@9G```$"@H$!`!H:FIH:).@F**C:`@&86>/IT-(80@(G@,;$[03%;>WM1"[
MMA,0N+<0M,'#%;6T#`S"N<O&_\VT$`S'O=#*OLG8RKN\T-'"WMC1R=ODT]/;
MR-G1.X,>(#0+,QL-2U5890:O")B6"I^:"$!-$F5I%"8T!LI@004)4I@RJ?(A
M$+`!F#%;("Y"LY7KV+*,N(9U0T>-FC!=#/Q,8\9-W"YKOKCYBDD3G1]MVM"5
MZS9MW#8_[1A\6"!B`8PD4+!4R:=FH(((ESQM"NB4DJ4(`@%B<?3H5<,S9?"]
MHJCQ8H42Q<R"0,NS0L8))=[^NCBWED5S>,^=K"#NFD>2>6O!),?KI32>QWSN
M$L2@0@`4+1HTD/"D3)@J")I6J@1UTM2`GQ10X&=)8"D$"TWI2V@Y3)B&9&N!
M&#:;H__:M]!NO06!NR-'N\!6ZJZMZ^1,8]+X^C$N4R9>F#%U$LYK.-GR`"_@
M24`"I0I$2&<"/JT4E9.:5Z">0KT$H).F\Z4@F<IGP)ZJ5&?>5)1MS.U>B\']
MYM9=:94%("[:/+=7<L=-((U,=!U&'2]\[2387H2)X\<.#(#P`0H;;)"#"$J4
MD8D^X0&@P`6BG*:/>P1E<IX!30&`'@%JA*>:`?>$=XIK^FG4&X0'TO+6@`':
M9N"!%6(T(8.^.-.D2'X%1A,(&193'&%^W)0,=BB,L,$".*RPA`$%G7?C)9@@
MH,HKG%!"P%3@E;&/)C9F<DI3"*`244,&D&56DD8Z,]>1M-G_!IR2P/!V(&\E
M`#B3@\910YR6SIE3%G//;"D.`X)P6,$,88X)`PPG*`%+)0`8\`\F<KHI'WH"
M]:D4%OE(A:,FD7R24"JNO3;6"!/TYFB1%!X9W("*SF41;R`Q>:RA_E5Z3$?.
M^H87@1J5U!,$O/E20@HFT+#!#3?`(((($@B!#R6M#C0*0+.JP1Z\:D02AIK_
M>`9?OL&B\E`^`HS`K%LEQ$6@DKOU%I+#CU[*J+;%-$>.;PMONS`SWD(30`TF
M?/#!"S.HH`(,$IS0`KM;*`'%)R?*RRHGI]%\+S]SNGIC*)FT-VN=!!OL:+$)
MW\;16D,7"S'"%T$[:+?`$=AI<7DQ_TDHHRO-)+$'`8QP@PHSE#P"#CBTL,()
M''#0P!-5A*&`)OT2U%Y3G?QS,RPVAK$)&IMQ%H&,<'H%%L$;(,W7;[1!NU;"
MQ#V+B^+&).V;XM$.UU$N$NZRL=446_1+I(=!34L`,^`0PP(CC+#``CFT<,()
M(C2@=A*28)59SP8!].IF`WF5#YX17!#!\,._7?>,9PP\4470+E,,M'&]%>FU
M;AD^G/2X51[]6AD;61M+FVLL\3EG51`ZMG"AH$*(8^(`0[JQ;R&&&)(]@4`$
M%+!YKYQ1N<K[_C+:7?#P)[S2F"=?^,%/D*KW+,IESVI)`PDM%%8]!S+P:G"9
M#><D]1<G6?^)&69A"P-*\((1J&\#J3,=#%;0`#$\X0E)>,(2H```"F2``A>X
MA/%@UC\U$.!O5,F=4X(G/.'U[#,(I$\8L."&BCS.@4Y[X@:EI9L44`YA&:%<
MPK:8P6(ECG/GT!+U0@+"M"C#!"H801I7=ZX5K(`#25B"$H0@A*2@*0,6R`"+
M*!$?O,UI53OD'YL(@C\*#(\`<*I;?%1QBC(TL5%0#!=&IC7%1UD1<DB#RQ8C
MY3@(L.6"E8R:U7ZSEYF,D`8X2.$)5B"!)"1!,DI0`G>6$I`+X%&//;,51*CB
M"5!LPBI7(5[P;'A#?T""9IOX"BJJ``4N.-%[D;0-)1UWN>IQLH+_5X0B@&;C
MR09&LGO=(^4PO#&!#ZQO3"N0']NJ`,,7"@%7XKF`#7%XB7Q580A#6$J-I-)+
M.?UPF,3,@$#S-S>XF4(52ZS"')U0N",9+I+A0A(DIZD;2"*,DU?$)J3X$KU<
M4%.B!3H8QL39BVB48`:I.Y<$9)D$6<9R"4M`PADX\4,*X'`]!$C($);P!)G^
MXX#VPIU-AZJ!@1H21_N<D43"``4A\+0(A5.8THRQR:JBA8&3U"A%*WI1HIV%
MDHJ+"]&VBE%.BI)9&.D/ED+2$QF@@$P+B$$KET!'(<02GTOQ1$WS=Q`UE*$*
M2'C"%*!@`%C!R1.#C(!`%VM4%M5L-?+A_Q$28"H$AEKO6%;=I-.,I#`M,JYR
M2'IH1CKZM(>2MH$7/"MH&P1"C3`@`"JX00S*)@'YQ1&FL\0'30<HHTA@`0I(
M"*X!```51+I'19@HY%"7BT,9*35YP<("$IQJURA$-8MAS>P6I[6X2&YQFQ9$
MF@0?M[VO@O:)T3HKDDK:B];&1"@HP,$&W*<V"=`C"5O(IUAHI"(#NNFOK'"$
MBHX*HWZLZ(;,O>G?``>LL)0!N'65I74-UUGM:M8M*<#H):,83?%^59/'@M1W
MUY)!D&23@DN28C>9ACFY0$`&-7@K"F@P-ABT0`)+F$(#DN*CWQE6'P@`;"OX
MAC_C605_PY,G<_\O(+SB'F0^R4N%0F,I2R18][,97LLE+2QB*]["JM9,@9=)
MC$5FF9BJFO6J9[6IP=G4)J+.@)X,!G230Z6`!FD<P0P^$./YBF`*^-6GC?@+
MN,R<YZ]80(`.HW)D6QI2N39M<D%^?%!@_18*P,4G%Q:0X82)^=-=KBH(Q!PI
MSV[RTRF00:DWG-&T*BV*V-0L]$*,$4\F0Y)VX:Q;:"&#`!@B.R$:`0UJ0#(5
MD.G/=MV7G`;2'KSY3#X_'&2C':WD@4IZTL\&F&NVLA7`#J&9G-XBJCOM:5'W
M^I-:IMRGK=K=T<IZ>Q`5\56M26MHE(`!.]AU&$O0:QG(8&1AHS'98K#_`1J4
M2H6+J$)X^+8B(P*O,W!24?$F?14EVS"/"&XR3IO]"K!8AMM*">X0-DWN<:][
M7*CF=P`B16KL0JOET(M+I^5-ZKA\-N;;71RZ/<PQ$,SYJW>I`(Q10"H5H(#8
M("+3"1H@@AB@#08Q$$$2D#`$21"@@)8XZHHBC;NG7#L3?K-I!C2@@4A/G$T&
M?<42[P%R*,32RN'V-*IE4/-QTUW<,Q?UA3$LZL5E&8N*.[F\M7BL7H#`$(;X
MP#5Q48(/F(M,IR/Z^G)P@B3@<PNR@YT8\CD$-(V'-(7,`!%U6,@<BD)>3Q'[
M30L"+[C!34V7L4?;[0IW<E>UYC8?]ZE337=4_V=WM#*`'JN=!L6[XWS4-X_6
M7&3P@A>,S/G\&=<'4$HV=+%Q!#!`@A)0D00.G$`"4ZCR4BI1"GOECP)DOV'Q
MKCY4TS.;,[94_^G?@TRIG`<L5<B_4O+O]N!&@=.@IG-5A6$EEQ$FIWNZ@7?1
M,RZ,\V6R]G(-Z&GN!FN74T(HT'S.EVJ[MA;806.I@P)ADCHWT`!3X!I3(`$<
M`'Y(P$QX8SSF=W'6=A5FMQY7P1FJYV1'E!G]0B<*H128AD_!%83_YWMR-X`H
M)VXV9V%UIX"0,G/NEG.FIF614EX?,1O2\`(;`#9[1CH7^'-G,3(T$(;$%F.J
M`P,[A@5)(`9J,P4K:/\OBY8)HJ$!%F`!94<\\D0\_2!/ZF=Q.-4S]%<WGN$F
M#]%MP#5',$5E3@"`=7>`HW9WG29F\29F_E9R5H1RMC=J*?=N1<.`D&,^'R$-
M7$@#,U`#([,"2#`%"V`"JE8"`6`")E`#83@#+P`B8W("+K0%6R`!8E`/9W!U
M6*$>PS2'%M!<H8>'J3>'",9UI/`9]N<)^:(0/7A/=,13+_1"1:"(CWB`X^*(
MGK9R7)9JM@>)X&A[EHA[HO9E3H@+SE$!YH1"'Q@#6*!89[``+Q`R)E"/15<J
MJY,#-Q`[+;0%]<`4F-`4J3=VR+A@^).,389@1D6#:*<FII!VX/$0T5B(3D7_
MC4]PC1E6=Y-H=]PX+MZX1;TG9F>!>Z`&CE:E>[M'03HW7H(Q0A60`BC%`2(`
M=5BP(@]``1)P="]0`S,@<#BP`#>0`V0"`V6#-EL@!%7'-ZY2"FB0>G)85`0E
M&D:U7&6GAX:D/_<"69\1"?BQ1`J!:50W74O@2DEP!.&6:EK6:QZ9C>LF9[XG
M@/VVD1D6DS,W;E*(B5`(*>F5$<K@&!_2`H#5`%M``#9E`1$@!!=(,C.V`2L4
M`S9V-B+@1NJB!`KWE!$`9#X$::NG6',84,BX7.OGAY,P4^WQ&N#QE0KA'0\V
M1_@D!$]05XFXD:O(>P=XFUFVC9EX:AW)EI:8,)-X_VI%>&%31559E@)\!@\-
M,%.O0%1HL)-A4RHY0)GJ(@;X)0:8UP#X5%C#`PJJ816D<15X5':,I9`3EPG\
MA`8+UR>^`QY8@$_=<4]4I@0\)9MI.9+CB)NZMY8FQYMTUVL!H&IM66YR5W)2
M50O\YHH!BD8BP@%5UU_#E`$&T``W<'1A8CIHDX*ZV`J.<$]GD%>A8"./4".A
M8`FV1(<!E7'&V#-`)2RG\!6/P%2Q!%S:]U(P15=T-)NZB9LHUY&?5IL^:IO1
M@Y+^%@!TZ6\"RGN.V'NRIAO%4B["1C*)`'Y0<`9/:5/#8U,(,`02L``G1%\]
M=4]#X`H^A$@`D#S?P5\(4/\&FH$[Y(%^#Z!'56F,K#<WYN$:T$61MW)/(D==
ML218,F2?M)ERMFEWAKJC/WIWGK:DCBB)`;"6`3JH"]@HAV!.4)>%-X`$EB$1
M-D5V^=,9:H`$LB,"2S<9]C4%=L53AOEH0697S$0?6.`W_2`*"6E(C36:I^<B
M'4>1#P8%^`2$03A9<?2G@(:CE<5I`+J-=(=X2HJD586DP0F2ANIK/@>M=\>6
M<U=SP6<+9C4!*="3,V"&WB<"6T!+,#-4`O4W@Z8$^"4$"O5*+00['"`&98`_
M=7@*;K<$0\`5;E-QC-9UH?=HV.8O[>D02E%E0!A+3E6--_I"Q0I3&FFMOC:Q
MR[K_C;XFL9$Z=[UWK2E`K=::J+>WB!4V:B90,@M0&6-J"G8R8.@WIXCTH:Y9
M!D\@.R2H-EN`!&I@`0]@`2SB6T.@!/KE&D=67.]''L/4AP?Q&?,1":O)"K2'
M3PI[H]28AELP!2]DEFAIK44ZL6)V")'*BA,;MI((K2J78<OZJ&/KC>!H:D4#
M#*KF&#.P`#?V"$A$"2>:?JJG``!S*Y?Q2O:U"$J`!0"`HCCB$,ST;=ZA;/\T
MJ_Y4$..1%1S7GLGC@]I'1U5FB.[$4_@E&54[!?,C!D:``[WIJ!V[K(>@:M6*
MI&&[M=<:H#[7L8]JL;%KCI_E:</0L1]@136``PW@,G#8_Q[(195%59X$]5QG
M\%N3%9OZ=S_&0Q\>QPK[&AX$N1Z=D3N&=5PVLK03.8A\2EE12XWT*5C9*1GD
MVP`]L`!(JK%@.XES.;:\1[$7:[9&^KJ^MJC4BI*)6I+;0RXS8`*&L`%5"@M8
M.E1VB*YX-(Q'A2."\TX=!P4/H7"0U1`/0:-MXV/!-$@M,@EJLD_*A*9;L42^
M.@0R)$<7V4[TB5_R4[ZFR@,+0+$`&J#0NG*(!YQ&6HYU=[$;J[70>G*+RC2:
MPWQ[5K(+4)B50`%Y5%0YU`]9*G8WE$/T<AF8IC-1!BP1#`F]BFGY)RR"A#_S
M]WKP02_ZDE`AK%#N]$)R1)\\-?\%5IL$:HQY$F!?IBH!/]#".$RQB[JU`1J_
M_!;#&PO#8N;'_*:-#'@6=)=%5B0#KA@I'[,`')`*"$`!#Q#)PQ@!QS4*I1$?
MKR'",140)])(OFH/J"D1"<%_F%9'W#FT7>R,Y]$)QKMVS)2O;&RU(YRJ:6B=
M;4P_;RP9;\P!/D#'>:RZ3,J*JJO'$MO''>G'XSB<2*-R6.4A+Q``OX#((R`"
M2?'(:[`&<1"GF6EH$+FKR(L%[.JNLXH0^#>F(XH0]+&:(=P=^$`CY#$OGK$)
MW>P[J1`6/KBP4[`%U6C&@C4_MXS+&HJ"O.S+<]EO&/O+S0K,J8;#&INQ,H=E
MK>B37'O_>+)("Q_PBHE`6`I@`6L@!5X0!V4W"0>E+V'!3)4+O:Y00+SBE:'\
M"@MQ"FQ7B$T[!.+Q-JDLSTNK)A)LSPH57$\`D#"4SYVKQOE,/RTDT`(]T`#:
MOBN'NR8`NPB]U#N,NS"\I`S]T)#"9V.S.BI@<&(2`RC`?&$25Q+0BQD0!UY`
M!$U@!I/\LHZP=M+%"C%+%0Z7O?I@SS_H'7M:B")G1\CE3W"CM)$@$4OK&O9,
M=4,@!&;)QO2#G:[TN>2;U"@H`D"`OF$+PY<MP[Y6J4;J:[2)V9EMFZG;D0GS
M,9"A!&JX.FJS-BTP-F@3.S>I6&M`!#P`!%3`L[:#'[\%$4DQ_\&_HPEGQQ[(
M\V#<T1WW\*OP^6WX$#<PXR*``M-+X94>%Q9A4+EE29ALK,+D*P8"+1EI(P&3
M&026O;K8BFJK*S)G.[&GB\>7C9^0.+$EU`)*\`A"\#I5,!5G@&GX,%,7@'%Q
MP`0^$`2W36"980I:3"]MZHO%0[3Q(5U+T&W(_:N'*Q8ZR$\1_`B3BROX9P_Y
MEW^)+5A3D,9Q+-FZG#8TN2XKT`),@`,X?+J9;:0N'K]>2]Z(E]G.FK8U0&PT
MD`/TNB\$H%"%-4CB40D90`=T^`!>T`12L`9MS6RKW%_OP0]+K''L@1"709^4
MB]B_>FD+\28%?N&&W8.$.`0E?;B*_?\$@2O"]),VZR(")K[+;;Y*+0`#*][B
M82LR>/YO>6SG\*O>-BZ)[_L80:DZM*-7^;,W\&=(D:8!D=SH=$`'VEQ<3_$V
MDW#)G[`>"9;$<^)72@&]$8[<?\7.]^`G2:1,<!T6?4U8T)W8,Q0>8;!320#G
M[+(N)KY*K[,"IU+G,#SC-N[B5+WG=,?K.#R)3?AO%VV*2Q`[7OD*DWX>2C!<
M$9!'<\CH>!3)<HBB!D9`I#<C1):EB\5U(FT`\)E_3TNC(@=@W6'<]V`KJ(FF
M#Z9_6'"(23$C(!Q<5IHW[UGB*4BJL#.9;B3G+4`$+/[B12HR>VX([#W,=QZI
MI,UOTT<J2@#_JJWB';^SI0Z\#^C'Z)(LC,@H4.YW=0.E0_,!`$7$Q`.U8*T"
MSD#;'7-TD1?I,KX:7$"+N/:0:6UCSY>&Q2<=W5`\B"ER(F40R[B\2O].]"U@
M-B<`!`._V2_^RS5NXR^^WDW=:].W`3%P`Q(PN(>N6Z\`$0,S?NBGL];.\1@G
M>F^C5TC&)J9@?N6)8%!17#S2Z34ZC7+$4S,O\T*0ZC_(SJMYN+]*EBMHV!UN
M#Q+Q#P:@V)`M`G/>`MZ7XJPD&3RP]$\_XT5*]7?NM2^\\,D*DB;`NWE_/SRK
M``:0!&4@T@\VI@:`!&AB0XV>1SM+A^1Y5,W&<%OI0T8\[0TI;0E1_^]V1?<G
M+$=X?\94!USJKLX_6*-H#//PKE_U3".EH.9K_CIN#MZ2B9UBP`,Y@.<&_V_^
MJ[IXKM[:#_[AK]X+#8LB@!E99_9GL%)4@0"31>ZKGP&M+_\[Z[+.%:+H$>V2
MS)#J"@@`!@@(!F%A6%5#0TI"0DM+2$M329&-D$)*2(M"0UB)B5500Z-(CX]/
M2HQ(4%AE566(4$A8!K983PUB8A(<'!(-#1PBP+P</C@!`1_,RA\F`3(RR\L?
M,A_5S<K4SMC;UA\O*CAB9P04`(1A95LK6V%H``!*4TI/2P8*%!0/_1K\#RQD
MV+=/`0$%`-0@4"@/S4("%RS0"3@P`H4("?\!8`EC:]VG*E64B'RD9,F3DXT>
M0=*$Q!24,J]`CE(RT^22)$DZB60%:]T01YX^85FR9<I),<$:;`FV)4D#$2N"
M)*NVK9LW;56Q:O7V[4,-%#&0`+A``$T84T(:M&B@I(Q"G$.V",E'X0)!@AH$
M[KL0@4!9A0;.&%`#@`"`"`HB9)#XX!]?"@0,H+%UYE!EF%A(92;Y,Z<C1Y&@
ME!3ZB93H5*B>3"DJ!$HID2"'M%P$1=3L65-6BVDZ!6D#8"*()&/&U6JWKL6)
M&\_Z0<4*)><B8($B9$KK24F:PDSR9$AW`X4-^QVO6,._BP8;$D*`YF`$Q(HM
M4$3L=W*AP)4I'P+_.5TVIR4B!9@)$HV`9*!I0E0"R4FK64>=$)LLTM*$F[AV
MVT^J!;-:,!*(P,$)PA%77#;+*6<5-B)B%<`+.#2PA#YJB#'%;PT\L<43LT1"
M5!(E<408&H*Q!T!B!`UT@0+IR9-0/(G!MUA`%""4$&#WG7'&?;:4\5$5B3"B
MRB*+!"B2:V1&6!UW)ZG&&A1+#/A3)F)&>*$D,^K"X3`GG`!$#BGV>96()FCC
M9Y_.S+``#"(@0``2)S1PP@HG0"6!44F8HHHK:&2JAAJM7(F&`A=D(.I`Z(WG
M%P!H$$:`D_)E<$%&[!&PGBV#$$*KEAL9D%E+!H)D"H!@@LD24;EQ-\F:_Y\Y
M<E*;C6@B884_W;3A;[Y\R`$/-XAXW*#,F!`HBMRF6,,,-*!P`TT-K"!!"S?D
M<,,",<0`0P.YJIJ>0K55<<:F"F3P`!VDPH<DDF41\FEBBPF$$0+I#$G`IO=M
M"I@AK@A6QBCY'GC*LRT%:&-NE-S$'1(A-?)$$@W>LVS'SDIR<G;4BN#A"=?>
MX*V@T#SS[54[WPSHS\_4\$*@-"RP!0<M2'!""S@LL,`&(VR`@[I8,(S`&0X9
M<'$9<4T1AAH1Y&7!7DA>-!Y"F[8'*@49_(-1>Z@>I&0AA"6$GY6"67F(:[)M
M4I(J'7]F$D['*JA)*ZC@A%0Q2,E%H)A"V/A;+_]00;K""D1D>^*?V`1*534[
M=_NS"2^,"XTX*[2P@01B<(`#U"@L<,/K,=#[L!((8#'C%I+(B`0"_5HP]C[O
MI9>809D61F2I##ED*WN%I#.(&GA;B=]^H_A'X":.L)1X)6F:],2`WR_%U&J.
MIX3*C!U>?GD++<``0Q,W='4SB0%XGLV@/2]C0@WCHL$(A.:T#7!`##E`P0M*
MMX$-J&`$-)/`$-1@`,,,86FJ,<H3R@``MI&*;'ZQ2%^4A*0(7(`LJ"*$/";&
M'H9$K'IYJPPB1"$A,#U.0(/S3$KNT2;0O,Q\#3!*;B!TB7N49$8<D!_\6A"O
M^?$)4#WSG.>ZY;,4^0S_&J0+E`QJL``:F(`&,U"!`VM@#66\`!N&8F(#AH2D
M(<`@!BA3!8_H8I>[\,4B&1BA\DKX-HG%PS!J^*/S;'4WZ^D-$8FP4&UF49/Q
MY1!"LX`3#E_6&UU8YV1$C!SAG-*A)<)/7C!@@LV&UKE`>:N**,IBZ(AS,V\)
M+5`0T($-9#"!"9A`!B\(0`$F4()G@*!;,T"!U!JP*C64@0,QX,`]6E$2#OIE
M'Z(R#ZE<99`0ON<]AD%5\JI)L,D,)AUE@*$,8_$1_W"I"K28A6K$A[+6**(3
MSX*$M+;0N)Q@8H?L&T;J'I4Z^<DO<Z0#E\Z`UJW]L=*4IZR!"6;P`AN0H`0I
M_R@``YI1`@A4H`(S&($*@CG`%\P@!U-`PP4,L"Y@/&$C93`$PU#UI'\%1'CG
M.6&H[H*>5"E)'NDI!,-DE5):!281X>Q2@7K%$SKA!&65"LD4;F@/1R2!%TQ1
M4":J<X^E^$($C^)G_&X0+_KYJ8JG/"4I#QK6T@WM!2/`@1]T4`$4F(`$#,"E
M+AG`@!(L``4X&(%&AU8#&L"`%EO(`0R$(($E6$VG$@M;'-8P$9B.RCS"LX`&
M1A6EA"PD/#?-2#H$X].K?2*<ZQ!%K]`9)I.DK!+5:<!G1,(=3DH`&$PIBK$R
M]!NLR@PJ\8.!NVX@!1B$]:!4G*+.KGC*9RQP:!"D`?\)=/#+"9#``[T,``/\
ML(,`C&`&,WAE"F80*+!$"@;NF,(0#K/"]2@*()'MQP/,8(8UQ"$.ZNW'V#"B
M$'O)8SQSJ]5Z**BE6!P")J.5C>#H.85("#A\K#W9Y%Z;E%T4136^$8:'.BF_
M&.`@!SF@`@P6"-9OW<\98?76T#QLW!IHM`(VL$$)=E"`%D]@16=<!@UH4(,5
MR8`!;DU!#520`PY,+@GY@(_=!C$DO#P@#E)@PA%ZX`,F2*&][IV(J\J2O/"8
M*IL*,2\ASA`+K<$$P+W"4`^78ATW#2%D(WD$C9(2C-WDQGR[>*V<D18O"^,`
M!UX892I/Z3^$DDZA(E9EH+#_2P,QRD"6.F"`"2J0`C\4X(LHH#$-/E!H%9C`
MT@50:`#&!<?L]"+(=I&5]>YK$0T\0`H]B`(?!!"%'P2!"E3P@JP;`QG,HJJ:
M^,VREO%FBWQ]@DRNN00FEK*%)>RBP/3@3B;"1.Q=N!ED0,P-;*FU@GB]:P%X
M]JV'.4SB<(AUQ",6\=""28,7%"#%-E#!`LY8@!UH5&B%\J*W(`!=/P0`C#B8
MD0CB)X8*H@,!88!"&!YR`5,_@`H_$``>\+#J(OR`"$QH@A2H0!&^$.R^I"X+
MK2C(,*WE+29""99W:($$\&6G*<9*%E".N`7SW>AD0+0DS";GBQ/$(`=WSG:(
M=R[6_YX'[:P<SF4%SET`$E2@#!&@@0P*H(,/(&$!,JB`*8-9@Q30\AH@"`!V
M<:"$=,GO!$!6``*&H*\AV<4"<?#"&IC0@S?D00`#8/41?@"$)I@A#L(C%<'\
M@NN<UFH0WEP'1X02FV"EHC-'+5;*56X*R26E*+LI"J7>7$EJ?2A^U<9S#'C.
M\W"3TJRDX^X$/C!TB=H@`">(`PX^,`$;^`$%4!@!"';`C!IL8`$,G4'M*_!+
M%(@`*2)X8PQ.@`0#5$&\"%`,!4P=!S,P`0A'>,,`WB```7!AR75?0WS[0;R!
M'0])Z5B/8*A',8Y@AF^&SX1I*7'4Q:N<MFVFIRZ:HK*3Z_^&0UCE)PP6L(;-
MDR[<@A9HXO9G9U5N$-!B'I"`C\8!(Y`")@`"-@`"*I`M"9@_,]!`+U`N(E8!
ME'8#2#,[.6!A-R`&1-$`X]52S4<%/M`#1>`&U2<`;^`$/<`#=6<&=+`&9N`%
ML%9Q[W%"?8$0YL415P-#'I$]P2)/D"!;)X$3]Z!RCP`S#+8+NO!L;[8;*.,;
M'7);>8(#:Z!MQS6`P?5M_[=0X\)0.[`#)$`"?J!BT)`"]%8`4C<"%4`"$U`Z
M9?@!*9`"E$8#.-`"EP,#&Y!=&\`T"\`!4R`S2*``>=$$3!`$0``$/7`$3N`&
MU/<&U\<#/A`$3>`%9B`%31`$/L#_`T1@!@]`/#X(?FES-8.P#GF#!971'R*7
M0RB3&^.#)IB@$H.S%%'8."TG?_$'<W?R"PRV`DVP`F<%:,=E7)X7:!R&7=.0
M2R6P2R!``BF02V3D`72U4"A6`)2&72C`4%\T`@O0`B*`>RA`1C40`^6X`"M0
M!2N0;P#@+U)`!#Z0B4=0!$[`!6[`!4Y0!$9@!)G(!+$VCS]0!%S0`U+P4O21
M&)F598&A'X<0D6%`&ZYA6DOQ,A""A/)T,@7V"%#58`WF&S(R/A#68"TG83[0
M`F9U7"S)8=XF8C"V0-,``2F``@'@![84C2!P@0E4`C)0`A5``Q,@47;E0`Z$
M`NJF40N@_P)XR&$C,"-.XP[RDP0B)1%2X`-'D)5.$`64Z`;[Z(\_D(E-('%$
MP`-1$(-`L`;"4Q<E="KU92N<=4@2*50),BTY02`:B1U-N(01UF8,=CY-.$\W
M@C*]^!L\T`(`)#1"PVU?"&X*)33<Y0$@X),T4`'8F#\E\`(;L&\TD)DF``$J
M``)$&36W!T;J]HT,M0PHL)HQ(`0<\#0W<`(P\`Y#TC9K$`22B(]<\`9OX(*L
M9@0SZ`-`$`3/UP.3&`4\(`6-Y2K%`T@+`9=5(D,1.1V_\F;TU`GJI'*4T(17
MR&9^^9=HIDFSF(M%$0Q&@)@`U))`%W2-.0.`Z`$3D`(5H`QU]?\"*/`!(P`I
M-CD!#&5OY^8!,A!&#81=XLA0'A5&39-,6R`"&R!,4Z,$@W$._"`%/&`$6TF)
M`N`&`S``;O"//3"#//`#%7J/,@@$3T8'\Z5'F@*=6"*1$\DR:7(2-,14(A&C
M)^,;,=>7;N9([8<^O>@;YYF>ZKF8I@1Z?(4#*C`!'&A<`8!79+0!,#`"`5!+
MW/5<SP5='H4"(W".#P0-&84#X)4T'+*E:24"#8`$\,`7&F`&0/`#4;";U2=]
M>>`&66D$/-`#1E`$17`$=OJA/*")I,B<F94J6$(97/9?6!`@+2%)0A!PLY%F
M@C.+2[$;(-EFSL9^(`,RSN:+#=`#*OG_2BSY2EDDI';(70'02ZMIGWV%`VX(
M0"D``G7%4`5`;_3&@7W55PLU`R40`"H``R<`#(U'3Z^#*`V0!%``'H=A`5[0
MIM0W`'F0!\[Z=F_*9*GFE5'0`T#`!#\P=TU`!7AG-OB%90CP99@1"^A$(:SP
M:VU!G311$@`"($9U#[NC"TYA26V6&\'P5$J1$R799D&ZF,>5F*63>Z6C"WZ(
M`^7V15%J70$@=210`,LP#0P0`#"``@QP40&@AP`K1KJGA_-BID^00H8@`2OP
M"_=0!8I"`!E`!]K:`W#'!W4`!W4P!W80=]?'@FX0!5'@!*((BIA(CTRP!@-Q
M<4KB/#ZE-8B0_R#H"@L70PNV00NKP";*TALMAQ2[4Z]VDK4W(BT\>G^Z8`0K
M(*2).;:O]`PT\!1>!`(I,&.'\@$0,`,,8`.EES\>Y8`C(`,)"`$K\HVA=P,M
MH'M?1()F*@3'DP[[=CGB!1XF]`!>$`1W*@!Y,`=CD`5CP`9S`*W\.(G6QX]_
M*IQ`4(\]\`-,\`!YE"294JBT<@A8(`1;('*N$`:*(!.+D!F'\SW>N3NYP&9Q
M-BF/9`\X4;6[8`0B,+;81;SC@@(KD"XE``+VIE`WD#HX\$LO4`$,``$[X`$K
M4FC+B[<@T+T?8"A/(SO=D7DP4`4&L`1#@`!LHP%D,04<4&T-X&]Y0?\'C5N/
M&CH'77`%6L`&>+"A^MBL<5H$//"GQ?FY:6D!%E=>@1$&XA08H@%LK<#`F0'!
M8N94LF4^E"(CQB9G2N%L#K8;;=*C]"0&/2`"V56&Q0M``C2(KLD!<;L#--`"
M(S`I#:IC;C5[-E``6X24">LM5L=%2L$A9P``5;`$*R`":J``A!$!\H&BD($%
M8I"\R6=J=$`'\Q@$05`$;X`'8W`%70`';V=]S;JAF'L$HB@%0=`#]`@$7E"*
M]!%^AH`90L%9KP#!_@6+8"(M"D*U:B(&.?%41L$+#$9@NI@4E8`358@4/2`!
M8$0NV)7"-X`%$O`$-T`N'Y"`,W!G8J`$+Y#_`INV`37@`2T&L84FCDKI5G@E
M!H1`'0U@#F>`!!P`'?IP$?(A7Y!Q!D<3!F&#=F;@B$RP@E&0!VEP!6E0!ZN6
ML[X9=WR`!P)0!-F:9&T:NA2G`8@!A#]E(&12A*[1*XAZKBGQ8%/[8+WXHWWY
M>%)((W[,(%@8##QP`MC%5^0R8RA0K#&P44U*`W[@`?C9`@"@`AX``2!@`F[%
M`$5'`IJY`5]4-!RP`9K9`OT6`83Q">)U!EB`4\>S?.I5$%4@!A6-T6M`!$!`
M!#_`!0+`!VSPQ37[!M=Z!%PP`/T[??SH:DPPTT$@HD'[`"B4ND\;(1Z12+71
M90L,NS,Z$DM(3_1G_Z,T$G/S5[7T:A*5RL[^%W5Z>*!\V``S`%W(.P.\E,D(
M(`2S!X<K8@*M5P`L\AMX*'5\JVX28!?O`06Y@!1"H%/*HQ@/@(,6$`$`QQ%H
ML,MQ`-*.ZX)Y4`=L8`>K%@4.QP-%,`!SP`<<Z@1.X+D01X]_FI!D81:!<3%>
M$B'D^@H;P5E!'0IE$CFY@11^G)?"4*P>[&"RQ7[PQV82P`/&"`V\-PW,8'4;
M\`$@@`(GH`0:M0$GL!JYZLD7B`,S@%$-H`:NDP(VH`/8.`&VMP`B,#P(X(<)
MDKPH@04'DP&WZ0-4@`[G8!`%QP_/%P1&<`11H'#&S*%%,(,_T'9X8`=V,/^G
M1?!\8?F(=_IJ#]`7EHT(??/3ZQ`+GBV=6B*[LG$)V2$C]]I^*&.2/ZH4&D28
M$<;!O?`#+:!%6:<,,@"KU`@!,E`N3;,"""`%`.!%%:N9Q1H&,5`#'&`+4T`!
M**`#NP2?*``#+7`")50%LI,30:P+<W$0&N`%6!D$I)@7KD(!8W-JCQBZ1^`&
M?'"YZOV//^"FD0L'<#``1D"03':GHN@%&N!W%#T+_"$8$1DDE]TK?(.7DX`^
MYRPCT,;4L<7436$2G'HGK&.8,3!0NVH-%3`!>4LZ(Z".2G"M)\"K9W!=^6`0
M)^`<5H(&4C`#.K`##+!=L3D,58`D!K!_B&(=]&#_%%`PQ!:P!E>)K0DI'\+C
M4F8@TE%N!&X0N7@`K9;HCT#``X%=!V-@!VJ,QJ)H!`\G!5Y0NGU1"%RF+Y\U
M"!3M7_]E[*'%"-*2J0G^/>RC(6U.?_KZU$K1<D9PY_?3#"D`42`@#CE@IA0`
M!$;``<]0(^=H#E)@`$@P`B90!@_``R^^W#8P`D*@`CYV!D)`S6>P`*M*+URS
M/4.`!I)U`73P!D7@`UY`!_#5#U7L!64Y@WE*B1L:=QF*G#V@V'60!G@0!=RM
M@G4G<9Q(S<5C7H0![!T!$T<["`M\?HV0J3-BA8[T,B.909G*(,`;DFS&'4?@
MA<^@[2`0=;;'8P`0!U2P_P0+,`(-0`$<@%T1L'8&(`1__B\24`&R9`,?X&,C
M(!</8.DC_KVSB1^O4!*2D7P7;_#/3(K_DG9-$(K_F)5%\(*\V9MV*GUV,`?3
MQP.<Z,N?2YSS%27.XS!94PB"5RN!9-F7%>P$HN"*%_.*@[Z2H.`6N1OG/,*&
M_`1'<`)V:$IZ#@*6&0"@O`#3+4QB4`9CXSHBL*=J\`0M@`))8`13X`$DD,,?
M@`,Q(#5;``#NM=<4P%V^U\H<X<!"@$YG8`8;JM)\:J*,5<4WV`30IZ>.S06&
M_8]<P`5_:@118+-OT/%$@.4F6HK$(SV?8C<+P67AA%CQ8##RT"6I$3Y(^#T:
M&?^CBJ_F,@*\^BJ\)WQ&S%`"#``"M0H(*B@;"S4O$DL&%BTH*B(44#B$'%X\
M-P4D!1`J+2,;&PT7&@\77@0H)B@K'%AE!@@&94-591$^45RY44X]1%YK:W0/
M#U1$1T=%46Y.1ST_/EQN/4P^/[E.7$1234QF34%`368/%.47!`AG"`1J"`AH
M:&=A96$&9Z]H``0``+!00TJ>)$GRI."3)4N$"$&(4&#`*4F6&!2X!6+!*5LR
M3L&X1<R4)0TD]&A`P]"+%Q]25/`P@<$."`$:S:#10D$#`$,^!*B!8P&-%S-$
MK/E19D,%$B1JB!&Q8`0*#@@46,A@0<2,%YPX)(&B1A__@'P4U@#Y<429&S=O
MPC&18F:-&6H]>)#E8D2ND2)O!D0A$J2)D3=<>GBATJ1),2),$C^PH*%<!#5A
MHA+(IP`-K#-8L(2YIR9?5P!EE"@14G#+D]%/MBQ!`O#T$"%)1"M!@D2A0HD%
M)4X1HUK(QHVQMS0P,@6%H1HU=(+P4`($"1LIKM*0D&')"0(M9J!X@F`#"A0X
M0.-HL6&"C0(GEL(POD`(A0=>`"R8H6+KB193`(C*<('"J#AK],"%``,((``/
M1/ABAAE2`!'7#SP<P8L/0/C``UZ!\7!A%#](\8`4U0"QEA=Q/$!'''1D$($"
M")1QAAK[*$#`*_;,<\\K[R"@_X8:50B4!'`)+63::`C-MA!MLMFV4$,&_4C0
M0`,=)!QQ*,R`W`PF?%`"2^;I(`,-,\30SQ0E+K#!%AF@@24.$J`!%`HRV$#"
M#&*L<$(#&]"P`!1T"#/%"":,8``4.>"P153E*!"!?P\$R,4`!7+Q0Q!!>&$&
M%4Q4.%8/Q_`@(C=%N#'`&T=4$\0:%E@@A1%'_`!$$&M1X05;%/!C0!58G,$/
M`02H8X`]-_ZJCJ]#_+:1DK`M0:1LHB&)[)(2#;20CQ,)),9P#8PP@B!6FB##
M#AYX\-P$,S30*`%>N&'`"#%H4$4,R(DPVPLIE`#!#C(D409O#?0D@@$4[(-#
ME2<@(/_!!BTDHB-EBSY@!@^/2N,#-Y4.9I@90?Q@Q(.^`$--$490D:H%%"A`
M`15'&,'$K$3\T`L5#[`81A50:`;`*_O\JO-E96`1BSVP$9000$4B`445`$%1
MF]'_*"$1LDX_@=%'1"JYQ&YB&'%##=_-9$@`X!90@`T>+)`!$4E($$%5*@RQ
MA'$JF'G"%B:\4$,*Y#XA2QA;K-"``?U%((0@&^C3P`(<E('&K;J60X$%<0@H
MP!%$4$&8.`RN_$`0%FKX`Q-K+#:,&71<H`^O`%#@Q0]$Q/&X&4!XN@8%\?P#
MQ68(^*P`B^[``DL86%0Q<Q55D(:00D0+870K2"NM_!!-/ZW_)&J_*3^:U1EE
MO4$*+W0]PPP?^$&"#A[H4,(4&2`0MQ`MU##"&3A\OX%3'(1A)98?[%D&$F<T
M<((:Y;#``P:&`A'L;@DM:$`$T#`$"6Q!#1F@BC><<)9I-(@)<?@%$>22L5=9
MR`=,H`,%%G4!!:CA5B[2T7LL<($($,!D=#",!11@`,U4X44&0$(5T%!"U,%B
M<9DI0QE\$YO;"$0ALV'-$*#W#R1<KXFB>9:2G$BDXPDI(T:(00!D\`$3?"\Y
M)=B!2PY!@"4TI0$*6$$`3-`"$;1@8"\8P1:PH!T5?(`&6U`"TI;`@2TT[`>#
M&P$.$$"!8G%@"@A(@O\X,`1%9<`,_T2(`L@\QX,@-*@)1/!!6:+0`R#PI74:
M<&&+6..S,$"!-/[@WXS"<`$S9(!%!FB'.M1PAA=1X)5=V0<MRT`\+)P2(M:[
MC;-LH\0A.%$A5+P-0Y99I"HRQ%IBR!H.9""#$I3@`T`QA`QV4@8O2.`D(Q@"
M!;HS@QN<(`8CL!)-.`">&Z``<0THB`0:4(7*>"$#,%#!!E8`@#,()"13X$`#
M&I`(-!"``K";T(6P800?%.$9/XA"@9S`.E^H")906,(03%F;'V$!"171%3\N
MD(&2`<!D[N"'/*+RF'6L"`"M$"(6DJ<$*$`Q>E*+R&R,>3V&**1:$U'6DIXP
MK1]%,VL-0/_!"T``@0J\@`90_<`,3D`!(8P`!"!`P1DR,(4<Q&`#-\#!"%X@
M`R]^IP4<L-,"5L$!$=P0`!%XP!1.@`,<_&T)PCF!W\H`"]&<-`-4\,&#[O(&
M/.0A"HAU@A/>0"!.ONH!^^A5+/Y1A=HLX4=/.%H5WD%"`K0P`J!]A:(LHX[%
MJ<%D"@#`#=U1PUZV(C,T*P,4`B(<,>B4IPJQ"$*@Q-LH#96H%+G60'O`"!H$
M@`$EH$])7C#(*JC@!C.Y%@=N,`+JYJ`I,PC`![`Y@QQP(*WL:D$;7P$`"T2@
M`76"`?^6(('[G"`).^11%>!J`2J\JD*<>L,<YO"&*+R!L0)@K!/_-,0##2PN
M=[Q\S1+V*!QZ_BJ7,M*'HOH12P6<`QT&@`=<5013`WRE16&8AXOD(439"J'!
M#?B(\IQED8,8"R*\/0AN=!/-@3:@!_-!10ED4(.9V$T":MB`";R#`P/<H"DO
M,),D-I#=-8()!]]MR@I:L(HAG#`62Q##=X>P!2J+5P+P[<<08GD!8K#E4C\H
M@A,F^E\"1<HN/F`1TFCFM*%U=`I*J(<:%K6BG)WT9KM25&H[<]);G@,+I^VG
M*SZ*!32TXU>OF4)(!CH%HBIA%@!!UHL)<I#4$#5:&(GF1K9@!!R8X#@O,$%,
MK`36[S0"!F*00!ERX,6O>H(&)4@!-IF[_P4)V"G%DWZ",4\<$@DHH0$K$($$
M1.#+>R#-H!E80V'HX(T(?2,(/0CP`/@@@&P0`0@/L)72C'G93^NFTF$XK0;6
MH('*J,%GCW['"R,`"WQ$H(7QV"P`=BF+*L#H9KZ4B'#FZ9&#*,]YS-QT;J26
MD&C]J"(-.4(.`D#Q.%Y%!<GQX@@XH(852(`#.!!"#'X2MW320"<!J$`*0NX1
MZ!&[`039S:01T0`.""$,2+C`XGH$!;AJP!LBHP-A/&0!.OP@+W.`PP".P.Y:
M80$!8<CT98$)I8((P<-E=B4:9JM1>H3A=(NCQXUD].Z:QC(=0AQ"&79W,R3@
M%<6\B0A"6!.UB?\H7,9)$$)`GN2D)15A!#MAK@KH,[`LS6`!#0B#!&*`)9`K
M-7^%^!XV=9VPFM8#"8KL3:^_*P$PQW,=)X6Z$N"+A@AH(`ZDBT`&'H#+J`B]
M"`3Z0<QJ6*.9TMBV$DD(:SRLJ*)G``!"F*=JAH!H?;3(1?9P4<^2YHH:&6`S
M^H#,Z&U,Z8$P9#9[Y^W=&Z*0'^$F2@,Y@@I`$(`7<"!/3:&!(-XY'B6+J1,J
M>`$AU!F`[ZD`S%`0XJ"N-A`D:/D$(O!=*38$H'<&N+(09;!GJ\<8)A,P9T`0
M8<`K=,`7%M`KM'`9'Q5<#;`%$8$$FA&!?48!<6!>2-!Y*:9#"2@C!P;_=95%
M&TM$"\)2#\^7(T/4:]07);EA1+V5$14!8POW4WGG<#\R!4:P`%VD`CG`-?%3
M`TB`)PN``C=`"%M@``J``RHP5H)@"#.@:XBC%5#P*_LC!+AR$!\'`P'8>;5A
M`!'06C/UA7!E#O=60CG$`6*@=TE`A30T#^3%*V<0$%DF7`V@!+JR#[>$#H]S
M`0CP!":8!"B8.B9U0KRD>]`38CH#/+A2#P8X!?.$7AGA(]Z'677&$!T!<YYH
M?0F1)-""$$5P`ZFF)1-0)16P`69P!@M0`CR!`S>`!A2`!=Z!"M\#5340$W:B
M%1MU!CW3+$L@`LKV9:=D-#(":4B#!)&Q8<-`_P&FTX1G*'QZIRPUI0[]@`4+
M<6*5IG>*0U(:H`$D<U!M%VOSA&=C1@`19#KIH#0&QQHAMAF^(D0A]E'"$6H#
M91`(T8DZE'`=P7=0<CS-TE,,400Q@!(FD`(!$#\FT!4G\`$>$"@+L``U5257
M^(L;(%8C(`)/@%:K\5I1)`1#T`)WL@(KD&=3T$B(^"M"T$0U8P#P2&VL1P!<
M5FS4%T_)HG:Q\!K=5Y(S$Q54,0PDHR((T(3"YQH(H'I*&0M.=!"7IG8EQE>Q
M0`^V)QP4\8^GF"2Y1Y`&:8IZET3.M`2K&``@H&J"%P,Z.0(>P``5X#X;4"A@
M-4\Q4"@9N0%TN'A3</]PQ`,%9P`%DZ9L(C!'0]``")`!M*0&;H-;*$F%&=`8
M+#($3["!`Q<28I!E/DA493D:-153-DE2P\!Z(X0`QT90*(DK;U@9@=E$LQ!3
MP6-3L^D*;L<1+R:)MF.9JK%,M`5CO(6057E,"[D%QH$_(7E:8E`#$)`"7*03
M<10#J]!>91@#AAD#,``;*%DS.S($)P`#(%%SL[$:,J)_0Q,U>9>`O$)+0_`C
M&ZB))V""6]!'&?&/2-0LL^`*:&`RHY`J_($`4-"/LU`/++5`LG`T-G4T(R9$
MT=@LPC-ZT=01E69ULV%39OE,17(UP%D0G':*N(4;3U`$Y%0#,I`"(R""5*#_
M`@S@`2F@:A-0`"F``M+9>73H/WY3<RW`&RVP!3`(`(0Y91)0&Q*`9U.@AO\0
M-!IU-1R8!!LE6\4S-:8!$AQ`<#PYBK:!$$KC@?:`*!K`'[S2*^&I-QEF81I@
M.J&!CZ<$E/:0?`"1=SR%5S:VF9%&&W2:@9:6>T0B$,#D1"!ZBJ2!$5!R!&JB
M72HW!>FB``%0`#OP5"FP`P40`"H``PU@-+[18$H0H5L0`VSBAF&0!-^)G<JH
M%<H38N>F++4A$`7A@95%6\)U&D^@93WI$<)1$7FG!#WC"E"'`&\8`?TP#XHT
MI$C@"F]X3VC@2_/P44L0&8[F#F?@-M8G&J4Q4+RQ_QJC1Z>TP77'@ZI#!26?
M2:=1=&Z!"@5YP@`V4`,(P'HH(#8Q\0(!,`'D<@.2.@O2Z*R9IP0GH`)V=33@
MB&PPT`(Q0&4BL(&L(2UZ=T,]151TYW`-M@06BEX8,5!+6A$9P;";@2,$R@^P
M4#R_&D^X,J;]`0!Z:(RKJJO[8!E#-#4)(36IX;`=Z#366AM#-75Y!U2GJ$-0
MU!"]=01/`"8E4`%/($('<X7QPT454`(H``/SQ(VY,ULMAP22D`.3>EDU%X`V
MMFR_=A!)T!%B<!JFZK).XWW;"!'2*%O8)VFX=S5(X!`=VSOW6$NLD;8U)J>:
M\0HG5+&.%@NMD`^Z=`9(L/\;&W$1,">A!I=$+ZM3EZ6D$1$E05(0ET8SEE4M
M@;H`.P$!(*`H)^`^VC$"4E4E*/`WX<@:_08%6X$`58`#FMH`4'"9G0>LHL%'
M,)!L+]EPRO(:;ZL\?THUPS:3F^$S-?2JXR@16!`0>C2WOW*LQ',;WG=$'JB/
M%[LK=1M+_&`9&=6)/7@M4L.!MD&XH#EZ#9>X%4$M99FJ-G6JG-8DX6<4)+H!
M8J`")4!Q!5`!^4-*4X`.>L<TK/%+.R1R>A6LOB904Z!#*Z9E4_J_52"<2W3`
MS(2]T&,TN/I""!".2J)@E_9\Q`L\`#%$O'$:"Z%V042)^[D[J55OA)8.U2*M
M$^O_?2_+&K!A:<I45!]1L[,UO'R*64%5$$>``Q6P1BB0J#K@$B0``A^``(-1
M@0J`IY-X2@<ANN>40`&Z`J+V!*Q!"^#88(Q8//B9H#;%3`1Q:;-%?+^B#P:P
M$,QR:6(\9O-`H!1<,T)P+5MP3$:#*Z()(_<6PCKS?&W*6^CE$1\A$*;ZLDNB
M=RW,)$'B@M<Z6PO16^6;!$<@N5MD`Q"PH@7@`6NT`$M@>B65`6?`@:LQ9AEE
MJB<`KRTYGPZDF[4TF$J@P%6P4UB<H,CBH6F:*]`;QMPH&Q)<C+44&<EG8E$R
MF\:D6?JGJXK"#K$08JF<M;W%&SUH</5KK6.LD,_2+,7$_Z="&&,_<L,FD"4@
M4`'WP@`UL``PH`01L`0KA`")N;6-:U-+I`0B<`,)=)DPYXZT<".88<70TSR]
M1#SXW,P[1;O"@P]AO&)T6LO(9XPAUC/!NSQ\Y0ZR4,^946\Z`G59^DL]:"P:
MX5O#YL?VJY!?245*Q#39]R2;MA&E=A(!T+.1S``F8',*0`0$8`%!\``&(&G8
M>TJW0[;(EAZ<J!K+HS,D]E'WJUFXPDOX#(Z?2;BU45/T\`I#5)7_D+O+@XF6
MV$N6)V]?44-+5#.EA"NUE,K',X12\V(M-KM.9$S)9#29IDP;+1L!_1I9"QR_
MP8-84VI9,@%^\*+O2P,Q0$_DP/\#;E`KDFH0HON%DS5]FSB.T*,9OO)\"WW`
M5RE;O5P&-0L0S%*_-B4+8KP\2F.J@7F)(DM\@RD\'TQA.:2@\T!9"?80M.IB
MQL),+DB;2+/!Q&E%@-P04W<:S@--1_5PPM5Y/0!=WE(!%=`2)3!X,EHS)@(`
M*OG.=<BDF\&@HR<<L>&R;\R[QNA+6)P9V,U3-1/;PQ942$0;5W,:IXI,T,.D
MO*2J\8S/ZI`.F8%STXW9QY0:>HS(IL@0K8V@F4;6HD$0];NMEX6]?'J]/-B#
M6GLM$L`#2R!D60(!$\`<-'#-[P0#72$&.)`>69MB4/R!%ORG*+DT+WA#(KO*
M6(W=QR3_K^@9X(G\(WIWF5&:M=_M?WIDF36#C[R4?SA42ZCI@J]1,VZCI]?2
M6]6"+/?=U*)QP$O$W^/I<-<K-!S*$0/^Y"'!`T^PA=L4W#NP1M=D`C2@OB.)
M5GDG:89-#Z=-K5R,W>V=8+.`SVI./)8UD$P"D`W'H1/]O:211TKRETWCQ6"8
M&=Z8#O4PQO6+&GIJ&@.1$5##+/=MY,;$1,6#UGH*$1(ZA&`=:KP!$9)VX"+P
M`=34OB`P`8;G$S0P`BP)@'EDF:2H/#:$<*$A;*4L#\?:1&8>/&I.)$9C$0I1
M<&8Y+0UF6X9;1'^L=_**JXH]C5`GV==S)(?K-GU*$7FDS]#,_T0ZONCZZCQ9
MZR/`P<:X"1Q08K9+^JL\@`.Z!L0UT+/>X<W5A;3*.*2(^S0U]=JSV]3&)':_
M$IA7;5-J3N2V31H#<2S3/(2(++9!]%&%;AIBZ"(S<]7$8X!TBI!O>^Q6LTQ#
M.)-C'.NQ'NU$(^EOS8/7`NGH-1`_CF)8@V-2I5TG5P/QF58SVE8!VVE"@TSH
M7,:KW,$%+>NK3#-DG<H#:^U_Z7`>(31/'HZW`UL!X781,9.:X4M*=#0S0\C'
MA)*0^?`^I7MK/O5K_K()/.!'56,5<2V`N(&`J+4X=GB-,#`C(*E3$+`?QWD^
M.3V%7,OZ6F(Q9?`B1N_0LT1.Y-ZGK/_S195Y1?_D5"0\-C\:,R7&TW[%^3=N
M]#X:3=WT4K1B3*3H(H[%D/FW>I?UEG_YO7:&>:R9T:0U-"!6.1JP]!020M``
MRK:)=4AW,RGY91S4P>+J,A5;2']ISI*Z!1%/^[[S/D*KB<M;,&NS1ZW"NIG*
MEJ9$,[4\KSD+Z`RSV3O&=>_P3J_H1DZ^J1V>/1FG<3IPWR50F8E>Q+$`1Y9W
M9ET&\KT%I5^UJ_D:-).@M4P+,M@.ET'OP3K[D/FJ%8'[$=_OQX(L?`P(2%!*
M2T)#2TE)AD-04$)30D)*2$-50X)8C%5895554$-#D:-*I:5+E$))6*RLH:^P
MH4BJB;5)#;C_N;IB#1(-8EM36Q(B(@U3O;AB1F$;*`L<#4N;H$M3UTE;#5N*
ME5!(X(R-4)MEG&5A9P@(!F'FK9Q8GJ!(B,%;^,+Y4XE/A?A)GCS9\@0<J5/9
M%"%*H@04K(:9%I&#Q\I3*X?@)FDR56J0$"15/HI*@NK;DBUB>.$*U@ME+GTJ
M?^%[@DR"+UPVCR4Y<B;&C1:XIF$QB2T;L">&/H73).\3E#-G#!A89^",.XH5
M05E2\B0;/WWX``8L5.L:04D?P1GL6DC8E"5*8@FR1(DIUHJ?9*D-Y?#5MTF.
M)@EY,FB)890Q<7+@X&O*P)2[7/:RF?/E3@0M;L0P)G0039(T@R'U_U:77!5S
MWY!,7:=&ZIEW\.:%&EIO($FOPE+V*[2D*TK1DBXA.678\"_'2V*-:\1W$\5W
MX_3&\D3=H:E(O;$HN782\N3%BWVQU*5,&^7SNO@=N7!BP0(8TJBI<BP$$;]"
MI!LY[SM$ZNJJ8<A#45[A$)+-%G`](89ON.Q&2Q+7N`67$H-!*,97NF$7BSR5
ME-$<5E>!@I$@H92BW"=<&>@/(5T9%9,$X>52&67E\6(3>#?AHIX%3XC0`F?4
MV(>4D)'D9U$9(I&33E2N=>+<17K5-P4O"!ZR8#8-CB4$,&--N2`2#"9C7I7#
MQ=)))6%\2)%5F9`H7%X<F6*:$DF`>1^"!O\BIDP#C$VF"WHR!<,+!R+T:=D1
M%"`QA2_4>7()A7!AUYLA6*19J9.70%%&5%094`84G`!H3ETGA2G0J1$6!6&$
M>L*XQ79#)J'26UT5A$4XC81Q529,@1J@.-'!0L]PD/8&UQ"$%&>8@>2MU(L(
M)^2HF"_2*K;8+A)L4<0#83A2EUS#'51*77'EE9JFG+;S9CH!,L?5J2W:DDBJ
M])J56'I=@854N''A"L55CO:Z25ZQ%!PN=FRAU1N\O2$SV7F$GA`MC-=27-F?
M%&,[Q;:L-!*G7Z)(LA2QX[X"3A56215&%0()@7*[%(+)S6#^1"(OO2D%XR)Y
M,$H@1B+<(#6)4C'_4]+(.P1/M!Q_!A]L6(OPQML/EGR"QQC$$4=K]4W`N`3H
M-L<X04$W"Y]:R+APS8674H*4,1P26+0#U:WU*8'RIUQ]A8W4]::J##_W4AP-
M0<:"],E^DQ@-JFP?_L6(6DN97&QOJUK(3UB8JV1U-+H4X_D*)^"H(X22T7AA
M`TF(/842VMVL9=J>H`.5IZ#$/6[<NG;;$"58G#'4([PX=DN8?4?XMZSD0<LY
M).'^:\X0E;:IN#S\353%+"!!_FV)DK:(C3;<I"0^8C:B!Z/GA3(6PPI7^_)S
MOMK@<BU+J5,@R4"L;A&N0#,S4L;__VO7:2S""6+5IS158!%`<H.ZW'2-_Q_P
MXT7@,D:>+;AL9<S1G@85YY1Q%`=Z9].+6JXG$,J991MO64*.;&0H77B-&.B[
M6BZ`P8](/"$9Q?B%,HQ``<'DJQ9."X@A0`6/=E4J1,A"V"B*XYN<!>,KY*,A
MZ2`SP?"L4!%$I%[!/C817KVB/J@(B<A(9B)5^&->+KF00*I%HV9AC#(QFN%,
M;(82FURH:T?0P*-H4;,X+8L1SY%'&%1&MZ?90A]3E&#0$JD,8(A/?#P37&5(
MTI"!$0ARHRB2:;PHBP,.@B.9O!\$[36^:[CQE!<CCQ7)<Z%(=24EEU-/!FBF
MBD)0HF2?K$NC3L,*=;0C$W0BG3:D&)FP0#$EU?]J9!5E&(R2":<4-(O:J22A
M$0W63184BB:JU,C`;3SR82UDXWG&*<DVOB\A8!E+$2B`/V/%)9>-V$LE&O4.
M`Z@!B<(40V,^0IXI-A`Q%^.:=V1$P;-$SI"R>J2\=H,*R"'+EGM<2%FH]!B5
MZ`DG%LL%YWA&*')N[F+XT)$P<.&/)8A-,+N9!,Q<UL%9V&UEG$C'HXQEGF/H
M:`BG).DP'68>Y/W"1K^X"8Q6(K3ZM,R$#I0)!+5$H:X8(D[#@N;"7OC"2!)*
M!!FES,]>>+6KIN^JJSR&P[A$S2A0P#"RND^<2K'+=3D''?41Y@P5M(WN-(M+
MB!EF_'PZ4'WJ<*BK<\3_T_*ECV[R8RP,!6-<"K9'HR9")7;$*$%O5+$8Y61*
M&"T498H!'L^)#IG'><*XS,J_;0AQ.Y14&R>Z"!M6D"XR;YG2(N/W-U91$;-\
M?:0$1TI#?T2M:RA!HP4SJ:Q"B&R>U,F(#=&(RAR1DUK@P0G8%!.Z7!2J%YN+
MD60(IQ$N]%`(X+O/8):EMG14ZC59`86%I(N/GSD($51JKQ0MBB6^HG!69VPJ
M2O9V$IW5Z6#8;,BP2G()N13+7LT:)SC;6#5#N<]:#O;90#"F(]\6)TE<T".8
M8$F2AB:.')OR5%1@2J!\J>2.H1798'AACY4$)'Z70]V)=>(P2,1U+">!H#4Z
M_RR$],X#'%8Q1TA(LU9)M=>-"J9L&S^;#!G%<:BHV+&7CG,LI12)$=X]U2U^
MAI9RE4,="`C@B,]TB/@=F7")$`(4$(HZ5:#.%JK@DF[+\\1Z&9,DB_#+6T/\
MFBH,<F6,JT1$\G2Z!(M31DYV+F7!6N%LB$0VV83;KN;Q+UV](0/%(BN%O*PK
MJ/@NIBN[1%SSZA*"U,(02$4=(MY<"WL(ZILYJU<M2AB<++9"=J^)2JY=@T'A
M&(T0K/031@\M7<ENPSS7%=VJ5D2)ZKS"SU5!AY!/\S\W:%A*]-GT/*--P%;,
MPCZ8._-GD%(A8=Z&(%%#HVYC?=A9+TLCU,Z=O)G$Y_\R=,H`&"'$)*R1OIM8
M]FM(1O1Q($0,GVE5M#11\SOC<>NIJ($=50ER*ZP]"YK0.A)>%K)^,H@09'`#
M)MNX80H)&UPM%S<@-%EW/OH!+Y&1`Y"Z`N#_0+WKU[`C@,\T(WPYV]G0$0-'
M"AXV0>DL[*`@2R,BHC:N#0```A``#>N`N'\,(`!,3_C"&)^G?@Y'C[@T]1:F
M%O<QT)K(J(42.<C0[1-1WG+>N:U#3JK.D>J-@&Z!JK%!T\;F)'8"K'J6G)--
M=#+=]ZJ0+,YHI^FT5!!```4H``!H>#@[HHX``22J'A:DG"+&>(C5T<9`#8,E
M6.@LKW`["#AT:AD=N8&@C%3_&2OH"I"8VR'O:1/1*2PO+:%6\",.\!X&,&@!
M^ZQ6M60^JT\?MZDR$,@?5J3#GFI``P":[O3J`T#R:LC^`'IH(,?B>8Q.)9!C
M,1ONG_IWH4"#H-F414U5B.8MUWGG+C_1.]C(3N9(T\JP'J$C:_D(=,+7`L"W
M`NB#50+W)Z)39SF3!/I1$9P`%9T6%=DG?=17?00`>>N`!AJX?:&D>7WT=8N0
M$5Q!->S&;O)27"O'$$HT1GD#&L:%2TM3.^YP.*S06DW1%P>C!&+`&#NX.0+(
M>R<@@,+'=SGT,_KT7&`E'EXA-#68#NC@<%,'?11H@4XW?1HX?0"P?2TC"IJG
M)69$_V[IAEGE\6+GAW[N9ES4E#CB4`]CP2+'PEBRP$O?H`D=M''"X7UZYPN>
MPW?!=P+!UP+"!RU]%T?8E5T1TS/'EAR>\'Q3QQI1)Q43.'T6B(586'UYP$Y8
MY'T.\CH/A&"Y@&YK)S4'$A88!PZ4]#AT.`M"Q(:B93+;DRG4XR_*H1=(U3XP
M=`(KL`+`UW?`%WQ^IUGRDVQ6HUG04GS;T&.ZXA_W!HD/QXQ3:'V22(67V$?&
M]!;W$S0U0SDHT6)R1!!N01/J1R\F)@:&D8:(ETV'$1"`\2A2)1#.Q'S+<1#(
MXE//@HNYF(N`*(!_*'RY^%7#YG?LLX<2TU5),`2#-!6NP?\I""!]K!%]5J@&
M`*``%^AT:M!X$NEX"L`'%[`W[)8VB'!Q<24,XTAGH>$8AW5&MN`]UCA&I8&.
M"S$AC>5]R)$*&N%K!I%)A.`PV"6(?!>$@`A\^8B/H`,M<!0QA=)WQ2`Q!$@M
M3V"0BY>0SX<`K;&0U&>%$3F)"A`!6HF1?!`!L!8TJ'`)QI*&@R&2JQ(_75.2
M4#-8TJ1Z:O@0W?-NZ"@0S/4S"7(VV41<FH=9-\*3/9F/0`F(^,B/PV<U/R(!
M!)B401@M1K<D$`<5LH.0"!"1$GF!T5A]CA<!%$`!6AD!>*``#T-4^*$49Z,6
M!L)V`D&2WPB2>IF&-6D=T*18'&'_2+:U"U)$EX=$6Y!U57QWCX.ICT$).KP'
M.DBY&$2(E(((`]$"#&J6.X\Y.PXG?1;I>!9(G8W7>!?`F5KYF11C#"&'']13
MBJZ7>_Z@FJ)14JY)'(FCAN0`"M<!1F1$EV8A&;LI1:MB/#MI+3WIA[VXCX')
MC]`RE!+#6>P3A.@C,>N3+8$5<\\9G17H=!%@G1$9`52HF1=PH78`FB^A8YAP
M/;C$AG`A+Z5X",6%EXWE+TAW/;P4,J-`;CQ%-84X3NTS+0TF0PT@B/?HE_88
ME((9.CZ9F(+8HSO:BR>`0MUP1/)0!JLQ@4Z7E5IY`11*F=:9F9JYF7.PD1$B
MGFE3'\]D_S>U(8HC6J(F>C#^LA1SZ)[%Y5O#!!E"98A?U9>,48"=)9Q#Z)OW
MR*-#V)LM8(_$.:![*)31X%30HRO.9P#/F)D7VID7B9%4&@'9::5G14T-.!1=
MAZ9+,!0M"&?'U8%C&FF*$PM2538E1(+RPSGG4X!^JIA]UYM]FHNX6*=VRGOY
M^(.+*0*Z**N@TUDX.JM%*JA']#]3T72->J$4`*41ZJ2=>:'*NID4,`?V,Q>L
MY3OZD9=JU@@/<FK'Y4>=&@G^`IMQQB5P9AZ^P&BGNI^"Z:H]BH\#*(2_&:N_
M"9S#B8]!J)Q]R:?Z&`-[ZC-'Z@[_0Y6-IY7,RJS'ZJC+&K`4D/\!"%L'S]J>
M791`HUJ:E302FJH1VDI-)\I![DDAM"6BP]!S6-67MNJ;^YB+0*FN/M$",1`#
MP?=[A&FGLUJR+-MWO&<,,.*3BR&(.7"8$K"O`329$/FO!IL!`QNT`8NP&5`'
M&?"I?H$$^&`-(%D*`Q%NB$<7M*`]W("7'+$_`7&6*V%*G7.@?_F3,*"N,)"R
M9JL9?SBR,#N8\:J+]ZJR^TB$2>FJ5P,M8VL,=NF4BY=]PIJ=&O"W&I`!VIF=
M0JL`%*`!%E"LRWJT]K.>LYD2-V1^R#$8W&`+2$</-*,]D)((!E9N_M1(X[2?
MYBJV/VFVIMN?_?F3>:JG^"J`*=N?^$K_LKD*+;8ZA`_6`(-(4@TQ2)OBKUFY
MF8`;N(J[F8)+O!E`K,:KL*^SES(!*%>;$!,;#F0*.27%5HVBM:3$43?KKG<J
MMF7K$SE@NJVKCR/KJI[%`4&HLJ[[NH"(KZ^ZIP'ZONSC,Y*1"Q\1-PC0.Y,)
MM`AK`?YK`1H0M/Y[O,9ZL`=[M%ZI,V'29%NCA&`1%N4X+AL$#O11"9T;01BU
M.4$ZJQP,F+WH$YIANASLJJLZB%;D(ZW[O:E[KO>HI[;[/O02%THZE7T+O/_K
MOP&<`<*KPP'LJ`"+L`=;!QH*2_%#+;@0.JMT(6*8"RC'K=^BN6ME"EI[9(7(
M60%*OO_)P8%9_[8A;+8E6YS&J5F5X2.$&7S`E[+I6Z`_B+YN2X#20`[K)PAA
ML)!-^KL':P$/D,=YG+B(*[C%"[!/>KB;"0<18&APVITY1%3'1@S'D!96]@@H
M-RDYJ<!IPQ4_,U([J92RBK)PR\E>W+[A^[IEVY_GBSJ$4,3'5JJV^KVJBXMW
M&X"!J)2`*`W#,7,5\80+B9$_C+@/0`>^[,L/D`%YW,?%^ZC`^[>$+'`0HUDW
MRW/1P)<Y84'#X9[CUUY;RV'%02&RTF+=*<NEV\GB"[??*\K!"8S,"0KW@V?Q
ML[V]V,JW&H2RBL0!N@*TK`3XA\O2UZ@'JP%Y'`?^[,]K\`#^C,/%6_^T@`L'
M&BJCANA5=(L3U^4SD:*U\$5!?@+#_H`,$]W,[_NV0(FZ-X"V*KR+='M=0S($
MTA9S\L"7QMF]?1B<P_FQZ-MW]3Q[BR>=3_JH&8#'#V`&/&T&7M`$<>`%9O``
M`US01GO0H'DCB\;,Z?.G2WD^X;$@=5.6US`HOO=5?><^%X(E]3NWLGK&Y(RZ
M("S.?UB[H6.`Y`8]NB85GX(E]=IWK9RVN&JJQ>`+J&#/49F!E(F\!XS'=.`%
M@.T%4L`$:R#4>QRX1PW`2*UD@L/4S5PH@J@\Y^,+Z&D/N\D!=PLM0]@G%T);
MUC7/;TO.6AP#.1"^[?PC:VR`,V,W(P85@[#_7B#+`:V\/BC[H\_\<T%1RP<I
ME=)IQ\;+S[U,!<)-!8,=!V80!WA<U#K\OXM-C(9R5=L`LBW+F[GXS`A"$\YR
M/O/JH\-973$!&9Z5OB"<`US\T:XK?.(<`SB@&?RXJD`X.!!2)YV0L2>A4<W,
MO?G(F$T&#.42E=+9I`"[SSJ-Q\:]!G'@RVM@X,"LQ\.\W$8KQ##T=SL)1U[=
MPJ^ZBYQ3OYG,Q7<+SSZ'9$C)>Q]]MJ<[RBO0Q3F``SD0PGE*G"U4>`=!-0X3
M,=S;T!5-$OZCC&@`X%5*O/Y+!WE,!VM@!@GNST(=!WM\PT3-PP^N`#%-A.T#
M5G.KR2;[ND-I1=IM_[)]B*O5Y487#@,C#GSLO;Z]N.(^L=XWD.(X$+OF*\:_
M@!2B018`0;DWRKT#>KN_H`AS,4BL(:R.2KP";@%K`.2%+=1$;@92X`5`;@%&
MN]P$S:QS0`!$Z.+#B)1\^GMI>[I`BJKVVKX?/;9+N2?@P7OA?,8!".9PZQ,J
M"\(?W>J@;K[(1SJ)]1EDP2<AZYO%F>?QW4>\DPY229E_?L#+O=,'CNA4(-1#
M?N3#'+PZ+;Q6B@;]Z'M#*=GH>\6E^]%?+<Z)*3&`*)`??`/NL>9`>!.W<%6Z
M..(<38"9`=+J2^I>#`/ARX]W2]F'T0#[0QA\%&>]8*<#>C6M-PG$465E$/]]
MTQGLP_X`7F#@/RW<R%[DBW[#S1ZP<X``8^M[A!DZPL?&HWSMY-V?ETZV*ZN/
M(>P>"[#>^!H-Y8.^F;&R+/W-(!Q\ZV/MQ#GS?Q@M%J0-#)A`9\/K2D!;\KNG
M*!\,Q[(RX4`]<VS3$:J91NO70>T%P]T$32`%QVX&4$\'`&RT=PS`FPFE=D#Q
M`,C"_Q>D:5O>XMOJYKV^Z9WF-X`#&[`!X9[B,)`^`YKMA,FCXYRRF]T+?"JS
MLCR`T:!8P]$B8WD*77'$N`HZ2MB*5=`.L=,*ZH#T/SSL<5#8PBT%@\T$44\%
M5`_41/VW"(NX6J^=7=_!+=O"N/J]9M_J*Q[FX+O_^JV.`["_`&WO]B2OG+O7
MU.)=^E_>BVZL",BP>W!-I^H;J"`A"H]Q%ID$"3JH\BM[7=;8-F&`!@!B``\H
M%9!/N+PLY$Y/!4U`!$$0!$1`!$R0Z)9O!D">Y#K]QYZ)`*0NA(*IG&V,LC!O
MNJD?YF"^]K"/`R2O_[$/"`L;@PL+.#`G)RLG(APB)RV1,#`KE8F)*Y&:(A);
M0E5#0@T<BR(MBXJ1*Q)B24)#2$M)6ZU+2D)"2TL-24\-(IF3+1(-GDA#564&
M!F@(9V<&6&'+S``$$1$7%!0:%@\/<5Y45%)$0#X^0$%$3>)25&9TW_/?&107
M$0IX")`W+<*18BB*$?#&_XT8"!/F6+@0!XZ#,7(X+%1H`\4;.`Q1I)@#1D08
MDA"VZ&>)T:-4JC@T:""D3)@J6S@D$D$)4R41O'H]T?5DRI0E2)#<>N)KI<Q@
M(%<F00(%2YDS"!"H,1#F*1:H"*I=RT8A@P5O=-:0H](DB`\>/]*M&S=V31QY
MW^39NZ!`'X*#2#TB!*E)$HP;#`T*QCAQ8Z&,.'(L&%%HQ(:,AP_?0!0C,<$5
M-X`A@F0RU25B6UP-@1*KP8G+BF`TXB5JBA(E2X1`"5/UB9"A6QI(."FBMXC8
M2D9?C6H@:QF7"-`0(``@GP)MV[R"C6/&3)/K3)@8Z?$#")`?3,9)>>?%BYDU
M#_\LV-M&P0X"89,G)>0+TJ/$AS$(.]Q?&#)%0H0(8A%%D#UD'PX$39)#)B-E
M<M(E,[&2A"U05(&$$%N8<@HF'!`CAAC%V/9*,EA`42$42B2AVU$K-$+,;4PE
M8X`:44U%&U3*,:?`<A%TE4$&&FCP0%CE>2%%64!LUYTZ4I1'#GE>K"'7>NV]
M]\\">N5WD$>3823(`I,I9IAA$E54X(!?"FA8?(#E@)!!,=14"2F+<"`3(\7<
M-AHH*4J@B$DJZ28!,4HI@4454`PQA`%GE*'$%!(X\B<G/P75U%,(`("&&@!D
M!8U4UBRWG`(4?&7JD&(U6<Y92JK#1!/O2)$=K/#$\8#_!D#>8X<!<<*`X)MP
MYO=0F18]Y-^8ANQ7R`W)`CC@(&@NX":7#N677R2]M5A*A[X5HVB%6,"RBYV]
MV;E2I"H-N@53L"!#&Q9"0!KI(YR(88MP+LT(P+X`3%6<&FJ@`4!==?7835Q#
M6L?$D43X\$.K03`1!!!$2$Q$Q>W8:D$W%$2P:PZ3)3080A+=AQA_*&^$<F&+
M#3("8]`&:$A$@_W5P@TGP$",(KZ1N]H4%5:!1;A#*)&;&+NY..B@8C@B1E"W
MS58%HO$*:B<Q/RE1H4LX+F=-,U%MRNESV/@HY!I>@..%Q40$,3'$0?#`G7=N
MLQ-E>MYT/,<9"6DI&'YE2N;R_P@KLVR(8M%6]#+AB2U$&,B^(BC1EC4UXDB@
MY'*0A-!"NU3&$+JIB*Z@*XGQ1*1;H+C$$UH'7=IN>#Y!VA.8"BPP<\KY*]7M
MUT#G%3UKF&$D=D'\P`,1/3AAQ`_,I^,=.NE(849Z5,X1QF`,.6Y01A81*PAC
MARFK,O>&<3]()B55LL@*(FG9Z[:9<\N(&$H\9<#G0IS.`2VZE0[B2N<RW86$
MP)1C#&$)4W"$B^QE(B5,(SG[$I4U:%0CWG'E1U^91_#(4A:W/<\(1>#!69JG
M#K>M0WK48\\<L,"?9#D$,,<RS`8<,Z#$(*LB,8L6#M1W`G(QHD.6:$%"3M$S
M._V)3O\XV0(6BE.%)WQ()JSX'R^F\+\.`?`U!NR%Z"PA(25P;AD0)`#!OE;!
M4#TG.K\;$G6&QX2TJ,4(1SA"6K;#`[2HXV(+FYYZ5`B%%H;O6.9+D\P,)Z`<
M&M)`UWJ$^G!"KTR(I(=V,J+Z4!$H)`@-";.(28L`&"D`KL1%*_D)+I;PH5%`
M8B02<,T0I!&&"BI'`?GP6M@B6!?V`,D;#U@#VLC!A(8YC'D]"&8=BW`$.MHQ
M8BC<XS;F,(2-!.A88A(0^!*G)AP:<G"/Z9(_)%4*,?C&D3%H423M%$356+$!
MNM!%_DYWB@Y%"I*$HE>@IO"$69SKE*@4@W"@`;"`H0&6^*C_2[\"9L8>=:4;
M8$';\-HVL1_T8'G&@Z,3B&D$$!I!A$%(9O60,!''O&P0D`&08Q9#0XO$K)`S
M%(0*/JHFB^3G+_ZP'&A6E(@-R71I+.(9*ZBXDBTL@19^VHSE?).M'^YO"TC-
M#8L6T8DG/-!V:!";&!70K^)DRAKY:,Y!,YA+(V6'H7`L@A.<$(4B&,$)7!BK
M6GM0%AX`(3QTV&.0ZC`$&T(+I=#ZZ.)*6L@QT="C.63,FZJU`I4DP9ZFS%E-
M9F(Y23&"$1+B:3&FD!M(H$)ICC6J)W^AB&TU@'5.^5<9!::IJ(`*JSNZP(\.
M]@VTR:J7;I-;18]0!+'6-HZX[4'Q_X!P)"_$-4A?J4,?0ZJ1O*K@N!Y=:4F?
M&=AK8M,@`CJ$YBSD$]T`HU>:N.R\.G2USZZ.IX=MVB4L!Z*C`"IIOMF$2EK!
ME*8\\%/[,FW82(O5?&PU+M09QU?=QCS9'@&M1^!!10<LQQX080U-DH>I-%`'
M)#CS/RX[K@I,JMP<4F1Q)YWA#/<Z88=H>`$Q$`'0AE!/I&F&+]GMS:"L.#K@
M7(@H/1E%=QM0WDFY$T*=[6%/GW",9$!%=P&3+VE%18`+X&.UN-2E&?0+V[@%
M,ZRU[0$/<!O'(CB,"$LV@\9P18$Y".&N+AM$A<$\@I4"2"-I^H]*-[RXE2I.
ML"*@7RQ^NO\;!IT"?3\DG5)50J'C0($G_>OI%,Y%U!M#R#>$"@T!P_#C3A$G
M.5$)%9$)P)Z-<;4ZXJ#"?H,`90#7\:QJ+6O;@-`.+=>C8W9``C:O^>8-H(`Q
MY%/986!P'QQ^U,Q?>HP0#8N+`S:M$8K<D#M9@PN?_"\)7CR4+5(D!I\DU4\J
M:6PD+^$(0DE@0@2$0ADRI88S,-JJH"*8N*_1%0O`)0Y4\$)9%K:JM`CX"%&(
MPD4="N\B<,<'%R7U.-`SE[K@00EY=:[BPES<&O8'IH71<,Q8BJ!A?#87']K"
M%))0XQ8IC36W6-TL!"@T+"@A*`@\+&6WL!MNC=.',@6@;9@RG$[_/0.,`!.8
MN+%!%X-Y(X-+;@+&I%`\=TLT"D?@3@_$&G1@^H`(Z=;8>O+Q;^?>%<+/C'5B
M]A,?D:'TH]""DTI\FHN)VV8H2'/GTAHP!0)ZL6CUS+9+@J:$G=03J$N+^XK'
M22@Q;"$X5YE15!D%QB&+,1]<N4>Y3S6D\33AJR,$PI.K+&40%A,MQD/Z>=*#
MJ[EX#.!.IZ;!^^,0Q\6I+RTP'YL'Y*;"DITGN$A]UZ6XHDZ\8E$ON450AJ`,
MIY0!"K>1!5!7)"B<$J.3/5U*%5JI'$U199;6()A!V>.C4\7!+;"2E3F,UYU@
M/M2B/:#M12'O`RG0(0YQ,-57UC,')3C3_\*1X=Y^0`9#R(#L?3Q$7%X_ZA"=
M<:`5N=A)MIMX6)&#*%*N9R)9$08HTB[;QFAG8"$OEANL`'R>%"BC\#]EIVT&
MD'P$8".G-578$`%<=F0(U5KC8!WOT`3G(#<_P&G"Q`-.4$RU54?,DQ;3`P[T
M\`#D)P1HABS/0@A^1"`8\7Y\H3ZA1P@L90BJ40RN(!2K0R%0X!,Z47<?XAK)
M8!R,9B)46`86DC^YL'&MUWN#PGN?Y1.O`$:15EJ[$RHTAT8_XA5!@BMT8`;C
MH6E-%F"L`F]OX`9DY09NL#P5U0X7(SUP\0UO47EU8'X%$D,#$A&)H1^=1W5P
M,@D_Z$C<@W4;</\#JT!/1P@;7S<:7J<+/N%U!#1\Q7$&0T.`5$@:0?$:^4=9
MUB5V8^<AR/8:%&A5G!)59<0C@<=\I2)^;?B&FR9E`K:":)56$X5;9O4J2`</
M4@(.IK8Q#.9@$U%K-W@(BL@?[><F>Z$7`'$E3[<`A<5UEQ@;,(($^A>.08$$
M3C$-RT`TH*`HBJ(+P8$BHT1*Z"5WH`$40O-MIA5S4;6/9F1DN%AIN)0PO-AD
MK%($\D9;8Q5@/P!O3O`#&%,=U6$KZF8K\\`&'%4XRO)",40@B,%^@P$1?9,F
MB8@3V/:-KW&2N/!QHY$H03$U'7=[KP$+Y2B.L7&*)PD;8<>*'@(4YHC_CK(8
M5?K(+U.%BVF(07%!![OX#ILF8+5E5L&D?6CQ;J_2#N;A%M\G#K8"%VE05R9C
M&8C8>8$34F<F+0W1>8+QE3S83F1'%-]HDR=Y#"<""\$A%+@0+KGP<3.I>@0T
M>Z/A"_1(#,@F%%4`%8PB%015AA'T=\PG'>('B%+BADK99"!45@\%3/964>K`
M`\)#!0CF!119E>!GE6,0!B4SC60I+=0B+8AQ`\6R+%2',EY2"'MQ`A*B<8>U
M$^"8"SQI0(DBDS.)A!.WFS:IFU]7(2^FB@!$3T`16N#63P!C53('2]FP'D`B
M)-\P'=61C-0A?>?P,,34`U$P5L34/&I!!$VR_S:<F9W!LYFVD@:DF8@ILST0
M,8V&@S)=:3B4P`E-E7]H1POC*!0J.1J*\IOE*`LK1Z`95Y,-E(6#5CI/L"?,
M62/.24&<,C#2:61<P57X11WG@91B<7AFX3!G%9[B&4>S,AY'TDOFB1[?ITLN
M&H-L\)X@LS((@1_;TWD1`2:%B)'^D1BFYY\$E#^WL$[T1$`'="\F,J`&Q(ZJ
M8Z3L**!RB9<+RA/'A@2T<:7YZ$_["#!F=*$%4RHS")'9"7[JUC8.\VE%P`5N
M$$?;,3<1TTLG2@44V896J6`:``<R2I]OXC?K!T/M=S*`RC*3H6,3IY)MITY!
M@6T?UPNOD*0R^:3($/\*P0&IA]*;3`J/J9<;Z'0HYX@56KJ/4=6E%XH/VA"0
MX)!N8PI^5&`.#G-]3^F4OK@=/K`.=O-\4L"BU/$6U_DC>%J:*S,)VM0FCP,G
ML9F1?I0#(W$UGK"2;4<:F)AZNJ!H*ZFDI=@4*-)>I5@&E7HB5'B3F+020G`&
MP0&*ADE?_$)+RC>=T6%N<>&&J.H6MFH6$15';O4=4M8\W6&>6O:B3."9ZTF1
M&[,-=<!"'GF?\'D0&)&:,!09DE%K"*(^]:@UL*!M)9(B2#4A%(=M03$T'#M[
M)L*Q0U..2LJ.-8D,2>!LFFHZ7D289_!*S-%/424JXB:=6\6N";6>YJ%I9E'_
M1W64?2)TIODJ,>K@6P\`F4>"'D.2M/8@'0.;B`9AL(D8&()1EE17,I5!C8L5
M2E$SL2YAE[.`L5N@?\<`LE@`EU-#ME=*&[TY0*,D!"?[/[3@4T-P(Y$F1EYS
MKC);,#2'9$F+7\%3)#I[IK/E5F[C,+-:,4<BIP(Y#AD#?O-@#P@%!RS$H_R!
MB&[R0@>Q?@[;I_X@3CO%.NS"%$]AA4+1?[>I)TT!LN!B>\?1ND.#*(<2"DM0
M-`@4MA2G%+U@2501!FI`9#,[:77AC]'!6DA9O-^WF0SC'?2V'>9)#FV#1TW0
MH>V*JN_Z6[ABG1;`!I-KGR:S++[Z$`>1/6(R((TX_Q)XT@H38BE<:X5RV1,2
M)[8?"[*=<R//\`R((I?W>PN)TG83\G8^M1.SP7>2]G>QQ!QY:TM\BU_GMF0I
M:@[V:@0^T*^ZI&ZS<AWQ<)3"(R5AX18TN*X4J;V<![XL8Z.-<Y;5N'YQ`C_W
MITXJR9+:)I>IV&PNMKH<>QS?-J'+$`:'PI?(<+\T::BW<17;9D:C0A?+L2EY
MFX9KJ*'!,Z=NJ'.C9J\\0`4RF$OB<209`PZ/Z9GI,0\:('@94+3RD`;;"[[M
M1R#W$3*`@;!3ZX@@(1#G4CK8%HZRX1*D>"%`,0NS"Z%=FPRM1`W%05I!Y@P$
M.+&',C4-%"-.,30SHB^).?\JN',[!:,-2LQ:YA8\Z?&WXW`QG!P$[2`/2-N&
M1M(D:),>WX<J;O$5"-5\\T`':3!<F/LW'%D('9$?GO=Y?5$)+9!$I:.<6'0,
M6H.`^?L*/?$)9\LUVLIH6;$,.+(O`4,CRW![R&"%+HDH?OP,RMP,@GRNUJ`I
MR0=0"/R!1UF\15(>UW'.0:"XN20/1#(>GJE'81&:4L)E2HQ+N,0&?<1^[!<G
M]HFC?]%Y&S(H=U8G6]<3O<#",;(UT##,`T2QYXB.T$`-WD9\SJPI%-0HG=.Z
M-OPIRPQNMB-?48$[%@K.:-0-N))+>-.9Y^$6Y;PV1/M]X/=\H^R9<$$'ZG8W
M%B#_O+EX<VL(!WPC,B`YGVR\%]92$UM7+N:B%.F4FWAW'$.ST/M[&WBGPUS#
MT5E!''U7T?M"BZ)HQVD;T5(!;HY,0?(EE,YQBZL%7"@-@J"YP2X:)40R/.?I
MSA2IC,E$`6>$AFFX3&B0&O*A)2`1#'WAQA9W3@!42F&[.BAYE]K&:,EL`,,\
M(HY](WV7%19M6MN<F%-APX!\/^A805DAR#/BG/SR'),<SF!:TQQ<*^.,E'$A
M!13S'6\UT^&'R@IF#Z3R(_]H#QZC`)G562N`"$:$"8]E"9Q0+GH&*3XE>]]B
M(O<(%53=*)AJ2>]"V<O`*5-!U@9`9`-\@9XRT1']*7MG_YC..8;\F)C;@*'#
MRUJM%9$VW<4LZMYB819!4%M7UDO>=VY*MPUE<P]ZJPU,IP`K)FVDH)^_A]3R
M9$J<8$5VER<>VW&V]PS.,#1^)GO:YFUYUYS](A58+923YMV>\FW4<%H@#=*A
MVMV4EMX&=4NF"GXUG1YQ(`56G&[J5CP]``1D501N8.-8IIU*AP\;B`\:V"/Y
MP`<*T'N;)6-DIZG%@.0FUE@T]B&L,[%38\,("`W2W13M<LT2OCN;LJ4`8UK_
M@N(4Q'=B:)C\T@R%*:&@8K=$9F1P/KR$-P_BYPUKLYG7P2IW6(=R5`0.Z:_T
ML$<[HK?.03!&G`='GN2<I!(-*O\&LO%_-'8NF>.*KV=)%*X,C/)R5!$*O9EW
M+W=5H6+1MA/F^<C-SDP<'*V/]*7F'$V+G#(J,T=SOH-0&KI@!R."XV$.$J6F
M;S``>/`&0&!D9A`$-[=:_#WHTEGH!<,<>1`!_O.7A$)%^!?'I/-)YP0424KA
MM+',WI;#),:.RN`IS`#K._+EN$-!IGZN9>ZIYNK,VAW(ICZSDSSKEJ:A>)-0
M9L`.)#AT8J6F4A8$!,`!+Y`"(T`!Z7$/&"KOR5X7D`P``Y#H76@UBC[QG@2`
M-#8%9EL%NQN*$5T<]Y,B4?-`T,P[=BN4EYTIF]+-)K_A_U*AMW/JRUPC6XVW
ML+0C&UC_-D"BVVE-ZUVL1K)"@DX@8&I:!$Q@`6&P`0%0`#8``3"00OP=>,X!
MZQ*D*0/@[-3NA12OZ`XH<3T66K3A\8#L#%7@MJ^0=]Q6@8FY(]R]*9$6JE1U
MKH@9<S./.V(^VJ3E=S-[\P;%924]Y_1`!#P;!0(@`'P@`$1``0V``B5@`SI0
M`"G``=Y`);=8P&Y^[@@@`!'`>N=B;7]Y<G,79W;G$SW&:-8-S=K*OOHK#595
M6I+&\-R-MX^\U4`)E'+?+UM=XB>.MV(407J_?%U1TO7L#6;`!*1V5ER0!UD@
M`#WP``9P`R_@`210``P``BH@@U^<WBJN]K$/-@8@`!!/*-4^_W?C1%3`-A,7
MGXE+=.8<?C^'?+;X*!4$T`RB.K,>WO"67^Z,4OO^Y`QG#@AH```$!(2%A8,*
M$8R-%!07%!F/&1D:E@]T<69$1P-S5U=P?'!7469*(R`%)#L,%1,E.!D/%I63
ME1&(`&IHB0!H",("!!(<QQ(2#<O+QB+'T"?2TAPG*RLGRDE#54I090;"A,`&
MY6=G565GY>4(:KV&"(4*]!'T]X,$]/JZOL#"[]`(##CHG1H#X,*Y&W0($3T$
M`/8U8@0I@B1*EKPT^>'DS0`\<+)<T9*&SQPR=0#<J,%@`@00,DK`FE`A1ZU;
M%"XI&!=,C2%@@M"H&:"@03)C1Y-!J_\F0H0U&-A:8+LF0MF3)4*P<`NC<"$!
M-<(0&`BS+JRP<KWRW5O;:%&C>84$"@7K+N!<L.;.K0L'3,VXAK[B38Q$L9*&
M!UZ8.'$SH`Z;QW#JU!D@8,"8-G1&?``Q(87G%"4FT)P@8\B#TY,>V=LI:)!<
MN0@$%#5J;&G3V]BLM8"Z>^H)#@VV*!&2M0J6LF#]*IA[EIT!@P8%S5M;+\*%
MZ]CWQ7T-W:]KO&39A17(,)]#1@JP,[I.P<(#)CZ<V,DRIPZ<QWGR\,&#QXV`
M_`*LL%DL,H`&0@4()CA#&$W8DMH%]@`SB%D("!5;,<?<YI0UUUPCU0J]K1##
M#2LX554#4RC_H6(9ZCS7VB%]@65A.=+1P]!TU*T'"83H&?+:CP+]$LP99(75
M2S`1?64>`6WMQ*0D#\31!`]%]'#$&W-T,08<=E!6&4AI",`#'STT$$`%!Z90
MH$PT)5@!`R]`$80&EU0DI'-=$7/;"1N"V,*??\(@%0PQ_#EB"QP\$UP22""A
M!%?/-:2`D._T)<YTB.#(EG6/0+C(I*X!*==W!Q$9CD(&\;3D!:P)$D$&:TSI
MQ']X"/"&&Q[E0=FM>,P!QQA9:#$`'2ULIF8))1CH9H*BU1!!'!9H`,FDB=!%
M(0(#`-"G-"`2&L.W,0BZVPTW&(KH,2ANTV@8P@3&STX,#=3:+L!0_UO(1*OI
M.*V]^OQ8'@!AL1,&5VJ<PPXO?OWDT"+M$>%##TYPX=\`E.%!V0!Y^)>'8W/8
M@8>N>62P0`D@()M"`""DK/*R$$`P`0H1U#)M1#L=.9!"`Q`@P@J$ZN8MN-_"
M(#2AW?ZFS!9)"('$$%!@P9>F\,8K'9.@!N:66YP^TBEZ_/J8UK]Z$0FI`3?J
M0X$]F5K4W@-K$/%#%!*_<>L;`M2=AZT8?S)&&F.P44<>3O001`,FI!"+FC&5
M_!G)G(GF!VD2/#`)(_0"]4Y8`Z!QPF[B_@STYS#H]HPV3RC]#;N!T8S/C67W
M2(A;$$:B]>Q-_LN+5YFV0\`%M#R@@7MQ4/_AL!?0GAW)`V9,R4,/1ACA1!3^
MU2W]?Q?C,5\;7?!AQQL],.$%%6*84,('GB6.>`H@*#L!`RWY00,`%E"PB.T#
M03<``H"V,"*Y.=P0[H@YP($`<1`#/E7E:*43PA#`D;!)H0%?79M.DQHAN]EA
MYSJK`=6-1J4Z>K!*`1I8@Q,&P`4O($8*3`#"#YH@!2JL04I!X,$1%L.%*#BA
M"$6`7F4H5K=<X<$^<)@#&_#`!2<$(85,6,(,"E0@T""H9#)H(N/>U#(&@.`$
M:Y"?`@!"GOH99``&&!H,R,6_&P@J!CD((`X6L(`<E.A$*#+=<;PB$7RA35,\
M6D\%MV;'>R1B'KK_6`2$9D<!.MCB,''XP1&(T(0@,+*%FVBD#]Q00QP>H0C/
MJV'<I$<QBMF!#5W(0A?<,"LN<`\(=```"IH8`/2YJ00!B"5H&,>95X!@`W'(
M`(0LYQ<OO@.,A"*C_[Z5`T'!(`<`7.,"6N`4X&SA"4H8@L$`PJ387?!LNM`'
MUMA#2-7<D3K:T:;:<G(:]YRFG!9(IP6DP+P@`($([O3!#X#@`QXT#Y.9])(;
M_'.K&N)J`-IK3!:L8(4L`'0.;B@"$>@@!!68X`4FB.*!:`++#WP@`&M"UA0]
M,($1^,X"Z+D=+[^HAMW\+VB$ZEPRVQ@Z#DC@F4B``A3:<:E[9,V.%,0@_^\(
MZ:F?O"Z"4"HG'<Q@!CI\U'=02LSR?A"$>/Y@>3AT0B8EABM;W0I7T'O#K#Y2
MGS2P@:!92(-\M""`'ZP!"S0P00UF0#Z70*`",@C`16,I430]L0([@``*XB>_
M1%BH('49"@%$9$8<0`5$'?(0&@4X#6EL80G<@`)7*G2(M<@NC_ABCT6DA9,[
M]N6GN_O=:=;@!3.L@0YT("T5J%`+R=&""C\HP@]F.UOF7;((^ZQA%*9'/2\)
MP)0D=,P8KO`%.5A!"UW0@ALR\`;EK@$!.<#H0R\*RRC&-9;8/=,$#I0@]M$@
MG;KT*9+^\<4(<&`WS#3*`3/T&_U!Q1G6:,`3AO^`A?J>`2*3JLXX\[BI5STB
M?G3*@"Z^@X`,QHP*0``""ZE@AC@@QJA4\$$0C"J%)C`AMDXXPE.-<$DNQ,TC
M%"-E)RG&!UW9ZFX#Z!(;TI"%-NA!#W)@@Q:^H(`IQ!8`,5#!#+![48B:X*)1
MY/%%8;$RES#`!.T)KT]M9C_-<>@)2-@"![8@!F8LPT1+289\%]@B_-JT,'S,
MT:LB(6"M[81":HB`!8173\%1H0E>,.H#J!`'.C"A>\G#)-RB<`097O)Y=)->
M'NS0)3?DY]!RNZK%[)"&CEFO"V#XPA?@`(8\+$`%2>``#6I@@HB>+)80Q:B:
MY#K76*9,)A-UB0DL<L?_)5?H+@/@@`K8.((;;,,86]C"%)[P!"LSPQD-V$89
MV+40FE%0$@]"VY?E9QV'&`)/%%A#/8/@@W<V82-$6*T4B$J%&,[3"%PXPA%Z
M`+%^1@&'@=ZA$.>08D(3VF[6JP,>9)P&.."!#VP@KA72<(4,O"``+_BW13<3
M@!\#7*[9_3&0F9B"E\`"331(35]_T2Z$#44%)9C!"-@Z@P7@``4X>`(6H$`<
M,6BY&8EZYA`@52%`=JJ;G6*517CD1WJ=`PT9H$."@>!('IAUS;)E0H690`4F
M-,^&>[8A)DV9;HSIY][6@SI_]@-00L_;)&.PSV-8G`4VC($+"U#3!SIM\.MB
M_S?(L52XJ&."K)0],04;>,#6HD:7RPUC`Q]`@69L4("7E.`%,7A"&>:[!65,
MX=<22`)D6>Z+>L"\FYS*(+5>Y`X*,($+`W#""KW@!7*;,`A1,(*$@_`#(O3`
M5E%(?>J-4`13XBT_`-V/'>;`G]KS0?9S,$ED[#`&7VGI/L#2@A9\10`3;%<&
M8S<X7;,;5XN:0-3)2ARRT,09&:R`#FJ[P)*[,PP1I`!.$$C!!R:@`QW8P`8?
M$$(8GG!X8S!##&*`IF3OVT"&P?R"&`15.+\B#PKT(,4"X`9'$`1%%2M$(`7L
M9`0],$]!4`1'(`"TIWJI=P1<,#TFP0<"P!^S1WNU9_\QVG,?0K0W<(!<76`%
M8-`%O_(%5Q!6=0`#Y4-7%H5=HS9P`]=*!Y(^TA<:%5`"?F`"98!]JD$`<M$=
M_R``(C`"(Z!,"S`#(.`'Y:<#,X`#)[`%0Y`$RB`&N[8$2H`$54`6:2%.C]='
M/V$O`/`<%_`#%M,?',$#3;`)3&`&%18$/2!//R!AJ=<8&;-/^R0`^W$WMI<'
MUE,?\M:!^^$K;!""]18L6F`%>D`&7@<&HC0`$6`"!>`'+5$"<85V,TB#`2`3
M3X2))(,L%.4^,8--NM`=J2(4`G`#'=<".;``&\!&.U8!-C`!$$4#"W`"R_!,
MT11377@&\^)X,$<=/J(/])+_`410&7)#1'#X!C[P0EY03[CU!JT7@'M6&5$P
M8I1A!UW0!2MF,1NS@?;1@3\D&7-`>T(41,,5+'J0`&,P!I-6!P^@`C+`:2@#
M$QKU:4%&@S+`/C"!/CG(&2```2-@"1E0#[>#B@$Q``L``0&P`#$`BPMP`SF@
M8VHR`_\6`#,0`XD74TR3#N?0<M/!._CG*37W+O9P`73@"6,@@!X&!&80!`+@
M`TT`!#P@@7Q6@5:5*X/&![M2=><8B.<(!Y%QCH1VCG4P!\.E!;TG&4DY!J%D
M!6T@!W*0`/O&!PB``T-@"TA@1@NP)F8G5P:7`F^"B;(D122#)@P``Y+S06<6
M#M$Q_Q=H,``MP``>8`*U1BYKA(1(N`$H4`,O$(6)!P55P`U8T"(&X"XIJ4L8
MQ#74$A'6(7.6]S&$5@1X,&UWQ@5`<&=&D'H>Y@8Z%("TXI/W9F+YL1_WYBM)
M292LJ3V@I`5U,%Q6<`5[XU4AP08C2`9]D``=(`IQ<`%```=IT(U$D)5-%)8Q
M:#@N<UU-9"`'\E8ET`"2DT$)21"O,0`XD`*!N0!OU`(X$(N(,D;DL@$W@")<
M2)B'61:JLY@SETV/"5H`0`%!H!^4]"M'$`=M8R7BYDY&($-1X!$EQD,>(42U
M<GNH^1'FR)I."7S>""RB](YCL(@J&$I:<`5U@&]?<`<O1O\?;V`'<-`8;P``
M&_`"Z?."I=9*$[`#L4!7L^1VVP4!<%(&\9-!/R&70"$0L39K&Y`-*$(;+K4%
M#0`<#1`#*Q!'A&D<7:8ZK$(8/:5-U((V%L$#'2H`0'`$7V<!="`%#:A51J!(
M4<`#$9-BDO$Q3B=$7:*!YYAB:9`&=9`%6R(9*P:5(C&;<)`'[ZB(!56"<@`&
M:>"APF<%R15$)`0'/-!0+)HLI#97,O`F5G2HS@D+9,D`-(`&TK(:NQ`=-SJ7
M8F!8)X`$(S<$PY$.2)`B4U!E+6!X2_`-2+H.RF$/QJ-%:U$1%/$J/3`'8O(#
M@=8#7E`$8-H#N\5G5R(`1S`Q=F#_'W;P@85X'^9(:)_P>U^0!9$Q@@]:;\G%
M!O@V8UK@=2NFFV0`J%"9`'LP8X]!&0;@4#'(=B?#CR7``&^5B:"A)BU:`2X#
M`1L@"6X)$=49%'(Q`$(``Q(P7P)SF&5`<MZ0!$&*(I`E4^E)(^\BJ]12#VNA
M#W30`Y1450)@1#Y`@1P!/5R00W6C,13S0T<IG$#D=8168H#(!EG@IE?`IFF@
M!6`0:4P)E5W`IJ\Y$MD*!U^P!WIP!V2@@@X@!UJ0!<4J`&8P`MDE$Y\12Q=%
MEC!:`?"*EFDI&BT#`9$S"1"B)(;@';8S`&K0`$,@'F(!#F$P<DMCL,$!354`
M!0L4'BWW_V5-<C7680]24`3[D8$#X`8\P`2F9T-'P&$Y5($F]C&H>92"R#=]
M4P<>@[)>]Z!OV@5?``9D0`97$$I>!2Q\,Z>0N&)9$+EMH*%6N3=U,$H14`/P
MFI:(BE$VB"8KVDK-.46B`0LR``!UDK72(2&V`P`#D`%E4!<!8PY:H0130&5)
MH")-L[9=]K9L$0EL,0@Q$P2X"41UX`9`4&%1Y1]N8`1`X*O6,WN3(;)Y<(Y&
MZ:!UZFZ$UHVUB9LR!@96$+F5BX)90@84>@7')4I!5*%?\+FTZ8T#H`%J("`Q
ML3ZQ`+6Q!$LZF+JR5#XRX*+KXP<>E1IH\SJXV[4/T!7!T`YC0?]R3P!_4R!'
M93!R;JN\FQ).OI`!1;!B73)H`U`$-MD1<E,9>1`%3U4$M%<';'I0QUH?PCF<
M(BB^@J@E?)-<P=*^$KJ"WAB;QU6AH2"<P9(%D6;$7\`&16``.*`"*&!\H"'`
M2HM1F,@9:,)\G^$9#%P``0`%Z:0:#\L:N:N[9L!!8O$<`RL$0(J%T*0$6$`6
M`[L7[M!XU;$/!":?=A`*%E,9'J-5.@E0NH)T`QJ^8^`QNO)#OA>YT/I)PV>(
M*W8?`W4'<M`&D=8%Q+6"T_I5!!4*1KR(0[NR6?``#:`"@#D#;"4#SX<^)5,R
MT><'+V%VK+0F148:*V`&9YRU[S+!_S+_`%00*K=3#F$`!1L<;+RV!$MPF`,3
M!L,&EU-CC$*8%O(0!T7`C1$*(!E8'QF3;H!X*QDHG!YS;T.4!R.8;RI(!L(9
M?(_QCIY,OV0PE6W`R5]0H01E!7VS8O.\SP,55B.1OTX@HFR%<-EE@[3L&21S
M?`EM:J'H&1/02@$``PI`!<A6$63X%S]"S,8,'E@@!!P\!4E0.MZ`I.J@QR]B
M"'Z%`&>@`#X@`%YWH1W#;AFX,7S`3__D,<4JG!PH1)(!!R4(:<]J!;\R$G/:
MONP;N9.[R600:5\PRDP9SR)!OY*6!I`X'WKP!41P`E?<B0L]:JT4T0R-)I_6
M2K,4BHQ3`B9`_YYBP#;Q(SG[DBF_D*D#8`;E<<%ET`V%)P9+(`9)PPU+<Z1O
M?'.O$3!A@`84<`2`"JVDR3=VP(<W33=5!8@A>*&*^T-LP&CT2\]7H+(1.IL2
M*KG=VKZ2=L^HS<G>*L_!$@JFO:?M2P9Y@`4C(#YLTB9F#:^SM#A0BSC,63Z8
M*'XJ<`9%5`0N9$A8VVIT[5.#<-<O,B2%*02']TR[ID"%^9%5@"<&$19GP")G
M\`!.4*U]ZJ%$F75YDWN!!I2]HKAVRB6S%Q)/+,DA(1)1K<2F_=10?<]4297L
M6[.A%`KV+6ER\-0#\``K,`-.Q%TI0Q,E>CYA+!-1A#C0QR;IHP(9X/\#SMA4
M+"1W6`M.R\T0`[`&4W,080"J6X@$22`&Q*$B7`C-TCQ9[M`<"!$&%[`&^0:;
MMQE*=J#.[+8Q65<WG[!BE^P879"40E2"43V;H>!5LRFYQZ7?=Z"AFMP&]3R5
M+Q9I]>O)]>W:DD8&<W`!*O`!,^$2RT)1)S-JS>E$HJ;;UC5P$5<KI$0$%H"?
MY93<U%%9]I(':^`:9Q$&A;DTH"H$2L!^J:JP9%%?3@,6DU5?84`!7%`'2+VR
M>5JS\[8]X5NS?'"A:3";M0DLHB`9PT7E,?L%O9=O5X#?3RX'>K";4:[)FPQC
M9+#5,IM<Q=4%>D"_F]R27G`"9-G`+B,:;H7_E@[.T)Z!4<R)<&ME`C,@!B81
M!70@!BI``R)P&@YF"UH#S/P"XG@-,*?BYVP[!.`.[DL`95K1-&0A-HG9%09`
M`%3`!_0K?/!NFYB;>^?-;GS0C2C(:'<:5H\A$D^=Y%W7!?@=LS$;Y2^V!ZT>
MY:KNL[(.!K3I=8#:!XW(!EYP!C=0VZX0NZRK\;34V[Z]VPJ\?.+W`3.`!$R@
M`#!``YU8`N$7`ZQE"S*#QA'K4W?-"P:P%WL=[N%>!8[2A4@:'NW@%VIPF#"=
M!G>P@J?<C3PMU%EP>Q=J$HK+!UT'IRN+[W)JU4J^B,1%E4PM!QKZ8CT+]B_F
M]9I\!Z0-J)++R7*0_P54@`2US<7R^E8+'KL:E8_1=W9U_QD%(E<R\`+?B83_
M)I!&]@%;$`=24$[7WB1TG0=4,"3KT-W?KO,R19@L,FP#H^YG4%\9P`4M-FDR
M-JWWENE06:R;_1C=*!G%F@7=NH)[0]^C+M7%M<D^:^5B7_LO=@>?"^OW7%`F
MR+YX<`$P\`(D,VHEX`'L2K5HDBQGG<"XG/?E`QJ!V7%+I%$M`PO''P#2:08<
M+G$T1QU\(`4%,\UE.P2`'NY;".Y0H!?1#+Q8``!>D`9;'4KYS/KJ6]-!%"Q.
MJ>^9KK)@``AR8%]::6Q:7VUM8&UD8(-7>G=?<GJ6<G)ME7M]>YZ>>F1W>_]D
M9(J$5VE&%"<U'P$?KP$@#`P5$Q,5)2F\*24!`3*\,L`RQKXIQL;`)@$O+Z\@
M,B!^#!`@M`P>'B0@(Q1>&189Y!04$>@*"N@1>&8(865A!@9E6%!52%!82$+Z
M6%C"A#E#<*`:`U,`.+ERI<T5*Z:^7,G2A0T<.'7FS*F3ILN8BW#LX-FH1<L8
M15JL:*F3I]2B+U;`E&*D9P^F3GLLF;ICR=*>!!@T65HDYXX5-D$,P*@1`!DQ
M8"E`E"B!+44PI[YV'=O5M(*T8\F`Q8**K8)9"&@93/!38,<.!C@LK!EG+H.&
M"^G4J>.SQD"8@`;._*W"#TH9)$J&["O#>*!@OP;_(KC10N;*G91@5%JY8O(C
MR(MCM%"T,P<.FS0QM<A163%C)D<PR60"P[./'CE]<N>^P[-F3DQW$MAN(W$,
MEPA)1GPP"\+L+JO"ILJ8FBQZ=:S5A>D*=O6I+QD?J#('`<%:A?([JEW#L<;+
M`W(1".#-N]=,/<+QL%39I^_P$,6$`23/&?880(<`F#3R118/93'&9A-ED<:$
M8XS1!4-CS)%''5UHT845@EQV!1QXP*&%(HJ44HD<HNAAFQR?@%)3;CE)PEL"
M#K211A12*-!`#"/,,(,*,GAP#56]2!>55+T,$QU7Q2#95##*4`6"5>)Y19X?
M$Y205BWE@2#"`W&,8T$$_Q3,%X%>?-B'!8#[0<&?8?K(6<6=6,@CD`$/L*&'
M(G>0,<9#5DA8DF@.CI&%%E=D-H8=`_`!1Q:;@4B&'F!H`2D;IF@"7$U_UG9;
M3Z1Z8EL?.#H@1P)[#$"%`@"4T<`*22!P1@PF>&`+-E/U.AVOPWRWE5512M.4
M,KY`4((P4C6GY0003``"+M!:PT`!'X@1AQ3BF),F?6T:D`\22/PG9V&'W2DG
M/H0Q1D`08UC"$Q@-,5)9%Q/FVP6#7X#1A89\U,'&:8U^0885"23`!AYY=)&)
M4#4E;*.+HY*J26^<)/`G'CQ2```:"`"PAA-:\$$!#>>A)2TV+%NYBU9971?S
M=/^_-/7R+=(FZ2S+TT9K%K03;#/!!PT$\<`#WG[+#AYKP+,?N4I$K1]A^Q$&
MA1)"#(%$%0@<T04G#NPQR16R+2)A%VAGD85#,-7QAAT=6MAA3(^`X:+:6H#Q
M,":5),QJ3W<4]1-./9&1<!MX%($T`6JH84$/;%PQ1AYYN%$%"BE4\($)S\Q2
M0>9,"I.==;Y<"<RRP30WU2TLXYQ+6;>HG,LMM?A1G@D`-$$F'1%D0$$&2],1
MV#U1%P_0\?@0O\\0%/#A\*B<-9J))%<<PJ@5A(@&!Q\#U+%H:-B;8D4;EU#:
M(M^?YN:BC#\YX'=1#C@`1QY'Q.'[[TQ$,:@5<`R0!H?_?&B"`BP`!#/0@0)5
MP,$'RB*MYRCC2;Q`';+$(Q6<>>469LD@SF0W.VA]B08&6L,#-*`!`D3@`GC!
MPP/^`H4A"$$(2B#7\0!RIRJ8*PP:L$.(_I0IM#7*;GT`0QH8@CTPS*$+_<-#
MOBS4KTY=`3=_RL(7[I`;]'W*$@G#2:K<9YM)V,$'5!AA!NC@@P&<)@USP,-(
MTI"'`>!!``+HT``&X(,'(.`&+XB*5YHTP>J@SBI+LM(&7]>LV+DN6KA@3NS0
M@P($4($.XM#`_2A@!POL1VM+@.%_9@B0%@*(#G.XPR+TQD/)6>B)I/C09DJB
MQ/G9P4,5ZD+=2F&%X-@$1*CJ_P-O=CFQGPC'$ZGRFQ;PX`0F-($*4O!!$>SP
MH.*D<5):8$,=WCB',7`(#'C@@@`LT`*PT*P7WS3&'TOWLIZIS"M3:0ZT,DBM
M1%X0:"7P@!\VD`$?6$`ND[1#!J"FA"<L(3'[F&$9H%`N*`!!"WMH@\88811"
M,,A?5X!)WJ[0A3K886"+@D.'.$,I*T`(8F+#40)ZTQ/;N.AO-O*;;=+`!1YP
MX0T#R(,=TI`%-F3!<"%(@X7&D`:39(1$`WB#Y"#%!!&\X!J^T`5U(L@5JH`G
M`#D[1LH@8,$LL>YG[?P9!R'@`6\0@`H6>,`XR#&'#!0O:N3ZSQ/R5`4#:&T*
M"`!"&_]\6:/`R4&G#"*BP2;!4S@(P*,2,02C&G*PB)*A1CWQFXMTD\N3:JPH
MMO'$%\;@!#?D80X7)8E"%T$&+5SV097Q$$;P$*F8\N$(2OC`#J@JGJQ@PSI4
M:@HM?C$-<V95D1.PA>N80Y5VYK86.Z@`"BS0!#.\QQSZQ)H0EO"?YI[!A@!2
M@@(&8!F*B1(BJQD#)0XVJ$&8)"2DX8A'_H>W%%VJKI@XJ6W\YK><H.JQ>M!8
M3H[BA#=<=@X4@DCU+!*I27F4#1;ZWP`$P(<WE.@"*%OM5[+2JYDE0X]=8I9M
M$:G!\^C6=;YM9RT84`UO1,`+(GS/&,PJA"<DH;G_6:X^A!#_!@H(P!.*>-@=
MUI:`S=B2.*N$91X$@%\+21-NHI')*!)F1=_DA+T)<V\6L:B^+W3!#3`M$:4@
MH5,D\D%2:$.C:2SZ!C>XP0@],`,,O.05[P!K&M01I[.TU"L+6P.1[3QG!AG8
M05R4A\,[*$`%OB&%HST@#118[A.>@.(A/(%<2W@")769@$;(I`U!W`,&,$7%
MD'ZA(V`8@$;J0(DV\$^F*<F;W>*7@*)@K">^5"D6W<>JC"WT"COF\8<8(;G2
MU&&.?+"#:>"@D3=&X0=1B`(/XM""%\A@`K`XG9:N\\"F)'+-V/CMF^&,%CE7
MQ;5:K7;M_+"#">`@`T0X&APN,(4G_\2PT`!)@@%\0(D$=*`#@6*H4#B1F?'I
M`4-O'(`=R'8ABD*J#GJS5Q_<1SY@_FT32$XLJX4S<(TY(@VD98-,BF,:-@P@
M"J7MGH3L\(8@K$$*/W@`$C80'F`$P`0RV.-2B3&6%+P`JE3M8+3N7)YJXP),
MSUX=K\3C06UON``34`$`F/"`*Y#;W/W09+E.S(,.U`A'.3G8Q40I"$H8!35S
M<,,<&-4O*QPQ#7S`0Z-&*2HJ#GE]IB*53]Z[<`?T01-B,XE-%V2%BE8D#2%)
MXQL$P"&+,T$##R`"!5I@@N_$XA7(F`6Q8/&*Z32%JVJY8+6U3:T[;YB0O&U=
MS[7M@3R_!?\%%*##%RZ0A'\J@;DV7,(2#&`$!TB"?!J+[QYDDIF'R(91C;A"
M4#F4$IAD`;^\'D-F$J%VBOTDODA.OA83Y@`,.#UPV#-)A]A0$?QNI`[<$X"!
M*R*`(%C`'%M`P32$D>QB#`,6)DA_RTN0B_)@,'9^B'_\?;;Y:BMUY^J,,^>W
ML0T(T``!7T`!_A0U0F!#2;`%!.`$JS)26G`'.:('\?,:FW$I8,`OOV=9J7`A
M=5<'&*%1$_<%\:5VKH9\R<=\PB$)?M-\(1`VE4$(L<2!F/5,$V)3=B`P`M`#
M""0"&_`"TQ(5)C<=O8!^ZK=^SN)^E<<6!9"$!4!M6Z4+O,`SY^'_3CXG?]R&
M%C1@,B]$@(;V!`8P`)4`!A@@!S0F"NZ#"3G1&Q?2!ED@`%$P!YQ!4Z(Q!J<!
M!VE@,(""*L6'(YV`9/'3ATN&?*269*5`47C%:QO!,'#0$(+0:T!0!0LP`\N!
M.MQ!%M(B`YPS%F(1`%;B;`5@.VB!A$H(=#8G.ZSS8&L6A3)G>1LF?SM`#F>5
M!/Z4`7,0>YCR!0;#-V)S*;Y!!K(D&G-0!'%4>W774[SX('*@&@U'4CV!`1C@
M:B7(<+K1?.X3,7JP*(8P=QE"APS38Q]1&G%@5#[(>*_0>*ZU+!\`#28'"RGG
M%<$P`9VX8=P0BJ)H#1.0'O0(,Q!V01B6_Q:>F!8DP`U5$`%3D`13(`9BD`04
MD`7-6`IW4($080J=H@FET`?10P9P$`4"P$P002\<:!*.0$OO95)LARJLYHRY
M`74+!Q1N)P<@Z"]T>"$0QP;55#W=LW7>4ST]L`"RL#GIEW['\D"BPW@F]P&_
M@B7'5@`<Y@%)N`U*Z`&+!`%M056%M"P_4V$95'.35VULT6(-T``'6`8]X"*7
M(AMCTR)4UQN-<`>AT05\4`1O4`@,(AK>XV1ST`B.``999"K)UX><$))[T'Q_
M&8C32"\52(<W10B&("&'D"D5@@<+$@<P,(X\^0+J-XD_Z`OE9W)-@@Q068]*
M60"?V1;35@OR=/\DFN@<5EEA6/DEUA!_+98$#?`$86`$<M`!0^$B1B$*N412
MI%"!^(4'1F`$$E<2%7$1CZ`HI9"<>9EJ)YDJ&)!\\84!)/F</W%+C/(17?`%
M>^!1_E((G"(<;3`&?)`&3+`")E`"A]>3)B`+Z:B9$J29?J14N=4<$)!G-J"$
MML-A\D>/KQ45NU!A&=9SJU@-M=!B4R`!!O`#9R@)9(`J+`DC?L,;/2$:<^0V
M7#`'D^4@%G$(A9(%=B6AR\F'\<.,T"E2[N8"S2@)]-(A>"=%]Y8WA3`HY),9
M%"$`#0`-/*F>ZSF4[1D5T!$ESU$"][<=*>".]YF$MN,6\O=LSL(5`!K_H)-7
M.V#RF@`P`$16"9H@'*(`>PG3*461:S_@!'C`!UG`DC))&H-2$N2CG:FVG"/Z
M;B/*C($H,7^)(P?``BY0:@=#$74'!_NS$FY84P*C-AO!!4K0#.I'F4,X%N`A
M"\106P\6I,!B.N/7%=JPE/$')E2E)3O#,W1F9YN*%AL$`9YX!A>0`7`@,;<!
M*)*P(CY!"A)1$@-0!%QP:UH@"8SB1G!S;T`T"B3)143&?.^F?+[TG`/G?'=J
MFW\"(7A#:W=%74A4@]HU!UPP!$QQ>.6W.>V)B<4B#:4#++UP)6BF%2D'+9FJ
MJ>ND.M%&+5I28;!CKF^Q80P0!D7`!B/%1:UJ_V2W`1QC(YX"8`11\$K"1U&\
ME@=T.`9D0`F<H)?QLUZ-QGPDRE[NDS%]&#\NX`(A4&J"(!J(HC:4LE\5B'=T
MB%D/,`,G%PQ3<14GMZ.\T)Y`NIG7L0M2,:YAP7-`TT%J(:16XDZIV:X85BT%
M>E@C9:*1U5[FU4-S$`4^8`1*U%-I$"D+LW62<R(GE6KQ8PF=(`<5FY(J^4LD
MR2HHV@>9@)@=L0B2PP9?<!']XB"&0"(_<`+(]@%+\F!6<8[-L`PN>Q5:D8XT
MTV`.1`P[)Z2<FEO2LC)5^;,\&SN1![3SFB-4!(&LMEYN%PJ00+"S6D8\M2%O
M@'%HHUU.9AF^Q';Q$_\<K88!?KBU<OI+BM6,F7$OI]$%M]%#9`!@G54A:(0'
M;H`%+U`!FM@<@-2RV<J>EBE.80$5+C,S#Q2X+2.DT4(>J>E!`5HM2*F*\VJ;
ME=!PK397&O,2$X$V;Q1E(I$'?!`%`3-$B%`20Y9%6PNY`]<!ILM\J.N^)TB-
MF?(0$V$A'N(1%3(;75"#&+%C:#`#0JJ)3O*WQ=">R)(DSY&/K^54/UA;I]@Z
MS0MG9P%G&3:%:B%M83"Y5>L)HJ03A?(1'%A@7(!W^C8`;C!@9T0&#")%PB%2
MQ\HJ+QRG[[M%7)MD@>-IMDA1:-,A*R$P/&4*OP=@5P8'/[``5.DD/EJ\RE#_
M#&!A,S+S'-.B5(GW351Q,PUDL[%3>>UW#5B581N6%M%R!F$3(ZR"&YU@,![!
M*";!!VWTM'NW=S%H(ID28Q#K/M+8IB-:L2K5<%VD(!1!*)UA(=9(R(2"1O]"
M6D6@`"A0`=.@Q%^!+$_!M\22P.`DI%?B8,LRKH)42+Y%?Z!\2!;L0?(ZQF4,
M"M()!E=;AYB5!9E2!SS&(3'%AAD)=IR&/=4)%,RXRS6,NEO;=MO;+Q)!$7A#
M$14B-Q_"$`Y14WXJ$FX@!6%0`Y_S.9MI?M4QE.0XR4XA.DBB9LL");J`0>^:
ME:*JN+E0?U^B,NF,%F0<(Q`HMM)9/6,P1X?@5T9P_T3\XZ]P1")IX`@*]<)R
MNLM[+*=[W(?OMLMGW+J5J[^*,EX3<IBW.ED785$"4`1F(`0+I+-\1"5.XK)-
MK+?$\*WD.BW2D+(!X!4>E&VC_#JT$ZK3%BT<ADA960OM'"-L!VM:<'$TE06W
MIC^*`F`;,3]O4(>T03&0FX+/B0$KZ+ZF*XU^J%*!`QL];+N@`4LBV\^2$S@B
M/&!1\`86,`*\XH340<#7[,3GI[=[JXE`XX2S0%73@4ZH6'/SMS(LP]+0HBM;
M/#OD$7EO]C,%&C8E15<#P`5=H$V/H%%!8`>.<!0;,3!SP`=31!,9XWQ-[0`=
M$*<AP-277;&_JK&CI#;CQ?^!`+8O>*=3<#,A?_(OW.,$4<`%&7`"GN,<:0:4
M9TTZ=)N.*0`F8HT+O0([^ED+G>B$275M49%;ZC'*U*:?,%V@QOH)-7$%/#8'
M`Y`!/T`;5S`'/!`YF#4`UO1$>!<34T2QO"S0S7?0-(S0I/9VCN8O%>+8'(A7
M:ZP2<F@:DP4I<S0`/8`%&^`YJK-43@R4(4VN4''`)<!MD3<M.>NIT<8`2IHS
M2>5.#%3*Y'S.'*:I&Q8&':!2.:$%`L`%>/`&3$`!46`%DC!'H3%3=P<1HK$9
M7X#4ILN,!SW>@2CC$M.0CV"+%@$2C:U3)6%87S`P;)0%0#5@1```)#<+*]-@
MT!'_E$\,3D\E0>R79[H"T]V6)3LW581D6[^ESN0\>=2B#3,GKQBN:E_@!C\P
M!T80!P]@!/TB$_XC`!BA-_O&TS[>!GT(XS#>`2M(WM*HRP+]6)X&6%]0!QQX
M$:>A*-=CBY<F7A=E!VVT8X/G"N7:*ROWQ-XD#(^*>(`4-$JY#01J"WK$9M3B
MR;A0#=22J3/7Y5Q^UV\FYFY7(V5.!$W09U[`!78C![RF43R`L*30$!DZ5[G!
MU,ZGYYGMON7]XGI>P^SU)VTP8XE><83<>RWH9!;A(*3QV+CF`Y?S'+C`5'^[
MF<MP#*>CCB&]`_>Y#?%J%LG`J>Q$?Q7.55*I5>=<>:5<_RTW-W^6%P88L!D)
MH!$]``0EU`0"$#E[D"%PU)$&LUV#0.+O->S&'@+%KM293:+-Q\M]R"(PH1*'
MHBETF)C11\C51RFQF@5SU#]$0``M$$&!6^E@<7YF)D'3<2TD8`.LN`-6D@Q6
MSGZFOA:>N-;OE)6@&L:R8RTX-P$&\'9[0"E<T`1T0`=N4(-\0)%\!\L"P"\0
M.1%3)+KOMO407^P0S]2_O'`\$2@:W^,7`@FVF&-X)S"D)$IN7!KX304(L+O+
MJ^2B<^EXRWY0<I0V0`(D8![-HKR$5"W7T+R+A-+5<JXS+?18R>#T>`8+R]U>
M$'H#<!'=DP"40^@=3BF;X&0(*_^Z>=[U7T_LPJ[L?_/!H9`2'K7Z]I(($@$1
M1R&M/27?:,,&W!.<&M#(;$;IP1(L$V0,)+UX$$`".O"/S9L,K*4Z[T?OSHO@
MYN$EV]9Y!,J:\@HFP!6O&WP'><`#%D``<1`%_<,%7+"=;V`%>5!?>7!3%`,3
M(.B<H0_Q%ROZQE[Q"Y<3BX`9C]!%";LH]PL(8%977VU7;'9U8VE78%IP5UUI
M8U<#&2L?%9H@G"6>*2DR)2"A*0$!HJ`IHR4RIS(5#`4%#!"V$+45(!43NQ,3
MFK^X##L,$QX,R;K)S#L[?LS)?G[#R;C0?A[090EL/Q0(3`-O>7!U77=U=6Q.
M/79:6FW_>GID\GL)"1CZ^B'](1TN`O;KT`&#@X,('>"C!P;,%S+Y_B60X\B*
ME2QINFBQ>'$,&SAPLI"Y8P5DG2QPCBA846.4)ET@/)4`):I"*U.H0,B0H6IG
M@%6@)E"S]NMES%T0@(&8D(RIL0D[AD&H<,L6,ZL,_!2;4!57L:RVPI`9$*<*
M!2T"C*3)(J</&#AHC[C10N;*G01MY"4XF("@7Q?_,``4^*^@OH0.^O31TZ:0
M'@<A#H3`D*#NER]6M&1AD\5B%DJ/X';Y;,=C%PUB%JB882*%K@JN2>D2U0G4
MJQ*O=NH>%0I$TJ9'.0DO"L&WLZ>::EE+6K46UVK*N#:-1FW"_YDL0!0HF,,C
MB(`V5N:!0<3%S9QZX1-\T;,7X3Z"@04'G+_OL,($BN^TV>.`H`,]8.!'DA97
M>+9(9U=DD<47FRG(!AMIK,4%&@MLL,$(JP6P20G&!/`!;I_0=`HJNO&$2@F\
MN"2,+38)]U)25"W%@`=;20=-+<P-`XUT5^78%%;40'!&#Q<$,8`;30QPQ15P
M)&!%&G8X,<`<60ABEY-WV+>7/O`5UH$__=1GD$**[3$/!@=@L`<95GRA'YN1
M6.'(6IAE4>`58XQA!7AL4)F'$"C0(.@,*-3P6@5^!#!"`RH$`(%N(WIX"BB>
M@/#34A.,XLMSO8P"#(J_<(54,L@,\_^,,;S8"`U6UO2X8C00A$$'%5T,X$,>
M77P!QGYC\#%`%)UI\=%Z#H"A!T&'^=7/?&#Z(^9]9GZQASX)Z/%D/%9FT85&
M2])%4AH-:7N%%F.8DU$9,[PP`Z&!?C"!#!\$4`,6&4A@@BN1HC+B3JOL@FF+
MPBV%2U(N'<H5,+Q`X$<!U4E5%%?99+7J55>%BM4U80@P0!I."*`..O2,,8``
M=FB4QDERY'.77UW.Y\(!!P#6+&+X]&'F2&:V<<<5:SF48!J0=#$&77+L41(9
M7VP$1AI\X-%%$6BH\,$'+]0P`PTUT`"#$">DNT`-L-CDTZ2NF,C3<$D%')-T
M:7,2C(Q46>7_`2T(KU@<5SL@D[=RK>)HRW/6:!6&'&S@P<4`BX!!TK9VX`I'
MGG:UD0][\"D;PLLPP^Q"09S?MQ<^>]PAAQYRD-'015WLF;0DE'@D4CT\?W%%
M/8\4Z,84*+R`R@LFK(N"!0(L@<,',^X0-P-B[S03I?SN`JI2,7GRG"W1+Q4,
MCL#,2,NAU5RO-XU9+<>J4W]G5<8>;`@@`!Z=Z7$'T$+#E6<6=\EQ4!]]#238
MEY>[[')!GDM,Z-I`!O>5SDH;(8,<K.`1-N1)(YF!!SRZ8#H[74$`#3#!U.(5
M`!.\(`87>,`*`@`"8LQ(.=K(%&]4P4*JO&03`4L8+F#"BU3A0BD0__"`!XI3
M0PCD;540FY$.I[$<6+$-&+@87!X&`(=W6&&!?)C$&%)GA6WI@3*".0C_"N(_
M_V%@,AA@CP,,TH<VR.&,<A"=Z3!3(#"@IUP@R97L)+BD.X"A"PZ$0QE,@)NI
M=7`$!AA``L20`AH]`QNGHMLO6`B4%%COA6KC!3/J-A5AH$I&,&(*5818`&1D
M18<,BX8HG7,+'HDE#W@P33R^8(?-C.$A=;E"'PSS)2X-9%F8R]P!ON0`%RAD
MC`HYXQWF04`K$8(,II/$6ABHA<M$(@L;L<@B"C2'!;R+`26800P>8(<O%`$+
M-;C1PD@PC7)VDADR2:<C4Q6J2/HP2'6SV/_?7F(Q8]@B;R1@V#1`>:-H?*64
MKV)`&+Y0ASF<XQS#[`*3QF#&AJ0,@%^TY3_&>+D#L."B%]U#'ZP0`K[@PP%[
M".D\3#<(`NVJ@AX90Y7&1:`I;D17VT()`FA0`@@$0`01.$("\&`$`(A@!L>8
MFPY+)43P(0^2,]E4J%Y(E8C5T&U_$X92:AHJH2AG8<C0BO:TH2-GK(I%J=JD
M6-@P@#IH(8JE:PP;XF''T>7#(!'](F#\`YB+=J`/7S@`']Y@!S+TP7/5TJC-
M[L`F>+A1$!O!R!3ED+1&N'17:WH$`%#0F@"L8`!\X.@7*/"$&Y@`%X:$0"=[
M\0MF:&6'P.A4PJK_.A5)2JRU,3Q8574AU6-,[%1$S%L*=:0-O['6?&W@@QN`
MUDK9Z<<N:1P=_MZCK+FZ`$W_4,,&3&`"#F0`"`)@0QOX8J8[W",!-[.(KF2G
MK<Q`LTVC(T-G%.@(0[`!`3-(P0M:P`/\\`$BUGK`!K*APUK(JVH+6,$-1L`:
M#6D#&?2,JL*2PA1/,KA@J8UJ55\UBUEXLAG..,YI'7PQJ^0M#&!0'QPV1@8M
MW.'$DF.,'NXQ1BXU]Q__"(@6@%H`'11@"75(`P8VIQ#2?1>\I]/5DEA:T@)]
M871W/+%^'"('+M`@`#18`1/(X#$I..$*#H@"%5H``F>0P`,OX,`4SF"`_R4D
M80H<$($(5J`"&KP@!4F9QB^,BCSH."=32&'54^39C+D5@`2BS+"@\Q:5YC3'
M&6'(P@#L8(<Y&&L]`P0O>[9$2V1]B7/].$`04E``&_QY!6TP2#YZ?)>%,%97
M)=6,@HP\"))4:1Z8N:(<F*`:`U"A"-DQ@`5\X`8"A`$(:3`##DS@*!T&8`$2
M0,(0JI`$"7"``R<X00P"_`05U(#8I)584_G&8!M"I]"W(.*/B''A9`BZ.O*4
M"JNF$09$="$/X7$?1.JRXO;LS\68-LP_#D`!T=J`!"3X@!E<,$MH"78/X#FL
M%M(P"(RPX9BR&Y<5[J+`8>H!#@3`01SZQ(4U6/^`"E%H`@4D(`8^.(`,;WB`
M`7*@@A'D8`$P:,`3&B"&-*]9#&?60!$B<(8J+&$%(Z`!'RUIQ.F5]C=!NH4.
M3R6-O?E3T.*3QFZEDHPS%)0,>3`6K*U5)?ZT^-)=^A)@]M>!`\2A!![P=#;.
MX(*^*`0#BYD'8[4@!P(FJ#$"(,``V.20/.WI#F6<AQ;JP(4F]"",UEKB`,Q@
M@0P,`0!%Z`(<V@`'(A1!2FT0``\>0`=P2&`+6$#`$<8!$6B.1`M16`,";D"#
M>'&HMSN8\U$1A:,B&K*<0YV;**>AVU-9A?=)[]$9/*('/&AA'OIIPV+:<A#!
M-,L?+P.,+Q,0`CB\0(?_^=S!`M(0LPZ,\3'%'%=#+O.%,=C!`"\P0F,RPP@4
MA^Y]?#`"$78<,[=P(0A>"(,9>!`'(LSA#D6@`0!`!R*A!RX`!DRP'4?0`D_`
M`Y#`!W7`!V.0,@D`!K)T!^12!P*P$A>B.QRB%1!@`S\R/M>3%<X`>]I03HC4
M7WXC2LWA'&=0%W<P!\>W8B&E$"PF4<TB'S"S8P%Q``U0`7]F`S8``@MP!R'`
M8HIA$=VB$>37!78P!2^`!T=F!0\7('C1!F"0!3RP!CC`!)%Q`!PC>4Q``1G@
M!&N5!7C`!EP0!P@@`%S``UF``3U```_P`!D0!FMP7CX0!8E`$G(P!GF`#X\`
M_TU?L`82$`,K(`(P@`,JL`$SL$-U]DD[Y!6>I!7'08FYEWM?P3>P8FA"LB9?
M`!<A)5AF)$9=\GQ_(1G2=P`68`(VX`<DD#<%4`5W(!D*D1E&]@6I8SIXD@8/
ML`!U8`5LHB=@8#,-D0<(<`(J@``=P`('0&5&(%P:\``4\`#:E0!'D`=SD!86
MT`1<,`9<0$!C8`$]8$9ML"`$<@5U\`4#T"=-(`!;>`5IE041``,J<`-5D(=*
M,`(R(#!V%CY=16C94&$&:6$7)FXN2'1GL`?E]W`B)3KX@P_4]WQ@PCG2YTM-
ML``FD`TDX&D%$``W(`5W\!\6*"=F=`4ZLX5Z(@`+\/\&LM,FG5$Z>R(%$H`"
M*W"+![`'1?`&;D`.4F`!9T`'<Z`G;Z`(<V`'D%!W10`'6.<$Q*@K^K$'<E`'
M>``'>#``9&$$YM>.NP(&/*`!,A<!$8`$$M`""S`"&X`"Z4)LDW(\)K@#%?:1
M1%B7^61A3=>)TG!G3A$&>_`9@V`F=2<'M700,F.1AB$87^0`!%`##)`"#$"7
M22&7,_``?7!\#S$Z])`7541!<[`!1\`@LR,(#)((9I`$&Q`%+],!7^`&>%`$
M#V`&#Q`!!,`%<_`&&M-^=]`!PK('>,`'</`&16`'3#,`7<`'!H59DQ`%N/:.
M[0A>^B$`0``$```%4!`'4O#_`%Y@!DUPAQEP`02``%`@!FB)`A\@`\<PBQ7F
M:71)EYUT2.5$';U%'`QP!GV0*VXA.F[U105Q.189)F*"`7FP`;O`:7\&:+)0
M`!"@`D70`7*@4/M1&8B5!>P!!R/P`^1G$0)P!''`!%Q`!`"`!E>`!VIB!20S
M!EJ6`;CF-`-@!%2B!?AAHG-0@4`C%VS`&&-0!WTX)0.0!0)0!%(0!W8P>GT0
M`EO8!DW``=\X!"-P`@1PC53``T5P!$>`FT<@`%'``R-#!Q&@!`N``B`@5+-`
MA#J@`_]6`,_@5:.4#;Z'*@:P4249.FZE$'X1,_\9'_R@!XWI!R5@`IWT9_C4
M22``_P6^U$QM48&8T7!7<`0H0`?(U`:U0@5(L`0P6@1F4`<N8`44:2<&,0``
M("QV<"QR<D;>]P9.\`9S('9_E82@DSH+US$#,*4^P`5'8`9'4!+99031=@$4
M@`(3\`$TD(])8`!FX`5`$`5O8`1YX`918`1&$`51``1K```P4`,A^)$`9P.<
M>$AK2B/B5`MAT`=%`SIZ\%<=D#^1<9B(:1@N,`<W4`(%4`(?\*<,DW8%`!4C
M8#\U,P]MXD9DX)!-T`(40`AM@`=>0`!V6`E%D`?]`!DAP`(PE@`"0`$[IGPL
M\%P'D(5=``9U4`1[\#*1$0++]8P]5AK%V)-X8`8:L`:QF?]=/!`!5Q`%$I`)
M`V,3'V`"*"`!$1`$1Q`$/7`$/D`$3<`$0!`'7O``8H`"(6ACG91[>4D=\3D5
MG58%@34/%-EB_F"G=QH?+G`$*G`,F3(+Y#0C7Y8-)L`'PR0Z>=%&:`2,=G@.
M(48!!*``!C`$2Z`!;&"DT'51:7(%;N`&T;>:9:<'`T`$=^`">P`'TP(8!]`?
MEW-%?O$86?`&V;DQFU>-3L`'/_`&:]`#&6``*C`P@#,C%6`"+5`&%E`$04`$
M00`$1,`$9A`'<4`!8;`!,F"7%7:)F2@-*H@\<DFU&F4F]]$?6S0?!,$LA:$_
M'6`&2NM#/O21QN!GT%`"%D`2@R#_9"C)6'.PN1+X&42P!`U0!ENP`30@!E3@
M!CWPL1:U2R<WC"6YOI'A)$5@`0EPL<>;.1C+`@J!47`W``I``$U0I720`6Z@
M@4?@?T00!EA@`4OP`=%#%9V(*`&``F$`NT#@`TW0!%X0!RQ[`0BP`#)08P#W
M9VB:8;UK;J?"%#O`#2=FM1_U1<TR5UH+40#4`03P`D.8K31R#"0\"R)0#XWU
M$`2$3&0P!D49+E`C`1*`!56P`0NP!1P@!'G+MPEP?.`A!\;I`BP`$!#K`&_P
M!M#XL&D"LA`+OS`#C0FP>5HJ`!&`!50P&6K8!8$X!WA`95/P`:4D2D,5`!N@
M`700!#[@_P5!(`54T'D4``4J`*\V8*:YFX+<2BI<E4.U^!\&M!?^L8/=5QC[
M@!#X\`4B``*R2(OYY`$\7+9^L`()8$=:,!I:V!$0,C1/I`=O@`5)@`0(```Y
M@`.=A0-:P+<=8`5YL%UI0@GK"XV[5`?/>,88=;$6M<Q\&P()H*SEEP4/``!V
MP`+=L"`7\21IP!TC<`S(,[K(X`'D-`-*T`1$T*%40`5F,,`1@`D34&,ZX&?O
MJ14*^4/),`M5X'V<S)\P["R9[!>'09%5S`$RX&\@J:VBU6E_Y@=*0#H,$E/E
M8@?`624$I`=I$`=0L`4G(`$-(`$KT`!+<`%E%T9VD`%*$`5B#/\9`"$9/9@&
M!-0'%D7&RMS,OHP!:;!W%[<&"E`$<I`(HP$A#[<D8&``,Q`=/$(J?PH"&N>Z
M0-"=%G`!$?`$AE(".^">[^E5-Z(PX",=87`?8M(_+N.?9=<LWG>U%X`"KH!V
M[+E#8SI:%U"!SP0/G\$&.;8@]7`'7!!"92`&99`!$1`&2@``W(<!X/$&!A`#
M9K`7+@`1P)3*.&,)4D`&S9PFAVN_6MS,!&$%D4<&/B`%&6`!7.`T#[((KKH1
M/G`"KN%;QW""33L!*-``&M`$01`'UJ@`80"FH.`'9GJ72R=N7&U4?L`-]\`/
M\-%%`U%V7C2\&."%,[`",/`"(3@+M$C_A%$!`$Y"+A;T&26V#IPQ.AW+!DS@
M!3Z=?P!`!90A#V0P!W&@!A3``[<J!>Z0E'@T!VR0`'!@`&@`!&`0&0ZP<U;0
MN`;8S"%0!W?0!3\@>7$@7$2P,85SE2$!#X5@!Q=PU`YC6[:P,!4&`0L``#\0
M!(P'#B,0$P%0`MA:8<2@D/R5>UB0&/G`/]#W@Y(!'S-<$%>;`-2\``HP72#0
M29XV-XO\94F@4*RC())P!PIR$5?@D%`"'NBE<AE@!`RT+2?C*WEB!T:`!=D5
M@3V0!YQ1!W0@!%A``0,`,VT0!PW@!0752S'CV6>P!@+@!'K@!CZ@7N\(!W1\
ME2I%(#`U`$,`_V==`1V@-`M^\`(G\''5C#M)X0H0\)$5QE^'-&CE1-Q;\GPR
M[B4R0QENAQ]](:`2H`%;H+1U*;8_[@=8L!9"\T!#`ZG.9"?O!I/(]`5X8(95
MR@-2K@X%-0>,,`!8``--D`<%8@1%P`==P`58T`"A]P![`+$#<`:!O<`\0P49
M0`!+8`!>,``8\`9FD@9O,"5X@`=VP!DJ10@L*04U$'L7$PV#?J`[T(S5+`%'
MS0`Z`<HZX-L(:4A>-0QE\$NI"";,DF^BMND3Z0!C0``GL`4C4`)VF:U?5@$9
MT`;K^!DYV@B[LAEV308:^!D$P@<]0"5\P`-.0%#J,`>.=@=Y@`5ED/]3<``&
MO4+R`_``"*`&@JT!,-,%&9`!3S`%%!"`:H`&`$!F3"``<&`&29,'&F/$X/XX
M#M1,2Q,E"^`CGDANH$0C]6X"4X``#?`!.](*\#K*C8SOSW`+8>!]8O>?`E%I
M]A%`=Z$'4'">IT#JV)I/%1`'#N%&29,&N(*%AU`@#^IH"L*+Z,`QF$7'B0`'
M;$!!;X``"`"K:AA%N@X'1`(`!&`!!"$`?$T!1&`!!```_YL!1/`&B^`.9)4'
M1]DGC*8.=')'GZ$$`>`W>G:"0V60+U`AA90+IS`!`#=46CUH.&(`,/;O6P3C
MR))%6Q)`*]8%2``"L1@`Y(RMY!Q[+U`$1J;_WE8Y!A"!%VVA!ZMC@3E&"6`P
M`$`P!K])QR.#66U@!]I!!HT#!EEI&FW`!@\P^0^`#T%``1J0`5&`?Q2@`!D`
M"!1T10-P8&U6<WE\;P-I<'5S=7!I75=?6FUZ9C,,?GX0%1"C#)Z?.SL>!:LD
M!24R$SL,H0$?,CLV'AY^NI^Z'CN?$!,&(1TN!RXAQLLN'<\A&"'.#@X)?0D8
M&`Y]V`D)?!$5'B05,A`D)#HZ)'XR)WUL65U@>G):75ED>WH.!R%MR&`:DV:,
M08,#W)#ITF4,FS%=X&CI,T8#G3MIWL!ADR;+HRL#O"`1T^"'@`=%XACAL>;'
M@PM-HO!)HP6.%3U9__#P&2!`P)R?/SEVT:+EX1@^3U+,\C2J::FGJZ*NVN6'
MP000,FJEV`$A551=4X5-./,,V8%C!Y+]>]8A08BS??0D<+#-6K>Y>@1D`.''
M1H$7'_S:8(`"PHPF7^:EN2+GT)4K>\JR.*!'3YLK;.9DV?Q(@!TY>BQ]D49&
MCI4!#ZCHL=*CR!@K'NDUN2`FQP81!AX,\-&EB>X\%HS,Z;)XS"4V.O/PS,.<
M^<9*6>RPL1EE1(4)##PT)?4T^R]54V5=S?HA`(@)X+^&KPKAC#$7\-&J9>;"
MP3$'=^1J^]9G#S:<`CA10U\Z?/`""3;8\($:,#Q`1AL.:/&::?A8D4`RUO]8
MTT9B</Q$DX1.S'&)'5I\X0!`6A0AA05Q@/9&$5ID,4868)!!@!!";`'#`EOD
M(=,;%%B`!T;3#=!#$T[`<<48=N@TP)-0#B`)1TQFH<45<`!@@@>S;`=!=][]
MLMXP(*1@IGGC%`!6`3M\94H8RBASC#$=+-/,6ACL0<8WUGS##S9W9#&`%BJT
MF8L)*2`X0Q!%R/$G)F#<`<9F5\BE1XVFI:$I&YQFL>0<`M@TQAQD'*+''5_T
M$`00/UR10!=V6'%%%E9H@0<"2V`A1`,G('"'`%;\D($/?-PAQQUM\$$%$7C(
MT48:<]BQTP#-,6?'E(]LQ(8=0:@P3)=.=?>=+K+_='F5F2D$D`(LNS"0"B]3
MN>M!&<HL<TP'VD!CEC,)5-9G-0GPHT<W7PR@QP;9%:!#"1^,LL48`[>!1QM=
M?$&&%;(2=845B3$$AQT@4T*4%6GP,``;7XP!1ZE6[-/&$48(8`8?"5#\F!9D
M".`%`E5`,44#(EP@J!P"&(''&%]T<<<>=OP`QQUMP6H'',KQ8?75=M3!$=5\
M2")``S*4XB68IZ`"#+CGKAM`5C)4(,N7WJGY%)QV3F-OG6FE%0(W<U7C]S65
M]2&I&PXT,$$!"'Z)PA;RE*C%''C4X;BG1,U#\K7;ZC0U/F#D`00E#`WU11O.
M.I`'&UR<04@:*,OZ!AT*_Q@PQ!)BB,`!2F[T@:5T6;!Q!1@Q\G%T=$_ND4`6
M5UN=!QYS<"0M'U/C$8>W8)I"-BJH5#7+N3*LF]7:$+3KA]F[C')&O<ND!9]9
MZMN5#<!\7A-_%'J@48'"!7P@0A!$\'!'1"WC@T.NT`8K70$?::B#YCZVP"N1
MH0<#^,*L&$)`R_S.)E(P`O(.*`^]`$`-94A"`SC0`C'0H0E9P$!C(-$&+=2C
M9@(8`QGL`(0@_.!"=T@>'Y8W-39@[2<#D``(P#6*LI5K?.4JA1\F4($RH4L&
M4.R>!W*!/6"`HCW_L!/[\D:G;_`)?OS!!M\&T(4BU``"`>"`%$;S!@L<X@M@
MR/]&RN@1H\=`ZX=-@IY$,/$#2W#0#A5$A!L&T(8>&$$.8Q"`%JP@!0*@H0P(
M4(($5@`#'$PA`T$X``:N<#$VT&,9&(`(LMS@!04\@`]PT(D.H0?$Y>$!#](*
M0PDFX"6XI4*)J.`.`YI8`G2EH`3`3-?AU`2,[)DO&>N[4S+P11<O.M.+`L/&
M%R@R@"N@X`5J&`,86E8')LSA&M@07,K2`)N-^3!:(`/9`B\Q!R[0R@YOR`--
M+"8'.<`!#G+@`P#.```*/.`!!B@#%H8`A22<(`8X6(`$,O`##,1($W,(`ALZ
M8)F.S(4,5XA93>"P2N&!C%I-4LX`,O`!46QG`K3T!"[_RS6*JX"@EV8")@A>
MNB[TD.L35SQ?W;1(C;FTQ4\#^Z(][O"?/G3!:1L`P*P2<X5N`L&+!=1#TKJ`
ML2NP+G)X8`X?ZM`D..1#"P/`0Q?:8`<G#&";]=`#&;3YA3<\X`D*``(!MC`$
M+"A!"5N0``QRL(`1<*`'P*I#Q<C`AR;DX5EI((,;OK"'/8!$K)E)SI.L]DH[
M4,M)`N###U!`R^U<I[-PZTY3>!G37I;@I2505_C.-CY0%`,:.]U;-3#P4W`^
M$W#AU,,5N,`'UY!A6XO1@ANDX`2*E:@/I?I"&N2PUJ19`3FM2P,LO=H%1[1,
M"]?Z@A7JT89(U.@(3F!"#WQ`_X`JP$`"6$``%%:`@PV,``4G&(!@*Y8%2&RD
M)G4(5!;F4!203N)J6O6HM$0ZV3S$`+0M12E*:WE2)\JT>ZB-*7K8)"]BT"FV
M(9B+-OK4-PX[LQI[R`\;ZM#"1\R$8W"0V0&_X"PP3&H.E0&#X/;`7+F`80Q9
M%>L8\I")*R702BX4%!L.P04W[`$,0,@``1H@!`0@X`D2P`$*:$"#%A1!QW*P
M*E4%$JU2`3<Z>'B291<!2\J";(=/$L#RQB"!62KXS0O>CMB8V,1?RM1,,PVF
MF?I2@*[L@!AR@L8S]D,7#'R8P_W1SS2<U0=9(6<,+;S$@\#P@RA8@0^#S-I/
M0','!__P`P,NP(`>D#,`.W2D#GG8[F+V"P<9>40`Y+P#R*;A0R!@80E*"$,8
MD-`"%=2@!DDH0A[&(%@68[0/8*A#':X@`(-)D'4)R:KP?F+F`?,DGF)M0`DJ
MP&UNPWELP^BV:8')2Q`TD:;F2<>7_FR`M0BZ+EYL9ACOPI]LX*M&9(!#&VA<
M3V.71@\#:((;?)"!4K]R##C[PJ7D@`TY$*_4-,&#`&14G.9=P1*/\RI.M/`-
M@?@@#".<@A"6$&44H.`!K^3H'(R#,51M)E@"<$$!?5>'-Z2S2:J$94@'\`8N
M#&"'!X;SMT_Z9IJ>=I8O-?>YL1(`!A2@*NQ.1C3L@R]X/]/_&\\$F*0PH:D^
M..LQCCI5&PJX"#.8@=C26E)#9G6(HC!IAROO@@#>0*DN1`+A@R7V&)C[&A>G
MP0(&6(+(04["#9R`#UK(@P#PP#4:86*L1+O"`=;JR3K(%RA`$:ED>U+J'A3&
M2T,'/;=I:FZESW2FHP>!+7@1#"PJ0QNP)[0UC,<G9G+8@EE(6A;V$`(R5*8?
MW[C4E3BF@>)J"@_X<`C>DU8'Z<*2#?AH1,LFM1&(]-TA%;NTIZR`AP@TH`4<
M2`(6.%#)!30!#'@`@@\Z)"6+_8Y&Q.[``;X`_5$I!_-SH-H;U%PMY>1A#3,@
M=-WF;6\6;DF'>@-X;MM6`<`4`.:1_QU540;N%@VQ!S!Q$6]UX3=@H%TQPC%R
M<"(,%S#&8QG:=1E=0`<"<&1:T'P75Q#TD!G,`10/43!X`$>/,2L0,116T`4/
M\5Q\P%0"```))00&L`4<$`,;<`-:X`!NL`9',"K+IE99T!A9\`9-`"$0834?
M-1US`'<\P7\!)G$*8`*?I6`)"&>GEV>FEX`OQ6UF`D4I,$2?0"_Y$FJQ9VAQ
M$51^8X%[P!";D7L<8S&:D`!R(!IDD!^/QP1ND$"G8PD-,12[50<.H2WW9`5Y
M,`?;9!S;E`^*T3N+H693F`!N0``M<`,$0``2(`$Y,`)"D``NT`5Y0$`;R%S0
MEP7+U@54H/\T'9%B`L`1CV!9:L834>)*;``$)S`!"YB`RNB&,I5T3'0>1>=F
M,O4*YM$F6*!)="%;?F-HIZ('QK.'_7(Q?_AR\U`B@Y@L^F!!FD%IGS,`3D!.
M#?$:9)`&/6`ASV(0'Y,&G@$&6#(C!V0E(U84T'<$><!88/``!#`%-X`%83`%
M'+``"^`$DT&(V2`'<$1_F#`'<!1'"6`%<!`!%$`$TM(A8?:%4-)L/.0$3W!&
M=+:,RIB&:<AM)]5$*'5:>=8].T`"U]@!L_4W<P$X2_.3>^!I"Y$&_,@0^&`E
M'(,T5F`'`O`%V=!=\O0%*?$X7/`(S8<SH,$&E9%`!8%JF)8'5M+_?+12*[6"
M<&RP/$&0!Y&2!V=@`%@@!@"`!D/P?4+@#\Y`6Z&T95_`=1O3+Y5Q!53``WB0
M!CPD+28)):Z4!P@P`]<!`>;VC"ZIAG5V>MXVDRBE=+P4`!-``E!`)QNV'W+A
M)W<`3:5Y!SN8?8^A7)?@=F#0!0+D%BZ@!ZTV(T;P`)B1![!H:BU#!KZI5G6`
M2L0F/(W0$1W!,2V3'W<PCSP!!!K9!@)```"``/RD`%`@`2)`!0<P&6G1`60@
MB=N5-)S"&#6C"3-$"2,&2UTXC'F@0&&U!BK0/581F4MGF0HH`]M6)O09F9UE
MA@.89P$``55P8<:P#?WB18(#/_R`41LS_R',90E'B7"L0P:P1P9S8!ICP`,/
M$!&:(0D(!T=6(`>$:`?M:1`/H6:<N#&R<@C,!08?PP=&T&IS8`8*0``(8`!H
M``!0``,M,`<L\*-IX0!+`F2]\Q`N<R5)4SD.\1-<-2V+@$HD:@0<$(=A`YG=
M!I.FAUK`9)/7<6[=]F9L>!WJ0A;Y,F@<!C#`=PUZ8I9@@#+V8`7^F#&/009]
M4`W&H%M+T@-,P!/Y9VJ5L$@BVA8YX54WJ&8')"L;TY<8PS%N8%D]T)Y'0`$1
M8*-AH"L-D%!!\*/3<!99IA@JLQARL8-C21Q<%3DX%V9D%F9\P`9"8`*H!9DP
M.7KDIH"D1V=K2/^`*!6F95("!L"3\:9AVGB@_)`?%X.D)4)]U6<EATA[=+&=
M#D!?01`'RH$/#,$Z"'<LU^!VVY<%3B``_'A`OW,L`=$&=U`$R.$$>4`!TWD&
M52`[8D!)"[`"`O"C\*%)9(`/0C$C]=`'$J1=E*!`S$.B!9:J.T0%*H!GWJ:E
M78I:J7=TI[6P7:I@PY"K_\E+):`&M<4GTF"'LY<`%^.;1PFAGS)LFI)[SN1U
M?<"3;.H%%&`U'',SVS<R-4$E!C$'43`H-'(EY(IQ,Z)(^9`&`%`%:$"=6/`$
M(I!0.9`!&`"DRI``,?((E;`QAW`'DKA-#S$=#_&%S6997=,\/2`"M@#_C:*`
M6C/UC&THJZAU%:/WF$1GAIE9>BF`!GL3/](`FMS`#W,J*_-`*YM!$.2TFOO0
MC6(D:K#!!F0@!057"$MR@QA#')`0"0]A8IEE$'"*,[!Q+,<Q'5?P!@!@``"`
M!5/P!`T``QN``TB0!C\Z&6T1*(Y;"2SC$1!$53)BHKS8;&'U)+#D!E4P`[]D
M;@:8AK:*@$FW+@R@F3+I66":JPB(`'/[D[1E>X"#5AN"#YQT8Y[R("WC+'W9
MEXY";QT)?5X0!W!G0/_($(K`>&0Y#SMA!\11$"QF52SF8GG@!M"S!F'0KDD@
M`7FU`!O0`'7P%I/!`@Z`"#-BK25R,7`P`#>[_Q'I"RJ<EV9\L'AV0`$H$`!(
M]UGUJ9F4J8!*8;R760H2RT2TU$2CQ[P9TA8^F6BZM;W;E([X5BHN1JX7@PCE
M*#@BFB<R\@!Q$#D<X4(;V)=I8%FF!@<()R,[U&K0=P5$]2R9<!E.0'=%8`!*
MD`1E8+3PN@3%E0`=`*0;EP\-42)V8!RC\DK)0<2&>;-/PAQNT"%CP`4X\`$?
MH,&EAZ6G%X>I-U,[X,$R"<*@U5E7"@((X*NT)48!\WMWL)QD(",/4BD)P$D@
M:S':);6S8B4=@&QSNADG-``22A!Q.AV3H"GX2*(S@1D71T`MTP;=X)'DM`9#
MH`898`%0=@,;L`$4D/\`1/`&6WP`'4E5$T0K;=`\0X%=5M,\RF99C4`M5G,R
MEJ4&+R`#<=RE-@F3S2B\R>@!'BQT)]52J1?(&X;"UE`9Q@(:`1$C,%P9BQ2(
MD9*:&K-=8*"]DXS)0<!?M6('"VRMG#@/#A$)/%&#^1!FK2:JLM(%DA`':'`$
M`G`!'*``2>!>`&`%/7$,&``\EU`K1`%'/TL4$O*XVZ*8`68U`K`&&X"?,G`>
MH8"E6RJ\%ONPQ:N\M`1G76(5VES2"`![/QE\Y#JN:I5<D&(L]8`L&RBG;"I!
MB2HA5Y(%%G!V#%$P3B!`T'(MDG!/D-.G<[>!CR-?LZ((F@$M%:$`"5P&0^#_
M`T_P7A(@`$7``W)Q<0=A'(S;F\P5T*RST9.5/*]4!`U@`G!H4F][>C+UGWGV
M"@M(TE?Q)7&&'4PTL71&9S/=L8VE5A;C8C42$-N$,7!$.H!3*JW6V%?RCS$;
MIP]`!T0,?3LDB=M2;?[7/$WY!B&Z@S.R7:/B5=#7!</R!7:@!A30!&4@`B,P
M`B"I&\T6(Y1R@QBMQ,XBA5SEGLB</-*2`3,`A]MFAG1\QPK82VLXL=O3GQ-K
MV-QFDXG=+W9A#XWAFZ42$)B0>Y.]G!'J*5R7?)KRIS(R%&U`!QJ`<)00.?<4
M"97U$_<$?:5175IP*7WI8@D@*6_T!4<0SP5C`#4:_P8*/0(2$`9`D`=2P`:U
MDGNF<4#QV&J,[8E=$&;-MDK2LP!9T;ML:)]7.JMZ?:5XO3V/"=,BK+PVV:MV
M4<EJA6^@P5QMT,)#T<X/RA`042OQJ`58.6*50!PS<@=K0`&E,1W7DF-=Z%&:
MD0^C(T%\D`7(TJ\6.2N+E#2-(`!U0`4-(`%5(`01H`!*4`4`@`=](`"%.!TT
MHK<$@24#0%'UQ3QC\(5Y\#Q7`P0<8`(PE:58ZFT<_,?[^27#,`K>Y@DM789?
M2@SX(C_3NQF':`_MS(\.U&\2XBD'!.2MMDU!W#P/,0^>M'<\H`"'S(,*I%5A
M#!%]JRDE(BM>54^PL0\NYO_C7*4(!FT!8H`""V`!:Z`!DJH&-./>'`/9LTO$
M4?`##E=?.^24G.=_7<,%)]#,$.;GJ0>QLKIT)%QG$``*)G69*#4+90AG,-XO
MY,I<VE4:5;Z]Y$J""$0Y5O((.;LMGFY]U'4'>/``<7&O=J=LRL8I!3&)7H6H
M$*%6&+-O8Y?(;!`JC#<'<7`&2X`"*N!/%""I%`"5-=)\(GH'6$+$D]!LV)=*
MS!$EU*)5"E`#Z_)+#?O7Y'8N^XGMX@8+5H'7GP4"VVX5`E@!!M`GEE$9SE(:
M]200+J2<D4P4"#?AR6<)U\+O^<<Z@L4Q46`&WYPTK/,<_HZ/RM81,X)P*PS>
M!\__Z?]]*T(`!7W53Q1P`1%0!'7B>T4P!WL`'YCA5:E4P)4W+2*O$S.Z`+,$
M17]]@-C.\@O;\K(JV(^Y8(7-'C=O`(#9&-J%J*<"PSXOJN-(*X]W)1+B0UDS
M'8RG*1)Q&3YP$7QW+3O!PS2K,EK#@YNA!8$2Y3CC8@^2^GKP`V9O`#FP`F@`
MDFB`!GHPD0G`!G*``=OIL0<4\`F4;R4I\M<V`#"P@&T3"@J([:;WL&;;TN<Q
M@-5]F>%2W6Y+#(2XG-N[D2&V@;..S_C,.I<@0:*C7'@P8ODGT)XD(U:0'VX0
M!R62,E,3^IQ"LP@T%#0Q#Y@`"%965UED7U=77UIU>'!$_VMQ"B(-0V4$$4TA
M+`<A"7L)H!UZA%IL6EEL:59Y`P)Y>'FQLCT()B`E*0$3$Q45(+>^)2"]OK?#
MO""\%;L0O!,0.\T3OQ,,#!#6UM*[T\\&"7)R;6#A=WT)G6U?8%E95U;L8VEI
M75=:IUE?9%9S>?*I7;IH070%#)DK/@C82Z2E"YPY;+(\M`-GC)8Q``=VL=CN
MBT4Y8$C)@=/DPH,X%B@($2-F!98?"38=.*`'U)TO=[3DJ7-%3T.,=08(Q=./
M%1X!?"B@P)4"5[%>QGX-*U9"&#)BR:3U8N#GFC)LUZZ!A4"VV;()W^[<*7>G
M)@87#N18^>(.S*&-:;)8R3)F3/]!G&#@P+F"<4R[@5^^Z-&3I8D",FSFI&$#
ME#(</'SJM"N<KV&64FG(^+4RD'2>.`00:'A`(<*0+3%.>$G0@87M$'H<M+E"
M1@^8-WFR[+'2A1%F/GCLV&$E(+D9'!]NR2A!C'HP85.E5DU6H<0T8LYZ=?7`
MX-DSK[VX5?,*H=<W.6T7+][3IX\<1?9.8<P2\/.8+E;(H<<>'70`2EP;E6+1
M.@DPID$$";#C4!IPU`''/'5`U$4[&PZ$CQ87VO,%&W#PQ04%59QQ20811/#$
M"A)D\,5,MKG0QR<5AI.'`'/XY5%1?""GW%$#C&&'!`&D4$$`24KU"U5/=B<,
M>+Z<5<S_5!60YX=6V#0392]D,;/+>VJ5J<=:B1SR61=L9-@.?QAIT5L?#KC`
MB0N;=-`&&Y1IH<\B>1A@019UU,$&'FW.82B%BEXVAV`E#F1/&O(,0EH=9H2Q
M1!@1(!!&:F5PP($;?=#(`@87[=%&7FD<002?4411"AY"!9F<'1;.<448'TA9
M@@PIW$*=5-U%B1U6RU1@5E763>#!EF2!&298UIPG#5EG.'`F&6"0<Z9<;=S!
MSA5LIO(9N7QF08X<G^C1FP,%@O/..F2DP8H25!`FD&!SV`%1AG8<!Q&%%@WB
M(4]=@%&'%`:\9D`$50QA0!E33+'&.1C8QD("]Y#QF18"4-$#_Q4*Q!$%&\OE
M$:20RM4A@`(TX`)L"L$&$\PPQQ*C\S`0)(/,,>+Y\4S/RUQ++38[L,=`MGJT
M0<8^=^RQUCIRD''/1AMNR-]DZG;;AV^*)=);`L19<4<;<K`Q0`-'I)'A484J
M-T:%_>81:4"&(2)G%GC\IT44&1B`1A5J&"#$$F4D<0(`;6`00JDS=;#''HMT
M(4`3/D30`@=!Z!0+47P,P$>_<_!!!PH!`)MD4TY.^4O.RCQY#)9@.C-!-+OX
M8MY9W&3#'@1G)'`VVE_0U\8XB!GV)E]]-:]%M_K8!48;GI&;!3V#R#&&`!SD
ML5&B%.&!AT,7MC(`/6GD]PX\8TBFR/\`/4AA`6M5(/$$$A*<$('C+L1TP*EZ
M$(6]?N"#`2``"4U0E``&D`=_&<4.?.@"%5;P`6#)`%A.^L5T?,$ZVB'K*CIK
M3S6<59YDA6EHW"C+"=$BO*:M8W)D.!Y!2K0\/MFP'G8A!#SV`J)ZX($<5W@4
MB-S``<W@A40/J0->K.`#)KQ!,EEH@R#681?^`*8O]HH"!="0@3`8``ME.$-N
M,!`3%H@B`0=(@!&(<`0`<2$/>AB#^4;'B"3"00`2J"`(4K?!#*;@@DW)F<[2
MD[M!=F-+N"N:-LJ20A5RPP#V.5N`OD8.ZK5#,\N;AR83$9($D29]Q=,6!G13
MAS3TBPD-:,C_1K!8J/^,C@Q%Z`%'NK"/Q!A$"_`0D#H.@H<H&&$`;D""`2C0
M!"QPP0Y6*-7&`BB''T3`![0J@A7T((=8,!`/%MH('\@%A1HDB4D8S*!TFB1(
M0YIED+J+1@FMQ4AFJ'"%WQA'M_30ASL$B#B?B<CR]DE%+:3A'A]K`[S@A8$[
M7.]0=K@`$M)FPS0,(`INV)$3^/"%+LQC#&ZZQ[S\]#0P"`(,;.`"'GC#!2@(
MB@<(,,,#W*"'_V'@'`)X@!&4PP,>S,&C_F(@1>"PD498`'4F2,$'DE250#*+
M*<(H)WC*@DX1EN><82I:(]_YR`CI`SY[<)<A-O(.=^PE?8@0A#C`_]`0>U@A
M?7H@XQTP(`>'1(8584##2.#`IU;UP`QF>"(;ZM&FY=@!0`:[@BK"`5)YY"$*
M8Z`>':C``R9(X0P&$!0?,("!,R6@#A1-`W(*<8<N#*!T`S.E9-:`@PL2M8,@
M`%91Q;F=W!T#A4T-4PJNP;OTO/.=8IE`\+@5+OC<P1"*J$<;]$+6B)0&'E\@
M#7$'`JY=>@AEM,)"!@)#UWG880!!((*B[)`^P[0I+Z0@34`XFCXXO&$`5K!:
M!-9@AB#\P`(7@((8U"!0`24`(V=5SEZ'.X`,[?6(1EB!"60`SF!AB75.H4IW
M@G5.\Q2RD,O@2GM^-S2RY)9:V1A3`L9!!O_XD-4=[DC,7N9RD?\<AE+_Z0+:
M*`)>M8PA,5>`0RP$\(0+M*FZ:4@;KG;<7:UM35=W2$-(_G.\"/'AQ2A[P!DB
M8(<Q.),`55``;:1HA>HRHI3I4]L<H,B7+O`!"0-F$CB1P:S7R0`J3VIM5I1Q
M%JV@.2O76J28>N>[JH(DA@<9;_JX12X/=;E#=#4QN:*``#4();%B`ZE0?G""
M,GS60GP:2/MXK*_/\.=Z,62%=[60&STDC`P]>(`")-"$/62!"&J(@!<(Y(DO
M6(A?%D(Q(QYE&,\08`:Y8%TOM@.571LX.U&",WA0J(QIL.XKV=A&A7WW5.#%
MI5M66Q]A..JQ<_'_,*P:%806\/``,2B!`C^8`YN>UP8OVX$*+6@`41H%!^[6
MH8%UX"YAKG>APUA."@+`B#^>YK2_60`!2F@`$/@`!`H@``$^:%`?7OH?<3?/
M(G.C:T4`Z@,<,.E7U/F9=H8AK&!_R;;J4=8VQ-(E9V`X+%SIBN\@X(<=E.'9
MZR!N<C6Z#H'H;5Z#*(A'V?$&"Q"```\8`!@<TH5UG`(/&8C!`KB0H7CW@RB"
M*51>ZH$1]'W!#G%@PA?VE`9U_#,!<\@``;`@`0Z$00,6"`,2BJ`'N*35H%DX
M'R*PR">!S..L:1#!"P)@@M3]^G4T:TIUG+2S-T?59]QX4N[4TXRC[8`\_[?E
MRLM!L@Y!6/[RQ,$E(3A)KC%TBS=DN.,1@H"'=L`B(A:UPAB\,(0%Q`%7<\`#
MAA1UXU2,82]]Z8(=2/0&-F5!W/JP0AL2$(5.O2@''&A`&!!`@>$[X!P=^(+;
MHO"&BEP(5_\4[]4U0(,/Y-J/@>_@FZF!9F[H+EI3,;\YQ13A\NQ@!Q6>%@3"
MD`#@[@/SE^_0^F#,%X.DUP':$B"(X#([@1'B=@5&8`$P4`;A4P?_4"@0""FK
ME%Y?`'QCP`=M(@@QE#920`!A(`8P@`,P<`-B$'3:\@5R4"=@<%U%(``.:!&&
M(A"#<`A2L`#>EPMH5E3A)TZ$%T+,X`=%TV`0YO].[:$L)D<671%_*A0\'A5\
M^&=YS!,@R440M&0(<I``#C`<Y98&XL,?7X4(4O``#=``?`!!6?`&3=![H$$B
M&?)/O>$;5Z!?349+H9$%/!`'+`)P(M`"-Y`#"T``-3$Y32,'<_`&`B``)8)1
M%Z47=)$%1P`=0Q4`)=`SMQ!^@7<EXC1(PJ(LRH(>M16$22A54K5(N(4M>Y!<
M3OB$I$$B/>%1G[$7QX."&\@.\]`O9851;&(!9@``3T`%`=,%>?!+?E$/%U$A
M75,';\`&7]`#32``.B<'?$!6&=`:J0$%#<`!2A<#1.`)"^<`8(!1R%%'RR%N
M7J4(7(`$0Z5'U\$LEJC_5+UF);PS%L-6;$AC-"97`5NBA&-Q!L.!<U.47):'
M".T`!GHP<_/B4>DU"&0@+FX3,)A!5X:2!Q90!"P"``UD!^Y`(>IR$/*0,%OW
M!@]@!DQ`!&]0$.)P!0/@,0]P`0J`!O93=A*`!%3P4FXA"FTR-Z7T77JS2UV`
M!B@P5#(``LU@5*^#"]O1@U="2-;B3M^A'LP@9^T4+;35)661#?PH"(A@%R(&
MD!]E$$^#>6/UE2(61&5X*#OB!LT1!0^0!P#P`V'0`_V"/O(@>S8G(@G0!4X`
M!$TP`)_Q-(N@"D<@=@1@`$G0`"*`!AI@!G70(`+E``7%8GE07!"!2YI'!@^P
M_P`F,%2H!17;890<5XEOII1.F7&+9Q9#4RU$N`NH^90DEPUA,!PY-PZ'X">V
M1)!50PB)D9L+F57VA#:"M1Q*!`=:,`!%X`9V``144`=A,`!*$`>IP%-]\09F
M<#Z?EP5K%36P*$5.DP5.8`9'X'-H<`8K<0(G<#Y<0)!/`PH%U2,"X`,^T9&#
M8$4#L`(O4$'1@0N?V7&>B1V?:4A.N0NO93M+U7*-](-"DT(D1RVOB96\81<S
M:!!HLRVXF9N'L)!5@X+VI#;-@3('10]>X`-L@`5C8``*,#YP(`A\(P#T(#;#
MQU88L`<*HPI@,`]!(`0(0```<`9ED#\YT``$B5[Z0/\&&-,'PR4`0$`/?8%+
M@]`&<(``/_D!)1``"T8=1Y54"*9XZ5=LC/=.W1$[/H,-!XI"1W-;%N::L!E6
M<V$0!@$?3=-15-0M7ODTW!)#(0%::1`PJ,<&9E`$=6``:4`'!N`&DT&0<!`%
M<Z`7"[D86*@8%E4$`Z`%?-`$HM8`4[!\50`%+;``.'`!*!B#X0(*(>"8>F`%
MYQ-HKS@0&3`"?1<`J5641GF4GOEQZ.248T%;WB$E0NE(1$B*CE2FKCFJ^1%B
M=&H0;9&FQ!.GC"D@T,-_`Q$1'9D&3>`&?```M'(&4K!EX6(&$G`&>/`%]=$'
M!C&J%]%6WJH'?/``88`%4%#_,4KP!#$P`BV0!U<@13QE7PX0JM,D!^.#*_^U
M$3^``P,6E!W7'3-39KRV,^<TCT'(`#Q3+1W7%<IVFJ%(IK[*`&$P"H2@%Y=W
M"`4A3W#:L6,E8FFJ>MDT*Y?A@'4@4GTJKP;G+PY@!1>`!F^`$[JW#C/7E]V2
M`%^`!X`Z!2O``2>P`E#``2,@`0.!"L+YAIXPG)2R9;%V&`.P!#4P8-C!%(%7
M5(`D>+Y2%5?!9K(:A)28<23WG]K02-8`L4_I!V'0!]RBE12Z==34MG!J2^$R
ME@N!+GR0B)@U`+O'!_G6!6K`4TX@!'.`#GM0!SF16+O1!DVS%W7Q+FQ``14C
M`CB`_P,M,`5$@`4XH`!LBPI*E%QW<`6OL!S"F7NED08`T'W&`!66>+6OFI_!
MEBQHUE3EH7@2MD((2J8K=QX>X`%EP+9R^K:)>A]P6KP0.H4`I1%JHT0.P0I;
M)@!.4"%8@)%X4`4#T"!GPP,:``=;Q[BJ@@^,"PI[0`5#T``MT`)%VQIQ``!;
MD'!#5B*'<`=LT()=`!&$HE&(T`,P8`OCU[I5>I09A$ZSNWX@('@51JL4JT*D
MR`"/5P:GZ)7&ZS3`9;S"YR[OH#?G4@K]X("F%&_M%@5PB0=*P`>H0`%QD%Z$
M80$6(&+W(`>"]1%T<@=V4`EAT``LH0`6```/D`%TD$RW*?]<`I(&7,"WVY4'
M]W#$4C`"NL"ZPF")KEJEFI@L6/*U50(!-5,[6@H6IYEL%&L-%YNFQ?LTXA)6
M;AN_>V`U'D40=E$*>-K!%H51/!`%A%(%%7$%/%`&>/`\I.$1E)%>_N2`2YH`
M<$`%`$`!4/!S%```G$('3&`%!P"`ZI`P-4$VBL('N%0/`M$\3*`"KF6UED@5
M_'D+;-:45?)@(<>U0C,6NP,F97MRU[*4V"!&'29/R96HC9LF6-D;4M063B,@
M9U-1&.%1/<(F_W0!3A"'!E`/7P`'9\`#Z$(I_7$/6Y:T@I``>!`'%)`$:$`$
MT\@B%$`!<U`;PH,(-Z6>TA<0'7+_$3.J%VKP`B7``,4B'9^L>#ECFD6H,U/I
ME+S3#0R\`Q5P#5/!`![@5%[QGT*Y)68ZR[%X56MA"#DG?&=3-12XIDW324+V
M>XV0!X<*!V]9.F=0!QR;`1?@BEB$0Z%7$;((!GUPG$I0!D"@`&NPPQ$``%3@
M`#/1!UIP/&F`@EA(&"GV,>T@9&D0`Y(X#=GAR4H"#!-0S_<X2`#]GXV4#"GW
MSR($IF(A9RG$"Q+FFFR+-FLA/1(,IS-H#K^50[@T/?=!&AUI.0\0`5R`2V-`
M!TTVHGF@D)E+$)NA%VAS:2@H-7J`!T5P!A20!V80"1F@`6M`!BYE*+W!&W+0
M`1B0&*H$_]3_P09T,`-54257XL2M!3M4XM1$0U45UHE)V!7MIW*BS91;[<4;
M-KSV-Q=!"EQWT""V)(/=0AH-,0]:,`=K0*+HQ097,%+Y@`"/RAM1\`03MQ#P
M$$/J@`B*01=%P`,78``]D`464`54<`1\8"<N8`5'P)>_-3D&XB?H_#$698<K
M(*4<=QT%O(.\YME`X]1+G:N,5)6=6"VF_0P[4``(W7CE@:#5@-"L[31M<:'K
M\`YH#1($*3Q3='MS`85]D04_8`1KT`3I,P=&T!>"804((`#N@))+,`"#H0CT
MPBV_?`HQY@06$`=DQP1I0`$]``=.(`"W]"ALLI!8"*ZYTA]O(O\0!%`#2@*@
M\OR_`TLLH=E4\YW`_BT62=@>^YW*3UG?`JZ@1.K5<OHTX1#60IJ%L[E#_$&0
MH6L*U2045H`P1$`!%O`#2H0`/<!#=;`$;J`N9\51'N4TQ"'4#_`$GM(`&H"6
M&-`&B)@'\/$\P`T&YK!A&Z*,^Z077#`"T8$-2TWDP3`-2A7`A2>:CN0+7/Q.
M0KD#6Y(57$&*:/L,+4=_7MT6(=$;6=7<GT!0V!L.N"1BM`@@C.(0[;`&(D#=
MR@@`/%!T<J`%!F`&M?;#?O++A"``SD2Y,0`#89`&=N(`TI<%"0"N^&'HY]`&
MAXH*Z(S.;K`%)D`=T?*__#DL1HX52.G_GXVTSURLB="@-)Z^Q:AM86H+#O$!
MAV2@*L>#-ECHF"'`"?5W#_K09ZN$414B`&Y`!G@@!13PJ(I``$6@)E=``0_@
M3PDS=#RUI@A_!%Y@`1$@!)F:`R+@!#;=/\X'HXQ0$(=>!V[@@#WR<':@!J@S
MB>C'6@!<[@(LP',V-.J^2$V5-&7J!ZD,%BK';/17[VTJ(,P=#N<0"IOPYP"2
M&->#8GW5)FN@`75P"E8V!P3@!"&1%P_0!"!5'$BK+O=A!T2P&GF(!"O1``\0
M!7O`"05"1GN0!VZ`\N?@!EPP<9HT#Y<Y8"#@%3Q8B4F5'>@.8<.V0BNT%3SO
MU$FS;`GJ.T`/_RW!4^_A4/G;`KI2<P?W&@*55;?Z01EL`A&S[09-T$;\(1D"
M@0:=HVW3&!$%22)"M@I&0`5>X`67H``1\,TKG@%#<`9P4!L.T!-_7LN?,!SW
M@$V%P08"T`(O8`*JS(-(M;I/,8_Z3$C*ENE_C]7J(6%;BEO9@-JO.3U6/CTW
M4>)>O1CG,*H"=1`<>\0#,=M?X`2'FGHA9@#.+(-,```Y%A'?"`A=>VQK%(8(
M"!87!A0/`&@&(@M$&"P.;%9R8%=]'0<'=U=:66-C:6-6/PTS'Q,[#!`3$Q4@
MM24E*;FWM;R]%;_`%;*SM,*TL<*QLA`0#+"RP;_-S,[,$R`3SK#,W/]^.V%]
M9&WC=V1@;7=R<FUD9.%@>GT)\PD.#IIDHE=?XF!=8_RRD&*3I0N<+PIXI,F2
M1DL>!7#`P!E#Y@N8!%]ZH`ESIL$4`P0NV#&B8(@2"0L,<.GP#TY#+5<2'.@@
M1V#!+O\$2/B`;9HR6K9V@;B58M;0$K]L11N6U!@(91.@4K,6C58V/]Z>N8+%
MX)4VKG[".-A#=D^Y<W?TJ+US)X&Y/GLZ=`CAPD6"-F#\P>0GAXP5@5_8=-'"
M)D^:.5\B]$ACA2";"'@(=[E"YDX'/0,((,#20`D2`D9ZQ`%018@$&$+>./@R
M1G`:`4;JL-."TZ9!(B.P+=-*ZU:)6D!O&<7_E73H4FC%C$:U-FPJL6C8NC)8
MWK6`'V=>OSH3"W>M.71I]\ASV[9-@CX..HP%8^4*')A7K'SA9V7,%5)9M-1)
MPQC`$2W^7(&'`@*D,1D\>MQE!@`*;-&"&`;$(8`C!D`QQ0DJB%#'.EW4@=,;
M4<R!TQ5C=)&?%@)$0<$+4<G"@!\_'?5;+\`%1^-QQ(#@U')0\8A,55%A!4$R
M67W%#3,P0G!&`N58<8XY9*BCQQ[TR"$/&'TD.!9>6J11ARBC9'$%B5G<846*
M^XVAQ1=J<"%.>V^@X00<75R4@!YRU!%!%0:<`,,34KQ!@69#3'$:"EO(`0<<
M6>1A1WLFPH&'*6/<_V2$!2TP4($'.V"U35)"':4C4*/R4I4P3*%J%57+<`.-
M;L0T<UTSV\1":X\0)!D&!DR2H8=\8)BCUK"5[8%G&PGJ41$98]CQ!9@"_56I
M%7W4@4<7!K)QA0(#M&-%&G9`T4,=<"381Y9:J"%!$NO&<<0#%R!@@!!;)-%"
M#!1D,<``8#"D145CS%%':W/`(?`#!J#`7#<0T"BC;S/R8M2H0#8WY%/(43<=
M<C_]D@TUNRE#JW;;)>"D'FW,QP\[[7@;;#MMP)7/%?^4J,4H.)4RV;-C+%HI
M&VD@P`5MIV@1011_)>`"!G@$(4`&91!`A!9R`%&&`09@L84('(C@0R9LU/]1
MD17(\E=BAWGP0;,"(P1`C5:PD/HPQ,``!QQ5M1#38L;#Z,TW5!Y/T]R+77E`
M\E=A[-&%%<J.75E>D(\)K!X.]`%F?%F\5U`I+HGI'AMP"-9E'6%PT1H;`&80
MA#I[C.4$'5%DL(8`6MS111-AA`&`:7ZB8=D=FUCD:P)\V$'N1`.\(=L#*`BC
MC34Q5H!+Q!)/#-1R&5NU,:H^>OPW]]E4XS'A#'C@P76',Y"X%59$*<>SOK;<
MSK/[D)%`"`F(J<48>0C`:,YI8$.E2#&'/,RA(+2I0QD&4*DKG&,-"J@#E<B@
MA>3Q(0,"R-(<@J`!!1```$\0P0H,D(?*.3`_9*/_DL'L,!$PC,0"=F#""&2!
M/FTLXQH3*($,J%<+9.0M.:CBAO;T9BN0M:IO?G-%IV81E6IHYTB(ZT.3RO&%
M%+9!'>CP"V7T@`&[9,%)>:`"$!I"B@`NQ!1`>X,=[K,_-H3A@%]0!QF"Q@0#
M?6$.`W""N^X0@@Y\X0$$H(`&$&"O$XSA`/ESB6&R((<$_:4A5H##%?@@@2U<
M8`,5\(DS_'!#;$Q/;AB[AFYJY+SI&$=3@:-.$9V!G%$M8P><FL6M<A4+PKU-
M&XF[PQ[DP+XO(&L/R-+$'LYAA3S((00.T,.S^O"%`9B(-JVADQV.X`8\?.%:
M8_#''-(PA#0$ZXIRZ$(&_Z30!E%TP0T/H``8\)>`-%B``@H`P!DX``,"S&0/
M)`+7*=K`&-0MC@UXP(,41I""%\B``07PBLA\*$I/UNA52(D%K)B2MX9E$ADM
M2B50<.2-'3`Q2##2AI!DA14_E.%.64+6L%#&%G'(00M1>(`<>(47,)1#"^/0
MF8GJ,(`".A,/:;`(8>8`A2R`DRU68,(1VA"V*-!!0O7HPP&^8`$````!2)A"
M&`1@"3UT*&P"[$*@S,&8,42A#!LHP0X*8-'P+12B*?C-C$Z%0TTA,9//.$HF
MN9<,9/2HHB^Z#A-'-C*M9,-\'L`"D_1PAW&T(R]7;"QETM`#/&```\/TI4!N
M]O\L)XW#2Q1,`Q]^P`=VT&P`52";8\D`!PWX(#YXZ,$/'N72#CP$"DMX`@&\
MP(4V7%8.AS'8`.Q@!RJX(5BF&$`$4%""K5!#H:U2QE#B.A12!J.NX`M9;R(*
MC59-IP(P6L9OFO@*D16IL-B#P`[66X9PM`QRD`VFFLB0!?5T8`]6`%#/#"(?
MX>&E"P(;@Q,4X*8VM,<-6,C+?`ZL!#2`00[[RN8!TS#<.(3A-"+@P3@<,(]O
ML:$P;LC#`-P@`#;D@P]-P($,8D&"\SE1*T>ZV&^D]]"ZZ6@Y."H.7_O*2O!>
M0Q@W9L8K!FN^;7S%K2-+G,KB*(>T-(ZQ79#'N1Q@ER__?+$^76H#SG#"A@"U
MH0=56.H=JAB%,&QB%##A@Q)6@"(B\.`(=F"#&WR@`3,40@0->`!#KG`'G#*D
M"VS@@Z08.``!U$$+3C#`!]1;@$9SLGS5***KDC-755UO%M\%QL3J:JO!VK`"
MTYDQ$@W'Q/(9KK"P@&6ME+2'*/DE+^+`2R/Q-!ZE(5.9?[E9?/S2QCJM@WA$
M2$-%OJ"%(@!@'Z*(61J"L-7]D:$+=\B#%#(@A"KTP`P/P$,"^C4F;!DD/\`<
M[AP*8X8YBZ`$USD?^F+,;A\6AV([!L;%'MHBP6FL&DS4\55,W;`)N)@9_VX&
M+-&'E3`D8!W$_J8ZFHPRB]3#_P$8J%S*OG"*$@G$G.[A,Q@$0`$?.+L]/Z!`
M(^=A#RW@X0P7P"GPLD`%!9RA!2(P0Q/2<(`^P"$/!L$Y@/%H+4<!]0T60``!
M)&`""#0:U3%&XKQMW-P<+854'>.1Q3IF*EDTU]1^\,"0FKA)A0K\U($U.%[:
MX](F-[E)6D#//'9916)+#GXDJF(7[(`')G#!#J^6#Q4L<`?T="#B:]K[S<91
M!S,@0`DMP`$'"%"'`^CK(!U"1X>,<(0\A*Z`$3#`"I+0O(0F](E'4CJIBM-<
M'9_J&!QKCL6"474713J\W'A1=C999)(:?-BQ/OLY$/X%>:B%U\B.CT4`PH8!
ML*$-<_\@`A_FD-^"L&$^%G@`/.A1K2N\(0[.TL,5?&"!K#7@!C@0`1#ZP(<H
M7+&*>O!'&D@<9SCP@0HQ&`(,L*`"#[#5&[0::>RU<PT>.@PZ.](W&+5URW!Z
MTB`^'_,Q(J4=L`1V!;=M_-!89I<RYS`.*O4FM*$%]7$*65`'<1`%Q5,.14`!
M13`9FJ"!SQ(!#T`1>,$.U<0%!.`$[=$#9:`$!@``)V$`"N`$8"`BZ?<L%"8`
M3A`$1F`'_4,$2T`#5=`"2'`#6\$51@)%_"<]0O%NIW)CS]$J@6,,F=1=&74W
M@<4C-?1B+V(^Y15V#E`.6:0.[`%,3@(\:5%.CZ0F^T,17.#_!0(P!@-P!74`
M!'.B)M'2!ID#`$!0$/5!7T<@&`;0`V"0!P\@=!Z$!1$P`!0P`,ET<'DQ!F[P
M!FX0!%%@/`/@`PWP`BEP`BU`3V4((YR2)*"W?PV3`C0R)*&B:<F!1++$2<P@
M/1*%%-A34;0R.*`G>PZ(2YCH:O.A4BV()XSU!3@Q(O*Q:W:@@6G`!7E@!#PP
M`'`@B"CD#WE``#Q@!UE@97+@'JA@>#Q@`6IP@U>E``^0`5XP!AW`)#23<U'@
M!$50!R(&!%50`UTQ`R,P`BAP%>O5*486A?NG*4AQ71ME,5D8BT@R'1=C/5S8
M0V^3#*ZW29[2#"Y&/NIS%]^$%W%D_RSKD!;I4$ZU$1_/6!%?9"Q7D`91H$9X
M0"8::`5=P`4*\`:EU6?,@@?.,@=H@`1#4`9J\`@4P`-24`4#D`ZHDP7!`@<#
M8`0"(`!X(``^8``+$``O4@$RL)7D93B1UHK4("1`4@P7Y2JMU`L\LC&OX@O!
MD'3-<)&R-ROJ19"!95)N(3P+MW!LH1;LP!ZB(!^Y9E3_(@=W(@=L8`=\<)BM
M,1FBP`9'P'=7]"LO-0>5D052(`%*$`8W>`9FD`=,<`9!50="F`88<`!ZP`9&
MD#8#``0`$`,SX#808'\%@&\O$F-@F2OK]2.TJ"-F699DV9:8)DL0L`N]@421
M-@&>DCY?D?]U7CF0)P4&%H$.:O$^ZN!D5<0^P`(&76*(76!@?/@7@58I!C$8
MHS`&W#='3`D&9D$S6<`%%"!T9X`$:.`%!+$&&I`'!C0'&?`#>H!(ZR<`<R``
M$7`"(_`"('!JL_(,/G%+SP-%JC8D"MD3R%&6'S4,V#`447%1H5("4AAIGZ=J
M41A87>$5SLE,$<@.%F$%C04S[8$S%7$?BX-`?Y%?BU,*9D,GII!?3&`!_5*!
M":<O:-``FLD1$4`'-_,`05`$`,IQ&3`G>?`&2LH'<9`$.3`#1<$]7<%NRY`5
M#.I$LT)Z1)0J$0FA\O9C+7)CO7%C8+B<J>:5S^,B8_@59V"BE<'_<#8UG<36
M'F!R,YNS,R3B)(1Q$^022?_`&&D0!W$`,^:P/VE@;!<R!55P`56`!40`)MJI
M!:?I!$#@`S]0!`,0!4=@!F$@`BK0"J`6*ZNV,!F):K;T(A`EH9:F*A,J#<_5
M?PGYFX'3BND3ENDSI_-1&6K1!UTP)0V'DMC9C`+!&.7T?-HI&'Q03?6!HXQA
M!Q8`!$_R+`61!D8@2$/0A#%P`PU0!&2!`7J0!<_''VS`!4!P!%$9<ARP`#/`
MH>!U/6IY0T%B)-J1H#O@0^.5BS9V5T"2BZ("@#[B*EUZ."65G`S@JQ'X36^0
M=@861\(W?(,A'ZB0#PU!;&DP26[`!G)0_S"%:@4#H`%OX'8%\45\<`1>X`5"
M8)4J@`,GH`%M\'>L$3KV`P=.\`-'4`1<P`04(`$CP!.O:"H]LC>Y(J+AHYPR
MYCTY`AP9%;#Y1F]&@5?UVD2K^C;KA1T#F1T,ZROAP0=?H$R+HWW"0U\:&"PW
M\Q<,83/,""!\>$"`!E,6\!ZN81]1,B$`$`;JP@$G(0%\<!F4P09%\`;)\Y+)
MDT?;*@&L$!5!L5<"V`TBBG32D8#&L2HV9I&:YB)%]K225E>&M:5%5BO8<6JK
MF+`=:0Z-%+8)8!;::0I=P!=X(3G8B5,X90?.Q%0"1`IP$(U7(!A$$`=_=B(V
MU4P\`!(*`!((L/\$"&`9[0$'=?`&0."'3A`%7$!BG"@%$8`#!EHJ/4$Q!=N@
M6[NOM2EU$P"+68@,W\6XR3`=Y=,P`Y@D1YL5&44=G()OUD`^LQ(59GA2[-!(
MNB1%[.$E=6(.YZ`LV!J.E($'Q<-\7Y"89.,>=&(B7T`$P49&Q)9V=Z`O```2
M:J``8?`$3:`L6E`P5N8&/<`%7%"/GNH&7-`#:X`$&_`"`0`"L-@4010-!WDX
M4Z$,HL:%3:0W051+,-*%?34XJ^II&5F0N?)O7[&*!G=V";*ZWID&[\&&OL1V
MFY4/6G`$0-`A=")`O@(&Z+H06O``;O`M0,4062#%>!`!0HD`I!$&`3/_`'H0
M5/2%!W/`PDYP!$<P`-7[!I>R!?`:`!^0`K]@R%IX76]CFR3##4[+4,\0.+BB
MH(.%1.O&*NHEE_F7;IQ22ZO8*6'!),;2%EDR;+!F@6=GD@#2'N'T%]:B+4SY
M/MCB$L67`99GNT_*!_#P4D<0+V<`!4A0!700;7"P!PX!&ST@`$6PS,O,P@*0
M1U*@`%#0`BCP`0%`%*9"5[/DBEG7H/0:9`V3-V_J79%<;\]07H*SOK7$OJLH
M>\JP5M>!/@9'K+K$6"S32'WQ8(RUJ`=",_5A!>0"-/EA$?<10`;#?>774X!,
MQ_@T`%X0`02`!4FP!`00!:)Y<TXPO4;P`U%`_WE%D-%.P`7[X@1N(`44T``H
M8`(!(`.Z$#&S2K7XBB2S^3Q)H;[64%WJ95A0-(`D)1V+S'5O<UA@]PRF!H7J
MDTS#8H'C4+8I<T6;,"9A\F$51\7[`1/!TH$E8GGCY)@\F<QX(`\.G0'R,JF5
MV($9_08^T`-14`0\`*H[N\S3NXD"\`8]0`41L`(U$``!D`(KG9`76H57\8LE
M8&2&XRD4!2L@$QW%D"OYFUWD-7O*R4I=(5BUF<EC:%+QF"7E(#\PT5_KD`\G
M<A-`8R`Y8S.FL+N6%SIY``!2"01!H#IVX$UD\`/1!P!BH``]L$UW,$U&\`8A
M[09KO8G`O<Q<\`;/7/]H3TD$%H`#)B`#'Z#2.\0+Q!ED-`T"1A92X;66W/.6
MSB-OJ<I_^??8RMG-83EPWJ"P+U(&\;A++-,RNB8?C65E@W$3E'(V-B$0`0TZ
M`:0%3``%(Q$O`("-."<'7$`'3=`$&A`$:M,^^D*](;W,46"]7-#,QKTO/<76
M/4``"R##>MW7TV6^X"Q8QQ!Z/J'=VUW)4L>K1U:1<QFG7[%6$&EJB`7*RUD&
MR=07!`PYO?1-%PRCA:HS`C%`/>,A68`'(:8MB_`N@_(`1/``%N`_=M"I/84M
M5V!@;N`$/0`$1.`#4D`$TYO"]OC1U&O<`E!^:]T$:K`"'$[(*SU=,^8]X47_
MJYE6XA(91*HG.#G<H*Y2/O";P^>]#2X&2S0N4OP+DN:P9+`V-F-"<952<?9=
M"CVS38#V!@_@`W;0!0"@.@KPGIO1`%7P9GDPN`.0!P%5!W9`E5R0(CRP!@;^
MT?;(Q[#^VX0K`'G@!E[P`&J@`AQNS3.,"W%U72).'43$'')CD22NH`:KI;LQ
M9*SZXEY!:JDH4EAQ4DV6,N^3MDM61:YF!2SD'MC"'_S1)<[+!G,P!]="`6M`
M=P@`!`BC`$LP!`W0`J43!7C04Q6$PIS(Q0/P&D3@!3Y`C:?>T3S``Z].TB2V
M+P+``T1`!QNNUQ\@`RO-TKDPM;'P"ET8>U.''+L0_YL:@\-O^12A%S=5*RNA
M2WN(97_I"W:"O@-8L$ME447"-R8RW[H#M+'Y_6$"M+O$Q1!JPP4^P`=,$`9F
M8`!($`9#D`3T4H*O!@<^0`114.O)?`336P19'@0_X#^@2GD97012[P8'7VA%
M\`-FP'E[K=<FP.LL[>M(8=T>M=U%*U@TS(N/2Z:2+)RQ=VK[*H7,N9Q;JXI:
MYV\$IPTV?BY-PCY0?3-\>NH]!5`WL2B.;S`\*3;X*0=\$`1V\`!5@`!G8`!J
M0`!A,`5+``>$&2QV$`8M$`%YD`6OOM%20`=FP`0ZR_5&8`0\6_!>?]P"X`9&
M8-<W\)HL3<B\OM)Z#8M79_]1CLVTLL";TK-ZUQ5=4.1B6J?W6;N<)?5ZG$*7
MU"`6QD)!"P9HS8@3_6(@(EMY=%<'YF_^`34'J#``/_`&8U`$3QX!:%`&5:"9
M!A`&51`!%U'F'0@(2S$-:P-'1SQ-#Q043#]%B$Y'1D=.3I!.;FX"`P,"`D54
M%F4X+RD@)0&JJZHE(*@5$!6O%;40$[.T$Q`0M+45$\&RO\"X$`R\R0P>R,P,
MSPQ^TM+)Q]#/?KP['GX>S+P,.V5[9&U@5FUM7V-S:6-=6?%=[EEC`W!I=75V
M=G5S?`/F7"'S!<\<`6N04%A2Q@""*@:$-+S`!0X5`6R.B%%B@4@/'T`R4,C@
MI8C_22=O!G`I0ND2IC=O/LDLHHC"BAJG9,A0]>'#JA2N9)0(!H)8L%S!<,TJ
MX0I74J=*ATUXEFR7'V37GNW8<169,FC)MEW=]BV<AS)ZKFA9*T<.&2ULX'2Q
M<B6+VC'Z\O"Q`X?-G`%YV-3A8T1`%BU7N`PHH@9&@RU"&`E)$H,#E`=O\@P8
MP\=+!AY1>O1HDL%"D")1!"CF"^=-E").N/RPY.23ZRB:0C=9HV3$!P@R4NSL
MZ9.G<*'%:H%0ZNL7*J"QJ`J3!>)6K0E^=C&H$.VJ]AW-N%(%M\S;+;/2"G@`
MSZ``^#![P,@'4PX,7"U?OJ3A(^"(OSIXV#%''7`,8$>`_UW8,<`;8]R1!A$/
M*"#"`AQ,L001%$"QQ1`$.-'%%UKH(4<>;BP8!0]',,$?;3P4P<4G;D3!!1>2
M\'#)$3#*^,:,101A1@8&X%!="D0.UU,`*:P2G'/+*46,<DPU=<PMU@5S5379
M<-<=`]I=N557W9%EWE1B954F?&24(\<7\F61AA7Y?"C%`P;FH\]_71QDD!U<
ML&$%&'E0T,`"*-S``1)%7"`"`$[,@0<7;UR1P!>"#<###S\804$3`OC@PQ%`
M5%*CBVXXP4.+D[BQ(VZJN<&%#UY0H$!O'PCU7``]"<53`$)%6<*33[J"RJ^[
MG.=4=UU-L(,LX$G#95;32"/F>O_>8"46E=%4RT`8>K#9AAQ6Y.<F7G5<H<<8
M=N#5CF#\P`''8##^,``08,CA@Q`HC+#`!EM$,,43/+3S`Q5&:`%&0:GZ8`07
M7CP`!!%!9!H;C498`LD1/=2(&Q=1Q)2:`#U(00``$2@``Y*HZ*3R3KBJ$AQ0
MOKXB\RO"HK)<55]1,QTTSF*'55=^?!GT>N59RPW/9"%SQAU7@-$&&5=88446
M<65!5Q=C9-'%NV/$90<??.0!ASW[;":%'4Y$(`0-&XR@@D1A_,"&$48P$86?
M61R$FQL]G!I$'!Y=&INJ'*]$"4N7&"&CCJI]<@01&E!@01,&F""4<$0F65QQ
MO`97@D[_,,]L\RQ`+<>E=LAH)\OJRT(0-#)76A/--CR/Q5XX['FSGG@0G*&.
M'&U(_845>(WQIQ9PY-&/HP,>"`<>`;'A1!U=V+=&$QH(T<`,.&S0`@4&4,&%
M$4V\X<,`\^`1Q?KK`\%#$%1$S$/%7,3H!&X6FR3C)@+L'Y,`.S()%1[P`"9D
M8`9"`9UP>'(D7.DD`"``791\\:NEE"`%%<A.5H!AG6J<YTOCF<KL;I>5K!Q#
M/>Q)QM*^H`Z[J"4?:4`,7MB0AY3`X4"=@,,_\&`$S+B!"$``@`*0<`(8C.`$
M+<C`&N(`D/75T`YLX,-MV/<#'Q0!@%$X1&J.`)N+<=$D,U+5_X["N(E5.8$)
M<:!#$#2P@`!`($G'644#>>4RIA2)2!4<5E$BF(*I/$6$L?/@E)3EK/*L)QO*
M..16P!*.V$&#6_FI2UW&\"XVC*%KZW)7\NHP@`>H@4Y9B`,%\O`#!)"L"E-H
M0`MRP`$11(!.@)D#&_CA#P'<CWTG\@$7%%2$E+C!"#WXHJAHHXEBSHACJ7F#
MJV1#!3/XP`(MF`$$)U`DEOV$.)>S(Z]*5XL+_NJ",@#!=HCQI:UXT"O!X(JT
MU,,-1(+#/=UP!E;`(KLPW`$Q4KN"N@CTKCDHJ!-[^<L:A"`!"3R@#F9X@*F<
MT`,Z5$$(6Y"`"$X@`CI<47D*XH(_-?\SQ?6)YJ,=LZ6-@)D:@/3OBLH\9A0L
M!I.6/DX*/7@`%C@P@A+TXH(N<YEP<K435\`Q<S"+$E""\\<)'*T;YX2=!ZQ1
MR!*:1:F,C!:8PB"'P["):OX0T!S\N57`A$@/#T```<*@@`?@P8``0("++A`&
M(8A``F*X@1KFH)CZO<A1`.G$2BT1&A]080U!>$,1?`":-TCB#7O)@RV/`!-7
MK71]EP@C3)SP@R#P@`X90,,*3/`K5#BPCA7`U0=,P*OG9&XG014..)OTE6.T
M+BQ7\4`!OH*Z>.HN&V2Z1M"V(9YGV/,*45L'&P2#!S[X$P^SM,,70G"`#CP`
M"A;HY1I^`+[_(0R!@`JH0A(D*@$A\"!L?\&-8C7C"0&4BHLG6L/D0F,$D!1A
M`'N!GL7H=LP9M:A^682-_UY%A0BH80DC@&`MDM0Y(J7L`R_PB:V0=$?0\1&H
MU>%%L:9T#6^0$%I;R?`B1^@E;E2KGFUX1SR`2]<W_,,3F_C"`5C`@@1(`0!,
M8,,:%$`!!&!!#6A`P!"J<`8E*`$+0]@,&1(P!O(.`"4I?9'AR`<$T?R`BSYH
M0J@&P$F6<)&ON$3-2EU4/YATXL@\R``"!C6#4]AL94FJ0"IDP+EM@O.TV\S<
MZ%Q'SQ(.S4Q@,M.TP!3/>6Z+#&QP!SS&D`8C7*`'`U`?BK[@@@,X_V``GW*"
M!1H@AC"H@0`$4(`!D`#1)2B!`$S0PAWNT`;--+$',]KRCB31@TRQY%1'\*LC
M>/#1'AA!R[3!LDM:"I.].<$(%D#`%%:`@P\(BYIQ[&-H6_83;7J.S2\S,!XS
M"";9<<FU\M1*()4QK4-BX\./),,[X''#+`P@`V;@PN/XDP4RU&-!7B@#!TX@
M!"R(001"6$(#5G`&)E@`#7&X0P<Z\`5+;<)41TBUQ61TB?45X0=$\`(0?$"$
M'V2Q8H(UB<8W?J.]*1PV]7,#$#0PYA@@<`+?7""2?I4"$[39%3A=F0+Q6$T.
M4N4:PG"J!Z,U3V>5J<\@QEH7M``8=R$V#_\:(,`N_>$).CP@L]L-0QA6L(&J
MZXL(6I""`@;@@CYT@1.O:>]L4KJ^^](H-9:B0QR:_(-6<[$2KF());YH$BXJ
M>:^9^%_:+P"%%:C`!!94.:Z6TV9;@4#P"<3C!8L4`%=P!Y'8N`7JKD$>0W+#
MVJYK)PB/<94PD&%KU`,"$WKP"2M$0:R0L-L`(-0$)EP`"T*`@B!4,`(:O$`$
M:;B#!B*0@`[@@0=NL`<0O$`$_I&]!UHN0@],+``II^;71P#H%?"PV$-<F:]A
ME&R2R_YT,;=@`29`^>)_Y;+#T]'EX22=3N%H1\'C$0*OS=;JY)F,;G!%P^"1
M;;.N48!KNZ[_!E#_%PZ@!PG0!&CP`%&`/E$0!.M#!0[1!&80!'00`090!E6`
M!(-"`S7P`2@@`%;`!4GP``D`!T`@`%V`!SY@!E)@!)V@"<=T:RSQ`]?32ZB&
M7D?@!G7P+5W@&D8`:]<7<AY#1F3D!D=@!A3P`%)P`RA@`D%U>"J#02#`0+AR
M"K,@<RJC"@069Z6##7EF0KQ@?U(E+8K4A5P(@%S0`_HD!TQ``$``4(KQ`VJ0
M(4M``00@!A*!!@"`!4FP`B,P`RZW`EU`!G00!CTP!J4R!_;@!*'B6.MS3/IE
M!#\P/H<`!&\@&DV@`#]`/?UQ"*WV9#^H*I]P2R[892!#&@"`!@NP@44A_RP_
M=0H3(%J[4D'5%!PL4RL_$4<!0"97T@W/,AZ9ITYA.`T@9#1<`8!LT`D"T`9&
M0(EYX`^A,`4X<`(-(`$&``4-4`4```!G(`0<@`,HX(<UL"@/$`%<,$EI,`"C
M004E4HFW9@DSDG=G=P0=$PH.PP.OE'!/-C^O=@BP01LRLA+WDVJ@B(X^X&]J
ML`(H\`*WX"N?@UH0D`H^<22V,G,X14<ZU3E8^'@_XV?UYVVZ18R]11;IP0`&
M``9\@%D)!PINH`564`0*<`,QH`1H$`8(H`908`#5N`1B<`(+H`*VQSTP(`($
M``9Z("*$P0,KD1)O((\:=TO_8UBH400A<0%2D/\'D'AK'Q%,B7,X^=.4^@.$
MG/`JBC!F"S`#:F9'0<$RP"!:#004.O4<S_83V\0R?>14T7!SNS4-//.%%G85
MZ:$>TL`,9Z`'<Y`!!/``+Y*`<I``:1`'88"3:*!I%Y!6^D90/-F'-8`"^P(#
M:Z`'XH8'/2!Q`P"*JK$P&%,QR[0^E?`:/<`$31`$"]..D.A%D_!%F4`QBH,)
M)=(JH!!KBX`%,%!FQ/`Y3.%`*#=:;,E@+?,Y!O8*6:@D+",#W,$[V'$M7.@'
M*(27NN,5RU``WGD[85`'JO(U<Y`'>?`%`P@&:9`'!+`$-XD`$4``FY8$V_5]
M(_`",Y`O*H`%6K`')SC_&N^%!]2714PY":B1F@QW")D@"9201;2VC`OS:RXQ
M"5LV"2@"A)H0EJ%A!L$&`S3P&[CP9H?7$VH6`*1%'"MG31+D379TA07F"O!W
M>;MUG<]@84BC+;B#.WD6!D2P!$@0!]]E!S'4!9H1!7F0`:>(``A0C5M`::U$
M=2.``E*J`C%`!/JA&E)`!US`'YYP!$]&A%=6!`AJ6+?&!1&3<)4($BV2@'90
M0Q-:,7777HR54OSC">/3!*(D!F49`&IV'#!CHL6Y.0IF?B[SA,@Q+)^#A1#6
M'LPPC(Y:2+NU'MCF#-:V+7/`C1D@`&T:4QI`$P\P0*>(!A0``"MP`R<P!2>P
M_P(PT`(&4(<+L``$T`D[T@-4P`.^!$"2\'PK!8D(JG!.\&6E@AH"L!>$5B#L
M^(ASQX^#LPDH)E)2D%!H<`(J@`(HTY`O4RN:8R2\4I%MIH4P=QS1MB2NTPU`
MXVW69EN22A;@`0Y3109!<!I22003J%YG<)-ED%;P>08W@`,B,`4B``,X@`1Y
M@`='@`!/4!%>!BN`45YTJAH<TP-`8#^+HRJ_MC'`A%C&HQ9UT#^F$DRX`4RV
M5J!YER-N\'`0J`$*T`!59SDEFB2Z0D>"JJC6I"0+%&VG!13@.A1E4J.]53NZ
M<S0V"C3-X@=A8`7]\`8-0P3SP@=Q4`9"@`!AD&/:*/\!"Q`#$G`#^R("5'`'
M8_`&P69<*S$`":6I>0`IC95]#"I8BF-+,J)\MR9Z8&0'5/,HF4(QM/9J*,(^
M(2>QC@4J5"`2P%D*X81'I94""C9:Q)$K@:I3B9I3.M%^<(8DTPD>@+1(/$=Y
MK\.7,DJT8&`(7*`U<'`$5#`:,XD&6(`%-K8""S`"-S`A(W`&?-`!#K`'45"-
M`I`'C!4%$4`'=Y`G*L$Q+@%`P)MJ,C()R-=E,1(%#[`&B'9DIVD2=,-%]/,:
M_]A8CR5&9SA\:W`!8@`#*/`!P``"MBB=K,AL=?0YW0I4?@JY1-)X%6"XXJ0>
M3(5_3867Q`@[1&L%/-0#5A/_!#0IGU.`!-IH`/6Y+S&P`F7`!`G@:+TW!Y$)
M&.:U!F40!`Z@!0!R/Q:#(V<;<J\!"B#Q`^8%0#[P`'0P>D#0=I,0O?V(IE&P
M,)I@O?=#FK\F!5Z@`4.@NC0`0<(101\`5+O""D/%"CU!<XK'OD"U$]*Y82-T
M6V2H6S8ZKO:D!6WZ!7K@!@B0!+!WC0IP!@;``3$0`ZM[1%R0`!B``7?07'9@
M`4>`26[P`$,`!.5I2T:0FA-S3*IQ";5Q(DQ0PZE$`5YP"9M@?7-WO,`+O7-,
MFGS;92O!!!RJ!G'U=\J1,A@)BSF%LZS0"G4T,];ZN'2YK;6U%=[93KH%>=OP
MG?CK_WG[,`9DL`=M8`9B@`7R"0`44`9#T``WX#8;@`(BT`06H`?`)@<=$`IU
M0!=VT'P$0`1\<$.<(+P\$I!*AEZP`2I20`%Q&$RMYB+(5YM%<*&N\FNT=H.(
MW'`Q8E>FX@5T,,LX;"L5]#(/5!P/9,GN'!S+20O.>;/@N@JN@`U;P<1Z&0W@
M\+.0MRWZRP97T`5RH`4]@`5HH`8X20%5\`0<0"@H0`/<LP53``>"8`<.`,)6
M@!@;6PD"H$.*I63Z%<.?@!NN<7T0VW85DT5/Q@6G$DS*IY60HJR94$PQ`@DA
M)1,"8`14T#``T(T!-@%[1&!!#,1QQF:'JZ)4F`NK"#.,1_^+;J3/OQA/D*>Y
MUB!"O=,&<``VPZ4I3Z`$0R`!@X`%JD0H,X!@^=(`#X`#(R`%8W`$;"`B9(!B
MS.H),*$:^C6*A7->[D,J(6L)=&,)A$4W%=.5#WH(]57(K,+3/_17#BT".%`#
M*>>6ELP*J`5.6)@*$-EXZYL<?.1X[.PYW.$-7<%;7?@ZU;D,7%$&;4!#/2"O
M$:"'3S![,!`!8PT#N8P"M*<"2JH"')`G?+`'#B`'7<`_YL5K,0&0&P-9$V-E
MMCEWEF!K/>@#/X`'8X`'>;!2QDMK(;O8SHS<MA%E5$`'"B`$?/@!3I@34#T<
MC+MXX11!G8/$=50Z%R0S0H6+==G_?ZXUC#QW"^2J.V4P!OX&`$EPC4D@!F(0
M`VTS`BV@:2>P`3@0`].*`J0*`S_@`,K3`2&@!\?X"3,B$WG-W/W8M@ZW?`PZ
M3'SU.$3@!&`P@#5T,:)Q$KC$/K$AO#P-"N_S5Q=0!F(031(4VJ\PL\$!EQ.Y
MK6PVW^QW0<Q1V>TKN9QGVM$BDL^`'<Q@864P!P20;S>0`T(P!1P@U&X#`U)@
M`8(@`;K=/1P``QJP!WTP!@*``2Z0`"?XNR4BJ\\,&X?3MO?#$NIV:WO%W41@
M`;(,!&.3!ST0&M3=CONCMRM11B@-0$N)"%*P!N`#YM1JWZ'SON[M.>#D.9.\
M?GA$,XY7_RR'5SHNBT'_IWD99MK^?)>[509?,($*T`(;T`!N16P;H`(;,`5'
M\`!G(`9+P(T-@`0WD`1CX.9I(``.<`!T+D7WPVLT<F2V]AK&F^BXM!*VACAO
MP`,/``!0P`$1D#&Y1E@RW1+X18KRJ$R64$:*T3]`(`H$L`5^QZ<^Q12:W#+A
M.I>3;(LKI[[X3F>'!W.:K6854(P6QA7L6D*RA04)D`5X@-L<,`17W`(XL"\+
MT``6@*1*$'L/-018``2]UP$J@0$=8)09IQBN4482:D;ZD^V2($Q,@`"IB@47
MP`3S8]C1&Y![CDPN<;R:$!LIU8(\0`1QH`!+,"$F0`O$&<GON_]--(,YGVY-
MGZZ^IX#ON8#OIM4KO](>[*3PG`<MWE`&9)`&/Y!IIJ0`6&#Q.)`#.,`!3Q"9
MM3SQ9;`"`'`'(=`!+L`$&D#&14E#&6H@SZ,2D05`C+C8A9QZ"/#%"M`$87<J
MD/^@>FZ;-](W6DFQ_WCG2_D#TWP&#1"<31U.1U$=%4#:(5HZ*4/U56_UPG*H
MWSI4S`D!/WMY83_*?E`&61!69M`#L@(`5?"O-P`#E1'`4%`&:,#%DYD%')X`
M<H`%56`%)M\'65#,8#?,==`QRV17>X73XWQ>$'<!!/`#.4V)M0:Q)QRRAT`W
M&J>@!NIP!UI,V^QO%(`$$H`#2[\+N=#_3;R@6O@/""DR*2`@)3*(B"DE)8(I
MCX\R)143$R4@$Q4@%8>3D824#!X>?A`0#'X,JJJI$&%<%$8"&1<$9TMB*S<Q
M,!(B$@U*:%!H#W4N!P<.=C``7PXL&!U]9&!M/6X#;T<"`FY115'@14=NYN91
M;F]11TY<;TX_1T5N34=&^/GS45Q']_A%PG$Q5Z1'CR/@VL&+XL3(CR8/'I1I
M(*)&B@FI*BR:(&,"A!0!4E2`4$%&`$F,$B4B9`C2(TJ92E2:J5'2!!`G00@J
M`<%#@5*G4JU"9>I,G3QYF%"X<*&,$HHG5L"`P6L%AP8Q)``8D,!%"!<66ABQ
MDB!!B`,=YH!)_U!'P!L!_+C(Y>*DKK@H;]VZ<U,PH-\B1GJ$B\(CB`]_B._Q
MX(&0;A$N`K@4-%).W)L!Y]ZL8T)%@8$P.`)@TC0I$Z<)(1E!8`1"DL9(B!B)
M+-1(4J$*N''K+,2;MJ#4H529&JIJQXXP=XY8R/#`@@8$4T2(D'H#!XX-(S8L
MR('%P@`7+$+<T9`ARYT$#C!@T$*E")P!`@8,D/RWKGTG;MRZ:<>%X5]R!B'D
M1`\^,):8/X&UXP\]</T3CA/AN"&7.F]PT<0:$1!`@`0S;&+:!`P8,M(+,\C$
M0`D?@-0:)(@$D-HBC,1XFR:4B)B;;HVX=`F(I!!7W'%S*+`$`&MX8?_&!=&=
MT,(-"VRP`0HST*`"$@+H048(++@`!@5V]+%'`AV$\$47[V@S0!Z8'2@.A$6X
M4V%#;0YT7T,],`9AG4;\IR</1CCQEA/W"/@7/_G!1<4:&5`0`18;8&(*B#L8
M`N(,,(C$P`@C@.)2BR'A-,@EALSH(8TWZL9;;9+TY,$.Q/DQ2AETB+&%`@_0
ML88%T;40PP(CH(`"#32@,,()%O#1QE<'R$%`%P>$D$`;<NS1Q39.",#'?`+,
M*2&@??+34$+NW"5.G3_DF4^;<PX&&&/\@`.0.'+ND]\`1DC!1',7J,'!!Z<,
MMP,$A4!@0A4T'*)`#)N,Q*)),A0R"(RA)KS_"02FE7IC)H8T,@D#K*[BQPZO
M>@'%&1I8$`$%%'#0PI)/!ONKKRJ<H($5'23SA0%P.!!"'U?H\<4<W?"!!Q[[
M13;70'3=,]@1/,!#F3M']_###X+UD.><]@U4D&#NWB/8.]WP%6%\/C3QPQH/
M9*``%@53[)$J)=T4!@P@F)#!!C)\4`$#"P>`&R$QRBCQ2)58C%LE;I.&"$9#
M??RJ%!I2\``:0RC!P0H+W"#=#+[.H`+G&XC`1C(NY(%&'5:0(8<<9&0QAWQV
MR*=?-[1'X=81_5681S_SU,6G8CP`P8,40?!@=>],6\TNA&SB<X34@CG?9IR:
M%08$$0]<H(`:)_A=_TK'.S&@%8ET9/J(;Y>PAAM/`%LR&@CM,T`);A#L0`E)
MM,DT`8R/L.+'Q\8IPP/"@``%4"`,OE@!,`@0D1L`*TK"&@$'^L`"9>3!`GFH
MPQ7NH(<V?&$,=A`:4M"D#<UH!E"/<8+M(-..^@2&,EPPGMG(\0^I^>`@>?+/
MF@+2NW4=1(746X?4F$"'#$0`#0V8007\@!$/5$!*`9@`"K:@@A&8`04Z>02H
M,F:(`'R`4R#)B4?>YA&*G0)QPJG8)G0B"5%\+X`6P$(!"1"&!JP`!S&(PQ'6
MP`0`T&`&,ZA!L$9P@?!T0`O92@,<UH(!!SA@#U:('1_0I)]SN`%0WFA"%/_X
M4"$C[+`@;LC#).<PAS3<+D)O^($/;A@0;^&N/Q#JTR4)Q*=P!!$N/&B"&1Y`
M`0`@80$I8`"("E"!''#`!)0800,H\(."I0\4.CF$"5"P@"HV205-0L$+/A`2
MF#PJ$\)A!0-(<CA.+`(3J##.#LH0!P,`@`!0D(`$.!"#%=2!!P2(`!1.X*L:
MC.`&:OA"!?%`!PKP@`\;=``R*MB!-IA2/D([FERBT`,+`,`)==#&.[Y!#A^X
M08-6&``>QM`-+;RG"(PQ2)_V@D)RX,-J+S6(2H-(%R!X@0EHBX`!3O`"Q'D`
M`B<@``IX,@,D#.`')>())TX%@0#,X`82F$(5PC#_!"A`80A(6$(2&K"D'"P`
M!34P@6L@4(I,F()B]\L-(I:HSC*8X0P("`,'G-2K!:"L#&IX0`3.<*\X,($/
M>PB/``Y(!0%8`0QZJ!D+%NL"!SS+E%";BP!\$($E+,$)8WA='M[`4818S0YD
ML$->TO`%U\%E';T;R#>\MABJ^<`PT;-A$._!!#,$P0P%-8`(L&@*^TE@#0O0
M&PAPD(<FO(!&#=-8!0)0@PUP0`E""$,8JF"`,U0!"4.H`A:F(`:MBN%R4_F<
M"<;;L'XYBF*!JT!;S1`&)'"@FC2H`8D6`(,IT($*7.!#&C(Z63PXX`MV`,`)
M'F">+^PA&8L]``9<@('0_TIH'W(I0@800.$ZA$`/<&"3"@=BA`Q4X0P7,`(9
M$O"%-/!A/T;@0@^$AR[[N(L'4SL(+8V'#T*]A0M&N!X1</L`!4#A!CV5@1,E
M4(05Z$V*7/!"B3`V*IS08`$<&,(6)""&,ISA#%!(0AG$,`5=V5$,(FC!"1K`
M@1-<I<PQ>-(,OFBI<9*F!**H@AFVVX(G@;4&-5!!#+9`ARCHX0XA=8@9G$"&
M+@P``3`PPQC`L)8#)'@/<V"#'?(`E[JTTD(44`,``"````M@'FWBQS8TL`41
M(($.`X!#&KYA%Y3ZP)/_@=#SH!>8'QCO>'&A4!%\0`0B2"&G6%A!AX()`1CT
M0/\(+\"$"8A`AQJ`BD88>\$(5M"`)6QA"PU(`G67(`$E/.4$)T#"%)0PA0;(
MDP._,+=TI'."'/2J!A\HC29X8P`Z*$$$O*+!!E0@R!50H`=L:(,T^L"'L@5A
M`%9@PP#.L(`@=*$+/3M+!<%P&;S`)<6`<@</-*!I"H0R'?39<!1^8`'K\I@*
MY<J'01:#NUC3,#`RE2EE7BE9)P0/"$&@0APH8(`&C"``^L,!$!2``AEH@CDO
M4%^3`S`L<V_A"61^@@&@\(0M<+<!#<""$!I@=3%@/8$K$$$#IE#U$_!B5S0P
M@4S0FP($4$`"./#5!J9R`P((@`QDN$,?0M`!!Q1Z#*G_ZP*:E#`#(L#A"G+0
M0Q\PT*POI#H^%X?'0;@`A#ADP`OQ88AF`K+A'-OK!TSP`A"B\$("$2$?,T_,
MG(P`8SY)[S$,@9!D`-(#768``$*(0=)OL@`O>.$$7ZR``1XP`Y'4:'XXV<#8
M&X`$)3QA"DE80AEZWH`RM!<+21#!5<@>=G!K'QB7J\XNKI-V0H"B@"L8092R
M@X(DL&$.6L@"F!Q`4M!^X0M7`$,?]*`&&E0I`8T$@`[0!W,@"_UQ%]G"&#A&
M>K(@`.R2)Z&F8@AQ!#[`!/A!&<7S/#Q`0U)S(/=!>CQ0((&26OXQ#_Z`%T>P
M8QI``$@@`L5G"B/P`$X``-N4_P)(L`8T<!$4TV0FL`'R=`(2<`+:UP(2(`0&
M(`0(4`8(@`5EL`3EQG5/$'T-8&9;8%E0`0/@!@,+T"2]8@(B$5=.H@(O@P5L
MP`<`=P=?XEA6<'AR@!Z.I05+,`-X`"8=T`&-%$ET84*T`TOD(%'BPH#G(@Y'
M0#6+00]W$6$$8FLJ-0]<PRTK%X*,P7JRA@\2$GO?P`,%M64;$$43L``60`09
M,`+;M`5&H`(7TU0HL`(^N`0CT`)<-G8(0&55D%U*8&WS!(7/]WQ+H'T4,4\Q
MD!4GX'42<`,W$!4CD")A,`4JH`+`\@(Y$`4)`!]W,(`U@P%W\`5ZIS-]-P:$
M9P1RD/\>!^`">W`4G)47%7*`;/*'?RA1Z/(\K$<U?X$8,$8UBXA2+>0U=<)R
MLO9R*P4OWM`#.V<`3Y`#)H`:,,`<%-`"*&`"2/`#(Z`_E5`"-8`#3P`#>-0"
M."`!6Z`D0A`58B`$2@`%0E!N1>AM6B5/20`,5.8+WA<#9L8!,!!V+3`")O`!
M",`!_?0!)A`#==`!74`699$,#G`'B8<!9^$"A[0$+V`&=R`-"I8&>>$6\'%)
M+88U*J2.=Z$G4O,[,,<GK3=KE%$$Y0(@75E+_H%Z8;D7M^,%%H``2K`"-(`3
M.(`&!O1+*(`&7K``4416))$"+T`#,2!?P'!V,(!N1&AU0O#_!$\@!$-0!EA0
M.=PF`2F)=4\A=BFY,NC6?6D62`IP!F60!#0@`R^P`&M0%GN@!XD5'GH`!E_2
M`<B`E%?P!#30!"/6`0G`!@NA6IS%AQ'X'W^X&,#I(/U!#NX02W4B-50#EO-P
M0UY3EGP22XMQ//4Q$%%@4[@G`1N@-R@@!FC02US%2PN`3)<@$AY0"3@!`C60
M`^XV;0T0D^C674\@?0A@74B`75.P!4(`#(NY5?.$;C?0?2)P`DRRC!8@`%Z0
M`6(05IZ8`'L`!F3`>&&B!W)@E*X9CA@`!T.P`!CU!0E`<7!!#G@!+W*16O3A
M%W]X(%YCB"H4'\,9&##&2O7(G*Q7_Y;"@P^MAVNR]C4X%@0$`'5`E@(SH!6U
M4`5+``1HH`(?4#<D8@(`LUPS@`-*,`3:%P-@I6=*\@14)00C\YA*@`10("M(
MT%WDI@0I*0)/@`1A-QU141W:X05@\`-T0``;8`(C0`$"D`=RT`<)`''.T@=R
MT"Q?X0(NP`5RY1UXH`5?4`=OT`-^XA8)@1?P42&D!QD4M2U*\Q<TIB?A\#P(
MX08'<01`4"ZQY#SX(&O`(U.&\3N56!?>D!!>``!*<`+'^`(P@``:4@4`<`0&
MH$TEH`(WT`!SZ@&T80)XM`!Q]T<X(*"%B01"P)A88`!5H%U"P`'4JI]#$(50
M)P;B=A7@MO\DNQ`#:Z`';I`!!!`#T]0`!&`$YZ$'>"`'=6B;X>@5(1`">'`&
M(M`#5D!:<L`&^`%YK(9*_XH0ZY!B#+$@@^(?>O(\4R,/JL2ISM,0J,=#"5)K
M!6(\^X"P?]@$%%`&F+-F(V"$"%`%$3``&2!E.0``"O`<0D`#XU0()#(".%!%
M-\`!$A`#FO-T2!"M93`$/#L%P)`$0I"S]WEU20`%XD81`4H54[$&`G`!0]("
M_@0#(J`!<,`&<F`--8,67S&O\WH%!B`!8Y``5F`%'/0%HK19#)%KL4<.`L$.
MG_0?;D$7;.(7M_8TI->JK-=R>/)R!@$@/@`$LX8?_^$/>Q$$=(#_!O2$`@'P
M`A)075CP`&G0`Y<Q`%*P'!P`!2(`(GY0`*V19S`KF6HJ`MV%54L`!5'Z%$L0
MDCSK7@T@!$G`954G!F(`#!31`BO0`E[`<'6'!)S#*RX)`'6@!UW`>!9:A_/J
M`F3P&8NWFGN7`$BA#76Q47)KE5CS'Q,E#O\A4T#`!%R046V!L&U"((S*6GRR
M<J]F-0)@!S2&(+U#&&9``4@@J]L4`P9`843P,];R`T+0*]MD"2:P`#1`,:7P
M`2,@!CTG`3"0`[`+DE=U7=56G]AF;@\<K5'HA-F&"]3*`4T@8")052-``[V"
M`L;6`5_PC<W"8.E1H6!@`!%0%HZ%`>(*_WF2T:^2.A>L9A<N-@Y^$9;\L"=2
MH#8]\!YX\`-[@5(V=T.D]XC1N7+RD`=CH(AA^1=&$`<<QP$YH`(]*`3OU`-D
M,`9\P`0($`,JT##J50+..`(=X0'C-`$TH)@-D*S:)P9R5`50$`900&;9-KO5
M9FY>AVUB0&X?.01+T`!>1P1K,`4GP)@X,`*?@P)48(?9&([I(:C(<`!6H`0$
MD`#4D`9X(`!`(`"=/``;:!>2@1<<1<II&1=S0:+^T!_%@R'6U02?%CR-.(C/
M&05$4"`_$*I4`Q#XR!CKXE)UX@-F8`$*$`:8\V1#D%=<(`=9<`1H<`,HH`)[
MJ<:G($R84$8?(?_"8;4!*P"M0V``3'@&2'"F.[L$0K`%'/"Z&AFTV#629`9N
M$M`#00``43@%*K/(,:`'X=@&>[`'?>``=I@,!#T&0G`!":`'6=#)NV8M\-&/
M$V6.I-P/G*>.%3UR/``A]T)'!?0#VX!#L$=#B!$$A$B/^2C,>**!"")34I!;
M-8LI(H``#\`%;9`%4C`%4**3-0`__S,*K')6._@!G_.7-U#'4+`%W955P3#(
M7D<1?+R8S5K.$HS42A`%07![:J`&4%`%SD<!KND";&`%CZ10BI5@;B`!"@#0
MBNH$1,`#`\`'G-0.A&(.D)<M<TV]5LFI/D`'TT<`<;"![-`#.!8N#P+_&.*K
M&%ZC2B@=<S"5#S_@!7IU!E.XR"T@TU'0!EW0`P;0)"9``RY(.!RS`T*1.-,T
M`MJ'1W8$A$^'"U7P!!S@=>56;D_0I4*`SA7LNEN`!&Y@!AKR`&M`EP]@!/S<
M=QR:'O-:H8O%`D0@`720T'P`&''`!6=2!P<X$)J1#F%C8^>XMG_!FPD!!+P4
M!S\@S/$`*""W0XH!@3!WTOAH0[<FG4%`Q030VE/HS09@`83VQ$H`)2\0`,SX
M`2$R1GNS"CU!3"90`P`L`Q/9NI7#LUIWP=8V!+7MI<UWK5.`SK[0`$7@!8])
M`>2J`%*0!D@Y?VP@?W;(8(ZV6$%@`',0`G#`_P?W\`#QD0=LH,H4TJG?,"&:
ML:IS&Q!\F#P:#02,"B&J1'D;N%&Q9Q]VTE&];(+K_;<WE*D%T=(78`!'Z',M
M<-].``9C``15@,:-8`(]M79K/!P<LS<3P$T'/II11F%,"`467&U3UGQG&JU3
MA<]"&(0:+@5W'-.)P@-]YUBP>2PUDP!V(`?)_0`(``=DT!9<P`0%.E)P<$GQ
M$0_@X"VP)K!\D6*1>H`-0@2:01<N^MZ@%CQE^:G!4Q`6:P0B".7T.#6N=]$\
MP`1Q8`$68`!)\%X+``4:``0^8P0*T`#BQ4V=L`D[`"*9,$8@LQHBX=\-<*8^
M.P77FMO8=Q58MP1(4/^T2(!E9(;4U<8%#["1+?`$%B!`\VH%>Z`>>JI0!T`&
M`\#/X!$!"`!:6H`'X.X%I)0%;,`7UR*63(,0:0LAZ9#$?C(7#&$$$A($UW)Q
M,0><YE(NCSB6@3$@XSW+?1*"/F!K\_C>TCGK<=`<\[T%OW@&&?`#=Z`%1K"Q
M-]`KS?@"+I\B(#$)FC`</B':=;,`(J!MUI>$S9>?4;55KSB26(I]7B<&0^`&
M&H#`-]`"6%!?;T`&6N!8#`IQR-`SX0@F$7`!78`>;<`'#^`#;`!QDXY1L[QB
M/0!R&Z8U"2+PJY6"$7$4D>&.!C$U,EJ^^<A*;`MC43``]DCQ"_OW?W]KH(?_
M-KRD!E4`#`B0`88W!Q5%`!P@S2J`'4ZR`31`(ML4$M>,"JZ2"CL0``O0`D*@
M`+5PQV(`=<^.SZ\MQSS+U64V=E7@!@"P*]?1*SZH`/YEE'J@2BV^!U@RXA&P
M!E<`)AA@!=(-!G=P!7Q@.W5`&/<@Y"H4O;L)OH^QHU(0`0!``9QU\)1!L?1H
MZH_X0UO#<@4A/!1(+JOTHD`0JC3F$+5%!W2P@B&+`!;``WC1!0)P)-FG'3$K
M+.L,"",J*BB"-1\!(!`,?@4['@PR(RT-"@9;*QQ32PU38@U84`U;$@VEGUM;
M2%Q;A`LJ-3,;"RT`1VD=64`:%'(A!RP8&%=K7`D=_RP.<F!:&`E7;TYX=D4\
M44X^/45.1TYN`F]<;N/746Y</U0``'%$1#U&\49%1ST^0/`]0$Q&/3T\/+9%
M,?(#"`^"1'X0,?B.QX][#GT$"0+OR)$B/YB8B1,G`P$`""+0B=:$S94>%K`D
M68#CA@H:*%9@4;&!T*08A3:@F/&!`8,".B#0D'!&B)(E4QIT*K7DB9(G'#B<
M*#4$R98G#99$:5!H!(JO-#=LN+'$"1D\/GC<`7:@`X8L3OCL8<'B`)DQ?5PD
MP,-EFI,>/P!286+0"!<G1:*$.W<D(!4*!JK$X2.`R!$NF!O["`SO1S<>3/S%
MJV>D6SDN10@^G"@OWC\>]_]\7,;X#P@5.AD4($"@AL*#)E$&S!E@),.0!0M@
M#/HZ"X?.!2)0T-B``P7RER9>T$2@8$0,#D*6H$HR)54#$1R>A!DRY8DG,6*,
M-%#!\I6*$0LVC!`;X8J=-VG\<L`!(71@!1=S]`%,"'>`@<$!>@SP!AMU%`&.
M16:80<4/3AQV412810&B``\8,,09;W3!1Q0"1=$8$#_T<)$\@&VFC1,\R.@$
M8B`6X0]`/\3HSY"P!>F#$2SR8!$/1'BQ1F[K6."%%$$((*$3<0#`00LXC.#5
M=,F)A9\@U&V0@U?WY2#$$`@@84(%']``@P3M)8'*%*6$M\4G2HD@@@]"L)2#
M<_O_Y:>?"A;(48<T';C@`H$=:-%#'0D,V$$?"3Q*AI59V-'#`P]H<\0^UG!3
MFA/]P%.$#Q2<$08`<%PA@!M`"/1B6O#TDZ,106236(SS(.:$BSGF,^2Q]\3H
M*ST['N$#$UX\0`$%&A!A!!-Q]%`.$`\`,$0,7GHY2PPW="F66"S=H!,-]-T@
M@1@BI&"##07(H-T-'$B0KRD-)&&*&!R8LD(+06!1;GWG>H7"!D:,,<87"800
M@J,81)A!'@^VA8$+=;'AAAU=7)O$$D?4$06333#Q$(?A"`".$P@8$$898;"Q
M!Q\#Y-A-/?<0P403"QG9ZP^E<3;C-D84"=!K`.4(1$+._QXT;!'T_!"$&:#&
M(<4/;CCA#HQ4,Y%!!$)X%>X,UNGT$DPCK`#N2[-8=X(8*'PP`TTCR-)"5`%'
MU4!42M"YA2D`*9`$#LB=2\C"/<S1A0,A.-#!`7I9T8,!;TSNPL1TA<`'%VRD
M888!")@QQSCG(,9$0E$(T,,W1C1AP!DTGV$$&5STT(22W-A#A!1KT&$&$3P`
ML760`.%JT3RI*10$C($UG6,03/"`#=$=RFB$#^Y@_<`:7AR!\Q&KS\-MDUR&
MA39+@MPWR`TH9!<G3"]LT$`,..0`0P-K<I#)*.)Y5[[*T``D+,$H3L@"JTXP
MB\2A:0%84)D=Y/`%/73@#G`HPO\9)."#$+"@`Q(;4`+8,(<LP.$'H&J"';@@
M`"Y$(WAH`,(\N%"\@D#&`$@8`A/@P**']&!'1L`11=S`A#5(JPG/`U8V+"*C
M(Z2*!T$@6JT(0CTB#,T>F]F51:P6!"EDB`I(-,P;@"##'E#!#'0@@@8D<*ZO
ML&L!(W".=.!8`Q.@#0<\J8$$D,"!&+1`7U-(PIJ0(`8)P"`3(IB"$$0@AB<<
MT`F5><`3D),?+]UG!#=HP`D08(<VK$4/=8C#"B2PA@1\L$`3PT`7T@`'/`@@
M=EYX`]&0-(`,G$$!Y@N"]3!#!P"L)PQ%R$,1W*"DTKAA`+,20!J^,(?*4.!X
MT=/&-9;_]YKMQ:@AW",,$'S`36YR9E@N4D@3O&`&)X4&1*.*PP/B0`<Z2*$)
M#S@!WA0VBQR\8CHJF,$+UC<#$WS@!D-H0`M@(((3G*`!2H#"$DX@`@E(`#V=
M$(,0DB(!'D@A#EX@P`D,):Y*BJ4!34B`,!*@!0M(8`L1<`!="/2+$%QA#'@8
M@!T$X*PHQ,$"`>'#`]00AWD\JP<#<$,<+($$`T0`-3^(P@^VP4)D?DP/#FA#
M%Z)@@6Q$Q`=%$`>+GKA4Y#6!FT"8R$/NL<TL5N0(5ON9%,CY`"K4:JMQB,"T
MXH#$'R`@;V(J!.(LN0$:S"`6-!@!#5X@`Q4X\@2'G,I5_E;0_R0@(0E8V4(5
MRC`%#HC@!Q$0"140@#C%*8PF-U#"%?I@P3VLX0(BP((I.38@O?AG`+"=0QW8
M(*DJ^&`.>+`,1C@T$!]DH`P*T$!56?2/BVAC`%K80\[<<`<'?($O3'!6%JT'
M(E2]YB%&@%$/B##=XI6UFYS9C$+>^3,G@6H-/'"#.8SP``(HP`+O]$(<&E"#
M^^AG8?IIWPST68,7T&"P()C!"9(@@8&U(!,./6G`D("%@')`"97UDUT1D($C
M/,">Z+KOP@@QA2[(P0$.T(,9%!"5(!!H<R%X1A:LA(>L9K4+`J``'8H0U#S\
M)0@T/@(!Q("`-5Q#`#\&1S/AR0,VP/\A('+`P(%6%82@E:8;J(K15:WF&5P%
MBPF]RI$W=T6/XDF!"4R@`CLUH`$@#(`/Z@U"!N9:$")0``9H&\0,XKB"#0#V
M!2;PIW]?`((:X.`36SKD"ACJMWQ-80HGB($(8A"#0P*!`@B@@P^D\`3$'LHF
MA%B!$:R@!PPX@`P^((`IA@"'1U%,#GS1Z;3,L-17$J'"%@Z".;(*!#2NP0EO
M0.8;<CT-//#AT10`PAHLL`8X=(`,+A*`02J2FFZ(0[V-"9*TC02C[$[D>?\8
MJXPR\H.U&A%4H/+"-F)T!"+0`514\$$3FI"!ETAG)S.@([MH4,<`!`#/`9"$
M!,J`@"?8\P;_,#!H5!PJ`H*V`.`';@![%;"&6@-`#5,(5R%>P@$JZ`%3"4C`
M%^(0A@:X%PUC*!#EP)#K+&1)`1L"@C>:$($@'"$./!!.B_W1NG.X$!Q60J8V
M],$#.H0!`7CH`#0NLNS1!(9YUU#-M(,4UAB1\>E@G<BV52:1,$?+`AGP,0V)
MUNV->($(19`"$<KP%3?6!#\P&:R]/Y#G?*,@8"=HP2N\$_`$FP(&.<B*`"70
M`S6;`5L9>,!=O;,`%*C``&S0`QCN<`<]Z"$+!-C"$`2@!0/PP"T$8J46OH#"
M*)IA#6[(`Q<L@]9ANF@>Q\Q#-(Z@&#>\H84824S?+9`$$3Q@#\V,__*Q]"'>
M8M:HF]UL<C:R+)&P-CDT:%79TYIPQ@>,[0%'<$,UM,$D^6+TJT6(@+L-/\<:
M?*6?,DA!ODO0Y[&P!'$+.,$*T+.OOYV@J$)(0L!28X$X4$%:'H%!<KK4@#F0
M@1E]L'AM4`=AL`6PT@&!42`=T`9\L'E9X`:^\WFZ90]-(`4R1`\_E#J'034[
M\@WJA1'<Q`0/4`8K@`1!$%164@]`,E;2EFU@]71D]#50Q'7<=0]--G5IY45&
ME!L4`!QO$`74%P17%P==Y!`Y4'8P40-^M7TUD`@@4`(E\`(H@`,MP6@XT`(B
M,&CH07`!PR=30346\`!80P$`<`%54&<J$/\#/V`%5I`%6=`&BV<%>6!`07`'
M+N``6>`H>Z!Z=G`%:?`&1V`&JQ9=M9%%NI)4X$`U(M(8P^0R-'4DV"`%:/!0
M2R``1<`'4^6"!K&"8_6",.@S,*)+U4`\5X6#@+$/34`'%I!9%D!CK[0]&H%U
MWT,8="`$ZR)G<^8E-Q`#,P`"3Q@`=K,!,:`_ZG=(0R`!!W8"`]<)=J))'/!#
M:]`1"D``O:$`#,1W5F`'8`!C#I,`>E`$8J``9%`@&Q,"?7`%<``'<S`'5\`&
M00`%[#!I:=&(3P1%T8<:2C)-'](C/!,$5$``B'8"KV<AJ<$#3=`/6Z9E$V&#
M/M,$!9%$UK,]NR7_;;TC$3SC,P^@`=2H`#W`!WD0/3\@B!80AE*0#68``"I@
M1_L%$P&@`C"`1S-``S(0`"40`&]4+BVA%#"PDWO3`$^`!`]%"EGQ0^=&`1$P
M-A%``%6@!D&0!7-@!V10(5P0!5;P!40P!5Z``7N@!PD`8G?0!>G(!W5@!74@
M@IXQ2\%B7:_1(6[`*SJ"&*-!-89X!%Y@`'[R!"[B`R+B>D:P>H=H#POI#A-A
M$!*1%@$!&*,"@Z[Q(SGH!19``-QA!':`!_X012)H`110?RIC!AI@`+!P-RLP
M`OMT*"W0`B9@;P'@?3?0`GXT+HW&:)FP!4N@+Z20+T'`!6B$=1EP`6A`_P!K
MH`56P`9]:`4#D!9O(`=D($E1H`P)L`=[0`9=4`=UD`;"D04#D#+0`P37D!K&
M`A"V$A!40S6YT@\^$B2Z@YEF@%;:T`]1D`=XD`:?PPT.`9B]8D5FE2R[UW?7
MIDNJ@@UA]3/FIAL```1X,`<6H4L6)2W4L@;,]WE;L%^%,`,UN3"&5P,@,`$5
M4)/:886#4(54"'"9L`*9P`$[206?XGP1<`$*H`8/@`=DD`5XT`5:D`4]8`9!
M,`<.H`4*L`5'0`:8P@=@()QY,`=C,`#30"OZ\#J7`9<'\2/SF54?^&3TX$1&
MT)9D%$VL1P0:\AMU0`:-UP5.E&WTZ4W1M#((>?\09/5TS.8$8Q567I0!:(`&
M<2``>,"D?=<1TT)L9X29&_`"_05^=B0=_I0"BP`"-KF+^05PR($X."!H@Y9H
M,>`%3L`$/F`&NZD`$>`$#@`&=7`$8[`'6?`8+;H'`H`$#<`$5Y``7:`!=9`'
M+F,'8Y`'KNHC75:EV]D/]7@0K(<9/C)#VWD15F,]1]<A30``9V``O[F55N`&
MTK8T$M$KAW@D#M&D430J2V<14^JD/&!_[45AP00B;U`CT;)F@0<^[B0!-1`+
ML<`3)H`"^^1/`5`!$&`"-Z$N(W!(](%^ZT=P,`!P5.`&OD$!6```3)`&>Y``
M=N`$:V`'P^`#"O``=9#_!5+0`EL@!7-`4A'P,6E`0EHP'*@Q*N^`&MNP(SO2
M9>0F$:TS$,R3-.9C(_ZP6V]P`4I`"DGP`T$%!-)%5A510\F2F$\'&T%0@53`
M74&[34+"3;PSAM1H`5%P.DB"*M#R`!:@`=\C!59K1"/07RJ)9X2P`?KT`1!0
M`36P`#@Q`X@S'8*P,`&'A4G0`@?5`O9`.@1``5R`%PF`:CU`!VS@`E;P!E^7
M!W#@!2N@!$:0!1,S`%9`!GIP!U_`J:Z*&1)1I1TRE9G1#^:9&@8!3DP:&,YB
MGOJ0&"-V%$EQ!C_00D=2(]1#;H#Q$(4A/4RR34'[,T!35IRQ$(8I9AH0`0"0
M_P%%P$IX,"/[@$;@-B548$1+(%A^54<O0";T]@$34`!BZ[7MB@+VAE_CLI.)
M!@,#%0]ME0>=)@Q@X#H^HP<L0`9N$(UFM@93<'L7AP&>E'%]\*)U0!DN`QL6
MP@42@AF`"!MI$40WAB3AX$0/T:3'DBH:H"=*P+3:LBHR8@\_LT1)DY`6,<%4
MH$O%YT75LW2S^S0:(2URY0,%2ASBF59><&[E5+S2<@-^M79L)QW[90*$N@,!
MD`,W(`(UD4]2*";4\:$ON0)%`*</D`7"T`=W4`=7,Y)7$`+F"S0.(6H_(%(9
M!V()<`=D\`4J@DQ6\@^0=$S2YPU_$2.]LPW2M)T^<O\0]/!$J.(#<4`!&1!X
M+.M$2_,0/J.KWB5E:!D/J_,\][!6I'A5A%$\%3B&%Y`!3"``?*"(Q`(;3?(`
M=``^P;,&5;``-'":B``"V4$3$NH''E`"9+M1"[`""^"G]#%W@W(#-T"V0&``
M'F<%EV(%5X`'%W606L`&Z+!4`:'*7-`&>]`'D.-I9'`%9&`%X'!S["DA`X`C
M2.(&C`B(^-`RIY<8].!B80H0F-%$Z(`1NG)59$4UHX)E1`,;K@L:0XLR8F=5
MK$L\V\-\-V64%L`$><`&+70.!)$C/]`$1N3(='!3(I"\'_`!3RB%\?.\$%`"
M]]H"-5%XB4"OKX`"/*E^?P+_!1OP!-Z8!K/J!5&09%J0!DU@`6[0!:2*"0.0
M!XE;!V[1`1U`4L*$&/7`EG_AE^/P!M+G&>0I?8!13-"L+8B1;:9"4P41$+0;
M&!(AT\^R;E8$(]-:&[PB=DPB!8/!/;"K,@51O.<6!T,0!E5``8UC!XI1!&5D
M-14HAE3@)&*F`&[4=@&0`OVL3Q```3*@5W"D`@'``!Y0`2E07YWE+O(G!4EP
MK^QT&U00''+@`AW0!78`*BI'M0KE1`+@!%[0`0Z@E2MF!`,`A)N!&5S0&,,R
M#FS9-:71#ZS'G?,P#UM%-?(0?2>C#:0-17IL5O,YU-6S@MD975:3#99+/?GP
M+,^S_P]4`!!$<#\P4`5K4`<DM]@QTF9,O4[J5']2\``B\"6#]0(ED`)U30,@
M\`$+XU=>,0.$&@GM.@NZ",J(\@2ZJ&A300!28$H'T`=6P`U!8`!+``!"8`#J
MN0828`QZT`6N.@!<L#W1IUZF<HK,&IZDW1K,)N"D_0]!M&OHT`2788G[$#0.
M85R]4G5,@(%,%X)NQ03DA0\Y75U>/>%$@&M1$`&]^0`\,`>HMMBU03U,S7Q&
M!%_+30$2L%_L>IH5(`,S$``3,`.A20/I9\/NUCXZ[!(TL$8P01TYD`,Q(`9H
M\`4#X@!P\#M-@`89H`&O0@14\$H-\`!<J07'?#*!@;^(D?\8RFP!!.N0W-3`
MI0$8490/IM(-6!1]B^U$8(-4638/$PRTVT0$37!=R*,0@\%\5!#6Q#,LAJX/
M01.Y//`8OM$$0/`&03KGK-MD?"Z\#]#!:Q`!U?'<IRG=.3X!-+`24B@5*%!'
M<T9O\W3*"S!?$(H?^=,"8G`$'N0";``\/L`-%S"W!PD'74`!3``&G*K,I"$0
MHG%,4:`&)Y`!?_=.9;0DQI,0#]$[K,=%1^`R0<(BU5HU,F(.EXT\01.T>GQT
M_1"T;=I%5&"!GEV>1KT/8/8`$?"PG^<#7;!BB!$81N(#4MO&&I`A:X!&$9>\
M+_`"'U`!)B`#`<8!."#P^E0"#+#_`RG03X$Z"RV@Y$W`%6@S`C2,'"+0Y'HQ
M`&G0!R&P!TP@$CT0*Z7%#%(0`43`!:$1(RS$-%"$1OS@,S\$(V%EF`N!@<=R
M$.UI,JHA(T==!.Z`-/Q;SU%4M#"XGU44[MS%)-'$*U9G!D@T5`00>'1@9FGP
MN^03ID$2/%([M6U5@:@E6-GAIXF0"!_``1L@`Q`P`2F@",`(C'[J)60K%NH+
M%AO``:F0`RL``(OW#WO@%E?`!`\;!6`@.6TA!W;`!$^A`3RP!N]@#E5W1JM"
MJ6$Z+/Y0$,I"&"HH/1#Q!L,A?<LSK4BR-.B,@1'\LP0!/=)FM($1M+)!-"YX
M?&OU55+`_YL7P,A-(-)P8!$&06T7!6Z!9P96&P<(($]UQ'8T^0$RD/8P4`,E
M4`'`J)(QJ4]S]LG4D0%TPS8YP&.,E`8)D`:A@@$=L`==T`.YSP=Z4"""W08\
M4`8YH$_+6P4G>&:373Q!%<W3-"3%!P@_0$P^1S\\B(A1/T1`1@,";UQ./3\_
M/44^/T5.CD8]/)9!A$9`/4<\ICVKK#V?350^3D9%1C^C03X^1$U-/D`:``H/
M#UX"8%E<GT#,S$%>Q'04&0]F4DUT"#@S'P'=`0$F,R(K*C4FWS0J*#0SYRHC
M(R@H<6+L*",X8FAA$5E=`YH(<-!'CI4?!"RPT8/!18<$:8*5@?^A8H82"X_&
M7!DS1X";-V_<.#DR$H@4(KNN,?E1*,JI(S"/""ABDDH4+FZX1.&ARX@3(D&.
MN#'BAJ>`+E&*L/K%S$<K5HA^-)'B0^F1'KN8!.%ABU>C-1$B:"CV(XT6`:B`
MZ#HTB$J<!Q<H6%@CQ8N7#!+,??@F(P"-%3'DS3"10L:+<R_:)1ZQK@:5)?)&
M+(#10,@9"EZXP+'3IP,9,F#65+F0)8$##'OT?#'#Q,(6"4H>\"@2A<V8.GS>
M1#ER4RG+-1;B$)%B9HT95US01EF^O$B1(T&H;'62E.4/(SM-.>%!)4.&`1@V
MVNGDHXF7E9;2@V()A%>AJ#Z"`.U!"0C_+"*M*5!X(&7-`"U\'*'))488D8L/
M9E@0P049T"$%%=>H<0,*+Y@`3@`3O-`"#!O0<$Y?X+R`@@HO?###!BC4,`,=
M6RQP`A)K2'#"%F)P,`4`;X3@@@,=]/'%`T)0<,4!&+210`@)S''$`V480,`#
M03`C@`!<7(7)`'8(X,0`3G`Q@#),F$'$$48@4D1118#T41$L\<!$(T(%<0E/
M;/(4!P%E8!'$:1AD<5U07DQ!P5J(^,`#5D0<:D1,/=CG!1"'P#1*769,0\P#
M1N!1ATO0.;*5?6L\D`$%%XQ%A7D60*%".R6\$``$)=R0`PHSE!A`"A4P($,-
M-+PP0SSNT&`!_UP^##!&$C"TL,(*$C0@Q0$AZ&&:`TTH$4<"+'2@1QMM@#&&
M'&,`L,`&3]!!AP)F3.+$&Y`(`$00'>61AVY58L(%3VI=!U,J48S$DRWR!>$*
M*KHT`1868531``%DW%&'@$FQJ4`<41)X!"=E(N**3P`S`2E71[S+!!654D,,
M$7ETD0<EJ0#!0Q`P$T&$J--8`&$<=!"`@X?AI``!`RITN*J%L%8P00HFF,!K
MT+5:$,4#3'!!A`@XW'`##B?$@,165^C1!Q@$3!%$!R%\?4=J;5QQ!17"9%`F
M'85\PIL=#[2`@P)-L,L)2?WR5@M+SE&7U$U&.+4+4%M=+.`#"H0Q!/\43W!P
MAA%<3.4#$P;VT,2;D"ZZGBZ$SG95**%;<KD7-5O0X!L;O<%#R$V,'E\09CR@
MGP9FU.Z6$",,]D$)$]A@`CP=HB/#7A\<YLYAO0:@`0]P#R`%#`OD@$/U58N0
M1!%@[,''$$L<\1`97R2`@1Y@@)&&3[,,[#E71<#10Q4M5.&%$;HIY<HJ.-7K
M1)<"6-ERR,2>/\WI!W2X0!B6,`0QB,$`7M@7==HCA5P00A.%&@50FF*)1)AN
M+8<H$!"ZHP'5R:4';.B"`$#Q+E>D@A=4$%4&QA('"WBA"10X045,((/@#4\%
MJ[+5K9(G`QF8H$(?.&(&CG##-P2!`^/:P`;_1B#%#2P@`EUPP!S48(`\N&`/
M9-@#!A+`D4CX("GXH5Q,HC``/*3!"@.@P@^H,R7Z7(4DM)C%#[CPG"[Q\6+]
MRIA/!`2-!UB``$I8PA(08(8WM$(03'@33S[G"$&X#'&Z:,J`,FD*3OA`"C/4
M`*DLP(0\I`$M46J4S*(TP@=H8"P9J"%=FH"%G;D*`B28`85^-0-O?*`PW9B`
M.%[@*Q1D(`IT>,`:J("`)XA`!`T8%V-P0`$N@"$*!,C`'AQR!SF000MX>,.9
M!B`O.L2!"D7(PU!^()0\4.D347@#E>;(%9?X1">SX`07DJ-./M!F)*!`!!TR
M((4!](`""+``4V3F_PS\R.RAUWE.H73!@UYPSADQ6^8@L..&Q5G@HQKP#A/P
MP(:=]("/RA@%$\SSEH\^@`Y>.!4=JJ`"=/RL!B@PT3Q<!8X2E*`;X@#J#"+@
MA&2.2@U(:(`8A!"&R,4`FA<8P!LB\(`$N.!\>C`('/@@`#[4`0YU^(4L!C"`
M?BG#$(Y8S@_60+FDN`$M]TP*F5C1KQ^XH2@#&XD3@B`<FIA!CC%;J>G>E0A$
M%*A,@Z!/19L`J5U,10J0)8(7I-">(NRS!T180S)#&@$*Q$$`<-#2NOSUKEQ(
MUI##BL-DF2`%"K3@'!7P@`ERFL04!<!5P"L!"&Z;@@G<E@(]4%T$\/2$!O\T
M(`E5F`('<-"")L@A`3Z(@`\P$`('[.$+68"#.Y,#"9#H)#E.X,1V.F4+"@@A
M!@1(#A=6,13:U$(IFG!%$7CBA#Q``I]O<(*A3`($)S`"/[T(Z`=!=Y5;H`1T
MNYC-#YB@L0)%<I5=6L1)I%###"A``1G@`1X&4`M#(-@'A9."(4NHS/.@!`T+
M,,$$"E"##9@`!!7092\)DP(0[+8;?4F!`KA@NPLKH0'/Y(`$1-""!<0`#QAP
M0!R>(`"'$.0*;"AK$01`3JE^]R.F$+$4WG25!X@!!RI8@05$3`0!P&\6KW/%
M&U8&A('ZH`O:%4EX/V$+CV'V%_))%'M*"S.!S4[_8$2@`A$,Q)8F;/`0E!T$
M$/@FE4$4\@)AH4(;JV2@`[4G%51(YNU>2@4J`.$!0YA!!7:`@AR8H`05\%6M
M<IJ"%)3@0B!(00`B``<I7``-:!C"%CAP@A.L``8YD(P='**!+<SA``])@!Q4
M-HN/Z,80/OD(B"D`!0JXS`D6:`"*:-6")$2`!VBY&'P7I9DO#,`"6$!"$^S@
MSHC%AYVH""%\F)+GPO($/W+B<T-[H1:0R7'!AN($#QHQ'#/$090*H(,`LL#5
M>T&*$14T3S(5T-D,6*!V?WW`!GR6#U<AS40;<,<O7UT"&4#`!#3PQP\R8(`E
M3$$,$OBUU18P@RI@H`-6_U##$ZQP``?P*`%?T&YX>;`E+ES"90.HPP"`0)<H
M"&`-',B!.E2P@"DTX:11R!@K;F&&O`$#`4/0@!WX,`"1M)D*/5@))PU5";4,
MYR3IL02B<L'!-AT6SX;:2GS27@0^O*P\Q4E0!BX@&S9L6+_-P,]D66H[`BA`
M+@_`V0-.``X8X.`%,JB`K%\0\N1]0`:N_BD-<A"!%4K!`%LP;@.RAH,IPJ`'
MU*V#`=3`HSY`JP-@V*H;='$$/D9!Q$PH@M)?MB4!Q"&IE2D#!6A3)EH,C!-9
M-T,$%,#%,E3!`IJ"`Y?.%8$Q/><3FG-9*%Y8L;CS!&9,&1`',[C?EU'V$F[@
MQ?\@KM$$4756"GE0NBNRLI5(,G[PU$`'?T4R!K`!+U`U%@(B)8!3)8(./N4-
MAB$6#P`$6`!D$B`!+9`#*$(#6)``!^`"1U!M>G`%<.`0?3`&4C5?O-$O16`!
MUB8)1X`?)$$%$1`<W$$,:Z`=_=)@M+`&"E`%2J`&````RI<'<\`'0&`!`(``
M"B`%9<(2\J$6NT`%]O9A+(%G==<>AE9)^6(HDD4(1%`+I=`,0%!#TV<!1W"$
M/+`3PP$$F4!!5.`%+MA9+[4&+54&1<8-`0!ZQR,#,\`-1]1J%@("*$`!8<$$
M6%`CY'`U%8$"23`'5T4%6&`!>E`'4J`%!V`%<^!.\Q7_7K^P!H9(!4XP)?K5
M`Z"(!G$P*@"039X%!`,4"9-0!`^`)V60,&%@`&@@$#-A`6A``!1`!XT@,G&H
M%B:1@X<0"F28+X(0C`/B?H0P7VOA%/8!!%X`-Y?3%+Q0C12`84'01G.V"ULA
M"#!C'P,5%B2&6E40`POP`2#P:LGS`K)6`Q7B<9DW`T(0*A'0!&4@!JL7`]>3
M(BH0`Q20`&3P``#@!7>@!TS@!`Z0!6DP!J&5!X;W'+W0=5RP9F_`!/>C.40`
M!<]4!G^U91^S&Q"G!@B#`&=@`&>``!E@!\[A`X=4#!YS";<`"]8`%/CA,I:4
MC&SA,<H(.].!%0-2)H40,D/Q_RB_T!_]D0%BT011D"6GT!6$`#/L-#(XDTQT
M8(>&=`8K(`(Y!0Y)<RL58")(5&.RI@(4$`06AP6I=P(W,"[LL`$X(`)%@`=B
M801?L`<"$`9?T`5ID$):\`56X)+QI%_@)@!XX"ZQ(Q-U`P]"$$N8T"B8@&U)
M(`9#@``&@`4$X(M4X`9V,!3#81Z+U@2'4E"?%$-KL%+\9RB&H';OPE!2J`D]
MD125P!6W\`MF`#]708Q-8'!&=0'"D9A<,"E:,5\!XP7%$0=O$0>Y,W&.<P,>
MDC0.6`(GYRKG\$LVI@8^4$)0T``QIX$;`$16M`)0$`$`0`%VX'-V,`0/4`=S
M4`=ID/\%63`&>>`<SD%T=1`)T/,`7!4'#=!Z*+``8>`#\G17B0D$%[`$#3`$
M:H"2!&`&PI<&=G!?+Q,4;^`(F.D@I],$MQDPOU`)?O::P=@,D10$/I$_$Q2,
M9A!19&)H@98[9E".%M`$?)`'DS!PO9`2I\):P#$JPV(N9@@`*^`AQ*1+>P$"
M'T`#1^0A)I<"VLF=#<`!=E-%4H0#,0`#6Q`&9]`%;;`M&D``>,`'>``'<+9A
M2?$),.-T;K!@/)`%3B"DR8(`<=!?%YD<;&`']V(!";.2&1`$=C`'<`!6?#`'
M>,H(A^`=B^0%AQ`?LX&,%:-V)HIG,B.IF25H+S%7/3`*S&#_!D[A'$<`(;!`
M%W6A`0O22'8@3OBB">WQ<,]`J@K`(,-"#"[(`2FB(H-1`7NX@"@"1"_@!Q-@
M`&J);C"W`F\Y+@M@9#=P`I&S!5^@!Z=A!!10!W:@*6PP!V155I\P,D!`5B&!
M!U_@!!F`F0^`1]>V'`,@;JER!F@P*/8EI@+`1O95!$'@"]'U>!":"2S!&^PW
M<)"$+WGV"[S0F[ZP"L<8'ZP5)8\RF47P4-5X'DQ@.[_X`UF"+P=T'?[%"/:W
M(!87JQDP!2'WAR7R4SQT@+35:B!0!3BDI\7%>M=S/3"0K$NP`1*0`)UQ`&,0
M!%U0K8!JK7EPJA=3"4Z@*5S%!W)0_P<]0!7R1!]1\E9[8P1-0`!/H`9H*%5E
MYQQ1D!,T<1*C6!R+2CI5L0BIVBCN1XS_2D'7('[Z,@NGB;#3T2\L!`UQT`2T
MHSK%P%6&H$$!,QM.P0,B1BJ=90')%'EE$`/M4"LE<J0@0$P3`"N]5`5$H``(
M@`6ZQ@'J*)>3D350H`8J8``/<7-Z,`9ZH$)OP`==,`99,`=1``3[A`AY0';K
M-1-L0@N:\%(\4!R0$A(]P'+7)D\C$6U9(B#O,B>&8F^AT$&%90@.]2!QZ`6@
MPPQO8BA/V`L"L@9K`!21I+?!J*WSZ@6A0KU.:9R-):(O0S+(:4BA]%*VHVW+
M4P,?P`"R]O]J,V`8[.@'!F`&`(`&9P`%O+8A+WNE."`!#V``:.D`1W(^?9``
M`-%&73"MFW@5(K8&'N%?1-`H^-,#;Y"M/O``TT<-$/(F01`X-Q'!M,%'H)"I
MAM(F]G:%XN=!'MI0J]1G6P9BSY%V4I"IIQ($6\9@F1",P[$&-P0I#O(F]($5
M32&B$!=3H3(JWA&K&@P#M((.8/EY"WA$OU0!:"`%!$"$0K"R,-#%+1`#'!`$
M:_`$-_`&"6!5&&![#@!.<S`'&U96]7<-QE$?,C.!,E,=N5`@,3J3O?G!(E$@
M0N%L,X%8X[@63[$>A%58^.$Q+P-#-[0Y,A/#>92U6?&)U[O#Q,C_!#XLMS[@
M!43`$HW`FHB79WFV4DFL'S5##!DP!+USN!6"*[)5$49D`@KPN&A@`+5(`!%@
M`$DP!$IPCW?@`P8@!&-PQB$P1@YQ!75P&U06((9T1JFP7B#&!4M(!SS@)>ZT
M7:%@"+>P$G_C,OH4$F[@'(7C,5%X":T`4"B<"``F)RM%!78(R6KQO(=R,0NV
MC):LP]<(A:#Z)IV&$HPL;I2ZA?(A!70@2J@<@'&`>C"@A[\#8Q#P`2&'-"^`
M-P"@!KI\$S\A'%IQQC/U!'/@<S>79"Y@!6R@!=J')0.`'9``"C,A$VQP)YLP
M=A+*!FZ0%#IAHF1R.:PE!=<\)6Z0J1:K_Q3MP<B'52"2@&;V-@I;N(QQ"!1L
M)U84M9N@L$$.J[<S*0A_);?46`WQL4^9X`LB"G?Q002UXQT7$!>7H@`$T``U
M$`"ZQ0`ET&H!0"$7`@!2@`8($`%\`!&G909>T`-G3`%#,`5VL`?FHRU6)0</
M^0\=,0?8+`!2(5[+$(:]-XIEAPCK8E(L%)HF>A-)02>5X!,BNA6(P!NV\"ZF
M@+PO9&B&HI$WY%!'UV=;L0J(,$)K4!Z27`E"7+N1Q&`&LP9R.XJA,,'^Z@P]
M?=;3<([$0&TCP$,V%@#RZ!>UDD09P`1Z'0<8(`=Y4$/ZX05>A`$6<`9A<`6F
M@0$8\`5W$"T0F?\%9+#`*/@17.`#:'<3?$L*($S"V"%/'I$3_=((^G*$5((Q
M]7P)!89^0H$54;*WXDBIC#`5O7`-<H)!@]!!MFTP`R>27.&T5/$,`+9@W"MH
M4P83@Q58#S)9W'LIEY),M4,!>4$8X1"6R5,#YZ``0*`?1^``8/!THP($>+`'
M(<`&!M``"*`''=`!!#P&79#&74!26]6Z'^$1=9(</0`AB4(;N_$Z5WN1)$56
M4[)"&T,4)/PZ/^LF]%$*US#!NU&;9%+;7B`GC/#F>?<@D!5)A;`=C!5?M!`=
M!G+#]<P+&MG/,.,6YR$4NF$+A[`*!@L4D-4+]6<!-*1,RX0`)_"5.$;_(?/P
MAQ'P)0+P!>E]!!:`878`!CS"!PUP`VH@1F,$$7E`P%J`)760!W"P85\>$KP1
MU&_2")B@%%J>$VZ0?W>E$Q%CGWR#$]^W"H20"CF<**-S";6`"4X;RBH%*?.Z
M90"V$KL)0I<@66QR0W*"":454UVGJ6[1=:_S)<W'&S>*?G:A$J3JBRH>!WBX
M`6]=1!4P#QN0`_\)`*<J`'W@`@D@`*-@!WJ@!W>0`'80!ASP`!TP1GO@`&G`
M!:9Q!6OVKJ<:U'DE$LW>'FSW?/]SM6HB['QS5U,2$CJ!%41'PA\J"-=A260^
M)8BP4J3@Z`]&[>9109%Y;V_"O4HQ62BA8*X0_VAQ0%E406%TT0A<PAUR^^<X
MHUGFI)P1@`!AX(NQ%%-8L`"K`K)_N`$<\`1A$`/:20=`X*QW,`!$@`=M0,!R
M(`=!4"-$P"-[$/=LP`4'7*9E1R6[J15<T0F6,`ARNV"`#2ESQ3?_XZDP8;7]
M,V?C-U?UG`I1O>"SD13^I:D#]\+C*!^"9CGH'&CS*ATF<1X$RPR'X`5QL$R>
MQ@1O<1X^,"4<?A)J83"EOWCPG`%+N(IR\19+0'-_Z`Z#\4,C4`-50"I%T`9R
M@`<&HP6(K0=D<`4*L`*&C>2(?0=X8`3>E`5?P!'=50J'\@S70061Y!N7(!^:
MQ00E;%GA]1PQ$1/1EO\3<\423\$>,&,EO"%W3N<2[>%0N7"%H&-:%00(3#X\
M051&/SX_1DUF3$8]/3Y!0#]4:W%F5$1`5`]Q4D1.`D5`1)L\1CQ`B5)49G%Q
M:Q01LQD:#Q90."@H-"8F,A40,BD!+P8(&EI664X95'L.>F!Z;4,W96`8>GL)
M;0(^8T5U>G)7?`-Y1S]1;XL_1YM!/S\]1T=`0$U438-'7&^<%"ERK^`]'D6X
MN.%RY!&B1SWHH6K(0Q61((,F1<E#,.*/)D0&]:A(<J0D(OQ\^/"RA@Z=-528
MF)'"XT>10T282&%IQDL3'C[B//!")<B_5#R.1#%RI(@3+CV(>,DDA8X%6[C_
M'CR@8"#&KE_&/L@H84+%!0U.]*3A<\2"D6YRVCC8@R6&@2YZ\B;X(D!`%@M<
M$H1H@X</&S=O!$1A\D!*E"ANBJR1$J0B%2H_G,PS$H4+%X$$#=[KD3`*08<^
M&D;T$44@Y`%1>N13!:3(&XQ,CTP:5).>[U6$=-9KJ16F3"D_@G0$PH2)JYZ.
M>+SR0K3'`#=.F!;!"*E'=DD^S*RQ0.&6!:$/",1`\0$"@PK`)J1X\0(`%RM7
MN##.$.5+7CU]=/'$"1'<<8<>!W:!AQ5%K&#`&PCR8<<5>51HA!HG*/"#`'EH
MIA(1K215DQ%/F0:::/<X\=@AJB'2D0]`&!$$<EQ$_W%$33QT!PDEJC`QT@_Y
M!"&DD,X%8000/!#!%!WB3993)J78LXZ04IC1DP]&A.>3)3S`,0`7AR!B3R3S
M`,D$2&98\(`&%IAQ2P9GP#!#``SX,<$.$!A3@P)97($'#W2@D4$=6I!A:`(#
MB'$#!7L`2(8<8[P!A@(H+!"!'5G@@>EB-Q$@0029X:%;$\V9,4^.1?3`A0"1
MG?8(4X<@V8,1CQP!R1%.8)E<#T$@4$8<]CQ2T4@UJ>0;C#\`)60]R0FY"I)8
M]F"&5K<0P<@:3`!18Q$^@"1D3B'Y0$4<7L#"`SH"K&,K)#6UPH]..=&!BP4O
M=4*`$C>@``(#$S``@@S&*/^0AAM`S((`#U^D804><,@1!+X9=+--'U8(8,T,
M*#0@0!=SV&'%`$:DPP0%%@#UQ@]6$L$#$TGZZ`:N"PFD&FF/I4KKS3>ADJM'
M#$4``'(-"?NC2I/48P0_\T`"I"E9[F,(:3UXD0$M+L'2B`\+<=O$)/KXM$H3
MF)#+&A]\O.P&N_0$L8\43<`DQ;QJ>E'E`PHL$4-[%500@`D?F!!!!@9$@`8%
M`^C1110^6*>%!0`T0$0"?22P!\62YF'`!C!$D04<<[1Q!8=X?.G$`$ZX$045
M7LQ#ZBE&G.;4:>SB2I#,(V4G46^B<$1BCCH.[<,FBASAG":HJ"0`&V\441$^
M1V#_"D<1#P"`C)IFA/2Z*C`2L49C\Z`$$ZE,"#"`.\H7.\CO.[$MA5`:9$!O
M3UY$L$4,,[C'+P@@!)`!%B(8X$4:DIO#&Y##ARS030T#D(8>R'"'+G`!#`F(
M0@MB$`0XP,$.8+C"/8H`F=(=XA&N\,(#3#42HP2--#.CQ$AB)"Q4`"D18FI-
ML)@CD>Z8;Q7)*F$3I%"5!ZPA"FP@0Q;L@!T!X,$_9+B"$R@`@*%<HA])(4A%
M?J"]H52&.6N0&P][\`8NJ.2&1+.$*9K@!3IDX(Q:>8"\#,`!?55@!P6```0^
M0#=0=>$+D[/"&Y@0A#S8X0%#4``<')"`!,A!#U_@0P(Z_^"`()S`#`.8`Q[2
M0,0:`:0'C\E,#QZ0`1\&82K*04ALB``[[\A0$CA4UF8F,9`FU.8(/B!%(FR(
MB,05JQ2#>*$(L36'+ERA"W#@0AZLT(<[)"`+L.$@8\RP"M+`S@?KJUY-@A`'
M.L0A)B'C2&]@I(_FE.L5N&@?!<KC0PLT(0(<&,$+:/""%`C#`P@8@!W8T$L,
M)(`-48A#$_(@``HT(`)7<``&''"')'YAD6TP0`V0$`7QX>%L\%@(/`3P!CXX
M00-HT``/!.`$)N#*:*^J"6D68J.(5.1W(0$*B(A`CYR<+Y?TX$UOA)6V24RD
M%$W0BA/(T(8!4$$`>=G#'3+UAO]_4(%-:T@6!P\!"2)`AVA6(HH4CL`'/#A!
M:<YJSCYF4L:KD"R-/J0"!70Q@[(&H`(>\``4$N"G/(R!#'K0@D_=T(4B7,``
M=+@#(>4@!_SHP9X70$$`<$"$A;PA-HF[JA=\,``!\($+%D"#!4H7#X7T#BDD
M<H)F-9L;52`D.YP(%Q`V`Q'SW>QF[$J2*1`2$=G0`0M(>(`<!A`'-P"HD`D@
M0^@&\+8'7.`!(8&6/7[@G&R-%G74\4+SV)"N0S@K"-:ZS$ZVMR8V64!-:Y@6
M`5:@@K)^``3N1$`'P#"'-.S!"N;X4ERX0#<+6$$P&&B#%=X;@CL,808FH($4
MTC`'/LS_@2$W84(&FC"^-[A!1B$RPJIDAQ2#**]UG6G-:2:2G&PA@D>X@HKY
M1%/:E6UB5D:#)@40H(0@<&$-1PBH`SIP@`ZP(0]XB`(1+$"`"]!A-XG+&1,N
MLHJ=]$0*/9A0'8I*FY,X#7Y3,>,%:*$F.GC!`DO(P0Q>4`,3C``%7@@!!L@`
MAR\0-`U^<<`7V(L$*4"0D7<``P3K:P$8F*`&(H@#PWJ:F,500`K7<0,XA'+-
M)IB.E+!346O688^GR.RC,'*."H$"$5SY[K*IQ4@M5Q$$08"C9-`,@@`*B0$7
M="`+B>$##]BD%2`@KA[$&NUN]N$%E?5@8UG@0ZJ,!=TCRVV'_W$@3P3^=HLR
M&@`&*##!#$;``0D(8!L'(D,"$(F'15Z!"@AH@!/NT`>")J"@BPR!'N:PA1K4
M8`D!P0,>8"R`'YBSBXGA01.L$X$S4*`)-]&.BA"3'4AHQU:*T.R-1FLTH,Q:
M).93B<`[G*,D%:4)3&J*(F1IAB;H03`KWH,`/-.#';.-'SE:FLI*,0^=>%0`
M"+&#%MAP55I'EPH\;,(^Y&6!"RC@`IV4EQIBH((/?(`&*MB`%/1@!0!I00Y#
ME4,'.E"'(9P@"7F`ZS:F<5`7$/(+(N#;`C*`R0H]E`GG&4A#$U*'+CS@;_W0
M+`],TQK-QH8I9K\)NV8%%),D@EN)0_\U<W($(B/5JB:XNFJ,"#&/6=+*!QD`
M0!3>NVP]A"X*'T&Y3F+"'52J&KH^F2(7%38`?##'%$.2JLJG90%QDAH70AB!
MS<OR`@MT`0P!XD,:VD`&@6(@"DF0@!+JH'2AMD&O+NB#'HP@6!G4H`414(AC
M!\"#3JY0L^([+#UD4Q$FI,H)#<&5:)Q2<H`C*5G_P(>N<A0E5')&(2\;NYZ[
MV")DH<((3"#`%`!@@5"^(1U<^(&/>X)R*L2H(4-REA28`*1D1:$.5C`&;N`#
M3+`&X/,M0X(20G%=9Z0F/J0`,%!E+Z`")0``/`"`A,`#`&1/=T`%:/!R8]`&
M?[5L";!B'1#_`@[@!BWP`J.W`1F`&&03!;2`)43`$(2P;I#P203A`WUQ$\G"
M&3F3"$TA&T:S*_WW")N0"C&E$HRA`7%`!`#8!6M!*WD'$6E3#]-T`4(@`0TP
M!5B@!&@0"4+(!4!@%;%@"?I4"CR&)*-U/C:!!UHP!TMQ(^X"$@(1$5UC%1I`
M`;9P7=<5!B,`#";```;0)D8@+QEP!,:T!UT@"Q=@!EJ0%QT`.26(`9:X!VE@
M`2.0`L2``@306(4!6100!$[``R#C"I7&?4$0"53`03:2(R22*A<F$H5F.\H#
M(LC!1TI()..!!DA0!@0`!Y0H!_W56`)@0X2@",F1'D9W`ES(`4D@_P4O`R25
MQ@[I9P`#!@3[=Q'&0D4LHQ)&X%970#HRXAP^X0/0%PDX-2T9P(?N<Q46$`$G
MP!XR``(&H`!"H``M)UEU(()S0`41T``7X!]ZP$B0TPT.(&9V\`828`(!(`,J
MH`"=,4EVP`5/:`2AP`4\(`6S\4E$$`4\8`BB8".M0RM#<R;LD!B*8038H1WZ
M8!0C<2:R``5"D`13D`1IH0<AX`U=4#8@R3M1D13=PCAG(`(<P`$GP`%+X`6/
M50G5\P/7D14&:"U\E`@]QDPJ81UP<`ZF$PDZL8HJ\7B%P$GCA!7C$2@BH$X!
M8`#JAP4?V$3EE0!\<`%($`,:``9DL`<=@/\!=X"0`M4&7A(!<[(W.*``C@$'
M+[8\0,!15`0$$3$/1=`7VQ(9L\)!I1$$6Q$!<5`'7X`\+S.'J7(CV1-::V``
M8K`%6]``'!`!=1`Y&/`%>,`0E!!+CAD)JL!)`'`&8G`"(L";$F`&1&0$4K`&
MT)5+;^.$%]$<W$$(/+0*(8,'4I@'.($Z1K&$.)53LQ`!,*<5&1`'&1`&)[`!
M*@``"I`$0@`%"(`&#W`%<I``7!`&#;`"9O`%J!<"XV5,"1E?<(`'5(`#P#`?
M*E`&UJ$0>A<^^#`)4%$T[<!1//`9'&0Z%"560Z`$0D``=8`!8$!1GU&9\&`K
M,Z(5.04%J+D%$@#_C3RP;`XP!NG"*UOC!(H@+B@W'@!0!D(0GRL@`B*0`6E`
M?"SA8_LG$R\!"J9@"B8!70B1$'904'-`&_N@,E-$--ER5$M&"^Y#`5K1.#@P
M`N29F@WP!$*``$YP;3V`!$N@!$YP!6O6`58`5X7D`&!@!W7`!6I``RD``O*!
M`E#P`"HR"JZD=Y.P#N#B!(D!)O;6%#61"T\@!DL@!E@P``>0`'F0&#>R._#@
M!$`@-1:P!@$Y!5-`HB*P`@`U!LCDHLG26_ID(U)1@!E``%4@`2UPHR(0!E:@
M!5&`$4*"&910"F;`)"#!"$63(T=`.D'&!G<@![(6''ST(Z-5)`BG:]HY_TY:
M<0%B,`(T@`">@I1*B006T`$N\`,(\*UV<'H)X&EMT`9RT`U[\`5V,`<"\``W
M8`)V&@POL`1C!R:I41.C=7E)HZ&:I1!=9*D/H`9",`1)L`0-(`$6(`VD<V"*
M$!O!TRTL00<`(`&HJ9HKT`)(L%&#-@A<,`>;1$I14)IG0`>CU00*L`5(Z9MS
MH`=UD!WBXP1L\"=4M*M9-%VD(FDL:2MYP`8"A0??"%U$@&^5-B[4X1)[N&OC
MI"89``4C,`/I^:DPL`(K(`8`X``'0`4$0`!AX%9>YFF2<R![0`;J^EA`8``H
M,`$@``$54`,`L`Z7@"1<DZ^T"'(HEP\P,BX1H/\&!F``2/`$22`&(@`%;`!J
M21$1G$%3^:`/9G`!\'FP*P`#,;`"!``F3($*>0`'LL9/%"4+/6!U4>`%2\`!
M+2`",&`&9'`X1(`'+[8';4`(EI!=?$8=BL=_@]`.YM4'=F"ISP($0JLZ,IEK
M%'`!9>D^=$`!,3`"$8``CQL#,0`#(B`$7=`'&;`$$@``<Y`%9X:"AG('6M`%
M75`'7^(#&@`#Q#`!'\`![%"K<:`('.D$(+(*2A()OJ4&`)`!XG$>52(%&C`$
M3_`$4R`!OQF;#5%VID$2%?$M(H0%#7`"C]L_%D`$D5"2K4,(43``>#`&;/`#
M:H``;M%8$9`$*W`")W#_%WH0!!:PLWF@!U=`!+EV"V"%"42A<HD#"5$P(0D`
M!Y8*7<Z)-H5`%%2@9./DCF>4`4D``QC%P#!P`\XH!'#0!09P`CE``%U@!6W0
M!QB@90>B!UE0!W5@!]=1"&=0`P%0`DY['8UU!`&Q?SQ034P@0JDA"V%P`SB@
M!L!E:I``/?S[!)Z*!E75164W$`:<)/D`(AI@`+&7(=CR$RKT0G_J6%<P!FO`
M`2H@`1GP!G*8`54@!AS`4%\P:G/`7#LJ+N0!<]:E)K%`%*F1"ALQ!@DP!AK9
MAE.DAFJ#<F2T%0I```I`3M=E`!*`EB+0`C?0`B)L:EFK!D;@#0_'K3LI.6#`
M_P=YT%AO$"-4L`#?90(X@`#SP`D<9!0"(`LC)`4<LH=GT`(-H%Q1,%J9]0!5
MX+^J*0(`4*XOHQK#8CZ;(`E\-"ZP,%PLLZR8MW!%P)ZT10`4L`8Y8B3:<Q5R
M(PD/T%B8!#4L?!5G-$Z?]P`L4Q&KTC")A&^HD#,Z#%T[AA*<A+2WX!(44`:]
MT@*0>P,+$`,W$`<\0`$$8`!<((+5%@(NX`*&Q%-VH+GI`I);P((`,P)6>@$`
MX`-S<`1X<`4%4S))IP6:X5NQ9#J?1'<7,`1+0*(<(`)(8,$W<@]"`Q3+.IM%
MHS803$4L!2.5YDKU<`]PT`9I\`;0A&L^1"HQT0H[M/\&.*4(-.4#6M%Y0TQJ
M:\"-#54'[#D'ME,/61,1%Z$V%R<>\J(!D(U=$FD`.+``"U#9,%`&7>`#%X``
M!K"5KND"!^`"=P`':0`I7OP&7:21=)`#+R`#,O`"-S`%#=``#Y`8>3`'0;`&
M/E!1&40Z#`$R-Z2_"$"FFHRC"H`=`Z%9L*-2.4$)U"@;622:S)$XND$%,_44
MR1,01Y!3IKQRK2!@:I`!9>1DB2`3FK`/U-6`:I*IV#0`=3`&=U`'^S8)-L0)
M='V_?-C>YJ$!`C8`<9P#E;T!(M`$#B`U0X``8!`-*V;3!V"L<P`&F=)8B,$0
M1X`&]/@!-;`!&[``%T!H`UC_KZL"<D:CNXES"%Z0M5C@OQ)@E(7%4:E1$%D2
MELZ9'(P6)NRB-MQ$XX-`(A',+3W$<@WX`$%``2O0`/6;%>"D%3[,/GR8%4P.
M!&]@!PH#!O%7&3%5"F="*JW@G>W(AV79>=LS`+\FQPLP!0_0<ULQ!09P!95H
MB2>H6R*7!H61!Y_Q%#Z%`S4@%L9``RC0MMER4NZ@-DT0/"95J$;@!?2KP"7*
M`<8,&46`:MTA<%]D/EL34\G2(Y@7),#A'9OU'3K1"L0A+V]SGDEN"V%N%6HT
M+TG;2=<5V&@,WV"@36%BSUJE<L-)+1&@`+PNO!GP$GAP!CA0V2?`!IT6!08P
M!%OP_P"=9HD)N6)Q=05N70=L8`>=P04#P`=1@`7!)@,FT`*BMP`(8`I24`1-
MX(!,9"JI4%@.VA0CTXYEL,`-H-S1YQM+*'"Z`0_90AJ:A6J_HPF20!E^)ZB-
MM2J'11"#AH3-80E@%=)_XUM!3#+N"'.VX&3V4`0#8`5=(#J)8.M.8W'\\'59
MF\OMZ&1I``4=O@!#4(()``1H4`5G\`8N8(DTWVG79L5DT+UUX`:-98QQ$`-[
M3@,*T``U8"F61X9TD!IT0`!MDLTD-1"I,`F8B0!"8`!U8!I4:.^U)'!$R*)]
MIT*I`$WR4,_G)ZA](3X#4/!I/SXUHLH])C=RPTE5NF2^[O^.M$!.<8`E&)\%
M6H`'BM'QE78FU"$(())34\J'>Z@F75`&'+X!9Y``&-`'%F``98`%43!T&'""
MHMT!TS"N&"`'6N`E730^S$4`"_!FKZH"#6`=/*!GM:I@5]4;]/#II9@0T,0/
MKL0%3O&*IS7C`@</5(0C/6+=JU&<D?"#2J%9[X?V$X?VV*$41G",B&</N=K&
MV[.'%R"\,-=ROF[**C,Z"A*^B!#XC&`J-2$>F7G+5!J\8X`%EKT!:"#:>@``
M2O`$$D`%HVV?(:!EUP8(>@X8(0E:=6]13FX#=7-4$B\F,R@T.6MN0$4"13R>
M/D!./T$^1T=&1D5<1YM<0#P]/47_4:E%MD8]GCQ&1["QHT$\3D>QN+$\/Z-,
MI$8\/KNHLVY1;P)N3@+9;EQ.PT4]UZ<_/+2G04UF#P\4%Q<4[Q09&1H6:T0_
M/7-P>4;C0$1,`'HQTR0($2IFXCS(H`````49XJ5!LF`#CC@A#H!!T&!%@P$'
M7+@(X:*#GI,.1A[`<*4.ER).N`RP`\>(&A0F/IB8!*"(%R`"C!!I(H4)$!^I
M>B!%MFL8%S<]3LF*4HQ5+AY'G#Q3*@5@$RI>FOU(E0P4$&5$2#US\J:(*5Q9
MN1W9QD61J;OB_AD1L"C*-Q],T#&,D,&"!G:$'T@YBV<,&S?$?!"9W*1R92D(
MU]!Y<,&A_P(*A-D\J=B@RX$#>1I8S.`@!"$7*[^0T=.!A>T.6O!\*\((3YT!
M/%;,R/GA0Q4>#^C\\")ELSTI2'\P*4H**UQB/7@5208+E60FR^*LL6`XCA0O
M#RP\B,-\<N`F0(`8).)C;)1MW_[M*M+L%"ZF1CA!2R[Q.3$`-=1,XU8/3-"A
M06$/PE-/,`*,`08<;_02A'Q2D,($%6"9L89F%"A`@`(10`3'$QLL```&+'0`
M!`<+B%"$`QT00A(&9-QQAP.V'9!`'0(X<\0;>?#A"!X$C/"!#!\$@$,#2P`@
M13_-K;>&.@31X44P_>3B0P_X^#=.=D;$005X4D00!@`$%&9/$_]>L+?,/^`1
MM2&>O#0#!#&C$+%?,_\A4Y\LW;B%RR:SS+5-%+34U81AY*D3SP-4!&$$'U9H
M,<!?/P!V5!#326'J>1J8J`"*&L"AQ`8Y8.1"'TQ$0($!5"1PFFLY[I&`''ID
MY``8&::U5Y)UP(&'#SF\$,"3)7RPP1099%,$$0NY$X\&RTA6E"D;CGG*+JS`
MA`T77E"P1!5-&-%6+U+$892801@$'BFC+#:.9.%ZDI4B?5YU)BIE^8`45/V8
M8JX;;V3H0V:;/6B!FDP4`4<6>431BR>!'C59O>=8D&($MCZ0QA`;B#$&2610
M$6<$/Z1T0`<=A."`'GW<L0<&-W\QAS__1E`S$QM\<(&&"B]$"<$,!E#0!!M?
M#!`$!5O$P$$8&CPPI@\#43$FFJS<->8;;N0AP`\78#'%!0)T\9L`7$CG0[WU
MH16$J4T0`811/^Q-7ZA!<'>$QJ,@)5E!/.P=A!G0^07*AOA$=8U\`)EA!@4/
M%O:`%S[DD08?3C03RS\`26'&/TTPD0YH*,K#1A(;*"#2`7!0,$42%*010@<S
MAU`(SGHDX$`?8'S1Q>/D9#.3'7@0P0$*Q8&`@]9.X'%'%STH(,(""ZP0`1,!
M\N"%UUA%P<7YZ),]P($_/`!`%5"<X<4<8^1AMAO\S9U6?:2F=1X5>NL6J;J3
M./D`H0=.Z,$__W[0B8,P86YY>X`]N/`&P-SI3!H[3U?T-AAX;"X*<\!#Z-!T
M./``$"Q$&0]H(F"!#+!!""OXP4@ZL(8&J``%4I#9[G:7`$$DX(?7LP(8>F"&
M-15A``+(`Q[2D`8!/.`&.0D`"@#@!COP0`!S*$(3'L#">W@A(%Y0SV1ZP(VF
MN$$``\`#'I!#`"@TH`%"(,`1K/`%./`A0U&A''CB,Q_+I"YOJ#-4_P(R)@,B
M\`@_`,ADBD(>*B!)?!\[RBYX0`5U,*$';Y`"0]3P$,)0@0MX>$EVB,$$+]`'
M"%)8@Q=2:`'04*"%:2B#`L@0D@108`4H&`$?",$"0N0H`7W@&082`/\&-F1!
M#F^@4QQ\P(<\P($-5IB#&XCP!.@%X`4Q0,.?T`B$R@@!`1;XQX8^]`H>G!$(
M>5@?V03P!B!<``%#$,(4WFB`(@2O#T3+D!'J,[<[X2D@1-!@6J9SCH&8H52G
M/$I4FF&6Z30A(H[,PP_,\+%Z<0=;F/K!`/J1`0,8@``$B(`&F/F&T*&B!P$-
MW`]2=X[5@30>%("#`."@!Y$(8`@+F$$.Y,`SV.QNF`G(T3"U`(<QW&$.1I""
M!;R`!S;@@:9SB`(1-,"!&N1D$@MH`!8RT`0G!`$`%)`"#X@"D"`X(7$^L``2
MT'`!,Q@H#T?(0!60L(0DB$$"(H!"$?I0LP3_[`$,<PB**1*)K[NE)0A4,,\R
M/M2#NU%!"E]9Y3W&D8PSQ8(H3;B``IIPQA]TR#T/!`(NT!.')@S`#3^@@LA4
M=0$JF&T5N`B56>9FBW^,9V2:K<,>OJ`'(3'A!#3X``<2@`&A=L`!/_0E!N20
MACI<00]C.$(8'S`'+:2A"Q>*@F@I,`(3!"``,C`!#1:0!`V,PI1,>$<IR/.4
M(M`A##=`P0*@X(.X60`-51!"$K;0``Z(X`E4N$-0D>N`/5RA+;-(W"05UU*C
MG.,5WO("<P"ZE;X%HQ?R$1$[B'`-5)#J/&O(&SYXH`$Z^*`(;S`"$,S`D!-%
M@`Y.R$-)FP&R^2`E_[9K,(,%&H*&"'3A5W?H0!\R@(,:!.!%&$AR<9$K/)$L
MMPMXZ$(;TG"*\;RA#D^U@A7PL#XN8`$G)0BS%)%``#2(U0E,`$`&NI`'`)R`
M`QE()0`X$`,HK.$(F47`7*<@A@9(P+\-4,`<B-M#7\F!#7P)'3YB&ZYSW.,<
MR=@;B,SS#WTA0SY82201-J.`"T@!?[B0BS,@"R9+^D``VHU#1!##523B3X'Q
M^4>F=`$$+SV```9``!KLT$,Y).`.".AN`+S@FD'4#+F^$DD'[N"I.A!U&&N@
M@$;S8`<M?($-U)[#$V<`)1`$8`93BL`9^6&!*!CB`0VX01+*`,\&F-D-5/]0
M@!"6\(1Y^OG/(A`!$IB@!YZ=!(AP@$PS.%:WQSVZ"<DX!V3IT`3`F&%/\JE.
M/^F0@1YC@BIGZ>=7BH*4+1VT84!8R#Q*I``+H)@O1S"8P>ZF4@0^8ZIJ4(`:
M!+"'/9RD"V*800!JX(:2)/G8?DV`[S#`[#0ZY@W+R0!0YE"'++3$#F3(`@^@
M,!P3@"!:XH7"`/2!AS?T>X@*D$`+<G"#%HC!#)Z@`!1$L(4G]/F-?^;`FP'P
MXP[\D,!MP(-_G!$?OL?GX,EPZ$'HDU)%UNLHE(O#K2[@!;CUPRL@0DBFC%!)
M+['%!Q2?!T,`$($F4,,4L8[/5@PV<&S92@$"T,/_CQ(0A0T$H`(W^(+OBCW,
M/O2!N,,DPQCXL$0H#^`-00"E'>PP!BLXA@QV.`(:<'`#%<C`VS*0P0V,,`;Z
M=4$/>X!#$<R`TQ$L0`(7V%`/'E`%#B"A"OP5P]L;<((3-.`(P=M#'_2@A:%2
M!9&'/5Q!`"^=54(8<D-!!8`$,D=!!;>2`4&`:@)B%O5"!6L0!T1@!*05!T#`
M!9342N]``)RG`60T#GX$!/AA0:3B!710(A<P`+\6/&9``Z^7!#(S,[?W0\+C
M`,@%!ETP?%90!THR`$@Q!S[8!405!6CD`VH0!A30`-X%7A]P`T3P5$UG!63`
M@PJ`!3$``U,0`5_B`P/`_P5JQT)J<%=O!'<<T``:T`8)8#Q6P`:W%X5^D4BI
M<Q[^]SB+A1GT41<^@'!#D3>3`1`!801!<`%GD`%$L#ZGQ0-ZTPQT8`%T<$"J
M$P?F80M!H`X@%5(EX@6QH$"@8`\!(DI]\R&*!U)\D`!D0`9:0``SD`(I\`"G
M$1)"I60Z,DQ[8`=\H`5CD`9:(%$@Z`ACD`5(%05\<`2=D5DH(`/?%0`T8`#K
M(P!?(`==$`5K4`53L"H4H`Y4P`,#`%=7X@1F\$Y(X&<-(`(K<`)#0`2X42%7
MX&MZ($(-5!E@X7]ZTS<'(6%&X6'0L8>1%&L)@6L6@`UO501'T0]QH(C/P`1;
MLO\&4O`4/:`9(X,Y+&16A!4$:R!^IM!8I<-B$4``>$!_5B``2#`#WN8$)+%#
M,U1<-$,S2?8K9'`%;``&:8!$?,`&=9`&6<`&L\`'`K`&"C`6$I"$*?`!,9"`
M`N!L=A`WJY8!=%!)03!8IS!8D8@%$O!&)[`"X7@&9)`&;Z`%6E!S6L`%OZ!P
M7R&`I#(FYV4Y'5)I!1%:%V1AZW`&!D`'`H`'`L`'?!`%?9-(XT$'I-`$6V(>
MU>`3JO8.6?,.5*!=J4,$9C`W1]$W13$4Z`$:=O`%3>4##<!M*M!;/M<!(S%,
M@\!D-'@`-N,`I)@%5N`C6L`&7?`%6?`&7,![/$`!1F#_!Q2P`-Z5`C*``@10
M17:0!G8`-X]%C8;).4.!'8,C`'20!"UP;R<@`L=Y!#H(F7>0FFH!"A\24&!Y
M%H#3CO#A6%Z1"]D9'_'"&6&```_P!E=P!5UP(*!PAY6WA^D@04(8!>B0'O2P
M$!'P`(@T']5(.O(!0'>S)1$Q!P/@-;<4)2*``2+Q4SG2!\`23`1FH"Y`"&3P
M5'(P/')P!:/9!KNI)%P0!SS`!T80`1O@+`%@`AN@!'3`99Q0!(^U4D81&$@A
M((,C2FIP`]_'`1RP`N#(`5*PFVR`#$Y0!/,1'Q_R80$1!89('^]13J1F*OP!
M':GC!9N7`0_P(`.@,]!U!'0S_Q3)D3JI-:7AI`@'D8@:0`\1@8`_FCA2H"&D
MT$WUD@Z&H0%L<`3J4`8XH`(T``"K.$R8N0=D\`4"-I(XTBML$!!Y<`=7H`6^
M]FN?8S\"("A\X`8^,`0X\2P?H`)6TGAX]A5F41;ELPJR<"U*D`,M@`5W]6<K
M`'[.-`#+,`Z[`%I-<&GUPA^)LR$UEDBF0P=_\PP&2`!8``5;\``;Y05I`"QZ
M@&ADHD"-6$0/HPZ;\P/:I1[I01X0@G9G95'>LIB!,1VM9`%I``2OI`0XP#VJ
M*!)^E61RH#.$0)(\$W3$,Z7V=`5C0`8QF(/K(TU<,)3)(`0T@(HRH`($X!<I
M=Y3V8/^/9S$XH-8-(4<`%&`&&G"14'`",$"&;T"3Z2D+_Y&>*C<F!+.'C188
M8!$0>T(!9:`$3RD!`.`$79!ZM2<'8Y!BFI89!W4>ZA"1M*`0S+H0ZD"!'88+
MW00BD#4^@;$.<"H%`&`!3X`#(Y`#/%!+OE)@>X`COB,\OR0'8!`\"4!)-&<%
M77`%;=`'#L!<:'0%Z00'I_4(,1`EQB@":R"64M`WH7<6`0(IMM"&?%@J880`
M2+`%0F`!0QEQ6"$5YQ`0B8D4B#0=JSI6A3D4`T6T2R`&(G"C'$`!;3`&O$.#
M(7`'>G>'TQ$B:T*0BMA5KA`'FZ$.BJ@.30`3LGH.CV4Z9C#_/HU)`74@!0J`
M;CD5`WEP&GWPM#?SBL!$",-C!5>P>F,098::!5I0M3V4!6A$!G.0![5H(7-@
M`#-0'.(%`'&[%ZN`%P@D%ZI`"RJV3VLR>4<`!`#0``#`!?MD$&MJ,'I9F!M"
M!+*P4BQ5'_.;2$>!#@"P!%O``1)P`BT0!K[&.\5U`'TP!RF7.AZK2LN`'IOC
M+M+U@,Q:)Q(D6OA'G2E41`A!GW9`!.C!`2HP`QQ`2RZ`7+X[@W='$C=S!5_@
M*Z1X!Y/;!:))!FW0!F!P!;]'1VR@!5O;IUP@`C.0-"\@!CX0$T>`:JAPQ$=`
M06=U)%S9"8'23^1@!&T4!\"A8AL'_R9WZ!5$<68K56/J:YUC(11K0`!"X+@W
MBJ-<8'M)YIER,`!D`AB+M`8"6$H*08&A@QE;(D&FHXA`\'FD`B*!P3C3D0ZI
MD@>SX`4T@@)#(`>G(3PDX5=/2US]9G=[<`=?8'MZT`9RD(8Q*9I@0`87$F6@
MK`59`,-SP`9D\``;8`*2@`)ET`0"4,1D\@I&P`0_,#B=D`I+Z2&FA$BA\P`(
M``!1\"GR02;CHS<'02J5459\-#?)`$#ZPZI!4"<(D`1X=0(Q@`,P$`%P(),.
MX)ELEG(@0YVE)1EA!(&#X[JC2P<VZP6;,+YX0A0"F!:&J0$$D$9%```;8!$*
MT`<E$1(EH?\'?2H'QYL`L%%[_>979*"U<\`'NW@%G\RR71!,=O=O;#``6C`'
M$:`"-5`<*@`SB[$W]>4*9R$F1XP*K]!-BE,$/D`!"$`!48"8P<`@JRJ'+'5X
M!K-`8P5X`;%%(KL%?P:Q,!`#2A!*1O`%)K&;*D8*?TR""#?-R4$%9,0F-LO.
MS/H#+V%AD!=Y8,%%`N`#&B`$"^"_%F"@O'-<>@##Q9?#0K<231L"\W<'"]T%
M:6"A7_#)5I`&8[`'(1`CCIP%`V!4=E!-46("#?```1'&2I$61T%ZQ\`4H9):
M\+L&G/=)`CA;9]$=?IBM>U(WDS$J@/<,1F`&$3`$?G:C,``#-W#_`A/S`&T3
M6-5*JW0B(@\4INM17\Y`D%IB!J,K!0E68_'X@*H4;0-``5C0`#`@`3'P`!GA
MF7]U@Z5,BF2`(R$A3"[P;W'=!J`,!MRM@P,PT2MQ>VA-7'>0`;))C#.P!`\@
M**&"#E1@0**="Z'B#+O0-[!P:V;`&Q<D'[=\%8W%V3@]"GMC%(!'-W2`M_TE
M`D-]`S>0`V*0-<E`#6<EI![[L7^\&;C*LWJI&:W[@'1`!^0@'>]XAY@A841A
M`7F@`"T0K@N``Q90,RZ0`%8@FEIP!Y_<S2DYH03F`&TP//-W$G<@!Z#\!3K(
M!0*0!30H/!@P,P[PG%P``#=0'#)``Q$[_P5/D`&3],:R`"@&]$`JAA3;(2A*
M<0[M(A2:(!VFHLS+`%G@(2@\D$J3,0IXF&,9T*MB<*/,E\TW8`!GE6AY`!7Q
MD6/4L9A?D1P$H3?HT+KK`5ET\@!)&5#T$0OA$FE,\`!V@``+,`(XL.D$4'\8
M``:E+$1Z8#QXP*APL,+#%.3$A5RJYR-M,.,`FD10=P?!LSM]D-&V*``*H`)H
M^R12M`3D,.&"0A6&@CKLB#BL(.(/DZO/<#B0=1`AUA644R_9FC=T0WGH@0!8
ML`52&0,KSN`48,BY``X)]`]QP#B(CLQXS!ZOZ@,WNQEB!03BD19KTFB9G4CI
MP`9HD.G[C`-"0/\'.0*\UB;#:7A::71=-S,;.RZ#)U&A:6`_Z,L%5G`27P"%
MH-X%<J#)<$``.#"],E`".P$#=+`-_S)"A@(*C'E0^P./A21Z9]*)TEY*0[&F
M]AA)6S'-JF4`?-8"J4VC,1`#%E`DIM+'^4$$JM05CF;LO'U0N6"SYZX.7:$9
M"*=`>^A'#^2`71!L/SP#,=``$5##66"\%KK0B&8@,LD&&#!_!BJ##&_CU<<'
M=F`$F&($PZJU?BKD?#H(<Q`'SS,#-5`#*G`"%-`)%6,-QR!;SD"=>')8<+M/
M]>$OB3,=.;TA@*1(]G@HO!`9%G`&2C`%53B&JLT!00,$XQ,$?D'UXV/_[0#E
M%4M_21+(V\F!X7526C\0%.IK+WF#K%=@`$@C`S70`DH@!6PP!F,`A*0LY%=@
M!V\P`'7-!D&5$0^ZKL!$PUD`E^OC`X7AFCFL!8+`XS9H:'=`!"=0"2C0`DM`
M`6SAZ.;S#2=?%ICF:)(A.(]?#(EOR_>N^@!DCV=2+D(!"!%#0A(M4!$*9P84
M=4Y!9E1!444]0$124DQ$04%,34Q!369T9DP]3DQ29AD9#W1T:VMF7D1O13Q`
M0#\_/#P]1ST^7Q0Q(S4+%$5P<F!M>GU[>L]Z5FP#?%E=;7TA'0X'!R$)<E]7
M77-N/5Y,N40]`GEO`EK08WAX;%=M<FU!4RHP_X8HB$!D`(\?I](=].$C"!`>
M1HX8\4&$AQ,B/T+MZM5CHH]=/X`T`6*D$Q$B36B=/.D0H9&70!Y<0)*D3),@
M80P\<"/`"1`J3'Y,JD2$B5&6J4")(F6*BR4J#RA0L/``DA=70(XXX1&*R,.7
M/7A\69,$QPLA`L"`T6+E3H(]^\C(V=.'C``^8ZY\D=/A@`L7'?2`^:+EB[4?
M#QYX\4&E2=4F1OCHD7.%CP`!\M@XNU+D"98,="Q8B!0V"D->EH+XZ&@D9)!3
M/QH&^7&D=EA0/E)OLA0;"!,J5*1XS6C4Q\'>0#0D_MG@R8,>E)K$\1*D=FXS
M4IIX;:A*2J@U<1Y0`?\2Y<C)JZPR4'#UP,*:K%RU?YT(Q,H1`@U4`+!"#9^6
M-F041L87=PB&QQARD=$&!GZ]58X58\"!QP!%>'%!!(FMX8X3>)`!UQ@"&''7
M'%<DT$$"5EA`QP.@K$&'#T<$8401QO%`T6Z^N&:<)9J0Y(-V,!;A1&LKG83)
M2&$UU(1W1>F22B:Y,.:%!F((\8`/41C1!!UQ>(=+#TQXT=AN*35!T2PJ-E%$
M%$S,\H`&Z25F@09KF-G+1AT=8>,75&QQ`S(.])'%-7!HH45>;5BAH!;:)-#'
M'6`XX`(&=Y!QA175I,&&-3XH4`8!&E@0Q0!X9+$'!@F048<`:7CX#0L'."#_
MP`"3^&#&`T0,%<6=N76"9%%2>&%&2+KT,%Q'O.#BR2=&B6)&=<!0=!,G#OG@
MR6M'_"#L!5M4\0`/;I@'WK,E401<<%*(1$5%ES01JAD]L#D:'1I0D`%5#["R
M!BT=Y1D6,#R`\<`",VQ`00>"WE/HH5K(8048#COS%J0)8."`'FU<:D6K7WQA
M!P\(($'`L/F`<8>D&,`%QAX=A.`""S##RD(?;+!YZQ%V[&K$<3\P$0=5Z'JQ
MXI-$^/"`)%GJ8B,18F9G"A'!/>1+#STX9`D11U#$0Y9!>-$$!5NHX444;QP!
MA!>R\."4%(TM204M;U>471`69!`'$#X]()T%4LVI_QX%I+@S440V3BVP,3A$
M<$<;8%BAQ15RD)$%Y(I&,YF"_-S1AP.HKF5%%FRDT<4`1%SX`!!XI*%%%F,H
MFH8=6>C!>0*R@^,"."RXX,`5;KC'QP"_V(@0'D=D$M9+&0'!"0]'>!$'+&(R
MP1`0<4#R29*<U"91C`Q=XH,4:Y@211#!*3`%!3W$DU$3P07!12BJ=<*V\UWZ
ML(84B-$IQ1%%-+&W5!2X4`0B,)K5_&0UR=N%%;!0@Q>TP`MZ2("C$@"@CLG!
M4`22AA[N(`?!R*$/&,"`'L@`H3K480YX$$#6N@:O'MBA#@/0%!_"U8,KR*4-
M"^I+S&!V`#E(P0)!R,,`A/\H)!ZD855.<$,1WO"&*+@AB0,8@`"8,(0<<,``
M%Z`*560A)J"HIB$\N`1&/C*UKL6!"49PPH^HH`8E9``(4EP:VYJ0+*X$`5C"
MVM>2V"$TIL0F-P]0@`(NI``"$"`"Z4(@0H`A/1]8804E>`$"TN``;W2P4AW[
M@NBLX(P[.(Y`5OB@!*/AR3&D80Y\R$,>BD"]-8`+#W`HE&5N<9`B#(`-6>A@
M!V06,Q?<(0]9P<,<5J<%/B1Q2%S`!Q[<T$1X""`*&9#`#800@7M1(`)3>4"7
MKK6+CZ`D"%PQ#K+`UX0P+JD)!`B#!6I1-JZH@AUWLH3_4&*&Z1SE$J.X7[%X
M8"'_;!*2``"P`!HELHN.'.<++0`!"IH@AXJEJ@V5LD(7QC"'UNT##*C,PEJ>
ML8>W8.QS7:C#"],@`!Y$@@M1A$,;]@`&-@B1#USP"`_F\`4&6>QE/.P`&+C@
M!3=T@0QW8,.LN'"$-V@!#"!B9A[P\`8C*$`)89C**^!$!U:HR`PC\06O>'$3
MD/`@3-[YC9C0H(8X2,()>B*?&7;#$&LUAA-"4TE1WD:*K/;@!U*HEU0(B08%
M>,$)16A-2[C"A"LL8`(C<$-;W@)1*YBC#JED`R=)*,4L.$Z"$63&%;+`V8EV
M(0MYR)H3Y!%#EO7!"G/(`Q_LH,)<%($-"7#`%^:0@!V"_\,*PGK#&!)PARN0
MU`A<2(-$!<`%`<P!#@,P`@$,@`@%K($*L_A!W:22@74AI'`[^Q$0PJ*+=H&3
M:7$P``$64YZ#A$(X1W$(2CX!!%5X37[`L:=QUI<O`$J%``J@`_]:`X3IL4\+
M*@#!#=@`A@CJX7%S.*$4!0`'135NJ8VS`@8"XX`]D.,+EE*0;V.T7=0QRE0D
M#*D=5/N[-_27"W.P0Q<8M$-88:`.:4B#'O;`U"#$@0I&R`-KWW!++:`C`UA8
M`@<4T"4JD.*:!+@`:"*1FZ!DS2@6R=9ZB_8#E$@!``K`WQ-9DHM0C&DD52[%
M2:BP!K<&Y[E!,987A):>]&23"?^![07_(&($,&S@!0:`RUS(``<VV($+/7C#
M'`3P0C8P2M!]D$-#'1!;CSZCP'WH@AK)'(DO9.$-3OAI@=;"V2Q(B`>WHL(/
M[G``%KCL=C$#1PCD4(<PU8TJ.KX,'^HP!C;4`0@`J`(:E`,<"UP`#0`@``7H
MM)AU9.(DH``G7I?EOU1<HI#?"I<ECC0F3JR+.UY#"752`1SV20%&[N3;>N"4
MF,3$(4])=`-/!'"'$8S`"`>`2V_M,"$>9(<'>4@Q[)";A03HHV(6\V@?)!C;
M-O`A"E)X@!'@@%&&]%D+`UK=%UI*(2I8U0X)T%U?2LU#%^O!#4VP0`34<($W
MV,$.<TC_0Q:T4(<\".!6JM&*$59QS4%F`!)?_9'__->07:#7$]_.B`4*:0$>
MO"$8W$X).Y27"4ZT*1-+*LJ2LK-F&=TUY/9:$;[DE"N>1'%6`]##`DY0!PQ<
M`0Q70*Z)I:#U*&#&#4+$0QL2,(:&=H/1T1BX-#``&!!%@>&77E<*[3"&+FB&
M'UFH0Q&H0`&`/D`R)L)=QV$5`CN$/`,(R(!Q4]PZ3>;A(J8PNA*)((L,1.`"
MRHG#)ZS,-E'/QEAW7%96@@`G!62`!P((2;L\H0E.--L3V4[*SMD'GF_?E0AO
M4DZYE5]=)W"!QU&4HAYP((*P2S2%NWK>FS)0YDK\P`EYD(,#_\@0VPYXHP_2
M:'3%PK$'H+:!4W$@PC,'0.\!0,.3:?!!'")@@"H8P`=:P#)_(7D\=`!CT`09
M4"]$8`>V-@!PT`7FP`9ZTB^7X0:3X!A]TPKB\5SG0@76`D[44A1&D1%<8GL\
M,`"Y@1*@('6@`'28X$6LQRRW\@!U8EZW$BJ)06[Y0@7\\WS.)`!Z``,BX`9Z
M\`4#H"=?]1/U%0%,X!,>R`59T`$N<'><HT'E)T%]\`6)0@YN``3U!`3%-41E
M,P>RDW]QH`&>(@09P`<#US+F=SL<!RL=X`8*@``1X`1CP%E\H`6G=')NP`5%
M("118"R?$!H)2!7.0WI<DFU$@!V6H/\\=^0.3"=R%,`#?*!>N.$;38=/7H`)
M7C%7V7$2X8&("V%D?<,W"9@81@</>&`'OP.$$J`$*J<%11`L#E$U<4`!`]$#
M?&`$Z^`#>6!^(=`-%M,'^^``C"9!;8!"</`%71`%18$U\`!C/+`&1U`B`Q`$
MUX0`BU`'<\=HG#-A(1"'X-`&9@`%9Y`!45`';/$HJ44A$9$MLV`&?,,>K8`=
MF4`%T[$)7I$4/=)-7$%ZC:<!:E-.,-0T7A0<P($)X<,=T%4TJM`>-'@*ZG"&
MV?0W%N`%@38K?)!*K'4'"$`'9$`&:<!/B]$+/W0!"D`!8.@#PO)7$U9)?Z$[
M!1)"M-,&==#_`U3P6J,34^\P!T-D!T&P!E1!!^M!!YK0`]Y8(`.'C!.F0[;U
M!0]P!E!``#Z@!R?".TME"V[P.SO#!/G2"K#P&RO(/F4I'R@!%%VF@JN@``H'
MC43`!4YP$YB@&N>2'4KG&VNF'2CAA:_F`X$5+%&A?*+A"FLP&T;@1#HV`'<0
M!VPP<'SP/:$'!$8Y0!00/F:P!JKH`"$@DU.(`6V(*HN3!EQ@!@MG!;&$&75P
M#GR`!]:R!A&``$.```]P!'R0!@7&#Q$D0>&(:CL4`@-``4(@!@`0!6[!!N\P
M1&XP`):U*J`FD5@E$E\4B5*W5KC0'4;Q@JG`-W%P!&[@D-KA/[K0_WIXF6S@
M8P:60`M#.2>C\0N=8)3*9YCEUB4D\75W<`0G(RM5]@,3X04BAU\1$"K*H1P]
M4$DM$P(6@RJ55&$1E(4F9S(K)TP=LS%S8"T9``!J(`1+@#Z2=06+(S%TP9M2
MN$.`009<4`4BT`#%J4G%Y08IE`=LD05V,)<K4A5)H0NR(8),@Q$B83W0]3;;
MJ0%F4%2]H(]F@%7>\3T+Z3].1VF6@%57015Q$`<6T1!F8"\YJ!C.TPKTZ41A
M=P1LX`!RD%P0T0,_9'H$`&Q2@4UTX@:H$EL6@XP2!)ISFI7DEP#.6`=6D`!J
MT05X(!,&@`4&D`0<4`46,`".94//@'XSQO^;X\A#@&$Q1*`$#=``!L`$*V="
M4D0J]%=C564WT\8.D2B>51-[[/,)JA!U7I"`YQ8%&9$1G9B9VL&!>"EUF'`M
M1'!&/U.4\<(=K.`**T('P`$]PL&?`[`'MC0.)?42CI$!%Q!`A@2M"E!TNY4J
M(!2G$Q9P%2.F5R`[%\,6!O8%8_`&%'`&6'`&=5BI%&!4A=)1D[$'\`JOY5=J
MMB.%>_``#;`"*HH'=6$-8/=\7.`4,J$!)UDG;/,;?+EZV\$L.W<2]*@B#%$U
MO=`)<7"8/_"CVD$^VL%M7@1\?*,<4C`C7!$54LHEX'$TX:$)/B``"3`K.!1:
MK2$%/P-`AC1`P1;_!V\@!Q;34.:'*ME:21B`H"/DKFM18/!Z!7;@`VBP!4)`
M`'RC!I58!YMR!711#G=0((TJ05)(KU*(`5GP`%L@`4_@!HQFC,MT&<3E!KY8
M%2\X1C(RJJNG"QE!+2WADNWA!322&\9A+EA%'`>KL2?A;<FV)"1;%1:1$5%Q
M+XEALM[!-B?A`US0!Q1B!W#0$U5#5P$4`0!52%A&!^S&:!$DA;H3CB$DIR2D
M.2-T5`4"*7C0!`;0`$*P'@/$!'S@9WJ!,9R%.=(`#1$D*:HVA1V@!0\PJ$Y@
M,2$`!GG@=I@1B$8`5NR#GDM#-2*1;"WQ1VUE4`DG4&_P(_#4&[,P/0@;_P2A
M&'OWA!(_HP&DD!4445_Q.99U$B88<01Z(``R$E-2YCQ1(4C!QKD$Q`5DD&BA
M>SLA])2\M3@3M3(2Q$G2<`=9X`8/4`4-@`7V(FP%84(C20Y=$$IR@+4;5"`)
M,([A<#L=8'8\H`9%P&@=P%1O($1O8".O*1Q6%@JEL#[;<1K6RQ!ENB7K]`:/
MX"5AH9->T%\\TH)&836F"C6:>918@POT:%7X<F/N<2OX\P-D@`?,LQ7J%0>L
M`%`UJY*V]P!`R%MSP9E^\8:Q<CE=8#(#1T&+2@T"X`4$<`9J@$T6D"X",`83
MIR".U:`;M,$;W(:E]A?=,,)Z<#H@M#M29&AL4/\V>B(<\G,3HM`=_,@S558D
M[-`SH=8\=$`+S&,$8'(380).%.$KLQ$;YR6SX4%`>A,%3@`FH:$!H5*4P5)/
M6!$$'N-$6[$)&*@`9!5L2?:L&D`%=:",HC2,M@,.(C0@^J!!?;#&M",';.`$
M:Y`!*\DBMR``6=`&&L6'N22G'308!59)]#J,Q.@`1%E3J,(Z5V",Q@0,N:`\
MR<880RD]XMM6NS!\_H->+N*!<24]O7`U88*4-E*>#F$CU-($L6`!!-`*^S,)
MC\">^%)F87*R_O,%*512UG(5NH@`80`%2(`$:/"L%_``;Y!+?,B9(9`[WB"3
M)V(I7\#'$W23$&(0^IC_OD6`4GE8NWB`%VTP.\Y`&/_1!UL;#K;3#4&0!'%`
M<)M&0<DE$73K=-I"/J*Z=&24&UWV&QBA";S`-,$!"B*Q";\1G9V0;;X"7<?&
M-H&T'HL!6!>;?!%-$:H`'EQB!:O2A6V"AF15!4J0!%LP!0!P31?`!*'#6GQ@
M!9M3QH["=Y,"%]_X*-"`61<T!G]V&Z+FHL?U>4J52\TL&&KA."83M'^Q<3.)
M!Q(@`;N5:+II!0)`-=9B%$7L/UZSD!U&1KQR$K)`1[3A!+OB@DKAU3S25>]U
M1\[#)<_B/S2G3400B%]EB/9"%9GP&PEM`6F7#DE<AV$0!D*@!%!@`"&=&&9@
M_TL"4`3?)P!4ZQ?AX#(JC7?.D"@]7;H),%&K4AZ\P"II8`_B;00N>E3,\`6?
M<P67`@9D$$+F-\)/>2(:$`,4\`70,!=WH`6YUXA%@A&D-T?`X2.\(+W0'1JN
M<&.T(=Y*$3T-RW2-P1A+YWM-`U8)-VSM*1'V,UW9=&/^\S:)0=<7H1YH@`8<
M705(@(Y)1H,^P$Q.5(UQX`:XR5LOS2`',,*F>SD=A8R,5FN#=M//1WBADP=A
MX00#4`<KYXR3PP9YJ"CB1[KB&-JDS0%$@%FTPP=YNW3OG#7Q]PF?,%A3@PL(
MK4U"<U7L$"8_(@O9`5V=.#_H4C2]DA)K9J0R:R\W!_\1MQ"E4J%-4[H.4%.Q
M9#`',8$("*`&:G`&52`$9P``V#0L>;`J;JZ25)`'?38`7&`'9*`';RK4(<"[
MLD-PN`L'0,D%3H0'.N9G1W<$QE5X8S`&,*8%FY+!<K&M(#34X7`%6(`#82!^
M9-`!;;#:QE'*5CT`;R`<8Z(\FU`M\^5EGT!II(`N$_$;;^,B^Z)]TS&^FKB0
M9"8+6BP5=/`:.Z/#C3Z#='`3C2$%!A<'%Q!L:A!L"'`&0]!7U<0$;P`'H44$
M"AUL4I!@WQD>%2L`G.,,J/*N3DX[0=6*,&3K'<F',_1\J<,H")_EAS('N-0,
M)C(.,FD["9`&&8`#."#86N#_`E^0#EO=&YQ@:Q/Q38.N"9LP/9R`"7CY-N]E
M4)?`>]M%>A`=*IM<[HEQ%;`L;AE`'0XAOC_SJ[1LF!K"!&WP!D/GRP.$!M>M
M!L*V!E'`!W/`!4R@T&>```K0`\#N%!J0IFJP!GNP:EE0((K64<48()N2!A*R
M1+,FKBVG6OAP!5I@!TQD!X>R5&Q`(+'U*)7D,G>G!W"P!!LP!0^`!PF`!R6Q
M758-B1)A99G(5A\1%G_D-FC3>J+Z$;Z!PV[G!O;V/'^#Z"J2[XE;;E(Z+2GQ
MRO)9F`+U`WK0`R-']M>$!EB`!+IV`5[`!;_SG52P7.@(``-P04Y@!AJ@N5$U
M!MX0_T$<U$&L[@!W,`!X8X&R,0?94"@1<G(#0%-DP%J$=BBMV(P<52"3CZ".
MPCE2T`(Y``A/4GE-0%1,/#Y$BT%`1$V*1(T^085`/C\_/#P_/CY,35)47DU4
M4D0^38V534V(3@)N7%QN/$UT%AH4&1D6%@\4``01N[D6I$1,5'$/S0\6O+X9
M:SQZ1``&"`0*"%!#6`81#T`"441TS0AG6&$&1VUR>4`/`&%#%V,=!RX)>G=R
M9,`XZ)!``#-)5)H(D,,0C)4L;/`,>),'C)XZ?/+4T3(F#1PV7_3L`:@G08>3
M"?;<P8`A"X`5(BQ$H>1%BB)7DH`PD7+$!Y`@GAY)`NK)9_^09$R&ACKU@TF0
M2J1:`>%1Q`F7-^5Z!)'"U0PN#70T7(@001L%"A<H_&I&IVT<=+IV41BWQXP!
M`V@`J*DBI(H!-0^`]EBC0,T%"P@,E/%&88`>+0+6`*BRY,$5#`<.8$A)QLH7
MDQW8-+$0I,@1)V3ZR=%#YDH:/@($#`"3H$N:.5VRC.DR9LR7.W>T7.F3@.7F
MDAU8"B@C),Z;GCM=%?4DQ4PR(D!^[I3"Y)+/ZX:X/V7BA4D/2J*D1%7EP\B1
MJDZBF.Z1R%.FHZ6\H+T```&`_PH0TXP93."2P5@4:"#%'5Z<$49B4""Q1!4`
MF-&#$T=$H4$90P@SV11B//%$!@+_X,&%&?TI8`<8';#`CQZ;70'&'@Z$0(8Y
M113!!1L..+"'%63<844:`\B6QV=?C,$'&W"DT8467X`!AA9UC-&'`Q@XD$`;
M5B00PCX%6>A&$&O0848H21'E2'Z+("4%4>,Y]8,I:3:Q!A%%)$,*$*UX<:8/
M7,AG1`^GR4<H?81R\H,13LQI!C`4*-"?-A<8,(0:&32C2R]FM.$%`FKTEP02
M52@`1)%.$)H!%DDH,4483W`@@@0-H/%`$6\T0P0/=5RQ!P87X7$'&&SXXV4"
M=0Q@!U9WH`1&&W=\P<9$RM)&QAA%<L$'E-(.,(<=:<"8Y6-UU*B9`WJ\4404
M/U`0P3%J_SVP1A.,!+&,%/2N$I0K3#BE4R.:+-/$#V@2BHH7#W@!Q!MN%/%)
M>TXX400?SQDQ7P]<3/1>$88@S,U=2X@Q!`$:O&4,%6W040862W`@1A)A>`%'
M.3P\(*D08C0`DP02M("#.!E`TL017/S@1+(#\,'%5#SM0<8>'3@`1AY99)$&
MBP1!.VP6<_!AQQA!?I%&T43,9@4<1TC!!QQ=Z)&<`WTD&4('+AS002(\"%`$
M%704`HP&"3<1!Q6-/)+O)(IP12\C0/S00P^BJ`)*:4Y(\J@9E#NLR@_O'3%1
M%$><5A47Y3#*A5:/2V$S%B\/<>D%&0!.!Q-WT"&$$&B0%0X76?_8P84/B$'1
M@!ABM'!#"RO$L(`%3>QR01Q$R#L'&WG`D44>/)B1`15U?"%'CVW@,4<68%R1
M@)9RJ-3&%QRE`23[;Z3R`Y!:S.%&#^-;X39+<#>+P9=1`(`7C.`&*:`C#ESI
M!1T.D1ZGM*E?V*&$,E0A%*!L(BE#><KCFN"%-0Q.$CTH0@]^LB@C;&)=(M31
M&U)5!!Z<I@>,BH(1@!"'"%1!`B)H0!*P`(`+/"`.0="#!:8`@#?,H0?':)L5
M!!`$"Z`A"3QK0`-PL``JW@`-&7`7%M2PBSA8@0U=Z,,=KL!$,\0!"%]H`W':
MD`8[M*T-/1K)'?3@#S(D*8U<"T)Y!'#_AR[`H0YUP,,8@*2''F&`("SI0`CJ
MT((D\.0(D%++&GYXB&10P0QO.@\1J+`&[RAC#8=0QBD:%PE0,($23Z&"*A.R
M.?K\P(*;\`'1G&"Q*'"AA3F*@GRB8!4N'`$(9KB`$#AP`I=MT0)K8((>*'"&
M'_3."`]@`F_FP`,Z7``!8A!!"V#0@AB<0`0C0,$&6D"A,S0`"<2(0AVZT(8Y
MX.$Y/WA`$]BPD@38<0Q:H"-!]""'.=)Q2B!I0Q<&P`-$L($,MX'#&.R@!2NT
M00]]Z,,>^D"&Y(3F!B9801.,(`5I].*'45&E%_;D)BEDX@>;)`4H3"$)H=3K
M)X_@3BM$P0FC_[3I*3RP6!&,\(:>]M0J;I"8#*/@AAE*00,(:)D(.#`%)``@
M4V10``6HQ\0'H*9(3*```K#@H#!XM0P($,((9C`#%<2@`4_8PA8,H(`B6`T/
MYR#<&BAP1CR`@2%D$,X=^I`U.?1!)'JX`AO2D$8MV&$F1P")%7JST"[(J`V0
M?0@80N`"*TS!!#)8W@_B\`L-Q$Z>B^"@*L6S!C,D!#LG]8DG*C&4ZHA'$S`-
MQ4Q5Z1U'K-0,R6S<#Z:RB4W84H87Z@$O$_<``H1A"3BD%1+00($L$*$'8&`8
MX;+0`3",P0T/$)X"MJN7#-`A`A+8P`@V@(,3)*$!LZK"`/IX!,0`@/\"!$`#
M-X;!!(5ZKP^'5,T<$Q`W,'IO2'GZ@1W(UP7>X"$-4+K"D[(`!ST<0`]8>,$'
M`C"#!A`@`UZ`QD=A:`24XL24H?#34X"BB<<IHB@<!.GB%M$OKHRB)D!AQ271
M<0C\C/@I%J.EHDR3'2+$X0)JP,(3&D`K)6"!`(&\BB.H$`4RH*L-8_B!`<2`
M!@2$`0M8($8$`'""!7@Y!K0ZKP2<D(`O]$`#[2"`&A2`!B4\00)5B(,`NH0!
M%R3'GOD\WQVJYKTO9,$)LKR::](P!CRP(0M6Z,(Z%^L`%N#A!#4(0`D^,(,<
M8$$NF5H#B762KYT@I15!B(XD'(<W$Q-A#5[_J"0$%R$*/YF!0.@9A1D'YT!^
M]:L[+CR"+4KC,!X`03]HJ`(47+4%5X5!64QX@&>9P(?OZ0&R`[A`&10#A3,(
M`\L`$,(-%C#>'#0@,5OH00+`T-XS$.#<95F"SD1``"YT(0%U<T$(QCV&DO0C
MK]Y;'Q?R-@8Y:"$-`/\6&-G`4,=^:0!#&($)2B`#&=0@!D.0*@7\5)[Q#"49
MV<DX$=0C.>R0,):A!LK&=<O:ZL0A#EY8A"K+!$I,VH0'LD8U%5!+'Z`<P80W
M!T(&$%"%,$!!"$-`PA2F$*@'9)$"3;"#'D(@QB]$!C%80$(9U("&(?@%"3'8
M@`I&L``83&$(6P@"__RHH(`+!(@;;U[!"=#PAC3TH6YVVY+^(NH/R(*!P;?\
M6F?\^"T^3(\-W6N;O/%@`0Y@-@4EH#`.SE!VHQ\B.T=9!1,RX1-'B,(I-VX$
M3$'A`Q[8RRF8R`03)DD'A9W:C/*2`@*]T!Y0^DD\H:>\(X*PB1YX(0(&P((2
M2!7T!K#+70H@0!SX<`>F"W0`)KSFM.\R;35`P6<CX/H-8+!4*9"A#7!P@LVV
MP8TD<&`%*\!"$=ZMR*CU8XY[4$F0R'`]-\C&?6W@B$3X(+[!$A8,&&!!"/)0
M!`HLP`0?$(`?H`)B\%Z\4&.A]B:O9!-&43B@``G3<11M4A[?<4EF``1'T/\4
M7G%RM"<X'51:"$0X/V!:N)40M"="B_)*V*$5E!`'"C`$N[<$0"<&@+9E:J`&
M:V`';[<':<`D?.`&=$``=R%L/8<%PP0#"[`!"[`"QR,!=`!19&0&$;`-0C@%
M(K`",-``=#`'Q=$!$N4/Z+<'ZU,^1.($<P`'!Z8%UC,S7G.&3Z(%9!`"+(`!
ML,$%%B`"*%`#`#@#.)`$?]$6%<=:H:8*1]$O([83TY$*JU83'C<G9G)*Y`&"
M3<`)?G))*(<FY-%!EPA+&',$(>1^WX$P:L`<Q,,R7-`$:F``[R4%:>``+J`'
M2J(1=B`%"F``9_`$2J`$2P`B)P`#,1`#+2`!TW?_`A<P8',0!<#`75BP!2>0
M/")01/CE`O\0$%^0?L]F!7(@+6_0`WY4!-XR`%9@!7F`!W9@!^LD-EK@``=0
M&X&$!VL@`2@@82\P`^1U`P@`%I"P@##&8JW`'H[0)JR&+RHGD$"1B9"@#*EF
M!@K3`P5R2<DT6Y88!YBD$U(`!#"D":3S!IOP`ZJG`6@P9`T0!E40&0Z"=$'0
M!?\S;GPP``46!`HP;"'R!$G0BSC@32=`*[\H`D+P`++A`[H0?`B@!`UP`MVT
M`D/P`S#2`7=@1^'8#VU0/GH`!GP@0VUT'@-@5VP$!UJ9!HAF!VP`;U*CA@P6
M!PV@`B\`@";P`C5@CT'#_P,CM!.G%%,S99&EE"_XTFFE@"]0H9"),U(=A`A!
M()&EY4!>8":X55I4X`.%.3`%102GH6OGH1Y2L"I;T`!8,)(/P%94,$)C<#X.
M0`9@U`99T`,44`5B(`$<\`2IB``2<).STC,V20&R,9D7$%^WV)HPP$U;0`1[
M$`+`PB57H#_7%RV"%04"8`=SD`=1T`0#L!%DL'<%EAL:@1D=\&Q?8`7E8P0-
M0`,O(&DR,&DH,`2)F7$:%SF;A!V5,(C8(1[)`!6IQB>X=8&6U$$+Q">:"$JH
MT`0/4'I^J3#+,'.*,'/NL5.I0`HN&`:Y.`5NH!\\<%@_X'8),&Y7`%%9X`9K
M0/\`3W`")]``?G$68H::W00#',`$`W`$9F`!6[956T!,N0D#3^`#7N(`=[`^
M6I`%JY$2_T90?)`%`N!+1"`;=?`T>\8;'3$`;$`W4:,E_.6%38"'W1D`(``"
M-9`$%@!$Y&EYIS4*ID`O#\@$!+)D?#):`5H3./$(;S%S"GF8K^8)D_1J;NIJ
M:[`&)A6G.65".M%!SZ!50B`!12``3F`%=\`'1F`E$;H'A>0`/`H$%A`&LO)-
M$@``<6`I6\`SW61I>3``HY$!$8`&!H`$.+0"W01Q03`CV0@&UZD%YX,!=_`U
M`O`#>6`'1N`)7D`H;V`^@:4;<#`'`M`%(="KA]2KOIG_`%;@`U,P`F<9`"E`
M`T.`0"-$GAMW6B.UI:Y0"@HI4P<9.6&:$*?@$Z.73*?FEV\1&',2I^0Z2?O9
M#%0P@IJV$UI:F,Y@0PW``QYQ=\CW;O^S&5&3!005!P"`7,W8`&IQ%@C:`,:3
M`Q1`)'.U7>HP3,W833>P!0^`!V0`BS)BJJFZ!VQ@/SU@!U.94Y,'!$;@=IUA
M->[D!EHP-R%`(Y3%#Q%*!DT@`6,%@"_0`FA@`1?HK.9Y)J$FK5[!07(J<HI#
MK:E6")XGICX@<\O0#-V!+^4Z+R]68Z#`:D.;M+F0;C_04&2P+$;PE8IT`+V:
M`/JJ1Q0@!$,IH@&2`68@A&*0_SP+H`!$XH)D@09EX'W-Z(LW<`(&``1/@VAD
MP!![4!Q]<`5YX*?*PC!N``2B0`19P(,`AP>Q\08G.V]/\S]V9GY6\``-,`(T
M4`,O0`,;H`09\"9)T6*IIDI.(5I<X04(A%LV@5("J9@G)T\^P)"7F!U;JGK-
M@"^8='*EE7*C$`0J.&(>RQW-8`%HP0U5T`/7)P=C,#/I6#=?$@)R``=O@(%!
M8`#HU0(B@`10$`'Z\9(B@(1BT*.$<18$<`;GI4TQ<`/3)P)A<`0!,9PET2-C
M-+A$$Q$#$`5F,!<^P!!VD#0"0#11``?$03Y]>SYV9DAD\`-),`(U,`,`B`,7
M8!.',/]3?C(OH;!RU:H>(U4(E6"Z>E03Z#")B(M)(=:/I!<***<>'N0,#V#"
MD@`*0.`$6[$)7G`@P:>*;W"KCO4&]/2K^T`&?)`(?JH`4D1,$H`$#P`\<8`&
M'("$,)`I&D`,FHH`0O=],9`#.7`#,;`":K`B\ILE%'4%`^`$//`&8S`M1D`'
MO3``>W`%[Q0+M(`'YK,E?C9(;G,2+F!G>]`#2K`!$!P`*!`&NW(*R4"M=Y*7
M!B21JI`?JB`*;UJ1B/L`Z9H(IE`=I8<O+`P*II6ZZ+"?S/!#JL`W\@D$7(`'
M4<`$4VQ<!+`0N1I(`@`';:`/+&`W6?`&JDL$9J`&23`%/;/_`A2`(<U@Q#"0
M`S@@`D_`5F<1`4&F!&+``<9S`SG0`C<I!6`@OSU"45HPE460!VRPDN9P)K2A
M!7DP"P*0$6S@4/"P6`CF9'23&9JA!\N!`C/PP"N@(&_"8AQLGZ=0)@B$I:I0
MNF;4'7J$2:C`"DE1'9@$"NIQ%*20>IP$2G:RG]SQ*)0,"812)-&3`5[%!7J0
M!6I(.G70!B[``BS0`6WP!M%S%AJ@`$BP!5C(`720-IH*`%N0Q=/'`1UR`;6Y
M54@@E.'[B]0,`Q=PS=`B$A$J!UF`-.Y$C@3E!6]P/F#0HUR0!\W;!59P!5K@
M;\%Y5\41;RZR&5RP`BBPN1MP!A9`_P5\<LBC\`DU80AE0C@)F!2LQ$FN4)AZ
M^1V@9WE)(5H_P1T+U`06'0<>))$B948+O8*Q*M@:T&X)(!QL8!I1D`9RN(YV
M$$_P!0#!-V2^N*QKD`&2<@9BX(LBV@!*@`!3V!\<,@3>%ZHQD)MAX#XAL5_V
M%'!S,`<#@&#4Q`1?B2Z#*P!SX!D3^P_C!@_[-1`G`<^:00`+0%8HT`)J$`>E
MX"]2T$G3;9^$S7K182^+LQU^PC@]Q@D/-%.%T`,)(5*?[`QR^GK5_7JTMY%;
M0046P`<.H`6V451;2UFU<01$H%56I@1)D$TWT``:H#WQ50^QXJBC$@9JA@9J
M<`95P-H2D/\\+=!-P5@$S?N<=V"H8-`%3-(U><`E`I`WM)$2$3$'5\,:(H%?
M$F6H*VX2\O8EM9P&0D#/,_`",*``0>")1A"K_1(*V,'0':36//"MIQ5JMW9*
M18&XF7#0>3EZFZF["7ER;4%)JD3>A"TG'*F0Z/"5G@$&:>`&;P`''>X&FV4S
M2'"98K"AW$0`7JI5N2.ILB(!?>$7H)**'`)%6`BJN;D"#P`;6!TD_$0&=?`M
MYK@'6O`&7-"9&"!1$#$&5Y`^$XL</1*A=%=(+M`C)<T"9&``*+"'"X`%IJQC
MPXN`3T&M/U`$04#)KT8G27X)FK!KF.!YI9`0I9=2#U"13(!R7M'_#//R"`G1
MK88X>@O$#&GP(\\BE0&L'Q$@*;@G!.P0*Z#*`;X0#&>0.V?PTK+R!%6`!5``
M5J!B`&&`!.=%E-+<Q2>`!40PP,^R&G0$>(OVE!Z.D@01N(0T41,E$HJ4)2F1
M`-'B/73DBLDA!?!H`B90`SC@YJZ;GZ,@.9<P<H_0+YQ4>K;6+^1YZMWQ7#IA
MB+H<!YXEGR1HKG+*R0MD'8,R*+OUK*B:5X$4!8KJ?$,`!550=:/"%\Q8X><F
M[F&0.P!0!E,P/&6P#E!P%^&>[>F[`L;L3<$HFVD`'/ZD![8Q!J3J$%%2'/RE
M!0\5H>=S?C5R'-'R$+G13V(4Y@:P`0M7_P$I4`-:6(CK.5*GD'**8'JML$D>
M=)"O#NP6;0:^%:O9X1,H]P`^Q!T62*Y:&@KK;1[N$1]1D`AH5%UV4%2JHP!5
M($7#(P0_WQ="ITTW(`1A(`1IK@;#8,5",/2Y-P1ET`Z)<09#,&17N+ZOW<4&
ML*MSU+?^<`6Z01MR8*K0<B7]``;$8:A:WP:IP1()(`=?M!L=`21L]`8:(`8H
M(`,@4`$5$``;($`@6U!+(5)$L%M`?J<<K.2,4`B;9+S;8`%.H"SYBPE_K9^9
M@G*%20>HAB^C@"^3QT&C=@3NQRY`4#X#``@#150:%PIA#1(<(AP2#4M02$DG
M*RL24PU/90`1"O]J95!59V%52$I89P8&9U!+#2(K+3`Q,;-B7G99=U9@>G)?
M5VQCOG?%=PD.>V3'"6U@"7IZ8&0)U7U?:7!S=G-U;%E9>4YF%"L?*1,3("8W
M%U0\1%1K5$Q$]4$^/S]41#Y`1$T"!@32I%_`!Q$,1(("((B=+WJN</%7K\F#
MBW3BQ'E@X8&9)E*H4/%BQDL0*7&\,`'"PTF4*#^(?!GPH\</)A8H*#"P19$(
M1@W$3$GRY(311@V$G"%``0`:`U64E,$224D8`PA601$BA@,E63!@M%CR`$X=
M,M/TW&ESI1N9/GWVR'60[$L;:&3D).@CK4V?-L[&V+$SX,V`.GSJS.'_`H2*
M%`0H`D"`4*'"BP84@C!ILD9*$"!!?@1I$GID27J;`Y)LTM@"`*Y3Q#088F&`
MWCL"?##QTH3)&HQTZ#S0D(&.2))KZ'2\&(<($2#Y>/SP\06(&2`/+F3H=*:G
M"*,G)(AOL.6["$=8REPU0.!IJ2I5(B'!FC4,%"53%'EMP9\#@#=RC-%+--!8
M84<=>EFS!S)[@'&',KT@L\L75HS!1AUY"#"`&U$(8`<?=N!1!!-2K&&!&#.`
MD(X?(,P@0@:;0><#$5+P,%IO/?#@0Q#.;2:2&?.8H8$:4"0A1!5/-*`$`%R`
MT45N/'"FDA?!"7>1!1H\X$5((YF8@08=B21%_V_X`&$%`0908$`20PQ11A5;
M+%+)"B<T(MXB(HB!1!E388&%)Z#$!\402,R'0'VE))&(!+"TL(((9[QQA19W
M.9``!M?4,48U>T6SX!YR[*&'%5]4TT$;60CV86%<N.&&87G,<6$4FGE!A0(B
MO"!#!1Y4(,,,*USPP'/3A;:C%&:8040/1QC!8Q,C-4&2!0046J@22XBQA!!4
ML)%'#TW,N,8\:\01W$4/T%'N&O:`A%(&'5F0D1E4D+:9%DO$P$$#7HG00"(<
MQ,)!+77^I(@$2TP%7WH1H&%?*%4)H<K$0RRQQ;_\GL#?"DE8D`=$#G3000@)
M@)'&%Y9RFL`=?4#SH/\59&`@5Q;;\(''``*\\484;FB8!QQLS!$%$/](84$$
M.;P``@,0@%!"#2>H04<3/1@!!!,^P.-%<>'^\(^T:YST``!%*G'?$T\(-04!
M'=IXM1DIF6$ENNK&P>Z,CE&!$;J=U5-B%U5LL($ECAH5"RT]P7!"`XJ*L<43
M4)SQ9A57*0``5*8(L40228011BH&#"$$)@"?,$L,(BAAQ!7(C-R!`WJ0L0<&
M=.TEJJA6I!&-''K8`4>&`N21H:MO]#P`'B$.P(7;-":'1M(@3,9`!1^,@(`%
M^&@&A-<D)D<%$#GZP^,:"BCQA!!#P(<$%&D_3D$13AC1P]5C$I%LN2G]^%'_
M#SOZT(09%V%70,KD`RIT00$YV`#J8M`"H[2`%C>00!B2!`4$+*%04+A*?$2!
M``(```%5$`+:EJ"$4WQN%/%1PBL:%8,;.&H*/3B&`S!`N[@LB':6\H4>VJ`%
M/`B@%UW``Q?P@`<^"&]X7(`5'N:PF![0J"#V8`(3S("`''Q`>A.`@`QB`(`Q
ML>1J3`@"&0;`&6DYIAY$L,`9IF"V,J`02?SB`!2<,`8N'&%&`=D-2<S%CR#\
M)@ZLX8$18B(/+]B$:-LS`A&T\(`&4$(L_F*4Z7```RB@`0M8@409L*(&+,#G
M*FI``PB%H`0DI`\+0T`%*2+Q!`E\918WH`4'@'`'_ST@HQI?`(,<6A:J:NSA
M"VP80/S`(0`^C"$+TZ`9'.P@/#X<[V9N(&1)>D.$SWAA#018P`<J,+VFO4`$
M$:`#$VS4&R!<00#VHT(<S""%Y^#$`$]`PN<,0(K88&P)44@`'Z(DMP>8BR/$
MH4-)AF.!##Q@#<H*@F;(Y`-__.".C'3D`Q>W!$R<(`<XN,$4#*`>5NP)`0``
M@.2J@(4P($`-(%S"$[8EA):*H@R$4M1W8@'+'-R``T0@0QML60TP@.$N&.@E
MJ.`@B*IEH0M\Z,(5>M&'*QSH9@/(0U0'<`2%:B9:O:F'2.@PA`68H`(0\(,6
M:;`"!;#&.?C@0=&DL*65^/]`"G10`*'<*#DH3.%BB6@`$_I0![R92R/"(8[=
MDA,<"F0@`X;UR$B^=P0N1*$(`G`"&"AP@A;&X!&):L$"*,D!(4`A/6<0`A9`
M"H!55J$,:`AI&38G&_(@`14P'4)^?E()61`,"4Y0AAY:AH'8R0$#(=A#R_3@
M+9@<00!=T$(6K-`%NY`!#H89`*MPY@0BK($T)XD;O4AS$`+$0&D08!H(:M"`
M!XP)'_K@`0]VHY$U;$F=!$#E*$@QA"2HU)4BL("!;@(0>DAK(_YT;QB)L)$,
M6(X`"J!`EJA@A`&$B`U\T`,`5E"+%6QA"&%`@AA@L-D&3L&S\3F2`="`ABJT
MB7+_`/!@&)0@A(M]N*3T]*0KY,0?6=0I##R@4#'TX(!=M&&&H.++'/A0A!\,
MX`M:4&X7NC`8/KS!"6X8@#-[%H4>[,8S0/!"NC+23H7ZY@%G6,`+4D"9"01@
M!%6P@!?`%S^O08L*R6JGT6!*N:D,Z@F8@(4$UI`%`>R#"2,9#974Y4\O5',S
M`-0`!0AP4@`HX`(6H!H7MI$`-?"G3A<.0Q)$<(/-TFE?'\86AD_ZIL^>X:0(
M",,0\,S&*DQL%2'LB5=BX2A'0,$,WO@"6NX@!RO\&'8#"N9TQN``.9"!N6G@
M@Q%S9CR;N:$(NI&"%'Y@!*-=Q`Q8:U<_L8"#KY:`,B;8_X`0,A"$EAA!K21R
M5V^DD`&JP"<2+74%+"Q!!3L,DD3"(9'<[+9.U)0H7>9:M"K0$,H$6P`(47``
M`B[-"#%L.@88C4$L;J"X!@QE"4/`"D=!J_$P8&&EISBU*L[@45<H@A(G8(0$
MDI`!F_F:5&WX`C/N(',YV,$'9OB!%:PAARMT@2T0+LP;-#2`'@1AL4S0AQ<Z
M8AQ\@$0D]'A`&$;P50B4``0R0,$0B.`$9O%O,U;E$;M5,2@DB#!)B3"=!!YP
MDVA?!-#KVI*T1?*;`%]D.Q_$2HI708`O+#PLM>!/##)*\19T>@&HL[B1RG`H
MR7W.*0@8A2DI=^HS>!(40U`"7O]A$1Z,L<T.?HEYS(_A"[^0@0N]L4W,H`$&
M*UPAV0*(?>R+_.6#:@:N'?F(/4+25GQ#09M.R^('%D``)Q2A"#8!2-;0K;=.
MM,D4][T3!PA`KZONQ@Q!N*;=J"#V:P*\2B1Y@$Y"ZL$J),P.:#C<#7#`?O;?
MH+8+$%P,PG/!/84T*UCQ8.3#T-%#004*"G,?27`QB[`O0I`$$H`$38`'8-`'
MO59+T:`'PN4`8$`K7%`J/P8-NI8&@U$'/N0J/:!E&I`E)F$1%K`1_$`C(V$K
M4H`U1R!U*B`9630!'W`#!X=\[A0:S6(_#W`(D0`?:B,"+;`V"D4/<`82AL96
M"/4]@`;_).I2=X9F73D1`03@0?F7!^EG6SBP60LP`C`@A`DT`B.``Y:0!*54
M!6J@?PA`8O6Q28>B!I]@2AX'!73(8K(Q'D_0.`\@`&G0!K^P(#NT(,@P1E$P
M!WK06\D@!VU`!FQP,V]P!,_6`U1P-(8%2(!V$7K#??'@!9S(B>'"`VN0`2=`
M`RE0`1-0`0&``E40!^/3!,T1!%6#$Q2`!6(@.B3$.*_0``I`!-*T&EX`2#1R
M&J.1+"RH3@?5&P`TA1'0"1=``79``+#00ILU>"BP`)4@A#BP`8@G`1#C)I9#
M<'EG>9&C!A]D'R3T)B&'!4IPAXY`'HE``#R0!U80@7O!.\*5_P!?X#L[UUMW
M``ZY,P9S<`3CHC-`D`$70``1D`&=H3=Q`'?M!&B=*!)9]8MH<`(S8(H@D`(?
M@`-GD`')<G3^4P]>$`%8,`53L%+NF`0<D`0*$!JBH4XI`7<^8BL%@2Q;$A!*
MF#\;H1P4L(S-F`%UH`&;E@.;M86"(P$*$#9K$`%ET``N)`9/@`6A1(7D5Q]4
ML88BA039D@2#L@2BH(X7TXX2(!2IDP$\,`RB4@VU]"FMMULT)`=)-@<#L$P"
M(`440`&_D1`HI0`*"5?F54!C`BW75!+2)BWTP@1T```QL$T34`(R8`(HD`0:
M\`,@\E:.00=H\`KV-3I/T`AG8`'5M/\C-+(1G?&+(9$L]K)8ZF0EZ\2)Y?*+
MXG<!RQ@!=D`!#:!98[@`*#`"27`$BI$'1Q`'&8``,)!1*X`$"A`!AE"%[6&5
MD(<%2'`Q6V!VIF1V>(8QY+$%Y;$%6+`&;+!#S"`'++,7+&,IM,,[<I`%=9`&
M44`$RC$D3_`=*XD%`)!8W$<B`,%6<$.8`;%8T@)F([!-%9"1*;`!!F`&409V
MB*D&8G`"8A!"22(""+`&VR-%CO%?!R4<""5@_C,2TI8<!\4;7$(2WD<</8D'
M:'`#&S`"U1A_59`';&`'3@`$4M`)`*!9"*,&/=F3"L"<:C`Q[1$Z)J<D0Q`)
M*I6'K94)!"C_'@J`![]`#9:R!R*3``O2,E1:#,Q5!S1Q$5J&`!R0`[1`20W`
M'@]0+S1"!"P(-_[EB?_#3A;1`"B`#C-H`CD0!JPX$-E'`0AP,6'08BV0!%30
M`])V=/7"7@<%8$"";3M22*?)3E$D16_VBW8C'.B'`RHP`S0P`AL@!CR0!;]#
M*U30%`#0`#@@!F&0D'>YG"F6:B;E%`:@>?\B!DH0'YFW!!6U*(P3EHL`!4"`
M%A#A2R'0`1C0*=4@GF/0!6/@@47`)1FP!"VPHAM``S.``BL0!FJF$M=%$G2@
M`7TC#W$0$G$@D41``"U@`B7`38WY`CD``)QXH2AA`08P!2%TFP`P_TA``BU2
MA!(!!J*FT8)9EBX;ZJA25$T\TH0;82MU```PL`&[N0`-8`%X<"'B<'0]2)(K
MT`!A8%C-J*I/X2=A```_BA^.\P2I-"C88C&+,I88HPBZ.`84$BJ^0$-T82DB
MTVN&X3MID`=%8`1,<`$<``,C,`,S\`(F$``T(`(4T`3!,6U555!S,R]V<Q*L
M00<(H`(R$%Y95`+?%`'A"F?8EI@7E!\28`'+@RPM>)H<P9J&)@^G`6#:51#W
M`!T]D'PHX1AC(`0+<`,Y,`(M(`04P`-<4`3PT$\\J@02,`0IA@:=T!XH90">
M5`6-AQ_GDTJ8=[);T%HJ^R^,DB=,,`=:8/\7O%8-,T0[(>``--,#49`'`C(&
M./,#%#`$#1`#E_H"NJ*U6W""%!H$=W015(F0\J(EZ.:*&<`!-0`".R!638,"
M')"TUG%=%H``23`%2X``%.`UNI$LP2@<RR$O:ZL1_\0<*SA@GY$/\`-MSP%`
M7:`H&1`'RX@`"D`E%H`EAQ4!31$!`"`5J152HK0*C3<5]8$$'P:`_&>RMFI?
M3W`Q27"'`:,(9^`$7>!K@H@,,^L`;9`';\`%`H`'5W`'79`A+X@`M[D`-/`!
M'W"U#(`"4Z``=^I]&:"_(44!!T4%^G`L5(0#-;`BZ6"TF'$2<`4`"(B43'!N
M%2$<!4$EZ'+$_V7_-QB!4&Q%#Z!!-%ES!#]@!A&@!GQI`5T0`50@`",I!(Q3
M!@20"DQA8)Z08"E&?B+%)ZB@"M!)<F4@">NC'@-L/N=32@=\N0!C"?MB`6F@
M2S,TNI8".V.P,\J&!UUP!UH@`,]F!F%P41LP`R9@`C*0PS0@`7'`(4<7!Q:@
M`)S,R3"L$OHPMSMB`66``P&P-.G``"5``T)`H3^0`5[<`%4`!/$#'2+!$;TA
M#QBA$1QQ3552+NI"+\3(B:GA`T7@!0HP!3\!`!DP!D2@R!$P!!S0`AQP85.`
M!`20$N*7G(C5HQY46J<5"E>ACND!4T*P/I1W!A`*<MA".HNR`HL@`0;P_P9M
M(*48(#*OLQ=@X"T>HAAL0`8=+$QT``4GH)N0_`%+4QDT8`!.(`AO-2Z(=9?P
MHB7]D`\QP589\`21`583X`<TV`(4`&@$$`8]&@=2/+XC<1$U*3=UPYKGDB[I
MPAONLH(TP@0Y\@!HX`H-P!1C$`5OT`1E(`&&UP(BL`7N:])'H+1@8B[+V!0_
M:GE[@A7J_%EJ_%JGEFJBLU(K=8#LJ`CP_!-;\`!9@`SW+#+#BF1I4`=U8`=C
M<*RM=R%O(`4$W84H4+2EB(HGX`4N04B7R1$PG1+2AD@TXD<4(`$H4`),XP<5
M4`(H\`0]B04A'0=&,$B@<1):IB5.E*C:2C=VP_].U^1>Q"(=B'0$XZ"G\'$&
M%Z`!8X`=`"`!Q;D`+2`&!$`:S1*J%&`!5%!`G=`4_C<H(Q:D?N*&KA9*:E`*
M(W0^(H17B\((G(<%/,`R-.0Z#G"LR,J!U#T-`V!=8'8"##L#)2P9$(`"%)#4
M\,!6+;@1RQ'#U]0NN:P2%"`"Q8NU6`<L6U`%#V`C?C8=V@98%^T8R&$E\Z(L
M()$<BEK9K&$$/J`!"G`H8_P`;$`!35F<&R"A%"`C/C`VKD8`YA4'%T!PH80`
MZLAX"-8>H^!&67'&"D'')-0FYF.28J#`WQ$>M'F(]QRL'9`%RG4AON,-9*`%
M1Y`!JZ`$"ZL"D>$T$$#_7B8=!5Q`(S1IC%?RK?(`D2V(4$%@!MED`M%39D\S
M`D]@`47`!8RA#S6=+&9@`;H'+8-%YN,R+G2@$L-8;O^P(T<@J!G0'@DV@@\P
M!TD`IN$!!0_P9$XP>W$``!<4!DS!$0#`>!\4";^]C`H@2JD`4E7X%*)#%.A#
M4O?!8IN#"3[Q'4@@!59`%R'@`C3D>EF0UHIA!VQ`(7E@Y55P43<@!E!``P&0
M`C6P`AE`-4YP>V*2DYJL)=("-KQ1+UGC`THP`C((`5EK`@N``+#8-3?!&_AS
M$5)`$85V''!#[9!*&M1F!*0=!<)D$13PDU_R`'70`C,P`AR@!O<=N*DKHZY.
M_SEHH`#I<@$&H+\>-^_)>0$7D'>JD&)!>C8KGAXF5JO1*QZ,0B<2Y`//,.J6
MH@79D`99P`9P``=CH`57T%?/RP$JF@,2$+0H@`-(2:';+A!`8B[GL@:`!C;N
M52^AT0-KL`1Q>HKH>F9#X`4Q,</_\S\8P4YA%`3]]J'?>U">D0_DVRK@S@=N
M`/2:?)<7D0;/N@49T`,Z\UA1D`9I,``\D`&1GF)9TN'>G!6/QN_C_J.><VH(
MB09ODGF%<EH#?#;:F<<P0"<G8`!&D``=X`(NT`=R*0!U\'I`HU1@<$Y2H`!"
MP-TJ\,C3N@!B<#UY]*A3=/+_I!+T\MDM'YBN*P8T</^N8$49-/"PZM50]`-H
M`&8:6Y*?O8'R&9$E*E_LV]-8Y19[3C`C<:!H\E('D&L$4G48ZBD`R2H`4?"\
M*<;-W;RX].1HG+R,/\HG:.\)).4G)K;&'A=K0?$O`2,67B$!"'`%97T%3U8$
M>7#J;/`-,$,&=M`#&@`G6]`"*#`#"["P+5`&%.#SD,I[R$%8]2)0R6(NXP((
M9H)4#PHQ)B`0#!4@)AM57CQ`041!0%)47G$/F69K:Y.41)H/=&:E='1>/T%,
M1$=V05Y45$P^LFL9``0":V8">'5S77=@?`)'DPH(!!$4%!89%!$*!&A52U5G
M!FJ[``@&X=W?867;95!AX0;_85A+#?#Q(B<M)R<B#6X8&'IX3DY1!M09DR9-
MEB]@K@PP0L>`$B0B5"S@MF%#&0I>I#3!9"8.G4Q>/-&)TZ3)@SB"-L7QY<4+
M$$)0%GRHX&="A1(O;D20THH)$!YFJ$C11#*(%)1$?@!I$N34R9%QXG@)LI$(
MCS<_?!"A8\$+G0P9%)1!$(4'$QY!!&BY\L5*%SY%XE)``,`9V&?4`*C!,D7,
MPRK<$*A1@X"N&C1JSIPI5R;,-G95H"1I(*'!%C&41:R(`>/$"BH8$G2)$@7@
M@#EIV*2Y0L;*F#QNB"CX)F2)A0=(-D@P0`&E&8Y'A5)9\^#!FI(HUWBD\REH
M$R)$_X`\4(-"Q@0&$";(H+'D`=4F0'Q$%:H\B`\JFYKX8+(F"/I4J5!2:5+K
MTNTU7AY8B$/!0!DD2H11Q`!$6```%0,,\,8<>RSTAAL/H-',,Q=0J,!A""#A
MEQ)#A('`-H>A`8`!=!6&#A;LA(/%$$]@5EE?#7`@0@LQM+!9!G>TP08711SA
MQ&ESS`&'%F"`D44:`_SP``4`(&&`$5),,0(,!EP0U6U4F-$$?K1L\L!OF)#"
M'%%4$,$3$&98L$(-*3#`P`0@?+#`$`](`01TZ'FQI10\_$"+GDQX!=(@:Z02
MU%0F15#A,QEH`(`06S201!)'U.&%&@V@T4,0%JQ1!R=1</^QA@)V39.!!100
MT`T:9T`!!1;JJ&'`-G2Q>D8W'V)1!CMEH(-$I!)4!H\$\\!PPPTQQ$#!%5VD
MD4</1;@Q0!YSU,%&%E?(<<6.7FA`P!E)/&G&$RJ,<$(#0DRQVVU>,&%&2X6B
MU!*\4:UQ%">7/$=)&!M\,,%U$%1@`@IGQ/%#$TPP(85&\_GP`Q&V$-%$2,W-
MDN5*0DG!!!T12+B,`0``,$0\6VQAQ``6(%#&`TYX80`'#8@005QQ9&!7!!%D
M\(#-!/2L%XDB_JP.`HZ=42LXBF$!!8!*P,,!!Q(\K=EF-^"`0PQ'Z-'%%7`4
MP84`?-BAA15DM"&'%6SDP40$9:C_V\"!$4B`P@L!I"!##2H84)QQRK$44E12
MT?L>%4&PP@3"%#2@@K]^0`!!G`NL_)'&"3>%GQETL#(QYBN].U105DELP6P]
MMXJ-C/%(\(,`&CAC1!0/8''"#1Q$$!X3#Q``P#04G(KJ!=3TK`8!"E0#`!H&
MK"@$B0:(B,:'852!Q!)/I!NS/?:LT`*-,5C=@AT)I&&D``*<MC48<LC1VAAX
M,*%``S#DT$(8%KR\P0POO###_"31L?-R[9*"4TPA%,X%96&34%A(,C`%%$P@
M.]@I@0EP@`4-;$(H3.@!>SYA@?D$BCF?B,I0]!0>KC!I,`A0&A(:<`(.3"$S
M/N`"JC+0_P38(4`)4U`#'9@0A#>X#P%H4``%-&`!(CYC&L4C%<ZJ@88R",%)
MB!$1818SA"4D`5A1HX?V6@`#SE1M`2L8P!VV]H4LY($/8^O"%]1GA3:XY@@:
MF$(,*B*!,BA!"4(X@1BV,(0(=,X+1*#"2#S7D>*,Y$^$^,U&@M`*3*RA0"*H
M006NLX-%O``'!K"`*<S0@RC\8!8F,<5&OH0>XVQ$"M!Y0`2(=Z%PV/&%(I!`
MI#AP`B8XH3AF"`(>>I"!X:VA!TXPPAND$($S+`$!$;@-$<$B#44=$8D$,$`5
M4+0+:TPQ#$HHF1B>5AD.;-%87\3!`DY`!SA888U[6(L>]'"'/?_TH0U$T@(;
MC&"!(:Q@`RC`P12@<`8%&*!GR4P.2YPS'$/"IR5F(`+&7"&)C30A#D,)PPT0
MX3@/:.>20J@3$[C@!A[X8BL"%$IQ/C&2EDC!86:P6?%$]"VWI4XS4A@`$'K@
MACRD00!2>``3W/"&`0B@!ZH\@P2JH``-/&"9=[D`,_%"C0\!9A>S^5D9WF&9
M!HAA"I/AP/9B4+6*+&`#+3"`$[Z0@`0X8!\=Z(`+.M`'+<SA"F.8@P\H4`46
M;F`$=42`SO1S&Y3HQS@)"]1R_%<*BC7!<ZYH)`]/0H4,&*!?%:B`![`C,!6$
M80T^<((;G"!`,YU'D:<(RMZ\<(0W"(#_![D#@`(:A0"WB<%%FJ'":X0$!P7U
MR0U1&!`?C/"`"Z#A"6$@P*F(6$1I0$,#QL79*EE%EYY),0R_>EH2A#"$(>"P
M`=KKGC@K,H(69`!\(<!`!PYP@+6Z(`%?L,,`T@"'.?`6F0]8P@AB4`4"8"E>
M[]J9SA#V0>405BJ%$@K"*A$FI@P%$P^8P@9>D`(/.'@'.-D`%"CP`]M&QRA>
M>*03U*8*+UB@4T<X31UZH`$*7(`X!HC4%IX0*1',`T%%*-\`G""`S;XA6GG`
M`X2>MXW=%;$X)>X=<BGDS&J,XV>%D0P+3Y`-="@A"5-8@;'$B8.[+F`*`FA#
M`L(;@@YTN1C._YI6,,;`A[EJ@`E#0$$^&^`,+ZTA$YM`+I<*Y=_B`/A+KJ@$
M5;*DIXEI;`W%7!,(/."''31B!@N0@`6$R2.M:$00/W`"$#8AIA^X80Y6$$#-
M%&"!"#Q!EDM8@A@D<(\3#`<`F8M")\N7AQSCH<9T&!$!Z'(!XAY5R(RB$)&K
M";UR/'G)28#5$(0P&1AT<;L;H.\#P+"'!&#``0[H0P+:H%[RR7@.<76#&31P
M`26@P`0TB$$8E+H?4F(N&GM+Q4:(<Q)/2*4DB=U()SZAL:'0@0`X,`$$=E``
M"-R-!B-(`@6`T-,B^,`(1%#.*5HR)OPPH0AS``,<@J`?.M`U"4L00O^+B#6/
M)E!``@B@@!F68H1JP<$.>7@#%WR0NPN`@P!#U!ER&R5DXSXS9.0H1V2@\(08
MB0$)3F0Q!V#0`G'>H`$(B$-`[M`':#L@`7L@0QW(-RV?`F,.,Y8%!="PX!$T
M@#>WD0*6,KRW#Y<"/$TP1<5`(F#*$04_"S-)!I;0+PAXP'$?J,$,1B`"-33!
MIU$PPN$"Q9(_Y9(*E@Y2$8Y2,P/4YHI.\PP1*,`!(0@!#4%8@Q&ZP`8VO-H-
M;A"`DK9^!I@WZJA@0:X&2ERA"[C^`B'CL6)FKV0Q+&$(4V@Q%W,``RPT00!9
MD&<[S]H!#-P!#C66<8VY<!H!G&=+!%C`"U3_`')G<J4K\\J/V5%B"0&VA!99
M>E=+2C*Q>+'DH85XP@9,\,`=!$!_,U!!#`P@!3?`A0>WR!CY/4&$A/*@"$[P
M`TR0"2FC!$_P0L%"2RU`!!G@-&C`!#]@!VTP!G;04=!B!P+`6S93''LU<ZK'
M>B:V1,\##B1"@OZ135<U&<&R&6'E!:QF!V-@!>[D;"$0/JH&$*958S1F!["S
M6AH0!C@P)5B@'[)$`,8A?B+U5^/1"B1Q2F$R+Q(#$I_`$@+4$1IP!H<P`0'P
M`3-``S,P`RBP``V@`0(P=2_A"H=3$AUQ%$T@"8'R&QZ&`,0V:BZF&2W`!!\7
M2P_0!#T@`'#P!6QP_UJEA0=<0`3$8P$YY0RH1W.-8ES`LU(D"$3@4`9*`RE6
M%2,RPD5(4`0#@0=LP!IM\'1FU0%=\`:48`3_UU,#$'IXP`/?0A=*L`(+(`(&
MT%AW=&)9,H7L5@HDE5_0<3BH!(QE4H49`WX4XS\9`(0F\`$F`']ZAP(;L`49
M,``Z1@G"F&$?@2]W0A]9D@%GP&(Q@CU<Y''T@`1WHA5%`%<#4!IU,``^H`%*
M4`8ZXUAZE7HEUHC3<`%1A3Q&4R+29%W@F!F>T0(B$`=7$"1=8`5@T`9Z`&UF
MM0=X$`42TP/_)RT#P`4]102LTBN0D@0(8`$M4V+O4BC,47:=@A^$]0!+L3DP
M4Q&%>I()`B9@?Z,<Q4$!9R!]>M>%-/",&R`"="``=K`I5?$N'8$Y[\(49I)A
- -%S=+GG$"1-<$@0``.S\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>o40024o4002417.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 o40024o4002417.gif
M1TE&.#EA+@#'`\0``,?'QY"/C____UE75_'Q\4M)2>/CXR\M+8*!@3T[.[FY
MN71S<]75U9Z=G:RKJV=E95E76"(?(```````````````````````````````
M`````````````````````````"'Y!```````+``````N`,<#``7_(!2-9&F>
M:*J*:NN^(PO/="37^)KOZ<W_OM\N*,01B[0C$J9<NII.7=0XI5:35VR6N>5V
MGU]P6#I&0;_G;GJ[SK:O[VI\.H_6G?=E'KDO]H5_0&4]@V:%)X$\B4.')HLY
MCU:-,9,DD3676I69,YQ>FY64H9XOI&*@HZ$VJJ8MK623KX2IM*BVL:RYM;B[
MC;*&O8>_B+JWOL6\QL+(Q\&%PX[,R\Z#T"76EM+/VM7<9=BBRMO4W]YCX*OD
MY^9AZ.[L:/!J\FST;O9P^'+Z=/QV_G@`ZA'(AZ")`0E&%"A0*HH`!2,,"&CH
M1("``P4(3#R%1`"`!0X4;'3EI("```H(_R`8"4O(``$9#;RDB&2F@08O!W!T
M.3+GSA\%`)`(RI"DNG8&`245=#3>#XM0HTJ="G7/@*M8LVK=>O5=TWE?ZX6]
M-S9?V7UG^RUY*<"`@H0TB[Q$L("`T+@\=3JXB/>'SP`"=/[D\3=P7\*&]QXX
MO&-NW;N#&UMTNYAQN;3_,`?4/)!S!`"@0XL>31KTG@"H4ZM>S1JU5W'=//M9
MJH@V(]E*<3-=\L"``02=G!P0X``PW,@Y$@B@*^"XT24-"!!8$'S)`0;2"RB@
MCAQ'`P,'`&#G_KR(`@81#FAT/@O)`P$,#$AO8#DY`@0)%M9'JKMV_]NP7<9#
M:002>%IK"+;V6O\R##83X#K_06*;A!%*TF`1`0#`7DM%$/!;=4N8I`!$GR#1
M```K5=8=#@8$\!)YY0EA$E0.E"A$BA&D9.,/#*`7P4H/[$?#`$4=@)"08#W(
MGY).,9GD#@E&J=H>!58IVH(.7CB.DV)Q29:79H&)EIAJD9F9F9NAV9F:!56(
MR8069BGG-&S.YJ8F6L969VY[[I:G@']"V*=_@P(8Z)*'-IGHDW-NN6B7CWX9
M:9B3CEEIF9>>F6F:FZ[9:9N%4AAJG'1^:N>H;]X)HJE\LNIGHWJZ2JBLAL(*
MJ*V"TBJJKJ0ZBBNBORH:+*.E#@NIL9(B2ZFREC*+J;.:0LNIM)Y2"RK_KZFB
MBJ>UIV*[;;'@^AINK-RV6NZKX]Z:;J[GSMINK>L"&Z^P\Q(K[KWDUGNLOLGR
MNZR_S0+\K,#1$CRMP=4B?.V[NS+<:[[XJALQNPIWZW"VWJYZ\;<3R]LQO1_;
M"_'($I-,<<C[HMRORO^R'+#+`\-<L,P'TYRPS0M7;*[.Z.)L,<_N`@VOSSL3
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MLY^_^_>CW[_Z^[-?`/$W/OT5D'\#]%\"`7A``3:0@.5#X`,5.$$&1M"!%X0@
MZS9(.P[RSH/$`R'S1$@]$G+/A.1#H0$S2$$66E"%$G2A_/XWPP76L((WE"']
M;+A#'/90AQC;F,;6]D,88M"(&NR@$C^XQ!`V<81/+&$43SC%%%9QA4AL819?
M>,48;C&'7RQB%X\XQO\D,O&,3D0C%-4H1392T8U6A",6RZA%.G)1CEZT(QCU
M*$8\DM&/9DRC(-<XR#86\HV'C&,BYPC(.C;RCHO,XR/W.,D^1O*/EPPD(3=I
M2$XBTI.*!"4C,^E(4D)2E)(T)255:4E48M*5FNRD+#\YRU#6<I2P+&4N3WG+
M5.YRE;]L92]?.<Q8TO*8MD0F+HNI2V;R4IF^="8PI2E,:!+3FL9,IC:7B<UF
M=O.9VXSF-Z<YSFJ&\YKGS"8WT^E-=H)SG?`4ISO).4]SQA.=]U2G///93GZ^
M<Y\`Q6=`]2G0@A+TH/T<:$(-NE"$_I.A#W4H/?TY485&M*$8O:A&*PI1CDH'
)U)X6S4$(```[
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>o40024o4002420.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 o40024o4002420.gif
M1TE&.#EA+@`&!.8``,S*RFQF9+JULH-\>D,[.DM#0=70S4]+2[.MJIN5DR(<
M&^7CXL*]NN'>W-[;V=G6U,G%Q/GY^%M34G)K:7IU<XJ'A]+.S$Y)2>[LZS4M
M+**<F=72T*6@G>GFY//Q\9Z:F8R$@2DB(6!96<?"P9*.CK:PKIB1COS\_#@R
M,(R'A>KHYL;`OH:`?2TF)>SJZ75P;E)(11P6%GAQ;MS9U_?V];^[NC$J*:RE
MH3HT,CPU-!@2$SXU,ZJEHY&)AFEB8//R\?#O[F!75=C4TA81$1D4%+ZXM6)<
M6OCW]HB#@>/@WF1;6%=03OGX]\S(QNOIYY"*B7YX=J:BH!X8&)6/C9:-BH^(
MA9V7E44_/3\X-NGGY3$H)XJ$@S<P+ZFCH"4>'D`Y.#LU-%Y75C0L*S(K*BHC
M(B<@(!T7%____^KGYJ^LJE=24NCEXV1>7<3#PV=?6_[^_OS[^_7T\X!Z>#,M
M+)B2D"LD)"XG)ZVGI<_,R8^+BOW]_4U'19.,B4=!03LS,140$"'Y!```````
M+``````N``8$``?_@`>"@X2%AH>(B0=_C(V.CY"1DI.4E9:7F)F:FYR=GI^@
MH:*CI*6FIZBIJJNLK:ZOL+&RL[2UMK>XN;J[O+V^O\#!PL/$Q<;'R,G*R\S-
MSL_0T=+3U-76U]C9VMO<W=[?X.'BX^3EYN?HZ=0Z,`6,*!)$L&8;3E)$*S\*
ML`H+3@58T)PH`\L+!@X]*)0X0P96B#-+##!0<B8#+"UG6C@PP.4,%U@=0R"!
M8N<,`5@$CG@9,N2ANU=CZ)AAI.`#"G4X<Q+S$H:-SY]`@PH-]>5!EJ-(DRI=
M&DJ'EZ=0HTJ=ZD6GU:M8LWK3\<5&+3\+>-1*L6%-#%IX4KPY*2L$C2M"_TS,
M\@$D`(0D9V,5F9&FQHF;!7],^-,"SF!8!=#D^*.CR8TA6B-+7C4DAIG+F#-K
MWASJ"H8SH$.+'DTZE!<)05*K7LVZ]>37L&/+KD4$\A]YL<I@"/!']YA8#[.0
M>6C1X9D.+(@#/R-G0\?BKQYR84"GXO(,$N)8-YZ!B(#MK\ID\7IEC5=8.G#(
M&X("]^SW\"7AJ`&@OOW[^/.'LC,@A?__``8H8'P$%FC@@;R0@0`4M?C@Q`8Z
MT"+`#1'8,8L9:`2!P0NS%`!$'24T81LL&@#!@`,TU!%+#`O0@<,2;T@02PYG
M+"*%$QK$HH!ZC,SQ&X)`3F;'%B04:>212"89"O\*`HS@Y)-01BEED%16:25.
M(\KRQ18)O%!5+'9@@(<5%F`ABPD8J$B+$$5DB5X#")B1``\RPC($FU+(@0$+
MLGS@@HH/\!F+&!Y80$4<`\SB!Q1(^+#/E9"F<YH(E%9JZ:68$B7$&IQVZNFG
MH#:EP*BDEFKJJ8]&JNJJK#Y31@&P8N%F*VZ<T(`#/<SBA@IDU*8K!@1DD%<L
M;KP1QP][Z.K$&`I$*(L;67RI:QP)D##!K*P4D,:V+&#;ZK?6*'"`&N26:^ZY
MZ(9"0!(_M.ONN_#&&TH,=FAA[[WXYJLON/SVZZ\M0^#PT1]U$."L*S&L`$!M
M&B21:BL*),$$"F%&("W_Q!T(0$$`(YP1@D-Z^#`"`A.<\:,K+9C<P`9?>`22
MQPA$8<,97\"2`QQEQ!##0VRY0H`#CY;1P4O_%@U-99LEK71GGY'FM-.FH=;:
MU%,;;?756(<R!!%<NP>+AAA@<(>WJKB!P0%76/BL"B$<3.P1:?"`@ZX_@"#'
M><1&6XL;+F3@Q<.O!('&X`BX[<J..."`=]:,#S-??I!'OE]_`E9>>>.89ZYY
M+0H(L,0?G:L9W1EX**"<<30$</KH5.!1$G2N/.0'`"R`%WM%`61A>RO$>6'`
M[JR$\(9%$@P?2WKKM;?Y\KH,F>3ST"_9I)344\_\]=A_2\2PK5PAQ_=RA`&"
M_P;<KQ*`$''0(`02:]0)BP`,Z.`''EZ[`K\.0P!N?_RUW-\__Q("X%P"0+;L
M&5`5"MB#(A;(M*<Y4#2A($(90D#!"EKP@A@\H`8W2"`NA$%6LY!#!!R@!P;%
M8@@/>,(?O$"0$VX``GVH11ATIP$IT$(*4(@`"&QQ`P&^H@=0",`"!!4+%D!@
M`U%H(0>72(H$+E`1#7S@`T-A!C_LX(I8S*(6M\C$+GKQBV`,HQC'2,8RFO&,
MO"#`X&8`A0*BH@!GH``2UB(+.!*@)"*HXQD&D(`(``8Q9U#!&WBCQSW,P`H=
M,HD1(N`'6?2!9E(00@+<:`IQV1`+`T/C&9G4ADYZ\O^3H`QE*,8PA0^8\I2H
M3*4J-<G*5DY&6]L:`"5-X09JD2`,NM(;+=SP@P'(H`6Z8H(`$+"89^DREQ<C
M5FAJ8#C>#:)FKB1C"P90@6I:\YK8S&8H<M"$!WCSF^`,ISBC2<YRIB,&`2`!
M!4X&"SJXH`0;,"%Z')"H/\S2%$U8PV%F@04!P*$)[(2%%'R``;G4@@-%:"8K
M!!`%)!Q!!K-80AX2$(#ZF9.)3GPB(J(HQ:=%<((8#&E(+TK2DKYB#CA`@0UG
M\0#0P,$'+-6``E8``8NRX@$?^$,)5F#353Q`"'<X`2%C\8`-I`":LL"I+91:
MBRA0P*1@S*A&#<'1CI8&%%7_W*)6MPK5KGIU%.*Z`BWL,((?`*%;LD#``NH0
M@#.82:`8R%49F/!46)3A!(,Q@PJFD!LX0%0*+N!#+&XD%S)$@$.QZ,(:""`'
M.#121P`XPT,Y5[ZO&M`S5O4H*,@P`1EX]K.@#:UH+4O:T@Y#/'D4S^)X=X8%
M>&%UM\,`%&#+6A!80`S`6X5T(-"#W*J".$;X@6]309R$#1<5PA/#'_8`!^7"
M@@@7.(L.HFO:[&6``]O*KG:WR]TTA&(.'^"!>,=+WO*:5Q0Z2*]ZU\O>]BJT
MNO"U;`M((``-$`T6'-@`"SA@!%GHP`%;L$4-?E`%_;G""R:(P!K`0(N`S:`+
M]R1%_QD@4X(21'@4(R@"!YC07UG8(0`#Z%E\-Q>"";S@Q"A.L8I7'`HL6*`!
M,(ZQC&=,8_2Z]\;M';&.2YL#(Q@!J;'P@0KBL,^T/L`6"#AR+9*,9"73@LFT
MF-\:WBJ+)13)?3MNG!E0D+@N>_G+8)X;*#";V:M^(@9CR(":U\SF-KLYRW`N
M:0Q:T`(#MR(,3&#"#XHPDU@$X0Q7",`;8NCGBL#@!%0.W!EF``0K7%@4?Y9!
M#XX@UD)G`+!RD,6?D3"%$^`R%GNH3PV0L-(X9VW+84XUF(GR@,&Y^M6PCC4:
M0J&``L#@UKC.M:YW;>I>EU,!=+8S*P)@`0-`=!8Q$,`,*O_["B@_V<FS<':T
MH;TB93.[%2R`@QX$.PLB7*:GON97#D9@@'*;^]SH3O?D0,#N=KO[W?`.M[SG
M78D!(,`6'Z!V+/*-;WW#@M^U`#@M/N``>[7@T:&P@A[:)0!PIP('Y0(RO?EU
MW>Y:G+O?#:]Y-[YQ&^/XX^^=N,@W*`$K6$$)M-B#$)QP@27[N]DO=X6TC=SD
M6BRA`4`(`BW`0*E$C[Q5)5ZQT(?>XA?3^.A']SC(;_SSIG-P"3[V<4-BT00/
MG.$'&,CD*XAPA3/`P.&J(,`9[AL+L9,=)6.OA=G5GG9:S'>U3E<5JE5-=S%_
M@LQEAB`HT.SFOOL][H"_GA3L`!EM,R2S%9.N60(<</A5D`$#=+###Q"[[QD,
M8`V-#]X"F$!Y620@"WV>10H:$')6C+[TJYB`A0//JKG7/=6LEK7L8TUK6^_Z
J]K=GO>YWS_O>^_[WP`^^\(=/_.(;__C(3[[RE\_\YCO_^="//CD#`0`[
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>o40024o4002415.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 o40024o4002415.gif
M1TE&.#EA;@!-`.8``-#-S5525*RJJFQI:IR:FN3BX5Y:7,K&Q;"MK6-@8:FF
MIKBUMCPY.W9S=#4R-$1`0LS*RF5B8QP9'%!,3>'@X.WL[,3"PB0B)4Q*3"LI
M*\[,RY&.CJ6AH8V)B=32TH%^?O#O[OCW]MK8V,+`P)N6E+2RLA,1%.?EY+NY
MN>#>W6=D9=+0S[VYN>OIZ7QY>M[=W)22DV]L;:"=G>7DX]O8UEI76-S;VGEU
M=MC6UNGHYW]\?9>5E;*OKXV*BU)/4"HG*8:%ACDV.(^,C:>DI%A45LS)R!D7
M&4$^0.SKZR(?(K>TM+6QKS<T-C(O,7IX>4=$1C\\/HJ)BTI'2)J7F'IW>,C&
MQI.0D<*_OH2`@-;4U(.!@GY[?`X-$+^]O6IF9XF'B8B&AH6#A%]<7K:SLQ`.
M$J.@H&%>7R\K+2<D)B`=(/O[^@T,#^CGY_'P[_7U]9:3E,O(QW)O<(V(AL7#
MP[JXN(>$@QX;'A<4%Z.@G^7CX[Z\O+V[N]?4U//S\Z.?H/___R'Y!```````
M+`````!N`$T```?_@'^"@X(*`6@F)A)G7@*$CY"1DI.4E9:7EVH"4"8U&PM5
M%D-.1V@Q*&J8JJNLK9<A+D8^(ZF/;2@J25X6KKV^OY-J/D9"E@4&1@:UP,S-
MJA-H'JH5-TP*R\[9VH($9-*K;7T/4C;;YLT`=XZ]"$<[Y_"]#5#8K0`33GWQ
M^Y<O/T/-&@3(P:^@)`X_LOG)0,>@PT$"M;%H`N>APP!AMD%@,,9B00PPS$%(
MPLMC/`QOSB'@(L(D/`Q6X%$YTL*E.2\ZXM488'-;CP#Q*$!1T#.;@C/[>%RH
M4+09A3,`]A$ATC2@CWU]R$2M^FL%&0K[8/#D^BN`F'UNFEPAZTL#F7+Q_^*,
M9>O*!Y%ZVJK\"$'750LR"/:IJ-/7U98,+^()8%*XK@^^YRH8`=MXE0<H+N(U
M`%.9E083`,_Q2-AYE88U/,ZY64.Y-"8>7!:<8Y#:M:HA9XANTZ'%]JH=9]9E
MT^#`]RH>=VIG6^/&N"H-=[[@]95AJ_-+,S+48.,,`XKKJMBH"/*=68V0X#'U
MZ7&!P/15";Y457,"'@`T`5J[B@&D:`$"0:Q1!CQJ=&#$%KT<8$0#_&@`PB,@
MC.'"$URL80T2^\PQ01`"O!>)&C"8L$8-^[1A`ADFV/'#&6B0L<8:2;BP`F3\
M@`!#&@,D9HD:.ZPA@0\DQN/&#6MXL8$0,F`1Q/\=8ECW4!LU&/%!&Y7T8"$;
M'`1921LI%$#C*AV8(!L=:3S@I$DK,"`!'N\I048<@F1)21\R-.'B&B:(P10K
M14A@Q`5%<*4&'4DT$1@A;$BQ!IN"6*'E(\?<088."ZR0!0H&V*$<)C<8<<=<
M7(4PQ`,,"%'`'W,<P<0<A`"A`B1]?)`$%!O41(@:9:"Q*24`^/!`%2_XD!E=
M%1``Q1DZ_#!!"H]HT1\A(D39@ZV1-""%)2!8D8$+#_Z10P9*-!;#&G<$L,"7
M-?1`2`D7,$!#)0!(@.$D%3Q!T2,O&-$M66H,8((2(2#`@`D^+%%?``0,$B85
MKSS`P20L)$&%/I!,$)K_*BA<8,04YHCPP`4S$#*#`A&D:,(`Y5BIFR4`&#'O
M(R$TD`:KDM0@'R8A^+"&`0-<L`T*31"1AR0A`,!%#$\D0480)3`;"00P1+&#
M##?8,?0C`!PQP=4?.G"H)15XL;$:`-BAS1!V>$'0)!08\4<17-S@0@T^&`!$
M&2A<#4,21IP1Q!DF<.%`#SK^H00:+NPIR10_*%[)%G>$9D$2SJCQ`1D;6/*!
M"VJ8\>@?-!QPP-II,)B#&B(DL<044I#1`1L?&-%%)3R0H8$D+9PZB-&]":+#
M5<S,((4$55QR!!UHORS)$5`$B$83&0F"0Q!D_*`\)&I88<((D?0Q086UJ9'!
M_UV"("'!KJY8\`,&W%D2`AD@#!"!)0&L`4461AQ!L>%V.&#$F82``Q304#Q(
M)&H-.FA",0RW!IK]`0,Q8,84)$`%QU&"!TWX0P!B0@DO.$`':7C"&N`2JQ_P
M0`U3L$-)"%$$%1C!!4H`@Q2,D(8C,.P/#3#"$/3`A2P(X@D,&,04'%`X5_0!
M!G>(PP<:P#5*/(%C**$$!4R@!S4H00)KP``89#`!"31$$$+X03G4L(<-U.`,
M-5B"%7Y@AP`0X44^^P,38E`!!]Q@$'98H``RL()?M&``:PC`TLYP@;5-P@-D
MP%`-4C()"]Q!$!8P`@*0L087F6`"F)R`$=#P@SMPX?\(6P!!'XYP!R\\*`.5
M?%@*3+"'(QR!$$F`@1H6(`$`KH(-#GB1`_CP!S6HP`[[B\0',"`(+41/$E60
MP!_&8`<%%*`&)A!"&SP@`SD,(`#83$,``-`M-20A&H((024_$*<@1.`"P:R!
M`>J0A@/\`@$_(-<.EJ$&*$00F1+0T1B>0`DUH($(9S`C&>SPC4@0((B#J,(:
MUB:"`'V@%EA8PQ&:^`<%K.$!^F$%CXRP!C,4=!!L,$(!(1&!^0D"!#X0SB/4
MP"XR-"$)7%#;G)ZP0I0^H`9!R$`8M-"$&"2@"4RHP1'&4(`"C&`'#'B"%PC6
M"QS$@5P]""8A(L`@2"P@"+?@&P0$?N`>0MB``$1P``$0(`$R',%#@PC#JP91
M`2OH@`-PD8$88K"#%O1!"$UH@BMC,`1]"&$"O3``%Z30/DFDSH&"*(`)5C:(
M(N15"P2(PA.,,(&5%<"0E4#!M9K"@K58(@()(,0)3'%($LA!`39`*[Q(XYL"
M!&&!&[@`J.*Q`F4Z)TU/6%'"#,*'1U[G!#+8``X>4MOTF`0"C#&N1=YP%N4^
M1`4<<ZY!1,"`+TDW'D*8[77/P0:L;G<;:J#G$=3U76W,H%1M:,,1:M"<\FH#
3=N/X@%3=^X?V_J(-UHU'(```.S\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>o40024o4002405.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 o40024o4002405.gif
M1TE&.#EAP0`F`.8``%Q44HV&@D,\.OKZ^?'P[9F2C?7T\OCX]\[)Q-72S8F"
M?9V6D:BBG4M#0M'-R2HC(^KHY51,2N[MZO?V]7UV<K2OJN;DX+JUL)&*A3,L
M+-G5T;VXL\G%P&5=6OS[^]W:UGAQ;N/@W(5^>@L(">3BWG1M:>'>VNCFX_W^
M_KFSKH%Z=?S\^\"[MB$;',*]N+:QK&UF8O#O[+&KIJ&:E92.B?/R\*RFH<7`
MNVEA7O+Q[ZZHI/KY^*2>F<C#O1D4%<S(PSTV-181$F%95C@Q,?S]_NSJZ-_<
MV%E23QX9&A`,#?CW]NOIYMO9U'!H9-#,QT=`/B<@(=;3SE!(1A,.$#<P,#HS
M,M30R]+/RL_+QW!F8E]75#`I*1L6%S\X-E=/3"4>'_S\_/W]_/[^__O[^O[_
M__W\_/[]_?O[^_[^_?GY^/W^_?S]_?S]_/OZ^?;U\_KZ^O?W]?O\^_W\_38O
M+OK[^_KY]]/0S-_<V#LT,]K7TRTG)_/T\OK[^OW]_?[^_O___R'Y!```````
M+`````#!`"8```?_@'^"@X-^97V"?F!]?2N(9&!J8'Z$E9:7F)F:FYR=GI^@
MH:*;?HR"?6-^JGXK*ZHHH[&RL[2UMI:KHZQI92MP<&!EJK?$Q<;'G&)E9F)B
M?ZJH:*:>9"A]$TPV*C@=*4HK863(@F3#E7[.M*7HBGU^9L]G?F&N?@,L'0F4
MX\5BJ&!D5DSR@T8:/$Z4_$S0($+`EQ8M'E`PL(Z?'P^ES)02YJY6J3YAP+SQ
MT&>')#!@SC!R\R)#D@J(^/5CI#&,.YL=,:$XY&?,F`0*H"!Y(H+%E2@$5(;9
MAPR-30_/P#B:5,O,CE9C=M3(PP,!(E4H+VQ)TJ$(4YFR2J7KXX$C.C4"_P]:
M0B%'CJHT+(`D$7"#0*\X9L;T44-$IB%%[V(447+&U@`L%S94"'!DRX@F:>:M
M*$-"RH@A(6*BY=2HE:-":=S`\L.FCQL7!6@4*+!@`PFJE<K(<8;F3H81&1`4
M.?&#0=<#?5#`DJF\490&$:+XJV7AR93K24:,>'"C^8H#)9(\<`$,E+ESB*B6
M>B8,Q1AI9\@T$^/GC9\0.+2<,`4FS(0`4I#0QR%@5,!%$%\\\$`04P@011AA
M5-(1:Q#,,4(050!!Q4,/""%!&F"@((XMY9`Q(EAK@'%'`U.4L,0`]`VCT1_I
M@-4'5>54LH(.()1`00=!)*%"&XP(]L,#7&#@!O\;:BB"@DU+6=.'&7W(\\8*
M8SC"2".&H."!!X*Q-0D](3F"@A]DL&63'VG0D$05%K#ESAH.``'%!WV(888'
M)F`0`'0<I/`$%RF<MH\J9*"1@P8+Z)%$"U1X`4(`-EQP!1P#,()HFNX0-,^A
M\CGCC$;0@`2AIH[X<88$*B0A111I'!`2JIV2L><*.;@0FACEB/;,=Q,8H$"#
M&J2"I04`)*&%"0.D,4`8:YP!X2*LA&'-"F>HM(8?**CAP2(!@='&`&>D:H@'
M!^1@P1)CB+&4(BB!L800(Y0`(I'0TA!$!#5@I,@.;@Q+11$)/!&$#H*5D6E_
M.YRP`0PM(#&$"#\L8<#_#FV$"-"4\V3Y1KF9NJ.1&E7"PT@YS?SA#K55[C!!
M#C%(P($(/HP@A&P56+`"?40JHM)%;MC0`@-IK&;&B"JO@((95D#A`PUF@#-&
M#1@DH<<5-3BQ@`MWP%&&&NY.L,,`<82AQADUM$OE4FGX),D`$!APP"1BD#0!
M"TW@(84,.4P"#GUI)(!'$CRT$L8.:<"1+`V&HC%`#5Z,T(4.`B21`1;H2#T`
M`33@@6`'/9R0RI3]H7..(2'P\(,D)"ERB!R)C#%`+\'T,8`%3DBP`@$+'`&$
M'BW4K!T7&4B1Q0;?^@''"GQ,,("X8_R@1Q<A2&6/KV9`6$?51^QWB`4J<)%$
M_P$64-#""%-DP$`?;[AQ@1<*N#$@'#S`<(<T?KPFP@(YT!$"#550@!(&X`$V
MH"`$*CB?=O`0A4D(0PQJ8,,,?/``)HRA#6$8PQI"4`4N7$!<8"E"%H(P@B1,
M(0@X0,#.5-:'-$1!"X]2@`8,4`8#2.`.3HB"!220-G_(APTKV($+I)`$`&QF
M!6NX8`(J\`$T4"D&&S`!6&*``3RT``0&<`(0O@`%*&AG!$A0`18L4(,)&(X-
M<4``!2*@!0K,@`%>&)\,,&"%'3BQ$FG*P1-&0`,B>>`"+!J!`&;`HB+B(`E/
MV``#.N!%$$R@#SDH@`^^X``P;)`"7QB!#T!P@SAN)_\*[A@`()-`RA**H`:N
M\``:_-"&',"P`]](`QO*T(84$`]/$*(/$WXS`B@(80,U$`W)#`""7LJ@!@9@
ME!8$L`4N9D``1RA*#EK!)AO,(3L-.,$:&A&"`E3!!P+(@P$J<`0DX$`".[A"
M!WSPA"<@(04&"`$$0A"`[(RO;V6($,=<<\@O!B%(8-2#"NX`$KG\Z@`?.!\/
M+.``#.CABSZHF0]*<`(&9.=`VOF"%0('`A*><YR#$D`7+B04*ES(`37``@A:
M,(4Y2($+(P`"$X:ABC"4@05(2`(,3#"!"<#!`P0`P`B>D(`#*$$"<.@#'!20
MA"_8(`9A,&`A#K`$SWBA"#/_<T@78"`"!=`@`!T8`@5I(`&E5D`//GAH$`+@
MAC<P00C$PT.]%/!009I@`T](@@]D8%$%'&``'UCI`BV@$C8,H`V;*<487-``
M$GZQEQW003`OP8HQ7&$*0Q7"'+@PA\I=2#L`.($)`-"")V@!``\0I`5DT-@2
MVN`$!7C`$#"0@!EDIP4!>,&!0`"#(6!3"[])P@P.T`;E02`!3G!#U4;`!2\$
M0`4%B`$",MD@$6P#)A-0P0@:L`=&+&40SY.`9[;0!"A\`71%<$,;/%"',"C!
M!*T*`@,DL``D<$$!.B`A#"!0@2$$00M84`#ZIM`%`8Q`#T)X0'9&$`$O<*$"
M).!!_UX?4+DF'``%`QA#&JX2H6VMH`@\RJLF9^`&5V#B(F6(P3KU2H4`<`"&
M0Y#!;XX@`P&T8`9+<(,!CC"".0`I"%`@I1"D@`0`,.$[`4#?`MQ0A"Z0<L&:
M3`()]4""(N3!!C"0`A!P8($&@!$)U_%!`TA0S"E\@83B6<`UD@4":XQA;H-`
M`1B$]44!L,`-JEC&/,I0AO*!40$X`')T7S`%*+B@`UQH`5DW8-(I@(`)'("I
M#[S``UZ"\0A!_H(*0@`#'RR@%&E`@`A20*1ZC,$#&60`9M\YAN]2]K!P,``'
M&(``$_0@KU5`P!AH@-DI`.$%`U#$`'B,OB'8(`^>V4X`"/_PO`3HI00U2(,2
M.+``&\C@QP(H0)(?H(4MV)<*(N#`$I;PA`PL0`,ID$'H#F"#)P1``S)0P`(2
ML`,_[!@),Z"2/)B2*#BPP+$/:$(%HF`""<0@!'9X`0BH$`0JN#,)0\#"`79`
M@Q*R]`DN<$,,O/R`Z*;!`-JX01%J$`#A!0$)0*#MQ)LP!2'88`%"T(,6[O!(
M2B3'IA723A=(<``38T(C@VGU"52`!/0%H`TH4,(+*&`#$IR!)"KA``"\H`,(
MQ&$,"-!"";"P`VN`X0-"`$$,\-PS1=3`"E:(`01PH)TDS(&3.2B[!4(0[*6)
MHQ0QV,$S2N0//TC@`P;X0XX(D:C_)91@"@V00@:@$!$]"*`!6X#"`YY0`AW0
MLP,JX`"F1+D@/&!``VU(0PU`T`0LN&%NME.")3U@@*6+X`4AR/LJ."!6+D;`
M!A#P27'?X8X58*%F7PB`K#"2B3,EIPT_`))VAJ!"=HRI(G\(`P%B$),TG5XN
M`<F!`7!3"`],P`T;$((/IJ`%!F@`SRB0AR[<H0:;8"*(%8`"$#YP`@2\H``*
MH``%1(`!'KP@#VX@#S;D!CZQ`V,0`RDP`U;@!FB03XJ"2J[0!TX1!JM44TJ`
M'#1B.G]P`#?```Q@&ZF0"W?7'R<@`I4G.M"'"ZW0!S'```+`!4]@8"4@`6N0
M#NK0*31"_P@M1``\8!E#Q5,KL$KT88/FH5@]@0E]<``@T"+6`R'TL!DY,1KG
M\`93DAQ$2'A5,BX&J&'G@0LDP2H^T`(BD`!2$`0L8";&(`;+D0@&H"]3D!T!
MD"4"D2?S,`KSD1`G!@;Z(@`04`K/<X52>`GN<09]EPF3P`8DD2J"D0E^$`<Q
M$!YS<$PZD`014`0^EX:$H%Q!L`4+$$?KXRQKX2NCD"?O=P8?``-?(`-C@`)H
M$(B=H#"$R"N9("<>T`IL\"Y(<PX$@`'@Q`$`4TP*0`<KDXNW,`]+(0-?$$X&
MT`!(P`*IP'TRH2<#4`0W8`)E\`RDZ(J94`[*`8B$P'M^L`,80?\RE\@>:7(`
M!?`%4J`!K?`#3L,![(`&Q&@+\P`&3B``0(``:O`!6P`$))`J@=A[*YAG8."-
MVD@(\X$0Y7`6E9`]?S`&++`%6[`!;%$#VN4%-<"0,Q$&::`"0:``;7`&+-`"
M$9`#:(`1\X@,*7F0!RD,8'`"`H!OR.$'=E`%04!J&DD,A@`&%I`!&0"/`Q``
M00`":;`"'K"2+)F4:$$0`Y`"^W("7=<'%8`$5)8*%E$*,S`%%!`#2O`!CF<%
M-G$&:ZB49#D:*+`&$M``A+,#-G$`,)`$1Z`$.5D,?4``$?`%/Y`&.8`##X98
MH5*6@+F4*X``7/``=H`2;A`%6Q`$-K#])C*Q`B2@!QFP&!O`!0"P!(&9F:/1
M"!6P%X3E`6G``T$P!R&@"@9Y"RCP`4C0`@CP`T\P!#<`!IHYF^-P=2GP)J'1
M0FR'`S^5,OS`&086`5MT`X(QE[1YG*/0"BR@5\X(!FY0.1C0)*?!#R7!`%]@
M.3+P5].)G-PI"S?R`9E$`?)C`0^Q`<V0'!;A#H%S`4P`!BC9G?`9"SPC`DF`
M![Y8`$G0`*7I"J<9G_XYFP,R!B'0!5,0`2X0.2(P`8=`@?_9H-UI!H>P`BX@
M`%/`!5.`!#=@<VN@!@[:H;3)&GXP-Q^@`GK0<A+0#.KGH2H:F(B!"JD1`E>0
)`S*RHK00"``[
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>o40024o4002418.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 o40024o4002418.gif
M1TE&.#EA+@`&!.8``')L:N7BX75P;N'>W#HS,J^LJK.MJX-]?)J5E4M$0^CF
MY:*=F]G6U=[;VIR8ER(<&Y*.CE)+2='-S*FCH1T7%^SKZ5Q54L3#P[ZZN6MD
M8L2^N_/Q\/?V]4([.=;2T>[LZ\/`OF1>7;>RL/#N[<K%P]30SJJDHIJ3D40^
M/:6AGQH4%*ZIIJJFI#`K*6!;6;NVL[BTLRTF)7]Z>'UX=HZ'A34M+):1CBDB
M(?'P[HN$@MO8UQ81$8:`?F)<6GER<'UV=/W]_)V7E1@2$D9`/V]H9N_M['QU
M<^/@WUY85<?"O[NWME!(1BXH)S<P+UM23Y:/C5-,2E1.3D`W-B8?'Q\9&?__
M_\S*RHJ'AU=24E!,3$]+2[FUM#(L*_3S\HB"@:RFH_CX]WIV=?S[^XZ+BJRG
MIFAB87AQ;C`I*%A/32LD(XJ%@Y:2D51,2S,M+/CW]SXW-AD3$YJ4DLK(R/GY
M^)")AU]96&!85<_,RT@_/40\.LS(QV1=6\[+RO7T\\_+R!40$"'Y!```````
M+``````N``8$``?_@%F"@X2%AH>(B5E_C(V.CY"1DI.4E9:7F)F:FYR=GI^@
MH:*CI*6FIZBIJJNLK:ZOL+&RL[2UMK>XN;J[O+V^O\#!PL/$Q<;'R,G*R\S-
MSL_0T=+3U-76U]C9VMO<W=[?X.'BX^3EYN?HZ>KK[.WN[_#Q\O/T]?;W^/GZ
M^_S]_O\``PH<2+"@P8,($RI<R+"APX>>5*BPM4`$%UH/!E3(0`M-DA<I:!G(
MH4;'Q%@/BA#QP2&!K"%`-&CH<D)6#@44X+#P(`06!3]?&`GH0@#6CA@/&%&(
M00&BTW`(HDJ=2K4J`I>@)FC=RK6KUPD1GHH=2]9:!P14_IR]$2M$%;9N_XO"
M<@NWBMQ7=/_$;?M6KUV^=>^ZBO`7P(88L:B0&`!"09`=LF(`F+$G;=G+U2!H
MWLRYLV<(6#]M&4VZM.G36["$DLBZM>O7$GMBGDV[]J,8FG\TF=6A"@8218S(
MZMWAA@@=36$1_\.R1:SE1/XJK]*!>9\SSZOD>5``>?8"2C[\B&S#!H_0MM,C
MP\*^O?OW\+$X!_6AOOW[^/-_(+(:MO_7LJDGX(`-=<#>1;/0`(8">]`BQ``U
M.0AA+0]&.$N%%$Y("P$*&(#8+#(88(`%!)8H#`4HIJCBBBQ2$*`G5<0HXXPT
MUEB%`*&@H...//;H(PILF2CDD/[LL.)P,Y;P8O\K#T001!4N2$&+&7U-6>4L
M5`:)Y96R9%E+"!Y,0>28YEAAYIEHIJFF%2Z$(L.;<,8IYYPR5$?FG7C*,T4,
M)\6R@P!\E+"`F,^)(8,31P0ARP$;)!7$`'VZ8L(1</PAPPA:NK+"`)7.@$,:
ML=#Q05H0!&#9*U!4P087?H@@BQ!?S,&!#MC-TL0;I^:IJRI6]6H5>IU\)>Q7
M8>UJ[+$/-1&5%\`.5H4)27`@92R$U4!``,)16P42!XRPA"R$X0"&"9$ZN\01
M/,Q2+0T!$`I+M6?<049D`B0519O(YAO*%?SVZ^^_`%\Q1"AK%KPFOI^TJ'"+
M2^KK\,//A.#``4P(0<;_$[#\,$(*(#S10A?-IJ(""0O\0<$4/6A0J2M"O+!!
M'1.ID!0L+3!0A02"&:5%`Z[*`MD?-DC@,PUCA,%`R7YFH(0<$+@+\=.6:"'U
MU%17;;463(1BX]8VX@C*PF"GV##49)=M]MEHIQT0UVS+Z/4G\<4=WWQJUVWW
M-H154<$$Y;9"6!DR;&`'N%58&X`9A'L!PP:[:<L`!V6H6S@&/6M;@PL?D!A+
M`@JT0(4!*]@R]MWZ7F#ZZ:BGKOH%2(3RV>N?A4SZ[+0KT\'I2&N+P!4]2%Y#
M+80I48!JA"\`FN_`VT5!WW[+R,`L%!`@?1NU0QSP]0$/#(K!W)^)</7@AR\,
M_Q?\SJ"]ME8,("WAAH^G+1Y$C%#LNU4T4`$+R='OQ,SL)_\[+3&HE_@<AKT"
M]NM\GNA>][[7B;"%;70#C&#U**"&-2#P%5-@P!U>4('6Q:('8GC#`S"0!%F<
M`"=_4(,"^.<*`PR@)S,X3"P6$(")\*`"3FL%`-S`!!6L0$FQX`(.5@"!"LQ@
M%BC`P`6.*,%=7>V)5\L:*-K6MK=YPH%@@V`3MZBV!TCM#?FC7XSTD"MGU0`*
M(^"(Y:2@```03@D,\$"FG&4"'"".?04`@1914:T(X(`_L4!!"9@`ASCD;A8_
MX^*=J,@V*W9";I!L#]T42<E*CJ(WSMNC*:80@A14`98`W]K2'&'A)2N-\A6E
M%&4MB*"`'%J2D@6(I2QG2<M:%B`*H7"`+G?)RU[ZT@&A?*4PATG,8AKSF,A,
MIC*7R<QF.O.9T(RF-*=)S6I:\YK8S*8VM\G-;GKSF^`,ISC'2<YRFO.<Z$RG
M.M?)SG:Z\YWPC*<\YTG/>MKSGOC,IS[WR<]^^O.?``VH0`=*T((:]*`(3>@V
$`@$`.S\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>o40024o4002419.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 o40024o4002419.gif
M1TE&.#EA+0#(`\0``,?'QY"/C____UE75UE76'1S<YZ=G4M)23T[.^/CXR\M
M+?'Q\8*!@=75U:RKJ[FYN6=E92(?(```````````````````````````````
M`````````````````````````"'Y!```````+``````M`,@#``7_("&.9&F>
M:!JM;.N^<"S/=&W?>*[O?.__P*!P2"P:C\BD<LEL.I_0J'1*K5JOV*QVR^UZ
MO^"P>$PNF\_HM'K-;KO?\+A\3J_;[_B\?L_O^_^`2@<#A`A1``*)!8<`5`"-
M4XB)4@`-A)20F%0&!H&>GZ!(DHFDI::G/X.$JZRMK@.AL;*SM+5@DK!1!P(.
M"E,"`53`PL&_Q;J\OH>)N;;.SX`&C]/4U=://P4!V]S=WM_'T.+CY.70!0\K
M!9U/`<,!F4WN"PKP4/`)V_%,\`4+TO<:)5BP;XF]`0(**K$7`=L3!`=60#1'
ML:(/;>`R?OLA[9I':Q9#BAQ)<@V$`,JB_PQ<%`5!0@=2&#0(L$!*`P,((4!Q
MF:"!`'9."@B`,*!!`B@/CD9P%]%)`)8(`C0K2=4B1HU8P^WH^+&KPJI@PXH=
M^V,`@Q4#6#H=NO0K$G='&3IML$";VR/P`N2[:P2>@@4)^!:QQR!AP!6!H:1%
MJY:L8UJJ7DEN]6/4J<NH'FO>S/GQ@``ZHQA(N""T$Y>=#$$1.K6=@-9K83=!
MV/C)WP2?53\YX!-WY]_`5UC&3%Q`JLG(5P5?SKPY+5Q2=O4R1JPZ]>C)*#%S
MSATL5Z\>LV7-VKV\^?-PX.F&`O@LL@?I1`,HG-))/MI0=I&"^81^A`<U/=%`
M`RL49AH3`S2EP/\`ZZ'G8!A7C0<.1^!U]>"%&&:(A53623',=1YJ]<2'(0I#
MBGOM<-.@ABQ2$:&$WE!887@MUFCCC3CFJ...//;HXX]`VH```PRLN`0$`@Q(
M#U($1F"D$@\(@&)^O345A3]+2H&D;$DP4,``#F3IA$Q)'ACDF64,5]QEQR6'
M')IPQOF;._LIIM=]FD0BF"A['N%0GH#**6@7W\U(C7@P3CCHHHR2I-X4[6$'
MGQ32^`?%?0+4MH1^B?`WI@"^``C%@`6RY42"*RSX9*-GOICH-C(:6@VKM-8*
MS6?<:+I0*2(R\2<CCO1IQ*]0$/N$L4'I:FN0KKX:JZS3+"OMM)]TLRK_$@($
M!D!]39`8!2^H?IN(L$-X"X6Y(VIKI5,J4GMF9&Z^4MF::[IK[[UT+*@,@T\@
M=)9+Y):59`0,$-0O(@@D\$#`/C#P2)AR\3/?`@Y$;!``+IUDG%.9N//$.BP4
MP#"^)`M';W%MQBMOR2RW?$8IZW;KP"7?]MIM8$"-",!3)?XR\P#<,E$*ERX7
M'4&AT"+Z:C=&-^WT%>BHDS,_[XS<PSSU6,T#/OH$Y`]`[0AD<-@1(*3U#@PA
MF\1$3L;\-(;-)OHLM&>_;??=-N"ZC;)O\1IHL77WH+:O@?,P^!*'*U$`WWB7
M%S>,<R?=^.24`X'.`P4$K41AG#1YK.=1."#`<0/7(J'`:)E.@8!/I2.!$-%'
M.%"Q45$,((T!K5<.'+PJLS+OR9CI+OSPQ!=O_/'()Z_\\LPW[_SST$<O_?34
M5V_]]=AGK_WVW'?O_??@AR_^^.27;_[YZ*>O_OKLM^_^^_#'+__\]->_1@KX
(YZ__""$``#L_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>o40024o4002406.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 o40024o4002406.gif
M1TE&.#EA;@`U`.8``/S\_'QT<]+-RD(Z.LK%PK.LJFQC85-*2CPT-9N4DH1[
M>>'=V^;CX61;6MG5TO?V]"LD)J2=FNCFX]30S>SJZ)B0CJ>@GKZXM<W(Q>/@
MWMS8UO#N[>[LZC(J++:PK>KHYDE`0?3S\4U%1<;`O?OZ^AD4&/7T\Y"(A?CX
M]][;V(F`?8!X=EI148V%@O'P[J.:EI2,BL*\N:REHHF"@'IQ;[JTL79N;?KZ
M^7%I:-?3T*FBH/KY^/CW]I**AUY5575L:HV&A+"JII6.C*VFI&]F9&=>7?/Q
M\*ZGI+BRK\"[N&)85WAN;,[*R*JDH7]V='%H9B0>(6E@7^_MZ_GX]R`9'<?"
MP+NVM,2_NUQ34H9^>[^YMDM"0D]&1E]65<2_O71J9Y.+BC<O,%=.3;VWLY^8
MEI&'@UU44[NULXN$@D<^/EI04%%(2/[^_OO[^_S\^_[^_<.^O/W]_;^ZM["J
MJ'-K:EM45(^*B9^7DXR#@8R%A$<_0$]'1TQ#0TQ$1)>.B____R'Y!```````
M+`````!N`#4```?_@'^"@X2%AH>&!#J(C(V.CY"1DI%Q54X3DYF:FYR2``5A
M<VR=I*6FD6P84%TFIZZOKFP.'24$L+>XFAAJ5"MMN<#!AW$I1`H@1L+*PFP$
M?AX-!:/+U)IQOX=L<%$?%@8WU>&32"N'/#45)G%+`N+NCSPV%85L*45W/']-
M1P#O_H@\B"PAM*/'EQI3_CC`P^"?0T,88&PPX6:#!`TN1@%(H&':PX]_=F2H
MD$-"OD$:G)P$R3+;BP6.VD0XT=*?@"PK!3W0T$_0'"@Q:KJC0*0*/2=T3B[`
M@@6;T&IC%(`C1*&#E5%3:*2Q\#1<FQ4I"K51@"/AGS%/#H3HB@M`AB-P_YQ*
M\.!4$(8P+@0Q^**BP@(2;&,):##`R0`=<?[$*=.*4`@E"1+_\?,"0@$*'@-W
MNB&C08(4#P1PR?%'PQVS@DB0Z<,C#@4D8L+\V*'9U(T33P@(P=*"`HLF<>XX
M*%1E`!(&0I:(B0#!:.U!;-J\F;0#S!H)%1`<(0(GBP(&"C*;.'#@!(@3%C!8
M6#-5\Q0F%FPH^0%#BP,-&?(BBA,!088<:N0`@!H.Y+'""Q\0@D(/)2!P@@0Y
MT+"`=L]1\`,4("B01118B,&"$D"$A8@7?0C@0!I5L.$"`A\DT,`+H^S`A`(#
ME$!#@NM<`$8'^OWQP%I":2""&0*TIYADC&30Q?\<1FPA1&("',"&'0B,\($.
M/H!@0Q=I)/B'``KT`(43TVR@A`IU/13'!0B@P8$F/#PQ0PC92:!8`CW\`888
M2HC!10(39("`-#X200`"5!0@"!M-4#%!9LM,,0&2@\0Q0A@P/*`)&Q$,0,$$
M$"`AB!1\P&0#`C.\D$\<`7!QD@=]49$&-H_U05LX/*#!Q:V5%@!!$SUED@$$
M3#P0A1*2Z:#&*'5$\8`4@H#:SA\;1&'$"E`T,`@<5`0%':\I8'`+&T>40"@A
M(PP0`:62D&##$FTD$<:T)N`@K@D#S"/(%`%TT0\)1UR1!!]0P"!('#]L`9@@
M;^#A0S[XSE`(`^)VL@#_'UST:%<8%;"+BAR>3M%``-C`440^#'0@JB!GA#&&
M($G0L$$8'4!AA4]0<#4(`U"0D9@75$S+<`!$%/(``Y!2^R8A#_S0@<Z#2)#&
MG)R$@$,";(R``!."M/%$!'^P$<0`&@CBAA@-Y!/"$E44T`$$>C3$`0@(;`!=
M#520!L`*(.1$01H>$-)&`C\$*\@'..0)70)IL*"Q$430`2TG%APP!1M%9(%-
M`3[82<$`(%`0=A!AR!'V"3T8<8`!)1#!`Z<EE#/(>%S\L@`$8$,'!A:B#\($
M!%<4$L<,$&"R:)1%-$$("3"(H2DG+JC[!Z@BH@""MS64T("FPVK^)1=2P`'%
M_P\ES/$'`Q!047&T4&BA&!H=)#-("!V<^T<\(J09`P11N#&(%`B(@`I6$@=0
M](X3"1"#!.)@``/0Y@TJB$(^'G``*(`A,3/PSQ]NP(+`V0$$8<C;'RI0`@,$
MZP9.0``*%(*``&1&"QUHR"!T`(&7,6T`4#A"I4Z@`!01(@EZ.`,I'L"'(+!!
M`U`PG@8&D`%!U"`-';@``"P`!6FP80@&>(`$Q*""!KG@`XARCB"JT`$TC,()
M81C.(*('!"3-K0]U^0H"BJ`?-B"!!7=H`)#^D((U"*$405@#!^(@!!!HJEY#
M&`4/#+"$XJ6@`PB`5@[$T,0D#*`,)9A!`4NP!EX!@/\&(+`3`,E$"`]`H(D'
M`P(5@%`()@R@`3*81@:PX(&M#8('1:"#QC01`@0$@5H(D,$?W!"!!F"C!AWP
M0`<R@(,2N,\$-H#!*&:`A0;4P@5U*('R4`(!??5':'\(P19HX!'T=0"<1L#"
MV)8VA2*0H0EJP`8;6L#$4E@@#?G0`@3LI`,]V*E0`5!``[)0`C'\(@)1H$T<
MN-``*D!!"@6@`@A6.(@L[,%.-]###/RW*!U0`28Z$4,);,"K&V2!!@U006(`
M,(,B,``$TV*#%1!0-E+P0`Q^8`-+I80!/GA@&G`H'0)HT`$JP(&/7;#%'S(0
M!C5`@0\[H$$)7D"(*6S!#G'_R)I1":$!/>C!+'&P``X5-0@K'``#'<`$&^20
M!@8TH0\)204"QI"T3#PR+$;H0@LR<(`$W(H-`=B"`Z`0A@%L(00B2P`VM("`
M+2"@`FXXP`#L-H@84$&(+EA#&/[YA[&40%]\3`,--CL("C0@`F=`0"L^@(4Q
M/$`,O_S#!XK@!(Z2P@L06$L5$("!`V1A8>$<P`J04`(E(`!K3>##TOYP!X=V
MX`,:@(#!9E=!"4RA!26T[1F@\%Q!N``'*S!#>`0!`#K080,^\,,?)/"#"+!!
M"P/("PI9L$=2"."4(T0`$5Q'B#L@0`!%0(`.TK"`'(0!I(*800FH(`(2K&`/
M7E+,_PF@``4!5``$>PC`(%(0AC!$X6`K8($$(."M/UB2`AR```$VH(8L9-4`
M&F9#`D!`FE/LX`=]&$(=J%`!X"H&!$X@0`=&((0BQ&#(F5%P%`=K@_;(`7@@
M@((8EJ+A/T@A0R)@)1MD<(`4$``"E)5`&.#`AOMF0`PGT!0'.D":">6@KIS8
M0`*40(4\V%80.8#",?I`@CF$`01S8!<:2L!$%E#!#H/(0!]Z\`8&,"$9?AA`
M#C"`A1\\@`45>$`"!H`!3AW@%U(P@!!^X0`(#*`'SPO"`1Y``3[48#JW$,!_
M#=&"#J0!`GCPD1R8`&M"8)</#>!"*/:%@P;L<HL@$*WHB-W@`SH@0`O]$$+1
MIH!0(.U@"!%HS!2Z<`0)/`$-%+T%FVH*'2[(ZCJ.R`,4]&`##JQA!0_X@`+6
M@$JC"8`G@H@!"XB0@6F0X0`4F`'`&3&!YP;@&\"XP``0/*H.'(#=<![$!Q8`
MZ\H,``)]B+`FY$`%"'2!X85P`PV64($BA!L7=UG?'R@@@A)PH0_UC@0`!'`$
M)C2&$VVH`@%N?HB9M>J`N3"!&G"@J3C`P0=1@(#->LV6!]C@"?U6!@&X0(<C
AS``$0)""!8[`J\"PX0'/4P8;&."$+@1``(9[SC("`0`[
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>o40024o4002407.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 o40024o4002407.gif
M1TE&.#EA7P`[`.8``%1+2XR%A&MC8>CFY"LD)CPT-&5;6G-L:^#=VO/R\3(J
M+%E14IR5D_/Q\!81%-'-RT,Z.\W(QMW:V<G%PDY%1=G6T[FTLN;CX?;U].SJ
MZ/#N[)*+B>KGYOW]_=30SJVGI>/@WJBAGZ:?G)6/C:*9F(5^?$I"0K^YMMS8
MUH)Z>7UV==;3T+6OK+BRL)F2COGX^)6-BLO&Q'IR<<*]NG1I9\"[N+2NJ_7S
M\EY55._LZVA?7L_*R'EP;Z2<F7YT<HF!?W!G99^:F;"IIK&JJ+JULUQ24<;!
MOB4?(:VEHEA.3LS'Q6A@7S<O,'AO;?'O[8^(AJZHIJJDHEU44V!65"`:'<S&
MPL2_O;VWM??V]6)96(%X=EA03J"9ED<^/TQ!0?[^_OO[^OS[^_GX]\?"P%5.
M3_GY^/OZ^:.=FEA045!'1TM$1/S\^Y^8E7YX=T=`0%Q45,C#P:NEI%Q35'MT
M<[>RL%]85W!H9[VVL[:PKYB1D+.NK+*LJW]W=9*+BY.,C/___R'Y!```````
M+`````!?`#L```?_@'^"@X2%$R,OA8J+C(V.CY"1CP%H"9*7F)F:D$V5FY^@
MH8X_GH,W.V:BJJN1)!`(@V4R#BZA$E`=CS<L%2"YK)DD"AZ#"0M3`J$L1P<1
M8(T@9`I'0S?`F"1',:9V#,F@+WMS14.-7TX[3S@UUY<,VJ9U--^B&A?M[77P
M@F!:`/3X`H*206`'H2@.=`A<^&E!`12".BCA0D4APXN7'$KX,^!)`0)4DH3!
M2-+1%S)D-!B!H*,*F2-'!I2<J2B,B31:"`CYDH`,%0<POM`$U2#'LTP8%#B@
M4$%03R9,"!`9NNF!`BIH8&%"0$#J(#$'DDCYD6;CEQQ&J3["8(+/%1E>_VH(
MC<1A`9,B8V(U42`@!P`5$U0D21-ET)<;O]0*\D#EP1\P8[Q,F.N(@Q0#4\CD
M&83%3L(<&Z@H"(`B!84R@E"DN5(HP5%!7R34&!GP#`%+@F`PX?#HPIL??-(`
MZ#,(C`H'1PA,`:(`5A\RO\8<>4,(2X$GKT&X<1"AN(^FJKYH,4`9Q!$XCFXL
M&"%&1XD#?@8-*.*@P`,P&*0P<1)@P:`1#O@W2!4.O#)('D=`8$,Q!&RC2@(%
M`$'(%RD$T8@8`LB00QA)A##"`5\\\$01$#C@PR`<N`$#&@<,T@<5Y0QR`A4%
M./C'&$Q04,L?7UQQQ$8<;.#,)P,H8`$_((P`P/]&BX`AQ!:\)=!@"SKLH$"-
M<3AP!R$V*`"!@!VT004Q,CJPA59_Q$"``C)]L0,$,55@!P5,'*#'!8E%<H,1
M5#!@01`\I%%'!)1-V`(%36#QAY0QG)'$%DO^L8NB@R2E`'1FA.`%$TM8@P4"
M63C`PB`=A$"%"6)TL%(3#M20!@4<5,$<`08((,`!45B@*QXEL-$##<#2P`,0
M4SB010E/3'!/(U84@.8*5*P0@Q<$P,#!:X704$2.773AP0Q,*&!"N"(H,(<8
M?X!@`!,^'%%`%PJ,T,!')H#`&0(AB*#OOOPJD<&_&3CQ11]'X/8("DE\0(B:
M":#0$@T%4.!&%F[P4,+_Q2D0$$4-0$!AS1\9$&'!!`W\\8&[$/!500<7$$'$
M`$+-``2AHO2A!FV.Y)"%"'DRG(`.'GS10`83$&&%!5"4T$8<5B3R2`<3Y,$"
M`MCB`Y:`CH3!!P\8%!)#`1@D4$0(BH'BQ#^01.`&1(6<L<0?9=B00=F?[$``
M";T5P(XB)5A$-RAJCMI(&3J$4&A$/@3P=RA?R\3(%S.HT;4B$)ZP."A!,)%#
M(PD(P`8C$%9Q^2?/Y5D(%$5\K(@37A@\.B8IH-%(!TN,T$@$M[VN"1I\-((`
M4XTPK#LF:PS7"!LEX*P($6DH/_PC`Q!`'","<.'(!W(\?XD'!"C,2(V.](&U
M__:/9&.C(OLL\L43U)$/"0E,K-!(^I2_P8#[D#"P@.N%4#`5Z#B($?X:(0`R
M\(\0`H@/(YR0!8,,L!$+V%\C2)""J@TB`@5PW`-K8H(G'(X0*_`6(X:PFPTN
M8@UIF!XC.B"`PBRB=":D'`'NYP@&`."`?TA!]F+8&@+0X1$@2`(2%E$"Q?&0
M$!IH$"0LP(0#+D"%1_S##!QP/D:\(`!-R-,-TO"_*/[A!%2,!`*8\`'*>``"
M9/(B&*OXN!I0P#&">,("G.!%08"Q.Y)X@@YX<Y(`F(Z',Y*?)+"@AG,Y@0!'
MJN,?+*"`94FB`@8P`0!P,+DZ"J")F<A`"Y[`&T7^020'F/0D*$`)`A:@1I2:
9`"42LK`&5*8R1QMPI2:0X``%**$1@0``.S\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>o40024o4002421.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 o40024o4002421.gif
M1TE&.#EA+0#'`\0``,?'QY"/C____UE75UE76"\M+4M)2?'Q\8*!@3T[.ZRK
MJW1S<]75U;FYN9Z=G>/CXV=E92(?(```````````````````````````````
M`````````````````````````"'Y!```````+``````M`,<#``7_8"2.9&F>
M:*JN;.N^<"S/=&W?>*[O?.__P*!P2"P:C\BD<LEL.I_0J'1*K5JOV*QVR^UZ
MO^"P>$PNF\_HM'K-;KO?\+A\3J_;[_B\?L_O^_^`@8(N#@$B#@M'``(#$0"&
M1HL`CI!%``J,CXH!"@":D0$)`@>51)H!`J5#F@6D1P8)(K"#M+51`;BYNKN\
MN#:>P,'"P\"VQL?(R7T+E[%'J`X,!P5'!PT1!@((1MF0`M=%`ZDB`I-%W>3@
M1=;8VL\"T=-(")<&RO?X.@/[_/W^__ML"!A(L*#!@P/S*5S(L.$4`_V<62H(
MX94X!0.H(1FGA&,2CQM5&0&I*)'#DRBA_R!<N=(&P)<O4\J<2;,FBT4#MREB
ML$]C)'-)`!SP%/2!+R1$E0#@.4#BQ($B;4J=&H.85:LV>FG52K6KUZ^V`CSX
M9L\(!&T#%/@D@JHL$G&DUIY;Q$!ND07NC!2@5B!O$01#'\@[,B#``KM@$].Y
MRCA8UJV0<RF>3+FRY<N8,VO>S+FSY\^@0XL>3;JTZ=.H4ZM>S;JUZ]>P8\N>
M3;NV[=NX<^O>S;NW[]_`@PL?3KRX\>/(DRM?SKRY\^?0HTN?3KVZ]>O8LVO?
MSKV[]^_@PXL?3[Z\^?/HTZM?S[Z]^_?PX\N?3[^^_?OX\^O?S[^___\`!BC@
M@`06:."!"":HX#>"##;HX(,01BCAA!16:.&%&&:HX88<=NCAAR"&*.*())9H
7XHDHIJCBBG@0X.*+,,8HXXPTUA@"`#L_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>o40024o4002408.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 o40024o4002408.gif
M1TE&.#EAB`(\`^8``)24E%-34^3DY-C8V)"0D+N[NY:6ELS,S'EY>8Z.CM75
MU=/3T^;FYEM;6[BXN.GIZ=+2TIB8F$5%18R,C'5U=9J:FJ"@H#(R,L_/S^SL
M[.KJZJ2DI)Z>GM#0T+:VMJ*BHN[N[IR<G/'Q\::FIOGY^7%Q<8J*BCHZ.C@X
M.#4U-;2TM&YN;JFIJ8B(B*JJJC8V-JZNKCP\/+&QL;*RLH:&AJRLK$E)2?/S
M\_3T]&9E96II:CX^/H*"@O___RLK*X2$A$!`0']_?WY^?DU-3?;V]F%A87Q\
M?$-#0_S\_%E75TQ*2G1S<SX[.VMK:V=G9V-C8X!^?UY>7F]O;X2"@\/#P\+"
MPL#`P,;&QL7%Q<3$Q,'!P;^_OY&/C\?'QY.3DY*2DKZ^OLC(R,G)R;V]O=W=
MW=_?W\K*RN#@X+R\O-S<W-[>WN+BXMO;V^/CX^'AX<O+R]K:VLC'QS`N+H.!
M@;FYN9V=G:NKJVQL;'!P<&!@8&1D9%!04']]?8%_@&AH:",?("'Y!```````
M+`````"(`CP#``?_@'^"@X2%AH>(B8J+C(V.CY"1DI.4E9:7F)F:FYR=GI^@
MH:*CI*6FIZBIJJNLK:ZOL+&RL[2UMK>XN;J[O+V^O\#!PL/$Q<;'R,G*R\S-
MSL_0T=+3U-76U]C9VMO<W=[?X.'BX^3EYN?HZ>KK[.WN[_#Q\O/T]?;W^/GZ
M^_S]_O\``PH<2+"@P8,($RI<R+"APX<0(TJ<2+&BQ8L8,VK<R+&CQX\@0XH<
M2;*DR9,H4ZI<R;*ERY<P8\J<2;.FS9LX<^K<R;.GSY]`@PH=2K2HT:-(DRI=
MRK2ITZ=0HTJ=2K6JU:M8LVK=RK6KUZ]@PXH=2[:LV;-HTZI=R[:MV[=P_^/*
MG4NWKMV[>//JW<NWK]^_@`,+'DRXL.'#B!,K7LRXL>/'D"-+GDRYLN7+F#-K
MWLRYL^?/H$.+'DVZM.G3J%.K7LVZM>O7L&/+GDV[MNW;N'/KWLV[M^_?P(,+
M'TZ\N/'CR),K7\Z\N?/GT*-+GTZ]NO7KV+-KW\Z]N_?OX,.+'T^^O/GSZ-.K
M7\^^O5@E7.K$L<,EAQSWD+FTZ<&_/W\[3."WF!+[M5%'$H,PL40<_'$A(&)+
MB-"#@X@DH4`/=CQ8F!(]B*#$(G+0@:&&@LG1AH>.7)@#B8!QT<,<C\@A0ALL
M_C5C)"XN42-?.?2@(R1R]$#'CGO5T4.`D<0APO\@<B3QH2!,(%A($G/,D<1]
M"2;!Q1)2#J)$EU`F@>0?37X891)HICF(F(4HL007;`K2)!=;/DGD2$I.XB*6
M2?#WHXN$S#%C'?)1^(>1<7!AQXQV,MBF""C*<:&."RK90QSS#3*AER?2%\>0
M?R@Q*!=TB+#BG2)AJF</4O8YZ1^`"M)CAH;,\2*3D`[BZ*,B6.AC(;L2LND?
M3,R(9:"7@HEJJG&LVBJK(K[9PR`B*BL(@V!B>^VTAHCJIR'!:DIAGX86D@.#
M/;1AAYW+>A3N(T:N>:L=/5PXB*TP&F+DCX)<B.2[@_18QR$`#\LAJ(DP86NS
M[7[D(KLITB@(N8+0RRW_F0S:L40.=5`HJ0@'YB"BH0S222<A%(-[L;B#(&JE
MHO<M04=],O<P<,,><7CS(TR,""6<]Y8;JLE<L)L#T>R^:7*^/UO[QYN&`)W@
M'":?J@35='0,,<X;G7AL(_0ZS75;2PCY2)\,CSU7M(V(*L*8Q-+)KR!"RT'U
M'%^;/+?2<-O-!=,3([@$W(?,_?2*Y<JAM-H=23IL(DE(>.J:"BP*]\I_Q`%C
M'0A?J^Q\AK=A.-V)MB&VKL"*$*L@63/^D>,*.,V$D2*,GD3I[&*^(!=Q&!['
MY_2!R?G)A)S\^R)I7YL#O80LH4!\KC=N9+IUY(`FJ?S%L77T<LV^GW]"3LY]
M_UYGHCG^^>BGK_[Z[+?O_OOPQR___/37;[][X.>O__[\]^___P`,(`#O9Q`!
M&O"`"$R@`OM#P((L\($0C"`"&T@0"5KP@ACD#P4'<H$4I.`%'@QA""]`P@YZ
M\`)RD$,)3]C!$KKPA29,@0M5B,(2II"$*I1A"U\X0ASF<(4UQ*$088C"%'YM
M@_X@X0M0`$(9BI"$(F2A$TT(11T2L8I6G"$-;4C#+6:QAT"\X@R):,04(C$@
M,>P@"E#P1!9B<8I2/&$/HTA',8XQC&^THA[=6,,LEM&()#PC0)BH0P^^8(D@
MI*(+W3C"-C:2CE$4(R.S",4J5I*&*4"!'7T(2!2<X/\$@OP')$/(QDQ^,)$F
M;*(A2UG(1V)1D42DY`Z_^$8>OJ"66_QC!X%@@SV$,HF&I&,309C(46:2E9;D
MHRM?N4@^KK"5:6SF,V4I!Q_X0`X?W$,.2O#+?H1PB3I\P0D(&<P.JE*$Q90B
M&YLIQRE:<IIZ?&<K(2E&%?[Q!!(8PA*$0(-N\H.53SRD(=-YSDB:LY9Y;&(:
MG;C'=,(RAO1\H3W_*(<3!$`'")C`!`C@SWV<@)A/)*0G&8K.DA:RF(3,HR8C
MR=!IIM*8WS3H(G.8`@D<00)/Z$,"OO`%`G"TH_DH)1,/251B?E2.PQ2A)E]:
MQU,>LH7T_*(<`7I,83Y1HA__/((-HJ"#.R"@!0D(JQ<```"@YH.8:TSK1P6*
MR*(&,Z9.O.4%UDG***[4H/-L9U$+"E=9=G`'$LB!%"C``P(D@`!?`$!BO?`%
ML^)CB6I=XUJ9:,ZA%A21K*3L*D_Y07024Z'P).I;40E%T;)0A:J<ZQ&<0($?
M1,`+!HA`!`Q`6P.4U;'V$.<XTPI93S+QMP.]I5M_6TJTEK.E35RC54NK7(B2
ML[-`E*$$]A"```PA!GMH``)H0(#:RE:VM<6M/=*ZQD.2%Z15/29DIYK6X+ZU
MLT]5(UUC*D\/WA6:,-Q!`W+0!#RL(`EZ6`%W"0"`[U:@`N"-@'CKL=;=^E:Y
MB#2E_WG'>4J1EO>#SU5H(H6;7I,:,H_0-2=HYZK-$B!@"C0P`@*"L%$"R_;`
M!Y9M"!9,#_)BF(WFY2UO!4I>XE:8L^M4:!1["UF!VK>XG<4QCD7K0B`\@0(H
M-L%A3>!3`,3VQ2$(`8QW1F-X2/:CD3TF>2DLWQXKE[CGY:PP=YQ)$+*QO6UN
MLYM-:\,HE&`"AR7`6+V`8!A'`,8'#D$=+-!E>7CRDSW^I(.9Z.`;FUFYBGXP
M4<L[Z4F?D)#C=+-]V_IF,';P!%%`0)7_+-LZA,`"%N!`!3B@Y0K4@0.H+G0\
M%`UF1/N6UBD8YUS!_.@U[KJ]PWRPC=MYXQ,$5]/`!2T3=_\0@"44UM6HW@"K
M48WJ05.;VA^0-3QR_64=C]/6NT5TI'<\:=_V5H9+Y+5O'ZE>,8-3G,^5845!
MS8,)P';5%MC`"%+]`0YP8`/1'L$(-O"!?FO['9_4[5##'6E;C]GAC\XTG$'X
M;7*:EK.8/;2#0:O"/&B7P*NNPP<$_@&"P[KD^MZ`R@$NVX.[(P8QT/B7:4WS
M<,N\UP]VN&X_"'%"1CCCM<[T*55X`B/P\PL&J(`%1LZ"@5-;WP(?>,DM<&`.
MN+P=*(B!N&%^`JU+5NM=IS78&?[M14>6TF;O<;I_2^3V`I3916A!@2L@Z`TT
MG>"I7KK=F_Z!:%>[`E=G1]C)#G;_KFO=Z^.>>=F[37:R9W+1XFXOA2-[RQ1L
M=05XF$(%\/YOJ*<:UBHO.:M/[?<9!UX=M-9XK;G>\$^.7=&L'SP;&_]ZR3X\
M]6O/-;<O\((=V)D"06B!`?(=;92S>M`J1S6,3[YT0I\^':ZO.>P+'_T3[$#L
M-(]]SV6>>MN+N^&'3L$0DF"#`!1!"GT(P@\2,'R`YQOOUP[]OE%=\H&K_/GI
M>'W78;X#_5/?^M+G>MK7>&H5@(>6=:V7:S90`GA0!$VP3RC6`@10!U+W?O"7
M;U+G?DLW`BS@`DV'?^AP?=-W??Z'?34'<_JG>@$(>8EW@)'V`C:0`SJP`EYE
M!&"E40`P_P)V0'#NEWSO9X%]EV\>Z`(#!X+G@()(>'@B6'TG>'A)N`/]AX*P
M5W8K2'A4B`)`X`2"M02$U0)(9V46``,P8`<#1W=+AW)]IW)1QX%VX($68'I&
M2`Y=%X5A%P-1*(6OYW^%)X54*(#Z5X5AIUOCM`<KD`,\(&5?D`"P%0$<P`)B
M2(868%L1(')!^'XCX`)V4`-B"`/N%X?E,(<H>(<`.'@F.(6DN'_]5WU["(CC
M1FM1T`0E(($$!@"P%0(?X`(PP`(JQP$`T%W_1G\KIX.:N(E!Z(ER"'M0:(=\
MF(I=!P1`4(*&UX?[EWV'%WT#V'TQL`((\%4^I8A_AH%-EVH58/];(>"#^C9R
MN%@#ZE@#+E",QB@.J)B,=GB'2+A_\YB$H;B'^HB'U3A]V1=]*&`#3:`#.6`$
M06`"&Q4!6?:#'%`'MK5YNEA_+#"1F=B&$VE_SO>.X,!__0>%.P`$R6A]],A_
MS\B/8A>2\0B%TYB"8A=S,0`$1[`'3^`'21``.;`$5-9^^5:)5+=Y`J>&+E`#
M=I")['AW\*>1X<"1'OF1=OB,SAB*S@B%41F%\JB,K,>1`"B%6>=]GA0#-B`!
MO90$YV<$.A!@2Q`$[(>!'+ATN@AP4&=_':B.8EB4*]=W5H>4WR"5,`F2(*F7
M(!F*\MB,1Z"4(MF4\DB'V@<$-N5U+Q#_`T.0`WYP!PV0!U+`8B9``S3``XGE
MDROGB&2H;QUH?Z`YC)^Y<AJ(E]_0ETPYCW_YDL[HC$=`ATM9E2K9E'T)DG5(
M:T"0!$,0`!*@:$"@!$ZP!$O0!$VP`B806RW``^S'B"-0<ATH`S(PE!LPAC4@
MFG9G!S!`A"I'*)7(9:BI#5,YE1^9C.0YE3%P!'])F]='E4O9CX@V!#0Y!$I0
M!-<%6`'@<4G0`"M@!(AUF8F%@2HGAC.0BSKH`D3(@1XXD1.Y<A8P:`7WH(`7
MGMSPFA;ZFGI9GG_YE+<ICZKID8"IC./D=0#V!$5``1\0`5'PE7M0HD^P`OM$
M`W@V?/8W`IL(_P,<^(@>N(DU<'<5"*']AF`&0*'<$)L[<`3J"9-&VI>NN9X@
MJ9Y2"7/D^9[SB'O6UP!3T`)3$`%B*`0U&05/L(T(H&)&,`6^"'#_YH@R,(9V
M)YUBN*:::`=MZ8.HYF^MIF!$J@U&BJ2PF:1,NI<8>J08&I6J::&("79`8'U[
M@`<$X&J.R`)&$`!)X`<E$`1&T`<;-0$F``!U8'>5R($"QP*:N*8PL*9#>7?-
M]Z`->6!U,%NWE:?88*A0RJ>#*@'.N)@B>5-2":5^V9I>)P$-$`!*H`-H60&@
MNH,$(`5YH`-&0`->0&"DQP$*27^KEG+Z5JHW&I2H2FUU`&CC:%NO"O^KUF"A
M2%JNZIFD?/J1Y@J;MGJN?!F;,'F5^=0$/[!/7W!J&Q"G93@!/]`"&J51[">J
M(U`!9&4`_L:!=X>.PVB4%\AJ0EI;MO53XFH-$E"Q%FM3-_6:-M6G?$JKZ!J;
MAEF><[B;3L!^!E!W+&`'IFH'%O!:!48`""F!&U"@_18!9/5G3#>G",N==)IJ
M6C9;7K!GSRJQ$TL-KXFD%WND2&M3&ZN81[JQ&<NK[]E_SK@'&?5O)5=R-SJ&
M#]JM%>!3!#9\+O"&/SM;2@=UP5B!>I=JA/*SML5300NV16L-2'M3Y8JQZ*JD
MMBH!3YNW25J>\K@'>S"L-$J7EZB=8AB1W2K_6]+Z8GD78Z_%B"CG@?97B07G
ML#%F6XSU!6,EMW-KM%IUKC=5L;0*J$I:MX9*DG>X`TH`!$-P!U_``2Z@`C+0
MHQ9(<C]+5@2WN`KI;_XV6[3%B"K7H!IX;7=*6[V89SQE6`GPN=0@NDMKL:-;
MKJ>[KJIIA_ED`TF:!"_YF!,0`C/@`'0@`_O6K5D&M(EE`'40CJKV9UEVOL`;
M6Z<VIQ'JLPW9:K%E`&`+M@F`9\X[#16KF-+[E4S;KK>*MW8;J!)0!#R``$Y@
M8EZJ`Q0@!!'``AY@!6"@`KKX8O$[B6J9?&4+7N!J91%@@1JXJH#V9PCVK&'U
MKQKUO]+PE:-[L:1;_\-XB[%\RY>`90-%\`,$*P0`@&J+R`$JZP%:D,$N`'"+
MJW2P%JH,JHNI9F7(2U9C56#-)WJF=J<'!K'):UB::@(FT`(P'`TS3,,U3,`T
MK*M*"@0!\`2A5L(L<')J&)TJX`%TX`$R,*<!!XX5R9T/"JXC#+%T]VIVFKGY
MJ\(&\*PGVXLF\`,T\`-C#`UEC,9F7,:C6Y[3U0<1D`#XYG1P+)V@7*!C.'#:
MV:!LF8ES281O"%[/&K1C!;%7YKY"2E8%ZVHV"P"V2'4$T`*7&<G/8,/`3,!E
M3+I*FP1G&88;L)`AH+XE[`(R4,=NFK@KYX&[:Z/9*G7+K+G[BW1O6[!6-O_+
MG,M8)'RS6E9PFSP!8NS+S4#`,@R6[HS&7TG)BID$"&``'^"(%M"H?5=@PU<#
M=8S'M2O-:6AR8:@"HHRC'_!J(>"J/L6YB"6T!?M=M=6+/958-XM@!=:M_3L!
MZKS.%4O)[TS#P@R6>^`$$V`!^U8!7U!OL`:V%H"+,["FM=N&^Y;0'!"AU>D!
M'F"=?>=GX$6+B\53/$6+WG7+0[M3G#O.8X6^1-O1R&"Q-L#.4@V6\1S5%IL$
M06`!+*#2B!56?Y9G'#!P40<#"TMP"ZF+(U`#.GV=Y8NY(IS(B2S4>Y:_;\N_
MBIC4M/S*4ARN3GT,9AS52F`#0V#5-A#8@!W/4F#_`NO;`I@I90]-`+*%:M_X
MTIN8Q.9H=S"@`CBZ;QI(R`N==+=,RU0\Q3UE6`2`9[U(BPU=Q04[I'V=#%1-
MU5$=U8--V(9-VY*:`X;U`T*``!0PIA/`B'YG6\/'`K3;HT89;:(JG<_)D-;6
MOG0'O+2<6(O%6,P;5K/84V&EO%7L!:^=#%\Y!+%]V(4]V[5=V(([!`W``SC)
M`W>@A12P!!-@TQ60`+T8W,8M`Y@8=>&H;]J*=T'8D'\7:+-,Q;08M+W(OWI&
M5MT(L%46SM^-#($MWH1=WA5.GTJ0X9):`GL0!3F``'H0V&BB`SSP`RB]`7U`
M`T@=AI4M<$18?TY'?Y4(_VL2ZFJ0ZZK$O;E@.[14W.`M1F">&^'%(-B#G>%6
MG>&#/01)KN1[,`0[\`<[@`)*'N6]U$O[-07W'`$L!EOJ:W<%JMF)Z\0869?7
MYK5+_-,V:[.)Z%.P)<Z*U>"*F."G;0)";@Q$K@2#O0=1/;A$/@1-'@#4I0<5
M%0!RH%5+-*DZX`3CMP1_QHWO"VLL,`,%X`$S4*!!&=.E6@,]F+"[^(:P1FI2
MC+R)?%B'-;1`[@67Z:]YQKQT7N?$T.>WK01-KN3TV4N]J0,!\`=`D`(5I;U'
M$``-(+@2`.AXP`/^"@`;D,2$L@&9^,P>,`95@`8.,.T[/7]U&7J^*XZ&#*ZE
MC?]GB\7F]\W+"+G=&M7JKBX,L%[DLM[DU/7G19`#1^`#*!``0"`'6]4`O5D$
MU'4"@IT'Z_<#!&!W&]"M^::=#M`%&(`!86`%:##IHWSM/FAM;CO%J@WG^TM@
M7Q#&_=O"CLW1YRX,?I[>3"ZXZTY=@"X!*"`'*$``#7`"<N"E8+F?2@!8\]X`
MO"P$%)S,[6?!#C`&!P`!$'``5[`%DRZ=/8J=[F=MT0WJ0!VWVWWQS_JOVYUG
M8?7QPC#K6&]=[`[H23"8V'0!2X``$B`'$D``L3D$,UF3`>"839``/Z!BPM==
MN*@"#@`&5I#P&"#T5>``'D#M!KJ&U+:J*NRJ0%W:JW[_\7,^[MA]VLUK]<`@
MN"*?WI`OJ=:%`C[`ZP'0?W*P`SEP`<S6``T0V!Z^C4O0`":&``G``UX``PY@
M!6-`!5UP``?P!F*0!5I`!P4P!E9@!0Z0BQ=YPJV&8-)MW4]OVH8/L_[JP@F`
MD$WM^+L`Z)`?^2'OY/2.`D<@?DX0`%T7!7(0`T^0!SDPF4X@!7Z@W@$P!=O8
M`OYI!Q<,^V;P!@<@!F&`!50`!F,`!EWP!E:PTW(*"",;%H0<%2$5$8H&C%X$
M$Q,$7U\$E98$"1,F)IJ;G`D$?Z*CI*6FIZBIJJNLK:ZOL+&RL[2UMK>XN;J[
MO+V^O\"L`0%[Q<1[0T,!23IR_SLV*"?(2T)#>S8!<B=1=SH!.E'##4U2$Q1W
M"#05&S`.6&('\6]O75=9557O6&@>,BX;@PA9J,`!D2)%``!@2N`E(:5+7R!M
MZK3)4K"+&#-JW,BQH\>/($.*#'9L&#%E>X;IB6%M3XXG0U8,29$DQ@4?*/9$
MR9&D"#9J4UJ8*)$'00LO%EBH&",&0X<.&#"8Z1*&JADL6*@4\`!#$$!"(3C4
MJ6"@`EDO:"DE!.#E2]I*F3AIFI"@;MV1>//JW<NWK]^_@#$:&[8GR3(C")XH
MD;`D0`,)1R[8.')"QYX40'80"_`DP)$F+5H`X!"AA1!.!CZP*+`E#`8%L!<<
MH`I/C/^6*EFL\*LQ0M`'"R&"(S+`5J&!"`G;`B"N<"$DNG3CT@U,O;KUZ]BS
M:]]N>%B2[PU62%%RI($3!$>&7%@_),J.)"\P)VF0Q`^/*%$BM=A0XT,"(T$0
M8($=,X"1A6MPI#'``AC,\\8!8E!1A182HC$#"U\!9U8==0#PQ5H1A+`66V[!
ME4DFT&W20G3;M>CBBS#&*..,AC40@![I\("'#Q(@P,,420S1``IRR!'`2\M(
M$,`4!I@@H`$_U`$0#/V,4)H7+LS@`!I54'%`@@-@<,"#"T"`P156;-'E&#/8
M,8(%8T7`R'&++&>6G`E50DDDD=3%IU!^FC#CH(06:NBAB-K_(DX2""2P0@!1
MI+"##E[D\8(2D?IP@AY%-(!.`$NL8\$B!EBPP0@NR%`E<1NHX($56F1QP``#
M*"`5/+:>J8465DCH@!T;&(*GG639.19Q#3E22728$"`7)'9-D.BTU%9K[;74
MG2"!,DE($4,2/R@!+@V4V=``-"N8D,0%0"130@0P;.`G`<=9,`(,!3@PR`?L
MJ,#K%6;`UL$!604,%1:QPDK%&##`*2<!7AP4@5F')(*G`8Z<"$I=!`@5770)
M8"ORR"27;'(M.QPA00S.2%"4$#``L`<"`?!@``)-U&%`$#ZL%T4?!HQ0AU$)
M"$5`!2/(L"M7,M@APU)47($%!`H,_QQ&%E?`I@`65F!U#QW`#E3!<A,K4D&<
M<Y+XB"8<+[1)H*"$<O+<=-=M][0V2&!##"><D,0*-.#K:0L!L$/#$P;,$,`?
M<OBQQ`1?L&`!!4X(X2$`$S\MQA4.>#"#!RH40$47LD(`@=570%"K&6A0046:
M=,"`81T%C15"'1-33#%R7G!,%\0+V17\77<7;_SQR/^5S-X[Q%"$$Q40P(,1
M=@CAQQ8N\%`"#$;XX$,`0N`!@`R"1)&$.A,3`$`%'HA9!1B=.\#:@6$<(&8\
M6!R@``0'C.$_K`6`@9LLP`&`B"419Q,(`8MEE[A=XA)Q`T7R)DC!"EK0%P&8
M3-]><"0_-/\``!MH00.$0``=+,$.*I"`#VP0A":L@`,"=$$4&@"T$'P@1!;P
MDAG>(`8PY,L#K.F"&<2`A2ITX0U;&$/]KH"&,10@3068@3\V(*HZB.T0!?S*
MPQ(P"8A]P8&7:(M%+DC&,IKQC*0(P!`B0Z03-"`*%:#!!CI%@")$04`_&((/
M@M""$B3!!*HR00,00``:)$5V*@!#%>QW@"QH`0U/K,H5I%:%!W7!"E<(PQCH
M,"$TT*%S*N!-!.RU@0\$9V)6)$0%E*6^WN5I$I0H41<K@<9:VO*6=K/13&[B
MQ@E\@'PZ"($!:D:`9!AI`J8I0@MD`(,5-(``4^A#"$;``E2I(`O_4#E`%<8`
MR3%H`2M<&X,5X.'(V'D@*V#8`A@L1,4(U(%?`[E=00X!G"\R1"%N0<M:WF()
MXN'RGP`-Z*'HLX<+R"$%<J!!`;Y0@#X880(-T`$"^K`')9Q`"&0Q@2%90(`\
M4,`"?!1F"%C`@AEHX0!7X.8F"Y`O*MQC"W0`70"_X@$J.""1VV1!(@!`.WO!
MR8H()(XE'/&%.3&'+6($GB0$RM2F.C4[WTG"">2`@B5$(!T5L$$)>*"'*"PA
M`?@)`+V^P(-?UJ`)33B$"9:S(G8X0(B.U`T:M"!$A&W!`V$SVW(V,$I3<86`
M8>E0->$I3*%*0CDC8L0^D_J0+SSUL9"-_^Q(GA$.&R"`!4^0``!<(`4\(.`.
M0\@#'NY@A"7P8`(T`(`%9$"`%1@A!)F8P@3:4@<6T*$+"!/#&^P!,`B\P0I@
MX(T%TH8)`Q`@!!NP`V\`\DXX?>"Y&)J8,!,RIRVJ#UEM22I<Y";9[GKWN[PX
MP1`ZDX,(4"`'1="H#J1`.1M@PSY&P,./+/`!&)B`!RV(``WV&X$/@)`%XJ20
M_N['2"P4(%AC2\XC`!`">V%H`RR@76^<RPX6]+5LAT!(`CBA/K;HJ5D.!*^(
M1TQB5UAC&%*XSQ,0\`,A!*`$4KB#!"2PA_0*(2@_(`!RV';?`!'$`/Q9*16P
MD$G[02`,6F!8A_\\]*&,`1D&-:"BE"K`KZ^<R@[`&82<J&P(`&S8!*!(5C^9
M1<L2F_G,)7YC`QHPA"),(0$\:,($OK.$*.SA"#MXIHZ7Y05DTF##7ZC`0+Q@
M`!;(``TJ<,`8^K&%-^R/81IZ"$20YCD+4&)B`:'GH`T@+$S7P1'/B9N'EW6B
M,:+YU*B&K!&*((4HZ$$'1C!""0B9@P`X,T@-H$`"$**G%O"`!TY"FB(B=B\9
MD)2O7N"/%3P03])@XCE>.%MO/E<'311U'1\0-'*68P`.(4+;*`)S&!\"QC*G
M^MSH_N<0S%6"$3BA`240P@RF$`Z"VH`"?TY$0P`P@6BVH!*$Z%!9(#S_`]E5
M0*/%5<@ZJ/A`I+G``]3<P!?`G`#5&ALXV65$6$*@B`X]A\R'[2+'OLC==)O\
MY!>,`4]*DS(G4.`'15B"'Z+@A!4@P`1]*"HC*$&#%OR`+1P809>),\J;LJ!)
MH:D()A0LB>/4EDK,_("S*CY*.[!`F!FG$UD4,3P]M666VS4URL=.]N+MH0%3
M^(`.4)">/4ATOS00`@]H8(1_$WI40DB`;-GRINAYF-@;"($]30"H%H@:L1$(
MNJID%X&Z,,("+GB3G.9TI[40!UJ5V+=A,T_N+Y;]\Z`_&1`:X(`1H"`%0P""
M''+``Q2MB!,M0(`7PD)W'CA+Q]'[,"@4^\4^_\T%4'7YT/H$?2_)6>`1.DZ:
M#"R]B,2+)0*8^%#'Q)U/ID-,691P1.BWS_UJO2`!'BA">3RS`PI,X=K\!L42
M"%D!.//@QCT''D,>DB<]5=RX?HH@O<Y&S[%X&<R8\P$C<$-6]'BE5`?V]&R_
M<WUHD53"(PD0`P#=-X$4."@V``,(,$/F$P5%8%R$]C`1X`4(0$C(=!2.T`=!
M`#F50")-EGEL41;ZQD5*90"(,!P>LC'T(EU6!!"W\Q4&(#PH`DLL"'9>IQP&
M4(%(F(3:P1,I@`(O$`4?@&45X!;+H1"E(00M0%:<P&W(='TZ1QRSI'DVM`$>
M>%@-H0B&<!P&$`DKF/\[IM(;'*!*^"<1?=)A^N00)B()R;$<2MB'?O@73G@!
M,;`'0F`!!9=[F-,6"3!1SF(";0&#^'14BL5DDP`B]&5<E%A4B!"'9H&)VR8G
M."1Y.P=BS!)+#;@6C55]R>%8?]B*KA@2JG<!YV-U,S`#_&:$QC5WFM!A(<)Q
M:&%4DW<Y^[0<8_&+)((YN[-3H[0!QU(6B.!_&1,M"[AO#N%AC=6`^Z9]K[B-
MW(@1,8!0>5`"R38&+-!Z>C(Q!A`1`,@(%5,LP#B,>-A*$4`)8/B%C$`J#380
MD[=3Q*$Q;6,)'S*)#9%]K`20&=.-")F0NR`!1'(-48``==`".8=\R&A<ZA/_
MD`=A5",2@;`D:<KB0+!4">G(8#K3;6-!%I,PD,^V,?\8@9:G6!Q9;@NAD#19
MD[(`!$"``DK053H0!*=%":"P/NF(D67#'&F3'`WQ0->5AQ?I(8>%.04Q,0,Q
ME"-2D"M(A0');8V`$$`)@0WD3S89EF)I"BT1:R70!S_P9R.W'(ZPBG2"$$:E
M6&BAE+[C)T6%CO37B=15C]AHE8<EB60#E^G83W#Q<=(REHB)F#G@0LBD4?O%
M17?(9&3S;10SB1NIE$"Y)Y'0$(DP2YB#,1]2+-2(BA#X(7=Y.<2AD6(4-X;Y
M<8GYFF'Y;T+E)RM":-2U;90')Q8SB2&)(N56;I68_WEZV("56%V3ARQNX188
M<X95F2P9PR=T\2QR$3*P69T)20,3P`C-`@G7=9OW:!:W$R=D<93VI#$0-'+$
M29@C0EU[22I'97GL.81=N6&-J3'0`I;6F9^MV`?9B7^/$&9&.2QG<T"5F9JS
M:2*_R3&C5IB2<#&3>(_'N9Y[B9PK&#R:$!H>TPG/(2CZV:%_&`05UQS;)7S<
MMA8$,72@R!S16"+-0I@G`I3Y=WW5]:!T<I02*GSDUD\307A"X0D92IT>&J1(
MJ&-'Q4K"IX:_>#;3539RPDJ9@*`LZ7H4MY(NV!!J^)*DLI[$*6D/=*$J,@53
MH%$8FJ%"6J84")J61X_%,?\GDQ`BN.,(N<-8>>B;?B(1/-HV)9IU[VFCMCEJ
M'/.;/(JA)H!C/;=?GV"FB+I]5MF`QW$GR.$696,<3;HV$?2G'X<)GN`)D*F5
MDI@VC:"B156%3FJI#52"A#>H^W5C&B5NB=JJ9=>5):(<&<FI2%6%*UFJOQ-N
M*I)T$Y$`:EBD5*B5'K:*57D);),)/=JC/DIX/_`#@@HMKAJM)Q=+.$J%9J,[
M<B)I;7.?NMJKD-`"^P6NA#=;PKJ*1\I[P5HB'B8\]WFJSWJA0E&H-.`)TR&M
M]IIJ*RBAMYD[^J:`@0(=`-N:/EJHXK:*VR4\5(B-)=I8__EQ<<&K&JH)A0JN
MSMK_<V!VKQB+9G$SD)]I>9$*%X1GGW-1IZT)+;]G`BUH(IBW$)*0DEKY=6[#
M"?1*>#0P!320EAZS8>`:&N%ZLSV7L4!+8D["194(BA(S-FO3JQ'DL*%6I]&"
M@^?)AE7Z8=<%DR#KI8)*LSSKK#OJ<RJB(H4:M&+[7=/H(1BV.S\8'5,J<OX*
M,AO*DOW4DB3JG2])FG&QJSP:J#N;K#P[KTH7;F,;N)'5-K:Y(6CK97;A)``)
MI<,3L"#S0-38J+DSN1H)HW>;M^,JIH;ZK?N5EE);A4@EN*+K5!L[F0BT4Y;+
MG0X$MW%[(@Z+?(>5@P?AJ*<;C&Q1-'P[IKG+H]`!KO,*_PH)*S$1,+K$&U!Z
MLJ_D&7;<*;4+V#;2R#9A1#:88S:S6[O(`A<M8+,TT`=S-P4XJZSN"K[B9INI
MF3M65+SH>TO1ZR&$-IAC]KK#TS;TUZ)S^86+L'6[DY''$8T;]@,_T@="(`1H
M"7>\VK?861<<]IG72A"$\`'I^\!G5)!AJ*V?0*<M"9"2"91BI)P3.GD28Z,1
M4:A@^GY!$,#<RP.>ZW/RZJPKHJ`=!YX;8BH;`,$T?$$BJI0MVI@@P[J0&YFQ
M5*5(6:(:R729L%_>*P0`@L0^:;-"8<`W.W?SJCZ*L(D<P@%B00@`4<-:/$&]
M$S=$F*OTVI)?";P<C#'-(GRME/^O(ZFOZIB]/."3`(S$1L"]?<#$<->Y4_!K
M/9<`@E8'P2%H<8C%OS'#6US(Q3,17O1A>P(*SR*3A*EYS.&13@E!F`E!-/LC
M;QQK2(S$*,B]:4D#O^:]/`#`LG4T8B$<84%?`.$5AMS*=?.[$"-4+>@[*YMY
M#7@)M+J@46N83INWX)K'`%S"`9S$=>R3/Y+'O_;&)4P##5J#P6%%5=8;6>S*
MU%PRF_F([TF8L3M4Q#F:JAFW&XJA!*R[6QM-G1P$*&C"<A=-H3S*R1S`0G#`
MPS<Q<;C*+.`"U43(U;S/U_*%^@2&NIQ/8->1V;@6.'RA?GNS/X#,WIN6"YW,
MOR9WW`O_QP%<PLD,QRB,S`!L!,!&=<@A:*="4BQ0`Y$W`OQ\TM4"H=@EC/T4
MJG-ID&KL$*J+O9T+=Z/<!SB=SN@LS+$FS$$@S!5M!$)0PL;<!STW!3N-&'T`
M9C#H3OS"`G9@!RX``Y'G`BA]U8BB3Q\)O),,H)&<BL$Z:ALJ$>"*R;\6Q\.,
M&`B@UIJ\R?`<U&DMP+_6K"@(=T+P`W0!@R`]`G8``S+PU_<,`U@]V(3ROJ<J
MM6L)NOR46!DCLSU'L9G\?F^-Q"-8V4(=P#>-R5/@UK&&&$.]Q$@=!']FISK&
M(:8"U3)0BW\-`U!&V*X=(X$BSOOE>QQ&C=DE1@Z!Q@_;K/XK_\P((,>7'6N5
M/8("'`0V.]=)%P2=C1@_/<?O]R.<##R.$&WT)8`N4`-/HP(JP$RL_=K>W2(R
MZ[MWG*'@2J[7B\/"B0D\>]&>O=R=;=F8[;F/\`G(Y+_$#2`EO-$_XI,H^Y9.
M+0A0#0.?`THJ($7??>#8X0E&_,FAO"*&JH=.B;LE&`GD)K&]'<#W_=YKK<G<
M:['JXZ@*X;M##<_!'<^@',6Y<SMOB"I^[2H.\.(Q-0,(/N/4T<1W_,0_,MX4
M_FP:1<K&/:Y?9@+^ZU"6O>'"7=D5/<JE_(%FP6^H5;-QE\Z<C%]^ME98I,K4
M=-TM[@!T0`?YTCDT'N9^T:P]A[/[=?_62\R]XH8B-2L$"(#183H7@SK*:CV"
M%##<=G[G`HR"^)7`.]<)99W3#B5W%IO7[A2'O<'B+>X!7/Y)G^0!'B#FDJX7
M><S"<)?'.XV"L39W6@O*FSP]`,*UFH#4;#V"PBW4>6[J)NPQ,"V#]_7&W"O`
MV+F+N-=3O3'2K/TT7,Y2+WY3,C#IP"X2R<S@T53"GBW'A.Z_P"S'"$`!`!+G
MX`K`IM[907#GB''DE2W,>"V_RN(A&@7K>CR^"K$<87$JBI[:C%X`D/1)G2/C
MP?[N':',$(W6I0[/&SW,=HX'L^8CH?$##N7<FZS<E@W=0_UKRFT$?Z8G(3F0
M10/NL#R]Z^/_3O9"37W]-.FN[I#$Z[\.[QR?$7&,UL!=YWC>[!10\B4O!2M0
M`B6P!,8-IDCMYL.,SC&OEJ!\UN_'T9$0X;&+P`[UXPQ1%FGHIA./ZP->`&.P
M!4@/!F/@0RK0\4X?#""_R=A^YR5?V4NP!/H.8R6P`BN@[^OWYFC]VSA]S`&,
MUXGH:^\'P'VP(O('@:"F46X>!$X2,2=J,7'XU%-M\?(#!KO"*UNP[D\?^+T@
MU-<N]0BP!"6/^,V^!"JO[WC0]4VP]7C069VUUB-8PK^=]DC-O?_FJ\9%=P(<
MSP^HAM(7[81^7?GHQPEDSS4@X(E&!VB@)EE`!;R"!K8O^+B?"QN^__NE)07K
M=_7`S_@KO_)24`(ZL/4PA@>//X+KQ]9H^<84^V^V*I&C_'I^;J`=L]G`%LLX
M)!"I9.Y3#0,N;O1J8@^[LDYHD/OJ7PLB3_(JO_+`7P+*7P(4,/Q;S_5=KP-<
M+P66#PA+"`A&0C1!?3PTBS\`!@8`7@F+-"V6+1,3`(X1(08)+30\/Q->!A$5
M(18;&Q9U%JL;(S4P,BH>'F-68%I95%M655I6?\7&Q\C)RLO,S<[/T-'2T]35
MUM?8V=K;W-W>W^#AXN//@^8(2^EX4G<KZ25X>/`44G@KZTTK@T8(%.?]"(*,
MFL)HR@0#(2H8^))I0B43+4Q,,.%ETR,#!/]:*$K@*`0'6!]:6?@HRT4M&3,\
M.'"`QHH5+56R8(DIC)S-FSASZMS)LZ?/GT"#DJ.PQ!\Z>"6DK-"AHQX\>>Z:
M2,GG5$B013RF_`@29!^/K!J__J!8)P+#B!,P)<@4,<&7300R?FU!($*$CR%'
MC!`9BP6,6BH<T"G0$J9,+%FNS!3*N+'CQY`C2YY,^6:)RTO@+;&W8H52>4GK
M29FZXDZ3?((0?!5H0A0_(3^T?A729Q$!+UX()/CQXQ+$%E,L$0!P-H@1'A.^
M=`*Y@<5>YB/LG%1)6!>5+%T0=PG3Y4KE[^##BQ]/OKSYSNW@36W"M/.ZSJ6;
MW+GC)]\=*>8,M07_'D2((DH\($+#!+I-D,`DHU!"PQ19F9```0ZMU@)'K\`2
MRP<6RL*"="@)!@8PUV%QQ15AF"&&&%V8I^**++;HXHLPEG!/9SKDH$,3?K3G
MF5*FM7/'C4LU@0`\JL4U$0U"&"&05KQ-X22!$!K80B(TF&#"%`)1$HH0!-&0
M@!>=U/$12!:N,H)?*'E`!QI;@.@+%F*,V,6<,-9IYYUXYJEG-O`MQ=2-[2DE
M(WP\KN"$#O7)>,<2/+Q%@`D_)"F$?S\\!!&!FWP!824-B=+E5U]5B6D$8HII
M84BLC&`2##,$1L<88[A)8A=4B!A&&'OFJNNNO/;ZG1/S+77/C_5Q=MEE_Q10
M$(\4.M"G@V>"(!?7HXOTT0=!#GZAZ8-@Y@;A@1`IN."U;7T)@"IU>)0A"\ZQ
M0$N:!8RA!1@O82=&&%508487^?KJ[[\`!RPP-O.UHQ1\=Y2P!#LE))O:(,PB
M:IH42P@QH6X/ZK9(*`Y6!,"!8$8`25QKA1+*QAL;J%P%L*22H5[LFH32+730
MNT45,=UZ1199A)$%3`,'+?301.O*3CM-@(99LL@:58@0BB+J#@4\F$#`%P]B
MM):5EGR)BB,=V47<1)>4W9I$!!A004@6J)L7"R[880<M*:V$!AI@7)<O%G/J
MK(466!0M^."$%TY9/?&H)T7#3:?CM'_]T+@"!?]!9*MI1=-.E*T!=:12@2./
M1!*ER9>(FK5''V`XIBRJ_O67##)X4$"\UO%\A1@FFA'&%57(:_COP`<O?#A%
M*7PL40XC_\_3"-BSCA$78WY;7+AI"@`J'#RBK1?;XQ87I)98V?'UJL`B4EZJ
M2O>Z"K>@,0;>P9!XA1EO<->=%7</K__^_/>/3%'^2(<@,C,H>23K@.:@@&80
M\`.W7"TN7^#>6QY1D4=$P&/#R0UN</.QW[1E.&$BDP50I:IWP2XEN"`,_*I@
M!C-@X85S>B$8!N._&MKPAD0;!/**TH_,W`,S`DP>LHPP!:M-ZVK<XR`%,R5!
MXF1*6V\A3@(@TK%35&#_3+!X!2N:PZ&9J60E#HC7%K1`A2[$*0PS^=L6P#`[
M'+KQC7#<$SH42!0=)B\S`BP*'A5FA`%-"R[<BLLFB%.1*&9P$QX#&_<FDIQ3
MH*),'-!B<^"V/ES003"RHU?.S'"%+OA"&,"881Q'2<I2DH<HF?$'/PZ8K!ZJ
MXQWR.`X-(!A!*$H/=)#@A!,O<I%!1M`+#N+$%5.7.NBXP`4U<($M9@#&2SI`
M7EKHSH@00Q/\C:$`=#"E-K?)3:'HD(<`L>,@%&:45!+12Q'DQ$(.="`0BDQL
M(K,@+R.AJ0(92&VI0-46MW@F--TB,"N970&V0(4JD*B@?]/"%L;@`154IYL0
M_XVH1,/Q37+^PXZH;*55*F$N1U3`+$=\BUWLHC94)"1TB.2>D1Q4%U.Q3B^I
M.I/<;'&+E:CD;KS0@L_H]1*%HH$.#D5#&R=*U*(:%1KD5&`J$6A'S`Q"(`V$
M8`4C0!R2I7.DJ$#%*[*'R"C6\VHB7=M>V,4N?KH.)<PL@`-4,@9>Q*0+:%AK
M&-LZAK6J!!='S:M>\PK`=PCPHON85&\D\J!:VD4AWHJ@(ZV8$+R,)`14104D
MN`>Z"E1(%EO$D*I6!9A;X"*,8N2%6NF@DC4)U0,SJ)L*]LK:UG:S'P',XS_Z
M\(,`C0)*A>5@!79K@-Q,\+"[#4'G*F2ALI3THUK%8O^9BLD*=[F.50U-B5H%
M,[LQD-8!-,,F=@'J`1FX]KO@A>,YC$!>0@AA$/Z9$!6]-*T)XI.WN+'B;L4D
M7`Z4#T-LX\!'=WO8=#G6%1Q`5<S4]Q?V-123-95K`7BQ!:&2]HL>@($+PDOA
M"O,O$;:5#89I:S+Q6:TB%51;64A:$50$]R,<^(@D-Q`2#$$VN*8B29EB41(7
M.+>S8,3%9]?*IBJ@,0M6*,!G52`#.XS`PDA.<N&X1H-*4=%*58)4DS]H$4=F
ME9<BCJ1RR:1/%\]W3*J;\3XG24DOXH+(,Y@=&-8\HC`<X`TSP6:K5``#O2CY
MSG@>F.:X)A$"@8(M*;L-)(+_FQ#(1L(+J5!%9C$$BP"/,+-M4]>,1S)C])UI
M531=Y@QBQR9@S*^%;\@")+!+BQHXY\AY3K6J=26^B%AI(B5[]27<(LSZI@*D
M`&"9^?;"XA8[NLN47J[JP)PZ?L;LK+`[8>R>2=`KO.$`57!!"4YP@@FHP-0V
M=LZJM\WM.IFM-9786.G0]@6$?%F_"HG$73(T9I'LLYB59L5C\3+F#Y#5+W^I
M@0EAYX&6O`$#<'B#`V@@`1_(80\U\(!)I&/D;CO\X>6IA*M#T:1*4<(@M$9(
M^2S`WY&::M=Z@6E,Y6TA8C?ZX_K<YV;9==;`6.$*&$C#&>"@`#5L(`<G2,$+
MJ.T'_Y3`@!8LV`#$AT[TR2CH9+7%<%9&P:U3F&K8\\WB"#\0<IBQ*^0DG_1C
MZWLJS&+VTC#8D"W&\(8%*$`!`U#``@Z@!BT,`05`V,$.8H""$P2!SC\/>M'W
MSO>@-)E!H`K0I)0$EJM=[Q7%9G')6TS"4U_:!6=ZSJ2+V3G+*I?J5=\L#&1G
MA0ZH@>8*Z``$%`"!`USA#B>(@03F7G<4Q,`$$4ZFT/M.^]K?Y"M]Z,_3)#4I
M17Q8;;'@M0@SJZ%VL4MN9^*+L%MFV8WK4^0L<,`6PB#Z#I@!`]@?/=KAX`$=
M`$$"1XA!ZJE=]QA,(,)ZM[WZU]^-/B3)'/R(/U<&]*##!_]?^"3D]>/E5@.Y
MV?@YK,!HK1!)+_,7D"<+=B`#TJ<O!]"`&-`!'7``HL<&-(<!5X`&10`$&AAW
M1W`$0$!W*'`!._`%139[['>"*#@-QG%1R6((55)_C\0Z5\=KQ0<S<:-O_G=J
MBL<<^V0'#G`%5K`2'V)=*K$%MW,[;H8!!X!]HK<``P`'$&`&6E``%1``'1AW
M)W"%,4!W+_`"14!G)IB"8CB&R<`/`&&&"L1`52)H5[0*QE=65I=M^M9_I^8<
MLH`^&X)L"H@8;:50])(%8O`&N*.$9K"$2P@!"P`':0`'$=@%!6`!40!^'Q@#
MWP=^<Q<#+Y`"0[!IJ$:&GDB&.O3_&JN$'[=E"FU8?':0;39X@ZYS@"IW)C7@
M140F`W_A`'DC#&1$!;<C!@ZHA('H@-M7!F4P`!`P`%<0`0T0`'L`!-0F`38@
M`=`H?M26`C9`9YWXB=AX@D:P83P`.480&\AA1<''+OWW?Y=&"ZYC!WS17)OG
M8*05+]@E.S\#.-OQ;(:HA`^(?8<X`&G0!@P@<S*@!1A@`7IP!$KPC."7D-&X
MA2B``CL@`S40AMDXD;5G!'&!"9AP-FDQ(/97?"91CG7X<_XW`HWV`3(P!OGR
M/@J&DF/024>(.[SX@&:'B*37`=B7B'#@A&4@`,38`'A0!$.@!$?@C$,P!$-Y
MD-`H=W1W_P([\'/72)%0N7=)L`=+<`<MH#5JT1H3@#TA,6#Y)C?&1X.M4`<P
M0%"]H`4J\#<S5`!4P!VX$P:_^&\=8'9HAX@+0)-H-P!/2`9DD`9E\`7?9P-#
M`(TV@)#.^(Q#*7?4=@*;V'!1^9A%=P(7(`=R<`1"@!&9\"@FL#**IA<V)C<Y
M*'+RM@%V`'-O``;2QT;S8P6Z2(B!6(@'@(@T>9>RJ9?;QX^?IP!ED`8*D`1S
M=P1[,)1#Z8S$*7YQ-W?4E@,P(#>0V9P0EPX-D`)_D`(Y8`131!=7(V)F`C=^
M80<Q$W28]0$<8`==,'K8L04.50`OE!BWLW:PB0%I!P':EW9G1_^7:<<&;%`&
M9R``:\"7`Y``*)`"OPF-&B@!07D$+R!^<Q=WXH<`_?>4SAFA>88`34`!31``
M)[`'0[`'",`1D*`V`39)J9A,[<)K+&!O6[``&/!O!=`%^--)O&@&-AF;B)A]
M<$"?9Y>C:J<`:9!V:L"C:L``:^`&:@`!>F`@>9`#$E")AQE^)[!Z'HB<.T``
MW@FA$GJE2"8%7T$/$*,#2\"&+E-\=$A6Q@8&2C@`89`W66`&V&%&V/>FHR>?
MLGEV>EFG3Y@&:<`&9'`&B]B7`^`&#_```U">`W``!E`$X#><T(@"+Y"42GD"
M*"`!%F!D5HJEE@I>/P`A$`$NHJ`)C+7_G<<4>9$'>2J`!0=0(@<0+[RX.R=R
M`&JW`+!*EV<GGW#@GWN9!FK`!@.@IWW9CV2@B&TPC,2H`A1@E$M*G$<`J5>(
MA>*'`@&@BI<:K15F6:<P61EA-<*D1>D3=/VD%W90`"OZ;"Z)!87X!A$(`1B0
MH[9YH[.ZJ_@Y`'NZFWD*!VQP!F1`@0S``&=P!@\@K#(0`,^H@4-I`\D*=P2*
MA9#Z`E(@87LAK0[[75=4>2.#*9_Z4E<W21L``UCPJ@?P$O<R)Q(8JZ-G=GJI
MJ^J:ISW*!FNP!O9*KVR0!F10!F2PJVX@``S0!FI0J!,PE$P9`QVX>JF7D!JX
M`Y#J>@"PG"?Z_[!*NU?%Y0E3Y*&'U9DPPVL8`@/%F*,[TX#HNB_:1WHYJHCT
MF79@2P9J4`9NL*^?IXA\";,QRZ=E``<%0`!28(5`D`+BMZ0*.IQQA[`7H`>T
MJ"H2N;2"&U$8TCEFD3'EQE]2JQ<60)(N@`7\J*+I6GI*"`$1J``YZ8282[,Y
M.Z\PJP9GL`9M<+9G4`:YNJN@RZ=\209K``-^,)C/^(Q;N`,:Z+/0:(E1*G=.
M`#L,&[B#^[O:U`H?]04L]5O!]6CG$P(J`*]IEW88,'JPJ:,#8)]G`+IO"P=N
M8+INL+W[V@8V&ZPH2[;ZN8@"H`8\L`=XZY!12HD?6(D<R+X2\`4PH/]6=':`
MP'N_W"2\`!`EPW$1B;9E'(`%/1JV4"B?2IB7.*J7I5N]NTH&1-H&$.P&WBNZ
M`B``]HJK,LNR&:``%I`'1+N83"EW<G<$OUF@QPD$1^`"GK0+L:=M^/O"I#02
M5,5$@V1B+(-BJ@`!;O"R^DES*NJ$B*B(]`JV?WJV;^O`V[N3^2H`;2"Z^=H&
MU1NSH"L`:=`%)="L($R[*+R!!=J!`QL``4```V`%$8``%D`',Y!W,+S&<%0'
M93%(B,0)6I5%%0`#"D"VV:NK%$AZ3K@`>GJC%(BG:K"R]JJR`E`&_L@`-KO$
M%<S$;K"G:Z#('M`'4<",B[ES,:"4([QZ"WK_A4<0`$M@`2L@`9`Z!!:P5G_!
MQJI\0PDQPW#\7B$0RQ4P`F:PKS&;I\UKF[LZO0H0NL/HP"M[MFYPLXJ<KX&:
MK\A<P4WL!FLP`'2``-#H@2E@MZF'PIX<S3O@@<,Y!$D0B<W*J!=P`@C@`+6P
MRN;</_`%Q\*T6[LE`PJ@KU!\KS=:ISTZS_`J`(]\SU!\!A",S,=LS!J@`0^@
MR*.[!@?``D80`"@<C:FGQ0*KS7M+B<<JF*MGR0V)`G)P`2]P?C!PSAX]//SU
MH2+MOQ7@`&10P<QLNN]:LHNX?6=0LVI`!KJIR,P\S`SP``&M`?F:`0(]T(':
M!@O``D*0!$H`!)@L_XD>.+0H+'<%*G>WF]0>2&TQ<`%U-\T7<`0`@`8?O=6_
M@V4H94&[I0+#O`;Z.8QXNHAPH)\RC;DG'<DR#0>-+``#+=?'/-`W':C'K`!T
ML`'#80$FL`<I`*F3.'<BO,79G)2>W+X,ZGJ+R:@I<`$24`=</=F#<VBX5*V1
M4`%CX`8:@-+>>Z^[6@9K\*-.J(C[Z@8@X`9_6L&!RM,,D`'^[-,#?0884``1
M*0,'8'8R4,F":0.9O*!,;=@=F,T?**4?/'Z0.HT8/024W=Q#LQ#EUDN<L`$*
M8+/XK`8V^P`Q/;IJD`;%"+.ERY^OK09M$*B-C-,9``("D`'LW=-PD`5I[/\!
M8H!V=*FBL1D&#O`#OOV;PTF[/[MZLYO<OWT".U=^TCC-SIW@`E-/U[-8!@`#
M9*#(%<RG%+@&V$ND[`JS^=G$`B#0B2SAQ]S>[,W3<`!M,0&?D<S2=/JG<&8"
MM%O8"\V!BIW<Y8><TMB0Y(<""K[C_J)$A[40#M`&&3#79Z"GHYV]HXUV1:ZG
M:I"]96#70Z[3QMS:>"W0`\"+>ID&:R#7:P`!N'JZ"]`!:.<%1R""(IS-/JMZ
MS'B<`8KCR-W8C?T"/#[GNQ)%FS##'A#73,RR_*F];'!VB]BCH%O,C(S7[!VH
M&C#D>+T&-HEV;""D/7IV^VJ;*PH!=*`$+_#BA:W_Z=6L@44+PG4'PG%.YZ2N
M)[=Q:*9`!S=]R-FM`6LPT&T@<Q"@JX>,=L(HU[!]US<MT(K>WHD^Y,2H`"H[
MLS=:C+:Y`&+0EJZ[A<_8R6I.RHO)D--,XY`ZNXJ9W*6>[7827YOP`6S0X2#P
M`-9]!C<+P<,XZ\P\L\(NNI$<X@R0TSG]`".>WN(NK+@*MO(YE]XM9"JP!.!G
M`P>IQ8=YK`).X-/<>CKW`J[WVS<NY]K^\"VB6%\P`G```I'\VCI=OGW>!CF9
MGZ#[A&F]G_Z<Z/(^[XG.`"#`WB(`VZ;+KC@:YL0X!AOP!3D0?L2YT$0IE%O8
MA9#ZV)1)U=3&\TJYA8T-__%&KR)5!0-/+J05S-/BSI]^6:@O2[:_.@#\3-=W
M#0(!/>\CCO(@D/*P/;/XJ7;%*-IG-P,($`#'JK<[8`,:2I@A'*`O<`&329F!
MS:B+B>:B?@)'W_?CH2DNL,BC+:2=O<BA"P?I.L@Y6^2B_=I5_@`KS_4IC]XK
M;[,OBY_L2J>_"@-Y\(Q#`/"(K7H'B9`G@,*22?=U+P<IT)`ZQY2>CMP-Z?>R
M_QVP)]<V2\%VK<PY*P;\>`9Z.8P3+.^MS=Y?K],\G=X9$/FI[08]BL]P0*]I
M0*2[B@4-<`2"^?:WB[?(NH$[(/=RX`,&I]$^;[<5+8T@//OH+QD',.1RK0'^
MF/_R=%T&88X!^3G`H/OJ-SWB7[__(@`((!F"&B`@1"(:`F1N96QK:F5G;&F+
M`U8-0YJ:-A*>GSM'HCM`.R<QI1(Q<CYR<A<O%RBG,3$[IC$HNBA_O;Z_P,'"
MP\3%QL?(R<K+S,W.S]#1TM/4U=;7V-G:V\<9#`("#-\"&0]K`FH8&`-L`@,*
M"P)K;0P9@^4:&2+[("*"]X-(X#`G:4`:-6<,LC$(9XP3"39L*(G8Z9.G4D=N
MW<IHZU:,6!<NI)AUJJ3)$R=X<5O)LJ7+ES!CRIQ)LZ;-;?88M'G`4QRZ`6&Z
M#(#C2(&",FKH\31D[T&]?_8T/"BDCTB&-F<8D2F3A@W_437L%`0YH@K($8ID
M(7K*6`J(IUI`S(HJ9>H4BA2U8J#4BQ+ES;^``PL>3+BPX<,L[VFH-VX2A"X=
M!@QX$SE-&3(\'PSZE^^?H7[>-)=K1`;.&0:1U*A.8]2"#2`Q1KFMN%9"1E)'
MXM:Z958";+YZ9^GEVS<EXN/(DRM?SKRY<]%.'[11DX;U@0X0('3``(?-5G+V
M1-C;;"C?>*8,G*XY0ST-F7=JUI21K,!*DA.^;_?^E#NWQE*G[("*6:7D)2!*
MNB"8X`DOO.#<@Q!&*.&$%%98CV8/7,;&?!`H,``&!QBEP!EN3.4//TSY\]EX
MBPDP'1ED5`>'&MZ=(<`9<`RP_X`8"9S0WRVV8<1?D''%=<(M)\1U1%Y'`J$@
M22FAT*`N%59IY9589JEE-`^`H($(:\"QP`!D=*A`CF]`L``<;8!WHB'B?=:/
M/QDH<F,92%5'26EGG-$&?1U8@8"/;<DFREIRD6)67DYB5-<L#;XP"TDC14GE
MEIAFJNFFG")F'@-C'H#C&P/,]XZ';J2G&0YRWG`#G>>!\(``I*618W>2E6JC
MK2#2D0<MN(ER:)"^*;GD!:3L@()&"*:0P@L'=L2@I)+ZU>FUV&:K[;;/Y)1=
M%E:H0486";WC71KSI->/G"BN*$@;Z]F:*YD'K3$46`H<<(`%#>R0`F^'YA9D
M*,+:=O^"++G\6Q>#(B6)(%]W2;H+MQ17;/'%F2Z&P1M:%`#!&F5*]B<EYYAW
MXC[MRJE(5O9Z*-F&9R"5XSO9.?"$*DD"2:1_:1&(PBMRW+4L7,/U-=)=1^\R
M,<9,-^WTTX:M`4$!,%0Q0,L0#."B/&=HM@^K..#PZKKKYM/B&0?-S(8;;D3"
M)QP*8(<!"S8@29>Q.]@0L%L2[,!*2"DT25Q*!SL[B[((4OLLU(PW[OCCV2@P
MA@PADAGWQZE"HNZ<(KCJ^;J#B*<34I%(LE7IYIY3AE$8C('';G<7Z=9<M61T
M02LO'+G;<`GWI4LN4B+]@K,I0&[\\<@G#XP#=F1WP`,>F@'_`68,E+%&>'/B
M(%#8K#)5CHMM*(45GEFI(4`:DJVVT`!T-)!S1W'A9IM_;BG[2J5[#1Y\+(%'
M2KRS(5&>``=(P(MM`"B/H%$'WI"&-BB"`1HHQ-=(``(<$($(8[.'(&:U!@94
M4`18Z9-[$N*5JX'E0Q:@@`3Z\A_>0.101=+=+@Z4OY0TZ`0`#-Q(_@>X`OKP
MAT#<T@&HH``WH"-?`S"B=#[S-2*([8(X0!F+-+-!GK`G*P9QC\S61P4C^,$)
M43C"D5)@&XV(HA/QPUE)?H<+PN&P82D02>[B:#C^J22(>,RC'I7SAJ,P0&H=
M6`@;ZB$`E(G`@B1PX@W$=J)RI.<>_S1J`VDB,8]*T$B0#LA#`!H0A0!((`D2
MX$$+^F,1VT@K+WH)G$?<^$8=$@XDL*!C\?9(RUK:TB8=2,,90):UKI1!,PR(
MXB&)0()B*I(?31G'-RC1MABY9PUM:\2?U,`")T1DDWT801\\T9?9&<M)*=D=
M#O%RH.`=#&%OU$5([D>\6[KSG?",'!D84,*#J(&*&G!5YQ9)S$2B[!];DXXD
MV,:5[AQD0^:#$1;V0)$`3,$#12B<2&1QI+F0`D%'.E`<39*@7%P@2A>0PTC6
M*9)VQO.D*$TI,A2P-I;"(9J<.^0B$5E,$2""*=(!QYWF4=`!(*0K?2J-&EI`
MB@"TH``8Z/]#"EP!.%?D#A4">A0*;)%*BEJJ.,URQ?\`&$"5>O6K*LW1C<@$
M+P\:,FR')`$2+.@&,@`D,[0B$33)X!42L4<-J4(*#!H0`R%L`50?*,(+@"8'
MAH7DAK50$%^&)YS@D,2QSAIL28FW3K!:]K*W').-VB2..;WJ!DYD)`V.$(`-
M=*"0(A!'!'6R!OE8!D]NF(<DL](&"R@A`&:`7ALR$`8@+/4%3E@"`GY@A":`
M<D&ZJ)8=L:HT*0TOI"+=:AR[BMGJ6M>'`]")4U2KC\Y];9AIL($/?&"`?ZKJ
M1N6C:VRAV:>`@N$)(9@<#,;`/`AL$X<!X($!`-`"&IA`""4(@B?_/](@KDXJ
M8<Y59TE#&I(&`\Y9UXVPA)%7AJO<R&N'/"O*!B"!5D@`5JL]!SK$U06WX2D<
MXE#`!KHPGRN8P0$&V("].O"!","@`AR(@`E:D(`:T&$`53!#`>JP`ALP"(`H
M",DNMCK1Z4X7<-2:L)2G_+0R+.:/7=K'!15I06(^H`BL0,$8Q)83:+8)$F)H
M0/4VI)/J=<`!-I55%US@`"M<@0T.^,`:V(`##&S!`00(`WT@:#X&I.$-(5A!
M%)20L,"-,U+\FZB#H2PE*EOZTMSZ96:Z9,&P+5++-B7!!I;J@QU`0!\/<,,N
MY4H&+"SA'&18@R+4X(`^.*"855!``62P_P5T8*`#'G#`.CH`!@=TP`UI@(!W
MXJ:`15@O!"7@P0<2D(3A&4YI(B$L*US!SEEB^MO@QI12J&C3L&&0D8L$@07V
ML(I7Q``!9+@1/5RTADH$`2G01+89:%`#$HB@`P?`0@%&0$2C)(4!9^A`&<P@
M2,M`(`T8N()04/R&`EB@`B/X0`@J,`$3]($"?HB"D:$[WI+[H,D7"+?*5UZE
M;]0#9:$-[3^UL`<<:M4'*2!`!LJPDS_B:0T4B!D9%."`*F#`!?/,@+('H`(L
M+"#9Y@/!`2IQ!@C(HPR_7L<!QA"&-WRC#`6P<0YH4`$[H,$,8NAZ%K#@``X$
M@:^N,/DKGLORNO_;O3EUZJX38\X]%9G`1R?@MDB'4`Z>2+)-<#""U1<`@PUD
M!P,WR`"K]H&&JYQ()Q_2`!*<&+H'+$0-$,"`&-``!C%T@`5=*`$J)+`')PAA
M`UK(0A>N4(4L>,`"JF\%MV$1TKO[_O>&T6#G+K@]1>J3`2MX+LZWC0(%?&,]
M'73#&RBG!BI8P`(T2,`Z;J!6(K2!#2)0:]@4@`42D".TB\P`!C.`!1E080$R
MJ,(!NM`%&7!@")42R0[R0``'@$$+55``#@`#";`#)?<*#09\"KB`-H%AW&-N
M:(4R"M``(35>L7!R%U``"!=;5\<.C6`!+1`!%(``"7``2(`$8'(5`Z#_5FLU
M%(DD$,74?4A``@]`!UHP-QB0`2]C>G5P!!(C:0W``6"`!@5`!\PS*`>8@`RX
MA$R8&(?T@!:D3_LP"&,@`;?#"G&D>P4@'V00"9+Q4HL``"9``#3``PD@`"3`
M`%O@`H<$`FK5`R1081G0`S-X@B=(AU8!`0PP`#6@`'055+HT!1+S1M"%``5@
M!40X`P80`"B0A"G7A)`8B=70#U!X03,E-H90!DL0`'NP;5<H!P?@;'BR)_*0
M!6!@`6C@`'7@`>:7!C*0``.0`0NP'JKQ`%W``FXP@PIP".&'@B)P9U=`!1Z3
M(WZX%5V0!+!`.$PE!Q)@`%:P!2KP`?T"!./%_U22>(W8V`S#U&5.9%.6^`\,
M``,$8`0=]@JZYP$XXDR0T$#VPH%@\`%7T%9PTR%;``.LXQ4C```J@((<@%0:
M0`0/``,.$(]=(`!CXB%L@!!NP`8;$"6&TV"M<`<L4``&D`1D=`*M0%W9N)$<
M&0Q.E$A0)$PWX#V%,`!?T`)#('=R@`6F4QILDR-E\'3S(09JL@Y&<34L$`(,
MIP!9LP$Y=@5(8`4;D``J``8;4`<6@`5&D08=``\=P@9!]0:,2$>P%'<G\`->
M8`,?)0&-^`H=^95@N7>7*$R-I`\9D`9/<`'4N&TG=P!MT@9PHQF2,!U<P0C2
MYR%&$0\P8`5XZ8=KX/\!+H`&1*`"+N`!53`"&P`#8C`4DM$A\\((\L$#<20E
ME,5MK1``!X,?$H"%8-F9&[EWW/-9PB<"/)$!"E`"K["9.'<">"`?:H!P9V`/
M&-1:N0('';)GK\ES!7``9'``<-`5"J`"-#`%,T`%69`%6T`%'I!+/A63&&`F
M1H$K`W``43`2UN9@@B=21](WL>"9WBF)>P=%^W`#FO$J3N$-`S`!*>`#0\`*
M3D`#!X!P/(=7;9@!/T$RFE4)(,``!^`!5G<`-+(&&.`%7H``1A`B17="76`&
M7:$C'=`!"[``9U)"9#!J=[%@),5@AV-*<O"='LJ$W>@JQ,0JY!8:[C`"MX/_
M`D<@!Q;0-9"P2TC1)FBC(T,1(PP',^1P`&$0!AK0A?-!!P9@`"U``#FR!<?&
M'DJ9`4.W`&H2H1)Z*M,I`9'U+)/68(<S.W?TH5KJ>_W43_X6.IMA'@H`!@:8
M`DDP`:6R/JKA'5MQ*D^Y.AA`5^@B#@.`!6-0C&G@`1M@`!/``Q80GVR@`*K1
M!JSQ)\_3!D[ZI"(R`$O@7%,B:8`S5:0P/UM:J7?GI0(A'O=0'N8Q`!#`B`1P
M`!$W'0AG&C$SC_3!4ECG'602#F4``2%R)DS'`17@<0BP`6Q@GVH`!P\`)I%0
M!3"`-HFZJ#P)``1&F9-%/`$B.Y;:K"L'DC<E"%`1_Q7V,`!F$`16L!5P4`!M
M``(N`A9(T9A98Q3+Y@8*@`&QQ0"J!@%U\`$PX`45X`5]B@<ZT(>FH099P`YP
MX%8,D#4ZXJ0BTB$8,`,V(#0,DEP%]E3Q<PO.VK#?!EJ<!QJ:$4'X4`ZK4T3L
M4"99T`CG0"(N@FQN\"<L)1GLL:]],B(;,[!":@$$L`1Z4`0R,"/4H1!M8Q`>
MDJ@2:A2/9P86"0O-I30!PAL[X+!$2V7[I*D:A%.]>@/?NA`"4`;@T`4\B9=K
M(!J"0`88P%)'$2/WXJEEP*LBH``>0`#[U0=%D`0.``&18$3NP`9BD&J>*B)R
M&S>BV@$YL!<_NR`:X1%%V_^W$N9=G%$G4V$>7@())>(..H$.5)"V1A$S6+$>
M'\)2@>0>^TH&.`('-X(:*F``!$``)B!<]#$4K<4V;X`#"3FU(N*DV]$Z`6!M
M4%(<NR$@N^&WM%M=_9!!HH%,&E!OENNM'B0('20`8(!LC+D5\P$/!@&@;3`?
MOPF7OYF09?`!1I```"`$*Y"O[[<`"62NO;H0-QFPV<&D&``#*V0I"4(2'D%#
M,5"[[`M64;0NXD!%=?*TI<.V&N"X=(D&;)`U<LH&"^`&N1*H?\B%!W$J4L,!
MM]H""(``U?JTZX$4/$E/8>"O<:,.OS:N"$`<0#M54&4+47("[1O"*85,]CD5
MXW'_(^+2%6G`-HC:K0)01%MPKNQP-6N@``^0JAB0$-V!$)2P`%T`!PQ`!Q70
M`A]```@P`SV`"&?)-G1U/?*A`F8BOA=L%#-0OEA5$E'51A(CPEP,3QE4>..1
M(6N+)V!!";%X`\A&!F!PDT.A%#6<*W$Z0DHA`!CPPVJ@`AM@`1OP!4*P!B=X
M`_-Q&63B%.!`)F[ZG$V:!7FP,(-S"K`1+9;2Q9)L2_Y@M5$A'6O3#H2JPC8"
M&I:!!AV2([I483<LLQ@@"=8C28L``6:P`%;``A]0`0;P`R7``(F$`]_'!KJ<
M*EDAG3RI'3F[`$(0+4RB%Z:P2GT1').\S'JT&2-9)XWA_Z/F6J/D(`A1)`D.
M,'6.L!69\YLT\@:6:R-LHP8>`@%;<'UU8`!!4`(F(`*;!T*V\IO@`)7KPY.(
M[)@N$`#`D5@>#"PUA"#,'-!`!">?\0!]PAXK;$^JEBKB`$$/8"O"M@"J$0FL
M<9.!6AF/<!H(MPXR$`$`0``3(`4T(`!(T`,X@!HCA`X0L)B[RAKJD!T>H@))
M@"2TP#O$`02ON\4"O=,#1)KEP4&-4`:\S#7A,QV'JZO"-A1]<KP>$B/P8!IE
MP`"6ZP[Z$@'[-05&P`,YJ%8@`"/0.R-S.YT@`M,8H`,VD`LV70M#8Q+`DS@\
M_=;)(QY2`0[/YR<:@!7R($FJ$?]O(*!JET$'$/"UH5P=XK(0$@HC"F`9X-`=
M6S`"6A"O2Y``92`&)MT&6Z%+(,,(WQMZ"_"@36D!I@0E5)47RX(XYPO0<)W:
MCS,>RD1OL;43J884JM9:>$4=9Z`"(ULY;&PF'1`)30T/9Z``=#`&$*"/"+`$
M9@`&2MJ%[K$:X!`OGHH!G9T=8Y`$1B+:J(1*OI,2E:+:WLTX/<$V\A!;?2)B
M:(-7,8,^^PH6;@`#,WR33(J77<@.5^<B0KT&6C"=%;`!(;`$$4`'9B"H?L(5
M7F%$Y?++H9<O>-`WQ%',3$+3-A0X=_'=%-XT]LD>X1`^/T<K7I'"?1*H9^((
MMVT9.F+_)@9!5VZ#+AP8'W"*`2J``"TP`W9@`6(P'2MLV;K,DXL0H1><'1W@
M!;ZQSXE5TT.>6$>#$MY6X4K.+<]M1-]`(J/3%<P]([4I2&M0!55[L1XBG63B
M';3204*]Y5D0`B,H`S"`BQK@!CF8(7``-Q+MOYZ=M8P7`+E10WQ!0T1N"A*3
M($O>Y]O26O3P1X">%5[Q6MKZO>8B`%9@1.3,QEP^(P^\7O+A!@.W8W:P`0Z`
M!+*B`(O45N<2J+_FV1V`!7Z0+#4=+7C.7"01/'[>ZM="*[`-3>[1%3LL+@7Q
MF(P0Q-GEO?.R)UUHO/'6-E\K<)L[`5\``V4P@X60'MW1")1P_\^/QP,,GMT-
MWLA&L^IQY.K:KBG@T*O>FA7L@>)<<1IP22/[*@G@(`.2@3[S8A`T<AG5$2-@
M@38%\`$S``,68`)3H`8D`(=W?0X><CYNFAT=XAH7Q=;`PB17+`O-M>T.KR7A
MX!0ABQ2?%^]=8U/<=P-=P;8J]A[$^`ZA6Z-($<YEL`56O0$HGP`5H`9$8-)I
M8`X#0`72S9O`W*1LX`*O$0K&K!'9O48<G!*RT#^!\_!$;R4,K<IHT^:%O38\
M`4W@`7VL<4"YLN4Z<B;-K4LQ4@9A8`$`4`<`X-$`,`"]2`2[L@!;L`$`D+5J
M`M,#(`-)D!99W!'`P<A'@B`,;T,@7/_T>B\AG/6T;:4GE#!"2RU)ENN!-0P#
M)]3N"[`.C4!)-0(!6(`&,&``7M`"!B!Y_2X>`@`!5"`&%7``T]F7'I(#%_'(
M<H_,L$L<L9`[!^L@>__ZSC%O*-SF[J&F6$$)OPFU(/!][R`#-,*8[P`'8<";
M0FU$FF/9R48%8\`!,#`";R``VE-(+JXF-J(FHLP.$6`;GL#S;E$@0Y[,"U-2
MW%UIL%_^RH%BX1[OS<USA$HC]^0/&N"]6Y"M9](!LX<!\B(9W$P&;0((:F5I
M9F58+@XP+AXB.!IN5PL0"F5L'1`#;'!P&WM`$A([.T!`.S&BIC$Q)R<H**RK
MK2^NK:TH?[C_N;J[O+V^O\#!PL/$Q<;'R,G*R\S-SL_0T=+3U-76P@QM`F5G
M961D:FED:6EEW&YJ9&4"`FIJ`P,J6/"9!V;P[N3@WG!KYIAG',C08N7#EP,,
MV`T@LX",FP$*X*094`9&`%!`5*$R=6)5JEBL0IZ8A>*%+%?74JI<R;*ERY<P
M8\J<2?.:@#7CU*PYHT\?/'!B8!P8X$;=@`4CZ"B`1VZI`C)LR&Q*<^;I@#49
MU+@YX"*$&C,;8&3(0`8>G`%IX"Q8^JU+'@FD3*7J^)&C2%<F3;G:N[>FW[^`
M`PL>3+BP895G'(YSLX8JF6YEU)PYPT9&!!CPRJQA`P'`!@5+X3DM_\.47!<Q
M4"=7M4,@PA49=:Z``)'A[+=Q]"KQ`"7!HR@@K#B"9+6W5:Q9K%XH3W&XN?/G
MT*-+GTZ]VYETDZEJ19?&C8`S![HL.`,!SCLV&PB`IG<6#ALU<'`?4#"QS9D'
M8#@$$4+``IVQ(`A`R`)I+34(&34,(<$1&8V"RBJJQ++**[5,B((JMM#R`G4<
M=NCAAR"&*.(9.$46V3<[#5*&=R`\L!E$95&D0@)O@(;!`F>Q\10;C&U"GV)A
MP%!''T8@4$$9&3"001L'8."41#H5$,411\@5EURP#%?+*S%0*$L*M+0BXIAD
MEFGFF6@R(]EDD97#QG=%K7-30J0-`,=2"_^H,((,F&"B4QILL-$&!EF(044:
M;3``&@LC<)"`$#Q4,98(;N!)#U1K=!#%@G25\AMP'8'TBG+%C43<!13VE>:J
MK+;JZJN'Z73&36=X)X`;Y+BAS3;V*8")KQV8$88'&V`2J%EKJ,$`'&]@@6@;
M"KAA!0L6$,!##6"T\4`&(L`'`7R9D-$&&P;8`-<.H3JHD2@2$@?+*Z[$<`&8
M>)5T"ZSXYJOOOOPJH^N*:[21Z'5K[&3K&@*PL0"!:8!FQ0(%C-"%>V5(HM,:
MVVK0AE9M4&'!!R%X\<,$`BA0\`,X/$#&%9FD$4X9,B2Q(+NGR/61EB71.QR8
M(;F2`G/]!BWTT$3_K^J0=[;>=*M6[`@@L(";H`7'%@K0@<8,`R2&F0`,/,!`
M8P-@L`85(1M000LKP(`3&5B),%M$=I:3A1XSL_L@NR*=,N$+8)H4JKW$\5U2
MT807;OCAAI%X1AL!,T#BTTZOX88;/*$EV@#S%:!`L0QT,`,<17VMCK8/A%$!
M#WW\4$<3!Y`&>@8"9*(`&P,(\@8""VK4H(,W:VE+<BCH)3AQ/V^(^/'()Z_\
M-(Q)+K#DBW-]*V12T:<C:`>DX8`:,'20$!4+%)Q0=THN$`(-)7RQ@0HF<+/)
M&0P<\.M"@QB@!(0UCQ)#*7ICV'//>#'%<@)'KWLM[X`(3*`"<\&X@-E'_RO^
MX)K`2)2LHYP%-`JX0AH\<(8KT,$=5.!&F]B`,3?`P`(`B`"C/!`&$3Q@14J:
M!#W$,8`I`.%"-$O%1T3R/^+`BQ5](QX*?@:T!1KQB$@4VDW6P(!L4(Y$34N(
MT\I"PT"980QJ*(`[7)")LU#E3A`<@`P,4``8G!`-.!#!3LC``!!`)3Y0@H`.
M+E2S")VB(WCD82U\Z(H=I`!5%/HC"BXPBR0:\I"(3-/7F,@.-W#C`=,K@S9P
M)0X%;`$"9&@6&1RP$Q4<X!M4:4,9X)`H!HBQ!F64@=J0D+`7,D`$$W$9''@"
M@R%@*$*B.,%<]G@7'[8B!5TB8DDN,*^1%#&1R/],IC*?PXXV3,YI3G-19&K5
MC0N.`09L>0HGVS`&+9BC'-K8V#:NH`(.#(`#6,"`"$2`B41E0`/B^$8Z#E`"
M=-%E7;F,A9?<%4SDI.`$Q2.)'.;ELV4:]*`(K<D2`W8K`8S%D>A05CO:((DT
MC*T.8.!>?,C)MH(5+!UL"(,!"#"!`VA@#0=XD^3<H"2>W,8A$Y``+3:B/W2!
MY(X\M!>7B&B2"Q'3)#]+J%"'2E1JP&Y6B^06$43P-<F,PSR9&$\!9"`C9RY@
M!B0\`QS*P("'8`$&7E@!`LR`A!L\0`,,F`@3&;"`J(`R"P'8@4GTQB[@V`46
M/>1+J/[H-U84<Y#'+*K_8`=+6&`T\:Q?<^@#1(`$$+`)I/!@PPP4<)V%R`!7
M$%"!0VBG$P6`808L8,$&UK>%1C"U+*5<0#B@BCM3X?)!_G.7N_@2ID'N$U4C
M*61A=\O;PDIQ3@\([EB:F('KW`9C2]%$.F!0#@74@`U??$`79%"#.L!@`S*P
M0`B6@`566E0`C4B8&R2R``+8X(__#,XH,A*J=^G1A\@99JIL0:H3]/:^^$TH
M)+GV6VW-!@<9\`<4'=FFJ7C@/7#P0"8*!H+->2$!=?!`%S8``"-I(%!I.`!6
MQAN.`7Q``@`M2:CL:$][ZG.?)TD.SW['-R)>(+\PCC$B$Z*-;8%``\'=E@B<
M_RD.R9PC1C)Z#!E4T`$U",!K7:B`"2;@`3",(`():,(75$:?B&C"/0.H@A2&
M2-!TW3)"[YKOEG@&.-FF@&]HEK&:UYQ`!JRHE.QP41M`(+#WM&F:T(+N&3S@
M#S@(A0PB@!T:)@"`&8"!6@`P`0(TMQ`2T:X]!ZB`!,X\1+_]1BY@]N5[`<CI
MD=B+;VP.M:@/UU`I,FY67G-'.D!)#D$L)"HRT,<6O(<#,EBA`"R@R`PJP`$3
M\&`,&N@&2^L$#PBDX0XGF-<L+.VIWED(Q7K-Z:@`^;,7C_K:V.;72L,IN77,
M1E!BH,\H[0P:<*C!`Z$T@PH2`@<(%"`-&J""'380@?\@P.`!H@3'DEK&!A68
M@0(`_=D>U647"`4NI\KIZUT&2<@A!C7;$(\XJ\0%9Z>E00`I8P,#WA"5M+2;
M/A212@$0U@X52`8"#NA"H`M@!Q80(`C<^D;M0$H[!9B@`4EX0<.5$QPPMTN?
M>M1KF.!+T$I+_.A('U,S!8;OCF4`!`BCS#G&6Q70),O63FO#`!P`%2U@X,@@
MH$,%O+`!+62<'ED@2MCZD&Q4_6Q4<Z79ID\%S%7,%:#)IE`,=-[3>5D[Z8`/
M?'0FY\!M,'&=ZN`L%$VD@C$P("I:Z&JE"#"H`Z@%`E38P!34X]"'8&X2$#C#
M`%A@@PL,E(CT.G/_>-BE4G'_*4,!-Q4>=?Y/OAM0\+C/O6!JM:N$C"6-WYFF
M-]BPH@=<H0,!@P,5)L,`!($F*E@0;0'H@"N>Y&@-HK%"%_"0@H'.BZ<.;Z\>
MN_2"V%9ZB)7&*_D%SM?`ZO[]\'\)%*4(O]E\1Q`BC,R;WE``AT#K#1K`+0]@
M!@7`#@K``@!``S/@4%46#F\@0P>P`5^P`B<P4(*S%Z1R(9NV3_\$=,43$CMP
M(91V`9[V1_%W@BBX$OW54%Z#*XY4279R!EA`6>I0!F*``6?U`&HQ!HQ1`!80
M`7TP`4L!!]]1%6$P'V]```E``T_P?6?68NAU9CKD)?M4*K_32[+08H(S+RG8
MA5X8_PU+%#G2PQW&A0$L,P`04`4]5BM@T#KE@`D;L`9:\`$;8`$PH`)P$%R1
M(09B,`\80`!*@`!"T`1^YX355CQT%!*9AH5#IX$]1VD^0T1?.(F4B`Q9UTP)
M413E4##HX`^8TP'C(&0%@`&Z$CM;-P(58`$;P`(J0`<)D0Z8$VX8(`,!\`(2
ML`?G14RH]W9\4TP&US/UE256>%,!5R]@\G>5F(S*R`M-U$3LT%6)X6/GP`YE
MH0#P014#0`<D)R!5D4(68`%FD')PT`%O``(B<`"7,`,(<`0ZIVSGMXNHQX@]
M='`\9$_UHHM\)0?+N(_\^%O0=!V*TVJUX@Y4E`F5``-O5O]!**1=+'`&!2`&
M"S"+'?!Y6#`!11`#8/*!>T%0N]A38(9BP+B!>.%WU?93_'B2R=A57`-)E",(
MZ/`-HZ2)/V$;8L2)[^``7_`%"4``,+`-C@0'&!`&5X`!5%`'%"!3@0,OD0B%
MQ4-([56%TI9'=]%^:,97PJ`$"B`"7("27(ET4G1Q*T)-#N$.B7$@2S$1Q'<`
M:$`9XL`&6D!O38``"=`&&5`IXB`L!U`%(9`#1X!76Q*)\'AF'3@AND280I0E
M+`:)#$=I[L<+=,`%<B`"2M"5E)EMOK<QL]0\W+`F9#`[U_$0\=%!9N`>1N8&
M;U`'+,`!%C`!&N`-$'`%76`&!]#_)%A@`'N`/T&'9O@81+I$"]'F<"1AC%HX
MDH2T;,(@`DGP!W$P!Y79G*+&`&A5%(]1,+1"0E\!-Z0$*&QP!FBP%&KP'NW`
M`17P9-1'.P*P``?P!F;P!NGI`3^P!T>PB#TCF/3Y=A="A:GB3_%%(6@&+^C%
M98VY"SV0G'&PE<YYH#*V+;3"#@CC(N/@/A/1#=M`.VE`51W0`1C`50=8!P#P
M!1`A>F]PA&$0!C=H#S+``Q?!/WJT'(>HBPIG'">1,P+W2^?G,\K6C@&J"W&P
M!'_0!LF)H$"*7U+$4`+S-2*4(Q3Z31-Q`!X``6:X``E#!QS@&5E`!F%@!F+P
M!EUP!2-Z_X08$!XCL`+FDCMVM'Z"V8M.B4=AXC<U^B6&6)*[*`PY(`*@$:1V
MVEL&4Q10M#&#X![C0`Z``A&;H`)A4``NT`71@G(PX`&4E088$)OJV219RIY.
M\E4Z(`'F4D<8,CRD(CAW5UL^XY^"\T>_Y&(D.43#(`>3>:>L2E@[42O<4#"U
M@F'D8'UVP@9F4&068`4UP`(>8`?RTP5.0D(8H*55,`97*@9FL*RSV0'AL0$Z
M,*8-HD_IE8$))Y6Y15M0B'YY5Q)0R)&M&JYK=BLK,CEL0AJ#0*'5`QI:0#4;
M0`<?```[B05KH0`8<*]4$"QH8`7W*@9<JJSL"0%FL`4)L`>\0?\*5>)7]8*!
M>3$APA0X"7>!0]0*Q%2QNHB,XIJQO46ND:%J"U$[:6$6H'$G"I`%5O"-%1`!
M!+!-"*(46-HL8V`%;Z"E)`JP$'"S5,`"3T`EF`H7#!),)R9;"Z>4M,53R_9'
M%ENQ&KNTO64?4.$-35$&-6(GHF&-`Q!N=#`#=<!K%F``85`5:=`""1`&78`%
MB5``5W`%PG*E73";]VJ&'D``<74$-F`#1S`S[1)TY@>J.:-SWEII'(EZ3#NX
MA+4.E1(5H;D>$+$4$(!\:H`!,/`#"1`"+C`!4V`!5[`48D`'9G`%6R`#6Q"I
M]GH%(1J;LSF;9E`%,$`!IW"W8PH*Z.+_B&IZ3]'6-Y!HNTA;0`1E/(3;NT)U
M$R:B"5O@)*&QN/8*%2K0!WXP`18@`TR&"4ZC`%=JL@*+!5B`I5TPHME[A#.;
MGEG@`2Z0!QEQMZ!`OG;E/Q+"$<6!?HB(?M_Z,W+@?7S#!%Q0O_9[O_A;OS_J
MN_RK/,`+%8(B&E@&#Y?`GFL0!A1P!RM0`0`@`PI0!6&PG1"0O5?@`&!0`%B0
MI4)I!F4KE/:0I<7J`1_``DVP`Z&`L+S!(,V&FZI0',MQM)[*OBX6A?2;OS9L
MO_O;OSI\.+JB59*A(U2[%DXR"6Y@!E:P`7<@!5)@`2X``5B0N99`ME2`!6A0
M!5B0!;,I!K%Y_Z7+*ING>P!;,`,%\`4[H,*@4+?EZRG\TS^K8+LB1GL`U9^%
M*)A^M\-VC$B30447M!X8H`5=P`8.P'\PT&M+$`06X``0T"28@`%B,*)7D*\?
MG+U:W`6F:P\SV[V%2@<;D`0G``1W2[X'.PIU4S/LY9\!%5#?AX_*<;%WW,I(
MQ`_TX"OE`0'.ZZ$>@`9F6P&6BP`>@`&7<+,*T`%:S(=80`57<`"-?!H%?,GL
M2:)-8@99\%4)$``7PANA<+`Q0"6DL,V>;(^'^,WT24@S;(*N7,X))'.@`0%K
MH09$,``1@`9:D'D-;`<AT`(M$`&3X*P8X*1?FKU50`</F058?+.)W/_(RYJ]
MZGF$LWD%'L`!1M`;GW"W&6$#2G`NGDPEVORS-!J%?C<+9Y;*%XNQYCS2B&,.
M`Y"OY(@!.(`#!^``8K`!'Z":*?L%!/`!"O`UP6P/LLG!5U`%`NVO6T`%]I"V
MC:R]->O%L^F#-!`%JA`7\0D$:%PEGDP*"Q(7P52?.#K.2&MZ^DC27HTX[S``
M'M"'8:``[2`&'A`!4U`!.[F3V=4!-R``8N"]ZSG)6MS3\`P&3[R]'"S)5Z"L
MZ0G88>`"%18*JB#1.X#&H5#&:<S-P/%VQ.1PA^AP/R6)7WW9A#,``[TY5M`D
M64`',A`"7V``*Z`'#;`!<%`#6?&`5Z`%!MW_N<0<PMF;!;*)H=%\&AP,L.G9
MO6@@@7[P&PQ2)72;J3&0PBK,LWVY'+OKA&AJL3F*V=`-*P+``E4@Q%9@!Q'@
M`2%@`1P0`4MM`PB@!G2`&1R'`1B,NF0[HA",Q6%@!5@P#@>0MEA@NC/;R$V2
MQ=>]`7H0GY\"''5;M^B2T<:MS=_Z?;VXU848W0K.+V>@!0>P`$'1!R9``+IL
M`75``!00!7O0!S5`59P1!E60I5CJS*BKK%O@`5M0`V%0S%>PU^L9!NH)L+[\
M!E4@`QS0!+V!"E1R`L-=T64LU3R;Q@MB6\[-<+MI>@N>Y/A2`$V2+"-@`JHX
M6@:PA!20!`$@5C-`_Q9BL`6G.^(P7N)B\%GQ?059`)N=*\G)W`7LB8X'$`9C
M,`(T8$OY`Q<G,`1H_`D^VR"?C.<WU)2$)"\N2L=*/NBM0KS9$`\&P`$;$`(D
MQ0,ET``-D`,T0$('4``8"@')FM[(_`9DC:5]F`40W-=;^NG'[+9?6@4S\`4!
MX!'";0,Q\-]5_<DJ7,94+=')MLJ4?>0BS0L#JIPY3.C`?AAF\*AC,`8>(`-U
MR`%"0`,M(`1&$`$_@``.X*QH@,7%JIY8^M?(;`]<C*7R@R>4/-O6^]=O\+9O
MH`4%L`%X$`"E@!$V@.?2"M7FRSL2S2"4C0*GA^#$)`P]T`:^'NP`?QA4`/\&
M5$`%'V`VW]@")=`"%+`$,*`&8U`L(7RSQ;JLG'X:F][F:4L%Y5X6X4&VE)P%
MW=[%LTD%4T4#=P#1"$N^8QKD"X+1VKS-/YN[(+W5_+Z<<?#K`;_S?@$/#I#N
M=1`!%4``)5`"4\`#5L!43O:E5"`#L8,!.\WI,%[77<"OR%P`3&X&\UWFI]'(
M`+NV35+U#E`!"+#JHZ#-)JP@=HOG&''VCAW<?E2(^*B+_*X$=*KS/)_W,1$9
M(2"O=<`!7R`$*^`$)J``."``-U`%6H"&9=29UU[7-ZB>6CI]!N``6I"VE"R4
M7:_%7R[YLQFB8\`"+9#RI_`)C-WRGFPN&*W&;Q__"FUG>N),]\'0`W]@![VN
M][@O$VJ0`2I0!Q_P`6Q=`DX0!3_P`1!@``\P#^^`!5:@`!$)]5>ZYLA\&E<P
M!C.@Q5E`R?.-YEKLQ3'.GNJI!2I084F`+C_.]AA!MW!QL+ID"J7`("]OY,[]
MW+A`^Y&)][F?_]<@"1L`"%X3-``F2U%[.4)V?@H0#&L0&).2&`=B9F9OFV)9
M6&&8G5=76J-F8F&IH)MOF0>6&%T%+A-^$B<[.Q(Q1S82OT!'$D?!O\0[,2<Q
M0#M`P4"W*1<7TM0I?]C9VMA)V$IRV^'BX^3EYN?HZ>KK[.WN[_#Q\O/T]?;W
M^/GZ^]L$7@2&_/#8,`6!_XXB+1`X@%,&AQL%!\QT@-5*3)<NJ,*<$H,*4Y4Q
MCP:\Z7(ES!6.F#1:.G#@S94"*BRTB)*+5PQ>PX@%:W:DIS.?S)3%T`4-"(IJ
MU"[P6\JTJ=.G4*-*G4JUJE5^"'A,$-(D1PLM%0C0F!+$P`,V<'`(@/@&`P26
MJBZ&N6B&I)@#6508V-`%0Y8K5+)8W)2I2]LW8C9UR.)@@PD]S&XB.V%#I[,=
MPGX-R^4,2(P4*9@YD[#C1#705U.K7LVZM>O7L&,S#6NA#X45-.QLF/`/0-H!
M`VXP@'B@P\21$>V^:7DJ#!8:0EA4\80%2Y935UI='!6&Y0$('0YH@?$%P:X3
M$O]0),-<>BCF7Y4[^USO'O/E"W+D*)7-O[___P`&**"`=&Q@04$(3$%`!194
ML$$!.-P`@P<@9*"&`I:H`<%RK:1R2BMF'!!&`1MD,9)U661!Q5QFS#5*%ZE$
MU!U+5'@@4QXGX'+34)ZAL!,TP!#%4XZE*<,,3S&\,,V`3#;IY)-01BGE#"-4
MT$(01@0AQ!0)M.!!!D2(8$`7(-QPPQH/3.(=2APMA\D;&LVU71957)%%%]7!
M&,8F7:R(2427@`%#!'V4AD)[)P25J'P]Y=*,9S?EJ`PR/#ISPGY29JKIIIQV
MZND[*L3T@Q`(E'"'$TU$<$`&)&@PA@`@B)"!<6Y=`F/_*'==PN85751A$IUV
M87$2GB%:U%PKDVCA`0L6#(&">BG$@,(>2:0@P1XU-2-!9^Y)ZBV1EWG&!!?D
MEFONN>1V\^FZ[+;K[KM.J2`#"V2MD,,34>0`@`)@"G``#B`PP,`"Q84GQDDA
M[BFB&%ATL1%@5U0'BD94(#8**G*U"$I+5M`Q`PMWG/"":3D.840,)>`Q:2Y'
ML'RDM\_FB(*DDHV+[LWEJ@OOSCSW[///'G`0@1$4(*!'%'E$T80%-Y!`1A<9
M".#&&A.]!:)W%[%"$BA=T!G820>,8J)%)9'D<$5WO6'%%A[8,8$-*:!PP:%'
M`!``#RL<Z>B..29S0LR2HC"R_Z0[_&SXX8@GOC,+!/#0@@4.)-#`Y$540`()
M`V``QP.0#+#``I-,LLDE6&-24B9F")M*%UJDJ-$F+I)$Q4EI]^D`#'7D<90<
M$C2P0Q-W`)!#3;CHHH020]B@Q"[/-G]4W#/GJ/CTU%=O_7\10$?`&RY\<$<4
M?B"0!A(#>*#`&6"2(((""DP$J!E7>`#&`IJ,=`4&;*#5`03TYVE8)AC;SL5R
M)08K%,`#&T#`$01G`QK\@@!5B()[EA&#)"#@!Q/(('26D(,B)&%;?WN!")]U
MO1*:\(0H9`H%GI`$/YB@`@6H`H:ZL`80F"$!'2B#`$C0@QX@`0<#(-T!NC""
M.D!M0_\5J8(+'(`!J2U@+GEJ3M>J0(7J\,H5E[#"&`H``P(TX&\2<$$23D`!
M*S1@9M**@02:,($$),``%0```0@0!!-,X`=7*AH%BA``&Z3PCX`,I"#+(84<
M)"$)2Q@!!#*PABLXX`!J$(,1SO<`)"`A`Q``3V'$L`46;``,`[A5*ZH``"\4
MX!580$R=5.$B%`D+1IH0416L@`8/U*$$GCE"`7)P@B2HX(MH/,$0A-#&%B0@
M`B80!"$`D``3M(`&-.`!'J<PR&I:\YK6*P(%2E`!!:P!3"!@WQG2T(4G>!-6
M.,#D<D+T"2O`X)$=2DP7P*`"+5J!3EK`4\->N3H5O=)AB3G_&"D\\($?#*$9
M!7#@$.S0@&1("P42$$("_D&`+T1@`@``P!<&T24:!`&#)N@#-D=*TI*ZZPDY
M,,(".M`&$&A@`#IDP`,4H`,!R`H$#P"=&3"0F+G\J447,=U)?#67/<G.3L(:
M1<2H4$6?(DP387#`"+QXDP*,(`E#<($>:#:$!K3`"&-Q9@4B,-8$$*"-`*&!
M,:%CTK:Z]:U-"D`2^*>&#)B)<^#$0!0$@`.`!?$5+>$$2E#7I@`F5:E,U:>P
MR(:%V=7%.1B)915&8(`2'&$/-8"!$:(`@Q7\C3(E()H0>,`#:!KS"U\P`0&8
M:4<3V+$%U(2K;&=+V]78H`%BT``#_U@E'!'@``E$Z$`.X``"$`1Q.2U!Q16:
MHY'"P*AK\N1(UU*TS^HT#*D-$P6O,O(&+-`!`$$(@`2\8(<*3$$&*QA*>F(P
MA"$L@0)X$((1>&""+P`@`A$HI5E-,-$NU?:_``[P4@PY!C(P0`,:P"D12$`$
M(ES!"!A(0QDP,!<,G")$"\,$ZK86L3V%PB36I8X57_3*P*Q(5RW)@@4FT`0;
M3,!`%I!!#H!0!#Q((#11^($1#A&^(`#```"((VOY*T<3"/C(2$YR.Q`0@`ET
MX0%2"Q,.U$>$`TR!#6IH`T0L@9)7("PQ=6%3[.3$J\46]4X'^YIUJH"%P68B
MJ@!@,AXL$/\"&5BA#B:PPP@`L`=<)$$'=VB"$/J``-YX(;\$:,$$[$L`LZ)#
M"7$0`1>43.E*P[4%22C!!&`P-1$0(4(W(`($S"*`#&"R`ZB(2$`Q5AB?HHU7
M$;M.)BF<BK\XIXK4,<P!&F:23&SA`SS(0P,,P($"#``"5S`!`HJPK2&D8`<!
MH```>""$%GCA"P8P0*,UVDR,HH,.7)`#$RQ-[G)?TPM/T(,?"A`UWX*@KR3`
M``<R`&4%M,4BJM9$1CA"6%!8Q#E7V((+9J"`HEHDQ)ZH8A6QX!=A>:(+6Z@!
M`"C0@`1L``MG.``!='`$T]SV,]9R`@UT$`0"D#4"&YVC&_F+#A'_Z,S<,(_Y
M"<6"@`C@0`2[!<&"?4B%$#Q@`&&@`@8Z@)@+RRA$,+H$<Z&(A9C4`0PPNN(H
M&LM483763E4L,Z_H:0$>.$$(&^B`&PK0@#TTP-DIT`]H9G8T/1`BM8T^:P9;
M8.1S].#E,L^[WA$'`PO8H0RR:BF\?5B#&C```U2HP@(@T!&>J@FY<$I%3[=+
M!1;`P!.\ZD[](E:VQHHX,*\4PQC*ZP4$(&`$85`#&`RY!S_D8FX7>`%H=M"`
M$@3@"4:P[Z'Y&W=TQ&$)>P^^\'OF23'<`$QE6(,(<&Y)&+RA#`>8I0+@D+!U
MZHI/(6J1)JB`"A7!R#J)MTC43;)4L:6(_XK[%(,65+"!$/"``AL00QFT4()A
MV.`FT5,2:&*PAR%(`;]OY$8`X6WGD`,B$`=U,'P*N("=X@4;L`4B8%,/D`%(
ML`9I00(?(`9NT`%H@`5P0`9O``&I@P4M(7D',R,LX1($8W5W$FL1PT^?T`DI
MPE0T:'6]X@`R(!-&$`)9X`958`!2\`0-D`1]M`R3(3=Q<S<_5@%`EFB)E@YR
M@'<,.(54*"#P901H4$,"$`9DD`%3E@$N,``1>``*X`9!I`!W4C$7!D"K8`9H
M``-TH"MVXC6!T34QR'ES4@5ZF'#4I04.H`(U,%8S@`4040=>5P)^X`=&4`11
M,(2D<2G28`-]4/\''#`!QI1!$U"%FKB)G%($#>`$"/`%57`&6&`%)(`$.'<%
M.R0"=85)DM`P6\!F9X,8AB$H+(`&^70P6%`%T'5U395Y).%YX)=X;!8Q50`&
MMV,!D%,%'3``#@"$2\"(0K`".J`#1O`$)8`O0W`"1R`$$<`#9^5&@L")Y%B.
M36(O.M`$@N8Y"G`Y-_``9L``2``"RN<O0)<8!5``MH9A(3)5#D`&V]4U^20L
MQ#AUIP,GUJ%4C45%UW%P8\!^(^`!^G@`5``#":$#.>`$\*6.>K`"*R`%1>!V
M$2`$[-4$]&5'YIB2*LD?%-`$.N`'3]`"P.$&H28":8`&K')S3M,!"N#_``"P
M7%H`>EDC!C)0!P8P!FW07:E`!5H`!H`A+%I0';;&$8UU76L6&%FP)ZEC0#+@
M`2DR!BD2<0EP+QE)`4[@!TZ@`SR@`WG@!SD0!`@`#7)%`="TDG9YEZI1`B50
M2'G0`@?@!B*@<VM`!1;@:0M&!,#1!1O@`6^1.@4`!L:2!1O``0```VI`"@W#
ME'10`'2@1=.1(KSR?4%9'7H8E*!)$E=0!;7D`&#0"EL@!E3@``[``V[9ECK@
M!$^0![:W!T7`B#Q@!$*@6LY$`'A9G,8)%?#UDCF`!PJ"`1D``G#P!0D@CY>#
M`VD`!Q!`!6,@>F&P!1O@`%E@!54T`T#&F"V8_S9PP`9O4$^?V688,QVIN8M[
M&!A6$%14``;YB`948`940`<RH`)HX``MX`<'H0-+L`)YH`-$>"]#4&BCA4$&
M8`(V@S,W(X7'>:$8N@T&L`(E0(U/H`-2,`(:(`)D,`)3H`;`10(X4`:2T#X=
M8`$<PQU$N0$L4`!FD)5W,@!D(`8,``(+\!>)MURI<W[5L06S4P5:P)!61P5K
MLT4.@`;+T4DU``;TE"\P*04K@):(D`118`-%(!9;XDPM,*$4>BX6FJ%H>IPS
M4"I-H`<AF0,B&H$FZ@)3A@,/@)VJ>04+4`!;@)!4<``%4`=68&$APC]T\$A@
MP`890)&@%YK!F*1,6?\GI>D)2=HU6[`%!>``,Z`"73!$#N`",E"*!)`O4:`'
M%,"E6&4#2:"J-'!6P"D$/Y"FLCJKZM`8+8"1;FH!:/(`9,`!!N!\.$`$&8`!
M"L`"=J"';R`#5X`&![``>.(=M1(+7UD'"O``N]98>,*+')&:XAF>"6<%5#1+
MNZ@%6Q"@*@`#6Q!FM40'55``/)";(;D"C+@'$J`$-F`R+2`$(&H$L4JK_OJO
MVX"#%5`"!C$#`B`P#``!%I<!5.!I;<`02?J8<**'RP4V1R<CN^@!`&`!(A$1
MHQ"II(FD]Z0%23H=26H%^90%6D!+.&@'<2@&58"I*O"86$`!>I";49`$#9#_
M!T-P#%%`L$7#`[$%L$1+J^QG!T&`!QLP`&>`91I`!?O2*CB0L`J0!F9@!S"`
M!G\QA]61$J>@:WC2G1M@!'1P!0.`=>>7>)=*KFN#LE30)TS99N@W!FB@`BQ0
M`YUZ!08$`S/PF'6P`@W0B'G@!$9P=D>@!$6P!`@`G`0@4D7[N&D*`R[`+%L`
M!S`E!A"@`79;(2*@`6G@.6G0='UR)Q=A'8:!,:#P"1'#.AOP!06`$3\%&/@$
M!EN0I)!:E;-D!2_(I&/PJ7R!`4BZ?C"@`ENT`0HJ!0$0`'B@!W&Y`TK`O!0@
M!:8'N=2+H3!@!Q8``6X`!Q<"$AFP`3+04FHP``J0_SD0T`56\`FGX'E!J2?;
ME7FR6ZE\>@5GT`;9.1UZ:`7=^C7H!ZDE$09(BI]]5P"Q4$5<5`,2^5T!$`7B
ME00LE$9[0`%FB0`44+T67)PC<(O#808"@`$P``%JD&?U&P;LPP88$I^KDR?6
M=05A(QBID)K^9`96D%\J<`8*4(I8:9K3D<-4L`5@L+)O"YM8X(?L-P-`1Q)H
M(`/#FX\RH`/)FP1F5W9&T0`(L`)W@`?`=\%:K)(PH`"0H'XBX(ROP`,.X`8^
MN@8",+X\905[P@K.,1U]TA%!9WZ>0`<<H%HC\`9TR(M5I(?3%;QT2Z7WU,.)
M5P`R,`(JP`9$AP5;\(<J0/\'AVH`DQ,`0Y"@XO4"-G`'?R976]S)Y9@!NM4%
M=)`%(@`'M8L&!%`&#R`K]&;#D^`KV=<B5<1JTI65>.)8A_P@*_*M6X!U(]8K
M/MS#!1"4]R2>6G!`PVL<B9&:C>P!#N`!*B`%#6"OJIH#>Y`"+Y`#"-`$)7"F
MGOS-PI<!9*``:-`%EKL%).P!7^#%JRP"#Y`&X3%$W1$+FH`1T,6?@B$7)N%8
M>+'""F<=5O##+)AXXEF[NCO$X`H&'C`#&V`'DK!K0/K,G.D`$3`YE2$!JSHS
M#;!-?N!'X/S1"_B'#K``-S<`:&`%"!0!;Z``'F"G:?`6%X,!H[`2<((G)+&U
M4Q?_=3>*"C<:E%1$T&BP!2GB"2HR2Y_)9FH+!AVH`M&T!6J`:BI2KA[@S,_,
M`T,H7M!V+3G0ED4`!"#]U<)'L&3\:6E0!71@`9.Y!0>0`&HP4YG`PA9F$?5$
M@R]H:Q=Q$4RUS/MY`/K[%_O$I(.,OTTY!F.`SLO%.JT3E6!@!RI`!1H2!BJ[
M!09$!RH@FS4@S0&@!(<[!!)@!#E``1-0!&`]VGG7!._E!66`!&F0'8I9MFY`
M!63`>%W3'7L=!@G@`.7:@O<IV5@`/T$:"W82E2IR%X`!J23[TT@:BY[)BZ2@
MOVA`3W;@`72P`)%$)W1R.Q.RF1'`P'M@`[H@`0CP!#9P_\VD7=[FM@)3X#AB
M9P89(`);\,$,$&IP,`)>,`(UH-9!!P:ER&NW1D5.>2<J^Z<0`-D)9QTLZ`E@
MX,=(FG@DV\.QQI2T^Y@%<+<>\`9I@'C@2DL+_4YL0P!/L`?+(P$V<*!J=`3F
M?>*5II8Q5@:MH`$"D`4U((:RD@41L`0-\`-@H`!J`#H\I1&E.$OZZ2O<9P4'
MXY0]WCIZ&SO(1I_Y-$5`O:2S%)YC``8RL$1@\-2[6-`P`0,R4``!R@/B]0M[
M0,%)H`1>C>)H?F0_`(Z+R2\!4P`50`:LC`%C<%\>0`4+D#F@T./'2$L%$!@N
MP1(W&M!$#L.IV:XLL`6,=*-5\/_(>HAK:]."P=LUA%T`-?"'&!!*K<.D5>``
M6.L`^;@!*]#=VU("2X!5)I[FJOY?6"`$--`'"7``+I4!:!`"[R9393``'Q`$
M''"H"X-X55`<%I8GI7`2IU,=3/JV*2(H%A!D;'`&570`,R`#5*14>LB+NWBI
MO)(%`BP#,I`%F7/HM4M/+-#E!S0%'W1C?Q8%![7J[CY;8"#!ID<`,Z!#!I).
M`J`!4-;H!1`&A4["%D`#!7`7`M5],X(23$4G;%8%,I!?)L`!0ZPB3"G9;WOH
MLX141JUP2>SM#D"^3)GA6T`'UUO9=.`">4"O%R`!3F#-$O#N+N]6:&`;%'`'
M?D`!8"#_`!N`!D3P`)RS`(@!J&`0$9G@"'1`@B;A(A.#$<C%=%@@FP40`75@
M!^!ZLK7[F:V#LL%[W!_!BS)\KEQN!@6WD"M;MQSO`&-``PU@`W)P6XW8\B__
M]B,E`V&A;:/R`1TP`NVH`6V@(?RSY&[!PC`K+/V."6$+)V7#PJAC)PY0BEK+
M.N!*C*/)Z4R:X(5-NX1-Y&^@!1[S,2H`'MT!<2?M,3+0MRB-`'N0\EW:``$`
M]ZQO35-%`\ZT)0.0`1PPHAE@PZ_PT,51'9$.!A90`A$`P+?"-1S1NQU`,*@3
ME(&A!6,@GLX?B\$;P'5"LN(90UHP%V"P13)@!RP`]E-$LEF`_P8S``,3@@9C
M,`)1@`)#\`3\%P6M__Z!%`()L.9"(`5&P#D1(`(W$##V!@AF!V]89F(',QM:
M;Q$Z44\)#H2$6%8#"RX&6!U=6%I;5U5455595%9@6E18659;JJ]55E9:I6A8
MJV9:604.,B.6&%BR8&`%'C`L=BH>'GTG13HQ$GM_UM?8V=K;W-W>W^#AXN/D
MY>;GZ.GJZ^SM[N_P\?+S].`$+2T()4XP.`H;.$2(`#'@0!8L;[H4$*,@C!8,
M55KP:/$A2Z<K8@I5@>'"0ATM"SI0<4'G2I8L552EG"7J5"I9I`Y609,%3,HK
M!V85L")C&00(5TY90=/+@PL7'HA:2/^BXPX0"1+J29U*M:K5JUBS:MW*M6N]
M!#1XE"ARYPV1+C`>8"`B`,*;*UVNC*D1!D*54#)D>*@Q@TX6,6$.76$1(0('
M"U0@H!DQP@'*,5MD6:F"ZQ.8R:]V:;GE,(MEFBFWC*'#L4J',*<^;3&63(8#
M%3,(E-@#U8;7V[ASZ][-N[?OWU--T#"RHH$.#FT\C'FP!0Z9`0HN>483YD`'
M-*I&&)G@88L5*EVRS+!0H8X%"P4.4/$@HPH84V#HH(G\'8NGR5IF63GYWA-*
ME%A<@85W=!0`0V,*F,&**Z6`X8`'*M`!H0$MY&&##4H`I^&&'';HX8<@ACC!
M#PC<400>1FS_,$('#(1AQP`#I$&&`F*(D<4!!W3AP0%7F.`'!7:$@0$&UP%`
MP'DJA*&``@:!PLL&J!1P62I4C$**=U>.0849;U4R%!6!N5(@,C(,V<H65(Q1
MS&LPJ/!@#19(D<00`81HYYUXYJGGGGQ.P`,%>-RQ!`(M3*#``P*X<`D<"F#P
M1ABE8"`@'!Z8$((#@1&)@1DP&,!!`1U<LL`"!VB!A0HJ5EE%>)EI48L68&PA
M:P$[P44*&JA0(487D#DPF@PNO-%02_NUXL$(+,"@5PU&)#$GG]!&*^VTU%:K
M#ECZ#&I$`A24`0((5Z2QY)(0_&5%!Q!@D(888`3FJAEA="$&"W44_X`!CD)B
MD`4:!Q0PABE5AK=?%;+F5\QF!=!TD$ECH+(%%@YIX0`:8SA0PQBGR>)J%Z,8
M6`,,,[PV013/6FORR2BGK#)P`)A@!`(4(##!!A2`D($(##R@``30E8M%>A#)
M&Y<6M-;@02J^YCB(D&_M<I"JICA-17ZN@#'&)V-<G<45J32\6BFTH$&Q@P7<
M]1T5J^77BPPP*(M,"0%DN/+<=-=M]]WH&$D`#S0D<*H!`@D$0G3H;B%#%ELH
ME$6R5/!XR,9H-`Z7&&9T<$`85[M:)146>3:*%I!%*>4L8%!Q11C>T5),E;5L
M02O1L5(F1GZBK0:&"C!\K((*$]PA-][`!_\O_/#6>J#`%3L=\``+%8#PP$`X
M#`!'J#EV8,7E$%1\@`)I=(!0%F&$,=086`S)BAEF<`U&@$)[;K#7M+ZD"GBJ
M6J'F*OB/X2\=#H#I4&2@D]46<.>"&LA@!BQ(P!"(Q\`&.O"!OQ&``!P``P>0
M@0$LV,"W,B``(L!!#650`*D.@*8K;($ZX#-#>*H3/C&0H@OWZD+Z-D<P4'3A
M59Z`A:MHI1^4;.$D-XQ5Y,*`."OXZVHJ*$`8WO"TT/CK00=T$QWL4`((6O&*
M6,RB/#*P@-TI@"`3&`$.,J"!`>!`#='9V9!V91":8`0N;SA`SS`0+WE=X8ZX
MT!+BUF>2`'EB/E3_H!)15F.%*VB!8PW2`AWJLYF)H:$*#B@`%G)4"OL\;`OR
MV0LSDI@`+7KRDZ`,939PP(8"'$H#$$B`!T20@0=T0`1NZ,"]#B"&TUUN&*,X
M!9BZ,`AX!48,<53A,.PS"C2AA'-A,$,17;&:5XQA/D%Q%2JR0`<PF`0E\2,:
M';90G5<PK``%HN`'-H`4.O!`E.A,ISJ'QX#998"#'IC"`=XI@#<(@`QL6,"]
M[FB%2MB$<U9P@`-*H<(NQ.N.5PAF*$PE(,Z=Y*&42\TL\@.3H<#"%8I\F"?<
M$\E&DD\8D1O&:FCE`3MLP(`S:`$XE*``$7!AG3"-J4P_I`!,:4``R_O!_P#H
M^89T9:`,(>G"&^A0!1MYQY^T*-\;,G*Z,."$EJ%@A2A,(J!2;"U]KX(:ZZA0
MMC$P@X?T$XT#MDF%2(*!E^"A3!>Z``8TT`%WL/'`!L!!!R[(002_FZE>]\I7
MK61A13G+P`<2D`9$J6$`,YC`&<H`HP.8X0LR>,-UW,/'*P@B+@@-T*X$-(RH
M^DN%6V,%P$1!,%I4H6&M:(5`856`0WK)=9.AE20@$)>#>(9T%3N@!V8`#A$D
MX0]QF$-?ATO<XL8C66=(PP<KD(`S9(`!;&##!(JPA7%-D@4S$`,&1&/:5;VA
M2_:IK7T$)`;.;0$#2'EH0U/BF=*E)":IV!H8/O\6R=;RZ&"7J0(X^]>!1Q'1
M)5E#`WM"1@=P]."W<7BI<1?,X`:#0PMM&$`6,`"!#[#@`:UD`W2$(`/HG(%+
MR7R#&4XKI4/"!0MK76N\[+.JIZV"$.\-+2[.5K7(+8!)@AA`&3"0+`\X8'T<
M@U4DT5:@=M%159](6'S8YF-PQ&$)?VC#;QU,Y2HW>`T9*.4A*K`%,C)@`&<@
M`14^$*H$)13%G9#!-@O@F6LB$S6J,,7#(#,@^R#N+D'AW-3.-H89F+(-I!)`
MSFB)A:-9)`S#H-5)QOK#<I&"M;*=`=M"!HX<B&!)5LZTIOOJ!@V080S9JT`6
M6.F&-."@#130P8T,`A[_-!#I#2-(CT$#=!+.R="I72@%QU#[GO6:#A=5\APN
MKN"`.AP``F#`,`C((`P5R"!RI+B"18GFUBH,("$K&0U1G*TL%81##GG=M+C'
M+<HS/"`-`Q#`XL1@,S<(('HYB((,EB3B*JC`L6\@BA8HY]0`-=2R@%'0+B(S
MBLQ.;14LK@4IAG$[%H0!#6H``2L+US93W:6T@902%33L0H/1:K_)L`.Y1T[R
MO3(@`^EF@`<,H(`,@$#0SC-#'NY0A5$M0#R\Q(`U<Y<XC-0H(U@`S.105XI5
M!$4FCS;=U"IC!3J`9SIA`,$-1%`0]Q3@AP#%DA&)"`$VO&$EHJ$#'9X)+!:4
M__SL:$=GC!@@`CA,(`(#P/`:UD`$$,`A`#8P@0..C87#"6T`5:"#%NZX*X/&
M)7SBQ<4P..;0[WPB"X]"L5,[,PH=1<#5Z'I#FC[^+\MX9PPI,0-T_"DKJYUP
MM[Q-N^I7;T4'=*&58MB`#,J@`1`P0`,BN($"FB`!&[3`.AB`0>3*6Q]1'/(M
M&*E,T6TTXYD0\Q0'TL+<"S*(AIJB[P3X`0$(D"1/6`UW5P=@P08/(Q>*YCU5
MVH(O8,#Z]KM?>#6P`QG4'0(6=-KV+B=(!(8@`2%<@6>>404'0#"RP$TO%C[I
MDT=48#EK-5Y.HU\C0``38`$G!P+=,V*XL#5CP`(&P/\W-"`#$/`S6]`O->`O
M!4,,A:0`9^`]IZ49^>%59O=^,CB#*F,!&Y`&:S`#)F`'SI4!;?!.(,`&=%`$
M1[`'00!J.0(&ZF$%X4$%<?0H:V4(!3`"$0`#]R1BM)9H#V(`$X`/5=!*"N`)
MJ(4V#D`8+3`%/^`"QS-VK44VQ7`9M',(;9`&AH0KGC`*1@0#3,`%?-B'?OB'
M?#AE-#B(A.@;!!`!;_``$3@&;B!W)W=N&&`"$C`-"&`%2[55:#-X\`(73K4%
M$2"!$5`&#P!:"R,QN".!/\`#'+`&3'(7:*`"I@,#$A*!4\`#%0`'V^4)X>$@
M2>$O&_-=<)`!PB`K`*4_!:#_`GL(B,K8AX)8B,[XC%P1!#2@`LM3!U=0!AEP
M`X@B`!%V`#!0!"=P`DD@"FPV,*2P1!HC"RK`/%[0A1X`!W&Q5GDF&C-@`";0
M!T(P!6.@(%=`)#B!`:Z!(P6P-RW0!6JP!1"@`&X0'SXF4%)20F^P4^5R5!S3
M5N`$C1B9D1J"`#Q0!QV0`%.``6KP`#>@`0S@!CMS`&#@!380`S\@!M[S!@5P
M!42Q$V4H!!7@`=\1!C"P?2U``$,2&.'14+3@`"'P`Q-0345G-57P!F2P`"[C
M`!!0``GP`RR@!O8B1U:@`G9@!S*P.Y'43S#T989$&9+15@6FD6JYEK>!`$;0
M`E;`_QAD@&$X8#-MT"@\X@%/(`%)('P>,#LU-0/65@4L``!HH$Q6(`8N0``)
MT`(FT!`9L3FF`'9$A4BH8#404P9OP`S&-U;/-)-W$1YT,`-MXS8%`!X84`9G
MP&J(9DBS@`9L&9NR>14E4`(<L`46P(.U1P31LP8#X"BU]`5#``1+8(]9T`%P
M(!\=<`;'$SZHL1H6\`7"D0"(EF*=@`JJL`ME8T*.-QE_<0!T!`:[55_':`>]
M\`JQPHN2-@-^5@48H`!K@`$'MXM6XP"S>9_X*0\K0`,#``85,`//(P)UAP$:
M1BJ44P!-8`,2T`!ZX`&FP$LL5DC(U`4J$)TF8`(N<#D/%?\UI<!>1"1GLX`E
M6Q,^$M,,;%,`+$`#%M!M,R!%SI877TD'=7$&@*=G:I(U!9"?.KJCZ3`!`I`!
M%D``81`X`Z$&#(!NCG(O=3`G/)`$)D`+$E,`-:`"IA`8Z5,`,K`!!&``N+8Y
M4Z,*Q*0%J+$*GZ`:55`=.((^-4)$5?,:N*,LN5.:W>8!@Z<`99`C4T,Q_F(%
M/-JG?@H.%4`"`E`!`-!2(H`#-\!!-G,&;H$!"Q`&/!``/.`'(5`N9K`%Y>4=
MII,^EH6C6Z!""F(**$$+N30*"],*CW9H9J`IX`F<"1$4HN`Z!&0'RF)`>K$E
M`P`!#D$P^@-Z?_JKP'H-,$`"`S#_`5-@1C@P1L]S`R30!CGR!C>V`0$PK48@
M!IAZ6FC".8KGG'>T8M9G)?IA*J:S"S5T$@@1&$NT5/?B5)Q8"3*T*\:@`BY`
MJUTI`V6#`==63%,"F\':KWT*!TA0!4O``1*7K`_``#B`!$C0!BZT/0K0!3J@
MH$_`'I^01,_45J5S$"DF(`?A.IN!.ZXQFA[06E>W$Y.!8H!Q"J`5%TMW8EH@
M"'%$2[Q`FLIB!S/P,(>UJZYR6O[:LSHJ$!Y0A0)Z`XEZ<B1`$)[14TM"``IJ
M`TE``U:@<UQI!P+5,`,S>'V$:"XT`E^P$VBS$[70,%Z#)IZ0&36"4`!R1[)P
M8@;U5/H%_T4PX"\*``<#>!*DX[-X.YMU:0<A<`4W@*@X8)+T5`:[H%T\8P5+
M8`,[D`<>\`9N\`8;(`0MT!Y9,&08(2]QM"EH\`%?``.Y*BFT@YW/%!G&QSDI
MH707!X=HX!B:!Z9W1$@.8`<NT#98H$_']$Q\^@T'!ES-F+>^BW;$*@04X`9$
M0`+)"H3WM`;&4+O(N0`U$`5."P/W(I-\`2NK.PJ[HEW@N1CW4`%5<)<\@@ON
M00NRDC5O.!F043J381*9@08U4`40<$*0`1['4%3'L@$;H`)O("EQP1(&U@:\
M^[L"C'8W0`=WD`#9R)O0(P*,)0!B\&,+`&;;10,!(`%18`(;</^:&\`",Y$2
MG6`Q'O!_71`!1M*%5L!*`E!U7O()]N,OQ6!$8U=-H%!TLE"&5@`!LZ`F_;0%
M1R,I,S`"'V`'-WP1[&5@P14'O3O`2JQI(F```<`!`Y%[W\*;Z%9/X+0DT#$[
M*Z"X0^`$%J`"E+$!&.``!G!U!G`'3XH&%F``8/$#/P`#N*<!/R6S54*^J?,=
MM%)--D&`E3`&OZ`%`[A0N%*YY-,%:,`1+G!OE(0U!J8$EY;$2QS)#N8&"&`#
M:!`04O=.=<<&"J`&.B<#6#``T<4S(Y`$$K`#`6`$(-@!5?``"S`!?0``"5`1
M!5`!C&D"^#`%$U`&(J`!M5<&0`<PM!/_.FK2/S:1-F@S%Q_PJ6!#%*6SNB]K
M(#+``B-P7DQT)@;V!W:PNY+<S51V!0VP`V9T`S:#88FZ!CS3$%&[)&P`!P/@
M``BP`K5!`#!">QT@`WW0!%[@`,2V?01@`A,@'/KX3@<KC.&A&@63&5<G"X%T
M-:E!!1DD@&Q*-#]V.P5@!E8``W;`&#*`$:<P!E>0S7<%R=Y<TGSE`A(P!")`
M`E,W$-G(00K`R6%H!M$!CQ@P!AS@`'N@H!30!0M`!F=P!17@!1&@`M2!`4DQ
M`Q40T#0P!16@FCJF`0F2!<\D-LUD#`X@I@!4-:Z`!BJ"$QW@0NO1'>HG"5A`
M!]1<`RR@1+2P_Q/@,&5*(`<F/=?$]05'D`,*C*A1?#.MI`9I<&,P<@9=``&*
M>0"5?`0!(,8:=@"[XR:1LS5_H07_'!8\H`(:5@;U%`H!AAWHR3_ERQ+'I'YU
M8`<=L"3JH7XJ\`K,`$QH0)IL`\H[M`5T/=OBU@='```L'1`XP]<KC0-?AF5M
M<`9MD2YT`)`1*P%2P`(0\*BH$#K@@6;P+`24;0%+(B2>\=FM50F@\QU6@RO%
M9"#)4@,*P`"KZ0K'B!VPT3CJ]]HP`-*!%-*T'=]5A@!1``9(P$HB@"AZO4%I
M4-QN4`:W=PG'(RDCT`!0(00((3&D:Q&[XE0P,($5\`4\8`)4,`"F&O\UIE(+
MN;9G#>TOIR`#=;!]P@#@`G`\9*@<;^7>$)(7%12`6"#?,-Y@%%`$9O1.+I=[
M+]T&)T?3`J`&;6"2I2W@"F``M.$'=&`CJW!]R=2V]B,VI!$"!K`JLW"=<$AP
ML5(++S$+#F`!8!$$=+`&B$H$#^`0]?E$_6,&_-/8*M!/GA#C;EY<3J`##)"H
MK`2$($`$#$#B:W`&:C!_`L"H\*ECJXD`>S`$%H`C^X1BZ-.V]E$,6_`&#E`!
M*&8_6A)(Z7D7\H-U]E%L)O`#03`!/[[2[71:QG!U#](N#O*5QT@'`Z@%;_[J
M?$4!1B!US.H\!WOG@HLHC$(&F.T&`W![_PW_(P60`WM0!#5P0U-S0]=W=`Y3
M2",0)%CP'K@R$S>*G:;R':3@"C`0`1(A!$;0CQTT`*&`"M<KGI(P%!#2"ZYG
M(\FXC,I(TK`>[W@3!%_`K#CP`&6`3VF0`23P3OF-[VE0!FL@`.CV`$@@<6<`
M!XIHR@@P'Q##T*4@()-1@`ZP`5IRLHHW(--..RFQ&3^D!7;P!1*!``A0U%C0
M*&@C&JN+*SYF.F,`(?RCDV)@!>WN[G\([_*>\W.#``E@O`R@!FJPYP#N[_CW
M``?+C=<&`1)WJ/E]`%.@H$)P'GXQ5==I5:M25@-R\5N3PU)R&;'E'?E15A8`
M`,,1,R8@IC!I0D1Q_[$#A`;KLU\?YWJRK?-T#THKP`,#P,!J($$%D9!R_*/E
M?+`SXEB=1D]DX`80@``!<`0I;0#(YT<IH3_>71/;'1-#(392<I:Y4@M;[@5]
M\#((4`$8D!_I8T12<C4G)%!4(&!2-$"J4/>PKT4-,`4.<`9DP.LI_)YL\`!+
M[W(^&$()TAV\W@9'ST5UD`=)D`,)P#7R`FR><748]3!Y9A^;X2HO7(#?<1#1
M'@)?(+D@&5G^8E#ZY?:H0#`/8D+LL3N](*.QW_Y6I`,>,`!M@%,Y$V$0L/>'
M2@0HK`9P``AF5EI;!0L0:QEE"F<::G5^-!946%1O75565EE86%9465M:6?]:
M8EE5F5I56F!C8V":55176&,C!`8>%C,8805;8EA::*];8U:%#E59="HP,!X%
M'F-_U=;7V-G:V]S=WM_@X>+CY.7FY^CIZNOL[>[O\/'R\]\1;F=J`@P"`@]M
M$&7(/"""0\,:,F0@C($AK0"8!6O*',#0P4T&,AM@.%`Q!DN72J=FR<)R!5DE
MD%12:7'5"HQ+,%6V;+'B@$X!`@ZZ7''0,12:F58<;J$3+4PA&3(TJO!`KZG3
MIU"C2IU*M:K5JUCIP1"11@$<-6<$W%,#0E_!B'#8L+FR88.*-Q#:B&"@8(``
M$4AN*'BS<TR7,%=.61DC<YC,F%90!1X\L\`865K_-&VBL@5+%30JO-`10\7F
M)C`%T-`!,YKTTC!CFB&=`4-&UM>P8\N>3;NV[=M.[3QP0^:>&WX,VC`8GB&#
M@#-DTJ01,Z)&%@5DR@A0H^8!"!`XD"`A`0("G2P8+&,Q4^57%DU:`JNH*0JT
MPU2=J""#-886&!D`L(1'4T`+%4)C%"`-:%MXH,(I:'A0@QTP;%`#;A!&*.&$
M%%9HX85AB%#<`VNLH489#P2W&P/&M7$&&PI`@`5_6-0%01=6O#'`&@]DAT0/
M)`PPAAEU3=1!&!A0--$"9@`@A`4RN``-'<>D5,LFG3!3R4)U@.>)0[2P`@8:
M#J"!AA7-=(3%%G:,,,(&_Q9<J.::;+;IYIMPKB&"!@)X"`<<TK$!07(:,K`&
M&P,,H,`!6UP!00<,+`(!!EE<H0`#.(!`1`](@'"`%6RTH8`"74!P1@==='#`
M&!&,L)0,K,G@`!B!T8*,+%6L.EB#6QSP7VB2R50(&JPTE)X6*MC!0@T?P&GL
ML<@FJ^RRZ;21`8>`0K"`&FL(>H9%#]2YQAEME&&&*F^0T4]7"XBZ!0:"@D`I
M$C@L*M8"8%`Q0)!I#$"%!5^P8)."(\A00!8`UU*H?(2M`@,+5[RQQ98!SK22
M*PZ!QM,J8S@@0PU),JOQQAQW[#&$PYT!!P9=O-$!'%W!T<]USX;X``95>&`%
M&?^'_.9&&F<HX(L#`Y!`!!':;9>!+PMVJ@"@&,BP00%4C%$#"W:LUTH!R/S'
MRD]@;%'#"%=<D74!=`SR6%!;RL1?O%F@P=H,J(*C1!PB</'QW'37;??=UR0Z
M@!A@K"<&!H<.QX`((CSP@`;693#`&VE5T06Z<(0U@!DJ6&#'`!H`38)V)`A0
M0`T;B*'``@@M<$K"S*C`@JHN!4A89,;0)\,(?VW!WY>L+$SU&%ZV8M,55#@P
M@PIL@T,'%W(P@??RS#?OO(5G]+*E"BZH<,486;A!.`AS/5"<!L8QP`86#EPQ
MT0$#9*``&B[48<$"V.$`M'8W9+'+T0.0,0`$8@33A4O_'H#!\`1D$]L19C!C
MB(P#1F`&3+AD)<@04'\"]),"S.`[5,`,#)P!#A$DX7D@#*$(1SB5`8!F):J;
MP:C`,``BB(`(-S`<"!"W`#$$BC('@`"GT``!8-4`!A@00`:N\\(;(4$#+*A#
M`<[P@)SQSPRA<(``/1`-EPAE&,3(A$M4=SH,@"9KO`.-%5K!NRW,8`96*(DS
M5.":;_3@@R2,HQSG2,=PF%`6!3B8#+;@``^\0022PD%Q-"0`"!1``5V1T0!,
MYX`-A$`&,MJ']X:8'4H180`6(``5-#"``W0`<CTD7L2VA(:I%<(AA"D0##X2
M%):043("*D3?9E"`*Y2G-6WT_T8<EE#'7OKRER-4@!:,,KL-L.`9*CA`I`A7
M'!!L:`#!Z0H#SC``-(R``P0(P172T"$&A$@#DN+<#3!`@"]8`0Z;TJ&@R"<#
M8L2+,C#)FFCFF2`9A&$9COE%@!PCD]"<T@,S\``GT(`J%8`C!R*(0QV`R="&
M.I1C$`"8`VK@@@V,@`4C``,;RL(][A%.0V=X%K4>H`8,L```&ZA#?MB@AN'H
M0X::$\$-NM`"`AS@`66`P*)^9+&?`(4PA)'G&(UA((#!HI7&`.I*_%E/%6SA
M#55@(U/`(0<X/O2J6,WJA4!5L8-9E`4;R`(#-)"Y2'GT68D0`!F&HP8K&(``
M#2I`H/_.P(`TB,N;Q<D.03*`!B]D2'$'>$,8LN"*4J[$/["`B67\8YD"O`4F
M_M%"?V1I.V3,Y)94M&4`<ZG5SGKVLQ::D@?LT!8SV0$-^R`1"0A'A`SLHPP,
M*,M8RV"%"D3`#C5H45A,Y$W!/>`&/I.?"*Z0H9>ARU98!&K61"&,F"Q7L@+]
M1672AHS(:($05Q)-:VIY!3H\`[3@#:]X9>,)#[C``B'@`-1D@`$.9>"%!''A
M=/KQ+!!P"`-YE`$5.M4&->1OB`:!;2"%2X81K&&&;GB``JH@C.OJCC"_N.Y+
MCB&:\B0P"V"0K`.V4(57?*E@WG6!!X8)!M:,]\0H3G%3U';_30-XP0LCT$A7
M.B!$&(+@!JVET7"<::*]E`<+$!!4I]A@N#JYP2(XN`$.DJP!`*#!M6MHPP)`
MX6!1N#,3J)!)Q=#@N"O$K@I9D^?#-+SAKJI@F%H0GHK7S.8VEP-T=3#`%RK@
M%C!@X`!9*,`;A&B=U3J3'\YR9KT.((8PU$4!5#!#!]APAH"`)1&$PX$(DJR%
M"4``RF;(6DSPN<^4,#B#5*3#:+"080'UCC2.@8DK>"+JUFRX"Q9SLZQG3>MJ
M?,`"%C!`!6)L!9V-H:*]%D,5.J"`$!7N<',27XH.P*/]A2HMFP(4'!)<%IF2
M``<#X($]+M*U\U3!44L%$(?E(Y,M_X4&LOM,#:JH^#6P41$&-?!`H?K&!"[8
M^][XSK>]K5KK?ON;CA\X4P3JP(("'&`!6I`!!SYP`#54H4$P6`/B]/%>102*
M?T%.PR$ZD`8UZ!10"EB#$(6X6A$(8`8(<,$9(""34#!8#+"C@DLX##`L2LPE
MJX"%&<PPE&"UQ@,V><8S:"D3#]1;WTB_-[__S?2F.^\#+JB``2R@@B[PS0,A
MJ(`%@D@%&'#``G`H"'"X=SVO=:'190@4NM9P"/W-*+7;&]P9"#`%80,%*&$#
M,P09FQ*76,&P"=Q28L)@AC>(H0`U82/US.0"%ZA*&DZ/O.1_:8$*>&$7J("!
M!6!0`0`8P/\.T8-!!%B@!A@^"T3M\L`5NJ"&#+1!`'HB]@/@,(`TH,P-;5@K
M,P5P@QL<@`.<&5"673$3T*`A)1`LV)<(2T$.A^'Y9E@]P/Y3B!F4Z0-M8<'D
MM\_]$48@`2'0LS`V`(`O>*$%4S"``\S@@)RDH:X#8`,9Y.0&#"Q``>_EA\<A
M``<&>!Q].:5#=P$"TH%C((`!/,<0HG0,K6`,HJ!%B94863-&69!!/-%`#/87
M&"`&.E$R4)0V*E`#:=)])%B"=U-Y+#``'8`&'.`%!"`$0D`#2]!',@`:7:!V
M%2,&%@$"`Z`R0Q0B;4![W+)@5U`&:F`^`D$X)"(")(`!?C0&*@#_-H\W6;8#
M"[VB*Z#P"O+A'P$2+Y6`!H!Q!0@H!LRV>H(E!CMA@FJXAARC``Z@!6ZP``[`
M`C3``S1``0B@`RA5!R$P`F$P`&>P!I?",\/!!BHS0_K``&XP;6E`:@`1*(`H
M`,Z4`3B&`4L``UKP##6P%*74A0\C-D)1&)>Q,!'$))L@"VAP!:5`7&A(>`W4
M!69`!6PXB[1H+`M`!^B2!1M@``8``+A``%$0!0@``!,0`06@)XT!`U80%FZ0
M#QIB.!E0+66P'%6@`&4@;6ZP!G[2!C<`!WZP!Q8`A3)@!S(#!@X@%*[P&,NU
M,!Y62I[0"OQ!-92!>,20$K1`7#OW?*90_XO\V(\64AZO-P`R\`5H4@=),@4K
ML`0F8`(M``,,``'H95%2YP$*<!<QM#)K``=ML`8=\!R\$2B\H1;O]042(`$Y
MP`)LI!&1\0MCE(Y_-PJDH`H5\PNW$R!=`F8"$@WLZ`I:T`6D0`7WY(]".92V
M(0-B8#AK8`8L$`$&L`$<P(L(D`,E4(PL<`8+T!QGX@4\``!B(`!$L%IN,%;!
M<63\$SF!L@"!TG&%\P$-<`1'$`4$L`$R,`VY(Q.:8&61,0C_L26$I9=50`?G
M2!.`V26-(6H9A@JK@`5$N9B,B14LD`6GUT,CH'4A8`$1(`1WL`((0`,?$!!T
MT!8?```\D`!4P/][DB9$&A`<9;``@*,&;:"":(DR;4`";6`%)A``-C`$>(`D
M'N!3HA!9#'A4A3$82_4EY`-TR>`!J[(P[5<`R^`1YR&+C3F=U.D4+A`&,20H
M$#`#ENEY=(<`1A`$1A`"7V$%%95)?=`'-7`&@,0A(9*-;G!PFX)(\\D&]T`$
M`L":$5`$-I`$%&`"(R!O+:DK"103,V$[#[94_2$@LF(3[H1X[9=*6-`H!U"=
M%GJA[C`&!Z`A@<(&#O!]"?`%/"`$=C@%1M`",Z``JO,!$6`"0H``!C``,]0M
M^[`&;L`&9E`N6@`!:N!V;B=(:L`&"[`!N*D$>R`%(9`2KQ([6T`PRZ7_":!Q
M#(@G<UNF8<Y)&N<H06A`"EE@!M_`!7'P!TL0IAA:IF9J!AA0'.*2!E6P`79H
M`!]0!RW0`C]@!#S@`1@0+!;@!3_PH@"0/J\EE@EQ?P=@9]#D!K57%Y'B,FM@
M`@U@`SL`!$8`"ZB`#*\@7<;@FT'Q)8A'"*C&'S7AG.UG$X/I$JGX#4SP1FW`
M2V;:JA9Z*!67`6=@!C(P`3\0!$CR`0G``PA``!B0B==$`#3@IQ#01!ZB`86S
M-Q"`9UJ@'_Y`!G`09"[T0H(T``!0!$,@`7C@5)DPH&'S$UR22I=AJEXB<Q$#
MJB/&)8!)0*EF!>!@!VW0!JXZK]0).($$`F0@_P9H4`$T8`1>L`$.D$D(T`(0
M``87):=!(`04P`,;0`8FXBQST4DZ12@.$`8"H':,,Q>Q)6GX^@$ZT``!@``R
MH"6VTR6#86JE!`L/*FI>PY*D82"I`3992C59HP7@D*JL2J\Z.Y1PL`"0LEIP
MT`5=L`$F\`,_$`)@``,$8`0(T!I/DTDT@`#@V0<J<`9T51P,,`!AT`&=5`#L
M509O<`!A$"X9P!MEH`&21@0,L`%^$``!\`&M,Q3.64J!27SNH64"%12(UQ]@
M,`VDVD=4M"I@$PYOM+.&ZX_2D@':\0!B0$4;D``FZ@%A,`,<8`1+P`,$,`(N
M\`%O%;7@20`*\'K%<?^Q/*(`&-`T8G$`!U`7OQ&$U`(")'!M#&`'49`$=SIA
M6L8E5-@KNV,,>[DP=$`,DV43J=%^T3"XX%"XA[N\LW@`6'`&E>*$9V(!$V`$
M)I!'N\BK/P!CM]:+"?"B1D`#9O`;H]N#=3$`61`&=/))9!`6V>*^[^4S)/``
M+1`%>@``&S94`7(]HW%*86,[`E)=!UHVDY632]&<R/L-22`'S-O`:K@W@4(^
M(\"4+=`'4V`@%L"BZ#<!NH9K$0``)B">1B`$&[``W,0/(/<G&-`&91$0_.`]
M@+0AL8472*`%#;`'3[`!RT`)^K1J\;)/MP,+%4BI8'8V?;LE[<>)">S`3"S_
ME)TT!NAE`1SP!<08!":@-'4P`G60`"W@>0:07E)G`KR*`$*0`%H`6X=#3=IX
MH^"$4VUP.,\2=Q$A'"#``&;P!!)@`R7@`']W&16T$JW#)<1P#/,1O!P6%`#,
M$,E0$Z#:Q([LC['RN"U@`@F0``#PO3S0BP``5KU8!TQ9`5D7`1,PQB/L`MHH
M'/U%(R_L6MYC.!S"/0]0+_'W(5W``@%P`B@P!`1P?`8D(%<#888,%"HP`A90
M`S>X8&"V$%WB6(X1CX_\S+2X$!M``'-*R01``$'``RTP`;OF2`#`E%\0`:$,
MN>*)`'W``7:ARFJ0!JDY27Q&(I(D%ONS`&@)`;&"_P!`@`(HT``6(%E4HPJB
MP!(_D8Y]8WD$$`%H@'MA(%E]F\1S24!3!<T278)GL@$3,`538(?;C-$<7`=U
ML`%2QY0`P`$<('743`-]8`13(`/YD#A@\3VCJP%,Y%H?4BZ!%20*T`%_9P%1
ML`,H$`-ZX`):V!['X!\`++.91``3D``LH">7$1I4I`)2K9Q9.M%6W7WH9P)3
MD,T\$+XT0`,F\,410&=/V8M?$`(AH%)*+<9&T`<1T'_;\W[%X5H:\,9\EA"C
M0VAH>C2%6AYUD`.X?`)/$`$"A1@-`3#^-`-U\&+FEP`&@`8P-QBBL1'GV"7^
M?'1)AW1+=]6<#5KB.05"$/^>2OU6YM=Y4X<F+E9^8QUG!&`"-!`$X$D#'?!>
M&N(&U^%,(<)_%QMD.7UG'7!_$.!EMB,:&U`$,8#+>V``',8*5U!-Q,`K8,`!
MCOW!Q&@"$:`SNX)XT3`&5+0%C8+9F9UOF]W9Y)U5",`#$S"L2T``=6#:(0#2
M[4W27U!.7V``3.D%"4`#H`V>/-!>WA,<DP@"FM(B;@`=QR$H0<*:8?!W#F&I
M'-``.Y`")]``2H28'6`,YP@+Y%<!)LW%!/``+$<4?110&\$V,F!0Y9WBM!8$
MN#`!4OL#!&#:7\>+4V<!OI@`N&!;^(W21M#C+;``P@%EN'VQ@B5_'5<MK!DD
MI_O_W(QL#`6P`3IPW"@0!1LP1H10'C;Q"TO)X6\EK%-`!I>">`4BU>>(&:2E
MXFCN9C10WW>XF3@^WQ\=`7*.:V\UW1;`VBV0L#PPFN%BURP<(OGY''X2+:I+
M$21#&F,T0+`@#180`"AP`D"`!QN@!0<0&*%QZ2%`X_BMU2:@`-=SC@4RJE:T
M$6E>ZBI&HE%+`3V^!+WJV!S.X20=`5X``*`LY[->M#SP`POI`(]B(JH<'*1&
M7X&H)ZI;Z7M;'JQC.W0@$Q;P!#MPW$F@>L(P$QE4`%'7BZU=AP#P'[Q3V:LB
M,504T:8^[N"%`$MP[C!8`CJP!#1``%Y0!W&Z<.@ESI7W_\V\F.W;G``60&.)
M2!P"\#B3%!'2<F=9($73(`U1"(_\A`81D`2X'`,TD(I;`@:DT$@`4'Y*/041
ML"]<PFJCT?$&@N+D/O*>9>X(T`1]T`)&4`(4\`.R_M&X=N?T_I3U[<4)L)`3
M<,U:L%:'`XW_4`;&\9$#(`OLYP(%-Q0.ND\"TNT)L`<G,.$`H`+0G34L0``X
MKM0T4`''M[>]0[Q["[@D'_9:50)+<`<\@(EH4/6;"0!F@GWS3N=6#P"S?LD+
MB>,ML.]XA5<49QQJL"EOD!1+"0`A0.95*!K!*T&.901'$`,[D`0$,`:,PA\1
M\`/S/0$3P`*$+`W1<(Y,PCM>$O]J8A_Z#Z4#*X`'SU&H=E`'`^L@8'4F[2W%
M:^V=7\#%2YW>)J`%_-!,&K(A`K`('0`V=`B>1A`!+L`TE]Y^02%JCE$#4?[H
M3X"TFH`&TVQ^+:##CO$*QJN<Q_#4TC`:HO_]P*0'3>MLV-L'!#`L9>+!4X=-
M2VW?Y<?%)K#4-/`#%3``83E$-Y`!R)JUO`T(5V`11CD-`0U?#F-C5G0S'I$%
MDV,%=4DG*#%1%06,!1M?!`ET5PY66P61*@X%#G2ND1YT5G^VM[BYNKN\O;Z_
MP,'"P\3%QL?(R<K+S,W.S]#1TM/4P`D$,%5;'C(S+"$$&^(6=185$1S@!!$5
M!@2B"2;_)A,T/#0N9&X/#R`B&2`#Q(AATT;!E0TM*#38$R.`!1E;K'APL<'"
M!AD.JE#9XL#$CA<I8N3X8$55!!H`T%31TFJ,`P\J9'@H0,?!JU9HQE2IQK.G
MSY]`@PH=2K2HT:/51A#P8FX$C!$;*%HD%Z%.NP@1O@#`:N#+%R\`XK6H1^/+
M`0$@,OC+H`'#@05IW$"X8H='B21*3IQ(LN%`%3I/1["0,8:*EBI69.C9@4*3
M$SI46$Q(@`:+%32S.+Y\J6)5)%AHT"`=3;JTZ=.H4ZM>W=.$$"%?ZGCH4@"&
M"CLN1I@S4*$=``-8T44`0*!X/!,M6DPQP8+!#2(B_)$9H&``_QPW;#K`X*&C
MP9`8*710>9,%,S>9!=!068FF0H,8+U[8J#"#`XP"8<!8&1-I"YU9-CG0F4TS
M(:8%:P@FJ.""##;HX(,(X-%'#5M4X<!@6JC`0D4A1##5.;U98$%7Q1DW`7)3
M\#!!&!D\AX,`:;!1'1L"*"`#"T'D$``0)]BP@1A9C(%&+"]-`D8!6[CTQ1X7
MI'!"%$)4D$46EFT!QDLY34(D+%I:@=B#8(8IYIADEFDF<P>$X=<(L=FV01T;
MA%#!!R-`)>(XQ&EE`'&C3-`"#SQ4P$8_.##@1AH#)"I`!RX00($100R1Q`0%
M3"FD)YP-"08=0VZ4P!Z-]4C!%E=44?]%3@)ZL,4V#J"J`AUC)*G%%6&8:>NM
MN.:JZZ[*%-"%6P'!$$$(&VAHP0@<;#"""S7$2:QN76W56U<GFL!#'SS`T`8.
M.+BQ@`)DP#'`&F6,84$?=^B0A!0)P)"32FALYH%-KAA)A0=]V)")2#`<I@6J
M,GC22)+_P323%52,Q^O"##?L\,,(*J#`&0,LT(4*%M4`@QU0&5".LA;(.=5P
M!AC`03L$S&/"%'WTT4(8-V2@0!@+D,%&7&M@H10/>B"```\LI$<3'37!Y%(K
M]`[)@A1'H"!?"W1H(?61\UY9@!67R5(U&&`<`/'78(<M]MC)U"P`&69<H0('
M+&S<[`<1)+#_E04<E",B.>>@4X$7)TY`3Q"`VY%!&6]T`0$;`\1%Q@$SC)B`
M"@BT4(.6LQ#=V1@UN5)3K&-\4$0*+\300`A<;X$&+%'7A$HEFW'*"!UDQR[[
M[+0S;(<86RB@Q0$%+&M'VRR(^)7'%81PMXB]<95R"R=.(8011H3@1D!8=)`H
M&VZ<@0$=&U3`PA8E(%#!!A',T*HKKPY)]+RGH%*`"4"\@,()36R@3263_&NE
M*S;59%-)+*B=``=(P`*N!C(1,($%LF"%&KB`62IH5D7*\0&J5,!N(1O.%Q+0
M@A_0($5&0``%8'"V!1Q``6E0PQK:0`8K6&`L&X#!$@(PA"),`1*R_Y@$T281
MH$;LQPXK8$P*=O`$%KQB#&`8D@<:L:7TE`0&&S"@%*=(Q2I*HP1W:$`2BK""
M)3@A#T5P@@[\X`0]Z.$)>LB!'HJ@Q2A$`8Q1T&(2DA"`/=1Q#T-0@A+NP#(^
M+`$*4)@#RZ"PA`8HP08-6(@$E)`$/TAA!7>()"3OT(052(&2*U@!'O``R2B<
MP`>@O$``Q+B"$I1@!3JH9"0Q*856ZN`)>;"B+&=)RUK:\I:XS*4N=\G+7OKR
ME\`,IC"'2<QB&O.8R$RF,I?)S&8Z\YG0C*8TITG-:EKSFMC,IC:WR<UN>O.;
MX`RG.,=)SG*:\YSH3*<ZU\G.=KKSG?",I_\\YTG/>MKSGOC,IS[WR<]^^O.?
M``VH0`=*T((:]*`(3:A"%\K0ACKTH1`EIQSFD`1;R&$)%N4"$W"QA#I<(A>,
MO,4<;I$$C3*!"RC%11ULP05@+`&CO<B!,))0AY8&(PYR^$,=F(#1E2I!IA$-
M*C+I(`<ZZ-$.<;`%49-Z"RY4E*FV6`(=6BH'.[3!%CF`J45A=XND?G094/T%
M[#8:#!%@-*FP4T`2*"K4MAZS#DK(:5*5L%(N**&I%77J+>10TC_(U19UF(-6
M7XJ+..1@I'/@PDH#Z]&B:M0.7)!#'.80!R;0U:-+:$-D4=I2QJ[4%GWUJP+L
M6@<[Q'6J9/U#'.S_H-H_T($)=%B"'7+JUMH&DPNLM452^ZK7/S!AM26M*$EM
MVMH_B$`.7(`I40N;5"8L]J1/5<)R^YI4IQ*5NG^@JTZ5H%>HAK:ULZVJ=&FK
MVY>B-0<ES:UMU\M++HRTJ]EMJ5WQNEU<?)>INVTI$]2K6YHF(0XHA6YKDV!4
M[#HUOP.6;W"+F]W/MA;`R?T#@>^J6]56%ZW\9:^&;1G6XE8VK$Y50H?OJU3D
M5G0.0(7O'"@KAXUVM\6'-7!).]I2!;08=D3M+BZN*]D_1)@),'YO:RDK8:\*
M><-(GB5G7?QCC=K7O>3U+4HKNH243E2X6KT%3)=PTB7P=:->7K%OJ2SA_XTF
M(0<M17.+G9P$,.,"N1C=LETG>F2,7M2O&,U!:I/,YWF>N;=]#C22]2CH0AOZ
MT(A.M*(7S>A&.WIA-"6N4L%J"^ZZUA=\[46DB<'57)QTJE3&J!)8JX0L_T'/
M?WCO'$Z:TD>[^E9CS46'B_'?BF)7TY+.1:R',6OX;G?%21`!$[ZKTSB$&L5;
M?;6RR?3=*K,VJ7*H:5*=[=HZ+&&D3E9I#E9*7=PRP;FFS0$=YH#4.43;#L*5
M,'$5.])QTR$'YZYH3:]*[<+B(L8>);:)==MIPB[[WP\B-A,4,&29,G7@Q<6Q
M+I**X/R&%]TM_6YBAXL+$2?8%HFU],$);F^LXO\TO57.16_MX.#E`OSD"](N
M8'-`\.H^5:<L+^YL,_Q;+E06NR6%\!+ZVE>Z3KS2GZWJ?Q/L<Z>VU*LQ[SB!
M0:M1S8J\HOM]K6\SC/*JJX;'.+WJ;JW-<#EH':MVX'**D1WCHR.7NQ@==L1W
MBN*?EWB.<&6XNML>V=EJW>NRMH4=R-K7J3[]#WO?;ZI3;/7"HP;.$D:Q'"RM
MA-\F'MY:M3%;HYK3.U/TL$"M<N.%N^(K$Q[Q+Y5IVI/@^<?S5?$<C>J4AYW=
M=*M;HT`5O>%GWR">HGD7/V6MJ6G/^VNRGA>N[[WPAT_\XAO_^,A/OO(9-M4Z
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M<2%6AJ[U7XNGAD?XAAVG"P26!`H`6R_(8!='@K"S5AR594SE;W@8B$WE7K.U
M_X<XV('NI5MR4($,9FEVA5.,>&"+V&MPZ(%0=7NV,&QTR%,KYF63>&HME6,G
M!E2F]5IV.(6+6($FIW()R`4IQDCD)EZFF%VLY8H,!HE$]8FW]V&JM8BPXXN2
MY8N56(E:]5.ZL&5I%V#9)5/H]P=:A7X3%569J(S.2%+4IU4Y0&&WP'KH5U+F
M=FIWM60G96ZLME'&>%(;-8XYY5[I"&7#^([P&(_R.(_T6(_V>(_XF(_ZN(_\
MV(_^^(\`&9`".9`$629*(`)RF%,>Q0L'N8UM0'V-UPM+0(D%69'&D`0]H`L]
M4%&$M@L8F7JREFNX8',6B8_B]I%F10<H*54H25MVT/\#K#4'=%`0;=@&:R4"
M-Y>1-65<"M`#/5`'/3!M-!D'9H61;8!3<;"12=`&-LD%/@E7"F!6.B4"D,64
M;4!>F25Y./F%="`"=*``5UF2R<<$(D!92U"'91D'9TF69LEQ9_D'"E!E!+>1
M;>!E3-`#\9:1+*<$5[61/E99/0!D?`ED'ZD`(T67.9`#6G=T*%675X5<-N:7
MOA68+8:7I<4%:H67DBF6Q]<&=%`'G_D'G@F:*S6:GPED)`EA2;61?OF1-O>1
MQB5;?^"7KYF1&-<&%)61DS6;&#E'NME2/:``<0!@3$62?LE(MNF:Q/F1F\F9
MQ6=5&'E7T-D#TFF3U.F59,G_!<)FG$F`5#O5!G40ETK0`QB%5!A%E=R55&U`
M<C0%7#W@E!NUD79`-*Q%!X8UG^SXGHFUFFM%G>M9FN%99<:6D<WIG,-GC#:%
MH)4F4VEFAFSF?6#FB>4G4P>94].7!/$G4X<59&3E9/XF8-?FH(P$H=$X4<S(
M5AAZ4CY&?08JD.%)=2T:HZ41?#):HS9ZHSB:HSJZH]144E-U66>V44>F91$V
M:MF%49NV<`H)6!2&4B-54SO%I)66B/@'5\XX4DMP5XEU;69&HSQ*?$F%;%/'
MBK>@77`5;&IW:2P:FQ[64JP(;5P%8!5V@+B`;-5%<"&F7]TYA5^*?+ME<DAE
M@D*F_U?!E6]&UPNKU5I9!6UUB(`AB&"M)0+:6)S:5V4+5EXBV:?#QU2*>5=O
MZ5OD1:A&%W:'R@MJ.9&`MU_F&)<>EJI[%UISU7%&]U^S6J9AJ:G'!U5V"&"$
MAW$:2E%-1UJ(:F&JA5N1UZH`%G;:E86ZII#<A:$V*:8SB*O%-U>+%W8K:(N9
MR%JO&HJAR%?/-V1QL*RFV&/3MH-^A6,3A5%2AU7FIH$5)0)MQEI`19'4.GNB
M!F5`17K96''SQ7HAA7C'B&=X@7%?Z*';1W[I)U43%65J5F:G9HZ]M7OW6K$6
M>[$8F[$:N[$<V[$>^[$@&[(B.[(D6[(F>[(HF[(JN[(LV]"R+ONR,!NS,CNS
M-%NS-GNS.)NS.KNS/-NS/ONS0!NT0CNT1%NT1GNT2)NT2KNT3-NT3ONT4!NU
M4CNU5%NU5GNU6)NU6KNU7-NU7ONU8!NV8CNV9%NV9GNV:)NV:KNV;-NV;ONV
M<!NW<CNW=%NW=GNW>)NW>KNW?-NW?ONW@!NX@CNXA%NXAGNXB)NXBKNXC-NX
MCONXD!NYDCNYE%NYEGNYF)NYFKNYG-NYGONYH!NZHCNZI%NZIGNZJ)NZJKNZ
4K-NZKONZL!N[LCN[M%N[21L(`#L_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>o40024o4002400.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 o40024o4002400.gif
M1TE&.#EA9`%+`.8``-S<W(F)B:FIJ<S,S.WM[5I:6L'!P34U-8^/CT1$1+JZ
MNN+BXAX>'N;FYM75U=?7U]G9V=C8V(:&AD%!02@H*+*RLN3DY"\O+\G)R;BX
MN`0$!)B8F+2TM+:VM@T-#:2DI*:FIG)R<J*BHLK*RJRLK,+"PKV]O9*2DF9F
M9I"0D$Y.3K"PL)N;FY65E3\_/R$A(>#@X"4E)6IJ:C`P,$Q,3(R,C&)B8AD9
M&6AH:&]O;X.#@W9V=L7%Q924E!04%*"@H(&!@7EY>61D9%965C@X.`@("#HZ
M.G!P<)V=G4I*2A$1$5%147Q\?'IZ>E-34UQ<7#P\/$='1V!@8'1T=#,S,VQL
M;%)24H"`@"LK*^_O[U]?7\_/SW]_?Y^?G[^_O_W]_?GY^:^OK_S\_/7U]?[^
M_M_?W_O[^_?W]_/S\^OKZ_#P\-+2TN[N[L?'Q^GIZ='1T=#0T/'Q\?3T]/KZ
M^O+R\O;V]NCHZ.KJZL[.SEY>7M/3TWY^?JZNKIZ>G@```/___R'Y!```````
M+`````!D`4L```?_@'^"@X2%AH=_<PX<&SHY-EJ1.4TI`AALB)F:FYR=GI^@
MH:*CI*6FIZBIJIX02%4N/GZRL[2R11=/"`9@J[V^O\#!PL/$Q9]W(C.UR\RT
M2CIZ9,;3U-76U]C9?P`J&LW?X%@@7]KEYN?HZ<5K+N"T/@P,-^ZS-S7J^/GZ
M^_EP-M[,7@S100)/`UZ$V#C(T`,%%8#+#H29PZ^BQ8L83WUAP8#9#10"%H"*
MDX')`68>9-C)R+*ERXQLG#"[T`(5#QH0ZXUXR;.G3VQP8M6BP$.:JC(%F&TP
M^K.ITZ>FD'BHY8$/N5\.3M:2@1"JUZ]@"4DH0JN(C0;#S"`0.DL%FK!P_^/Z
MW)#3PX8SQA1HG36DJ]R_@/4)J.4#3K4L$VI9$1.XL>-R&6J]P&1-S)-:(1YK
MWEP,P[Q9,])D(Y.GU@;.J%.G0K/7#Q$(Y;[8>-=!M>W;GXZ\&W#NC@I:5,;@
M'DZ<T)N<!M+9Z3A+2/'GM\TPE[4'WYM:`*!KY\R"UHRKZ@+0NK"]?.,&2F9Y
MV*+/S`5:&<S+CXN`%@I^'"`2\3N__\\T[\ER@P,5_3:+`OXE^-,)M'!A40<0
MY:'@A"\E-HM(%9DADRP>\$;AAQ8M`)$,&)%`BPX@IKC/'K24@!$;4\DR@8HT
MJD.$>N!9%,(L1>!5XX_9F`'1$"R90,MI0"99#?\>M'C!DAP0%:#DE,:()XL&
M;[$4`VB=Q)'%EVIT8L:76<1ARAD.E%!!&&%DT`8`/HXB1@,C*,!F&"8,8`=3
MH(BAQI=9AI)&&8268:8G9)"9!1V&@*'HHY!&RE\A<13J1BEG`&#`FF%TP`,`
MDW)RQAH==('`J2>(4`$&=N3X1P*S,.!2:1QRLL`,%^0Z@PW":2)"KA?,@"$H
M:[1@`Q$^Y%0$`T1(<<(:C'5"!PDA1!$#6;1X0`$-.U0@!R@@X'H!$1Z"4L,+
M\3!@1`6=J"$#L!=D5D@(\-9K[[T[:()"NA?$Z0D`&]A@Q'17WF!$'@@,X*HA
M9W"0@Q'I,5,$!4D$0<+_I7^\,,N,+9DX"P&;;+$,%+TBP@4M['GR108WTB,+
M`TYN0D`*,;I<!`*4<7+R+&&(`@8*M&C`KB8$#$$+$688TH[+S4B@R=*R9/&)
M`4LP[8<'&&BB@#++:)!360+\`9$6+ETWBQXA,T-R)CO+DC(G``1X)10LP-%`
M%@0X`,(3'<V`UB8FL.7'1PH`P$86=T"@@!81R^+#!YVT[4?/HH@!]"P:<)`)
M&$;0DH34ABC`Q>BDC]ZX'P643KH$=3Q-"^B;9`%%T$348%`6:41`0@$=Q7"'
M)A($O40%#40[!@0KV!`#0!)(0TL0+KE!2W*:B,Q,%*(=(OG;FK#0N`<!@)P)
M_Z.<=`'1#28L/$@=(.0TA<ZT4%[YCI@/70@8<OLQ1,F>:/'Z*%#S`^PR48*:
M:4`'&$-$ZS0!`8AX(#N:0(,7,&`46IS`)7.@!>2J1XLHT&("V2M$#5#&B3Y@
MRP\S>$,J!@`1!OQM$W"HF1^0Q+;XE8(,.X"(!C[`ISMTCB_\Z]__1!'``1XB
M`S5[@0E003]9+$$4M.C"2XZ4MEF(0`@=#.(?ZC,+[AT"/9A;0RK$(`4J>B)X
MZ@E3#7EFBB_@`"*/&\0=DC*+*&BQ$_Z;A1$]441-Q(U'($@%%P44@5!$\24U
M<Q`'9\&"+\!J%FLCQ"#]X$5#T%$63U`%!FKF`U",(?\G)-"$Y.1'BB_LH"P\
M^`,8DN"Y4N0Q:@`<(B*:Z(=,IN(+'K1/&"S@B4.Z!").6Z0L$/`',7!-%I$4
MQ"0K28A/TL(PJ6#0+(P0BF/ZX0BBM.$IR!"$;+FA:K-`0:B$J,=8EC,3%*!%
M'WJQ@=/9@@)#.,$E$&%&EGS!EYFPGBR"B08+R0B"?^@""3/!)%JH$16GG`4-
M0D$#6B0@FVQ$!1DD`)$3^F$'XR0G+(DH2T.@H19+[$466!#`93#`"1+``'AH
M49V69($6]D.$/OV@R&WXTP\@%(1`NZB)$M0B6DQT:"@,)`L70%06I#0%&8#P
M-3^(\Q2O%*`Y-WJ(!=0B9K[_J(,`4$"$STC,"5YPWBQ(U!((T*)<,FT0(=)@
M32KP`@0#1<0#:A'"4Z!1%N0!!5']D(2C3JX70*@%D5`1U3UVHH^9R`F"B)&%
M,`1A"%CHVFG8H@*7*(`6PTKK+')0B#.T3!9$$,-E>9H),<@0JZ>H0-`R>HC6
M,,&O23V%&]+)H9T0MJ.?0"PB/NN'"U:##@&081$(0(598,$EW;P24#4K"\[>
M;W8*W4+CF$F(P,XBKZB0PTU1Y(DS6#0^:T2J2.6VGE04=JI2S<0(9T$$\55C
M"UZE:15X1!&6["4&G)@I#@Z!AKT68$MNV\08:"N+$'P+%1R@Q0W<NXF$RN(%
M_C+$_RC'JQ[JAN*\'#TG(K*PUR$<BAIF>*0L:J#:63R`)6:H65^K*`NR596H
M7B.M)MI`L">(\11BD$$'<X8(,E3@A$6@7GC_NHHLD-?"H,!P*'2+"`<0V`\)
ML*TI+!#A3'R`DVY(PXE84E!9O);%?G`Q?V\J8TVLH34:0($!M`@&/;`@"BIL
M<`M!L!)#?&$`EW.<YC8AN19$ZE%)\X21*VQ>W/+1T(9(PP]G40`%,%@08%@#
M$E2`UD*TX&I.Z($)RA!H0IBA#;-1SP8U]F"62%,69<@O+9Y86E;6`LF>9H$,
M!30#%[B`"C>H:$TVX84G#XX(0X@$#2Y@4?V]T*\N\VTG!O_-(5AK-+U+1O0A
M/B`X`5W`UE1@0$XV6(@$=^T&M7;!`:XE&6C^X3*S`&A%OC"=XZJZ+9L00T/C
MV@DPA*$;[M#`$EAP8DZ`@0.Y=$<1=H`V3TC.94+F!+.OYFP\2GL33-Y$'13P
M#X&K8`.P,00`6(!OEVF`!AGH]!]&.V*,&&D65:CW![K`\DH?`@P58'D7/L#:
M3*B!!UW000A0H(4J,.$$*W"`R#]A@0ZT@`DYB(06A!`""7R@#7?41!E^(/.J
M6UWF`ECN)LA@`)DK0.ND*(/,^4"*-F"=3YX8`P9^((&=:T$&00"Z`Q:X"3FL
M(0PG"`(.\J""OA<`!4'8@`)^9V?_4ON!`8'BAVZN%%LJ.?X7.:!%("OB`*^Z
M(.J/SSPJVE"SRU<D\K/8M>9'OPHRY+FW_&A`S8K`8]*[WA08@,@+#'N.@*/^
M];A7ZB7]0%9\F,"!C\Z]\#]1!AVZO!QJ.-TZA\_\4-SU:@<UQQ<V)(L9-/_Z
MGQ!#_O:#CN=[(./8#[\F@F(?\FGC!"?40``J]RCSBP(-97!_*,!0!CALX0VM
M$H4<_ORE^M;[S^K3"630`&MP?PL`=IZ`!A]&"'(0?<1`?P?F25F@16-2<XB`
M!@"P!5L``0XX"#6@0_FB#1QP.@4@?YW`![EB!%`P`U3@`E'`!,>G"2'``/("
M"E]@`#D`_P580`50<`%80`-70""?,`2VY@+B`@6V-@&AY`D)<"\'D'"=<&=,
M$`58,`-&@`4QD`"+!0H.0`14D%F"8`0S`(7"P!&]]PE6,"X(P"<[<`'!E(`?
M(`4'@`5$,&XS<(:$0$M^$`)H-PT*D!,44%>?4!]%D"5?P`,GH0'JQ@F_45F@
M<`8[\CA=X08X4`0:0$-ZY0?N!D5^`#VF``;_X`,!4#+P-PI>$&"%(`M29`PG
M8U2AT!'>H`4EPTIBQ@D#T!$TX"*"\`5P@@AS`$Y\,73%\`%4<6R@4!\>$"UG
M@`>P$@4!B`B-&`K2=&.%P`2R$&=)Y@>NR(G*1@H;(H2H<(I^@/]:?Z!E?K"*
MQ="*HM`1$G`2,8`A_E.+FO`&L6!]G@1=LW``8"@,9P!ZL^`#BWB,'.(!'N`-
M&C`!,9@)T0@*H>9_A,`'LB`"HN`_VVA(?J`!!$F0,0!^GI`>U*0*XO@-Z$@,
MZOB*?H``9Y`4-Q!*\>@)5M)X`F9[?O`"RS<,;;!H#Y:0G4"(#T`H`#``(K`\
M-I")CO@)UN@'!5<(:+0"$ZF-I"`+,E`H95!GH)!.![`*XE@!CV)6YS@-)0D*
M'0$$?_`%->`!12`!UBB/F=`^?B"1HI`&>^4'12`#QK@*=;`6M7`!9!@*R%@(
M#O`>'D"4H?``Q94`K;<`L_,"P<<)%/G_E"=Y"B2@!!JP`W5IBJA("*KHE4YI
MDBWU!P+P`AK0#FJ)"&K@/S?``0[I"6#@8#S2!727"F;@!9%5"_J("ERT!$HW
M`99X`3'%B'Y0E)^0!39`D#)P`EUP`C)`D`6`>9K0F*/`(4JG=/<`"G#@!`5)
M`Q*```%@`SZ`B9X@CI64F:RXF6#I!\XE"&6@%:.9"1L060P@`Z?2!"[P`IY0
M`4UU`RE09:-@`KXF"R@@C*-``%XPH`3J!5O0@9Q0!EX0D)X@!GH@`!+`!3H`
M`FN@GYY@!U[`D5Q8H`4*CGT2`7CG=&W0`'WH;R-0`@LS`+LP#6[@!3`@"F_@
M!<;X:5ZPCYS`KP9M\`$ZL`$9X``66E6\I1X%D$JCL``Y0##U4!OBMZ2K8`8G
M`&#+$`-Y<`(ED$#\A0<BD`,/(3$AD&I,^J6J``$R4&Q!LRU"L`,Z<"H!L`<R
ML`0',&NU$`4=\(Q@6J>"\@1P:C7,H`%&L(5V^J>H$`<;8'AZ2A4R8*.`FJBE
M\``;``5-Y0XQP`4E@("*6JFF0``&L`$[4``),`,Q$`\O<`%0X`154`,K``!T
':JE?&@@`.S\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>o40024o4002409.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 o40024o4002409.gif
M1TE&.#EA2@)>`:(&`/___\S,S)F9F69F9C,S,P```/___P```"'Y!`$```8`
M+`````!*`EX!``/_:+K<_C#*2:N]..O-N_]@*(YD:9YHJJYLZ[YP+,]T;=]V
M@.]\[__`H'!(!`@&`IV`(%`$`DV%($FL6J_8K';+A0R@SR>`8!@;IN<F`=!M
MN]_PN'QN&"#+B^9105ZGZ8"!@H.$A1MC!#IE=G\&!8Y240T`88J&EYB9FILV
M!(D*8U!1CX^-#0&>GI6KK*VNK["QLK.TM;:WN+FZN[R]OK_`P<+#Q,7&QF=W
M4D\#!@'-7W66#ZC'UM?8V=K;W-W>W^#AXE]'848*`T8Z4`#-$M7B\?+S]/7V
M]_CY\<[I94\,`=@XF08!GKZ#"!,J7,BPH<-8)PP^G$BQHL6+&#/^,R%1_Z/'
MCR!#BAQY*V(BDBA3JES)\J#)EC!CRIQ)D]?+FCB['2&`)*?/G]AN`ATZ;$DJ
MGD23*M4E=*E37`..>DKRM*K5,$VO:FTE=>K6KTFS@OW:U9.=*6/3SA2KUFI4
MJ5..1#V+MJW=D&SO)I7[UNNJ*7;,(J&JM_##O(9]1J4:E_"KN('I)IZL#S%E
MF7(=[P(\=[#FRZ"W60Z]<K$QR(+KDEY=;#1KD9FW<>;I^;7M7:YO:USRF=ML
MGG%U"X>5>SC%V/4@=U9M7'?QY@UY*YQ-MS?TQ,^O(T3N\+=D[8:S@\<G/:-R
MVLS'?Q6O?A[WD-Z#MZ_*?GZX\BQ1H[=>Z;W]D?_U_>?;63E15ULE?2$E((`<
MG;0@>4PHY=U@77WQ($@!7G@:@5:=)Y6%&FJ488C"X/>544>!2.)%(Z[8BW];
MH9B*BBY2U&*-N9B85H(TXGA8@SYJ`V-:?/48)$,W'AF+CH;UI*1#23[)RI"%
M+2%E0U%>^023E-FAI4)92DGE9%Q^64^82I8)6CEF5@9DF[B,&9J3<-J#)HY+
M&/D:FW6>^6:?2W+8')V`[O-GH:WD"9Z:B&ISIX9RZN9EH^$\^J"B\T5(Z3>6
M_A>I<7QNRDVG\V$J(*&B9D/J>)]>9V6JHAU:IZD7H@KK,:M"URJKFMYJC3-4
M^`/01I10T-&7M)(8JJ__Q33&3%1L(-($.^Y$<.R5@M;8*[/$,"$`)8I\,H5`
MT41CK8-:)EOCLMP&(T`!U?*A!`$%Z%`*&N>:F6V0MK;KBS/P+O`,`WO<*PG!
M!22,;IH*BKFPO_^>P00Z#O01R3L/^VC:EY-"_(L>=WSKS,A0_.%'O@SKR3!_
M'ML"F!ZI,!/L&1NAS.^V9K+;,BY.D'!MB.JVV>_.M>3:)<ZSJDRT+$8;%G2?
M0R\-D:RU(ETHHU*WTK1=3R/:<=:S;*W6QKY:#;;65)?:,+,ZG\V*V%^1W6[4
M;M?L<\:+KNWOJW6[`K=;9G/[==^5_.U4U^UB#;;A2LF]=-L:*AU4VGOV-WC6
M_W0+&#,XC-/4%Q*.@PVYYD=Q3OF<%1(>1N;ME<7IZ:"5Q;+4BH-7EBK==!Z3
MC*G,+O7EI2:8HC>ZQR2[ZI4$WMQ.9C$_X^LE_(SZ\,B',?IMSJ/ZN>G1XQV:
MC*R#'3YE@,W(\ER5PGY9==5/Z3WYV?MNO3C%MU0[X<`['1AZ$]7/TOB$NY]6
MY)(:%JDO,==K'Q0D=Y7XR6\A_DN)`)$'P*$X4"011$D%D9?`GY2O>2K)X$@Z
MJ$"9'2Y^,!$A?)17POZP$"8$Y-]:#GB7#2HP?_;;W[YFV+W5D+"%87@A?#Z7
MGIRHT",3!.(/+W+!I1Q1(S8$8A07@L*K/!$C2P2B]?_>]Y`/`F<L5[1($K5H
M0O+0PHM3_$D8*Y)&)0J1&V9YC`[;.)0U3B2+9+2</:BW)2(^<#TT/-$;\\B5
M/UZC0GY<C1T=@D-"R@*/Q;C=(/6R2(9`TI&K,Z0Q;L?`R51R.I/$Y%^X:`WG
M?6@XGTQ((T4IBU4V:RY4X:-S`MFA3K+R,:'<S%L^$T?CI/(@N;RE'DOYEJAI
M$CNT?(HKA1D+.KJ"><XDS2\AQ,P7V;(61HDF:WHV`NEM)9C51-`Q$P7+&AFA
M)Q*+PI;R,+."D+(JRPPG+,9HO6*.4SOD6$6]S(`&-)S,G5Q[ISR;><UZ@O!(
M9RF#0!*Q!P/T@0WX`FA;P#G_T.0]$)KWG`\BID$&?)'B8@X0153:$L^*SI.!
M.]'F>/CP"9HUXJ.F`$CYU,(WD_)B:,S+Z(62,2UU-F-@Y2+(*02:%(K:=(M_
ML2>@R&$A;S4A'52@U@2\Z922'A467L)HH_C!ADH()"`"$VI(B0J4FEYU,^83
MU33CH=**IK2@6EIK.*QZ5LOULJTADNLWZ'E4K=835GKU!EY%Z5=6#/9!@>4&
M76V:S=GQU4>)%9)1A9G36BSV2)'-QF%;6-A:3'9%F;W&)5G9V5N,MD:A/<9C
M':E47VQV/JDUQFO[EE*=NH]2L27&:9583-G"%;+)W-UGJU?:H@P7L<&%R6QO
MQ9_B_VX(4;EUUV_=YA<7?K$;R[U.=#]V7(\=A3&[O,]T09O<TMB6:!4ZZ#C.
MNZ#M6A.3MV,O,%:+W!X2A;X[X]WSZG'9O)97@_*%F"GWN\<`M\>]NMAMRVH+
MOGPH^#\(CE-W?05-ZXY7LP9>Z7]%TE^/U9:<VR$KB2+LL@O[J[5LS+!V2'S&
M"5/JP^9QL78W_)$.^PK%NS&Q?5C\2!V+JK(CD7%S>!P+(;>IL1+TL7J(_`H;
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M^_)XL$U2-(1+$5Z25QT.-E8`,ZS5ZH'W:N`E$(<JXAD%:(+!'@"N3B.QW#Y\
M]*D@CAU$+'0:J(!$3/-0NF7S^C(POA"SVP)19;1T`<WP@S(D&A)Z7\56?[8T
MT))Q[S+H8=UU:#=L*#ZVZH;<12[_!TLYO/TM(WS;&6`%-T@$7A@>?=K.[M[F
MR'+=\H^/17C551*Q*9-;:#?I=N*VNEIBRW2:#EB6?N9Y6V(;=`]FSTFGU)?8
MP2AM\9([D:P@L*&UK&PVSQTG,02._/3&L;]O);1;M^#;#0^ID6LELU[W((\8
M7Z/$9[ON.G'\"/<G>.1IGCZ85ZS:1]A$!4;^\GV/SNB1N'C64MXIB?U\%R=/
MV:@G.]84L;QY.#^8@;8]+*''QNG%V/J^RA[XJ5?(\>F!QM\O>/6@3SY"=/]N
MWA>QKHS6L/3UX7!+FM;ZKU?=\,&RUN6_B/!_*3[V;^%\GTR3^J+5>Q]3%/X\
M=G^6V[_'__W?_:'`]W[]P?`=FH9["V%^:%46_P>`NO5=`TAU#`%_UH!UN*.`
ML@47J!1\QG5'$CB!%+B`77&!^4</[5=B!Y4@':A:KB,<E02!\_5T;W&"*-@5
M]2<3BU1VTE5`30:#$?@A.Q0:BS2"Y#1N.KA7V[-``"=J&/@++/A]0CB$XB`?
M!@6$&)2$YS>#=G6$9W1]3BA\BV&%>$&%-V6%,=1&-KB%L_!SE`2&"09]4_)T
M<0(%$>*%.K@K5G%%97A239@CM+&'<CB'II865X1MSL4+`R:%0XB&@!2"WC!^
M;9B'A!AXFM*'6[@36O@41W2'1MAY1<$C4X$[?VB&1(B%EJB&MO^P68.8(W)3
M&]*QBE\#A:"H$SVH%"IT>J>8A8XA)X317.8CB12(B$0A0O!6B_,$B;;W3*9D
MB`KHBVI$BK/@3%6$3:LP(P<B?.]1B:]8(EV(?`08#Z<EC,^4==;X#;UTC:+U
MB3410?3DC2(U4O44CO+@BJY(CMB(C-RSC7.E2=X(B4NH6=+HCO)(@O0X*LPH
M1UGHAJ+@&'8PC1_Q&UGWC]8DBBM1/UA37+?8D+L3*L[BD+KD+3%1/SA46![R
M%TMA%+PH3\J(06`@,`57,\6B<T0(&$$(<$[GCV6%D`FHD=@4BTL7'.B&;^H`
M+.W@DMC%@`8%'-F2D7IQC#2)DT88D,'_X"TM^0D#`U0Z8"XLMPW"`SHH!I'P
MPWE,F9-<R40!LP#B,@H:%U'44(S8)$F]PRK,<00E:7_9^!$`4RUEJ0`PA98"
MTW';($GQ:!_R]I7/9(XVDD[ZAB\6LW%AM7_-<CPK4I$"^!AQ231T>!`@$P6?
MP$]ZH`8%EY:"%7=!XG\WN45LZ);=09A4!)=.@`1=%5%4(92R88%7\D$TD@2*
MLI12$CK5%Y8N,74B0%4H.)EWP1S%Q(=/E@3L*)QXB)ORL&C0P7EF01O5<8OI
MH9ROP(&<QH?8J7J\Z2>*R%I3421$R0P<J%_C>)#4V1C,^8:H8"&3J9Y(B9X(
MDI#TR1,RR$0Z_^F=]EA-BZ&;4U*=\(F162=)+D0H`>J/9Y&@*'6@Z6DY]!D9
MUN48!+I%V_*@]#D%T8E^L]>=Z?.=9'2;&EI*!^J@"!E?R;,V&UBB*F*>%5J>
M%GJ4\!B@A`@<FO@LZ_F.J$D_`YDXC(%%FN&*"9DBA'*3#&J=JV`:CO,YHSD=
M<[E`^?DK.RJ8:!481EHB6V(=7J26L@%+O/-ZSEE7X;F=BK>B-QJ*'T@\42JE
M.<(85<I?%LE]CBF0'JJF?J892^H><1HK<TJGR-*/O)@Z:+JG?(HLIM2'70H]
M^SFHL/(R_5%_?!%^7ZJH5K$Y-!&IDEH5;UFF_9.FEPIT_9@2EMJI,?_B?VW*
M,YPJJCXB%XWJ$:&*JDGYIC\BJ*Z:7T.JJ?7H@+/J2'X*0:>:JV;VC*[PI%`J
MJ[Y:-WRQJ@BR?*U:K)*B"G`Y4HQ('+W*K)L"DQ)(><M*K<.!45XZK=H**W-Q
M?-GZK==&H[(WKN2Z)^Y9FECAK>EJ4NCZKKCEKO(J3_%:KX5RK_C:)_JZKW#2
MK_YJ)@`;L%)&K`3[B@-[L$^2L`J+6?3:L(3$L!"+(Q([L2Y2L18[8@^;L2U$
M#1\`G!Q[C0X`E_@V,6D@5@"AI2%[5@W0;=."%?[4F?VVLH+9LCR!!U/!!Q#%
M;T-%LS7;``.0<!RG<"`U"5NBLCX+KPZP&'O_>98\BVZ4FK0.>0II0`8H)PU8
M:S-2^X\M>Y#/P`Y`&2^>N;53>PKF8C=V<Y5D*[(;N[9G@[%N"QYP&[>X]IM(
M2[>L-+=XVX!VN[>@J+=^BW^)&K@*"+B$^QJ&>[C!9K"*>TN)V[A(R+B0BTF/
M.[F>U+:6>RN5F[F%L;F<BWJ#^[D#Y;FB.W:86[I;=;JHFZ^JN[K\VKJN^Z^P
M&[L".[NT6["A>[N4:[NZN["\V[L.*[G`ZS:D.[Q.]+O&BUK(F[SD);S,NS3%
M^[Q`$;W2ZW[+6[WUE;O8BSS4N[V5>KW>NV/@&[X'-K[DJWW:>[YO:[[J6[<A
M`++M*S7=&[\A-`$S_].22D>_W!L![?`%/_4M8CNS^JLZ&#,M6&N58SO`A#,!
M]"(0"Z>U"DR\$M`.]>*T#_`N"9/!&KS!'-S!'OS!(!S"(CS")%S")GS"*)S"
M*KS"+-S"+OS",!S#,CS#-%S#-CS#%)`$CV"U>CE4-5`*,P#$,G!R,4#$,&#$
M+]##+I!Q,\#$,N#$,B#$,2#%1_P.[-!1G(DQ/[S%-(#$+N#%+0#&+*#$+0#%
M,&#&+X#&+T#%:UP#5EL0)+L,*-NT-##'+,#&2^S&=JP">ZP"9%S&=?S&3\S%
M3>S&QK(!?3P(B2P(BQP(`""SFM#(@"#)=$#)G'#)F)S)FKS)G-S)GOS)H/\<
MRJ(\RJ1<RJ9\RJB<RJJ\RJS<RJ[\RK`<R[(\R[1<R[9\R[B<R[J\RYO`&T.'
M`;Q!=!`0S$@7!487+?F6`L\`.D\K`<1\3L-LLNL4"8I`S"BPS*H)S"8+S1>\
MS>-"S0(3P"1P3JJ*`?U[<`@<SOU0S`,A"7F2`N2<S!=`S*+`<,D\S=-L<\TL
M`KZ<SCDLS61,SR6CSUW5.UU0"JBPSR$5$&^LQ&&P3UCL4(_<44:`QR.0F8Q@
M`<5RMH(<5@$`T7\0LV+0T2:`T>(,`1M]<"1M<V/`F9HIT5*PTG?C!!5L`0'A
MQ%[\5#\%#0S]!^I@R1C`Q!_=R"/-3A=<T?P@#2__W0Z0;`((;;(54-1%.RQ#
M_=)KP$_,`-0X`,1+`"S]T&W#;-0.<'$-E0A6FP@.O`+IMD]#!QA-?09?M=)D
M[0X/90H*'0)K'1!M?01O_6UJ+!!H<=:HL+/`(M.YAG+-H)KD#,=D*58%O6_\
M4-9G0'!\_,:,`!B1L,_N_+1I?0?/(-EB3`)<308+M+.:+=:3("]ES<0G=])6
M`,0?G7-QW$Z@D-&*R0`1[0BLC<YJ;0GUT@RAL)G='-<2D-MYV03]V]L+\-ME
MP%"WO03$'0%-)2\+]P2&;;=#JP.)T`_BG-"-'0'^M`[>@I>K>=T@X,16\E1H
MX5*38-M_/#!2.=ZZS5"N_RT"L/T(B8U.M+T(U?+'#O52NUW;;<#5OQU$$Q`*
M4]VU`"[8Z/#6%ZT(`%`O#K+?0*M.ADT%'F7!S:W5%M!2$6X0%,X`RJ#&WH9N
MU)W9<,CA46W9[-C36JQO]JQO"6V69%G9B*T:YHW@M]W@!H=N'A7@*4#@7VO=
M!]Y2?XSAHP#D(?[:*)<$5ONUPG+!U=S,`SV5*<<'R\`"1DX&!=":ZL38)DX-
M/I74094'*DX!6^X(7LY-(67A*"T)9WW`(@75)@$*9JW2727=WWW4%X,6.RWB
M-K[A^`+E^*O@.QXL_82<_`#D*`#$/?'DT5#H!#/E8&[E_WWI.=<%'[[,?.`9
M3/_P4Y8@!I*0T3,SXT_UDXS!4_Y,`G&H<I_>GB`B,'H`V#P<ZDY5!S\I5:*N
MUK;IZN5`&WHMZW`=TR5NYYB=ZE+E!.8-`ND],>_"U_TY['(,Y\A],`GZR-#`
M!E!5E>N=`LT^+?!"#I\N[4AW#NC@#D?WK`&1[;A.!192WR"PZ1DM>+P!ZF%E
M[G6`[BMYZ]M.,P,=E%W@50M@=.#,DC53.!$E\,ZPD@?7KM=<..S4FNN`<98`
M+C@W$&+@!`P/"FG+$1`?"1)O<\,R\%@Q,!B_$0<_#9)>`A:/<8@N,D?G\.;P
MD_[0KH6>=!W/\A\/+%.N!`4'+AY]\4A'+!BW\7QL#@,TCR_K;?"A#K.2H/!)
JAW0#[^":G/.78/6&@/6%L/*9$/6;X/6\'/9B/_9D7_9F?_9H_P()```[
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>o40024o4002410.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 o40024o4002410.gif
M1TE&.#EAV@`N`.8``*>EI;:UM2,@()64D^?EXPH("8V+BY"-C$(^/5Q96KV[
MNLS+RU104*VKJ]?5TRTI*'9U=/GX^(."@M;5U3$N+DA&1M[<W-33TYF7E1T:
M&LC'QSTY.<'`P+FWMU!-33<U-EA65JNIJ<K)R:ZMK*BFIF]M;='/SA@6%YJ8
MF(:%A142$L3#PVYK:6=E99V9EV%?7Y^=G'IW=L&_O;*OKE]<6R\M+#DV-C\\
M/%I86"@F)BLI*3LX.0\-#?/R\?'Q\45#1&MI:>/CX^WKZN/BX:FFI1(/$'MX
M><C&Q$Q)1S,P+UM85XJ'AK6SLT9%1=+1T<[,R\;%Q8J(B'1Q;VMH9\[,S-W<
MVNOJZAH7%TI(2'%N;N'AX7AT<;RYMKBVM.GHZ$Y+3$Y,3$Q*2BDG*%)/3XV*
MAS(O+R`='FEG9J6DI)R:FE945-K9V82#A,+"PD9"07U[>VEG:).0CK:RK[.R
MLJ:CH*.BHZ">GD(_/Z.@GDA$0]O8U8!]?6-@7VUK;`<%!O___R'Y!```````
M+`````#:`"X```?_@'^"@X2%0T0U?HJ+C!]1/H61DI.4E9:7F)F:FYR=GI\C
MB8RCI!4KGZBIJJNLK:Z2$0<ZI"<_%4IC(#]FI22OO\#!PL.40R^C%6QS3I%K
M"A"BBQ"0Q-76U]B378PG:D&91W>,/!?9YN?HK$N,.%J=3TF+!1WI]?;WD@<\
MB@4!J!$PY/G"1[`@-CR+'I13->**HBM0#$J<^*K+/C\V-+2:P<N/CF\40XK<
MU..!(C&G7&&XF(#:R)<P"468PB_B+R*+HL3<"9.(0S\&@D5@H"@#SZ,AD2BJ
MX?)7E9\ED$HE^.0GO6%2BC:=RC6;$D4/JA'X&:*K66P1!"C:8XVFGSMG_^,2
MXZ*(QS6<?NS*W?N+C*(-UPB8]*.1K^%5@XU<B_#5#XI(/21('K#USPC)3"I%
M8"*A!`@P'EZP`5!YD`@#)7(UX0/A`+-)D26P`3FIP8L2)?Q%BH!&L@201WP+
M'RZ9MB`8)<X,G+0F36<P(#R4.*"[$&\)-'YH_S$&`IJ%@Q]?BZ%(9R$"C!)$
M<J-(,2PF/TEA-"[HPF!%*D;5<!<)O:(&E?0@1DV1D*?(<@?()]\$A33&P"1>
ML*"@'P4L)\@*]_E1!"F/.50A-A@HXD%_HWQ1"`V*`"%)#^)0F`(5I@T`AR1+
M7'3#:W_TP$2+?IA'B!`7`1A@/(K8)$A6BHAG&O\'3'*@EA\8--F&!9$HY<>#
MD>#ET7)><+"$D8(X\.0-_`DB`@1EO"&(0SP49@U>99!8(B'L^:%>)!LL59HD
M8RD2U&YN75&=(/[Y(60E0[38SY&+1%7)8&Y.DN>5D:SD9R8A*A*I)'5M.@Q>
M*LA9P``#VDG-%BE&0A>%8%IBI5Z2.+"(BC_N4X"GDB3Z4`!^^7$"!I=`ZJHB
M6!(R*06:5*%H"P-P0$5EG6(#IYR$P?`3$)"@Z@>MA*"8UR:#&35)6G\5`N1_
MF0Q!9`X>`ANLIL-22H@>%V6QR1!]7(3?!R\,@*-:\TBK2)SG+:)1KWZ$\8>V
M=Q(2+KCEPO838(3T\-/_H9<(R(BC[Q)FB8.%/+'(GYPL<4,&I.SWQY-*5F/@
MB`4?*`@=BWR1X+:1>%O`GI)8N?,DYR9LKJVX4M+#D_9F(FPE5A8KR-&*)(V*
M"!SP&.=@/A+3@Y59$[K(57_0O)0B#0_R5*J9R#'R)$<LXMX@A6*<,=*:+$T)
MR`WRDU(JC!FLK<+6"#$IV'`O8B$1^N)<Z44@,-&4%PU4YI8?:#2UV6`;T!>T
MW!V3W''1@S0=R1!C\),"CF;.8(@!:#Q;"!,VB/C'JN)68Q&%]/U1J(41-#3K
M)##$KH@-9YSQ`AB)8$&?%RG\],$8DKU0@8UE#A*T&-MEW^H@4`-5-[R5X&U(
M_PN+G-#$"R]DQ\.'3Y?NAPH?G"^!$C]<A$4Y%E,XJ##K^&&&)$*X@@K81X@G
M[*,(W)+$`,"0N"*4H0DI@$T+S+`A1N1`#1;ZD0KV(4"4%2$_!6#0)![P0<]9
MPFZ34$,1!"`UR$"C@HJH!03V]@<FT"`:W&@"&HRE"!-I[4EEJ48$3&`!*VQB
MB!/@V6'^$($)&!$3!!#!`D08";7ACA@NX(<2E\A%2_2`2,@2!KG\0(,NFM$3
MF?+#_ER!I"N`[HQPA,RK%O**MJ$MCGBTA*P448$M<J(*1,H`%?-(2$G$81&`
M8P4!2D6.2CRA##H00!D$X`U*R,`&;UO1&VR0@0RHH/\)72.$%#HI@`R4(0,)
M+&`%/B#),F#!$B;+@"1W0,,LJ4"$0K@!7%*1AS(,,F1)^(!NR"!(2@R@`ADH
M0@9^P+O);<"/EU#6(EHFB;;5P`XAJ``9*4&73!:B!Z4;`!4L\(1C>)-["Y#!
M%0JP``Z@CA!'N,(#YJ"`+KR3$.H:U90X4,L"^<$(*[@`!]ZG"I.`3DSYP=8A
M"2=*/\"!"E:@VE8BP*/[I4(!1/)#'R[1M@(@8`<RFP1=4DD(6<%*=WYXIM$>
M<-)J.N0.6&!`[@:QC5!I@CP9R`$%$F%35!B4$O'<00N*@`._,/1I#GFC(";W
M3V@6P@O'^-TEMK%+.Q;-!/_6I$0$;N`8041`0F6+1`!;&@DQA?&)0%M?==`Z
MB744!D@]_<1/V78%N"!.$4<5!'N,0`TJP<)`)XE@)GH``7WQ(#.8V.,BQ(!8
M26#UG#(Q@$,V5(`Z*'&K9"V$F!CQLTD,(0VQRX\`9CJ(=0318C!#!:H.*H!=
M#L$D>14$&H3'@QH$41(89<05(%`'&$FB.2!('!;66,CB7F((+4C<^^0GF3?H
MHB.+4`%EC$M=3ER`!O&9D`5C0-KJ>E>KL-.NAO+0AN^:UQ,1$$$#4.`;-MB!
)`WX][WD#`0`[
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>o40024o4002411.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 o40024o4002411.gif
M1TE&.#EA>P`7`.8``,'`P!L7%X."@D5#1`P)"FUH9O3T\Q$.#NKIZ)>4D]73
MT=74U-#.S2`='D1`/AL9&>7DY#`M+5E652\K*D],3!82$BLH*2\J*,7#PLO)
MR;:SLC4R,24B(GAU=(V+BX>$@[NXMH>#@6YL:U1147-P<&AE9,;%Q=_>W41!
M03HV-DE&18*`?]K9V*NHIZ&=G*>EI3HX."4@'V-A8*RJJEA44J&?GGAW=S\]
M/6EG9TI(2"HG)KNZN7=Q;IR9EXB&AC\[.EE76*:DHZNGI)&.C()^?$Y)1XR)
MB'UY>')N;9>6EH:!?D5$1,"]NY*/CYR:FGU[>\"^O5A23UY:64E$0DA"0#0P
M+TY+2;:UM6);6'QX=5U85F=@7(>%@SXY-W%K9["MJ^#>W5-/3EU74_7T\X%[
M=T,\.8%\>G)M:JNIIP<%!O___P``````````````````````````````````
M`````````````````````````````````````````````````"'Y!```````
M+`````![`!<```?_@&J"@VIC&%P2"X2+C(V.CY"1DI.4E8-!*A5I!#66GI^@
MH:*$"%.;*41,"*.LK:ZA#`=I`2`@-`$IK[JM!04:NXM0#6E&3!QI:3$7P)]"
M0@JO",@"S(((#01'"00'$BT@"8K5E,@BKPK3XQ)I)!W</3V9:0#CY&E`KPSI
MS!!I*"V;6OS8I$+(JE`&'B6<A(P"HX62%!Q4@RX--340775(,^,&`0S'=)Q8
M9,!!@),@!IW<X6)"@`D,,$RH$("!H),U$@2HX,"FFI,E!)DX:4(-,@(G!6%P
M0-/!P1$!2C!PJ89!@#0'`B!18P*9#2,[';"P=FL""`TON;YD8+)3BY,!_Z2L
M>A#`0QH<)-*4R*AF@29DR+8:Q0HX300"@`\(0H8-\(95R`8(`H",7N$T:F8@
M!MQ`T8!-LM(X&088A9H,1PN3$+2A,&DUE`FG\?!A,[(-1GT`2<.`&P1&(Y!]
M2!`!F2+`,A*$1D'<^.`T(SX\0/9BL$/8E0=O2)!`3?$&&H(@?J+F,\$.3Y"M
M4!`D0]6C'1)$[LLX`0K`V)'I^)#!0IH-&.25Q@)I7&&!!2^DT=TB_1@F2()I
M5`?8;R(@LX,:`F2'C`6_V6718)+E9UD:US5H@R`PI)%#><B,D)`/R)`PD0$-
M"2*+9!7.ID:#BL7VP$BH<;2C?W91)@(%F#$2V_]%TGR(3`""9)BDE".&V%4:
M)\XGXF`R3/;D!1?(`@.+\PBR`&D!])!0D!?-9QX]:AS3(S(K8HB,,F&FL<0\
M%J4QII+[#$8-,LO8.:6&:81X0HL@>EEFC?E=U@"9<%8U$#)=5G018I*]B>(F
M^5TDY65[4I9AB(LL:68Z=T:)C*N/)BH4,CA8)XA\L=89FP@*]*K`2)X.8@`&
MLA`P@SX?QBEKL,5!J:JA-?BJ`!@$)&$!$!'\29(L!R34!'6#%2HEK",^H,@*
MR/A@JP'^Q1IB@[6J48($JP6+`#1JV#!-DQ=I@B,R'KR'5:B"!!DP!/.B@0(%
M.%B0!`%\"8)N&A)T($O_!+^U:BBYSZ'@SB87(O/`!RH`5JX$*WB7Q@,)?%`.
MI1('($$"-R"3`8')<DI?&@U(<,RKSZK,L@S&$4C$`RT0T`0C()SP\U%0+):&
MN*\:6NYTR'0@2`J%<5VFUVE80!%IR*2P2K`Y7*;":?OXRUIAK6$6M!.A(6.%
M(#?<\$$#(!"PH"!9G*&$`2&XY,!(@O3B@B`:],)X+V-%ME0`BPM">``.+`XY
M1B8Y4(`U(9Q4P$)#;*X&`B[<XD`("1G0RR]JA%#`$&2]Q+KCKOM""`,%V#X(
M`AO\<`0'4131A00\;,$#&5^THF4]T%/"0@E5%!"&%E&4P0,52F#@RO/1AP^)
?'`$:2%&$&%Y@8<80$[$"OOCPQR^(#@&,(/_]@0``.S\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>o40024o4002412.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 o40024o4002412.gif
M1TE&.#EAYP`I`.8``,_+R%-04,C&QDU*2@P*"BTI*.[M[$5"0K:SLI&.CFQH
M9Z2BH8:#@KV[NKBVM6%>7101$MW;VGUZ>5).3/+Q\>;DXY62D3`M+%Y:6NKI
MZ'9R<"4B(65B83TZ.>?EY*RIJ,'`P+"NK,"^O)V9F(%]?(B%A>GHY]C7U=32
MT34S,JFFI=+1T'%M;&UJ:<+`OIN8EXV*B<3"P$$]/:"=G-31SL;$PO;V]1@5
M%8V)A\[-S.SKZD5!/YF6E,K(Q^#>W!T:&SDV-:NGI,W,RGEU=./BX-;5U-[<
MVTA$1"DE)2$='4M(1W1Q;_7T]*NHIZ.@GVAE8[.PK]G8UEA44][=W+JXM_GX
M^(.`?N'@WNCGYI*/CH^,BA`.#M#.S:^LJWUY=Y>5E"LH)XJ(B)>4D_O[^_CX
M]_'P[]?5T_W]_?S\^]K9V%I75QL7%_3T\ZFGI4(_/V1@7E934N[MZ^_N[O7U
M]*>DH\?%PY.2D?KZ^<S)R#,O+_?W]J^MK-73T5E65?___P<%!B'Y!```````
M+`````#G`"D```?_@'Z"@X)D(ED2'S:$C(V.CY"1DI.4E9:7F)F:FYIC5'T0
MH01+BYRFIZBIJJNLJ#HL!`5`!BX;!#BMN;J[O+VZ#4EY0A8#?A,!.!`QOLS-
MSL^\(D@6@@HDQ@1#2AW0W=[?X(Y"2`Y^.1A;#]A_3Q`*8@Y7X?/T]:IC1S!E
M(T@7<,43W&R0(N7/GRT%^BA<R+"APX<0(TJ<2+&BQ8L8,VK<R!&#'R$0\`S8
MLL0/@#4KM*S!L8:$P9<P8\J<2;.FS9LX<^K<R;.GSY]`8Q+PT^?(CSQX"B&A
MTX5`C95!HTJ=2K6JU:L^"9@@0(!#*4''//R94:#$#JQHTZI=RW8J`;$P_[X*
ML@`AQY$U/\),:,NWK]^_5]\.;52A@Y(:!,;N!<RXL>/'!@7;B%"#49,_3A[\
M>0,!LN?/H*V^_2-@R989A,:TV,+E2.C7L&/G)(!FAQ,R4@C(X&%`D(X+-W++
M'DX\-NT=1_SH@-'A#X0."L_ZO*"@NH(-,P/D,=AA@$PD-`<:E((=9@<9.F_\
MN="\I@SKUV%N4'/S09+BC;42@#"HP9\6[0$%AP`F5""`&S-I`85!3200TQI1
MT!0```8!$$!,+0R14PHC_*&`@S4-(8`!:0@0X!\#\'&3!P?@QQ@!"!BT@B!;
MB8'"?5&)$<9+1V#0F4%*S/$'$E>`!P0&%_SA4?^2.X#RTH057B@#!BG\4<`%
M6QR0@AH_.(<D>@8-<4(*'RKAW1]YJ`%&3$%<^,<-:K28XD%2M$C``!<XZ<$#
M:AKD!@;877G`8A>H48"+4A'0AD$)#")%$A2XEN..?UA@0A%$O+3%&2E@L,(?
M1XRQ`@5(A.#'$$_H$$,=3U+XAX4<%"'&'3>$(48!5;A`A!-_3)&#$$R\%`(;
M#"A``15R//"##2)XL`5,;?X!8PT&]#%G#'A$X,4:'T7@PA\>H%#'%']880`?
M<FP11ADQC*'$#QDTP,2/B/ZDJ$%)#!+#'U2`&)2.!D5*`!8M&I3#$A:\\$<.
M'/QAAQ,%^/$'`AI`H$/_E7]`^6H`):0AP7VV1DP`"R!LX$>69+S4AP`>JO`'
M#V%X(08$"T@`[84'7`%!``BDR-]\0G"+!!A^O(6GQ!$41,4;8?!JP8<C0#`#
M!O4"=:]!"`@RQP8/5(`C4`#_X4>29L#Q$@=X"*'9"=XQT$#$?X`0@PHJ)/G'
M!#081,,$6R2`0AD%A"RQ`B#`G4(<*K/\X1\Z9H$"W52_%.T`9="M18K<?J""
M2GY`P"T$+,*=@6L6,&#K'PDH\$41="M1M;V+&L3"(%8DX4*'_U(:`0L%,+$=
MOGX8`=X>8FR```,1TZP%!"7\>`$9`QQ`1@H!8)`$"G`([B$($(P!AQ42&]1'
M_P[N.*@C!PY`T(+=!D6;@@](##!!B@3HD<(!''`;@!)E@'L`W#V0`!*B<(#3
MI<X+4+C!$,KS.IX08`\ON8$`!$&!#0R`#`@"&Z74((<S9"$F)XA=$BK@!Y:M
MP08C<(,._$`'F(3@#&?P#Q`\$#P(:(]P?R!!%4)@@I>X@0(A6)R.MG`"/ZP@
M,9)S4PG\8(,#S`D&8Z``!KBU@C&4P']P&T`&_+`@`RJ``#,ZP;,:Z$"QO.0)
M@V``C"J@GIA``(D.Q`D<YR@3KL`$CC+9@A=^X`8?W)$F>)Q)(*65&&YM89`O
M061DR)B5.?SN(!'PC1*28``ZX/$%-B`"#Q0I&Q%@P?\`7V@+MSC)2*P,!0<P
M`<(@ZD``#-A``HG9`01L4(0+7(`$0*@:$-C'EC64TB]#J0"]_O`!08S!)4[0
M@1*`8`3^J"`)';@!`Q[YRVJ6<C`:BJ`/"N&Z#SR`!UF8I0H(0(9H:L":Z&3D
M8,9PJ)<<H!3NXDH>4K`!$>R+"A7XP0&DD\Y^NF@P?N@!'B4P"-R@R083>,`8
MR.,'!T7.GQ`=#D#],`-?&F0+N!!$!)!0S"9```%<&$4$.B#+B)H4-A,=`Q3`
M@Z\)^J$!W/)#.8^0`2N,[`D;:.=)=PJ9B0J""`-`X@W,X(=Q]L8/75C#!/Q`
M@L3DE*=0=8Q/!X&'#CQK"V:OB,`&&#`(5`+!!E10``(*0`<^F/6L:$VK6M?*
MUK:Z]:UPC:M<YTK7NMKUKF\E*B0\\`'@Q*`%?1C$&!CPAS6,P``1N($)[,'8
MQCIV$ECH``18$$G!(B`%^X&`!A[+V<YR-@)`T,T'SGH(&>R'!'+QK&I7ZPTB
M<&"8!Y'6[%A+V]I"HPQX4``+1&"&"#GGJ+8-KG![480-)*$/2.#`<)?+W%74
/``,G$,(0EMC<ZBXW$``[
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>o40024o4002413.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 o40024o4002413.gif
M1TE&.#EAYP`@`.8``):3DBTI**FFI?/R\=#/SLC'QUA44VYK:O;V]5-.3'EV
M=9&-C$U*2>;DXPT+"\"^O101$5Y;6FMH9\'`P#8S,K"MK%514=O8U65B8=_=
MW<O)R+RYN#HV-GYZ>4`]/(V+B:VJJ3`M+-G7UH*`@",@(')N;75R<.KIZ(J&
M@YV:F(J'ADM'1NWLZAT:&L+`OJ>CH=?6U9B6E7QX=8%^?#LY.=O9V&EF9$5"
M0=+1T<?$PT-`/Q$.#][<VL7"P;Z\NR@E)6)?71<4%.CGY920CG9Q;KVYMJ">
MG=/2T<[,RN?EXX2`?B`='>SKZN+@W[>VM;:SL;*PL*JGI:2@G^_O[Z>DHX."
M@IZ<FYN8ED)!0:>EI)N9F6=B7C,O+A`-#8>$@UM85SPX-Q(/$`@&!PH("1D7
M%_GX^.[M[$5#1.7DX\_+R.3BX;>UL_O[^_KZ^=;4U/CX]^GHYHR)B,/"P$=#
M0D=%1:2BH:NIJ)",B;JVM/'P\,/!P%E65=73T1L7%____P<%!B'Y!```````
M+`````#G`"````?_@'Z"@X2%AH(B?"`?>XT1'R!\DI.4E9:7F)F:FYR=GI^@
MH:*CER*'IX9E&UQ]#G^OL`Y]L[2UMK>XN;J[O+V^O\#!PL/$N`&HR'XU";#-
MSL_0T=+3U-76U]C9VMO<W7]]R:E7%"T4*T$[6W<2)*[>[_#Q\O/T];#@X8,;
M-&-$+H)E^'P($>*%FA1<["E<R+"A0VGX\L6@T"@$A!`'"`@RL\'`G#4I_HAQ
M]["DR9,HHT5$5@8$AS6"U(`X0**%"C,`KW!9\B<!""YB4@H=2I3>RE-F#/S9
M8VA`BA\KT/@1T@'"MP%^!J`84[2KUZ_35JI90*'6"AFON-@`T#1"GQ5=_UYQ
M4$,(21"P>/,6Q3?`@"L(`0)8=<:!@H$H44PT6D+2@1*<A3+PE!8F@>4$'J`%
M\!!T3(+!S;@^<Y#`U69GI(-:$Q-F!;4;DYNIWC9;;S=P:.!^V4#7CQH-:/N$
M$,DA6I@Y0WB@<O%#&HD"&@O$@!9"R'`=+$B^\L+L&;@^?ZI,<!:D@'9I5[`$
M2$*-SQYG9'IP^^'#]KL^921`B%+&T)`_-A`P'"QAS$+1!QM@E4P%H#DS$A=^
M.,!5`$!0T$P--OQQ!0!_D/%%`F*0@(,28@3PQ8#?^`&>>'^0``0=#CA@@1@T
MF%B<&#HD$``)K[1@A@)<).$B&7]`\(4.L[E'@O\Y%HRQ@A^9<;!'"W_0P(4!
M9'C`@0%WD1&!A1*8$8!]MVT0A@FGO,>''P3<`$M4^1CRP33'O/(#&P6P8`$L
M1ECQ!QH,!/&`"#]:D$<-.]300QY$IKCB!`Z8044&"H#CP`0U3,`&!#9,X<,%
M$KPR1QMN@)&$"T=H(<83!3`1`2SN20#'!@A$,(,?5-`@1`$BB#%!$SF<888<
M)WPPAAH/-,!`!6T<0"8W?<00A(*&J`G0#"8H(`8'U,;I1QE@2%-G>%3\@0(4
ML&``PQ)^A!$!'W_\X`<$$R1PAAT.Q.&LH^%-$(0?)?PPAJ43=""&'P%`,<(?
M!(3Z2A)GK$=&"!-P@4#_%T#8`>L>$A3P!PA5U%G!#`Y<0/&<9R`@1A4"W-"`
M`RK$<`9[SV[3QP%'$8+!'PH8X@4$?;S@[2`9A!'-N`"$VC$L/S0A`P%_'#">
M`PC7:P$3::2!%K\L=MK&"`2'6G6H$SC\!\3K_1'`!&>PD74*JL4ZG@`A^_''
MKUF#,8$)?\P<G@`,O)%U''[7K$T?'TQ[2@T0.*"!(1HP,`8##_3G+0JUP3)N
M"3GTD86?KX@1!0*A,I!!`!$D<>D6'+A`A@0#CF'&#"$X840+"P0QA`]A_X&P
M$5!0<(+925@0`GMK_U`&"7OL^8K<?]!]#!EU`!!$'&&4W3=[+%,P11`1,'#&
M_PE&&XY-'RF,@0(J7N`H52%FR-`'&1:`8'DX`^B@F=U_+'&$&T@H#BS0Q),P
M:`$-+%"*%(0`@1S@(`,\>@4&$``''C#@4AHX`LXBI#V$Z0`&2*B!V7J0`1T@
M;P)B`(`(,O">YW%L;E7P$1XXX`8"Z&$,VO,;R\:P!@(<@0$!>(,"S'<^$2QA
M#%E`169,<#]")$$"1.+"$>+4N6H$(7//"(-HQE"^,&1N#!"831C.TPP/9*8`
M7X"%&'8`C1V(9AHQ^@,7JZ'%5[B1B-<`!UK$8(4F#@)<8B@!*LQ`!#&HSX^G
MF%/-#H"`&B`@@GC$(SC*0(17W$!HAN"!%R6`#`+,0?\,>TA".#ADN"5@@8V1
MC"0^RC`$\(AA"1$`@`8@XX<YB*0$M&R*#"Z2@61T()7`).)*<M"!$(@F"!Y0
M@1#\(`57B($![SM$&>XP!@Y$\Q`M#*8V[9,S/Q2AF.X(PA,&P`!8Z.!QJ!B"
M&+AP34*4H9S;C&=>NCF(L31G#"!8PQN#P)9T;JN7AN`#>.1)4*_0TYU2@``$
M*O`?-5)`(Z?(P1+(4(&`#K2@&!7*00NQ`0C,H0PEJ$T8,/"`4[A`!PZ00`T&
M00`09?2E*-EH(3`0!AZ4004-ZE`$4J"<0J"A`RT(P`+*$(7FP/2H)9$I(4#@
M@!0(8@,6&DT"4L"'90Z""5)MRD$CMLK5KGKUJV`-JUC'2M:RFO6L:$VK6M6*
M`6\9D2D`B0()L/B*+M0B"",=FE[WRM>^^O6O@`VL8/W0"$.((`4'"$P`*."%
G2%0BEX.-K&0G2]G*6K:PELVL9C?+V<[Z]0L=\*QH1TO:TN8C$``[
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>o40024o4002414.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 o40024o4002414.gif
M1TE&.#EAYP`M`.8``-73T;V\N\'`P#PY.5U;6OS\_*&?GLC&QFQH9GAU=.7D
MY+6RL=_=W)V;FM74U%5242PI*$5#0VAE9'UZ>7-P<&5B8=/1T(V+BJRJJO7U
M]$E%1;^]O)*/CUE65<;%Q9F6E7%M;,3"P@P*"SDV-6UJ:30Q,4Q)2HJ(B,S*
MR>/AX;BVM1L9&8%^?182$HF&A;:UM9>6E86"@=K9V,K(QU!.36)?7:FFI3`M
M+=_>W8*`?[&OKI:2D28C(Z:DH]+0SZ>EI>CGYKJXMBHG)JNIJ-C6U9*1D=#.
MS?/R\4`]/5Q85Z2BH=;4T\+`OR`='9N8EJZLJZFGINWKZD],3'1P;K*PL&YL
M:^_N[>3BXL7#PHJ(AA@5%6]L;(>%A1$.#I>4D^KIZ/3T\X."@JNGI%A44DI(
M2"0@'UE75X>$@_CX]Y&-B6EG9TY)1][<VZ^MK3HX..?EY%A23VEH:+:SLGEW
M=_#O[DY+2T1`/K.QL,W+RQ,0$,_-S*BDHR\J*!L7%P<%!O___R'Y!```````
M+`````#G`"T```?_@'^"@X2%AH8R?@2'C(V.CY"1DI.4E9:7F)F10PV#(WYA
MFJ*CI*6FIZB18``]7B1_$%V"#GY^+ZFXN;J[O)4`6%X)'1I]?4()"K4H?SFU
M,F"]T=+3U)-?``!>-7Q^+<4:)&)?@B^U<V"U'2\_U>WN[[L&77XB?6-G`-"'
M5;41$[4OPBR"1["@P4H__`#``>E++3\K5M12\&/%P8L8,PH"@V09(P42H"5\
M6$O$'P<6-:I<20V''#MJ&B7T\D<-R5IV!$7`P+*G3U0*-'01T0)"(RFUC+BY
MZ<>#H"I]^$B=2K6JU:M8LVK=RK6KUZ]@PXH=F_5/(@,X$NDKA*XD4S^#_\*\
MG4NWKMV[>//JW<NWK]^_=@6YT2&HCX!#&-[.\^-F4#G`D"-+GDRYLN6'@CC<
M$`3CPJ$Y3$7@:.)GSB!:EU.K7LVZ==V-(A3\$1#A$!FFC2_XX3G(M>_?P(/K
M'=2%W1=9A11`\'-#Q$.:7\04$DZ]NO76?\#T4"2HR5IRM700>/B=T*?KZ-.K
MW\ND11DO/!S\B7"8$+_&7Y8W9B1WO?__`"8FQQ]FP/!'%082LAP'@A@@@AG:
M!=/!A#R-!."%&%('1@DE_.%"3`*$,HA#-ZSR!1@:8"!!,=]TP),`=FE@PXPV
M=/"6"#0VP(->(-AH%P$S&F!":UV<QQ0(-'[@Q_\%)=2%Q&)W53`>75(V80-U
ML_FQ@0=DG-0'(7+!4$X9@XAS"&IT#7!"$"F<H,&-?S1P`@IZZ$7`FW:=0,0)
M4!1`VFI>G#"7#0><<,(_``PYETE]Y/6`HG,%:A26,([PAQ2"P(6#`7\0T(0,
M<@0QSB#8`&```JC*\`=>",#HAQ9/L$'"0R8M]T`*?CP`P`+.54&$"LX9`$`-
M?L0@P1Y(E+:%%DQ8,,!#)USI!Q$5^*&&#$'DD2L16&CQ0`.Y4C"`$DX0@00>
M3OB1APH6)-L#%TN<(`(0"CQ``Q$^&&F#H`\ERJRS?O#@`P!(Q/$''@]P,$,$
M-Z"P1+(-Y.!#N@G,F@3_MEHT$0(.+/@AZ1_?^E$&%LYAYZH#8?`$@0?U_'%#
M#J3NT,$(C=82%1\:R`8E7:W6`L,&4M"!ITER#)%"#'ZP(0$,'_#`0!)07!"#
M#G6@D8<-86Q1#@`T.,&!&0=HZT>TM838P14T!,%!"5=\>P$"!_B!``<F%$`#
M`$0\\$<+3WQ0@T,`.%%#`2(L,(00!90PQ91^V!`%-@8H9(+78+=`Q`1;A+!9
M$@B@48$6;W`QAQ4B'##$&'L'6@(:)JAP1A(&U-;$QS<P(`()2KJ6I1]5O!!3
M!"C(\84"72C`00="&--!`EYX@<VH@T1P5\]=S)"L#OV9]($%`?@A!!`<#.'#
M_QPZT.-'``&<\`826$-PQ`A8Y)&!`2=$D>S8TH;`P@F1KVX&'N:#F]SHM@0_
MI,$%C++`$SRC!0#4X4LB")0?F+"II=3"!CJ8D!TD-[_ZT>`/VA(!HQ`P`XCL
MS20C.$`2&!6H!P!P'EJ@@!)@\;'=2``/-/#-'Y(!$0[4A@P"^,(7/)``&?"A
M`V>0`T/84BJ&2,\N/2N=].[0,7K`0@H9*($04C"%*B0A`>7@P0@"@`$$3*$,
M6//#%0*@FPRX``%;^!/9DD:`$RC!#R,X0@=\X(<FC$`"<9L"W0!@P#`D\`,D
M`$$7$@5!"0IA#B$(0LGV19)$N1&.F]&"'R(P0AAIX?\/6C!)"0[0`1:>X`%\
M+,'+!*`!&IY@4A180`9JAIT_E&P.L@A#B#;0B"\`8QME>$AMO#`]5UU`A1FX
M7ZW\0`4`IF`.'U`"Z"@0@"RP(`!C*,`*TAB#/[QI!ST@```D,C8`A&$(1U@!
M#=Y`@`/$8(LDD,,IWR`%&0RRD(S"@`TD0#I&VG('5!@`&CHPA0!,$@MA2*CD
MP"G.%1S@`R[8@$E0Y2H&<(`+0/`#*4V)N!I@(0<&J-$?^%!#2_%1A_.IA1M&
M((,PN$"(A%@%`L;0AZ'TP0ZH0H"P&.*JNM"@"+7(PPYF@"=Z"""8/!"`$"*P
M`0PXAP`>`->2/#`>%E2K"0+_<$X>VN`!"UI+``(PP)_&,(-T;=(#-LB#"+@0
MA#I4P0V1(T$%1""`%HC``"%(E@'<T(*LEH"J?PW`<FK!`K""U0][W6I7^[B!
M`'"C`0%X`%`#MH`@",$/,+`#75M``9MHX*%Y^.L$&C"`SI;!54"H%DIU4XL:
M"``%(OH#`%@P@A;XH0\:\((2&]'3#/D6/2MX!3EUEYV2K8`G<U!`!XHQ@@3T
M``"C6D4K)#`A%NWPM]B]S@WDD`#@#,)'?L`4&1R`1.$)PB7!(`9S)]0!"=!D
M5=F-KWS_0HB2&:4VI.H!'^;1@A&$`WJ&F*^`!WP70G``,VX`@Q%HV@T$!"$?
MA,`!_P!R6@P)P)?`&,XP7`8!!@G4P@,0$``<2`IA06Q`#,/H@W.JPDL-NWC`
MR6G2#^@S(BR<8;E=Z$-[O8`%`!QBN"\.LF\148(PT`<,7I``S830`2\\]Q$`
M\*J0IPR@0WA`"A&X@`#Z,`(6\+*7`)"#-KA!Y3)7^1!^($,8RD.(:\RTIC>Y
M`8OF3.<ZV_G.>,ZSGO?,YS[[^<^`#K2@]<P(""2TS6(@08KGP8<RV/8A??`"
MFW]"Z4IC(@)D($"2E]N$8G1@#6M(`A]4;+,.F-?2J$ZU)<P0`6],R`L&<$(2
MEML"(="LU@GPL:IWS6M(A($"0@P"`O9;#P3L@`4T'0,6>D[-[&8?P@LW&,$\
MRE`#)7Z!!.[IP:2=S6U>-^FY8,"!%T8P@C-@8=O=3G>J4;`"`_0@`26H@Q>6
9J.YZ-]L,.6:!KNW-;V;+8=_]#GA/`@$`.S\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
